Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2024-03-16
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| A1BG | -0.1319328 | 0.1278318 | -0.2607576 | -0.1720191 | -0.3210962 |
| A1BG-AS1 | -0.0678519 | 0.2071759 | -0.2840668 | -0.0749338 | -0.1634942 |
| A1CF | -0.4654375 | -0.7224130 | -1.6006643 | -0.7897859 | -1.0218382 |
| A2M | -0.3200584 | -0.6487938 | -1.3830212 | -0.5156872 | -1.0206657 |
| A2M-AS1 | 1.0579585 | 1.7188397 | -0.0914010 | 0.6786488 | -0.7617889 |
| A2ML1 | -0.3188359 | -0.4680800 | -0.9475040 | -0.4679375 | -0.6469161 |
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genes_in_profile | 22269 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 16317 |
| num_profile_genes_not_in_sets | 5952 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used:
GMT file of genesets:| Gene sets metrics | |
|---|---|
| num_genesets | 7647 |
| num_genesets_excluded | 2159 |
| num_genesets_included | 5488 |
| ADOS | diagnosis | iIQ | iLang | motor | Count |
|---|---|---|---|---|---|
| -1 | -1 | -1 | -1 | -1 | 12355 |
| 1 | -1 | -1 | -1 | -1 | 1497 |
| -1 | 0 | -1 | -1 | -1 | 1 |
| -1 | 1 | -1 | -1 | -1 | 569 |
| 1 | 1 | -1 | -1 | -1 | 1323 |
| -1 | -1 | 1 | -1 | -1 | 29 |
| 1 | -1 | 1 | -1 | -1 | 9 |
| -1 | 1 | 1 | -1 | -1 | 36 |
| 1 | 1 | 1 | -1 | -1 | 97 |
| 1 | -1 | -1 | 0 | -1 | 1 |
| -1 | -1 | -1 | 1 | -1 | 279 |
| 1 | -1 | -1 | 1 | -1 | 538 |
| -1 | 1 | -1 | 1 | -1 | 62 |
| 1 | 1 | -1 | 1 | -1 | 1134 |
| 1 | -1 | 0 | 1 | -1 | 1 |
| -1 | -1 | 1 | 1 | -1 | 41 |
| 1 | -1 | 1 | 1 | -1 | 68 |
| -1 | 1 | 1 | 1 | -1 | 31 |
| 1 | 1 | 1 | 1 | -1 | 859 |
| -1 | -1 | -1 | -1 | 0 | 1 |
| -1 | -1 | -1 | -1 | 1 | 1432 |
| 0 | -1 | -1 | -1 | 1 | 1 |
| 1 | -1 | -1 | -1 | 1 | 135 |
| -1 | 1 | -1 | -1 | 1 | 123 |
| 1 | 1 | -1 | -1 | 1 | 108 |
| -1 | -1 | 1 | -1 | 1 | 62 |
| 1 | -1 | 1 | -1 | 1 | 16 |
| -1 | 1 | 1 | -1 | 1 | 42 |
| 1 | 1 | 1 | -1 | 1 | 47 |
| -1 | -1 | -1 | 1 | 1 | 185 |
| 1 | -1 | -1 | 1 | 1 | 140 |
| -1 | 1 | -1 | 1 | 1 | 23 |
| 1 | 1 | -1 | 1 | 1 | 186 |
| -1 | -1 | 1 | 1 | 1 | 87 |
| 1 | -1 | 1 | 1 | 1 | 91 |
| -1 | 1 | 1 | 1 | 1 | 45 |
| 1 | 1 | 1 | 1 | 1 | 615 |
Gene sets by sector
| s.ADOS | s.diagnosis | s.iIQ | s.iLang | s.motor | Count |
|---|---|---|---|---|---|
| -1 | -1 | -1 | -1 | -1 | 32 |
| -1 | 1 | -1 | -1 | -1 | 10 |
| 1 | 1 | -1 | -1 | -1 | 13 |
| 1 | 1 | 1 | -1 | -1 | 3 |
| -1 | -1 | -1 | 1 | -1 | 1 |
| 1 | 1 | -1 | 1 | -1 | 6 |
| 1 | 1 | 1 | 1 | -1 | 4 |
| -1 | -1 | -1 | -1 | 1 | 5 |
| 1 | 1 | -1 | -1 | 1 | 1 |
| -1 | -1 | 1 | 1 | 1 | 5 |
| 1 | -1 | 1 | 1 | 1 | 3 |
| -1 | 1 | 1 | 1 | 1 | 7 |
| 1 | 1 | 1 | 1 | 1 | 477 |
Interactive enrichment scatterplot
All sets with FDR<0.05. Try hovering over the points.
Top N sets irrespective of FDR. Try hovering over the points.
A heatmap of S values for top results
A plot of effect size versus significance
Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.
Results table
Top N= 50 gene sets
## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.| set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.ADOS | s.diagnosis | s.iIQ | s.iLang | s.motor | p.ADOS | p.diagnosis | p.iIQ | p.iLang | p.motor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XENOBIOTIC GLUCURONIDATION | 7 | 4.89e-03 | 6.01e-02 | 1.68 | -0.764 | -0.758 | -0.815 | -0.844 | -0.54400 | 4.61e-04 | 5.10e-04 | 1.87e-04 | 1.11e-04 | 1.26e-02 |
| FLAVONOID GLUCURONIDATION | 5 | 5.52e-02 | 3.11e-01 | 1.58 | -0.716 | -0.694 | -0.749 | -0.820 | -0.50500 | 5.59e-03 | 7.17e-03 | 3.73e-03 | 1.49e-03 | 5.03e-02 |
| FOREBRAIN NEURON FATE COMMITMENT | 7 | 4.55e-03 | 5.75e-02 | 1.46 | 0.400 | 0.636 | 0.785 | 0.644 | 0.73800 | 6.70e-02 | 3.54e-03 | 3.20e-04 | 3.17e-03 | 7.22e-04 |
| FLAVONE METABOLIC PROCESS | 6 | 4.50e-02 | 2.76e-01 | 1.45 | -0.672 | -0.607 | -0.711 | -0.772 | -0.43900 | 4.33e-03 | 1.01e-02 | 2.55e-03 | 1.06e-03 | 6.26e-02 |
| POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION OF STAT PROTEIN | 16 | 1.24e-06 | 5.72e-05 | 1.45 | -0.526 | -0.635 | -0.678 | -0.649 | -0.73000 | 2.69e-04 | 1.08e-05 | 2.65e-06 | 6.84e-06 | 4.22e-07 |
| PROTEIN UFMYLATION | 6 | 6.38e-03 | 7.37e-02 | 1.44 | 0.707 | 0.712 | 0.758 | 0.704 | 0.00627 | 2.70e-03 | 2.54e-03 | 1.31e-03 | 2.83e-03 | 9.79e-01 |
| ROSTROCAUDAL NEURAL TUBE PATTERNING | 10 | 3.30e-03 | 4.49e-02 | 1.40 | 0.666 | 0.634 | 0.675 | 0.634 | 0.50400 | 2.64e-04 | 5.17e-04 | 2.19e-04 | 5.14e-04 | 5.76e-03 |
| MIDBRAIN HINDBRAIN BOUNDARY DEVELOPMENT | 7 | 4.08e-02 | 2.61e-01 | 1.39 | 0.642 | 0.639 | 0.668 | 0.662 | 0.47900 | 3.25e-03 | 3.43e-03 | 2.21e-03 | 2.44e-03 | 2.83e-02 |
| PROTEIN POLYUFMYLATION | 5 | 5.99e-02 | 3.24e-01 | 1.39 | 0.664 | 0.721 | 0.725 | 0.659 | 0.10900 | 1.01e-02 | 5.24e-03 | 4.98e-03 | 1.07e-02 | 6.72e-01 |
| PROXIMAL DISTAL PATTERN FORMATION INVOLVED IN NEPHRON DEVELOPMENT | 5 | 1.14e-01 | 4.61e-01 | 1.38 | 0.573 | 0.605 | 0.658 | 0.634 | 0.61100 | 2.64e-02 | 1.92e-02 | 1.08e-02 | 1.42e-02 | 1.81e-02 |
| SINOATRIAL NODE CELL DEVELOPMENT | 5 | 9.23e-02 | 4.13e-01 | 1.37 | 0.482 | 0.602 | 0.689 | 0.596 | 0.68000 | 6.17e-02 | 1.98e-02 | 7.60e-03 | 2.10e-02 | 8.45e-03 |
| CELLULAR GLUCURONIDATION | 21 | 1.55e-06 | 6.93e-05 | 1.37 | -0.556 | -0.630 | -0.670 | -0.672 | -0.52000 | 1.04e-05 | 5.79e-07 | 1.05e-07 | 9.57e-08 | 3.68e-05 |
| RRNA TRANSPORT | 5 | 1.45e-01 | 5.11e-01 | 1.36 | 0.593 | 0.678 | 0.685 | 0.591 | 0.47100 | 2.16e-02 | 8.67e-03 | 7.98e-03 | 2.20e-02 | 6.80e-02 |
| STEM CELL FATE SPECIFICATION | 6 | 1.62e-02 | 1.44e-01 | 1.36 | 0.473 | 0.619 | 0.720 | 0.456 | 0.71400 | 4.47e-02 | 8.65e-03 | 2.26e-03 | 5.29e-02 | 2.46e-03 |
| SINOATRIAL NODE CELL DIFFERENTIATION | 6 | 4.36e-02 | 2.71e-01 | 1.33 | 0.458 | 0.515 | 0.643 | 0.581 | 0.72900 | 5.22e-02 | 2.90e-02 | 6.36e-03 | 1.37e-02 | 1.99e-03 |
| PATTERN SPECIFICATION INVOLVED IN KIDNEY DEVELOPMENT | 8 | 3.11e-02 | 2.22e-01 | 1.30 | 0.562 | 0.615 | 0.622 | 0.575 | 0.52400 | 5.93e-03 | 2.61e-03 | 2.31e-03 | 4.89e-03 | 1.03e-02 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO CHROMATIN | 6 | 6.04e-02 | 3.25e-01 | 1.29 | 0.696 | 0.566 | 0.543 | 0.617 | 0.43600 | 3.16e-03 | 1.63e-02 | 2.13e-02 | 8.85e-03 | 6.44e-02 |
| GRANULOCYTE COLONY STIMULATING FACTOR PRODUCTION | 5 | 8.74e-02 | 4.00e-01 | 1.27 | 0.746 | 0.656 | 0.527 | 0.593 | -0.04290 | 3.89e-03 | 1.11e-02 | 4.13e-02 | 2.17e-02 | 8.68e-01 |
| PROTEIN DNA COVALENT CROSS LINKING REPAIR | 6 | 7.65e-02 | 3.75e-01 | 1.26 | 0.617 | 0.538 | 0.677 | 0.613 | 0.28800 | 8.88e-03 | 2.25e-02 | 4.10e-03 | 9.27e-03 | 2.22e-01 |
| REGULATION OF ENAMEL MINERALIZATION | 7 | 5.69e-02 | 3.15e-01 | 1.26 | -0.591 | -0.490 | -0.591 | -0.647 | -0.47800 | 6.77e-03 | 2.46e-02 | 6.81e-03 | 3.03e-03 | 2.85e-02 |
| EPITHELIAL MESENCHYMAL CELL SIGNALING | 6 | 4.89e-02 | 2.89e-01 | 1.26 | 0.347 | 0.426 | 0.653 | 0.569 | 0.72900 | 1.41e-01 | 7.05e-02 | 5.59e-03 | 1.58e-02 | 1.98e-03 |
| COMMON BILE DUCT DEVELOPMENT | 5 | 3.85e-02 | 2.54e-01 | 1.23 | 0.646 | 0.581 | 0.549 | 0.411 | 0.54800 | 1.24e-02 | 2.43e-02 | 3.36e-02 | 1.12e-01 | 3.40e-02 |
| MOTOR LEARNING | 7 | 3.82e-02 | 2.53e-01 | 1.22 | 0.547 | 0.642 | 0.567 | 0.452 | 0.50600 | 1.21e-02 | 3.28e-03 | 9.41e-03 | 3.82e-02 | 2.05e-02 |
| PANCREATIC A CELL DIFFERENTIATION | 11 | 5.07e-03 | 6.20e-02 | 1.22 | 0.476 | 0.504 | 0.696 | 0.551 | 0.46500 | 6.24e-03 | 3.79e-03 | 6.44e-05 | 1.57e-03 | 7.58e-03 |
| REGULATION OF AMACRINE CELL DIFFERENTIATION | 6 | 1.59e-02 | 1.42e-01 | 1.21 | 0.308 | 0.636 | 0.603 | 0.560 | 0.53400 | 1.92e-01 | 6.95e-03 | 1.05e-02 | 1.75e-02 | 2.34e-02 |
| REGULATION OF LOCOMOTION INVOLVED IN LOCOMOTORY BEHAVIOR | 5 | 1.42e-01 | 5.08e-01 | 1.20 | 0.576 | 0.593 | 0.668 | 0.534 | 0.18500 | 2.57e-02 | 2.17e-02 | 9.71e-03 | 3.85e-02 | 4.73e-01 |
| RESPONSE TO SODIUM ARSENITE | 6 | 1.51e-01 | 5.20e-01 | 1.20 | 0.444 | 0.549 | 0.658 | 0.540 | 0.47400 | 5.98e-02 | 1.98e-02 | 5.25e-03 | 2.21e-02 | 4.42e-02 |
| CARDIOBLAST PROLIFERATION | 11 | 9.77e-03 | 9.98e-02 | 1.20 | 0.458 | 0.551 | 0.577 | 0.579 | 0.50900 | 8.52e-03 | 1.54e-03 | 9.27e-04 | 8.92e-04 | 3.48e-03 |
| NEGATIVE REGULATION OF NUCLEASE ACTIVITY | 7 | 7.45e-02 | 3.69e-01 | 1.19 | 0.596 | 0.552 | 0.491 | 0.610 | 0.39100 | 6.36e-03 | 1.15e-02 | 2.46e-02 | 5.16e-03 | 7.34e-02 |
| TRANSLATIONAL TERMINATION | 15 | 2.39e-03 | 3.51e-02 | 1.19 | 0.566 | 0.532 | 0.598 | 0.583 | 0.34500 | 1.46e-04 | 3.64e-04 | 5.99e-05 | 9.22e-05 | 2.08e-02 |
| RESPONSE TO PROSTAGLANDIN D | 5 | 2.43e-01 | 6.48e-01 | 1.16 | -0.488 | -0.551 | -0.528 | -0.618 | -0.38100 | 5.88e-02 | 3.29e-02 | 4.10e-02 | 1.68e-02 | 1.40e-01 |
| AIM2 INFLAMMASOME COMPLEX ASSEMBLY | 5 | 2.96e-01 | 7.07e-01 | 1.16 | -0.432 | -0.490 | -0.621 | -0.560 | -0.46400 | 9.40e-02 | 5.78e-02 | 1.61e-02 | 3.02e-02 | 7.25e-02 |
| SENSORY PERCEPTION OF BITTER TASTE | 44 | 9.84e-10 | 7.26e-08 | 1.15 | -0.506 | -0.522 | -0.569 | -0.537 | -0.43700 | 6.43e-09 | 2.09e-09 | 6.54e-11 | 6.78e-10 | 5.30e-07 |
| OLIGOPEPTIDE IMPORT ACROSS PLASMA MEMBRANE | 5 | 2.76e-01 | 6.86e-01 | 1.14 | -0.528 | -0.466 | -0.579 | -0.530 | -0.43800 | 4.08e-02 | 7.12e-02 | 2.49e-02 | 4.02e-02 | 8.95e-02 |
| NEGATIVE REGULATION OF AUTOPHAGY OF MITOCHONDRION | 7 | 1.41e-01 | 5.06e-01 | 1.14 | 0.581 | 0.568 | 0.530 | 0.504 | 0.32600 | 7.75e-03 | 9.29e-03 | 1.52e-02 | 2.08e-02 | 1.36e-01 |
| CEREBRAL CORTEX GABAERGIC INTERNEURON DIFFERENTIATION | 10 | 1.26e-02 | 1.20e-01 | 1.14 | 0.317 | 0.451 | 0.618 | 0.484 | 0.61600 | 8.24e-02 | 1.36e-02 | 7.12e-04 | 7.98e-03 | 7.42e-04 |
| RIBOSOMAL SMALL SUBUNIT EXPORT FROM NUCLEUS | 8 | 7.72e-02 | 3.77e-01 | 1.14 | 0.500 | 0.507 | 0.621 | 0.509 | 0.38400 | 1.43e-02 | 1.30e-02 | 2.36e-03 | 1.27e-02 | 6.00e-02 |
| SENSORY PERCEPTION OF SMELL | 380 | 3.00e-100 | 7.22e-97 | 1.14 | -0.390 | -0.511 | -0.593 | -0.508 | -0.52100 | 3.91e-39 | 4.01e-66 | 1.54e-88 | 3.18e-65 | 1.88e-68 |
| HIS PURKINJE SYSTEM DEVELOPMENT | 7 | 5.05e-02 | 2.93e-01 | 1.14 | 0.577 | 0.489 | 0.463 | 0.499 | 0.50400 | 8.23e-03 | 2.52e-02 | 3.40e-02 | 2.21e-02 | 2.09e-02 |
| CARDIAC PACEMAKER CELL DEVELOPMENT | 9 | 6.15e-02 | 3.29e-01 | 1.13 | 0.445 | 0.511 | 0.552 | 0.525 | 0.48700 | 2.07e-02 | 7.99e-03 | 4.16e-03 | 6.38e-03 | 1.14e-02 |
| CELLULAR RESPONSE TO SODIUM ARSENITE | 5 | 2.68e-01 | 6.76e-01 | 1.12 | 0.371 | 0.518 | 0.636 | 0.505 | 0.43900 | 1.51e-01 | 4.50e-02 | 1.38e-02 | 5.07e-02 | 8.88e-02 |
| POSITIVE REGULATION OF PROTEIN MONOUBIQUITINATION | 5 | 2.66e-01 | 6.73e-01 | 1.11 | 0.516 | 0.586 | 0.575 | 0.527 | 0.11800 | 4.57e-02 | 2.32e-02 | 2.59e-02 | 4.14e-02 | 6.48e-01 |
| MACROPHAGE COLONY STIMULATING FACTOR PRODUCTION | 7 | 1.69e-02 | 1.49e-01 | 1.11 | 0.665 | 0.531 | 0.354 | 0.576 | -0.21900 | 2.29e-03 | 1.49e-02 | 1.05e-01 | 8.35e-03 | 3.16e-01 |
| MRNA 3 END PROCESSING BY STEM LOOP BINDING AND CLEAVAGE | 6 | 6.09e-02 | 3.26e-01 | 1.11 | 0.482 | 0.296 | 0.489 | 0.645 | 0.49600 | 4.10e-02 | 2.09e-01 | 3.79e-02 | 6.18e-03 | 3.53e-02 |
| RNA GUANINE N7 METHYLATION | 6 | 1.20e-01 | 4.73e-01 | 1.10 | 0.449 | 0.513 | 0.655 | 0.444 | 0.36100 | 5.70e-02 | 2.96e-02 | 5.47e-03 | 5.94e-02 | 1.26e-01 |
| RESPONSE TO OXYGEN GLUCOSE DEPRIVATION | 11 | 2.76e-02 | 2.05e-01 | 1.10 | 0.549 | 0.471 | 0.549 | 0.574 | 0.24300 | 1.61e-03 | 6.80e-03 | 1.60e-03 | 9.85e-04 | 1.64e-01 |
| APOPTOTIC PROCESS INVOLVED IN HEART MORPHOGENESIS | 7 | 2.14e-02 | 1.74e-01 | 1.10 | 0.219 | 0.448 | 0.618 | 0.335 | 0.68200 | 3.15e-01 | 4.02e-02 | 4.65e-03 | 1.25e-01 | 1.79e-03 |
| RRNA PSEUDOURIDINE SYNTHESIS | 7 | 5.29e-02 | 3.04e-01 | 1.09 | 0.336 | 0.435 | 0.680 | 0.542 | 0.37000 | 1.24e-01 | 4.62e-02 | 1.83e-03 | 1.30e-02 | 9.04e-02 |
| SERINE PHOSPHORYLATION OF STAT PROTEIN | 20 | 4.31e-05 | 1.35e-03 | 1.09 | -0.368 | -0.499 | -0.501 | -0.468 | -0.57000 | 4.34e-03 | 1.12e-04 | 1.04e-04 | 2.89e-04 | 1.03e-05 |
| CARDIAC PACEMAKER CELL DIFFERENTIATION | 11 | 1.40e-02 | 1.29e-01 | 1.08 | 0.416 | 0.477 | 0.488 | 0.469 | 0.55800 | 1.70e-02 | 6.11e-03 | 5.07e-03 | 7.06e-03 | 1.34e-03 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.ADOS | s.diagnosis | s.iIQ | s.iLang | s.motor | p.ADOS | p.diagnosis | p.iIQ | p.iLang | p.motor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XENOBIOTIC GLUCURONIDATION | 7 | 4.89e-03 | 6.01e-02 | 1.6800 | -7.64e-01 | -7.58e-01 | -8.15e-01 | -8.44e-01 | -5.44e-01 | 4.61e-04 | 5.10e-04 | 1.87e-04 | 1.11e-04 | 1.26e-02 |
| FLAVONOID GLUCURONIDATION | 5 | 5.52e-02 | 3.11e-01 | 1.5800 | -7.16e-01 | -6.94e-01 | -7.49e-01 | -8.20e-01 | -5.05e-01 | 5.59e-03 | 7.17e-03 | 3.73e-03 | 1.49e-03 | 5.03e-02 |
| FOREBRAIN NEURON FATE COMMITMENT | 7 | 4.55e-03 | 5.75e-02 | 1.4600 | 4.00e-01 | 6.36e-01 | 7.85e-01 | 6.44e-01 | 7.38e-01 | 6.70e-02 | 3.54e-03 | 3.20e-04 | 3.17e-03 | 7.22e-04 |
| FLAVONE METABOLIC PROCESS | 6 | 4.50e-02 | 2.76e-01 | 1.4500 | -6.72e-01 | -6.07e-01 | -7.11e-01 | -7.72e-01 | -4.39e-01 | 4.33e-03 | 1.01e-02 | 2.55e-03 | 1.06e-03 | 6.26e-02 |
| POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION OF STAT PROTEIN | 16 | 1.24e-06 | 5.72e-05 | 1.4500 | -5.26e-01 | -6.35e-01 | -6.78e-01 | -6.49e-01 | -7.30e-01 | 2.69e-04 | 1.08e-05 | 2.65e-06 | 6.84e-06 | 4.22e-07 |
| PROTEIN UFMYLATION | 6 | 6.38e-03 | 7.37e-02 | 1.4400 | 7.07e-01 | 7.12e-01 | 7.58e-01 | 7.04e-01 | 6.27e-03 | 2.70e-03 | 2.54e-03 | 1.31e-03 | 2.83e-03 | 9.79e-01 |
| ROSTROCAUDAL NEURAL TUBE PATTERNING | 10 | 3.30e-03 | 4.49e-02 | 1.4000 | 6.66e-01 | 6.34e-01 | 6.75e-01 | 6.34e-01 | 5.04e-01 | 2.64e-04 | 5.17e-04 | 2.19e-04 | 5.14e-04 | 5.76e-03 |
| MIDBRAIN HINDBRAIN BOUNDARY DEVELOPMENT | 7 | 4.08e-02 | 2.61e-01 | 1.3900 | 6.42e-01 | 6.39e-01 | 6.68e-01 | 6.62e-01 | 4.79e-01 | 3.25e-03 | 3.43e-03 | 2.21e-03 | 2.44e-03 | 2.83e-02 |
| PROTEIN POLYUFMYLATION | 5 | 5.99e-02 | 3.24e-01 | 1.3900 | 6.64e-01 | 7.21e-01 | 7.25e-01 | 6.59e-01 | 1.09e-01 | 1.01e-02 | 5.24e-03 | 4.98e-03 | 1.07e-02 | 6.72e-01 |
| PROXIMAL DISTAL PATTERN FORMATION INVOLVED IN NEPHRON DEVELOPMENT | 5 | 1.14e-01 | 4.61e-01 | 1.3800 | 5.73e-01 | 6.05e-01 | 6.58e-01 | 6.34e-01 | 6.11e-01 | 2.64e-02 | 1.92e-02 | 1.08e-02 | 1.42e-02 | 1.81e-02 |
| SINOATRIAL NODE CELL DEVELOPMENT | 5 | 9.23e-02 | 4.13e-01 | 1.3700 | 4.82e-01 | 6.02e-01 | 6.89e-01 | 5.96e-01 | 6.80e-01 | 6.17e-02 | 1.98e-02 | 7.60e-03 | 2.10e-02 | 8.45e-03 |
| CELLULAR GLUCURONIDATION | 21 | 1.55e-06 | 6.93e-05 | 1.3700 | -5.56e-01 | -6.30e-01 | -6.70e-01 | -6.72e-01 | -5.20e-01 | 1.04e-05 | 5.79e-07 | 1.05e-07 | 9.57e-08 | 3.68e-05 |
| RRNA TRANSPORT | 5 | 1.45e-01 | 5.11e-01 | 1.3600 | 5.93e-01 | 6.78e-01 | 6.85e-01 | 5.91e-01 | 4.71e-01 | 2.16e-02 | 8.67e-03 | 7.98e-03 | 2.20e-02 | 6.80e-02 |
| STEM CELL FATE SPECIFICATION | 6 | 1.62e-02 | 1.44e-01 | 1.3600 | 4.73e-01 | 6.19e-01 | 7.20e-01 | 4.56e-01 | 7.14e-01 | 4.47e-02 | 8.65e-03 | 2.26e-03 | 5.29e-02 | 2.46e-03 |
| SINOATRIAL NODE CELL DIFFERENTIATION | 6 | 4.36e-02 | 2.71e-01 | 1.3300 | 4.58e-01 | 5.15e-01 | 6.43e-01 | 5.81e-01 | 7.29e-01 | 5.22e-02 | 2.90e-02 | 6.36e-03 | 1.37e-02 | 1.99e-03 |
| PATTERN SPECIFICATION INVOLVED IN KIDNEY DEVELOPMENT | 8 | 3.11e-02 | 2.22e-01 | 1.3000 | 5.62e-01 | 6.15e-01 | 6.22e-01 | 5.75e-01 | 5.24e-01 | 5.93e-03 | 2.61e-03 | 2.31e-03 | 4.89e-03 | 1.03e-02 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO CHROMATIN | 6 | 6.04e-02 | 3.25e-01 | 1.2900 | 6.96e-01 | 5.66e-01 | 5.43e-01 | 6.17e-01 | 4.36e-01 | 3.16e-03 | 1.63e-02 | 2.13e-02 | 8.85e-03 | 6.44e-02 |
| GRANULOCYTE COLONY STIMULATING FACTOR PRODUCTION | 5 | 8.74e-02 | 4.00e-01 | 1.2700 | 7.46e-01 | 6.56e-01 | 5.27e-01 | 5.93e-01 | -4.29e-02 | 3.89e-03 | 1.11e-02 | 4.13e-02 | 2.17e-02 | 8.68e-01 |
| PROTEIN DNA COVALENT CROSS LINKING REPAIR | 6 | 7.65e-02 | 3.75e-01 | 1.2600 | 6.17e-01 | 5.38e-01 | 6.77e-01 | 6.13e-01 | 2.88e-01 | 8.88e-03 | 2.25e-02 | 4.10e-03 | 9.27e-03 | 2.22e-01 |
| REGULATION OF ENAMEL MINERALIZATION | 7 | 5.69e-02 | 3.15e-01 | 1.2600 | -5.91e-01 | -4.90e-01 | -5.91e-01 | -6.47e-01 | -4.78e-01 | 6.77e-03 | 2.46e-02 | 6.81e-03 | 3.03e-03 | 2.85e-02 |
| EPITHELIAL MESENCHYMAL CELL SIGNALING | 6 | 4.89e-02 | 2.89e-01 | 1.2600 | 3.47e-01 | 4.26e-01 | 6.53e-01 | 5.69e-01 | 7.29e-01 | 1.41e-01 | 7.05e-02 | 5.59e-03 | 1.58e-02 | 1.98e-03 |
| COMMON BILE DUCT DEVELOPMENT | 5 | 3.85e-02 | 2.54e-01 | 1.2300 | 6.46e-01 | 5.81e-01 | 5.49e-01 | 4.11e-01 | 5.48e-01 | 1.24e-02 | 2.43e-02 | 3.36e-02 | 1.12e-01 | 3.40e-02 |
| MOTOR LEARNING | 7 | 3.82e-02 | 2.53e-01 | 1.2200 | 5.47e-01 | 6.42e-01 | 5.67e-01 | 4.52e-01 | 5.06e-01 | 1.21e-02 | 3.28e-03 | 9.41e-03 | 3.82e-02 | 2.05e-02 |
| PANCREATIC A CELL DIFFERENTIATION | 11 | 5.07e-03 | 6.20e-02 | 1.2200 | 4.76e-01 | 5.04e-01 | 6.96e-01 | 5.51e-01 | 4.65e-01 | 6.24e-03 | 3.79e-03 | 6.44e-05 | 1.57e-03 | 7.58e-03 |
| REGULATION OF AMACRINE CELL DIFFERENTIATION | 6 | 1.59e-02 | 1.42e-01 | 1.2100 | 3.08e-01 | 6.36e-01 | 6.03e-01 | 5.60e-01 | 5.34e-01 | 1.92e-01 | 6.95e-03 | 1.05e-02 | 1.75e-02 | 2.34e-02 |
| REGULATION OF LOCOMOTION INVOLVED IN LOCOMOTORY BEHAVIOR | 5 | 1.42e-01 | 5.08e-01 | 1.2000 | 5.76e-01 | 5.93e-01 | 6.68e-01 | 5.34e-01 | 1.85e-01 | 2.57e-02 | 2.17e-02 | 9.71e-03 | 3.85e-02 | 4.73e-01 |
| RESPONSE TO SODIUM ARSENITE | 6 | 1.51e-01 | 5.20e-01 | 1.2000 | 4.44e-01 | 5.49e-01 | 6.58e-01 | 5.40e-01 | 4.74e-01 | 5.98e-02 | 1.98e-02 | 5.25e-03 | 2.21e-02 | 4.42e-02 |
| CARDIOBLAST PROLIFERATION | 11 | 9.77e-03 | 9.98e-02 | 1.2000 | 4.58e-01 | 5.51e-01 | 5.77e-01 | 5.79e-01 | 5.09e-01 | 8.52e-03 | 1.54e-03 | 9.27e-04 | 8.92e-04 | 3.48e-03 |
| NEGATIVE REGULATION OF NUCLEASE ACTIVITY | 7 | 7.45e-02 | 3.69e-01 | 1.1900 | 5.96e-01 | 5.52e-01 | 4.91e-01 | 6.10e-01 | 3.91e-01 | 6.36e-03 | 1.15e-02 | 2.46e-02 | 5.16e-03 | 7.34e-02 |
| TRANSLATIONAL TERMINATION | 15 | 2.39e-03 | 3.51e-02 | 1.1900 | 5.66e-01 | 5.32e-01 | 5.98e-01 | 5.83e-01 | 3.45e-01 | 1.46e-04 | 3.64e-04 | 5.99e-05 | 9.22e-05 | 2.08e-02 |
| RESPONSE TO PROSTAGLANDIN D | 5 | 2.43e-01 | 6.48e-01 | 1.1600 | -4.88e-01 | -5.51e-01 | -5.28e-01 | -6.18e-01 | -3.81e-01 | 5.88e-02 | 3.29e-02 | 4.10e-02 | 1.68e-02 | 1.40e-01 |
| AIM2 INFLAMMASOME COMPLEX ASSEMBLY | 5 | 2.96e-01 | 7.07e-01 | 1.1600 | -4.32e-01 | -4.90e-01 | -6.21e-01 | -5.60e-01 | -4.64e-01 | 9.40e-02 | 5.78e-02 | 1.61e-02 | 3.02e-02 | 7.25e-02 |
| SENSORY PERCEPTION OF BITTER TASTE | 44 | 9.84e-10 | 7.26e-08 | 1.1500 | -5.06e-01 | -5.22e-01 | -5.69e-01 | -5.37e-01 | -4.37e-01 | 6.43e-09 | 2.09e-09 | 6.54e-11 | 6.78e-10 | 5.30e-07 |
| OLIGOPEPTIDE IMPORT ACROSS PLASMA MEMBRANE | 5 | 2.76e-01 | 6.86e-01 | 1.1400 | -5.28e-01 | -4.66e-01 | -5.79e-01 | -5.30e-01 | -4.38e-01 | 4.08e-02 | 7.12e-02 | 2.49e-02 | 4.02e-02 | 8.95e-02 |
| NEGATIVE REGULATION OF AUTOPHAGY OF MITOCHONDRION | 7 | 1.41e-01 | 5.06e-01 | 1.1400 | 5.81e-01 | 5.68e-01 | 5.30e-01 | 5.04e-01 | 3.26e-01 | 7.75e-03 | 9.29e-03 | 1.52e-02 | 2.08e-02 | 1.36e-01 |
| CEREBRAL CORTEX GABAERGIC INTERNEURON DIFFERENTIATION | 10 | 1.26e-02 | 1.20e-01 | 1.1400 | 3.17e-01 | 4.51e-01 | 6.18e-01 | 4.84e-01 | 6.16e-01 | 8.24e-02 | 1.36e-02 | 7.12e-04 | 7.98e-03 | 7.42e-04 |
| RIBOSOMAL SMALL SUBUNIT EXPORT FROM NUCLEUS | 8 | 7.72e-02 | 3.77e-01 | 1.1400 | 5.00e-01 | 5.07e-01 | 6.21e-01 | 5.09e-01 | 3.84e-01 | 1.43e-02 | 1.30e-02 | 2.36e-03 | 1.27e-02 | 6.00e-02 |
| SENSORY PERCEPTION OF SMELL | 380 | 2.88e-100 | 7.22e-97 | 1.1400 | -3.90e-01 | -5.11e-01 | -5.93e-01 | -5.08e-01 | -5.21e-01 | 3.91e-39 | 4.01e-66 | 1.54e-88 | 3.18e-65 | 1.88e-68 |
| HIS PURKINJE SYSTEM DEVELOPMENT | 7 | 5.05e-02 | 2.93e-01 | 1.1400 | 5.77e-01 | 4.89e-01 | 4.63e-01 | 4.99e-01 | 5.04e-01 | 8.23e-03 | 2.52e-02 | 3.40e-02 | 2.21e-02 | 2.09e-02 |
| CARDIAC PACEMAKER CELL DEVELOPMENT | 9 | 6.15e-02 | 3.29e-01 | 1.1300 | 4.45e-01 | 5.11e-01 | 5.52e-01 | 5.25e-01 | 4.87e-01 | 2.07e-02 | 7.99e-03 | 4.16e-03 | 6.38e-03 | 1.14e-02 |
| CELLULAR RESPONSE TO SODIUM ARSENITE | 5 | 2.68e-01 | 6.76e-01 | 1.1200 | 3.71e-01 | 5.18e-01 | 6.36e-01 | 5.05e-01 | 4.39e-01 | 1.51e-01 | 4.50e-02 | 1.38e-02 | 5.07e-02 | 8.88e-02 |
| POSITIVE REGULATION OF PROTEIN MONOUBIQUITINATION | 5 | 2.66e-01 | 6.73e-01 | 1.1100 | 5.16e-01 | 5.86e-01 | 5.75e-01 | 5.27e-01 | 1.18e-01 | 4.57e-02 | 2.32e-02 | 2.59e-02 | 4.14e-02 | 6.48e-01 |
| MACROPHAGE COLONY STIMULATING FACTOR PRODUCTION | 7 | 1.69e-02 | 1.49e-01 | 1.1100 | 6.65e-01 | 5.31e-01 | 3.54e-01 | 5.76e-01 | -2.19e-01 | 2.29e-03 | 1.49e-02 | 1.05e-01 | 8.35e-03 | 3.16e-01 |
| MRNA 3 END PROCESSING BY STEM LOOP BINDING AND CLEAVAGE | 6 | 6.09e-02 | 3.26e-01 | 1.1100 | 4.82e-01 | 2.96e-01 | 4.89e-01 | 6.45e-01 | 4.96e-01 | 4.10e-02 | 2.09e-01 | 3.79e-02 | 6.18e-03 | 3.53e-02 |
| RNA GUANINE N7 METHYLATION | 6 | 1.20e-01 | 4.73e-01 | 1.1000 | 4.49e-01 | 5.13e-01 | 6.55e-01 | 4.44e-01 | 3.61e-01 | 5.70e-02 | 2.96e-02 | 5.47e-03 | 5.94e-02 | 1.26e-01 |
| RESPONSE TO OXYGEN GLUCOSE DEPRIVATION | 11 | 2.76e-02 | 2.05e-01 | 1.1000 | 5.49e-01 | 4.71e-01 | 5.49e-01 | 5.74e-01 | 2.43e-01 | 1.61e-03 | 6.80e-03 | 1.60e-03 | 9.85e-04 | 1.64e-01 |
| APOPTOTIC PROCESS INVOLVED IN HEART MORPHOGENESIS | 7 | 2.14e-02 | 1.74e-01 | 1.1000 | 2.19e-01 | 4.48e-01 | 6.18e-01 | 3.35e-01 | 6.82e-01 | 3.15e-01 | 4.02e-02 | 4.65e-03 | 1.25e-01 | 1.79e-03 |
| RRNA PSEUDOURIDINE SYNTHESIS | 7 | 5.29e-02 | 3.04e-01 | 1.0900 | 3.36e-01 | 4.35e-01 | 6.80e-01 | 5.42e-01 | 3.70e-01 | 1.24e-01 | 4.62e-02 | 1.83e-03 | 1.30e-02 | 9.04e-02 |
| SERINE PHOSPHORYLATION OF STAT PROTEIN | 20 | 4.31e-05 | 1.35e-03 | 1.0900 | -3.68e-01 | -4.99e-01 | -5.01e-01 | -4.68e-01 | -5.70e-01 | 4.34e-03 | 1.12e-04 | 1.04e-04 | 2.89e-04 | 1.03e-05 |
| CARDIAC PACEMAKER CELL DIFFERENTIATION | 11 | 1.40e-02 | 1.29e-01 | 1.0800 | 4.16e-01 | 4.77e-01 | 4.88e-01 | 4.69e-01 | 5.58e-01 | 1.70e-02 | 6.11e-03 | 5.07e-03 | 7.06e-03 | 1.34e-03 |
| NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION INVOLVED IN PROSTATE GLAND DEVELOPMENT | 6 | 8.88e-03 | 9.32e-02 | 1.0800 | 5.51e-01 | 7.65e-01 | 4.68e-01 | 2.37e-01 | 5.87e-02 | 1.94e-02 | 1.18e-03 | 4.71e-02 | 3.14e-01 | 8.03e-01 |
| NORADRENERGIC NEURON DIFFERENTIATION | 10 | 1.90e-02 | 1.61e-01 | 1.0800 | 4.03e-01 | 5.21e-01 | 5.30e-01 | 3.94e-01 | 5.45e-01 | 2.72e-02 | 4.33e-03 | 3.71e-03 | 3.11e-02 | 2.82e-03 |
| POSITIVE REGULATION OF RESPONSE TO TYPE II INTERFERON | 6 | 1.24e-01 | 4.80e-01 | 1.0800 | -6.56e-01 | -4.92e-01 | -4.46e-01 | -4.81e-01 | -2.51e-01 | 5.41e-03 | 3.69e-02 | 5.88e-02 | 4.14e-02 | 2.87e-01 |
| SENSORY PERCEPTION OF CHEMICAL STIMULUS | 455 | 2.11e-103 | 1.59e-99 | 1.0700 | -3.84e-01 | -4.84e-01 | -5.54e-01 | -4.88e-01 | -4.76e-01 | 4.74e-45 | 1.96e-70 | 4.54e-92 | 1.23e-71 | 3.01e-68 |
| TELOMERE TETHERING AT NUCLEAR PERIPHERY | 6 | 1.45e-01 | 5.12e-01 | 1.0700 | -4.45e-01 | -4.38e-01 | -5.23e-01 | -4.10e-01 | -5.58e-01 | 5.89e-02 | 6.33e-02 | 2.64e-02 | 8.22e-02 | 1.78e-02 |
| COMMA SHAPED BODY MORPHOGENESIS | 5 | 2.01e-01 | 5.92e-01 | 1.0700 | 2.47e-01 | 4.41e-01 | 5.69e-01 | 4.30e-01 | 6.14e-01 | 3.38e-01 | 8.79e-02 | 2.76e-02 | 9.56e-02 | 1.73e-02 |
| POSITIVE REGULATION OF DOPAMINERGIC NEURON DIFFERENTIATION | 5 | 3.18e-01 | 7.29e-01 | 1.0600 | 5.01e-01 | 5.15e-01 | 4.44e-01 | 4.94e-01 | 4.14e-01 | 5.23e-02 | 4.59e-02 | 8.53e-02 | 5.55e-02 | 1.08e-01 |
| PROTEIN K27 LINKED UBIQUITINATION | 7 | 1.56e-01 | 5.28e-01 | 1.0500 | 4.61e-01 | 5.00e-01 | 4.68e-01 | 4.64e-01 | 4.65e-01 | 3.47e-02 | 2.20e-02 | 3.21e-02 | 3.36e-02 | 3.30e-02 |
| RNA IMPORT INTO MITOCHONDRION | 5 | 2.29e-01 | 6.32e-01 | 1.0500 | 4.66e-01 | 3.57e-01 | 5.66e-01 | 6.10e-01 | 2.65e-01 | 7.13e-02 | 1.67e-01 | 2.83e-02 | 1.82e-02 | 3.05e-01 |
| INTERLEUKIN 3 MEDIATED SIGNALING PATHWAY | 6 | 6.41e-02 | 3.37e-01 | 1.0500 | 6.03e-01 | 5.72e-01 | 3.91e-01 | 4.53e-01 | -2.27e-01 | 1.05e-02 | 1.52e-02 | 9.74e-02 | 5.46e-02 | 3.35e-01 |
| DETECTION OF STIMULUS INVOLVED IN SENSORY PERCEPTION | 469 | 3.87e-101 | 1.46e-97 | 1.0500 | -3.72e-01 | -4.70e-01 | -5.44e-01 | -4.76e-01 | -4.62e-01 | 1.49e-43 | 1.03e-68 | 2.10e-91 | 3.54e-70 | 2.98e-66 |
| ALKALOID METABOLIC PROCESS | 7 | 3.98e-02 | 2.57e-01 | 1.0500 | -4.90e-01 | -2.91e-01 | -5.38e-01 | -6.35e-01 | -2.78e-01 | 2.49e-02 | 1.82e-01 | 1.37e-02 | 3.61e-03 | 2.03e-01 |
| TELENCEPHALON REGIONALIZATION | 13 | 1.16e-03 | 1.97e-02 | 1.0500 | 2.04e-01 | 3.31e-01 | 6.01e-01 | 4.10e-01 | 6.42e-01 | 2.02e-01 | 3.87e-02 | 1.76e-04 | 1.04e-02 | 6.14e-05 |
| PTERIDINE CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 12 | 1.41e-02 | 1.30e-01 | 1.0400 | 5.66e-01 | 4.24e-01 | 4.26e-01 | 5.73e-01 | 2.79e-01 | 6.89e-04 | 1.10e-02 | 1.06e-02 | 5.81e-04 | 9.47e-02 |
| RESPONSE TO ACTINOMYCIN D | 5 | 3.25e-01 | 7.35e-01 | 1.0400 | 3.75e-01 | 3.96e-01 | 5.12e-01 | 5.81e-01 | 4.29e-01 | 1.46e-01 | 1.25e-01 | 4.75e-02 | 2.45e-02 | 9.68e-02 |
| EPITHELIAL CELL PROLIFERATION INVOLVED IN SALIVARY GLAND MORPHOGENESIS | 5 | 4.15e-01 | 7.98e-01 | 1.0400 | 5.17e-01 | 5.69e-01 | 4.68e-01 | 4.66e-01 | 2.32e-01 | 4.54e-02 | 2.76e-02 | 7.00e-02 | 7.11e-02 | 3.68e-01 |
| METAPHASE ANAPHASE TRANSITION OF MEIOTIC CELL CYCLE | 5 | 1.00e-01 | 4.30e-01 | 1.0400 | 2.47e-01 | 2.68e-01 | 5.96e-01 | 6.20e-01 | 4.55e-01 | 3.38e-01 | 2.99e-01 | 2.11e-02 | 1.63e-02 | 7.78e-02 |
| DETECTION OF CHEMICAL STIMULUS INVOLVED IN SENSORY PERCEPTION OF TASTE | 46 | 5.02e-08 | 2.89e-06 | 1.0400 | -4.45e-01 | -4.60e-01 | -5.21e-01 | -5.00e-01 | -3.81e-01 | 1.80e-07 | 6.60e-08 | 9.56e-10 | 4.22e-09 | 7.60e-06 |
| EMBRYONIC HEART TUBE LEFT RIGHT PATTERN FORMATION | 5 | 2.64e-01 | 6.72e-01 | 1.0400 | 2.65e-01 | 3.80e-01 | 5.42e-01 | 4.38e-01 | 6.13e-01 | 3.05e-01 | 1.41e-01 | 3.58e-02 | 8.95e-02 | 1.76e-02 |
| REGULATION OF SECONDARY HEART FIELD CARDIOBLAST PROLIFERATION | 9 | 5.69e-02 | 3.15e-01 | 1.0400 | 3.56e-01 | 4.62e-01 | 4.89e-01 | 5.20e-01 | 4.75e-01 | 6.45e-02 | 1.63e-02 | 1.11e-02 | 6.87e-03 | 1.36e-02 |
| MEIOTIC ATTACHMENT OF TELOMERE TO NUCLEAR ENVELOPE | 5 | 1.78e-01 | 5.63e-01 | 1.0300 | -3.99e-01 | -3.91e-01 | -5.12e-01 | -3.53e-01 | -6.02e-01 | 1.23e-01 | 1.30e-01 | 4.74e-02 | 1.72e-01 | 1.98e-02 |
| NEGATIVE REGULATION OF INTERFERON ALPHA PRODUCTION | 6 | 1.37e-01 | 5.00e-01 | 1.0300 | 6.37e-01 | 5.35e-01 | 3.45e-01 | 4.93e-01 | -6.92e-02 | 6.92e-03 | 2.33e-02 | 1.43e-01 | 3.64e-02 | 7.69e-01 |
| DETECTION OF VIRUS | 6 | 3.07e-01 | 7.19e-01 | 1.0300 | 5.07e-01 | 5.31e-01 | 4.56e-01 | 5.31e-01 | 1.70e-01 | 3.16e-02 | 2.43e-02 | 5.32e-02 | 2.42e-02 | 4.71e-01 |
| FATTY ACYL COA CATABOLIC PROCESS | 5 | 4.52e-01 | 8.21e-01 | 1.0200 | 4.19e-01 | 4.15e-01 | 5.25e-01 | 5.23e-01 | 3.90e-01 | 1.05e-01 | 1.08e-01 | 4.19e-02 | 4.29e-02 | 1.31e-01 |
| URONIC ACID METABOLIC PROCESS | 26 | 1.25e-04 | 3.28e-03 | 1.0200 | -4.03e-01 | -4.94e-01 | -4.90e-01 | -4.69e-01 | -4.11e-01 | 3.71e-04 | 1.31e-05 | 1.55e-05 | 3.41e-05 | 2.87e-04 |
| PROTEIN LOCALIZATION TO CENP A CONTAINING CHROMATIN | 16 | 1.43e-03 | 2.33e-02 | 1.0200 | 3.87e-01 | 4.33e-01 | 6.06e-01 | 5.16e-01 | 2.44e-01 | 7.37e-03 | 2.68e-03 | 2.72e-05 | 3.48e-04 | 9.13e-02 |
| FARNESYL DIPHOSPHATE METABOLIC PROCESS | 6 | 2.91e-01 | 7.01e-01 | 1.0200 | 4.02e-01 | 3.77e-01 | 4.91e-01 | 5.14e-01 | 4.71e-01 | 8.85e-02 | 1.09e-01 | 3.75e-02 | 2.93e-02 | 4.55e-02 |
| TELOMERASE HOLOENZYME COMPLEX ASSEMBLY | 6 | 5.40e-02 | 3.07e-01 | 1.0100 | 4.03e-01 | 3.20e-01 | 5.52e-01 | 6.60e-01 | 1.53e-01 | 8.76e-02 | 1.74e-01 | 1.92e-02 | 5.09e-03 | 5.17e-01 |
| PROTEIN LOCALIZATION TO SITE OF DOUBLE STRAND BREAK | 6 | 1.36e-01 | 4.99e-01 | 1.0100 | 3.84e-01 | 2.97e-01 | 5.13e-01 | 6.24e-01 | 3.72e-01 | 1.03e-01 | 2.07e-01 | 2.95e-02 | 8.08e-03 | 1.15e-01 |
| DOUBLE STRAND BREAK REPAIR VIA SYNTHESIS DEPENDENT STRAND ANNEALING | 8 | 1.26e-01 | 4.82e-01 | 1.0100 | 5.86e-01 | 4.90e-01 | 3.89e-01 | 4.99e-01 | 1.85e-01 | 4.11e-03 | 1.63e-02 | 5.68e-02 | 1.45e-02 | 3.66e-01 |
| POSITIVE REGULATION OF ENAMEL MINERALIZATION | 5 | 4.14e-01 | 7.98e-01 | 1.0100 | -4.66e-01 | -3.77e-01 | -4.88e-01 | -5.43e-01 | -3.55e-01 | 7.12e-02 | 1.44e-01 | 5.90e-02 | 3.55e-02 | 1.69e-01 |
| HISTONE H3 K9 METHYLATION | 5 | 3.98e-01 | 7.86e-01 | 1.0100 | 5.78e-01 | 5.21e-01 | 4.01e-01 | 4.81e-01 | 1.31e-01 | 2.52e-02 | 4.38e-02 | 1.20e-01 | 6.26e-02 | 6.12e-01 |
| URETER MORPHOGENESIS | 7 | 4.30e-02 | 2.69e-01 | 1.0100 | 1.88e-01 | 3.07e-01 | 5.89e-01 | 3.42e-01 | 6.48e-01 | 3.89e-01 | 1.59e-01 | 6.93e-03 | 1.18e-01 | 2.97e-03 |
| FOREBRAIN REGIONALIZATION | 24 | 7.84e-05 | 2.27e-03 | 0.9980 | 2.98e-01 | 3.90e-01 | 5.59e-01 | 4.21e-01 | 5.14e-01 | 1.15e-02 | 9.40e-04 | 2.12e-06 | 3.53e-04 | 1.28e-05 |
| NEGATIVE REGULATION OF ERYTHROCYTE DIFFERENTIATION | 8 | 2.82e-02 | 2.08e-01 | 0.9910 | 3.19e-01 | 2.64e-01 | 4.54e-01 | 6.08e-01 | 4.86e-01 | 1.18e-01 | 1.96e-01 | 2.63e-02 | 2.91e-03 | 1.73e-02 |
| MONOTERPENOID METABOLIC PROCESS | 6 | 3.48e-01 | 7.50e-01 | 0.9880 | -4.45e-01 | -5.28e-01 | -4.79e-01 | -4.06e-01 | -3.26e-01 | 5.90e-02 | 2.52e-02 | 4.23e-02 | 8.51e-02 | 1.66e-01 |
| REGULATION OF MESONEPHROS DEVELOPMENT | 5 | 3.54e-02 | 2.41e-01 | 0.9870 | -5.28e-02 | 2.46e-01 | 5.92e-01 | 3.14e-01 | 6.80e-01 | 8.38e-01 | 3.41e-01 | 2.18e-02 | 2.23e-01 | 8.48e-03 |
| STRAND INVASION | 6 | 1.36e-01 | 4.98e-01 | 0.9870 | 2.71e-01 | 2.28e-01 | 5.15e-01 | 4.92e-01 | 5.84e-01 | 2.50e-01 | 3.33e-01 | 2.90e-02 | 3.67e-02 | 1.33e-02 |
| CARTILAGE MORPHOGENESIS | 10 | 1.04e-01 | 4.41e-01 | 0.9860 | 3.87e-01 | 4.81e-01 | 5.14e-01 | 4.15e-01 | 3.95e-01 | 3.41e-02 | 8.50e-03 | 4.90e-03 | 2.31e-02 | 3.04e-02 |
| POSITIVE REGULATION OF PROTEIN SUMOYLATION | 12 | 4.40e-02 | 2.72e-01 | 0.9830 | 5.18e-01 | 5.15e-01 | 4.06e-01 | 4.99e-01 | 1.39e-01 | 1.88e-03 | 2.02e-03 | 1.48e-02 | 2.74e-03 | 4.03e-01 |
| SINOATRIAL NODE DEVELOPMENT | 12 | 2.52e-02 | 1.94e-01 | 0.9820 | 2.88e-01 | 3.89e-01 | 5.53e-01 | 4.13e-01 | 5.04e-01 | 8.38e-02 | 1.97e-02 | 9.15e-04 | 1.33e-02 | 2.50e-03 |
| TRNA THREONYLCARBAMOYLADENOSINE MODIFICATION | 5 | 2.60e-01 | 6.66e-01 | 0.9810 | 3.76e-01 | 4.68e-01 | 5.18e-01 | 3.09e-01 | 4.89e-01 | 1.45e-01 | 6.97e-02 | 4.49e-02 | 2.32e-01 | 5.85e-02 |
| PROTECTION FROM NON HOMOLOGOUS END JOINING AT TELOMERE | 8 | 7.27e-02 | 3.65e-01 | 0.9800 | 4.21e-01 | 3.97e-01 | 4.23e-01 | 3.89e-01 | 5.43e-01 | 3.91e-02 | 5.17e-02 | 3.82e-02 | 5.64e-02 | 7.82e-03 |
| ETHANOL OXIDATION | 9 | 7.86e-02 | 3.80e-01 | 0.9800 | -3.02e-01 | -3.48e-01 | -5.72e-01 | -4.61e-01 | -4.57e-01 | 1.16e-01 | 7.09e-02 | 2.98e-03 | 1.67e-02 | 1.76e-02 |
| CHOLINE METABOLIC PROCESS | 6 | 3.81e-01 | 7.78e-01 | 0.9760 | -4.06e-01 | -4.17e-01 | -4.61e-01 | -5.08e-01 | -3.79e-01 | 8.49e-02 | 7.70e-02 | 5.05e-02 | 3.13e-02 | 1.08e-01 |
| TRYPTOPHAN CATABOLIC PROCESS TO KYNURENINE | 5 | 4.14e-01 | 7.98e-01 | 0.9740 | -3.01e-01 | -3.97e-01 | -5.18e-01 | -4.95e-01 | -4.32e-01 | 2.44e-01 | 1.24e-01 | 4.50e-02 | 5.50e-02 | 9.44e-02 |
| PROTEIN UNFOLDING | 5 | 2.40e-01 | 6.44e-01 | 0.9710 | 2.68e-01 | 4.47e-01 | 6.19e-01 | 4.15e-01 | 3.42e-01 | 3.00e-01 | 8.37e-02 | 1.64e-02 | 1.08e-01 | 1.86e-01 |
| INTRACELLULAR SPHINGOLIPID HOMEOSTASIS | 5 | 4.39e-01 | 8.11e-01 | 0.9700 | 4.49e-01 | 4.99e-01 | 4.09e-01 | 4.78e-01 | 3.09e-01 | 8.22e-02 | 5.35e-02 | 1.13e-01 | 6.42e-02 | 2.32e-01 |
| CEREBELLAR PURKINJE CELL GRANULE CELL PRECURSOR CELL SIGNALING INVOLVED IN REGULATION OF GRANULE CELL PRECURSOR CELL PROLIFERATION | 5 | 2.59e-01 | 6.66e-01 | 0.9690 | 2.35e-01 | 3.19e-01 | 5.47e-01 | 3.58e-01 | 5.95e-01 | 3.62e-01 | 2.16e-01 | 3.41e-02 | 1.66e-01 | 2.11e-02 |
| POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 7 | 1.60e-01 | 5.36e-01 | 0.9660 | 4.98e-01 | 3.88e-01 | 4.49e-01 | 5.70e-01 | 8.57e-02 | 2.24e-02 | 7.51e-02 | 3.95e-02 | 8.99e-03 | 6.95e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION BY GLUCOSE | 6 | 1.28e-01 | 4.86e-01 | 0.9660 | 1.88e-01 | 4.31e-01 | 4.96e-01 | 3.64e-01 | 5.77e-01 | 4.24e-01 | 6.75e-02 | 3.53e-02 | 1.22e-01 | 1.44e-02 |
| REGULATION OF TRANSLATIONAL TERMINATION | 8 | 2.08e-01 | 6.03e-01 | 0.9650 | 4.44e-01 | 4.03e-01 | 5.03e-01 | 4.45e-01 | 3.49e-01 | 2.96e-02 | 4.86e-02 | 1.38e-02 | 2.93e-02 | 8.74e-02 |
| REGULATION OF MESODERM DEVELOPMENT | 6 | 7.24e-02 | 3.65e-01 | 0.9610 | -5.55e-01 | -6.03e-01 | -2.60e-01 | -4.03e-01 | 1.51e-01 | 1.86e-02 | 1.06e-02 | 2.70e-01 | 8.77e-02 | 5.21e-01 |
| POSITIVE REGULATION OF TAU PROTEIN KINASE ACTIVITY | 8 | 2.34e-01 | 6.36e-01 | 0.9560 | 4.33e-01 | 5.00e-01 | 4.45e-01 | 4.15e-01 | 3.26e-01 | 3.41e-02 | 1.42e-02 | 2.92e-02 | 4.20e-02 | 1.11e-01 |
| MITOCHONDRIAL RIBOSOME ASSEMBLY | 10 | 5.60e-02 | 3.13e-01 | 0.9560 | 4.50e-01 | 4.22e-01 | 4.54e-01 | 3.69e-01 | 4.38e-01 | 1.38e-02 | 2.07e-02 | 1.30e-02 | 4.34e-02 | 1.65e-02 |
| CELLULAR RESPONSE TO UV C | 5 | 4.32e-01 | 8.07e-01 | 0.9550 | 4.71e-01 | 4.67e-01 | 4.07e-01 | 5.38e-01 | 1.36e-01 | 6.84e-02 | 7.08e-02 | 1.15e-01 | 3.74e-02 | 5.98e-01 |
| REGULATION OF PRIMARY MIRNA PROCESSING | 5 | 1.76e-01 | 5.62e-01 | 0.9540 | 1.92e-01 | 4.87e-01 | 5.31e-01 | 4.26e-01 | 4.15e-01 | 4.56e-01 | 5.91e-02 | 3.98e-02 | 9.88e-02 | 1.08e-01 |
| EMBRYONIC PROCESS INVOLVED IN FEMALE PREGNANCY | 6 | 9.93e-02 | 4.28e-01 | 0.9530 | 1.27e-01 | 2.69e-01 | 5.06e-01 | 3.03e-01 | 6.87e-01 | 5.90e-01 | 2.53e-01 | 3.19e-02 | 1.99e-01 | 3.57e-03 |
| NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OSMOTIC STRESS | 5 | 3.87e-01 | 7.80e-01 | 0.9510 | 4.71e-01 | 5.78e-01 | 4.25e-01 | 4.05e-01 | 7.32e-02 | 6.83e-02 | 2.53e-02 | 1.00e-01 | 1.17e-01 | 7.77e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO HYPOXIA | 9 | 1.86e-01 | 5.72e-01 | 0.9490 | 4.89e-01 | 4.63e-01 | 4.58e-01 | 4.20e-01 | 2.46e-01 | 1.11e-02 | 1.62e-02 | 1.72e-02 | 2.90e-02 | 2.02e-01 |
| DETECTION OF MUSCLE STRETCH | 7 | 3.17e-01 | 7.27e-01 | 0.9450 | -4.26e-01 | -4.87e-01 | -4.58e-01 | -4.85e-01 | -1.74e-01 | 5.08e-02 | 2.57e-02 | 3.57e-02 | 2.64e-02 | 4.25e-01 |
| FOLIC ACID CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 7 | 1.32e-01 | 4.92e-01 | 0.9440 | 5.80e-01 | 3.81e-01 | 3.49e-01 | 5.32e-01 | 6.19e-02 | 7.83e-03 | 8.07e-02 | 1.09e-01 | 1.47e-02 | 7.77e-01 |
| AMACRINE CELL DIFFERENTIATION | 12 | 1.42e-02 | 1.31e-01 | 0.9430 | 2.58e-01 | 4.95e-01 | 5.02e-01 | 3.96e-01 | 4.11e-01 | 1.22e-01 | 2.98e-03 | 2.60e-03 | 1.74e-02 | 1.36e-02 |
| NEGATIVE REGULATION OF LAMELLIPODIUM ASSEMBLY | 5 | 2.99e-01 | 7.11e-01 | 0.9400 | -5.14e-01 | -5.98e-01 | -3.69e-01 | -3.34e-01 | -1.20e-01 | 4.65e-02 | 2.06e-02 | 1.53e-01 | 1.96e-01 | 6.43e-01 |
| MELANOCYTE PROLIFERATION | 5 | 4.81e-01 | 8.35e-01 | 0.9400 | -4.38e-01 | -4.93e-01 | -4.41e-01 | -3.70e-01 | -3.42e-01 | 8.97e-02 | 5.62e-02 | 8.77e-02 | 1.52e-01 | 1.86e-01 |
| POST EMBRYONIC CAMERA TYPE EYE DEVELOPMENT | 8 | 8.64e-02 | 3.98e-01 | 0.9370 | 5.02e-01 | 4.19e-01 | 4.19e-01 | 3.54e-01 | 3.88e-01 | 1.40e-02 | 4.01e-02 | 4.02e-02 | 8.26e-02 | 5.76e-02 |
| TYPE II HYPERSENSITIVITY | 5 | 1.02e-01 | 4.34e-01 | 0.9360 | -6.14e-01 | -4.38e-01 | -1.74e-01 | -4.37e-01 | 2.91e-01 | 1.73e-02 | 9.00e-02 | 5.00e-01 | 9.04e-02 | 2.60e-01 |
| MRNA 3 SPLICE SITE RECOGNITION | 6 | 2.06e-01 | 5.99e-01 | 0.9350 | 2.61e-01 | 2.99e-01 | 5.70e-01 | 4.12e-01 | 4.70e-01 | 2.69e-01 | 2.05e-01 | 1.56e-02 | 8.03e-02 | 4.61e-02 |
| SPINAL CORD ASSOCIATION NEURON DIFFERENTIATION | 12 | 1.43e-02 | 1.31e-01 | 0.9340 | 2.87e-01 | 2.74e-01 | 4.80e-01 | 3.79e-01 | 5.83e-01 | 8.53e-02 | 1.00e-01 | 3.95e-03 | 2.31e-02 | 4.68e-04 |
| REGULATION OF MALE GONAD DEVELOPMENT | 8 | 2.66e-01 | 6.73e-01 | 0.9330 | 4.85e-01 | 4.39e-01 | 4.45e-01 | 4.26e-01 | 2.52e-01 | 1.76e-02 | 3.14e-02 | 2.92e-02 | 3.70e-02 | 2.17e-01 |
| POSITIVE REGULATION OF GASTRO INTESTINAL SYSTEM SMOOTH MUSCLE CONTRACTION | 5 | 1.06e-01 | 4.46e-01 | 0.9330 | 4.43e-01 | 5.98e-01 | 3.46e-01 | 2.45e-01 | 3.69e-01 | 8.62e-02 | 2.05e-02 | 1.80e-01 | 3.44e-01 | 1.53e-01 |
| CELLULAR RESPONSE TO OXYGEN GLUCOSE DEPRIVATION | 5 | 5.09e-01 | 8.53e-01 | 0.9330 | 3.68e-01 | 3.60e-01 | 4.64e-01 | 5.14e-01 | 3.54e-01 | 1.54e-01 | 1.63e-01 | 7.26e-02 | 4.63e-02 | 1.71e-01 |
| MITOCHONDRIAL ELECTRON TRANSPORT UBIQUINOL TO CYTOCHROME C | 12 | 5.70e-02 | 3.16e-01 | 0.9320 | 4.44e-01 | 3.98e-01 | 3.92e-01 | 4.97e-01 | 3.35e-01 | 7.69e-03 | 1.70e-02 | 1.88e-02 | 2.86e-03 | 4.45e-02 |
| REGULATION OF CYTOCHROME C OXIDASE ACTIVITY | 5 | 1.28e-01 | 4.85e-01 | 0.9320 | 4.33e-01 | 2.45e-01 | 5.52e-01 | 4.75e-01 | 3.01e-01 | 9.36e-02 | 3.42e-01 | 3.27e-02 | 6.60e-02 | 2.44e-01 |
| POSITIVE REGULATION OF NUCLEASE ACTIVITY | 7 | 2.13e-01 | 6.08e-01 | 0.9310 | 2.93e-01 | 4.06e-01 | 4.43e-01 | 3.95e-01 | 5.13e-01 | 1.80e-01 | 6.30e-02 | 4.23e-02 | 7.02e-02 | 1.87e-02 |
| PURKINJE MYOCYTE TO VENTRICULAR CARDIAC MUSCLE CELL COMMUNICATION | 6 | 1.78e-01 | 5.63e-01 | 0.9310 | -4.12e-01 | -2.98e-01 | -3.78e-01 | -5.77e-01 | -3.63e-01 | 8.07e-02 | 2.06e-01 | 1.09e-01 | 1.44e-02 | 1.23e-01 |
| SNRNA MODIFICATION | 6 | 3.43e-01 | 7.50e-01 | 0.9300 | 4.17e-01 | 4.54e-01 | 5.15e-01 | 4.50e-01 | 1.35e-01 | 7.69e-02 | 5.42e-02 | 2.90e-02 | 5.62e-02 | 5.68e-01 |
| DNA REPLICATION DEPENDENT CHROMATIN ASSEMBLY | 6 | 1.71e-01 | 5.55e-01 | 0.9300 | 3.77e-01 | 4.51e-01 | 3.89e-01 | 5.59e-01 | 2.36e-01 | 1.10e-01 | 5.56e-02 | 9.89e-02 | 1.77e-02 | 3.17e-01 |
| RHOMBOMERE DEVELOPMENT | 8 | 2.03e-01 | 5.96e-01 | 0.9300 | 4.80e-01 | 4.91e-01 | 4.61e-01 | 3.69e-01 | 2.09e-01 | 1.88e-02 | 1.61e-02 | 2.39e-02 | 7.08e-02 | 3.06e-01 |
| DEPYRIMIDINATION | 8 | 2.71e-01 | 6.79e-01 | 0.9290 | 4.23e-01 | 3.95e-01 | 4.23e-01 | 4.81e-01 | 3.42e-01 | 3.82e-02 | 5.28e-02 | 3.81e-02 | 1.84e-02 | 9.44e-02 |
| NEGATIVE REGULATION OF DELAYED RECTIFIER POTASSIUM CHANNEL ACTIVITY | 10 | 1.07e-01 | 4.48e-01 | 0.9290 | -3.28e-01 | -4.35e-01 | -4.73e-01 | -4.91e-01 | -3.17e-01 | 7.21e-02 | 1.73e-02 | 9.55e-03 | 7.22e-03 | 8.21e-02 |
| ANDROGEN BIOSYNTHETIC PROCESS | 10 | 8.35e-02 | 3.91e-01 | 0.9280 | -4.99e-01 | -3.51e-01 | -4.33e-01 | -4.73e-01 | -2.79e-01 | 6.26e-03 | 5.46e-02 | 1.77e-02 | 9.55e-03 | 1.27e-01 |
| DOLICHYL DIPHOSPHATE METABOLIC PROCESS | 5 | 3.55e-01 | 7.55e-01 | 0.9280 | 4.86e-01 | 5.03e-01 | 3.75e-01 | 3.45e-01 | 3.35e-01 | 6.00e-02 | 5.15e-02 | 1.47e-01 | 1.81e-01 | 1.94e-01 |
| REGULATION OF DEOXYRIBONUCLEASE ACTIVITY | 10 | 1.06e-01 | 4.47e-01 | 0.9270 | 3.94e-01 | 3.58e-01 | 4.13e-01 | 4.63e-01 | 4.35e-01 | 3.09e-02 | 4.97e-02 | 2.36e-02 | 1.12e-02 | 1.72e-02 |
| REGULATION OF MITOCHONDRIAL RNA CATABOLIC PROCESS | 5 | 5.31e-01 | 8.63e-01 | 0.9260 | 5.03e-01 | 4.51e-01 | 4.13e-01 | 4.16e-01 | 2.41e-01 | 5.16e-02 | 8.06e-02 | 1.10e-01 | 1.07e-01 | 3.51e-01 |
| GROWTH PLATE CARTILAGE CHONDROCYTE DIFFERENTIATION | 10 | 1.16e-01 | 4.64e-01 | 0.9260 | 3.17e-01 | 4.12e-01 | 5.37e-01 | 4.19e-01 | 3.52e-01 | 8.29e-02 | 2.42e-02 | 3.28e-03 | 2.18e-02 | 5.39e-02 |
| POSITIVE REGULATION OF GONAD DEVELOPMENT | 8 | 2.65e-01 | 6.73e-01 | 0.9260 | 5.06e-01 | 4.30e-01 | 4.05e-01 | 4.73e-01 | 1.67e-01 | 1.31e-02 | 3.50e-02 | 4.74e-02 | 2.05e-02 | 4.13e-01 |
| PROTEIN C LINKED GLYCOSYLATION | 6 | 6.69e-02 | 3.45e-01 | 0.9240 | 5.70e-01 | 3.51e-01 | 3.02e-01 | 4.01e-01 | 3.92e-01 | 1.57e-02 | 1.37e-01 | 2.00e-01 | 8.90e-02 | 9.67e-02 |
| S SHAPED BODY MORPHOGENESIS | 7 | 2.78e-01 | 6.88e-01 | 0.9230 | 3.34e-01 | 3.67e-01 | 4.44e-01 | 4.07e-01 | 4.92e-01 | 1.26e-01 | 9.28e-02 | 4.18e-02 | 6.24e-02 | 2.41e-02 |
| REGULATION OF RETROGRADE PROTEIN TRANSPORT ER TO CYTOSOL | 12 | 5.55e-02 | 3.12e-01 | 0.9220 | 3.78e-01 | 4.25e-01 | 4.79e-01 | 3.54e-01 | 4.15e-01 | 2.34e-02 | 1.08e-02 | 4.07e-03 | 3.39e-02 | 1.28e-02 |
| CARDIAC VENTRICLE FORMATION | 8 | 2.43e-01 | 6.48e-01 | 0.9220 | 3.57e-01 | 4.16e-01 | 4.63e-01 | 3.82e-01 | 4.35e-01 | 8.01e-02 | 4.14e-02 | 2.35e-02 | 6.14e-02 | 3.32e-02 |
| PROTEIN LIPOYLATION | 5 | 7.85e-02 | 3.80e-01 | 0.9210 | 4.51e-02 | 2.61e-01 | 4.82e-01 | 4.76e-01 | 5.65e-01 | 8.61e-01 | 3.13e-01 | 6.19e-02 | 6.54e-02 | 2.86e-02 |
| POSITIVE REGULATION OF APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 6 | 1.84e-01 | 5.70e-01 | 0.9200 | 4.93e-01 | 6.01e-01 | 3.48e-01 | 3.47e-01 | -7.73e-03 | 3.66e-02 | 1.08e-02 | 1.39e-01 | 1.41e-01 | 9.74e-01 |
| POSITIVE REGULATION OF PROTEIN DEUBIQUITINATION | 5 | 2.82e-01 | 6.93e-01 | 0.9200 | 4.74e-01 | 3.07e-01 | 3.98e-01 | 4.20e-01 | 4.38e-01 | 6.66e-02 | 2.34e-01 | 1.23e-01 | 1.04e-01 | 8.96e-02 |
| GROWTH PLATE CARTILAGE CHONDROCYTE DEVELOPMENT | 5 | 3.10e-01 | 7.22e-01 | 0.9170 | 1.86e-01 | 3.95e-01 | 5.42e-01 | 3.51e-01 | 4.83e-01 | 4.71e-01 | 1.26e-01 | 3.59e-02 | 1.75e-01 | 6.16e-02 |
| TRACHEA CARTILAGE DEVELOPMENT | 7 | 3.17e-01 | 7.27e-01 | 0.9160 | 3.94e-01 | 5.02e-01 | 4.27e-01 | 3.95e-01 | 3.07e-01 | 7.12e-02 | 2.14e-02 | 5.04e-02 | 7.03e-02 | 1.60e-01 |
| NEUTROPHIL MEDIATED KILLING OF GRAM NEGATIVE BACTERIUM | 6 | 2.85e-02 | 2.09e-01 | 0.9160 | 5.81e-01 | 5.46e-01 | 1.25e-01 | 3.92e-01 | -1.86e-01 | 1.38e-02 | 2.06e-02 | 5.95e-01 | 9.64e-02 | 4.31e-01 |
| EPITHELIAL CELL PROLIFERATION INVOLVED IN PROSTATE GLAND DEVELOPMENT | 10 | 5.34e-02 | 3.06e-01 | 0.9140 | 4.25e-01 | 5.78e-01 | 4.34e-01 | 3.20e-01 | 1.75e-01 | 1.99e-02 | 1.56e-03 | 1.75e-02 | 8.00e-02 | 3.37e-01 |
| SPINDLE ASSEMBLY INVOLVED IN FEMALE MEIOSIS | 9 | 9.85e-02 | 4.27e-01 | 0.9130 | 3.44e-01 | 4.76e-01 | 4.55e-01 | 4.96e-01 | 1.85e-01 | 7.39e-02 | 1.33e-02 | 1.80e-02 | 9.96e-03 | 3.36e-01 |
| OUTER MITOCHONDRIAL MEMBRANE ORGANIZATION | 15 | 2.98e-03 | 4.15e-02 | 0.9110 | 4.10e-01 | 2.38e-01 | 4.57e-01 | 5.14e-01 | 3.63e-01 | 5.97e-03 | 1.10e-01 | 2.17e-03 | 5.64e-04 | 1.50e-02 |
| PROTEIN IMPORT INTO PEROXISOME MEMBRANE | 6 | 2.91e-01 | 7.02e-01 | 0.9100 | 2.38e-01 | 3.99e-01 | 5.42e-01 | 3.71e-01 | 4.25e-01 | 3.13e-01 | 9.07e-02 | 2.14e-02 | 1.15e-01 | 7.16e-02 |
| COPI COATED VESICLE BUDDING | 6 | 2.64e-01 | 6.72e-01 | 0.9100 | 2.34e-01 | 3.88e-01 | 5.11e-01 | 4.74e-01 | 3.70e-01 | 3.21e-01 | 1.00e-01 | 3.03e-02 | 4.45e-02 | 1.16e-01 |
| PYRIDINE CONTAINING COMPOUND CATABOLIC PROCESS | 8 | 7.53e-02 | 3.72e-01 | 0.9080 | 5.12e-01 | 5.39e-01 | 3.23e-01 | 3.80e-01 | -1.51e-01 | 1.21e-02 | 8.32e-03 | 1.13e-01 | 6.29e-02 | 4.61e-01 |
| HEAT ACCLIMATION | 5 | 2.55e-01 | 6.62e-01 | 0.9050 | 1.66e-01 | 3.16e-01 | 4.69e-01 | 2.78e-01 | 6.28e-01 | 5.20e-01 | 2.22e-01 | 6.93e-02 | 2.82e-01 | 1.50e-02 |
| L CYSTINE TRANSPORT | 6 | 4.43e-01 | 8.13e-01 | 0.9040 | -4.94e-01 | -3.93e-01 | -4.08e-01 | -4.62e-01 | -1.98e-01 | 3.62e-02 | 9.51e-02 | 8.33e-02 | 5.00e-02 | 4.01e-01 |
| FOREBRAIN DORSAL VENTRAL PATTERN FORMATION | 7 | 3.17e-01 | 7.27e-01 | 0.9010 | 2.89e-01 | 3.63e-01 | 5.09e-01 | 4.00e-01 | 4.19e-01 | 1.85e-01 | 9.59e-02 | 1.97e-02 | 6.66e-02 | 5.47e-02 |
| CEREBRAL CORTEX REGIONALIZATION | 7 | 1.22e-01 | 4.75e-01 | 0.8990 | 2.37e-01 | 3.69e-01 | 5.24e-01 | 2.74e-01 | 5.17e-01 | 2.78e-01 | 9.09e-02 | 1.65e-02 | 2.10e-01 | 1.78e-02 |
| REGULATION OF GUANYLATE CYCLASE ACTIVITY | 6 | 2.25e-01 | 6.26e-01 | 0.8990 | -5.71e-01 | -3.54e-01 | -3.25e-01 | -4.91e-01 | -1.06e-01 | 1.55e-02 | 1.33e-01 | 1.68e-01 | 3.74e-02 | 6.53e-01 |
| PERICENTRIC HETEROCHROMATIN FORMATION | 5 | 9.41e-02 | 4.16e-01 | 0.8990 | 1.25e-01 | 3.11e-01 | 5.11e-01 | 1.60e-01 | 6.40e-01 | 6.27e-01 | 2.29e-01 | 4.80e-02 | 5.37e-01 | 1.32e-02 |
| REGULATION OF PROTEIN MONOUBIQUITINATION | 6 | 3.74e-01 | 7.73e-01 | 0.8990 | 4.49e-01 | 4.43e-01 | 4.43e-01 | 4.60e-01 | 3.68e-02 | 5.69e-02 | 6.02e-02 | 6.01e-02 | 5.08e-02 | 8.76e-01 |
| COP9 SIGNALOSOME ASSEMBLY | 5 | 2.80e-01 | 6.90e-01 | 0.8980 | 3.63e-01 | 2.04e-01 | 4.63e-01 | 5.04e-01 | 4.06e-01 | 1.59e-01 | 4.29e-01 | 7.31e-02 | 5.11e-02 | 1.16e-01 |
| CHONDROCYTE DEVELOPMENT INVOLVED IN ENDOCHONDRAL BONE MORPHOGENESIS | 8 | 1.04e-01 | 4.39e-01 | 0.8920 | 2.00e-01 | 4.14e-01 | 5.10e-01 | 4.25e-01 | 3.78e-01 | 3.27e-01 | 4.25e-02 | 1.24e-02 | 3.73e-02 | 6.38e-02 |
| ASCENDING AORTA DEVELOPMENT | 5 | 3.03e-01 | 7.15e-01 | 0.8910 | 2.97e-01 | 5.11e-01 | 4.86e-01 | 2.63e-01 | 3.73e-01 | 2.49e-01 | 4.77e-02 | 5.99e-02 | 3.08e-01 | 1.49e-01 |
| RESPONSE TO INTERLEUKIN 7 | 12 | 3.75e-02 | 2.50e-01 | 0.8900 | 3.31e-01 | 2.83e-01 | 5.01e-01 | 5.00e-01 | 3.19e-01 | 4.68e-02 | 9.02e-02 | 2.68e-03 | 2.71e-03 | 5.58e-02 |
| REGULATION OF NATURAL KILLER CELL CHEMOTAXIS | 8 | 3.34e-01 | 7.40e-01 | 0.8880 | -4.19e-01 | -3.76e-01 | -4.49e-01 | -4.31e-01 | -2.90e-01 | 4.00e-02 | 6.59e-02 | 2.77e-02 | 3.47e-02 | 1.56e-01 |
| NEGATIVE REGULATION OF MIRNA PROCESSING | 9 | 1.43e-01 | 5.09e-01 | 0.8880 | 2.81e-01 | 4.07e-01 | 5.32e-01 | 3.68e-01 | 3.56e-01 | 1.45e-01 | 3.47e-02 | 5.74e-03 | 5.62e-02 | 6.48e-02 |
| NEGATIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 7 | 1.43e-01 | 5.09e-01 | 0.8870 | 4.91e-01 | 4.70e-01 | 2.94e-01 | 4.84e-01 | -6.55e-02 | 2.44e-02 | 3.13e-02 | 1.78e-01 | 2.66e-02 | 7.64e-01 |
| POSITIVE REGULATION OF INTERFERON BETA PRODUCTION | 37 | 2.16e-05 | 7.57e-04 | 0.8860 | 4.79e-01 | 4.29e-01 | 3.54e-01 | 4.68e-01 | 1.64e-01 | 4.58e-07 | 6.16e-06 | 1.93e-04 | 8.25e-07 | 8.49e-02 |
| DETECTION OF STIMULUS | 589 | 3.87e-88 | 7.28e-85 | 0.8860 | -3.25e-01 | -3.98e-01 | -4.62e-01 | -4.05e-01 | -3.80e-01 | 1.63e-41 | 1.47e-61 | 2.41e-82 | 1.08e-63 | 3.63e-56 |
| CALCIUM ACTIVATED PHOSPHOLIPID SCRAMBLING | 5 | 5.76e-01 | 8.84e-01 | 0.8820 | -4.21e-01 | -3.66e-01 | -4.21e-01 | -5.01e-01 | -1.94e-01 | 1.03e-01 | 1.56e-01 | 1.03e-01 | 5.26e-02 | 4.52e-01 |
| NEGATIVE REGULATION OF PROTEIN EXIT FROM ENDOPLASMIC RETICULUM | 10 | 4.32e-02 | 2.70e-01 | 0.8810 | 2.87e-01 | 3.06e-01 | 5.16e-01 | 3.20e-01 | 4.81e-01 | 1.16e-01 | 9.40e-02 | 4.68e-03 | 7.98e-02 | 8.40e-03 |
| MEMBRANE DEPOLARIZATION DURING SA NODE CELL ACTION POTENTIAL | 5 | 1.87e-01 | 5.72e-01 | 0.8810 | -5.52e-01 | -3.90e-01 | -2.15e-01 | -5.13e-01 | -9.82e-02 | 3.25e-02 | 1.31e-01 | 4.05e-01 | 4.70e-02 | 7.04e-01 |
| NEGATIVE REGULATION OF CGMP MEDIATED SIGNALING | 6 | 3.59e-01 | 7.58e-01 | 0.8800 | -4.71e-01 | -3.80e-01 | -3.68e-01 | -5.18e-01 | -6.97e-02 | 4.55e-02 | 1.07e-01 | 1.18e-01 | 2.80e-02 | 7.67e-01 |
| INTERMEDIATE FILAMENT BUNDLE ASSEMBLY | 8 | 1.15e-01 | 4.62e-01 | 0.8800 | 4.65e-01 | 2.87e-01 | 4.52e-01 | 4.55e-01 | 2.54e-01 | 2.27e-02 | 1.59e-01 | 2.70e-02 | 2.57e-02 | 2.13e-01 |
| ISOCITRATE METABOLIC PROCESS | 5 | 3.22e-01 | 7.32e-01 | 0.8790 | 2.49e-01 | 4.41e-01 | 4.18e-01 | 4.40e-01 | 3.86e-01 | 3.35e-01 | 8.77e-02 | 1.06e-01 | 8.86e-02 | 1.35e-01 |
| REGULATION OF BRANCHING INVOLVED IN LUNG MORPHOGENESIS | 6 | 5.56e-01 | 8.77e-01 | 0.8780 | 3.76e-01 | 4.02e-01 | 4.37e-01 | 4.17e-01 | 3.22e-01 | 1.11e-01 | 8.81e-02 | 6.36e-02 | 7.71e-02 | 1.72e-01 |
| REGULATION OF PHOSPHOLIPID CATABOLIC PROCESS | 7 | 1.23e-01 | 4.78e-01 | 0.8770 | 4.43e-01 | 4.96e-01 | 4.42e-01 | 3.51e-01 | -8.46e-02 | 4.23e-02 | 2.29e-02 | 4.30e-02 | 1.07e-01 | 6.98e-01 |
| POSITIVE REGULATION OF MITOTIC SISTER CHROMATID SEGREGATION | 6 | 1.54e-01 | 5.25e-01 | 0.8770 | 3.00e-01 | 5.01e-01 | 4.85e-01 | 4.35e-01 | 5.08e-02 | 2.03e-01 | 3.35e-02 | 3.96e-02 | 6.50e-02 | 8.29e-01 |
| MODULATION OF MICROTUBULE CYTOSKELETON INVOLVED IN CEREBRAL CORTEX RADIAL GLIA GUIDED MIGRATION | 5 | 5.43e-01 | 8.69e-01 | 0.8760 | -4.34e-01 | -3.86e-01 | -3.56e-01 | -4.65e-01 | -2.97e-01 | 9.32e-02 | 1.35e-01 | 1.68e-01 | 7.17e-02 | 2.50e-01 |
| GABAERGIC NEURON DIFFERENTIATION | 19 | 3.74e-03 | 4.98e-02 | 0.8740 | 2.28e-01 | 4.00e-01 | 4.81e-01 | 3.59e-01 | 4.38e-01 | 8.47e-02 | 2.52e-03 | 2.81e-04 | 6.79e-03 | 9.60e-04 |
| REGULATION OF FOREBRAIN NEURON DIFFERENTIATION | 5 | 4.15e-01 | 7.98e-01 | 0.8740 | 2.25e-01 | 4.16e-01 | 4.49e-01 | 3.51e-01 | 4.63e-01 | 3.84e-01 | 1.07e-01 | 8.22e-02 | 1.74e-01 | 7.27e-02 |
| CEREBRAL CORTEX GABAERGIC INTERNEURON DEVELOPMENT | 6 | 2.76e-01 | 6.85e-01 | 0.8730 | 1.84e-01 | 3.42e-01 | 4.74e-01 | 3.11e-01 | 5.38e-01 | 4.34e-01 | 1.46e-01 | 4.42e-02 | 1.87e-01 | 2.26e-02 |
| PROTEIN DENEDDYLATION | 11 | 1.73e-02 | 1.51e-01 | 0.8730 | 3.63e-01 | 3.23e-01 | 3.11e-01 | 4.54e-01 | 4.72e-01 | 3.69e-02 | 6.35e-02 | 7.44e-02 | 9.15e-03 | 6.73e-03 |
| NEGATIVE REGULATION OF POST TRANSCRIPTIONAL GENE SILENCING | 12 | 1.42e-01 | 5.08e-01 | 0.8730 | 3.29e-01 | 3.94e-01 | 4.60e-01 | 3.96e-01 | 3.59e-01 | 4.86e-02 | 1.80e-02 | 5.76e-03 | 1.75e-02 | 3.13e-02 |
| REGULATION OF ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS | 5 | 3.58e-01 | 7.57e-01 | 0.8720 | 5.10e-01 | 3.46e-01 | 4.11e-01 | 4.59e-01 | 2.29e-02 | 4.83e-02 | 1.80e-01 | 1.12e-01 | 7.54e-02 | 9.29e-01 |
| BUD ELONGATION INVOLVED IN LUNG BRANCHING | 7 | 1.96e-01 | 5.84e-01 | 0.8700 | 1.99e-01 | 3.78e-01 | 4.35e-01 | 3.72e-01 | 4.96e-01 | 3.61e-01 | 8.32e-02 | 4.60e-02 | 8.85e-02 | 2.31e-02 |
| MAST CELL CYTOKINE PRODUCTION | 6 | 2.09e-01 | 6.03e-01 | 0.8700 | 5.39e-01 | 4.75e-01 | 2.36e-01 | 4.28e-01 | 4.29e-02 | 2.23e-02 | 4.38e-02 | 3.17e-01 | 6.98e-02 | 8.56e-01 |
| NEGATIVE REGULATION OF OSTEOCLAST DEVELOPMENT | 5 | 5.66e-01 | 8.81e-01 | 0.8700 | -4.19e-01 | -3.96e-01 | -3.61e-01 | -4.72e-01 | -2.67e-01 | 1.05e-01 | 1.26e-01 | 1.62e-01 | 6.76e-02 | 3.01e-01 |
| NEGATIVE REGULATION OF HYPOXIA INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 6 | 3.71e-01 | 7.71e-01 | 0.8690 | 5.02e-01 | 4.25e-01 | 3.90e-01 | 3.52e-01 | 2.15e-01 | 3.32e-02 | 7.16e-02 | 9.78e-02 | 1.35e-01 | 3.62e-01 |
| NEGATIVE REGULATION OF CERAMIDE BIOSYNTHETIC PROCESS | 5 | 2.98e-01 | 7.10e-01 | 0.8640 | 1.45e-01 | 1.85e-01 | 4.33e-01 | 3.60e-01 | 6.13e-01 | 5.75e-01 | 4.73e-01 | 9.39e-02 | 1.64e-01 | 1.77e-02 |
| ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS | 24 | 2.08e-03 | 3.15e-02 | 0.8640 | 4.48e-01 | 3.42e-01 | 4.23e-01 | 4.64e-01 | 1.85e-01 | 1.43e-04 | 3.74e-03 | 3.33e-04 | 8.40e-05 | 1.17e-01 |
| POSITIVE REGULATION OF HIGH DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 7 | 8.79e-02 | 4.00e-01 | 0.8630 | -1.65e-01 | -1.53e-01 | -4.64e-01 | -3.26e-01 | -6.10e-01 | 4.51e-01 | 4.84e-01 | 3.35e-02 | 1.35e-01 | 5.17e-03 |
| URETER DEVELOPMENT | 18 | 3.88e-03 | 5.11e-02 | 0.8630 | 2.24e-01 | 2.93e-01 | 5.03e-01 | 3.51e-01 | 4.81e-01 | 9.94e-02 | 3.14e-02 | 2.17e-04 | 9.99e-03 | 4.09e-04 |
| CELLULAR RESPONSE TO HISTAMINE | 7 | 9.23e-02 | 4.13e-01 | 0.8620 | 4.95e-01 | 4.66e-01 | 2.34e-01 | 4.40e-01 | -1.81e-01 | 2.33e-02 | 3.27e-02 | 2.84e-01 | 4.40e-02 | 4.07e-01 |
| MESENCHYMAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 6 | 3.02e-01 | 7.14e-01 | 0.8620 | 3.06e-01 | 3.46e-01 | 3.76e-01 | 4.96e-01 | 3.76e-01 | 1.94e-01 | 1.42e-01 | 1.10e-01 | 3.53e-02 | 1.10e-01 |
| POSITIVE REGULATION OF CHONDROCYTE PROLIFERATION | 8 | 2.27e-01 | 6.28e-01 | 0.8620 | 2.36e-01 | 3.85e-01 | 4.77e-01 | 3.44e-01 | 4.39e-01 | 2.48e-01 | 5.93e-02 | 1.94e-02 | 9.23e-02 | 3.16e-02 |
| PROTECTION FROM NATURAL KILLER CELL MEDIATED CYTOTOXICITY | 6 | 9.28e-04 | 1.65e-02 | 0.8620 | -4.85e-01 | -2.59e-01 | 2.72e-01 | 1.17e-01 | 5.94e-01 | 3.97e-02 | 2.72e-01 | 2.48e-01 | 6.21e-01 | 1.18e-02 |
| RESPONSE TO IRON II ION | 6 | 9.81e-02 | 4.26e-01 | 0.8620 | 5.23e-01 | 3.76e-01 | 4.39e-01 | 2.96e-01 | 2.18e-01 | 2.66e-02 | 1.11e-01 | 6.27e-02 | 2.09e-01 | 3.55e-01 |
| POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 8 | 1.04e-01 | 4.41e-01 | 0.8600 | 1.93e-01 | 3.65e-01 | 5.20e-01 | 4.47e-01 | 3.16e-01 | 3.44e-01 | 7.41e-02 | 1.09e-02 | 2.85e-02 | 1.21e-01 |
| TAIL ANCHORED MEMBRANE PROTEIN INSERTION INTO ER MEMBRANE | 15 | 7.91e-02 | 3.82e-01 | 0.8590 | 4.18e-01 | 3.79e-01 | 4.31e-01 | 4.32e-01 | 2.19e-01 | 5.07e-03 | 1.11e-02 | 3.85e-03 | 3.74e-03 | 1.42e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 6 MEDIATED SIGNALING PATHWAY | 8 | 2.50e-01 | 6.57e-01 | 0.8570 | -3.69e-01 | -3.22e-01 | -3.90e-01 | -3.90e-01 | -4.37e-01 | 7.11e-02 | 1.15e-01 | 5.59e-02 | 5.58e-02 | 3.23e-02 |
| POSITIVE REGULATION OF DNA LIGATION | 5 | 2.89e-01 | 6.98e-01 | 0.8560 | 1.24e-01 | 2.05e-01 | 4.27e-01 | 3.01e-01 | 6.34e-01 | 6.30e-01 | 4.28e-01 | 9.86e-02 | 2.43e-01 | 1.41e-02 |
| GDP MANNOSE METABOLIC PROCESS | 7 | 8.64e-02 | 3.98e-01 | 0.8540 | 2.39e-01 | 1.19e-01 | 4.17e-01 | 4.35e-01 | 5.43e-01 | 2.73e-01 | 5.87e-01 | 5.61e-02 | 4.62e-02 | 1.28e-02 |
| REGULATION OF RRNA PROCESSING | 16 | 7.05e-02 | 3.59e-01 | 0.8520 | 3.55e-01 | 3.69e-01 | 4.20e-01 | 4.18e-01 | 3.36e-01 | 1.39e-02 | 1.06e-02 | 3.61e-03 | 3.82e-03 | 2.01e-02 |
| POSITIVE REGULATION OF NUCLEAR CELL CYCLE DNA REPLICATION | 5 | 6.74e-01 | 9.28e-01 | 0.8520 | 3.54e-01 | 3.81e-01 | 4.18e-01 | 4.27e-01 | 3.14e-01 | 1.70e-01 | 1.41e-01 | 1.06e-01 | 9.82e-02 | 2.24e-01 |
| RRNA BASE METHYLATION | 9 | 8.97e-02 | 4.06e-01 | 0.8520 | 3.92e-01 | 2.65e-01 | 4.79e-01 | 4.66e-01 | 2.33e-01 | 4.17e-02 | 1.69e-01 | 1.27e-02 | 1.55e-02 | 2.25e-01 |
| CILIARY NEUROTROPHIC FACTOR MEDIATED SIGNALING PATHWAY | 5 | 4.74e-01 | 8.31e-01 | 0.8500 | -4.68e-01 | -4.94e-01 | -3.84e-01 | -2.97e-01 | -1.52e-01 | 7.00e-02 | 5.56e-02 | 1.37e-01 | 2.50e-01 | 5.56e-01 |
| PONS DEVELOPMENT | 11 | 1.48e-01 | 5.15e-01 | 0.8500 | 3.99e-01 | 3.36e-01 | 4.42e-01 | 3.99e-01 | 3.09e-01 | 2.18e-02 | 5.38e-02 | 1.11e-02 | 2.21e-02 | 7.64e-02 |
| MITOCHONDRIAL CYTOCHROME C OXIDASE ASSEMBLY | 25 | 1.68e-03 | 2.65e-02 | 0.8500 | 3.31e-01 | 2.82e-01 | 4.26e-01 | 4.49e-01 | 3.87e-01 | 4.19e-03 | 1.47e-02 | 2.25e-04 | 1.02e-04 | 8.16e-04 |
| REGULATION OF CHAPERONE MEDIATED AUTOPHAGY | 8 | 7.44e-02 | 3.69e-01 | 0.8490 | 7.37e-02 | 2.41e-01 | 4.72e-01 | 3.10e-01 | 5.81e-01 | 7.18e-01 | 2.39e-01 | 2.08e-02 | 1.29e-01 | 4.40e-03 |
| NEGATIVE REGULATION OF UBIQUITIN PROTEIN LIGASE ACTIVITY | 9 | 8.20e-02 | 3.87e-01 | 0.8480 | 1.57e-01 | 2.28e-01 | 4.72e-01 | 4.28e-01 | 4.85e-01 | 4.14e-01 | 2.36e-01 | 1.42e-02 | 2.62e-02 | 1.17e-02 |
| NEGATIVE REGULATION OF AMINE METABOLIC PROCESS | 6 | 1.33e-01 | 4.93e-01 | 0.8480 | -5.73e-01 | -3.83e-01 | -1.80e-01 | -4.29e-01 | 1.64e-01 | 1.50e-02 | 1.04e-01 | 4.45e-01 | 6.89e-02 | 4.87e-01 |
| KERATINOCYTE APOPTOTIC PROCESS | 7 | 1.48e-01 | 5.15e-01 | 0.8470 | 4.09e-01 | 5.09e-01 | 3.24e-01 | 2.82e-01 | 3.29e-01 | 6.11e-02 | 1.97e-02 | 1.38e-01 | 1.96e-01 | 1.32e-01 |
| URATE TRANSPORT | 11 | 1.10e-01 | 4.54e-01 | 0.8470 | -2.27e-01 | -3.57e-01 | -4.76e-01 | -3.88e-01 | -4.01e-01 | 1.93e-01 | 4.04e-02 | 6.21e-03 | 2.58e-02 | 2.12e-02 |
| CITRATE METABOLIC PROCESS | 5 | 3.14e-01 | 7.26e-01 | 0.8430 | 5.53e-01 | 4.53e-01 | 2.21e-01 | 3.62e-01 | -1.45e-01 | 3.24e-02 | 7.94e-02 | 3.93e-01 | 1.61e-01 | 5.76e-01 |
| REGULATION OF DNA LIGATION | 6 | 3.19e-01 | 7.30e-01 | 0.8420 | 1.86e-01 | 2.73e-01 | 4.30e-01 | 3.22e-01 | 5.57e-01 | 4.30e-01 | 2.47e-01 | 6.81e-02 | 1.71e-01 | 1.81e-02 |
| POSITIVE REGULATION OF B CELL RECEPTOR SIGNALING PATHWAY | 10 | 7.92e-02 | 3.82e-01 | 0.8410 | 4.47e-01 | 3.70e-01 | 4.28e-01 | 4.33e-01 | -8.19e-03 | 1.44e-02 | 4.26e-02 | 1.91e-02 | 1.76e-02 | 9.64e-01 |
| GALACTOLIPID BIOSYNTHETIC PROCESS | 6 | 2.20e-01 | 6.17e-01 | 0.8410 | -4.09e-01 | -3.09e-01 | -2.87e-01 | -4.24e-01 | -4.26e-01 | 8.29e-02 | 1.90e-01 | 2.24e-01 | 7.19e-02 | 7.06e-02 |
| REGULATION OF XENOBIOTIC DETOXIFICATION BY TRANSMEMBRANE EXPORT ACROSS THE PLASMA MEMBRANE | 12 | 1.29e-01 | 4.87e-01 | 0.8400 | -4.33e-01 | -4.57e-01 | -3.45e-01 | -4.14e-01 | -1.35e-01 | 9.36e-03 | 6.08e-03 | 3.83e-02 | 1.29e-02 | 4.19e-01 |
| APOPTOTIC PROCESS INVOLVED IN BLOOD VESSEL MORPHOGENESIS | 5 | 4.39e-01 | 8.11e-01 | 0.8400 | 4.72e-01 | 4.54e-01 | 2.74e-01 | 4.10e-01 | 1.83e-01 | 6.78e-02 | 7.86e-02 | 2.88e-01 | 1.13e-01 | 4.79e-01 |
| POSITIVE REGULATION OF APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS | 5 | 3.14e-01 | 7.26e-01 | 0.8400 | 4.28e-01 | 5.68e-01 | 2.99e-01 | 3.28e-01 | 4.68e-02 | 9.74e-02 | 2.79e-02 | 2.47e-01 | 2.04e-01 | 8.56e-01 |
| POSITIVE REGULATION OF BASEMENT MEMBRANE ASSEMBLY INVOLVED IN EMBRYONIC BODY MORPHOGENESIS | 5 | 5.63e-01 | 8.79e-01 | 0.8380 | -2.50e-01 | -3.59e-01 | -4.92e-01 | -3.90e-01 | -3.42e-01 | 3.33e-01 | 1.65e-01 | 5.66e-02 | 1.31e-01 | 1.85e-01 |
| REGULATION OF RIBONUCLEASE ACTIVITY | 9 | 2.08e-01 | 6.03e-01 | 0.8380 | 3.69e-01 | 4.37e-01 | 4.73e-01 | 3.36e-01 | 1.92e-01 | 5.55e-02 | 2.30e-02 | 1.39e-02 | 8.07e-02 | 3.17e-01 |
| DNA UNWINDING INVOLVED IN DNA REPLICATION | 21 | 7.76e-03 | 8.52e-02 | 0.8370 | 3.02e-01 | 3.36e-01 | 4.25e-01 | 3.44e-01 | 4.43e-01 | 1.65e-02 | 7.69e-03 | 7.41e-04 | 6.35e-03 | 4.36e-04 |
| RESPIRATORY CHAIN COMPLEX III ASSEMBLY | 12 | 4.23e-02 | 2.67e-01 | 0.8370 | 5.19e-01 | 4.44e-01 | 3.40e-01 | 3.14e-01 | 1.38e-01 | 1.85e-03 | 7.70e-03 | 4.14e-02 | 5.97e-02 | 4.09e-01 |
| TENDON DEVELOPMENT | 5 | 1.91e-01 | 5.78e-01 | 0.8360 | 2.99e-02 | 2.75e-01 | 4.84e-01 | 2.22e-01 | 5.83e-01 | 9.08e-01 | 2.88e-01 | 6.07e-02 | 3.91e-01 | 2.41e-02 |
| NEGATIVE REGULATION OF TRIGLYCERIDE BIOSYNTHETIC PROCESS | 5 | 3.03e-01 | 7.15e-01 | 0.8330 | -3.05e-01 | -4.04e-01 | -5.02e-01 | -2.33e-01 | -3.64e-01 | 2.38e-01 | 1.18e-01 | 5.21e-02 | 3.67e-01 | 1.58e-01 |
| FERMENTATION | 5 | 3.80e-01 | 7.78e-01 | 0.8330 | 1.96e-01 | 2.68e-01 | 4.00e-01 | 2.85e-01 | 5.85e-01 | 4.47e-01 | 3.00e-01 | 1.22e-01 | 2.70e-01 | 2.34e-02 |
| TETRAHYDROFOLATE BIOSYNTHETIC PROCESS | 5 | 4.05e-01 | 7.92e-01 | 0.8320 | 4.99e-01 | 3.27e-01 | 2.91e-01 | 4.98e-01 | 5.17e-02 | 5.31e-02 | 2.06e-01 | 2.60e-01 | 5.36e-02 | 8.41e-01 |
| NEGATIVE REGULATION OF ACTIN NUCLEATION | 9 | 6.45e-02 | 3.38e-01 | 0.8320 | 2.17e-01 | 4.60e-01 | 4.92e-01 | 3.79e-01 | 2.17e-01 | 2.59e-01 | 1.68e-02 | 1.06e-02 | 4.91e-02 | 2.60e-01 |
| PROTEIN LOCALIZATION TO CHROMOSOME CENTROMERIC REGION | 38 | 2.41e-04 | 5.45e-03 | 0.8310 | 3.53e-01 | 3.61e-01 | 4.16e-01 | 4.49e-01 | 2.47e-01 | 1.66e-04 | 1.17e-04 | 9.05e-06 | 1.65e-06 | 8.42e-03 |
| CYTOLYSIS | 7 | 2.06e-02 | 1.70e-01 | 0.8300 | 3.22e-02 | -4.66e-02 | -4.63e-01 | -3.90e-01 | -5.65e-01 | 8.83e-01 | 8.31e-01 | 3.41e-02 | 7.41e-02 | 9.59e-03 |
| NEPHRIC DUCT FORMATION | 5 | 1.71e-01 | 5.55e-01 | 0.8290 | 9.62e-02 | 2.79e-01 | 5.73e-01 | 2.87e-01 | 4.36e-01 | 7.10e-01 | 2.80e-01 | 2.64e-02 | 2.67e-01 | 9.14e-02 |
| PROTEIN K6 LINKED UBIQUITINATION | 11 | 1.92e-01 | 5.80e-01 | 0.8280 | 3.32e-01 | 3.94e-01 | 3.84e-01 | 4.18e-01 | 3.14e-01 | 5.65e-02 | 2.38e-02 | 2.76e-02 | 1.65e-02 | 7.14e-02 |
| NEGATIVE REGULATION OF ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 7 | 8.77e-02 | 4.00e-01 | 0.8270 | 1.62e-01 | 4.52e-01 | 5.03e-01 | 3.65e-01 | 2.58e-01 | 4.59e-01 | 3.83e-02 | 2.11e-02 | 9.47e-02 | 2.37e-01 |
| VIRAL BUDDING | 25 | 3.58e-03 | 4.80e-02 | 0.8260 | 4.20e-01 | 3.31e-01 | 4.16e-01 | 4.10e-01 | 2.37e-01 | 2.77e-04 | 4.15e-03 | 3.20e-04 | 3.85e-04 | 4.06e-02 |
| MITOTIC DNA REPLICATION CHECKPOINT SIGNALING | 10 | 3.90e-02 | 2.55e-01 | 0.8260 | 3.27e-01 | 3.65e-01 | 3.71e-01 | 5.40e-01 | 1.15e-01 | 7.35e-02 | 4.59e-02 | 4.22e-02 | 3.08e-03 | 5.29e-01 |
| NEGATIVE REGULATION OF VITAMIN D BIOSYNTHETIC PROCESS | 5 | 5.54e-01 | 8.76e-01 | 0.8260 | 3.48e-01 | 3.35e-01 | 3.46e-01 | 4.07e-01 | 4.05e-01 | 1.78e-01 | 1.95e-01 | 1.81e-01 | 1.15e-01 | 1.17e-01 |
| REGULATION OF RIBOSOME BIOGENESIS | 9 | 2.82e-01 | 6.93e-01 | 0.8260 | 4.47e-01 | 3.45e-01 | 3.84e-01 | 4.37e-01 | 1.58e-01 | 2.01e-02 | 7.33e-02 | 4.63e-02 | 2.32e-02 | 4.11e-01 |
| NEGATIVE REGULATION OF NOREPINEPHRINE SECRETION | 5 | 3.00e-02 | 2.17e-01 | 0.8260 | 2.16e-01 | 1.07e-01 | 5.93e-01 | 3.63e-01 | 3.74e-01 | 4.02e-01 | 6.78e-01 | 2.15e-02 | 1.60e-01 | 1.47e-01 |
| CYTOCHROME COMPLEX ASSEMBLY | 38 | 2.43e-04 | 5.45e-03 | 0.8250 | 3.75e-01 | 3.31e-01 | 4.04e-01 | 4.15e-01 | 3.10e-01 | 6.32e-05 | 4.13e-04 | 1.64e-05 | 9.66e-06 | 9.46e-04 |
| NEPHRIC DUCT MORPHOGENESIS | 10 | 2.33e-01 | 6.36e-01 | 0.8240 | 2.90e-01 | 3.16e-01 | 4.46e-01 | 3.72e-01 | 3.96e-01 | 1.13e-01 | 8.34e-02 | 1.46e-02 | 4.16e-02 | 3.00e-02 |
| MEIOTIC SPINDLE ORGANIZATION | 18 | 6.17e-03 | 7.19e-02 | 0.8220 | 2.73e-01 | 3.36e-01 | 4.25e-01 | 4.95e-01 | 2.52e-01 | 4.49e-02 | 1.36e-02 | 1.79e-03 | 2.77e-04 | 6.45e-02 |
| NEGATIVE REGULATION OF IRE1 MEDIATED UNFOLDED PROTEIN RESPONSE | 5 | 4.28e-01 | 8.05e-01 | 0.8220 | 2.25e-01 | 4.17e-01 | 4.52e-01 | 2.57e-01 | 4.25e-01 | 3.83e-01 | 1.07e-01 | 7.99e-02 | 3.19e-01 | 9.99e-02 |
| REGULATION OF MIRNA CATABOLIC PROCESS | 9 | 3.16e-01 | 7.27e-01 | 0.8200 | 3.48e-01 | 4.35e-01 | 4.34e-01 | 3.82e-01 | 1.69e-01 | 7.06e-02 | 2.40e-02 | 2.42e-02 | 4.70e-02 | 3.80e-01 |
| POSITIVE REGULATION OF APOPTOTIC CELL CLEARANCE | 8 | 1.70e-01 | 5.55e-01 | 0.8190 | -3.32e-01 | -3.00e-01 | -3.72e-01 | -5.31e-01 | -2.22e-01 | 1.04e-01 | 1.41e-01 | 6.88e-02 | 9.25e-03 | 2.76e-01 |
| AMYGDALA DEVELOPMENT | 5 | 3.71e-01 | 7.71e-01 | 0.8190 | 3.22e-01 | 3.93e-01 | 4.01e-01 | 4.98e-01 | 4.80e-02 | 2.12e-01 | 1.28e-01 | 1.20e-01 | 5.38e-02 | 8.53e-01 |
| POINTED END ACTIN FILAMENT CAPPING | 7 | 3.98e-01 | 7.86e-01 | 0.8180 | -3.15e-01 | -4.13e-01 | -4.75e-01 | -3.64e-01 | -2.03e-01 | 1.49e-01 | 5.84e-02 | 2.96e-02 | 9.57e-02 | 3.51e-01 |
| CGMP CATABOLIC PROCESS | 5 | 5.63e-01 | 8.79e-01 | 0.8180 | -4.75e-01 | -4.67e-01 | -3.13e-01 | -3.57e-01 | -1.20e-02 | 6.60e-02 | 7.08e-02 | 2.26e-01 | 1.67e-01 | 9.63e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 10 | 1.57e-01 | 5.28e-01 | 0.8170 | 2.23e-01 | 3.35e-01 | 4.80e-01 | 4.02e-01 | 3.38e-01 | 2.23e-01 | 6.66e-02 | 8.57e-03 | 2.76e-02 | 6.44e-02 |
| REGULATION OF ATRIAL CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 6 | 4.93e-04 | 1.00e-02 | 0.8170 | -4.00e-01 | 1.18e-01 | -2.53e-01 | -5.20e-01 | -4.00e-01 | 8.97e-02 | 6.15e-01 | 2.84e-01 | 2.75e-02 | 9.01e-02 |
| CONSTITUTIVE SECRETORY PATHWAY | 7 | 3.43e-01 | 7.49e-01 | 0.8160 | 2.17e-01 | 3.40e-01 | 4.88e-01 | 3.75e-01 | 3.53e-01 | 3.20e-01 | 1.19e-01 | 2.52e-02 | 8.62e-02 | 1.06e-01 |
| REGULATION OF UBIQUITIN PROTEIN LIGASE ACTIVITY | 18 | 1.29e-02 | 1.22e-01 | 0.8160 | 2.74e-01 | 2.38e-01 | 4.29e-01 | 4.35e-01 | 4.00e-01 | 4.45e-02 | 8.04e-02 | 1.62e-03 | 1.39e-03 | 3.29e-03 |
| L SERINE TRANSPORT | 7 | 3.19e-01 | 7.30e-01 | 0.8150 | 5.10e-01 | 4.23e-01 | 3.23e-01 | 3.46e-01 | 2.65e-02 | 1.94e-02 | 5.24e-02 | 1.39e-01 | 1.13e-01 | 9.03e-01 |
| REGULATION OF TRANSCRIPTION BY GLUCOSE | 8 | 1.61e-01 | 5.36e-01 | 0.8150 | 1.35e-01 | 2.51e-01 | 4.20e-01 | 3.25e-01 | 5.48e-01 | 5.10e-01 | 2.19e-01 | 3.95e-02 | 1.12e-01 | 7.24e-03 |
| REGULATION OF ODONTOGENESIS | 18 | 2.45e-02 | 1.91e-01 | 0.8140 | 2.64e-01 | 3.54e-01 | 3.97e-01 | 3.83e-01 | 4.05e-01 | 5.24e-02 | 9.38e-03 | 3.52e-03 | 4.87e-03 | 2.96e-03 |
| REGULATION OF GONAD DEVELOPMENT | 12 | 1.46e-01 | 5.13e-01 | 0.8130 | 4.55e-01 | 3.47e-01 | 3.46e-01 | 4.28e-01 | 1.76e-01 | 6.32e-03 | 3.76e-02 | 3.81e-02 | 1.02e-02 | 2.91e-01 |
| NEPHRON TUBULE FORMATION | 20 | 5.87e-03 | 6.90e-02 | 0.8130 | 2.24e-01 | 3.07e-01 | 4.50e-01 | 3.07e-01 | 4.69e-01 | 8.29e-02 | 1.74e-02 | 4.95e-04 | 1.74e-02 | 2.82e-04 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OSMOTIC STRESS | 8 | 1.62e-01 | 5.39e-01 | 0.8130 | 4.45e-01 | 5.27e-01 | 2.89e-01 | 3.04e-01 | 8.90e-02 | 2.91e-02 | 9.80e-03 | 1.57e-01 | 1.36e-01 | 6.63e-01 |
| PROTEIN PEPTIDYL PROLYL ISOMERIZATION | 19 | 6.72e-03 | 7.65e-02 | 0.8120 | 4.53e-01 | 3.39e-01 | 3.82e-01 | 4.40e-01 | 2.41e-02 | 6.36e-04 | 1.06e-02 | 3.95e-03 | 8.90e-04 | 8.56e-01 |
| CORTISOL SECRETION | 5 | 1.12e-01 | 4.56e-01 | 0.8120 | 3.47e-01 | 4.04e-01 | 2.11e-01 | 4.06e-01 | 4.08e-01 | 1.79e-01 | 1.18e-01 | 4.15e-01 | 1.16e-01 | 1.14e-01 |
| REGULATION OF CD4 POSITIVE CD25 POSITIVE ALPHA BETA REGULATORY T CELL DIFFERENTIATION | 5 | 5.61e-01 | 8.79e-01 | 0.8110 | -2.88e-01 | -3.13e-01 | -3.72e-01 | -3.44e-01 | -4.70e-01 | 2.65e-01 | 2.25e-01 | 1.50e-01 | 1.83e-01 | 6.90e-02 |
| NEGATIVE REGULATION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION | 5 | 1.86e-01 | 5.72e-01 | 0.8110 | 4.99e-01 | 1.92e-01 | 2.82e-01 | 5.22e-01 | 1.41e-01 | 5.33e-02 | 4.57e-01 | 2.75e-01 | 4.34e-02 | 5.84e-01 |
| POSITIVE REGULATION OF UBIQUITIN PROTEIN LIGASE ACTIVITY | 9 | 1.86e-01 | 5.72e-01 | 0.8100 | 3.90e-01 | 2.48e-01 | 3.86e-01 | 4.42e-01 | 3.15e-01 | 4.29e-02 | 1.98e-01 | 4.51e-02 | 2.16e-02 | 1.02e-01 |
| PURINE DEOXYRIBONUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 6 | 3.44e-01 | 7.50e-01 | 0.8100 | 4.75e-01 | 3.37e-01 | 3.91e-01 | 3.47e-01 | 2.07e-01 | 4.39e-02 | 1.52e-01 | 9.76e-02 | 1.40e-01 | 3.79e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO STRESS | 17 | 4.85e-02 | 2.89e-01 | 0.8090 | 2.73e-01 | 3.41e-01 | 4.30e-01 | 4.18e-01 | 3.24e-01 | 5.16e-02 | 1.50e-02 | 2.15e-03 | 2.81e-03 | 2.08e-02 |
| REGULATION OF HEXOKINASE ACTIVITY | 7 | 2.86e-01 | 6.94e-01 | 0.8090 | 3.17e-01 | 2.82e-01 | 4.36e-01 | 3.14e-01 | 4.30e-01 | 1.46e-01 | 1.96e-01 | 4.56e-02 | 1.50e-01 | 4.88e-02 |
| MEIOTIC SPINDLE ASSEMBLY | 12 | 4.34e-02 | 2.71e-01 | 0.8080 | 3.11e-01 | 4.07e-01 | 4.10e-01 | 4.66e-01 | 7.49e-02 | 6.18e-02 | 1.46e-02 | 1.40e-02 | 5.16e-03 | 6.53e-01 |
| REGULATION OF RNA POLYMERASE II TRANSCRIPTION PREINITIATION COMPLEX ASSEMBLY | 7 | 1.64e-01 | 5.41e-01 | 0.8080 | 3.17e-01 | 3.59e-01 | 3.58e-01 | 5.28e-01 | 1.31e-01 | 1.47e-01 | 1.00e-01 | 1.01e-01 | 1.56e-02 | 5.48e-01 |
| REGULATION OF CD8 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 8 | 2.57e-01 | 6.64e-01 | 0.8080 | 2.94e-01 | 2.72e-01 | 4.69e-01 | 4.46e-01 | 2.70e-01 | 1.50e-01 | 1.82e-01 | 2.15e-02 | 2.87e-02 | 1.87e-01 |
| POSITIVE REGULATION OF MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 6 | 1.72e-01 | 5.56e-01 | 0.8080 | 3.98e-01 | 3.84e-01 | 2.48e-01 | 5.01e-01 | 1.86e-01 | 9.18e-02 | 1.03e-01 | 2.93e-01 | 3.36e-02 | 4.31e-01 |
| ENDOSOME TO LYSOSOME TRANSPORT VIA MULTIVESICULAR BODY SORTING PATHWAY | 17 | 5.60e-02 | 3.13e-01 | 0.8080 | 3.77e-01 | 3.21e-01 | 4.22e-01 | 4.11e-01 | 2.45e-01 | 7.04e-03 | 2.20e-02 | 2.62e-03 | 3.32e-03 | 8.08e-02 |
| GALACTOSE CATABOLIC PROCESS | 5 | 4.82e-01 | 8.37e-01 | 0.8070 | 5.04e-01 | 4.27e-01 | 2.83e-01 | 3.29e-01 | 1.63e-01 | 5.09e-02 | 9.84e-02 | 2.73e-01 | 2.03e-01 | 5.27e-01 |
| NEUROENDOCRINE CELL DIFFERENTIATION | 16 | 1.85e-02 | 1.59e-01 | 0.8070 | 1.68e-01 | 2.79e-01 | 4.53e-01 | 3.58e-01 | 4.59e-01 | 2.45e-01 | 5.31e-02 | 1.69e-03 | 1.32e-02 | 1.47e-03 |
| ENDOPLASMIC RETICULUM TO CYTOSOL TRANSPORT | 27 | 6.68e-03 | 7.63e-02 | 0.8070 | 3.31e-01 | 3.59e-01 | 3.87e-01 | 4.20e-01 | 2.93e-01 | 2.92e-03 | 1.24e-03 | 4.94e-04 | 1.56e-04 | 8.40e-03 |
| PROTON MOTIVE FORCE DRIVEN ATP SYNTHESIS | 65 | 1.00e-06 | 4.72e-05 | 0.8060 | 3.76e-01 | 3.76e-01 | 4.08e-01 | 3.90e-01 | 2.22e-01 | 1.58e-07 | 1.58e-07 | 1.31e-08 | 5.19e-08 | 1.96e-03 |
| DNA REPLICATION CHECKPOINT SIGNALING | 18 | 1.25e-02 | 1.20e-01 | 0.8060 | 2.77e-01 | 3.26e-01 | 4.19e-01 | 4.78e-01 | 2.49e-01 | 4.20e-02 | 1.67e-02 | 2.10e-03 | 4.40e-04 | 6.69e-02 |
| REGULATION OF SYNAPTIC TRANSMISSION DOPAMINERGIC | 9 | 1.90e-01 | 5.78e-01 | 0.8050 | 2.84e-01 | 3.32e-01 | 4.89e-01 | 3.21e-01 | 3.40e-01 | 1.40e-01 | 8.47e-02 | 1.11e-02 | 9.50e-02 | 7.76e-02 |
| NEGATIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 6 | 1.74e-01 | 5.59e-01 | 0.8050 | 3.91e-01 | 2.48e-01 | 4.06e-01 | 5.19e-01 | 7.77e-03 | 9.68e-02 | 2.92e-01 | 8.52e-02 | 2.78e-02 | 9.74e-01 |
| CARDIAC SEPTUM CELL DIFFERENTIATION | 5 | 4.52e-01 | 8.21e-01 | 0.8050 | 3.65e-01 | 4.32e-01 | 3.01e-01 | 3.35e-01 | 3.54e-01 | 1.57e-01 | 9.42e-02 | 2.43e-01 | 1.95e-01 | 1.71e-01 |
| CELLULAR RESPONSE TO MURAMYL DIPEPTIDE | 8 | 1.09e-01 | 4.51e-01 | 0.8040 | 5.27e-01 | 4.72e-01 | 2.35e-01 | 2.79e-01 | -1.08e-01 | 9.77e-03 | 2.06e-02 | 2.50e-01 | 1.72e-01 | 5.97e-01 |
| STEM CELL FATE COMMITMENT | 10 | 6.04e-02 | 3.25e-01 | 0.8040 | 2.14e-01 | 4.26e-01 | 4.12e-01 | 2.32e-01 | 4.42e-01 | 2.42e-01 | 1.98e-02 | 2.40e-02 | 2.03e-01 | 1.56e-02 |
| REGULATION OF LIPID TRANSPORTER ACTIVITY | 6 | 3.07e-01 | 7.19e-01 | 0.8030 | -1.33e-01 | -2.16e-01 | -4.71e-01 | -3.51e-01 | -4.85e-01 | 5.73e-01 | 3.59e-01 | 4.55e-02 | 1.37e-01 | 3.97e-02 |
| POSITIVE REGULATION OF UBIQUITIN PROTEIN TRANSFERASE ACTIVITY | 19 | 1.86e-02 | 1.59e-01 | 0.8030 | 3.57e-01 | 2.68e-01 | 4.08e-01 | 4.42e-01 | 2.89e-01 | 7.04e-03 | 4.32e-02 | 2.09e-03 | 8.39e-04 | 2.93e-02 |
| REGULATION OF HOMOPHILIC CELL ADHESION | 5 | 5.21e-01 | 8.58e-01 | 0.8030 | -1.91e-01 | -3.18e-01 | -4.80e-01 | -3.86e-01 | -3.56e-01 | 4.60e-01 | 2.18e-01 | 6.29e-02 | 1.35e-01 | 1.68e-01 |
| UBIQUITIN DEPENDENT ENDOCYTOSIS | 7 | 2.49e-01 | 6.56e-01 | 0.8020 | 4.17e-01 | 4.66e-01 | 4.01e-01 | 2.46e-01 | 1.78e-01 | 5.62e-02 | 3.26e-02 | 6.65e-02 | 2.59e-01 | 4.15e-01 |
| CARDIAC CHAMBER FORMATION | 12 | 1.51e-01 | 5.20e-01 | 0.8020 | 2.94e-01 | 3.09e-01 | 4.19e-01 | 3.42e-01 | 4.10e-01 | 7.74e-02 | 6.36e-02 | 1.19e-02 | 4.01e-02 | 1.40e-02 |
| ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS BY CYTOCHROME C | 6 | 1.38e-01 | 5.01e-01 | 0.8020 | 5.52e-03 | 1.67e-01 | 3.97e-01 | 3.28e-01 | 5.91e-01 | 9.81e-01 | 4.80e-01 | 9.21e-02 | 1.64e-01 | 1.21e-02 |
| OUTER EAR MORPHOGENESIS | 7 | 7.47e-02 | 3.70e-01 | 0.8010 | 1.49e-01 | 2.41e-01 | 3.15e-01 | 4.19e-01 | 5.36e-01 | 4.96e-01 | 2.70e-01 | 1.49e-01 | 5.47e-02 | 1.41e-02 |
| RESPIRATORY CHAIN COMPLEX IV ASSEMBLY | 29 | 1.11e-03 | 1.90e-02 | 0.8010 | 3.16e-01 | 2.62e-01 | 3.99e-01 | 4.28e-01 | 3.62e-01 | 3.24e-03 | 1.47e-02 | 1.96e-04 | 6.63e-05 | 7.34e-04 |
| REGULATION OF NUCLEASE ACTIVITY | 22 | 2.27e-02 | 1.81e-01 | 0.8010 | 3.55e-01 | 3.50e-01 | 3.66e-01 | 3.94e-01 | 3.22e-01 | 3.91e-03 | 4.52e-03 | 2.93e-03 | 1.36e-03 | 9.00e-03 |
| NEGATIVE REGULATION OF TRANSCRIPTION REGULATORY REGION DNA BINDING | 11 | 1.27e-01 | 4.84e-01 | 0.8000 | 2.39e-01 | 2.57e-01 | 4.56e-01 | 3.59e-01 | 4.25e-01 | 1.71e-01 | 1.40e-01 | 8.87e-03 | 3.90e-02 | 1.46e-02 |
| LEUCINE IMPORT ACROSS PLASMA MEMBRANE | 5 | 4.16e-01 | 7.99e-01 | 0.7990 | 3.83e-01 | 5.21e-01 | 3.12e-01 | 2.84e-01 | 2.04e-01 | 1.38e-01 | 4.37e-02 | 2.27e-01 | 2.71e-01 | 4.30e-01 |
| NEGATIVE REGULATION OF MONOCYTE CHEMOTACTIC PROTEIN 1 PRODUCTION | 6 | 1.15e-01 | 4.62e-01 | 0.7990 | -5.10e-02 | -3.13e-01 | -5.30e-01 | -3.32e-01 | -3.83e-01 | 8.29e-01 | 1.85e-01 | 2.46e-02 | 1.59e-01 | 1.04e-01 |
| CARBON DIOXIDE TRANSPORT | 15 | 1.10e-01 | 4.53e-01 | 0.7980 | -4.06e-01 | -4.01e-01 | -3.90e-01 | -3.43e-01 | -2.06e-01 | 6.47e-03 | 7.22e-03 | 8.85e-03 | 2.16e-02 | 1.67e-01 |
| NEGATIVE REGULATION OF NUCLEOTIDE BIOSYNTHETIC PROCESS | 6 | 2.39e-01 | 6.42e-01 | 0.7980 | -5.41e-01 | -4.21e-01 | -2.41e-01 | -3.01e-01 | 1.36e-01 | 2.17e-02 | 7.42e-02 | 3.06e-01 | 2.01e-01 | 5.65e-01 |
| POSITIVE REGULATION OF CENTRIOLE REPLICATION | 9 | 2.66e-01 | 6.73e-01 | 0.7980 | 3.13e-01 | 3.14e-01 | 3.84e-01 | 4.72e-01 | 2.64e-01 | 1.04e-01 | 1.03e-01 | 4.62e-02 | 1.42e-02 | 1.70e-01 |
| CRANIAL SUTURE MORPHOGENESIS | 8 | 2.22e-02 | 1.79e-01 | 0.7970 | 4.46e-02 | 1.50e-01 | 5.42e-01 | 3.18e-01 | 4.64e-01 | 8.27e-01 | 4.63e-01 | 7.89e-03 | 1.20e-01 | 2.30e-02 |
| PROTEIN DE ADP RIBOSYLATION | 5 | 3.79e-01 | 7.75e-01 | 0.7940 | 4.61e-01 | 4.11e-01 | 2.68e-01 | 2.96e-01 | 3.00e-01 | 7.42e-02 | 1.12e-01 | 3.00e-01 | 2.51e-01 | 2.45e-01 |
| ANTIGEN PROCESSING AND PRESENTATION ENDOGENOUS LIPID ANTIGEN VIA MHC CLASS IB | 5 | 1.07e-02 | 1.07e-01 | 0.7930 | -2.42e-01 | -5.83e-01 | -3.32e-01 | 3.65e-02 | -3.46e-01 | 3.48e-01 | 2.41e-02 | 1.99e-01 | 8.88e-01 | 1.80e-01 |
| REGULATION OF TOOTH MINERALIZATION | 10 | 2.91e-01 | 7.03e-01 | 0.7920 | -3.64e-01 | -3.38e-01 | -3.48e-01 | -4.31e-01 | -2.70e-01 | 4.61e-02 | 6.43e-02 | 5.66e-02 | 1.82e-02 | 1.40e-01 |
| CHONDROCYTE DIFFERENTIATION INVOLVED IN ENDOCHONDRAL BONE MORPHOGENESIS | 15 | 3.86e-02 | 2.54e-01 | 0.7910 | 2.09e-01 | 3.03e-01 | 4.72e-01 | 3.96e-01 | 3.34e-01 | 1.62e-01 | 4.20e-02 | 1.56e-03 | 7.99e-03 | 2.50e-02 |
| PROTEIN RNA COMPLEX DISASSEMBLY | 8 | 2.73e-01 | 6.81e-01 | 0.7910 | 3.93e-01 | 3.97e-01 | 3.11e-01 | 4.59e-01 | 8.03e-02 | 5.43e-02 | 5.18e-02 | 1.27e-01 | 2.46e-02 | 6.94e-01 |
| MATERNAL PROCESS INVOLVED IN PARTURITION | 5 | 1.78e-01 | 5.63e-01 | 0.7910 | 9.96e-02 | 4.20e-01 | 3.84e-01 | 2.07e-01 | 4.99e-01 | 7.00e-01 | 1.04e-01 | 1.37e-01 | 4.22e-01 | 5.35e-02 |
| POLYPRENOL METABOLIC PROCESS | 23 | 7.44e-03 | 8.26e-02 | 0.7910 | 4.65e-01 | 4.01e-01 | 2.91e-01 | 3.88e-01 | 1.14e-01 | 1.14e-04 | 8.82e-04 | 1.55e-02 | 1.27e-03 | 3.42e-01 |
| VACUOLE FUSION | 12 | 1.26e-01 | 4.83e-01 | 0.7900 | 3.27e-01 | 3.10e-01 | 4.63e-01 | 3.87e-01 | 2.41e-01 | 5.01e-02 | 6.34e-02 | 5.53e-03 | 2.04e-02 | 1.49e-01 |
| NEURON FATE COMMITMENT | 73 | 1.61e-10 | 1.28e-08 | 0.7890 | 1.96e-01 | 2.70e-01 | 4.29e-01 | 3.56e-01 | 4.48e-01 | 3.87e-03 | 6.54e-05 | 2.37e-10 | 1.41e-07 | 3.53e-11 |
| CONVERGENT EXTENSION INVOLVED IN ORGANOGENESIS | 5 | 3.06e-02 | 2.20e-01 | 0.7880 | -2.64e-01 | -1.79e-01 | 4.61e-02 | 4.71e-02 | 7.18e-01 | 3.07e-01 | 4.89e-01 | 8.58e-01 | 8.55e-01 | 5.42e-03 |
| RESPONSE TO NEMATODE | 7 | 3.84e-01 | 7.79e-01 | 0.7880 | 3.28e-01 | 3.12e-01 | 4.67e-01 | 3.61e-01 | 2.60e-01 | 1.32e-01 | 1.52e-01 | 3.23e-02 | 9.86e-02 | 2.34e-01 |
| OPSONIZATION | 16 | 3.60e-02 | 2.43e-01 | 0.7870 | -3.88e-01 | -3.81e-01 | -3.32e-01 | -4.58e-01 | -5.88e-02 | 7.23e-03 | 8.34e-03 | 2.14e-02 | 1.52e-03 | 6.84e-01 |
| CHITIN METABOLIC PROCESS | 6 | 3.40e-02 | 2.34e-01 | 0.7860 | -1.18e-01 | -2.09e-01 | -4.93e-01 | -1.07e-01 | -5.54e-01 | 6.18e-01 | 3.76e-01 | 3.66e-02 | 6.51e-01 | 1.88e-02 |
| NEGATIVE REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 6 | 3.47e-01 | 7.50e-01 | 0.7860 | 1.21e-01 | 2.36e-01 | 4.12e-01 | 3.34e-01 | 5.16e-01 | 6.07e-01 | 3.16e-01 | 8.03e-02 | 1.57e-01 | 2.86e-02 |
| ELASTIN CATABOLIC PROCESS | 5 | 5.09e-01 | 8.53e-01 | 0.7860 | -4.17e-01 | -3.89e-01 | -3.15e-01 | -2.92e-01 | -3.28e-01 | 1.06e-01 | 1.32e-01 | 2.22e-01 | 2.59e-01 | 2.04e-01 |
| REGULATION OF AUTOPHAGY OF MITOCHONDRION IN RESPONSE TO MITOCHONDRIAL DEPOLARIZATION | 13 | 7.99e-02 | 3.82e-01 | 0.7850 | 3.92e-01 | 2.79e-01 | 3.41e-01 | 3.86e-01 | 3.46e-01 | 1.43e-02 | 8.18e-02 | 3.33e-02 | 1.59e-02 | 3.08e-02 |
| TRANSCRIPTION ELONGATION COUPLED CHROMATIN REMODELING | 7 | 4.28e-01 | 8.05e-01 | 0.7850 | 4.74e-01 | 3.72e-01 | 3.32e-01 | 3.59e-01 | 1.17e-01 | 2.99e-02 | 8.85e-02 | 1.28e-01 | 1.00e-01 | 5.91e-01 |
| LEUKOTRIENE TRANSPORT | 7 | 5.22e-01 | 8.59e-01 | 0.7840 | -3.44e-01 | -3.03e-01 | -4.16e-01 | -4.10e-01 | -2.53e-01 | 1.15e-01 | 1.65e-01 | 5.69e-02 | 6.01e-02 | 2.46e-01 |
| VALINE METABOLIC PROCESS | 7 | 3.97e-01 | 7.86e-01 | 0.7840 | 4.54e-01 | 3.83e-01 | 2.74e-01 | 4.20e-01 | 1.06e-01 | 3.77e-02 | 7.95e-02 | 2.09e-01 | 5.43e-02 | 6.27e-01 |
| NEURON FATE SPECIFICATION | 34 | 1.65e-04 | 3.97e-03 | 0.7840 | 2.04e-01 | 3.03e-01 | 4.25e-01 | 3.19e-01 | 4.45e-01 | 3.91e-02 | 2.19e-03 | 1.81e-05 | 1.28e-03 | 7.10e-06 |
| PROTEIN IMPORT INTO MITOCHONDRIAL MATRIX | 19 | 7.36e-03 | 8.21e-02 | 0.7830 | 4.65e-01 | 3.56e-01 | 3.79e-01 | 3.33e-01 | 1.28e-01 | 4.54e-04 | 7.22e-03 | 4.26e-03 | 1.19e-02 | 3.34e-01 |
| NEGATIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT VIA HIGH VOLTAGE GATED CALCIUM CHANNEL | 5 | 1.07e-01 | 4.47e-01 | 0.7830 | -1.83e-01 | 6.77e-03 | -3.70e-01 | -4.72e-01 | -4.69e-01 | 4.78e-01 | 9.79e-01 | 1.52e-01 | 6.75e-02 | 6.92e-02 |
| SOMATIC MOTOR NEURON DIFFERENTIATION | 5 | 3.64e-01 | 7.64e-01 | 0.7830 | 3.65e-01 | 2.34e-01 | 2.92e-01 | 3.58e-01 | 4.58e-01 | 1.57e-01 | 3.66e-01 | 2.57e-01 | 1.65e-01 | 7.58e-02 |
| ISOLEUCINE TRANSPORT | 5 | 6.47e-01 | 9.17e-01 | 0.7820 | 3.10e-01 | 4.45e-01 | 3.82e-01 | 3.54e-01 | 2.15e-01 | 2.29e-01 | 8.48e-02 | 1.39e-01 | 1.70e-01 | 4.04e-01 |
| REGULATION OF OPSONIZATION | 10 | 1.76e-01 | 5.60e-01 | 0.7820 | -3.36e-01 | -3.07e-01 | -3.25e-01 | -4.60e-01 | -2.96e-01 | 6.56e-02 | 9.25e-02 | 7.51e-02 | 1.18e-02 | 1.05e-01 |
| RESPONSE TO ERYTHROPOIETIN | 7 | 1.77e-01 | 5.62e-01 | 0.7820 | 3.70e-01 | 5.36e-01 | 3.06e-01 | 3.05e-01 | -1.90e-02 | 9.01e-02 | 1.40e-02 | 1.60e-01 | 1.62e-01 | 9.31e-01 |
| MIDDLE EAR MORPHOGENESIS | 20 | 1.39e-02 | 1.28e-01 | 0.7810 | 2.10e-01 | 2.93e-01 | 4.09e-01 | 3.26e-01 | 4.54e-01 | 1.04e-01 | 2.31e-02 | 1.56e-03 | 1.16e-02 | 4.34e-04 |
| FAT PAD DEVELOPMENT | 8 | 4.42e-01 | 8.13e-01 | 0.7800 | 3.68e-01 | 3.92e-01 | 3.95e-01 | 3.93e-01 | 9.54e-02 | 7.15e-02 | 5.48e-02 | 5.30e-02 | 5.45e-02 | 6.40e-01 |
| NEGATIVE REGULATION OF AUTOPHAGOSOME ASSEMBLY | 12 | 1.49e-01 | 5.17e-01 | 0.7800 | 4.20e-01 | 3.36e-01 | 3.03e-01 | 4.31e-01 | 2.05e-01 | 1.18e-02 | 4.40e-02 | 6.92e-02 | 9.77e-03 | 2.19e-01 |
| PROTEIN LOCALIZATION TO CONDENSED CHROMOSOME | 15 | 4.53e-02 | 2.77e-01 | 0.7800 | 3.05e-01 | 3.51e-01 | 3.29e-01 | 4.19e-01 | 3.29e-01 | 4.11e-02 | 1.84e-02 | 2.72e-02 | 4.98e-03 | 2.76e-02 |
| NEGATIVE REGULATION OF CELL CYCLE CHECKPOINT | 6 | 3.94e-01 | 7.85e-01 | 0.7800 | 2.94e-01 | 4.43e-01 | 3.47e-01 | 3.98e-01 | 2.15e-01 | 2.12e-01 | 6.04e-02 | 1.41e-01 | 9.13e-02 | 3.61e-01 |
| CELLULAR RESPONSE TO HYDROPEROXIDE | 8 | 3.95e-01 | 7.85e-01 | 0.7800 | -2.50e-01 | -3.76e-01 | -4.13e-01 | -3.70e-01 | -3.11e-01 | 2.21e-01 | 6.55e-02 | 4.33e-02 | 7.01e-02 | 1.28e-01 |
| TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE PHOSPHATASE SIGNALING PATHWAY | 6 | 6.02e-01 | 9.00e-01 | 0.7790 | -4.18e-01 | -3.60e-01 | -3.33e-01 | -3.62e-01 | -2.46e-01 | 7.63e-02 | 1.27e-01 | 1.58e-01 | 1.24e-01 | 2.97e-01 |
| REGULATION OF CALCIUM ION EXPORT ACROSS PLASMA MEMBRANE | 5 | 4.02e-02 | 2.59e-01 | 0.7790 | -1.57e-01 | -1.19e-01 | 4.14e-01 | 2.17e-01 | 5.91e-01 | 5.44e-01 | 6.45e-01 | 1.09e-01 | 4.02e-01 | 2.20e-02 |
| MATURATION OF LSU RRNA FROM TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 16 | 7.98e-02 | 3.82e-01 | 0.7790 | 2.72e-01 | 3.63e-01 | 4.01e-01 | 3.21e-01 | 3.70e-01 | 5.92e-02 | 1.20e-02 | 5.52e-03 | 2.61e-02 | 1.04e-02 |
| ATP SYNTHESIS COUPLED ELECTRON TRANSPORT | 85 | 7.69e-09 | 5.03e-07 | 0.7790 | 3.66e-01 | 3.23e-01 | 3.70e-01 | 4.07e-01 | 2.58e-01 | 5.59e-09 | 2.69e-07 | 3.72e-09 | 8.71e-11 | 4.01e-05 |
| GALACTOLIPID METABOLIC PROCESS | 9 | 1.55e-01 | 5.25e-01 | 0.7770 | -2.78e-01 | -2.45e-01 | -3.19e-01 | -4.24e-01 | -4.30e-01 | 1.48e-01 | 2.03e-01 | 9.73e-02 | 2.75e-02 | 2.56e-02 |
| SNRNA TRANSCRIPTION | 19 | 3.24e-02 | 2.29e-01 | 0.7760 | 3.63e-01 | 2.80e-01 | 3.96e-01 | 3.92e-01 | 2.84e-01 | 6.14e-03 | 3.47e-02 | 2.78e-03 | 3.07e-03 | 3.18e-02 |
| MITOTIC DNA REPLICATION | 15 | 1.29e-01 | 4.87e-01 | 0.7750 | 3.25e-01 | 3.05e-01 | 3.94e-01 | 3.66e-01 | 3.36e-01 | 2.93e-02 | 4.07e-02 | 8.16e-03 | 1.40e-02 | 2.44e-02 |
| ANTERIOR COMMISSURE MORPHOGENESIS | 7 | 4.73e-01 | 8.31e-01 | 0.7750 | 3.86e-01 | 3.00e-01 | 3.58e-01 | 3.68e-01 | 3.12e-01 | 7.70e-02 | 1.69e-01 | 1.01e-01 | 9.22e-02 | 1.52e-01 |
| POSITIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 25 | 7.43e-03 | 8.26e-02 | 0.7750 | 3.46e-01 | 3.06e-01 | 3.67e-01 | 3.46e-01 | 3.62e-01 | 2.71e-03 | 8.03e-03 | 1.47e-03 | 2.74e-03 | 1.71e-03 |
| URETERIC BUD FORMATION | 7 | 1.76e-01 | 5.61e-01 | 0.7740 | 5.36e-02 | 2.21e-01 | 4.36e-01 | 3.19e-01 | 5.06e-01 | 8.06e-01 | 3.12e-01 | 4.58e-02 | 1.44e-01 | 2.04e-02 |
| GERM CELL PROLIFERATION | 10 | 2.23e-01 | 6.23e-01 | 0.7740 | 4.64e-01 | 4.29e-01 | 2.93e-01 | 3.34e-01 | 3.75e-02 | 1.10e-02 | 1.89e-02 | 1.08e-01 | 6.73e-02 | 8.37e-01 |
| OXIDATIVE PHOSPHORYLATION | 126 | 5.68e-13 | 6.29e-11 | 0.7740 | 3.54e-01 | 3.25e-01 | 3.83e-01 | 3.83e-01 | 2.74e-01 | 6.82e-12 | 3.04e-10 | 1.13e-13 | 1.14e-13 | 1.13e-07 |
| MEIOTIC CELL CYCLE PHASE TRANSITION | 13 | 2.31e-02 | 1.84e-01 | 0.7730 | 2.07e-01 | 2.68e-01 | 4.92e-01 | 4.28e-01 | 2.41e-01 | 1.97e-01 | 9.49e-02 | 2.12e-03 | 7.60e-03 | 1.32e-01 |
| REGULATION OF SNRNA TRANSCRIPTION BY RNA POLYMERASE II | 5 | 3.13e-01 | 7.25e-01 | 0.7710 | 4.73e-01 | 2.77e-01 | 3.92e-01 | 3.45e-01 | 1.45e-01 | 6.68e-02 | 2.84e-01 | 1.29e-01 | 1.81e-01 | 5.74e-01 |
| RIBOSOMAL SUBUNIT EXPORT FROM NUCLEUS | 14 | 1.86e-01 | 5.72e-01 | 0.7710 | 3.86e-01 | 3.69e-01 | 3.85e-01 | 3.71e-01 | 1.51e-01 | 1.24e-02 | 1.68e-02 | 1.27e-02 | 1.61e-02 | 3.28e-01 |
| METANEPHRIC MESENCHYMAL CELL DIFFERENTIATION | 5 | 5.16e-01 | 8.56e-01 | 0.7700 | 2.47e-01 | 2.88e-01 | 3.47e-01 | 4.47e-01 | 3.59e-01 | 3.39e-01 | 2.65e-01 | 1.79e-01 | 8.32e-02 | 1.65e-01 |
| TRNA THIO MODIFICATION | 5 | 7.21e-01 | 9.39e-01 | 0.7700 | 3.16e-01 | 3.38e-01 | 3.75e-01 | 3.34e-01 | 3.57e-01 | 2.22e-01 | 1.91e-01 | 1.47e-01 | 1.96e-01 | 1.67e-01 |
| RIBOSOMAL LARGE SUBUNIT BIOGENESIS | 70 | 1.60e-07 | 8.44e-06 | 0.7700 | 3.68e-01 | 4.00e-01 | 3.91e-01 | 3.15e-01 | 2.11e-01 | 9.85e-08 | 6.80e-09 | 1.58e-08 | 5.25e-06 | 2.25e-03 |
| CELLULAR RESPONSE TO IRON ION | 8 | 4.56e-02 | 2.78e-01 | 0.7690 | 4.98e-02 | 7.39e-02 | 2.91e-01 | 2.47e-01 | 6.62e-01 | 8.07e-01 | 7.18e-01 | 1.54e-01 | 2.27e-01 | 1.18e-03 |
| RESPONSE TO YEAST | 7 | 4.24e-03 | 5.49e-02 | 0.7690 | 1.60e-01 | 1.15e-02 | -4.98e-01 | -1.83e-01 | -5.34e-01 | 4.65e-01 | 9.58e-01 | 2.26e-02 | 4.02e-01 | 1.44e-02 |
| PYRIMIDINE NUCLEOSIDE BIOSYNTHETIC PROCESS | 5 | 2.00e-01 | 5.90e-01 | 0.7690 | 4.17e-01 | 4.92e-01 | 1.93e-01 | 2.87e-01 | 2.36e-01 | 1.07e-01 | 5.66e-02 | 4.55e-01 | 2.67e-01 | 3.61e-01 |
| POSITIVE REGULATION OF GASTRULATION | 6 | 1.92e-01 | 5.80e-01 | 0.7680 | 9.18e-02 | 3.91e-01 | 4.30e-01 | 2.58e-01 | 4.21e-01 | 6.97e-01 | 9.71e-02 | 6.84e-02 | 2.74e-01 | 7.44e-02 |
| NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 4.46e-01 | 8.17e-01 | 0.7670 | 2.42e-01 | 2.30e-01 | 4.89e-01 | 3.57e-01 | 3.34e-01 | 3.49e-01 | 3.74e-01 | 5.85e-02 | 1.67e-01 | 1.96e-01 |
| PROXIMAL DISTAL PATTERN FORMATION | 34 | 1.62e-04 | 3.91e-03 | 0.7670 | 2.11e-01 | 3.73e-01 | 4.22e-01 | 2.92e-01 | 3.76e-01 | 3.29e-02 | 1.68e-04 | 2.09e-05 | 3.17e-03 | 1.47e-04 |
| AMMONIUM HOMEOSTASIS | 5 | 6.55e-01 | 9.20e-01 | 0.7660 | -3.20e-01 | -4.04e-01 | -3.53e-01 | -4.10e-01 | -1.72e-01 | 2.15e-01 | 1.18e-01 | 1.72e-01 | 1.12e-01 | 5.05e-01 |
| EMBRYONIC SKELETAL JOINT MORPHOGENESIS | 11 | 7.95e-02 | 3.82e-01 | 0.7660 | 1.61e-01 | 2.18e-01 | 4.08e-01 | 4.20e-01 | 4.13e-01 | 3.57e-01 | 2.11e-01 | 1.92e-02 | 1.59e-02 | 1.77e-02 |
| REGULATION OF ANTIMICROBIAL PEPTIDE PRODUCTION | 9 | 1.50e-01 | 5.19e-01 | 0.7660 | -2.71e-01 | -1.66e-01 | -3.95e-01 | -3.98e-01 | -4.13e-01 | 1.59e-01 | 3.88e-01 | 4.02e-02 | 3.86e-02 | 3.17e-02 |
| REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CONTRACTION | 10 | 4.65e-02 | 2.82e-01 | 0.7650 | -1.38e-01 | -3.67e-01 | -3.86e-01 | -1.98e-01 | -4.94e-01 | 4.48e-01 | 4.48e-02 | 3.47e-02 | 2.77e-01 | 6.79e-03 |
| HYPOTHALAMUS CELL MIGRATION | 6 | 4.66e-01 | 8.26e-01 | 0.7650 | -4.89e-01 | -3.59e-01 | -3.02e-01 | -3.54e-01 | -3.18e-02 | 3.81e-02 | 1.28e-01 | 2.00e-01 | 1.33e-01 | 8.93e-01 |
| REGULATION OF BRANCHING INVOLVED IN URETERIC BUD MORPHOGENESIS | 19 | 1.93e-02 | 1.62e-01 | 0.7650 | 2.04e-01 | 3.03e-01 | 3.98e-01 | 2.99e-01 | 4.52e-01 | 1.24e-01 | 2.24e-02 | 2.68e-03 | 2.40e-02 | 6.54e-04 |
| MESANGIAL CELL DEVELOPMENT | 6 | 1.74e-01 | 5.59e-01 | 0.7640 | 1.32e-01 | 3.81e-01 | 3.84e-01 | 1.60e-01 | 4.99e-01 | 5.75e-01 | 1.06e-01 | 1.03e-01 | 4.98e-01 | 3.44e-02 |
| POSITIVE REGULATION OF INTERLEUKIN 23 PRODUCTION | 7 | 1.34e-01 | 4.96e-01 | 0.7640 | -9.40e-02 | -1.02e-01 | -3.25e-01 | -3.15e-01 | -6.00e-01 | 6.67e-01 | 6.41e-01 | 1.36e-01 | 1.49e-01 | 6.00e-03 |
| ENDODERMAL CELL FATE SPECIFICATION | 8 | 3.47e-01 | 7.50e-01 | 0.7640 | 3.45e-01 | 3.36e-01 | 3.19e-01 | 3.26e-01 | 3.78e-01 | 9.11e-02 | 1.00e-01 | 1.18e-01 | 1.10e-01 | 6.39e-02 |
| REGULATION OF MITOCHONDRIAL MRNA STABILITY | 7 | 5.04e-01 | 8.50e-01 | 0.7630 | 2.49e-01 | 2.82e-01 | 4.14e-01 | 4.04e-01 | 3.25e-01 | 2.53e-01 | 1.96e-01 | 5.81e-02 | 6.41e-02 | 1.36e-01 |
| NON LYTIC VIRAL RELEASE | 14 | 8.49e-02 | 3.94e-01 | 0.7620 | 3.42e-01 | 2.68e-01 | 4.20e-01 | 4.13e-01 | 2.10e-01 | 2.67e-02 | 8.26e-02 | 6.50e-03 | 7.42e-03 | 1.74e-01 |
| NEGATIVE REGULATION OF AUTOPHAGOSOME MATURATION | 5 | 4.54e-01 | 8.22e-01 | 0.7610 | 1.54e-01 | 2.19e-01 | 4.01e-01 | 4.29e-01 | 4.03e-01 | 5.51e-01 | 3.95e-01 | 1.20e-01 | 9.64e-02 | 1.19e-01 |
| DEOXYRIBONUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 8 | 3.53e-01 | 7.53e-01 | 0.7610 | 4.15e-01 | 3.71e-01 | 3.29e-01 | 3.00e-01 | 2.67e-01 | 4.21e-02 | 6.95e-02 | 1.07e-01 | 1.41e-01 | 1.91e-01 |
| REGULATION OF SPINDLE ORGANIZATION | 46 | 4.23e-04 | 8.82e-03 | 0.7610 | 3.47e-01 | 3.44e-01 | 3.70e-01 | 3.76e-01 | 2.49e-01 | 4.65e-05 | 5.47e-05 | 1.44e-05 | 1.02e-05 | 3.43e-03 |
| PROTEIN LOCALIZATION TO BASOLATERAL PLASMA MEMBRANE | 7 | 7.88e-02 | 3.81e-01 | 0.7610 | 2.37e-01 | 2.49e-01 | 2.32e-01 | 2.79e-01 | 5.73e-01 | 2.78e-01 | 2.53e-01 | 2.88e-01 | 2.00e-01 | 8.65e-03 |
| PURINE NUCLEOSIDE TRIPHOSPHATE CATABOLIC PROCESS | 5 | 5.47e-01 | 8.72e-01 | 0.7580 | 2.60e-01 | 3.14e-01 | 3.65e-01 | 2.50e-01 | 4.62e-01 | 3.15e-01 | 2.24e-01 | 1.58e-01 | 3.33e-01 | 7.38e-02 |
| CEREBRAL CORTEX NEURON DIFFERENTIATION | 24 | 1.71e-02 | 1.50e-01 | 0.7580 | 2.51e-01 | 3.08e-01 | 4.09e-01 | 3.36e-01 | 3.68e-01 | 3.35e-02 | 9.06e-03 | 5.17e-04 | 4.35e-03 | 1.78e-03 |
| GLOMERULAR MESANGIAL CELL DEVELOPMENT | 5 | 1.88e-01 | 5.73e-01 | 0.7570 | 1.19e-01 | 3.97e-01 | 4.01e-01 | 1.09e-01 | 4.79e-01 | 6.45e-01 | 1.25e-01 | 1.20e-01 | 6.73e-01 | 6.37e-02 |
| REGULATION OF PROTEIN LOCALIZATION TO CHROMATIN | 10 | 1.08e-01 | 4.51e-01 | 0.7570 | 4.61e-01 | 3.35e-01 | 2.24e-01 | 4.23e-01 | 1.42e-01 | 1.16e-02 | 6.69e-02 | 2.21e-01 | 2.06e-02 | 4.38e-01 |
| CHAPERONE MEDIATED AUTOPHAGY | 14 | 8.51e-02 | 3.95e-01 | 0.7560 | 1.80e-01 | 2.82e-01 | 4.12e-01 | 3.40e-01 | 4.17e-01 | 2.44e-01 | 6.81e-02 | 7.57e-03 | 2.74e-02 | 6.93e-03 |
| TRANSLOCATION OF MOLECULES INTO HOST | 7 | 3.79e-01 | 7.75e-01 | 0.7550 | 1.94e-01 | 2.47e-01 | 4.05e-01 | 2.86e-01 | 4.76e-01 | 3.75e-01 | 2.57e-01 | 6.38e-02 | 1.90e-01 | 2.93e-02 |
| DOPAMINERGIC NEURON DIFFERENTIATION | 40 | 1.04e-04 | 2.86e-03 | 0.7550 | 2.18e-01 | 3.05e-01 | 3.82e-01 | 3.35e-01 | 4.14e-01 | 1.73e-02 | 8.38e-04 | 2.88e-05 | 2.48e-04 | 5.76e-06 |
| SENSORY PERCEPTION OF TASTE | 66 | 4.91e-06 | 1.97e-04 | 0.7530 | -3.75e-01 | -3.47e-01 | -3.45e-01 | -3.74e-01 | -2.14e-01 | 1.35e-07 | 1.06e-06 | 1.20e-06 | 1.49e-07 | 2.60e-03 |
| POSITIVE REGULATION OF INTERLEUKIN 1 ALPHA PRODUCTION | 6 | 3.04e-01 | 7.17e-01 | 0.7520 | 4.67e-01 | 3.29e-01 | 2.18e-01 | 3.66e-01 | 2.41e-01 | 4.76e-02 | 1.63e-01 | 3.55e-01 | 1.20e-01 | 3.06e-01 |
| RRNA MODIFICATION | 32 | 5.11e-04 | 1.03e-02 | 0.7520 | 3.30e-01 | 2.39e-01 | 4.04e-01 | 3.92e-01 | 2.86e-01 | 1.22e-03 | 1.93e-02 | 7.59e-05 | 1.22e-04 | 5.09e-03 |
| LIPID DIGESTION | 21 | 2.76e-03 | 3.92e-02 | 0.7510 | -3.18e-01 | -1.97e-01 | -3.74e-01 | -4.75e-01 | -2.44e-01 | 1.17e-02 | 1.18e-01 | 3.02e-03 | 1.66e-04 | 5.27e-02 |
| MITOCHONDRIAL RESPIRATORY CHAIN COMPLEX ASSEMBLY | 92 | 9.56e-09 | 6.15e-07 | 0.7500 | 3.23e-01 | 3.07e-01 | 3.75e-01 | 3.84e-01 | 2.74e-01 | 8.43e-08 | 3.52e-07 | 4.75e-10 | 1.82e-10 | 5.34e-06 |
| KIDNEY MESENCHYME DEVELOPMENT | 16 | 5.36e-02 | 3.06e-01 | 0.7500 | 2.13e-01 | 2.90e-01 | 3.86e-01 | 4.00e-01 | 3.53e-01 | 1.41e-01 | 4.43e-02 | 7.56e-03 | 5.60e-03 | 1.46e-02 |
| G2 MI TRANSITION OF MEIOTIC CELL CYCLE | 7 | 1.47e-01 | 5.15e-01 | 0.7500 | 2.22e-01 | 3.21e-01 | 4.95e-01 | 3.94e-01 | 9.64e-02 | 3.10e-01 | 1.41e-01 | 2.33e-02 | 7.09e-02 | 6.59e-01 |
| CELL MOTILITY INVOLVED IN CEREBRAL CORTEX RADIAL GLIA GUIDED MIGRATION | 8 | 4.70e-01 | 8.30e-01 | 0.7500 | -3.00e-01 | -2.98e-01 | -3.45e-01 | -3.73e-01 | -3.54e-01 | 1.42e-01 | 1.45e-01 | 9.13e-02 | 6.80e-02 | 8.26e-02 |
| ESTROGEN METABOLIC PROCESS | 39 | 1.89e-03 | 2.91e-02 | 0.7500 | -3.08e-01 | -3.58e-01 | -3.75e-01 | -3.50e-01 | -2.76e-01 | 8.78e-04 | 1.11e-04 | 4.98e-05 | 1.55e-04 | 2.88e-03 |
| SEMICIRCULAR CANAL MORPHOGENESIS | 7 | 1.65e-01 | 5.45e-01 | 0.7500 | 3.49e-01 | 3.52e-01 | 2.24e-01 | 3.76e-01 | 3.52e-01 | 1.10e-01 | 1.06e-01 | 3.04e-01 | 8.47e-02 | 1.07e-01 |
| MYCOTOXIN METABOLIC PROCESS | 6 | 3.94e-01 | 7.85e-01 | 0.7490 | -3.73e-01 | -2.55e-01 | -2.89e-01 | -4.85e-01 | -1.98e-01 | 1.14e-01 | 2.80e-01 | 2.20e-01 | 3.98e-02 | 4.02e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN VIA MHC CLASS IB | 18 | 3.44e-04 | 7.45e-03 | 0.7480 | 4.50e-03 | 1.91e-01 | 4.47e-01 | 3.32e-01 | 4.62e-01 | 9.74e-01 | 1.61e-01 | 1.01e-03 | 1.47e-02 | 6.93e-04 |
| SOMITE ROSTRAL CAUDAL AXIS SPECIFICATION | 10 | 2.44e-01 | 6.48e-01 | 0.7480 | 3.48e-01 | 2.96e-01 | 3.20e-01 | 3.35e-01 | 3.70e-01 | 5.67e-02 | 1.05e-01 | 7.96e-02 | 6.67e-02 | 4.30e-02 |
| REGULATION OF BASEMENT MEMBRANE ORGANIZATION | 11 | 1.64e-01 | 5.42e-01 | 0.7480 | -2.04e-01 | -3.40e-01 | -4.47e-01 | -3.60e-01 | -2.69e-01 | 2.42e-01 | 5.07e-02 | 1.02e-02 | 3.86e-02 | 1.22e-01 |
| POSITIVE REGULATION OF SARCOMERE ORGANIZATION | 6 | 2.86e-01 | 6.94e-01 | 0.7480 | -4.21e-01 | -3.43e-01 | -2.06e-01 | -4.23e-01 | -2.07e-01 | 7.44e-02 | 1.46e-01 | 3.81e-01 | 7.28e-02 | 3.79e-01 |
| NEGATIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE I | 11 | 1.04e-01 | 4.40e-01 | 0.7470 | 3.40e-01 | 3.26e-01 | 3.75e-01 | 2.44e-01 | 3.70e-01 | 5.12e-02 | 6.13e-02 | 3.14e-02 | 1.62e-01 | 3.35e-02 |
| SOMATOSTATIN RECEPTOR SIGNALING PATHWAY | 5 | 3.26e-01 | 7.35e-01 | 0.7470 | 9.18e-02 | 2.85e-01 | 3.29e-01 | 2.90e-01 | 5.25e-01 | 7.22e-01 | 2.70e-01 | 2.02e-01 | 2.61e-01 | 4.19e-02 |
| REGULATION OF CDC42 PROTEIN SIGNAL TRANSDUCTION | 8 | 5.17e-02 | 3.00e-01 | 0.7460 | -2.17e-01 | -5.21e-02 | -3.96e-01 | -4.25e-01 | -4.12e-01 | 2.87e-01 | 7.99e-01 | 5.22e-02 | 3.76e-02 | 4.36e-02 |
| RETINAL CELL PROGRAMMED CELL DEATH | 6 | 3.85e-01 | 7.79e-01 | 0.7460 | -3.27e-01 | -3.55e-01 | -4.48e-01 | -3.48e-01 | -4.70e-02 | 1.66e-01 | 1.32e-01 | 5.71e-02 | 1.40e-01 | 8.42e-01 |
| REGULATION OF MITOTIC SPINDLE ASSEMBLY | 22 | 3.59e-02 | 2.43e-01 | 0.7460 | 3.54e-01 | 3.37e-01 | 3.81e-01 | 3.21e-01 | 2.63e-01 | 4.00e-03 | 6.15e-03 | 1.95e-03 | 9.21e-03 | 3.30e-02 |
| COMPLEMENT ACTIVATION LECTIN PATHWAY | 11 | 2.30e-01 | 6.33e-01 | 0.7440 | -2.46e-01 | -2.51e-01 | -3.84e-01 | -4.07e-01 | -3.42e-01 | 1.57e-01 | 1.50e-01 | 2.75e-02 | 1.93e-02 | 4.93e-02 |
| XENOBIOTIC EXPORT FROM CELL | 26 | 9.67e-03 | 9.91e-02 | 0.7440 | -3.35e-01 | -3.32e-01 | -3.43e-01 | -4.33e-01 | -1.59e-01 | 3.07e-03 | 3.34e-03 | 2.46e-03 | 1.30e-04 | 1.61e-01 |
| VIRION ASSEMBLY | 34 | 4.13e-03 | 5.38e-02 | 0.7440 | 3.42e-01 | 3.15e-01 | 3.79e-01 | 3.49e-01 | 2.68e-01 | 5.64e-04 | 1.47e-03 | 1.30e-04 | 4.32e-04 | 6.94e-03 |
| DORSAL SPINAL CORD DEVELOPMENT | 20 | 7.79e-03 | 8.53e-02 | 0.7430 | 2.55e-01 | 2.17e-01 | 3.64e-01 | 3.01e-01 | 4.66e-01 | 4.86e-02 | 9.31e-02 | 4.81e-03 | 1.98e-02 | 3.04e-04 |
| MITOCHONDRIAL RNA CATABOLIC PROCESS | 6 | 5.15e-01 | 8.56e-01 | 0.7430 | 3.89e-01 | 3.05e-01 | 3.41e-01 | 3.08e-01 | 3.12e-01 | 9.90e-02 | 1.95e-01 | 1.49e-01 | 1.92e-01 | 1.86e-01 |
| METANEPHRIC S SHAPED BODY MORPHOGENESIS | 5 | 5.75e-01 | 8.84e-01 | 0.7430 | 2.97e-01 | 2.69e-01 | 3.11e-01 | 3.15e-01 | 4.42e-01 | 2.49e-01 | 2.97e-01 | 2.29e-01 | 2.23e-01 | 8.72e-02 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 37 | 5.72e-04 | 1.13e-02 | 0.7420 | 3.05e-01 | 2.59e-01 | 3.56e-01 | 4.16e-01 | 3.03e-01 | 1.34e-03 | 6.42e-03 | 1.79e-04 | 1.19e-05 | 1.44e-03 |
| NEGATIVE REGULATION OF OLIGODENDROCYTE DIFFERENTIATION | 14 | 1.31e-01 | 4.90e-01 | 0.7420 | 2.26e-01 | 2.53e-01 | 4.03e-01 | 3.70e-01 | 3.69e-01 | 1.42e-01 | 1.01e-01 | 9.02e-03 | 1.66e-02 | 1.67e-02 |
| ONCOGENE INDUCED CELL SENESCENCE | 6 | 4.98e-01 | 8.46e-01 | 0.7420 | 4.04e-01 | 4.13e-01 | 2.52e-01 | 3.77e-01 | 1.05e-01 | 8.63e-02 | 7.95e-02 | 2.85e-01 | 1.10e-01 | 6.55e-01 |
| PROTEASOME ASSEMBLY | 11 | 4.27e-02 | 2.69e-01 | 0.7420 | 4.05e-01 | 1.80e-01 | 3.53e-01 | 4.10e-01 | 2.48e-01 | 2.01e-02 | 3.00e-01 | 4.27e-02 | 1.86e-02 | 1.54e-01 |
| LOCOMOTION INVOLVED IN LOCOMOTORY BEHAVIOR | 11 | 2.57e-01 | 6.64e-01 | 0.7420 | 4.28e-01 | 3.63e-01 | 3.39e-01 | 3.34e-01 | 9.08e-02 | 1.39e-02 | 3.69e-02 | 5.15e-02 | 5.48e-02 | 6.02e-01 |
| NEURAL CREST CELL MIGRATION INVOLVED IN AUTONOMIC NERVOUS SYSTEM DEVELOPMENT | 6 | 4.41e-01 | 8.13e-01 | 0.7410 | -4.05e-01 | -2.36e-01 | -3.07e-01 | -3.94e-01 | -2.82e-01 | 8.56e-02 | 3.16e-01 | 1.93e-01 | 9.46e-02 | 2.31e-01 |
| POSITIVE REGULATION OF RRNA PROCESSING | 10 | 3.33e-01 | 7.40e-01 | 0.7410 | 2.74e-01 | 3.32e-01 | 3.67e-01 | 2.99e-01 | 3.73e-01 | 1.34e-01 | 6.92e-02 | 4.43e-02 | 1.02e-01 | 4.10e-02 |
| NOTOCHORD MORPHOGENESIS | 8 | 1.43e-01 | 5.09e-01 | 0.7390 | 6.81e-02 | 2.41e-01 | 4.01e-01 | 3.49e-01 | 4.48e-01 | 7.39e-01 | 2.38e-01 | 4.96e-02 | 8.72e-02 | 2.82e-02 |
| GLUTATHIONE CATABOLIC PROCESS | 7 | 6.86e-03 | 7.77e-02 | 0.7390 | -2.50e-01 | -1.22e-01 | 3.15e-01 | -4.71e-02 | 6.06e-01 | 2.51e-01 | 5.75e-01 | 1.49e-01 | 8.29e-01 | 5.49e-03 |
| NEGATIVE REGULATION OF NEUTROPHIL MIGRATION | 5 | 5.70e-02 | 3.16e-01 | 0.7390 | 1.78e-01 | -1.11e-01 | -4.37e-01 | -2.82e-01 | -4.82e-01 | 4.91e-01 | 6.69e-01 | 9.09e-02 | 2.75e-01 | 6.21e-02 |
| REGULATION OF PROTEIN K48 LINKED UBIQUITINATION | 6 | 5.38e-01 | 8.66e-01 | 0.7390 | 3.35e-01 | 3.87e-01 | 3.47e-01 | 4.02e-01 | 2.71e-02 | 1.55e-01 | 1.00e-01 | 1.41e-01 | 8.81e-02 | 9.09e-01 |
| EMBRYONIC DIGESTIVE TRACT MORPHOGENESIS | 17 | 4.35e-02 | 2.71e-01 | 0.7380 | 1.88e-01 | 3.35e-01 | 3.98e-01 | 3.37e-01 | 3.55e-01 | 1.79e-01 | 1.67e-02 | 4.51e-03 | 1.63e-02 | 1.14e-02 |
| ESTABLISHMENT OF LEFT RIGHT ASYMMETRY | 6 | 1.38e-01 | 5.01e-01 | 0.7380 | 3.88e-01 | 3.70e-01 | 4.30e-01 | 1.81e-01 | 2.00e-01 | 9.98e-02 | 1.16e-01 | 6.84e-02 | 4.44e-01 | 3.97e-01 |
| MITOCHONDRIAL ELECTRON TRANSPORT NADH TO UBIQUINONE | 43 | 1.42e-03 | 2.33e-02 | 0.7380 | 3.43e-01 | 3.66e-01 | 3.57e-01 | 3.53e-01 | 2.01e-01 | 9.74e-05 | 3.33e-05 | 5.03e-05 | 6.17e-05 | 2.23e-02 |
| NEGATIVE REGULATION OF GLYCOLYTIC PROCESS | 17 | 6.23e-02 | 3.31e-01 | 0.7370 | 2.61e-01 | 2.61e-01 | 3.52e-01 | 4.08e-01 | 3.41e-01 | 6.20e-02 | 6.28e-02 | 1.19e-02 | 3.59e-03 | 1.48e-02 |
| POSITIVE REGULATION OF PINOCYTOSIS | 7 | 3.90e-01 | 7.82e-01 | 0.7370 | 3.19e-01 | 2.90e-01 | 2.93e-01 | 4.42e-01 | 2.74e-01 | 1.43e-01 | 1.83e-01 | 1.79e-01 | 4.30e-02 | 2.09e-01 |
| REGULATION OF ENDODEOXYRIBONUCLEASE ACTIVITY | 8 | 3.87e-01 | 7.80e-01 | 0.7360 | 3.12e-01 | 2.77e-01 | 3.07e-01 | 3.71e-01 | 3.70e-01 | 1.27e-01 | 1.76e-01 | 1.32e-01 | 6.95e-02 | 7.00e-02 |
| METANEPHRIC TUBULE FORMATION | 6 | 1.92e-01 | 5.80e-01 | 0.7360 | 3.52e-01 | 4.12e-01 | 4.04e-01 | 1.54e-01 | 2.47e-01 | 1.36e-01 | 8.04e-02 | 8.62e-02 | 5.15e-01 | 2.94e-01 |
| CELL FATE DETERMINATION | 42 | 7.34e-05 | 2.15e-03 | 0.7360 | 2.53e-01 | 2.86e-01 | 3.90e-01 | 2.85e-01 | 4.04e-01 | 4.62e-03 | 1.36e-03 | 1.21e-05 | 1.41e-03 | 5.83e-06 |
| SIGNAL TRANSDUCTION INVOLVED IN REGULATION OF GENE EXPRESSION | 22 | 2.25e-02 | 1.81e-01 | 0.7360 | 2.38e-01 | 2.73e-01 | 4.16e-01 | 3.21e-01 | 3.65e-01 | 5.36e-02 | 2.68e-02 | 7.19e-04 | 9.05e-03 | 3.02e-03 |
| COMMON MYELOID PROGENITOR CELL PROLIFERATION | 9 | 3.48e-01 | 7.50e-01 | 0.7340 | 3.59e-01 | 3.23e-01 | 3.09e-01 | 4.39e-01 | 1.28e-01 | 6.22e-02 | 9.34e-02 | 1.08e-01 | 2.25e-02 | 5.06e-01 |
| RIBOSOMAL SMALL SUBUNIT ASSEMBLY | 18 | 5.88e-02 | 3.20e-01 | 0.7340 | 2.32e-01 | 3.44e-01 | 3.78e-01 | 2.96e-01 | 3.68e-01 | 8.80e-02 | 1.16e-02 | 5.45e-03 | 2.97e-02 | 6.88e-03 |
| POSITIVE REGULATION OF PROTEIN KINASE A SIGNALING | 12 | 1.90e-01 | 5.78e-01 | 0.7330 | -4.28e-01 | -4.01e-01 | -2.64e-01 | -3.34e-01 | -1.08e-01 | 1.02e-02 | 1.62e-02 | 1.13e-01 | 4.50e-02 | 5.17e-01 |
| DISTAL CONVOLUTED TUBULE DEVELOPMENT | 5 | 6.45e-01 | 9.16e-01 | 0.7330 | 2.36e-01 | 2.35e-01 | 4.33e-01 | 3.56e-01 | 3.34e-01 | 3.61e-01 | 3.62e-01 | 9.37e-02 | 1.68e-01 | 1.95e-01 |
| MATURATION OF SSU RRNA | 51 | 4.56e-06 | 1.86e-04 | 0.7320 | 2.42e-01 | 2.23e-01 | 3.98e-01 | 3.49e-01 | 3.85e-01 | 2.74e-03 | 5.94e-03 | 8.94e-07 | 1.65e-05 | 1.93e-06 |
| GAMMA AMINOBUTYRIC ACID BIOSYNTHETIC PROCESS | 6 | 4.08e-01 | 7.94e-01 | 0.7320 | 1.15e-01 | 2.36e-01 | 3.60e-01 | 2.98e-01 | 4.99e-01 | 6.25e-01 | 3.16e-01 | 1.27e-01 | 2.07e-01 | 3.43e-02 |
| NEGATIVE REGULATION OF APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 6 | 6.45e-02 | 3.38e-01 | 0.7310 | -2.20e-02 | 2.21e-01 | 4.63e-01 | 8.25e-02 | 5.14e-01 | 9.26e-01 | 3.48e-01 | 4.95e-02 | 7.26e-01 | 2.91e-02 |
| NEGATIVE REGULATION OF ATP BIOSYNTHETIC PROCESS | 5 | 3.39e-01 | 7.44e-01 | 0.7310 | -5.02e-01 | -3.74e-01 | -1.99e-01 | -2.48e-01 | 2.04e-01 | 5.19e-02 | 1.47e-01 | 4.41e-01 | 3.37e-01 | 4.30e-01 |
| NEGATIVE REGULATION OF MEIOTIC CELL CYCLE PHASE TRANSITION | 5 | 3.82e-01 | 7.78e-01 | 0.7310 | 1.19e-01 | 1.41e-01 | 4.12e-01 | 4.20e-01 | 3.92e-01 | 6.45e-01 | 5.84e-01 | 1.10e-01 | 1.04e-01 | 1.29e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 18 | 1.93e-02 | 1.62e-01 | 0.7310 | -4.34e-01 | -2.63e-01 | -3.03e-01 | -3.76e-01 | -2.09e-01 | 1.44e-03 | 5.33e-02 | 2.63e-02 | 5.68e-03 | 1.25e-01 |
| REGULATION OF LUNG BLOOD PRESSURE | 5 | 4.99e-01 | 8.47e-01 | 0.7300 | -3.56e-01 | -3.18e-01 | -3.64e-01 | -2.32e-01 | -3.44e-01 | 1.69e-01 | 2.18e-01 | 1.59e-01 | 3.68e-01 | 1.83e-01 |
| REGULATION OF PROTEIN OLIGOMERIZATION | 5 | 2.31e-01 | 6.33e-01 | 0.7290 | 7.52e-02 | 1.49e-01 | 4.68e-01 | 4.23e-01 | 3.25e-01 | 7.71e-01 | 5.63e-01 | 6.98e-02 | 1.01e-01 | 2.08e-01 |
| REGULATION OF DELAYED RECTIFIER POTASSIUM CHANNEL ACTIVITY | 18 | 5.20e-02 | 3.01e-01 | 0.7290 | -3.29e-01 | -2.74e-01 | -3.37e-01 | -4.43e-01 | -1.98e-01 | 1.58e-02 | 4.45e-02 | 1.33e-02 | 1.14e-03 | 1.46e-01 |
| NEGATIVE REGULATION OF IMMATURE T CELL PROLIFERATION | 5 | 3.66e-01 | 7.66e-01 | 0.7290 | 1.90e-01 | 2.85e-01 | 4.79e-01 | 4.05e-01 | 1.46e-01 | 4.61e-01 | 2.69e-01 | 6.37e-02 | 1.17e-01 | 5.73e-01 |
| B 1 B CELL DIFFERENTIATION | 5 | 3.47e-01 | 7.50e-01 | 0.7290 | 2.60e-01 | 2.15e-01 | 3.61e-01 | 5.17e-01 | 1.41e-01 | 3.13e-01 | 4.05e-01 | 1.62e-01 | 4.54e-02 | 5.84e-01 |
| PROTEIN LOCALIZATION TO GOLGI MEMBRANE | 5 | 3.02e-01 | 7.14e-01 | 0.7290 | 4.19e-01 | 5.22e-01 | 2.30e-01 | 1.76e-01 | 1.33e-02 | 1.05e-01 | 4.34e-02 | 3.73e-01 | 4.96e-01 | 9.59e-01 |
| CARDIAC MUSCLE CELL FATE COMMITMENT | 11 | 3.30e-01 | 7.38e-01 | 0.7290 | 3.42e-01 | 4.12e-01 | 3.33e-01 | 3.13e-01 | 1.88e-01 | 4.94e-02 | 1.79e-02 | 5.62e-02 | 7.22e-02 | 2.81e-01 |
| DNA TOPOLOGICAL CHANGE | 9 | 4.58e-01 | 8.23e-01 | 0.7280 | 3.96e-01 | 3.21e-01 | 3.39e-01 | 3.58e-01 | 1.66e-01 | 3.96e-02 | 9.55e-02 | 7.84e-02 | 6.32e-02 | 3.88e-01 |
| MATURATION OF LSU RRNA | 27 | 1.58e-02 | 1.42e-01 | 0.7270 | 3.38e-01 | 3.82e-01 | 3.44e-01 | 2.93e-01 | 2.52e-01 | 2.36e-03 | 5.84e-04 | 1.96e-03 | 8.48e-03 | 2.33e-02 |
| POSITIVE REGULATION OF ER ASSOCIATED UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 5 | 4.51e-01 | 8.21e-01 | 0.7270 | 3.49e-01 | 3.05e-01 | 2.46e-01 | 4.67e-01 | 1.87e-01 | 1.76e-01 | 2.38e-01 | 3.41e-01 | 7.08e-02 | 4.68e-01 |
| CORPUS CALLOSUM MORPHOGENESIS | 6 | 6.46e-01 | 9.16e-01 | 0.7260 | 2.65e-01 | 2.68e-01 | 3.68e-01 | 4.07e-01 | 2.91e-01 | 2.61e-01 | 2.56e-01 | 1.19e-01 | 8.46e-02 | 2.16e-01 |
| REGULATION OF MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 15 | 2.53e-02 | 1.94e-01 | 0.7250 | 3.61e-01 | 3.08e-01 | 2.37e-01 | 3.97e-01 | 2.95e-01 | 1.55e-02 | 3.92e-02 | 1.12e-01 | 7.78e-03 | 4.77e-02 |
| LEUKOCYTE AGGREGATION | 12 | 4.48e-02 | 2.75e-01 | 0.7250 | 3.47e-01 | 4.71e-01 | 2.70e-01 | 3.25e-01 | -6.72e-02 | 3.73e-02 | 4.71e-03 | 1.06e-01 | 5.09e-02 | 6.87e-01 |
| NEGATIVE REGULATION OF DNA TEMPLATED DNA REPLICATION | 9 | 2.60e-01 | 6.66e-01 | 0.7250 | 1.74e-01 | 2.18e-01 | 4.32e-01 | 3.27e-01 | 3.93e-01 | 3.65e-01 | 2.58e-01 | 2.49e-02 | 8.90e-02 | 4.14e-02 |
| NEGATIVE REGULATION OF CELL PROLIFERATION INVOLVED IN KIDNEY DEVELOPMENT | 6 | 6.99e-02 | 3.57e-01 | 0.7240 | 4.18e-02 | 2.02e-01 | 5.16e-01 | 3.92e-01 | 2.49e-01 | 8.59e-01 | 3.92e-01 | 2.86e-02 | 9.64e-02 | 2.90e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 101 | 1.25e-09 | 9.04e-08 | 0.7240 | 3.02e-01 | 2.94e-01 | 3.59e-01 | 4.02e-01 | 2.37e-01 | 1.53e-07 | 3.18e-07 | 4.64e-10 | 2.97e-12 | 3.76e-05 |
| POSITIVE REGULATION OF HAIR FOLLICLE DEVELOPMENT | 12 | 1.14e-01 | 4.60e-01 | 0.7230 | 2.27e-01 | 3.77e-01 | 3.94e-01 | 3.80e-01 | 1.72e-01 | 1.74e-01 | 2.36e-02 | 1.80e-02 | 2.28e-02 | 3.02e-01 |
| POSITIVE REGULATION OF HELICASE ACTIVITY | 6 | 1.05e-01 | 4.42e-01 | 0.7230 | 3.58e-01 | 3.30e-01 | 1.63e-01 | 2.55e-01 | -4.40e-01 | 1.29e-01 | 1.62e-01 | 4.89e-01 | 2.80e-01 | 6.18e-02 |
| AMINOPHOSPHOLIPID TRANSLOCATION | 6 | 4.00e-01 | 7.88e-01 | 0.7210 | -1.22e-01 | -3.02e-01 | -3.58e-01 | -2.71e-01 | -4.61e-01 | 6.06e-01 | 2.01e-01 | 1.29e-01 | 2.51e-01 | 5.06e-02 |
| POSITIVE REGULATION OF PLASMINOGEN ACTIVATION | 8 | 3.73e-01 | 7.72e-01 | 0.7200 | 4.10e-01 | 4.08e-01 | 3.11e-01 | 2.94e-01 | -3.52e-02 | 4.44e-02 | 4.58e-02 | 1.28e-01 | 1.50e-01 | 8.63e-01 |
| RIBOSOMAL SMALL SUBUNIT BIOGENESIS | 101 | 4.12e-11 | 3.61e-09 | 0.7200 | 2.29e-01 | 2.57e-01 | 3.98e-01 | 3.19e-01 | 3.73e-01 | 6.87e-05 | 8.33e-06 | 4.57e-12 | 2.94e-08 | 8.78e-11 |
| NEGATIVE REGULATION OF RESPIRATORY BURST | 6 | 7.11e-01 | 9.35e-01 | 0.7200 | 3.68e-01 | 3.94e-01 | 3.29e-01 | 3.30e-01 | 1.02e-01 | 1.18e-01 | 9.49e-02 | 1.63e-01 | 1.62e-01 | 6.65e-01 |
| PROTEIN DEGLUTAMYLATION | 6 | 6.73e-01 | 9.27e-01 | 0.7200 | -2.74e-01 | -2.67e-01 | -3.79e-01 | -3.29e-01 | -3.46e-01 | 2.45e-01 | 2.58e-01 | 1.08e-01 | 1.63e-01 | 1.43e-01 |
| CHAPERONE COFACTOR DEPENDENT PROTEIN REFOLDING | 32 | 2.71e-03 | 3.88e-02 | 0.7190 | 2.27e-01 | 2.61e-01 | 3.63e-01 | 3.73e-01 | 3.57e-01 | 2.64e-02 | 1.07e-02 | 3.72e-04 | 2.63e-04 | 4.82e-04 |
| REGULATION OF POLYAMINE TRANSMEMBRANE TRANSPORT | 5 | 7.52e-01 | 9.51e-01 | 0.7190 | 3.48e-01 | 2.79e-01 | 3.53e-01 | 4.07e-01 | 1.68e-01 | 1.78e-01 | 2.80e-01 | 1.72e-01 | 1.15e-01 | 5.14e-01 |
| MAINTENANCE OF APICAL BASAL CELL POLARITY | 10 | 1.44e-01 | 5.10e-01 | 0.7190 | 1.72e-01 | 2.05e-01 | 3.25e-01 | 3.79e-01 | 4.43e-01 | 3.47e-01 | 2.62e-01 | 7.52e-02 | 3.81e-02 | 1.52e-02 |
| INTERFERON BETA PRODUCTION | 56 | 6.19e-05 | 1.87e-03 | 0.7190 | 3.87e-01 | 3.73e-01 | 3.11e-01 | 3.31e-01 | 1.45e-01 | 5.48e-07 | 1.37e-06 | 5.54e-05 | 1.78e-05 | 5.97e-02 |
| EMBRYONIC BRAIN DEVELOPMENT | 16 | 9.81e-02 | 4.26e-01 | 0.7180 | 2.74e-01 | 2.77e-01 | 3.24e-01 | 3.31e-01 | 3.86e-01 | 5.78e-02 | 5.51e-02 | 2.50e-02 | 2.18e-02 | 7.45e-03 |
| REGULATION OF ELECTRON TRANSFER ACTIVITY | 6 | 2.63e-01 | 6.70e-01 | 0.7160 | 3.64e-01 | 2.04e-01 | 4.21e-01 | 3.64e-01 | 1.72e-01 | 1.23e-01 | 3.88e-01 | 7.43e-02 | 1.23e-01 | 4.65e-01 |
| NEGATIVE REGULATION OF LIPOPROTEIN LIPASE ACTIVITY | 8 | 1.54e-01 | 5.25e-01 | 0.7160 | -2.07e-01 | -1.76e-01 | -2.66e-01 | -3.70e-01 | -4.80e-01 | 3.11e-01 | 3.90e-01 | 1.92e-01 | 6.96e-02 | 1.86e-02 |
| CENP A CONTAINING CHROMATIN ASSEMBLY | 9 | 3.84e-01 | 7.79e-01 | 0.7150 | 3.58e-01 | 2.62e-01 | 3.15e-01 | 4.23e-01 | 1.91e-01 | 6.31e-02 | 1.74e-01 | 1.02e-01 | 2.78e-02 | 3.22e-01 |
| PYRUVATE FAMILY AMINO ACID METABOLIC PROCESS | 5 | 2.23e-01 | 6.23e-01 | 0.7150 | -3.38e-01 | -7.26e-02 | -2.99e-01 | -4.73e-01 | -2.80e-01 | 1.91e-01 | 7.78e-01 | 2.47e-01 | 6.69e-02 | 2.78e-01 |
| MATURATION OF SSU RRNA FROM TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 34 | 4.79e-04 | 9.77e-03 | 0.7140 | 2.66e-01 | 2.13e-01 | 3.91e-01 | 3.34e-01 | 3.60e-01 | 7.22e-03 | 3.14e-02 | 7.81e-05 | 7.54e-04 | 2.81e-04 |
| NEUTROPHIL EXTRAVASATION | 11 | 1.28e-02 | 1.21e-01 | 0.7140 | 4.05e-01 | 4.39e-01 | 1.27e-01 | 3.37e-01 | -1.53e-01 | 2.00e-02 | 1.16e-02 | 4.67e-01 | 5.27e-02 | 3.79e-01 |
| PROTEIN INSERTION INTO ER MEMBRANE BY STOP TRANSFER MEMBRANE ANCHOR SEQUENCE | 10 | 3.05e-01 | 7.18e-01 | 0.7140 | 3.96e-01 | 2.81e-01 | 3.11e-01 | 3.47e-01 | 2.39e-01 | 3.03e-02 | 1.24e-01 | 8.82e-02 | 5.76e-02 | 1.90e-01 |
| RNA POLYMERASE II PREINITIATION COMPLEX ASSEMBLY | 53 | 9.25e-05 | 2.61e-03 | 0.7140 | 2.71e-01 | 3.50e-01 | 3.55e-01 | 3.54e-01 | 2.49e-01 | 6.50e-04 | 1.04e-05 | 7.64e-06 | 8.34e-06 | 1.69e-03 |
| REGULATION OF PROTEIN FOLDING | 8 | 3.50e-01 | 7.52e-01 | 0.7140 | 2.25e-01 | 2.05e-01 | 3.92e-01 | 3.01e-01 | 4.15e-01 | 2.69e-01 | 3.15e-01 | 5.49e-02 | 1.40e-01 | 4.22e-02 |
| MIDBODY ABSCISSION | 17 | 9.91e-02 | 4.28e-01 | 0.7130 | 3.38e-01 | 2.91e-01 | 3.89e-01 | 3.62e-01 | 1.66e-01 | 1.58e-02 | 3.77e-02 | 5.50e-03 | 9.76e-03 | 2.35e-01 |
| REGULATION OF PROTON TRANSPORT | 16 | 7.93e-02 | 3.82e-01 | 0.7130 | 2.66e-01 | 2.22e-01 | 4.00e-01 | 3.56e-01 | 3.20e-01 | 6.52e-02 | 1.24e-01 | 5.58e-03 | 1.38e-02 | 2.69e-02 |
| POSITIVE REGULATION OF URINE VOLUME | 13 | 9.38e-02 | 4.16e-01 | 0.7130 | 1.67e-01 | 3.18e-01 | 3.80e-01 | 3.59e-01 | 3.25e-01 | 2.97e-01 | 4.69e-02 | 1.76e-02 | 2.50e-02 | 4.22e-02 |
| CARDIAC CELL FATE COMMITMENT | 16 | 1.60e-01 | 5.34e-01 | 0.7130 | 3.09e-01 | 3.32e-01 | 3.35e-01 | 3.04e-01 | 3.13e-01 | 3.25e-02 | 2.16e-02 | 2.03e-02 | 3.50e-02 | 3.01e-02 |
| RIBOSOME ASSEMBLY | 58 | 3.24e-05 | 1.08e-03 | 0.7130 | 3.20e-01 | 3.31e-01 | 3.58e-01 | 2.97e-01 | 2.84e-01 | 2.48e-05 | 1.33e-05 | 2.45e-06 | 9.12e-05 | 1.86e-04 |
| CELL PROLIFERATION INVOLVED IN HEART MORPHOGENESIS | 20 | 4.68e-02 | 2.83e-01 | 0.7130 | 2.49e-01 | 3.40e-01 | 3.35e-01 | 3.36e-01 | 3.25e-01 | 5.37e-02 | 8.47e-03 | 9.54e-03 | 9.37e-03 | 1.18e-02 |
| SPINAL CORD MOTOR NEURON CELL FATE SPECIFICATION | 10 | 1.73e-01 | 5.57e-01 | 0.7130 | 1.71e-01 | 2.96e-01 | 3.89e-01 | 2.13e-01 | 4.41e-01 | 3.50e-01 | 1.06e-01 | 3.30e-02 | 2.43e-01 | 1.57e-02 |
| NEGATIVE REGULATION OF PHOSPHOLIPASE ACTIVITY | 7 | 2.39e-01 | 6.44e-01 | 0.7130 | -1.83e-01 | -4.22e-01 | -4.40e-01 | -2.50e-01 | -2.01e-01 | 4.01e-01 | 5.31e-02 | 4.39e-02 | 2.52e-01 | 3.57e-01 |
| MDA 5 SIGNALING PATHWAY | 11 | 2.96e-01 | 7.07e-01 | 0.7130 | 3.15e-01 | 4.04e-01 | 3.41e-01 | 3.47e-01 | 9.40e-02 | 7.00e-02 | 2.04e-02 | 5.04e-02 | 4.61e-02 | 5.89e-01 |
| NEGATIVE REGULATION OF LAMELLIPODIUM ORGANIZATION | 7 | 5.77e-01 | 8.85e-01 | 0.7130 | -3.65e-01 | -4.19e-01 | -3.17e-01 | -2.83e-01 | -1.35e-01 | 9.42e-02 | 5.50e-02 | 1.46e-01 | 1.94e-01 | 5.36e-01 |
| LEUKOCYTE CHEMOTAXIS INVOLVED IN INFLAMMATORY RESPONSE | 8 | 3.33e-01 | 7.40e-01 | 0.7120 | 2.09e-01 | 2.11e-01 | 3.98e-01 | 2.80e-01 | 4.26e-01 | 3.05e-01 | 3.01e-01 | 5.14e-02 | 1.70e-01 | 3.69e-02 |
| GALACTOSE METABOLIC PROCESS | 8 | 3.44e-01 | 7.50e-01 | 0.7110 | 4.33e-01 | 4.05e-01 | 2.20e-01 | 3.20e-01 | 5.32e-02 | 3.38e-02 | 4.71e-02 | 2.82e-01 | 1.17e-01 | 7.94e-01 |
| TRNA 5 LEADER REMOVAL | 13 | 1.03e-01 | 4.36e-01 | 0.7100 | 2.20e-01 | 2.04e-01 | 4.08e-01 | 4.04e-01 | 2.92e-01 | 1.70e-01 | 2.02e-01 | 1.08e-02 | 1.17e-02 | 6.88e-02 |
| DNA REPLICATION INITIATION | 35 | 8.50e-03 | 9.10e-02 | 0.7090 | 3.47e-01 | 3.17e-01 | 3.51e-01 | 3.57e-01 | 1.75e-01 | 3.79e-04 | 1.16e-03 | 3.21e-04 | 2.54e-04 | 7.33e-02 |
| AEROBIC RESPIRATION | 170 | 2.39e-14 | 3.15e-12 | 0.7090 | 3.30e-01 | 3.13e-01 | 3.43e-01 | 3.47e-01 | 2.38e-01 | 1.04e-13 | 1.71e-12 | 1.20e-14 | 5.27e-15 | 8.33e-08 |
| MRNA CIS SPLICING VIA SPLICEOSOME | 26 | 4.15e-02 | 2.64e-01 | 0.7090 | 3.21e-01 | 2.99e-01 | 3.55e-01 | 3.45e-01 | 2.54e-01 | 4.59e-03 | 8.26e-03 | 1.71e-03 | 2.34e-03 | 2.51e-02 |
| ATF6 MEDIATED UNFOLDED PROTEIN RESPONSE | 8 | 4.67e-01 | 8.27e-01 | 0.7080 | 2.03e-01 | 2.80e-01 | 3.54e-01 | 3.36e-01 | 3.79e-01 | 3.21e-01 | 1.70e-01 | 8.32e-02 | 1.00e-01 | 6.33e-02 |
| REGULATION OF ODONTOGENESIS OF DENTIN CONTAINING TOOTH | 12 | 1.94e-01 | 5.81e-01 | 0.7080 | 2.14e-01 | 2.83e-01 | 3.35e-01 | 3.62e-01 | 3.63e-01 | 1.98e-01 | 8.95e-02 | 4.47e-02 | 3.00e-02 | 2.94e-02 |
| POSITIVE REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 10 | 3.38e-01 | 7.43e-01 | 0.7080 | 3.03e-01 | 2.97e-01 | 3.50e-01 | 2.78e-01 | 3.48e-01 | 9.68e-02 | 1.04e-01 | 5.50e-02 | 1.28e-01 | 5.69e-02 |
| RESPONSE TO UV C | 14 | 2.06e-01 | 5.99e-01 | 0.7070 | 3.58e-01 | 3.14e-01 | 3.02e-01 | 4.04e-01 | 1.39e-01 | 2.04e-02 | 4.20e-02 | 5.06e-02 | 8.81e-03 | 3.68e-01 |
| RESPONSE TO INCREASED OXYGEN LEVELS | 24 | 4.76e-02 | 2.86e-01 | 0.7070 | 2.55e-01 | 3.07e-01 | 3.62e-01 | 3.30e-01 | 3.16e-01 | 3.04e-02 | 9.11e-03 | 2.14e-03 | 5.11e-03 | 7.28e-03 |
| RESPONSE TO LECTIN | 22 | 1.80e-02 | 1.57e-01 | 0.7060 | -1.94e-01 | -2.96e-01 | -3.97e-01 | -2.57e-01 | -3.86e-01 | 1.16e-01 | 1.61e-02 | 1.26e-03 | 3.68e-02 | 1.70e-03 |
| NEGATIVE REGULATION OF LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL | 11 | 3.68e-01 | 7.68e-01 | 0.7060 | -2.62e-01 | -3.15e-01 | -3.45e-01 | -3.69e-01 | -2.73e-01 | 1.32e-01 | 7.02e-02 | 4.76e-02 | 3.42e-02 | 1.17e-01 |
| INDUCTION OF BACTERIAL AGGLUTINATION | 6 | 2.76e-02 | 2.05e-01 | 0.7060 | 4.20e-01 | 3.04e-01 | -7.50e-02 | -4.43e-02 | -4.70e-01 | 7.49e-02 | 1.97e-01 | 7.50e-01 | 8.51e-01 | 4.60e-02 |
| NEUTROPHIL MEDIATED KILLING OF SYMBIONT CELL | 12 | 3.96e-02 | 2.57e-01 | 0.7050 | 4.31e-01 | 4.15e-01 | 1.55e-01 | 2.97e-01 | -1.65e-01 | 9.67e-03 | 1.29e-02 | 3.54e-01 | 7.51e-02 | 3.23e-01 |
| REGULATION OF LENS FIBER CELL DIFFERENTIATION | 9 | 3.85e-01 | 7.79e-01 | 0.7050 | 1.92e-01 | 2.47e-01 | 3.59e-01 | 3.19e-01 | 4.10e-01 | 3.19e-01 | 1.99e-01 | 6.18e-02 | 9.79e-02 | 3.31e-02 |
| ATTACHMENT OF GPI ANCHOR TO PROTEIN | 6 | 5.09e-01 | 8.53e-01 | 0.7040 | 1.42e-01 | 2.02e-01 | 3.79e-01 | 3.58e-01 | 4.04e-01 | 5.46e-01 | 3.91e-01 | 1.08e-01 | 1.29e-01 | 8.66e-02 |
| REGULATION OF CELLULAR RESPONSE TO OSMOTIC STRESS | 13 | 1.18e-01 | 4.69e-01 | 0.7040 | 3.04e-01 | 4.30e-01 | 2.95e-01 | 3.15e-01 | 1.80e-01 | 5.78e-02 | 7.27e-03 | 6.59e-02 | 4.89e-02 | 2.61e-01 |
| MITOCHONDRIAL TRANSLATION | 130 | 7.34e-11 | 6.21e-09 | 0.7040 | 2.98e-01 | 3.15e-01 | 3.41e-01 | 3.58e-01 | 2.52e-01 | 4.58e-09 | 5.40e-10 | 1.98e-11 | 1.75e-12 | 7.00e-07 |
| NEGATIVE REGULATION OF MUSCLE ORGAN DEVELOPMENT | 9 | 1.86e-01 | 5.72e-01 | 0.7040 | 8.60e-02 | 2.72e-01 | 3.92e-01 | 2.46e-01 | 4.46e-01 | 6.55e-01 | 1.57e-01 | 4.14e-02 | 2.01e-01 | 2.06e-02 |
| POSITIVE REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 5 | 7.31e-01 | 9.45e-01 | 0.7040 | -4.22e-01 | -3.70e-01 | -2.73e-01 | -3.06e-01 | -1.08e-01 | 1.02e-01 | 1.52e-01 | 2.90e-01 | 2.36e-01 | 6.77e-01 |
| LUNG SACCULE DEVELOPMENT | 10 | 1.94e-01 | 5.80e-01 | 0.7030 | 1.63e-01 | 2.30e-01 | 3.96e-01 | 3.98e-01 | 3.15e-01 | 3.72e-01 | 2.09e-01 | 2.99e-02 | 2.92e-02 | 8.41e-02 |
| REGULATION OF VERY LOW DENSITY LIPOPROTEIN PARTICLE REMODELING | 6 | 3.81e-02 | 2.52e-01 | 0.7030 | -3.87e-01 | -2.84e-02 | -1.91e-01 | -4.72e-01 | -2.92e-01 | 1.01e-01 | 9.04e-01 | 4.18e-01 | 4.55e-02 | 2.16e-01 |
| REGULATION OF ACROSOME REACTION | 17 | 1.26e-01 | 4.83e-01 | 0.7020 | -3.62e-01 | -2.81e-01 | -3.11e-01 | -3.96e-01 | -1.71e-01 | 9.84e-03 | 4.45e-02 | 2.62e-02 | 4.67e-03 | 2.21e-01 |
| CELLULAR RESPONSE TO NITROGEN STARVATION | 12 | 1.73e-01 | 5.57e-01 | 0.7020 | 3.95e-01 | 3.93e-01 | 2.38e-01 | 3.54e-01 | 2.39e-02 | 1.78e-02 | 1.83e-02 | 1.53e-01 | 3.38e-02 | 8.86e-01 |
| CAMP CATABOLIC PROCESS | 9 | 5.02e-01 | 8.48e-01 | 0.7010 | -3.24e-01 | -3.39e-01 | -3.81e-01 | -3.27e-01 | -1.41e-01 | 9.26e-02 | 7.83e-02 | 4.81e-02 | 8.92e-02 | 4.62e-01 |
| OLIGOSACCHARIDE LIPID INTERMEDIATE BIOSYNTHETIC PROCESS | 20 | 6.41e-02 | 3.37e-01 | 0.7010 | 4.03e-01 | 3.45e-01 | 2.70e-01 | 3.39e-01 | 1.50e-01 | 1.82e-03 | 7.57e-03 | 3.68e-02 | 8.64e-03 | 2.46e-01 |
| PERICYTE CELL DIFFERENTIATION | 11 | 1.66e-01 | 5.46e-01 | 0.7010 | 2.89e-01 | 4.29e-01 | 3.04e-01 | 2.53e-01 | 2.59e-01 | 9.67e-02 | 1.37e-02 | 8.13e-02 | 1.46e-01 | 1.38e-01 |
| SPERMIDINE METABOLIC PROCESS | 6 | 5.52e-01 | 8.75e-01 | 0.7000 | 1.85e-01 | 2.20e-01 | 3.73e-01 | 2.66e-01 | 4.45e-01 | 4.34e-01 | 3.50e-01 | 1.14e-01 | 2.59e-01 | 5.93e-02 |
| POSITIVE REGULATION OF PHOSPHOLIPASE A2 ACTIVITY | 5 | 2.66e-01 | 6.73e-01 | 0.6990 | 5.26e-01 | 2.39e-01 | 2.28e-01 | 3.19e-01 | 3.11e-02 | 4.17e-02 | 3.54e-01 | 3.76e-01 | 2.16e-01 | 9.04e-01 |
| 5S CLASS RRNA TRANSCRIPTION BY RNA POLYMERASE III | 6 | 2.41e-01 | 6.45e-01 | 0.6990 | 3.85e-01 | 2.42e-01 | 2.75e-01 | 2.40e-01 | 3.86e-01 | 1.03e-01 | 3.06e-01 | 2.43e-01 | 3.09e-01 | 1.01e-01 |
| MUSCULAR SEPTUM MORPHOGENESIS | 5 | 3.14e-01 | 7.25e-01 | 0.6990 | 4.75e-02 | 1.65e-01 | 4.42e-01 | 1.78e-01 | 4.81e-01 | 8.54e-01 | 5.23e-01 | 8.70e-02 | 4.90e-01 | 6.25e-02 |
| REGULATION OF LYSOSOME SIZE | 8 | 2.35e-01 | 6.37e-01 | 0.6980 | 1.18e-01 | 1.88e-01 | 4.36e-01 | 2.70e-01 | 4.18e-01 | 5.63e-01 | 3.57e-01 | 3.27e-02 | 1.87e-01 | 4.04e-02 |
| NEGATIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 14 | 1.37e-01 | 4.99e-01 | 0.6980 | 2.89e-01 | 2.22e-01 | 3.11e-01 | 3.89e-01 | 3.26e-01 | 6.07e-02 | 1.50e-01 | 4.39e-02 | 1.18e-02 | 3.48e-02 |
| REGULATION OF ER ASSOCIATED UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 7 | 4.49e-01 | 8.20e-01 | 0.6970 | 2.76e-01 | 2.52e-01 | 2.79e-01 | 3.83e-01 | 3.49e-01 | 2.06e-01 | 2.47e-01 | 2.00e-01 | 7.94e-02 | 1.10e-01 |
| REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 10 | 1.37e-01 | 5.00e-01 | 0.6970 | 2.39e-01 | 1.52e-01 | 2.94e-01 | 3.29e-01 | 4.60e-01 | 1.90e-01 | 4.05e-01 | 1.07e-01 | 7.19e-02 | 1.18e-02 |
| REGULATION OF TYPE B PANCREATIC CELL PROLIFERATION | 13 | 1.01e-01 | 4.33e-01 | 0.6970 | 1.85e-01 | 3.00e-01 | 3.89e-01 | 2.14e-01 | 4.05e-01 | 2.48e-01 | 6.14e-02 | 1.50e-02 | 1.81e-01 | 1.15e-02 |
| REGULATION OF UBIQUITIN PROTEIN TRANSFERASE ACTIVITY | 36 | 2.88e-04 | 6.33e-03 | 0.6970 | 2.39e-01 | 1.83e-01 | 3.59e-01 | 3.93e-01 | 3.34e-01 | 1.31e-02 | 5.68e-02 | 1.96e-04 | 4.40e-05 | 5.29e-04 |
| NEGATIVE REGULATION OF RIBOSOME BIOGENESIS | 7 | 4.62e-01 | 8.25e-01 | 0.6960 | 3.48e-01 | 2.06e-01 | 3.22e-01 | 3.82e-01 | 2.68e-01 | 1.11e-01 | 3.45e-01 | 1.40e-01 | 7.98e-02 | 2.20e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR | 16 | 1.14e-01 | 4.60e-01 | 0.6960 | 3.04e-01 | 3.02e-01 | 2.97e-01 | 4.02e-01 | 2.28e-01 | 3.55e-02 | 3.67e-02 | 3.99e-02 | 5.39e-03 | 1.15e-01 |
| ACYLGLYCEROL TRANSPORT | 8 | 1.05e-01 | 4.43e-01 | 0.6960 | -8.41e-02 | -6.92e-02 | -3.83e-01 | -2.29e-01 | -5.23e-01 | 6.80e-01 | 7.35e-01 | 6.08e-02 | 2.63e-01 | 1.04e-02 |
| METANEPHRIC GLOMERULAR MESANGIUM DEVELOPMENT | 5 | 3.46e-01 | 7.50e-01 | 0.6960 | 4.44e-01 | 4.66e-01 | 2.00e-01 | 1.68e-01 | 4.48e-02 | 8.59e-02 | 7.14e-02 | 4.39e-01 | 5.14e-01 | 8.62e-01 |
| PHENYLPROPANOID METABOLIC PROCESS | 7 | 8.27e-02 | 3.89e-01 | 0.6950 | -2.47e-01 | -1.78e-01 | -3.40e-01 | -5.23e-01 | -4.40e-02 | 2.57e-01 | 4.15e-01 | 1.20e-01 | 1.66e-02 | 8.40e-01 |
| CALCIUM ION TRANSMEMBRANE TRANSPORT VIA HIGH VOLTAGE GATED CALCIUM CHANNEL | 18 | 1.32e-02 | 1.24e-01 | 0.6950 | -3.47e-01 | -1.96e-01 | -2.81e-01 | -4.51e-01 | -2.05e-01 | 1.08e-02 | 1.50e-01 | 3.89e-02 | 9.13e-04 | 1.32e-01 |
| EMBRYONIC FORELIMB MORPHOGENESIS | 33 | 1.15e-02 | 1.12e-01 | 0.6950 | 2.59e-01 | 2.83e-01 | 3.66e-01 | 3.30e-01 | 3.05e-01 | 1.00e-02 | 4.94e-03 | 2.78e-04 | 1.03e-03 | 2.41e-03 |
| LYSOSOMAL LUMEN ACIDIFICATION | 20 | 2.88e-02 | 2.11e-01 | 0.6950 | 1.58e-01 | 2.74e-01 | 3.88e-01 | 3.38e-01 | 3.43e-01 | 2.22e-01 | 3.41e-02 | 2.63e-03 | 8.79e-03 | 8.00e-03 |
| BUNDLE OF HIS CELL TO PURKINJE MYOCYTE SIGNALING | 7 | 3.60e-01 | 7.59e-01 | 0.6950 | -2.85e-01 | -2.43e-01 | -2.53e-01 | -3.72e-01 | -3.73e-01 | 1.91e-01 | 2.65e-01 | 2.47e-01 | 8.82e-02 | 8.71e-02 |
| REGULATION OF INNER EAR AUDITORY RECEPTOR CELL DIFFERENTIATION | 9 | 4.15e-01 | 7.98e-01 | 0.6940 | 1.87e-01 | 2.92e-01 | 3.63e-01 | 3.13e-01 | 3.64e-01 | 3.31e-01 | 1.29e-01 | 5.96e-02 | 1.04e-01 | 5.86e-02 |
| POST TRANSLATIONAL PROTEIN TARGETING TO ENDOPLASMIC RETICULUM MEMBRANE | 15 | 9.58e-02 | 4.20e-01 | 0.6940 | 2.89e-01 | 3.31e-01 | 4.11e-01 | 3.31e-01 | 9.80e-02 | 5.26e-02 | 2.63e-02 | 5.84e-03 | 2.66e-02 | 5.11e-01 |
| REGULATION OF AEROBIC RESPIRATION | 30 | 2.46e-02 | 1.91e-01 | 0.6940 | 3.18e-01 | 3.10e-01 | 3.55e-01 | 3.18e-01 | 2.38e-01 | 2.54e-03 | 3.29e-03 | 7.65e-04 | 2.57e-03 | 2.41e-02 |
| FLAVIN CONTAINING COMPOUND METABOLIC PROCESS | 6 | 6.09e-01 | 9.03e-01 | 0.6930 | 2.63e-01 | 3.58e-01 | 4.15e-01 | 2.91e-01 | 1.61e-01 | 2.64e-01 | 1.29e-01 | 7.81e-02 | 2.16e-01 | 4.95e-01 |
| MITOCHONDRIAL ELECTRON TRANSPORT SUCCINATE TO UBIQUINONE | 5 | 6.79e-01 | 9.28e-01 | 0.6930 | 3.93e-01 | 2.64e-01 | 3.24e-01 | 3.83e-01 | 7.11e-02 | 1.28e-01 | 3.07e-01 | 2.10e-01 | 1.38e-01 | 7.83e-01 |
| REGULATION OF MEIOTIC CELL CYCLE PHASE TRANSITION | 10 | 6.78e-02 | 3.49e-01 | 0.6930 | 1.10e-01 | 1.85e-01 | 4.61e-01 | 3.65e-01 | 2.96e-01 | 5.47e-01 | 3.10e-01 | 1.15e-02 | 4.57e-02 | 1.05e-01 |
| CELLULAR RESPONSE TO HEPARIN | 5 | 5.58e-01 | 8.78e-01 | 0.6930 | 4.66e-01 | 3.07e-01 | 2.76e-01 | 3.04e-01 | 2.78e-02 | 7.14e-02 | 2.34e-01 | 2.86e-01 | 2.40e-01 | 9.14e-01 |
| POSITIVE REGULATION OF MELANOCYTE DIFFERENTIATION | 5 | 6.96e-01 | 9.31e-01 | 0.6920 | -3.05e-01 | -3.13e-01 | -3.95e-01 | -3.55e-01 | -7.81e-02 | 2.37e-01 | 2.26e-01 | 1.26e-01 | 1.69e-01 | 7.62e-01 |
| AV NODE CELL TO BUNDLE OF HIS CELL SIGNALING | 11 | 1.02e-01 | 4.35e-01 | 0.6920 | -4.21e-01 | -2.90e-01 | -2.03e-01 | -3.57e-01 | -2.21e-01 | 1.56e-02 | 9.53e-02 | 2.45e-01 | 4.03e-02 | 2.04e-01 |
| PROTEIN K11 LINKED UBIQUITINATION | 28 | 3.68e-03 | 4.91e-02 | 0.6920 | 3.18e-01 | 2.15e-01 | 3.32e-01 | 4.23e-01 | 2.06e-01 | 3.57e-03 | 4.92e-02 | 2.35e-03 | 1.06e-04 | 5.92e-02 |
| NEGATIVE REGULATION OF LENS FIBER CELL DIFFERENTIATION | 6 | 4.91e-01 | 8.42e-01 | 0.6920 | 1.19e-01 | 2.76e-01 | 3.65e-01 | 2.40e-01 | 4.44e-01 | 6.12e-01 | 2.41e-01 | 1.22e-01 | 3.08e-01 | 5.94e-02 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR | 43 | 7.73e-04 | 1.42e-02 | 0.6920 | 2.88e-01 | 3.02e-01 | 3.33e-01 | 3.97e-01 | 1.91e-01 | 1.07e-03 | 6.04e-04 | 1.61e-04 | 6.78e-06 | 3.06e-02 |
| NEGATIVE REGULATION OF STEM CELL POPULATION MAINTENANCE | 24 | 5.89e-02 | 3.21e-01 | 0.6910 | 3.05e-01 | 2.79e-01 | 3.57e-01 | 3.69e-01 | 2.08e-01 | 9.68e-03 | 1.79e-02 | 2.48e-03 | 1.73e-03 | 7.78e-02 |
| MITOCHONDRIAL PROTON TRANSPORTING ATP SYNTHASE COMPLEX ASSEMBLY | 8 | 3.13e-01 | 7.25e-01 | 0.6910 | 3.96e-01 | 3.12e-01 | 3.50e-01 | 2.61e-01 | 1.83e-01 | 5.23e-02 | 1.26e-01 | 8.68e-02 | 2.01e-01 | 3.71e-01 |
| RIBOSOME BIOGENESIS | 304 | 1.01e-27 | 4.48e-25 | 0.6910 | 2.83e-01 | 2.93e-01 | 3.76e-01 | 3.11e-01 | 2.71e-01 | 2.13e-17 | 1.57e-18 | 1.30e-29 | 1.02e-20 | 3.82e-16 |
| REGULATION OF DEVELOPMENT HETEROCHRONIC | 12 | 1.30e-01 | 4.87e-01 | 0.6900 | 1.68e-01 | 2.61e-01 | 3.12e-01 | 2.68e-01 | 4.59e-01 | 3.14e-01 | 1.18e-01 | 6.13e-02 | 1.08e-01 | 5.89e-03 |
| MESANGIAL CELL DIFFERENTIATION | 7 | 1.79e-01 | 5.63e-01 | 0.6900 | 2.28e-01 | 4.37e-01 | 3.10e-01 | 1.46e-01 | 3.40e-01 | 2.95e-01 | 4.52e-02 | 1.55e-01 | 5.04e-01 | 1.20e-01 |
| REGULATION OF HIGH DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 10 | 5.74e-02 | 3.16e-01 | 0.6900 | -1.54e-01 | -7.83e-02 | -3.48e-01 | -2.50e-01 | -5.13e-01 | 4.00e-01 | 6.68e-01 | 5.69e-02 | 1.72e-01 | 5.00e-03 |
| TETRAHYDROBIOPTERIN METABOLIC PROCESS | 8 | 3.10e-01 | 7.22e-01 | 0.6900 | 3.45e-01 | 2.95e-01 | 2.29e-01 | 3.83e-01 | 2.64e-01 | 9.08e-02 | 1.49e-01 | 2.62e-01 | 6.04e-02 | 1.96e-01 |
| MAINTENANCE OF PROTEIN LOCALIZATION IN ENDOPLASMIC RETICULUM | 12 | 3.85e-02 | 2.54e-01 | 0.6890 | 2.56e-01 | 3.47e-01 | 4.61e-01 | 2.49e-01 | 1.23e-01 | 1.25e-01 | 3.76e-02 | 5.68e-03 | 1.36e-01 | 4.61e-01 |
| FATTY ACID OMEGA OXIDATION | 5 | 5.67e-01 | 8.81e-01 | 0.6890 | -3.28e-01 | -3.16e-01 | -4.03e-01 | -2.38e-01 | -2.20e-01 | 2.04e-01 | 2.21e-01 | 1.18e-01 | 3.57e-01 | 3.94e-01 |
| DE NOVO PROTEIN FOLDING | 41 | 7.10e-04 | 1.32e-02 | 0.6890 | 2.21e-01 | 2.41e-01 | 3.51e-01 | 3.58e-01 | 3.42e-01 | 1.44e-02 | 7.57e-03 | 1.01e-04 | 7.43e-05 | 1.49e-04 |
| POSITIVE REGULATION BY HOST OF VIRAL GENOME REPLICATION | 10 | 1.57e-01 | 5.28e-01 | 0.6890 | 3.97e-01 | 2.21e-01 | 2.43e-01 | 3.88e-01 | 2.43e-01 | 2.95e-02 | 2.26e-01 | 1.84e-01 | 3.38e-02 | 1.84e-01 |
| REGULATION OF EXIT FROM MITOSIS | 18 | 1.01e-03 | 1.77e-02 | 0.6890 | 6.32e-02 | 3.57e-02 | 2.79e-01 | 2.94e-01 | 5.52e-01 | 6.43e-01 | 7.93e-01 | 4.01e-02 | 3.10e-02 | 4.96e-05 |
| POSITIVE REGULATION OF AXON EXTENSION INVOLVED IN AXON GUIDANCE | 7 | 5.34e-01 | 8.64e-01 | 0.6890 | -3.11e-01 | -3.18e-01 | -2.69e-01 | -3.68e-01 | -2.62e-01 | 1.54e-01 | 1.45e-01 | 2.18e-01 | 9.21e-02 | 2.29e-01 |
| RIBOSOMAL LARGE SUBUNIT ASSEMBLY | 24 | 8.07e-02 | 3.84e-01 | 0.6890 | 3.15e-01 | 3.21e-01 | 3.43e-01 | 3.15e-01 | 2.34e-01 | 7.47e-03 | 6.48e-03 | 3.64e-03 | 7.48e-03 | 4.72e-02 |
| RESPONSE TO L GLUTAMATE | 14 | 3.08e-01 | 7.19e-01 | 0.6890 | 2.89e-01 | 3.14e-01 | 3.59e-01 | 3.02e-01 | 2.68e-01 | 6.10e-02 | 4.16e-02 | 2.02e-02 | 5.00e-02 | 8.31e-02 |
| INTESTINAL CHOLESTEROL ABSORPTION | 18 | 3.92e-02 | 2.55e-01 | 0.6880 | -2.89e-01 | -2.04e-01 | -3.42e-01 | -4.29e-01 | -2.17e-01 | 3.36e-02 | 1.34e-01 | 1.20e-02 | 1.63e-03 | 1.10e-01 |
| CHONDROCYTE HYPERTROPHY | 6 | 5.35e-01 | 8.65e-01 | 0.6880 | 1.24e-01 | 2.00e-01 | 3.71e-01 | 3.21e-01 | 4.21e-01 | 5.99e-01 | 3.97e-01 | 1.16e-01 | 1.74e-01 | 7.39e-02 |
| ANTIGEN PROCESSING AND PRESENTATION OF LIPID ANTIGEN VIA MHC CLASS IB | 7 | 1.51e-02 | 1.36e-01 | 0.6880 | -2.41e-01 | -4.82e-01 | -3.08e-01 | 1.18e-02 | -2.96e-01 | 2.70e-01 | 2.72e-02 | 1.58e-01 | 9.57e-01 | 1.75e-01 |
| NITRIC OXIDE TRANSPORT | 5 | 9.43e-03 | 9.76e-02 | 0.6870 | -5.62e-01 | -2.50e-01 | -2.75e-01 | -1.18e-01 | 6.79e-02 | 2.96e-02 | 3.32e-01 | 2.88e-01 | 6.48e-01 | 7.93e-01 |
| POSITIVE REGULATION OF PHOSPHOLIPID TRANSLOCATION | 5 | 5.53e-01 | 8.76e-01 | 0.6860 | -2.64e-01 | -3.97e-01 | -3.07e-01 | -1.92e-01 | -3.35e-01 | 3.07e-01 | 1.25e-01 | 2.35e-01 | 4.57e-01 | 1.94e-01 |
| MITOTIC CHROMOSOME CONDENSATION | 19 | 2.57e-02 | 1.96e-01 | 0.6860 | 2.82e-01 | 1.85e-01 | 3.78e-01 | 3.79e-01 | 2.65e-01 | 3.36e-02 | 1.62e-01 | 4.35e-03 | 4.26e-03 | 4.55e-02 |
| POSITIVE REGULATION OF T CELL RECEPTOR SIGNALING PATHWAY | 16 | 1.57e-02 | 1.41e-01 | 0.6860 | 8.46e-02 | 1.58e-01 | 3.92e-01 | 3.58e-01 | 3.95e-01 | 5.58e-01 | 2.72e-01 | 6.67e-03 | 1.31e-02 | 6.25e-03 |
| SERINE TRANSPORT | 9 | 4.29e-01 | 8.05e-01 | 0.6850 | 4.01e-01 | 3.52e-01 | 2.99e-01 | 2.77e-01 | 1.34e-01 | 3.72e-02 | 6.75e-02 | 1.20e-01 | 1.50e-01 | 4.86e-01 |
| NUCLEOSOME ORGANIZATION | 119 | 1.42e-09 | 9.96e-08 | 0.6850 | 3.17e-01 | 3.04e-01 | 3.59e-01 | 3.33e-01 | 1.89e-01 | 2.16e-09 | 9.61e-09 | 1.30e-11 | 3.52e-10 | 3.79e-04 |
| NEGATIVE REGULATION OF MEGAKARYOCYTE DIFFERENTIATION | 18 | 7.88e-02 | 3.81e-01 | 0.6840 | 2.72e-01 | 2.63e-01 | 4.05e-01 | 3.20e-01 | 2.42e-01 | 4.58e-02 | 5.34e-02 | 2.95e-03 | 1.87e-02 | 7.58e-02 |
| MESENCHYMAL CELL DEVELOPMENT | 6 | 6.38e-01 | 9.13e-01 | 0.6840 | 2.20e-01 | 3.50e-01 | 3.92e-01 | 3.27e-01 | 1.91e-01 | 3.51e-01 | 1.38e-01 | 9.68e-02 | 1.65e-01 | 4.18e-01 |
| BILE ACID AND BILE SALT TRANSPORT | 28 | 1.37e-03 | 2.26e-02 | 0.6830 | -1.30e-01 | -1.96e-01 | -4.12e-01 | -2.95e-01 | -3.92e-01 | 2.35e-01 | 7.21e-02 | 1.59e-04 | 6.80e-03 | 3.26e-04 |
| METANEPHRIC TUBULE MORPHOGENESIS | 11 | 9.78e-02 | 4.26e-01 | 0.6830 | 3.45e-01 | 4.27e-01 | 3.52e-01 | 1.83e-01 | 8.89e-02 | 4.74e-02 | 1.42e-02 | 4.34e-02 | 2.93e-01 | 6.10e-01 |
| CELL DIFFERENTIATION INVOLVED IN PHENOTYPIC SWITCHING | 5 | 8.22e-01 | 9.71e-01 | 0.6830 | 3.31e-01 | 3.40e-01 | 3.25e-01 | 3.55e-01 | 9.42e-02 | 2.00e-01 | 1.88e-01 | 2.08e-01 | 1.69e-01 | 7.15e-01 |
| MODULATION OF INHIBITORY POSTSYNAPTIC POTENTIAL | 7 | 3.80e-01 | 7.77e-01 | 0.6830 | -4.00e-01 | -4.45e-01 | -2.24e-01 | -2.40e-01 | 2.22e-02 | 6.71e-02 | 4.16e-02 | 3.04e-01 | 2.71e-01 | 9.19e-01 |
| REGULATION OF DNA TEMPLATED DNA REPLICATION INITIATION | 15 | 2.52e-01 | 6.58e-01 | 0.6820 | 3.29e-01 | 3.42e-01 | 3.14e-01 | 2.91e-01 | 2.40e-01 | 2.75e-02 | 2.19e-02 | 3.53e-02 | 5.12e-02 | 1.08e-01 |
| DTMP METABOLIC PROCESS | 6 | 4.41e-01 | 8.12e-01 | 0.6820 | 4.21e-01 | 3.87e-01 | 1.85e-01 | 2.99e-01 | 1.22e-01 | 7.42e-02 | 1.01e-01 | 4.33e-01 | 2.05e-01 | 6.05e-01 |
| POSITIVE REGULATION OF THYROID HORMONE GENERATION | 5 | 1.44e-01 | 5.11e-01 | 0.6820 | 2.39e-01 | 5.34e-01 | 3.19e-01 | 1.25e-01 | -7.45e-02 | 3.55e-01 | 3.86e-02 | 2.17e-01 | 6.30e-01 | 7.73e-01 |
| TRANS SYNAPTIC SIGNALING BY LIPID | 7 | 6.39e-01 | 9.14e-01 | 0.6820 | -3.35e-01 | -2.89e-01 | -3.55e-01 | -3.62e-01 | -1.14e-01 | 1.25e-01 | 1.85e-01 | 1.04e-01 | 9.76e-02 | 6.01e-01 |
| NEGATIVE REGULATION OF CELL FATE COMMITMENT | 11 | 3.43e-01 | 7.50e-01 | 0.6820 | 2.41e-01 | 2.59e-01 | 3.43e-01 | 2.84e-01 | 3.76e-01 | 1.67e-01 | 1.37e-01 | 4.85e-02 | 1.03e-01 | 3.10e-02 |
| NEGATIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 6 | 3.76e-01 | 7.75e-01 | 0.6810 | -2.85e-01 | -3.34e-01 | -3.33e-01 | -3.94e-01 | 7.71e-02 | 2.27e-01 | 1.57e-01 | 1.58e-01 | 9.48e-02 | 7.44e-01 |
| SEGMENT SPECIFICATION | 16 | 1.93e-01 | 5.80e-01 | 0.6810 | 2.28e-01 | 2.66e-01 | 3.71e-01 | 3.17e-01 | 3.22e-01 | 1.15e-01 | 6.55e-02 | 1.03e-02 | 2.82e-02 | 2.56e-02 |
| INTRACELLULAR GLUTAMATE HOMEOSTASIS | 5 | 2.83e-01 | 6.93e-01 | 0.6810 | 3.65e-01 | 3.13e-01 | 1.31e-01 | 3.64e-01 | -2.86e-01 | 1.58e-01 | 2.25e-01 | 6.11e-01 | 1.58e-01 | 2.67e-01 |
| NEGATIVE REGULATION OF RIG I SIGNALING PATHWAY | 8 | 3.85e-01 | 7.79e-01 | 0.6810 | 1.59e-01 | 3.06e-01 | 3.38e-01 | 2.98e-01 | 3.76e-01 | 4.35e-01 | 1.34e-01 | 9.83e-02 | 1.44e-01 | 6.55e-02 |
| OPTIC CUP MORPHOGENESIS INVOLVED IN CAMERA TYPE EYE DEVELOPMENT | 7 | 3.26e-01 | 7.35e-01 | 0.6800 | 3.40e-01 | 2.64e-01 | 2.24e-01 | 3.10e-01 | 3.63e-01 | 1.19e-01 | 2.27e-01 | 3.05e-01 | 1.55e-01 | 9.67e-02 |
| NATURAL KILLER CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 30 | 6.30e-03 | 7.29e-02 | 0.6800 | -2.06e-01 | -2.80e-01 | -3.27e-01 | -2.98e-01 | -3.83e-01 | 5.07e-02 | 7.99e-03 | 1.94e-03 | 4.78e-03 | 2.84e-04 |
| PROTEIN REFOLDING | 27 | 1.76e-03 | 2.75e-02 | 0.6800 | 1.54e-01 | 2.10e-01 | 4.15e-01 | 3.63e-01 | 3.01e-01 | 1.66e-01 | 5.91e-02 | 1.86e-04 | 1.10e-03 | 6.81e-03 |
| DENDRITE SELF AVOIDANCE | 14 | 1.11e-01 | 4.55e-01 | 0.6800 | -3.25e-01 | -3.30e-01 | -2.49e-01 | -3.87e-01 | -1.90e-01 | 3.52e-02 | 3.27e-02 | 1.06e-01 | 1.21e-02 | 2.19e-01 |
| PROTEIN FOLDING IN ENDOPLASMIC RETICULUM | 12 | 3.77e-01 | 7.75e-01 | 0.6790 | 3.67e-01 | 3.21e-01 | 2.90e-01 | 3.60e-01 | 1.01e-01 | 2.76e-02 | 5.45e-02 | 8.20e-02 | 3.08e-02 | 5.44e-01 |
| PEPTIDYL PROLINE MODIFICATION | 33 | 5.73e-03 | 6.79e-02 | 0.6790 | 3.58e-01 | 2.94e-01 | 3.26e-01 | 3.68e-01 | 6.81e-02 | 3.67e-04 | 3.42e-03 | 1.18e-03 | 2.55e-04 | 4.98e-01 |
| NEURAL TUBE PATTERNING | 39 | 3.86e-03 | 5.09e-02 | 0.6790 | 3.17e-01 | 3.00e-01 | 2.97e-01 | 3.35e-01 | 2.66e-01 | 6.24e-04 | 1.19e-03 | 1.32e-03 | 2.95e-04 | 4.04e-03 |
| NEGATIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR PRODUCTION | 22 | 1.92e-02 | 1.62e-01 | 0.6790 | -2.01e-01 | -1.90e-01 | -3.38e-01 | -2.98e-01 | -4.25e-01 | 1.03e-01 | 1.23e-01 | 6.00e-03 | 1.56e-02 | 5.50e-04 |
| PERIPHERAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 15 | 1.76e-01 | 5.61e-01 | 0.6780 | 1.90e-01 | 2.59e-01 | 3.58e-01 | 3.02e-01 | 3.70e-01 | 2.02e-01 | 8.19e-02 | 1.63e-02 | 4.26e-02 | 1.32e-02 |
| NEGATIVE REGULATION OF RESPIRATORY BURST INVOLVED IN INFLAMMATORY RESPONSE | 5 | 7.89e-01 | 9.63e-01 | 0.6780 | 3.01e-01 | 3.30e-01 | 3.80e-01 | 3.16e-01 | 1.27e-01 | 2.44e-01 | 2.01e-01 | 1.41e-01 | 2.21e-01 | 6.22e-01 |
| NEGATIVE REGULATION OF SECONDARY METABOLITE BIOSYNTHETIC PROCESS | 5 | 8.38e-01 | 9.73e-01 | 0.6770 | -3.60e-01 | -3.43e-01 | -3.10e-01 | -3.18e-01 | -1.21e-01 | 1.63e-01 | 1.84e-01 | 2.30e-01 | 2.18e-01 | 6.39e-01 |
| NAIL DEVELOPMENT | 11 | 1.57e-01 | 5.28e-01 | 0.6770 | 1.19e-01 | 2.24e-01 | 4.09e-01 | 2.42e-01 | 4.10e-01 | 4.95e-01 | 1.98e-01 | 1.87e-02 | 1.64e-01 | 1.85e-02 |
| REGULATION OF COMPLEMENT ACTIVATION CLASSICAL PATHWAY | 9 | 3.77e-01 | 7.75e-01 | 0.6770 | -1.96e-01 | -2.94e-01 | -4.18e-01 | -3.25e-01 | -2.31e-01 | 3.09e-01 | 1.26e-01 | 2.99e-02 | 9.15e-02 | 2.29e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 5 | 8.30e-01 | 9.73e-01 | 0.6770 | 2.83e-01 | 2.65e-01 | 3.31e-01 | 3.43e-01 | 2.84e-01 | 2.73e-01 | 3.04e-01 | 2.00e-01 | 1.85e-01 | 2.72e-01 |
| REGULATION OF CHLORIDE TRANSPORT | 6 | 5.21e-01 | 8.58e-01 | 0.6760 | -1.49e-01 | -2.82e-01 | -3.51e-01 | -3.56e-01 | -3.26e-01 | 5.27e-01 | 2.32e-01 | 1.36e-01 | 1.31e-01 | 1.67e-01 |
| REGULATION OF FAS SIGNALING PATHWAY | 6 | 4.91e-01 | 8.42e-01 | 0.6760 | 4.04e-01 | 2.76e-01 | 2.29e-01 | 4.05e-01 | -4.70e-02 | 8.67e-02 | 2.42e-01 | 3.31e-01 | 8.59e-02 | 8.42e-01 |
| REGULATION OF NODAL SIGNALING PATHWAY INVOLVED IN DETERMINATION OF LEFT RIGHT ASYMMETRY | 5 | 1.08e-01 | 4.49e-01 | 0.6760 | -3.13e-01 | -5.99e-02 | 1.54e-01 | 2.47e-02 | 5.75e-01 | 2.25e-01 | 8.17e-01 | 5.52e-01 | 9.24e-01 | 2.59e-02 |
| MITOCHONDRIAL ELECTRON TRANSPORT CYTOCHROME C TO OXYGEN | 19 | 1.86e-02 | 1.59e-01 | 0.6760 | 2.41e-01 | 1.60e-01 | 2.93e-01 | 3.56e-01 | 4.00e-01 | 6.91e-02 | 2.29e-01 | 2.68e-02 | 7.17e-03 | 2.54e-03 |
| APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS | 27 | 9.64e-03 | 9.89e-02 | 0.6760 | 1.77e-01 | 3.08e-01 | 3.92e-01 | 2.66e-01 | 3.25e-01 | 1.10e-01 | 5.66e-03 | 4.23e-04 | 1.68e-02 | 3.42e-03 |
| ADENINE TRANSPORT | 5 | 4.44e-01 | 8.14e-01 | 0.6750 | 3.39e-01 | 3.02e-01 | 3.70e-01 | 1.89e-01 | 2.79e-01 | 1.90e-01 | 2.43e-01 | 1.52e-01 | 4.65e-01 | 2.79e-01 |
| REGULATION OF LYMPHOID PROGENITOR CELL DIFFERENTIATION | 12 | 2.35e-01 | 6.37e-01 | 0.6750 | 2.97e-01 | 2.42e-01 | 3.01e-01 | 4.17e-01 | 2.12e-01 | 7.48e-02 | 1.46e-01 | 7.14e-02 | 1.23e-02 | 2.04e-01 |
| LIPID DROPLET DISASSEMBLY | 6 | 7.48e-01 | 9.51e-01 | 0.6750 | 2.71e-01 | 3.17e-01 | 3.26e-01 | 3.64e-01 | 2.09e-01 | 2.50e-01 | 1.79e-01 | 1.67e-01 | 1.23e-01 | 3.74e-01 |
| CELLULAR RESPONSE TO ARSENIC CONTAINING SUBSTANCE | 17 | 4.78e-02 | 2.86e-01 | 0.6740 | 1.87e-01 | 3.30e-01 | 4.02e-01 | 3.37e-01 | 1.88e-01 | 1.82e-01 | 1.83e-02 | 4.09e-03 | 1.61e-02 | 1.80e-01 |
| REGULATION OF ENDOSOME SIZE | 13 | 1.02e-01 | 4.34e-01 | 0.6740 | 1.80e-01 | 1.83e-01 | 3.81e-01 | 3.99e-01 | 2.92e-01 | 2.61e-01 | 2.54e-01 | 1.74e-02 | 1.28e-02 | 6.86e-02 |
| POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR RESULTING IN TRANSCRIPTION OF P21 CLASS MEDIATOR | 5 | 6.17e-01 | 9.06e-01 | 0.6740 | 3.96e-01 | 3.89e-01 | 2.47e-01 | 2.64e-01 | -1.24e-01 | 1.25e-01 | 1.32e-01 | 3.40e-01 | 3.06e-01 | 6.31e-01 |
| CD4 POSITIVE CD25 POSITIVE ALPHA BETA REGULATORY T CELL DIFFERENTIATION | 8 | 3.94e-01 | 7.85e-01 | 0.6740 | -2.09e-01 | -2.34e-01 | -3.57e-01 | -2.31e-01 | -4.18e-01 | 3.06e-01 | 2.51e-01 | 8.06e-02 | 2.57e-01 | 4.04e-02 |
| PURINE NUCLEOTIDE SALVAGE | 10 | 3.31e-01 | 7.39e-01 | 0.6740 | 4.18e-01 | 3.41e-01 | 2.79e-01 | 2.91e-01 | 1.83e-02 | 2.20e-02 | 6.22e-02 | 1.26e-01 | 1.11e-01 | 9.20e-01 |
| NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 29 | 6.03e-03 | 7.06e-02 | 0.6740 | 2.37e-01 | 2.06e-01 | 3.15e-01 | 3.63e-01 | 3.53e-01 | 2.73e-02 | 5.54e-02 | 3.31e-03 | 7.26e-04 | 9.99e-04 |
| ALPHA LINOLENIC ACID METABOLIC PROCESS | 9 | 5.29e-01 | 8.62e-01 | 0.6730 | 3.11e-01 | 3.23e-01 | 2.92e-01 | 3.71e-01 | 1.69e-01 | 1.06e-01 | 9.32e-02 | 1.29e-01 | 5.39e-02 | 3.79e-01 |
| GASTRIC MOTILITY | 5 | 2.56e-01 | 6.62e-01 | 0.6730 | 3.00e-01 | 4.21e-01 | 1.79e-01 | 2.29e-01 | 3.18e-01 | 2.45e-01 | 1.03e-01 | 4.89e-01 | 3.75e-01 | 2.18e-01 |
| FORELIMB MORPHOGENESIS | 39 | 7.32e-03 | 8.18e-02 | 0.6730 | 2.74e-01 | 2.87e-01 | 3.40e-01 | 3.13e-01 | 2.86e-01 | 3.04e-03 | 1.96e-03 | 2.38e-04 | 7.07e-04 | 2.03e-03 |
| REGULATION OF SPINDLE ASSEMBLY | 32 | 2.57e-02 | 1.96e-01 | 0.6730 | 3.08e-01 | 2.92e-01 | 3.39e-01 | 3.19e-01 | 2.37e-01 | 2.60e-03 | 4.22e-03 | 9.11e-04 | 1.81e-03 | 2.02e-02 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO OXIDATIVE STRESS | 8 | 4.19e-01 | 8.00e-01 | 0.6720 | -3.34e-01 | -3.90e-01 | -2.72e-01 | -3.35e-01 | 3.14e-02 | 1.01e-01 | 5.59e-02 | 1.83e-01 | 1.00e-01 | 8.78e-01 |
| NEGATIVE REGULATION OF RNA SPLICING | 25 | 4.99e-02 | 2.92e-01 | 0.6720 | 2.73e-01 | 2.67e-01 | 3.14e-01 | 3.43e-01 | 2.98e-01 | 1.82e-02 | 2.07e-02 | 6.60e-03 | 2.96e-03 | 9.78e-03 |
| ADENYLATE CYCLASE INHIBITING G PROTEIN COUPLED GLUTAMATE RECEPTOR SIGNALING PATHWAY | 9 | 2.28e-01 | 6.30e-01 | 0.6720 | -3.59e-01 | -2.51e-01 | -2.26e-01 | -3.24e-01 | -3.22e-01 | 6.21e-02 | 1.92e-01 | 2.41e-01 | 9.26e-02 | 9.48e-02 |
| POSITIVE REGULATION OF LIPOPROTEIN PARTICLE CLEARANCE | 11 | 1.09e-01 | 4.51e-01 | 0.6710 | -1.34e-01 | -1.07e-01 | -3.61e-01 | -2.90e-01 | -4.54e-01 | 4.40e-01 | 5.40e-01 | 3.81e-02 | 9.56e-02 | 9.05e-03 |
| NEGATIVE REGULATION OF VASCULAR ENDOTHELIAL CELL PROLIFERATION | 21 | 2.40e-02 | 1.88e-01 | 0.6710 | -2.03e-01 | -3.11e-01 | -3.85e-01 | -3.64e-01 | -1.76e-01 | 1.07e-01 | 1.35e-02 | 2.26e-03 | 3.84e-03 | 1.63e-01 |
| ELASTIN METABOLIC PROCESS | 8 | 6.34e-01 | 9.12e-01 | 0.6710 | -3.46e-01 | -3.13e-01 | -3.21e-01 | -3.48e-01 | -9.00e-02 | 8.99e-02 | 1.25e-01 | 1.16e-01 | 8.87e-02 | 6.59e-01 |
| POSITIVE REGULATION OF ODONTOGENESIS | 7 | 1.84e-01 | 5.70e-01 | 0.6710 | 1.36e-01 | 4.14e-01 | 3.22e-01 | 2.21e-01 | 3.28e-01 | 5.32e-01 | 5.79e-02 | 1.40e-01 | 3.11e-01 | 1.33e-01 |
| GOLGI VESICLE BUDDING | 10 | 2.40e-01 | 6.44e-01 | 0.6690 | 1.84e-01 | 2.87e-01 | 3.22e-01 | 3.74e-01 | 2.97e-01 | 3.13e-01 | 1.16e-01 | 7.80e-02 | 4.08e-02 | 1.04e-01 |
| MYELOID DENDRITIC CELL DIFFERENTIATION | 20 | 8.33e-02 | 3.90e-01 | 0.6690 | -3.78e-01 | -3.19e-01 | -2.58e-01 | -3.63e-01 | -6.91e-02 | 3.46e-03 | 1.34e-02 | 4.59e-02 | 4.98e-03 | 5.93e-01 |
| MEIOTIC CHROMOSOME CONDENSATION | 6 | 7.02e-01 | 9.32e-01 | 0.6680 | 2.02e-01 | 2.46e-01 | 3.49e-01 | 3.51e-01 | 3.15e-01 | 3.92e-01 | 2.97e-01 | 1.38e-01 | 1.36e-01 | 1.81e-01 |
| RRNA METHYLATION | 24 | 5.11e-03 | 6.23e-02 | 0.6680 | 3.24e-01 | 1.74e-01 | 3.21e-01 | 3.54e-01 | 2.87e-01 | 6.01e-03 | 1.41e-01 | 6.47e-03 | 2.71e-03 | 1.48e-02 |
| NEGATIVE REGULATION OF HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 14 | 1.56e-01 | 5.26e-01 | 0.6680 | 2.90e-01 | 2.30e-01 | 3.11e-01 | 4.20e-01 | 1.90e-01 | 5.99e-02 | 1.36e-01 | 4.42e-02 | 6.55e-03 | 2.19e-01 |
| LATERAL MESODERM DEVELOPMENT | 15 | 3.80e-03 | 5.03e-02 | 0.6680 | -7.64e-02 | 7.91e-02 | 3.01e-01 | 2.01e-01 | 5.50e-01 | 6.09e-01 | 5.96e-01 | 4.33e-02 | 1.79e-01 | 2.26e-04 |
| BONE MARROW DEVELOPMENT | 9 | 5.03e-01 | 8.49e-01 | 0.6670 | 2.51e-01 | 2.19e-01 | 3.46e-01 | 3.57e-01 | 2.95e-01 | 1.93e-01 | 2.55e-01 | 7.26e-02 | 6.38e-02 | 1.25e-01 |
| TRACHEA DEVELOPMENT | 18 | 7.20e-03 | 8.08e-02 | 0.6670 | 1.07e-01 | 2.54e-01 | 3.51e-01 | 3.75e-01 | 3.23e-01 | 4.31e-01 | 6.20e-02 | 9.87e-03 | 5.91e-03 | 1.76e-02 |
| REGULATION OF ER TO GOLGI VESICLE MEDIATED TRANSPORT | 10 | 3.06e-01 | 7.18e-01 | 0.6660 | 2.97e-01 | 2.31e-01 | 2.66e-01 | 3.83e-01 | 2.91e-01 | 1.04e-01 | 2.06e-01 | 1.45e-01 | 3.58e-02 | 1.11e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DEVELOPMENT | 12 | 1.23e-01 | 4.77e-01 | 0.6660 | 1.98e-01 | 3.30e-01 | 3.35e-01 | 1.80e-01 | 3.89e-01 | 2.36e-01 | 4.78e-02 | 4.42e-02 | 2.82e-01 | 1.97e-02 |
| REGULATION OF APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 13 | 7.79e-02 | 3.78e-01 | 0.6660 | 2.19e-01 | 4.04e-01 | 3.87e-01 | 1.96e-01 | 2.10e-01 | 1.72e-01 | 1.16e-02 | 1.57e-02 | 2.20e-01 | 1.89e-01 |
| NEGATIVE REGULATION OF T CELL MEDIATED CYTOTOXICITY | 10 | 3.47e-01 | 7.50e-01 | 0.6660 | -2.89e-01 | -3.87e-01 | -3.03e-01 | -2.34e-01 | -2.51e-01 | 1.13e-01 | 3.41e-02 | 9.72e-02 | 2.01e-01 | 1.69e-01 |
| REGULATION OF SOMITOGENESIS | 6 | 3.65e-02 | 2.46e-01 | 0.6650 | 7.67e-02 | 4.46e-01 | 2.48e-01 | 8.82e-02 | 4.09e-01 | 7.45e-01 | 5.83e-02 | 2.93e-01 | 7.08e-01 | 8.29e-02 |
| NEURON FATE DETERMINATION | 10 | 8.65e-02 | 3.98e-01 | 0.6640 | 4.58e-02 | 6.14e-02 | 3.57e-01 | 2.87e-01 | 4.75e-01 | 8.02e-01 | 7.37e-01 | 5.04e-02 | 1.17e-01 | 9.26e-03 |
| 7 METHYLGUANOSINE CAP HYPERMETHYLATION | 8 | 1.52e-01 | 5.21e-01 | 0.6640 | 6.19e-02 | 1.45e-01 | 4.31e-01 | 3.38e-01 | 3.40e-01 | 7.62e-01 | 4.78e-01 | 3.46e-02 | 9.76e-02 | 9.63e-02 |
| NEGATIVE REGULATION OF DEFENSE RESPONSE TO BACTERIUM | 5 | 8.53e-02 | 3.95e-01 | 0.6640 | 7.69e-03 | -2.87e-01 | -2.58e-01 | -3.13e-01 | -4.40e-01 | 9.76e-01 | 2.67e-01 | 3.18e-01 | 2.26e-01 | 8.81e-02 |
| LOOP OF HENLE DEVELOPMENT | 12 | 2.43e-01 | 6.48e-01 | 0.6640 | 2.40e-01 | 2.81e-01 | 2.91e-01 | 2.70e-01 | 3.83e-01 | 1.50e-01 | 9.17e-02 | 8.10e-02 | 1.05e-01 | 2.17e-02 |
| POSITIVE REGULATION OF BROWN FAT CELL DIFFERENTIATION | 15 | 2.65e-01 | 6.73e-01 | 0.6630 | 2.46e-01 | 3.23e-01 | 3.32e-01 | 2.85e-01 | 2.89e-01 | 9.87e-02 | 3.03e-02 | 2.58e-02 | 5.64e-02 | 5.24e-02 |
| DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR RESULTING IN CELL CYCLE ARREST | 18 | 1.25e-01 | 4.81e-01 | 0.6630 | 2.71e-01 | 2.69e-01 | 3.24e-01 | 3.92e-01 | 1.88e-01 | 4.62e-02 | 4.85e-02 | 1.74e-02 | 3.95e-03 | 1.68e-01 |
| PYRUVATE TRANSPORT | 7 | 3.82e-01 | 7.78e-01 | 0.6630 | 4.25e-01 | 2.31e-01 | 2.83e-01 | 3.45e-01 | 7.94e-02 | 5.15e-02 | 2.89e-01 | 1.94e-01 | 1.14e-01 | 7.16e-01 |
| CEREBELLAR GRANULAR LAYER FORMATION | 6 | 5.32e-01 | 8.63e-01 | 0.6630 | -2.90e-01 | -3.58e-01 | -2.79e-01 | -3.86e-01 | -3.81e-02 | 2.19e-01 | 1.29e-01 | 2.37e-01 | 1.02e-01 | 8.72e-01 |
| DNA CYTOSINE DEAMINATION | 9 | 3.80e-01 | 7.77e-01 | 0.6620 | -4.03e-01 | -2.57e-01 | -2.63e-01 | -3.40e-01 | -1.59e-01 | 3.62e-02 | 1.82e-01 | 1.71e-01 | 7.72e-02 | 4.08e-01 |
| REGULATION OF DNA DIRECTED DNA POLYMERASE ACTIVITY | 9 | 1.31e-01 | 4.90e-01 | 0.6620 | 2.03e-01 | 7.21e-02 | 3.26e-01 | 3.21e-01 | 4.27e-01 | 2.91e-01 | 7.08e-01 | 9.00e-02 | 9.55e-02 | 2.66e-02 |
| SUBTELOMERIC HETEROCHROMATIN FORMATION | 8 | 1.49e-01 | 5.17e-01 | 0.6620 | 1.97e-01 | 1.85e-01 | 2.56e-01 | 1.72e-01 | 5.19e-01 | 3.34e-01 | 3.66e-01 | 2.09e-01 | 3.99e-01 | 1.10e-02 |
| INDOLE CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 5 | 6.53e-01 | 9.20e-01 | 0.6620 | -3.80e-01 | -3.79e-01 | -2.24e-01 | -2.55e-01 | -1.88e-01 | 1.42e-01 | 1.43e-01 | 3.86e-01 | 3.24e-01 | 4.66e-01 |
| NEGATIVE REGULATION OF PROTEIN KINASE ACTIVITY BY REGULATION OF PROTEIN PHOSPHORYLATION | 6 | 6.66e-01 | 9.24e-01 | 0.6620 | 4.16e-01 | 3.39e-01 | 2.48e-01 | 2.89e-01 | 6.59e-02 | 7.78e-02 | 1.50e-01 | 2.92e-01 | 2.20e-01 | 7.80e-01 |
| PROTEIN LOCALIZATION TO CILIARY TRANSITION ZONE | 8 | 3.46e-01 | 7.50e-01 | 0.6610 | 3.20e-01 | 3.72e-01 | 2.23e-01 | 3.25e-01 | 2.02e-01 | 1.17e-01 | 6.84e-02 | 2.75e-01 | 1.12e-01 | 3.21e-01 |
| REGULATION OF MITOCHONDRIAL ATP SYNTHESIS COUPLED ELECTRON TRANSPORT | 7 | 1.01e-01 | 4.31e-01 | 0.6610 | 3.64e-01 | 1.40e-01 | 2.91e-01 | 2.52e-01 | 3.70e-01 | 9.58e-02 | 5.22e-01 | 1.82e-01 | 2.49e-01 | 9.03e-02 |
| POSITIVE REGULATION OF VIRAL LIFE CYCLE | 23 | 4.32e-02 | 2.70e-01 | 0.6600 | 3.44e-01 | 3.62e-01 | 3.11e-01 | 2.41e-01 | 1.78e-01 | 4.27e-03 | 2.66e-03 | 9.87e-03 | 4.54e-02 | 1.40e-01 |
| REGULATION OF OXIDATIVE PHOSPHORYLATION | 21 | 1.00e-01 | 4.30e-01 | 0.6590 | 3.06e-01 | 3.00e-01 | 3.39e-01 | 2.72e-01 | 2.50e-01 | 1.51e-02 | 1.74e-02 | 7.23e-03 | 3.10e-02 | 4.70e-02 |
| PROTEIN DNA COMPLEX ASSEMBLY | 203 | 1.27e-14 | 1.71e-12 | 0.6590 | 2.91e-01 | 2.98e-01 | 3.37e-01 | 3.27e-01 | 2.02e-01 | 8.06e-13 | 2.44e-13 | 1.22e-16 | 9.61e-16 | 6.65e-07 |
| PROTEIN HEXAMERIZATION | 9 | 2.69e-01 | 6.78e-01 | 0.6580 | 9.33e-02 | 2.49e-01 | 3.79e-01 | 3.05e-01 | 3.55e-01 | 6.28e-01 | 1.96e-01 | 4.88e-02 | 1.13e-01 | 6.52e-02 |
| RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 55 | 4.52e-04 | 9.33e-03 | 0.6580 | 3.37e-01 | 2.97e-01 | 2.99e-01 | 3.08e-01 | 2.18e-01 | 1.57e-05 | 1.37e-04 | 1.23e-04 | 7.81e-05 | 5.25e-03 |
| MAINTENANCE OF PROTEIN LOCATION IN MITOCHONDRION | 5 | 7.40e-01 | 9.49e-01 | 0.6580 | 3.66e-01 | 3.37e-01 | 2.53e-01 | 2.67e-01 | 2.25e-01 | 1.57e-01 | 1.92e-01 | 3.26e-01 | 3.01e-01 | 3.84e-01 |
| RESPONSE TO COBALT ION | 9 | 3.78e-01 | 7.75e-01 | 0.6580 | 2.40e-01 | 3.82e-01 | 3.48e-01 | 2.12e-01 | 2.51e-01 | 2.12e-01 | 4.74e-02 | 7.05e-02 | 2.72e-01 | 1.92e-01 |
| PRIMARY MIRNA PROCESSING | 18 | 1.02e-01 | 4.35e-01 | 0.6580 | 2.20e-01 | 2.26e-01 | 3.13e-01 | 3.55e-01 | 3.30e-01 | 1.07e-01 | 9.63e-02 | 2.16e-02 | 9.12e-03 | 1.52e-02 |
| CARDIAC MUSCLE MYOBLAST PROLIFERATION | 7 | 4.37e-01 | 8.09e-01 | 0.6580 | 2.82e-01 | 3.29e-01 | 3.79e-01 | 3.17e-01 | -2.18e-04 | 1.96e-01 | 1.31e-01 | 8.22e-02 | 1.46e-01 | 9.99e-01 |
| VENTRAL MIDLINE DEVELOPMENT | 6 | 5.38e-01 | 8.66e-01 | 0.6570 | 1.09e-01 | 1.86e-01 | 3.18e-01 | 2.78e-01 | 4.55e-01 | 6.43e-01 | 4.29e-01 | 1.77e-01 | 2.38e-01 | 5.36e-02 |
| FLAVONOID METABOLIC PROCESS | 11 | 4.54e-01 | 8.22e-01 | 0.6570 | -2.47e-01 | -2.44e-01 | -3.50e-01 | -3.14e-01 | -3.00e-01 | 1.56e-01 | 1.60e-01 | 4.44e-02 | 7.12e-02 | 8.44e-02 |
| UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS VIA THE C END DEGRON RULE PATHWAY | 12 | 3.16e-01 | 7.27e-01 | 0.6570 | 2.64e-01 | 2.11e-01 | 3.45e-01 | 3.66e-01 | 2.54e-01 | 1.13e-01 | 2.07e-01 | 3.86e-02 | 2.81e-02 | 1.27e-01 |
| CHAPERONE MEDIATED PROTEIN COMPLEX ASSEMBLY | 21 | 2.40e-02 | 1.88e-01 | 0.6570 | 1.57e-01 | 1.70e-01 | 3.47e-01 | 3.48e-01 | 3.70e-01 | 2.14e-01 | 1.76e-01 | 5.98e-03 | 5.78e-03 | 3.35e-03 |
| SMOOTH MUSCLE ADAPTATION | 5 | 9.40e-02 | 4.16e-01 | 0.6570 | 3.60e-01 | 4.51e-01 | 3.08e-01 | 2.08e-02 | -5.88e-02 | 1.64e-01 | 8.07e-02 | 2.34e-01 | 9.36e-01 | 8.20e-01 |
| NEGATIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 13 | 4.96e-02 | 2.91e-01 | 0.6560 | 5.85e-02 | 2.39e-01 | 4.20e-01 | 2.26e-01 | 3.78e-01 | 7.15e-01 | 1.36e-01 | 8.73e-03 | 1.58e-01 | 1.82e-02 |
| MITOTIC METAPHASE CHROMOSOME ALIGNMENT | 58 | 1.04e-04 | 2.86e-03 | 0.6560 | 2.84e-01 | 2.68e-01 | 3.57e-01 | 3.55e-01 | 1.57e-01 | 1.79e-04 | 4.21e-04 | 2.54e-06 | 2.87e-06 | 3.83e-02 |
| PUTRESCINE METABOLIC PROCESS | 7 | 6.31e-01 | 9.10e-01 | 0.6560 | 3.47e-01 | 2.90e-01 | 2.51e-01 | 3.72e-01 | 1.55e-01 | 1.12e-01 | 1.83e-01 | 2.49e-01 | 8.84e-02 | 4.77e-01 |
| NADH DEHYDROGENASE COMPLEX ASSEMBLY | 52 | 1.01e-03 | 1.77e-02 | 0.6560 | 2.60e-01 | 2.79e-01 | 3.55e-01 | 3.35e-01 | 2.16e-01 | 1.19e-03 | 5.03e-04 | 9.50e-06 | 2.91e-05 | 7.03e-03 |
| RESPONSE TO HYPEROXIA | 18 | 1.69e-01 | 5.53e-01 | 0.6560 | 2.19e-01 | 2.81e-01 | 3.35e-01 | 3.25e-01 | 2.92e-01 | 1.08e-01 | 3.92e-02 | 1.40e-02 | 1.68e-02 | 3.18e-02 |
| POSITIVE REGULATION OF SPINDLE ASSEMBLY | 8 | 6.69e-01 | 9.25e-01 | 0.6560 | 2.65e-01 | 2.72e-01 | 3.16e-01 | 3.42e-01 | 2.63e-01 | 1.94e-01 | 1.82e-01 | 1.22e-01 | 9.43e-02 | 1.98e-01 |
| NEGATIVE REGULATION OF CHEMOKINE C C MOTIF LIGAND 5 PRODUCTION | 5 | 4.20e-01 | 8.00e-01 | 0.6560 | 4.53e-01 | 3.47e-01 | 1.44e-01 | 2.54e-01 | 1.35e-01 | 7.93e-02 | 1.79e-01 | 5.77e-01 | 3.25e-01 | 6.01e-01 |
| RESPONSE TO BACTERIAL LIPOPROTEIN | 10 | 7.64e-02 | 3.74e-01 | 0.6550 | 4.44e-01 | 2.74e-01 | 2.11e-01 | 2.70e-01 | -2.00e-01 | 1.51e-02 | 1.33e-01 | 2.47e-01 | 1.40e-01 | 2.75e-01 |
| LYMPHOID PROGENITOR CELL DIFFERENTIATION | 24 | 2.00e-02 | 1.67e-01 | 0.6550 | 2.41e-01 | 2.33e-01 | 3.00e-01 | 3.94e-01 | 2.67e-01 | 4.07e-02 | 4.84e-02 | 1.10e-02 | 8.28e-04 | 2.36e-02 |
| GPI ANCHOR METABOLIC PROCESS | 31 | 2.50e-02 | 1.93e-01 | 0.6550 | 2.37e-01 | 2.50e-01 | 3.51e-01 | 3.27e-01 | 2.82e-01 | 2.26e-02 | 1.59e-02 | 7.15e-04 | 1.61e-03 | 6.50e-03 |
| REGULATION OF G2 MI TRANSITION OF MEIOTIC CELL CYCLE | 5 | 2.67e-01 | 6.74e-01 | 0.6540 | 7.07e-02 | 1.45e-01 | 4.76e-01 | 3.24e-01 | 2.65e-01 | 7.84e-01 | 5.74e-01 | 6.51e-02 | 2.10e-01 | 3.04e-01 |
| NEGATIVE REGULATION OF GLIAL CELL MIGRATION | 6 | 7.56e-01 | 9.51e-01 | 0.6540 | 3.05e-01 | 3.21e-01 | 3.12e-01 | 3.58e-01 | 8.10e-02 | 1.96e-01 | 1.73e-01 | 1.85e-01 | 1.29e-01 | 7.31e-01 |
| REGULATION OF REGULATORY NCRNA PROCESSING | 16 | 7.41e-02 | 3.68e-01 | 0.6540 | 1.27e-01 | 1.88e-01 | 3.84e-01 | 2.75e-01 | 3.92e-01 | 3.79e-01 | 1.93e-01 | 7.90e-03 | 5.70e-02 | 6.57e-03 |
| MITOCHONDRIAL GENE EXPRESSION | 162 | 4.54e-12 | 4.43e-10 | 0.6540 | 2.65e-01 | 2.75e-01 | 3.21e-01 | 3.33e-01 | 2.59e-01 | 5.81e-09 | 1.48e-09 | 1.76e-12 | 2.36e-13 | 1.20e-08 |
| 2FE 2S CLUSTER ASSEMBLY | 9 | 1.88e-01 | 5.73e-01 | 0.6540 | 4.16e-01 | 3.16e-01 | 2.16e-01 | 2.36e-01 | 2.29e-01 | 3.08e-02 | 1.01e-01 | 2.61e-01 | 2.20e-01 | 2.35e-01 |
| TRNA 5 END PROCESSING | 15 | 5.99e-02 | 3.24e-01 | 0.6530 | 1.73e-01 | 1.57e-01 | 3.84e-01 | 3.73e-01 | 2.91e-01 | 2.47e-01 | 2.94e-01 | 9.95e-03 | 1.23e-02 | 5.08e-02 |
| METANEPHRIC NEPHRON TUBULE MORPHOGENESIS | 8 | 3.75e-01 | 7.74e-01 | 0.6530 | 2.48e-01 | 3.38e-01 | 3.45e-01 | 1.77e-01 | 3.15e-01 | 2.24e-01 | 9.74e-02 | 9.08e-02 | 3.86e-01 | 1.23e-01 |
| POSITIVE REGULATION OF CELL CELL ADHESION MEDIATED BY INTEGRIN | 6 | 4.27e-01 | 8.05e-01 | 0.6520 | -4.48e-01 | -2.51e-01 | -2.37e-01 | -3.20e-01 | 4.56e-02 | 5.73e-02 | 2.88e-01 | 3.14e-01 | 1.75e-01 | 8.47e-01 |
| POSITIVE REGULATION OF KIDNEY DEVELOPMENT | 9 | 2.18e-01 | 6.16e-01 | 0.6510 | 1.93e-01 | 1.53e-01 | 3.85e-01 | 2.56e-01 | 3.88e-01 | 3.17e-01 | 4.27e-01 | 4.56e-02 | 1.84e-01 | 4.40e-02 |
| MAINTENANCE OF PROTEIN LOCALIZATION IN ORGANELLE | 41 | 6.29e-04 | 1.21e-02 | 0.6510 | 2.60e-01 | 2.77e-01 | 3.85e-01 | 3.39e-01 | 1.27e-01 | 4.03e-03 | 2.11e-03 | 1.99e-05 | 1.73e-04 | 1.59e-01 |
| POSITIVE REGULATION OF ANTIMICROBIAL HUMORAL RESPONSE | 8 | 4.25e-01 | 8.04e-01 | 0.6510 | -2.03e-01 | -1.76e-01 | -3.87e-01 | -3.14e-01 | -3.21e-01 | 3.19e-01 | 3.88e-01 | 5.83e-02 | 1.24e-01 | 1.16e-01 |
| REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 4.86e-01 | 8.38e-01 | 0.6500 | 2.99e-01 | 3.39e-01 | 2.46e-01 | 3.09e-01 | 2.52e-01 | 1.43e-01 | 9.73e-02 | 2.28e-01 | 1.30e-01 | 2.18e-01 |
| ATTACHMENT OF MITOTIC SPINDLE MICROTUBULES TO KINETOCHORE | 21 | 4.06e-02 | 2.61e-01 | 0.6500 | 2.84e-01 | 3.02e-01 | 3.84e-01 | 3.08e-01 | 9.05e-02 | 2.43e-02 | 1.66e-02 | 2.32e-03 | 1.45e-02 | 4.73e-01 |
| NEGATIVE REGULATION OF DOUBLE STRAND BREAK REPAIR VIA NONHOMOLOGOUS END JOINING | 7 | 4.97e-01 | 8.45e-01 | 0.6500 | 4.31e-01 | 3.05e-01 | 2.09e-01 | 3.13e-01 | -3.65e-02 | 4.81e-02 | 1.62e-01 | 3.39e-01 | 1.51e-01 | 8.67e-01 |
| NEGATIVE REGULATION OF CHROMATIN ORGANIZATION | 5 | 5.70e-01 | 8.82e-01 | 0.6490 | -9.07e-02 | -2.61e-01 | -3.22e-01 | -1.91e-01 | -4.53e-01 | 7.25e-01 | 3.12e-01 | 2.13e-01 | 4.60e-01 | 7.93e-02 |
| DEVELOPMENTAL INDUCTION | 33 | 6.19e-03 | 7.20e-02 | 0.6490 | 2.14e-01 | 2.36e-01 | 3.03e-01 | 2.98e-01 | 3.73e-01 | 3.31e-02 | 1.87e-02 | 2.57e-03 | 3.06e-03 | 2.09e-04 |
| CELLULAR RESPONSE TO ANTIBIOTIC | 11 | 5.15e-01 | 8.56e-01 | 0.6490 | 2.61e-01 | 2.69e-01 | 3.47e-01 | 3.35e-01 | 2.18e-01 | 1.34e-01 | 1.22e-01 | 4.60e-02 | 5.43e-02 | 2.11e-01 |
| RETINAL CONE CELL DEVELOPMENT | 11 | 2.38e-01 | 6.41e-01 | 0.6490 | -3.12e-01 | -3.17e-01 | -2.87e-01 | -3.73e-01 | 3.96e-02 | 7.28e-02 | 6.85e-02 | 9.98e-02 | 3.23e-02 | 8.20e-01 |
| RESPONSE TO FRUCTOSE | 8 | 3.78e-01 | 7.75e-01 | 0.6480 | 3.41e-01 | 3.40e-01 | 2.78e-01 | 2.00e-01 | 2.66e-01 | 9.49e-02 | 9.57e-02 | 1.74e-01 | 3.28e-01 | 1.93e-01 |
| AMINOPHOSPHOLIPID TRANSPORT | 8 | 8.82e-02 | 4.01e-01 | 0.6480 | 3.13e-02 | -2.68e-01 | -3.52e-01 | -1.72e-01 | -4.39e-01 | 8.78e-01 | 1.89e-01 | 8.43e-02 | 4.01e-01 | 3.14e-02 |
| CORNIFICATION | 9 | 1.71e-01 | 5.55e-01 | 0.6470 | -1.76e-01 | -1.21e-01 | -2.82e-01 | -4.05e-01 | -3.60e-01 | 3.61e-01 | 5.28e-01 | 1.42e-01 | 3.54e-02 | 6.13e-02 |
| CELLULAR RESPONSE TO NICOTINE | 8 | 4.60e-01 | 8.23e-01 | 0.6470 | 2.37e-01 | 1.74e-01 | 3.65e-01 | 3.35e-01 | 2.94e-01 | 2.47e-01 | 3.93e-01 | 7.35e-02 | 1.01e-01 | 1.49e-01 |
| REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO STRESS | 32 | 9.39e-03 | 9.74e-02 | 0.6470 | 2.03e-01 | 2.08e-01 | 3.38e-01 | 3.06e-01 | 3.55e-01 | 4.72e-02 | 4.16e-02 | 9.36e-04 | 2.73e-03 | 5.05e-04 |
| HISTONE MRNA METABOLIC PROCESS | 24 | 3.42e-03 | 4.63e-02 | 0.6470 | 2.49e-01 | 1.49e-01 | 3.02e-01 | 4.25e-01 | 2.50e-01 | 3.50e-02 | 2.06e-01 | 1.05e-02 | 3.11e-04 | 3.38e-02 |
| DECIDUALIZATION | 24 | 8.71e-03 | 9.22e-02 | 0.6470 | 1.79e-01 | 3.35e-01 | 3.26e-01 | 3.29e-01 | 2.44e-01 | 1.30e-01 | 4.50e-03 | 5.76e-03 | 5.20e-03 | 3.85e-02 |
| NEGATIVE REGULATION OF UBIQUITIN PROTEIN TRANSFERASE ACTIVITY | 15 | 1.07e-02 | 1.07e-01 | 0.6470 | 6.99e-02 | 4.99e-02 | 3.13e-01 | 3.52e-01 | 4.35e-01 | 6.39e-01 | 7.38e-01 | 3.57e-02 | 1.84e-02 | 3.54e-03 |
| POSITIVE REGULATION OF RAC PROTEIN SIGNAL TRANSDUCTION | 5 | 7.94e-02 | 3.82e-01 | 0.6470 | 1.92e-01 | -8.50e-03 | -1.15e-01 | 2.07e-01 | -5.70e-01 | 4.58e-01 | 9.74e-01 | 6.56e-01 | 4.22e-01 | 2.72e-02 |
| REGULATION OF MACROPHAGE PROLIFERATION | 7 | 2.85e-01 | 6.93e-01 | 0.6460 | -3.00e-01 | -1.57e-01 | -3.20e-01 | -2.59e-01 | -3.65e-01 | 1.69e-01 | 4.72e-01 | 1.42e-01 | 2.35e-01 | 9.43e-02 |
| UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS VIA THE MULTIVESICULAR BODY SORTING PATHWAY | 35 | 3.03e-03 | 4.19e-02 | 0.6460 | 3.33e-01 | 2.21e-01 | 2.91e-01 | 3.33e-01 | 2.50e-01 | 6.57e-04 | 2.36e-02 | 2.86e-03 | 6.56e-04 | 1.05e-02 |
| ER ASSOCIATED MISFOLDED PROTEIN CATABOLIC PROCESS | 12 | 3.29e-01 | 7.37e-01 | 0.6460 | 2.80e-01 | 2.98e-01 | 2.65e-01 | 3.29e-01 | 2.68e-01 | 9.27e-02 | 7.38e-02 | 1.12e-01 | 4.81e-02 | 1.08e-01 |
| RESPONSE TO CORTICOTROPIN RELEASING HORMONE | 5 | 3.31e-01 | 7.39e-01 | 0.6460 | 5.03e-03 | 2.64e-01 | 4.28e-01 | 1.61e-01 | 3.72e-01 | 9.84e-01 | 3.06e-01 | 9.77e-02 | 5.34e-01 | 1.49e-01 |
| BASE EXCISION REPAIR AP SITE FORMATION | 12 | 4.06e-01 | 7.93e-01 | 0.6450 | 3.18e-01 | 2.65e-01 | 3.03e-01 | 2.99e-01 | 2.53e-01 | 5.66e-02 | 1.12e-01 | 6.92e-02 | 7.25e-02 | 1.29e-01 |
| POSITIVE REGULATION OF EPIDERMAL GROWTH FACTOR ACTIVATED RECEPTOR ACTIVITY | 5 | 4.67e-03 | 5.84e-02 | 0.6450 | -2.12e-01 | -5.54e-01 | -1.59e-01 | 1.88e-01 | -6.01e-02 | 4.12e-01 | 3.18e-02 | 5.38e-01 | 4.67e-01 | 8.16e-01 |
| POSITIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 65 | 1.30e-04 | 3.39e-03 | 0.6450 | 2.49e-01 | 3.07e-01 | 3.16e-01 | 3.00e-01 | 2.65e-01 | 5.29e-04 | 1.83e-05 | 1.04e-05 | 2.93e-05 | 2.25e-04 |
| REGULATION OF APOPTOTIC PROCESS IN BONE MARROW CELL | 5 | 4.95e-01 | 8.44e-01 | 0.6450 | -3.57e-01 | -4.09e-01 | -2.94e-01 | -1.41e-01 | -1.22e-01 | 1.67e-01 | 1.13e-01 | 2.55e-01 | 5.86e-01 | 6.36e-01 |
| U4 SNRNA 3 END PROCESSING | 8 | 4.74e-02 | 2.85e-01 | 0.6430 | -1.13e-01 | 1.44e-01 | 2.81e-01 | 1.35e-02 | 5.49e-01 | 5.81e-01 | 4.81e-01 | 1.69e-01 | 9.47e-01 | 7.19e-03 |
| LIVER REGENERATION | 28 | 4.89e-02 | 2.89e-01 | 0.6430 | 2.92e-01 | 2.78e-01 | 2.84e-01 | 3.30e-01 | 2.47e-01 | 7.41e-03 | 1.08e-02 | 9.23e-03 | 2.48e-03 | 2.39e-02 |
| POSITIVE REGULATION OF BLOOD VESSEL REMODELING | 6 | 2.68e-01 | 6.75e-01 | 0.6430 | 2.86e-01 | 3.79e-01 | 3.14e-01 | 2.26e-01 | -1.95e-01 | 2.25e-01 | 1.08e-01 | 1.83e-01 | 3.37e-01 | 4.09e-01 |
| POSITIVE REGULATION OF PYROPTOSIS | 5 | 5.10e-01 | 8.53e-01 | 0.6430 | -2.11e-02 | -2.12e-01 | -3.87e-01 | -2.30e-01 | -4.07e-01 | 9.35e-01 | 4.12e-01 | 1.34e-01 | 3.73e-01 | 1.15e-01 |
| REGULATION OF MEMBRANE REPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 6 | 3.93e-01 | 7.84e-01 | 0.6430 | -2.77e-01 | -1.21e-01 | -2.78e-01 | -4.36e-01 | -2.32e-01 | 2.40e-01 | 6.07e-01 | 2.39e-01 | 6.41e-02 | 3.26e-01 |
| RRNA METABOLIC PROCESS | 254 | 3.42e-19 | 6.60e-17 | 0.6420 | 2.60e-01 | 2.62e-01 | 3.42e-01 | 3.01e-01 | 2.60e-01 | 9.67e-13 | 6.44e-13 | 5.30e-21 | 1.30e-16 | 8.52e-13 |
| BASEMENT MEMBRANE ASSEMBLY | 9 | 6.57e-01 | 9.20e-01 | 0.6410 | -2.95e-01 | -3.26e-01 | -3.03e-01 | -3.22e-01 | -1.51e-01 | 1.26e-01 | 9.00e-02 | 1.16e-01 | 9.44e-02 | 4.34e-01 |
| CHAPERONE MEDIATED PROTEIN FOLDING | 74 | 4.05e-05 | 1.30e-03 | 0.6410 | 2.57e-01 | 2.66e-01 | 3.14e-01 | 3.25e-01 | 2.65e-01 | 1.33e-04 | 7.38e-05 | 3.02e-06 | 1.35e-06 | 7.89e-05 |
| CELLULAR RESPONSE TO CAFFEINE | 11 | 1.82e-01 | 5.67e-01 | 0.6410 | -3.29e-01 | -2.99e-01 | -2.02e-01 | -3.71e-01 | -1.86e-01 | 5.85e-02 | 8.60e-02 | 2.46e-01 | 3.31e-02 | 2.85e-01 |
| REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 44 | 4.98e-04 | 1.01e-02 | 0.6410 | 3.24e-01 | 2.51e-01 | 2.87e-01 | 2.82e-01 | 2.85e-01 | 1.97e-04 | 3.99e-03 | 9.83e-04 | 1.21e-03 | 1.09e-03 |
| MANCHETTE ASSEMBLY | 6 | 5.63e-01 | 8.79e-01 | 0.6410 | -2.09e-01 | -3.30e-01 | -3.64e-01 | -3.43e-01 | -8.73e-02 | 3.76e-01 | 1.62e-01 | 1.22e-01 | 1.45e-01 | 7.11e-01 |
| LACRIMAL GLAND DEVELOPMENT | 7 | 5.48e-01 | 8.73e-01 | 0.6410 | 1.87e-01 | 3.05e-01 | 2.93e-01 | 2.79e-01 | 3.45e-01 | 3.91e-01 | 1.62e-01 | 1.80e-01 | 2.02e-01 | 1.14e-01 |
| ANDROGEN METABOLIC PROCESS | 29 | 2.07e-02 | 1.70e-01 | 0.6400 | -2.71e-01 | -2.64e-01 | -3.62e-01 | -2.72e-01 | -2.49e-01 | 1.15e-02 | 1.38e-02 | 7.36e-04 | 1.13e-02 | 2.03e-02 |
| LIPOXYGENASE PATHWAY | 11 | 3.53e-01 | 7.53e-01 | 0.6400 | 2.71e-01 | 3.87e-01 | 3.08e-01 | 2.89e-01 | 9.06e-02 | 1.20e-01 | 2.62e-02 | 7.65e-02 | 9.71e-02 | 6.03e-01 |
| MESONEPHRIC TUBULE FORMATION | 10 | 1.56e-01 | 5.26e-01 | 0.6400 | 4.59e-02 | 2.28e-01 | 3.97e-01 | 2.35e-01 | 3.78e-01 | 8.01e-01 | 2.13e-01 | 2.96e-02 | 1.97e-01 | 3.87e-02 |
| AUTOPHAGIC CELL DEATH | 9 | 2.56e-01 | 6.62e-01 | 0.6400 | 4.01e-01 | 2.41e-01 | 2.85e-01 | 2.76e-01 | 1.82e-01 | 3.74e-02 | 2.10e-01 | 1.39e-01 | 1.51e-01 | 3.44e-01 |
| METANEPHRIC MESENCHYME DEVELOPMENT | 14 | 1.30e-01 | 4.90e-01 | 0.6400 | 1.30e-01 | 2.16e-01 | 3.36e-01 | 3.36e-01 | 3.47e-01 | 4.01e-01 | 1.61e-01 | 2.96e-02 | 2.96e-02 | 2.47e-02 |
| REGULATION OF PRE MIRNA PROCESSING | 6 | 5.26e-01 | 8.60e-01 | 0.6400 | 3.67e-01 | 2.56e-01 | 3.38e-01 | 2.67e-01 | 1.52e-01 | 1.20e-01 | 2.78e-01 | 1.51e-01 | 2.57e-01 | 5.18e-01 |
| CELLULAR RESPONSE TO ELECTRICAL STIMULUS | 13 | 1.70e-01 | 5.55e-01 | 0.6400 | 3.63e-01 | 3.67e-01 | 2.02e-01 | 3.19e-01 | -1.33e-02 | 2.35e-02 | 2.20e-02 | 2.07e-01 | 4.64e-02 | 9.34e-01 |
| U2 TYPE PRESPLICEOSOME ASSEMBLY | 22 | 4.60e-03 | 5.81e-02 | 0.6390 | 1.77e-01 | 1.30e-01 | 3.89e-01 | 3.59e-01 | 2.85e-01 | 1.51e-01 | 2.91e-01 | 1.60e-03 | 3.60e-03 | 2.07e-02 |
| PHOSPHATIDYLETHANOLAMINE BIOSYNTHETIC PROCESS | 10 | 4.30e-01 | 8.05e-01 | 0.6390 | 2.47e-01 | 2.68e-01 | 2.81e-01 | 2.71e-01 | 3.52e-01 | 1.76e-01 | 1.43e-01 | 1.24e-01 | 1.38e-01 | 5.40e-02 |
| CELLULAR RESPONSE TO EXOGENOUS DSRNA | 16 | 3.02e-01 | 7.14e-01 | 0.6390 | 2.92e-01 | 2.89e-01 | 2.90e-01 | 3.05e-01 | 2.51e-01 | 4.33e-02 | 4.54e-02 | 4.47e-02 | 3.49e-02 | 8.18e-02 |
| REGULATION OF NOREPINEPHRINE SECRETION | 13 | 6.68e-04 | 1.26e-02 | 0.6390 | 1.11e-01 | -6.22e-03 | 3.96e-01 | 2.03e-01 | 4.45e-01 | 4.87e-01 | 9.69e-01 | 1.34e-02 | 2.06e-01 | 5.50e-03 |
| POSITIVE REGULATION OF UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 8 | 1.08e-01 | 4.51e-01 | 0.6390 | 4.21e-01 | 3.77e-01 | 2.43e-01 | 1.33e-01 | -1.10e-01 | 3.91e-02 | 6.46e-02 | 2.35e-01 | 5.16e-01 | 5.92e-01 |
| NEGATIVE REGULATION OF FEEDING BEHAVIOR | 6 | 1.38e-01 | 5.01e-01 | 0.6390 | -2.41e-01 | -8.99e-02 | -2.12e-01 | -1.74e-01 | -5.16e-01 | 3.07e-01 | 7.03e-01 | 3.68e-01 | 4.61e-01 | 2.85e-02 |
| POSITIVE REGULATION OF CD8 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 5 | 4.01e-01 | 7.88e-01 | 0.6380 | 3.80e-01 | 1.69e-01 | 3.06e-01 | 3.75e-01 | -2.59e-02 | 1.42e-01 | 5.13e-01 | 2.36e-01 | 1.46e-01 | 9.20e-01 |
| NEGATIVE REGULATION OF EPIDERMAL GROWTH FACTOR ACTIVATED RECEPTOR ACTIVITY | 13 | 1.52e-01 | 5.21e-01 | 0.6380 | 1.39e-01 | 2.09e-01 | 2.93e-01 | 2.98e-01 | 4.12e-01 | 3.84e-01 | 1.92e-01 | 6.78e-02 | 6.31e-02 | 1.01e-02 |
| EMBRYONIC CAMERA TYPE EYE DEVELOPMENT | 37 | 6.41e-03 | 7.40e-02 | 0.6380 | 1.93e-01 | 2.36e-01 | 3.31e-01 | 3.03e-01 | 3.36e-01 | 4.20e-02 | 1.32e-02 | 4.89e-04 | 1.43e-03 | 4.04e-04 |
| NEGATIVE REGULATION OF VOLTAGE GATED POTASSIUM CHANNEL ACTIVITY | 18 | 9.44e-02 | 4.16e-01 | 0.6380 | -2.55e-01 | -3.94e-01 | -3.21e-01 | -2.40e-01 | -1.61e-01 | 6.12e-02 | 3.83e-03 | 1.82e-02 | 7.78e-02 | 2.36e-01 |
| PROTEIN NEDDYLATION | 28 | 1.93e-03 | 2.95e-02 | 0.6380 | 2.42e-01 | 1.58e-01 | 2.56e-01 | 3.52e-01 | 3.65e-01 | 2.64e-02 | 1.49e-01 | 1.90e-02 | 1.27e-03 | 8.18e-04 |
| REGULATION OF RESPONSE TO OSMOTIC STRESS | 16 | 1.15e-01 | 4.62e-01 | 0.6370 | 2.65e-01 | 3.97e-01 | 2.80e-01 | 2.62e-01 | 1.75e-01 | 6.61e-02 | 6.02e-03 | 5.22e-02 | 6.91e-02 | 2.24e-01 |
| REGULATION OF DOPAMINERGIC NEURON DIFFERENTIATION | 12 | 2.68e-01 | 6.76e-01 | 0.6370 | 1.57e-01 | 2.26e-01 | 3.08e-01 | 2.77e-01 | 3.98e-01 | 3.48e-01 | 1.75e-01 | 6.44e-02 | 9.64e-02 | 1.70e-02 |
| PHAGOCYTOSIS RECOGNITION | 28 | 1.47e-02 | 1.34e-01 | 0.6370 | -2.91e-01 | -2.95e-01 | -2.98e-01 | -3.78e-01 | -5.05e-02 | 7.64e-03 | 6.86e-03 | 6.38e-03 | 5.42e-04 | 6.43e-01 |
| POSITIVE REGULATION OF NEUTROPHIL ACTIVATION | 6 | 4.84e-01 | 8.38e-01 | 0.6360 | 2.01e-01 | 3.73e-01 | 3.14e-01 | 3.35e-01 | 1.22e-01 | 3.93e-01 | 1.14e-01 | 1.84e-01 | 1.55e-01 | 6.06e-01 |
| DEOXYRIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 4.36e-01 | 8.09e-01 | 0.6360 | 4.00e-01 | 3.49e-01 | 1.81e-01 | 2.95e-01 | -5.09e-02 | 5.00e-02 | 8.74e-02 | 3.76e-01 | 1.49e-01 | 8.03e-01 |
| PLATELET DEGRANULATION | 7 | 1.82e-01 | 5.67e-01 | 0.6360 | 6.38e-02 | -1.34e-01 | -3.61e-01 | -1.37e-01 | -4.83e-01 | 7.70e-01 | 5.40e-01 | 9.83e-02 | 5.32e-01 | 2.69e-02 |
| POSITIVE REGULATION OF SODIUM PROTON ANTIPORTER ACTIVITY | 5 | 6.86e-01 | 9.31e-01 | 0.6340 | 3.70e-01 | 3.24e-01 | 1.91e-01 | 3.10e-01 | 1.65e-01 | 1.52e-01 | 2.09e-01 | 4.61e-01 | 2.30e-01 | 5.24e-01 |
| SYNAPTIC VESICLE LUMEN ACIDIFICATION | 14 | 1.34e-01 | 4.96e-01 | 0.6340 | 1.54e-01 | 3.23e-01 | 3.26e-01 | 2.81e-01 | 2.97e-01 | 3.18e-01 | 3.62e-02 | 3.46e-02 | 6.87e-02 | 5.45e-02 |
| ENDOCARDIAL CUSHION TO MESENCHYMAL TRANSITION | 6 | 3.61e-01 | 7.59e-01 | 0.6340 | 2.05e-01 | 4.02e-01 | 3.50e-01 | 1.22e-01 | 2.45e-01 | 3.83e-01 | 8.80e-02 | 1.37e-01 | 6.04e-01 | 2.99e-01 |
| KERATINIZATION | 80 | 8.58e-12 | 7.88e-10 | 0.6340 | -2.24e-01 | -1.94e-01 | -2.78e-01 | -4.33e-01 | -2.20e-01 | 5.35e-04 | 2.74e-03 | 1.66e-05 | 2.02e-11 | 6.59e-04 |
| CYTIDINE TO URIDINE EDITING | 12 | 4.52e-01 | 8.21e-01 | 0.6340 | -2.48e-01 | -2.53e-01 | -3.01e-01 | -3.26e-01 | -2.81e-01 | 1.37e-01 | 1.29e-01 | 7.08e-02 | 5.06e-02 | 9.22e-02 |
| DERMATAN SULFATE PROTEOGLYCAN METABOLIC PROCESS | 11 | 2.93e-01 | 7.04e-01 | 0.6330 | 2.60e-01 | 3.37e-01 | 2.51e-01 | 2.88e-01 | 2.72e-01 | 1.35e-01 | 5.29e-02 | 1.49e-01 | 9.82e-02 | 1.19e-01 |
| NEGATIVE REGULATION OF FILOPODIUM ASSEMBLY | 5 | 5.38e-01 | 8.66e-01 | 0.6330 | -2.79e-01 | -1.69e-01 | -2.19e-01 | -4.03e-01 | -2.90e-01 | 2.80e-01 | 5.12e-01 | 3.97e-01 | 1.19e-01 | 2.61e-01 |
| VIRAL RELEASE FROM HOST CELL | 28 | 5.42e-02 | 3.08e-01 | 0.6330 | 2.94e-01 | 2.46e-01 | 3.25e-01 | 3.31e-01 | 1.96e-01 | 7.07e-03 | 2.43e-02 | 2.93e-03 | 2.43e-03 | 7.32e-02 |
| CELL FATE SPECIFICATION | 107 | 1.41e-09 | 9.96e-08 | 0.6320 | 1.67e-01 | 2.40e-01 | 3.35e-01 | 2.64e-01 | 3.64e-01 | 2.84e-03 | 1.84e-05 | 2.12e-09 | 2.34e-06 | 7.51e-11 |
| SEX DETERMINATION | 18 | 1.03e-01 | 4.37e-01 | 0.6320 | 1.78e-01 | 2.37e-01 | 3.64e-01 | 2.39e-01 | 3.49e-01 | 1.91e-01 | 8.23e-02 | 7.45e-03 | 7.91e-02 | 1.03e-02 |
| HEPOXILIN METABOLIC PROCESS | 9 | 3.47e-01 | 7.50e-01 | 0.6310 | 2.33e-01 | 4.06e-01 | 2.96e-01 | 2.47e-01 | 1.76e-01 | 2.26e-01 | 3.51e-02 | 1.25e-01 | 1.99e-01 | 3.60e-01 |
| CARBON CATABOLITE REGULATION OF TRANSCRIPTION | 7 | 5.91e-01 | 8.94e-01 | 0.6310 | 1.48e-01 | 2.58e-01 | 3.16e-01 | 2.57e-01 | 3.80e-01 | 4.99e-01 | 2.37e-01 | 1.48e-01 | 2.40e-01 | 8.16e-02 |
| MESODERMAL CELL FATE SPECIFICATION | 12 | 2.97e-01 | 7.08e-01 | 0.6310 | 2.08e-01 | 2.49e-01 | 2.88e-01 | 2.51e-01 | 3.83e-01 | 2.13e-01 | 1.36e-01 | 8.43e-02 | 1.32e-01 | 2.14e-02 |
| PLASMA CELL DIFFERENTIATION | 8 | 1.43e-01 | 5.09e-01 | 0.6300 | 3.49e-01 | 4.23e-01 | 1.51e-01 | 2.21e-01 | 1.56e-01 | 8.75e-02 | 3.82e-02 | 4.60e-01 | 2.80e-01 | 4.44e-01 |
| RESPONSE TO ARSENIC CONTAINING SUBSTANCE | 31 | 3.67e-02 | 2.47e-01 | 0.6300 | 2.53e-01 | 3.29e-01 | 3.18e-01 | 3.09e-01 | 1.68e-01 | 1.46e-02 | 1.53e-03 | 2.20e-03 | 2.91e-03 | 1.06e-01 |
| POSITIVE REGULATION OF DEOXYRIBONUCLEASE ACTIVITY | 5 | 7.29e-01 | 9.44e-01 | 0.6300 | 2.39e-01 | 2.29e-01 | 2.52e-01 | 2.96e-01 | 3.69e-01 | 3.55e-01 | 3.75e-01 | 3.29e-01 | 2.52e-01 | 1.53e-01 |
| GENERAL ADAPTATION SYNDROME BEHAVIORAL PROCESS | 5 | 4.68e-01 | 8.28e-01 | 0.6290 | -3.80e-01 | -3.58e-01 | -1.06e-01 | -2.15e-01 | 2.56e-01 | 1.41e-01 | 1.65e-01 | 6.83e-01 | 4.05e-01 | 3.21e-01 |
| POSITIVE REGULATION OF B CELL DIFFERENTIATION | 14 | 1.45e-01 | 5.12e-01 | 0.6290 | 3.75e-01 | 2.73e-01 | 2.00e-01 | 3.71e-01 | 5.31e-02 | 1.51e-02 | 7.70e-02 | 1.95e-01 | 1.62e-02 | 7.31e-01 |
| INNATE IMMUNE RESPONSE IN MUCOSA | 26 | 6.02e-02 | 3.25e-01 | 0.6290 | 2.23e-01 | 3.25e-01 | 3.41e-01 | 2.64e-01 | 2.34e-01 | 4.94e-02 | 4.13e-03 | 2.65e-03 | 1.98e-02 | 3.86e-02 |
| IMMUNE RESPONSE INHIBITING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 9 | 2.57e-01 | 6.63e-01 | 0.6280 | -1.93e-01 | -3.42e-01 | -3.25e-01 | -3.52e-01 | -1.01e-01 | 3.16e-01 | 7.54e-02 | 9.12e-02 | 6.75e-02 | 6.00e-01 |
| NEGATIVE REGULATION OF WNT SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 7 | 4.09e-01 | 7.94e-01 | 0.6280 | 8.73e-02 | 1.66e-01 | 2.91e-01 | 1.91e-01 | 4.87e-01 | 6.89e-01 | 4.46e-01 | 1.82e-01 | 3.83e-01 | 2.55e-02 |
| RESPONSE TO HISTAMINE | 11 | 2.32e-01 | 6.34e-01 | 0.6270 | 3.26e-01 | 3.65e-01 | 2.07e-01 | 3.30e-01 | 2.69e-02 | 6.09e-02 | 3.59e-02 | 2.34e-01 | 5.77e-02 | 8.77e-01 |
| RESPONSE TO SYMBIONT | 6 | 8.01e-01 | 9.67e-01 | 0.6270 | -2.28e-01 | -2.82e-01 | -3.55e-01 | -2.73e-01 | -2.46e-01 | 3.32e-01 | 2.31e-01 | 1.32e-01 | 2.48e-01 | 2.97e-01 |
| XMP METABOLIC PROCESS | 7 | 3.24e-01 | 7.33e-01 | 0.6270 | 3.54e-01 | 1.75e-01 | 3.34e-01 | 3.15e-01 | 1.61e-01 | 1.05e-01 | 4.23e-01 | 1.25e-01 | 1.48e-01 | 4.62e-01 |
| EGG ACTIVATION | 11 | 2.04e-01 | 5.97e-01 | 0.6260 | -3.59e-01 | -2.57e-01 | -3.09e-01 | -3.16e-01 | 3.42e-02 | 3.91e-02 | 1.39e-01 | 7.59e-02 | 6.93e-02 | 8.44e-01 |
| STRESS GRANULE DISASSEMBLY | 5 | 5.26e-01 | 8.60e-01 | 0.6260 | 4.19e-01 | 2.70e-01 | 1.29e-01 | 3.55e-01 | 9.94e-03 | 1.05e-01 | 2.95e-01 | 6.18e-01 | 1.69e-01 | 9.69e-01 |
| REGULATION OF MONOCYTE EXTRAVASATION | 7 | 5.03e-01 | 8.49e-01 | 0.6260 | -2.12e-01 | -3.32e-01 | -3.50e-01 | -1.71e-01 | -2.91e-01 | 3.32e-01 | 1.28e-01 | 1.09e-01 | 4.32e-01 | 1.83e-01 |
| EMBRYONIC CAMERA TYPE EYE MORPHOGENESIS | 26 | 4.78e-02 | 2.86e-01 | 0.6260 | 1.90e-01 | 2.35e-01 | 3.15e-01 | 2.86e-01 | 3.45e-01 | 9.43e-02 | 3.77e-02 | 5.49e-03 | 1.15e-02 | 2.34e-03 |
| PERISTALSIS | 12 | 5.68e-02 | 3.15e-01 | 0.6250 | 3.24e-01 | 3.35e-01 | 2.31e-01 | 1.50e-01 | 3.14e-01 | 5.23e-02 | 4.46e-02 | 1.66e-01 | 3.69e-01 | 6.00e-02 |
| TRICUSPID VALVE MORPHOGENESIS | 5 | 5.84e-01 | 8.90e-01 | 0.6250 | -4.24e-01 | -3.29e-01 | -1.57e-01 | -2.58e-01 | -1.03e-01 | 1.00e-01 | 2.02e-01 | 5.43e-01 | 3.17e-01 | 6.89e-01 |
| MACROPHAGE APOPTOTIC PROCESS | 14 | 6.11e-02 | 3.28e-01 | 0.6240 | 2.20e-01 | 2.68e-01 | 2.19e-01 | 3.20e-01 | 3.46e-01 | 1.54e-01 | 8.26e-02 | 1.56e-01 | 3.83e-02 | 2.51e-02 |
| NEGATIVE REGULATION OF MRNA PROCESSING | 22 | 1.22e-01 | 4.75e-01 | 0.6240 | 2.81e-01 | 2.40e-01 | 2.83e-01 | 3.43e-01 | 2.36e-01 | 2.26e-02 | 5.13e-02 | 2.16e-02 | 5.37e-03 | 5.52e-02 |
| CALCITONIN FAMILY RECEPTOR SIGNALING PATHWAY | 8 | 5.21e-01 | 8.58e-01 | 0.6240 | -3.25e-01 | -3.69e-01 | -2.25e-01 | -3.09e-01 | -5.12e-02 | 1.12e-01 | 7.10e-02 | 2.71e-01 | 1.30e-01 | 8.02e-01 |
| DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION RESULTING IN TRANSCRIPTION | 18 | 7.56e-02 | 3.72e-01 | 0.6240 | 2.95e-01 | 3.51e-01 | 2.53e-01 | 3.39e-01 | 1.18e-02 | 3.01e-02 | 9.85e-03 | 6.33e-02 | 1.27e-02 | 9.31e-01 |
| DEVELOPMENT OF SECONDARY FEMALE SEXUAL CHARACTERISTICS | 6 | 7.80e-01 | 9.59e-01 | 0.6240 | 2.31e-01 | 2.64e-01 | 3.66e-01 | 2.82e-01 | 2.28e-01 | 3.26e-01 | 2.62e-01 | 1.20e-01 | 2.32e-01 | 3.33e-01 |
| MITOTIC CYTOKINETIC PROCESS | 26 | 3.88e-02 | 2.54e-01 | 0.6240 | 3.13e-01 | 2.67e-01 | 3.28e-01 | 3.28e-01 | 6.96e-02 | 5.75e-03 | 1.85e-02 | 3.83e-03 | 3.79e-03 | 5.39e-01 |
| PEPTIDYL THREONINE DEPHOSPHORYLATION | 18 | 5.80e-02 | 3.18e-01 | 0.6240 | 3.32e-01 | 1.88e-01 | 2.80e-01 | 3.14e-01 | 2.58e-01 | 1.49e-02 | 1.67e-01 | 3.94e-02 | 2.13e-02 | 5.82e-02 |
| SUBSTRATE DEPENDENT CELL MIGRATION CELL EXTENSION | 8 | 3.76e-01 | 7.75e-01 | 0.6230 | -1.43e-01 | -2.99e-01 | -3.28e-01 | -3.33e-01 | -2.45e-01 | 4.84e-01 | 1.43e-01 | 1.08e-01 | 1.03e-01 | 2.30e-01 |
| AMMONIUM ION METABOLIC PROCESS | 22 | 1.94e-01 | 5.80e-01 | 0.6230 | -2.97e-01 | -2.81e-01 | -2.89e-01 | -3.16e-01 | -1.94e-01 | 1.60e-02 | 2.25e-02 | 1.88e-02 | 1.03e-02 | 1.16e-01 |
| AMP BIOSYNTHETIC PROCESS | 12 | 3.22e-01 | 7.32e-01 | 0.6230 | 3.56e-01 | 3.07e-01 | 3.01e-01 | 2.46e-01 | 1.27e-01 | 3.29e-02 | 6.60e-02 | 7.07e-02 | 1.40e-01 | 4.47e-01 |
| RESPONSE TO CORTICOSTERONE | 12 | 3.24e-01 | 7.34e-01 | 0.6230 | 1.84e-01 | 3.21e-01 | 3.19e-01 | 2.49e-01 | 2.95e-01 | 2.70e-01 | 5.44e-02 | 5.53e-02 | 1.35e-01 | 7.71e-02 |
| REGULATION OF GLUCOCORTICOID SECRETION | 10 | 2.04e-01 | 5.97e-01 | 0.6230 | 2.57e-01 | 3.18e-01 | 2.12e-01 | 2.62e-01 | 3.28e-01 | 1.60e-01 | 8.21e-02 | 2.46e-01 | 1.51e-01 | 7.28e-02 |
| PHOSPHATE ION HOMEOSTASIS | 20 | 4.76e-02 | 2.86e-01 | 0.6230 | -3.71e-01 | -2.83e-01 | -2.40e-01 | -3.26e-01 | 7.74e-02 | 4.08e-03 | 2.83e-02 | 6.29e-02 | 1.17e-02 | 5.49e-01 |
| REGULATION OF CATECHOLAMINE UPTAKE INVOLVED IN SYNAPTIC TRANSMISSION | 8 | 2.36e-01 | 6.39e-01 | 0.6220 | 2.29e-01 | 2.60e-01 | 2.18e-01 | 1.82e-01 | 4.31e-01 | 2.61e-01 | 2.02e-01 | 2.86e-01 | 3.72e-01 | 3.47e-02 |
| POSITIVE REGULATION OF PHOSPHOLIPID BIOSYNTHETIC PROCESS | 9 | 2.84e-01 | 6.93e-01 | 0.6220 | -2.58e-01 | -3.40e-01 | -3.86e-01 | -2.22e-01 | -7.82e-02 | 1.81e-01 | 7.70e-02 | 4.48e-02 | 2.50e-01 | 6.85e-01 |
| G1 TO G0 TRANSITION | 19 | 9.39e-02 | 4.16e-01 | 0.6220 | 2.64e-01 | 2.45e-01 | 3.72e-01 | 3.08e-01 | 1.54e-01 | 4.64e-02 | 6.40e-02 | 5.03e-03 | 2.00e-02 | 2.46e-01 |
| CYTOLYSIS BY HOST OF SYMBIONT CELLS | 7 | 1.16e-03 | 1.97e-02 | 0.6220 | 3.21e-01 | 1.30e-01 | -7.21e-02 | -2.29e-01 | -4.57e-01 | 1.41e-01 | 5.51e-01 | 7.41e-01 | 2.94e-01 | 3.63e-02 |
| MAINTENANCE OF PROTEIN LOCATION IN NUCLEUS | 23 | 5.89e-03 | 6.90e-02 | 0.6210 | 2.22e-01 | 2.13e-01 | 3.59e-01 | 3.94e-01 | 8.61e-02 | 6.55e-02 | 7.69e-02 | 2.87e-03 | 1.08e-03 | 4.75e-01 |
| REGULATION OF PROTEIN ADP RIBOSYLATION | 8 | 4.78e-01 | 8.33e-01 | 0.6210 | 2.49e-01 | 3.96e-01 | 2.85e-01 | 2.23e-01 | 1.91e-01 | 2.22e-01 | 5.27e-02 | 1.62e-01 | 2.75e-01 | 3.50e-01 |
| NEGATIVE REGULATION OF CD8 POSITIVE ALPHA BETA T CELL ACTIVATION | 8 | 2.40e-01 | 6.44e-01 | 0.6210 | 9.43e-03 | 9.38e-02 | 2.74e-01 | 2.15e-01 | 5.05e-01 | 9.63e-01 | 6.46e-01 | 1.79e-01 | 2.92e-01 | 1.33e-02 |
| REGULATION OF URINE VOLUME | 20 | 3.21e-02 | 2.27e-01 | 0.6210 | 1.10e-01 | 2.36e-01 | 3.49e-01 | 3.17e-01 | 3.09e-01 | 3.94e-01 | 6.72e-02 | 6.93e-03 | 1.42e-02 | 1.67e-02 |
| MUCOCILIARY CLEARANCE | 8 | 3.51e-01 | 7.52e-01 | 0.6200 | -1.56e-01 | -3.36e-01 | -2.99e-01 | -2.98e-01 | -2.63e-01 | 4.44e-01 | 9.95e-02 | 1.43e-01 | 1.44e-01 | 1.98e-01 |
| RESPIRATORY ELECTRON TRANSPORT CHAIN | 107 | 8.50e-07 | 4.05e-05 | 0.6200 | 2.90e-01 | 2.62e-01 | 2.98e-01 | 3.23e-01 | 1.96e-01 | 2.19e-07 | 2.77e-06 | 9.87e-08 | 7.31e-09 | 4.47e-04 |
| DOUBLE STRAND BREAK REPAIR VIA SINGLE STRAND ANNEALING | 6 | 6.13e-01 | 9.05e-01 | 0.6200 | 3.63e-01 | 3.17e-01 | 1.86e-01 | 3.42e-01 | -3.16e-02 | 1.24e-01 | 1.79e-01 | 4.30e-01 | 1.46e-01 | 8.93e-01 |
| TRNA THREONYLCARBAMOYLADENOSINE METABOLIC PROCESS | 15 | 2.67e-01 | 6.75e-01 | 0.6200 | 2.44e-01 | 2.54e-01 | 2.93e-01 | 2.56e-01 | 3.31e-01 | 1.01e-01 | 8.86e-02 | 4.98e-02 | 8.64e-02 | 2.65e-02 |
| REGULATION OF TETRAPYRROLE METABOLIC PROCESS | 8 | 3.30e-01 | 7.38e-01 | 0.6200 | -3.75e-01 | -3.96e-01 | -2.18e-01 | -1.80e-01 | 8.20e-02 | 6.61e-02 | 5.23e-02 | 2.85e-01 | 3.78e-01 | 6.88e-01 |
| REGULATION OF T CELL CHEMOTAXIS | 16 | 3.31e-02 | 2.31e-01 | 0.6200 | -1.60e-01 | -9.82e-02 | -2.91e-01 | -2.39e-01 | -4.55e-01 | 2.68e-01 | 4.97e-01 | 4.37e-02 | 9.72e-02 | 1.62e-03 |
| ALPHA KETOGLUTARATE TRANSPORT | 7 | 8.67e-02 | 3.98e-01 | 0.6200 | -4.79e-01 | -2.61e-01 | 1.96e-02 | -1.95e-01 | 2.21e-01 | 2.81e-02 | 2.32e-01 | 9.28e-01 | 3.72e-01 | 3.12e-01 |
| POSITIVE REGULATION OF VITAMIN D RECEPTOR SIGNALING PATHWAY | 6 | 4.83e-01 | 8.37e-01 | 0.6200 | 3.34e-01 | 4.09e-01 | 1.79e-01 | 2.65e-01 | 5.94e-02 | 1.57e-01 | 8.30e-02 | 4.47e-01 | 2.61e-01 | 8.01e-01 |
| CYTOPLASMIC TRANSLATION | 141 | 2.14e-12 | 2.14e-10 | 0.6200 | 1.92e-01 | 2.46e-01 | 3.70e-01 | 2.60e-01 | 2.87e-01 | 8.18e-05 | 4.72e-07 | 3.16e-14 | 9.47e-08 | 4.03e-09 |
| NEGATIVE REGULATION OF PHOTORECEPTOR CELL DIFFERENTIATION | 6 | 3.71e-01 | 7.71e-01 | 0.6200 | -3.06e-02 | 1.10e-01 | 2.95e-01 | 1.54e-01 | 5.10e-01 | 8.97e-01 | 6.42e-01 | 2.11e-01 | 5.14e-01 | 3.04e-02 |
| NEGATIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 6 | 5.19e-01 | 8.57e-01 | 0.6190 | -3.22e-01 | -1.72e-01 | -2.63e-01 | -2.85e-01 | -3.15e-01 | 1.71e-01 | 4.66e-01 | 2.65e-01 | 2.26e-01 | 1.81e-01 |
| CORNIFIED ENVELOPE ASSEMBLY | 6 | 5.28e-01 | 8.60e-01 | 0.6190 | 2.52e-01 | 1.76e-01 | 3.71e-01 | 3.63e-01 | 1.38e-01 | 2.85e-01 | 4.55e-01 | 1.16e-01 | 1.24e-01 | 5.57e-01 |
| POSITIVE REGULATION OF ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 26 | 1.28e-02 | 1.21e-01 | 0.6190 | 1.75e-01 | 1.87e-01 | 3.69e-01 | 3.47e-01 | 2.47e-01 | 1.22e-01 | 9.94e-02 | 1.12e-03 | 2.21e-03 | 2.92e-02 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION INDEPENDENT DECAY | 7 | 4.74e-01 | 8.31e-01 | 0.6190 | 1.69e-01 | 3.40e-01 | 3.21e-01 | 3.16e-01 | 1.89e-01 | 4.38e-01 | 1.19e-01 | 1.41e-01 | 1.48e-01 | 3.87e-01 |
| RESPONSE TO MISFOLDED PROTEIN | 23 | 9.03e-02 | 4.07e-01 | 0.6180 | 2.92e-01 | 2.77e-01 | 2.52e-01 | 3.34e-01 | 2.14e-01 | 1.54e-02 | 2.17e-02 | 3.61e-02 | 5.56e-03 | 7.61e-02 |
| FAS SIGNALING PATHWAY | 8 | 4.97e-01 | 8.45e-01 | 0.6180 | 2.99e-01 | 2.39e-01 | 2.76e-01 | 3.95e-01 | 5.28e-02 | 1.43e-01 | 2.42e-01 | 1.77e-01 | 5.28e-02 | 7.96e-01 |
| PSEUDOURIDINE SYNTHESIS | 17 | 9.27e-02 | 4.13e-01 | 0.6180 | 1.72e-01 | 1.75e-01 | 3.75e-01 | 2.85e-01 | 3.15e-01 | 2.20e-01 | 2.10e-01 | 7.44e-03 | 4.18e-02 | 2.44e-02 |
| CELLULAR RESPONSE TO INCREASED OXYGEN LEVELS | 10 | 4.05e-01 | 7.92e-01 | 0.6180 | 2.88e-01 | 2.40e-01 | 2.72e-01 | 2.49e-01 | 3.23e-01 | 1.15e-01 | 1.88e-01 | 1.36e-01 | 1.72e-01 | 7.66e-02 |
| POSITIVE REGULATION OF PROTEIN EXIT FROM ENDOPLASMIC RETICULUM | 12 | 1.86e-01 | 5.72e-01 | 0.6170 | 3.84e-01 | 3.88e-01 | 1.99e-01 | 2.09e-01 | -4.26e-03 | 2.13e-02 | 1.99e-02 | 2.33e-01 | 2.11e-01 | 9.80e-01 |
| MESENCHYMAL TO EPITHELIAL TRANSITION | 18 | 2.34e-01 | 6.36e-01 | 0.6170 | 2.17e-01 | 2.49e-01 | 3.37e-01 | 3.24e-01 | 2.30e-01 | 1.11e-01 | 6.77e-02 | 1.33e-02 | 1.72e-02 | 9.06e-02 |
| PROTON TRANSPORTING TWO SECTOR ATPASE COMPLEX ASSEMBLY | 15 | 1.94e-01 | 5.80e-01 | 0.6170 | 2.58e-01 | 2.15e-01 | 3.40e-01 | 2.62e-01 | 2.90e-01 | 8.40e-02 | 1.50e-01 | 2.26e-02 | 7.88e-02 | 5.20e-02 |
| REGULATION BY VIRUS OF VIRAL PROTEIN LEVELS IN HOST CELL | 7 | 5.91e-01 | 8.94e-01 | 0.6170 | 2.90e-01 | 1.87e-01 | 3.04e-01 | 3.81e-01 | 1.55e-01 | 1.85e-01 | 3.90e-01 | 1.64e-01 | 8.08e-02 | 4.77e-01 |
| POSITIVE REGULATION OF PROTEIN POLYUBIQUITINATION | 15 | 3.63e-02 | 2.45e-01 | 0.6170 | 4.39e-01 | 3.05e-01 | 1.24e-01 | 2.81e-01 | 1.43e-02 | 3.24e-03 | 4.09e-02 | 4.05e-01 | 5.94e-02 | 9.23e-01 |
| NEGATIVE REGULATION OF NEURON MIGRATION | 9 | 5.32e-01 | 8.63e-01 | 0.6170 | -2.59e-01 | -2.06e-01 | -2.70e-01 | -3.25e-01 | -3.03e-01 | 1.78e-01 | 2.86e-01 | 1.61e-01 | 9.09e-02 | 1.16e-01 |
| REGULATION OF PLASMA CELL DIFFERENTIATION | 5 | 2.29e-01 | 6.31e-01 | 0.6160 | 3.01e-01 | 3.52e-01 | 1.19e-01 | 3.83e-01 | 6.71e-02 | 2.44e-01 | 1.73e-01 | 6.45e-01 | 1.38e-01 | 7.95e-01 |
| LYSOSOMAL MEMBRANE ORGANIZATION | 14 | 2.15e-01 | 6.11e-01 | 0.6160 | 2.93e-01 | 2.51e-01 | 3.55e-01 | 3.07e-01 | 1.02e-01 | 5.77e-02 | 1.04e-01 | 2.16e-02 | 4.67e-02 | 5.07e-01 |
| CELL PROLIFERATION INVOLVED IN METANEPHROS DEVELOPMENT | 9 | 4.56e-01 | 8.22e-01 | 0.6160 | 1.32e-01 | 2.11e-01 | 3.34e-01 | 3.15e-01 | 3.25e-01 | 4.91e-01 | 2.72e-01 | 8.24e-02 | 1.01e-01 | 9.14e-02 |
| XYLULOSE 5 PHOSPHATE METABOLIC PROCESS | 6 | 4.73e-01 | 8.31e-01 | 0.6160 | 2.67e-01 | 1.98e-01 | 3.19e-01 | 4.08e-01 | 1.91e-02 | 2.57e-01 | 4.02e-01 | 1.76e-01 | 8.34e-02 | 9.35e-01 |
| NOTOCHORD DEVELOPMENT | 19 | 2.20e-02 | 1.77e-01 | 0.6160 | 7.41e-02 | 2.58e-01 | 3.80e-01 | 2.49e-01 | 3.16e-01 | 5.76e-01 | 5.13e-02 | 4.10e-03 | 5.99e-02 | 1.71e-02 |
| TRANS SYNAPTIC SIGNALING BY TRANS SYNAPTIC COMPLEX | 6 | 5.38e-01 | 8.66e-01 | 0.6150 | -2.64e-01 | -4.05e-01 | -2.42e-01 | -2.84e-01 | -7.80e-02 | 2.62e-01 | 8.61e-02 | 3.05e-01 | 2.28e-01 | 7.41e-01 |
| REGULATION OF MITOTIC SISTER CHROMATID SEGREGATION | 54 | 2.42e-04 | 5.45e-03 | 0.6150 | 2.30e-01 | 2.11e-01 | 3.12e-01 | 3.63e-01 | 2.27e-01 | 3.45e-03 | 7.19e-03 | 7.28e-05 | 3.88e-06 | 3.96e-03 |
| SNRNA TRANSCRIPTION BY RNA POLYMERASE II | 16 | 2.91e-01 | 7.02e-01 | 0.6140 | 3.11e-01 | 2.45e-01 | 3.08e-01 | 3.04e-01 | 1.82e-01 | 3.14e-02 | 8.96e-02 | 3.31e-02 | 3.50e-02 | 2.09e-01 |
| NEGATIVE REGULATION OF CALCIUM ION DEPENDENT EXOCYTOSIS | 8 | 3.53e-01 | 7.53e-01 | 0.6140 | 1.06e-01 | 1.29e-01 | 3.51e-01 | 3.41e-01 | 3.31e-01 | 6.02e-01 | 5.29e-01 | 8.57e-02 | 9.45e-02 | 1.05e-01 |
| POSITIVE REGULATION OF MITOPHAGY IN RESPONSE TO MITOCHONDRIAL DEPOLARIZATION | 8 | 4.03e-01 | 7.90e-01 | 0.6140 | 3.46e-01 | 2.02e-01 | 2.35e-01 | 2.94e-01 | 2.73e-01 | 9.06e-02 | 3.22e-01 | 2.50e-01 | 1.49e-01 | 1.81e-01 |
| POSITIVE REGULATION OF BMP SIGNALING PATHWAY | 40 | 9.06e-03 | 9.48e-02 | 0.6140 | 2.38e-01 | 3.26e-01 | 3.09e-01 | 2.49e-01 | 2.36e-01 | 9.10e-03 | 3.56e-04 | 7.18e-04 | 6.40e-03 | 9.83e-03 |
| NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO STRESS | 8 | 3.89e-01 | 7.82e-01 | 0.6130 | 1.52e-01 | 1.08e-01 | 3.30e-01 | 2.78e-01 | 3.94e-01 | 4.55e-01 | 5.97e-01 | 1.06e-01 | 1.74e-01 | 5.38e-02 |
| TYPE I PNEUMOCYTE DIFFERENTIATION | 8 | 6.27e-01 | 9.09e-01 | 0.6130 | 3.74e-01 | 2.89e-01 | 2.51e-01 | 2.82e-01 | 1.01e-01 | 6.71e-02 | 1.57e-01 | 2.19e-01 | 1.68e-01 | 6.19e-01 |
| REGULATION OF RESPONSE TO DRUG | 15 | 3.17e-01 | 7.27e-01 | 0.6130 | -3.54e-01 | -3.03e-01 | -2.36e-01 | -3.10e-01 | -8.05e-02 | 1.76e-02 | 4.20e-02 | 1.13e-01 | 3.76e-02 | 5.89e-01 |
| PURINE DEOXYRIBONUCLEOTIDE CATABOLIC PROCESS | 10 | 3.05e-01 | 7.18e-01 | 0.6130 | 2.35e-01 | 2.00e-01 | 3.84e-01 | 2.82e-01 | 2.30e-01 | 1.97e-01 | 2.73e-01 | 3.54e-02 | 1.22e-01 | 2.08e-01 |
| NEGATIVE REGULATION OF RESPONSE TO OXIDATIVE STRESS | 11 | 3.86e-01 | 7.80e-01 | 0.6130 | -3.32e-01 | -3.44e-01 | -2.39e-01 | -2.98e-01 | 4.03e-02 | 5.66e-02 | 4.84e-02 | 1.70e-01 | 8.74e-02 | 8.17e-01 |
| POSITIVE REGULATION BY SYMBIONT OF ENTRY INTO HOST | 14 | 2.07e-01 | 6.01e-01 | 0.6130 | 3.70e-01 | 3.58e-01 | 2.37e-01 | 2.19e-01 | 8.18e-02 | 1.66e-02 | 2.05e-02 | 1.25e-01 | 1.56e-01 | 5.96e-01 |
| POSITIVE REGULATION OF INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 12 | 2.49e-04 | 5.57e-03 | 0.6120 | -1.67e-01 | -9.85e-03 | 3.50e-01 | 3.23e-01 | 3.46e-01 | 3.16e-01 | 9.53e-01 | 3.58e-02 | 5.29e-02 | 3.78e-02 |
| POSTSYNAPTIC MEMBRANE ASSEMBLY | 7 | 5.02e-01 | 8.48e-01 | 0.6120 | -3.13e-01 | -1.67e-01 | -2.39e-01 | -3.58e-01 | -2.51e-01 | 1.52e-01 | 4.45e-01 | 2.74e-01 | 1.01e-01 | 2.49e-01 |
| VESICLE TARGETING ROUGH ER TO CIS GOLGI | 25 | 8.32e-02 | 3.90e-01 | 0.6120 | 2.77e-01 | 2.98e-01 | 3.38e-01 | 2.87e-01 | 1.07e-01 | 1.64e-02 | 9.84e-03 | 3.44e-03 | 1.29e-02 | 3.55e-01 |
| POSITIVE REGULATION OF ACROSOME REACTION | 11 | 1.09e-01 | 4.51e-01 | 0.6120 | -3.53e-01 | -1.70e-01 | -2.17e-01 | -4.17e-01 | -9.98e-03 | 4.26e-02 | 3.30e-01 | 2.13e-01 | 1.67e-02 | 9.54e-01 |
| PROTEIN EXIT FROM ENDOPLASMIC RETICULUM | 48 | 5.29e-03 | 6.39e-02 | 0.6120 | 2.86e-01 | 3.05e-01 | 2.72e-01 | 3.16e-01 | 1.61e-01 | 6.10e-04 | 2.59e-04 | 1.12e-03 | 1.54e-04 | 5.42e-02 |
| SENSORY PERCEPTION | 881 | 9.46e-59 | 1.42e-55 | 0.6120 | -2.43e-01 | -2.74e-01 | -3.09e-01 | -2.87e-01 | -2.50e-01 | 1.84e-34 | 2.09e-43 | 7.09e-55 | 1.12e-47 | 2.02e-36 |
| POSITIVE REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 31 | 3.75e-02 | 2.50e-01 | 0.6110 | 2.38e-01 | 2.40e-01 | 2.94e-01 | 2.79e-01 | 3.09e-01 | 2.17e-02 | 2.09e-02 | 4.63e-03 | 7.27e-03 | 2.88e-03 |
| NEGATIVE REGULATION OF STEM CELL DIFFERENTIATION | 26 | 4.11e-03 | 5.37e-02 | 0.6110 | 1.35e-01 | 1.16e-01 | 2.85e-01 | 3.31e-01 | 3.89e-01 | 2.33e-01 | 3.04e-01 | 1.19e-02 | 3.49e-03 | 6.03e-04 |
| PROTEIN MATURATION BY IRON SULFUR CLUSTER TRANSFER | 15 | 2.44e-01 | 6.48e-01 | 0.6110 | 2.85e-01 | 2.45e-01 | 2.80e-01 | 2.55e-01 | 2.98e-01 | 5.57e-02 | 1.01e-01 | 6.00e-02 | 8.75e-02 | 4.58e-02 |
| TACHYKININ RECEPTOR SIGNALING PATHWAY | 8 | 3.28e-01 | 7.37e-01 | 0.6110 | 3.69e-01 | 3.92e-01 | 1.49e-01 | 2.32e-01 | -8.36e-02 | 7.07e-02 | 5.46e-02 | 4.65e-01 | 2.56e-01 | 6.82e-01 |
| MULTIVESICULAR BODY ORGANIZATION | 32 | 1.42e-02 | 1.31e-01 | 0.6110 | 2.71e-01 | 1.91e-01 | 3.08e-01 | 3.47e-01 | 2.19e-01 | 7.86e-03 | 6.10e-02 | 2.60e-03 | 6.88e-04 | 3.20e-02 |
| NEGATIVE REGULATION OF MHC CLASS II BIOSYNTHETIC PROCESS | 6 | 1.32e-01 | 4.92e-01 | 0.6100 | 4.33e-01 | 2.79e-01 | -1.25e-02 | 3.03e-01 | -1.24e-01 | 6.62e-02 | 2.37e-01 | 9.58e-01 | 1.98e-01 | 6.00e-01 |
| FOREBRAIN RADIAL GLIAL CELL DIFFERENTIATION | 7 | 3.12e-01 | 7.23e-01 | 0.6100 | 1.71e-01 | 1.04e-01 | 3.06e-01 | 4.18e-01 | 2.53e-01 | 4.34e-01 | 6.33e-01 | 1.61e-01 | 5.57e-02 | 2.47e-01 |
| AUTOPHAGOSOME LYSOSOME FUSION | 9 | 1.45e-01 | 5.11e-01 | 0.6100 | 2.02e-01 | 2.78e-01 | 2.03e-01 | 3.42e-01 | 3.08e-01 | 2.94e-01 | 1.48e-01 | 2.92e-01 | 7.53e-02 | 1.09e-01 |
| PRIMITIVE STREAK FORMATION | 10 | 4.61e-02 | 2.81e-01 | 0.6090 | 6.52e-02 | 3.49e-01 | 3.65e-01 | 8.88e-02 | 3.23e-01 | 7.21e-01 | 5.62e-02 | 4.58e-02 | 6.27e-01 | 7.73e-02 |
| ERBB2 ERBB4 SIGNALING PATHWAY | 5 | 7.77e-01 | 9.58e-01 | 0.6090 | -1.86e-01 | -2.11e-01 | -2.75e-01 | -3.24e-01 | -3.34e-01 | 4.72e-01 | 4.14e-01 | 2.87e-01 | 2.10e-01 | 1.96e-01 |
| IMMUNOGLOBULIN V D J RECOMBINATION | 8 | 5.62e-01 | 8.79e-01 | 0.6090 | 2.96e-01 | 1.85e-01 | 2.76e-01 | 3.59e-01 | 2.08e-01 | 1.47e-01 | 3.66e-01 | 1.76e-01 | 7.84e-02 | 3.09e-01 |
| RESPIRATORY BURST INVOLVED IN DEFENSE RESPONSE | 16 | 3.47e-01 | 7.50e-01 | 0.6090 | 3.13e-01 | 2.88e-01 | 3.04e-01 | 2.76e-01 | 1.48e-01 | 3.04e-02 | 4.65e-02 | 3.55e-02 | 5.59e-02 | 3.06e-01 |
| HEART VALVE FORMATION | 15 | 2.30e-01 | 6.32e-01 | 0.6090 | 1.96e-01 | 3.35e-01 | 3.36e-01 | 2.65e-01 | 1.91e-01 | 1.89e-01 | 2.45e-02 | 2.41e-02 | 7.60e-02 | 2.01e-01 |
| INHIBITION OF NEUROEPITHELIAL CELL DIFFERENTIATION | 5 | 1.75e-01 | 5.60e-01 | 0.6090 | -6.92e-02 | 2.33e-01 | 2.12e-01 | 1.12e-01 | 5.04e-01 | 7.89e-01 | 3.67e-01 | 4.11e-01 | 6.63e-01 | 5.11e-02 |
| NUCLEAR PORE LOCALIZATION | 5 | 1.45e-01 | 5.11e-01 | 0.6080 | 4.16e-01 | 3.24e-01 | -2.97e-02 | 2.89e-01 | -8.81e-02 | 1.07e-01 | 2.10e-01 | 9.08e-01 | 2.64e-01 | 7.33e-01 |
| POSITIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 66 | 3.71e-04 | 7.96e-03 | 0.6080 | 3.05e-01 | 2.85e-01 | 2.62e-01 | 3.26e-01 | 1.42e-01 | 1.86e-05 | 6.03e-05 | 2.26e-04 | 4.68e-06 | 4.58e-02 |
| SMOOTH MUSCLE CELL MATRIX ADHESION | 6 | 4.25e-01 | 8.04e-01 | 0.6080 | 2.55e-01 | 4.26e-01 | 3.07e-01 | 1.70e-01 | -1.27e-02 | 2.80e-01 | 7.09e-02 | 1.92e-01 | 4.71e-01 | 9.57e-01 |
| REGULATION OF ADIPONECTIN SECRETION | 7 | 3.25e-02 | 2.29e-01 | 0.6080 | 1.95e-01 | 6.45e-02 | -2.83e-01 | -2.67e-01 | -4.19e-01 | 3.72e-01 | 7.68e-01 | 1.95e-01 | 2.21e-01 | 5.46e-02 |
| TRANSCRIPTION PREINITIATION COMPLEX ASSEMBLY | 66 | 1.59e-04 | 3.89e-03 | 0.6080 | 2.26e-01 | 3.12e-01 | 3.01e-01 | 2.93e-01 | 2.10e-01 | 1.47e-03 | 1.19e-05 | 2.30e-05 | 3.74e-05 | 3.19e-03 |
| NLS BEARING PROTEIN IMPORT INTO NUCLEUS | 19 | 1.01e-01 | 4.31e-01 | 0.6080 | 3.51e-01 | 2.64e-01 | 2.29e-01 | 3.52e-01 | 4.57e-03 | 8.03e-03 | 4.67e-02 | 8.44e-02 | 7.84e-03 | 9.73e-01 |
| TROPHOBLAST GIANT CELL DIFFERENTIATION | 12 | 2.94e-01 | 7.05e-01 | 0.6070 | 1.37e-01 | 2.59e-01 | 3.70e-01 | 2.78e-01 | 2.62e-01 | 4.12e-01 | 1.20e-01 | 2.64e-02 | 9.50e-02 | 1.17e-01 |
| NEGATIVE REGULATION OF FIBROBLAST GROWTH FACTOR PRODUCTION | 5 | 1.73e-01 | 5.58e-01 | 0.6070 | -2.53e-01 | -1.67e-01 | 1.20e-01 | -1.77e-01 | 4.81e-01 | 3.27e-01 | 5.18e-01 | 6.41e-01 | 4.94e-01 | 6.27e-02 |
| SEQUESTERING OF BMP IN EXTRACELLULAR MATRIX | 5 | 5.12e-01 | 8.55e-01 | 0.6070 | -4.35e-01 | -2.03e-01 | -1.51e-01 | -3.39e-01 | -8.08e-03 | 9.22e-02 | 4.32e-01 | 5.58e-01 | 1.89e-01 | 9.75e-01 |
| REGULATION OF LIPOPHAGY | 5 | 7.23e-01 | 9.41e-01 | 0.6070 | 1.86e-01 | 2.96e-01 | 2.60e-01 | 2.81e-01 | 3.15e-01 | 4.71e-01 | 2.51e-01 | 3.13e-01 | 2.77e-01 | 2.22e-01 |
| BRANCHING MORPHOGENESIS OF A NERVE | 10 | 1.87e-01 | 5.72e-01 | 0.6070 | 3.60e-01 | 2.13e-01 | 1.82e-01 | 4.00e-01 | -1.05e-02 | 4.87e-02 | 2.44e-01 | 3.19e-01 | 2.84e-02 | 9.54e-01 |
| PROTON TRANSPORTING V TYPE ATPASE COMPLEX ASSEMBLY | 7 | 4.73e-01 | 8.31e-01 | 0.6060 | 9.93e-02 | 1.03e-01 | 3.29e-01 | 2.63e-01 | 4.12e-01 | 6.49e-01 | 6.36e-01 | 1.32e-01 | 2.28e-01 | 5.90e-02 |
| NEGATIVE REGULATION OF MACROPHAGE CYTOKINE PRODUCTION | 12 | 9.15e-02 | 4.11e-01 | 0.6060 | 2.41e-01 | 4.26e-01 | 2.55e-01 | 2.51e-01 | 1.66e-02 | 1.49e-01 | 1.07e-02 | 1.26e-01 | 1.32e-01 | 9.21e-01 |
| POLYAMINE METABOLIC PROCESS | 15 | 3.67e-01 | 7.67e-01 | 0.6060 | 2.50e-01 | 2.31e-01 | 2.98e-01 | 3.36e-01 | 2.24e-01 | 9.34e-02 | 1.22e-01 | 4.57e-02 | 2.44e-02 | 1.33e-01 |
| PROTEIN LOCALIZATION TO PLASMA MEMBRANE RAFT | 5 | 1.73e-01 | 5.57e-01 | 0.6060 | 2.14e-01 | 8.65e-02 | 1.00e-01 | 1.92e-01 | 5.17e-01 | 4.07e-01 | 7.38e-01 | 6.99e-01 | 4.57e-01 | 4.54e-02 |
| AXONEMAL CENTRAL APPARATUS ASSEMBLY | 6 | 4.23e-01 | 8.03e-01 | 0.6060 | -2.57e-01 | -2.75e-01 | -3.81e-01 | -2.82e-01 | 2.28e-02 | 2.76e-01 | 2.44e-01 | 1.06e-01 | 2.32e-01 | 9.23e-01 |
| RESPIRATORY BURST INVOLVED IN INFLAMMATORY RESPONSE | 9 | 2.03e-01 | 5.96e-01 | 0.6050 | 2.44e-01 | 1.37e-01 | 3.72e-01 | 2.82e-01 | 2.64e-01 | 2.05e-01 | 4.77e-01 | 5.30e-02 | 1.43e-01 | 1.70e-01 |
| NUCLEOTIDE EXCISION REPAIR DNA GAP FILLING | 6 | 4.81e-01 | 8.35e-01 | 0.6050 | 1.86e-01 | 7.82e-02 | 2.90e-01 | 3.60e-01 | 3.34e-01 | 4.30e-01 | 7.40e-01 | 2.18e-01 | 1.27e-01 | 1.57e-01 |
| NUCLEOTIDE SALVAGE | 17 | 7.91e-02 | 3.82e-01 | 0.6050 | 3.98e-01 | 3.40e-01 | 1.75e-01 | 2.40e-01 | -5.88e-02 | 4.50e-03 | 1.52e-02 | 2.11e-01 | 8.64e-02 | 6.75e-01 |
| IMMUNE RESPONSE INHIBITING SIGNAL TRANSDUCTION | 11 | 1.96e-01 | 5.84e-01 | 0.6050 | -1.55e-01 | -2.75e-01 | -3.63e-01 | -3.42e-01 | -1.32e-01 | 3.72e-01 | 1.15e-01 | 3.71e-02 | 4.93e-02 | 4.48e-01 |
| ADENYLATE CYCLASE ACTIVATING ADRENERGIC RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART PROCESS | 9 | 5.36e-01 | 8.66e-01 | 0.6040 | -3.49e-01 | -3.63e-01 | -2.26e-01 | -2.43e-01 | -4.34e-02 | 6.99e-02 | 5.93e-02 | 2.40e-01 | 2.07e-01 | 8.22e-01 |
| REGULATION OF PROTEIN SUMOYLATION | 21 | 7.27e-02 | 3.65e-01 | 0.6040 | 2.77e-01 | 2.38e-01 | 2.54e-01 | 3.80e-01 | 1.49e-01 | 2.78e-02 | 5.94e-02 | 4.41e-02 | 2.56e-03 | 2.37e-01 |
| NEUTROPHIL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 20 | 2.43e-02 | 1.90e-01 | 0.6040 | 2.89e-01 | 3.67e-01 | 2.54e-01 | 2.63e-01 | -1.12e-01 | 2.51e-02 | 4.45e-03 | 4.95e-02 | 4.20e-02 | 3.87e-01 |
| POSITIVE REGULATION OF ANIMAL ORGAN MORPHOGENESIS | 34 | 2.49e-03 | 3.63e-02 | 0.6040 | 1.39e-01 | 2.66e-01 | 2.89e-01 | 2.39e-01 | 3.66e-01 | 1.61e-01 | 7.29e-03 | 3.56e-03 | 1.61e-02 | 2.18e-04 |
| EPITHELIAL TO MESENCHYMAL TRANSITION INVOLVED IN ENDOCARDIAL CUSHION FORMATION | 18 | 9.32e-02 | 4.14e-01 | 0.6040 | 1.40e-01 | 3.04e-01 | 3.34e-01 | 2.55e-01 | 2.75e-01 | 3.04e-01 | 2.56e-02 | 1.41e-02 | 6.08e-02 | 4.37e-02 |
| RIBONUCLEOPROTEIN COMPLEX BIOGENESIS | 448 | 2.13e-31 | 1.07e-28 | 0.6040 | 2.43e-01 | 2.37e-01 | 3.26e-01 | 2.88e-01 | 2.45e-01 | 9.93e-19 | 7.90e-18 | 2.49e-32 | 1.19e-25 | 6.52e-19 |
| MULTI PASS TRANSMEMBRANE PROTEIN INSERTION INTO ER MEMBRANE | 8 | 6.95e-01 | 9.31e-01 | 0.6030 | 2.98e-01 | 2.45e-01 | 2.55e-01 | 3.30e-01 | 2.03e-01 | 1.45e-01 | 2.29e-01 | 2.12e-01 | 1.06e-01 | 3.20e-01 |
| CYCLIC NUCLEOTIDE CATABOLIC PROCESS | 14 | 3.55e-01 | 7.55e-01 | 0.6030 | -3.51e-01 | -3.24e-01 | -2.50e-01 | -2.69e-01 | -2.86e-02 | 2.31e-02 | 3.56e-02 | 1.06e-01 | 8.17e-02 | 8.53e-01 |
| REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS | 37 | 8.69e-03 | 9.22e-02 | 0.6030 | 2.05e-01 | 1.93e-01 | 3.07e-01 | 2.81e-01 | 3.33e-01 | 3.12e-02 | 4.25e-02 | 1.22e-03 | 3.08e-03 | 4.55e-04 |
| REGULATION OF GERM CELL PROLIFERATION | 7 | 2.75e-01 | 6.83e-01 | 0.6030 | 3.56e-01 | 3.42e-01 | 1.16e-01 | 1.60e-01 | -2.83e-01 | 1.03e-01 | 1.17e-01 | 5.94e-01 | 4.64e-01 | 1.94e-01 |
| POSITIVE REGULATION OF MONOCYTE DIFFERENTIATION | 10 | 1.52e-01 | 5.21e-01 | 0.6020 | 2.00e-01 | 4.24e-01 | 2.73e-01 | 2.01e-01 | 1.68e-01 | 2.75e-01 | 2.03e-02 | 1.34e-01 | 2.71e-01 | 3.58e-01 |
| REGULATION OF PROTEIN NEDDYLATION | 19 | 1.24e-02 | 1.19e-01 | 0.6020 | 2.22e-01 | 1.63e-01 | 1.99e-01 | 3.25e-01 | 3.75e-01 | 9.45e-02 | 2.18e-01 | 1.34e-01 | 1.40e-02 | 4.62e-03 |
| HISTAMINE METABOLIC PROCESS | 6 | 5.60e-01 | 8.78e-01 | 0.6020 | -1.58e-01 | -9.20e-02 | -2.90e-01 | -2.89e-01 | -4.02e-01 | 5.04e-01 | 6.96e-01 | 2.19e-01 | 2.21e-01 | 8.83e-02 |
| REGULATION OF ANIMAL ORGAN FORMATION | 27 | 2.66e-02 | 2.01e-01 | 0.6010 | 1.46e-01 | 2.38e-01 | 3.01e-01 | 2.80e-01 | 3.39e-01 | 1.89e-01 | 3.19e-02 | 6.85e-03 | 1.19e-02 | 2.30e-03 |
| PHOSPHOLIPASE C ACTIVATING DOPAMINE RECEPTOR SIGNALING PATHWAY | 9 | 3.82e-02 | 2.53e-01 | 0.6010 | 4.31e-01 | 3.82e-01 | 9.69e-02 | 1.16e-01 | 8.46e-02 | 2.52e-02 | 4.71e-02 | 6.15e-01 | 5.48e-01 | 6.60e-01 |
| REGULATION OF KIDNEY DEVELOPMENT | 32 | 3.24e-02 | 2.29e-01 | 0.6010 | 1.81e-01 | 2.45e-01 | 3.15e-01 | 2.78e-01 | 3.04e-01 | 7.70e-02 | 1.67e-02 | 2.06e-03 | 6.49e-03 | 2.90e-03 |
| INTERLEUKIN 23 PRODUCTION | 9 | 8.24e-02 | 3.88e-01 | 0.6010 | 1.16e-01 | 2.80e-02 | -2.67e-01 | -1.72e-01 | -4.96e-01 | 5.48e-01 | 8.84e-01 | 1.66e-01 | 3.72e-01 | 9.94e-03 |
| MICROGLIA DIFFERENTIATION | 11 | 3.15e-01 | 7.26e-01 | 0.6010 | 3.06e-01 | 3.95e-01 | 2.38e-01 | 2.34e-01 | 2.85e-03 | 7.93e-02 | 2.32e-02 | 1.72e-01 | 1.79e-01 | 9.87e-01 |
| ERBB4 ERBB4 SIGNALING PATHWAY | 6 | 1.77e-01 | 5.62e-01 | 0.6010 | -2.91e-02 | -2.32e-01 | -2.93e-01 | -3.60e-01 | -3.01e-01 | 9.02e-01 | 3.24e-01 | 2.14e-01 | 1.27e-01 | 2.02e-01 |
| PREVENTION OF POLYSPERMY | 7 | 1.98e-01 | 5.87e-01 | 0.6010 | -3.88e-01 | -1.96e-01 | -1.44e-01 | -2.64e-01 | 2.84e-01 | 7.51e-02 | 3.68e-01 | 5.08e-01 | 2.26e-01 | 1.93e-01 |
| TRNA TRANSCRIPTION | 11 | 4.37e-01 | 8.10e-01 | 0.6000 | 2.65e-01 | 2.62e-01 | 2.98e-01 | 2.21e-01 | 2.90e-01 | 1.28e-01 | 1.32e-01 | 8.71e-02 | 2.05e-01 | 9.58e-02 |
| MATERNAL PLACENTA DEVELOPMENT | 33 | 2.73e-03 | 3.90e-02 | 0.6000 | 1.76e-01 | 3.26e-01 | 2.95e-01 | 2.96e-01 | 2.20e-01 | 7.94e-02 | 1.19e-03 | 3.37e-03 | 3.27e-03 | 2.85e-02 |
| NEURONAL SIGNAL TRANSDUCTION | 7 | 1.07e-01 | 4.47e-01 | 0.6000 | 8.87e-02 | 4.13e-01 | 3.69e-01 | 1.94e-01 | 8.87e-02 | 6.85e-01 | 5.82e-02 | 9.08e-02 | 3.75e-01 | 6.85e-01 |
| NEGATIVE REGULATION OF SYNAPSE ORGANIZATION | 11 | 6.28e-01 | 9.09e-01 | 0.6000 | 2.71e-01 | 2.66e-01 | 2.85e-01 | 2.90e-01 | 2.25e-01 | 1.20e-01 | 1.26e-01 | 1.02e-01 | 9.54e-02 | 1.97e-01 |
| REGULATION OF MEMBRANE REPOLARIZATION DURING VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL | 5 | 7.01e-01 | 9.32e-01 | 0.6000 | -2.34e-01 | -3.27e-01 | -2.63e-01 | -3.49e-01 | -8.90e-02 | 3.66e-01 | 2.06e-01 | 3.09e-01 | 1.76e-01 | 7.31e-01 |
| TESTOSTERONE BIOSYNTHETIC PROCESS | 11 | 3.82e-01 | 7.78e-01 | 0.6000 | -2.02e-01 | -1.89e-01 | -2.89e-01 | -2.44e-01 | -3.75e-01 | 2.47e-01 | 2.78e-01 | 9.72e-02 | 1.60e-01 | 3.13e-02 |
| METHYLGLYOXAL METABOLIC PROCESS | 6 | 1.84e-01 | 5.71e-01 | 0.6000 | 1.50e-01 | 2.41e-02 | 3.88e-01 | 3.44e-01 | 2.60e-01 | 5.24e-01 | 9.19e-01 | 1.00e-01 | 1.44e-01 | 2.70e-01 |
| REGULATION OF NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING 2 SIGNALING PATHWAY | 10 | 4.85e-01 | 8.38e-01 | 0.5990 | 3.61e-01 | 3.15e-01 | 2.11e-01 | 2.65e-01 | 1.20e-01 | 4.80e-02 | 8.43e-02 | 2.49e-01 | 1.46e-01 | 5.13e-01 |
| DE NOVO AMP BIOSYNTHETIC PROCESS | 8 | 6.44e-01 | 9.15e-01 | 0.5990 | 3.38e-01 | 2.51e-01 | 2.91e-01 | 2.92e-01 | 1.10e-01 | 9.77e-02 | 2.20e-01 | 1.54e-01 | 1.53e-01 | 5.91e-01 |
| POSITIVE REGULATION OF METAPHASE ANAPHASE TRANSITION OF CELL CYCLE | 15 | 5.67e-02 | 3.15e-01 | 0.5990 | 3.30e-01 | 1.87e-01 | 1.97e-01 | 4.06e-01 | 1.02e-01 | 2.67e-02 | 2.10e-01 | 1.87e-01 | 6.43e-03 | 4.93e-01 |
| ENDONUCLEOLYTIC CLEAVAGE IN ITS1 TO SEPARATE SSU RRNA FROM 5 8S RRNA AND LSU RRNA FROM TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 10 | 8.51e-02 | 3.95e-01 | 0.5980 | 1.60e-01 | 5.86e-02 | 3.56e-01 | 2.48e-01 | 3.75e-01 | 3.80e-01 | 7.48e-01 | 5.14e-02 | 1.74e-01 | 3.98e-02 |
| PROTEIN LOCALIZATION TO NUCLEAR ENVELOPE | 13 | 4.41e-01 | 8.13e-01 | 0.5980 | 2.80e-01 | 3.01e-01 | 2.61e-01 | 3.27e-01 | 1.19e-01 | 8.08e-02 | 6.03e-02 | 1.03e-01 | 4.12e-02 | 4.57e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER INVOLVED IN CELLULAR RESPONSE TO CHEMICAL STIMULUS | 17 | 3.52e-01 | 7.53e-01 | 0.5980 | 2.68e-01 | 3.03e-01 | 2.99e-01 | 3.01e-01 | 1.17e-01 | 5.55e-02 | 3.06e-02 | 3.28e-02 | 3.14e-02 | 4.04e-01 |
| ACTIVATION OF PROTEIN KINASE C ACTIVITY | 5 | 9.49e-02 | 4.18e-01 | 0.5980 | 3.74e-01 | 4.58e-01 | 1.96e-02 | 7.82e-02 | 3.27e-02 | 1.48e-01 | 7.60e-02 | 9.40e-01 | 7.62e-01 | 8.99e-01 |
| TRNA AMINOACYLATION FOR MITOCHONDRIAL PROTEIN TRANSLATION | 8 | 6.15e-01 | 9.06e-01 | 0.5980 | 2.94e-01 | 2.18e-01 | 2.40e-01 | 3.43e-01 | 2.20e-01 | 1.50e-01 | 2.86e-01 | 2.40e-01 | 9.31e-02 | 2.82e-01 |
| METANEPHRIC DISTAL TUBULE DEVELOPMENT | 7 | 7.63e-01 | 9.54e-01 | 0.5970 | 2.92e-01 | 2.27e-01 | 3.04e-01 | 3.12e-01 | 1.75e-01 | 1.81e-01 | 2.99e-01 | 1.64e-01 | 1.53e-01 | 4.22e-01 |
| REGULATION OF PROTEIN EXIT FROM ENDOPLASMIC RETICULUM | 24 | 1.31e-01 | 4.90e-01 | 0.5970 | 3.01e-01 | 3.03e-01 | 2.96e-01 | 2.44e-01 | 1.66e-01 | 1.06e-02 | 1.02e-02 | 1.22e-02 | 3.86e-02 | 1.60e-01 |
| HISTONE DEACETYLATION | 19 | 1.71e-01 | 5.55e-01 | 0.5970 | 1.95e-01 | 2.32e-01 | 2.99e-01 | 3.31e-01 | 2.57e-01 | 1.40e-01 | 8.04e-02 | 2.43e-02 | 1.24e-02 | 5.24e-02 |
| PROTEIN TRANSPORT TO VACUOLE INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS VIA THE MULTIVESICULAR BODY SORTING PATHWAY | 15 | 1.39e-01 | 5.03e-01 | 0.5970 | 2.79e-01 | 1.59e-01 | 2.47e-01 | 3.33e-01 | 2.85e-01 | 6.09e-02 | 2.87e-01 | 9.73e-02 | 2.58e-02 | 5.58e-02 |
| NUCLEAR MIGRATION ALONG MICROTUBULE | 5 | 5.77e-01 | 8.85e-01 | 0.5970 | -3.74e-01 | -2.55e-01 | -1.34e-01 | -3.65e-01 | -1.14e-02 | 1.48e-01 | 3.23e-01 | 6.03e-01 | 1.57e-01 | 9.65e-01 |
| NECROPTOTIC SIGNALING PATHWAY | 8 | 3.87e-01 | 7.80e-01 | 0.5970 | 3.94e-01 | 2.65e-01 | 1.90e-01 | 2.53e-01 | 1.74e-01 | 5.34e-02 | 1.95e-01 | 3.53e-01 | 2.15e-01 | 3.94e-01 |
| DETERMINATION OF LEFT RIGHT ASYMMETRY IN LATERAL MESODERM | 8 | 1.15e-01 | 4.62e-01 | 0.5970 | -1.33e-01 | -9.67e-03 | 2.30e-01 | 1.61e-01 | 5.09e-01 | 5.14e-01 | 9.62e-01 | 2.59e-01 | 4.31e-01 | 1.26e-02 |
| INTERLEUKIN 21 PRODUCTION | 5 | 4.07e-01 | 7.93e-01 | 0.5970 | -4.09e-02 | -1.16e-01 | -2.41e-01 | -6.35e-02 | -5.28e-01 | 8.74e-01 | 6.54e-01 | 3.50e-01 | 8.06e-01 | 4.10e-02 |
| MEIOTIC CELL CYCLE CHECKPOINT SIGNALING | 8 | 3.08e-01 | 7.19e-01 | 0.5960 | 3.36e-01 | 2.41e-01 | 1.83e-01 | 3.61e-01 | -1.44e-01 | 9.93e-02 | 2.37e-01 | 3.71e-01 | 7.70e-02 | 4.82e-01 |
| VESICLE TARGETING TO FROM OR WITHIN GOLGI | 32 | 6.63e-02 | 3.44e-01 | 0.5960 | 2.61e-01 | 2.67e-01 | 3.15e-01 | 3.08e-01 | 1.49e-01 | 1.05e-02 | 8.96e-03 | 2.04e-03 | 2.56e-03 | 1.45e-01 |
| INTERFERON ALPHA PRODUCTION | 27 | 1.83e-02 | 1.58e-01 | 0.5960 | 3.56e-01 | 3.16e-01 | 1.80e-01 | 3.07e-01 | 4.18e-02 | 1.36e-03 | 4.47e-03 | 1.05e-01 | 5.70e-03 | 7.07e-01 |
| ANDROGEN CATABOLIC PROCESS | 5 | 3.38e-01 | 7.44e-01 | 0.5960 | -8.91e-02 | -1.83e-01 | -3.75e-01 | -7.42e-02 | -4.09e-01 | 7.30e-01 | 4.78e-01 | 1.46e-01 | 7.74e-01 | 1.14e-01 |
| RNA SPLICING VIA ENDONUCLEOLYTIC CLEAVAGE AND LIGATION | 14 | 4.36e-01 | 8.09e-01 | 0.5960 | 2.34e-01 | 2.86e-01 | 3.30e-01 | 2.92e-01 | 1.55e-01 | 1.29e-01 | 6.37e-02 | 3.24e-02 | 5.85e-02 | 3.16e-01 |
| MITOCHONDRIAL RNA PROCESSING | 20 | 2.30e-01 | 6.32e-01 | 0.5960 | 2.48e-01 | 2.61e-01 | 2.74e-01 | 3.16e-01 | 2.25e-01 | 5.52e-02 | 4.34e-02 | 3.40e-02 | 1.45e-02 | 8.17e-02 |
| REGULATION OF DNA TOPOISOMERASE ATP HYDROLYZING ACTIVITY | 5 | 3.97e-01 | 7.86e-01 | 0.5950 | 2.88e-01 | 8.18e-02 | 1.77e-01 | 3.61e-01 | 3.22e-01 | 2.64e-01 | 7.51e-01 | 4.94e-01 | 1.62e-01 | 2.13e-01 |
| ICOSANOID CATABOLIC PROCESS | 9 | 1.18e-01 | 4.68e-01 | 0.5950 | 2.47e-01 | 1.86e-01 | 3.76e-01 | 1.80e-01 | 2.92e-01 | 1.99e-01 | 3.35e-01 | 5.09e-02 | 3.51e-01 | 1.29e-01 |
| REGULATION OF CHROMOSOME CONDENSATION | 13 | 4.34e-01 | 8.08e-01 | 0.5950 | 2.07e-01 | 2.21e-01 | 3.37e-01 | 2.76e-01 | 2.70e-01 | 1.97e-01 | 1.68e-01 | 3.56e-02 | 8.46e-02 | 9.18e-02 |
| HYDROGEN SULFIDE METABOLIC PROCESS | 6 | 3.16e-01 | 7.27e-01 | 0.5950 | 2.11e-01 | 1.94e-01 | 1.54e-01 | 2.66e-01 | 4.21e-01 | 3.70e-01 | 4.10e-01 | 5.13e-01 | 2.60e-01 | 7.39e-02 |
| REGULATION OF HELICASE ACTIVITY | 10 | 1.86e-01 | 5.72e-01 | 0.5950 | 3.53e-01 | 3.21e-01 | 1.70e-01 | 2.08e-01 | -2.33e-01 | 5.31e-02 | 7.87e-02 | 3.53e-01 | 2.55e-01 | 2.03e-01 |
| ENDONUCLEOLYTIC CLEAVAGE OF TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 17 | 3.96e-02 | 2.57e-01 | 0.5950 | 9.64e-02 | 1.31e-01 | 3.69e-01 | 2.23e-01 | 3.76e-01 | 4.91e-01 | 3.50e-01 | 8.39e-03 | 1.11e-01 | 7.26e-03 |
| POSITIVE REGULATION OF NITRIC OXIDE MEDIATED SIGNAL TRANSDUCTION | 5 | 8.81e-01 | 9.79e-01 | 0.5950 | -2.67e-01 | -3.03e-01 | -2.58e-01 | -2.82e-01 | -2.11e-01 | 3.00e-01 | 2.41e-01 | 3.17e-01 | 2.75e-01 | 4.14e-01 |
| POSITIVE REGULATION OF HYPERSENSITIVITY | 5 | 2.96e-02 | 2.15e-01 | 0.5940 | -3.75e-01 | -1.61e-02 | 1.32e-01 | 9.55e-02 | 4.31e-01 | 1.46e-01 | 9.50e-01 | 6.09e-01 | 7.11e-01 | 9.51e-02 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 5 | 6.62e-01 | 9.22e-01 | 0.5940 | -3.05e-01 | -1.80e-01 | -2.31e-01 | -2.64e-01 | -3.25e-01 | 2.38e-01 | 4.87e-01 | 3.72e-01 | 3.07e-01 | 2.09e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION REGULATORY REGION DNA BINDING | 22 | 5.56e-02 | 3.12e-01 | 0.5940 | 1.83e-01 | 3.20e-01 | 3.53e-01 | 2.10e-01 | 2.21e-01 | 1.37e-01 | 9.45e-03 | 4.16e-03 | 8.84e-02 | 7.28e-02 |
| POSITIVE REGULATION OF IMMATURE T CELL PROLIFERATION | 5 | 3.67e-01 | 7.68e-01 | 0.5940 | 4.10e-01 | 3.65e-01 | 5.93e-02 | 1.09e-01 | -1.91e-01 | 1.13e-01 | 1.57e-01 | 8.18e-01 | 6.74e-01 | 4.60e-01 |
| ATRIOVENTRICULAR NODE DEVELOPMENT | 9 | 4.82e-01 | 8.36e-01 | 0.5940 | 2.63e-01 | 3.60e-01 | 2.38e-01 | 2.49e-01 | 1.89e-01 | 1.71e-01 | 6.15e-02 | 2.17e-01 | 1.96e-01 | 3.27e-01 |
| TRACHEA MORPHOGENESIS | 11 | 5.68e-02 | 3.15e-01 | 0.5940 | 1.43e-01 | 1.74e-01 | 2.60e-01 | 4.24e-01 | 2.35e-01 | 4.13e-01 | 3.18e-01 | 1.36e-01 | 1.50e-02 | 1.77e-01 |
| REGULATION OF MESODERMAL CELL FATE SPECIFICATION | 5 | 5.91e-01 | 8.94e-01 | 0.5940 | 9.30e-02 | 1.14e-01 | 2.30e-01 | 2.56e-01 | 4.60e-01 | 7.19e-01 | 6.59e-01 | 3.73e-01 | 3.21e-01 | 7.46e-02 |
| NEGATIVE REGULATION OF TRIGLYCERIDE CATABOLIC PROCESS | 5 | 2.75e-01 | 6.83e-01 | 0.5930 | 3.13e-01 | 2.91e-01 | -6.96e-02 | 6.34e-02 | -4.00e-01 | 2.26e-01 | 2.59e-01 | 7.88e-01 | 8.06e-01 | 1.21e-01 |
| PRIMARY AMINO COMPOUND BIOSYNTHETIC PROCESS | 6 | 8.08e-01 | 9.67e-01 | 0.5930 | -2.85e-01 | -3.30e-01 | -2.65e-01 | -2.29e-01 | -1.96e-01 | 2.26e-01 | 1.62e-01 | 2.61e-01 | 3.30e-01 | 4.06e-01 |
| MRNA ALTERNATIVE POLYADENYLATION | 5 | 6.77e-01 | 9.28e-01 | 0.5930 | 3.28e-01 | 2.11e-01 | 1.96e-01 | 3.91e-01 | 9.15e-02 | 2.04e-01 | 4.14e-01 | 4.48e-01 | 1.30e-01 | 7.23e-01 |
| ANTRAL OVARIAN FOLLICLE GROWTH | 11 | 2.26e-01 | 6.27e-01 | 0.5930 | -1.68e-01 | -3.27e-01 | -3.80e-01 | -2.27e-01 | -1.41e-01 | 3.34e-01 | 6.01e-02 | 2.91e-02 | 1.93e-01 | 4.17e-01 |
| NEGATIVE REGULATION OF DNA REPAIR | 33 | 4.15e-02 | 2.64e-01 | 0.5930 | 3.07e-01 | 3.11e-01 | 2.41e-01 | 3.00e-01 | 1.13e-01 | 2.27e-03 | 2.01e-03 | 1.68e-02 | 2.90e-03 | 2.61e-01 |
| AMYLIN RECEPTOR SIGNALING PATHWAY | 6 | 3.50e-01 | 7.52e-01 | 0.5920 | -3.91e-01 | -3.29e-01 | -4.68e-02 | -2.17e-01 | 2.01e-01 | 9.68e-02 | 1.63e-01 | 8.43e-01 | 3.58e-01 | 3.95e-01 |
| COMPLEMENT ACTIVATION ALTERNATIVE PATHWAY | 16 | 2.01e-01 | 5.92e-01 | 0.5920 | -1.56e-01 | -2.13e-01 | -3.62e-01 | -2.83e-01 | -2.65e-01 | 2.81e-01 | 1.41e-01 | 1.21e-02 | 5.02e-02 | 6.70e-02 |
| ANTIMICROBIAL PEPTIDE PRODUCTION | 11 | 4.33e-02 | 2.70e-01 | 0.5920 | -7.09e-02 | 1.94e-02 | -3.14e-01 | -2.49e-01 | -4.30e-01 | 6.84e-01 | 9.11e-01 | 7.16e-02 | 1.53e-01 | 1.36e-02 |
| CD8 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 15 | 1.56e-01 | 5.28e-01 | 0.5920 | 1.67e-01 | 1.39e-01 | 3.12e-01 | 3.42e-01 | 2.98e-01 | 2.63e-01 | 3.50e-01 | 3.63e-02 | 2.20e-02 | 4.57e-02 |
| PROTEIN MATURATION BY PROTEIN FOLDING | 7 | 6.03e-01 | 9.00e-01 | 0.5910 | 2.32e-01 | 1.61e-01 | 2.49e-01 | 3.05e-01 | 3.39e-01 | 2.87e-01 | 4.60e-01 | 2.54e-01 | 1.63e-01 | 1.20e-01 |
| REGULATION OF AMINO ACID TRANSMEMBRANE TRANSPORT | 14 | 3.55e-01 | 7.55e-01 | 0.5910 | 2.73e-01 | 2.79e-01 | 2.87e-01 | 3.35e-01 | 5.35e-02 | 7.73e-02 | 7.04e-02 | 6.27e-02 | 3.02e-02 | 7.29e-01 |
| PURINE CONTAINING COMPOUND SALVAGE | 14 | 2.13e-01 | 6.08e-01 | 0.5900 | 3.82e-01 | 3.25e-01 | 2.17e-01 | 2.22e-01 | 1.32e-02 | 1.34e-02 | 3.51e-02 | 1.60e-01 | 1.50e-01 | 9.32e-01 |
| MESODERMAL CELL FATE COMMITMENT | 17 | 1.07e-01 | 4.47e-01 | 0.5900 | 1.81e-01 | 2.18e-01 | 2.88e-01 | 1.85e-01 | 3.88e-01 | 1.96e-01 | 1.20e-01 | 3.96e-02 | 1.86e-01 | 5.62e-03 |
| POSITIVE REGULATION OF DNA TEMPLATED DNA REPLICATION | 12 | 2.36e-01 | 6.40e-01 | 0.5900 | 1.53e-01 | 1.60e-01 | 3.44e-01 | 3.48e-01 | 2.44e-01 | 3.58e-01 | 3.37e-01 | 3.92e-02 | 3.67e-02 | 1.44e-01 |
| POSITIVE REGULATION OF NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING SIGNALING PATHWAY | 7 | 2.25e-01 | 6.25e-01 | 0.5900 | 2.91e-01 | 3.63e-01 | 1.69e-01 | 1.39e-01 | 2.88e-01 | 1.82e-01 | 9.64e-02 | 4.38e-01 | 5.23e-01 | 1.87e-01 |
| PRO B CELL DIFFERENTIATION | 12 | 2.54e-01 | 6.60e-01 | 0.5890 | 2.69e-01 | 2.25e-01 | 2.37e-01 | 3.90e-01 | 1.25e-01 | 1.06e-01 | 1.77e-01 | 1.55e-01 | 1.92e-02 | 4.53e-01 |
| REGULATION OF CELL FATE SPECIFICATION | 24 | 3.85e-02 | 2.54e-01 | 0.5890 | 1.46e-01 | 2.23e-01 | 2.76e-01 | 2.82e-01 | 3.47e-01 | 2.15e-01 | 5.83e-02 | 1.94e-02 | 1.67e-02 | 3.24e-03 |
| PLATELET ACTIVATING FACTOR METABOLIC PROCESS | 8 | 6.70e-01 | 9.25e-01 | 0.5890 | -2.21e-01 | -2.10e-01 | -2.69e-01 | -3.22e-01 | -2.80e-01 | 2.79e-01 | 3.03e-01 | 1.88e-01 | 1.15e-01 | 1.70e-01 |
| CELL DIFFERENTIATION IN SPINAL CORD | 49 | 1.07e-03 | 1.85e-02 | 0.5890 | 1.63e-01 | 2.12e-01 | 3.25e-01 | 2.37e-01 | 3.37e-01 | 4.82e-02 | 1.02e-02 | 8.43e-05 | 4.06e-03 | 4.37e-05 |
| REGULATION OF TRANSCRIPTION REGULATORY REGION DNA BINDING | 37 | 9.89e-03 | 1.01e-01 | 0.5890 | 1.84e-01 | 2.91e-01 | 3.43e-01 | 2.30e-01 | 2.40e-01 | 5.29e-02 | 2.21e-03 | 3.03e-04 | 1.53e-02 | 1.15e-02 |
| ATTACHMENT OF SPINDLE MICROTUBULES TO KINETOCHORE | 49 | 1.04e-02 | 1.04e-01 | 0.5890 | 2.60e-01 | 2.65e-01 | 3.03e-01 | 3.06e-01 | 1.51e-01 | 1.61e-03 | 1.34e-03 | 2.45e-04 | 2.06e-04 | 6.70e-02 |
| DNA PROTECTION | 6 | 4.92e-01 | 8.42e-01 | 0.5880 | 3.30e-01 | 2.53e-01 | 1.53e-01 | 3.70e-01 | 1.15e-01 | 1.62e-01 | 2.84e-01 | 5.16e-01 | 1.16e-01 | 6.27e-01 |
| 3 UTR MEDIATED MRNA DESTABILIZATION | 19 | 4.46e-02 | 2.74e-01 | 0.5880 | 2.07e-01 | 2.06e-01 | 2.29e-01 | 3.48e-01 | 2.95e-01 | 1.19e-01 | 1.20e-01 | 8.42e-02 | 8.60e-03 | 2.58e-02 |
| RESPONSE TO X RAY | 28 | 4.97e-02 | 2.91e-01 | 0.5880 | 2.90e-01 | 2.05e-01 | 2.90e-01 | 3.01e-01 | 2.13e-01 | 7.96e-03 | 6.10e-02 | 7.95e-03 | 5.84e-03 | 5.06e-02 |
| CEREBELLAR GRANULAR LAYER MORPHOGENESIS | 8 | 4.09e-01 | 7.94e-01 | 0.5870 | -2.54e-01 | -3.25e-01 | -2.60e-01 | -3.20e-01 | 6.85e-02 | 2.13e-01 | 1.12e-01 | 2.02e-01 | 1.17e-01 | 7.37e-01 |
| PROPIONATE METABOLIC PROCESS | 5 | 1.42e-02 | 1.31e-01 | 0.5870 | -8.42e-02 | -3.23e-04 | -2.03e-01 | -2.84e-01 | 4.65e-01 | 7.44e-01 | 9.99e-01 | 4.33e-01 | 2.72e-01 | 7.17e-02 |
| PROTEIN INSERTION INTO MITOCHONDRIAL INNER MEMBRANE | 12 | 2.39e-02 | 1.88e-01 | 0.5870 | 1.90e-01 | 1.23e-01 | 3.13e-01 | 1.27e-01 | 4.23e-01 | 2.54e-01 | 4.59e-01 | 6.01e-02 | 4.46e-01 | 1.11e-02 |
| POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 21 | 2.32e-01 | 6.34e-01 | 0.5870 | 2.53e-01 | 2.42e-01 | 2.92e-01 | 2.67e-01 | 2.55e-01 | 4.46e-02 | 5.50e-02 | 2.06e-02 | 3.42e-02 | 4.28e-02 |
| CELLULAR RESPONSE TO DSRNA | 22 | 1.17e-01 | 4.65e-01 | 0.5870 | 3.08e-01 | 2.60e-01 | 2.24e-01 | 2.95e-01 | 2.12e-01 | 1.25e-02 | 3.49e-02 | 6.90e-02 | 1.67e-02 | 8.52e-02 |
| POSITIVE REGULATION OF INTERLEUKIN 18 PRODUCTION | 8 | 7.63e-01 | 9.54e-01 | 0.5860 | -2.25e-01 | -2.59e-01 | -2.96e-01 | -3.11e-01 | -2.03e-01 | 2.70e-01 | 2.05e-01 | 1.47e-01 | 1.28e-01 | 3.20e-01 |
| RIBOSOMAL LARGE SUBUNIT EXPORT FROM NUCLEUS | 7 | 5.88e-01 | 8.92e-01 | 0.5860 | 3.51e-01 | 3.56e-01 | 2.37e-01 | 1.84e-01 | 5.89e-02 | 1.08e-01 | 1.03e-01 | 2.78e-01 | 3.99e-01 | 7.87e-01 |
| LUNG VASCULATURE DEVELOPMENT | 8 | 2.27e-02 | 1.81e-01 | 0.5860 | -3.27e-01 | -9.86e-02 | 2.50e-01 | 2.80e-02 | 4.04e-01 | 1.09e-01 | 6.29e-01 | 2.21e-01 | 8.91e-01 | 4.78e-02 |
| MEIOTIC CHROMOSOME SEPARATION | 8 | 6.67e-01 | 9.24e-01 | 0.5860 | 1.54e-01 | 2.20e-01 | 3.13e-01 | 2.88e-01 | 3.00e-01 | 4.52e-01 | 2.80e-01 | 1.25e-01 | 1.58e-01 | 1.42e-01 |
| CELLULAR RESPONSE TO LAMINAR FLUID SHEAR STRESS | 8 | 6.48e-01 | 9.17e-01 | 0.5850 | 2.95e-01 | 3.43e-01 | 2.27e-01 | 2.54e-01 | 1.49e-01 | 1.49e-01 | 9.26e-02 | 2.66e-01 | 2.13e-01 | 4.67e-01 |
| METANEPHRIC NEPHRON DEVELOPMENT | 40 | 2.07e-02 | 1.70e-01 | 0.5850 | 2.61e-01 | 2.93e-01 | 2.77e-01 | 2.40e-01 | 2.31e-01 | 4.22e-03 | 1.36e-03 | 2.40e-03 | 8.50e-03 | 1.13e-02 |
| C TERMINAL PROTEIN LIPIDATION | 5 | 4.94e-01 | 8.44e-01 | 0.5850 | -9.68e-02 | -3.59e-01 | -3.64e-01 | -1.99e-01 | -1.78e-01 | 7.08e-01 | 1.64e-01 | 1.58e-01 | 4.42e-01 | 4.91e-01 |
| ENDOCARDIUM MORPHOGENESIS | 6 | 8.74e-01 | 9.78e-01 | 0.5850 | 3.00e-01 | 2.82e-01 | 2.59e-01 | 2.85e-01 | 1.56e-01 | 2.04e-01 | 2.32e-01 | 2.72e-01 | 2.27e-01 | 5.09e-01 |
| NEGATIVE REGULATION OF ENDOPLASMIC RETICULUM STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 19 | 1.79e-01 | 5.63e-01 | 0.5840 | 1.80e-01 | 1.89e-01 | 3.28e-01 | 2.69e-01 | 3.06e-01 | 1.73e-01 | 1.53e-01 | 1.34e-02 | 4.24e-02 | 2.10e-02 |
| CELLULAR RESPIRATION | 216 | 4.19e-12 | 4.15e-10 | 0.5840 | 2.55e-01 | 2.57e-01 | 2.92e-01 | 2.89e-01 | 2.04e-01 | 1.09e-10 | 7.36e-11 | 1.41e-13 | 2.48e-13 | 2.47e-07 |
| REGULATION OF NEUTROPHIL DEGRANULATION | 8 | 7.98e-02 | 3.82e-01 | 0.5840 | 3.09e-01 | 3.91e-01 | 5.62e-02 | 2.33e-01 | -1.88e-01 | 1.31e-01 | 5.57e-02 | 7.83e-01 | 2.53e-01 | 3.56e-01 |
| ATRIOVENTRICULAR CANAL DEVELOPMENT | 13 | 4.54e-01 | 8.22e-01 | 0.5840 | 2.35e-01 | 3.27e-01 | 2.83e-01 | 2.69e-01 | 1.63e-01 | 1.43e-01 | 4.11e-02 | 7.77e-02 | 9.34e-02 | 3.08e-01 |
| REGULATION OF PENTOSE PHOSPHATE SHUNT | 7 | 7.24e-01 | 9.41e-01 | 0.5840 | 2.74e-01 | 2.40e-01 | 2.31e-01 | 3.03e-01 | 2.51e-01 | 2.09e-01 | 2.71e-01 | 2.90e-01 | 1.66e-01 | 2.50e-01 |
| HISTONE UBIQUITINATION | 8 | 6.17e-01 | 9.06e-01 | 0.5830 | 2.85e-01 | 2.70e-01 | 2.29e-01 | 3.53e-01 | 9.46e-02 | 1.63e-01 | 1.85e-01 | 2.61e-01 | 8.42e-02 | 6.43e-01 |
| RESPONSE TO CELL CYCLE CHECKPOINT SIGNALING | 7 | 1.67e-01 | 5.48e-01 | 0.5830 | 1.39e-01 | 7.30e-02 | 4.07e-01 | 2.53e-01 | 2.93e-01 | 5.24e-01 | 7.38e-01 | 6.22e-02 | 2.46e-01 | 1.80e-01 |
| CENTRIOLE ELONGATION | 8 | 7.80e-01 | 9.59e-01 | 0.5830 | 3.03e-01 | 2.76e-01 | 2.58e-01 | 3.06e-01 | 1.07e-01 | 1.38e-01 | 1.77e-01 | 2.06e-01 | 1.34e-01 | 5.99e-01 |
| POSITIVE REGULATION OF FC RECEPTOR MEDIATED STIMULATORY SIGNALING PATHWAY | 5 | 7.52e-01 | 9.51e-01 | 0.5830 | -1.59e-01 | -2.92e-01 | -3.69e-01 | -2.04e-01 | -2.27e-01 | 5.38e-01 | 2.58e-01 | 1.53e-01 | 4.30e-01 | 3.80e-01 |
| ATP BIOSYNTHETIC PROCESS | 89 | 5.27e-05 | 1.61e-03 | 0.5830 | 2.70e-01 | 2.68e-01 | 2.99e-01 | 2.61e-01 | 1.93e-01 | 1.03e-05 | 1.26e-05 | 1.08e-06 | 2.14e-05 | 1.64e-03 |
| PURINE NUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 20 | 9.80e-02 | 4.26e-01 | 0.5820 | 3.47e-01 | 2.79e-01 | 2.79e-01 | 2.36e-01 | 8.31e-02 | 7.26e-03 | 3.06e-02 | 3.08e-02 | 6.81e-02 | 5.20e-01 |
| FUNGIFORM PAPILLA DEVELOPMENT | 6 | 1.85e-01 | 5.72e-01 | 0.5820 | -1.62e-02 | 6.74e-03 | 2.75e-01 | 3.60e-01 | 3.65e-01 | 9.45e-01 | 9.77e-01 | 2.44e-01 | 1.27e-01 | 1.22e-01 |
| ACTIVATION INDUCED CELL DEATH OF T CELLS | 8 | 7.80e-01 | 9.60e-01 | 0.5820 | 2.83e-01 | 2.62e-01 | 2.88e-01 | 3.06e-01 | 1.13e-01 | 1.66e-01 | 2.00e-01 | 1.58e-01 | 1.34e-01 | 5.79e-01 |
| REGULATION OF LYSOSOMAL LUMEN PH | 27 | 2.75e-02 | 2.05e-01 | 0.5810 | 1.34e-01 | 2.22e-01 | 3.29e-01 | 3.07e-01 | 2.60e-01 | 2.29e-01 | 4.62e-02 | 3.07e-03 | 5.69e-03 | 1.92e-02 |
| REGULATION OF MIDBRAIN DOPAMINERGIC NEURON DIFFERENTIATION | 5 | 6.78e-01 | 9.28e-01 | 0.5810 | 1.68e-01 | 2.81e-01 | 2.33e-01 | 2.03e-01 | 3.68e-01 | 5.15e-01 | 2.77e-01 | 3.68e-01 | 4.33e-01 | 1.55e-01 |
| SEMICIRCULAR CANAL DEVELOPMENT | 9 | 2.49e-01 | 6.55e-01 | 0.5810 | 2.38e-01 | 3.03e-01 | 1.81e-01 | 2.45e-01 | 3.10e-01 | 2.16e-01 | 1.16e-01 | 3.47e-01 | 2.02e-01 | 1.08e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL CHEMOTAXIS | 5 | 8.65e-01 | 9.78e-01 | 0.5810 | -2.63e-01 | -2.15e-01 | -3.17e-01 | -3.12e-01 | -1.53e-01 | 3.08e-01 | 4.04e-01 | 2.20e-01 | 2.27e-01 | 5.53e-01 |
| NEGATIVE REGULATION OF PINOCYTOSIS | 5 | 2.12e-01 | 6.07e-01 | 0.5800 | -3.53e-01 | -1.28e-01 | 9.64e-02 | -2.36e-01 | 3.62e-01 | 1.72e-01 | 6.20e-01 | 7.09e-01 | 3.61e-01 | 1.61e-01 |
| DOUBLE STRAND BREAK REPAIR VIA BREAK INDUCED REPLICATION | 12 | 4.86e-01 | 8.38e-01 | 0.5800 | 1.85e-01 | 2.29e-01 | 2.85e-01 | 2.53e-01 | 3.23e-01 | 2.67e-01 | 1.70e-01 | 8.69e-02 | 1.28e-01 | 5.24e-02 |
| PROTEIN INSERTION INTO ER MEMBRANE | 28 | 1.20e-01 | 4.73e-01 | 0.5800 | 2.89e-01 | 2.66e-01 | 2.69e-01 | 3.15e-01 | 1.05e-01 | 8.23e-03 | 1.49e-02 | 1.36e-02 | 3.91e-03 | 3.37e-01 |
| GOLGI VESICLE FUSION TO TARGET MEMBRANE | 5 | 5.48e-01 | 8.73e-01 | 0.5800 | 6.98e-02 | 3.24e-01 | 3.16e-01 | 1.82e-01 | 3.06e-01 | 7.87e-01 | 2.10e-01 | 2.21e-01 | 4.82e-01 | 2.36e-01 |
| CELLULAR RESPONSE TO GLUCOSE STARVATION | 49 | 6.26e-03 | 7.26e-02 | 0.5800 | 2.21e-01 | 2.26e-01 | 3.22e-01 | 2.77e-01 | 2.37e-01 | 7.33e-03 | 6.29e-03 | 9.76e-05 | 8.05e-04 | 4.03e-03 |
| OLIGODENDROCYTE PROGENITOR PROLIFERATION | 8 | 5.85e-01 | 8.90e-01 | 0.5800 | -3.65e-01 | -2.89e-01 | -2.27e-01 | -2.57e-01 | 4.45e-02 | 7.37e-02 | 1.57e-01 | 2.66e-01 | 2.08e-01 | 8.28e-01 |
| NUCLEAR MEMBRANE REASSEMBLY | 25 | 2.13e-02 | 1.74e-01 | 0.5800 | 1.96e-01 | 1.87e-01 | 3.45e-01 | 3.47e-01 | 1.54e-01 | 8.91e-02 | 1.06e-01 | 2.85e-03 | 2.69e-03 | 1.83e-01 |
| CARDIAC CONDUCTION SYSTEM DEVELOPMENT | 37 | 2.92e-02 | 2.13e-01 | 0.5800 | 1.97e-01 | 2.71e-01 | 3.01e-01 | 2.50e-01 | 2.66e-01 | 3.80e-02 | 4.26e-03 | 1.55e-03 | 8.59e-03 | 5.08e-03 |
| PROTEIN LOCALIZATION TO NUCLEOLUS | 18 | 2.76e-01 | 6.85e-01 | 0.5800 | 2.61e-01 | 2.93e-01 | 3.10e-01 | 2.24e-01 | 1.89e-01 | 5.56e-02 | 3.12e-02 | 2.29e-02 | 9.95e-02 | 1.66e-01 |
| POSITIVE REGULATION BY HOST OF VIRAL TRANSCRIPTION | 17 | 1.40e-01 | 5.04e-01 | 0.5790 | 2.64e-01 | 2.38e-01 | 3.20e-01 | 3.26e-01 | 3.05e-02 | 5.92e-02 | 8.89e-02 | 2.25e-02 | 2.01e-02 | 8.28e-01 |
| REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR RESULTING IN TRANSCRIPTION OF P21 CLASS MEDIATOR | 6 | 6.33e-01 | 9.12e-01 | 0.5790 | 3.67e-01 | 3.42e-01 | 1.60e-01 | 2.18e-01 | -1.02e-01 | 1.19e-01 | 1.47e-01 | 4.98e-01 | 3.55e-01 | 6.64e-01 |
| EXTRACELLULAR EXOSOME ASSEMBLY | 7 | 3.93e-01 | 7.84e-01 | 0.5790 | 4.12e-01 | 3.15e-01 | 1.48e-01 | 1.77e-01 | -1.12e-01 | 5.89e-02 | 1.48e-01 | 4.96e-01 | 4.17e-01 | 6.08e-01 |
| CELLULAR RESPONSE TO ATP | 16 | 1.16e-01 | 4.64e-01 | 0.5790 | 2.75e-01 | 3.37e-01 | 2.55e-01 | 2.70e-01 | -8.80e-02 | 5.70e-02 | 1.96e-02 | 7.76e-02 | 6.15e-02 | 5.42e-01 |
| MITOTIC SISTER CHROMATID SEGREGATION | 180 | 1.67e-12 | 1.69e-10 | 0.5780 | 2.65e-01 | 2.06e-01 | 2.72e-01 | 3.32e-01 | 1.94e-01 | 8.02e-10 | 1.82e-06 | 3.19e-10 | 1.61e-14 | 6.82e-06 |
| NEGATIVE REGULATION OF TELOMERE MAINTENANCE VIA TELOMERASE | 19 | 1.35e-01 | 4.97e-01 | 0.5780 | 2.68e-01 | 2.06e-01 | 2.34e-01 | 3.49e-01 | 2.08e-01 | 4.31e-02 | 1.20e-01 | 7.75e-02 | 8.42e-03 | 1.16e-01 |
| POSITIVE REGULATION OF PROTEIN K63 LINKED UBIQUITINATION | 7 | 2.98e-01 | 7.10e-01 | 0.5780 | 4.02e-01 | 3.22e-01 | 6.16e-02 | 2.40e-01 | -8.41e-02 | 6.52e-02 | 1.40e-01 | 7.78e-01 | 2.72e-01 | 7.00e-01 |
| REGULATION OF WOUND HEALING SPREADING OF EPIDERMAL CELLS | 8 | 2.53e-01 | 6.59e-01 | 0.5780 | -6.57e-02 | -2.14e-01 | -3.94e-01 | -1.48e-01 | -3.28e-01 | 7.48e-01 | 2.95e-01 | 5.39e-02 | 4.69e-01 | 1.09e-01 |
| CHONDROBLAST DIFFERENTIATION | 5 | 5.17e-01 | 8.56e-01 | 0.5780 | 2.18e-02 | 4.31e-04 | 2.63e-01 | 2.05e-01 | 4.71e-01 | 9.33e-01 | 9.99e-01 | 3.08e-01 | 4.27e-01 | 6.79e-02 |
| AV NODE CELL TO BUNDLE OF HIS CELL COMMUNICATION | 14 | 1.89e-01 | 5.74e-01 | 0.5780 | -3.49e-01 | -2.50e-01 | -1.85e-01 | -2.78e-01 | -1.95e-01 | 2.37e-02 | 1.06e-01 | 2.31e-01 | 7.12e-02 | 2.06e-01 |
| PYRIMIDINE DEOXYRIBONUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 6 | 3.82e-01 | 7.78e-01 | 0.5780 | 2.71e-01 | 7.48e-02 | 2.01e-01 | 3.51e-01 | 3.03e-01 | 2.51e-01 | 7.51e-01 | 3.95e-01 | 1.37e-01 | 1.98e-01 |
| LEUKOCYTE ADHESION TO ARTERIAL ENDOTHELIAL CELL | 6 | 1.63e-01 | 5.40e-01 | 0.5770 | 4.67e-01 | 2.61e-01 | 1.01e-01 | 1.17e-01 | -1.53e-01 | 4.77e-02 | 2.68e-01 | 6.68e-01 | 6.18e-01 | 5.17e-01 |
| RENAL RESPONSE TO BLOOD FLOW INVOLVED IN CIRCULATORY RENIN ANGIOTENSIN REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 6 | 6.93e-01 | 9.31e-01 | 0.5770 | -2.16e-01 | -2.43e-01 | -3.70e-01 | -2.70e-01 | -1.34e-01 | 3.60e-01 | 3.03e-01 | 1.16e-01 | 2.52e-01 | 5.70e-01 |
| KETONE BODY METABOLIC PROCESS | 10 | 4.60e-01 | 8.23e-01 | 0.5770 | -1.77e-01 | -2.70e-01 | -3.62e-01 | -2.17e-01 | -2.26e-01 | 3.34e-01 | 1.40e-01 | 4.72e-02 | 2.35e-01 | 2.16e-01 |
| POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA1 PRODUCTION | 6 | 4.05e-01 | 7.92e-01 | 0.5770 | -2.06e-01 | -8.13e-02 | -3.34e-01 | -2.52e-01 | -3.30e-01 | 3.82e-01 | 7.30e-01 | 1.57e-01 | 2.85e-01 | 1.61e-01 |
| POSITIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 122 | 1.82e-08 | 1.12e-06 | 0.5770 | 3.07e-01 | 2.23e-01 | 2.44e-01 | 3.17e-01 | 1.69e-01 | 4.49e-09 | 2.12e-05 | 3.11e-06 | 1.38e-09 | 1.29e-03 |
| TRANSCRIPTION BY RNA POLYMERASE III | 59 | 1.03e-03 | 1.80e-02 | 0.5770 | 3.25e-01 | 2.76e-01 | 2.39e-01 | 2.64e-01 | 1.56e-01 | 1.57e-05 | 2.42e-04 | 1.49e-03 | 4.53e-04 | 3.85e-02 |
| ESCRT COMPLEX DISASSEMBLY | 10 | 1.44e-01 | 5.10e-01 | 0.5770 | 1.32e-01 | 8.49e-02 | 3.73e-01 | 3.19e-01 | 2.60e-01 | 4.70e-01 | 6.42e-01 | 4.13e-02 | 8.06e-02 | 1.54e-01 |
| CILIARY BODY MORPHOGENESIS | 5 | 1.51e-01 | 5.20e-01 | 0.5770 | -8.27e-02 | -2.42e-01 | 2.25e-02 | 9.22e-02 | 5.08e-01 | 7.49e-01 | 3.49e-01 | 9.30e-01 | 7.21e-01 | 4.89e-02 |
| NEGATIVE REGULATION OF THYMOCYTE APOPTOTIC PROCESS | 10 | 4.89e-02 | 2.89e-01 | 0.5770 | -6.84e-02 | -4.00e-02 | 2.27e-01 | 2.56e-01 | 4.57e-01 | 7.08e-01 | 8.26e-01 | 2.13e-01 | 1.61e-01 | 1.23e-02 |
| BILE ACID SIGNALING PATHWAY | 11 | 2.66e-01 | 6.74e-01 | 0.5760 | -6.37e-02 | -1.43e-01 | -2.92e-01 | -1.91e-01 | -4.32e-01 | 7.15e-01 | 4.13e-01 | 9.36e-02 | 2.73e-01 | 1.32e-02 |
| AUTOPHAGOSOME MATURATION | 60 | 1.63e-03 | 2.59e-02 | 0.5760 | 2.84e-01 | 2.35e-01 | 2.93e-01 | 2.91e-01 | 1.58e-01 | 1.38e-04 | 1.61e-03 | 8.59e-05 | 9.54e-05 | 3.43e-02 |
| NEGATIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION ELONGATION | 22 | 4.82e-02 | 2.88e-01 | 0.5760 | 1.67e-01 | 1.25e-01 | 3.04e-01 | 3.17e-01 | 3.10e-01 | 1.76e-01 | 3.12e-01 | 1.35e-02 | 1.01e-02 | 1.20e-02 |
| PRIMITIVE HEMOPOIESIS | 8 | 6.82e-01 | 9.29e-01 | 0.5750 | 1.94e-01 | 3.05e-01 | 2.93e-01 | 2.19e-01 | 2.58e-01 | 3.42e-01 | 1.35e-01 | 1.52e-01 | 2.82e-01 | 2.07e-01 |
| TRANSCRIPTION INITIATION AT RNA POLYMERASE III PROMOTER | 8 | 5.27e-01 | 8.60e-01 | 0.5750 | 2.93e-01 | 2.87e-01 | 1.89e-01 | 2.72e-01 | 2.31e-01 | 1.52e-01 | 1.60e-01 | 3.56e-01 | 1.82e-01 | 2.59e-01 |
| REGULATION OF ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 29 | 3.16e-02 | 2.25e-01 | 0.5750 | 2.97e-01 | 3.14e-01 | 2.52e-01 | 2.80e-01 | -4.09e-02 | 5.65e-03 | 3.45e-03 | 1.87e-02 | 8.98e-03 | 7.03e-01 |
| MRNA 5 SPLICE SITE RECOGNITION | 10 | 5.53e-01 | 8.76e-01 | 0.5750 | 3.47e-01 | 2.88e-01 | 2.09e-01 | 2.62e-01 | 1.23e-01 | 5.77e-02 | 1.14e-01 | 2.53e-01 | 1.52e-01 | 5.01e-01 |
| CHEMOKINE C C MOTIF LIGAND 5 PRODUCTION | 10 | 2.41e-01 | 6.44e-01 | 0.5740 | 2.86e-01 | 3.91e-01 | 2.25e-01 | 1.41e-01 | 1.55e-01 | 1.17e-01 | 3.23e-02 | 2.17e-01 | 4.41e-01 | 3.95e-01 |
| DAMP METABOLIC PROCESS | 7 | 4.07e-01 | 7.93e-01 | 0.5740 | 2.53e-01 | 1.87e-01 | 3.74e-01 | 2.76e-01 | 1.21e-01 | 2.47e-01 | 3.92e-01 | 8.68e-02 | 2.06e-01 | 5.80e-01 |
| NEGATIVE REGULATION OF MACROPHAGE APOPTOTIC PROCESS | 7 | 2.69e-01 | 6.78e-01 | 0.5740 | 2.25e-01 | 2.28e-01 | 1.60e-01 | 3.52e-01 | 2.78e-01 | 3.02e-01 | 2.97e-01 | 4.65e-01 | 1.07e-01 | 2.02e-01 |
| NOSE DEVELOPMENT | 16 | 3.47e-01 | 7.50e-01 | 0.5740 | 1.95e-01 | 2.06e-01 | 3.05e-01 | 2.57e-01 | 2.99e-01 | 1.76e-01 | 1.53e-01 | 3.45e-02 | 7.56e-02 | 3.87e-02 |
| MUSCLE CELL FATE COMMITMENT | 20 | 2.07e-01 | 6.02e-01 | 0.5740 | 2.41e-01 | 2.86e-01 | 2.63e-01 | 2.27e-01 | 2.61e-01 | 6.18e-02 | 2.66e-02 | 4.20e-02 | 7.93e-02 | 4.30e-02 |
| POSITIVE REGULATION OF CHEMOKINE C C MOTIF LIGAND 5 PRODUCTION | 5 | 2.14e-01 | 6.09e-01 | 0.5730 | 1.19e-01 | 4.34e-01 | 3.07e-01 | 2.69e-02 | 1.76e-01 | 6.45e-01 | 9.26e-02 | 2.35e-01 | 9.17e-01 | 4.96e-01 |
| NEGATIVE REGULATION BY HOST OF VIRAL GENOME REPLICATION | 9 | 2.83e-01 | 6.93e-01 | 0.5730 | -3.17e-01 | -3.63e-01 | -1.48e-01 | -2.15e-01 | 1.67e-01 | 9.99e-02 | 5.93e-02 | 4.41e-01 | 2.65e-01 | 3.84e-01 |
| REGULATION OF RESPIRATORY BURST INVOLVED IN INFLAMMATORY RESPONSE | 7 | 3.16e-01 | 7.27e-01 | 0.5730 | 2.43e-01 | 8.07e-02 | 3.23e-01 | 2.91e-01 | 2.71e-01 | 2.65e-01 | 7.12e-01 | 1.39e-01 | 1.82e-01 | 2.14e-01 |
| RESPONSE TO INSECTICIDE | 6 | 6.24e-01 | 9.09e-01 | 0.5730 | 7.59e-02 | 2.37e-01 | 2.96e-01 | 1.86e-01 | 3.80e-01 | 7.48e-01 | 3.15e-01 | 2.09e-01 | 4.30e-01 | 1.07e-01 |
| DETOXIFICATION OF NITROGEN COMPOUND | 5 | 5.51e-01 | 8.75e-01 | 0.5730 | 1.74e-01 | 3.79e-01 | 2.77e-01 | 2.74e-01 | 5.10e-02 | 5.01e-01 | 1.42e-01 | 2.84e-01 | 2.89e-01 | 8.43e-01 |
| RESPONSE TO GRAVITY | 9 | 2.02e-01 | 5.96e-01 | 0.5730 | -3.64e-01 | -1.99e-01 | -2.82e-01 | -2.74e-01 | 3.55e-02 | 5.87e-02 | 3.02e-01 | 1.43e-01 | 1.54e-01 | 8.54e-01 |
| MITOCHONDRIAL DNA REPAIR | 5 | 5.71e-01 | 8.83e-01 | 0.5720 | -1.98e-04 | 4.58e-02 | 2.65e-01 | 1.54e-01 | 4.81e-01 | 9.99e-01 | 8.59e-01 | 3.04e-01 | 5.50e-01 | 6.25e-02 |
| DERMATAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS | 8 | 3.87e-01 | 7.80e-01 | 0.5720 | 2.03e-01 | 3.20e-01 | 2.11e-01 | 2.27e-01 | 2.97e-01 | 3.21e-01 | 1.17e-01 | 3.02e-01 | 2.67e-01 | 1.46e-01 |
| NEGATIVE REGULATION OF SYNAPTIC TRANSMISSION GABAERGIC | 6 | 8.15e-02 | 3.86e-01 | 0.5720 | 3.14e-01 | 4.17e-01 | 1.88e-01 | -2.84e-02 | 1.38e-01 | 1.83e-01 | 7.72e-02 | 4.25e-01 | 9.04e-01 | 5.59e-01 |
| ESTABLISHMENT OF BLOOD BRAIN BARRIER | 14 | 1.35e-01 | 4.97e-01 | 0.5720 | 6.05e-02 | 1.81e-01 | 2.97e-01 | 1.60e-01 | 4.20e-01 | 6.95e-01 | 2.41e-01 | 5.46e-02 | 3.00e-01 | 6.45e-03 |
| PURINE DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS | 5 | 7.95e-01 | 9.65e-01 | 0.5720 | 2.66e-01 | 2.31e-01 | 3.16e-01 | 3.19e-01 | 3.50e-02 | 3.03e-01 | 3.72e-01 | 2.21e-01 | 2.17e-01 | 8.92e-01 |
| REGULATION OF PROSTATIC BUD FORMATION | 5 | 2.44e-01 | 6.48e-01 | 0.5710 | -1.69e-01 | 1.34e-01 | 3.16e-01 | 1.25e-01 | 4.05e-01 | 5.14e-01 | 6.04e-01 | 2.21e-01 | 6.28e-01 | 1.17e-01 |
| INTESTINAL LIPID ABSORPTION | 22 | 7.08e-02 | 3.60e-01 | 0.5700 | -1.97e-01 | -1.41e-01 | -2.91e-01 | -3.29e-01 | -2.71e-01 | 1.09e-01 | 2.53e-01 | 1.80e-02 | 7.54e-03 | 2.79e-02 |
| POSITIVE REGULATION OF PROSTAGLANDIN BIOSYNTHETIC PROCESS | 7 | 1.25e-01 | 4.80e-01 | 0.5700 | 3.92e-01 | 3.62e-01 | 1.63e-01 | 4.53e-02 | -1.04e-01 | 7.23e-02 | 9.68e-02 | 4.54e-01 | 8.36e-01 | 6.32e-01 |
| NEGATIVE REGULATION OF CHROMOSOME SEGREGATION | 50 | 2.65e-04 | 5.86e-03 | 0.5700 | 1.89e-01 | 1.64e-01 | 2.79e-01 | 3.51e-01 | 2.48e-01 | 2.11e-02 | 4.48e-02 | 6.35e-04 | 1.78e-05 | 2.42e-03 |
| NEURAL PLATE MORPHOGENESIS | 5 | 2.93e-01 | 7.04e-01 | 0.5700 | -1.80e-01 | -1.84e-01 | 1.49e-01 | 1.10e-01 | 4.74e-01 | 4.87e-01 | 4.76e-01 | 5.65e-01 | 6.69e-01 | 6.67e-02 |
| REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 13 | 4.21e-01 | 8.00e-01 | 0.5700 | 1.88e-01 | 2.81e-01 | 3.09e-01 | 2.04e-01 | 2.71e-01 | 2.40e-01 | 7.97e-02 | 5.40e-02 | 2.03e-01 | 9.05e-02 |
| POSITIVE REGULATION OF INTEGRIN ACTIVATION | 11 | 2.84e-01 | 6.93e-01 | 0.5690 | -5.38e-02 | -1.53e-01 | -2.88e-01 | -2.24e-01 | -4.06e-01 | 7.57e-01 | 3.79e-01 | 9.81e-02 | 1.99e-01 | 1.98e-02 |
| POSITIVE REGULATION OF COMPLEMENT ACTIVATION | 7 | 8.43e-04 | 1.52e-02 | 0.5690 | 1.40e-01 | 3.15e-01 | -2.87e-01 | -2.63e-01 | -2.31e-01 | 5.22e-01 | 1.49e-01 | 1.89e-01 | 2.28e-01 | 2.89e-01 |
| REGULATION OF BRANCHING MORPHOGENESIS OF A NERVE | 5 | 2.71e-01 | 6.79e-01 | 0.5680 | 3.58e-01 | 2.03e-01 | 2.20e-02 | 3.66e-01 | -1.38e-01 | 1.65e-01 | 4.31e-01 | 9.32e-01 | 1.57e-01 | 5.92e-01 |
| POSITIVE REGULATION OF PROTEIN NEDDYLATION | 5 | 4.15e-01 | 7.98e-01 | 0.5680 | 3.26e-01 | 1.54e-01 | 1.21e-01 | 3.98e-01 | 1.42e-01 | 2.06e-01 | 5.52e-01 | 6.39e-01 | 1.24e-01 | 5.82e-01 |
| MITOTIC G2 M TRANSITION CHECKPOINT | 50 | 2.02e-04 | 4.77e-03 | 0.5680 | 2.53e-01 | 2.06e-01 | 2.39e-01 | 3.73e-01 | 1.43e-01 | 1.94e-03 | 1.17e-02 | 3.52e-03 | 5.06e-06 | 8.04e-02 |
| RESOLUTION OF MEIOTIC RECOMBINATION INTERMEDIATES | 15 | 3.50e-01 | 7.52e-01 | 0.5680 | 2.85e-01 | 2.25e-01 | 2.86e-01 | 3.21e-01 | 7.93e-02 | 5.62e-02 | 1.32e-01 | 5.55e-02 | 3.16e-02 | 5.95e-01 |
| REGULATION OF GLUTAMATE SECRETION NEUROTRANSMISSION | 5 | 6.08e-01 | 9.03e-01 | 0.5670 | 3.08e-01 | 3.17e-01 | 1.50e-01 | 2.15e-01 | -2.40e-01 | 2.33e-01 | 2.20e-01 | 5.61e-01 | 4.04e-01 | 3.53e-01 |
| REGULATION OF INTERLEUKIN 6 MEDIATED SIGNALING PATHWAY | 11 | 4.57e-01 | 8.22e-01 | 0.5670 | -1.55e-01 | -1.58e-01 | -2.81e-01 | -2.84e-01 | -3.36e-01 | 3.72e-01 | 3.64e-01 | 1.07e-01 | 1.02e-01 | 5.39e-02 |
| NEGATIVE REGULATION OF MICROGLIAL CELL ACTIVATION | 8 | 7.66e-01 | 9.54e-01 | 0.5670 | 2.20e-01 | 2.64e-01 | 3.14e-01 | 2.90e-01 | 1.44e-01 | 2.82e-01 | 1.96e-01 | 1.24e-01 | 1.55e-01 | 4.81e-01 |
| REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 37 | 3.47e-02 | 2.37e-01 | 0.5670 | 2.71e-01 | 2.12e-01 | 2.68e-01 | 2.95e-01 | 2.10e-01 | 4.28e-03 | 2.56e-02 | 4.83e-03 | 1.91e-03 | 2.70e-02 |
| RESPONSE TO STILBENOID | 8 | 2.44e-01 | 6.48e-01 | 0.5670 | -3.77e-01 | -1.45e-01 | -1.71e-01 | -3.54e-01 | 5.81e-02 | 6.50e-02 | 4.77e-01 | 4.01e-01 | 8.31e-02 | 7.76e-01 |
| REGULATION OF ARTERY MORPHOGENESIS | 11 | 3.09e-01 | 7.20e-01 | 0.5660 | -3.25e-01 | -2.68e-01 | -2.43e-01 | -2.67e-01 | 1.13e-01 | 6.21e-02 | 1.23e-01 | 1.63e-01 | 1.25e-01 | 5.15e-01 |
| PROTEIN SIALYLATION | 5 | 8.01e-01 | 9.67e-01 | 0.5660 | 2.51e-01 | 3.61e-01 | 2.50e-01 | 2.52e-01 | 3.19e-02 | 3.31e-01 | 1.62e-01 | 3.32e-01 | 3.29e-01 | 9.02e-01 |
| GOLGI LUMEN ACIDIFICATION | 10 | 3.39e-01 | 7.45e-01 | 0.5660 | 1.10e-01 | 2.07e-01 | 3.46e-01 | 3.14e-01 | 2.17e-01 | 5.48e-01 | 2.56e-01 | 5.80e-02 | 8.58e-02 | 2.35e-01 |
| PROTEIN RETENTION IN ER LUMEN | 8 | 2.30e-01 | 6.32e-01 | 0.5660 | 2.16e-01 | 2.96e-01 | 3.88e-01 | 1.73e-01 | 7.07e-02 | 2.89e-01 | 1.47e-01 | 5.72e-02 | 3.96e-01 | 7.29e-01 |
| NATURAL KILLER CELL CHEMOTAXIS | 10 | 5.70e-01 | 8.82e-01 | 0.5660 | -2.85e-01 | -2.25e-01 | -2.73e-01 | -2.42e-01 | -2.35e-01 | 1.19e-01 | 2.19e-01 | 1.35e-01 | 1.85e-01 | 1.98e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO SYNAPSE | 6 | 1.18e-01 | 4.67e-01 | 0.5660 | -3.84e-01 | -7.50e-02 | 8.74e-03 | -3.24e-01 | 2.49e-01 | 1.03e-01 | 7.51e-01 | 9.70e-01 | 1.69e-01 | 2.92e-01 |
| INTERNEURON MIGRATION | 14 | 4.53e-01 | 8.21e-01 | 0.5660 | 2.42e-01 | 2.30e-01 | 3.01e-01 | 2.41e-01 | 2.44e-01 | 1.17e-01 | 1.36e-01 | 5.09e-02 | 1.18e-01 | 1.14e-01 |
| PROTEIN SIDE CHAIN DEGLUTAMYLATION | 5 | 8.80e-01 | 9.79e-01 | 0.5660 | -1.81e-01 | -2.83e-01 | -3.00e-01 | -2.28e-01 | -2.55e-01 | 4.83e-01 | 2.73e-01 | 2.45e-01 | 3.76e-01 | 3.24e-01 |
| DERMATAN SULFATE METABOLIC PROCESS | 8 | 7.34e-01 | 9.46e-01 | 0.5650 | 2.50e-01 | 2.74e-01 | 2.35e-01 | 2.82e-01 | 2.16e-01 | 2.21e-01 | 1.80e-01 | 2.49e-01 | 1.67e-01 | 2.89e-01 |
| EMBRYONIC SKELETAL JOINT DEVELOPMENT | 15 | 1.20e-01 | 4.73e-01 | 0.5650 | 6.65e-02 | 1.37e-01 | 3.22e-01 | 2.88e-01 | 3.31e-01 | 6.56e-01 | 3.59e-01 | 3.10e-02 | 5.38e-02 | 2.63e-02 |
| REGULATION OF CELL CHEMOTAXIS TO FIBROBLAST GROWTH FACTOR | 9 | 6.32e-01 | 9.11e-01 | 0.5650 | -2.73e-01 | -3.11e-01 | -2.18e-01 | -2.74e-01 | -1.58e-01 | 1.55e-01 | 1.06e-01 | 2.57e-01 | 1.54e-01 | 4.13e-01 |
| CARDIAC NEURAL CREST CELL DIFFERENTIATION INVOLVED IN HEART DEVELOPMENT | 16 | 2.06e-02 | 1.70e-01 | 0.5640 | -1.04e-02 | 1.92e-01 | 3.02e-01 | 2.41e-01 | 3.65e-01 | 9.42e-01 | 1.84e-01 | 3.68e-02 | 9.56e-02 | 1.16e-02 |
| IRE1 MEDIATED UNFOLDED PROTEIN RESPONSE | 20 | 1.21e-01 | 4.75e-01 | 0.5640 | 2.38e-01 | 2.90e-01 | 2.44e-01 | 1.96e-01 | 2.83e-01 | 6.59e-02 | 2.49e-02 | 5.92e-02 | 1.29e-01 | 2.82e-02 |
| NEGATIVE REGULATION OF MITOCHONDRIAL FUSION | 7 | 3.63e-01 | 7.62e-01 | 0.5640 | 3.70e-01 | 1.91e-01 | 1.24e-01 | 3.52e-01 | 7.61e-02 | 9.03e-02 | 3.82e-01 | 5.70e-01 | 1.06e-01 | 7.27e-01 |
| MEMBRANE REPOLARIZATION DURING ATRIAL CARDIAC MUSCLE CELL ACTION POTENTIAL | 6 | 1.14e-02 | 1.12e-01 | 0.5640 | 1.16e-01 | 5.00e-01 | 1.19e-01 | -8.61e-02 | -1.80e-01 | 6.23e-01 | 3.38e-02 | 6.13e-01 | 7.15e-01 | 4.44e-01 |
| DISRUPTION OF PLASMA MEMBRANE INTEGRITY IN ANOTHER ORGANISM | 6 | 8.14e-01 | 9.69e-01 | 0.5640 | 2.01e-01 | 1.68e-01 | 2.89e-01 | 2.92e-01 | 2.84e-01 | 3.93e-01 | 4.77e-01 | 2.20e-01 | 2.16e-01 | 2.29e-01 |
| POSITIVE REGULATION OF AMYLOID FIBRIL FORMATION | 5 | 2.49e-01 | 6.56e-01 | 0.5640 | -5.04e-02 | -7.92e-03 | -2.47e-01 | -2.94e-02 | -5.03e-01 | 8.45e-01 | 9.76e-01 | 3.40e-01 | 9.09e-01 | 5.13e-02 |
| POSITIVE REGULATION OF LYMPHOCYTE CHEMOTAXIS | 20 | 1.32e-01 | 4.93e-01 | 0.5640 | -1.81e-01 | -1.52e-01 | -2.79e-01 | -2.62e-01 | -3.40e-01 | 1.61e-01 | 2.40e-01 | 3.09e-02 | 4.28e-02 | 8.46e-03 |
| REGULATION OF VERY LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 5 | 1.51e-01 | 5.20e-01 | 0.5630 | 1.28e-01 | 2.96e-01 | 1.40e-01 | 1.34e-01 | -4.19e-01 | 6.19e-01 | 2.52e-01 | 5.89e-01 | 6.03e-01 | 1.05e-01 |
| REGULATION OF RELAXATION OF CARDIAC MUSCLE | 6 | 4.25e-01 | 8.04e-01 | 0.5630 | -2.77e-01 | -3.73e-01 | -2.52e-01 | -1.37e-01 | 1.37e-01 | 2.40e-01 | 1.14e-01 | 2.85e-01 | 5.61e-01 | 5.62e-01 |
| NEGATIVE REGULATION OF B CELL DIFFERENTIATION | 6 | 1.79e-01 | 5.63e-01 | 0.5630 | 2.10e-01 | 2.53e-01 | 1.40e-01 | 6.39e-02 | 4.30e-01 | 3.74e-01 | 2.83e-01 | 5.53e-01 | 7.86e-01 | 6.81e-02 |
| VITAMIN A METABOLIC PROCESS | 8 | 7.69e-02 | 3.76e-01 | 0.5620 | -1.34e-01 | -3.38e-01 | -2.57e-01 | -3.43e-01 | 1.64e-02 | 5.13e-01 | 9.80e-02 | 2.08e-01 | 9.30e-02 | 9.36e-01 |
| SPERMIDINE TRANSPORT | 5 | 2.39e-01 | 6.44e-01 | 0.5620 | 2.60e-01 | 3.39e-01 | 9.87e-02 | 3.47e-01 | 4.89e-02 | 3.13e-01 | 1.89e-01 | 7.02e-01 | 1.79e-01 | 8.50e-01 |
| CELLULAR RESPONSE TO PEPTIDOGLYCAN | 6 | 6.09e-04 | 1.19e-02 | 0.5610 | 2.71e-01 | 3.72e-01 | -1.20e-01 | -2.97e-01 | 2.13e-03 | 2.50e-01 | 1.15e-01 | 6.10e-01 | 2.07e-01 | 9.93e-01 |
| PROTEIN MATURATION BY 4FE 4S CLUSTER TRANSFER | 7 | 7.08e-01 | 9.34e-01 | 0.5610 | 2.78e-01 | 2.13e-01 | 2.16e-01 | 2.78e-01 | 2.62e-01 | 2.03e-01 | 3.28e-01 | 3.23e-01 | 2.03e-01 | 2.31e-01 |
| GLYCOSYLCERAMIDE BIOSYNTHETIC PROCESS | 8 | 3.96e-01 | 7.85e-01 | 0.5610 | -2.69e-01 | -2.19e-01 | -1.72e-01 | -2.41e-01 | -3.27e-01 | 1.88e-01 | 2.84e-01 | 3.99e-01 | 2.39e-01 | 1.10e-01 |
| REGULATION OF WNT SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 9 | 5.33e-01 | 8.64e-01 | 0.5610 | 1.65e-01 | 1.84e-01 | 2.89e-01 | 1.94e-01 | 3.64e-01 | 3.92e-01 | 3.40e-01 | 1.33e-01 | 3.13e-01 | 5.89e-02 |
| MAST CELL DIFFERENTIATION | 6 | 3.51e-01 | 7.52e-01 | 0.5600 | -2.73e-02 | 2.30e-01 | 3.23e-01 | 2.03e-01 | 3.39e-01 | 9.08e-01 | 3.30e-01 | 1.70e-01 | 3.89e-01 | 1.51e-01 |
| POSITIVE REGULATION OF THE FORCE OF HEART CONTRACTION | 5 | 3.94e-01 | 7.85e-01 | 0.5600 | -1.92e-01 | -4.52e-02 | -1.88e-01 | -4.00e-01 | -2.83e-01 | 4.58e-01 | 8.61e-01 | 4.68e-01 | 1.21e-01 | 2.74e-01 |
| REGULATION OF RESPONSE TO TYPE II INTERFERON | 14 | 5.28e-01 | 8.60e-01 | 0.5600 | -2.47e-01 | -2.83e-01 | -2.96e-01 | -2.72e-01 | -1.08e-01 | 1.09e-01 | 6.70e-02 | 5.52e-02 | 7.84e-02 | 4.86e-01 |
| REGULATION OF SARCOMERE ORGANIZATION | 9 | 3.22e-01 | 7.32e-01 | 0.5600 | -2.92e-01 | -2.12e-01 | -1.63e-01 | -3.59e-01 | -1.67e-01 | 1.29e-01 | 2.70e-01 | 3.97e-01 | 6.22e-02 | 3.85e-01 |
| NEGATIVE REGULATION OF MACROAUTOPHAGY | 31 | 7.12e-02 | 3.61e-01 | 0.5600 | 2.59e-01 | 2.04e-01 | 2.57e-01 | 3.02e-01 | 2.18e-01 | 1.24e-02 | 4.98e-02 | 1.32e-02 | 3.58e-03 | 3.57e-02 |
| ADRENAL GLAND DEVELOPMENT | 27 | 8.12e-02 | 3.85e-01 | 0.5600 | 2.00e-01 | 1.74e-01 | 2.77e-01 | 2.77e-01 | 3.00e-01 | 7.23e-02 | 1.17e-01 | 1.29e-02 | 1.26e-02 | 7.00e-03 |
| 7 METHYLGUANOSINE RNA CAPPING | 8 | 7.62e-01 | 9.54e-01 | 0.5600 | 2.87e-01 | 2.14e-01 | 2.61e-01 | 3.05e-01 | 1.55e-01 | 1.60e-01 | 2.96e-01 | 2.02e-01 | 1.35e-01 | 4.48e-01 |
| HOST MEDIATED REGULATION OF INTESTINAL MICROBIOTA COMPOSITION | 9 | 6.71e-01 | 9.25e-01 | 0.5600 | -2.45e-01 | -2.46e-01 | -2.45e-01 | -3.29e-01 | -1.56e-01 | 2.02e-01 | 2.01e-01 | 2.03e-01 | 8.77e-02 | 4.19e-01 |
| METANEPHRIC COLLECTING DUCT DEVELOPMENT | 10 | 3.63e-01 | 7.62e-01 | 0.5600 | 1.56e-01 | 2.76e-01 | 3.67e-01 | 2.47e-01 | 1.30e-01 | 3.92e-01 | 1.31e-01 | 4.46e-02 | 1.77e-01 | 4.75e-01 |
| NEGATIVE REGULATION OF T HELPER 2 CELL DIFFERENTIATION | 5 | 8.73e-01 | 9.78e-01 | 0.5590 | 2.87e-01 | 2.37e-01 | 2.31e-01 | 2.56e-01 | 2.35e-01 | 2.66e-01 | 3.59e-01 | 3.70e-01 | 3.22e-01 | 3.62e-01 |
| NEUTROPHIL DIFFERENTIATION | 11 | 7.88e-02 | 3.81e-01 | 0.5590 | 9.44e-02 | 2.89e-01 | 3.71e-01 | 2.77e-01 | 7.76e-02 | 5.88e-01 | 9.74e-02 | 3.31e-02 | 1.12e-01 | 6.56e-01 |
| NEGATIVE REGULATION OF LIPASE ACTIVITY | 16 | 2.57e-01 | 6.64e-01 | 0.5590 | -1.37e-01 | -1.70e-01 | -2.82e-01 | -2.71e-01 | -3.35e-01 | 3.44e-01 | 2.38e-01 | 5.08e-02 | 6.09e-02 | 2.04e-02 |
| TELOMERE MAINTENANCE IN RESPONSE TO DNA DAMAGE | 29 | 3.07e-02 | 2.20e-01 | 0.5590 | 2.57e-01 | 2.65e-01 | 2.28e-01 | 2.13e-01 | 2.82e-01 | 1.67e-02 | 1.35e-02 | 3.39e-02 | 4.76e-02 | 8.63e-03 |
| SKELETAL MUSCLE THIN FILAMENT ASSEMBLY | 7 | 7.10e-01 | 9.35e-01 | 0.5590 | -2.23e-01 | -2.45e-01 | -2.28e-01 | -3.13e-01 | -2.29e-01 | 3.06e-01 | 2.63e-01 | 2.97e-01 | 1.51e-01 | 2.93e-01 |
| REGULATION OF NMDA RECEPTOR ACTIVITY | 17 | 1.79e-01 | 5.63e-01 | 0.5590 | -2.49e-01 | -1.60e-01 | -2.60e-01 | -2.66e-01 | -2.94e-01 | 7.56e-02 | 2.53e-01 | 6.36e-02 | 5.79e-02 | 3.57e-02 |
| COLLECTING DUCT DEVELOPMENT | 15 | 1.85e-01 | 5.72e-01 | 0.5590 | 1.52e-01 | 2.85e-01 | 3.53e-01 | 2.47e-01 | 1.47e-01 | 3.08e-01 | 5.57e-02 | 1.78e-02 | 9.72e-02 | 3.25e-01 |
| CELL CYCLE DNA REPLICATION | 42 | 2.06e-02 | 1.70e-01 | 0.5580 | 2.39e-01 | 1.96e-01 | 2.81e-01 | 2.93e-01 | 2.25e-01 | 7.47e-03 | 2.80e-02 | 1.61e-03 | 1.02e-03 | 1.15e-02 |
| NEGATIVE REGULATION BY HOST OF VIRAL PROCESS | 14 | 8.17e-02 | 3.87e-01 | 0.5570 | -3.10e-01 | -3.72e-01 | -1.64e-01 | -1.55e-01 | 1.59e-01 | 4.47e-02 | 1.61e-02 | 2.88e-01 | 3.14e-01 | 3.03e-01 |
| NEGATIVE REGULATION OF HUMORAL IMMUNE RESPONSE MEDIATED BY CIRCULATING IMMUNOGLOBULIN | 11 | 5.12e-01 | 8.54e-01 | 0.5570 | -3.23e-01 | -2.92e-01 | -2.51e-01 | -2.10e-01 | -1.16e-01 | 6.35e-02 | 9.38e-02 | 1.49e-01 | 2.28e-01 | 5.06e-01 |
| REGULATION OF ENDOTHELIAL TUBE MORPHOGENESIS | 6 | 4.62e-01 | 8.25e-01 | 0.5570 | -8.95e-02 | -2.21e-01 | -3.39e-01 | -9.39e-02 | -3.59e-01 | 7.04e-01 | 3.48e-01 | 1.50e-01 | 6.90e-01 | 1.28e-01 |
| PHOSPHAGEN METABOLIC PROCESS | 5 | 8.27e-01 | 9.72e-01 | 0.5570 | -1.24e-01 | -2.48e-01 | -3.06e-01 | -1.96e-01 | -3.17e-01 | 6.30e-01 | 3.37e-01 | 2.35e-01 | 4.48e-01 | 2.20e-01 |
| REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 77 | 3.68e-04 | 7.90e-03 | 0.5560 | 2.18e-01 | 2.73e-01 | 2.65e-01 | 2.57e-01 | 2.25e-01 | 9.23e-04 | 3.53e-05 | 5.62e-05 | 9.72e-05 | 6.36e-04 |
| POSITIVE REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION | 11 | 1.31e-01 | 4.91e-01 | 0.5560 | 2.63e-01 | 3.30e-01 | 3.32e-01 | 1.32e-01 | 6.06e-02 | 1.31e-01 | 5.82e-02 | 5.66e-02 | 4.50e-01 | 7.28e-01 |
| PROTEIN TO MEMBRANE DOCKING | 5 | 8.73e-01 | 9.78e-01 | 0.5560 | 2.20e-01 | 3.31e-01 | 2.79e-01 | 2.21e-01 | 1.55e-01 | 3.94e-01 | 2.00e-01 | 2.80e-01 | 3.91e-01 | 5.49e-01 |
| PROTEIN TRANSMEMBRANE IMPORT INTO INTRACELLULAR ORGANELLE | 35 | 6.36e-02 | 3.36e-01 | 0.5560 | 2.62e-01 | 2.37e-01 | 2.94e-01 | 2.60e-01 | 1.73e-01 | 7.22e-03 | 1.53e-02 | 2.65e-03 | 7.72e-03 | 7.60e-02 |
| REGULATION OF ACTIN NUCLEATION | 38 | 5.76e-03 | 6.81e-02 | 0.5560 | 3.08e-01 | 3.03e-01 | 2.12e-01 | 2.65e-01 | -8.03e-02 | 1.00e-03 | 1.24e-03 | 2.34e-02 | 4.65e-03 | 3.92e-01 |
| LIMB BUD FORMATION | 9 | 6.07e-01 | 9.02e-01 | 0.5560 | 2.68e-01 | 3.45e-01 | 2.25e-01 | 2.50e-01 | 6.90e-02 | 1.64e-01 | 7.33e-02 | 2.43e-01 | 1.93e-01 | 7.20e-01 |
| TRNA WOBBLE BASE MODIFICATION | 20 | 2.05e-01 | 5.99e-01 | 0.5550 | 2.59e-01 | 1.91e-01 | 2.49e-01 | 2.81e-01 | 2.54e-01 | 4.52e-02 | 1.40e-01 | 5.38e-02 | 2.97e-02 | 4.95e-02 |
| REGULATION OF MITOCHONDRIAL TRANSCRIPTION | 5 | 4.03e-02 | 2.59e-01 | 0.5550 | -1.14e-01 | -2.57e-01 | 2.99e-01 | 1.56e-01 | 3.40e-01 | 6.59e-01 | 3.20e-01 | 2.47e-01 | 5.47e-01 | 1.88e-01 |
| ORGAN INDUCTION | 22 | 8.75e-02 | 4.00e-01 | 0.5550 | 1.37e-01 | 2.11e-01 | 2.58e-01 | 2.60e-01 | 3.33e-01 | 2.67e-01 | 8.69e-02 | 3.58e-02 | 3.48e-02 | 6.89e-03 |
| EMBRYONIC HINDLIMB MORPHOGENESIS | 27 | 9.27e-02 | 4.13e-01 | 0.5550 | 1.50e-01 | 2.13e-01 | 2.93e-01 | 2.64e-01 | 2.91e-01 | 1.78e-01 | 5.59e-02 | 8.35e-03 | 1.77e-02 | 8.90e-03 |
| POLYAMINE BIOSYNTHETIC PROCESS | 12 | 4.71e-01 | 8.30e-01 | 0.5550 | 2.07e-01 | 1.76e-01 | 2.55e-01 | 3.14e-01 | 2.65e-01 | 2.14e-01 | 2.90e-01 | 1.26e-01 | 5.98e-02 | 1.12e-01 |
| REGULATION OF RNA BINDING | 7 | 4.35e-01 | 8.09e-01 | 0.5540 | 3.63e-01 | 1.55e-01 | 1.68e-01 | 3.46e-01 | 5.47e-02 | 9.58e-02 | 4.76e-01 | 4.42e-01 | 1.13e-01 | 8.02e-01 |
| ATRIAL CARDIAC MUSCLE TISSUE DEVELOPMENT | 21 | 1.20e-01 | 4.72e-01 | 0.5540 | 1.15e-01 | 2.17e-01 | 2.97e-01 | 2.11e-01 | 3.38e-01 | 3.61e-01 | 8.57e-02 | 1.86e-02 | 9.36e-02 | 7.27e-03 |
| RNA CAPPING | 35 | 3.00e-03 | 4.17e-02 | 0.5540 | 1.39e-01 | 1.43e-01 | 3.41e-01 | 3.04e-01 | 2.43e-01 | 1.54e-01 | 1.44e-01 | 4.89e-04 | 1.84e-03 | 1.30e-02 |
| POSITIVE REGULATION OF DNA DEMETHYLATION | 8 | 5.50e-01 | 8.74e-01 | 0.5540 | -1.63e-01 | -3.14e-01 | -3.31e-01 | -1.74e-01 | -2.04e-01 | 4.24e-01 | 1.24e-01 | 1.05e-01 | 3.94e-01 | 3.18e-01 |
| TRIGLYCERIDE RICH LIPOPROTEIN PARTICLE CLEARANCE | 7 | 4.90e-02 | 2.89e-01 | 0.5540 | 1.24e-01 | 3.23e-01 | 9.12e-02 | 3.75e-02 | -4.21e-01 | 5.69e-01 | 1.39e-01 | 6.76e-01 | 8.63e-01 | 5.37e-02 |
| POSITIVE REGULATION OF T HELPER 1 CELL DIFFERENTIATION | 6 | 4.25e-02 | 2.68e-01 | 0.5530 | 3.54e-01 | 2.13e-01 | -2.21e-01 | -7.53e-02 | -2.85e-01 | 1.33e-01 | 3.66e-01 | 3.49e-01 | 7.49e-01 | 2.26e-01 |
| CELLULAR RESPONSE TO COCAINE | 8 | 3.28e-01 | 7.37e-01 | 0.5530 | 3.45e-01 | 2.07e-01 | 1.27e-01 | 2.98e-01 | -1.99e-01 | 9.12e-02 | 3.10e-01 | 5.33e-01 | 1.45e-01 | 3.30e-01 |
| RESPONSE TO CAFFEINE | 15 | 1.32e-01 | 4.92e-01 | 0.5530 | -3.27e-01 | -3.02e-01 | -1.42e-01 | -2.80e-01 | -9.51e-02 | 2.82e-02 | 4.27e-02 | 3.42e-01 | 6.02e-02 | 5.24e-01 |
| PIGMENT GRANULE MATURATION | 10 | 3.10e-01 | 7.22e-01 | 0.5530 | 3.18e-01 | 1.60e-01 | 2.50e-01 | 2.57e-01 | 2.25e-01 | 8.18e-02 | 3.80e-01 | 1.71e-01 | 1.59e-01 | 2.19e-01 |
| REGULATION OF T HELPER 1 CELL DIFFERENTIATION | 11 | 1.79e-02 | 1.56e-01 | 0.5530 | 3.91e-01 | 3.68e-01 | 8.93e-03 | 8.65e-02 | -1.01e-01 | 2.46e-02 | 3.48e-02 | 9.59e-01 | 6.19e-01 | 5.62e-01 |
| PENTOSE PHOSPHATE SHUNT NON OXIDATIVE BRANCH | 6 | 8.15e-01 | 9.69e-01 | 0.5530 | 2.22e-01 | 1.79e-01 | 2.64e-01 | 2.53e-01 | 3.01e-01 | 3.47e-01 | 4.48e-01 | 2.63e-01 | 2.83e-01 | 2.01e-01 |
| PARATHYROID GLAND DEVELOPMENT | 7 | 7.77e-02 | 3.78e-01 | 0.5530 | 6.98e-02 | 1.31e-01 | 1.65e-01 | 3.77e-01 | 3.38e-01 | 7.49e-01 | 5.49e-01 | 4.51e-01 | 8.37e-02 | 1.22e-01 |
| CALCIUM ION IMPORT ACROSS PLASMA MEMBRANE | 52 | 6.93e-03 | 7.84e-02 | 0.5530 | -2.92e-01 | -2.37e-01 | -2.33e-01 | -2.85e-01 | -1.68e-01 | 2.63e-04 | 3.15e-03 | 3.70e-03 | 3.69e-04 | 3.56e-02 |
| NEGATIVE REGULATION OF CHEMOKINE C X C MOTIF LIGAND 2 PRODUCTION | 5 | 6.42e-01 | 9.14e-01 | 0.5530 | -9.18e-02 | -3.24e-01 | -3.17e-01 | -1.97e-01 | -2.30e-01 | 7.22e-01 | 2.10e-01 | 2.19e-01 | 4.46e-01 | 3.74e-01 |
| PYRIMIDINE CONTAINING COMPOUND SALVAGE | 7 | 7.11e-02 | 3.61e-01 | 0.5530 | 3.19e-01 | 3.35e-01 | -9.54e-02 | 5.12e-02 | -2.82e-01 | 1.44e-01 | 1.25e-01 | 6.62e-01 | 8.14e-01 | 1.96e-01 |
| PROTEIN LOCALIZATION TO MEMBRANE RAFT | 9 | 1.98e-01 | 5.87e-01 | 0.5520 | 3.40e-01 | 1.61e-01 | 1.40e-01 | 2.86e-01 | 2.49e-01 | 7.69e-02 | 4.02e-01 | 4.68e-01 | 1.37e-01 | 1.96e-01 |
| REGULATION OF ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE OR POLYSACCHARIDE ANTIGEN VIA MHC CLASS II | 5 | 5.02e-01 | 8.48e-01 | 0.5520 | -2.97e-02 | -1.67e-01 | -3.10e-01 | -3.30e-01 | -2.66e-01 | 9.08e-01 | 5.17e-01 | 2.29e-01 | 2.01e-01 | 3.03e-01 |
| NUCLEOTIDE SUGAR BIOSYNTHETIC PROCESS | 19 | 8.25e-02 | 3.88e-01 | 0.5520 | 1.23e-01 | 9.69e-02 | 2.89e-01 | 2.69e-01 | 3.53e-01 | 3.52e-01 | 4.65e-01 | 2.93e-02 | 4.22e-02 | 7.77e-03 |
| NEGATIVE REGULATION OF DNA REPLICATION | 24 | 1.95e-01 | 5.83e-01 | 0.5520 | 2.14e-01 | 2.45e-01 | 2.96e-01 | 2.99e-01 | 1.46e-01 | 6.97e-02 | 3.76e-02 | 1.20e-02 | 1.11e-02 | 2.15e-01 |
| RNA SPLICING VIA TRANSESTERIFICATION REACTIONS | 286 | 1.77e-16 | 2.77e-14 | 0.5520 | 2.27e-01 | 2.13e-01 | 2.86e-01 | 3.02e-01 | 1.85e-01 | 3.91e-11 | 5.30e-10 | 7.76e-17 | 1.44e-18 | 6.73e-08 |
| SPLICEOSOMAL CONFORMATIONAL CHANGES TO GENERATE CATALYTIC CONFORMATION | 5 | 2.32e-02 | 1.85e-01 | 0.5520 | -7.87e-02 | 2.38e-02 | 2.62e-01 | 4.59e-01 | 1.35e-01 | 7.60e-01 | 9.27e-01 | 3.10e-01 | 7.57e-02 | 6.00e-01 |
| REGULATION OF GERMINAL CENTER FORMATION | 8 | 4.75e-01 | 8.32e-01 | 0.5510 | 2.31e-01 | 1.51e-01 | 2.39e-01 | 3.82e-01 | 1.57e-01 | 2.59e-01 | 4.59e-01 | 2.41e-01 | 6.10e-02 | 4.43e-01 |
| RESPONSE TO GRAM POSITIVE BACTERIUM | 5 | 6.99e-01 | 9.31e-01 | 0.5510 | 3.28e-01 | 3.12e-01 | 2.51e-01 | 1.44e-01 | 1.23e-01 | 2.04e-01 | 2.27e-01 | 3.31e-01 | 5.76e-01 | 6.34e-01 |
| REGULATION OF PROTEIN KINASE C ACTIVITY | 5 | 6.41e-01 | 9.14e-01 | 0.5510 | -3.76e-01 | -1.97e-01 | -2.05e-01 | -2.39e-01 | -1.57e-01 | 1.45e-01 | 4.46e-01 | 4.28e-01 | 3.56e-01 | 5.42e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO HYPOXIA | 11 | 4.66e-01 | 8.26e-01 | 0.5510 | 3.62e-01 | 2.56e-01 | 1.95e-01 | 2.59e-01 | 3.64e-02 | 3.75e-02 | 1.42e-01 | 2.62e-01 | 1.37e-01 | 8.34e-01 |
| XENOBIOTIC TRANSPORT ACROSS BLOOD BRAIN BARRIER | 6 | 5.97e-01 | 8.98e-01 | 0.5510 | -2.06e-01 | -1.46e-01 | -3.18e-01 | -2.00e-01 | -3.14e-01 | 3.83e-01 | 5.35e-01 | 1.78e-01 | 3.97e-01 | 1.83e-01 |
| POSITIVE REGULATION OF MONOCYTE CHEMOTACTIC PROTEIN 1 PRODUCTION | 15 | 5.76e-03 | 6.81e-02 | 0.5510 | 3.27e-01 | 2.13e-01 | -5.62e-02 | 2.98e-02 | -3.83e-01 | 2.84e-02 | 1.54e-01 | 7.06e-01 | 8.42e-01 | 1.01e-02 |
| MAINTENANCE OF PRESYNAPTIC ACTIVE ZONE STRUCTURE | 6 | 8.64e-01 | 9.78e-01 | 0.5500 | -1.77e-01 | -2.23e-01 | -2.80e-01 | -2.79e-01 | -2.55e-01 | 4.52e-01 | 3.44e-01 | 2.35e-01 | 2.37e-01 | 2.80e-01 |
| EXOCYST LOCALIZATION | 5 | 1.79e-01 | 5.63e-01 | 0.5500 | -3.36e-01 | 1.06e-02 | -1.34e-01 | -3.32e-01 | -2.47e-01 | 1.93e-01 | 9.67e-01 | 6.03e-01 | 1.99e-01 | 3.38e-01 |
| REGULATION OF MACROPHAGE FUSION | 5 | 1.13e-01 | 4.57e-01 | 0.5500 | 1.00e-01 | -5.90e-02 | -4.39e-01 | -2.11e-01 | -2.27e-01 | 6.98e-01 | 8.19e-01 | 8.90e-02 | 4.14e-01 | 3.80e-01 |
| POSITIVE REGULATION OF KERATINOCYTE PROLIFERATION | 15 | 1.86e-01 | 5.72e-01 | 0.5500 | -1.65e-01 | -1.30e-01 | -2.31e-01 | -2.83e-01 | -3.53e-01 | 2.68e-01 | 3.82e-01 | 1.21e-01 | 5.78e-02 | 1.80e-02 |
| TYPE II PNEUMOCYTE DIFFERENTIATION | 6 | 6.74e-01 | 9.28e-01 | 0.5500 | 2.31e-01 | 1.78e-01 | 2.25e-01 | 3.72e-01 | 1.68e-01 | 3.28e-01 | 4.51e-01 | 3.40e-01 | 1.15e-01 | 4.76e-01 |
| REGULATION OF PRO B CELL DIFFERENTIATION | 8 | 3.38e-01 | 7.43e-01 | 0.5490 | 2.31e-01 | 1.93e-01 | 2.18e-01 | 4.01e-01 | 5.27e-02 | 2.58e-01 | 3.44e-01 | 2.87e-01 | 4.95e-02 | 7.96e-01 |
| MITOTIC SPINDLE ORGANIZATION | 125 | 2.93e-07 | 1.49e-05 | 0.5490 | 2.67e-01 | 2.03e-01 | 2.61e-01 | 3.01e-01 | 1.72e-01 | 2.48e-07 | 8.76e-05 | 4.61e-07 | 5.91e-09 | 8.76e-04 |
| POSITIVE REGULATION OF TRANSCRIPTION ELONGATION BY RNA POLYMERASE II | 48 | 1.12e-02 | 1.11e-01 | 0.5480 | 2.07e-01 | 2.40e-01 | 2.55e-01 | 2.54e-01 | 2.66e-01 | 1.32e-02 | 3.96e-03 | 2.25e-03 | 2.31e-03 | 1.45e-03 |
| RNA 5 END PROCESSING | 21 | 5.69e-02 | 3.15e-01 | 0.5480 | 1.28e-01 | 1.55e-01 | 3.53e-01 | 2.73e-01 | 2.46e-01 | 3.11e-01 | 2.18e-01 | 5.07e-03 | 3.02e-02 | 5.08e-02 |
| POSITIVE REGULATION OF TOLERANCE INDUCTION | 11 | 2.71e-01 | 6.79e-01 | 0.5480 | -2.67e-01 | -3.41e-01 | -2.68e-01 | -1.87e-01 | 7.85e-02 | 1.26e-01 | 4.99e-02 | 1.24e-01 | 2.83e-01 | 6.52e-01 |
| FEMALE MEIOSIS CHROMOSOME SEGREGATION | 6 | 7.03e-01 | 9.32e-01 | 0.5480 | 1.25e-01 | 2.07e-01 | 2.83e-01 | 3.18e-01 | 2.46e-01 | 5.97e-01 | 3.81e-01 | 2.30e-01 | 1.77e-01 | 2.96e-01 |
| IMP BIOSYNTHETIC PROCESS | 10 | 4.59e-01 | 8.23e-01 | 0.5480 | 3.23e-01 | 1.89e-01 | 2.62e-01 | 2.83e-01 | 1.07e-01 | 7.70e-02 | 3.01e-01 | 1.51e-01 | 1.21e-01 | 5.57e-01 |
| MAINTENANCE OF ORGANELLE LOCATION | 13 | 1.15e-01 | 4.62e-01 | 0.5480 | -1.35e-01 | -2.70e-01 | -2.09e-01 | -1.71e-01 | -3.69e-01 | 4.01e-01 | 9.15e-02 | 1.91e-01 | 2.87e-01 | 2.14e-02 |
| THYMOCYTE APOPTOTIC PROCESS | 20 | 9.57e-02 | 4.20e-01 | 0.5480 | 1.15e-01 | 1.34e-01 | 2.57e-01 | 2.56e-01 | 3.70e-01 | 3.74e-01 | 3.00e-01 | 4.63e-02 | 4.74e-02 | 4.16e-03 |
| SUGAR MEDIATED SIGNALING PATHWAY | 9 | 6.57e-01 | 9.20e-01 | 0.5480 | 1.85e-01 | 2.53e-01 | 3.33e-01 | 2.20e-01 | 2.06e-01 | 3.35e-01 | 1.90e-01 | 8.38e-02 | 2.53e-01 | 2.85e-01 |
| TRANSDIFFERENTIATION | 7 | 4.99e-01 | 8.47e-01 | 0.5480 | 2.03e-01 | 3.39e-01 | 2.94e-01 | 1.13e-01 | 2.11e-01 | 3.52e-01 | 1.21e-01 | 1.78e-01 | 6.06e-01 | 3.34e-01 |
| BRUSH BORDER ASSEMBLY | 7 | 6.35e-01 | 9.12e-01 | 0.5470 | -3.01e-01 | -2.15e-01 | -1.84e-01 | -2.63e-01 | -2.44e-01 | 1.68e-01 | 3.24e-01 | 3.99e-01 | 2.29e-01 | 2.64e-01 |
| NEGATIVE REGULATION OF PROTEIN K63 LINKED UBIQUITINATION | 5 | 1.74e-01 | 5.59e-01 | 0.5470 | -9.75e-02 | -1.28e-01 | 2.10e-01 | -5.02e-02 | 4.77e-01 | 7.06e-01 | 6.21e-01 | 4.17e-01 | 8.46e-01 | 6.50e-02 |
| MITOTIC G1 S TRANSITION CHECKPOINT SIGNALING | 29 | 4.16e-02 | 2.64e-01 | 0.5470 | 1.65e-01 | 2.20e-01 | 2.83e-01 | 3.18e-01 | 2.06e-01 | 1.24e-01 | 3.99e-02 | 8.45e-03 | 3.00e-03 | 5.49e-02 |
| POSITIVE REGULATION OF CHEMOKINE C X C MOTIF LIGAND 2 PRODUCTION | 11 | 4.62e-01 | 8.25e-01 | 0.5470 | 3.08e-01 | 2.90e-01 | 2.02e-01 | 2.10e-01 | 1.89e-01 | 7.72e-02 | 9.60e-02 | 2.46e-01 | 2.28e-01 | 2.77e-01 |
| SUCKLING BEHAVIOR | 12 | 2.73e-01 | 6.81e-01 | 0.5470 | 2.86e-01 | 3.52e-01 | 2.32e-01 | 1.84e-01 | -7.87e-02 | 8.62e-02 | 3.49e-02 | 1.64e-01 | 2.70e-01 | 6.37e-01 |
| IMMUNE COMPLEX CLEARANCE | 5 | 6.04e-01 | 9.01e-01 | 0.5470 | -3.53e-01 | -1.57e-01 | -2.49e-01 | -2.57e-01 | -1.49e-01 | 1.72e-01 | 5.44e-01 | 3.35e-01 | 3.20e-01 | 5.64e-01 |
| GLIAL CELL FATE SPECIFICATION | 7 | 4.17e-01 | 7.99e-01 | 0.5460 | 1.45e-01 | 1.40e-01 | 3.39e-01 | 1.58e-01 | 3.43e-01 | 5.06e-01 | 5.22e-01 | 1.20e-01 | 4.70e-01 | 1.16e-01 |
| CLUSTERING OF VOLTAGE GATED SODIUM CHANNELS | 6 | 8.78e-01 | 9.79e-01 | 0.5460 | -2.93e-01 | -2.93e-01 | -2.20e-01 | -2.65e-01 | -8.79e-02 | 2.14e-01 | 2.14e-01 | 3.51e-01 | 2.61e-01 | 7.09e-01 |
| NEURAL PLATE ANTERIOR POSTERIOR REGIONALIZATION | 5 | 1.25e-01 | 4.80e-01 | 0.5460 | -1.52e-01 | 7.08e-02 | 2.99e-01 | 3.00e-01 | 3.00e-01 | 5.55e-01 | 7.84e-01 | 2.46e-01 | 2.45e-01 | 2.46e-01 |
| MITOTIC G2 DNA DAMAGE CHECKPOINT SIGNALING | 34 | 1.87e-02 | 1.59e-01 | 0.5450 | 2.54e-01 | 1.81e-01 | 2.34e-01 | 3.41e-01 | 1.70e-01 | 1.03e-02 | 6.84e-02 | 1.81e-02 | 5.80e-04 | 8.54e-02 |
| MEIOTIC DNA DOUBLE STRAND BREAK FORMATION | 6 | 8.03e-01 | 9.67e-01 | 0.5450 | -2.30e-01 | -2.99e-01 | -2.36e-01 | -2.95e-01 | -1.12e-01 | 3.30e-01 | 2.05e-01 | 3.17e-01 | 2.10e-01 | 6.36e-01 |
| LATE ENDOSOME TO LYSOSOME TRANSPORT | 21 | 6.81e-02 | 3.50e-01 | 0.5450 | 2.74e-01 | 1.65e-01 | 2.90e-01 | 3.20e-01 | 9.03e-02 | 2.97e-02 | 1.91e-01 | 2.15e-02 | 1.11e-02 | 4.74e-01 |
| PROTEIN HISTIDYL MODIFICATION TO DIPHTHAMIDE | 6 | 6.99e-01 | 9.31e-01 | 0.5450 | 2.75e-01 | 2.18e-01 | 2.30e-01 | 1.93e-01 | 2.88e-01 | 2.43e-01 | 3.55e-01 | 3.29e-01 | 4.13e-01 | 2.22e-01 |
| REGULATION OF PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 12 | 4.16e-01 | 7.99e-01 | 0.5440 | 2.35e-01 | 2.64e-01 | 2.59e-01 | 3.22e-01 | 2.53e-02 | 1.59e-01 | 1.13e-01 | 1.20e-01 | 5.35e-02 | 8.79e-01 |
| POSITIVE REGULATION OF TELOMERASE RNA LOCALIZATION TO CAJAL BODY | 14 | 2.83e-01 | 6.93e-01 | 0.5440 | 1.87e-01 | 1.61e-01 | 3.09e-01 | 3.32e-01 | 1.72e-01 | 2.25e-01 | 2.96e-01 | 4.52e-02 | 3.16e-02 | 2.64e-01 |
| PYRIMIDINE DIMER REPAIR | 9 | 6.83e-01 | 9.30e-01 | 0.5440 | 2.95e-01 | 2.72e-01 | 2.11e-01 | 2.37e-01 | 1.85e-01 | 1.25e-01 | 1.57e-01 | 2.72e-01 | 2.18e-01 | 3.37e-01 |
| PEPTIDYL HISTIDINE MODIFICATION | 8 | 5.70e-01 | 8.83e-01 | 0.5440 | 3.13e-01 | 2.29e-01 | 2.45e-01 | 2.05e-01 | 2.10e-01 | 1.26e-01 | 2.62e-01 | 2.30e-01 | 3.16e-01 | 3.04e-01 |
| NEGATIVE REGULATION OF CHROMOSOME ORGANIZATION | 89 | 3.32e-05 | 1.10e-03 | 0.5440 | 2.38e-01 | 2.06e-01 | 2.42e-01 | 3.04e-01 | 2.15e-01 | 1.04e-04 | 7.85e-04 | 7.92e-05 | 7.03e-07 | 4.60e-04 |
| REGULATION OF DNA TEMPLATED DNA REPLICATION | 46 | 1.46e-02 | 1.33e-01 | 0.5440 | 2.20e-01 | 1.88e-01 | 2.87e-01 | 2.85e-01 | 2.21e-01 | 9.97e-03 | 2.77e-02 | 7.64e-04 | 8.15e-04 | 9.36e-03 |
| LEYDIG CELL DIFFERENTIATION | 9 | 7.95e-01 | 9.65e-01 | 0.5440 | 2.81e-01 | 2.51e-01 | 2.47e-01 | 2.82e-01 | 1.18e-01 | 1.45e-01 | 1.92e-01 | 2.00e-01 | 1.44e-01 | 5.40e-01 |
| PROTEIN FOLDING | 209 | 6.53e-11 | 5.65e-09 | 0.5440 | 2.41e-01 | 2.25e-01 | 2.72e-01 | 2.97e-01 | 1.59e-01 | 1.84e-09 | 2.12e-08 | 1.28e-11 | 1.24e-13 | 7.76e-05 |
| EXTRACELLULAR VESICLE BIOGENESIS | 25 | 1.79e-01 | 5.63e-01 | 0.5440 | 3.13e-01 | 2.90e-01 | 2.20e-01 | 2.45e-01 | 7.17e-02 | 6.76e-03 | 1.20e-02 | 5.73e-02 | 3.37e-02 | 5.35e-01 |
| TONGUE MORPHOGENESIS | 10 | 2.16e-01 | 6.12e-01 | 0.5430 | 3.26e-02 | 8.88e-02 | 3.02e-01 | 3.01e-01 | 3.23e-01 | 8.58e-01 | 6.27e-01 | 9.81e-02 | 9.88e-02 | 7.70e-02 |
| PHAGOSOME ACIDIFICATION | 7 | 2.15e-01 | 6.11e-01 | 0.5430 | 2.80e-01 | 2.34e-01 | -3.16e-02 | 1.63e-01 | -3.67e-01 | 1.99e-01 | 2.84e-01 | 8.85e-01 | 4.54e-01 | 9.30e-02 |
| RESPONSE TO MITOCHONDRIAL DEPOLARISATION | 19 | 1.92e-01 | 5.80e-01 | 0.5430 | 2.97e-01 | 1.89e-01 | 2.45e-01 | 2.71e-01 | 1.95e-01 | 2.51e-02 | 1.54e-01 | 6.45e-02 | 4.06e-02 | 1.42e-01 |
| REGULATION OF CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 30 | 2.58e-02 | 1.97e-01 | 0.5430 | -3.08e-01 | -1.76e-01 | -2.28e-01 | -2.97e-01 | -1.73e-01 | 3.55e-03 | 9.50e-02 | 3.08e-02 | 4.90e-03 | 1.02e-01 |
| PROTEIN K29 LINKED UBIQUITINATION | 7 | 6.99e-01 | 9.31e-01 | 0.5430 | 3.09e-01 | 2.42e-01 | 2.08e-01 | 3.07e-01 | -5.58e-02 | 1.56e-01 | 2.67e-01 | 3.40e-01 | 1.60e-01 | 7.98e-01 |
| METAPHASE CHROMOSOME ALIGNMENT | 97 | 6.37e-05 | 1.91e-03 | 0.5430 | 2.17e-01 | 2.32e-01 | 2.88e-01 | 2.90e-01 | 1.64e-01 | 2.14e-04 | 7.88e-05 | 9.63e-07 | 7.66e-07 | 5.32e-03 |
| PURINE DEOXYRIBONUCLEOTIDE METABOLIC PROCESS | 16 | 2.50e-01 | 6.57e-01 | 0.5430 | 2.55e-01 | 1.91e-01 | 3.08e-01 | 2.95e-01 | 1.07e-01 | 7.70e-02 | 1.85e-01 | 3.31e-02 | 4.12e-02 | 4.57e-01 |
| PROTEIN LOCALIZATION TO NUCLEOPLASM | 13 | 2.60e-02 | 1.98e-01 | 0.5430 | 2.59e-01 | 8.86e-02 | 3.37e-01 | 2.63e-01 | 1.93e-01 | 1.06e-01 | 5.80e-01 | 3.53e-02 | 1.01e-01 | 2.29e-01 |
| POSITIVE REGULATION OF CHROMOSOME SEGREGATION | 27 | 1.10e-01 | 4.52e-01 | 0.5430 | 2.29e-01 | 2.13e-01 | 3.04e-01 | 2.97e-01 | 1.26e-01 | 3.96e-02 | 5.57e-02 | 6.20e-03 | 7.55e-03 | 2.56e-01 |
| TRYPTOPHAN TRANSPORT | 5 | 8.72e-01 | 9.78e-01 | 0.5420 | 1.93e-01 | 2.59e-01 | 2.60e-01 | 3.05e-01 | 1.71e-01 | 4.54e-01 | 3.17e-01 | 3.15e-01 | 2.37e-01 | 5.08e-01 |
| NEUROBLAST DIFFERENTIATION | 8 | 6.25e-01 | 9.09e-01 | 0.5420 | 1.15e-01 | 1.34e-01 | 2.88e-01 | 2.77e-01 | 3.21e-01 | 5.75e-01 | 5.11e-01 | 1.58e-01 | 1.75e-01 | 1.16e-01 |
| MEIOTIC CELL CYCLE PROCESS INVOLVED IN OOCYTE MATURATION | 6 | 2.12e-01 | 6.07e-01 | 0.5420 | -3.48e-02 | 4.63e-02 | 1.86e-01 | 2.96e-01 | 4.10e-01 | 8.83e-01 | 8.44e-01 | 4.30e-01 | 2.10e-01 | 8.21e-02 |
| TRACHEA FORMATION | 7 | 3.19e-02 | 2.27e-01 | 0.5420 | -4.04e-02 | 5.61e-02 | 2.49e-01 | 4.09e-01 | 2.44e-01 | 8.53e-01 | 7.97e-01 | 2.53e-01 | 6.12e-02 | 2.64e-01 |
| MESENCHYMAL STEM CELL MAINTENANCE INVOLVED IN NEPHRON MORPHOGENESIS | 6 | 4.62e-01 | 8.25e-01 | 0.5410 | 1.24e-01 | 3.15e-01 | 3.67e-01 | 1.41e-01 | 1.53e-01 | 6.00e-01 | 1.82e-01 | 1.19e-01 | 5.49e-01 | 5.17e-01 |
| REGULATION OF HAIR FOLLICLE DEVELOPMENT | 19 | 2.68e-02 | 2.02e-01 | 0.5410 | 1.48e-01 | 2.77e-01 | 2.93e-01 | 3.24e-01 | 5.89e-02 | 2.65e-01 | 3.68e-02 | 2.68e-02 | 1.46e-02 | 6.57e-01 |
| LYSOSOMAL PROTEIN CATABOLIC PROCESS | 19 | 1.83e-01 | 5.70e-01 | 0.5410 | 1.99e-01 | 2.26e-01 | 2.66e-01 | 3.35e-01 | 1.38e-01 | 1.33e-01 | 8.85e-02 | 4.49e-02 | 1.15e-02 | 2.96e-01 |
| MITOTIC SPINDLE ASSEMBLY | 67 | 2.06e-04 | 4.81e-03 | 0.5410 | 3.05e-01 | 1.99e-01 | 2.26e-01 | 2.93e-01 | 1.50e-01 | 1.53e-05 | 4.90e-03 | 1.35e-03 | 3.31e-05 | 3.42e-02 |
| POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 5 | 8.54e-01 | 9.76e-01 | 0.5400 | 1.76e-01 | 1.91e-01 | 3.08e-01 | 3.18e-01 | 1.67e-01 | 4.94e-01 | 4.59e-01 | 2.33e-01 | 2.19e-01 | 5.17e-01 |
| PLANAR CELL POLARITY PATHWAY INVOLVED IN NEURAL TUBE CLOSURE | 11 | 1.32e-01 | 4.93e-01 | 0.5400 | -2.29e-02 | 1.75e-01 | 2.51e-01 | 1.17e-01 | 4.29e-01 | 8.95e-01 | 3.14e-01 | 1.50e-01 | 5.02e-01 | 1.38e-02 |
| SYMPATHETIC NEURON PROJECTION EXTENSION | 5 | 6.56e-01 | 9.20e-01 | 0.5400 | -1.73e-01 | -7.62e-02 | -2.35e-01 | -2.12e-01 | -3.94e-01 | 5.03e-01 | 7.68e-01 | 3.63e-01 | 4.12e-01 | 1.27e-01 |
| REGULATION OF T HELPER 17 CELL LINEAGE COMMITMENT | 7 | 6.05e-01 | 9.01e-01 | 0.5390 | 3.26e-01 | 3.49e-01 | 1.70e-01 | 1.74e-01 | 5.83e-02 | 1.35e-01 | 1.10e-01 | 4.36e-01 | 4.24e-01 | 7.90e-01 |
| REGULATION OF MACROPHAGE APOPTOTIC PROCESS | 11 | 3.03e-01 | 7.16e-01 | 0.5390 | 2.54e-01 | 2.43e-01 | 1.66e-01 | 2.85e-01 | 2.41e-01 | 1.45e-01 | 1.62e-01 | 3.40e-01 | 1.01e-01 | 1.66e-01 |
| LEUCINE TRANSPORT | 10 | 1.87e-01 | 5.72e-01 | 0.5390 | 1.85e-01 | 3.98e-01 | 2.35e-01 | 1.47e-01 | 1.49e-01 | 3.12e-01 | 2.94e-02 | 1.99e-01 | 4.20e-01 | 4.16e-01 |
| ENDOSOMAL LUMEN ACIDIFICATION | 12 | 1.88e-01 | 5.73e-01 | 0.5390 | 1.63e-02 | 1.52e-01 | 3.03e-01 | 2.45e-01 | 3.40e-01 | 9.22e-01 | 3.62e-01 | 6.90e-02 | 1.41e-01 | 4.16e-02 |
| RESPONSE TO PEPTIDOGLYCAN | 13 | 1.33e-04 | 3.43e-03 | 0.5390 | 3.34e-01 | 3.89e-01 | 6.03e-03 | -1.09e-01 | -1.25e-01 | 3.71e-02 | 1.52e-02 | 9.70e-01 | 4.96e-01 | 4.36e-01 |
| 3 UTR MEDIATED MRNA STABILIZATION | 20 | 1.12e-01 | 4.56e-01 | 0.5390 | 2.53e-01 | 2.17e-01 | 1.89e-01 | 2.65e-01 | 2.70e-01 | 4.97e-02 | 9.23e-02 | 1.43e-01 | 4.03e-02 | 3.68e-02 |
| INTERLEUKIN 33 MEDIATED SIGNALING PATHWAY | 7 | 3.00e-01 | 7.13e-01 | 0.5390 | -2.96e-01 | -2.73e-01 | -8.23e-02 | -3.07e-01 | 1.65e-01 | 1.75e-01 | 2.11e-01 | 7.06e-01 | 1.60e-01 | 4.51e-01 |
| THYMIC T CELL SELECTION | 23 | 1.69e-05 | 6.04e-04 | 0.5390 | -1.62e-01 | -6.79e-03 | 3.14e-01 | 2.08e-01 | 3.49e-01 | 1.80e-01 | 9.55e-01 | 9.15e-03 | 8.40e-02 | 3.73e-03 |
| REGULATION OF TAU PROTEIN KINASE ACTIVITY | 13 | 1.57e-01 | 5.28e-01 | 0.5380 | 3.50e-01 | 3.51e-01 | 1.36e-01 | 1.59e-01 | -1.19e-02 | 2.87e-02 | 2.84e-02 | 3.95e-01 | 3.22e-01 | 9.41e-01 |
| EMBRYONIC SKELETAL SYSTEM MORPHOGENESIS | 93 | 1.30e-06 | 5.96e-05 | 0.5380 | 1.18e-01 | 2.05e-01 | 2.87e-01 | 2.55e-01 | 2.95e-01 | 5.00e-02 | 6.25e-04 | 1.78e-06 | 2.19e-05 | 9.01e-07 |
| POSITIVE REGULATION OF GRANULOCYTE DIFFERENTIATION | 9 | 2.51e-01 | 6.58e-01 | 0.5380 | 2.94e-01 | 1.87e-01 | 1.78e-01 | 3.22e-01 | -1.81e-01 | 1.27e-01 | 3.31e-01 | 3.56e-01 | 9.48e-02 | 3.46e-01 |
| NEUTROPHIL DEGRANULATION | 13 | 1.66e-01 | 5.46e-01 | 0.5380 | 2.96e-01 | 3.43e-01 | 1.53e-01 | 1.85e-01 | -1.60e-01 | 6.43e-02 | 3.22e-02 | 3.38e-01 | 2.47e-01 | 3.17e-01 |
| DEOXYRIBONUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 5 | 7.07e-01 | 9.34e-01 | 0.5370 | 2.06e-01 | 1.29e-01 | 3.17e-01 | 3.37e-01 | 1.26e-01 | 4.26e-01 | 6.17e-01 | 2.19e-01 | 1.92e-01 | 6.25e-01 |
| REGULATION OF BRANCHING INVOLVED IN PROSTATE GLAND MORPHOGENESIS | 5 | 4.16e-01 | 7.99e-01 | 0.5370 | -1.17e-01 | -3.57e-02 | 2.74e-01 | 7.36e-02 | 4.40e-01 | 6.50e-01 | 8.90e-01 | 2.89e-01 | 7.76e-01 | 8.87e-02 |
| NEGATIVE REGULATION OF NEUTROPHIL ACTIVATION | 6 | 2.84e-01 | 6.93e-01 | 0.5370 | 2.92e-01 | 2.24e-01 | -7.78e-02 | 1.87e-02 | -3.83e-01 | 2.16e-01 | 3.43e-01 | 7.41e-01 | 9.37e-01 | 1.04e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF ENDOGENOUS PEPTIDE ANTIGEN | 25 | 4.74e-03 | 5.89e-02 | 0.5370 | 1.21e-02 | 1.24e-01 | 3.20e-01 | 2.65e-01 | 3.16e-01 | 9.17e-01 | 2.83e-01 | 5.64e-03 | 2.16e-02 | 6.18e-03 |
| TRANSCRIPTION INITIATION AT RNA POLYMERASE II PROMOTER | 95 | 1.84e-04 | 4.40e-03 | 0.5370 | 2.28e-01 | 2.42e-01 | 2.62e-01 | 2.46e-01 | 2.21e-01 | 1.20e-04 | 4.62e-05 | 1.05e-05 | 3.30e-05 | 2.03e-04 |
| PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 22 | 7.26e-02 | 3.65e-01 | 0.5370 | 1.99e-01 | 2.53e-01 | 2.67e-01 | 3.30e-01 | 6.54e-02 | 1.06e-01 | 3.99e-02 | 2.99e-02 | 7.37e-03 | 5.96e-01 |
| TYPE B PANCREATIC CELL PROLIFERATION | 27 | 6.20e-02 | 3.30e-01 | 0.5370 | 2.25e-01 | 2.74e-01 | 2.63e-01 | 1.69e-01 | 2.55e-01 | 4.30e-02 | 1.38e-02 | 1.82e-02 | 1.29e-01 | 2.18e-02 |
| POSITIVE REGULATION OF MITOCHONDRIAL TRANSLATION | 16 | 4.30e-01 | 8.06e-01 | 0.5360 | 1.63e-01 | 1.97e-01 | 2.91e-01 | 2.53e-01 | 2.72e-01 | 2.60e-01 | 1.72e-01 | 4.38e-02 | 8.01e-02 | 6.00e-02 |
| POSITIVE REGULATION OF HAIR FOLLICLE MATURATION | 5 | 2.54e-01 | 6.60e-01 | 0.5360 | -1.63e-01 | 6.93e-02 | 3.06e-01 | 2.09e-01 | 3.46e-01 | 5.29e-01 | 7.88e-01 | 2.37e-01 | 4.19e-01 | 1.81e-01 |
| AMINE CATABOLIC PROCESS | 15 | 4.62e-01 | 8.25e-01 | 0.5360 | -2.98e-01 | -2.82e-01 | -2.02e-01 | -2.59e-01 | -1.07e-01 | 4.55e-02 | 5.87e-02 | 1.75e-01 | 8.26e-02 | 4.75e-01 |
| REGULATION OF BINDING OF SPERM TO ZONA PELLUCIDA | 5 | 4.23e-01 | 8.03e-01 | 0.5360 | -1.71e-01 | -8.56e-02 | -3.42e-01 | -3.59e-01 | -7.05e-02 | 5.09e-01 | 7.40e-01 | 1.85e-01 | 1.64e-01 | 7.85e-01 |
| REPLICATION BORN DOUBLE STRAND BREAK REPAIR VIA SISTER CHROMATID EXCHANGE | 6 | 8.60e-01 | 9.78e-01 | 0.5360 | 1.86e-01 | 1.95e-01 | 2.53e-01 | 2.54e-01 | 2.93e-01 | 4.30e-01 | 4.07e-01 | 2.83e-01 | 2.82e-01 | 2.13e-01 |
| OXYGEN TRANSPORT | 15 | 5.09e-01 | 8.53e-01 | 0.5360 | -2.83e-01 | -2.87e-01 | -2.37e-01 | -2.23e-01 | -1.38e-01 | 5.81e-02 | 5.42e-02 | 1.12e-01 | 1.35e-01 | 3.53e-01 |
| TYROSINE CATABOLIC PROCESS | 6 | 2.60e-01 | 6.67e-01 | 0.5350 | 2.09e-01 | 2.06e-01 | 2.95e-02 | 3.23e-02 | -4.46e-01 | 3.75e-01 | 3.83e-01 | 9.00e-01 | 8.91e-01 | 5.88e-02 |
| NEGATIVE REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 9 | 2.93e-01 | 7.04e-01 | 0.5350 | 7.86e-02 | 1.50e-01 | 3.47e-01 | 3.13e-01 | 1.97e-01 | 6.83e-01 | 4.37e-01 | 7.15e-02 | 1.03e-01 | 3.07e-01 |
| NEGATIVE REGULATION OF MULTICELLULAR ORGANISM GROWTH | 12 | 2.66e-01 | 6.73e-01 | 0.5340 | 1.78e-01 | 1.01e-01 | 2.81e-01 | 2.29e-01 | 3.35e-01 | 2.87e-01 | 5.45e-01 | 9.18e-02 | 1.70e-01 | 4.44e-02 |
| RESPONSE TO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR | 9 | 3.59e-01 | 7.57e-01 | 0.5340 | 1.02e-01 | 3.02e-01 | 2.61e-01 | 2.03e-01 | 2.72e-01 | 5.96e-01 | 1.17e-01 | 1.75e-01 | 2.91e-01 | 1.57e-01 |
| NEGATIVE REGULATION BY HOST OF VIRAL TRANSCRIPTION | 14 | 1.87e-01 | 5.72e-01 | 0.5340 | 1.49e-01 | 1.34e-01 | 2.25e-01 | 3.20e-01 | 3.03e-01 | 3.36e-01 | 3.85e-01 | 1.45e-01 | 3.81e-02 | 4.95e-02 |
| NEGATIVE REGULATION OF B CELL APOPTOTIC PROCESS | 16 | 4.99e-01 | 8.47e-01 | 0.5330 | 2.13e-01 | 2.23e-01 | 2.78e-01 | 2.92e-01 | 1.62e-01 | 1.40e-01 | 1.22e-01 | 5.42e-02 | 4.31e-02 | 2.61e-01 |
| CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 38 | 2.36e-02 | 1.87e-01 | 0.5330 | 1.33e-01 | 2.30e-01 | 2.92e-01 | 2.30e-01 | 2.74e-01 | 1.57e-01 | 1.41e-02 | 1.82e-03 | 1.40e-02 | 3.46e-03 |
| FUNGIFORM PAPILLA MORPHOGENESIS | 5 | 5.67e-01 | 8.81e-01 | 0.5330 | 3.46e-02 | 8.07e-02 | 3.00e-01 | 3.23e-01 | 2.86e-01 | 8.93e-01 | 7.55e-01 | 2.45e-01 | 2.10e-01 | 2.69e-01 |
| IMMATURE B CELL DIFFERENTIATION | 12 | 1.47e-01 | 5.15e-01 | 0.5330 | 2.58e-01 | 1.47e-01 | 1.59e-01 | 3.55e-01 | 2.10e-01 | 1.22e-01 | 3.77e-01 | 3.41e-01 | 3.31e-02 | 2.07e-01 |
| POSITIVE THYMIC T CELL SELECTION | 14 | 2.20e-03 | 3.28e-02 | 0.5330 | -1.96e-01 | -1.73e-02 | 2.93e-01 | 1.82e-01 | 3.55e-01 | 2.04e-01 | 9.11e-01 | 5.75e-02 | 2.39e-01 | 2.14e-02 |
| B CELL APOPTOTIC PROCESS | 26 | 9.06e-02 | 4.08e-01 | 0.5330 | 2.93e-01 | 2.40e-01 | 1.86e-01 | 2.84e-01 | 1.58e-01 | 9.62e-03 | 3.43e-02 | 1.01e-01 | 1.22e-02 | 1.63e-01 |
| SYNAPTIC TRANSMISSION DOPAMINERGIC | 28 | 7.44e-02 | 3.69e-01 | 0.5330 | 1.77e-01 | 2.34e-01 | 2.71e-01 | 1.82e-01 | 3.01e-01 | 1.06e-01 | 3.18e-02 | 1.29e-02 | 9.46e-02 | 5.86e-03 |
| VESICLE COATING | 38 | 5.88e-02 | 3.20e-01 | 0.5330 | 2.32e-01 | 2.24e-01 | 2.95e-01 | 2.67e-01 | 1.47e-01 | 1.34e-02 | 1.71e-02 | 1.63e-03 | 4.43e-03 | 1.17e-01 |
| GLUCURONATE CATABOLIC PROCESS TO XYLULOSE 5 PHOSPHATE | 5 | 5.02e-01 | 8.48e-01 | 0.5320 | 2.37e-01 | 7.88e-02 | 2.69e-01 | 3.82e-01 | 4.83e-02 | 3.58e-01 | 7.60e-01 | 2.98e-01 | 1.39e-01 | 8.52e-01 |
| SPERM EJACULATION | 5 | 7.70e-01 | 9.56e-01 | 0.5320 | 1.21e-01 | 8.64e-02 | 2.50e-01 | 2.73e-01 | 3.52e-01 | 6.40e-01 | 7.38e-01 | 3.33e-01 | 2.90e-01 | 1.73e-01 |
| POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 7 | 4.62e-02 | 2.81e-01 | 0.5320 | -3.73e-01 | -1.91e-01 | 4.90e-02 | 5.86e-02 | 3.18e-01 | 8.73e-02 | 3.82e-01 | 8.22e-01 | 7.88e-01 | 1.45e-01 |
| CELLULAR RESPONSE TO ACIDIC PH | 16 | 8.30e-03 | 8.95e-02 | 0.5320 | -3.09e-01 | -1.27e-01 | -1.01e-01 | -3.33e-01 | 2.23e-01 | 3.23e-02 | 3.78e-01 | 4.86e-01 | 2.09e-02 | 1.23e-01 |
| NEGATIVE REGULATION OF MESENCHYMAL CELL APOPTOTIC PROCESS | 10 | 2.66e-01 | 6.73e-01 | 0.5320 | 1.51e-02 | 8.48e-02 | 2.59e-01 | 1.20e-01 | 4.40e-01 | 9.34e-01 | 6.43e-01 | 1.57e-01 | 5.11e-01 | 1.59e-02 |
| VITAMIN B6 METABOLIC PROCESS | 5 | 6.78e-01 | 9.28e-01 | 0.5310 | 1.02e-01 | 2.78e-01 | 3.57e-01 | 2.15e-01 | 1.45e-01 | 6.93e-01 | 2.81e-01 | 1.67e-01 | 4.05e-01 | 5.75e-01 |
| BEHAVIORAL RESPONSE TO NICOTINE | 9 | 1.11e-01 | 4.54e-01 | 0.5310 | 4.03e-02 | 2.96e-01 | 3.66e-01 | 2.14e-01 | 1.17e-01 | 8.34e-01 | 1.24e-01 | 5.74e-02 | 2.67e-01 | 5.44e-01 |
| SISTER CHROMATID SEGREGATION | 221 | 1.27e-12 | 1.31e-10 | 0.5310 | 2.34e-01 | 1.95e-01 | 2.51e-01 | 3.05e-01 | 1.83e-01 | 2.17e-09 | 6.05e-07 | 1.17e-10 | 5.50e-15 | 2.85e-06 |
| ACETYLCHOLINE SECRETION | 5 | 1.45e-01 | 5.11e-01 | 0.5310 | -3.10e-01 | -2.01e-02 | 2.60e-01 | 6.18e-02 | 3.37e-01 | 2.30e-01 | 9.38e-01 | 3.13e-01 | 8.11e-01 | 1.92e-01 |
| METANEPHRIC PART OF URETERIC BUD DEVELOPMENT | 6 | 8.34e-01 | 9.73e-01 | 0.5310 | 2.13e-01 | 1.72e-01 | 2.66e-01 | 3.23e-01 | 1.78e-01 | 3.67e-01 | 4.66e-01 | 2.59e-01 | 1.70e-01 | 4.51e-01 |
| NEGATIVE REGULATION OF ATP DEPENDENT ACTIVITY | 17 | 2.93e-01 | 7.04e-01 | 0.5310 | 2.51e-01 | 3.13e-01 | 2.19e-01 | 2.66e-01 | 4.55e-02 | 7.31e-02 | 2.55e-02 | 1.18e-01 | 5.79e-02 | 7.46e-01 |
| TRIGLYCERIDE RICH LIPOPROTEIN PARTICLE REMODELING | 12 | 2.54e-04 | 5.64e-03 | 0.5310 | -3.09e-01 | 9.56e-02 | -8.94e-02 | -3.35e-01 | -2.38e-01 | 6.36e-02 | 5.66e-01 | 5.92e-01 | 4.45e-02 | 1.54e-01 |
| COPPER ION HOMEOSTASIS | 17 | 2.40e-01 | 6.44e-01 | 0.5300 | 3.11e-01 | 2.47e-01 | 2.58e-01 | 2.10e-01 | 1.14e-01 | 2.63e-02 | 7.79e-02 | 6.55e-02 | 1.35e-01 | 4.14e-01 |
| MAST CELL CHEMOTAXIS | 10 | 5.71e-01 | 8.83e-01 | 0.5300 | 1.30e-01 | 1.37e-01 | 2.77e-01 | 2.54e-01 | 3.23e-01 | 4.76e-01 | 4.52e-01 | 1.29e-01 | 1.65e-01 | 7.69e-02 |
| POLE PLASM ASSEMBLY | 6 | 6.90e-01 | 9.31e-01 | 0.5300 | -1.27e-01 | -2.00e-01 | -2.15e-01 | -1.89e-01 | -3.79e-01 | 5.90e-01 | 3.97e-01 | 3.63e-01 | 4.23e-01 | 1.08e-01 |
| NEUTROPHIL MEDIATED CYTOTOXICITY | 14 | 1.61e-01 | 5.36e-01 | 0.5300 | 2.99e-01 | 3.09e-01 | 1.32e-01 | 2.53e-01 | -1.24e-01 | 5.30e-02 | 4.54e-02 | 3.93e-01 | 1.02e-01 | 4.22e-01 |
| CRANIAL NERVE FORMATION | 10 | 3.64e-01 | 7.64e-01 | 0.5300 | 2.43e-01 | 2.69e-01 | 2.16e-01 | 1.39e-01 | 2.88e-01 | 1.83e-01 | 1.40e-01 | 2.36e-01 | 4.45e-01 | 1.15e-01 |
| RETROTRANSPOSON SILENCING BY HETEROCHROMATIN FORMATION | 15 | 1.79e-01 | 5.63e-01 | 0.5300 | -7.02e-02 | -2.11e-01 | -2.91e-01 | -2.54e-01 | -2.87e-01 | 6.38e-01 | 1.57e-01 | 5.13e-02 | 8.89e-02 | 5.40e-02 |
| REGULATION OF LEUKOCYTE ADHESION TO ARTERIAL ENDOTHELIAL CELL | 5 | 2.20e-01 | 6.17e-01 | 0.5290 | 4.14e-01 | 2.30e-01 | 8.24e-02 | 4.32e-02 | -2.16e-01 | 1.09e-01 | 3.73e-01 | 7.50e-01 | 8.67e-01 | 4.02e-01 |
| REGULATION OF GAMMA DELTA T CELL DIFFERENTIATION | 9 | 4.75e-01 | 8.32e-01 | 0.5290 | 1.24e-01 | 2.01e-01 | 3.56e-01 | 2.56e-01 | 1.78e-01 | 5.19e-01 | 2.96e-01 | 6.45e-02 | 1.83e-01 | 3.54e-01 |
| HIGH DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 17 | 1.43e-03 | 2.33e-02 | 0.5290 | -1.60e-01 | 5.44e-02 | -2.25e-01 | -2.31e-01 | -3.84e-01 | 2.54e-01 | 6.98e-01 | 1.08e-01 | 9.90e-02 | 6.16e-03 |
| CELLULAR RESPONSE TO GAMMA RADIATION | 26 | 6.69e-02 | 3.45e-01 | 0.5290 | 1.65e-01 | 1.55e-01 | 2.93e-01 | 3.15e-01 | 2.06e-01 | 1.45e-01 | 1.70e-01 | 9.62e-03 | 5.40e-03 | 6.87e-02 |
| LATE ENDOSOME TO VACUOLE TRANSPORT | 36 | 5.82e-02 | 3.19e-01 | 0.5290 | 2.12e-01 | 1.91e-01 | 2.90e-01 | 2.52e-01 | 2.24e-01 | 2.78e-02 | 4.78e-02 | 2.56e-03 | 8.76e-03 | 2.02e-02 |
| SEROTONIN METABOLIC PROCESS | 10 | 5.72e-01 | 8.83e-01 | 0.5290 | -3.14e-01 | -3.12e-01 | -1.86e-01 | -2.16e-01 | 4.26e-02 | 8.56e-02 | 8.71e-02 | 3.09e-01 | 2.36e-01 | 8.16e-01 |
| B CELL LINEAGE COMMITMENT | 6 | 6.41e-01 | 9.14e-01 | 0.5290 | 1.91e-01 | 2.00e-01 | 2.28e-01 | 3.66e-01 | 1.29e-01 | 4.17e-01 | 3.95e-01 | 3.32e-01 | 1.21e-01 | 5.85e-01 |
| REGULATION OF PLASMINOGEN ACTIVATION | 18 | 1.23e-01 | 4.78e-01 | 0.5280 | 3.13e-01 | 3.36e-01 | 1.74e-01 | 1.78e-01 | -7.98e-02 | 2.16e-02 | 1.35e-02 | 2.01e-01 | 1.91e-01 | 5.58e-01 |
| V D J RECOMBINATION | 19 | 5.04e-02 | 2.93e-01 | 0.5280 | 1.01e-01 | 7.48e-02 | 2.68e-01 | 3.12e-01 | 3.07e-01 | 4.47e-01 | 5.72e-01 | 4.31e-02 | 1.87e-02 | 2.04e-02 |
| SERTOLI CELL DIFFERENTIATION | 17 | 4.86e-01 | 8.38e-01 | 0.5280 | 2.15e-01 | 2.07e-01 | 2.71e-01 | 2.51e-01 | 2.30e-01 | 1.25e-01 | 1.39e-01 | 5.28e-02 | 7.28e-02 | 1.01e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRIAL MEMBRANE | 37 | 5.59e-03 | 6.68e-02 | 0.5280 | 1.70e-01 | 1.08e-01 | 2.70e-01 | 2.53e-01 | 3.18e-01 | 7.42e-02 | 2.56e-01 | 4.46e-03 | 7.65e-03 | 8.24e-04 |
| GLANDULAR EPITHELIAL CELL MATURATION | 9 | 3.44e-01 | 7.50e-01 | 0.5280 | 2.01e-01 | 3.55e-01 | 2.05e-01 | 2.46e-01 | 9.91e-02 | 2.96e-01 | 6.54e-02 | 2.88e-01 | 2.01e-01 | 6.07e-01 |
| REGULATION OF MITOCHONDRIAL TRANSLATION | 25 | 1.55e-01 | 5.26e-01 | 0.5280 | 2.61e-01 | 1.89e-01 | 2.74e-01 | 2.76e-01 | 1.52e-01 | 2.38e-02 | 1.01e-01 | 1.79e-02 | 1.68e-02 | 1.88e-01 |
| AMYLOID BETA CLEARANCE BY TRANSCYTOSIS | 7 | 4.31e-01 | 8.06e-01 | 0.5270 | 1.48e-01 | 1.25e-01 | 2.69e-01 | 3.82e-01 | 1.51e-01 | 4.99e-01 | 5.67e-01 | 2.17e-01 | 8.05e-02 | 4.90e-01 |
| LATE ENDOSOME TO VACUOLE TRANSPORT VIA MULTIVESICULAR BODY SORTING PATHWAY | 26 | 6.83e-02 | 3.51e-01 | 0.5270 | 2.01e-01 | 1.31e-01 | 2.60e-01 | 2.65e-01 | 2.87e-01 | 7.56e-02 | 2.46e-01 | 2.16e-02 | 1.91e-02 | 1.14e-02 |
| REGULATION OF TESTOSTERONE BIOSYNTHETIC PROCESS | 7 | 8.23e-01 | 9.71e-01 | 0.5270 | -1.45e-01 | -1.94e-01 | -2.93e-01 | -2.37e-01 | -2.78e-01 | 5.07e-01 | 3.74e-01 | 1.80e-01 | 2.77e-01 | 2.03e-01 |
| COMPLEMENT RECEPTOR MEDIATED SIGNALING PATHWAY | 12 | 3.03e-03 | 4.19e-02 | 0.5270 | -1.94e-02 | -7.43e-02 | -4.12e-01 | -3.00e-01 | -1.07e-01 | 9.08e-01 | 6.56e-01 | 1.35e-02 | 7.16e-02 | 5.20e-01 |
| POSITIVE REGULATION OF CHROMOSOME CONDENSATION | 8 | 7.94e-01 | 9.65e-01 | 0.5270 | 1.96e-01 | 1.83e-01 | 2.72e-01 | 2.95e-01 | 2.11e-01 | 3.36e-01 | 3.71e-01 | 1.83e-01 | 1.49e-01 | 3.02e-01 |
| POSITIVE REGULATION OF PLATELET AGGREGATION | 11 | 2.99e-01 | 7.11e-01 | 0.5260 | 2.91e-01 | 2.49e-01 | 1.49e-01 | 3.15e-01 | -8.96e-02 | 9.43e-02 | 1.53e-01 | 3.91e-01 | 7.06e-02 | 6.07e-01 |
| CARDIAC RIGHT VENTRICLE MORPHOGENESIS | 21 | 1.05e-01 | 4.42e-01 | 0.5260 | 8.90e-02 | 1.45e-01 | 3.16e-01 | 2.37e-01 | 3.02e-01 | 4.80e-01 | 2.52e-01 | 1.22e-02 | 6.01e-02 | 1.65e-02 |
| REGULATION OF THYROID HORMONE GENERATION | 7 | 4.51e-01 | 8.21e-01 | 0.5260 | 1.00e-01 | 3.34e-01 | 3.07e-01 | 1.53e-01 | 1.92e-01 | 6.46e-01 | 1.26e-01 | 1.59e-01 | 4.85e-01 | 3.79e-01 |
| ANGIOGENESIS INVOLVED IN CORONARY VASCULAR MORPHOGENESIS | 5 | 7.96e-01 | 9.65e-01 | 0.5250 | -1.82e-01 | -1.09e-01 | -2.39e-01 | -2.39e-01 | -3.41e-01 | 4.81e-01 | 6.74e-01 | 3.55e-01 | 3.54e-01 | 1.87e-01 |
| REGULATION OF ENTRY OF BACTERIUM INTO HOST CELL | 7 | 3.08e-01 | 7.19e-01 | 0.5250 | -1.38e-01 | -1.66e-01 | -3.14e-01 | -3.61e-01 | -1.95e-02 | 5.28e-01 | 4.47e-01 | 1.50e-01 | 9.82e-02 | 9.29e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 34 | 2.72e-02 | 2.04e-01 | 0.5250 | 1.73e-01 | 2.32e-01 | 2.42e-01 | 2.95e-01 | 2.15e-01 | 8.02e-02 | 1.94e-02 | 1.47e-02 | 2.93e-03 | 2.98e-02 |
| BRONCHIOLE DEVELOPMENT | 5 | 4.87e-01 | 8.38e-01 | 0.5250 | -3.11e-01 | -2.85e-01 | -2.88e-01 | -1.04e-01 | -5.87e-02 | 2.28e-01 | 2.70e-01 | 2.64e-01 | 6.87e-01 | 8.20e-01 |
| MITOCHONDRIAL TRANSMEMBRANE TRANSPORT | 59 | 7.40e-03 | 8.24e-02 | 0.5240 | 2.81e-01 | 2.47e-01 | 2.55e-01 | 2.43e-01 | 1.03e-01 | 1.88e-04 | 1.04e-03 | 6.95e-04 | 1.22e-03 | 1.71e-01 |
| MAINTENANCE OF PROTEIN LOCATION IN EXTRACELLULAR REGION | 8 | 7.10e-01 | 9.35e-01 | 0.5240 | -2.68e-01 | -1.81e-01 | -2.31e-01 | -2.48e-01 | -2.36e-01 | 1.89e-01 | 3.75e-01 | 2.59e-01 | 2.24e-01 | 2.49e-01 |
| THYMOCYTE MIGRATION | 7 | 2.33e-01 | 6.36e-01 | 0.5240 | -2.51e-01 | -8.83e-02 | -1.54e-01 | -1.76e-01 | -3.87e-01 | 2.50e-01 | 6.86e-01 | 4.82e-01 | 4.20e-01 | 7.64e-02 |
| REGULATION OF ADHERENS JUNCTION ORGANIZATION | 5 | 2.38e-01 | 6.41e-01 | 0.5240 | 3.58e-01 | 1.71e-01 | 2.67e-02 | 2.36e-01 | 2.47e-01 | 1.65e-01 | 5.09e-01 | 9.18e-01 | 3.61e-01 | 3.39e-01 |
| NEGATIVE REGULATION OF KERATINOCYTE DIFFERENTIATION | 9 | 6.84e-01 | 9.30e-01 | 0.5240 | -2.93e-01 | -2.87e-01 | -2.17e-01 | -1.93e-01 | -1.49e-01 | 1.28e-01 | 1.36e-01 | 2.59e-01 | 3.17e-01 | 4.39e-01 |
| NEGATIVE REGULATION OF RECEPTOR RECYCLING | 5 | 3.55e-01 | 7.55e-01 | 0.5240 | -2.36e-02 | -1.31e-01 | 1.61e-01 | 2.15e-01 | 4.29e-01 | 9.27e-01 | 6.11e-01 | 5.33e-01 | 4.05e-01 | 9.63e-02 |
| ANAGEN | 5 | 4.74e-01 | 8.31e-01 | 0.5240 | -2.48e-01 | -3.52e-01 | -2.80e-01 | -5.30e-02 | -8.81e-02 | 3.37e-01 | 1.73e-01 | 2.79e-01 | 8.37e-01 | 7.33e-01 |
| ENDOTHELIAL CELL ACTIVATION | 11 | 1.28e-01 | 4.85e-01 | 0.5230 | 2.69e-01 | 2.26e-01 | 1.19e-01 | 3.09e-01 | -2.03e-01 | 1.23e-01 | 1.95e-01 | 4.94e-01 | 7.57e-02 | 2.44e-01 |
| POSITIVE REGULATION OF MACROPHAGE DERIVED FOAM CELL DIFFERENTIATION | 19 | 2.10e-01 | 6.05e-01 | 0.5230 | -1.98e-01 | -1.50e-01 | -3.01e-01 | -2.75e-01 | -2.13e-01 | 1.35e-01 | 2.57e-01 | 2.30e-02 | 3.76e-02 | 1.08e-01 |
| RETROGRADE TRANS SYNAPTIC SIGNALING | 10 | 6.99e-01 | 9.31e-01 | 0.5230 | -2.28e-01 | -1.93e-01 | -2.91e-01 | -2.70e-01 | -1.62e-01 | 2.12e-01 | 2.89e-01 | 1.11e-01 | 1.39e-01 | 3.76e-01 |
| POSITIVE REGULATION OF OPSONIZATION | 8 | 4.36e-01 | 8.09e-01 | 0.5230 | -2.25e-01 | -1.78e-01 | -1.83e-01 | -3.66e-01 | -1.54e-01 | 2.71e-01 | 3.83e-01 | 3.69e-01 | 7.31e-02 | 4.51e-01 |
| REGULATION OF INTESTINAL LIPID ABSORPTION | 10 | 3.71e-02 | 2.49e-01 | 0.5230 | -1.14e-01 | 4.65e-02 | -2.51e-01 | -3.78e-01 | -2.29e-01 | 5.32e-01 | 7.99e-01 | 1.70e-01 | 3.86e-02 | 2.10e-01 |
| SNRNA TRANSCRIPTION BY RNA POLYMERASE III | 8 | 6.83e-01 | 9.30e-01 | 0.5230 | 3.35e-01 | 2.40e-01 | 2.12e-01 | 2.24e-01 | 9.00e-02 | 1.00e-01 | 2.40e-01 | 2.99e-01 | 2.73e-01 | 6.59e-01 |
| NEURAL CREST CELL FATE COMMITMENT | 6 | 4.08e-01 | 7.94e-01 | 0.5230 | 1.08e-01 | 3.49e-01 | 2.34e-01 | 1.02e-01 | 2.73e-01 | 6.48e-01 | 1.39e-01 | 3.20e-01 | 6.64e-01 | 2.47e-01 |
| T FOLLICULAR HELPER CELL DIFFERENTIATION | 7 | 4.96e-01 | 8.45e-01 | 0.5230 | -1.18e-01 | -2.54e-01 | -2.87e-01 | -8.74e-02 | -3.23e-01 | 5.87e-01 | 2.44e-01 | 1.88e-01 | 6.89e-01 | 1.39e-01 |
| REGULATION OF HISTONE DEACETYLATION | 5 | 4.57e-01 | 8.22e-01 | 0.5230 | 1.17e-01 | 6.39e-02 | 1.88e-01 | 3.74e-01 | 2.82e-01 | 6.51e-01 | 8.05e-01 | 4.66e-01 | 1.47e-01 | 2.74e-01 |
| GLYCOLIPID TRANSPORT | 8 | 6.58e-01 | 9.20e-01 | 0.5230 | 1.86e-01 | 2.87e-01 | 2.27e-01 | 2.63e-01 | 1.87e-01 | 3.63e-01 | 1.59e-01 | 2.65e-01 | 1.98e-01 | 3.59e-01 |
| NEPHRIC DUCT DEVELOPMENT | 14 | 5.55e-01 | 8.77e-01 | 0.5220 | 1.77e-01 | 1.91e-01 | 2.75e-01 | 2.39e-01 | 2.69e-01 | 2.51e-01 | 2.15e-01 | 7.49e-02 | 1.22e-01 | 8.14e-02 |
| DTTP METABOLIC PROCESS | 5 | 2.82e-01 | 6.93e-01 | 0.5220 | 1.62e-01 | -6.74e-02 | 1.31e-01 | 3.02e-01 | 3.66e-01 | 5.30e-01 | 7.94e-01 | 6.11e-01 | 2.43e-01 | 1.57e-01 |
| MEMBRANE DEPOLARIZATION DURING AV NODE CELL ACTION POTENTIAL | 6 | 1.58e-01 | 5.30e-01 | 0.5220 | -4.26e-01 | -1.18e-01 | 1.43e-02 | -2.70e-01 | 6.42e-02 | 7.09e-02 | 6.17e-01 | 9.52e-01 | 2.51e-01 | 7.85e-01 |
| REGULATION OF CENTRIOLE REPLICATION | 23 | 2.57e-01 | 6.64e-01 | 0.5220 | 2.12e-01 | 1.86e-01 | 2.51e-01 | 2.88e-01 | 2.16e-01 | 7.78e-02 | 1.23e-01 | 3.73e-02 | 1.67e-02 | 7.24e-02 |
| SUCCINYL COA CATABOLIC PROCESS | 6 | 6.71e-01 | 9.25e-01 | 0.5220 | 2.90e-01 | 2.27e-01 | 2.97e-01 | 2.19e-01 | 2.72e-02 | 2.19e-01 | 3.35e-01 | 2.08e-01 | 3.52e-01 | 9.08e-01 |
| REGULATION OF MEMBRANE REPOLARIZATION DURING ACTION POTENTIAL | 9 | 4.23e-01 | 8.03e-01 | 0.5220 | -2.66e-01 | -1.17e-01 | -2.35e-01 | -3.47e-01 | -1.11e-01 | 1.68e-01 | 5.44e-01 | 2.21e-01 | 7.15e-02 | 5.65e-01 |
| MITOTIC CELL CYCLE CHECKPOINT SIGNALING | 139 | 3.97e-09 | 2.67e-07 | 0.5220 | 2.01e-01 | 1.77e-01 | 2.51e-01 | 3.21e-01 | 1.85e-01 | 4.11e-05 | 3.16e-04 | 3.19e-07 | 6.26e-11 | 1.67e-04 |
| EPITHELIAL TUBE BRANCHING INVOLVED IN LUNG MORPHOGENESIS | 30 | 1.21e-01 | 4.73e-01 | 0.5220 | 1.98e-01 | 2.55e-01 | 2.45e-01 | 2.69e-01 | 1.88e-01 | 6.06e-02 | 1.56e-02 | 2.04e-02 | 1.06e-02 | 7.41e-02 |
| UBIQUITIN DEPENDENT ERAD PATHWAY | 82 | 4.79e-04 | 9.77e-03 | 0.5220 | 1.95e-01 | 2.34e-01 | 2.48e-01 | 2.58e-01 | 2.26e-01 | 2.32e-03 | 2.46e-04 | 1.06e-04 | 5.18e-05 | 3.91e-04 |
| POSITIVE REGULATION OF NECROPTOTIC PROCESS | 7 | 3.26e-02 | 2.29e-01 | 0.5220 | 2.05e-02 | -3.04e-01 | -2.94e-01 | 9.99e-02 | -2.87e-01 | 9.25e-01 | 1.64e-01 | 1.77e-01 | 6.47e-01 | 1.89e-01 |
| MITOTIC DNA INTEGRITY CHECKPOINT SIGNALING | 84 | 7.58e-05 | 2.21e-03 | 0.5210 | 2.11e-01 | 2.01e-01 | 2.57e-01 | 3.16e-01 | 1.46e-01 | 8.40e-04 | 1.44e-03 | 4.66e-05 | 5.72e-07 | 2.05e-02 |
| INTRACILIARY TRANSPORT INVOLVED IN CILIUM ASSEMBLY | 6 | 8.86e-01 | 9.80e-01 | 0.5210 | -2.00e-01 | -2.67e-01 | -2.95e-01 | -2.40e-01 | -1.25e-01 | 3.95e-01 | 2.57e-01 | 2.11e-01 | 3.09e-01 | 5.94e-01 |
| ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 14 | 2.47e-01 | 6.53e-01 | 0.5210 | 3.33e-01 | 2.37e-01 | 1.36e-01 | 2.83e-01 | 7.69e-02 | 3.09e-02 | 1.25e-01 | 3.78e-01 | 6.67e-02 | 6.18e-01 |
| MELANOCYTE DIFFERENTIATION | 24 | 1.52e-01 | 5.21e-01 | 0.5210 | -2.03e-01 | -2.60e-01 | -3.08e-01 | -2.44e-01 | -9.03e-02 | 8.45e-02 | 2.75e-02 | 8.99e-03 | 3.88e-02 | 4.44e-01 |
| REGULATION OF DEFENSE RESPONSE TO FUNGUS | 5 | 2.37e-01 | 6.40e-01 | 0.5210 | 3.56e-01 | 1.39e-01 | -1.69e-01 | 4.32e-02 | -3.08e-01 | 1.68e-01 | 5.92e-01 | 5.13e-01 | 8.67e-01 | 2.34e-01 |
| ENDOTHELIN RECEPTOR SIGNALING PATHWAY | 10 | 2.59e-01 | 6.65e-01 | 0.5210 | 4.35e-02 | 1.51e-01 | 2.49e-01 | 2.83e-01 | 3.23e-01 | 8.12e-01 | 4.08e-01 | 1.73e-01 | 1.21e-01 | 7.69e-02 |
| REGULATION OF LYMPHOCYTE CHEMOTAXIS | 26 | 2.84e-02 | 2.09e-01 | 0.5210 | -1.31e-01 | -1.02e-01 | -2.39e-01 | -2.06e-01 | -3.80e-01 | 2.49e-01 | 3.69e-01 | 3.51e-02 | 6.97e-02 | 7.91e-04 |
| REGULATION OF MESODERMAL CELL DIFFERENTIATION | 9 | 2.84e-01 | 6.93e-01 | 0.5210 | 1.60e-02 | 1.54e-01 | 2.11e-01 | 9.75e-02 | 4.40e-01 | 9.34e-01 | 4.25e-01 | 2.73e-01 | 6.12e-01 | 2.24e-02 |
| REGULATION OF RNA POLYMERASE II REGULATORY REGION SEQUENCE SPECIFIC DNA BINDING | 8 | 5.57e-01 | 8.77e-01 | 0.5210 | 5.02e-02 | 1.44e-01 | 3.17e-01 | 2.30e-01 | 3.08e-01 | 8.06e-01 | 4.79e-01 | 1.21e-01 | 2.61e-01 | 1.32e-01 |
| GROWTH PLATE CARTILAGE DEVELOPMENT | 20 | 1.40e-01 | 5.04e-01 | 0.5210 | 1.11e-01 | 2.43e-01 | 2.99e-01 | 1.67e-01 | 2.87e-01 | 3.91e-01 | 6.00e-02 | 2.08e-02 | 1.95e-01 | 2.60e-02 |
| POSITIVE REGULATION OF BLOOD BRAIN BARRIER PERMEABILITY | 5 | 8.62e-01 | 9.78e-01 | 0.5200 | -2.02e-01 | -2.17e-01 | -2.89e-01 | -1.75e-01 | -2.63e-01 | 4.35e-01 | 4.02e-01 | 2.63e-01 | 4.98e-01 | 3.08e-01 |
| G PROTEIN COUPLED GLUTAMATE RECEPTOR SIGNALING PATHWAY | 14 | 2.42e-01 | 6.47e-01 | 0.5200 | -3.32e-01 | -1.77e-01 | -1.75e-01 | -2.84e-01 | -1.32e-01 | 3.13e-02 | 2.51e-01 | 2.56e-01 | 6.60e-02 | 3.92e-01 |
| MITOCHONDRIAL RNA METABOLIC PROCESS | 51 | 6.45e-03 | 7.44e-02 | 0.5200 | 2.04e-01 | 1.60e-01 | 2.52e-01 | 2.69e-01 | 2.60e-01 | 1.18e-02 | 4.83e-02 | 1.88e-03 | 9.04e-04 | 1.29e-03 |
| HEMIDESMOSOME ASSEMBLY | 6 | 8.27e-01 | 9.72e-01 | 0.5200 | -2.86e-01 | -2.50e-01 | -2.19e-01 | -1.97e-01 | -1.97e-01 | 2.25e-01 | 2.88e-01 | 3.53e-01 | 4.03e-01 | 4.03e-01 |
| NEGATIVE REGULATION OF HAIR FOLLICLE DEVELOPMENT | 5 | 2.83e-01 | 6.93e-01 | 0.5200 | 7.23e-02 | 2.86e-01 | 3.20e-01 | 2.76e-01 | -6.97e-02 | 7.79e-01 | 2.68e-01 | 2.16e-01 | 2.86e-01 | 7.87e-01 |
| MODULATION BY VIRUS OF HOST PROCESS | 7 | 6.06e-01 | 9.01e-01 | 0.5200 | 3.02e-01 | 1.38e-01 | 2.15e-01 | 3.28e-01 | 7.64e-02 | 1.66e-01 | 5.27e-01 | 3.25e-01 | 1.33e-01 | 7.26e-01 |
| CELL PROLIFERATION IN HINDBRAIN | 16 | 4.47e-01 | 8.17e-01 | 0.5200 | 2.02e-01 | 2.13e-01 | 3.04e-01 | 2.31e-01 | 1.95e-01 | 1.62e-01 | 1.40e-01 | 3.52e-02 | 1.10e-01 | 1.76e-01 |
| BRANCHED CHAIN AMINO ACID BIOSYNTHETIC PROCESS | 5 | 1.28e-01 | 4.86e-01 | 0.5200 | 7.36e-02 | 1.46e-01 | 1.05e-01 | 3.63e-01 | 3.17e-01 | 7.76e-01 | 5.72e-01 | 6.85e-01 | 1.59e-01 | 2.20e-01 |
| PEPTIDYL ARGININE MODIFICATION | 10 | 8.99e-02 | 4.06e-01 | 0.5200 | -1.57e-01 | -1.55e-01 | 1.14e-01 | 4.99e-02 | 4.54e-01 | 3.91e-01 | 3.96e-01 | 5.32e-01 | 7.85e-01 | 1.30e-02 |
| CENTROMERIC SISTER CHROMATID COHESION | 10 | 1.85e-01 | 5.72e-01 | 0.5190 | 1.10e-01 | 9.81e-02 | 2.32e-01 | 3.66e-01 | 2.46e-01 | 5.46e-01 | 5.91e-01 | 2.05e-01 | 4.51e-02 | 1.78e-01 |
| ENDODERMAL CELL FATE COMMITMENT | 15 | 3.03e-01 | 7.15e-01 | 0.5190 | 2.38e-01 | 1.86e-01 | 1.92e-01 | 3.00e-01 | 2.26e-01 | 1.10e-01 | 2.12e-01 | 1.98e-01 | 4.41e-02 | 1.30e-01 |
| HIPPOCAMPAL NEURON APOPTOTIC PROCESS | 6 | 4.24e-01 | 8.03e-01 | 0.5190 | 3.71e-01 | 2.90e-01 | 1.09e-01 | 1.41e-01 | 1.25e-01 | 1.15e-01 | 2.19e-01 | 6.45e-01 | 5.49e-01 | 5.97e-01 |
| POSITIVE REGULATION OF CALCIUM ION IMPORT ACROSS PLASMA MEMBRANE | 11 | 4.94e-01 | 8.44e-01 | 0.5190 | -2.27e-01 | -2.93e-01 | -2.21e-01 | -1.68e-01 | -2.34e-01 | 1.92e-01 | 9.27e-02 | 2.05e-01 | 3.35e-01 | 1.78e-01 |
| PURINE RIBONUCLEOTIDE SALVAGE | 7 | 6.42e-01 | 9.14e-01 | 0.5180 | 3.60e-01 | 2.77e-01 | 1.68e-01 | 1.85e-01 | 6.55e-04 | 9.91e-02 | 2.04e-01 | 4.41e-01 | 3.98e-01 | 9.98e-01 |
| C TERMINAL PROTEIN AMINO ACID MODIFICATION | 12 | 5.84e-01 | 8.90e-01 | 0.5180 | -1.67e-01 | -2.45e-01 | -3.07e-01 | -2.47e-01 | -1.59e-01 | 3.17e-01 | 1.41e-01 | 6.56e-02 | 1.38e-01 | 3.41e-01 |
| PURINE RIBONUCLEOSIDE SALVAGE | 6 | 3.90e-01 | 7.82e-01 | 0.5180 | 3.74e-01 | 3.31e-01 | 7.50e-02 | 1.15e-01 | 3.31e-03 | 1.13e-01 | 1.60e-01 | 7.51e-01 | 6.26e-01 | 9.89e-01 |
| MULTINUCLEAR OSTEOCLAST DIFFERENTIATION | 8 | 7.31e-01 | 9.44e-01 | 0.5180 | 2.91e-01 | 2.38e-01 | 1.87e-01 | 3.03e-01 | 2.20e-02 | 1.54e-01 | 2.44e-01 | 3.58e-01 | 1.38e-01 | 9.14e-01 |
| CAMP METABOLIC PROCESS | 23 | 1.91e-01 | 5.78e-01 | 0.5180 | -2.06e-01 | -1.65e-01 | -2.60e-01 | -3.07e-01 | -1.93e-01 | 8.79e-02 | 1.72e-01 | 3.09e-02 | 1.08e-02 | 1.10e-01 |
| REGULATION OF LIGASE ACTIVITY | 7 | 3.58e-01 | 7.57e-01 | 0.5180 | 1.78e-02 | 2.53e-02 | 3.21e-01 | 1.76e-01 | 3.65e-01 | 9.35e-01 | 9.08e-01 | 1.42e-01 | 4.19e-01 | 9.42e-02 |
| NEGATIVE REGULATION OF MONOCYTE CHEMOTAXIS | 6 | 5.53e-01 | 8.76e-01 | 0.5180 | 3.37e-01 | 2.91e-01 | 1.98e-01 | 1.34e-01 | -1.14e-01 | 1.53e-01 | 2.17e-01 | 4.02e-01 | 5.69e-01 | 6.28e-01 |
| FUSED ANTRUM STAGE | 6 | 4.37e-01 | 8.09e-01 | 0.5180 | -1.36e-01 | -3.52e-01 | -3.16e-01 | -1.59e-01 | -1.35e-02 | 5.64e-01 | 1.36e-01 | 1.79e-01 | 5.00e-01 | 9.54e-01 |
| WYBUTOSINE METABOLIC PROCESS | 6 | 5.26e-01 | 8.60e-01 | 0.5170 | 2.21e-01 | 3.15e-01 | 1.63e-01 | 2.96e-01 | 7.48e-02 | 3.49e-01 | 1.81e-01 | 4.89e-01 | 2.09e-01 | 7.51e-01 |
| CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 26 | 1.93e-01 | 5.80e-01 | 0.5170 | 1.75e-01 | 2.18e-01 | 2.68e-01 | 2.09e-01 | 2.72e-01 | 1.23e-01 | 5.43e-02 | 1.78e-02 | 6.52e-02 | 1.64e-02 |
| T HELPER 1 CELL DIFFERENTIATION | 23 | 9.62e-03 | 9.89e-02 | 0.5170 | 3.31e-01 | 2.90e-01 | 9.33e-02 | 2.42e-01 | 8.19e-02 | 6.04e-03 | 1.61e-02 | 4.38e-01 | 4.43e-02 | 4.97e-01 |
| SPHINGOMYELIN BIOSYNTHETIC PROCESS | 11 | 1.13e-01 | 4.58e-01 | 0.5170 | 3.76e-01 | 1.55e-01 | 6.59e-02 | 2.64e-01 | -1.67e-01 | 3.07e-02 | 3.74e-01 | 7.05e-01 | 1.29e-01 | 3.39e-01 |
| POSITIVE REGULATION OF CELL GROWTH INVOLVED IN CARDIAC MUSCLE CELL DEVELOPMENT | 8 | 1.52e-01 | 5.20e-01 | 0.5170 | 5.34e-02 | 3.10e-01 | 3.67e-01 | 1.57e-01 | 9.61e-02 | 7.94e-01 | 1.29e-01 | 7.21e-02 | 4.42e-01 | 6.38e-01 |
| REGULATION OF UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 13 | 1.88e-01 | 5.73e-01 | 0.5170 | 3.39e-01 | 2.18e-01 | 2.15e-01 | 2.23e-01 | -9.28e-02 | 3.41e-02 | 1.73e-01 | 1.80e-01 | 1.64e-01 | 5.62e-01 |
| HIGH DENSITY LIPOPROTEIN PARTICLE ASSEMBLY | 13 | 1.44e-02 | 1.31e-01 | 0.5170 | -2.92e-01 | -8.65e-03 | -2.02e-01 | -3.10e-01 | -2.11e-01 | 6.79e-02 | 9.57e-01 | 2.07e-01 | 5.30e-02 | 1.87e-01 |
| MIDBRAIN DOPAMINERGIC NEURON DIFFERENTIATION | 17 | 3.80e-01 | 7.78e-01 | 0.5170 | 2.01e-01 | 2.54e-01 | 2.27e-01 | 2.66e-01 | 1.99e-01 | 1.52e-01 | 6.97e-02 | 1.05e-01 | 5.75e-02 | 1.55e-01 |
| NEGATIVE REGULATION OF METALLOPEPTIDASE ACTIVITY | 12 | 6.05e-01 | 9.01e-01 | 0.5170 | -2.29e-01 | -1.79e-01 | -2.47e-01 | -3.06e-01 | -1.65e-01 | 1.69e-01 | 2.83e-01 | 1.38e-01 | 6.62e-02 | 3.23e-01 |
| CITRULLINE METABOLIC PROCESS | 7 | 7.34e-01 | 9.46e-01 | 0.5170 | -3.09e-01 | -2.05e-01 | -1.74e-01 | -3.11e-01 | -4.78e-02 | 1.57e-01 | 3.48e-01 | 4.25e-01 | 1.55e-01 | 8.27e-01 |
| POSITIVE REGULATION OF RECEPTOR CLUSTERING | 6 | 2.08e-01 | 6.03e-01 | 0.5160 | 3.07e-01 | 4.39e-02 | -1.37e-01 | 4.14e-02 | -3.87e-01 | 1.93e-01 | 8.52e-01 | 5.61e-01 | 8.60e-01 | 1.01e-01 |
| SNORNA LOCALIZATION | 6 | 3.77e-01 | 7.75e-01 | 0.5160 | -2.23e-01 | -3.09e-01 | -1.50e-01 | -1.18e-01 | 2.92e-01 | 3.45e-01 | 1.90e-01 | 5.24e-01 | 6.16e-01 | 2.16e-01 |
| REGULATION OF POSTSYNAPTIC NEUROTRANSMITTER RECEPTOR ACTIVITY | 5 | 7.70e-01 | 9.55e-01 | 0.5160 | -3.03e-01 | -1.60e-01 | -1.66e-01 | -2.96e-01 | -1.85e-01 | 2.41e-01 | 5.36e-01 | 5.21e-01 | 2.52e-01 | 4.74e-01 |
| MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS | 158 | 1.19e-08 | 7.53e-07 | 0.5160 | 2.37e-01 | 1.78e-01 | 2.49e-01 | 2.92e-01 | 1.76e-01 | 2.59e-07 | 1.08e-04 | 6.63e-08 | 2.32e-10 | 1.37e-04 |
| HISTONE MRNA CATABOLIC PROCESS | 15 | 1.59e-01 | 5.32e-01 | 0.5160 | 2.07e-01 | 1.25e-01 | 2.38e-01 | 3.62e-01 | 1.42e-01 | 1.64e-01 | 4.02e-01 | 1.11e-01 | 1.53e-02 | 3.40e-01 |
| REGULATION OF PHOSPHOLIPASE C ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 6 | 3.66e-01 | 7.66e-01 | 0.5160 | 3.25e-01 | 1.01e-01 | 2.21e-01 | 3.10e-01 | -7.37e-02 | 1.68e-01 | 6.69e-01 | 3.48e-01 | 1.89e-01 | 7.54e-01 |
| PURINE NUCLEOSIDE DIPHOSPHATE BIOSYNTHETIC PROCESS | 6 | 7.27e-01 | 9.43e-01 | 0.5150 | 1.91e-01 | 3.02e-01 | 2.27e-01 | 2.81e-01 | 8.56e-02 | 4.17e-01 | 2.00e-01 | 3.36e-01 | 2.33e-01 | 7.17e-01 |
| POSITIVE REGULATION OF PROTEIN UBIQUITINATION | 100 | 1.13e-05 | 4.15e-04 | 0.5150 | 2.72e-01 | 1.86e-01 | 2.23e-01 | 2.86e-01 | 1.60e-01 | 2.59e-06 | 1.27e-03 | 1.17e-04 | 7.91e-07 | 5.82e-03 |
| NUCLEOBASE CONTAINING SMALL MOLECULE BIOSYNTHETIC PROCESS | 15 | 1.04e-01 | 4.42e-01 | 0.5150 | 3.05e-01 | 3.27e-01 | 1.40e-01 | 1.59e-01 | 1.42e-01 | 4.05e-02 | 2.83e-02 | 3.49e-01 | 2.87e-01 | 3.41e-01 |
| RESPONSE TO LIGHT INTENSITY | 16 | 2.62e-01 | 6.70e-01 | 0.5150 | -2.60e-01 | -2.84e-01 | -2.74e-01 | -1.59e-01 | -1.27e-01 | 7.17e-02 | 4.89e-02 | 5.75e-02 | 2.70e-01 | 3.80e-01 |
| CARDIAC MUSCLE CELL CARDIAC MUSCLE CELL ADHESION | 7 | 3.46e-01 | 7.50e-01 | 0.5150 | -1.16e-04 | -2.46e-01 | -2.74e-01 | -1.91e-01 | -3.05e-01 | 1.00e+00 | 2.59e-01 | 2.09e-01 | 3.82e-01 | 1.62e-01 |
| GMP BIOSYNTHETIC PROCESS | 13 | 1.22e-01 | 4.76e-01 | 0.5150 | 3.44e-01 | 1.79e-01 | 2.39e-01 | 2.08e-01 | 1.19e-01 | 3.19e-02 | 2.63e-01 | 1.36e-01 | 1.94e-01 | 4.58e-01 |
| REGULATION OF CIRCADIAN SLEEP WAKE CYCLE NON REM SLEEP | 5 | 8.40e-02 | 3.92e-01 | 0.5140 | 1.38e-01 | 2.57e-01 | 1.05e-01 | -1.32e-01 | 3.89e-01 | 5.93e-01 | 3.20e-01 | 6.84e-01 | 6.09e-01 | 1.32e-01 |
| POSITIVE REGULATION OF MORPHOGENESIS OF AN EPITHELIUM | 33 | 4.29e-02 | 2.69e-01 | 0.5140 | 1.31e-01 | 1.71e-01 | 2.47e-01 | 2.30e-01 | 3.23e-01 | 1.94e-01 | 8.99e-02 | 1.41e-02 | 2.20e-02 | 1.32e-03 |
| POSITIVE REGULATION OF TRANSLATION IN RESPONSE TO STRESS | 6 | 8.14e-01 | 9.69e-01 | 0.5140 | -1.82e-01 | -2.18e-01 | -3.16e-01 | -1.88e-01 | -2.20e-01 | 4.39e-01 | 3.56e-01 | 1.80e-01 | 4.25e-01 | 3.50e-01 |
| FOREBRAIN NEURON DIFFERENTIATION | 42 | 2.76e-02 | 2.05e-01 | 0.5140 | 2.07e-01 | 2.82e-01 | 2.46e-01 | 1.93e-01 | 2.09e-01 | 2.04e-02 | 1.54e-03 | 5.87e-03 | 3.00e-02 | 1.89e-02 |
| AORTA SMOOTH MUSCLE TISSUE MORPHOGENESIS | 6 | 3.25e-01 | 7.35e-01 | 0.5140 | 2.17e-01 | 1.07e-01 | -1.54e-01 | 5.46e-02 | -4.23e-01 | 3.57e-01 | 6.51e-01 | 5.14e-01 | 8.17e-01 | 7.28e-02 |
| RNA SPLICING | 421 | 2.10e-21 | 4.93e-19 | 0.5130 | 2.05e-01 | 1.93e-01 | 2.59e-01 | 2.80e-01 | 1.96e-01 | 5.28e-13 | 1.19e-11 | 6.90e-20 | 6.19e-23 | 5.10e-12 |
| NUCLEAR ENVELOPE ORGANIZATION | 52 | 6.52e-03 | 7.48e-02 | 0.5130 | 2.45e-01 | 1.84e-01 | 2.46e-01 | 3.09e-01 | 1.13e-01 | 2.24e-03 | 2.14e-02 | 2.17e-03 | 1.13e-04 | 1.60e-01 |
| REGULATION OF TRANSLATIONAL ELONGATION | 12 | 6.15e-01 | 9.06e-01 | 0.5130 | 2.78e-01 | 2.62e-01 | 2.03e-01 | 2.21e-01 | 1.65e-01 | 9.57e-02 | 1.16e-01 | 2.24e-01 | 1.85e-01 | 3.22e-01 |
| REGULATION OF PHOSPHATIDYLINOSITOL DEPHOSPHORYLATION | 5 | 7.89e-01 | 9.63e-01 | 0.5130 | -1.64e-01 | -2.86e-01 | -3.04e-01 | -2.46e-01 | -3.87e-02 | 5.26e-01 | 2.68e-01 | 2.40e-01 | 3.40e-01 | 8.81e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 82 | 4.39e-04 | 9.11e-03 | 0.5120 | 1.95e-01 | 2.16e-01 | 2.49e-01 | 2.88e-01 | 1.78e-01 | 2.26e-03 | 7.04e-04 | 9.44e-05 | 6.47e-06 | 5.27e-03 |
| SPLICEOSOMAL SNRNP ASSEMBLY | 43 | 6.79e-02 | 3.50e-01 | 0.5110 | 2.17e-01 | 2.07e-01 | 2.47e-01 | 2.63e-01 | 2.03e-01 | 1.37e-02 | 1.87e-02 | 5.04e-03 | 2.83e-03 | 2.14e-02 |
| MITOTIC NUCLEAR DIVISION | 270 | 3.70e-14 | 4.80e-12 | 0.5110 | 2.13e-01 | 1.79e-01 | 2.57e-01 | 2.82e-01 | 1.97e-01 | 1.67e-09 | 4.01e-07 | 3.61e-13 | 1.60e-15 | 2.57e-08 |
| POSITIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION ELONGATION | 61 | 4.62e-03 | 5.82e-02 | 0.5110 | 1.97e-01 | 2.19e-01 | 2.31e-01 | 2.37e-01 | 2.54e-01 | 7.82e-03 | 3.12e-03 | 1.79e-03 | 1.34e-03 | 5.87e-04 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS BY VEGF ACTIVATED VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 5 | 2.03e-01 | 5.96e-01 | 0.5110 | 1.11e-01 | -1.43e-02 | 3.40e-01 | 1.37e-01 | 3.37e-01 | 6.67e-01 | 9.56e-01 | 1.88e-01 | 5.96e-01 | 1.92e-01 |
| UBIQUITIN DEPENDENT GLYCOPROTEIN ERAD PATHWAY | 7 | 4.76e-01 | 8.33e-01 | 0.5100 | 1.86e-01 | 3.36e-01 | 2.24e-01 | 2.46e-01 | -4.82e-02 | 3.95e-01 | 1.24e-01 | 3.04e-01 | 2.60e-01 | 8.25e-01 |
| POSITIVE REGULATION OF SKELETAL MUSCLE TISSUE REGENERATION | 5 | 1.15e-01 | 4.63e-01 | 0.5100 | 8.09e-02 | 3.41e-01 | 8.50e-02 | 1.05e-02 | 3.61e-01 | 7.54e-01 | 1.87e-01 | 7.42e-01 | 9.68e-01 | 1.62e-01 |
| REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 21 | 2.30e-01 | 6.32e-01 | 0.5100 | 2.48e-01 | 1.88e-01 | 2.14e-01 | 3.15e-01 | 1.34e-01 | 4.87e-02 | 1.35e-01 | 8.97e-02 | 1.24e-02 | 2.89e-01 |
| RESPONSE TO MURAMYL DIPEPTIDE | 20 | 3.55e-01 | 7.55e-01 | 0.5100 | 2.86e-01 | 2.29e-01 | 2.05e-01 | 2.52e-01 | 1.41e-01 | 2.66e-02 | 7.57e-02 | 1.13e-01 | 5.09e-02 | 2.75e-01 |
| NEGATIVE REGULATION OF COLLAGEN METABOLIC PROCESS | 12 | 1.43e-01 | 5.09e-01 | 0.5100 | -1.43e-01 | -1.49e-01 | -1.54e-01 | -1.53e-01 | -4.13e-01 | 3.91e-01 | 3.72e-01 | 3.56e-01 | 3.60e-01 | 1.33e-02 |
| IRON SULFUR CLUSTER ASSEMBLY | 27 | 2.63e-02 | 1.99e-01 | 0.5100 | 2.41e-01 | 1.83e-01 | 1.82e-01 | 2.09e-01 | 3.02e-01 | 3.03e-02 | 9.94e-02 | 1.01e-01 | 6.01e-02 | 6.55e-03 |
| EXONUCLEOLYTIC CATABOLISM OF DEADENYLATED MRNA | 13 | 1.39e-01 | 5.04e-01 | 0.5100 | -8.18e-03 | 8.81e-02 | 2.00e-01 | 1.22e-01 | 4.44e-01 | 9.59e-01 | 5.82e-01 | 2.11e-01 | 4.45e-01 | 5.61e-03 |
| GLYCOSYL COMPOUND BIOSYNTHETIC PROCESS | 21 | 5.73e-02 | 3.16e-01 | 0.5100 | 2.81e-01 | 3.24e-01 | 1.46e-01 | 1.98e-01 | 1.23e-01 | 2.56e-02 | 1.02e-02 | 2.46e-01 | 1.16e-01 | 3.29e-01 |
| POSITIVE REGULATION OF POST TRANSLATIONAL PROTEIN MODIFICATION | 146 | 3.02e-08 | 1.79e-06 | 0.5100 | 2.79e-01 | 1.97e-01 | 2.10e-01 | 2.88e-01 | 1.29e-01 | 6.05e-09 | 4.09e-05 | 1.21e-05 | 1.86e-09 | 7.33e-03 |
| REGULATION OF FEMALE GONAD DEVELOPMENT | 7 | 5.02e-01 | 8.49e-01 | 0.5100 | 3.07e-01 | 1.83e-01 | 1.24e-01 | 3.34e-01 | -6.92e-02 | 1.59e-01 | 4.01e-01 | 5.69e-01 | 1.26e-01 | 7.51e-01 |
| REGULATION OF CELLULAR RESPONSE TO MACROPHAGE COLONY STIMULATING FACTOR STIMULUS | 6 | 1.56e-01 | 5.28e-01 | 0.5100 | 3.56e-01 | 3.40e-01 | -3.74e-02 | 1.20e-01 | -4.51e-02 | 1.31e-01 | 1.50e-01 | 8.74e-01 | 6.11e-01 | 8.48e-01 |
| POSITIVE REGULATION OF SECONDARY METABOLITE BIOSYNTHETIC PROCESS | 9 | 6.23e-01 | 9.08e-01 | 0.5090 | 2.82e-01 | 2.15e-01 | 2.64e-01 | 2.53e-01 | 9.30e-03 | 1.43e-01 | 2.64e-01 | 1.70e-01 | 1.89e-01 | 9.61e-01 |
| VACUOLAR PROTON TRANSPORTING V TYPE ATPASE COMPLEX ASSEMBLY | 5 | 3.53e-01 | 7.53e-01 | 0.5090 | -8.84e-02 | -1.61e-01 | 1.41e-01 | 2.01e-02 | 4.53e-01 | 7.32e-01 | 5.33e-01 | 5.84e-01 | 9.38e-01 | 7.94e-02 |
| DIACYLGLYCEROL CATABOLIC PROCESS | 5 | 2.55e-02 | 1.95e-01 | 0.5090 | -2.47e-01 | 2.04e-01 | -1.22e-01 | -3.74e-01 | -4.55e-02 | 3.38e-01 | 4.29e-01 | 6.38e-01 | 1.48e-01 | 8.60e-01 |
| METANEPHROS DEVELOPMENT | 91 | 2.26e-04 | 5.16e-03 | 0.5090 | 1.67e-01 | 2.27e-01 | 2.62e-01 | 2.23e-01 | 2.47e-01 | 5.99e-03 | 1.79e-04 | 1.52e-05 | 2.37e-04 | 4.62e-05 |
| 4FE 4S CLUSTER ASSEMBLY | 5 | 4.46e-01 | 8.17e-01 | 0.5090 | 3.58e-01 | 3.41e-01 | 6.56e-02 | 9.63e-02 | 3.35e-02 | 1.66e-01 | 1.87e-01 | 7.99e-01 | 7.09e-01 | 8.97e-01 |
| NEGATIVE REGULATION OF MYOSIN LIGHT CHAIN PHOSPHATASE ACTIVITY | 5 | 6.75e-01 | 9.28e-01 | 0.5090 | 2.92e-01 | 2.46e-01 | 1.39e-01 | 1.79e-01 | -2.48e-01 | 2.58e-01 | 3.40e-01 | 5.90e-01 | 4.89e-01 | 3.37e-01 |
| PROTEIN QUALITY CONTROL FOR MISFOLDED OR INCOMPLETELY SYNTHESIZED PROTEINS | 29 | 4.84e-02 | 2.89e-01 | 0.5080 | 1.97e-01 | 2.00e-01 | 2.10e-01 | 3.10e-01 | 1.99e-01 | 6.68e-02 | 6.28e-02 | 5.05e-02 | 3.81e-03 | 6.37e-02 |
| INTESTINAL STEM CELL HOMEOSTASIS | 6 | 4.06e-02 | 2.61e-01 | 0.5080 | 3.64e-02 | -6.91e-02 | -2.78e-01 | -4.11e-01 | -7.62e-02 | 8.77e-01 | 7.70e-01 | 2.38e-01 | 8.12e-02 | 7.47e-01 |
| BRANCH ELONGATION OF AN EPITHELIUM | 19 | 1.18e-01 | 4.67e-01 | 0.5080 | 6.39e-02 | 1.99e-01 | 3.06e-01 | 1.59e-01 | 3.09e-01 | 6.30e-01 | 1.32e-01 | 2.09e-02 | 2.31e-01 | 1.96e-02 |
| RETICULOPHAGY | 18 | 3.60e-01 | 7.59e-01 | 0.5080 | 2.13e-01 | 2.41e-01 | 2.57e-01 | 2.90e-01 | 6.71e-02 | 1.17e-01 | 7.62e-02 | 5.94e-02 | 3.31e-02 | 6.22e-01 |
| ENDOPLASMIC RETICULUM TUBULAR NETWORK FORMATION | 5 | 8.70e-01 | 9.78e-01 | 0.5080 | 3.26e-01 | 2.16e-01 | 1.67e-01 | 2.73e-01 | 4.97e-02 | 2.07e-01 | 4.03e-01 | 5.17e-01 | 2.90e-01 | 8.47e-01 |
| POSITIVE REGULATION OF KILLING OF CELLS OF ANOTHER ORGANISM | 8 | 3.09e-01 | 7.20e-01 | 0.5080 | 2.90e-02 | -1.61e-01 | -2.62e-01 | -2.15e-01 | -3.41e-01 | 8.87e-01 | 4.32e-01 | 1.99e-01 | 2.93e-01 | 9.45e-02 |
| NEURON CELL CELL ADHESION | 13 | 5.53e-01 | 8.76e-01 | 0.5080 | -2.35e-01 | -3.05e-01 | -2.20e-01 | -2.35e-01 | -7.54e-02 | 1.42e-01 | 5.67e-02 | 1.70e-01 | 1.42e-01 | 6.38e-01 |
| POSITIVE REGULATION OF CONNECTIVE TISSUE REPLACEMENT | 12 | 8.39e-02 | 3.92e-01 | 0.5070 | -1.59e-01 | -2.88e-01 | -2.10e-01 | -3.24e-01 | -1.92e-02 | 3.41e-01 | 8.45e-02 | 2.08e-01 | 5.17e-02 | 9.09e-01 |
| PROLACTIN SECRETION | 5 | 8.01e-01 | 9.66e-01 | 0.5070 | -4.31e-02 | -1.63e-01 | -3.04e-01 | -2.09e-01 | -3.05e-01 | 8.68e-01 | 5.29e-01 | 2.38e-01 | 4.19e-01 | 2.38e-01 |
| CANONICAL WNT SIGNALING PATHWAY INVOLVED IN CARDIAC MUSCLE CELL FATE COMMITMENT | 5 | 8.17e-01 | 9.70e-01 | 0.5070 | 2.84e-01 | 3.43e-01 | 1.68e-01 | 1.76e-01 | -6.43e-03 | 2.71e-01 | 1.84e-01 | 5.16e-01 | 4.96e-01 | 9.80e-01 |
| NEGATIVE REGULATION OF MYOBLAST PROLIFERATION | 9 | 3.53e-02 | 2.40e-01 | 0.5070 | -1.51e-01 | -1.34e-01 | -6.56e-02 | -2.95e-01 | -3.53e-01 | 4.33e-01 | 4.86e-01 | 7.33e-01 | 1.25e-01 | 6.63e-02 |
| MITOCHONDRIAL RNA 3 END PROCESSING | 5 | 8.55e-01 | 9.76e-01 | 0.5070 | 1.32e-01 | 2.58e-01 | 3.03e-01 | 1.63e-01 | 2.34e-01 | 6.08e-01 | 3.18e-01 | 2.41e-01 | 5.28e-01 | 3.65e-01 |
| PEPTIDYL SERINE AUTOPHOSPHORYLATION | 8 | 6.63e-01 | 9.22e-01 | 0.5070 | 2.73e-01 | 1.80e-01 | 1.83e-01 | 3.26e-01 | 9.93e-02 | 1.82e-01 | 3.77e-01 | 3.69e-01 | 1.10e-01 | 6.27e-01 |
| KINETOCHORE ORGANIZATION | 20 | 1.75e-01 | 5.60e-01 | 0.5070 | 2.44e-01 | 1.48e-01 | 2.35e-01 | 3.23e-01 | 1.25e-01 | 5.93e-02 | 2.51e-01 | 6.83e-02 | 1.24e-02 | 3.34e-01 |
| NEGATIVE REGULATION OF OXIDATIVE STRESS INDUCED NEURON INTRINSIC APOPTOTIC SIGNALING PATHWAY | 12 | 3.30e-01 | 7.38e-01 | 0.5060 | 1.75e-01 | 1.09e-01 | 2.51e-01 | 3.36e-01 | 1.94e-01 | 2.95e-01 | 5.12e-01 | 1.32e-01 | 4.36e-02 | 2.45e-01 |
| LUNG SECRETORY CELL DIFFERENTIATION | 11 | 2.13e-01 | 6.08e-01 | 0.5060 | 2.37e-01 | 1.48e-01 | 1.45e-01 | 3.38e-01 | 2.07e-01 | 1.73e-01 | 3.96e-01 | 4.05e-01 | 5.22e-02 | 2.36e-01 |
| OTOLITH DEVELOPMENT | 10 | 6.78e-01 | 9.28e-01 | 0.5060 | -1.35e-01 | -2.24e-01 | -2.87e-01 | -1.91e-01 | -2.62e-01 | 4.60e-01 | 2.20e-01 | 1.16e-01 | 2.96e-01 | 1.51e-01 |
| NEGATIVE REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 20 | 4.76e-02 | 2.86e-01 | 0.5060 | 1.73e-02 | 1.82e-01 | 3.17e-01 | 1.89e-01 | 2.94e-01 | 8.93e-01 | 1.59e-01 | 1.42e-02 | 1.43e-01 | 2.29e-02 |
| COCHLEA MORPHOGENESIS | 23 | 5.53e-02 | 3.11e-01 | 0.5060 | 9.25e-02 | 1.84e-01 | 2.22e-01 | 1.55e-01 | 3.74e-01 | 4.42e-01 | 1.27e-01 | 6.55e-02 | 1.97e-01 | 1.90e-03 |
| REGULATION OF IRE1 MEDIATED UNFOLDED PROTEIN RESPONSE | 14 | 9.52e-02 | 4.19e-01 | 0.5050 | 1.72e-01 | 2.94e-01 | 1.87e-01 | 1.06e-01 | 3.06e-01 | 2.66e-01 | 5.67e-02 | 2.27e-01 | 4.94e-01 | 4.75e-02 |
| MESENCHYME MIGRATION | 5 | 5.83e-01 | 8.90e-01 | 0.5050 | -3.29e-02 | 1.52e-01 | 2.56e-01 | 2.15e-01 | 3.46e-01 | 8.99e-01 | 5.56e-01 | 3.22e-01 | 4.05e-01 | 1.81e-01 |
| NEUROEPITHELIAL CELL DIFFERENTIATION | 38 | 2.48e-03 | 3.61e-02 | 0.5050 | 4.14e-02 | 1.66e-01 | 2.87e-01 | 1.45e-01 | 3.50e-01 | 6.59e-01 | 7.59e-02 | 2.18e-03 | 1.23e-01 | 1.88e-04 |
| REGULATION OF CATECHOLAMINE METABOLIC PROCESS | 18 | 4.31e-01 | 8.06e-01 | 0.5050 | 1.50e-01 | 2.05e-01 | 2.67e-01 | 2.23e-01 | 2.62e-01 | 2.69e-01 | 1.31e-01 | 4.99e-02 | 1.01e-01 | 5.39e-02 |
| REGULATION OF RESPIRATORY GASEOUS EXCHANGE | 21 | 2.86e-01 | 6.94e-01 | 0.5040 | 2.19e-01 | 1.59e-01 | 2.47e-01 | 2.61e-01 | 2.27e-01 | 8.19e-02 | 2.06e-01 | 5.01e-02 | 3.81e-02 | 7.17e-02 |
| PROTEIN TARGETING TO MITOCHONDRION | 101 | 3.19e-05 | 1.07e-03 | 0.5040 | 2.52e-01 | 1.88e-01 | 2.56e-01 | 2.53e-01 | 1.61e-01 | 1.17e-05 | 1.12e-03 | 8.66e-06 | 1.12e-05 | 5.20e-03 |
| NEGATIVE REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 8 | 1.52e-01 | 5.21e-01 | 0.5040 | -3.78e-01 | -2.27e-01 | 2.87e-02 | -2.17e-01 | 1.10e-01 | 6.42e-02 | 2.67e-01 | 8.88e-01 | 2.88e-01 | 5.90e-01 |
| SENSORY PERCEPTION OF SOUR TASTE | 9 | 6.34e-02 | 3.35e-01 | 0.5040 | -3.25e-01 | -1.36e-01 | 2.93e-02 | -3.04e-01 | 1.91e-01 | 9.13e-02 | 4.79e-01 | 8.79e-01 | 1.14e-01 | 3.21e-01 |
| ADP TRANSPORT | 10 | 3.56e-01 | 7.57e-01 | 0.5040 | 3.33e-01 | 2.61e-01 | 1.71e-01 | 1.65e-01 | -1.36e-01 | 6.86e-02 | 1.52e-01 | 3.48e-01 | 3.66e-01 | 4.55e-01 |
| REGULATION OF SYNAPTIC VESICLE PRIMING | 7 | 2.44e-01 | 6.48e-01 | 0.5040 | -1.39e-02 | -1.49e-02 | 2.61e-01 | 5.70e-02 | 4.27e-01 | 9.49e-01 | 9.46e-01 | 2.31e-01 | 7.94e-01 | 5.06e-02 |
| NEGATIVE REGULATION OF OXIDATIVE PHOSPHORYLATION | 8 | 5.47e-01 | 8.73e-01 | 0.5040 | 2.60e-01 | 2.00e-01 | 2.95e-01 | 1.86e-01 | 1.56e-01 | 2.02e-01 | 3.26e-01 | 1.48e-01 | 3.63e-01 | 4.45e-01 |
| POSITIVE REGULATION OF CGMP MEDIATED SIGNALING | 5 | 5.26e-01 | 8.60e-01 | 0.5040 | 9.43e-02 | 5.63e-02 | 3.51e-01 | 2.75e-01 | 2.07e-01 | 7.15e-01 | 8.27e-01 | 1.73e-01 | 2.88e-01 | 4.23e-01 |
| INTRACELLULAR NITROGEN HOMEOSTASIS | 5 | 7.03e-01 | 9.32e-01 | 0.5040 | -3.63e-02 | -1.02e-01 | -3.11e-01 | -2.71e-01 | -2.68e-01 | 8.88e-01 | 6.92e-01 | 2.28e-01 | 2.95e-01 | 2.99e-01 |
| ENTEROENDOCRINE CELL DIFFERENTIATION | 36 | 6.84e-02 | 3.51e-01 | 0.5030 | 1.59e-01 | 1.91e-01 | 2.98e-01 | 2.43e-01 | 2.09e-01 | 9.93e-02 | 4.68e-02 | 2.00e-03 | 1.16e-02 | 2.97e-02 |
| ANTIFUNGAL INNATE IMMUNE RESPONSE | 19 | 1.13e-01 | 4.59e-01 | 0.5030 | -5.34e-02 | -1.16e-01 | -3.01e-01 | -2.36e-01 | -3.01e-01 | 6.87e-01 | 3.80e-01 | 2.32e-02 | 7.53e-02 | 2.30e-02 |
| REGULATION OF CONNECTIVE TISSUE REPLACEMENT | 15 | 3.02e-02 | 2.18e-01 | 0.5030 | -8.47e-02 | -1.87e-01 | -2.76e-01 | -3.50e-01 | -1.10e-01 | 5.70e-01 | 2.09e-01 | 6.45e-02 | 1.88e-02 | 4.62e-01 |
| PROTEIN SULFATION | 6 | 8.17e-01 | 9.70e-01 | 0.5030 | -3.15e-01 | -2.60e-01 | -1.68e-01 | -2.27e-01 | 7.82e-02 | 1.81e-01 | 2.70e-01 | 4.76e-01 | 3.35e-01 | 7.40e-01 |
| POSITIVE REGULATION OF CELLULAR RESPIRATION | 13 | 2.23e-01 | 6.23e-01 | 0.5030 | 1.03e-01 | 8.62e-02 | 3.18e-01 | 2.50e-01 | 2.66e-01 | 5.20e-01 | 5.90e-01 | 4.69e-02 | 1.18e-01 | 9.63e-02 |
| SPINAL CORD MOTOR NEURON DIFFERENTIATION | 28 | 9.63e-02 | 4.22e-01 | 0.5030 | 1.15e-01 | 1.69e-01 | 2.86e-01 | 2.01e-01 | 2.99e-01 | 2.94e-01 | 1.23e-01 | 8.79e-03 | 6.58e-02 | 6.24e-03 |
| NEGATIVE REGULATION OF CELL VOLUME | 5 | 3.53e-01 | 7.53e-01 | 0.5030 | 2.96e-02 | 1.04e-01 | -2.74e-01 | -1.91e-01 | -3.60e-01 | 9.09e-01 | 6.87e-01 | 2.89e-01 | 4.61e-01 | 1.63e-01 |
| MESENCHYMAL TO EPITHELIAL TRANSITION INVOLVED IN METANEPHROS MORPHOGENESIS | 11 | 6.18e-01 | 9.07e-01 | 0.5030 | 1.47e-01 | 2.12e-01 | 2.71e-01 | 2.80e-01 | 1.86e-01 | 3.99e-01 | 2.24e-01 | 1.20e-01 | 1.08e-01 | 2.85e-01 |
| POSITIVE REGULATION OF T CELL TOLERANCE INDUCTION | 8 | 2.34e-01 | 6.36e-01 | 0.5030 | -1.74e-01 | -3.39e-01 | -2.66e-01 | -1.41e-01 | 1.31e-01 | 3.95e-01 | 9.72e-02 | 1.93e-01 | 4.89e-01 | 5.22e-01 |
| FATTY ACID DERIVATIVE CATABOLIC PROCESS | 17 | 1.98e-01 | 5.86e-01 | 0.5030 | 2.29e-01 | 1.49e-01 | 2.89e-01 | 2.28e-01 | 2.06e-01 | 1.02e-01 | 2.86e-01 | 3.92e-02 | 1.03e-01 | 1.42e-01 |
| REGULATION OF RECEPTOR CLUSTERING | 13 | 2.08e-01 | 6.03e-01 | 0.5020 | 3.71e-01 | 2.15e-01 | 1.11e-01 | 2.25e-01 | -7.74e-02 | 2.07e-02 | 1.79e-01 | 4.87e-01 | 1.61e-01 | 6.29e-01 |
| ANTERIOR POSTERIOR PATTERN SPECIFICATION | 209 | 5.96e-13 | 6.50e-11 | 0.5020 | 1.11e-01 | 1.92e-01 | 2.72e-01 | 2.21e-01 | 2.83e-01 | 5.69e-03 | 1.80e-06 | 1.09e-11 | 3.55e-08 | 1.62e-12 |
| SIRNA MEDIATED RETROTRANSPOSON SILENCING BY HETEROCHROMATIN FORMATION | 11 | 1.80e-01 | 5.64e-01 | 0.5020 | 2.30e-02 | -1.79e-01 | -3.01e-01 | -1.94e-01 | -3.03e-01 | 8.95e-01 | 3.05e-01 | 8.40e-02 | 2.65e-01 | 8.20e-02 |
| NEGATIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT | 29 | 5.68e-02 | 3.15e-01 | 0.5020 | -1.35e-01 | -2.76e-01 | -2.74e-01 | -2.22e-01 | -1.82e-01 | 2.07e-01 | 9.99e-03 | 1.06e-02 | 3.83e-02 | 9.02e-02 |
| GLIAL CELL FATE COMMITMENT | 13 | 3.28e-01 | 7.37e-01 | 0.5020 | 1.34e-01 | 1.01e-01 | 2.74e-01 | 2.03e-01 | 3.29e-01 | 4.02e-01 | 5.29e-01 | 8.77e-02 | 2.06e-01 | 4.01e-02 |
| DE NOVO CENTRIOLE ASSEMBLY | 6 | 7.16e-01 | 9.37e-01 | 0.5020 | 1.99e-01 | 9.62e-02 | 2.77e-01 | 2.96e-01 | 1.96e-01 | 3.98e-01 | 6.83e-01 | 2.40e-01 | 2.09e-01 | 4.06e-01 |
| POSTSYNAPTIC CYTOSKELETON ORGANIZATION | 17 | 2.30e-01 | 6.32e-01 | 0.5020 | 1.90e-01 | 2.31e-01 | 2.35e-01 | 3.17e-01 | 8.27e-02 | 1.76e-01 | 9.86e-02 | 9.31e-02 | 2.37e-02 | 5.55e-01 |
| PIGMENT GRANULE LOCALIZATION | 23 | 8.55e-02 | 3.95e-01 | 0.5020 | 2.48e-01 | 2.44e-01 | 2.43e-01 | 2.56e-01 | -7.49e-02 | 3.91e-02 | 4.27e-02 | 4.33e-02 | 3.34e-02 | 5.34e-01 |
| CARTILAGE DEVELOPMENT INVOLVED IN ENDOCHONDRAL BONE MORPHOGENESIS | 33 | 2.90e-02 | 2.12e-01 | 0.5010 | 9.91e-02 | 2.37e-01 | 2.89e-01 | 1.89e-01 | 2.58e-01 | 3.24e-01 | 1.85e-02 | 4.04e-03 | 6.05e-02 | 1.05e-02 |
| DIPEPTIDE TRANSMEMBRANE TRANSPORT | 7 | 8.52e-01 | 9.76e-01 | 0.5010 | -2.14e-01 | -2.04e-01 | -2.90e-01 | -2.31e-01 | -1.62e-01 | 3.26e-01 | 3.50e-01 | 1.84e-01 | 2.91e-01 | 4.57e-01 |
| CHROMATIN LOOPING | 11 | 1.77e-02 | 1.54e-01 | 0.5010 | 3.84e-02 | -3.67e-02 | 2.48e-01 | 3.79e-01 | 2.08e-01 | 8.25e-01 | 8.33e-01 | 1.54e-01 | 2.96e-02 | 2.33e-01 |
| NEGATIVE REGULATION OF TYPE B PANCREATIC CELL APOPTOTIC PROCESS | 6 | 5.12e-01 | 8.54e-01 | 0.5010 | 2.19e-01 | 2.20e-01 | 2.78e-01 | 8.93e-02 | 2.64e-01 | 3.53e-01 | 3.51e-01 | 2.39e-01 | 7.05e-01 | 2.62e-01 |
| MITOTIC SISTER CHROMATID SEPARATION | 62 | 1.08e-04 | 2.95e-03 | 0.5010 | 1.85e-01 | 1.32e-01 | 2.21e-01 | 3.19e-01 | 2.20e-01 | 1.15e-02 | 7.30e-02 | 2.62e-03 | 1.36e-05 | 2.73e-03 |
| TERPENOID CATABOLIC PROCESS | 8 | 6.09e-01 | 9.03e-01 | 0.5010 | 1.31e-01 | 2.80e-01 | 3.15e-01 | 2.00e-01 | 1.27e-01 | 5.22e-01 | 1.70e-01 | 1.23e-01 | 3.26e-01 | 5.33e-01 |
| FORMATION OF ANATOMICAL BOUNDARY | 7 | 5.54e-01 | 8.76e-01 | 0.5010 | 1.58e-01 | 3.51e-01 | 2.61e-01 | 1.35e-01 | 1.26e-01 | 4.68e-01 | 1.07e-01 | 2.32e-01 | 5.35e-01 | 5.65e-01 |
| CHORIO ALLANTOIC FUSION | 7 | 5.44e-01 | 8.70e-01 | 0.5000 | 4.61e-02 | 1.59e-01 | 2.92e-01 | 2.82e-01 | 2.42e-01 | 8.33e-01 | 4.66e-01 | 1.82e-01 | 1.96e-01 | 2.68e-01 |
| NEGATIVE REGULATION OF CELLULAR SENESCENCE | 25 | 1.48e-01 | 5.16e-01 | 0.5000 | 2.09e-01 | 1.85e-01 | 2.12e-01 | 3.02e-01 | 1.89e-01 | 7.02e-02 | 1.08e-01 | 6.61e-02 | 8.86e-03 | 1.02e-01 |
| LEUKOTRIENE CATABOLIC PROCESS | 6 | 2.31e-01 | 6.33e-01 | 0.5000 | 1.74e-01 | 3.44e-02 | 3.04e-01 | 1.44e-01 | 3.25e-01 | 4.61e-01 | 8.84e-01 | 1.97e-01 | 5.41e-01 | 1.68e-01 |
| POSITIVE REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 11 | 6.69e-02 | 3.45e-01 | 0.5000 | 1.72e-01 | 2.17e-01 | 3.66e-01 | 1.06e-01 | 1.67e-01 | 3.23e-01 | 2.12e-01 | 3.56e-02 | 5.43e-01 | 3.37e-01 |
| REGULATION OF ANTIMICROBIAL HUMORAL RESPONSE | 12 | 4.47e-01 | 8.17e-01 | 0.5000 | -1.27e-01 | -1.15e-01 | -2.84e-01 | -2.13e-01 | -3.07e-01 | 4.47e-01 | 4.89e-01 | 8.88e-02 | 2.01e-01 | 6.51e-02 |
| NEGATIVE REGULATION OF INTERFERON BETA PRODUCTION | 15 | 2.14e-02 | 1.74e-01 | 0.5000 | 2.00e-01 | 3.18e-01 | 2.99e-01 | 4.62e-02 | 1.31e-01 | 1.80e-01 | 3.31e-02 | 4.46e-02 | 7.57e-01 | 3.81e-01 |
| ASPARAGINE METABOLIC PROCESS | 5 | 4.20e-01 | 8.00e-01 | 0.5000 | 5.86e-02 | 2.28e-03 | 3.38e-01 | 2.83e-01 | 2.28e-01 | 8.21e-01 | 9.93e-01 | 1.90e-01 | 2.74e-01 | 3.77e-01 |
| NEGATIVE REGULATION OF SYNCYTIUM FORMATION BY PLASMA MEMBRANE FUSION | 5 | 4.51e-01 | 8.21e-01 | 0.5000 | 3.03e-01 | 1.16e-01 | -9.37e-02 | 1.12e-01 | -3.51e-01 | 2.40e-01 | 6.53e-01 | 7.17e-01 | 6.64e-01 | 1.75e-01 |
| MITOCHONDRIAL RESPIRASOME ASSEMBLY | 10 | 4.09e-01 | 7.94e-01 | 0.5000 | 2.52e-01 | 1.20e-01 | 2.11e-01 | 2.31e-01 | 2.72e-01 | 1.67e-01 | 5.11e-01 | 2.48e-01 | 2.07e-01 | 1.36e-01 |
| SIRNA PROCESSING | 9 | 6.16e-01 | 9.06e-01 | 0.5000 | 2.08e-01 | 1.61e-01 | 2.32e-01 | 3.34e-01 | 1.22e-01 | 2.80e-01 | 4.03e-01 | 2.28e-01 | 8.25e-02 | 5.25e-01 |
| NEGATIVE REGULATION OF T CELL DIFFERENTIATION IN THYMUS | 10 | 4.80e-01 | 8.35e-01 | 0.5000 | 1.12e-01 | 1.81e-01 | 3.24e-01 | 2.68e-01 | 1.64e-01 | 5.39e-01 | 3.20e-01 | 7.58e-02 | 1.42e-01 | 3.69e-01 |
| REGULATION OF MRNA SPLICING VIA SPLICEOSOME | 95 | 5.45e-04 | 1.08e-02 | 0.4990 | 2.15e-01 | 2.02e-01 | 2.56e-01 | 2.70e-01 | 1.54e-01 | 2.87e-04 | 6.64e-04 | 1.64e-05 | 5.24e-06 | 9.49e-03 |
| MRNA SPLICE SITE RECOGNITION | 35 | 9.09e-02 | 4.08e-01 | 0.4990 | 2.65e-01 | 2.09e-01 | 2.53e-01 | 2.38e-01 | 1.21e-01 | 6.71e-03 | 3.21e-02 | 9.64e-03 | 1.48e-02 | 2.14e-01 |
| MAMMARY GLAND EPITHELIAL CELL DIFFERENTIATION | 17 | 9.90e-02 | 4.28e-01 | 0.4990 | 4.11e-02 | 1.16e-01 | 2.14e-01 | 2.26e-01 | 3.70e-01 | 7.69e-01 | 4.08e-01 | 1.26e-01 | 1.06e-01 | 8.28e-03 |
| MITOTIC INTRA S DNA DAMAGE CHECKPOINT SIGNALING | 17 | 3.49e-01 | 7.51e-01 | 0.4990 | 2.12e-01 | 2.00e-01 | 2.69e-01 | 2.96e-01 | 6.57e-02 | 1.30e-01 | 1.54e-01 | 5.49e-02 | 3.47e-02 | 6.39e-01 |
| GLUCOCORTICOID SECRETION | 12 | 3.85e-01 | 7.79e-01 | 0.4990 | 1.60e-01 | 2.13e-01 | 1.88e-01 | 2.23e-01 | 3.05e-01 | 3.38e-01 | 2.02e-01 | 2.59e-01 | 1.80e-01 | 6.75e-02 |
| CELLULAR RESPONSE TO OXIDISED LOW DENSITY LIPOPROTEIN PARTICLE STIMULUS | 14 | 6.18e-02 | 3.30e-01 | 0.4990 | 3.56e-01 | 3.13e-01 | 5.04e-02 | 1.32e-01 | -6.68e-02 | 2.12e-02 | 4.28e-02 | 7.44e-01 | 3.92e-01 | 6.65e-01 |
| CARDIOBLAST DIFFERENTIATION | 17 | 4.27e-01 | 8.05e-01 | 0.4990 | 1.54e-01 | 2.27e-01 | 2.70e-01 | 1.84e-01 | 2.58e-01 | 2.72e-01 | 1.05e-01 | 5.37e-02 | 1.88e-01 | 6.58e-02 |
| PEPTIDYL ARGININE METHYLATION | 7 | 2.83e-01 | 6.93e-01 | 0.4990 | -1.94e-01 | -2.20e-01 | 5.39e-04 | -8.17e-02 | 3.95e-01 | 3.74e-01 | 3.14e-01 | 9.98e-01 | 7.08e-01 | 7.03e-02 |
| NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 110 | 6.37e-05 | 1.91e-03 | 0.4990 | 1.78e-01 | 1.93e-01 | 2.73e-01 | 2.56e-01 | 1.99e-01 | 1.24e-03 | 4.62e-04 | 7.73e-07 | 3.52e-06 | 3.10e-04 |
| POSITIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION | 25 | 4.15e-02 | 2.64e-01 | 0.4990 | 5.59e-02 | 1.43e-01 | 2.64e-01 | 2.54e-01 | 3.01e-01 | 6.28e-01 | 2.17e-01 | 2.21e-02 | 2.82e-02 | 9.11e-03 |
| NEGATIVE REGULATION OF BROWN FAT CELL DIFFERENTIATION | 5 | 7.72e-01 | 9.57e-01 | 0.4980 | 1.61e-01 | 2.91e-01 | 2.29e-01 | 2.76e-01 | 9.63e-02 | 5.32e-01 | 2.60e-01 | 3.76e-01 | 2.85e-01 | 7.09e-01 |
| NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING 1 SIGNALING PATHWAY | 7 | 6.99e-02 | 3.57e-01 | 0.4980 | 4.11e-01 | 1.80e-01 | -4.54e-02 | 2.02e-01 | 5.94e-02 | 5.95e-02 | 4.09e-01 | 8.35e-01 | 3.54e-01 | 7.85e-01 |
| PEXOPHAGY | 6 | 7.52e-01 | 9.51e-01 | 0.4980 | 1.91e-01 | 1.40e-01 | 2.26e-01 | 3.40e-01 | 1.61e-01 | 4.19e-01 | 5.52e-01 | 3.38e-01 | 1.49e-01 | 4.96e-01 |
| MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 26 | 3.52e-02 | 2.39e-01 | 0.4980 | 2.39e-01 | 2.42e-01 | 1.56e-01 | 2.89e-01 | 1.56e-01 | 3.47e-02 | 3.24e-02 | 1.67e-01 | 1.08e-02 | 1.70e-01 |
| PURINE NUCLEOBASE BIOSYNTHETIC PROCESS | 9 | 5.04e-01 | 8.50e-01 | 0.4980 | 3.16e-01 | 1.74e-01 | 2.36e-01 | 2.36e-01 | 7.92e-02 | 1.01e-01 | 3.65e-01 | 2.20e-01 | 2.20e-01 | 6.81e-01 |
| NEGATIVE REGULATION OF DOUBLE STRAND BREAK REPAIR VIA HOMOLOGOUS RECOMBINATION | 19 | 3.51e-01 | 7.52e-01 | 0.4980 | 2.31e-01 | 2.86e-01 | 2.15e-01 | 2.51e-01 | 5.88e-02 | 8.17e-02 | 3.09e-02 | 1.05e-01 | 5.82e-02 | 6.57e-01 |
| INTESTINAL EPITHELIAL STRUCTURE MAINTENANCE | 8 | 1.43e-01 | 5.09e-01 | 0.4980 | 2.95e-01 | 2.46e-01 | 1.55e-01 | 5.43e-02 | 2.70e-01 | 1.48e-01 | 2.28e-01 | 4.46e-01 | 7.90e-01 | 1.87e-01 |
| NEGATIVE REGULATION OF GONADOTROPIN SECRETION | 7 | 6.27e-01 | 9.09e-01 | 0.4970 | -2.33e-01 | -2.01e-01 | -2.04e-01 | -3.32e-01 | 3.30e-02 | 2.86e-01 | 3.58e-01 | 3.51e-01 | 1.28e-01 | 8.80e-01 |
| REGULATION OF RESPONSE TO FOOD | 14 | 1.62e-02 | 1.44e-01 | 0.4970 | 2.70e-01 | 1.90e-01 | 1.94e-01 | 6.90e-02 | 3.09e-01 | 8.00e-02 | 2.18e-01 | 2.08e-01 | 6.55e-01 | 4.50e-02 |
| POSITIVE REGULATION OF RNA BINDING | 5 | 7.52e-01 | 9.51e-01 | 0.4970 | 2.98e-01 | 1.55e-01 | 1.44e-01 | 3.28e-01 | 7.98e-02 | 2.49e-01 | 5.49e-01 | 5.78e-01 | 2.04e-01 | 7.57e-01 |
| CHROMOSOME SEPARATION | 81 | 2.44e-05 | 8.47e-04 | 0.4970 | 2.06e-01 | 1.46e-01 | 2.20e-01 | 3.11e-01 | 1.97e-01 | 1.34e-03 | 2.30e-02 | 6.35e-04 | 1.33e-06 | 2.21e-03 |
| HYPOXIA INDUCIBLE FACTOR 1ALPHA SIGNALING PATHWAY | 5 | 2.64e-01 | 6.72e-01 | 0.4970 | 2.12e-01 | -4.22e-02 | 1.45e-01 | 1.82e-01 | 3.82e-01 | 4.12e-01 | 8.70e-01 | 5.75e-01 | 4.80e-01 | 1.39e-01 |
| LABYRINTHINE LAYER BLOOD VESSEL DEVELOPMENT | 18 | 3.94e-01 | 7.85e-01 | 0.4970 | 1.33e-01 | 2.27e-01 | 2.78e-01 | 2.13e-01 | 2.34e-01 | 3.27e-01 | 9.60e-02 | 4.08e-02 | 1.17e-01 | 8.53e-02 |
| NEGATIVE REGULATION OF NUCLEAR DIVISION | 63 | 2.39e-03 | 3.51e-02 | 0.4970 | 1.84e-01 | 1.53e-01 | 2.57e-01 | 2.83e-01 | 2.09e-01 | 1.16e-02 | 3.61e-02 | 4.25e-04 | 1.01e-04 | 4.13e-03 |
| DNA INTEGRATION | 8 | 4.52e-01 | 8.21e-01 | 0.4970 | 2.32e-01 | 3.20e-01 | 1.47e-01 | 2.52e-01 | 7.11e-02 | 2.56e-01 | 1.17e-01 | 4.71e-01 | 2.17e-01 | 7.28e-01 |
| ERBB2 SIGNALING PATHWAY | 18 | 3.51e-01 | 7.52e-01 | 0.4960 | -1.76e-01 | -1.77e-01 | -2.31e-01 | -2.90e-01 | -2.16e-01 | 1.96e-01 | 1.93e-01 | 9.01e-02 | 3.31e-02 | 1.13e-01 |
| EYELID DEVELOPMENT IN CAMERA TYPE EYE | 13 | 5.05e-01 | 8.50e-01 | 0.4960 | 1.50e-01 | 2.27e-01 | 2.50e-01 | 1.63e-01 | 2.88e-01 | 3.48e-01 | 1.57e-01 | 1.18e-01 | 3.08e-01 | 7.18e-02 |
| REGULATION OF MEMBRANE REPOLARIZATION | 36 | 3.40e-02 | 2.34e-01 | 0.4960 | -2.45e-01 | -1.59e-01 | -2.26e-01 | -3.10e-01 | -1.17e-01 | 1.10e-02 | 9.80e-02 | 1.89e-02 | 1.28e-03 | 2.24e-01 |
| IMP METABOLIC PROCESS | 17 | 4.42e-01 | 8.13e-01 | 0.4960 | 2.77e-01 | 2.09e-01 | 2.27e-01 | 2.69e-01 | 4.18e-02 | 4.81e-02 | 1.35e-01 | 1.05e-01 | 5.49e-02 | 7.65e-01 |
| VOLUNTARY SKELETAL MUSCLE CONTRACTION | 5 | 2.53e-01 | 6.59e-01 | 0.4960 | -7.92e-02 | 4.48e-02 | 3.55e-01 | 2.98e-02 | 3.33e-01 | 7.59e-01 | 8.62e-01 | 1.69e-01 | 9.08e-01 | 1.97e-01 |
| POSITIVE REGULATION OF SISTER CHROMATID COHESION | 9 | 7.51e-02 | 3.71e-01 | 0.4960 | 7.37e-03 | -5.38e-02 | 1.77e-01 | 3.26e-01 | 3.25e-01 | 9.69e-01 | 7.80e-01 | 3.58e-01 | 9.06e-02 | 9.18e-02 |
| BRONCHUS DEVELOPMENT | 11 | 4.77e-01 | 8.33e-01 | 0.4960 | 1.17e-01 | 1.76e-01 | 2.25e-01 | 1.54e-01 | 3.56e-01 | 5.02e-01 | 3.12e-01 | 1.97e-01 | 3.76e-01 | 4.09e-02 |
| DOUBLE STRAND BREAK REPAIR INVOLVED IN MEIOTIC RECOMBINATION | 11 | 7.14e-01 | 9.36e-01 | 0.4960 | -2.23e-01 | -2.88e-01 | -2.29e-01 | -2.32e-01 | -8.47e-02 | 2.00e-01 | 9.85e-02 | 1.89e-01 | 1.84e-01 | 6.27e-01 |
| REGULATION OF INTESTINAL ABSORPTION | 12 | 2.19e-02 | 1.77e-01 | 0.4950 | 1.63e-02 | 7.62e-02 | -2.44e-01 | -3.04e-01 | -2.97e-01 | 9.22e-01 | 6.48e-01 | 1.44e-01 | 6.87e-02 | 7.53e-02 |
| PIRNA PROCESSING | 24 | 5.54e-02 | 3.12e-01 | 0.4950 | -9.67e-02 | -2.74e-01 | -2.86e-01 | -1.75e-01 | -2.19e-01 | 4.12e-01 | 2.00e-02 | 1.52e-02 | 1.38e-01 | 6.34e-02 |
| REGULATION OF PROTEIN UBIQUITINATION | 180 | 2.46e-08 | 1.48e-06 | 0.4950 | 2.11e-01 | 1.82e-01 | 2.37e-01 | 2.67e-01 | 2.00e-01 | 1.07e-06 | 2.53e-05 | 4.33e-08 | 5.97e-10 | 3.59e-06 |
| RRNA TRANSCRIPTION | 37 | 1.39e-02 | 1.28e-01 | 0.4950 | 9.66e-02 | 1.47e-01 | 2.32e-01 | 1.82e-01 | 3.57e-01 | 3.09e-01 | 1.21e-01 | 1.47e-02 | 5.55e-02 | 1.74e-04 |
| POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 30 | 1.22e-01 | 4.75e-01 | 0.4950 | 1.85e-01 | 1.86e-01 | 2.87e-01 | 2.72e-01 | 1.41e-01 | 8.02e-02 | 7.71e-02 | 6.59e-03 | 1.00e-02 | 1.81e-01 |
| ARGININE CATABOLIC PROCESS | 11 | 4.64e-01 | 8.25e-01 | 0.4950 | -1.93e-01 | -1.39e-01 | -2.14e-01 | -3.28e-01 | -1.86e-01 | 2.69e-01 | 4.25e-01 | 2.18e-01 | 5.93e-02 | 2.87e-01 |
| NCRNA PROCESSING | 419 | 1.46e-19 | 2.90e-17 | 0.4950 | 2.00e-01 | 1.87e-01 | 2.60e-01 | 2.39e-01 | 2.12e-01 | 1.97e-12 | 5.44e-11 | 6.01e-20 | 4.19e-17 | 1.07e-13 |
| WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 5 | 6.91e-01 | 9.31e-01 | 0.4950 | 2.01e-01 | 1.91e-01 | 1.56e-01 | 1.46e-01 | 3.49e-01 | 4.36e-01 | 4.59e-01 | 5.47e-01 | 5.73e-01 | 1.76e-01 |
| NEGATIVE REGULATION OF PROTEIN MATURATION | 27 | 7.97e-02 | 3.82e-01 | 0.4940 | 3.13e-01 | 2.83e-01 | 1.61e-01 | 1.94e-01 | -5.34e-02 | 4.94e-03 | 1.09e-02 | 1.48e-01 | 8.11e-02 | 6.31e-01 |
| ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 44 | 4.91e-02 | 2.89e-01 | 0.4940 | 2.72e-01 | 2.30e-01 | 2.27e-01 | 2.53e-01 | 3.99e-02 | 1.80e-03 | 8.25e-03 | 9.10e-03 | 3.74e-03 | 6.47e-01 |
| DNA INTEGRITY CHECKPOINT SIGNALING | 131 | 7.95e-07 | 3.83e-05 | 0.4940 | 2.04e-01 | 1.88e-01 | 2.28e-01 | 2.95e-01 | 1.65e-01 | 5.38e-05 | 1.95e-04 | 6.33e-06 | 5.35e-09 | 1.08e-03 |
| TELOMERE ORGANIZATION | 178 | 2.95e-08 | 1.76e-06 | 0.4930 | 1.98e-01 | 1.97e-01 | 2.53e-01 | 2.80e-01 | 1.52e-01 | 5.11e-06 | 5.89e-06 | 5.70e-09 | 1.13e-10 | 4.83e-04 |
| ENDOCARDIAL CUSHION DEVELOPMENT | 54 | 3.43e-03 | 4.64e-02 | 0.4930 | 1.05e-01 | 1.94e-01 | 2.58e-01 | 2.22e-01 | 2.80e-01 | 1.83e-01 | 1.36e-02 | 1.03e-03 | 4.72e-03 | 3.64e-04 |
| METANEPHRIC NEPHRON MORPHOGENESIS | 24 | 3.93e-01 | 7.85e-01 | 0.4930 | 2.14e-01 | 2.14e-01 | 2.45e-01 | 2.29e-01 | 1.97e-01 | 6.89e-02 | 7.01e-02 | 3.79e-02 | 5.22e-02 | 9.40e-02 |
| REGULATION OF MITOTIC NUCLEAR DIVISION | 118 | 3.66e-06 | 1.55e-04 | 0.4930 | 1.74e-01 | 1.54e-01 | 2.53e-01 | 2.73e-01 | 2.25e-01 | 1.11e-03 | 3.81e-03 | 2.11e-06 | 3.08e-07 | 2.39e-05 |
| SOFT PALATE DEVELOPMENT | 5 | 4.05e-01 | 7.92e-01 | 0.4930 | 1.32e-01 | 1.58e-01 | 9.18e-02 | 7.84e-02 | 4.31e-01 | 6.09e-01 | 5.40e-01 | 7.22e-01 | 7.62e-01 | 9.52e-02 |
| RETROGRADE TRANS SYNAPTIC SIGNALING BY LIPID | 5 | 6.89e-01 | 9.31e-01 | 0.4930 | -2.72e-01 | -1.54e-01 | -2.88e-01 | -2.48e-01 | -2.75e-02 | 2.92e-01 | 5.50e-01 | 2.65e-01 | 3.37e-01 | 9.15e-01 |
| INTEGRATED STRESS RESPONSE SIGNALING | 42 | 7.54e-02 | 3.72e-01 | 0.4930 | 1.94e-01 | 1.98e-01 | 2.34e-01 | 2.35e-01 | 2.36e-01 | 2.97e-02 | 2.62e-02 | 8.57e-03 | 8.36e-03 | 8.23e-03 |
| SNRNA METABOLIC PROCESS | 53 | 3.73e-02 | 2.49e-01 | 0.4920 | 2.07e-01 | 1.95e-01 | 2.54e-01 | 2.40e-01 | 1.97e-01 | 9.01e-03 | 1.39e-02 | 1.36e-03 | 2.49e-03 | 1.32e-02 |
| TRNA TRANSPORT | 6 | 3.22e-01 | 7.33e-01 | 0.4920 | 6.36e-02 | 4.02e-02 | 3.50e-01 | 2.93e-01 | 1.69e-01 | 7.87e-01 | 8.65e-01 | 1.38e-01 | 2.15e-01 | 4.73e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN VIA MHC CLASS I | 37 | 1.50e-02 | 1.36e-01 | 0.4920 | 9.60e-02 | 2.04e-01 | 2.58e-01 | 2.47e-01 | 2.52e-01 | 3.12e-01 | 3.20e-02 | 6.60e-03 | 9.35e-03 | 8.01e-03 |
| LIPOPHAGY | 7 | 7.86e-01 | 9.61e-01 | 0.4920 | 2.40e-01 | 2.53e-01 | 1.91e-01 | 1.81e-01 | 2.25e-01 | 2.71e-01 | 2.46e-01 | 3.82e-01 | 4.07e-01 | 3.03e-01 |
| SUPPRESSION OF VIRAL RELEASE BY HOST | 15 | 4.53e-01 | 8.21e-01 | 0.4910 | 2.78e-01 | 1.94e-01 | 1.80e-01 | 2.81e-01 | 1.22e-01 | 6.24e-02 | 1.93e-01 | 2.27e-01 | 5.92e-02 | 4.12e-01 |
| PROTEIN INSERTION INTO MEMBRANE | 73 | 1.67e-03 | 2.65e-02 | 0.4910 | 1.74e-01 | 1.60e-01 | 2.65e-01 | 2.47e-01 | 2.32e-01 | 1.00e-02 | 1.78e-02 | 8.78e-05 | 2.67e-04 | 6.01e-04 |
| REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 83 | 9.50e-04 | 1.68e-02 | 0.4910 | 1.84e-01 | 1.75e-01 | 2.59e-01 | 2.67e-01 | 1.96e-01 | 3.77e-03 | 5.90e-03 | 4.52e-05 | 2.55e-05 | 2.01e-03 |
| NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA1 PRODUCTION | 6 | 6.57e-01 | 9.20e-01 | 0.4910 | 3.34e-01 | 2.58e-01 | 7.18e-02 | 2.26e-01 | -8.38e-02 | 1.57e-01 | 2.74e-01 | 7.61e-01 | 3.37e-01 | 7.22e-01 |
| REGULATION OF CALCIDIOL 1 MONOOXYGENASE ACTIVITY | 7 | 2.96e-01 | 7.07e-01 | 0.4910 | 3.12e-01 | 2.41e-01 | -7.83e-03 | 3.04e-02 | -2.91e-01 | 1.53e-01 | 2.69e-01 | 9.71e-01 | 8.89e-01 | 1.82e-01 |
| MONOCYTE CHEMOTACTIC PROTEIN 1 PRODUCTION | 21 | 1.18e-03 | 2.00e-02 | 0.4910 | 2.19e-01 | 6.25e-02 | -1.92e-01 | -7.36e-02 | -3.83e-01 | 8.23e-02 | 6.20e-01 | 1.29e-01 | 5.59e-01 | 2.35e-03 |
| NUCLEOLUS ORGANIZATION | 16 | 3.34e-01 | 7.40e-01 | 0.4910 | 1.43e-01 | 1.47e-01 | 2.12e-01 | 2.44e-01 | 3.07e-01 | 3.20e-01 | 3.09e-01 | 1.43e-01 | 9.07e-02 | 3.34e-02 |
| PHAGOLYSOSOME ASSEMBLY | 17 | 4.19e-02 | 2.66e-01 | 0.4910 | 2.15e-01 | 2.53e-01 | 1.64e-01 | 2.37e-01 | -2.18e-01 | 1.25e-01 | 7.08e-02 | 2.40e-01 | 9.03e-02 | 1.20e-01 |
| MRNA PROCESSING | 450 | 7.03e-22 | 1.71e-19 | 0.4910 | 2.04e-01 | 1.77e-01 | 2.46e-01 | 2.74e-01 | 1.80e-01 | 1.05e-13 | 1.34e-10 | 3.62e-19 | 1.75e-23 | 6.07e-11 |
| TRANS SYNAPTIC SIGNALING MODULATING SYNAPTIC TRANSMISSION | 10 | 3.90e-01 | 7.82e-01 | 0.4910 | -2.01e-01 | -2.96e-01 | -1.66e-01 | -2.38e-01 | -1.70e-01 | 2.71e-01 | 1.05e-01 | 3.65e-01 | 1.93e-01 | 3.53e-01 |
| NUCLEOSIDE TRIPHOSPHATE BIOSYNTHETIC PROCESS | 113 | 1.58e-04 | 3.89e-03 | 0.4910 | 2.28e-01 | 2.28e-01 | 2.44e-01 | 2.15e-01 | 1.77e-01 | 2.77e-05 | 2.93e-05 | 7.60e-06 | 8.03e-05 | 1.11e-03 |
| NEGATIVE REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 5 | 8.71e-01 | 9.78e-01 | 0.4910 | 2.94e-01 | 2.68e-01 | 1.74e-01 | 2.08e-01 | -9.49e-02 | 2.55e-01 | 2.99e-01 | 5.01e-01 | 4.21e-01 | 7.13e-01 |
| NEGATIVE REGULATION OF ENDOPLASMIC RETICULUM CALCIUM ION CONCENTRATION | 7 | 7.07e-01 | 9.34e-01 | 0.4900 | 3.38e-01 | 2.69e-01 | 1.31e-01 | 1.91e-01 | -3.16e-03 | 1.21e-01 | 2.18e-01 | 5.49e-01 | 3.82e-01 | 9.88e-01 |
| CELLULAR RESPONSE TO LEUCINE STARVATION | 12 | 3.25e-01 | 7.35e-01 | 0.4900 | 2.08e-01 | 1.05e-01 | 2.18e-01 | 3.38e-01 | 1.55e-01 | 2.12e-01 | 5.27e-01 | 1.91e-01 | 4.25e-02 | 3.52e-01 |
| NUCLEOSIDE SALVAGE | 8 | 9.00e-02 | 4.06e-01 | 0.4900 | 3.02e-01 | 3.79e-01 | 3.04e-02 | 6.25e-02 | 2.13e-02 | 1.40e-01 | 6.31e-02 | 8.82e-01 | 7.60e-01 | 9.17e-01 |
| OXIDATIVE RNA DEMETHYLATION | 5 | 4.80e-01 | 8.35e-01 | 0.4900 | 3.43e-01 | 1.42e-01 | 1.56e-01 | 1.70e-01 | 2.22e-01 | 1.84e-01 | 5.81e-01 | 5.45e-01 | 5.11e-01 | 3.90e-01 |
| CORTICOSTERONE SECRETION | 5 | 5.46e-01 | 8.71e-01 | 0.4900 | -1.03e-01 | 8.98e-02 | 2.92e-01 | 1.17e-01 | 3.50e-01 | 6.90e-01 | 7.28e-01 | 2.59e-01 | 6.50e-01 | 1.75e-01 |
| POSITIVE REGULATION OF G0 TO G1 TRANSITION | 5 | 1.38e-01 | 5.01e-01 | 0.4900 | -1.84e-01 | 3.51e-02 | -1.14e-01 | -3.41e-01 | 2.75e-01 | 4.75e-01 | 8.92e-01 | 6.59e-01 | 1.87e-01 | 2.87e-01 |
| DEHYDROASCORBIC ACID TRANSPORT | 9 | 5.67e-01 | 8.81e-01 | 0.4900 | 2.36e-01 | 2.62e-01 | 2.21e-01 | 1.27e-01 | 2.25e-01 | 2.20e-01 | 1.74e-01 | 2.51e-01 | 5.09e-01 | 2.43e-01 |
| SPLICEOSOMAL TRI SNRNP COMPLEX ASSEMBLY | 19 | 4.77e-01 | 8.33e-01 | 0.4900 | 2.68e-01 | 2.47e-01 | 1.95e-01 | 2.48e-01 | 8.69e-02 | 4.34e-02 | 6.23e-02 | 1.41e-01 | 6.09e-02 | 5.12e-01 |
| NEGATIVE REGULATION OF SKELETAL MUSCLE CELL DIFFERENTIATION | 5 | 8.35e-01 | 9.73e-01 | 0.4900 | -2.83e-01 | -1.75e-01 | -1.53e-01 | -3.00e-01 | -1.24e-01 | 2.73e-01 | 4.97e-01 | 5.53e-01 | 2.45e-01 | 6.30e-01 |
| PRESYNAPTIC MEMBRANE ORGANIZATION | 6 | 7.29e-01 | 9.44e-01 | 0.4890 | -3.22e-01 | -1.63e-01 | -1.93e-01 | -2.39e-01 | -1.23e-01 | 1.72e-01 | 4.90e-01 | 4.12e-01 | 3.11e-01 | 6.03e-01 |
| POSITIVE REGULATION OF ENDOCYTIC RECYCLING | 8 | 2.85e-01 | 6.93e-01 | 0.4890 | 2.96e-01 | 1.55e-01 | 4.39e-03 | 2.12e-01 | -2.88e-01 | 1.47e-01 | 4.49e-01 | 9.83e-01 | 3.00e-01 | 1.58e-01 |
| L PROLINE BIOSYNTHETIC PROCESS | 6 | 6.29e-01 | 9.10e-01 | 0.4890 | 3.46e-01 | 1.84e-01 | 1.87e-01 | 1.98e-01 | 1.07e-01 | 1.42e-01 | 4.34e-01 | 4.27e-01 | 4.01e-01 | 6.51e-01 |
| ATP METABOLIC PROCESS | 124 | 3.88e-05 | 1.26e-03 | 0.4890 | 2.28e-01 | 2.32e-01 | 2.52e-01 | 2.08e-01 | 1.63e-01 | 1.12e-05 | 8.02e-06 | 1.24e-06 | 6.44e-05 | 1.72e-03 |
| OXIDATIVE DEMETHYLATION | 14 | 3.37e-01 | 7.43e-01 | 0.4890 | -1.33e-01 | -2.71e-01 | -3.07e-01 | -1.88e-01 | -1.36e-01 | 3.88e-01 | 7.93e-02 | 4.65e-02 | 2.24e-01 | 3.79e-01 |
| NEGATIVE REGULATION OF FIBROBLAST MIGRATION | 10 | 1.46e-01 | 5.14e-01 | 0.4880 | 3.43e-01 | 2.97e-01 | 3.57e-02 | 1.76e-01 | 2.06e-02 | 6.05e-02 | 1.04e-01 | 8.45e-01 | 3.34e-01 | 9.10e-01 |
| ADP BIOSYNTHETIC PROCESS | 5 | 7.68e-01 | 9.55e-01 | 0.4880 | 2.82e-01 | 2.49e-01 | 1.15e-01 | 2.88e-01 | 2.51e-02 | 2.74e-01 | 3.36e-01 | 6.56e-01 | 2.65e-01 | 9.23e-01 |
| ARTERIAL ENDOTHELIAL CELL DIFFERENTIATION | 6 | 7.65e-01 | 9.54e-01 | 0.4880 | 2.26e-01 | 2.19e-01 | 1.90e-01 | 1.55e-01 | 2.80e-01 | 3.37e-01 | 3.54e-01 | 4.20e-01 | 5.10e-01 | 2.34e-01 |
| BUNDLE OF HIS CELL TO PURKINJE MYOCYTE COMMUNICATION | 15 | 4.39e-01 | 8.11e-01 | 0.4880 | -1.57e-01 | -2.06e-01 | -2.15e-01 | -2.53e-01 | -2.45e-01 | 2.92e-01 | 1.66e-01 | 1.49e-01 | 8.92e-02 | 1.01e-01 |
| REGULATION OF POST TRANSLATIONAL PROTEIN MODIFICATION | 262 | 8.99e-13 | 9.67e-11 | 0.4880 | 2.16e-01 | 1.86e-01 | 2.18e-01 | 2.75e-01 | 1.83e-01 | 1.76e-09 | 2.21e-07 | 1.25e-09 | 1.67e-14 | 3.52e-07 |
| PROTEIN LOCALIZATION TO CHROMATIN | 56 | 4.23e-02 | 2.67e-01 | 0.4870 | 2.37e-01 | 2.23e-01 | 2.39e-01 | 2.48e-01 | 1.16e-01 | 2.19e-03 | 3.95e-03 | 1.96e-03 | 1.33e-03 | 1.34e-01 |
| DIADENOSINE POLYPHOSPHATE METABOLIC PROCESS | 6 | 6.69e-02 | 3.45e-01 | 0.4870 | 1.87e-01 | -7.09e-02 | -2.42e-01 | -2.52e-01 | -2.74e-01 | 4.29e-01 | 7.64e-01 | 3.05e-01 | 2.84e-01 | 2.44e-01 |
| EMBRYONIC SKELETAL SYSTEM DEVELOPMENT | 126 | 5.75e-08 | 3.26e-06 | 0.4870 | 9.67e-02 | 1.87e-01 | 2.53e-01 | 2.23e-01 | 2.81e-01 | 6.08e-02 | 2.85e-04 | 9.10e-07 | 1.53e-05 | 4.88e-08 |
| POSITIVE REGULATION OF ADIPOSE TISSUE DEVELOPMENT | 10 | 2.93e-01 | 7.04e-01 | 0.4870 | -3.65e-02 | -1.63e-01 | -3.42e-01 | -2.25e-01 | -2.04e-01 | 8.42e-01 | 3.71e-01 | 6.12e-02 | 2.18e-01 | 2.63e-01 |
| POLY N ACETYLLACTOSAMINE METABOLIC PROCESS | 7 | 2.20e-01 | 6.17e-01 | 0.4870 | 2.17e-01 | 2.13e-01 | -1.31e-01 | 4.35e-03 | -3.57e-01 | 3.20e-01 | 3.30e-01 | 5.47e-01 | 9.84e-01 | 1.02e-01 |
| RNA DECAPPING | 19 | 1.86e-01 | 5.72e-01 | 0.4870 | 2.26e-01 | 1.79e-01 | 1.72e-01 | 2.99e-01 | 1.87e-01 | 8.77e-02 | 1.78e-01 | 1.96e-01 | 2.38e-02 | 1.59e-01 |
| CELL CYCLE CHECKPOINT SIGNALING | 188 | 1.25e-10 | 1.02e-08 | 0.4870 | 1.96e-01 | 1.67e-01 | 2.23e-01 | 2.95e-01 | 1.83e-01 | 3.39e-06 | 7.67e-05 | 1.31e-07 | 2.84e-12 | 1.50e-05 |
| BASE EXCISION REPAIR GAP FILLING | 14 | 6.25e-01 | 9.09e-01 | 0.4860 | 1.56e-01 | 1.93e-01 | 2.81e-01 | 2.33e-01 | 2.04e-01 | 3.11e-01 | 2.10e-01 | 6.90e-02 | 1.31e-01 | 1.85e-01 |
| NADH METABOLIC PROCESS | 11 | 6.05e-01 | 9.01e-01 | 0.4860 | 2.25e-01 | 2.76e-01 | 1.84e-01 | 2.10e-01 | 1.77e-01 | 1.96e-01 | 1.13e-01 | 2.90e-01 | 2.27e-01 | 3.09e-01 |
| NEGATIVE REGULATION OF REGULATORY T CELL DIFFERENTIATION | 7 | 4.35e-01 | 8.09e-01 | 0.4860 | 7.62e-02 | -4.58e-03 | 2.16e-01 | 2.87e-01 | 3.19e-01 | 7.27e-01 | 9.83e-01 | 3.23e-01 | 1.88e-01 | 1.44e-01 |
| REGULATION OF ASPARTIC TYPE PEPTIDASE ACTIVITY | 10 | 2.19e-01 | 6.17e-01 | 0.4860 | 3.41e-01 | 2.32e-01 | 6.99e-03 | 1.75e-01 | -1.87e-01 | 6.16e-02 | 2.03e-01 | 9.69e-01 | 3.37e-01 | 3.06e-01 |
| POSITIVE REGULATION OF CENTRIOLE ELONGATION | 5 | 7.26e-01 | 9.43e-01 | 0.4860 | 1.65e-01 | 1.56e-01 | 1.78e-01 | 3.30e-01 | 2.09e-01 | 5.23e-01 | 5.46e-01 | 4.90e-01 | 2.01e-01 | 4.18e-01 |
| FORMATION OF TRANSLATION PREINITIATION COMPLEX | 7 | 6.31e-01 | 9.11e-01 | 0.4860 | 1.76e-01 | 2.84e-01 | 3.07e-01 | 1.69e-01 | 4.03e-02 | 4.19e-01 | 1.94e-01 | 1.59e-01 | 4.39e-01 | 8.54e-01 |
| PROTEIN HETEROTETRAMERIZATION | 15 | 1.12e-01 | 4.56e-01 | 0.4860 | 2.82e-01 | 1.14e-01 | 1.44e-01 | 3.33e-01 | 1.09e-01 | 5.82e-02 | 4.45e-01 | 3.34e-01 | 2.56e-02 | 4.66e-01 |
| DUCTUS ARTERIOSUS CLOSURE | 5 | 3.46e-01 | 7.50e-01 | 0.4860 | -9.31e-02 | 1.26e-01 | 3.39e-01 | 2.80e-02 | 3.10e-01 | 7.18e-01 | 6.26e-01 | 1.89e-01 | 9.14e-01 | 2.31e-01 |
| REGULATION OF SYNAPSE MATURATION | 20 | 4.92e-01 | 8.42e-01 | 0.4860 | 2.27e-01 | 2.25e-01 | 2.54e-01 | 2.13e-01 | 1.53e-01 | 7.88e-02 | 8.13e-02 | 4.91e-02 | 9.84e-02 | 2.36e-01 |
| REGULATION OF ANTIBACTERIAL PEPTIDE PRODUCTION | 7 | 3.46e-01 | 7.50e-01 | 0.4850 | -1.07e-01 | 2.92e-02 | -2.47e-01 | -2.79e-01 | -2.90e-01 | 6.24e-01 | 8.93e-01 | 2.57e-01 | 2.01e-01 | 1.83e-01 |
| PROTEIN LOCALIZATION TO CHROMOSOME | 113 | 8.60e-05 | 2.47e-03 | 0.4850 | 2.24e-01 | 1.96e-01 | 2.25e-01 | 2.76e-01 | 1.43e-01 | 3.87e-05 | 3.17e-04 | 3.61e-05 | 4.12e-07 | 8.62e-03 |
| SPHINGOLIPID TRANSLOCATION | 5 | 9.06e-01 | 9.84e-01 | 0.4850 | -2.39e-01 | -1.98e-01 | -2.50e-01 | -1.91e-01 | -2.01e-01 | 3.54e-01 | 4.43e-01 | 3.34e-01 | 4.60e-01 | 4.37e-01 |
| REGULATION OF GLOMERULUS DEVELOPMENT | 5 | 3.95e-01 | 7.85e-01 | 0.4850 | -8.64e-02 | -1.11e-01 | 2.57e-01 | 1.49e-01 | 3.57e-01 | 7.38e-01 | 6.68e-01 | 3.19e-01 | 5.65e-01 | 1.67e-01 |
| REGULATION OF POSTSYNAPTIC SPECIALIZATION ASSEMBLY | 13 | 3.29e-01 | 7.37e-01 | 0.4850 | -3.32e-01 | -2.50e-01 | -1.10e-01 | -1.97e-01 | 1.08e-01 | 3.83e-02 | 1.18e-01 | 4.91e-01 | 2.18e-01 | 5.01e-01 |
| POSITIVE REGULATION OF LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 10 | 7.06e-01 | 9.33e-01 | 0.4850 | -2.33e-01 | -2.29e-01 | -2.50e-01 | -2.58e-01 | -9.06e-03 | 2.02e-01 | 2.10e-01 | 1.71e-01 | 1.58e-01 | 9.60e-01 |
| ATRIAL SEPTUM MORPHOGENESIS | 15 | 5.01e-01 | 8.48e-01 | 0.4850 | 1.27e-01 | 2.09e-01 | 2.46e-01 | 2.04e-01 | 2.71e-01 | 3.94e-01 | 1.61e-01 | 9.91e-02 | 1.71e-01 | 6.91e-02 |
| OSTEOCLAST PROLIFERATION | 11 | 5.11e-01 | 8.54e-01 | 0.4850 | 2.13e-01 | 2.71e-01 | 1.74e-01 | 2.46e-01 | 1.59e-01 | 2.22e-01 | 1.19e-01 | 3.16e-01 | 1.57e-01 | 3.60e-01 |
| NEGATIVE REGULATION OF MEMBRANE DEPOLARIZATION | 7 | 7.06e-01 | 9.33e-01 | 0.4850 | 1.83e-01 | 2.83e-01 | 1.87e-01 | 2.22e-01 | 1.94e-01 | 4.01e-01 | 1.95e-01 | 3.93e-01 | 3.09e-01 | 3.73e-01 |
| RNA EXPORT FROM NUCLEUS | 83 | 1.90e-03 | 2.92e-02 | 0.4850 | 2.61e-01 | 2.08e-01 | 2.25e-01 | 2.51e-01 | 9.93e-02 | 3.86e-05 | 1.03e-03 | 3.92e-04 | 7.75e-05 | 1.18e-01 |
| REGULATION OF ERYTHROCYTE DIFFERENTIATION | 44 | 7.73e-03 | 8.50e-02 | 0.4850 | 1.77e-01 | 2.07e-01 | 1.91e-01 | 2.58e-01 | 2.40e-01 | 4.17e-02 | 1.76e-02 | 2.87e-02 | 3.02e-03 | 5.84e-03 |
| NEGATIVE REGULATION OF TUBULIN DEACETYLATION | 5 | 6.56e-01 | 9.20e-01 | 0.4850 | -2.44e-01 | -2.06e-01 | -1.83e-01 | -2.18e-01 | 2.28e-01 | 3.45e-01 | 4.25e-01 | 4.79e-01 | 3.99e-01 | 3.77e-01 |
| REGULATION OF MORPHOGENESIS OF A BRANCHING STRUCTURE | 48 | 2.20e-02 | 1.77e-01 | 0.4840 | 1.60e-01 | 1.90e-01 | 2.24e-01 | 2.18e-01 | 2.74e-01 | 5.49e-02 | 2.24e-02 | 7.34e-03 | 8.90e-03 | 1.02e-03 |
| TRANSCRIPTION BY RNA POLYMERASE I | 68 | 4.86e-03 | 5.99e-02 | 0.4840 | 1.56e-01 | 1.95e-01 | 2.57e-01 | 2.03e-01 | 2.55e-01 | 2.58e-02 | 5.53e-03 | 2.45e-04 | 3.75e-03 | 2.78e-04 |
| NEGATIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 13 | 5.07e-01 | 8.52e-01 | 0.4840 | -1.76e-01 | -1.84e-01 | -2.65e-01 | -2.98e-01 | -1.04e-01 | 2.72e-01 | 2.50e-01 | 9.85e-02 | 6.29e-02 | 5.15e-01 |
| TRICARBOXYLIC ACID CYCLE | 29 | 2.88e-01 | 6.97e-01 | 0.4840 | 2.45e-01 | 2.55e-01 | 2.13e-01 | 2.24e-01 | 1.17e-01 | 2.22e-02 | 1.74e-02 | 4.73e-02 | 3.69e-02 | 2.74e-01 |
| MALE SEX DETERMINATION | 11 | 3.21e-01 | 7.32e-01 | 0.4840 | 9.82e-02 | 2.00e-01 | 3.12e-01 | 1.10e-01 | 2.74e-01 | 5.73e-01 | 2.52e-01 | 7.28e-02 | 5.28e-01 | 1.15e-01 |
| VITAMIN E METABOLIC PROCESS | 6 | 2.45e-01 | 6.50e-01 | 0.4840 | 9.47e-02 | 4.01e-01 | 2.10e-01 | 8.78e-02 | 1.10e-01 | 6.88e-01 | 8.87e-02 | 3.72e-01 | 7.09e-01 | 6.41e-01 |
| NEGATIVE REGULATION OF MYOTUBE DIFFERENTIATION | 17 | 2.09e-01 | 6.03e-01 | 0.4830 | 4.22e-02 | 1.08e-01 | 2.52e-01 | 1.67e-01 | 3.59e-01 | 7.63e-01 | 4.39e-01 | 7.17e-02 | 2.32e-01 | 1.05e-02 |
| CELL FATE COMMITMENT | 279 | 4.14e-13 | 4.86e-11 | 0.4830 | 1.52e-01 | 1.91e-01 | 2.55e-01 | 2.14e-01 | 2.52e-01 | 1.25e-05 | 4.10e-08 | 2.08e-13 | 7.92e-10 | 4.50e-13 |
| POSITIVE REGULATION OF DNA BINDING | 41 | 8.71e-02 | 3.99e-01 | 0.4830 | 1.93e-01 | 2.35e-01 | 2.72e-01 | 2.03e-01 | 1.62e-01 | 3.27e-02 | 9.29e-03 | 2.54e-03 | 2.48e-02 | 7.34e-02 |
| REGULATION OF NEUTROPHIL ACTIVATION | 15 | 1.72e-01 | 5.56e-01 | 0.4830 | 2.85e-01 | 3.12e-01 | 1.20e-01 | 1.40e-01 | -1.42e-01 | 5.56e-02 | 3.62e-02 | 4.21e-01 | 3.46e-01 | 3.40e-01 |
| POSITIVE REGULATION OF MRNA PROCESSING | 28 | 6.28e-02 | 3.33e-01 | 0.4830 | 1.01e-01 | 1.78e-01 | 2.61e-01 | 2.71e-01 | 2.23e-01 | 3.54e-01 | 1.02e-01 | 1.67e-02 | 1.31e-02 | 4.12e-02 |
| POLY A PLUS MRNA EXPORT FROM NUCLEUS | 18 | 5.15e-01 | 8.56e-01 | 0.4830 | 2.32e-01 | 1.91e-01 | 2.19e-01 | 2.75e-01 | 1.41e-01 | 8.87e-02 | 1.61e-01 | 1.08e-01 | 4.36e-02 | 2.99e-01 |
| REGULATION OF TRANSCRIPTION BY RNA POLYMERASE III | 28 | 5.24e-02 | 3.02e-01 | 0.4830 | 3.35e-01 | 2.27e-01 | 1.40e-01 | 2.21e-01 | 3.57e-02 | 2.16e-03 | 3.80e-02 | 1.98e-01 | 4.29e-02 | 7.44e-01 |
| NEGATIVE REGULATION OF GLIAL CELL DIFFERENTIATION | 27 | 1.55e-01 | 5.25e-01 | 0.4830 | 1.32e-01 | 1.50e-01 | 2.41e-01 | 2.09e-01 | 3.03e-01 | 2.37e-01 | 1.79e-01 | 3.02e-02 | 6.06e-02 | 6.40e-03 |
| ROOF OF MOUTH DEVELOPMENT | 90 | 4.19e-04 | 8.76e-03 | 0.4830 | 1.42e-01 | 1.83e-01 | 2.55e-01 | 2.34e-01 | 2.44e-01 | 1.97e-02 | 2.65e-03 | 2.84e-05 | 1.28e-04 | 6.17e-05 |
| BROWN FAT CELL DIFFERENTIATION | 53 | 1.84e-02 | 1.58e-01 | 0.4830 | 2.22e-01 | 2.49e-01 | 2.26e-01 | 1.80e-01 | 1.95e-01 | 5.18e-03 | 1.71e-03 | 4.41e-03 | 2.32e-02 | 1.38e-02 |
| HEMATOPOIETIC STEM CELL PROLIFERATION | 33 | 1.47e-01 | 5.15e-01 | 0.4830 | 2.00e-01 | 2.46e-01 | 2.20e-01 | 2.54e-01 | 1.40e-01 | 4.69e-02 | 1.44e-02 | 2.89e-02 | 1.16e-02 | 1.64e-01 |
| REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 12 | 3.47e-01 | 7.50e-01 | 0.4830 | 2.49e-01 | 1.39e-01 | 2.59e-01 | 2.09e-01 | 2.02e-01 | 1.36e-01 | 4.04e-01 | 1.20e-01 | 2.10e-01 | 2.25e-01 |
| DETERMINATION OF LIVER LEFT RIGHT ASYMMETRY | 5 | 1.43e-01 | 5.09e-01 | 0.4820 | 2.70e-01 | -5.52e-02 | 2.41e-02 | 2.62e-01 | 2.96e-01 | 2.96e-01 | 8.31e-01 | 9.26e-01 | 3.10e-01 | 2.52e-01 |
| REGULATION OF BILE ACID BIOSYNTHETIC PROCESS | 12 | 5.39e-01 | 8.67e-01 | 0.4820 | -2.72e-01 | -3.08e-01 | -1.66e-01 | -1.91e-01 | -8.93e-03 | 1.03e-01 | 6.51e-02 | 3.19e-01 | 2.52e-01 | 9.57e-01 |
| NEGATIVE REGULATION OF METALLOENDOPEPTIDASE ACTIVITY | 8 | 7.63e-01 | 9.54e-01 | 0.4820 | -1.68e-01 | -2.09e-01 | -2.56e-01 | -2.91e-01 | -1.04e-01 | 4.10e-01 | 3.07e-01 | 2.10e-01 | 1.55e-01 | 6.12e-01 |
| DORSAL VENTRAL NEURAL TUBE PATTERNING | 24 | 1.73e-01 | 5.57e-01 | 0.4820 | 1.99e-01 | 2.01e-01 | 1.86e-01 | 2.48e-01 | 2.38e-01 | 9.20e-02 | 8.87e-02 | 1.15e-01 | 3.53e-02 | 4.39e-02 |
| RESPONSE TO ETHER | 11 | 2.92e-01 | 7.03e-01 | 0.4820 | 2.61e-01 | 2.60e-01 | 1.26e-01 | 1.74e-01 | 2.24e-01 | 1.34e-01 | 1.35e-01 | 4.68e-01 | 3.17e-01 | 1.98e-01 |
| POSITIVE REGULATION OF RECEPTOR BINDING | 6 | 4.63e-01 | 8.25e-01 | 0.4820 | 1.42e-01 | 3.66e-02 | 1.41e-01 | 3.05e-01 | 3.13e-01 | 5.47e-01 | 8.77e-01 | 5.51e-01 | 1.96e-01 | 1.85e-01 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 SIGNALING PATHWAY | 6 | 6.76e-01 | 9.28e-01 | 0.4820 | 1.37e-01 | 2.45e-01 | 3.11e-01 | 1.09e-01 | 2.11e-01 | 5.61e-01 | 2.98e-01 | 1.87e-01 | 6.44e-01 | 3.71e-01 |
| MAGNESIUM ION TRANSPORT | 16 | 3.33e-01 | 7.40e-01 | 0.4820 | -2.94e-01 | -3.01e-01 | -1.59e-01 | -1.72e-01 | -1.05e-03 | 4.15e-02 | 3.70e-02 | 2.72e-01 | 2.35e-01 | 9.94e-01 |
| N TERMINAL PROTEIN AMINO ACID ACETYLATION | 15 | 6.26e-01 | 9.09e-01 | 0.4820 | 1.60e-01 | 2.20e-01 | 2.55e-01 | 2.08e-01 | 2.23e-01 | 2.83e-01 | 1.40e-01 | 8.67e-02 | 1.64e-01 | 1.35e-01 |
| MEMBRANOUS SEPTUM MORPHOGENESIS | 8 | 3.06e-01 | 7.18e-01 | 0.4820 | -6.93e-02 | 6.12e-02 | 3.05e-01 | 1.73e-01 | 3.16e-01 | 7.34e-01 | 7.65e-01 | 1.35e-01 | 3.96e-01 | 1.21e-01 |
| MANNOSE METABOLIC PROCESS | 9 | 5.16e-01 | 8.56e-01 | 0.4810 | 1.07e-01 | 1.27e-01 | 2.34e-01 | 3.08e-01 | 2.33e-01 | 5.77e-01 | 5.09e-01 | 2.24e-01 | 1.09e-01 | 2.26e-01 |
| IRIS MORPHOGENESIS | 10 | 4.58e-01 | 8.22e-01 | 0.4810 | 9.99e-02 | 9.74e-02 | 1.86e-01 | 2.18e-01 | 3.60e-01 | 5.84e-01 | 5.94e-01 | 3.08e-01 | 2.32e-01 | 4.84e-02 |
| POSITIVE REGULATION OF T HELPER 2 CELL DIFFERENTIATION | 7 | 1.93e-01 | 5.80e-01 | 0.4810 | 3.06e-01 | 3.49e-01 | -4.24e-03 | 5.22e-02 | -1.16e-01 | 1.61e-01 | 1.10e-01 | 9.85e-01 | 8.11e-01 | 5.95e-01 |
| POSITIVE REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 12 | 6.19e-01 | 9.07e-01 | 0.4810 | 1.63e-01 | 2.71e-01 | 2.61e-01 | 2.20e-01 | 1.20e-01 | 3.27e-01 | 1.04e-01 | 1.17e-01 | 1.87e-01 | 4.70e-01 |
| NEGATIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 32 | 4.56e-02 | 2.78e-01 | 0.4810 | 1.45e-01 | 1.34e-01 | 2.13e-01 | 2.71e-01 | 2.70e-01 | 1.56e-01 | 1.91e-01 | 3.66e-02 | 7.89e-03 | 8.18e-03 |
| MICROGLIAL CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 5 | 1.36e-01 | 4.99e-01 | 0.4810 | 1.41e-01 | -7.10e-02 | -3.45e-01 | -2.55e-01 | -1.50e-01 | 5.86e-01 | 7.83e-01 | 1.82e-01 | 3.24e-01 | 5.62e-01 |
| PROTEIN RNA COMPLEX ORGANIZATION | 205 | 8.20e-09 | 5.32e-07 | 0.4810 | 1.94e-01 | 1.76e-01 | 2.46e-01 | 2.57e-01 | 1.90e-01 | 1.76e-06 | 1.45e-05 | 1.28e-09 | 2.12e-10 | 2.73e-06 |
| REGULATION OF MDA 5 SIGNALING PATHWAY | 7 | 6.93e-01 | 9.31e-01 | 0.4810 | 2.28e-01 | 3.17e-01 | 2.09e-01 | 1.73e-01 | -7.02e-02 | 2.97e-01 | 1.47e-01 | 3.37e-01 | 4.28e-01 | 7.48e-01 |
| MRNA EXPORT FROM NUCLEUS | 62 | 8.83e-03 | 9.31e-02 | 0.4800 | 2.66e-01 | 1.92e-01 | 2.17e-01 | 2.55e-01 | 1.04e-01 | 2.98e-04 | 8.90e-03 | 3.07e-03 | 5.08e-04 | 1.58e-01 |
| NEGATIVE REGULATION OF VASOCONSTRICTION | 8 | 4.63e-01 | 8.25e-01 | 0.4800 | -1.40e-01 | -1.22e-01 | -2.82e-01 | -3.29e-01 | -8.76e-02 | 4.92e-01 | 5.50e-01 | 1.67e-01 | 1.07e-01 | 6.68e-01 |
| ERROR FREE TRANSLESION SYNTHESIS | 5 | 2.08e-01 | 6.03e-01 | 0.4800 | 5.32e-02 | -1.99e-01 | 1.10e-01 | 1.73e-01 | 3.82e-01 | 8.37e-01 | 4.41e-01 | 6.70e-01 | 5.03e-01 | 1.39e-01 |
| NEGATIVE REGULATION OF SEQUESTERING OF TRIGLYCERIDE | 6 | 3.04e-01 | 7.16e-01 | 0.4800 | 1.22e-01 | -8.22e-02 | -3.27e-01 | -1.24e-01 | -2.93e-01 | 6.05e-01 | 7.27e-01 | 1.65e-01 | 5.98e-01 | 2.14e-01 |
| CANONICAL WNT SIGNALING PATHWAY INVOLVED IN OSTEOBLAST DIFFERENTIATION | 7 | 6.04e-01 | 9.01e-01 | 0.4790 | -3.04e-01 | -2.62e-01 | -1.63e-01 | -1.43e-01 | 1.47e-01 | 1.64e-01 | 2.30e-01 | 4.54e-01 | 5.12e-01 | 5.01e-01 |
| RIBOSOME DISASSEMBLY | 12 | 1.62e-01 | 5.38e-01 | 0.4790 | 2.44e-01 | 2.80e-01 | 9.79e-02 | 2.52e-01 | -1.37e-01 | 1.44e-01 | 9.28e-02 | 5.57e-01 | 1.30e-01 | 4.12e-01 |
| NEGATIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL PROLIFERATION INVOLVED IN SPROUTING ANGIOGENESIS | 22 | 4.00e-01 | 7.88e-01 | 0.4790 | -2.54e-01 | -2.22e-01 | -2.26e-01 | -2.08e-01 | -1.47e-01 | 3.94e-02 | 7.14e-02 | 6.68e-02 | 9.07e-02 | 2.31e-01 |
| DEDIFFERENTIATION | 11 | 2.82e-01 | 6.93e-01 | 0.4790 | 1.98e-01 | 2.30e-01 | 1.34e-01 | 2.13e-01 | 2.73e-01 | 2.55e-01 | 1.87e-01 | 4.43e-01 | 2.22e-01 | 1.17e-01 |
| REGULATION OF EPINEPHRINE SECRETION | 7 | 1.49e-01 | 5.17e-01 | 0.4790 | -1.67e-01 | -3.35e-01 | -1.36e-02 | -5.93e-02 | 2.93e-01 | 4.43e-01 | 1.25e-01 | 9.50e-01 | 7.86e-01 | 1.80e-01 |
| PROTEIN LOCALIZATION TO NUCLEAR BODY | 11 | 5.16e-01 | 8.56e-01 | 0.4790 | 1.99e-01 | 1.26e-01 | 2.81e-01 | 2.47e-01 | 1.85e-01 | 2.53e-01 | 4.69e-01 | 1.07e-01 | 1.56e-01 | 2.89e-01 |
| NCRNA EXPORT FROM NUCLEUS | 9 | 6.55e-01 | 9.20e-01 | 0.4790 | 1.02e-01 | 1.41e-01 | 2.47e-01 | 2.71e-01 | 2.54e-01 | 5.95e-01 | 4.63e-01 | 1.99e-01 | 1.59e-01 | 1.87e-01 |
| MEGAKARYOCYTE DIFFERENTIATION | 61 | 1.34e-02 | 1.26e-01 | 0.4790 | 1.65e-01 | 2.38e-01 | 2.45e-01 | 2.24e-01 | 1.87e-01 | 2.58e-02 | 1.29e-03 | 9.22e-04 | 2.42e-03 | 1.16e-02 |
| HINDGUT DEVELOPMENT | 8 | 1.70e-01 | 5.55e-01 | 0.4790 | -1.80e-01 | -1.60e-01 | 1.83e-01 | 5.90e-02 | 3.67e-01 | 3.78e-01 | 4.34e-01 | 3.71e-01 | 7.73e-01 | 7.24e-02 |
| REGULATION OF MITOCHONDRIAL GENE EXPRESSION | 30 | 3.27e-02 | 2.29e-01 | 0.4790 | 1.99e-01 | 1.15e-01 | 2.78e-01 | 2.56e-01 | 1.84e-01 | 5.97e-02 | 2.76e-01 | 8.43e-03 | 1.52e-02 | 8.18e-02 |
| TROPHECTODERMAL CELL DIFFERENTIATION | 19 | 1.87e-01 | 5.72e-01 | 0.4790 | 7.09e-02 | 1.70e-01 | 2.39e-01 | 1.44e-01 | 3.42e-01 | 5.92e-01 | 2.00e-01 | 7.12e-02 | 2.76e-01 | 9.75e-03 |
| REGULATION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ACTIVITY | 8 | 6.46e-02 | 3.38e-01 | 0.4790 | -1.23e-01 | 1.56e-01 | 2.91e-01 | 2.17e-01 | 2.40e-01 | 5.46e-01 | 4.46e-01 | 1.54e-01 | 2.87e-01 | 2.40e-01 |
| TELOMERE MAINTENANCE VIA SEMI CONSERVATIVE REPLICATION | 9 | 6.00e-01 | 8.98e-01 | 0.4790 | 1.96e-01 | 1.47e-01 | 1.69e-01 | 2.54e-01 | 2.75e-01 | 3.08e-01 | 4.44e-01 | 3.79e-01 | 1.87e-01 | 1.53e-01 |
| PHOSPHOLIPID EFFLUX | 14 | 4.21e-03 | 5.46e-02 | 0.4780 | -3.68e-01 | -4.53e-02 | -8.23e-02 | -2.52e-01 | -1.45e-01 | 1.71e-02 | 7.69e-01 | 5.94e-01 | 1.02e-01 | 3.49e-01 |
| THREONINE METABOLIC PROCESS | 5 | 1.65e-01 | 5.44e-01 | 0.4780 | 9.50e-02 | 4.40e-02 | 1.24e-01 | 4.28e-01 | 1.38e-01 | 7.13e-01 | 8.65e-01 | 6.32e-01 | 9.73e-02 | 5.92e-01 |
| POSITIVE REGULATION OF MITOPHAGY | 7 | 6.89e-01 | 9.31e-01 | 0.4780 | -4.67e-02 | -1.22e-01 | -2.85e-01 | -2.38e-01 | -2.72e-01 | 8.31e-01 | 5.75e-01 | 1.92e-01 | 2.76e-01 | 2.13e-01 |
| CELL FATE COMMITMENT INVOLVED IN FORMATION OF PRIMARY GERM LAYER | 32 | 1.19e-01 | 4.69e-01 | 0.4780 | 1.66e-01 | 1.84e-01 | 2.26e-01 | 1.93e-01 | 2.81e-01 | 1.04e-01 | 7.10e-02 | 2.72e-02 | 5.92e-02 | 5.97e-03 |
| NEGATIVE REGULATION OF EPINEPHRINE SECRETION | 5 | 2.55e-01 | 6.62e-01 | 0.4780 | -9.16e-02 | -2.28e-01 | 1.71e-01 | 1.62e-01 | 3.35e-01 | 7.23e-01 | 3.78e-01 | 5.08e-01 | 5.32e-01 | 1.94e-01 |
| POSITIVE REGULATION OF ERAD PATHWAY | 13 | 5.43e-01 | 8.69e-01 | 0.4780 | 1.64e-01 | 1.64e-01 | 2.07e-01 | 2.65e-01 | 2.47e-01 | 3.07e-01 | 3.05e-01 | 1.96e-01 | 9.79e-02 | 1.23e-01 |
| POSITIVE REGULATION OF INTERFERON ALPHA PRODUCTION | 21 | 1.53e-01 | 5.22e-01 | 0.4770 | 2.76e-01 | 2.53e-01 | 1.33e-01 | 2.54e-01 | 7.35e-02 | 2.87e-02 | 4.44e-02 | 2.92e-01 | 4.39e-02 | 5.60e-01 |
| RESPIRATORY BURST | 33 | 1.12e-01 | 4.56e-01 | 0.4770 | 2.67e-01 | 2.30e-01 | 1.96e-01 | 1.98e-01 | 1.60e-01 | 7.93e-03 | 2.22e-02 | 5.10e-02 | 4.88e-02 | 1.12e-01 |
| MINERALOCORTICOID SECRETION | 7 | 2.55e-01 | 6.62e-01 | 0.4770 | 2.01e-02 | -2.39e-01 | -2.68e-01 | -3.35e-03 | -3.13e-01 | 9.27e-01 | 2.73e-01 | 2.19e-01 | 9.88e-01 | 1.52e-01 |
| REGULATION OF GLUCAGON SECRETION | 8 | 2.81e-02 | 2.08e-01 | 0.4770 | 3.03e-01 | 1.86e-01 | -7.94e-03 | 9.34e-02 | 3.04e-01 | 1.38e-01 | 3.63e-01 | 9.69e-01 | 6.47e-01 | 1.37e-01 |
| DETECTION OF BACTERIUM | 16 | 2.54e-01 | 6.61e-01 | 0.4770 | 2.78e-01 | 3.04e-01 | 1.29e-01 | 1.96e-01 | -4.82e-02 | 5.43e-02 | 3.52e-02 | 3.73e-01 | 1.74e-01 | 7.39e-01 |
| SKELETAL MUSCLE TISSUE GROWTH | 9 | 7.39e-01 | 9.49e-01 | 0.4760 | 1.73e-01 | 1.90e-01 | 2.10e-01 | 1.83e-01 | 2.89e-01 | 3.69e-01 | 3.23e-01 | 2.76e-01 | 3.43e-01 | 1.34e-01 |
| NEGATIVE REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 66 | 1.05e-03 | 1.81e-02 | 0.4760 | 2.14e-01 | 1.71e-01 | 2.11e-01 | 3.06e-01 | 1.16e-01 | 2.60e-03 | 1.64e-02 | 3.09e-03 | 1.67e-05 | 1.02e-01 |
| POSITIVE REGULATION OF ATTACHMENT OF SPINDLE MICROTUBULES TO KINETOCHORE | 11 | 4.48e-01 | 8.19e-01 | 0.4760 | 1.90e-01 | 1.77e-01 | 3.13e-01 | 2.28e-01 | 9.65e-02 | 2.74e-01 | 3.09e-01 | 7.25e-02 | 1.91e-01 | 5.79e-01 |
| CHROMOSOME ATTACHMENT TO THE NUCLEAR ENVELOPE | 7 | 4.96e-01 | 8.45e-01 | 0.4760 | -9.83e-02 | -9.34e-02 | -2.36e-01 | -8.70e-02 | -3.81e-01 | 6.52e-01 | 6.69e-01 | 2.81e-01 | 6.90e-01 | 8.08e-02 |
| ADULT FEEDING BEHAVIOR | 9 | 8.04e-02 | 3.84e-01 | 0.4760 | 2.92e-01 | 2.67e-01 | 1.66e-01 | 1.34e-02 | 2.06e-01 | 1.29e-01 | 1.66e-01 | 3.89e-01 | 9.44e-01 | 2.84e-01 |
| POSITIVE REGULATION OF AUTOPHAGOSOME ASSEMBLY | 18 | 3.37e-01 | 7.43e-01 | 0.4760 | 2.49e-01 | 1.97e-01 | 1.92e-01 | 2.97e-01 | 2.11e-02 | 6.71e-02 | 1.47e-01 | 1.58e-01 | 2.94e-02 | 8.77e-01 |
| REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 32 | 1.33e-01 | 4.93e-01 | 0.4760 | 2.81e-01 | 2.49e-01 | 1.69e-01 | 2.24e-01 | 8.15e-02 | 5.92e-03 | 1.47e-02 | 9.85e-02 | 2.84e-02 | 4.25e-01 |
| POSITIVE REGULATION OF HEPATIC STELLATE CELL ACTIVATION | 5 | 2.47e-01 | 6.53e-01 | 0.4760 | 2.72e-01 | 2.87e-01 | -1.01e-01 | -8.11e-02 | -2.30e-01 | 2.92e-01 | 2.66e-01 | 6.96e-01 | 7.54e-01 | 3.73e-01 |
| OBSERVATIONAL LEARNING | 7 | 8.97e-01 | 9.82e-01 | 0.4750 | -2.43e-01 | -1.82e-01 | -2.21e-01 | -2.60e-01 | -1.33e-01 | 2.65e-01 | 4.04e-01 | 3.12e-01 | 2.34e-01 | 5.43e-01 |
| DEOXYRIBONUCLEOTIDE CATABOLIC PROCESS | 28 | 2.61e-01 | 6.67e-01 | 0.4750 | 2.66e-01 | 2.15e-01 | 2.17e-01 | 2.21e-01 | 1.15e-01 | 1.50e-02 | 4.93e-02 | 4.68e-02 | 4.27e-02 | 2.93e-01 |
| NUCLEAR MEMBRANE ORGANIZATION | 42 | 2.37e-02 | 1.87e-01 | 0.4750 | 2.01e-01 | 1.48e-01 | 2.47e-01 | 2.94e-01 | 1.26e-01 | 2.41e-02 | 9.71e-02 | 5.55e-03 | 9.86e-04 | 1.56e-01 |
| POSITIVE REGULATION OF RETINOIC ACID RECEPTOR SIGNALING PATHWAY | 5 | 6.19e-02 | 3.30e-01 | 0.4750 | 3.58e-03 | -6.87e-02 | -5.80e-02 | 2.55e-01 | 3.90e-01 | 9.89e-01 | 7.90e-01 | 8.22e-01 | 3.22e-01 | 1.31e-01 |
| ADENYLATE CYCLASE INHIBITING SEROTONIN RECEPTOR SIGNALING PATHWAY | 7 | 5.13e-01 | 8.55e-01 | 0.4750 | 3.51e-02 | 8.23e-02 | 1.53e-01 | 1.14e-01 | 4.25e-01 | 8.72e-01 | 7.06e-01 | 4.82e-01 | 6.00e-01 | 5.12e-02 |
| PROTEIN N LINKED GLYCOSYLATION | 68 | 1.07e-02 | 1.07e-01 | 0.4750 | 2.60e-01 | 2.18e-01 | 1.97e-01 | 2.48e-01 | 9.98e-02 | 2.10e-04 | 1.88e-03 | 4.93e-03 | 4.01e-04 | 1.54e-01 |
| REGULATION OF B CELL DIFFERENTIATION | 31 | 1.86e-01 | 5.72e-01 | 0.4750 | 2.03e-01 | 2.17e-01 | 2.03e-01 | 2.51e-01 | 1.82e-01 | 5.02e-02 | 3.65e-02 | 5.01e-02 | 1.58e-02 | 7.97e-02 |
| EARLY ENDOSOME TO GOLGI TRANSPORT | 13 | 6.51e-01 | 9.18e-01 | 0.4750 | 1.86e-01 | 1.87e-01 | 2.52e-01 | 1.90e-01 | 2.37e-01 | 2.46e-01 | 2.42e-01 | 1.15e-01 | 2.36e-01 | 1.39e-01 |
| DNA TEMPLATED TRANSCRIPTION INITIATION | 135 | 1.86e-05 | 6.57e-04 | 0.4750 | 1.88e-01 | 1.97e-01 | 2.24e-01 | 2.26e-01 | 2.23e-01 | 1.60e-04 | 7.50e-05 | 6.95e-06 | 5.73e-06 | 7.63e-06 |
| NEGATIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 19 | 2.30e-01 | 6.32e-01 | 0.4740 | 2.86e-01 | 1.80e-01 | 1.88e-01 | 2.14e-01 | 1.73e-01 | 3.08e-02 | 1.75e-01 | 1.56e-01 | 1.07e-01 | 1.92e-01 |
| NOREPINEPHRINE BIOSYNTHETIC PROCESS | 8 | 3.32e-01 | 7.40e-01 | 0.4740 | 1.31e-02 | 2.12e-01 | 3.06e-01 | 6.28e-02 | 2.86e-01 | 9.49e-01 | 2.98e-01 | 1.33e-01 | 7.58e-01 | 1.61e-01 |
| ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE | 13 | 1.87e-01 | 5.72e-01 | 0.4740 | -9.37e-03 | 9.32e-02 | 1.92e-01 | 8.24e-02 | 4.16e-01 | 9.53e-01 | 5.61e-01 | 2.31e-01 | 6.07e-01 | 9.47e-03 |
| SKELETAL MUSCLE FIBER DIFFERENTIATION | 8 | 4.07e-01 | 7.93e-01 | 0.4740 | -4.40e-02 | 1.37e-01 | 2.66e-01 | 8.05e-02 | 3.56e-01 | 8.29e-01 | 5.02e-01 | 1.93e-01 | 6.93e-01 | 8.13e-02 |
| REGULATION OF PHENOTYPIC SWITCHING | 6 | 2.62e-01 | 6.70e-01 | 0.4740 | 2.95e-01 | 2.59e-01 | -1.03e-01 | 6.25e-02 | -2.36e-01 | 2.10e-01 | 2.72e-01 | 6.64e-01 | 7.91e-01 | 3.16e-01 |
| CELLULAR RESPONSE TO FLUID SHEAR STRESS | 21 | 3.02e-01 | 7.14e-01 | 0.4740 | 2.77e-01 | 2.55e-01 | 1.80e-01 | 1.86e-01 | 1.24e-01 | 2.77e-02 | 4.34e-02 | 1.52e-01 | 1.39e-01 | 3.25e-01 |
| OLFACTORY BULB INTERNEURON DEVELOPMENT | 7 | 8.11e-01 | 9.68e-01 | 0.4740 | -1.22e-01 | -1.29e-01 | -2.19e-01 | -2.24e-01 | -3.08e-01 | 5.75e-01 | 5.53e-01 | 3.16e-01 | 3.05e-01 | 1.59e-01 |
| CAMP BIOSYNTHETIC PROCESS | 10 | 2.35e-01 | 6.37e-01 | 0.4740 | -1.29e-01 | -3.65e-02 | -1.89e-01 | -3.33e-01 | -2.45e-01 | 4.81e-01 | 8.42e-01 | 3.01e-01 | 6.83e-02 | 1.80e-01 |
| G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 1157 | 4.97e-47 | 6.23e-44 | 0.4730 | -1.75e-01 | -2.04e-01 | -2.42e-01 | -2.24e-01 | -2.07e-01 | 7.48e-24 | 8.14e-32 | 6.27e-44 | 5.69e-38 | 1.18e-32 |
| NEGATIVE REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 11 | 2.59e-01 | 6.65e-01 | 0.4730 | -2.49e-01 | -2.79e-01 | -1.32e-01 | -1.24e-01 | 2.26e-01 | 1.53e-01 | 1.08e-01 | 4.50e-01 | 4.77e-01 | 1.94e-01 |
| INTESTINAL EPITHELIAL CELL MATURATION | 6 | 1.41e-01 | 5.07e-01 | 0.4730 | 1.98e-01 | 9.80e-02 | 9.16e-03 | 2.55e-01 | 3.31e-01 | 4.00e-01 | 6.78e-01 | 9.69e-01 | 2.79e-01 | 1.60e-01 |
| CENTROSOME SEPARATION | 15 | 2.13e-01 | 6.08e-01 | 0.4730 | 2.63e-01 | 1.38e-01 | 1.65e-01 | 3.28e-01 | 3.34e-02 | 7.81e-02 | 3.57e-01 | 2.69e-01 | 2.80e-02 | 8.23e-01 |
| REGULATION OF CELL PROLIFERATION INVOLVED IN KIDNEY DEVELOPMENT | 16 | 2.55e-01 | 6.62e-01 | 0.4730 | 1.06e-01 | 1.56e-01 | 2.95e-01 | 2.74e-01 | 1.61e-01 | 4.61e-01 | 2.81e-01 | 4.08e-02 | 5.80e-02 | 2.66e-01 |
| RENAL VESICLE DEVELOPMENT | 18 | 5.72e-01 | 8.83e-01 | 0.4730 | 1.94e-01 | 1.96e-01 | 2.26e-01 | 2.20e-01 | 2.18e-01 | 1.53e-01 | 1.50e-01 | 9.64e-02 | 1.06e-01 | 1.09e-01 |
| MICROGLIAL CELL MIGRATION | 8 | 4.57e-01 | 8.22e-01 | 0.4730 | 2.79e-01 | 3.15e-01 | 7.51e-02 | 1.56e-01 | -1.28e-01 | 1.72e-01 | 1.23e-01 | 7.13e-01 | 4.44e-01 | 5.29e-01 |
| POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS | 25 | 4.02e-01 | 7.89e-01 | 0.4730 | 2.24e-01 | 2.53e-01 | 2.22e-01 | 2.29e-01 | 8.77e-02 | 5.30e-02 | 2.85e-02 | 5.47e-02 | 4.77e-02 | 4.48e-01 |
| CONNECTIVE TISSUE REPLACEMENT | 20 | 8.47e-02 | 3.94e-01 | 0.4720 | -1.64e-01 | -2.16e-01 | -2.34e-01 | -3.08e-01 | -1.44e-02 | 2.05e-01 | 9.41e-02 | 6.98e-02 | 1.72e-02 | 9.11e-01 |
| SPINDLE ORGANIZATION | 194 | 1.59e-07 | 8.44e-06 | 0.4720 | 2.05e-01 | 1.90e-01 | 2.31e-01 | 2.57e-01 | 1.60e-01 | 8.78e-07 | 4.92e-06 | 2.69e-08 | 6.38e-10 | 1.27e-04 |
| REGULATION OF MAST CELL CHEMOTAXIS | 7 | 8.15e-01 | 9.69e-01 | 0.4720 | 1.45e-01 | 1.25e-01 | 2.17e-01 | 2.18e-01 | 3.03e-01 | 5.06e-01 | 5.68e-01 | 3.21e-01 | 3.17e-01 | 1.65e-01 |
| MEDIUM CHAIN FATTY ACID CATABOLIC PROCESS | 5 | 7.03e-01 | 9.32e-01 | 0.4720 | 3.16e-01 | 1.83e-01 | 1.12e-01 | 1.82e-01 | -2.11e-01 | 2.21e-01 | 4.79e-01 | 6.65e-01 | 4.82e-01 | 4.14e-01 |
| COMPLEMENT ACTIVATION | 58 | 3.92e-04 | 8.32e-03 | 0.4720 | -9.83e-02 | -1.21e-01 | -2.41e-01 | -2.78e-01 | -2.51e-01 | 1.95e-01 | 1.10e-01 | 1.51e-03 | 2.45e-04 | 9.43e-04 |
| HEPARAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS POLYSACCHARIDE CHAIN BIOSYNTHETIC PROCESS | 8 | 1.33e-01 | 4.94e-01 | 0.4720 | 1.64e-01 | 6.98e-02 | -2.72e-01 | -6.84e-02 | -3.35e-01 | 4.21e-01 | 7.33e-01 | 1.84e-01 | 7.38e-01 | 1.00e-01 |
| AROMATIC AMINO ACID TRANSPORT | 9 | 6.93e-01 | 9.31e-01 | 0.4720 | 1.77e-01 | 1.99e-01 | 2.46e-01 | 2.95e-01 | 6.72e-02 | 3.59e-01 | 3.01e-01 | 2.02e-01 | 1.26e-01 | 7.27e-01 |
| DUMP METABOLIC PROCESS | 7 | 7.54e-01 | 9.51e-01 | 0.4720 | 3.29e-01 | 2.25e-01 | 1.41e-01 | 2.06e-01 | 3.77e-02 | 1.32e-01 | 3.03e-01 | 5.18e-01 | 3.46e-01 | 8.63e-01 |
| SPERM DNA CONDENSATION | 17 | 2.04e-01 | 5.97e-01 | 0.4720 | -2.48e-01 | -2.07e-01 | -1.35e-01 | -2.47e-01 | -1.96e-01 | 7.62e-02 | 1.39e-01 | 3.35e-01 | 7.76e-02 | 1.62e-01 |
| MESONEPHRIC TUBULE MORPHOGENESIS | 64 | 1.27e-02 | 1.21e-01 | 0.4710 | 1.60e-01 | 1.81e-01 | 2.39e-01 | 2.18e-01 | 2.44e-01 | 2.71e-02 | 1.25e-02 | 9.57e-04 | 2.52e-03 | 7.34e-04 |
| PYRIMIDINE DEOXYRIBONUCLEOTIDE METABOLIC PROCESS | 23 | 1.89e-01 | 5.74e-01 | 0.4710 | 2.79e-01 | 1.90e-01 | 1.61e-01 | 2.45e-01 | 1.49e-01 | 2.05e-02 | 1.16e-01 | 1.81e-01 | 4.16e-02 | 2.16e-01 |
| REGULATION OF MITOCHONDRIAL ELECTRON TRANSPORT NADH TO UBIQUINONE | 6 | 2.70e-01 | 6.79e-01 | 0.4710 | 1.03e-01 | -5.37e-02 | 2.36e-01 | 1.36e-01 | 3.66e-01 | 6.62e-01 | 8.20e-01 | 3.16e-01 | 5.64e-01 | 1.20e-01 |
| TRANSCRIPTION DEPENDENT TETHERING OF RNA POLYMERASE II GENE DNA AT NUCLEAR PERIPHERY | 7 | 8.17e-01 | 9.70e-01 | 0.4710 | 2.00e-01 | 1.29e-01 | 2.55e-01 | 2.70e-01 | 1.66e-01 | 3.60e-01 | 5.55e-01 | 2.43e-01 | 2.16e-01 | 4.47e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OSMOTIC STRESS | 10 | 5.33e-01 | 8.64e-01 | 0.4710 | 2.84e-01 | 3.00e-01 | 1.74e-01 | 1.28e-01 | 6.89e-02 | 1.20e-01 | 1.01e-01 | 3.41e-01 | 4.82e-01 | 7.06e-01 |
| TANGENTIAL MIGRATION FROM THE SUBVENTRICULAR ZONE TO THE OLFACTORY BULB | 7 | 8.84e-01 | 9.80e-01 | 0.4710 | -1.76e-01 | -1.59e-01 | -2.50e-01 | -2.67e-01 | -1.78e-01 | 4.20e-01 | 4.67e-01 | 2.53e-01 | 2.21e-01 | 4.14e-01 |
| REGULATION OF SISTER CHROMATID SEGREGATION | 104 | 3.10e-05 | 1.05e-03 | 0.4710 | 1.79e-01 | 1.65e-01 | 2.23e-01 | 2.85e-01 | 1.77e-01 | 1.59e-03 | 3.68e-03 | 8.26e-05 | 5.23e-07 | 1.83e-03 |
| GLYCERALDEHYDE 3 PHOSPHATE METABOLIC PROCESS | 6 | 4.19e-01 | 8.00e-01 | 0.4710 | 9.38e-02 | 3.27e-01 | 2.41e-01 | 2.17e-01 | 2.27e-02 | 6.91e-01 | 1.65e-01 | 3.07e-01 | 3.57e-01 | 9.23e-01 |
| PEPTIDE CROSS LINKING | 27 | 7.38e-02 | 3.68e-01 | 0.4700 | -1.14e-01 | -1.73e-01 | -3.14e-01 | -2.15e-01 | -1.83e-01 | 3.04e-01 | 1.19e-01 | 4.75e-03 | 5.33e-02 | 1.00e-01 |
| REGULATION OF PROTEIN KINASE A SIGNALING | 20 | 3.15e-01 | 7.26e-01 | 0.4700 | -2.85e-01 | -2.57e-01 | -1.73e-01 | -1.83e-01 | -1.01e-01 | 2.74e-02 | 4.62e-02 | 1.81e-01 | 1.56e-01 | 4.33e-01 |
| CONSTITUTIVE HETEROCHROMATIN FORMATION | 11 | 3.17e-01 | 7.27e-01 | 0.4700 | 1.19e-01 | 1.02e-01 | 2.07e-01 | 1.11e-01 | 3.76e-01 | 4.93e-01 | 5.58e-01 | 2.35e-01 | 5.22e-01 | 3.10e-02 |
| COLLAGEN ACTIVATED TYROSINE KINASE RECEPTOR SIGNALING PATHWAY | 8 | 7.30e-01 | 9.44e-01 | 0.4700 | -2.01e-01 | -1.50e-01 | -1.76e-01 | -2.38e-01 | -2.65e-01 | 3.24e-01 | 4.62e-01 | 3.89e-01 | 2.45e-01 | 1.94e-01 |
| CARNITINE TRANSMEMBRANE TRANSPORT | 6 | 5.74e-01 | 8.84e-01 | 0.4700 | 2.87e-01 | 8.89e-02 | 1.37e-01 | 3.26e-01 | 7.09e-02 | 2.24e-01 | 7.06e-01 | 5.60e-01 | 1.66e-01 | 7.63e-01 |
| REGULATION OF BROWN FAT CELL DIFFERENTIATION | 24 | 3.39e-01 | 7.44e-01 | 0.4700 | 2.01e-01 | 2.52e-01 | 2.12e-01 | 1.93e-01 | 1.86e-01 | 8.79e-02 | 3.28e-02 | 7.16e-02 | 1.02e-01 | 1.15e-01 |
| RIBOFLAVIN METABOLIC PROCESS | 5 | 6.93e-01 | 9.31e-01 | 0.4700 | 1.32e-01 | 2.64e-01 | 3.17e-01 | 1.82e-01 | 1.07e-02 | 6.09e-01 | 3.07e-01 | 2.20e-01 | 4.81e-01 | 9.67e-01 |
| PROTEIN DEUBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 5 | 2.92e-01 | 7.03e-01 | 0.4700 | -3.90e-02 | -3.56e-01 | -2.06e-01 | 7.87e-03 | -2.23e-01 | 8.80e-01 | 1.68e-01 | 4.24e-01 | 9.76e-01 | 3.88e-01 |
| REGULATION OF ANGIOTENSIN LEVELS IN BLOOD | 8 | 3.39e-01 | 7.44e-01 | 0.4700 | 1.37e-01 | 3.30e-02 | -1.73e-01 | -2.57e-02 | -4.12e-01 | 5.02e-01 | 8.71e-01 | 3.97e-01 | 9.00e-01 | 4.34e-02 |
| REGULATION OF NADP METABOLIC PROCESS | 9 | 8.01e-01 | 9.66e-01 | 0.4700 | 2.35e-01 | 1.81e-01 | 1.89e-01 | 2.48e-01 | 1.88e-01 | 2.23e-01 | 3.48e-01 | 3.25e-01 | 1.98e-01 | 3.28e-01 |
| ISOTYPE SWITCHING TO IGA ISOTYPES | 8 | 7.38e-01 | 9.49e-01 | 0.4690 | 1.17e-01 | 2.60e-01 | 2.55e-01 | 1.97e-01 | 1.87e-01 | 5.67e-01 | 2.03e-01 | 2.11e-01 | 3.34e-01 | 3.59e-01 |
| NEGATIVE REGULATION OF HUMORAL IMMUNE RESPONSE | 16 | 5.86e-01 | 8.91e-01 | 0.4690 | -1.90e-01 | -2.26e-01 | -2.51e-01 | -1.77e-01 | -1.98e-01 | 1.89e-01 | 1.17e-01 | 8.27e-02 | 2.20e-01 | 1.71e-01 |
| POSITIVE REGULATION OF ISOTYPE SWITCHING TO IGA ISOTYPES | 6 | 7.32e-01 | 9.45e-01 | 0.4690 | 1.32e-01 | 2.84e-01 | 2.97e-01 | 1.39e-01 | 1.20e-01 | 5.74e-01 | 2.28e-01 | 2.08e-01 | 5.55e-01 | 6.09e-01 |
| NEGATIVE REGULATION OF TELOMERE MAINTENANCE | 32 | 1.30e-01 | 4.87e-01 | 0.4690 | 2.32e-01 | 1.90e-01 | 1.81e-01 | 2.58e-01 | 1.74e-01 | 2.29e-02 | 6.30e-02 | 7.56e-02 | 1.15e-02 | 8.87e-02 |
| DEOXYRIBONUCLEOSIDE CATABOLIC PROCESS | 6 | 7.90e-01 | 9.63e-01 | 0.4690 | -1.37e-01 | -1.43e-01 | -1.89e-01 | -1.60e-01 | -3.45e-01 | 5.62e-01 | 5.44e-01 | 4.22e-01 | 4.97e-01 | 1.43e-01 |
| POSITIVE REGULATION OF CARDIAC MUSCLE ADAPTATION | 9 | 3.05e-01 | 7.18e-01 | 0.4690 | 5.92e-02 | 1.02e-01 | 2.60e-01 | 5.84e-02 | 3.67e-01 | 7.58e-01 | 5.97e-01 | 1.77e-01 | 7.62e-01 | 5.63e-02 |
| ESTABLISHMENT OF RNA LOCALIZATION | 147 | 7.31e-07 | 3.55e-05 | 0.4690 | 2.36e-01 | 1.72e-01 | 2.20e-01 | 2.75e-01 | 1.01e-01 | 7.96e-07 | 3.11e-04 | 4.18e-06 | 8.22e-09 | 3.49e-02 |
| BASEMENT MEMBRANE ORGANIZATION | 36 | 1.44e-01 | 5.11e-01 | 0.4680 | -1.89e-01 | -2.42e-01 | -2.39e-01 | -2.43e-01 | -9.53e-02 | 4.92e-02 | 1.21e-02 | 1.32e-02 | 1.15e-02 | 3.22e-01 |
| ATRIAL CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 9 | 1.92e-03 | 2.94e-02 | 0.4680 | -1.34e-01 | 2.56e-01 | -5.99e-02 | -2.80e-01 | -2.33e-01 | 4.88e-01 | 1.84e-01 | 7.56e-01 | 1.46e-01 | 2.27e-01 |
| SNRNA TRANSPORT | 6 | 8.43e-01 | 9.75e-01 | 0.4680 | 1.94e-01 | 1.06e-01 | 2.26e-01 | 2.58e-01 | 2.30e-01 | 4.11e-01 | 6.52e-01 | 3.37e-01 | 2.74e-01 | 3.30e-01 |
| HINDLIMB MORPHOGENESIS | 35 | 8.57e-02 | 3.96e-01 | 0.4680 | 1.05e-01 | 1.68e-01 | 2.52e-01 | 2.03e-01 | 2.75e-01 | 2.82e-01 | 8.61e-02 | 9.98e-03 | 3.77e-02 | 4.86e-03 |
| NON CANONICAL WNT SIGNALING PATHWAY VIA JNK CASCADE | 6 | 4.21e-01 | 8.00e-01 | 0.4680 | -1.98e-01 | -8.60e-02 | 4.21e-02 | -1.22e-02 | 4.13e-01 | 4.01e-01 | 7.15e-01 | 8.58e-01 | 9.59e-01 | 7.97e-02 |
| GRANZYME MEDIATED PROGRAMMED CELL DEATH SIGNALING PATHWAY | 8 | 4.52e-01 | 8.21e-01 | 0.4680 | 1.96e-01 | 9.56e-02 | 2.29e-01 | 3.42e-01 | 4.31e-02 | 3.38e-01 | 6.40e-01 | 2.61e-01 | 9.39e-02 | 8.33e-01 |
| CELLULAR RESPONSE TO AMMONIUM ION | 5 | 6.54e-01 | 9.20e-01 | 0.4680 | -2.03e-01 | -2.01e-01 | -2.82e-01 | -8.91e-02 | -2.23e-01 | 4.31e-01 | 4.36e-01 | 2.75e-01 | 7.30e-01 | 3.89e-01 |
| GLUCOSE IMPORT ACROSS PLASMA MEMBRANE | 5 | 1.86e-01 | 5.72e-01 | 0.4680 | -1.35e-01 | 4.96e-02 | 2.05e-01 | -1.85e-01 | 3.49e-01 | 6.02e-01 | 8.48e-01 | 4.27e-01 | 4.75e-01 | 1.76e-01 |
| PROTEIN TRANSMEMBRANE TRANSPORT | 64 | 1.46e-02 | 1.33e-01 | 0.4670 | 1.82e-01 | 1.83e-01 | 2.64e-01 | 2.39e-01 | 1.60e-01 | 1.18e-02 | 1.15e-02 | 2.64e-04 | 9.56e-04 | 2.69e-02 |
| PURINE DEOXYRIBONUCLEOSIDE METABOLIC PROCESS | 5 | 7.52e-01 | 9.51e-01 | 0.4670 | 2.42e-01 | 2.30e-01 | 2.35e-01 | 1.88e-01 | -1.28e-01 | 3.50e-01 | 3.73e-01 | 3.62e-01 | 4.66e-01 | 6.20e-01 |
| REGULATION OF CELL GROWTH INVOLVED IN CARDIAC MUSCLE CELL DEVELOPMENT | 19 | 2.21e-01 | 6.19e-01 | 0.4670 | 1.88e-01 | 2.99e-01 | 2.58e-01 | 1.54e-01 | 5.48e-02 | 1.55e-01 | 2.40e-02 | 5.15e-02 | 2.44e-01 | 6.79e-01 |
| REGULATION OF CYTOPLASMIC TRANSLATIONAL INITIATION | 7 | 3.42e-01 | 7.48e-01 | 0.4670 | -2.23e-01 | -3.25e-01 | -2.06e-01 | -5.12e-02 | 1.32e-01 | 3.06e-01 | 1.36e-01 | 3.45e-01 | 8.15e-01 | 5.44e-01 |
| MITOCHONDRIAL DNA METABOLIC PROCESS | 23 | 9.38e-02 | 4.16e-01 | 0.4670 | 4.28e-02 | 9.01e-02 | 2.69e-01 | 1.86e-01 | 3.18e-01 | 7.23e-01 | 4.54e-01 | 2.58e-02 | 1.22e-01 | 8.19e-03 |
| REGULATION OF THYMOCYTE APOPTOTIC PROCESS | 14 | 1.21e-01 | 4.74e-01 | 0.4670 | -4.41e-02 | 5.56e-02 | 1.97e-01 | 1.85e-01 | 3.74e-01 | 7.75e-01 | 7.18e-01 | 2.01e-01 | 2.32e-01 | 1.53e-02 |
| REGULATION OF SMOOTHENED SIGNALING PATHWAY INVOLVED IN DORSAL VENTRAL NEURAL TUBE PATTERNING | 11 | 5.67e-01 | 8.81e-01 | 0.4670 | 2.69e-01 | 2.22e-01 | 1.47e-01 | 2.11e-01 | 1.74e-01 | 1.22e-01 | 2.02e-01 | 3.98e-01 | 2.26e-01 | 3.19e-01 |
| SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 182 | 2.12e-08 | 1.30e-06 | 0.4670 | 1.94e-01 | 1.76e-01 | 2.11e-01 | 2.70e-01 | 1.78e-01 | 6.62e-06 | 4.20e-05 | 9.30e-07 | 3.09e-10 | 3.32e-05 |
| NEGATIVE REGULATION OF TRANSMISSION OF NERVE IMPULSE | 6 | 3.45e-01 | 7.50e-01 | 0.4660 | -2.81e-02 | 8.45e-02 | 1.89e-01 | -5.92e-02 | 4.12e-01 | 9.05e-01 | 7.20e-01 | 4.22e-01 | 8.02e-01 | 8.02e-02 |
| POSTSYNAPSE TO NUCLEUS SIGNALING PATHWAY | 6 | 2.61e-01 | 6.67e-01 | 0.4660 | 3.86e-01 | 1.12e-01 | 1.30e-02 | 2.32e-01 | 4.28e-02 | 1.02e-01 | 6.34e-01 | 9.56e-01 | 3.25e-01 | 8.56e-01 |
| ANTIBACTERIAL PEPTIDE PRODUCTION | 9 | 5.35e-02 | 3.06e-01 | 0.4660 | 1.01e-01 | 2.13e-01 | -1.81e-01 | -1.23e-01 | -3.38e-01 | 5.99e-01 | 2.70e-01 | 3.47e-01 | 5.22e-01 | 7.93e-02 |
| REGULATION OF PHOSPHOLIPID TRANSLOCATION | 6 | 7.13e-01 | 9.36e-01 | 0.4660 | -1.14e-01 | -2.37e-01 | -1.82e-01 | -1.53e-01 | -3.03e-01 | 6.29e-01 | 3.16e-01 | 4.40e-01 | 5.16e-01 | 1.99e-01 |
| ORNITHINE METABOLIC PROCESS | 9 | 1.80e-01 | 5.63e-01 | 0.4660 | 2.76e-01 | 2.71e-01 | 1.77e-01 | 5.40e-02 | -1.83e-01 | 1.51e-01 | 1.60e-01 | 3.59e-01 | 7.79e-01 | 3.41e-01 |
| RESPONSE TO SELENIUM ION | 8 | 1.42e-01 | 5.08e-01 | 0.4660 | -2.04e-01 | -5.88e-02 | 1.71e-01 | 1.42e-01 | 3.50e-01 | 3.17e-01 | 7.73e-01 | 4.03e-01 | 4.87e-01 | 8.64e-02 |
| T TUBULE ORGANIZATION | 6 | 3.98e-01 | 7.86e-01 | 0.4660 | -1.67e-01 | -1.04e-01 | -1.74e-01 | -3.84e-01 | -2.19e-02 | 4.79e-01 | 6.58e-01 | 4.60e-01 | 1.03e-01 | 9.26e-01 |
| NEGATIVE REGULATION OF SMOOTHENED SIGNALING PATHWAY INVOLVED IN DORSAL VENTRAL NEURAL TUBE PATTERNING | 7 | 8.07e-01 | 9.67e-01 | 0.4660 | 2.29e-01 | 1.64e-01 | 1.80e-01 | 2.15e-01 | 2.43e-01 | 2.95e-01 | 4.53e-01 | 4.11e-01 | 3.24e-01 | 2.65e-01 |
| CELLULAR RESPONSE TO COPPER ION | 25 | 2.42e-02 | 1.89e-01 | 0.4650 | 1.29e-01 | 2.37e-01 | 2.97e-01 | 9.43e-02 | 2.15e-01 | 2.66e-01 | 4.00e-02 | 1.00e-02 | 4.14e-01 | 6.25e-02 |
| MESENCHYME MORPHOGENESIS | 60 | 1.23e-03 | 2.06e-02 | 0.4650 | 6.70e-02 | 1.62e-01 | 2.55e-01 | 2.04e-01 | 2.81e-01 | 3.69e-01 | 3.04e-02 | 6.28e-04 | 6.32e-03 | 1.68e-04 |
| MODULATION OF PROCESS OF ANOTHER ORGANISM | 19 | 2.61e-02 | 1.98e-01 | 0.4650 | 3.17e-01 | 1.63e-01 | 4.09e-03 | 1.78e-01 | -2.40e-01 | 1.67e-02 | 2.19e-01 | 9.75e-01 | 1.80e-01 | 7.06e-02 |
| POSITIVE REGULATION OF CHROMOSOME SEPARATION | 29 | 5.31e-02 | 3.05e-01 | 0.4650 | 2.50e-01 | 1.38e-01 | 1.80e-01 | 3.08e-01 | 8.87e-02 | 2.00e-02 | 1.99e-01 | 9.39e-02 | 4.13e-03 | 4.08e-01 |
| NEGATIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 14 | 4.83e-01 | 8.37e-01 | 0.4650 | -2.48e-01 | -1.50e-01 | -1.80e-01 | -2.55e-01 | -1.87e-01 | 1.09e-01 | 3.33e-01 | 2.44e-01 | 9.84e-02 | 2.26e-01 |
| REGULATION OF PROTEIN DEUBIQUITINATION | 10 | 4.09e-01 | 7.94e-01 | 0.4650 | 2.75e-01 | 1.03e-01 | 1.59e-01 | 2.71e-01 | 1.75e-01 | 1.32e-01 | 5.73e-01 | 3.85e-01 | 1.37e-01 | 3.38e-01 |
| OXALOACETATE METABOLIC PROCESS | 9 | 8.01e-02 | 3.83e-01 | 0.4640 | -2.76e-02 | -7.99e-04 | 3.87e-02 | 1.43e-01 | 4.39e-01 | 8.86e-01 | 9.97e-01 | 8.41e-01 | 4.59e-01 | 2.24e-02 |
| REGULATION OF TRANSCRIPTION BY RNA POLYMERASE I | 45 | 4.03e-02 | 2.59e-01 | 0.4640 | 1.81e-01 | 1.81e-01 | 2.07e-01 | 1.99e-01 | 2.61e-01 | 3.57e-02 | 3.52e-02 | 1.65e-02 | 2.11e-02 | 2.49e-03 |
| APOPTOTIC PROCESS IN BONE MARROW CELL | 6 | 3.05e-01 | 7.17e-01 | 0.4640 | -2.49e-01 | -3.67e-01 | -1.36e-01 | 1.37e-02 | 1.95e-03 | 2.91e-01 | 1.19e-01 | 5.64e-01 | 9.54e-01 | 9.93e-01 |
| LOW DENSITY LIPOPROTEIN PARTICLE REMODELING | 16 | 4.07e-02 | 2.61e-01 | 0.4640 | -1.84e-01 | 2.47e-04 | -2.07e-01 | -3.00e-01 | -2.21e-01 | 2.01e-01 | 9.99e-01 | 1.51e-01 | 3.80e-02 | 1.26e-01 |
| ADHESION OF SYMBIONT TO HOST CELL | 8 | 6.76e-01 | 9.28e-01 | 0.4640 | 2.01e-01 | 1.55e-01 | 1.56e-01 | 2.36e-01 | 2.66e-01 | 3.26e-01 | 4.46e-01 | 4.45e-01 | 2.48e-01 | 1.92e-01 |
| SEQUESTERING OF IRON ION | 6 | 5.88e-01 | 8.92e-01 | 0.4640 | -2.46e-02 | 1.35e-01 | 2.59e-01 | 2.16e-01 | 2.87e-01 | 9.17e-01 | 5.66e-01 | 2.73e-01 | 3.59e-01 | 2.23e-01 |
| MYELOID LEUKOCYTE CYTOKINE PRODUCTION | 50 | 5.50e-03 | 6.61e-02 | 0.4640 | 2.66e-01 | 2.92e-01 | 1.48e-01 | 1.87e-01 | 5.13e-02 | 1.16e-03 | 3.61e-04 | 7.00e-02 | 2.19e-02 | 5.31e-01 |
| CELL FATE COMMITMENT INVOLVED IN PATTERN SPECIFICATION | 11 | 1.29e-01 | 4.87e-01 | 0.4640 | 7.96e-03 | 7.70e-02 | 3.18e-01 | 8.54e-02 | 3.17e-01 | 9.64e-01 | 6.58e-01 | 6.81e-02 | 6.24e-01 | 6.83e-02 |
| MIDBRAIN DEVELOPMENT | 86 | 3.47e-03 | 4.68e-02 | 0.4630 | 2.04e-01 | 2.01e-01 | 2.12e-01 | 2.53e-01 | 1.54e-01 | 1.06e-03 | 1.29e-03 | 6.89e-04 | 4.83e-05 | 1.34e-02 |
| GLYCINE IMPORT ACROSS PLASMA MEMBRANE | 5 | 7.21e-01 | 9.39e-01 | 0.4630 | 3.79e-03 | 9.04e-02 | 3.05e-01 | 2.18e-01 | 2.57e-01 | 9.88e-01 | 7.26e-01 | 2.37e-01 | 3.99e-01 | 3.20e-01 |
| SOMATIC STEM CELL POPULATION MAINTENANCE | 65 | 1.02e-03 | 1.78e-02 | 0.4630 | 1.28e-01 | 2.05e-01 | 2.18e-01 | 1.55e-01 | 2.91e-01 | 7.37e-02 | 4.27e-03 | 2.41e-03 | 3.02e-02 | 5.00e-05 |
| CELL PROLIFERATION INVOLVED IN KIDNEY DEVELOPMENT | 22 | 1.94e-01 | 5.81e-01 | 0.4630 | 1.00e-01 | 1.70e-01 | 2.79e-01 | 2.51e-01 | 1.87e-01 | 4.17e-01 | 1.68e-01 | 2.36e-02 | 4.14e-02 | 1.29e-01 |
| PROGESTERONE METABOLIC PROCESS | 16 | 6.18e-01 | 9.07e-01 | 0.4630 | -1.65e-01 | -2.24e-01 | -2.36e-01 | -1.88e-01 | -2.16e-01 | 2.54e-01 | 1.22e-01 | 1.02e-01 | 1.94e-01 | 1.35e-01 |
| CELLULAR RESPONSE TO NITROSATIVE STRESS | 6 | 1.60e-01 | 5.35e-01 | 0.4630 | -1.47e-01 | -1.93e-01 | 1.34e-01 | 2.27e-01 | 2.93e-01 | 5.33e-01 | 4.12e-01 | 5.69e-01 | 3.36e-01 | 2.14e-01 |
| REGULATION OF NEUTROPHIL EXTRAVASATION | 5 | 4.35e-01 | 8.09e-01 | 0.4630 | 2.24e-01 | 3.18e-01 | 6.63e-02 | 2.38e-01 | 4.81e-02 | 3.86e-01 | 2.18e-01 | 7.97e-01 | 3.57e-01 | 8.52e-01 |
| ENDOCARDIAL CUSHION MORPHOGENESIS | 44 | 4.66e-02 | 2.82e-01 | 0.4630 | 1.14e-01 | 1.83e-01 | 2.48e-01 | 2.09e-01 | 2.50e-01 | 1.91e-01 | 3.61e-02 | 4.40e-03 | 1.64e-02 | 4.05e-03 |
| CARDIAC NEURAL CREST CELL DEVELOPMENT INVOLVED IN OUTFLOW TRACT MORPHOGENESIS | 13 | 1.93e-01 | 5.80e-01 | 0.4630 | -2.63e-02 | 1.64e-01 | 2.49e-01 | 1.36e-01 | 3.26e-01 | 8.70e-01 | 3.07e-01 | 1.21e-01 | 3.97e-01 | 4.16e-02 |
| REGULATION OF AUTOPHAGOSOME ASSEMBLY | 42 | 7.35e-02 | 3.66e-01 | 0.4630 | 2.22e-01 | 1.94e-01 | 2.05e-01 | 2.78e-01 | 9.08e-02 | 1.29e-02 | 2.99e-02 | 2.18e-02 | 1.82e-03 | 3.09e-01 |
| REGULATION OF APOPTOTIC CELL CLEARANCE | 10 | 7.64e-01 | 9.54e-01 | 0.4630 | -1.84e-01 | -2.04e-01 | -2.00e-01 | -2.60e-01 | -1.75e-01 | 3.13e-01 | 2.63e-01 | 2.74e-01 | 1.54e-01 | 3.39e-01 |
| NEGATIVE REGULATION OF MEIOTIC CELL CYCLE | 17 | 3.41e-01 | 7.47e-01 | 0.4630 | 1.88e-01 | 1.22e-01 | 2.64e-01 | 2.58e-01 | 1.65e-01 | 1.79e-01 | 3.84e-01 | 5.94e-02 | 6.53e-02 | 2.38e-01 |
| NEUTROPHIL APOPTOTIC PROCESS | 8 | 3.08e-01 | 7.19e-01 | 0.4620 | 1.59e-01 | 4.77e-02 | -1.17e-01 | -5.54e-02 | -4.12e-01 | 4.36e-01 | 8.15e-01 | 5.67e-01 | 7.86e-01 | 4.38e-02 |
| SEQUESTERING OF EXTRACELLULAR LIGAND FROM RECEPTOR | 11 | 6.67e-01 | 9.24e-01 | 0.4620 | -1.71e-01 | -1.56e-01 | -1.99e-01 | -2.67e-01 | -2.22e-01 | 3.26e-01 | 3.70e-01 | 2.54e-01 | 1.25e-01 | 2.01e-01 |
| DETECTION OF TEMPERATURE STIMULUS INVOLVED IN THERMOCEPTION | 5 | 4.36e-01 | 8.09e-01 | 0.4620 | -1.24e-01 | -2.54e-01 | -1.85e-01 | -2.72e-01 | 1.61e-01 | 6.31e-01 | 3.26e-01 | 4.75e-01 | 2.92e-01 | 5.33e-01 |
| ACETYL COA BIOSYNTHETIC PROCESS FROM PYRUVATE | 9 | 2.37e-01 | 6.40e-01 | 0.4620 | 5.48e-02 | 2.21e-02 | 1.41e-01 | 2.71e-01 | 3.41e-01 | 7.76e-01 | 9.08e-01 | 4.62e-01 | 1.59e-01 | 7.62e-02 |
| CELLULAR RESPONSE TO L GLUTAMATE | 5 | 7.40e-01 | 9.49e-01 | 0.4620 | 1.35e-02 | 1.34e-01 | 1.95e-01 | 1.93e-01 | 3.47e-01 | 9.58e-01 | 6.05e-01 | 4.51e-01 | 4.55e-01 | 1.79e-01 |
| FIBRINOLYSIS | 27 | 1.14e-01 | 4.61e-01 | 0.4620 | -1.09e-01 | -1.10e-01 | -2.16e-01 | -2.02e-01 | -3.19e-01 | 3.25e-01 | 3.23e-01 | 5.20e-02 | 6.89e-02 | 4.13e-03 |
| NEGATIVE REGULATION OF PEPTIDYL LYSINE ACETYLATION | 6 | 8.53e-01 | 9.76e-01 | 0.4620 | 1.22e-01 | 1.02e-01 | 2.47e-01 | 2.55e-01 | 2.48e-01 | 6.04e-01 | 6.65e-01 | 2.94e-01 | 2.79e-01 | 2.93e-01 |
| SIGNAL PEPTIDE PROCESSING | 13 | 6.97e-01 | 9.31e-01 | 0.4620 | 2.71e-01 | 2.23e-01 | 1.77e-01 | 2.39e-01 | 3.78e-02 | 9.11e-02 | 1.64e-01 | 2.70e-01 | 1.35e-01 | 8.14e-01 |
| METHYLGUANOSINE CAP DECAPPING | 16 | 8.81e-02 | 4.01e-01 | 0.4610 | 1.93e-01 | 1.67e-01 | 1.40e-01 | 3.30e-01 | 1.39e-01 | 1.82e-01 | 2.46e-01 | 3.31e-01 | 2.24e-02 | 3.35e-01 |
| HEPARIN BIOSYNTHETIC PROCESS | 11 | 3.92e-01 | 7.83e-01 | 0.4610 | -1.74e-02 | -6.38e-02 | -2.73e-01 | -1.87e-01 | -3.15e-01 | 9.20e-01 | 7.14e-01 | 1.17e-01 | 2.83e-01 | 7.06e-02 |
| DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 70 | 1.07e-02 | 1.07e-01 | 0.4610 | 1.99e-01 | 1.84e-01 | 2.09e-01 | 2.52e-01 | 1.78e-01 | 3.99e-03 | 7.70e-03 | 2.46e-03 | 2.66e-04 | 9.86e-03 |
| COMPLEMENT ACTIVATION CLASSICAL PATHWAY | 34 | 1.75e-01 | 5.60e-01 | 0.4610 | -1.71e-01 | -1.83e-01 | -2.20e-01 | -2.55e-01 | -1.90e-01 | 8.36e-02 | 6.44e-02 | 2.61e-02 | 1.00e-02 | 5.55e-02 |
| NEGATIVE REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 19 | 3.95e-01 | 7.85e-01 | 0.4610 | 1.93e-01 | 2.48e-01 | 2.57e-01 | 1.55e-01 | 1.52e-01 | 1.45e-01 | 6.16e-02 | 5.21e-02 | 2.42e-01 | 2.51e-01 |
| RENAL FILTRATION | 25 | 2.24e-01 | 6.24e-01 | 0.4610 | -2.38e-01 | -1.72e-01 | -1.99e-01 | -2.87e-01 | -6.20e-02 | 3.91e-02 | 1.37e-01 | 8.55e-02 | 1.30e-02 | 5.91e-01 |
| TYPE I INTERFERON PRODUCTION | 115 | 1.10e-04 | 2.99e-03 | 0.4600 | 2.52e-01 | 2.44e-01 | 1.79e-01 | 2.13e-01 | 1.05e-01 | 2.92e-06 | 6.04e-06 | 9.19e-04 | 7.90e-05 | 5.11e-02 |
| CARDIAC MYOFIBRIL ASSEMBLY | 19 | 4.24e-01 | 8.03e-01 | 0.4600 | -2.20e-01 | -1.61e-01 | -2.00e-01 | -2.79e-01 | -1.39e-01 | 9.68e-02 | 2.24e-01 | 1.32e-01 | 3.49e-02 | 2.94e-01 |
| REGULATION OF EXTRACELLULAR MATRIX CONSTITUENT SECRETION | 9 | 7.51e-01 | 9.51e-01 | 0.4600 | 2.29e-01 | 2.15e-01 | 1.80e-01 | 1.80e-01 | 2.20e-01 | 2.34e-01 | 2.64e-01 | 3.49e-01 | 3.50e-01 | 2.54e-01 |
| DIRECT OSSIFICATION | 7 | 3.59e-01 | 7.58e-01 | 0.4600 | -3.04e-01 | -9.02e-02 | -8.64e-02 | -2.38e-01 | 2.16e-01 | 1.63e-01 | 6.79e-01 | 6.92e-01 | 2.76e-01 | 3.22e-01 |
| ALDITOL BIOSYNTHETIC PROCESS | 5 | 1.12e-01 | 4.56e-01 | 0.4600 | 8.76e-02 | 3.28e-02 | -8.03e-02 | -3.06e-02 | 4.42e-01 | 7.35e-01 | 8.99e-01 | 7.56e-01 | 9.06e-01 | 8.69e-02 |
| INTERLEUKIN 18 MEDIATED SIGNALING PATHWAY | 9 | 7.11e-01 | 9.35e-01 | 0.4600 | -1.98e-01 | -2.24e-01 | -2.27e-01 | -2.65e-01 | 9.02e-03 | 3.04e-01 | 2.44e-01 | 2.37e-01 | 1.68e-01 | 9.63e-01 |
| PURINE DEOXYRIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 10 | 4.53e-01 | 8.21e-01 | 0.4600 | 2.41e-01 | 1.28e-01 | 2.52e-01 | 2.70e-01 | 2.63e-02 | 1.88e-01 | 4.83e-01 | 1.68e-01 | 1.39e-01 | 8.86e-01 |
| PHOSPHATIDYLSERINE ACYL CHAIN REMODELING | 9 | 3.07e-01 | 7.19e-01 | 0.4600 | 4.81e-02 | -1.17e-01 | -2.31e-01 | -1.96e-01 | -3.22e-01 | 8.03e-01 | 5.42e-01 | 2.31e-01 | 3.08e-01 | 9.45e-02 |
| RESPONSE TO MUSCLE INACTIVITY | 9 | 2.52e-01 | 6.58e-01 | 0.4600 | -1.21e-01 | -3.91e-02 | -1.85e-01 | -3.49e-01 | -1.98e-01 | 5.30e-01 | 8.39e-01 | 3.35e-01 | 7.00e-02 | 3.04e-01 |
| REGULATION OF NUCLEAR CELL CYCLE DNA REPLICATION | 12 | 7.88e-01 | 9.63e-01 | 0.4600 | 1.68e-01 | 1.84e-01 | 2.53e-01 | 2.25e-01 | 1.86e-01 | 3.15e-01 | 2.69e-01 | 1.29e-01 | 1.78e-01 | 2.64e-01 |
| DORSAL AORTA DEVELOPMENT | 10 | 2.17e-01 | 6.13e-01 | 0.4600 | -1.23e-02 | 1.53e-01 | 2.51e-01 | 1.61e-02 | 3.53e-01 | 9.46e-01 | 4.02e-01 | 1.70e-01 | 9.30e-01 | 5.33e-02 |
| UBIQUINONE METABOLIC PROCESS | 19 | 5.35e-01 | 8.65e-01 | 0.4600 | 2.02e-01 | 1.99e-01 | 2.00e-01 | 2.48e-01 | 1.71e-01 | 1.28e-01 | 1.34e-01 | 1.31e-01 | 6.12e-02 | 1.97e-01 |
| PROTEIN POLY ADP RIBOSYLATION | 10 | 4.66e-01 | 8.26e-01 | 0.4590 | 1.40e-01 | 6.69e-02 | 2.17e-01 | 3.01e-01 | 2.22e-01 | 4.45e-01 | 7.14e-01 | 2.34e-01 | 9.90e-02 | 2.25e-01 |
| REGULATION OF B CELL APOPTOTIC PROCESS | 20 | 4.61e-01 | 8.24e-01 | 0.4590 | 2.53e-01 | 2.08e-01 | 1.75e-01 | 2.48e-01 | 1.06e-01 | 4.98e-02 | 1.07e-01 | 1.76e-01 | 5.47e-02 | 4.12e-01 |
| CORPUS CALLOSUM DEVELOPMENT | 26 | 3.91e-01 | 7.83e-01 | 0.4590 | 1.75e-01 | 2.07e-01 | 2.58e-01 | 2.20e-01 | 1.50e-01 | 1.22e-01 | 6.79e-02 | 2.28e-02 | 5.21e-02 | 1.85e-01 |
| N ACETYLGLUCOSAMINE METABOLIC PROCESS | 16 | 6.27e-01 | 9.09e-01 | 0.4590 | 1.44e-01 | 2.01e-01 | 2.41e-01 | 2.10e-01 | 2.19e-01 | 3.19e-01 | 1.63e-01 | 9.57e-02 | 1.46e-01 | 1.30e-01 |
| MICROGLIAL CELL MEDIATED CYTOTOXICITY | 5 | 5.86e-01 | 8.91e-01 | 0.4590 | 3.50e-01 | 2.14e-01 | -1.51e-02 | 1.53e-01 | -1.38e-01 | 1.75e-01 | 4.07e-01 | 9.53e-01 | 5.54e-01 | 5.93e-01 |
| HYALOID VASCULAR PLEXUS REGRESSION | 7 | 5.99e-01 | 8.98e-01 | 0.4590 | -1.92e-01 | -2.15e-01 | -1.77e-01 | -3.09e-01 | 3.69e-02 | 3.80e-01 | 3.24e-01 | 4.18e-01 | 1.57e-01 | 8.66e-01 |
| NUCLEOSIDE TRANSPORT | 10 | 6.65e-01 | 9.23e-01 | 0.4590 | -1.81e-01 | -1.26e-01 | -2.07e-01 | -2.91e-01 | -1.87e-01 | 3.22e-01 | 4.91e-01 | 2.57e-01 | 1.11e-01 | 3.05e-01 |
| THYROID STIMULATING HORMONE SECRETING CELL DIFFERENTIATION | 6 | 8.35e-01 | 9.73e-01 | 0.4590 | 1.87e-01 | 2.21e-01 | 2.67e-01 | 1.34e-01 | 1.95e-01 | 4.27e-01 | 3.49e-01 | 2.58e-01 | 5.71e-01 | 4.09e-01 |
| HINDBRAIN MATURATION | 5 | 3.76e-01 | 7.75e-01 | 0.4590 | 1.51e-01 | 3.52e-03 | 3.03e-01 | 1.72e-01 | 2.58e-01 | 5.60e-01 | 9.89e-01 | 2.41e-01 | 5.05e-01 | 3.18e-01 |
| POSITIVE REGULATION OF CHEMOKINE C X C MOTIF LIGAND 1 PRODUCTION | 5 | 8.70e-01 | 9.78e-01 | 0.4590 | -1.70e-01 | -1.06e-01 | -1.85e-01 | -2.20e-01 | -2.96e-01 | 5.10e-01 | 6.81e-01 | 4.73e-01 | 3.95e-01 | 2.52e-01 |
| PRESYNAPTIC ACTIVE ZONE ORGANIZATION | 8 | 8.56e-01 | 9.77e-01 | 0.4590 | -1.34e-01 | -1.59e-01 | -2.59e-01 | -2.37e-01 | -2.10e-01 | 5.13e-01 | 4.36e-01 | 2.04e-01 | 2.46e-01 | 3.04e-01 |
| ADENOHYPOPHYSIS DEVELOPMENT | 16 | 5.59e-01 | 8.78e-01 | 0.4590 | 1.54e-01 | 2.38e-01 | 2.46e-01 | 1.68e-01 | 2.04e-01 | 2.87e-01 | 9.96e-02 | 8.84e-02 | 2.45e-01 | 1.58e-01 |
| ACUTE INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 24 | 2.38e-01 | 6.42e-01 | 0.4580 | -2.81e-01 | -2.44e-01 | -1.49e-01 | -2.19e-01 | 3.41e-02 | 1.70e-02 | 3.85e-02 | 2.05e-01 | 6.31e-02 | 7.73e-01 |
| VENTRAL SPINAL CORD DEVELOPMENT | 45 | 2.42e-02 | 1.89e-01 | 0.4580 | 1.01e-01 | 1.60e-01 | 2.58e-01 | 1.69e-01 | 2.82e-01 | 2.42e-01 | 6.36e-02 | 2.80e-03 | 4.92e-02 | 1.07e-03 |
| PARALLEL ACTIN FILAMENT BUNDLE ASSEMBLY | 7 | 4.43e-01 | 8.13e-01 | 0.4580 | -2.50e-01 | -1.49e-01 | -9.81e-02 | -3.40e-01 | -2.05e-02 | 2.52e-01 | 4.95e-01 | 6.53e-01 | 1.20e-01 | 9.25e-01 |
| THYMUS DEVELOPMENT | 49 | 1.43e-03 | 2.33e-02 | 0.4580 | 9.91e-02 | 1.49e-01 | 2.26e-01 | 2.82e-01 | 2.17e-01 | 2.30e-01 | 7.18e-02 | 6.17e-03 | 6.30e-04 | 8.47e-03 |
| CHORIONIC TROPHOBLAST CELL PROLIFERATION | 5 | 1.68e-01 | 5.50e-01 | 0.4580 | -1.11e-01 | 1.69e-01 | 3.33e-02 | -6.38e-02 | 4.05e-01 | 6.68e-01 | 5.14e-01 | 8.97e-01 | 8.05e-01 | 1.17e-01 |
| PROTEIN LOCALIZATION TO AXON | 9 | 2.21e-01 | 6.20e-01 | 0.4580 | -2.63e-01 | -1.81e-01 | 6.06e-02 | -7.99e-03 | 3.22e-01 | 1.72e-01 | 3.47e-01 | 7.53e-01 | 9.67e-01 | 9.41e-02 |
| REGULATION OF ARACHIDONIC ACID SECRETION | 7 | 8.25e-01 | 9.72e-01 | 0.4580 | -1.95e-01 | -2.81e-01 | -2.40e-01 | -1.86e-01 | -1.42e-02 | 3.71e-01 | 1.98e-01 | 2.72e-01 | 3.93e-01 | 9.48e-01 |
| FATTY ACID ALPHA OXIDATION | 8 | 5.16e-01 | 8.56e-01 | 0.4570 | 2.79e-01 | 2.21e-01 | 1.11e-01 | 1.73e-01 | 2.01e-01 | 1.72e-01 | 2.80e-01 | 5.88e-01 | 3.97e-01 | 3.24e-01 |
| SOMATIC STEM CELL DIVISION | 11 | 6.68e-01 | 9.24e-01 | 0.4570 | 9.76e-02 | 2.05e-01 | 2.43e-01 | 1.85e-01 | 2.54e-01 | 5.75e-01 | 2.40e-01 | 1.63e-01 | 2.88e-01 | 1.45e-01 |
| PURINE DEOXYRIBONUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 6 | 5.96e-01 | 8.97e-01 | 0.4570 | 1.20e-01 | 1.04e-01 | 3.32e-01 | 2.21e-01 | 1.58e-01 | 6.12e-01 | 6.58e-01 | 1.59e-01 | 3.49e-01 | 5.03e-01 |
| RESPONSE TO FOOD | 35 | 9.55e-02 | 4.19e-01 | 0.4570 | 2.63e-01 | 2.46e-01 | 1.99e-01 | 1.66e-01 | 1.13e-01 | 7.15e-03 | 1.19e-02 | 4.18e-02 | 8.91e-02 | 2.49e-01 |
| NEGATIVE REGULATION OF CHOLESTEROL EFFLUX | 22 | 3.20e-03 | 4.39e-02 | 0.4570 | 7.51e-02 | 1.13e-02 | -8.01e-02 | 3.47e-02 | -4.42e-01 | 5.42e-01 | 9.27e-01 | 5.15e-01 | 7.78e-01 | 3.27e-04 |
| REGULATION OF T HELPER 2 CELL DIFFERENTIATION | 12 | 2.77e-01 | 6.87e-01 | 0.4570 | 2.98e-01 | 3.03e-01 | 9.39e-02 | 1.37e-01 | 3.03e-02 | 7.37e-02 | 6.95e-02 | 5.73e-01 | 4.11e-01 | 8.56e-01 |
| PH REDUCTION | 6 | 2.56e-01 | 6.63e-01 | 0.4570 | -7.59e-02 | 3.41e-02 | 3.53e-01 | 1.45e-01 | 2.38e-01 | 7.48e-01 | 8.85e-01 | 1.34e-01 | 5.38e-01 | 3.14e-01 |
| POSITIVE REGULATION OF PROTEOGLYCAN BIOSYNTHETIC PROCESS | 5 | 8.56e-01 | 9.77e-01 | 0.4570 | -3.19e-01 | -1.85e-01 | -1.25e-01 | -2.37e-01 | 3.53e-02 | 2.17e-01 | 4.74e-01 | 6.28e-01 | 3.60e-01 | 8.91e-01 |
| HYPERSENSITIVITY | 12 | 3.05e-01 | 7.18e-01 | 0.4570 | -3.36e-01 | -1.96e-01 | -1.31e-01 | -1.76e-01 | 9.31e-02 | 4.36e-02 | 2.39e-01 | 4.32e-01 | 2.91e-01 | 5.77e-01 |
| SPLEEN DEVELOPMENT | 38 | 1.36e-01 | 4.98e-01 | 0.4560 | 1.87e-01 | 1.76e-01 | 2.17e-01 | 2.65e-01 | 1.58e-01 | 4.57e-02 | 5.97e-02 | 2.08e-02 | 4.75e-03 | 9.10e-02 |
| REGULATION OF MEMBRANE DEPOLARIZATION DURING ACTION POTENTIAL | 6 | 3.40e-01 | 7.47e-01 | 0.4560 | -2.66e-01 | -3.58e-02 | 7.90e-02 | -1.73e-01 | 3.17e-01 | 2.60e-01 | 8.79e-01 | 7.37e-01 | 4.62e-01 | 1.79e-01 |
| REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 110 | 2.12e-04 | 4.88e-03 | 0.4560 | 2.03e-01 | 1.83e-01 | 2.10e-01 | 2.68e-01 | 1.33e-01 | 2.39e-04 | 8.88e-04 | 1.43e-04 | 1.23e-06 | 1.58e-02 |
| PROTEIN LOCALIZATION TO ENDOPLASMIC RETICULUM EXIT SITE | 6 | 3.79e-01 | 7.76e-01 | 0.4560 | 1.56e-01 | -3.21e-02 | -1.27e-01 | 9.69e-02 | -3.96e-01 | 5.07e-01 | 8.92e-01 | 5.89e-01 | 6.81e-01 | 9.31e-02 |
| SA NODE CELL TO ATRIAL CARDIAC MUSCLE CELL COMMUNICATION | 11 | 3.45e-01 | 7.50e-01 | 0.4560 | -2.52e-01 | -1.49e-01 | -1.14e-01 | -2.60e-01 | -2.03e-01 | 1.48e-01 | 3.93e-01 | 5.14e-01 | 1.35e-01 | 2.43e-01 |
| MEIOTIC SISTER CHROMATID COHESION | 13 | 5.58e-01 | 8.78e-01 | 0.4560 | 2.95e-01 | 2.13e-01 | 1.37e-01 | 2.36e-01 | 3.00e-02 | 6.57e-02 | 1.84e-01 | 3.94e-01 | 1.41e-01 | 8.51e-01 |
| SNRNA CATABOLIC PROCESS | 5 | 3.71e-01 | 7.71e-01 | 0.4550 | 3.23e-01 | 3.53e-02 | -4.36e-02 | 2.32e-01 | -2.14e-01 | 2.10e-01 | 8.91e-01 | 8.66e-01 | 3.68e-01 | 4.08e-01 |
| REGULATION OF DNA DAMAGE CHECKPOINT | 23 | 1.29e-01 | 4.87e-01 | 0.4550 | 2.09e-01 | 2.04e-01 | 1.56e-01 | 2.85e-01 | 1.28e-01 | 8.24e-02 | 9.00e-02 | 1.95e-01 | 1.81e-02 | 2.89e-01 |
| FLOOR PLATE DEVELOPMENT | 11 | 2.51e-02 | 1.94e-01 | 0.4550 | -3.37e-01 | -9.19e-02 | 1.47e-01 | -5.30e-02 | 2.46e-01 | 5.27e-02 | 5.98e-01 | 4.00e-01 | 7.61e-01 | 1.58e-01 |
| REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 104 | 1.36e-04 | 3.48e-03 | 0.4550 | 1.59e-01 | 1.46e-01 | 2.27e-01 | 2.55e-01 | 2.10e-01 | 5.20e-03 | 9.89e-03 | 6.38e-05 | 7.11e-06 | 2.14e-04 |
| HYPOTHALAMUS GONADOTROPHIN RELEASING HORMONE NEURON DIFFERENTIATION | 7 | 6.32e-01 | 9.11e-01 | 0.4550 | -2.64e-01 | -1.71e-01 | -2.11e-01 | -2.29e-01 | 1.06e-01 | 2.26e-01 | 4.35e-01 | 3.34e-01 | 2.94e-01 | 6.27e-01 |
| PULMONARY ARTERY MORPHOGENESIS | 6 | 4.71e-01 | 8.30e-01 | 0.4550 | -1.56e-01 | -1.51e-01 | 1.17e-01 | 1.08e-02 | 3.82e-01 | 5.07e-01 | 5.22e-01 | 6.21e-01 | 9.63e-01 | 1.05e-01 |
| NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING 2 SIGNALING PATHWAY | 18 | 3.23e-01 | 7.33e-01 | 0.4550 | 2.86e-01 | 2.05e-01 | 1.47e-01 | 2.10e-01 | 1.32e-01 | 3.59e-02 | 1.32e-01 | 2.79e-01 | 1.23e-01 | 3.32e-01 |
| POSITIVE REGULATION OF CELL PROLIFERATION IN BONE MARROW | 6 | 8.22e-01 | 9.71e-01 | 0.4550 | -2.18e-01 | -1.96e-01 | -2.16e-01 | -1.37e-01 | -2.35e-01 | 3.55e-01 | 4.06e-01 | 3.59e-01 | 5.62e-01 | 3.18e-01 |
| INTRACELLULAR PROTEIN TRANSMEMBRANE TRANSPORT | 52 | 6.48e-02 | 3.38e-01 | 0.4550 | 1.87e-01 | 1.90e-01 | 2.54e-01 | 2.22e-01 | 1.46e-01 | 1.95e-02 | 1.76e-02 | 1.51e-03 | 5.65e-03 | 6.77e-02 |
| MRNA TRANSPORT | 113 | 8.72e-05 | 2.49e-03 | 0.4540 | 2.32e-01 | 1.67e-01 | 2.11e-01 | 2.63e-01 | 1.04e-01 | 2.10e-05 | 2.12e-03 | 1.03e-04 | 1.32e-06 | 5.63e-02 |
| FOREBRAIN GENERATION OF NEURONS | 51 | 7.95e-02 | 3.82e-01 | 0.4540 | 1.84e-01 | 2.34e-01 | 2.24e-01 | 2.00e-01 | 1.66e-01 | 2.32e-02 | 3.76e-03 | 5.61e-03 | 1.34e-02 | 4.07e-02 |
| LIPOXIN METABOLIC PROCESS | 5 | 6.35e-01 | 9.12e-01 | 0.4540 | 2.50e-01 | 3.50e-01 | 8.55e-02 | 9.87e-02 | -6.36e-02 | 3.33e-01 | 1.75e-01 | 7.41e-01 | 7.02e-01 | 8.06e-01 |
| NEGATIVE REGULATION OF PROTEIN UBIQUITINATION | 69 | 2.32e-03 | 3.43e-02 | 0.4540 | 1.18e-01 | 1.33e-01 | 2.25e-01 | 2.15e-01 | 2.79e-01 | 9.07e-02 | 5.63e-02 | 1.20e-03 | 2.04e-03 | 6.08e-05 |
| TRYPTOPHAN CATABOLIC PROCESS | 9 | 8.15e-01 | 9.69e-01 | 0.4540 | -1.66e-01 | -1.46e-01 | -2.33e-01 | -2.67e-01 | -1.77e-01 | 3.89e-01 | 4.48e-01 | 2.26e-01 | 1.65e-01 | 3.58e-01 |
| HEMATOPOIETIC OR LYMPHOID ORGAN DEVELOPMENT | 98 | 2.07e-07 | 1.07e-05 | 0.4540 | 6.87e-02 | 1.19e-01 | 2.46e-01 | 2.64e-01 | 2.38e-01 | 2.40e-01 | 4.19e-02 | 2.54e-05 | 6.31e-06 | 4.49e-05 |
| NUCLEAR EXPORT | 157 | 3.79e-06 | 1.58e-04 | 0.4540 | 2.53e-01 | 1.98e-01 | 1.89e-01 | 2.44e-01 | 8.35e-02 | 4.20e-08 | 1.79e-05 | 4.46e-05 | 1.30e-07 | 7.10e-02 |
| DENDRITE ARBORIZATION | 10 | 7.41e-01 | 9.49e-01 | 0.4530 | -2.05e-01 | -1.83e-01 | -1.75e-01 | -2.58e-01 | -1.81e-01 | 2.62e-01 | 3.17e-01 | 3.38e-01 | 1.57e-01 | 3.21e-01 |
| NCRNA METABOLIC PROCESS | 607 | 5.28e-23 | 1.47e-20 | 0.4530 | 1.91e-01 | 1.74e-01 | 2.28e-01 | 2.27e-01 | 1.87e-01 | 1.02e-15 | 2.02e-13 | 7.30e-22 | 9.34e-22 | 2.96e-15 |
| PYRIMIDINE NUCLEOTIDE CATABOLIC PROCESS | 21 | 3.11e-01 | 7.23e-01 | 0.4530 | 2.53e-01 | 2.09e-01 | 1.57e-01 | 2.15e-01 | 1.66e-01 | 4.50e-02 | 9.78e-02 | 2.13e-01 | 8.86e-02 | 1.89e-01 |
| EMBRYONIC DIGESTIVE TRACT DEVELOPMENT | 33 | 1.11e-01 | 4.55e-01 | 0.4530 | 1.49e-01 | 2.29e-01 | 2.68e-01 | 1.57e-01 | 1.86e-01 | 1.40e-01 | 2.25e-02 | 7.72e-03 | 1.19e-01 | 6.49e-02 |
| REGULATION OF MRNA PROCESSING | 116 | 3.99e-04 | 8.44e-03 | 0.4530 | 2.04e-01 | 1.74e-01 | 2.27e-01 | 2.44e-01 | 1.48e-01 | 1.42e-04 | 1.18e-03 | 2.42e-05 | 5.56e-06 | 5.73e-03 |
| PEROXISOME FISSION | 9 | 6.54e-01 | 9.20e-01 | 0.4530 | 2.98e-01 | 2.42e-01 | 1.66e-01 | 1.51e-01 | 8.75e-02 | 1.22e-01 | 2.09e-01 | 3.89e-01 | 4.33e-01 | 6.49e-01 |
| POSITIVE REGULATION OF MEGAKARYOCYTE DIFFERENTIATION | 10 | 5.58e-01 | 8.77e-01 | 0.4530 | 2.12e-01 | 2.65e-01 | 1.44e-01 | 2.09e-01 | 1.60e-01 | 2.47e-01 | 1.47e-01 | 4.30e-01 | 2.53e-01 | 3.80e-01 |
| PROTEIN N LINKED GLYCOSYLATION VIA ASPARAGINE | 23 | 3.87e-01 | 7.80e-01 | 0.4530 | 2.43e-01 | 1.82e-01 | 2.04e-01 | 2.58e-01 | 6.47e-02 | 4.32e-02 | 1.31e-01 | 8.97e-02 | 3.22e-02 | 5.91e-01 |
| RNA SURVEILLANCE | 17 | 2.52e-01 | 6.59e-01 | 0.4530 | 5.55e-02 | 1.21e-01 | 2.07e-01 | 1.33e-01 | 3.56e-01 | 6.92e-01 | 3.89e-01 | 1.39e-01 | 3.43e-01 | 1.11e-02 |
| RESPONSE TO PHORBOL 13 ACETATE 12 MYRISTATE | 10 | 3.76e-02 | 2.51e-01 | 0.4520 | 2.71e-01 | 3.02e-01 | 6.12e-02 | 5.38e-03 | 1.91e-01 | 1.38e-01 | 9.84e-02 | 7.38e-01 | 9.76e-01 | 2.95e-01 |
| CHROMOSOME LOCALIZATION | 117 | 1.61e-04 | 3.91e-03 | 0.4520 | 1.90e-01 | 1.94e-01 | 2.40e-01 | 2.53e-01 | 9.77e-02 | 3.87e-04 | 2.92e-04 | 7.41e-06 | 2.35e-06 | 6.79e-02 |
| RETINAL CONE CELL DIFFERENTIATION | 13 | 5.10e-01 | 8.53e-01 | 0.4520 | -2.61e-01 | -1.91e-01 | -1.84e-01 | -2.48e-01 | 6.61e-02 | 1.04e-01 | 2.32e-01 | 2.50e-01 | 1.22e-01 | 6.80e-01 |
| REGULATION OF T CELL COSTIMULATION | 5 | 8.03e-01 | 9.67e-01 | 0.4520 | 1.10e-01 | 1.10e-01 | 2.56e-01 | 3.05e-01 | 1.48e-01 | 6.71e-01 | 6.71e-01 | 3.22e-01 | 2.38e-01 | 5.67e-01 |
| DENTINOGENESIS | 6 | 4.08e-02 | 2.61e-01 | 0.4520 | -2.55e-01 | 8.53e-02 | 5.91e-02 | -2.53e-01 | -2.54e-01 | 2.79e-01 | 7.18e-01 | 8.02e-01 | 2.83e-01 | 2.82e-01 |
| NEGATIVE REGULATION OF DNA RECOMBINATION | 45 | 8.82e-02 | 4.01e-01 | 0.4520 | 2.20e-01 | 2.21e-01 | 1.91e-01 | 1.99e-01 | 1.76e-01 | 1.08e-02 | 1.05e-02 | 2.66e-02 | 2.08e-02 | 4.07e-02 |
| MACROPHAGE CYTOKINE PRODUCTION | 36 | 1.83e-02 | 1.58e-01 | 0.4520 | 2.39e-01 | 3.09e-01 | 1.49e-01 | 1.58e-01 | 6.27e-02 | 1.29e-02 | 1.32e-03 | 1.22e-01 | 1.01e-01 | 5.15e-01 |
| DENDRITIC TRANSPORT | 12 | 2.27e-01 | 6.28e-01 | 0.4520 | 3.08e-01 | 9.78e-02 | 1.70e-01 | 2.61e-01 | 4.99e-02 | 6.49e-02 | 5.58e-01 | 3.08e-01 | 1.17e-01 | 7.65e-01 |
| PROTEIN TARGETING TO LYSOSOME | 31 | 6.89e-02 | 3.53e-01 | 0.4510 | 2.73e-01 | 2.30e-01 | 1.27e-01 | 2.39e-01 | -5.78e-02 | 8.59e-03 | 2.70e-02 | 2.22e-01 | 2.10e-02 | 5.78e-01 |
| RESPONSE TO CORTISOL | 6 | 4.88e-01 | 8.39e-01 | 0.4510 | -1.11e-01 | -1.95e-01 | -1.87e-01 | -3.28e-01 | -1.04e-01 | 6.39e-01 | 4.08e-01 | 4.29e-01 | 1.64e-01 | 6.60e-01 |
| REGULATION OF HEART MORPHOGENESIS | 10 | 4.39e-01 | 8.11e-01 | 0.4510 | -2.13e-02 | 5.71e-02 | 2.00e-01 | 1.24e-01 | 3.81e-01 | 9.07e-01 | 7.55e-01 | 2.74e-01 | 4.99e-01 | 3.71e-02 |
| REGULATION OF MOTOR NEURON APOPTOTIC PROCESS | 15 | 3.97e-01 | 7.86e-01 | 0.4510 | 2.34e-01 | 2.40e-01 | 2.12e-01 | 1.26e-01 | 1.74e-01 | 1.17e-01 | 1.07e-01 | 1.54e-01 | 3.96e-01 | 2.43e-01 |
| POSITIVE REGULATION OF AXON GUIDANCE | 5 | 4.51e-01 | 8.21e-01 | 0.4510 | -3.68e-02 | -8.84e-02 | 2.00e-01 | 3.04e-02 | 3.92e-01 | 8.87e-01 | 7.32e-01 | 4.39e-01 | 9.06e-01 | 1.29e-01 |
| VITAMIN K METABOLIC PROCESS | 10 | 4.55e-01 | 8.22e-01 | 0.4510 | 5.47e-02 | 1.72e-01 | 1.95e-01 | 9.65e-02 | 3.52e-01 | 7.64e-01 | 3.46e-01 | 2.86e-01 | 5.97e-01 | 5.40e-02 |
| METANEPHROS MORPHOGENESIS | 30 | 3.76e-01 | 7.75e-01 | 0.4510 | 1.78e-01 | 2.05e-01 | 2.31e-01 | 2.22e-01 | 1.64e-01 | 9.07e-02 | 5.21e-02 | 2.82e-02 | 3.53e-02 | 1.19e-01 |
| REGULATION OF MICROGLIAL CELL ACTIVATION | 20 | 1.10e-01 | 4.53e-01 | 0.4510 | 1.79e-01 | 2.06e-01 | 2.39e-01 | 2.61e-01 | -6.18e-02 | 1.66e-01 | 1.10e-01 | 6.39e-02 | 4.36e-02 | 6.33e-01 |
| REGULATION OF GLYCOGEN STARCH SYNTHASE ACTIVITY | 5 | 5.72e-01 | 8.83e-01 | 0.4510 | -2.87e-01 | -2.92e-01 | -5.04e-02 | -1.97e-02 | 1.80e-01 | 2.66e-01 | 2.58e-01 | 8.45e-01 | 9.39e-01 | 4.85e-01 |
| METANEPHRIC GLOMERULUS VASCULATURE DEVELOPMENT | 9 | 6.17e-01 | 9.06e-01 | 0.4510 | 1.80e-01 | 2.98e-01 | 1.83e-01 | 1.44e-01 | 1.68e-01 | 3.51e-01 | 1.21e-01 | 3.42e-01 | 4.55e-01 | 3.84e-01 |
| NEGATIVE REGULATION OF GLIOGENESIS | 44 | 1.36e-02 | 1.27e-01 | 0.4510 | 1.03e-01 | 1.33e-01 | 2.02e-01 | 1.66e-01 | 3.27e-01 | 2.36e-01 | 1.28e-01 | 2.04e-02 | 5.71e-02 | 1.77e-04 |
| WOUND HEALING SPREADING OF EPIDERMAL CELLS | 21 | 4.87e-01 | 8.39e-01 | 0.4510 | -1.89e-01 | -1.84e-01 | -2.56e-01 | -2.25e-01 | -1.33e-01 | 1.34e-01 | 1.45e-01 | 4.19e-02 | 7.45e-02 | 2.92e-01 |
| COLUMNAR CUBOIDAL EPITHELIAL CELL MATURATION | 13 | 1.79e-01 | 5.63e-01 | 0.4510 | 1.98e-01 | 2.64e-01 | 1.17e-01 | 2.34e-01 | 1.61e-01 | 2.16e-01 | 9.98e-02 | 4.64e-01 | 1.44e-01 | 3.15e-01 |
| GROWTH HORMONE SECRETION | 13 | 6.14e-01 | 9.06e-01 | 0.4510 | 2.31e-01 | 2.69e-01 | 1.63e-01 | 1.98e-01 | 1.07e-01 | 1.49e-01 | 9.34e-02 | 3.08e-01 | 2.17e-01 | 5.03e-01 |
| NEGATIVE REGULATION OF COMPLEMENT ACTIVATION | 12 | 5.66e-01 | 8.81e-01 | 0.4500 | -8.23e-02 | -1.80e-01 | -2.82e-01 | -1.63e-01 | -2.41e-01 | 6.22e-01 | 2.81e-01 | 9.07e-02 | 3.30e-01 | 1.49e-01 |
| REGULATION OF OSTEOCLAST DEVELOPMENT | 11 | 7.11e-01 | 9.35e-01 | 0.4500 | -1.13e-01 | -1.38e-01 | -2.22e-01 | -2.02e-01 | -2.85e-01 | 5.17e-01 | 4.27e-01 | 2.03e-01 | 2.47e-01 | 1.02e-01 |
| PROTEIN DEPALMITOYLATION | 8 | 4.11e-02 | 2.62e-01 | 0.4500 | 8.54e-03 | -1.33e-01 | -7.33e-02 | 1.01e-01 | 4.12e-01 | 9.67e-01 | 5.16e-01 | 7.20e-01 | 6.20e-01 | 4.37e-02 |
| MITOCHONDRIAL MEMBRANE ORGANIZATION | 113 | 8.85e-05 | 2.52e-03 | 0.4500 | 1.57e-01 | 1.40e-01 | 2.39e-01 | 2.36e-01 | 2.13e-01 | 3.82e-03 | 1.03e-02 | 1.11e-05 | 1.51e-05 | 8.92e-05 |
| UDP N ACETYLGLUCOSAMINE METABOLIC PROCESS | 14 | 6.41e-01 | 9.14e-01 | 0.4500 | 1.23e-01 | 1.87e-01 | 2.49e-01 | 2.32e-01 | 1.91e-01 | 4.25e-01 | 2.26e-01 | 1.07e-01 | 1.33e-01 | 2.15e-01 |
| ANIMAL ORGAN FORMATION | 66 | 5.02e-03 | 6.15e-02 | 0.4500 | 1.03e-01 | 1.72e-01 | 2.37e-01 | 2.00e-01 | 2.56e-01 | 1.47e-01 | 1.54e-02 | 8.65e-04 | 4.88e-03 | 3.26e-04 |
| NEGATIVE REGULATION OF VASCULAR WOUND HEALING | 7 | 7.73e-02 | 3.77e-01 | 0.4500 | -5.00e-02 | 2.55e-01 | 2.53e-01 | -1.05e-01 | 2.43e-01 | 8.19e-01 | 2.42e-01 | 2.46e-01 | 6.30e-01 | 2.65e-01 |
| REGULATION OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR SIGNALING PATHWAY | 15 | 1.56e-01 | 5.26e-01 | 0.4490 | 1.58e-01 | 7.37e-02 | 1.74e-01 | 1.47e-01 | 3.46e-01 | 2.90e-01 | 6.21e-01 | 2.44e-01 | 3.25e-01 | 2.02e-02 |
| REGULATION OF MEMBRANE DEPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 5 | 5.62e-01 | 8.79e-01 | 0.4490 | -3.05e-01 | -9.32e-02 | 2.69e-02 | -1.74e-01 | 2.63e-01 | 2.38e-01 | 7.18e-01 | 9.17e-01 | 5.00e-01 | 3.08e-01 |
| REGULATION OF TRANSCRIPTION ELONGATION BY RNA POLYMERASE II | 85 | 4.48e-03 | 5.67e-02 | 0.4490 | 1.97e-01 | 1.73e-01 | 2.06e-01 | 2.39e-01 | 1.84e-01 | 1.72e-03 | 5.79e-03 | 1.01e-03 | 1.43e-04 | 3.43e-03 |
| ACROSOME REACTION | 40 | 7.58e-02 | 3.72e-01 | 0.4490 | -2.07e-01 | -1.43e-01 | -2.02e-01 | -2.64e-01 | -1.66e-01 | 2.32e-02 | 1.17e-01 | 2.68e-02 | 3.84e-03 | 6.94e-02 |
| PARAXIAL MESODERM FORMATION | 7 | 2.96e-01 | 7.07e-01 | 0.4490 | -2.27e-01 | -3.61e-02 | 1.86e-01 | 2.56e-02 | 3.37e-01 | 2.99e-01 | 8.69e-01 | 3.94e-01 | 9.06e-01 | 1.22e-01 |
| GAMMA AMINOBUTYRIC ACID METABOLIC PROCESS | 8 | 6.70e-01 | 9.25e-01 | 0.4490 | 5.27e-02 | 1.27e-01 | 2.05e-01 | 2.14e-01 | 3.08e-01 | 7.96e-01 | 5.34e-01 | 3.15e-01 | 2.95e-01 | 1.31e-01 |
| CALCIUM ION EXPORT ACROSS PLASMA MEMBRANE | 9 | 8.67e-02 | 3.98e-01 | 0.4490 | -1.03e-01 | -1.51e-01 | 2.27e-01 | 1.04e-01 | 3.25e-01 | 5.92e-01 | 4.33e-01 | 2.38e-01 | 5.88e-01 | 9.15e-02 |
| ENDOCRINE PANCREAS DEVELOPMENT | 46 | 5.40e-02 | 3.07e-01 | 0.4490 | 1.44e-01 | 1.70e-01 | 2.71e-01 | 2.10e-01 | 1.85e-01 | 9.04e-02 | 4.58e-02 | 1.49e-03 | 1.37e-02 | 2.98e-02 |
| ESTROGEN BIOSYNTHETIC PROCESS | 11 | 7.27e-01 | 9.43e-01 | 0.4490 | -1.56e-01 | -2.00e-01 | -1.97e-01 | -2.33e-01 | -2.08e-01 | 3.69e-01 | 2.50e-01 | 2.57e-01 | 1.80e-01 | 2.31e-01 |
| INTRACELLULAR PHOSPHATE ION HOMEOSTASIS | 10 | 3.82e-01 | 7.78e-01 | 0.4490 | -2.32e-01 | -2.02e-01 | -1.62e-01 | -1.92e-01 | 2.08e-01 | 2.04e-01 | 2.68e-01 | 3.74e-01 | 2.92e-01 | 2.54e-01 |
| REGULATION OF STEM CELL DIFFERENTIATION | 78 | 7.10e-04 | 1.32e-02 | 0.4490 | 1.48e-01 | 1.48e-01 | 1.98e-01 | 2.44e-01 | 2.43e-01 | 2.42e-02 | 2.41e-02 | 2.52e-03 | 1.98e-04 | 2.02e-04 |
| MAMMARY GLAND INVOLUTION | 8 | 6.89e-01 | 9.31e-01 | 0.4490 | 2.24e-01 | 3.09e-01 | 1.79e-01 | 1.46e-01 | -4.97e-02 | 2.74e-01 | 1.30e-01 | 3.80e-01 | 4.75e-01 | 8.08e-01 |
| ANTEROGRADE DENDRITIC TRANSPORT OF NEUROTRANSMITTER RECEPTOR COMPLEX | 5 | 7.14e-01 | 9.36e-01 | 0.4490 | 3.33e-01 | 1.34e-01 | 1.23e-01 | 2.23e-01 | -8.93e-02 | 1.98e-01 | 6.05e-01 | 6.35e-01 | 3.88e-01 | 7.29e-01 |
| REGULATION OF BLOOD VOLUME BY RENIN ANGIOTENSIN | 6 | 1.85e-01 | 5.72e-01 | 0.4480 | 5.91e-02 | -3.03e-01 | -2.33e-01 | -1.68e-02 | -2.27e-01 | 8.02e-01 | 1.99e-01 | 3.23e-01 | 9.43e-01 | 3.36e-01 |
| REGULATION OF RNA SPLICING | 163 | 4.28e-06 | 1.75e-04 | 0.4480 | 1.74e-01 | 1.74e-01 | 2.32e-01 | 2.51e-01 | 1.53e-01 | 1.22e-04 | 1.24e-04 | 3.01e-07 | 3.31e-08 | 7.44e-04 |
| MICTURITION | 8 | 4.01e-01 | 7.88e-01 | 0.4480 | -3.24e-01 | -1.63e-01 | -8.92e-02 | -1.47e-01 | 2.01e-01 | 1.13e-01 | 4.26e-01 | 6.62e-01 | 4.71e-01 | 3.26e-01 |
| MATURE CONVENTIONAL DENDRITIC CELL DIFFERENTIATION | 5 | 2.95e-01 | 7.07e-01 | 0.4480 | -2.59e-02 | 4.56e-02 | -2.71e-01 | -3.33e-01 | -1.18e-01 | 9.20e-01 | 8.60e-01 | 2.94e-01 | 1.98e-01 | 6.48e-01 |
| SPINAL CORD DEVELOPMENT | 99 | 1.13e-04 | 3.04e-03 | 0.4480 | 1.12e-01 | 1.51e-01 | 2.34e-01 | 1.77e-01 | 2.82e-01 | 5.41e-02 | 9.31e-03 | 5.92e-05 | 2.33e-03 | 1.22e-06 |
| REGULATION OF MESENCHYMAL CELL PROLIFERATION | 32 | 2.57e-02 | 1.96e-01 | 0.4480 | 4.53e-02 | 1.18e-01 | 2.28e-01 | 2.31e-01 | 2.81e-01 | 6.58e-01 | 2.46e-01 | 2.57e-02 | 2.34e-02 | 5.87e-03 |
| PLASMA MEMBRANE REPAIR | 27 | 1.11e-01 | 4.54e-01 | 0.4480 | 1.03e-01 | 1.24e-01 | 2.75e-01 | 1.73e-01 | 2.62e-01 | 3.56e-01 | 2.64e-01 | 1.33e-02 | 1.19e-01 | 1.83e-02 |
| VESICLE TETHERING INVOLVED IN EXOCYTOSIS | 9 | 6.07e-01 | 9.02e-01 | 0.4480 | -1.01e-01 | -1.94e-01 | -2.97e-01 | -2.29e-01 | -1.11e-01 | 6.01e-01 | 3.14e-01 | 1.23e-01 | 2.34e-01 | 5.65e-01 |
| CELLULAR RESPONSE TO X RAY | 11 | 7.35e-01 | 9.47e-01 | 0.4480 | 1.62e-01 | 1.76e-01 | 2.05e-01 | 2.62e-01 | 1.81e-01 | 3.52e-01 | 3.12e-01 | 2.40e-01 | 1.33e-01 | 2.98e-01 |
| PROTEIN SUMOYLATION | 64 | 8.45e-04 | 1.52e-02 | 0.4480 | 2.00e-01 | 1.55e-01 | 1.82e-01 | 3.00e-01 | 1.16e-01 | 5.60e-03 | 3.21e-02 | 1.18e-02 | 3.37e-05 | 1.09e-01 |
| IMMATURE T CELL PROLIFERATION | 12 | 6.80e-01 | 9.28e-01 | 0.4480 | 2.55e-01 | 2.55e-01 | 1.89e-01 | 1.83e-01 | -2.76e-02 | 1.26e-01 | 1.26e-01 | 2.56e-01 | 2.72e-01 | 8.69e-01 |
| REGULATION OF METAPHASE PLATE CONGRESSION | 13 | 3.55e-01 | 7.55e-01 | 0.4480 | 1.73e-01 | 2.08e-01 | 2.85e-01 | 2.13e-01 | 6.98e-04 | 2.81e-01 | 1.93e-01 | 7.48e-02 | 1.83e-01 | 9.97e-01 |
| APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 42 | 4.35e-02 | 2.71e-01 | 0.4470 | 1.36e-01 | 2.05e-01 | 2.78e-01 | 1.68e-01 | 1.84e-01 | 1.28e-01 | 2.13e-02 | 1.80e-03 | 5.95e-02 | 3.88e-02 |
| NEGATIVE REGULATION OF GLYCOGEN METABOLIC PROCESS | 10 | 6.83e-01 | 9.30e-01 | 0.4470 | -2.35e-01 | -2.19e-01 | -2.12e-01 | -2.19e-01 | 6.13e-02 | 1.97e-01 | 2.29e-01 | 2.46e-01 | 2.30e-01 | 7.37e-01 |
| DICARBOXYLIC ACID CATABOLIC PROCESS | 18 | 5.73e-02 | 3.16e-01 | 0.4470 | 1.93e-01 | 1.63e-01 | 1.37e-01 | 3.34e-01 | 7.87e-02 | 1.57e-01 | 2.31e-01 | 3.13e-01 | 1.43e-02 | 5.63e-01 |
| NEGATIVE REGULATION OF POST TRANSLATIONAL PROTEIN MODIFICATION | 86 | 2.81e-04 | 6.18e-03 | 0.4470 | 1.20e-01 | 1.31e-01 | 2.16e-01 | 2.35e-01 | 2.58e-01 | 5.49e-02 | 3.51e-02 | 5.42e-04 | 1.69e-04 | 3.44e-05 |
| NEGATIVE REGULATION OF RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 43 | 3.40e-02 | 2.34e-01 | 0.4470 | 1.02e-01 | 1.65e-01 | 2.53e-01 | 1.55e-01 | 2.72e-01 | 2.46e-01 | 6.10e-02 | 4.09e-03 | 7.92e-02 | 1.99e-03 |
| TELOMERASE RNA LOCALIZATION | 18 | 1.39e-01 | 5.03e-01 | 0.4470 | 8.72e-02 | 7.55e-02 | 2.29e-01 | 2.91e-01 | 2.22e-01 | 5.22e-01 | 5.79e-01 | 9.22e-02 | 3.26e-02 | 1.02e-01 |
| NEGATIVE REGULATION OF CALCIUM ION IMPORT | 10 | 7.40e-01 | 9.49e-01 | 0.4470 | -2.15e-01 | -2.82e-01 | -2.18e-01 | -1.56e-01 | -4.43e-02 | 2.38e-01 | 1.22e-01 | 2.33e-01 | 3.92e-01 | 8.08e-01 |
| HEPARAN SULFATE PROTEOGLYCAN CATABOLIC PROCESS | 8 | 6.52e-01 | 9.19e-01 | 0.4470 | 1.07e-01 | 2.08e-01 | 3.10e-01 | 1.59e-01 | 1.54e-01 | 6.01e-01 | 3.09e-01 | 1.29e-01 | 4.36e-01 | 4.51e-01 |
| DETERMINATION OF DORSAL VENTRAL ASYMMETRY | 11 | 6.85e-01 | 9.30e-01 | 0.4470 | -2.23e-01 | -2.76e-01 | -2.12e-01 | -1.70e-01 | 7.96e-03 | 2.01e-01 | 1.13e-01 | 2.23e-01 | 3.28e-01 | 9.64e-01 |
| ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 15 | 4.53e-01 | 8.21e-01 | 0.4470 | 2.30e-01 | 2.09e-01 | 1.68e-01 | 1.67e-01 | 2.17e-01 | 1.23e-01 | 1.61e-01 | 2.61e-01 | 2.63e-01 | 1.47e-01 |
| REGULATION OF NITRIC OXIDE MEDIATED SIGNAL TRANSDUCTION | 11 | 8.39e-01 | 9.73e-01 | 0.4470 | -2.33e-01 | -2.39e-01 | -2.07e-01 | -2.04e-01 | -5.86e-02 | 1.80e-01 | 1.70e-01 | 2.35e-01 | 2.41e-01 | 7.36e-01 |
| POSITIVE REGULATION OF DENDRITIC SPINE MAINTENANCE | 5 | 1.65e-01 | 5.44e-01 | 0.4460 | -9.90e-02 | 1.85e-01 | -1.58e-01 | -3.03e-01 | -1.96e-01 | 7.01e-01 | 4.74e-01 | 5.42e-01 | 2.40e-01 | 4.48e-01 |
| PLASMA MEMBRANE TO ENDOSOME TRANSPORT | 8 | 8.05e-01 | 9.67e-01 | 0.4460 | 2.48e-01 | 2.32e-01 | 1.60e-01 | 2.34e-01 | -5.98e-02 | 2.24e-01 | 2.56e-01 | 4.34e-01 | 2.51e-01 | 7.69e-01 |
| REGULATION OF TORC2 SIGNALING | 6 | 6.63e-01 | 9.22e-01 | 0.4460 | 2.44e-01 | 1.87e-01 | 7.81e-02 | 2.10e-01 | -2.33e-01 | 3.00e-01 | 4.28e-01 | 7.40e-01 | 3.73e-01 | 3.22e-01 |
| POSITIVE REGULATION OF RNA SPLICING | 37 | 7.63e-02 | 3.74e-01 | 0.4460 | 1.11e-01 | 1.91e-01 | 2.47e-01 | 2.34e-01 | 1.86e-01 | 2.44e-01 | 4.47e-02 | 9.30e-03 | 1.39e-02 | 5.01e-02 |
| PHOSPHATIDYLINOSITOL MEDIATED SIGNALING | 26 | 3.38e-01 | 7.44e-01 | 0.4460 | -1.95e-01 | -2.13e-01 | -1.87e-01 | -2.11e-01 | -1.90e-01 | 8.56e-02 | 5.97e-02 | 9.97e-02 | 6.26e-02 | 9.39e-02 |
| SODIUM DEPENDENT PHOSPHATE TRANSPORT | 12 | 5.91e-01 | 8.94e-01 | 0.4460 | -2.51e-01 | -1.97e-01 | -1.59e-01 | -2.64e-01 | 4.30e-02 | 1.33e-01 | 2.37e-01 | 3.40e-01 | 1.13e-01 | 7.97e-01 |
| REGULATION OF LIPOPROTEIN LIPASE ACTIVITY | 16 | 2.26e-01 | 6.28e-01 | 0.4460 | -2.32e-01 | -1.35e-01 | -1.35e-01 | -2.23e-01 | -2.42e-01 | 1.08e-01 | 3.52e-01 | 3.51e-01 | 1.22e-01 | 9.33e-02 |
| THERMOCEPTION | 8 | 2.55e-01 | 6.62e-01 | 0.4460 | -1.73e-01 | -3.12e-01 | -7.01e-02 | -9.88e-02 | 2.38e-01 | 3.96e-01 | 1.27e-01 | 7.32e-01 | 6.28e-01 | 2.43e-01 |
| PURINE RIBONUCLEOSIDE CATABOLIC PROCESS | 6 | 8.73e-01 | 9.78e-01 | 0.4450 | 3.00e-01 | 2.21e-01 | 1.29e-01 | 2.07e-01 | -1.51e-02 | 2.03e-01 | 3.49e-01 | 5.83e-01 | 3.81e-01 | 9.49e-01 |
| SPINDLE ASSEMBLY | 127 | 4.09e-04 | 8.62e-03 | 0.4450 | 2.04e-01 | 1.95e-01 | 2.11e-01 | 2.42e-01 | 1.26e-01 | 6.91e-05 | 1.45e-04 | 4.16e-05 | 2.56e-06 | 1.42e-02 |
| MRNA 3 END PROCESSING | 49 | 3.49e-03 | 4.70e-02 | 0.4450 | 2.04e-01 | 1.17e-01 | 1.87e-01 | 3.03e-01 | 1.27e-01 | 1.33e-02 | 1.58e-01 | 2.32e-02 | 2.45e-04 | 1.24e-01 |
| PHAGOSOME MATURATION | 28 | 1.50e-01 | 5.19e-01 | 0.4450 | 2.54e-01 | 2.50e-01 | 1.61e-01 | 1.99e-01 | -7.52e-02 | 2.00e-02 | 2.20e-02 | 1.41e-01 | 6.77e-02 | 4.91e-01 |
| NEGATIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 43 | 1.63e-02 | 1.45e-01 | 0.4450 | 1.10e-01 | 2.13e-01 | 2.26e-01 | 2.36e-01 | 1.84e-01 | 2.14e-01 | 1.55e-02 | 1.04e-02 | 7.44e-03 | 3.66e-02 |
| MAINTENANCE OF CENTROSOME LOCATION | 6 | 1.87e-01 | 5.72e-01 | 0.4450 | 2.36e-01 | 1.32e-02 | 1.30e-01 | 2.07e-01 | -2.87e-01 | 3.18e-01 | 9.55e-01 | 5.80e-01 | 3.80e-01 | 2.23e-01 |
| TRICARBOXYLIC ACID METABOLIC PROCESS | 14 | 3.66e-01 | 7.66e-01 | 0.4450 | 1.75e-01 | 2.60e-01 | 1.66e-01 | 2.36e-01 | 1.29e-01 | 2.57e-01 | 9.19e-02 | 2.82e-01 | 1.27e-01 | 4.05e-01 |
| PEPTIDYL LYSINE HYDROXYLATION | 8 | 8.85e-02 | 4.01e-01 | 0.4450 | -6.43e-02 | 6.36e-02 | 2.81e-01 | 2.99e-01 | 1.44e-01 | 7.53e-01 | 7.56e-01 | 1.69e-01 | 1.42e-01 | 4.80e-01 |
| PLUS END DIRECTED ORGANELLE TRANSPORT ALONG MICROTUBULE | 7 | 3.45e-01 | 7.50e-01 | 0.4440 | -3.39e-02 | -2.83e-01 | -3.06e-01 | -1.13e-01 | -9.82e-02 | 8.77e-01 | 1.95e-01 | 1.61e-01 | 6.04e-01 | 6.53e-01 |
| MITOTIC NUCLEAR MEMBRANE ORGANIZATION | 10 | 3.42e-01 | 7.48e-01 | 0.4440 | 1.80e-04 | 1.12e-01 | 2.88e-01 | 2.31e-01 | 2.20e-01 | 9.99e-01 | 5.39e-01 | 1.15e-01 | 2.06e-01 | 2.28e-01 |
| REGULATION OF CARDIAC MUSCLE CELL MEMBRANE POTENTIAL | 7 | 4.53e-01 | 8.21e-01 | 0.4440 | 3.08e-01 | 1.44e-01 | -7.71e-03 | 1.21e-01 | -2.58e-01 | 1.58e-01 | 5.09e-01 | 9.72e-01 | 5.78e-01 | 2.37e-01 |
| PARASYMPATHETIC NERVOUS SYSTEM DEVELOPMENT | 17 | 2.78e-01 | 6.88e-01 | 0.4440 | 7.91e-02 | 2.27e-01 | 2.28e-01 | 1.84e-01 | 2.31e-01 | 5.72e-01 | 1.05e-01 | 1.03e-01 | 1.89e-01 | 9.88e-02 |
| APOPTOTIC CHROMOSOME CONDENSATION | 6 | 5.24e-01 | 8.60e-01 | 0.4440 | 2.95e-02 | -4.95e-02 | 1.46e-01 | 2.22e-01 | 3.51e-01 | 9.00e-01 | 8.34e-01 | 5.35e-01 | 3.45e-01 | 1.37e-01 |
| TRNA PSEUDOURIDINE SYNTHESIS | 6 | 7.47e-01 | 9.51e-01 | 0.4440 | 8.71e-02 | 6.03e-02 | 1.83e-01 | 1.39e-01 | 3.65e-01 | 7.12e-01 | 7.98e-01 | 4.36e-01 | 5.56e-01 | 1.22e-01 |
| IMP CATABOLIC PROCESS | 5 | 8.31e-01 | 9.73e-01 | 0.4440 | 1.84e-01 | 1.08e-01 | 2.38e-01 | 3.01e-01 | 6.55e-02 | 4.75e-01 | 6.74e-01 | 3.56e-01 | 2.44e-01 | 8.00e-01 |
| PITUITARY GLAND DEVELOPMENT | 40 | 2.86e-02 | 2.10e-01 | 0.4440 | 6.33e-02 | 1.31e-01 | 2.33e-01 | 1.59e-01 | 3.11e-01 | 4.88e-01 | 1.51e-01 | 1.09e-02 | 8.12e-02 | 6.74e-04 |
| SECONDARY HEART FIELD SPECIFICATION | 11 | 2.11e-01 | 6.06e-01 | 0.4440 | -8.32e-02 | -7.94e-02 | 1.39e-01 | 5.87e-02 | 4.01e-01 | 6.33e-01 | 6.49e-01 | 4.25e-01 | 7.36e-01 | 2.12e-02 |
| POSITIVE REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 7 | 2.62e-01 | 6.70e-01 | 0.4440 | -2.33e-01 | -2.09e-01 | -2.96e-01 | -1.02e-01 | 2.83e-02 | 2.87e-01 | 3.38e-01 | 1.74e-01 | 6.39e-01 | 8.97e-01 |
| POSITIVE REGULATION OF ASPARTIC TYPE PEPTIDASE ACTIVITY | 8 | 4.13e-01 | 7.98e-01 | 0.4440 | 2.95e-01 | 1.91e-01 | 5.59e-03 | 2.12e-01 | -1.69e-01 | 1.48e-01 | 3.50e-01 | 9.78e-01 | 2.99e-01 | 4.09e-01 |
| BRANCHING INVOLVED IN PROSTATE GLAND MORPHOGENESIS | 12 | 1.87e-01 | 5.72e-01 | 0.4440 | -1.91e-02 | 3.53e-02 | 2.80e-01 | 1.07e-01 | 3.24e-01 | 9.09e-01 | 8.32e-01 | 9.31e-02 | 5.20e-01 | 5.17e-02 |
| MITOCHONDRIAL TRANSCRIPTION | 19 | 1.13e-01 | 4.57e-01 | 0.4430 | 8.15e-02 | 3.16e-02 | 2.35e-01 | 1.74e-01 | 3.21e-01 | 5.39e-01 | 8.12e-01 | 7.58e-02 | 1.89e-01 | 1.53e-02 |
| PROTEIN DEGLYCOSYLATION | 15 | 2.73e-01 | 6.81e-01 | 0.4430 | 1.63e-01 | 2.19e-01 | 1.92e-01 | 2.89e-01 | 3.87e-02 | 2.73e-01 | 1.42e-01 | 1.97e-01 | 5.26e-02 | 7.95e-01 |
| LYMPH NODE DEVELOPMENT | 18 | 3.53e-03 | 4.74e-02 | 0.4430 | -1.45e-02 | -1.98e-02 | 2.41e-01 | 3.12e-01 | 2.00e-01 | 9.15e-01 | 8.84e-01 | 7.64e-02 | 2.18e-02 | 1.41e-01 |
| POSITIVE REGULATION OF TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 6 | 9.08e-01 | 9.85e-01 | 0.4430 | 2.36e-01 | 2.47e-01 | 1.69e-01 | 1.71e-01 | 1.47e-01 | 3.17e-01 | 2.94e-01 | 4.73e-01 | 4.68e-01 | 5.33e-01 |
| PROTEIN IMPORT INTO PEROXISOME MATRIX RECEPTOR RECYCLING | 6 | 1.42e-01 | 5.08e-01 | 0.4430 | -4.36e-02 | 1.17e-01 | 1.39e-01 | 2.90e-01 | 2.78e-01 | 8.53e-01 | 6.19e-01 | 5.56e-01 | 2.19e-01 | 2.38e-01 |
| REGULATION OF LYSOSOMAL PROTEIN CATABOLIC PROCESS | 11 | 6.84e-01 | 9.30e-01 | 0.4430 | 1.88e-01 | 2.14e-01 | 2.01e-01 | 2.69e-01 | 4.48e-02 | 2.81e-01 | 2.18e-01 | 2.48e-01 | 1.22e-01 | 7.97e-01 |
| REDUCTION OF FOOD INTAKE IN RESPONSE TO DIETARY EXCESS | 5 | 6.28e-01 | 9.09e-01 | 0.4430 | -2.00e-01 | -1.83e-01 | -1.26e-01 | -7.45e-02 | -3.19e-01 | 4.40e-01 | 4.79e-01 | 6.26e-01 | 7.73e-01 | 2.17e-01 |
| POSITIVE REGULATION OF T HELPER 17 CELL DIFFERENTIATION | 8 | 7.84e-01 | 9.61e-01 | 0.4430 | 1.48e-01 | 1.49e-01 | 1.77e-01 | 2.36e-01 | 2.54e-01 | 4.68e-01 | 4.66e-01 | 3.85e-01 | 2.48e-01 | 2.13e-01 |
| NUCLEAR MRNA SURVEILLANCE | 10 | 4.28e-01 | 8.05e-01 | 0.4430 | -1.25e-02 | 2.98e-02 | 1.81e-01 | 1.02e-01 | 3.89e-01 | 9.45e-01 | 8.70e-01 | 3.22e-01 | 5.75e-01 | 3.30e-02 |
| OLIGOPEPTIDE TRANSMEMBRANE TRANSPORT | 9 | 7.81e-01 | 9.60e-01 | 0.4430 | -2.30e-01 | -1.80e-01 | -2.47e-01 | -2.00e-01 | -9.75e-02 | 2.32e-01 | 3.49e-01 | 2.00e-01 | 2.98e-01 | 6.13e-01 |
| REGULATION OF ISOTYPE SWITCHING | 37 | 1.55e-01 | 5.26e-01 | 0.4420 | 1.80e-01 | 2.29e-01 | 1.98e-01 | 2.29e-01 | 1.39e-01 | 5.79e-02 | 1.61e-02 | 3.68e-02 | 1.61e-02 | 1.42e-01 |
| REGULATION OF MITOTIC CELL CYCLE SPINDLE ASSEMBLY CHECKPOINT | 21 | 3.83e-01 | 7.79e-01 | 0.4420 | 1.83e-01 | 1.66e-01 | 2.23e-01 | 2.76e-01 | 9.34e-02 | 1.47e-01 | 1.87e-01 | 7.74e-02 | 2.88e-02 | 4.59e-01 |
| VIRAL TRANSCRIPTION | 50 | 4.86e-02 | 2.89e-01 | 0.4420 | 1.91e-01 | 1.71e-01 | 1.87e-01 | 2.38e-01 | 1.95e-01 | 1.93e-02 | 3.62e-02 | 2.24e-02 | 3.60e-03 | 1.73e-02 |
| BASE CONVERSION OR SUBSTITUTION EDITING | 19 | 6.81e-01 | 9.29e-01 | 0.4420 | -2.10e-01 | -2.08e-01 | -2.17e-01 | -2.15e-01 | -1.20e-01 | 1.12e-01 | 1.16e-01 | 1.02e-01 | 1.05e-01 | 3.65e-01 |
| REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 17 | 3.74e-01 | 7.73e-01 | 0.4420 | 1.96e-01 | 1.79e-01 | 2.14e-01 | 1.42e-01 | 2.42e-01 | 1.61e-01 | 2.02e-01 | 1.26e-01 | 3.11e-01 | 8.37e-02 |
| ORGANELLE DISASSEMBLY | 137 | 3.44e-05 | 1.13e-03 | 0.4410 | 2.46e-01 | 2.00e-01 | 1.74e-01 | 2.40e-01 | 8.21e-02 | 6.91e-07 | 5.43e-05 | 4.42e-04 | 1.18e-06 | 9.71e-02 |
| CONVERGENT EXTENSION INVOLVED IN AXIS ELONGATION | 6 | 2.99e-01 | 7.11e-01 | 0.4410 | -2.19e-01 | 1.22e-02 | 1.64e-01 | 8.40e-02 | 3.35e-01 | 3.52e-01 | 9.59e-01 | 4.87e-01 | 7.22e-01 | 1.55e-01 |
| ENDOPLASMIC RETICULUM TO GOLGI VESICLE MEDIATED TRANSPORT | 127 | 1.32e-04 | 3.42e-03 | 0.4410 | 2.17e-01 | 1.77e-01 | 1.98e-01 | 2.53e-01 | 1.13e-01 | 2.31e-05 | 5.81e-04 | 1.16e-04 | 8.28e-07 | 2.82e-02 |
| COENZYME A METABOLIC PROCESS | 19 | 1.83e-01 | 5.70e-01 | 0.4410 | 2.30e-01 | 1.53e-01 | 1.34e-01 | 2.11e-01 | 2.36e-01 | 8.33e-02 | 2.48e-01 | 3.11e-01 | 1.11e-01 | 7.47e-02 |
| EXOCRINE PANCREAS DEVELOPMENT | 7 | 4.84e-01 | 8.38e-01 | 0.4410 | -2.80e-02 | 1.37e-01 | 2.14e-01 | 1.28e-02 | 3.58e-01 | 8.98e-01 | 5.30e-01 | 3.26e-01 | 9.53e-01 | 1.01e-01 |
| POST FERTILIZATION EPIGENETIC REGULATION OF GENE EXPRESSION | 13 | 4.11e-01 | 7.95e-01 | 0.4410 | 7.85e-02 | 8.09e-02 | 2.45e-01 | 2.59e-01 | 2.33e-01 | 6.24e-01 | 6.13e-01 | 1.26e-01 | 1.06e-01 | 1.46e-01 |
| DNA LIGATION | 16 | 4.55e-01 | 8.22e-01 | 0.4400 | 1.32e-01 | 1.45e-01 | 2.79e-01 | 1.90e-01 | 2.04e-01 | 3.62e-01 | 3.15e-01 | 5.32e-02 | 1.89e-01 | 1.58e-01 |
| PROTEIN PROCESSING INVOLVED IN PROTEIN TARGETING TO MITOCHONDRION | 7 | 1.49e-01 | 5.17e-01 | 0.4400 | -1.14e-02 | -1.02e-01 | -9.49e-02 | 1.18e-01 | -4.00e-01 | 9.58e-01 | 6.40e-01 | 6.64e-01 | 5.88e-01 | 6.66e-02 |
| NEGATIVE REGULATION OF ERAD PATHWAY | 6 | 3.97e-01 | 7.86e-01 | 0.4400 | 1.31e-01 | -1.48e-02 | 9.10e-02 | 1.34e-01 | 3.87e-01 | 5.78e-01 | 9.50e-01 | 6.99e-01 | 5.69e-01 | 1.01e-01 |
| PROTEIN LOCALIZATION TO MITOCHONDRION | 126 | 2.07e-04 | 4.82e-03 | 0.4400 | 1.93e-01 | 1.66e-01 | 2.33e-01 | 2.24e-01 | 1.55e-01 | 1.79e-04 | 1.30e-03 | 6.07e-06 | 1.38e-05 | 2.66e-03 |
| NEGATIVE REGULATION OF CELL ADHESION MOLECULE PRODUCTION | 10 | 6.40e-01 | 9.14e-01 | 0.4400 | -6.39e-02 | -1.05e-01 | -2.22e-01 | -2.24e-01 | -2.81e-01 | 7.26e-01 | 5.65e-01 | 2.24e-01 | 2.19e-01 | 1.24e-01 |
| DEVELOPMENT OF SECONDARY SEXUAL CHARACTERISTICS | 9 | 7.61e-01 | 9.54e-01 | 0.4400 | 2.38e-01 | 2.52e-01 | 1.79e-01 | 1.41e-01 | 1.46e-01 | 2.16e-01 | 1.91e-01 | 3.52e-01 | 4.63e-01 | 4.48e-01 |
| POSITIVE REGULATION OF DOUBLE STRAND BREAK REPAIR VIA NONHOMOLOGOUS END JOINING | 14 | 7.56e-01 | 9.51e-01 | 0.4400 | 1.79e-01 | 1.79e-01 | 2.05e-01 | 2.21e-01 | 1.96e-01 | 2.45e-01 | 2.45e-01 | 1.85e-01 | 1.52e-01 | 2.04e-01 |
| ASTRAL MICROTUBULE ORGANIZATION | 10 | 5.94e-01 | 8.96e-01 | 0.4400 | 2.08e-01 | 2.24e-01 | 1.40e-01 | 2.60e-01 | 1.10e-01 | 2.54e-01 | 2.20e-01 | 4.42e-01 | 1.54e-01 | 5.46e-01 |
| GOLGI DISASSEMBLY | 6 | 7.39e-01 | 9.49e-01 | 0.4400 | 2.09e-01 | 7.31e-02 | 1.73e-01 | 3.01e-01 | 1.55e-01 | 3.76e-01 | 7.56e-01 | 4.63e-01 | 2.02e-01 | 5.10e-01 |
| RELAXATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE | 6 | 8.00e-01 | 9.66e-01 | 0.4390 | 1.07e-01 | 6.64e-02 | 1.92e-01 | 2.51e-01 | 2.78e-01 | 6.50e-01 | 7.78e-01 | 4.15e-01 | 2.87e-01 | 2.38e-01 |
| MITOCHONDRION ORGANIZATION | 523 | 4.90e-18 | 8.99e-16 | 0.4390 | 1.96e-01 | 1.75e-01 | 2.16e-01 | 2.22e-01 | 1.69e-01 | 1.84e-14 | 7.10e-12 | 2.56e-17 | 4.05e-18 | 4.08e-11 |
| NEGATIVE REGULATION OF P38MAPK CASCADE | 8 | 3.46e-01 | 7.50e-01 | 0.4390 | 3.45e-01 | 2.20e-01 | 1.30e-01 | 9.36e-02 | -1.93e-02 | 9.15e-02 | 2.82e-01 | 5.24e-01 | 6.47e-01 | 9.25e-01 |
| NEGATIVE REGULATION OF MIRNA METABOLIC PROCESS | 26 | 3.92e-01 | 7.84e-01 | 0.4390 | 1.79e-01 | 2.17e-01 | 1.97e-01 | 2.03e-01 | 1.84e-01 | 1.15e-01 | 5.50e-02 | 8.17e-02 | 7.32e-02 | 1.05e-01 |
| BRANCHED CHAIN AMINO ACID TRANSPORT | 13 | 4.08e-01 | 7.94e-01 | 0.4390 | 1.57e-01 | 3.06e-01 | 2.03e-01 | 1.38e-01 | 1.21e-01 | 3.27e-01 | 5.64e-02 | 2.05e-01 | 3.90e-01 | 4.49e-01 |
| MEDIUM CHAIN FATTY ACYL COA METABOLIC PROCESS | 6 | 7.05e-01 | 9.33e-01 | 0.4390 | -1.97e-02 | 1.55e-01 | 2.47e-01 | 1.13e-01 | 3.08e-01 | 9.33e-01 | 5.11e-01 | 2.95e-01 | 6.33e-01 | 1.91e-01 |
| MESENCHYMAL CELL APOPTOTIC PROCESS | 15 | 2.13e-01 | 6.08e-01 | 0.4390 | 1.26e-02 | 6.57e-02 | 2.30e-01 | 8.95e-02 | 3.57e-01 | 9.33e-01 | 6.60e-01 | 1.23e-01 | 5.48e-01 | 1.66e-02 |
| POSITIVE REGULATION OF HEPATOCYTE PROLIFERATION | 10 | 6.68e-01 | 9.24e-01 | 0.4390 | 2.21e-01 | 2.44e-01 | 2.12e-01 | 1.87e-01 | -6.71e-02 | 2.25e-01 | 1.81e-01 | 2.46e-01 | 3.07e-01 | 7.13e-01 |
| REGULATION OF VOLTAGE GATED SODIUM CHANNEL ACTIVITY | 8 | 4.00e-01 | 7.88e-01 | 0.4390 | -1.90e-01 | -2.47e-01 | -1.39e-01 | -1.13e-01 | 2.52e-01 | 3.53e-01 | 2.26e-01 | 4.95e-01 | 5.79e-01 | 2.17e-01 |
| FUCOSE CATABOLIC PROCESS | 9 | 3.22e-01 | 7.32e-01 | 0.4390 | -1.01e-01 | -7.58e-02 | -1.90e-01 | -5.63e-02 | -3.71e-01 | 5.99e-01 | 6.94e-01 | 3.24e-01 | 7.70e-01 | 5.40e-02 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY NOREPINEPHRINE EPINEPHRINE | 8 | 4.03e-01 | 7.90e-01 | 0.4390 | 1.92e-01 | 1.14e-01 | 1.72e-01 | 9.46e-02 | 3.22e-01 | 3.46e-01 | 5.77e-01 | 3.99e-01 | 6.43e-01 | 1.15e-01 |
| GEPHYRIN CLUSTERING INVOLVED IN POSTSYNAPTIC DENSITY ASSEMBLY | 5 | 8.67e-01 | 9.78e-01 | 0.4390 | 8.51e-02 | 2.39e-01 | 2.40e-01 | 1.22e-01 | 2.35e-01 | 7.42e-01 | 3.54e-01 | 3.52e-01 | 6.38e-01 | 3.62e-01 |
| ORNITHINE TRANSPORT | 6 | 1.17e-01 | 4.65e-01 | 0.4380 | 2.58e-02 | 1.68e-01 | 1.60e-01 | 1.95e-01 | -3.16e-01 | 9.13e-01 | 4.77e-01 | 4.98e-01 | 4.08e-01 | 1.80e-01 |
| ACTIN FILAMENT BASED TRANSPORT | 21 | 2.21e-01 | 6.19e-01 | 0.4380 | -2.35e-01 | -1.45e-01 | -1.76e-01 | -2.91e-01 | -2.47e-02 | 6.22e-02 | 2.51e-01 | 1.63e-01 | 2.11e-02 | 8.45e-01 |
| DOUBLE STRAND BREAK REPAIR VIA NONHOMOLOGOUS END JOINING | 65 | 3.03e-02 | 2.18e-01 | 0.4380 | 2.07e-01 | 1.69e-01 | 2.02e-01 | 2.43e-01 | 1.45e-01 | 3.98e-03 | 1.84e-02 | 4.81e-03 | 7.17e-04 | 4.26e-02 |
| SUBSTANTIA NIGRA DEVELOPMENT | 40 | 8.25e-02 | 3.88e-01 | 0.4380 | 1.81e-01 | 1.58e-01 | 1.97e-01 | 2.70e-01 | 1.50e-01 | 4.72e-02 | 8.44e-02 | 3.13e-02 | 3.09e-03 | 1.01e-01 |
| DRINKING BEHAVIOR | 8 | 6.36e-01 | 9.13e-01 | 0.4380 | 2.57e-01 | 9.64e-02 | 1.73e-01 | 2.82e-01 | 8.57e-02 | 2.08e-01 | 6.37e-01 | 3.97e-01 | 1.68e-01 | 6.75e-01 |
| ETHANOL METABOLIC PROCESS | 19 | 4.24e-01 | 8.03e-01 | 0.4380 | -9.10e-02 | -1.40e-01 | -2.52e-01 | -1.86e-01 | -2.56e-01 | 4.92e-01 | 2.91e-01 | 5.70e-02 | 1.61e-01 | 5.31e-02 |
| NETRIN ACTIVATED SIGNALING PATHWAY | 9 | 7.95e-01 | 9.65e-01 | 0.4380 | -1.67e-01 | -1.59e-01 | -2.64e-01 | -2.38e-01 | -1.09e-01 | 3.87e-01 | 4.08e-01 | 1.70e-01 | 2.16e-01 | 5.71e-01 |
| REGULATION OF SEROTONIN SECRETION | 6 | 7.97e-01 | 9.66e-01 | 0.4380 | 1.21e-01 | 8.93e-02 | 2.31e-01 | 1.45e-01 | 3.07e-01 | 6.08e-01 | 7.05e-01 | 3.26e-01 | 5.39e-01 | 1.92e-01 |
| NEGATIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II | 895 | 1.89e-33 | 1.09e-30 | 0.4380 | 1.59e-01 | 1.69e-01 | 2.16e-01 | 2.22e-01 | 2.03e-01 | 5.57e-16 | 9.67e-18 | 4.10e-28 | 1.31e-29 | 4.98e-25 |
| LIPID DROPLET FORMATION | 13 | 7.99e-01 | 9.66e-01 | 0.4370 | 2.02e-01 | 2.16e-01 | 2.03e-01 | 2.35e-01 | 8.98e-02 | 2.08e-01 | 1.78e-01 | 2.06e-01 | 1.43e-01 | 5.75e-01 |
| REGULATION OF VITAMIN D BIOSYNTHETIC PROCESS | 7 | 9.32e-01 | 9.90e-01 | 0.4370 | 2.38e-01 | 1.93e-01 | 1.85e-01 | 2.22e-01 | 1.18e-01 | 2.75e-01 | 3.77e-01 | 3.96e-01 | 3.09e-01 | 5.89e-01 |
| HIGH DENSITY LIPOPROTEIN PARTICLE REMODELING | 16 | 5.05e-05 | 1.55e-03 | 0.4370 | -1.68e-01 | 1.89e-01 | -5.85e-02 | -2.09e-01 | -2.83e-01 | 2.43e-01 | 1.91e-01 | 6.85e-01 | 1.49e-01 | 4.97e-02 |
| AMINOGLYCOSIDE ANTIBIOTIC METABOLIC PROCESS | 10 | 6.90e-01 | 9.31e-01 | 0.4370 | -1.13e-01 | -2.18e-01 | -2.26e-01 | -1.25e-01 | -2.53e-01 | 5.36e-01 | 2.32e-01 | 2.16e-01 | 4.93e-01 | 1.66e-01 |
| GROWTH INVOLVED IN HEART MORPHOGENESIS | 5 | 2.44e-01 | 6.48e-01 | 0.4370 | -2.24e-01 | 4.27e-02 | 2.50e-01 | 1.36e-01 | 2.41e-01 | 3.86e-01 | 8.69e-01 | 3.33e-01 | 6.00e-01 | 3.51e-01 |
| SKELETAL MUSCLE SATELLITE CELL ACTIVATION | 8 | 4.28e-01 | 8.05e-01 | 0.4370 | -1.76e-01 | -1.04e-01 | -1.93e-01 | -3.34e-01 | 2.10e-02 | 3.88e-01 | 6.10e-01 | 3.44e-01 | 1.02e-01 | 9.18e-01 |
| INNER EAR RECEPTOR CELL FATE COMMITMENT | 5 | 6.56e-01 | 9.20e-01 | 0.4370 | -9.00e-02 | -2.66e-02 | 2.32e-01 | 1.51e-01 | 3.25e-01 | 7.28e-01 | 9.18e-01 | 3.70e-01 | 5.59e-01 | 2.08e-01 |
| REGULATION OF CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 26 | 3.00e-02 | 2.17e-01 | 0.4370 | -2.45e-01 | -9.18e-02 | -1.51e-01 | -3.07e-01 | -7.32e-02 | 3.09e-02 | 4.18e-01 | 1.82e-01 | 6.67e-03 | 5.18e-01 |
| CYCLOOXYGENASE PATHWAY | 9 | 3.92e-01 | 7.84e-01 | 0.4370 | 2.58e-01 | 1.02e-01 | 2.30e-01 | 2.47e-01 | -1.76e-03 | 1.80e-01 | 5.97e-01 | 2.32e-01 | 2.00e-01 | 9.93e-01 |
| REPLICATIVE SENESCENCE | 17 | 3.51e-01 | 7.52e-01 | 0.4370 | 1.87e-01 | 2.22e-01 | 2.69e-01 | 1.42e-01 | 1.19e-01 | 1.82e-01 | 1.14e-01 | 5.49e-02 | 3.12e-01 | 3.94e-01 |
| REGULATION OF MEGAKARYOCYTE DIFFERENTIATION | 35 | 2.83e-01 | 6.93e-01 | 0.4370 | 1.56e-01 | 2.04e-01 | 2.28e-01 | 2.02e-01 | 1.77e-01 | 1.10e-01 | 3.69e-02 | 1.93e-02 | 3.83e-02 | 6.93e-02 |
| POSITIVE REGULATION OF FAT CELL DIFFERENTIATION | 67 | 1.42e-02 | 1.31e-01 | 0.4370 | 1.72e-01 | 2.32e-01 | 2.07e-01 | 1.69e-01 | 1.89e-01 | 1.50e-02 | 1.04e-03 | 3.36e-03 | 1.68e-02 | 7.31e-03 |
| PROSTATIC BUD FORMATION | 8 | 1.46e-01 | 5.12e-01 | 0.4360 | -2.77e-01 | -5.69e-02 | 1.21e-01 | 3.63e-02 | 3.08e-01 | 1.75e-01 | 7.80e-01 | 5.55e-01 | 8.59e-01 | 1.32e-01 |
| NEGATIVE REGULATION OF MITOCHONDRION ORGANIZATION | 48 | 7.06e-02 | 3.59e-01 | 0.4360 | 2.17e-01 | 1.63e-01 | 1.88e-01 | 2.24e-01 | 1.75e-01 | 9.34e-03 | 5.07e-02 | 2.39e-02 | 7.17e-03 | 3.56e-02 |
| BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR SIGNALING PATHWAY | 6 | 7.89e-01 | 9.63e-01 | 0.4360 | 1.81e-01 | 2.24e-01 | 1.39e-01 | 1.69e-01 | 2.43e-01 | 4.42e-01 | 3.43e-01 | 5.56e-01 | 4.74e-01 | 3.03e-01 |
| GLYCEROL ETHER METABOLIC PROCESS | 21 | 5.74e-01 | 8.84e-01 | 0.4350 | -2.01e-01 | -1.76e-01 | -2.00e-01 | -2.40e-01 | -1.44e-01 | 1.11e-01 | 1.63e-01 | 1.13e-01 | 5.68e-02 | 2.52e-01 |
| NEGATIVE REGULATION OF MYOFIBROBLAST DIFFERENTIATION | 6 | 6.79e-01 | 9.28e-01 | 0.4350 | 3.98e-02 | 5.54e-04 | 1.89e-01 | 1.24e-01 | 3.70e-01 | 8.66e-01 | 9.98e-01 | 4.23e-01 | 5.98e-01 | 1.17e-01 |
| ARTICULAR CARTILAGE DEVELOPMENT | 5 | 8.69e-01 | 9.78e-01 | 0.4350 | -1.99e-01 | -1.50e-01 | -2.16e-01 | -1.39e-01 | -2.47e-01 | 4.42e-01 | 5.60e-01 | 4.02e-01 | 5.90e-01 | 3.38e-01 |
| HYPOTHALAMUS CELL DIFFERENTIATION | 12 | 6.54e-02 | 3.40e-01 | 0.4350 | -2.50e-02 | 1.36e-01 | 9.13e-02 | 3.71e-02 | 4.01e-01 | 8.81e-01 | 4.16e-01 | 5.84e-01 | 8.24e-01 | 1.62e-02 |
| NEGATIVE REGULATION OF LEUKOCYTE DEGRANULATION | 12 | 1.15e-01 | 4.63e-01 | 0.4350 | 2.14e-01 | 2.39e-01 | -4.73e-02 | 3.61e-02 | -2.88e-01 | 1.98e-01 | 1.52e-01 | 7.77e-01 | 8.29e-01 | 8.46e-02 |
| MONOCYTE ACTIVATION | 12 | 2.03e-01 | 5.96e-01 | 0.4350 | -4.91e-02 | -1.94e-02 | -2.86e-01 | -1.88e-01 | -2.62e-01 | 7.69e-01 | 9.08e-01 | 8.63e-02 | 2.58e-01 | 1.16e-01 |
| ESTABLISHMENT OF PIGMENT GRANULE LOCALIZATION | 21 | 2.13e-01 | 6.08e-01 | 0.4340 | 2.24e-01 | 2.13e-01 | 1.98e-01 | 2.12e-01 | -9.38e-02 | 7.53e-02 | 9.06e-02 | 1.16e-01 | 9.24e-02 | 4.57e-01 |
| GLYCOSYLCERAMIDE CATABOLIC PROCESS | 6 | 5.30e-01 | 8.63e-01 | 0.4340 | 1.79e-01 | 1.89e-01 | 8.12e-02 | 9.22e-02 | -3.25e-01 | 4.47e-01 | 4.24e-01 | 7.30e-01 | 6.96e-01 | 1.68e-01 |
| REGULATION OF ISOTYPE SWITCHING TO IGE ISOTYPES | 6 | 9.59e-01 | 9.94e-01 | 0.4340 | 2.05e-01 | 2.11e-01 | 1.91e-01 | 2.23e-01 | 1.26e-01 | 3.85e-01 | 3.71e-01 | 4.19e-01 | 3.44e-01 | 5.92e-01 |
| THALAMUS DEVELOPMENT | 11 | 2.44e-01 | 6.48e-01 | 0.4340 | -1.04e-01 | -4.96e-02 | 1.57e-01 | 1.12e-01 | 3.72e-01 | 5.50e-01 | 7.76e-01 | 3.68e-01 | 5.20e-01 | 3.28e-02 |
| L SERINE BIOSYNTHETIC PROCESS | 5 | 6.59e-01 | 9.21e-01 | 0.4340 | 2.56e-01 | 7.41e-02 | 1.34e-01 | 3.04e-01 | -8.30e-02 | 3.22e-01 | 7.74e-01 | 6.03e-01 | 2.39e-01 | 7.48e-01 |
| INTRACELLULAR DISTRIBUTION OF MITOCHONDRIA | 7 | 7.96e-01 | 9.65e-01 | 0.4340 | 2.21e-01 | 2.50e-01 | 1.37e-01 | 2.40e-01 | 1.91e-02 | 3.11e-01 | 2.52e-01 | 5.29e-01 | 2.71e-01 | 9.30e-01 |
| CELLULAR RESPONSE TO IONIZING RADIATION | 68 | 7.50e-03 | 8.31e-02 | 0.4340 | 1.71e-01 | 1.58e-01 | 1.98e-01 | 2.61e-01 | 1.64e-01 | 1.49e-02 | 2.42e-02 | 4.81e-03 | 1.94e-04 | 1.96e-02 |
| CYTOPLASMIC TRANSLATIONAL ELONGATION | 5 | 9.15e-01 | 9.86e-01 | 0.4340 | 1.27e-01 | 9.08e-02 | 2.39e-01 | 2.16e-01 | 2.45e-01 | 6.24e-01 | 7.25e-01 | 3.55e-01 | 4.02e-01 | 3.43e-01 |
| MESENCHYMAL CELL PROLIFERATION | 43 | 8.26e-03 | 8.92e-02 | 0.4340 | 2.76e-02 | 1.02e-01 | 2.34e-01 | 1.97e-01 | 2.89e-01 | 7.54e-01 | 2.47e-01 | 7.89e-03 | 2.55e-02 | 1.04e-03 |
| INTRACELLULAR ESTROGEN RECEPTOR SIGNALING PATHWAY | 53 | 8.94e-02 | 4.05e-01 | 0.4340 | 2.04e-01 | 2.35e-01 | 2.10e-01 | 1.77e-01 | 1.27e-01 | 1.03e-02 | 3.08e-03 | 8.19e-03 | 2.61e-02 | 1.11e-01 |
| NEGATIVE REGULATION OF T CELL MIGRATION | 6 | 4.59e-01 | 8.23e-01 | 0.4340 | -7.57e-02 | -3.34e-01 | -2.41e-01 | -9.88e-02 | -5.22e-02 | 7.48e-01 | 1.56e-01 | 3.07e-01 | 6.75e-01 | 8.25e-01 |
| REGULATION OF VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL | 12 | 5.17e-01 | 8.56e-01 | 0.4330 | -7.44e-02 | -1.69e-01 | -2.40e-01 | -2.43e-01 | -1.93e-01 | 6.55e-01 | 3.11e-01 | 1.50e-01 | 1.46e-01 | 2.47e-01 |
| MULTIVESICULAR BODY SORTING PATHWAY | 46 | 7.33e-02 | 3.66e-01 | 0.4330 | 2.15e-01 | 1.46e-01 | 2.01e-01 | 2.35e-01 | 1.57e-01 | 1.17e-02 | 8.77e-02 | 1.85e-02 | 5.79e-03 | 6.60e-02 |
| CELLULAR METABOLIC COMPOUND SALVAGE | 29 | 1.48e-01 | 5.16e-01 | 0.4330 | 2.63e-01 | 2.67e-01 | 1.57e-01 | 1.47e-01 | 2.86e-02 | 1.43e-02 | 1.28e-02 | 1.44e-01 | 1.70e-01 | 7.90e-01 |
| MAGNESIUM ION HOMEOSTASIS | 10 | 7.12e-01 | 9.35e-01 | 0.4330 | -2.04e-01 | -2.64e-01 | -1.57e-01 | -2.03e-01 | -1.02e-01 | 2.65e-01 | 1.49e-01 | 3.91e-01 | 2.65e-01 | 5.76e-01 |
| SEQUESTERING OF ACTIN MONOMERS | 6 | 2.20e-01 | 6.17e-01 | 0.4330 | -1.68e-01 | -7.04e-03 | 2.67e-01 | 1.91e-01 | 2.27e-01 | 4.75e-01 | 9.76e-01 | 2.58e-01 | 4.19e-01 | 3.36e-01 |
| POSITIVE REGULATION OF B CELL ACTIVATION | 79 | 3.16e-03 | 4.34e-02 | 0.4330 | 2.28e-01 | 2.15e-01 | 1.59e-01 | 2.41e-01 | 7.80e-02 | 4.64e-04 | 9.69e-04 | 1.45e-02 | 2.14e-04 | 2.31e-01 |
| NEGATIVE REGULATION OF POTASSIUM ION TRANSPORT | 36 | 1.51e-01 | 5.20e-01 | 0.4330 | -1.37e-01 | -2.31e-01 | -2.30e-01 | -1.96e-01 | -1.55e-01 | 1.56e-01 | 1.65e-02 | 1.71e-02 | 4.16e-02 | 1.07e-01 |
| REGULATION OF SKELETAL MUSCLE TISSUE GROWTH | 6 | 6.27e-01 | 9.09e-01 | 0.4320 | 1.21e-02 | 9.70e-02 | 1.70e-01 | 2.24e-02 | 3.85e-01 | 9.59e-01 | 6.81e-01 | 4.71e-01 | 9.24e-01 | 1.03e-01 |
| NUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 38 | 7.85e-02 | 3.80e-01 | 0.4320 | 2.70e-01 | 2.47e-01 | 1.62e-01 | 1.63e-01 | -6.33e-03 | 3.98e-03 | 8.42e-03 | 8.40e-02 | 8.15e-02 | 9.46e-01 |
| CELLULAR RESPONSE TO HYDROGEN PEROXIDE | 65 | 1.16e-02 | 1.13e-01 | 0.4320 | 2.15e-01 | 1.73e-01 | 1.82e-01 | 2.66e-01 | 8.24e-02 | 2.66e-03 | 1.56e-02 | 1.13e-02 | 2.13e-04 | 2.50e-01 |
| MOTOR NEURON APOPTOTIC PROCESS | 21 | 4.34e-01 | 8.08e-01 | 0.4320 | 2.19e-01 | 1.95e-01 | 2.05e-01 | 1.65e-01 | 1.77e-01 | 8.18e-02 | 1.23e-01 | 1.03e-01 | 1.90e-01 | 1.61e-01 |
| AXON CHOICE POINT RECOGNITION | 7 | 5.52e-01 | 8.76e-01 | 0.4320 | -2.15e-01 | -3.36e-01 | -1.13e-01 | -1.10e-01 | 5.54e-02 | 3.26e-01 | 1.24e-01 | 6.06e-01 | 6.14e-01 | 8.00e-01 |
| NEUTROPHIL MEDIATED IMMUNITY | 36 | 3.46e-02 | 2.37e-01 | 0.4320 | 2.24e-01 | 2.53e-01 | 1.61e-01 | 1.87e-01 | -1.08e-01 | 2.01e-02 | 8.74e-03 | 9.51e-02 | 5.22e-02 | 2.60e-01 |
| REGULATION OF NODAL SIGNALING PATHWAY | 9 | 3.14e-01 | 7.26e-01 | 0.4310 | -1.79e-01 | -4.79e-02 | 1.15e-01 | 1.43e-02 | 3.72e-01 | 3.51e-01 | 8.03e-01 | 5.51e-01 | 9.41e-01 | 5.35e-02 |
| POSITIVE REGULATION OF GAMMA DELTA T CELL DIFFERENTIATION | 7 | 8.63e-01 | 9.78e-01 | 0.4310 | 2.10e-01 | 1.90e-01 | 2.48e-01 | 2.08e-01 | 3.55e-02 | 3.36e-01 | 3.85e-01 | 2.56e-01 | 3.42e-01 | 8.71e-01 |
| MONOCYTE AGGREGATION | 5 | 5.59e-01 | 8.78e-01 | 0.4310 | 1.87e-01 | 3.12e-01 | 1.83e-01 | 2.66e-02 | -1.38e-01 | 4.70e-01 | 2.27e-01 | 4.78e-01 | 9.18e-01 | 5.92e-01 |
| REGULATION OF GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 7 | 3.89e-01 | 7.82e-01 | 0.4310 | 1.66e-01 | 6.02e-02 | 9.03e-02 | 2.93e-01 | 2.46e-01 | 4.48e-01 | 7.83e-01 | 6.79e-01 | 1.79e-01 | 2.60e-01 |
| NCRNA TRANSCRIPTION | 134 | 9.56e-05 | 2.68e-03 | 0.4310 | 1.47e-01 | 1.73e-01 | 2.08e-01 | 2.03e-01 | 2.22e-01 | 3.22e-03 | 5.43e-04 | 3.14e-05 | 4.99e-05 | 9.26e-06 |
| REGULATION OF HISTONE H3 K4 METHYLATION | 11 | 4.33e-01 | 8.07e-01 | 0.4300 | -1.08e-01 | -1.02e-01 | -1.84e-01 | -9.89e-02 | -3.46e-01 | 5.37e-01 | 5.56e-01 | 2.90e-01 | 5.70e-01 | 4.71e-02 |
| SPINAL CORD PATTERNING | 21 | 1.58e-01 | 5.30e-01 | 0.4300 | 3.52e-02 | 1.02e-01 | 2.75e-01 | 1.76e-01 | 2.59e-01 | 7.80e-01 | 4.18e-01 | 2.92e-02 | 1.62e-01 | 4.01e-02 |
| REGULATION OF CHROMOSOME SEGREGATION | 129 | 1.26e-05 | 4.60e-04 | 0.4300 | 1.79e-01 | 1.43e-01 | 1.97e-01 | 2.64e-01 | 1.56e-01 | 4.48e-04 | 5.10e-03 | 1.15e-04 | 2.15e-07 | 2.26e-03 |
| REGULATION OF HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 40 | 3.08e-02 | 2.21e-01 | 0.4300 | 2.40e-01 | 1.41e-01 | 1.52e-01 | 2.74e-01 | 9.91e-02 | 8.75e-03 | 1.23e-01 | 9.59e-02 | 2.76e-03 | 2.78e-01 |
| ERAD PATHWAY | 108 | 1.09e-03 | 1.88e-02 | 0.4300 | 1.69e-01 | 1.84e-01 | 1.97e-01 | 2.25e-01 | 1.81e-01 | 2.36e-03 | 9.25e-04 | 4.02e-04 | 5.36e-05 | 1.13e-03 |
| NEGATIVE REGULATION OF NEURON DIFFERENTIATION | 72 | 4.78e-03 | 5.92e-02 | 0.4300 | 9.58e-02 | 1.76e-01 | 2.43e-01 | 1.84e-01 | 2.28e-01 | 1.60e-01 | 9.92e-03 | 3.60e-04 | 6.97e-03 | 8.39e-04 |
| CD8 POSITIVE ALPHA BETA T CELL PROLIFERATION | 9 | 2.52e-01 | 6.58e-01 | 0.4300 | -1.95e-02 | 8.43e-02 | 3.17e-01 | 2.11e-01 | 1.80e-01 | 9.19e-01 | 6.61e-01 | 9.96e-02 | 2.73e-01 | 3.50e-01 |
| POSITIVE REGULATION OF DOUBLE STRAND BREAK REPAIR VIA HOMOLOGOUS RECOMBINATION | 34 | 2.16e-01 | 6.12e-01 | 0.4300 | 1.58e-01 | 1.88e-01 | 2.28e-01 | 2.44e-01 | 1.13e-01 | 1.12e-01 | 5.75e-02 | 2.13e-02 | 1.37e-02 | 2.52e-01 |
| NEGATIVE REGULATION OF AMINO ACID TRANSPORT | 16 | 4.23e-02 | 2.67e-01 | 0.4300 | 2.54e-01 | 2.47e-01 | 1.05e-01 | 6.12e-02 | 2.10e-01 | 7.83e-02 | 8.67e-02 | 4.66e-01 | 6.72e-01 | 1.46e-01 |
| REGULATION OF GENE SILENCING BY REGULATORY NCRNA | 29 | 2.63e-01 | 6.70e-01 | 0.4300 | 1.95e-01 | 1.64e-01 | 1.75e-01 | 2.25e-01 | 1.97e-01 | 6.98e-02 | 1.27e-01 | 1.04e-01 | 3.62e-02 | 6.56e-02 |
| LUTEOLYSIS | 6 | 8.65e-01 | 9.78e-01 | 0.4300 | -1.66e-01 | -2.28e-01 | -1.79e-01 | -2.52e-01 | -9.71e-02 | 4.82e-01 | 3.34e-01 | 4.46e-01 | 2.84e-01 | 6.80e-01 |
| REGULATION OF APPETITE | 19 | 7.30e-02 | 3.66e-01 | 0.4300 | 2.34e-01 | 2.51e-01 | 1.37e-01 | 8.29e-02 | 2.03e-01 | 7.73e-02 | 5.81e-02 | 3.03e-01 | 5.32e-01 | 1.26e-01 |
| REGULATION OF DNA BINDING | 82 | 1.14e-02 | 1.12e-01 | 0.4290 | 1.48e-01 | 1.73e-01 | 2.28e-01 | 2.21e-01 | 1.78e-01 | 2.04e-02 | 6.62e-03 | 3.64e-04 | 5.31e-04 | 5.36e-03 |
| ENDOPLASMIC RETICULUM MEMBRANE ORGANIZATION | 12 | 4.29e-01 | 8.05e-01 | 0.4290 | 2.54e-01 | 1.33e-01 | 1.37e-01 | 2.88e-01 | -2.69e-02 | 1.27e-01 | 4.26e-01 | 4.11e-01 | 8.45e-02 | 8.72e-01 |
| NUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 169 | 1.19e-05 | 4.36e-04 | 0.4290 | 1.97e-01 | 1.99e-01 | 2.18e-01 | 1.77e-01 | 1.65e-01 | 1.03e-05 | 8.13e-06 | 9.92e-07 | 7.22e-05 | 2.06e-04 |
| REGULATION OF FC GAMMA RECEPTOR SIGNALING PATHWAY INVOLVED IN PHAGOCYTOSIS | 5 | 5.31e-01 | 8.63e-01 | 0.4290 | 1.92e-01 | -2.11e-02 | 1.83e-01 | 3.15e-01 | 1.20e-01 | 4.57e-01 | 9.35e-01 | 4.78e-01 | 2.22e-01 | 6.43e-01 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE ADAPTATION | 8 | 9.02e-01 | 9.84e-01 | 0.4290 | -1.59e-01 | -1.98e-01 | -2.52e-01 | -1.80e-01 | -1.55e-01 | 4.37e-01 | 3.31e-01 | 2.18e-01 | 3.77e-01 | 4.48e-01 |
| GLOMERULAR EPITHELIAL CELL DEVELOPMENT | 12 | 3.72e-01 | 7.71e-01 | 0.4290 | -2.47e-01 | -2.09e-01 | -1.45e-01 | -1.54e-01 | 1.87e-01 | 1.39e-01 | 2.11e-01 | 3.86e-01 | 3.55e-01 | 2.61e-01 |
| RESPONSE TO MUSCLE STRETCH | 24 | 4.58e-01 | 8.23e-01 | 0.4290 | -2.07e-01 | -2.11e-01 | -2.33e-01 | -1.84e-01 | -9.29e-02 | 7.92e-02 | 7.38e-02 | 4.80e-02 | 1.19e-01 | 4.31e-01 |
| PROTEIN ACTIVATION CASCADE | 17 | 7.14e-01 | 9.36e-01 | 0.4290 | -1.86e-01 | -2.24e-01 | -2.12e-01 | -2.13e-01 | -9.45e-02 | 1.83e-01 | 1.10e-01 | 1.30e-01 | 1.29e-01 | 5.00e-01 |
| DNA CONFORMATION CHANGE | 88 | 1.40e-03 | 2.30e-02 | 0.4290 | 2.08e-01 | 1.82e-01 | 1.65e-01 | 2.22e-01 | 1.78e-01 | 7.50e-04 | 3.22e-03 | 7.52e-03 | 3.24e-04 | 3.98e-03 |
| GERMINAL CENTER FORMATION | 14 | 4.59e-01 | 8.23e-01 | 0.4290 | 2.00e-01 | 1.33e-01 | 1.89e-01 | 2.96e-01 | 5.58e-02 | 1.95e-01 | 3.88e-01 | 2.21e-01 | 5.55e-02 | 7.18e-01 |
| NEGATIVE REGULATION OF CENTROSOME DUPLICATION | 12 | 8.47e-01 | 9.76e-01 | 0.4290 | 1.88e-01 | 1.89e-01 | 2.29e-01 | 2.19e-01 | 1.12e-01 | 2.61e-01 | 2.56e-01 | 1.70e-01 | 1.89e-01 | 5.02e-01 |
| RESPONSE TO L PHENYLALANINE DERIVATIVE | 6 | 6.92e-01 | 9.31e-01 | 0.4290 | 1.21e-01 | 3.03e-02 | 2.43e-01 | 1.86e-01 | 2.73e-01 | 6.09e-01 | 8.98e-01 | 3.02e-01 | 4.31e-01 | 2.46e-01 |
| POSITIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 44 | 1.62e-01 | 5.38e-01 | 0.4290 | 1.85e-01 | 1.58e-01 | 2.11e-01 | 2.28e-01 | 1.68e-01 | 3.36e-02 | 6.96e-02 | 1.54e-02 | 9.00e-03 | 5.38e-02 |
| PEROXISOMAL TRANSPORT | 22 | 3.83e-01 | 7.79e-01 | 0.4290 | 1.37e-01 | 1.27e-01 | 2.29e-01 | 2.48e-01 | 1.87e-01 | 2.67e-01 | 3.02e-01 | 6.33e-02 | 4.38e-02 | 1.29e-01 |
| ENERGY DERIVATION BY OXIDATION OF ORGANIC COMPOUNDS | 305 | 2.60e-09 | 1.78e-07 | 0.4290 | 1.73e-01 | 1.82e-01 | 2.19e-01 | 2.14e-01 | 1.64e-01 | 2.14e-07 | 4.83e-08 | 4.34e-11 | 1.19e-10 | 8.61e-07 |
| MITOCHONDRIAL TRANSPORT | 181 | 1.77e-06 | 7.82e-05 | 0.4280 | 1.72e-01 | 1.53e-01 | 2.34e-01 | 2.27e-01 | 1.56e-01 | 6.44e-05 | 3.87e-04 | 5.38e-08 | 1.40e-07 | 3.04e-04 |
| SKELETAL MUSCLE SATELLITE CELL MAINTENANCE INVOLVED IN SKELETAL MUSCLE REGENERATION | 5 | 6.03e-01 | 9.00e-01 | 0.4280 | -2.33e-01 | -1.30e-01 | 2.35e-02 | -2.07e-01 | 2.62e-01 | 3.67e-01 | 6.15e-01 | 9.27e-01 | 4.22e-01 | 3.10e-01 |
| ANTEROGRADE NEURONAL DENSE CORE VESICLE TRANSPORT | 6 | 7.63e-01 | 9.54e-01 | 0.4280 | 2.65e-01 | 1.05e-01 | 1.99e-01 | 2.41e-01 | 6.73e-02 | 2.62e-01 | 6.55e-01 | 3.98e-01 | 3.06e-01 | 7.75e-01 |
| T HELPER 1 CELL CYTOKINE PRODUCTION | 8 | 3.53e-01 | 7.53e-01 | 0.4280 | -4.10e-02 | -6.59e-02 | -2.27e-01 | -3.14e-01 | -1.65e-01 | 8.41e-01 | 7.47e-01 | 2.67e-01 | 1.24e-01 | 4.18e-01 |
| DNA TEMPLATED DNA REPLICATION | 158 | 1.07e-05 | 3.95e-04 | 0.4280 | 1.82e-01 | 1.47e-01 | 2.19e-01 | 2.38e-01 | 1.55e-01 | 7.66e-05 | 1.45e-03 | 2.08e-06 | 2.40e-07 | 7.62e-04 |
| POSITIVE REGULATION OF ACTIVIN RECEPTOR SIGNALING PATHWAY | 8 | 3.29e-01 | 7.37e-01 | 0.4270 | -6.59e-02 | -1.00e-02 | 1.59e-01 | 2.12e-01 | 3.29e-01 | 7.47e-01 | 9.61e-01 | 4.36e-01 | 3.00e-01 | 1.07e-01 |
| RESPONSE TO TOPOLOGICALLY INCORRECT PROTEIN | 155 | 2.37e-06 | 1.03e-04 | 0.4270 | 1.12e-01 | 1.57e-01 | 2.18e-01 | 2.11e-01 | 2.31e-01 | 1.57e-02 | 7.15e-04 | 2.81e-06 | 6.04e-06 | 7.04e-07 |
| MITOCHONDRIAL PROTEIN CATABOLIC PROCESS | 6 | 8.02e-01 | 9.67e-01 | 0.4270 | 1.68e-01 | 2.17e-01 | 1.98e-01 | 2.57e-01 | -4.25e-02 | 4.75e-01 | 3.57e-01 | 4.01e-01 | 2.76e-01 | 8.57e-01 |
| NADPH OXIDATION | 5 | 2.69e-01 | 6.77e-01 | 0.4270 | -2.76e-01 | 4.95e-02 | -1.60e-01 | -2.79e-01 | -1.42e-02 | 2.86e-01 | 8.48e-01 | 5.35e-01 | 2.79e-01 | 9.56e-01 |
| NEGATIVE REGULATION OF SYNAPSE ASSEMBLY | 8 | 8.84e-01 | 9.80e-01 | 0.4270 | 1.57e-01 | 1.81e-01 | 1.98e-01 | 1.67e-01 | 2.40e-01 | 4.42e-01 | 3.74e-01 | 3.32e-01 | 4.14e-01 | 2.40e-01 |
| NEGATIVE REGULATION OF STEROL TRANSPORT | 31 | 1.58e-04 | 3.89e-03 | 0.4270 | 3.92e-02 | 4.73e-02 | -3.54e-02 | 1.38e-02 | -4.21e-01 | 7.06e-01 | 6.48e-01 | 7.33e-01 | 8.94e-01 | 5.04e-05 |
| CHROMOSOME ORGANIZATION | 606 | 2.07e-23 | 5.98e-21 | 0.4270 | 1.91e-01 | 1.57e-01 | 1.98e-01 | 2.50e-01 | 1.37e-01 | 8.04e-16 | 3.69e-11 | 6.73e-17 | 6.88e-26 | 7.32e-09 |
| PROTEIN RETENTION IN GOLGI APPARATUS | 5 | 3.64e-01 | 7.63e-01 | 0.4270 | 1.70e-01 | -8.20e-02 | -2.39e-01 | 7.92e-02 | -2.88e-01 | 5.11e-01 | 7.51e-01 | 3.55e-01 | 7.59e-01 | 2.64e-01 |
| BASE EXCISION REPAIR | 42 | 1.94e-01 | 5.80e-01 | 0.4270 | 1.54e-01 | 1.71e-01 | 2.14e-01 | 2.19e-01 | 1.88e-01 | 8.33e-02 | 5.53e-02 | 1.62e-02 | 1.43e-02 | 3.54e-02 |
| SPLICEOSOMAL COMPLEX ASSEMBLY | 75 | 3.10e-03 | 4.27e-02 | 0.4260 | 1.90e-01 | 1.25e-01 | 2.24e-01 | 2.25e-01 | 1.72e-01 | 4.39e-03 | 6.04e-02 | 8.05e-04 | 7.70e-04 | 1.02e-02 |
| POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 54 | 9.05e-02 | 4.07e-01 | 0.4260 | 1.55e-01 | 1.65e-01 | 2.21e-01 | 2.00e-01 | 2.04e-01 | 4.91e-02 | 3.56e-02 | 5.01e-03 | 1.10e-02 | 9.38e-03 |
| REGULATION OF PINOCYTOSIS | 12 | 5.67e-01 | 8.81e-01 | 0.4260 | 3.92e-02 | 1.16e-01 | 2.11e-01 | 1.59e-01 | 3.11e-01 | 8.14e-01 | 4.86e-01 | 2.05e-01 | 3.39e-01 | 6.22e-02 |
| GAS TRANSPORT | 22 | 5.60e-01 | 8.78e-01 | 0.4260 | -2.40e-01 | -2.12e-01 | -1.76e-01 | -2.01e-01 | -9.00e-02 | 5.18e-02 | 8.58e-02 | 1.54e-01 | 1.02e-01 | 4.65e-01 |
| VERY LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 7 | 5.23e-02 | 3.02e-01 | 0.4260 | -6.62e-02 | 2.09e-01 | 3.98e-02 | -2.37e-02 | -3.63e-01 | 7.62e-01 | 3.38e-01 | 8.55e-01 | 9.14e-01 | 9.67e-02 |
| POSITIVE REGULATION OF MEMBRANE POTENTIAL | 15 | 5.12e-01 | 8.54e-01 | 0.4260 | 1.89e-01 | 1.31e-01 | 2.15e-01 | 1.75e-01 | 2.27e-01 | 2.04e-01 | 3.81e-01 | 1.49e-01 | 2.39e-01 | 1.27e-01 |
| MONOCYTE EXTRAVASATION | 10 | 3.43e-01 | 7.50e-01 | 0.4260 | 2.57e-02 | -1.02e-01 | -2.59e-01 | -5.32e-02 | -3.17e-01 | 8.88e-01 | 5.75e-01 | 1.55e-01 | 7.71e-01 | 8.28e-02 |
| NEGATIVE REGULATION OF INTERLEUKIN 5 PRODUCTION | 7 | 7.64e-01 | 9.54e-01 | 0.4260 | 1.18e-01 | 1.02e-01 | 2.77e-01 | 2.34e-01 | 1.61e-01 | 5.89e-01 | 6.41e-01 | 2.04e-01 | 2.84e-01 | 4.62e-01 |
| REGULATION OF FERTILIZATION | 17 | 3.48e-01 | 7.50e-01 | 0.4260 | -2.20e-01 | -1.29e-01 | -2.22e-01 | -2.57e-01 | -3.63e-02 | 1.17e-01 | 3.57e-01 | 1.13e-01 | 6.63e-02 | 7.96e-01 |
| NEGATIVE REGULATION OF SOMATIC STEM CELL POPULATION MAINTENANCE | 5 | 9.63e-01 | 9.94e-01 | 0.4260 | 1.80e-01 | 2.27e-01 | 2.36e-01 | 1.66e-01 | 1.19e-01 | 4.85e-01 | 3.79e-01 | 3.61e-01 | 5.21e-01 | 6.45e-01 |
| APOPTOTIC MITOCHONDRIAL CHANGES | 105 | 2.60e-03 | 3.74e-02 | 0.4260 | 1.62e-01 | 1.71e-01 | 2.37e-01 | 2.11e-01 | 1.58e-01 | 4.02e-03 | 2.47e-03 | 2.69e-05 | 1.85e-04 | 5.17e-03 |
| LEUKOCYTE MIGRATION INVOLVED IN INFLAMMATORY RESPONSE | 19 | 8.82e-02 | 4.01e-01 | 0.4260 | 2.18e-01 | 2.71e-01 | 9.45e-02 | 2.20e-01 | -5.70e-02 | 1.00e-01 | 4.10e-02 | 4.76e-01 | 9.74e-02 | 6.67e-01 |
| PHARYNGEAL ARCH ARTERY MORPHOGENESIS | 10 | 4.07e-01 | 7.93e-01 | 0.4260 | -3.25e-01 | -2.32e-01 | -7.46e-02 | -1.16e-01 | 5.43e-02 | 7.54e-02 | 2.04e-01 | 6.83e-01 | 5.26e-01 | 7.66e-01 |
| CYTOPLASMIC SEQUESTERING OF TRANSCRIPTION FACTOR | 11 | 7.38e-01 | 9.49e-01 | 0.4260 | 2.55e-01 | 1.68e-01 | 1.56e-01 | 2.19e-01 | 1.25e-01 | 1.43e-01 | 3.35e-01 | 3.71e-01 | 2.08e-01 | 4.73e-01 |
| REGULATION OF CELL FATE COMMITMENT | 41 | 1.16e-01 | 4.63e-01 | 0.4250 | 1.06e-01 | 1.81e-01 | 2.35e-01 | 1.86e-01 | 2.18e-01 | 2.40e-01 | 4.53e-02 | 9.17e-03 | 3.97e-02 | 1.59e-02 |
| DE NOVO CENTRIOLE ASSEMBLY INVOLVED IN MULTI CILIATED EPITHELIAL CELL DIFFERENTIATION | 5 | 7.93e-01 | 9.65e-01 | 0.4250 | 1.19e-01 | 1.37e-02 | 2.08e-01 | 2.40e-01 | 2.56e-01 | 6.45e-01 | 9.58e-01 | 4.21e-01 | 3.52e-01 | 3.21e-01 |
| ANTIGEN PROCESSING AND PRESENTATION VIA MHC CLASS IB | 25 | 1.59e-03 | 2.54e-02 | 0.4250 | -6.42e-02 | 2.44e-03 | 2.36e-01 | 2.42e-01 | 2.50e-01 | 5.78e-01 | 9.83e-01 | 4.11e-02 | 3.59e-02 | 3.07e-02 |
| RECEPTOR TRANSACTIVATION | 5 | 1.31e-01 | 4.90e-01 | 0.4250 | -1.85e-01 | -3.77e-01 | 4.89e-02 | -3.53e-02 | 2.19e-02 | 4.74e-01 | 1.44e-01 | 8.50e-01 | 8.91e-01 | 9.33e-01 |
| T CELL DIFFERENTIATION IN THYMUS | 84 | 2.18e-06 | 9.59e-05 | 0.4250 | 4.03e-02 | 8.28e-02 | 2.43e-01 | 2.42e-01 | 2.34e-01 | 5.23e-01 | 1.89e-01 | 1.15e-04 | 1.28e-04 | 2.10e-04 |
| TONGUE DEVELOPMENT | 20 | 2.06e-01 | 5.99e-01 | 0.4250 | 6.46e-02 | 6.34e-02 | 2.11e-01 | 2.30e-01 | 2.75e-01 | 6.17e-01 | 6.24e-01 | 1.03e-01 | 7.54e-02 | 3.35e-02 |
| POLAR BODY EXTRUSION AFTER MEIOTIC DIVISIONS | 5 | 9.18e-01 | 9.86e-01 | 0.4250 | -1.67e-01 | -1.30e-01 | -2.28e-01 | -2.74e-01 | -9.32e-02 | 5.17e-01 | 6.16e-01 | 3.77e-01 | 2.88e-01 | 7.18e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 4 PRODUCTION | 7 | 4.42e-01 | 8.13e-01 | 0.4250 | -7.82e-02 | 1.48e-01 | 2.65e-01 | 8.63e-02 | 2.74e-01 | 7.20e-01 | 4.97e-01 | 2.25e-01 | 6.93e-01 | 2.10e-01 |
| POSITIVE REGULATION OF EMBRYONIC DEVELOPMENT | 21 | 3.82e-01 | 7.78e-01 | 0.4250 | 1.79e-01 | 2.61e-01 | 1.90e-01 | 1.48e-01 | 1.50e-01 | 1.55e-01 | 3.85e-02 | 1.31e-01 | 2.41e-01 | 2.35e-01 |
| NEGATIVE REGULATION OF DNA BINDING | 33 | 4.37e-02 | 2.71e-01 | 0.4250 | 1.34e-01 | 1.07e-01 | 1.79e-01 | 2.72e-01 | 2.13e-01 | 1.81e-01 | 2.89e-01 | 7.54e-02 | 6.89e-03 | 3.44e-02 |
| MITOCHONDRIAL RNA MODIFICATION | 9 | 7.24e-01 | 9.41e-01 | 0.4250 | 1.55e-01 | 1.31e-01 | 1.68e-01 | 2.63e-01 | 2.04e-01 | 4.20e-01 | 4.95e-01 | 3.84e-01 | 1.71e-01 | 2.90e-01 |
| SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 168 | 6.69e-06 | 2.62e-04 | 0.4250 | 1.50e-01 | 1.54e-01 | 2.11e-01 | 2.27e-01 | 1.95e-01 | 7.64e-04 | 5.62e-04 | 2.48e-06 | 3.66e-07 | 1.33e-05 |
| MONOACYLGLYCEROL BIOSYNTHETIC PROCESS | 5 | 1.41e-01 | 5.06e-01 | 0.4250 | -1.65e-01 | 4.42e-02 | 7.80e-02 | -8.00e-02 | -3.73e-01 | 5.24e-01 | 8.64e-01 | 7.63e-01 | 7.57e-01 | 1.49e-01 |
| NEGATIVE REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING | 24 | 2.68e-01 | 6.75e-01 | 0.4250 | 2.07e-01 | 1.37e-01 | 1.68e-01 | 2.66e-01 | 1.40e-01 | 7.88e-02 | 2.47e-01 | 1.54e-01 | 2.39e-02 | 2.36e-01 |
| INTERLEUKIN 1 ALPHA PRODUCTION | 11 | 7.05e-01 | 9.33e-01 | 0.4250 | 1.92e-01 | 2.36e-01 | 1.58e-01 | 2.24e-01 | 1.11e-01 | 2.69e-01 | 1.76e-01 | 3.65e-01 | 1.98e-01 | 5.23e-01 |
| CADMIUM ION TRANSMEMBRANE TRANSPORT | 6 | 5.95e-01 | 8.97e-01 | 0.4250 | 2.72e-01 | 2.78e-01 | 3.17e-02 | 1.62e-01 | -3.53e-02 | 2.48e-01 | 2.38e-01 | 8.93e-01 | 4.93e-01 | 8.81e-01 |
| ASYMMETRIC CELL DIVISION | 18 | 3.30e-01 | 7.38e-01 | 0.4240 | 2.53e-01 | 2.26e-01 | 1.56e-01 | 1.68e-01 | -1.12e-01 | 6.30e-02 | 9.71e-02 | 2.52e-01 | 2.17e-01 | 4.12e-01 |
| REGULATION OF PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 10 | 8.28e-01 | 9.72e-01 | 0.4240 | 2.31e-01 | 2.34e-01 | 1.54e-01 | 1.94e-01 | 1.03e-01 | 2.05e-01 | 2.01e-01 | 3.98e-01 | 2.89e-01 | 5.72e-01 |
| AMELOBLAST DIFFERENTIATION | 5 | 3.56e-01 | 7.55e-01 | 0.4240 | -2.65e-01 | -4.44e-02 | 2.11e-01 | -4.32e-02 | 2.48e-01 | 3.05e-01 | 8.63e-01 | 4.14e-01 | 8.67e-01 | 3.37e-01 |
| PEPTIDYL LYSINE MONOMETHYLATION | 9 | 6.00e-01 | 8.98e-01 | 0.4240 | 2.63e-01 | 1.58e-01 | 2.20e-01 | 1.69e-01 | 9.65e-02 | 1.73e-01 | 4.11e-01 | 2.53e-01 | 3.81e-01 | 6.16e-01 |
| MYELOID PROGENITOR CELL DIFFERENTIATION | 9 | 9.18e-02 | 4.11e-01 | 0.4240 | 2.64e-01 | 7.70e-02 | 4.50e-03 | 2.57e-01 | 1.95e-01 | 1.70e-01 | 6.89e-01 | 9.81e-01 | 1.81e-01 | 3.12e-01 |
| DORSAL VENTRAL AXIS SPECIFICATION | 12 | 2.36e-01 | 6.40e-01 | 0.4240 | -5.01e-02 | -2.31e-02 | 1.40e-01 | 1.49e-01 | 3.67e-01 | 7.64e-01 | 8.90e-01 | 4.00e-01 | 3.72e-01 | 2.75e-02 |
| ADHERENS JUNCTION MAINTENANCE | 7 | 7.29e-01 | 9.44e-01 | 0.4240 | -1.62e-01 | -1.47e-01 | -2.04e-01 | -3.00e-01 | -2.52e-02 | 4.57e-01 | 5.01e-01 | 3.51e-01 | 1.70e-01 | 9.08e-01 |
| GLUTAMATE CATABOLIC PROCESS | 7 | 1.29e-02 | 1.22e-01 | 0.4240 | 3.34e-02 | 5.05e-02 | 1.71e-02 | 3.66e-01 | 2.05e-01 | 8.78e-01 | 8.17e-01 | 9.38e-01 | 9.38e-02 | 3.47e-01 |
| REGULATION OF VESICLE SIZE | 19 | 3.16e-01 | 7.27e-01 | 0.4240 | 7.94e-02 | 1.08e-01 | 2.14e-01 | 2.37e-01 | 2.44e-01 | 5.49e-01 | 4.16e-01 | 1.06e-01 | 7.34e-02 | 6.54e-02 |
| G1 TO G0 TRANSITION INVOLVED IN CELL DIFFERENTIATION | 6 | 1.22e-01 | 4.76e-01 | 0.4240 | 2.19e-02 | 5.63e-02 | 3.72e-01 | 1.93e-01 | 2.26e-02 | 9.26e-01 | 8.11e-01 | 1.14e-01 | 4.14e-01 | 9.24e-01 |
| POSITIVE REGULATION OF STRIATED MUSCLE CONTRACTION | 13 | 4.01e-02 | 2.59e-01 | 0.4240 | -1.51e-01 | 9.41e-02 | 2.65e-01 | 7.98e-02 | 2.68e-01 | 3.47e-01 | 5.57e-01 | 9.84e-02 | 6.18e-01 | 9.46e-02 |
| POSITIVE REGULATION OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR SIGNALING PATHWAY | 9 | 4.65e-01 | 8.25e-01 | 0.4240 | 1.54e-01 | 7.31e-02 | 2.06e-01 | 1.24e-01 | 3.05e-01 | 4.25e-01 | 7.04e-01 | 2.84e-01 | 5.21e-01 | 1.13e-01 |
| POSITIVE REGULATION OF DNA CATABOLIC PROCESS | 5 | 8.41e-01 | 9.74e-01 | 0.4240 | 2.29e-01 | 2.86e-01 | 1.05e-01 | 1.65e-01 | -8.13e-02 | 3.75e-01 | 2.67e-01 | 6.86e-01 | 5.22e-01 | 7.53e-01 |
| NEGATIVE REGULATION OF SYNAPTIC TRANSMISSION GLUTAMATERGIC | 8 | 5.10e-01 | 8.54e-01 | 0.4240 | -2.25e-01 | -1.25e-01 | -1.26e-01 | -2.84e-01 | 1.29e-01 | 2.71e-01 | 5.39e-01 | 5.36e-01 | 1.65e-01 | 5.27e-01 |
| POSITIVE REGULATION OF GROWTH HORMONE SECRETION | 9 | 7.12e-01 | 9.35e-01 | 0.4230 | 2.17e-01 | 2.88e-01 | 1.42e-01 | 1.62e-01 | 5.48e-02 | 2.60e-01 | 1.35e-01 | 4.60e-01 | 3.99e-01 | 7.76e-01 |
| POSITIVE REGULATION OF NEURON DIFFERENTIATION | 91 | 1.72e-03 | 2.70e-02 | 0.4230 | 1.40e-01 | 1.36e-01 | 2.27e-01 | 1.87e-01 | 2.34e-01 | 2.14e-02 | 2.46e-02 | 1.86e-04 | 2.07e-03 | 1.10e-04 |
| RESPONSE TO EPIDERMAL GROWTH FACTOR | 44 | 1.26e-02 | 1.20e-01 | 0.4230 | 5.69e-02 | 1.73e-01 | 2.06e-01 | 1.39e-01 | 2.90e-01 | 5.14e-01 | 4.72e-02 | 1.81e-02 | 1.10e-01 | 8.60e-04 |
| PEPTIDYL L CYSTEINE S PALMITOYLATION | 20 | 1.77e-01 | 5.62e-01 | 0.4230 | 2.26e-01 | 2.05e-01 | 1.19e-01 | 2.68e-01 | -1.97e-02 | 8.07e-02 | 1.13e-01 | 3.57e-01 | 3.81e-02 | 8.79e-01 |
| GLOMERULUS VASCULATURE MORPHOGENESIS | 6 | 7.70e-01 | 9.55e-01 | 0.4230 | 5.70e-02 | 1.37e-01 | 2.30e-01 | 7.05e-02 | 3.15e-01 | 8.09e-01 | 5.60e-01 | 3.29e-01 | 7.65e-01 | 1.82e-01 |
| ORGANELLE INHERITANCE | 15 | 2.20e-01 | 6.17e-01 | 0.4230 | 1.12e-01 | 6.82e-02 | 2.09e-01 | 3.03e-01 | 1.63e-01 | 4.53e-01 | 6.48e-01 | 1.61e-01 | 4.25e-02 | 2.74e-01 |
| REGULATION OF SERINE TYPE PEPTIDASE ACTIVITY | 7 | 9.32e-01 | 9.90e-01 | 0.4230 | -1.64e-01 | -1.59e-01 | -2.30e-01 | -2.36e-01 | -1.36e-01 | 4.54e-01 | 4.68e-01 | 2.91e-01 | 2.80e-01 | 5.34e-01 |
| FAT CELL PROLIFERATION | 14 | 2.17e-01 | 6.14e-01 | 0.4230 | 2.35e-01 | 2.69e-01 | 9.25e-02 | 1.52e-01 | 1.40e-01 | 1.27e-01 | 8.17e-02 | 5.49e-01 | 3.26e-01 | 3.63e-01 |
| REGULATION OF METALLOENDOPEPTIDASE ACTIVITY | 15 | 6.95e-01 | 9.31e-01 | 0.4230 | -1.72e-01 | -1.77e-01 | -2.07e-01 | -2.52e-01 | -1.05e-01 | 2.47e-01 | 2.34e-01 | 1.65e-01 | 9.06e-02 | 4.81e-01 |
| RESPONSE TO FORSKOLIN | 14 | 3.32e-01 | 7.39e-01 | 0.4230 | -2.27e-01 | -1.38e-01 | -1.93e-01 | -2.56e-01 | 7.24e-02 | 1.41e-01 | 3.73e-01 | 2.12e-01 | 9.70e-02 | 6.39e-01 |
| OOCYTE CONSTRUCTION | 8 | 4.12e-01 | 7.98e-01 | 0.4230 | 2.86e-02 | 1.77e-03 | -1.04e-01 | -1.45e-01 | -3.82e-01 | 8.89e-01 | 9.93e-01 | 6.12e-01 | 4.78e-01 | 6.12e-02 |
| POSITIVE REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNITY | 33 | 6.69e-04 | 1.26e-02 | 0.4220 | -1.88e-01 | -3.23e-01 | -1.53e-01 | -3.37e-02 | -1.19e-01 | 6.10e-02 | 1.32e-03 | 1.29e-01 | 7.38e-01 | 2.38e-01 |
| CENTROMERE COMPLEX ASSEMBLY | 28 | 2.31e-01 | 6.33e-01 | 0.4220 | 1.75e-01 | 1.14e-01 | 1.93e-01 | 2.40e-01 | 2.00e-01 | 1.09e-01 | 2.97e-01 | 7.65e-02 | 2.82e-02 | 6.68e-02 |
| VACUOLAR ACIDIFICATION | 32 | 2.56e-01 | 6.63e-01 | 0.4220 | 1.15e-01 | 1.47e-01 | 2.31e-01 | 2.08e-01 | 2.17e-01 | 2.58e-01 | 1.51e-01 | 2.38e-02 | 4.19e-02 | 3.39e-02 |
| POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION INVOLVED IN LUNG MORPHOGENESIS | 5 | 8.86e-01 | 9.80e-01 | 0.4220 | 2.31e-01 | 2.51e-01 | 1.81e-01 | 1.42e-01 | -9.36e-02 | 3.70e-01 | 3.31e-01 | 4.84e-01 | 5.83e-01 | 7.17e-01 |
| DETERMINATION OF DIGESTIVE TRACT LEFT RIGHT ASYMMETRY | 6 | 4.63e-01 | 8.25e-01 | 0.4220 | -4.04e-02 | -1.39e-01 | 1.07e-01 | 1.40e-01 | 3.54e-01 | 8.64e-01 | 5.54e-01 | 6.49e-01 | 5.51e-01 | 1.33e-01 |
| REGULATION OF ERAD PATHWAY | 19 | 2.43e-01 | 6.47e-01 | 0.4220 | 1.03e-01 | 6.63e-02 | 1.71e-01 | 1.99e-01 | 3.07e-01 | 4.37e-01 | 6.17e-01 | 1.96e-01 | 1.34e-01 | 2.06e-02 |
| TRNA PROCESSING | 128 | 5.64e-04 | 1.12e-02 | 0.4220 | 1.64e-01 | 1.63e-01 | 2.17e-01 | 1.98e-01 | 1.95e-01 | 1.33e-03 | 1.48e-03 | 2.24e-05 | 1.08e-04 | 1.37e-04 |
| POSITIVE REGULATION OF MAST CELL CHEMOTAXIS | 5 | 6.32e-01 | 9.11e-01 | 0.4210 | 2.31e-01 | 2.44e-02 | 1.73e-01 | 2.07e-01 | 2.26e-01 | 3.72e-01 | 9.25e-01 | 5.03e-01 | 4.24e-01 | 3.81e-01 |
| SPHINGOMYELIN METABOLIC PROCESS | 20 | 1.93e-01 | 5.80e-01 | 0.4210 | 2.94e-01 | 1.80e-01 | 1.56e-01 | 1.78e-01 | -5.18e-02 | 2.27e-02 | 1.64e-01 | 2.27e-01 | 1.68e-01 | 6.88e-01 |
| POSITIVE REGULATION OF MHC CLASS I BIOSYNTHETIC PROCESS | 6 | 7.05e-01 | 9.33e-01 | 0.4210 | -2.69e-01 | -2.66e-01 | -1.16e-01 | -7.35e-02 | 1.26e-01 | 2.54e-01 | 2.59e-01 | 6.23e-01 | 7.55e-01 | 5.94e-01 |
| INNER MITOCHONDRIAL MEMBRANE ORGANIZATION | 36 | 7.97e-03 | 8.65e-02 | 0.4210 | 1.70e-01 | 7.52e-02 | 1.93e-01 | 1.57e-01 | 2.85e-01 | 7.72e-02 | 4.35e-01 | 4.51e-02 | 1.03e-01 | 3.13e-03 |
| INTESTINAL HEXOSE ABSORPTION | 5 | 4.02e-01 | 7.89e-01 | 0.4210 | 4.17e-02 | -1.65e-01 | -1.71e-01 | -2.33e-01 | -2.55e-01 | 8.72e-01 | 5.23e-01 | 5.07e-01 | 3.67e-01 | 3.24e-01 |
| TETRAPYRROLE CATABOLIC PROCESS | 13 | 4.06e-01 | 7.93e-01 | 0.4210 | -2.18e-01 | -2.30e-01 | -1.11e-01 | -2.27e-01 | -1.14e-01 | 1.73e-01 | 1.51e-01 | 4.90e-01 | 1.57e-01 | 4.78e-01 |
| SOMATOTROPIN SECRETING CELL DIFFERENTIATION | 5 | 4.20e-01 | 8.00e-01 | 0.4210 | -1.49e-01 | 1.12e-01 | 1.50e-01 | -1.14e-01 | 3.27e-01 | 5.63e-01 | 6.64e-01 | 5.60e-01 | 6.59e-01 | 2.06e-01 |
| INDOLE CONTAINING COMPOUND METABOLIC PROCESS | 22 | 3.72e-01 | 7.71e-01 | 0.4210 | -2.46e-01 | -1.87e-01 | -1.51e-01 | -2.43e-01 | 1.17e-02 | 4.55e-02 | 1.29e-01 | 2.21e-01 | 4.89e-02 | 9.24e-01 |
| DEOXYRIBONUCLEOTIDE METABOLIC PROCESS | 42 | 9.69e-02 | 4.24e-01 | 0.4210 | 2.46e-01 | 1.59e-01 | 1.76e-01 | 2.25e-01 | 9.77e-02 | 5.71e-03 | 7.43e-02 | 4.83e-02 | 1.17e-02 | 2.73e-01 |
| SPECIFICATION OF ANIMAL ORGAN IDENTITY | 35 | 1.26e-01 | 4.82e-01 | 0.4210 | 1.04e-01 | 1.32e-01 | 1.99e-01 | 1.75e-01 | 2.80e-01 | 2.86e-01 | 1.76e-01 | 4.18e-02 | 7.29e-02 | 4.13e-03 |
| REGULATION OF DOUBLE STRAND BREAK REPAIR VIA NONHOMOLOGOUS END JOINING | 26 | 3.87e-01 | 7.80e-01 | 0.4210 | 2.47e-01 | 1.81e-01 | 1.66e-01 | 2.30e-01 | 5.52e-02 | 2.95e-02 | 1.10e-01 | 1.43e-01 | 4.27e-02 | 6.26e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY CIRCULATORY RENIN ANGIOTENSIN | 14 | 3.52e-01 | 7.53e-01 | 0.4200 | -1.42e-02 | -8.53e-02 | -2.58e-01 | -1.30e-01 | -2.93e-01 | 9.27e-01 | 5.81e-01 | 9.51e-02 | 3.98e-01 | 5.76e-02 |
| ER TO GOLGI CERAMIDE TRANSPORT | 5 | 9.38e-01 | 9.92e-01 | 0.4200 | 2.11e-01 | 1.49e-01 | 2.32e-01 | 1.96e-01 | 1.31e-01 | 4.13e-01 | 5.63e-01 | 3.68e-01 | 4.47e-01 | 6.12e-01 |
| TRANSFERRIN TRANSPORT | 10 | 6.87e-01 | 9.31e-01 | 0.4200 | 2.63e-01 | 1.70e-01 | 1.19e-01 | 2.53e-01 | 2.50e-02 | 1.50e-01 | 3.53e-01 | 5.14e-01 | 1.66e-01 | 8.91e-01 |
| FATTY ACID BETA OXIDATION USING ACYL COA DEHYDROGENASE | 12 | 8.52e-01 | 9.76e-01 | 0.4200 | 1.62e-01 | 1.83e-01 | 2.32e-01 | 1.92e-01 | 1.61e-01 | 3.31e-01 | 2.73e-01 | 1.64e-01 | 2.49e-01 | 3.33e-01 |
| NEGATIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 12 | 2.38e-01 | 6.42e-01 | 0.4200 | 2.43e-01 | 3.20e-01 | 1.00e-01 | 6.85e-02 | -5.27e-03 | 1.44e-01 | 5.48e-02 | 5.48e-01 | 6.81e-01 | 9.75e-01 |
| POSITIVE REGULATION OF SEQUESTERING OF TRIGLYCERIDE | 9 | 6.39e-01 | 9.14e-01 | 0.4200 | 6.80e-02 | 2.06e-01 | 2.34e-01 | 2.17e-01 | 1.67e-01 | 7.24e-01 | 2.85e-01 | 2.24e-01 | 2.61e-01 | 3.87e-01 |
| ELECTRON TRANSPORT CHAIN | 156 | 1.73e-04 | 4.14e-03 | 0.4200 | 1.92e-01 | 1.72e-01 | 2.04e-01 | 2.16e-01 | 1.47e-01 | 3.42e-05 | 2.03e-04 | 1.10e-05 | 3.29e-06 | 1.54e-03 |
| REGULATION OF CELL CYCLE CHECKPOINT | 45 | 4.98e-02 | 2.92e-01 | 0.4200 | 1.88e-01 | 1.74e-01 | 1.73e-01 | 2.65e-01 | 1.03e-01 | 2.94e-02 | 4.37e-02 | 4.50e-02 | 2.06e-03 | 2.33e-01 |
| BIOLOGICAL PHASE | 11 | 3.67e-01 | 7.68e-01 | 0.4200 | -3.12e-01 | -2.21e-01 | -9.60e-02 | -1.27e-01 | -6.81e-02 | 7.31e-02 | 2.04e-01 | 5.82e-01 | 4.67e-01 | 6.96e-01 |
| CARDIAC MUSCLE CELL MYOBLAST DIFFERENTIATION | 12 | 6.56e-01 | 9.20e-01 | 0.4200 | 9.67e-02 | 1.60e-01 | 2.50e-01 | 1.34e-01 | 2.47e-01 | 5.62e-01 | 3.37e-01 | 1.34e-01 | 4.22e-01 | 1.39e-01 |
| RESPONSE TO HEPARIN | 7 | 4.32e-01 | 8.06e-01 | 0.4200 | 3.40e-01 | 1.46e-01 | 7.62e-02 | 1.25e-01 | -1.33e-01 | 1.19e-01 | 5.04e-01 | 7.27e-01 | 5.67e-01 | 5.42e-01 |
| NOTCH SIGNALING INVOLVED IN HEART DEVELOPMENT | 11 | 6.87e-01 | 9.31e-01 | 0.4200 | 1.54e-01 | 1.26e-01 | 2.45e-01 | 1.69e-01 | 2.19e-01 | 3.78e-01 | 4.70e-01 | 1.60e-01 | 3.31e-01 | 2.09e-01 |
| GRANULOCYTE ACTIVATION | 49 | 1.50e-04 | 3.73e-03 | 0.4190 | 2.44e-01 | 2.66e-01 | 1.05e-01 | 7.01e-02 | -1.73e-01 | 3.16e-03 | 1.27e-03 | 2.04e-01 | 3.96e-01 | 3.64e-02 |
| REGULATION OF SOMATIC STEM CELL POPULATION MAINTENANCE | 12 | 4.08e-01 | 7.94e-01 | 0.4190 | -1.14e-02 | 1.17e-01 | 1.95e-01 | 1.23e-01 | 3.30e-01 | 9.46e-01 | 4.81e-01 | 2.43e-01 | 4.60e-01 | 4.80e-02 |
| CLEARANCE OF FOREIGN INTRACELLULAR NUCLEIC ACIDS | 6 | 6.13e-01 | 9.05e-01 | 0.4190 | -2.85e-01 | -7.96e-02 | -1.32e-01 | -2.12e-01 | -1.59e-01 | 2.26e-01 | 7.36e-01 | 5.75e-01 | 3.68e-01 | 5.00e-01 |
| DNA DAMAGE RESPONSE | 835 | 1.59e-29 | 7.48e-27 | 0.4190 | 1.79e-01 | 1.63e-01 | 1.94e-01 | 2.37e-01 | 1.52e-01 | 1.22e-18 | 9.86e-16 | 1.63e-21 | 2.76e-31 | 6.97e-14 |
| ION CHANNEL MODULATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 8 | 6.40e-01 | 9.14e-01 | 0.4190 | -1.88e-01 | -4.96e-02 | -1.87e-01 | -2.50e-01 | -2.00e-01 | 3.57e-01 | 8.08e-01 | 3.60e-01 | 2.20e-01 | 3.27e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY | 310 | 8.10e-10 | 6.03e-08 | 0.4190 | 1.70e-01 | 1.71e-01 | 2.16e-01 | 2.30e-01 | 1.34e-01 | 2.60e-07 | 2.36e-07 | 5.67e-11 | 3.27e-12 | 5.24e-05 |
| DERMATAN SULFATE BIOSYNTHETIC PROCESS | 5 | 9.20e-01 | 9.86e-01 | 0.4190 | 1.52e-01 | 2.09e-01 | 1.61e-01 | 1.81e-01 | 2.24e-01 | 5.57e-01 | 4.19e-01 | 5.32e-01 | 4.83e-01 | 3.86e-01 |
| BONE CELL DEVELOPMENT | 17 | 5.39e-01 | 8.67e-01 | 0.4190 | -1.15e-01 | -1.36e-01 | -1.98e-01 | -1.68e-01 | -2.77e-01 | 4.13e-01 | 3.32e-01 | 1.58e-01 | 2.31e-01 | 4.83e-02 |
| DETOXIFICATION OF INORGANIC COMPOUND | 21 | 3.32e-02 | 2.31e-01 | 0.4190 | 1.05e-01 | 9.33e-02 | 2.79e-01 | 1.03e-01 | 2.59e-01 | 4.03e-01 | 4.59e-01 | 2.68e-02 | 4.13e-01 | 4.01e-02 |
| MACROPHAGE COLONY STIMULATING FACTOR SIGNALING PATHWAY | 7 | 1.25e-01 | 4.82e-01 | 0.4190 | 1.58e-01 | 3.81e-01 | 6.16e-02 | -3.80e-02 | -7.79e-03 | 4.70e-01 | 8.11e-02 | 7.78e-01 | 8.62e-01 | 9.72e-01 |
| ER OVERLOAD RESPONSE | 11 | 3.02e-01 | 7.14e-01 | 0.4190 | -1.07e-01 | 1.74e-02 | 1.60e-01 | 3.38e-02 | 3.69e-01 | 5.38e-01 | 9.20e-01 | 3.57e-01 | 8.46e-01 | 3.39e-02 |
| AGGREPHAGY | 10 | 3.07e-01 | 7.19e-01 | 0.4180 | 2.50e-01 | 1.99e-01 | 5.37e-02 | 2.63e-01 | 3.50e-02 | 1.72e-01 | 2.75e-01 | 7.69e-01 | 1.50e-01 | 8.48e-01 |
| NEGATIVE REGULATION OF PEPTIDYL CYSTEINE S NITROSYLATION | 7 | 3.62e-01 | 7.62e-01 | 0.4180 | -2.03e-01 | -3.14e-01 | -2.18e-02 | -3.31e-02 | 1.83e-01 | 3.53e-01 | 1.50e-01 | 9.20e-01 | 8.79e-01 | 4.01e-01 |
| CELLULAR RESPONSE TO THYROID HORMONE STIMULUS | 16 | 4.13e-01 | 7.98e-01 | 0.4180 | 1.34e-01 | 1.23e-01 | 1.57e-01 | 2.12e-01 | 2.68e-01 | 3.54e-01 | 3.93e-01 | 2.78e-01 | 1.41e-01 | 6.31e-02 |
| NEGATIVE REGULATION OF RESPONSE TO TYPE II INTERFERON | 7 | 3.87e-01 | 7.80e-01 | 0.4180 | 2.87e-03 | -2.12e-01 | -2.85e-01 | -1.95e-01 | -1.01e-01 | 9.89e-01 | 3.31e-01 | 1.91e-01 | 3.71e-01 | 6.45e-01 |
| FRUCTOSE 1 6 BISPHOSPHATE METABOLIC PROCESS | 9 | 8.77e-01 | 9.79e-01 | 0.4180 | -2.04e-01 | -1.71e-01 | -2.15e-01 | -2.33e-01 | -5.54e-02 | 2.90e-01 | 3.74e-01 | 2.63e-01 | 2.26e-01 | 7.73e-01 |
| NEGATIVE REGULATION OF DNA METABOLIC PROCESS | 135 | 9.31e-04 | 1.65e-02 | 0.4180 | 1.94e-01 | 1.89e-01 | 1.92e-01 | 2.17e-01 | 1.31e-01 | 1.03e-04 | 1.46e-04 | 1.12e-04 | 1.30e-05 | 8.74e-03 |
| AUTOCRINE SIGNALING | 7 | 3.60e-01 | 7.58e-01 | 0.4180 | 2.52e-01 | 1.73e-01 | 2.55e-02 | 2.83e-01 | 2.48e-02 | 2.49e-01 | 4.28e-01 | 9.07e-01 | 1.95e-01 | 9.09e-01 |
| REGULATION OF ACUTE INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 15 | 2.05e-01 | 5.97e-01 | 0.4180 | -2.83e-01 | -2.06e-01 | -1.41e-01 | -1.17e-01 | 1.36e-01 | 5.79e-02 | 1.67e-01 | 3.43e-01 | 4.32e-01 | 3.63e-01 |
| PEPTIDOGLYCAN METABOLIC PROCESS | 6 | 8.63e-01 | 9.78e-01 | 0.4180 | -7.91e-02 | -1.68e-01 | -2.68e-01 | -2.14e-01 | -1.50e-01 | 7.37e-01 | 4.77e-01 | 2.55e-01 | 3.64e-01 | 5.24e-01 |
| DETECTION OF OTHER ORGANISM | 19 | 4.89e-02 | 2.89e-01 | 0.4180 | 2.78e-01 | 2.52e-01 | -3.08e-04 | 1.00e-01 | -1.54e-01 | 3.57e-02 | 5.76e-02 | 9.98e-01 | 4.50e-01 | 2.44e-01 |
| DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS | 14 | 5.00e-01 | 8.48e-01 | 0.4180 | 2.37e-01 | 1.11e-01 | 1.69e-01 | 2.53e-01 | 1.17e-01 | 1.24e-01 | 4.73e-01 | 2.74e-01 | 1.02e-01 | 4.50e-01 |
| MAINTENANCE OF PROTEIN LOCATION IN CELL | 60 | 8.87e-03 | 9.32e-02 | 0.4180 | 1.59e-01 | 1.65e-01 | 2.48e-01 | 2.37e-01 | 6.67e-02 | 3.29e-02 | 2.74e-02 | 9.02e-04 | 1.50e-03 | 3.71e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 6 | 2.12e-01 | 6.07e-01 | 0.4180 | 2.21e-01 | 3.39e-01 | 2.00e-02 | 0.00e+00 | 9.93e-02 | 3.48e-01 | 1.50e-01 | 9.32e-01 | 1.00e+00 | 6.74e-01 |
| MIDGUT DEVELOPMENT | 10 | 1.50e-01 | 5.19e-01 | 0.4170 | -3.01e-01 | -7.04e-02 | 5.71e-03 | -1.06e-01 | 2.60e-01 | 9.92e-02 | 7.00e-01 | 9.75e-01 | 5.63e-01 | 1.55e-01 |
| MEGAKARYOCYTE DEVELOPMENT | 22 | 1.46e-01 | 5.12e-01 | 0.4170 | 1.27e-01 | 2.76e-01 | 1.87e-01 | 1.57e-01 | 1.50e-01 | 3.01e-01 | 2.52e-02 | 1.30e-01 | 2.02e-01 | 2.24e-01 |
| REGULATION OF ATPASE COUPLED CALCIUM TRANSMEMBRANE TRANSPORTER ACTIVITY | 6 | 8.05e-01 | 9.67e-01 | 0.4170 | -1.84e-01 | -2.47e-01 | -2.47e-01 | -9.83e-02 | -9.18e-02 | 4.36e-01 | 2.95e-01 | 2.94e-01 | 6.77e-01 | 6.97e-01 |
| NEURAL CREST FORMATION | 15 | 5.11e-01 | 8.54e-01 | 0.4170 | 1.17e-01 | 2.10e-01 | 1.83e-01 | 1.62e-01 | 2.37e-01 | 4.33e-01 | 1.59e-01 | 2.20e-01 | 2.76e-01 | 1.12e-01 |
| PROTEIN DEMETHYLATION | 9 | 5.95e-01 | 8.97e-01 | 0.4170 | 2.64e-01 | 2.49e-01 | 6.70e-02 | 1.86e-01 | -5.48e-02 | 1.70e-01 | 1.96e-01 | 7.28e-01 | 3.33e-01 | 7.76e-01 |
| REGULATION OF ATP DEPENDENT ACTIVITY | 61 | 3.78e-02 | 2.52e-01 | 0.4170 | 1.87e-01 | 2.27e-01 | 1.81e-01 | 2.17e-01 | 8.70e-02 | 1.15e-02 | 2.20e-03 | 1.47e-02 | 3.38e-03 | 2.40e-01 |
| REGULATION OF CELLULAR RESPIRATION | 46 | 1.18e-01 | 4.69e-01 | 0.4160 | 1.36e-01 | 1.83e-01 | 2.46e-01 | 1.77e-01 | 1.73e-01 | 1.11e-01 | 3.19e-02 | 3.94e-03 | 3.83e-02 | 4.22e-02 |
| EPITHELIAL CELL PROLIFERATION INVOLVED IN LUNG MORPHOGENESIS | 10 | 7.51e-01 | 9.51e-01 | 0.4160 | 2.09e-01 | 2.27e-01 | 2.27e-01 | 1.60e-01 | 7.37e-03 | 2.53e-01 | 2.13e-01 | 2.13e-01 | 3.80e-01 | 9.68e-01 |
| SMOOTHENED SIGNALING PATHWAY INVOLVED IN DORSAL VENTRAL NEURAL TUBE PATTERNING | 13 | 4.47e-01 | 8.17e-01 | 0.4160 | 2.66e-01 | 1.95e-01 | 1.01e-01 | 1.94e-01 | 1.28e-01 | 9.65e-02 | 2.24e-01 | 5.30e-01 | 2.27e-01 | 4.26e-01 |
| CELL DIFFERENTIATION INVOLVED IN EMBRYONIC PLACENTA DEVELOPMENT | 24 | 4.52e-01 | 8.21e-01 | 0.4160 | 1.25e-01 | 1.76e-01 | 2.43e-01 | 2.07e-01 | 1.55e-01 | 2.88e-01 | 1.35e-01 | 3.94e-02 | 7.86e-02 | 1.89e-01 |
| B CELL PROLIFERATION INVOLVED IN IMMUNE RESPONSE | 6 | 2.30e-01 | 6.32e-01 | 0.4160 | 1.98e-01 | 1.81e-01 | -2.02e-01 | -2.28e-02 | -2.44e-01 | 4.02e-01 | 4.42e-01 | 3.92e-01 | 9.23e-01 | 3.01e-01 |
| OSMOSENSORY SIGNALING PATHWAY | 5 | 1.88e-01 | 5.73e-01 | 0.4150 | 2.19e-01 | 2.25e-01 | -2.31e-02 | -1.93e-01 | -1.89e-01 | 3.95e-01 | 3.83e-01 | 9.29e-01 | 4.54e-01 | 4.64e-01 |
| REGULATION OF INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 10 | 7.73e-01 | 9.57e-01 | 0.4150 | -8.96e-02 | -1.11e-01 | -2.15e-01 | -1.64e-01 | -2.81e-01 | 6.24e-01 | 5.44e-01 | 2.38e-01 | 3.69e-01 | 1.24e-01 |
| EMBRYONIC CAMERA TYPE EYE FORMATION | 11 | 5.70e-01 | 8.82e-01 | 0.4150 | 1.49e-01 | 1.16e-01 | 1.45e-01 | 1.70e-01 | 2.95e-01 | 3.92e-01 | 5.05e-01 | 4.05e-01 | 3.30e-01 | 9.04e-02 |
| ERBB3 SIGNALING PATHWAY | 5 | 8.07e-01 | 9.67e-01 | 0.4150 | -3.59e-05 | -2.78e-02 | -2.41e-01 | -1.25e-01 | -3.12e-01 | 1.00e+00 | 9.14e-01 | 3.50e-01 | 6.28e-01 | 2.26e-01 |
| TORC1 SIGNALING | 96 | 1.24e-03 | 2.08e-02 | 0.4150 | 1.97e-01 | 1.45e-01 | 1.83e-01 | 2.53e-01 | 1.20e-01 | 8.31e-04 | 1.40e-02 | 1.89e-03 | 1.85e-05 | 4.22e-02 |
| SYNAPTIC VESICLE CYTOSKELETAL TRANSPORT | 18 | 6.11e-01 | 9.04e-01 | 0.4150 | 1.71e-01 | 1.31e-01 | 1.97e-01 | 2.24e-01 | 1.91e-01 | 2.08e-01 | 3.37e-01 | 1.48e-01 | 9.92e-02 | 1.61e-01 |
| ENDOCRINE SYSTEM DEVELOPMENT | 137 | 4.14e-05 | 1.32e-03 | 0.4150 | 1.10e-01 | 1.41e-01 | 2.17e-01 | 2.02e-01 | 2.28e-01 | 2.57e-02 | 4.41e-03 | 1.15e-05 | 4.47e-05 | 4.05e-06 |
| SOMATIC DIVERSIFICATION OF IMMUNE RECEPTORS VIA SOMATIC MUTATION | 13 | 7.80e-01 | 9.60e-01 | 0.4150 | 1.80e-01 | 2.13e-01 | 2.35e-01 | 1.69e-01 | 1.02e-01 | 2.60e-01 | 1.84e-01 | 1.43e-01 | 2.93e-01 | 5.24e-01 |
| INOSITOL METABOLIC PROCESS | 8 | 3.70e-01 | 7.70e-01 | 0.4140 | -9.53e-02 | -6.18e-03 | 6.74e-02 | -4.95e-02 | 3.94e-01 | 6.41e-01 | 9.76e-01 | 7.41e-01 | 8.09e-01 | 5.34e-02 |
| LNCRNA MEDIATED POST TRANSCRIPTIONAL GENE SILENCING | 9 | 5.89e-01 | 8.92e-01 | 0.4140 | 2.21e-01 | 1.70e-01 | 2.36e-01 | 1.90e-01 | -4.65e-02 | 2.51e-01 | 3.77e-01 | 2.21e-01 | 3.23e-01 | 8.09e-01 |
| LEUKOTRIENE D4 METABOLIC PROCESS | 8 | 1.81e-01 | 5.66e-01 | 0.4140 | -5.98e-02 | 1.31e-01 | 3.34e-01 | 7.92e-02 | 1.82e-01 | 7.70e-01 | 5.20e-01 | 1.02e-01 | 6.98e-01 | 3.73e-01 |
| PHOTOTRANSDUCTION | 42 | 1.78e-01 | 5.63e-01 | 0.4140 | -2.42e-01 | -1.87e-01 | -1.75e-01 | -2.05e-01 | -7.12e-02 | 6.55e-03 | 3.60e-02 | 4.95e-02 | 2.16e-02 | 4.25e-01 |
| REGULATION OF GLIAL CELL PROLIFERATION | 37 | 1.11e-01 | 4.54e-01 | 0.4140 | 1.56e-01 | 1.97e-01 | 1.68e-01 | 1.73e-01 | 2.24e-01 | 9.98e-02 | 3.81e-02 | 7.76e-02 | 6.87e-02 | 1.85e-02 |
| VITAMIN D3 METABOLIC PROCESS | 6 | 6.90e-01 | 9.31e-01 | 0.4140 | -1.67e-01 | -1.82e-01 | -1.57e-01 | -2.81e-01 | 8.44e-02 | 4.79e-01 | 4.41e-01 | 5.07e-01 | 2.34e-01 | 7.20e-01 |
| POSITIVE REGULATION OF TRIGLYCERIDE LIPASE ACTIVITY | 9 | 5.26e-01 | 8.60e-01 | 0.4140 | -3.07e-01 | -1.78e-01 | -1.02e-01 | -1.60e-01 | -9.58e-02 | 1.10e-01 | 3.55e-01 | 5.95e-01 | 4.07e-01 | 6.19e-01 |
| POSITIVE REGULATION OF DNA RECOMBINATION | 67 | 3.38e-02 | 2.34e-01 | 0.4140 | 1.61e-01 | 1.80e-01 | 2.07e-01 | 2.36e-01 | 1.20e-01 | 2.29e-02 | 1.08e-02 | 3.39e-03 | 8.37e-04 | 8.88e-02 |
| NEGATIVE REGULATION OF TORC1 SIGNALING | 46 | 2.01e-02 | 1.67e-01 | 0.4140 | 1.48e-01 | 1.13e-01 | 1.84e-01 | 2.69e-01 | 1.74e-01 | 8.24e-02 | 1.87e-01 | 3.08e-02 | 1.57e-03 | 4.14e-02 |
| POSITIVE REGULATION OF ERYTHROCYTE DIFFERENTIATION | 31 | 1.09e-01 | 4.51e-01 | 0.4140 | 1.41e-01 | 1.93e-01 | 1.60e-01 | 2.08e-01 | 2.12e-01 | 1.75e-01 | 6.28e-02 | 1.22e-01 | 4.51e-02 | 4.09e-02 |
| DENDRITIC CELL APOPTOTIC PROCESS | 11 | 3.96e-01 | 7.85e-01 | 0.4130 | -1.40e-01 | -2.58e-01 | -1.54e-01 | -2.28e-01 | -9.53e-02 | 4.21e-01 | 1.39e-01 | 3.75e-01 | 1.91e-01 | 5.84e-01 |
| FOREGUT MORPHOGENESIS | 10 | 2.86e-01 | 6.94e-01 | 0.4130 | 2.70e-03 | 4.02e-02 | 2.15e-01 | 2.72e-01 | 2.21e-01 | 9.88e-01 | 8.26e-01 | 2.38e-01 | 1.37e-01 | 2.26e-01 |
| MATURATION OF 5 8S RRNA | 35 | 4.30e-02 | 2.69e-01 | 0.4130 | 1.26e-01 | 1.56e-01 | 2.21e-01 | 1.01e-01 | 2.68e-01 | 1.98e-01 | 1.10e-01 | 2.38e-02 | 3.02e-01 | 6.14e-03 |
| MULTI CILIATED EPITHELIAL CELL DIFFERENTIATION | 9 | 6.57e-01 | 9.20e-01 | 0.4130 | 1.53e-01 | 1.49e-01 | 2.83e-01 | 1.85e-01 | 1.04e-01 | 4.26e-01 | 4.38e-01 | 1.42e-01 | 3.37e-01 | 5.89e-01 |
| SEQUESTERING OF METAL ION | 10 | 1.37e-01 | 5.00e-01 | 0.4130 | 9.46e-02 | 2.24e-01 | 1.50e-01 | 2.91e-01 | 6.57e-02 | 6.04e-01 | 2.20e-01 | 4.12e-01 | 1.11e-01 | 7.19e-01 |
| NEGATIVE REGULATION OF DENDRITE DEVELOPMENT | 8 | 7.90e-01 | 9.63e-01 | 0.4130 | 9.78e-02 | 7.94e-02 | 2.33e-01 | 2.32e-01 | 2.15e-01 | 6.32e-01 | 6.97e-01 | 2.53e-01 | 2.55e-01 | 2.93e-01 |
| REGULATION OF INTEGRIN ACTIVATION | 17 | 3.71e-01 | 7.71e-01 | 0.4130 | -3.14e-02 | -1.13e-01 | -2.24e-01 | -1.86e-01 | -2.68e-01 | 8.23e-01 | 4.22e-01 | 1.10e-01 | 1.83e-01 | 5.58e-02 |
| POSITIVE REGULATION OF RESPONSE TO TUMOR CELL | 15 | 6.91e-01 | 9.31e-01 | 0.4130 | -2.32e-01 | -1.74e-01 | -2.02e-01 | -1.91e-01 | -9.38e-02 | 1.20e-01 | 2.43e-01 | 1.76e-01 | 2.01e-01 | 5.29e-01 |
| CELL CYCLE G2 M PHASE TRANSITION | 148 | 6.93e-06 | 2.69e-04 | 0.4130 | 1.85e-01 | 1.48e-01 | 1.88e-01 | 2.59e-01 | 1.08e-01 | 1.04e-04 | 1.92e-03 | 7.75e-05 | 5.36e-08 | 2.28e-02 |
| NEGATIVE REGULATION OF DENDRITIC SPINE DEVELOPMENT | 12 | 7.49e-01 | 9.51e-01 | 0.4120 | -1.37e-01 | -1.63e-01 | -2.49e-01 | -1.58e-01 | -1.94e-01 | 4.12e-01 | 3.27e-01 | 1.35e-01 | 3.42e-01 | 2.45e-01 |
| POSITIVE REGULATION OF MICROTUBULE NUCLEATION | 7 | 6.40e-01 | 9.14e-01 | 0.4120 | 1.14e-01 | 1.85e-01 | 1.26e-01 | 1.10e-01 | 3.08e-01 | 6.03e-01 | 3.97e-01 | 5.65e-01 | 6.15e-01 | 1.58e-01 |
| NEGATIVE REGULATION OF GLIAL CELL PROLIFERATION | 17 | 3.23e-01 | 7.33e-01 | 0.4120 | 1.48e-01 | 1.91e-01 | 1.40e-01 | 1.81e-01 | 2.44e-01 | 2.92e-01 | 1.72e-01 | 3.18e-01 | 1.97e-01 | 8.21e-02 |
| EPITHELIAL CELL MATURATION | 24 | 5.05e-01 | 8.50e-01 | 0.4120 | 1.60e-01 | 2.06e-01 | 1.89e-01 | 1.98e-01 | 1.64e-01 | 1.75e-01 | 8.04e-02 | 1.10e-01 | 9.32e-02 | 1.64e-01 |
| CENTRAL NERVOUS SYSTEM MATURATION | 6 | 1.96e-01 | 5.84e-01 | 0.4120 | 1.56e-01 | -5.49e-02 | 2.21e-01 | 1.16e-01 | 2.84e-01 | 5.09e-01 | 8.16e-01 | 3.50e-01 | 6.24e-01 | 2.29e-01 |
| THORAX AND ANTERIOR ABDOMEN DETERMINATION | 5 | 1.67e-01 | 5.46e-01 | 0.4120 | 1.46e-01 | 3.34e-01 | 2.19e-02 | -1.04e-01 | 1.59e-01 | 5.73e-01 | 1.96e-01 | 9.32e-01 | 6.87e-01 | 5.37e-01 |
| HEART FORMATION | 33 | 9.72e-02 | 4.24e-01 | 0.4120 | 7.56e-02 | 9.86e-02 | 2.01e-01 | 1.45e-01 | 3.04e-01 | 4.52e-01 | 3.27e-01 | 4.57e-02 | 1.49e-01 | 2.49e-03 |
| BRANCHING INVOLVED IN BLOOD VESSEL MORPHOGENESIS | 36 | 1.78e-01 | 5.63e-01 | 0.4120 | 9.21e-02 | 1.59e-01 | 2.30e-01 | 1.82e-01 | 2.23e-01 | 3.39e-01 | 9.90e-02 | 1.71e-02 | 5.88e-02 | 2.04e-02 |
| NEPHRON MORPHOGENESIS | 77 | 2.29e-02 | 1.83e-01 | 0.4110 | 1.32e-01 | 1.67e-01 | 2.18e-01 | 1.91e-01 | 2.00e-01 | 4.56e-02 | 1.13e-02 | 9.51e-04 | 3.71e-03 | 2.40e-03 |
| MYELOID DENDRITIC CELL ACTIVATION | 29 | 3.01e-01 | 7.13e-01 | 0.4110 | -2.26e-01 | -2.14e-01 | -1.48e-01 | -2.23e-01 | -2.46e-02 | 3.51e-02 | 4.61e-02 | 1.68e-01 | 3.73e-02 | 8.18e-01 |
| POSITIVE REGULATION OF GLIAL CELL PROLIFERATION | 19 | 4.65e-01 | 8.26e-01 | 0.4110 | 1.89e-01 | 2.42e-01 | 1.69e-01 | 1.43e-01 | 1.61e-01 | 1.55e-01 | 6.73e-02 | 2.01e-01 | 2.82e-01 | 2.25e-01 |
| REGULATION OF HISTONE ACETYLATION | 18 | 3.15e-01 | 7.26e-01 | 0.4110 | 1.63e-01 | 1.66e-01 | 1.71e-01 | 2.82e-01 | 8.14e-02 | 2.33e-01 | 2.22e-01 | 2.09e-01 | 3.85e-02 | 5.50e-01 |
| VENTRAL SPINAL CORD INTERNEURON DIFFERENTIATION | 13 | 1.70e-01 | 5.54e-01 | 0.4110 | -1.69e-02 | 9.36e-02 | 2.65e-01 | 4.20e-02 | 2.97e-01 | 9.16e-01 | 5.59e-01 | 9.82e-02 | 7.93e-01 | 6.37e-02 |
| ISOLEUCINE METABOLIC PROCESS | 6 | 3.39e-01 | 7.44e-01 | 0.4110 | -1.37e-02 | -4.17e-02 | 5.84e-02 | 2.23e-01 | 3.38e-01 | 9.54e-01 | 8.60e-01 | 8.04e-01 | 3.44e-01 | 1.52e-01 |
| AUTOPHAGOSOME MEMBRANE DOCKING | 7 | 7.31e-01 | 9.44e-01 | 0.4110 | 2.96e-01 | 1.46e-01 | 1.49e-01 | 1.93e-01 | -2.44e-02 | 1.75e-01 | 5.02e-01 | 4.94e-01 | 3.77e-01 | 9.11e-01 |
| ENDOTHELIAL CELL MORPHOGENESIS | 9 | 5.27e-01 | 8.60e-01 | 0.4110 | -3.07e-01 | -1.58e-01 | -4.72e-02 | -1.86e-01 | 1.15e-01 | 1.11e-01 | 4.12e-01 | 8.06e-01 | 3.34e-01 | 5.49e-01 |
| BOX C D SNORNP ASSEMBLY | 10 | 3.46e-01 | 7.50e-01 | 0.4110 | 2.62e-02 | 6.13e-02 | 1.33e-01 | 2.70e-02 | 3.82e-01 | 8.86e-01 | 7.37e-01 | 4.67e-01 | 8.82e-01 | 3.63e-02 |
| REGULATION OF NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING SIGNALING PATHWAY | 14 | 4.70e-01 | 8.30e-01 | 0.4110 | 2.71e-01 | 2.30e-01 | 1.29e-01 | 1.35e-01 | 8.85e-02 | 7.94e-02 | 1.36e-01 | 4.05e-01 | 3.81e-01 | 5.67e-01 |
| SMOOTH MUSCLE CELL CHEMOTAXIS | 9 | 8.51e-01 | 9.76e-01 | 0.4110 | -2.11e-01 | -1.31e-01 | -1.78e-01 | -2.36e-01 | -1.41e-01 | 2.72e-01 | 4.96e-01 | 3.54e-01 | 2.21e-01 | 4.65e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II | 1193 | 1.00e-37 | 8.39e-35 | 0.4110 | 1.49e-01 | 1.82e-01 | 2.04e-01 | 2.02e-01 | 1.77e-01 | 4.51e-18 | 3.02e-26 | 1.35e-32 | 7.37e-32 | 6.50e-25 |
| NUCLEAR RNA SURVEILLANCE | 14 | 2.26e-01 | 6.28e-01 | 0.4110 | -4.96e-02 | 3.54e-02 | 1.48e-01 | 3.80e-02 | 3.76e-01 | 7.48e-01 | 8.19e-01 | 3.39e-01 | 8.05e-01 | 1.48e-02 |
| CELLULAR RESPONSE TO PURINE CONTAINING COMPOUND | 14 | 3.01e-01 | 7.13e-01 | 0.4100 | -1.91e-01 | -1.64e-01 | -1.06e-01 | -2.46e-01 | -1.83e-01 | 2.16e-01 | 2.88e-01 | 4.92e-01 | 1.11e-01 | 2.37e-01 |
| NEGATIVE T CELL SELECTION | 13 | 4.45e-02 | 2.74e-01 | 0.4100 | -1.67e-01 | -1.05e-01 | 1.94e-01 | 1.40e-01 | 2.69e-01 | 2.97e-01 | 5.12e-01 | 2.27e-01 | 3.81e-01 | 9.33e-02 |
| POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO TELOMERE | 9 | 7.24e-01 | 9.41e-01 | 0.4100 | 1.20e-01 | 7.71e-02 | 2.44e-01 | 2.23e-01 | 1.96e-01 | 5.33e-01 | 6.89e-01 | 2.05e-01 | 2.47e-01 | 3.08e-01 |
| NEGATIVE REGULATION OF ALPHA BETA T CELL DIFFERENTIATION | 27 | 3.20e-01 | 7.31e-01 | 0.4100 | 1.46e-01 | 1.24e-01 | 2.05e-01 | 2.45e-01 | 1.72e-01 | 1.90e-01 | 2.66e-01 | 6.58e-02 | 2.78e-02 | 1.23e-01 |
| NEGATIVE REGULATION OF JUN KINASE ACTIVITY | 14 | 5.27e-01 | 8.60e-01 | 0.4090 | 2.58e-01 | 1.62e-01 | 1.85e-01 | 2.00e-01 | -1.20e-02 | 9.40e-02 | 2.95e-01 | 2.30e-01 | 1.94e-01 | 9.38e-01 |
| ERBB4 SIGNALING PATHWAY | 10 | 3.95e-01 | 7.85e-01 | 0.4090 | -3.28e-02 | -1.01e-01 | -1.78e-01 | -2.52e-01 | -2.47e-01 | 8.58e-01 | 5.81e-01 | 3.29e-01 | 1.67e-01 | 1.76e-01 |
| POSITIVE REGULATION OF DENDRITE DEVELOPMENT | 15 | 6.54e-01 | 9.20e-01 | 0.4090 | -2.50e-01 | -2.32e-01 | -1.63e-01 | -1.52e-01 | -4.13e-02 | 9.42e-02 | 1.20e-01 | 2.75e-01 | 3.07e-01 | 7.82e-01 |
| REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 72 | 1.75e-02 | 1.53e-01 | 0.4090 | 1.57e-01 | 1.46e-01 | 1.85e-01 | 2.23e-01 | 1.93e-01 | 2.11e-02 | 3.17e-02 | 6.51e-03 | 1.09e-03 | 4.53e-03 |
| REGULATION OF CEREBELLAR GRANULE CELL PRECURSOR PROLIFERATION | 11 | 6.35e-01 | 9.12e-01 | 0.4090 | 1.03e-01 | 1.55e-01 | 2.69e-01 | 1.34e-01 | 2.06e-01 | 5.56e-01 | 3.73e-01 | 1.22e-01 | 4.41e-01 | 2.38e-01 |
| AMINO ACID ACTIVATION | 43 | 9.31e-02 | 4.14e-01 | 0.4090 | 2.00e-01 | 1.50e-01 | 1.61e-01 | 2.46e-01 | 1.35e-01 | 2.30e-02 | 8.88e-02 | 6.73e-02 | 5.28e-03 | 1.26e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPIRATION | 10 | 8.05e-01 | 9.67e-01 | 0.4090 | 1.77e-01 | 1.57e-01 | 2.47e-01 | 1.95e-01 | 1.11e-01 | 3.33e-01 | 3.90e-01 | 1.76e-01 | 2.87e-01 | 5.44e-01 |
| MESODERMAL CELL DIFFERENTIATION | 34 | 1.21e-01 | 4.75e-01 | 0.4090 | 1.60e-01 | 1.96e-01 | 1.85e-01 | 1.23e-01 | 2.31e-01 | 1.07e-01 | 4.74e-02 | 6.14e-02 | 2.13e-01 | 1.95e-02 |
| ADENYLATE CYCLASE INHIBITING DOPAMINE RECEPTOR SIGNALING PATHWAY | 5 | 7.93e-01 | 9.65e-01 | 0.4090 | -3.16e-02 | 5.87e-02 | 1.77e-01 | 3.63e-02 | 3.61e-01 | 9.03e-01 | 8.20e-01 | 4.93e-01 | 8.88e-01 | 1.63e-01 |
| MATURATION OF 5 8S RRNA FROM TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 25 | 6.32e-02 | 3.35e-01 | 0.4090 | 8.46e-02 | 1.33e-01 | 1.93e-01 | 6.22e-02 | 3.18e-01 | 4.64e-01 | 2.49e-01 | 9.45e-02 | 5.90e-01 | 5.92e-03 |
| NUCLEAR TRANSPORT | 314 | 6.09e-10 | 4.63e-08 | 0.4080 | 2.16e-01 | 1.69e-01 | 1.80e-01 | 2.24e-01 | 9.42e-02 | 4.73e-11 | 2.76e-07 | 4.27e-08 | 8.16e-12 | 4.11e-03 |
| POSITIVE REGULATION OF RYANODINE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 8 | 3.95e-01 | 7.85e-01 | 0.4080 | -2.87e-01 | -2.16e-01 | 9.43e-04 | -2.94e-02 | 1.90e-01 | 1.59e-01 | 2.90e-01 | 9.96e-01 | 8.85e-01 | 3.53e-01 |
| TRIGEMINAL NERVE DEVELOPMENT | 10 | 3.90e-01 | 7.82e-01 | 0.4070 | 1.11e-01 | 2.57e-01 | 1.76e-01 | 4.28e-02 | 2.34e-01 | 5.44e-01 | 1.60e-01 | 3.34e-01 | 8.15e-01 | 1.99e-01 |
| PROTEIN TARGETING TO PEROXISOME | 19 | 5.31e-01 | 8.63e-01 | 0.4070 | 1.21e-01 | 1.23e-01 | 1.95e-01 | 2.17e-01 | 2.26e-01 | 3.62e-01 | 3.53e-01 | 1.41e-01 | 1.01e-01 | 8.79e-02 |
| ENGULFMENT OF APOPTOTIC CELL | 15 | 6.78e-01 | 9.28e-01 | 0.4070 | 1.27e-01 | 1.31e-01 | 2.31e-01 | 1.73e-01 | 2.21e-01 | 3.94e-01 | 3.79e-01 | 1.21e-01 | 2.45e-01 | 1.38e-01 |
| REGULATION OF ATTACHMENT OF MITOTIC SPINDLE MICROTUBULES TO KINETOCHORE | 8 | 4.24e-01 | 8.03e-01 | 0.4070 | 1.62e-01 | 1.69e-01 | 2.87e-01 | 1.66e-01 | -3.45e-02 | 4.27e-01 | 4.08e-01 | 1.60e-01 | 4.17e-01 | 8.66e-01 |
| RESOLUTION OF RECOMBINATION INTERMEDIATES | 6 | 6.92e-01 | 9.31e-01 | 0.4070 | 1.97e-01 | 2.49e-01 | 9.10e-02 | 1.71e-01 | 1.66e-01 | 4.03e-01 | 2.91e-01 | 7.00e-01 | 4.69e-01 | 4.82e-01 |
| REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY | 58 | 2.61e-02 | 1.98e-01 | 0.4070 | 9.65e-02 | 1.44e-01 | 2.40e-01 | 2.07e-01 | 1.88e-01 | 2.04e-01 | 5.84e-02 | 1.55e-03 | 6.48e-03 | 1.31e-02 |
| NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 5 | 7.07e-01 | 9.34e-01 | 0.4070 | 1.86e-01 | 2.10e-01 | 5.38e-02 | 1.93e-01 | -2.17e-01 | 4.72e-01 | 4.16e-01 | 8.35e-01 | 4.54e-01 | 4.02e-01 |
| GLOSSOPHARYNGEAL NERVE DEVELOPMENT | 5 | 8.87e-01 | 9.80e-01 | 0.4070 | -1.49e-01 | -2.02e-01 | -1.44e-01 | -2.23e-01 | -1.79e-01 | 5.65e-01 | 4.34e-01 | 5.77e-01 | 3.87e-01 | 4.88e-01 |
| CELLULAR RESPONSE TO UV B | 12 | 7.59e-01 | 9.52e-01 | 0.4070 | 1.82e-01 | 2.55e-01 | 1.74e-01 | 1.66e-01 | 9.92e-02 | 2.75e-01 | 1.27e-01 | 2.97e-01 | 3.20e-01 | 5.52e-01 |
| CARDIAC VASCULAR SMOOTH MUSCLE CELL DIFFERENTIATION | 10 | 6.94e-01 | 9.31e-01 | 0.4070 | 1.15e-01 | 1.56e-01 | 2.78e-01 | 1.69e-01 | 1.49e-01 | 5.31e-01 | 3.93e-01 | 1.28e-01 | 3.55e-01 | 4.16e-01 |
| AMMONIUM TRANSMEMBRANE TRANSPORT | 12 | 2.33e-01 | 6.36e-01 | 0.4070 | -1.84e-01 | -1.40e-01 | -1.20e-01 | -3.01e-01 | 8.23e-02 | 2.69e-01 | 4.00e-01 | 4.71e-01 | 7.10e-02 | 6.22e-01 |
| ESTABLISHMENT OF MITOTIC SPINDLE LOCALIZATION | 40 | 1.66e-01 | 5.46e-01 | 0.4060 | 1.76e-01 | 1.44e-01 | 2.00e-01 | 2.48e-01 | 1.10e-01 | 5.43e-02 | 1.16e-01 | 2.83e-02 | 6.75e-03 | 2.28e-01 |
| DISRUPTION OF CELLULAR ANATOMICAL STRUCTURE IN ANOTHER ORGANISM | 10 | 8.44e-01 | 9.75e-01 | 0.4060 | -1.88e-01 | -2.43e-01 | -1.79e-01 | -1.48e-01 | -1.28e-01 | 3.04e-01 | 1.83e-01 | 3.26e-01 | 4.17e-01 | 4.83e-01 |
| OUTER DYNEIN ARM ASSEMBLY | 23 | 2.66e-02 | 2.00e-01 | 0.4060 | -1.75e-01 | -1.29e-01 | -1.64e-01 | -2.67e-01 | 1.39e-01 | 1.47e-01 | 2.83e-01 | 1.72e-01 | 2.69e-02 | 2.48e-01 |
| CELLULAR RESPONSE TO TOPOLOGICALLY INCORRECT PROTEIN | 106 | 7.47e-04 | 1.38e-02 | 0.4060 | 1.17e-01 | 1.68e-01 | 1.97e-01 | 2.03e-01 | 2.06e-01 | 3.71e-02 | 2.81e-03 | 4.42e-04 | 3.10e-04 | 2.46e-04 |
| ERYTHROCYTE HOMEOSTASIS | 135 | 1.01e-03 | 1.77e-02 | 0.4050 | 1.60e-01 | 1.68e-01 | 1.97e-01 | 2.01e-01 | 1.77e-01 | 1.32e-03 | 7.32e-04 | 7.89e-05 | 5.62e-05 | 3.93e-04 |
| REGULATION OF BARBED END ACTIN FILAMENT CAPPING | 5 | 6.09e-01 | 9.03e-01 | 0.4050 | 1.05e-01 | -1.96e-02 | -5.60e-02 | 7.67e-02 | -3.79e-01 | 6.85e-01 | 9.39e-01 | 8.28e-01 | 7.66e-01 | 1.42e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CELL CORTEX | 6 | 5.87e-01 | 8.91e-01 | 0.4050 | 2.48e-01 | 9.67e-02 | 6.15e-02 | 2.95e-01 | 4.74e-02 | 2.93e-01 | 6.82e-01 | 7.94e-01 | 2.11e-01 | 8.40e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO NUCLEOLUS | 10 | 6.88e-01 | 9.31e-01 | 0.4050 | 1.47e-01 | 2.63e-01 | 1.74e-01 | 1.81e-01 | 1.00e-01 | 4.21e-01 | 1.50e-01 | 3.41e-01 | 3.23e-01 | 5.83e-01 |
| EOSINOPHIL MIGRATION | 31 | 1.47e-01 | 5.15e-01 | 0.4050 | -1.77e-01 | -9.84e-02 | -1.90e-01 | -2.56e-01 | -1.47e-01 | 8.87e-02 | 3.43e-01 | 6.74e-02 | 1.38e-02 | 1.58e-01 |
| POSITIVE REGULATION BY HOST OF VIRAL PROCESS | 20 | 5.60e-01 | 8.78e-01 | 0.4050 | 1.97e-01 | 1.79e-01 | 1.56e-01 | 2.29e-01 | 1.26e-01 | 1.26e-01 | 1.65e-01 | 2.26e-01 | 7.67e-02 | 3.29e-01 |
| GLUCOSAMINE CONTAINING COMPOUND CATABOLIC PROCESS | 9 | 3.84e-01 | 7.79e-01 | 0.4050 | 2.76e-02 | -3.53e-02 | -2.12e-01 | -1.61e-02 | -3.41e-01 | 8.86e-01 | 8.55e-01 | 2.70e-01 | 9.33e-01 | 7.64e-02 |
| REGULATION OF DNA REPAIR | 205 | 4.36e-08 | 2.56e-06 | 0.4040 | 1.57e-01 | 1.63e-01 | 1.74e-01 | 2.36e-01 | 1.62e-01 | 1.02e-04 | 5.62e-05 | 1.72e-05 | 6.04e-09 | 6.06e-05 |
| REGULATION OF CARDIOBLAST DIFFERENTIATION | 5 | 8.06e-01 | 9.67e-01 | 0.4040 | 1.15e-01 | 2.96e-01 | 1.95e-01 | 1.47e-01 | 5.27e-02 | 6.56e-01 | 2.51e-01 | 4.50e-01 | 5.69e-01 | 8.38e-01 |
| POSITIVE REGULATION OF CHOLESTEROL STORAGE | 8 | 8.54e-01 | 9.76e-01 | 0.4040 | -8.63e-02 | -1.04e-01 | -2.15e-01 | -1.57e-01 | -2.72e-01 | 6.72e-01 | 6.11e-01 | 2.93e-01 | 4.41e-01 | 1.82e-01 |
| NEGATIVE REGULATION OF MACROPHAGE DIFFERENTIATION | 8 | 4.64e-01 | 8.25e-01 | 0.4040 | -8.62e-02 | -1.70e-02 | -2.16e-01 | -2.94e-01 | -1.50e-01 | 6.73e-01 | 9.33e-01 | 2.89e-01 | 1.50e-01 | 4.62e-01 |
| RNA SECONDARY STRUCTURE UNWINDING | 8 | 7.75e-01 | 9.58e-01 | 0.4040 | -2.34e-01 | -1.40e-01 | -2.06e-01 | -2.15e-01 | -3.46e-03 | 2.51e-01 | 4.92e-01 | 3.13e-01 | 2.92e-01 | 9.86e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CELL CORTEX | 9 | 6.90e-01 | 9.31e-01 | 0.4040 | 2.62e-01 | 1.31e-01 | 1.13e-01 | 2.46e-01 | 6.24e-02 | 1.73e-01 | 4.96e-01 | 5.56e-01 | 2.01e-01 | 7.46e-01 |
| MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA PRODUCTION | 6 | 1.90e-02 | 1.61e-01 | 0.4040 | 1.63e-01 | 1.90e-01 | -1.41e-01 | -2.39e-01 | 1.53e-01 | 4.89e-01 | 4.20e-01 | 5.49e-01 | 3.11e-01 | 5.16e-01 |
| POST CHAPERONIN TUBULIN FOLDING PATHWAY | 6 | 1.22e-01 | 4.75e-01 | 0.4040 | 1.59e-01 | 4.19e-02 | -7.27e-02 | 3.03e-01 | -1.98e-01 | 5.01e-01 | 8.59e-01 | 7.58e-01 | 1.99e-01 | 4.00e-01 |
| REGULATION OF HEMATOPOIETIC STEM CELL PROLIFERATION | 15 | 7.04e-01 | 9.33e-01 | 0.4040 | 1.26e-01 | 1.21e-01 | 2.02e-01 | 2.11e-01 | 2.17e-01 | 3.98e-01 | 4.17e-01 | 1.75e-01 | 1.58e-01 | 1.46e-01 |
| NUCLEOTIDE SUGAR METABOLIC PROCESS | 37 | 1.43e-01 | 5.09e-01 | 0.4030 | 1.33e-01 | 1.07e-01 | 1.96e-01 | 2.28e-01 | 2.07e-01 | 1.61e-01 | 2.61e-01 | 3.94e-02 | 1.62e-02 | 2.91e-02 |
| KILLING BY HOST OF SYMBIONT CELLS | 28 | 2.41e-04 | 5.45e-03 | 0.4030 | 3.04e-01 | 1.88e-01 | 5.71e-03 | -9.68e-03 | -1.86e-01 | 5.34e-03 | 8.54e-02 | 9.58e-01 | 9.29e-01 | 8.85e-02 |
| ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 74 | 9.61e-03 | 9.89e-02 | 0.4030 | 1.05e-01 | 1.70e-01 | 2.03e-01 | 1.96e-01 | 2.07e-01 | 1.18e-01 | 1.14e-02 | 2.47e-03 | 3.56e-03 | 2.11e-03 |
| NEGATIVE REGULATION OF LYMPHOCYTE MIGRATION | 15 | 4.47e-01 | 8.18e-01 | 0.4030 | -7.73e-02 | -2.27e-01 | -2.42e-01 | -1.36e-01 | -1.67e-01 | 6.04e-01 | 1.29e-01 | 1.04e-01 | 3.62e-01 | 2.62e-01 |
| POSITIVE REGULATION OF MUCUS SECRETION | 5 | 8.70e-01 | 9.78e-01 | 0.4030 | 2.88e-01 | 2.12e-01 | 1.07e-01 | 1.24e-01 | -8.74e-02 | 2.65e-01 | 4.12e-01 | 6.78e-01 | 6.31e-01 | 7.35e-01 |
| TOLERANCE INDUCTION DEPENDENT UPON IMMUNE RESPONSE | 5 | 6.54e-01 | 9.20e-01 | 0.4030 | -1.50e-01 | -2.81e-01 | -9.59e-02 | -1.58e-01 | 1.63e-01 | 5.60e-01 | 2.77e-01 | 7.10e-01 | 5.42e-01 | 5.27e-01 |
| PEROXISOME ORGANIZATION | 34 | 3.87e-01 | 7.80e-01 | 0.4030 | 1.99e-01 | 1.65e-01 | 1.94e-01 | 1.98e-01 | 1.36e-01 | 4.42e-02 | 9.51e-02 | 5.07e-02 | 4.58e-02 | 1.71e-01 |
| DENDRITIC CELL ANTIGEN PROCESSING AND PRESENTATION | 14 | 5.24e-02 | 3.02e-01 | 0.4030 | 2.98e-02 | 9.27e-02 | -2.19e-01 | -1.99e-01 | -2.55e-01 | 8.47e-01 | 5.48e-01 | 1.57e-01 | 1.97e-01 | 9.80e-02 |
| REVERSE CHOLESTEROL TRANSPORT | 20 | 3.88e-04 | 8.25e-03 | 0.4030 | -2.06e-01 | 9.07e-02 | -9.57e-02 | -2.20e-01 | -2.32e-01 | 1.11e-01 | 4.83e-01 | 4.59e-01 | 8.80e-02 | 7.24e-02 |
| CELLULAR RESPONSE TO INTERFERON ALPHA | 7 | 8.69e-01 | 9.78e-01 | 0.4030 | 9.84e-02 | 9.07e-02 | 2.31e-01 | 1.70e-01 | 2.48e-01 | 6.52e-01 | 6.78e-01 | 2.89e-01 | 4.35e-01 | 2.55e-01 |
| CELLULAR RESPONSE TO OXYGEN LEVELS | 160 | 3.95e-05 | 1.28e-03 | 0.4030 | 1.76e-01 | 1.76e-01 | 1.86e-01 | 1.66e-01 | 1.95e-01 | 1.27e-04 | 1.23e-04 | 4.77e-05 | 2.83e-04 | 2.11e-05 |
| REGULATION OF PROSTAGLANDIN SECRETION | 13 | 1.42e-01 | 5.07e-01 | 0.4020 | -9.33e-02 | 5.42e-02 | -1.72e-01 | -2.11e-01 | -2.76e-01 | 5.60e-01 | 7.35e-01 | 2.84e-01 | 1.87e-01 | 8.49e-02 |
| RESPONSE TO IRON ION | 28 | 9.45e-02 | 4.17e-01 | 0.4020 | 1.45e-01 | 1.32e-01 | 1.34e-01 | 1.62e-01 | 2.81e-01 | 1.84e-01 | 2.26e-01 | 2.19e-01 | 1.38e-01 | 9.97e-03 |
| SHORT CHAIN FATTY ACID CATABOLIC PROCESS | 7 | 1.53e-01 | 5.22e-01 | 0.4020 | -4.16e-03 | -1.60e-01 | -8.63e-02 | 4.62e-02 | 3.55e-01 | 9.85e-01 | 4.63e-01 | 6.92e-01 | 8.32e-01 | 1.03e-01 |
| POSITIVE REGULATION OF NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 5 | 8.87e-01 | 9.80e-01 | 0.4020 | 1.99e-01 | 2.48e-01 | 1.21e-01 | 2.14e-01 | -4.67e-03 | 4.41e-01 | 3.36e-01 | 6.41e-01 | 4.08e-01 | 9.86e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE III | 17 | 3.81e-01 | 7.78e-01 | 0.4020 | 2.83e-01 | 1.72e-01 | 9.56e-02 | 2.05e-01 | -2.94e-02 | 4.32e-02 | 2.20e-01 | 4.95e-01 | 1.44e-01 | 8.34e-01 |
| RNA METHYLATION | 86 | 2.36e-03 | 3.48e-02 | 0.4020 | 1.52e-01 | 1.08e-01 | 2.18e-01 | 2.14e-01 | 1.83e-01 | 1.50e-02 | 8.33e-02 | 4.85e-04 | 5.84e-04 | 3.41e-03 |
| REGULATION OF VASCULAR WOUND HEALING | 13 | 8.81e-02 | 4.01e-01 | 0.4020 | -7.13e-03 | 2.10e-01 | 2.55e-01 | -2.33e-03 | 2.28e-01 | 9.64e-01 | 1.89e-01 | 1.12e-01 | 9.88e-01 | 1.54e-01 |
| NEGATIVE REGULATION OF VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 14 | 2.57e-01 | 6.63e-01 | 0.4020 | 2.26e-02 | 1.58e-01 | 2.91e-01 | 1.21e-01 | 1.91e-01 | 8.84e-01 | 3.06e-01 | 5.95e-02 | 4.34e-01 | 2.15e-01 |
| PLASMA MEMBRANE TUBULATION | 19 | 3.99e-01 | 7.87e-01 | 0.4010 | 2.65e-01 | 2.18e-01 | 1.03e-01 | 1.79e-01 | 2.32e-02 | 4.55e-02 | 1.00e-01 | 4.38e-01 | 1.76e-01 | 8.61e-01 |
| REGULATION OF MACROPHAGE DERIVED FOAM CELL DIFFERENTIATION | 33 | 2.58e-01 | 6.64e-01 | 0.4010 | -1.52e-01 | -1.20e-01 | -2.20e-01 | -2.02e-01 | -1.84e-01 | 1.30e-01 | 2.32e-01 | 2.86e-02 | 4.41e-02 | 6.75e-02 |
| MACROAUTOPHAGY | 317 | 1.86e-09 | 1.28e-07 | 0.4010 | 1.92e-01 | 1.55e-01 | 1.86e-01 | 2.15e-01 | 1.38e-01 | 3.85e-09 | 2.01e-06 | 1.31e-08 | 4.19e-11 | 2.43e-05 |
| ZINC ION IMPORT INTO ORGANELLE | 9 | 4.88e-01 | 8.39e-01 | 0.4010 | -1.01e-01 | -3.02e-02 | 1.41e-01 | 5.68e-02 | 3.55e-01 | 5.99e-01 | 8.75e-01 | 4.62e-01 | 7.68e-01 | 6.50e-02 |
| REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DEDIFFERENTIATION | 5 | 1.95e-01 | 5.83e-01 | 0.4010 | 9.21e-02 | 1.87e-01 | -1.32e-02 | 1.63e-01 | 3.01e-01 | 7.21e-01 | 4.70e-01 | 9.59e-01 | 5.28e-01 | 2.44e-01 |
| NEUROBLAST MIGRATION | 6 | 6.22e-01 | 9.08e-01 | 0.4000 | -1.71e-01 | -8.30e-02 | 1.39e-01 | 2.81e-02 | 3.23e-01 | 4.69e-01 | 7.25e-01 | 5.55e-01 | 9.05e-01 | 1.71e-01 |
| POSITIVE REGULATION OF CARDIOCYTE DIFFERENTIATION | 18 | 4.60e-01 | 8.23e-01 | 0.4000 | 1.99e-01 | 2.47e-01 | 2.05e-01 | 1.33e-01 | 4.12e-03 | 1.44e-01 | 6.97e-02 | 1.33e-01 | 3.27e-01 | 9.76e-01 |
| PATTERN SPECIFICATION PROCESS | 457 | 1.53e-16 | 2.45e-14 | 0.4000 | 1.04e-01 | 1.68e-01 | 2.16e-01 | 1.72e-01 | 2.11e-01 | 1.43e-04 | 6.59e-10 | 2.12e-15 | 3.01e-10 | 1.06e-14 |
| LEUKOTRIENE D4 BIOSYNTHETIC PROCESS | 6 | 2.48e-01 | 6.54e-01 | 0.4000 | -1.35e-02 | 1.48e-01 | 3.50e-01 | 6.65e-02 | 1.06e-01 | 9.54e-01 | 5.31e-01 | 1.38e-01 | 7.78e-01 | 6.54e-01 |
| ATRIOVENTRICULAR VALVE FORMATION | 8 | 1.64e-01 | 5.42e-01 | 0.4000 | -6.76e-02 | 2.39e-01 | 2.37e-01 | 1.25e-01 | 1.63e-01 | 7.41e-01 | 2.42e-01 | 2.46e-01 | 5.40e-01 | 4.26e-01 |
| RNA LOCALIZATION | 183 | 5.01e-07 | 2.45e-05 | 0.4000 | 1.90e-01 | 1.29e-01 | 1.89e-01 | 2.45e-01 | 1.07e-01 | 9.05e-06 | 2.69e-03 | 9.82e-06 | 1.15e-08 | 1.28e-02 |
| DISTAL TUBULE DEVELOPMENT | 12 | 7.81e-01 | 9.60e-01 | 0.4000 | 1.14e-01 | 1.47e-01 | 1.98e-01 | 2.20e-01 | 1.93e-01 | 4.93e-01 | 3.77e-01 | 2.34e-01 | 1.86e-01 | 2.48e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL PROLIFERATION | 10 | 5.09e-01 | 8.53e-01 | 0.4000 | -2.53e-01 | -1.93e-01 | -2.42e-02 | -1.38e-01 | 1.97e-01 | 1.66e-01 | 2.91e-01 | 8.95e-01 | 4.49e-01 | 2.81e-01 |
| POSITIVE REGULATION OF PROTEIN MATURATION | 27 | 8.25e-02 | 3.88e-01 | 0.4000 | 2.07e-01 | 2.87e-01 | 1.62e-01 | 9.02e-02 | -1.56e-02 | 6.25e-02 | 9.92e-03 | 1.45e-01 | 4.17e-01 | 8.88e-01 |
| RESPONSE TO FUNGICIDE | 7 | 3.17e-01 | 7.27e-01 | 0.4000 | 1.93e-01 | 1.50e-01 | 4.72e-02 | 3.10e-01 | 3.88e-02 | 3.77e-01 | 4.93e-01 | 8.29e-01 | 1.55e-01 | 8.59e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 184 | 5.44e-05 | 1.66e-03 | 0.3990 | 1.54e-01 | 1.67e-01 | 2.10e-01 | 2.11e-01 | 1.40e-01 | 3.21e-04 | 9.57e-05 | 8.94e-07 | 8.15e-07 | 1.04e-03 |
| T CELL TOLERANCE INDUCTION | 14 | 1.67e-01 | 5.47e-01 | 0.3990 | -2.19e-01 | -2.32e-01 | -9.51e-02 | -4.11e-02 | 2.17e-01 | 1.56e-01 | 1.33e-01 | 5.38e-01 | 7.90e-01 | 1.60e-01 |
| POSITIVE REGULATION OF INFLAMMASOME MEDIATED SIGNALING PATHWAY | 18 | 1.22e-01 | 4.75e-01 | 0.3990 | -1.09e-02 | -1.91e-01 | -1.98e-01 | -1.62e-01 | -2.40e-01 | 9.36e-01 | 1.61e-01 | 1.46e-01 | 2.35e-01 | 7.82e-02 |
| PLANAR CELL POLARITY PATHWAY INVOLVED IN AXIS ELONGATION | 6 | 3.79e-01 | 7.75e-01 | 0.3990 | -3.25e-01 | -7.32e-02 | -2.08e-02 | -1.02e-01 | 1.93e-01 | 1.67e-01 | 7.56e-01 | 9.30e-01 | 6.64e-01 | 4.14e-01 |
| MITOPHAGY | 34 | 5.15e-02 | 2.99e-01 | 0.3980 | 2.68e-01 | 1.46e-01 | 1.43e-01 | 1.79e-01 | 1.15e-01 | 6.88e-03 | 1.41e-01 | 1.49e-01 | 7.07e-02 | 2.45e-01 |
| PYRIMIDINE DEOXYRIBONUCLEOSIDE METABOLIC PROCESS | 5 | 7.74e-01 | 9.57e-01 | 0.3980 | 2.85e-01 | 2.46e-01 | 3.33e-02 | 1.24e-01 | -2.39e-02 | 2.70e-01 | 3.41e-01 | 8.97e-01 | 6.31e-01 | 9.26e-01 |
| NEGATIVE REGULATION OF CELL GROWTH INVOLVED IN CARDIAC MUSCLE CELL DEVELOPMENT | 12 | 6.17e-01 | 9.06e-01 | 0.3980 | 2.29e-01 | 2.67e-01 | 1.55e-01 | 1.06e-01 | 1.20e-02 | 1.70e-01 | 1.10e-01 | 3.52e-01 | 5.24e-01 | 9.43e-01 |
| RESPONSE TO GAMMA RADIATION | 50 | 1.83e-02 | 1.58e-01 | 0.3980 | 1.40e-01 | 1.02e-01 | 1.97e-01 | 2.64e-01 | 1.43e-01 | 8.58e-02 | 2.12e-01 | 1.62e-02 | 1.26e-03 | 8.06e-02 |
| POSITIVE REGULATION OF MIRNA PROCESSING | 5 | 6.04e-01 | 9.01e-01 | 0.3980 | -1.20e-01 | -1.77e-01 | 1.05e-01 | 9.41e-02 | 3.05e-01 | 6.43e-01 | 4.92e-01 | 6.85e-01 | 7.16e-01 | 2.38e-01 |
| MITOCHONDRIAL CALCIUM ION TRANSMEMBRANE TRANSPORT | 18 | 2.71e-01 | 6.79e-01 | 0.3980 | 1.90e-01 | 1.59e-01 | 1.22e-01 | 2.70e-01 | 9.58e-02 | 1.63e-01 | 2.42e-01 | 3.69e-01 | 4.77e-02 | 4.82e-01 |
| POSITIVE REGULATION OF ASTROCYTE DIFFERENTIATION | 13 | 5.37e-01 | 8.66e-01 | 0.3980 | 5.47e-02 | 1.47e-01 | 2.68e-01 | 1.46e-01 | 2.02e-01 | 7.33e-01 | 3.59e-01 | 9.45e-02 | 3.63e-01 | 2.08e-01 |
| POSITIVE REGULATION OF CYTOPLASMIC TRANSLATION | 14 | 4.63e-01 | 8.25e-01 | 0.3980 | 2.33e-01 | 2.19e-01 | 2.02e-01 | 1.22e-01 | -1.10e-02 | 1.31e-01 | 1.56e-01 | 1.91e-01 | 4.28e-01 | 9.43e-01 |
| STRESS GRANULE ASSEMBLY | 29 | 7.32e-02 | 3.66e-01 | 0.3970 | 1.57e-01 | 1.06e-01 | 1.36e-01 | 2.55e-01 | 1.97e-01 | 1.42e-01 | 3.25e-01 | 2.06e-01 | 1.76e-02 | 6.62e-02 |
| SPHINGOMYELIN CATABOLIC PROCESS | 8 | 2.48e-01 | 6.54e-01 | 0.3970 | 2.18e-01 | 1.75e-01 | 2.60e-01 | 5.57e-02 | 9.54e-02 | 2.87e-01 | 3.91e-01 | 2.02e-01 | 7.85e-01 | 6.40e-01 |
| POSITIVE REGULATION OF FATTY ACID BETA OXIDATION | 10 | 5.01e-01 | 8.48e-01 | 0.3970 | 1.54e-01 | 2.30e-01 | 1.17e-01 | 1.95e-01 | 1.71e-01 | 3.98e-01 | 2.08e-01 | 5.22e-01 | 2.85e-01 | 3.50e-01 |
| POSITIVE REGULATION OF SYNAPTIC PLASTICITY | 10 | 5.72e-01 | 8.83e-01 | 0.3970 | 2.36e-01 | 1.84e-01 | 2.16e-01 | 1.45e-01 | -2.07e-02 | 1.96e-01 | 3.15e-01 | 2.36e-01 | 4.28e-01 | 9.10e-01 |
| PROTEIN EXPORT FROM NUCLEUS | 59 | 1.22e-02 | 1.18e-01 | 0.3970 | 2.61e-01 | 1.76e-01 | 1.16e-01 | 2.07e-01 | 4.52e-02 | 5.26e-04 | 1.92e-02 | 1.24e-01 | 5.95e-03 | 5.48e-01 |
| CONVERGENT EXTENSION | 15 | 3.05e-01 | 7.18e-01 | 0.3970 | -2.02e-02 | 6.47e-02 | 1.74e-01 | 1.51e-01 | 3.16e-01 | 8.92e-01 | 6.64e-01 | 2.43e-01 | 3.10e-01 | 3.43e-02 |
| SUCCINATE TRANSMEMBRANE TRANSPORT | 6 | 8.02e-01 | 9.67e-01 | 0.3970 | -1.35e-04 | 9.81e-02 | 2.61e-01 | 1.52e-01 | 2.38e-01 | 1.00e+00 | 6.77e-01 | 2.69e-01 | 5.18e-01 | 3.14e-01 |
| PROTEIN LOCALIZATION TO CELL CORTEX | 11 | 7.81e-01 | 9.60e-01 | 0.3970 | 1.94e-01 | 1.21e-01 | 1.62e-01 | 2.36e-01 | 1.51e-01 | 2.64e-01 | 4.87e-01 | 3.52e-01 | 1.75e-01 | 3.87e-01 |
| BEHAVIORAL RESPONSE TO ETHANOL | 10 | 5.20e-01 | 8.57e-01 | 0.3970 | -2.37e-01 | -1.33e-01 | -8.59e-02 | -2.58e-01 | -9.79e-02 | 1.95e-01 | 4.66e-01 | 6.38e-01 | 1.58e-01 | 5.92e-01 |
| DNA REPAIR | 565 | 2.20e-18 | 4.15e-16 | 0.3960 | 1.72e-01 | 1.50e-01 | 1.82e-01 | 2.29e-01 | 1.40e-01 | 2.61e-12 | 1.00e-09 | 1.42e-13 | 1.42e-20 | 1.17e-08 |
| MEMBRANE RAFT LOCALIZATION | 8 | 5.36e-01 | 8.66e-01 | 0.3960 | -2.98e-01 | -2.15e-01 | -8.73e-02 | -9.77e-02 | -7.12e-02 | 1.45e-01 | 2.92e-01 | 6.69e-01 | 6.32e-01 | 7.27e-01 |
| NEUTROPHIL CLEARANCE | 6 | 6.36e-01 | 9.13e-01 | 0.3960 | 2.78e-01 | 1.41e-01 | -2.98e-02 | 7.78e-02 | -2.30e-01 | 2.39e-01 | 5.50e-01 | 8.99e-01 | 7.41e-01 | 3.29e-01 |
| MICROGLIAL CELL PROLIFERATION | 8 | 1.88e-02 | 1.60e-01 | 0.3960 | -1.92e-03 | 2.96e-01 | -9.97e-02 | -1.35e-01 | -2.03e-01 | 9.92e-01 | 1.48e-01 | 6.25e-01 | 5.09e-01 | 3.20e-01 |
| REGULATION OF PROTEIN POLYUBIQUITINATION | 26 | 2.15e-01 | 6.11e-01 | 0.3960 | 2.69e-01 | 1.80e-01 | 1.26e-01 | 1.71e-01 | 8.11e-02 | 1.77e-02 | 1.11e-01 | 2.65e-01 | 1.30e-01 | 4.74e-01 |
| SNRNA 3 END PROCESSING | 20 | 2.75e-01 | 6.84e-01 | 0.3960 | 7.70e-02 | 1.87e-01 | 2.00e-01 | 8.70e-02 | 2.61e-01 | 5.51e-01 | 1.48e-01 | 1.21e-01 | 5.01e-01 | 4.32e-02 |
| REGULATION OF KIDNEY SIZE | 5 | 6.92e-01 | 9.31e-01 | 0.3960 | -3.19e-02 | -9.50e-02 | 1.61e-01 | 1.49e-01 | 3.14e-01 | 9.02e-01 | 7.13e-01 | 5.33e-01 | 5.64e-01 | 2.24e-01 |
| POSITIVE REGULATION OF DENDRITIC CELL CYTOKINE PRODUCTION | 13 | 3.86e-02 | 2.54e-01 | 0.3960 | 2.87e-01 | 1.30e-01 | -1.33e-01 | 8.34e-03 | -1.99e-01 | 7.32e-02 | 4.18e-01 | 4.07e-01 | 9.58e-01 | 2.13e-01 |
| NEGATIVE REGULATION OF T CELL APOPTOTIC PROCESS | 24 | 1.04e-02 | 1.04e-01 | 0.3960 | -1.09e-01 | -1.21e-01 | 3.62e-02 | 5.85e-02 | 3.54e-01 | 3.54e-01 | 3.05e-01 | 7.59e-01 | 6.20e-01 | 2.68e-03 |
| POSITIVE REGULATION OF STEM CELL POPULATION MAINTENANCE | 46 | 5.44e-02 | 3.08e-01 | 0.3950 | 1.11e-01 | 1.27e-01 | 1.68e-01 | 1.88e-01 | 2.53e-01 | 1.91e-01 | 1.35e-01 | 4.87e-02 | 2.73e-02 | 2.96e-03 |
| REGULATION OF ALTERNATIVE MRNA SPLICING VIA SPLICEOSOME | 50 | 2.32e-01 | 6.36e-01 | 0.3950 | 1.94e-01 | 1.82e-01 | 1.95e-01 | 1.87e-01 | 1.11e-01 | 1.75e-02 | 2.57e-02 | 1.68e-02 | 2.24e-02 | 1.74e-01 |
| ESTABLISHMENT OF CENTROSOME LOCALIZATION | 10 | 6.94e-01 | 9.31e-01 | 0.3950 | -1.19e-01 | -1.85e-01 | -1.49e-01 | -1.50e-01 | -2.52e-01 | 5.15e-01 | 3.11e-01 | 4.16e-01 | 4.12e-01 | 1.68e-01 |
| REGULATION OF T CELL RECEPTOR SIGNALING PATHWAY | 43 | 7.27e-02 | 3.65e-01 | 0.3950 | 1.15e-01 | 1.46e-01 | 2.20e-01 | 2.40e-01 | 1.26e-01 | 1.91e-01 | 9.67e-02 | 1.27e-02 | 6.47e-03 | 1.54e-01 |
| REGULATION OF CORTISOL BIOSYNTHETIC PROCESS | 7 | 9.17e-01 | 9.86e-01 | 0.3950 | 1.72e-01 | 1.40e-01 | 2.31e-01 | 2.08e-01 | 1.01e-01 | 4.29e-01 | 5.22e-01 | 2.91e-01 | 3.40e-01 | 6.44e-01 |
| REGULATION OF DOSAGE COMPENSATION BY INACTIVATION OF X CHROMOSOME | 9 | 5.80e-01 | 8.87e-01 | 0.3950 | 2.01e-01 | 1.84e-01 | 8.64e-02 | 1.80e-01 | -2.05e-01 | 2.96e-01 | 3.40e-01 | 6.54e-01 | 3.50e-01 | 2.87e-01 |
| ATRIOVENTRICULAR VALVE DEVELOPMENT | 29 | 1.76e-01 | 5.60e-01 | 0.3950 | 5.49e-02 | 1.50e-01 | 2.29e-01 | 1.89e-01 | 2.06e-01 | 6.09e-01 | 1.63e-01 | 3.29e-02 | 7.88e-02 | 5.46e-02 |
| TUBULIN COMPLEX ASSEMBLY | 8 | 2.67e-01 | 6.74e-01 | 0.3950 | 1.57e-01 | 1.05e-01 | 8.34e-02 | 3.04e-01 | -1.43e-01 | 4.43e-01 | 6.07e-01 | 6.83e-01 | 1.36e-01 | 4.83e-01 |
| SNO S RNA PROCESSING | 12 | 1.62e-01 | 5.37e-01 | 0.3950 | -1.75e-01 | -9.81e-02 | -3.59e-02 | -4.62e-02 | 3.34e-01 | 2.93e-01 | 5.56e-01 | 8.30e-01 | 7.82e-01 | 4.49e-02 |
| REGULATORY NCRNA MEDIATED GENE SILENCING | 609 | 3.02e-17 | 5.29e-15 | 0.3940 | -1.60e-01 | -1.80e-01 | -1.97e-01 | -1.68e-01 | -1.74e-01 | 1.43e-11 | 2.81e-14 | 8.50e-17 | 1.26e-12 | 2.49e-13 |
| POSITIVE REGULATION OF TOOTH MINERALIZATION | 7 | 8.32e-01 | 9.73e-01 | 0.3940 | -2.14e-01 | -1.38e-01 | -1.30e-01 | -2.69e-01 | -4.11e-02 | 3.28e-01 | 5.26e-01 | 5.52e-01 | 2.18e-01 | 8.51e-01 |
| PROTEIN IMPORT | 7 | 9.30e-01 | 9.90e-01 | 0.3940 | 1.73e-01 | 1.86e-01 | 2.27e-01 | 1.92e-01 | 4.95e-02 | 4.28e-01 | 3.93e-01 | 2.98e-01 | 3.80e-01 | 8.21e-01 |
| SPHINGOLIPID MEDIATED SIGNALING PATHWAY | 18 | 6.40e-01 | 9.14e-01 | 0.3940 | 1.28e-01 | 1.93e-01 | 2.37e-01 | 1.59e-01 | 1.41e-01 | 3.46e-01 | 1.56e-01 | 8.12e-02 | 2.44e-01 | 2.99e-01 |
| POSITIVE REGULATION OF VIRAL PROCESS | 62 | 7.58e-02 | 3.72e-01 | 0.3940 | 2.16e-01 | 1.76e-01 | 1.69e-01 | 1.84e-01 | 1.22e-01 | 3.28e-03 | 1.66e-02 | 2.12e-02 | 1.20e-02 | 9.56e-02 |
| AXON MIDLINE CHOICE POINT RECOGNITION | 5 | 9.66e-01 | 9.94e-01 | 0.3940 | -2.33e-01 | -2.14e-01 | -1.71e-01 | -1.51e-01 | -4.99e-02 | 3.66e-01 | 4.06e-01 | 5.07e-01 | 5.59e-01 | 8.47e-01 |
| REGULATION OF CHONDROCYTE DEVELOPMENT | 6 | 8.01e-01 | 9.66e-01 | 0.3940 | 1.27e-02 | 1.83e-01 | 2.33e-01 | 1.41e-01 | 2.18e-01 | 9.57e-01 | 4.39e-01 | 3.24e-01 | 5.50e-01 | 3.55e-01 |
| REGULATION OF RESPIRATORY BURST | 16 | 1.57e-01 | 5.28e-01 | 0.3940 | 2.69e-01 | 1.20e-01 | 9.31e-02 | 1.72e-01 | 1.73e-01 | 6.25e-02 | 4.05e-01 | 5.19e-01 | 2.33e-01 | 2.31e-01 |
| MAINTENANCE OF ANIMAL ORGAN IDENTITY | 5 | 8.32e-01 | 9.73e-01 | 0.3940 | 2.24e-02 | -1.29e-01 | -2.18e-01 | -6.51e-02 | -2.93e-01 | 9.31e-01 | 6.18e-01 | 3.98e-01 | 8.01e-01 | 2.56e-01 |
| DETOXIFICATION OF COPPER ION | 15 | 3.98e-03 | 5.22e-02 | 0.3940 | -9.62e-02 | -1.60e-02 | 2.25e-01 | -1.00e-01 | 2.91e-01 | 5.19e-01 | 9.15e-01 | 1.31e-01 | 5.03e-01 | 5.12e-02 |
| CAVEOLA ASSEMBLY | 5 | 6.14e-01 | 9.06e-01 | 0.3930 | 7.61e-02 | 1.36e-01 | 1.37e-01 | -2.96e-02 | 3.33e-01 | 7.68e-01 | 5.98e-01 | 5.97e-01 | 9.09e-01 | 1.97e-01 |
| REGULATION OF VENTRICULAR CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 22 | 2.67e-01 | 6.75e-01 | 0.3930 | -2.14e-01 | -1.55e-01 | -1.28e-01 | -2.62e-01 | -1.48e-02 | 8.29e-02 | 2.09e-01 | 3.00e-01 | 3.33e-02 | 9.04e-01 |
| INTERLEUKIN 6 MEDIATED SIGNALING PATHWAY | 25 | 3.71e-01 | 7.71e-01 | 0.3930 | -1.02e-01 | -1.11e-01 | -2.33e-01 | -1.94e-01 | -2.01e-01 | 3.80e-01 | 3.37e-01 | 4.39e-02 | 9.35e-02 | 8.24e-02 |
| CHROMOSOME SEGREGATION | 409 | 1.05e-13 | 1.30e-11 | 0.3930 | 1.74e-01 | 1.44e-01 | 1.86e-01 | 2.36e-01 | 1.14e-01 | 1.67e-09 | 5.77e-07 | 9.83e-11 | 2.32e-16 | 7.07e-05 |
| MAMMARY GLAND BRANCHING INVOLVED IN PREGNANCY | 6 | 6.26e-01 | 9.09e-01 | 0.3930 | -1.66e-01 | 9.28e-03 | -1.44e-01 | -2.62e-01 | -1.94e-01 | 4.81e-01 | 9.69e-01 | 5.41e-01 | 2.66e-01 | 4.11e-01 |
| NEGATIVE REGULATION OF VIRAL INDUCED CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 35 | 1.11e-01 | 4.54e-01 | 0.3930 | 1.29e-01 | 1.68e-01 | 1.58e-01 | 1.41e-01 | 2.55e-01 | 1.85e-01 | 8.53e-02 | 1.07e-01 | 1.49e-01 | 9.15e-03 |
| NEGATIVE REGULATION OF MEMBRANE POTENTIAL | 12 | 7.36e-01 | 9.48e-01 | 0.3930 | 1.40e-01 | 2.08e-01 | 1.75e-01 | 1.30e-01 | 2.10e-01 | 4.02e-01 | 2.12e-01 | 2.93e-01 | 4.36e-01 | 2.08e-01 |
| SEGMENTATION | 99 | 1.54e-03 | 2.47e-02 | 0.3930 | 8.41e-02 | 1.43e-01 | 2.19e-01 | 1.72e-01 | 2.22e-01 | 1.48e-01 | 1.36e-02 | 1.63e-04 | 3.19e-03 | 1.35e-04 |
| POSITIVE REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 10 | 4.17e-01 | 7.99e-01 | 0.3930 | 9.50e-02 | 1.63e-02 | 2.46e-01 | 2.28e-01 | 1.81e-01 | 6.03e-01 | 9.29e-01 | 1.78e-01 | 2.12e-01 | 3.22e-01 |
| SKELETAL MUSCLE SATELLITE CELL DIFFERENTIATION | 9 | 6.41e-01 | 9.14e-01 | 0.3930 | -2.08e-01 | -1.12e-01 | -1.18e-01 | -2.79e-01 | -8.09e-02 | 2.80e-01 | 5.60e-01 | 5.41e-01 | 1.47e-01 | 6.74e-01 |
| POSITIVE REGULATION OF MITOTIC SISTER CHROMATID SEPARATION | 18 | 1.09e-01 | 4.51e-01 | 0.3930 | 2.24e-01 | 6.41e-02 | 1.10e-01 | 2.90e-01 | 6.20e-02 | 1.00e-01 | 6.38e-01 | 4.21e-01 | 3.30e-02 | 6.49e-01 |
| WNT SIGNALING PATHWAY INVOLVED IN MIDBRAIN DOPAMINERGIC NEURON DIFFERENTIATION | 12 | 8.24e-01 | 9.71e-01 | 0.3930 | 1.92e-01 | 2.01e-01 | 1.52e-01 | 2.11e-01 | 9.67e-02 | 2.49e-01 | 2.28e-01 | 3.63e-01 | 2.05e-01 | 5.62e-01 |
| NUCLEAR CHROMOSOME SEGREGATION | 307 | 3.79e-10 | 2.94e-08 | 0.3930 | 1.74e-01 | 1.42e-01 | 1.90e-01 | 2.36e-01 | 1.11e-01 | 1.59e-07 | 1.89e-05 | 9.89e-09 | 1.24e-12 | 8.63e-04 |
| POSITIVE REGULATION OF CHROMATIN BINDING | 9 | 5.55e-01 | 8.77e-01 | 0.3930 | 1.26e-01 | 9.23e-03 | 1.74e-01 | 2.41e-01 | 2.23e-01 | 5.11e-01 | 9.62e-01 | 3.66e-01 | 2.11e-01 | 2.47e-01 |
| SYNAPTIC VESICLE TRANSPORT | 40 | 1.40e-01 | 5.04e-01 | 0.3930 | 2.01e-01 | 1.30e-01 | 1.57e-01 | 2.26e-01 | 1.45e-01 | 2.78e-02 | 1.54e-01 | 8.50e-02 | 1.34e-02 | 1.14e-01 |
| CRISTAE FORMATION | 15 | 4.86e-01 | 8.38e-01 | 0.3930 | 1.93e-01 | 8.11e-02 | 1.81e-01 | 2.14e-01 | 1.78e-01 | 1.95e-01 | 5.86e-01 | 2.25e-01 | 1.52e-01 | 2.33e-01 |
| ABSCISSION | 6 | 4.71e-01 | 8.30e-01 | 0.3920 | 1.42e-01 | -4.64e-02 | 8.33e-02 | 1.84e-01 | 3.01e-01 | 5.46e-01 | 8.44e-01 | 7.24e-01 | 4.35e-01 | 2.02e-01 |
| REGULATION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION | 17 | 2.95e-01 | 7.07e-01 | 0.3920 | 2.28e-01 | 1.08e-01 | 1.11e-01 | 2.54e-01 | 1.17e-01 | 1.04e-01 | 4.41e-01 | 4.29e-01 | 6.99e-02 | 4.05e-01 |
| REGULATION OF GLUTAMATE RECEPTOR CLUSTERING | 6 | 7.00e-01 | 9.32e-01 | 0.3920 | 3.02e-01 | 1.16e-01 | 5.36e-02 | 2.15e-01 | -1.57e-02 | 2.01e-01 | 6.21e-01 | 8.20e-01 | 3.62e-01 | 9.47e-01 |
| MESENDODERM DEVELOPMENT | 9 | 4.41e-01 | 8.12e-01 | 0.3920 | -1.03e-03 | 5.83e-02 | 1.38e-01 | 2.05e-01 | 2.98e-01 | 9.96e-01 | 7.62e-01 | 4.73e-01 | 2.86e-01 | 1.22e-01 |
| ETHANOLAMINE CONTAINING COMPOUND METABOLIC PROCESS | 8 | 9.00e-01 | 9.83e-01 | 0.3910 | -1.44e-01 | -1.27e-01 | -1.69e-01 | -2.08e-01 | -2.12e-01 | 4.82e-01 | 5.34e-01 | 4.08e-01 | 3.09e-01 | 3.00e-01 |
| MOTOR BEHAVIOR | 22 | 6.00e-01 | 8.98e-01 | 0.3910 | 1.54e-01 | 1.31e-01 | 1.98e-01 | 2.19e-01 | 1.57e-01 | 2.12e-01 | 2.86e-01 | 1.08e-01 | 7.50e-02 | 2.01e-01 |
| PURINE NUCLEOSIDE BIOSYNTHETIC PROCESS | 10 | 5.73e-01 | 8.84e-01 | 0.3910 | 2.50e-01 | 2.44e-01 | 1.13e-01 | 9.48e-02 | 9.51e-02 | 1.71e-01 | 1.81e-01 | 5.36e-01 | 6.04e-01 | 6.02e-01 |
| NEGATIVE REGULATION OF B CELL RECEPTOR SIGNALING PATHWAY | 8 | 9.16e-01 | 9.86e-01 | 0.3910 | -1.66e-01 | -1.94e-01 | -1.99e-01 | -2.16e-01 | -3.63e-02 | 4.15e-01 | 3.42e-01 | 3.30e-01 | 2.90e-01 | 8.59e-01 |
| SOMITOGENESIS | 64 | 3.42e-03 | 4.63e-02 | 0.3910 | 2.73e-02 | 9.96e-02 | 2.15e-01 | 1.55e-01 | 2.68e-01 | 7.05e-01 | 1.68e-01 | 2.87e-03 | 3.18e-02 | 2.11e-04 |
| RECOMBINATIONAL REPAIR | 169 | 1.03e-05 | 3.85e-04 | 0.3910 | 1.71e-01 | 1.57e-01 | 1.76e-01 | 2.40e-01 | 1.01e-01 | 1.30e-04 | 4.22e-04 | 7.64e-05 | 7.02e-08 | 2.36e-02 |
| CD40 SIGNALING PATHWAY | 15 | 6.95e-01 | 9.31e-01 | 0.3910 | 1.95e-01 | 2.23e-01 | 1.44e-01 | 1.71e-01 | 1.23e-01 | 1.91e-01 | 1.35e-01 | 3.33e-01 | 2.52e-01 | 4.11e-01 |
| ESTABLISHMENT OF PLANAR POLARITY OF EMBRYONIC EPITHELIUM | 16 | 2.71e-01 | 6.79e-01 | 0.3910 | -1.10e-03 | 1.06e-01 | 2.11e-01 | 5.51e-02 | 3.07e-01 | 9.94e-01 | 4.61e-01 | 1.44e-01 | 7.03e-01 | 3.37e-02 |
| LUNG EPITHELIUM DEVELOPMENT | 44 | 2.97e-01 | 7.08e-01 | 0.3910 | 1.62e-01 | 1.71e-01 | 1.89e-01 | 1.82e-01 | 1.68e-01 | 6.27e-02 | 4.95e-02 | 3.00e-02 | 3.64e-02 | 5.41e-02 |
| MESENCHYMAL EPITHELIAL CELL SIGNALING | 7 | 3.72e-01 | 7.71e-01 | 0.3910 | -2.26e-02 | -5.96e-02 | -3.20e-01 | -1.68e-01 | -1.35e-01 | 9.17e-01 | 7.85e-01 | 1.43e-01 | 4.42e-01 | 5.37e-01 |
| ADIPONECTIN ACTIVATED SIGNALING PATHWAY | 7 | 7.16e-01 | 9.37e-01 | 0.3910 | 1.13e-01 | 4.97e-02 | 1.22e-01 | 2.11e-01 | 2.79e-01 | 6.04e-01 | 8.20e-01 | 5.76e-01 | 3.34e-01 | 2.01e-01 |
| METANEPHRIC GLOMERULUS DEVELOPMENT | 16 | 5.16e-01 | 8.56e-01 | 0.3910 | 1.62e-01 | 2.17e-01 | 1.68e-01 | 1.07e-01 | 1.99e-01 | 2.62e-01 | 1.33e-01 | 2.43e-01 | 4.60e-01 | 1.69e-01 |
| CGMP MEDIATED SIGNALING | 30 | 2.56e-01 | 6.63e-01 | 0.3900 | -2.34e-01 | -1.84e-01 | -1.62e-01 | -1.51e-01 | -1.22e-01 | 2.68e-02 | 8.13e-02 | 1.24e-01 | 1.51e-01 | 2.47e-01 |
| HOMOCYSTEINE METABOLIC PROCESS | 13 | 1.68e-02 | 1.48e-01 | 0.3900 | -1.11e-01 | -1.03e-01 | -1.71e-01 | -8.96e-02 | 3.04e-01 | 4.90e-01 | 5.22e-01 | 2.86e-01 | 5.76e-01 | 5.77e-02 |
| FEMALE MEIOSIS I | 13 | 5.11e-01 | 8.54e-01 | 0.3900 | 1.39e-01 | 1.14e-01 | 2.58e-01 | 2.14e-01 | 8.78e-02 | 3.87e-01 | 4.76e-01 | 1.08e-01 | 1.81e-01 | 5.84e-01 |
| AMP METABOLIC PROCESS | 22 | 6.34e-01 | 9.12e-01 | 0.3900 | 2.02e-01 | 1.95e-01 | 1.99e-01 | 1.74e-01 | 6.03e-02 | 1.00e-01 | 1.13e-01 | 1.06e-01 | 1.59e-01 | 6.24e-01 |
| GLOMERULAR EPITHELIAL CELL DIFFERENTIATION | 21 | 2.02e-01 | 5.96e-01 | 0.3900 | -1.99e-01 | -1.70e-01 | -1.73e-01 | -1.98e-01 | 1.20e-01 | 1.14e-01 | 1.77e-01 | 1.69e-01 | 1.16e-01 | 3.42e-01 |
| MITOCHONDRION ENDOPLASMIC RETICULUM MEMBRANE TETHERING | 7 | 2.17e-01 | 6.14e-01 | 0.3900 | 3.26e-01 | 5.09e-02 | -7.60e-02 | 6.41e-02 | -1.83e-01 | 1.35e-01 | 8.16e-01 | 7.28e-01 | 7.69e-01 | 4.01e-01 |
| CELLULAR RESPONSE TO ZINC ION | 23 | 1.21e-02 | 1.17e-01 | 0.3900 | 6.29e-02 | 1.10e-01 | 2.26e-01 | 5.72e-03 | 2.92e-01 | 6.02e-01 | 3.61e-01 | 6.08e-02 | 9.62e-01 | 1.54e-02 |
| NEGATIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL MIGRATION | 21 | 4.95e-01 | 8.44e-01 | 0.3900 | -1.50e-01 | -1.93e-01 | -2.41e-01 | -1.52e-01 | -1.05e-01 | 2.34e-01 | 1.26e-01 | 5.61e-02 | 2.27e-01 | 4.05e-01 |
| CARDIOLIPIN METABOLIC PROCESS | 14 | 2.19e-01 | 6.16e-01 | 0.3900 | 2.32e-01 | 1.37e-01 | 1.54e-01 | 9.85e-02 | 2.15e-01 | 1.34e-01 | 3.74e-01 | 3.20e-01 | 5.23e-01 | 1.64e-01 |
| ENDOSOME TO LYSOSOME TRANSPORT | 70 | 7.10e-02 | 3.61e-01 | 0.3900 | 1.74e-01 | 1.94e-01 | 2.12e-01 | 1.80e-01 | 8.50e-02 | 1.19e-02 | 5.08e-03 | 2.21e-03 | 9.40e-03 | 2.19e-01 |
| RETINOL METABOLIC PROCESS | 50 | 1.75e-01 | 5.60e-01 | 0.3900 | -1.37e-01 | -1.42e-01 | -2.03e-01 | -2.02e-01 | -1.77e-01 | 9.34e-02 | 8.32e-02 | 1.32e-02 | 1.35e-02 | 3.08e-02 |
| B CELL CHEMOTAXIS | 7 | 4.83e-01 | 8.37e-01 | 0.3900 | -4.91e-02 | 1.86e-03 | -2.14e-01 | -2.85e-01 | -1.50e-01 | 8.22e-01 | 9.93e-01 | 3.26e-01 | 1.92e-01 | 4.92e-01 |
| LEFT RIGHT AXIS SPECIFICATION | 13 | 5.73e-01 | 8.84e-01 | 0.3890 | 1.70e-01 | 1.05e-01 | 1.44e-01 | 2.57e-01 | 1.57e-01 | 2.88e-01 | 5.13e-01 | 3.68e-01 | 1.08e-01 | 3.26e-01 |
| REGULATION OF STRESS GRANULE ASSEMBLY | 8 | 5.54e-01 | 8.76e-01 | 0.3890 | 1.88e-01 | 1.74e-01 | 7.52e-02 | 1.71e-01 | 2.26e-01 | 3.57e-01 | 3.95e-01 | 7.13e-01 | 4.02e-01 | 2.68e-01 |
| NEGATIVE REGULATION OF MEMBRANE PERMEABILITY | 20 | 6.16e-01 | 9.06e-01 | 0.3890 | 1.56e-01 | 1.48e-01 | 1.68e-01 | 1.89e-01 | 2.03e-01 | 2.27e-01 | 2.51e-01 | 1.93e-01 | 1.44e-01 | 1.15e-01 |
| CONVERGENT EXTENSION INVOLVED IN GASTRULATION | 9 | 7.67e-01 | 9.55e-01 | 0.3890 | 3.45e-02 | 1.52e-01 | 2.17e-01 | 1.22e-01 | 2.56e-01 | 8.58e-01 | 4.31e-01 | 2.59e-01 | 5.26e-01 | 1.84e-01 |
| REGULATION OF DENDRITE EXTENSION | 26 | 5.54e-01 | 8.76e-01 | 0.3890 | -1.74e-01 | -1.76e-01 | -2.14e-01 | -1.97e-01 | -7.78e-02 | 1.24e-01 | 1.21e-01 | 5.93e-02 | 8.27e-02 | 4.92e-01 |
| MESONEPHROS DEVELOPMENT | 99 | 9.98e-03 | 1.01e-01 | 0.3890 | 1.27e-01 | 1.49e-01 | 2.05e-01 | 1.86e-01 | 1.91e-01 | 2.93e-02 | 1.05e-02 | 4.13e-04 | 1.35e-03 | 1.04e-03 |
| SOMITE DEVELOPMENT | 82 | 1.97e-04 | 4.65e-03 | 0.3890 | 1.67e-02 | 8.24e-02 | 2.09e-01 | 1.62e-01 | 2.73e-01 | 7.94e-01 | 1.97e-01 | 1.07e-03 | 1.14e-02 | 1.89e-05 |
| NEURAL PLATE DEVELOPMENT | 8 | 3.37e-01 | 7.43e-01 | 0.3890 | -1.55e-01 | -2.04e-01 | 2.09e-02 | 7.47e-02 | 2.82e-01 | 4.49e-01 | 3.17e-01 | 9.18e-01 | 7.14e-01 | 1.67e-01 |
| POST ANAL TAIL MORPHOGENESIS | 18 | 7.31e-02 | 3.66e-01 | 0.3890 | 8.88e-03 | 9.92e-02 | 1.46e-01 | 2.19e-01 | 2.69e-01 | 9.48e-01 | 4.66e-01 | 2.83e-01 | 1.08e-01 | 4.82e-02 |
| TRANSCRIPTION COUPLED NUCLEOTIDE EXCISION REPAIR | 10 | 6.69e-01 | 9.25e-01 | 0.3890 | 1.28e-01 | 5.10e-02 | 1.61e-01 | 2.08e-01 | 2.51e-01 | 4.84e-01 | 7.80e-01 | 3.79e-01 | 2.54e-01 | 1.69e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF ENDOGENOUS ANTIGEN | 32 | 6.94e-03 | 7.84e-02 | 0.3890 | 1.90e-02 | 2.98e-02 | 2.16e-01 | 2.51e-01 | 2.01e-01 | 8.52e-01 | 7.70e-01 | 3.47e-02 | 1.40e-02 | 4.89e-02 |
| PURINE NUCLEOSIDE CATABOLIC PROCESS | 8 | 8.46e-01 | 9.76e-01 | 0.3890 | 2.62e-01 | 1.83e-01 | 1.02e-01 | 1.91e-01 | -4.20e-02 | 1.99e-01 | 3.70e-01 | 6.16e-01 | 3.49e-01 | 8.37e-01 |
| PROTEIN DNA COMPLEX DISASSEMBLY | 21 | 5.23e-02 | 3.02e-01 | 0.3890 | 9.72e-02 | 7.07e-02 | 2.54e-01 | 9.66e-02 | 2.51e-01 | 4.40e-01 | 5.75e-01 | 4.41e-02 | 4.43e-01 | 4.65e-02 |
| PEPTIDYL LYSINE OXIDATION | 5 | 4.77e-01 | 8.33e-01 | 0.3890 | 6.48e-02 | 3.38e-01 | 1.79e-01 | 1.44e-02 | 2.34e-02 | 8.02e-01 | 1.91e-01 | 4.88e-01 | 9.56e-01 | 9.28e-01 |
| NEGATIVE REGULATION OF RNA BIOSYNTHETIC PROCESS | 1217 | 1.46e-36 | 1.10e-33 | 0.3880 | 1.39e-01 | 1.47e-01 | 1.92e-01 | 2.03e-01 | 1.79e-01 | 3.19e-16 | 5.68e-18 | 1.72e-29 | 8.31e-33 | 5.02e-26 |
| PHARYNGEAL SYSTEM DEVELOPMENT | 30 | 1.54e-01 | 5.25e-01 | 0.3880 | 6.01e-02 | 1.33e-01 | 2.25e-01 | 2.09e-01 | 1.88e-01 | 5.69e-01 | 2.06e-01 | 3.32e-02 | 4.72e-02 | 7.54e-02 |
| CELLULAR RESPONSE TO ETHANOL | 11 | 8.73e-01 | 9.78e-01 | 0.3880 | -2.15e-01 | -2.10e-01 | -1.46e-01 | -1.94e-01 | -3.50e-02 | 2.17e-01 | 2.27e-01 | 4.00e-01 | 2.66e-01 | 8.41e-01 |
| DOUBLE STRAND BREAK REPAIR | 294 | 1.37e-09 | 9.85e-08 | 0.3880 | 1.72e-01 | 1.48e-01 | 1.71e-01 | 2.30e-01 | 1.29e-01 | 3.70e-07 | 1.18e-05 | 4.65e-07 | 1.05e-11 | 1.36e-04 |
| POSITIVE REGULATION OF T CELL DIFFERENTIATION IN THYMUS | 10 | 5.22e-01 | 8.58e-01 | 0.3880 | -2.66e-02 | 2.71e-02 | 2.24e-01 | 1.65e-01 | 2.68e-01 | 8.84e-01 | 8.82e-01 | 2.19e-01 | 3.67e-01 | 1.42e-01 |
| REGULATION OF CHROMOSOME ORGANIZATION | 239 | 2.63e-10 | 2.06e-08 | 0.3880 | 1.51e-01 | 1.23e-01 | 1.69e-01 | 2.46e-01 | 1.54e-01 | 6.07e-05 | 1.03e-03 | 6.53e-06 | 5.46e-11 | 4.29e-05 |
| REGULATION OF SODIUM DEPENDENT PHOSPHATE TRANSPORT | 5 | 8.75e-01 | 9.78e-01 | 0.3880 | 1.48e-01 | 2.06e-01 | 1.96e-01 | 6.27e-02 | 2.10e-01 | 5.65e-01 | 4.25e-01 | 4.49e-01 | 8.08e-01 | 4.17e-01 |
| REGULATION OF PRESYNAPSE ORGANIZATION | 28 | 4.40e-02 | 2.72e-01 | 0.3880 | 2.48e-02 | 9.65e-02 | 2.25e-01 | 5.89e-02 | 2.94e-01 | 8.20e-01 | 3.77e-01 | 3.92e-02 | 5.89e-01 | 7.06e-03 |
| TRNA SURVEILLANCE | 8 | 3.68e-01 | 7.69e-01 | 0.3880 | -1.58e-01 | -5.45e-02 | -3.87e-02 | -1.15e-01 | 3.28e-01 | 4.39e-01 | 7.89e-01 | 8.50e-01 | 5.74e-01 | 1.08e-01 |
| POSITIVE REGULATION OF ISOTYPE SWITCHING | 28 | 4.55e-01 | 8.22e-01 | 0.3880 | 1.67e-01 | 1.83e-01 | 1.75e-01 | 2.23e-01 | 9.26e-02 | 1.27e-01 | 9.34e-02 | 1.09e-01 | 4.09e-02 | 3.96e-01 |
| INTRACELLULAR TRANSPORT OF VIRUS | 10 | 5.63e-01 | 8.79e-01 | 0.3880 | 2.28e-01 | 1.28e-01 | 9.32e-02 | 1.97e-01 | 1.85e-01 | 2.12e-01 | 4.82e-01 | 6.10e-01 | 2.80e-01 | 3.11e-01 |
| POSITIVE REGULATION OF BLOOD PRESSURE | 32 | 1.70e-02 | 1.50e-01 | 0.3880 | 2.49e-01 | 1.98e-01 | 1.96e-01 | 9.81e-02 | 3.09e-02 | 1.48e-02 | 5.27e-02 | 5.45e-02 | 3.37e-01 | 7.62e-01 |
| POSITIVE REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 7 | 2.48e-01 | 6.54e-01 | 0.3880 | 3.83e-02 | -5.15e-02 | 1.32e-01 | 3.21e-01 | 1.61e-01 | 8.61e-01 | 8.13e-01 | 5.46e-01 | 1.42e-01 | 4.61e-01 |
| POSITIVE REGULATION OF CELL MIGRATION BY VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 8 | 4.00e-01 | 7.88e-01 | 0.3870 | 3.95e-02 | -1.57e-02 | 2.60e-01 | 1.53e-01 | 2.40e-01 | 8.47e-01 | 9.39e-01 | 2.03e-01 | 4.55e-01 | 2.41e-01 |
| OVULATION CYCLE PROCESS | 50 | 5.90e-02 | 3.21e-01 | 0.3870 | -1.04e-01 | -1.57e-01 | -2.16e-01 | -2.21e-01 | -1.39e-01 | 2.03e-01 | 5.48e-02 | 8.28e-03 | 6.93e-03 | 8.94e-02 |
| CITRATE TRANSPORT | 5 | 3.88e-01 | 7.81e-01 | 0.3870 | -1.28e-01 | -3.13e-01 | 1.76e-02 | 5.38e-02 | 1.81e-01 | 6.20e-01 | 2.26e-01 | 9.46e-01 | 8.35e-01 | 4.84e-01 |
| INOSINE METABOLIC PROCESS | 5 | 9.29e-01 | 9.90e-01 | 0.3870 | 2.10e-01 | 2.67e-01 | 1.48e-01 | 1.14e-01 | -1.56e-03 | 4.16e-01 | 3.02e-01 | 5.68e-01 | 6.60e-01 | 9.95e-01 |
| POSITIVE REGULATION OF ANTIGEN PROCESSING AND PRESENTATION | 9 | 9.47e-03 | 9.79e-02 | 0.3870 | 2.50e-01 | 2.30e-01 | -8.13e-02 | -1.66e-01 | 7.70e-03 | 1.93e-01 | 2.33e-01 | 6.73e-01 | 3.88e-01 | 9.68e-01 |
| DNA TEMPLATED TRANSCRIPTION ELONGATION | 132 | 9.04e-04 | 1.62e-02 | 0.3870 | 1.71e-01 | 1.42e-01 | 1.77e-01 | 1.97e-01 | 1.74e-01 | 6.98e-04 | 4.89e-03 | 4.60e-04 | 8.93e-05 | 5.50e-04 |
| PROTEIN TRANSPORT WITHIN LIPID BILAYER | 6 | 8.14e-01 | 9.69e-01 | 0.3870 | 2.50e-01 | 1.95e-01 | 1.37e-01 | 1.04e-01 | 1.39e-01 | 2.88e-01 | 4.08e-01 | 5.61e-01 | 6.60e-01 | 5.54e-01 |
| INTRACELLULAR ZINC ION HOMEOSTASIS | 36 | 8.32e-02 | 3.90e-01 | 0.3870 | 5.87e-02 | 1.53e-01 | 2.36e-01 | 1.13e-01 | 2.33e-01 | 5.42e-01 | 1.13e-01 | 1.43e-02 | 2.42e-01 | 1.54e-02 |
| REGULATION OF POTASSIUM ION EXPORT ACROSS PLASMA MEMBRANE | 8 | 5.65e-01 | 8.81e-01 | 0.3870 | -3.81e-02 | -8.26e-02 | -2.89e-01 | -1.79e-01 | -1.60e-01 | 8.52e-01 | 6.86e-01 | 1.57e-01 | 3.80e-01 | 4.32e-01 |
| DENDRITIC CELL CYTOKINE PRODUCTION | 19 | 6.75e-04 | 1.27e-02 | 0.3870 | 3.03e-01 | 1.97e-01 | -1.16e-01 | 3.41e-02 | -6.10e-02 | 2.20e-02 | 1.36e-01 | 3.81e-01 | 7.97e-01 | 6.45e-01 |
| GLYCINE BIOSYNTHETIC PROCESS | 7 | 3.90e-01 | 7.82e-01 | 0.3870 | 8.68e-02 | 1.98e-01 | -4.43e-02 | 2.13e-03 | -3.17e-01 | 6.91e-01 | 3.63e-01 | 8.39e-01 | 9.92e-01 | 1.46e-01 |
| NEGATIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROCESS | 1436 | 1.52e-41 | 1.43e-38 | 0.3860 | 1.49e-01 | 1.48e-01 | 1.86e-01 | 2.04e-01 | 1.71e-01 | 3.23e-21 | 4.96e-21 | 3.13e-32 | 2.22e-38 | 2.01e-27 |
| CORTISOL METABOLIC PROCESS | 12 | 3.78e-01 | 7.75e-01 | 0.3860 | 3.70e-02 | 1.53e-01 | 2.89e-01 | 1.36e-01 | 1.50e-01 | 8.24e-01 | 3.58e-01 | 8.35e-02 | 4.15e-01 | 3.68e-01 |
| REGULATION OF DNA TEMPLATED TRANSCRIPTION ELONGATION | 102 | 4.22e-03 | 5.46e-02 | 0.3860 | 1.63e-01 | 1.39e-01 | 1.71e-01 | 1.92e-01 | 1.92e-01 | 4.45e-03 | 1.53e-02 | 2.85e-03 | 7.82e-04 | 7.98e-04 |
| TRNA METABOLIC PROCESS | 190 | 3.03e-05 | 1.03e-03 | 0.3860 | 1.65e-01 | 1.49e-01 | 1.83e-01 | 1.82e-01 | 1.81e-01 | 8.62e-05 | 4.03e-04 | 1.35e-05 | 1.46e-05 | 1.65e-05 |
| ROUNDABOUT SIGNALING PATHWAY | 5 | 8.05e-01 | 9.67e-01 | 0.3860 | 7.52e-02 | -7.38e-02 | -1.91e-01 | -4.99e-02 | -3.14e-01 | 7.71e-01 | 7.75e-01 | 4.60e-01 | 8.47e-01 | 2.23e-01 |
| ORGAN OR TISSUE SPECIFIC IMMUNE RESPONSE | 41 | 1.67e-01 | 5.47e-01 | 0.3860 | 1.21e-01 | 2.06e-01 | 1.90e-01 | 1.59e-01 | 1.74e-01 | 1.79e-01 | 2.22e-02 | 3.50e-02 | 7.90e-02 | 5.38e-02 |
| CHONDROCYTE DEVELOPMENT | 32 | 2.63e-02 | 1.99e-01 | 0.3860 | 3.44e-02 | 1.93e-01 | 2.00e-01 | 1.75e-01 | 1.99e-01 | 7.37e-01 | 5.84e-02 | 4.99e-02 | 8.62e-02 | 5.16e-02 |
| GANGLIOSIDE CATABOLIC PROCESS | 7 | 9.18e-01 | 9.86e-01 | 0.3860 | 2.36e-01 | 2.16e-01 | 1.63e-01 | 1.40e-01 | 2.12e-02 | 2.80e-01 | 3.21e-01 | 4.56e-01 | 5.23e-01 | 9.23e-01 |
| NEGATIVE REGULATION OF TRANSLATIONAL ELONGATION | 5 | 6.48e-01 | 9.17e-01 | 0.3860 | -1.12e-01 | -2.23e-01 | -1.66e-01 | -1.15e-01 | 2.14e-01 | 6.64e-01 | 3.87e-01 | 5.21e-01 | 6.57e-01 | 4.07e-01 |
| REGULATION OF POSTSYNAPTIC DENSITY ASSEMBLY | 11 | 6.27e-01 | 9.09e-01 | 0.3860 | -2.72e-01 | -1.91e-01 | -6.80e-02 | -1.60e-01 | 9.22e-02 | 1.19e-01 | 2.73e-01 | 6.96e-01 | 3.60e-01 | 5.97e-01 |
| PROTEIN GERANYLGERANYLATION | 6 | 2.87e-01 | 6.96e-01 | 0.3860 | -2.07e-01 | -1.30e-01 | -9.34e-03 | 1.05e-01 | 2.79e-01 | 3.79e-01 | 5.82e-01 | 9.68e-01 | 6.57e-01 | 2.36e-01 |
| TELOMERE MAINTENANCE | 149 | 4.55e-05 | 1.42e-03 | 0.3860 | 1.49e-01 | 1.36e-01 | 1.85e-01 | 2.37e-01 | 1.33e-01 | 1.63e-03 | 4.14e-03 | 9.96e-05 | 6.08e-07 | 4.93e-03 |
| RADIAL GLIAL CELL DIFFERENTIATION | 14 | 5.57e-01 | 8.77e-01 | 0.3860 | 6.57e-02 | 5.57e-02 | 1.90e-01 | 1.97e-01 | 2.58e-01 | 6.70e-01 | 7.18e-01 | 2.18e-01 | 2.02e-01 | 9.52e-02 |
| EMBRYONIC EYE MORPHOGENESIS | 35 | 3.10e-01 | 7.21e-01 | 0.3850 | 1.08e-01 | 1.32e-01 | 2.01e-01 | 1.82e-01 | 2.15e-01 | 2.69e-01 | 1.78e-01 | 3.98e-02 | 6.30e-02 | 2.76e-02 |
| MRNA TRANSCRIPTION | 47 | 7.35e-02 | 3.66e-01 | 0.3850 | 2.02e-01 | 1.79e-01 | 1.35e-01 | 2.33e-01 | 5.68e-02 | 1.67e-02 | 3.33e-02 | 1.10e-01 | 5.73e-03 | 5.01e-01 |
| RETINOIC ACID METABOLIC PROCESS | 33 | 1.48e-01 | 5.16e-01 | 0.3850 | -8.13e-02 | -1.30e-01 | -2.15e-01 | -2.24e-01 | -1.69e-01 | 4.19e-01 | 1.97e-01 | 3.29e-02 | 2.57e-02 | 9.29e-02 |
| NEGATIVE REGULATION OF AMINE TRANSPORT | 28 | 9.43e-02 | 4.16e-01 | 0.3850 | 1.86e-01 | 1.51e-01 | 1.77e-01 | 1.02e-01 | 2.23e-01 | 8.92e-02 | 1.67e-01 | 1.05e-01 | 3.51e-01 | 4.13e-02 |
| NCRNA CATABOLIC PROCESS | 54 | 1.54e-01 | 5.25e-01 | 0.3850 | 1.76e-01 | 1.41e-01 | 1.84e-01 | 2.05e-01 | 1.46e-01 | 2.50e-02 | 7.23e-02 | 1.96e-02 | 9.00e-03 | 6.32e-02 |
| REGULATION OF MONOATOMIC ANION TRANSMEMBRANE TRANSPORT | 8 | 3.29e-01 | 7.37e-01 | 0.3850 | -8.26e-02 | -2.83e-01 | -1.93e-01 | -1.03e-01 | 1.16e-01 | 6.86e-01 | 1.65e-01 | 3.45e-01 | 6.14e-01 | 5.71e-01 |
| NEGATIVE REGULATION OF PROGRAMMED NECROTIC CELL DEATH | 21 | 1.09e-01 | 4.51e-01 | 0.3850 | 2.12e-01 | 1.43e-01 | 9.85e-02 | 1.37e-01 | 2.33e-01 | 9.21e-02 | 2.57e-01 | 4.34e-01 | 2.78e-01 | 6.42e-02 |
| NEGATIVE REGULATION OF TRIGLYCERIDE METABOLIC PROCESS | 15 | 1.31e-01 | 4.90e-01 | 0.3850 | 3.43e-03 | 6.89e-03 | -2.03e-01 | -4.38e-02 | -3.24e-01 | 9.82e-01 | 9.63e-01 | 1.73e-01 | 7.69e-01 | 2.99e-02 |
| SCHWANN CELL MIGRATION | 5 | 8.20e-01 | 9.71e-01 | 0.3850 | 2.90e-01 | 1.59e-01 | 2.50e-02 | 1.77e-01 | -7.96e-02 | 2.61e-01 | 5.37e-01 | 9.23e-01 | 4.92e-01 | 7.58e-01 |
| POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 16 | 5.15e-01 | 8.56e-01 | 0.3840 | 2.52e-01 | 1.39e-01 | 1.56e-01 | 2.01e-01 | 6.90e-03 | 8.04e-02 | 3.37e-01 | 2.79e-01 | 1.64e-01 | 9.62e-01 |
| RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 31 | 1.96e-01 | 5.84e-01 | 0.3840 | 2.49e-01 | 2.12e-01 | 1.48e-01 | 1.35e-01 | -6.02e-03 | 1.62e-02 | 4.09e-02 | 1.53e-01 | 1.92e-01 | 9.54e-01 |
| REGULATION OF CALCIUM ION TRANSPORT INTO CYTOSOL | 18 | 3.45e-01 | 7.50e-01 | 0.3840 | 1.64e-01 | 2.53e-01 | 1.65e-01 | 8.61e-02 | 1.50e-01 | 2.30e-01 | 6.36e-02 | 2.25e-01 | 5.27e-01 | 2.72e-01 |
| MACROPINOCYTOSIS | 10 | 3.52e-01 | 7.53e-01 | 0.3840 | 2.06e-01 | 2.72e-01 | 1.59e-01 | 1.70e-02 | 7.32e-02 | 2.59e-01 | 1.36e-01 | 3.85e-01 | 9.26e-01 | 6.88e-01 |
| RESPONSE TO COPPER ION | 35 | 2.93e-02 | 2.14e-01 | 0.3840 | 9.28e-02 | 1.71e-01 | 2.35e-01 | 6.91e-02 | 2.23e-01 | 3.42e-01 | 8.01e-02 | 1.62e-02 | 4.79e-01 | 2.26e-02 |
| NEGATIVE REGULATION OF ANTIGEN PROCESSING AND PRESENTATION | 9 | 3.74e-01 | 7.73e-01 | 0.3840 | -1.86e-01 | -1.37e-01 | -2.58e-01 | -9.39e-02 | -1.36e-01 | 3.34e-01 | 4.76e-01 | 1.80e-01 | 6.26e-01 | 4.81e-01 |
| RESPONSE TO VITAMIN A | 15 | 4.84e-01 | 8.38e-01 | 0.3840 | 1.74e-02 | 5.67e-02 | 1.92e-01 | 1.53e-01 | 2.89e-01 | 9.07e-01 | 7.04e-01 | 1.99e-01 | 3.04e-01 | 5.28e-02 |
| REGULATION OF MELANOCYTE DIFFERENTIATION | 6 | 9.39e-01 | 9.92e-01 | 0.3840 | -1.52e-01 | -1.27e-01 | -2.33e-01 | -1.86e-01 | -1.38e-01 | 5.19e-01 | 5.90e-01 | 3.24e-01 | 4.30e-01 | 5.57e-01 |
| CHONDROITIN SULFATE BIOSYNTHETIC PROCESS | 18 | 5.18e-01 | 8.57e-01 | 0.3840 | 2.33e-01 | 2.00e-01 | 1.07e-01 | 1.94e-01 | 6.14e-02 | 8.75e-02 | 1.41e-01 | 4.32e-01 | 1.54e-01 | 6.52e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS EXONUCLEOLYTIC | 20 | 1.94e-01 | 5.80e-01 | 0.3840 | 3.04e-02 | 5.52e-02 | 1.32e-01 | 1.36e-01 | 3.28e-01 | 8.14e-01 | 6.69e-01 | 3.07e-01 | 2.93e-01 | 1.12e-02 |
| GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 6 | 6.50e-01 | 9.18e-01 | 0.3830 | 6.51e-02 | 1.22e-01 | 8.28e-02 | 1.13e-01 | 3.29e-01 | 7.82e-01 | 6.06e-01 | 7.25e-01 | 6.33e-01 | 1.62e-01 |
| MACROPHAGE FUSION | 6 | 3.46e-01 | 7.50e-01 | 0.3830 | 2.09e-01 | 8.60e-02 | -2.16e-01 | -2.61e-02 | -2.20e-01 | 3.75e-01 | 7.15e-01 | 3.60e-01 | 9.12e-01 | 3.50e-01 |
| GOLGI RIBBON FORMATION | 10 | 4.18e-01 | 8.00e-01 | 0.3830 | 1.82e-01 | 1.38e-01 | 8.53e-02 | 2.72e-01 | 1.17e-01 | 3.20e-01 | 4.51e-01 | 6.40e-01 | 1.36e-01 | 5.22e-01 |
| ZYMOGEN INHIBITION | 7 | 8.16e-01 | 9.70e-01 | 0.3830 | 2.53e-01 | 2.14e-01 | 7.97e-02 | 1.21e-01 | -1.26e-01 | 2.46e-01 | 3.27e-01 | 7.15e-01 | 5.79e-01 | 5.63e-01 |
| MRNA METABOLIC PROCESS | 743 | 4.70e-24 | 1.49e-21 | 0.3830 | 1.61e-01 | 1.28e-01 | 1.85e-01 | 2.22e-01 | 1.43e-01 | 6.67e-14 | 2.48e-09 | 7.56e-18 | 4.71e-25 | 3.30e-11 |
| FIBROBLAST APOPTOTIC PROCESS | 25 | 1.19e-01 | 4.72e-01 | 0.3830 | 2.87e-02 | 3.38e-02 | 2.05e-01 | 2.03e-01 | 2.48e-01 | 8.04e-01 | 7.70e-01 | 7.56e-02 | 7.91e-02 | 3.19e-02 |
| DETECTION OF CALCIUM ION | 13 | 6.79e-01 | 9.28e-01 | 0.3830 | -2.23e-01 | -2.20e-01 | -1.62e-01 | -1.14e-01 | -9.46e-02 | 1.63e-01 | 1.69e-01 | 3.11e-01 | 4.77e-01 | 5.55e-01 |
| CELL MIGRATION INVOLVED IN HEART DEVELOPMENT | 21 | 2.42e-02 | 1.89e-01 | 0.3830 | -1.04e-01 | 1.10e-01 | 1.98e-01 | 6.50e-03 | 2.91e-01 | 4.10e-01 | 3.82e-01 | 1.16e-01 | 9.59e-01 | 2.12e-02 |
| RRNA 3 END PROCESSING | 10 | 1.16e-01 | 4.63e-01 | 0.3830 | -8.86e-02 | -1.28e-02 | 1.56e-02 | -1.83e-01 | 3.23e-01 | 6.28e-01 | 9.44e-01 | 9.32e-01 | 3.15e-01 | 7.65e-02 |
| FOREBRAIN MORPHOGENESIS | 13 | 5.12e-01 | 8.54e-01 | 0.3830 | 4.37e-02 | 1.31e-01 | 1.77e-01 | 1.96e-01 | 2.41e-01 | 7.85e-01 | 4.15e-01 | 2.70e-01 | 2.22e-01 | 1.33e-01 |
| CARDIAC NEURAL CREST CELL MIGRATION INVOLVED IN OUTFLOW TRACT MORPHOGENESIS | 11 | 3.82e-01 | 7.78e-01 | 0.3830 | -3.13e-02 | 1.69e-01 | 2.21e-01 | 7.91e-02 | 2.49e-01 | 8.57e-01 | 3.32e-01 | 2.05e-01 | 6.49e-01 | 1.53e-01 |
| VESICLE TETHERING TO GOLGI | 5 | 2.55e-01 | 6.62e-01 | 0.3830 | 5.11e-02 | -1.87e-01 | -9.33e-02 | 9.91e-02 | 3.00e-01 | 8.43e-01 | 4.69e-01 | 7.18e-01 | 7.01e-01 | 2.45e-01 |
| REGULATION OF HYALURONAN BIOSYNTHETIC PROCESS | 8 | 7.29e-01 | 9.44e-01 | 0.3830 | 1.65e-01 | 2.57e-01 | 1.54e-01 | 1.43e-01 | -9.52e-02 | 4.18e-01 | 2.09e-01 | 4.52e-01 | 4.84e-01 | 6.41e-01 |
| PROTEIN DNA COMPLEX ORGANIZATION | 796 | 3.82e-24 | 1.31e-21 | 0.3830 | 1.66e-01 | 1.45e-01 | 1.74e-01 | 2.18e-01 | 1.42e-01 | 1.77e-15 | 3.38e-12 | 6.61e-17 | 1.15e-25 | 1.03e-11 |
| DOSAGE COMPENSATION | 27 | 4.10e-01 | 7.95e-01 | 0.3820 | 2.12e-01 | 2.11e-01 | 1.34e-01 | 1.96e-01 | 1.63e-03 | 5.61e-02 | 5.79e-02 | 2.27e-01 | 7.79e-02 | 9.88e-01 |
| ALTERNATIVE MRNA SPLICING VIA SPLICEOSOME | 66 | 1.08e-01 | 4.49e-01 | 0.3820 | 1.73e-01 | 1.49e-01 | 1.94e-01 | 2.01e-01 | 1.26e-01 | 1.51e-02 | 3.59e-02 | 6.39e-03 | 4.72e-03 | 7.78e-02 |
| IMMUNOGLOBULIN PRODUCTION INVOLVED IN IMMUNOGLOBULIN MEDIATED IMMUNE RESPONSE | 56 | 1.41e-01 | 5.07e-01 | 0.3820 | 1.71e-01 | 1.92e-01 | 1.66e-01 | 2.00e-01 | 1.12e-01 | 2.68e-02 | 1.31e-02 | 3.15e-02 | 9.72e-03 | 1.47e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION OF NUCLEOLAR LARGE RRNA BY RNA POLYMERASE I | 10 | 1.33e-01 | 4.93e-01 | 0.3820 | -1.36e-01 | -1.85e-01 | -3.18e-02 | 9.68e-02 | 2.87e-01 | 4.56e-01 | 3.10e-01 | 8.62e-01 | 5.96e-01 | 1.16e-01 |
| CARBOHYDRATE MEDIATED SIGNALING | 11 | 8.39e-01 | 9.73e-01 | 0.3820 | 2.23e-01 | 2.26e-01 | 1.56e-01 | 1.39e-01 | 3.18e-02 | 2.00e-01 | 1.94e-01 | 3.70e-01 | 4.25e-01 | 8.55e-01 |
| SISTER CHROMATID COHESION | 53 | 1.87e-02 | 1.59e-01 | 0.3820 | 2.04e-01 | 1.18e-01 | 1.37e-01 | 2.50e-01 | 9.39e-02 | 1.01e-02 | 1.36e-01 | 8.55e-02 | 1.64e-03 | 2.37e-01 |
| REGULATION OF PHOSPHATE TRANSPORT | 6 | 6.57e-01 | 9.20e-01 | 0.3820 | 1.88e-01 | 2.46e-01 | 1.24e-01 | 2.91e-02 | 1.83e-01 | 4.25e-01 | 2.96e-01 | 5.99e-01 | 9.02e-01 | 4.38e-01 |
| POSITIVE REGULATION OF HETEROTYPIC CELL CELL ADHESION | 14 | 2.13e-01 | 6.08e-01 | 0.3820 | 1.17e-01 | 5.38e-02 | -1.27e-01 | -9.05e-02 | -3.24e-01 | 4.47e-01 | 7.27e-01 | 4.12e-01 | 5.58e-01 | 3.60e-02 |
| NEGATIVE REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 12 | 2.41e-01 | 6.44e-01 | 0.3820 | -1.57e-01 | -2.01e-01 | 1.13e-02 | -2.05e-03 | 2.84e-01 | 3.48e-01 | 2.29e-01 | 9.46e-01 | 9.90e-01 | 8.85e-02 |
| PANCREATIC JUICE SECRETION | 11 | 6.65e-01 | 9.23e-01 | 0.3810 | -1.65e-01 | -2.52e-01 | -1.92e-01 | -1.29e-01 | 3.35e-02 | 3.44e-01 | 1.48e-01 | 2.69e-01 | 4.58e-01 | 8.48e-01 |
| POSITIVE REGULATION OF LONG TERM NEURONAL SYNAPTIC PLASTICITY | 6 | 6.30e-01 | 9.10e-01 | 0.3810 | 7.51e-02 | 1.23e-01 | -1.03e-01 | -1.01e-01 | -3.22e-01 | 7.50e-01 | 6.03e-01 | 6.63e-01 | 6.68e-01 | 1.71e-01 |
| SECRETION OF LYSOSOMAL ENZYMES | 7 | 4.80e-01 | 8.35e-01 | 0.3810 | 1.01e-01 | 1.80e-01 | 2.99e-01 | 1.11e-01 | 2.69e-02 | 6.43e-01 | 4.08e-01 | 1.70e-01 | 6.12e-01 | 9.02e-01 |
| NEURAL NUCLEUS DEVELOPMENT | 61 | 1.23e-01 | 4.78e-01 | 0.3810 | 1.45e-01 | 1.52e-01 | 1.84e-01 | 1.98e-01 | 1.67e-01 | 5.03e-02 | 3.99e-02 | 1.27e-02 | 7.36e-03 | 2.44e-02 |
| PROTEASOMAL PROTEIN CATABOLIC PROCESS | 509 | 6.64e-16 | 9.80e-14 | 0.3810 | 1.58e-01 | 1.52e-01 | 1.71e-01 | 2.20e-01 | 1.39e-01 | 1.15e-09 | 4.00e-09 | 3.53e-11 | 1.63e-17 | 8.33e-08 |
| CELLULAR RESPONSE TO ALDOSTERONE | 7 | 3.14e-01 | 7.26e-01 | 0.3810 | -2.15e-01 | -7.82e-02 | -6.48e-03 | -2.99e-01 | 5.72e-02 | 3.24e-01 | 7.20e-01 | 9.76e-01 | 1.71e-01 | 7.93e-01 |
| CAP DEPENDENT TRANSLATIONAL INITIATION | 7 | 9.05e-01 | 9.84e-01 | 0.3810 | 1.45e-01 | 9.55e-02 | 2.18e-01 | 2.02e-01 | 1.64e-01 | 5.05e-01 | 6.62e-01 | 3.19e-01 | 3.55e-01 | 4.53e-01 |
| POSTREPLICATION REPAIR | 33 | 1.09e-01 | 4.51e-01 | 0.3810 | 1.96e-01 | 8.42e-02 | 1.70e-01 | 2.14e-01 | 1.58e-01 | 5.08e-02 | 4.02e-01 | 9.11e-02 | 3.38e-02 | 1.17e-01 |
| PROTEIN LOCALIZATION TO LYSOSOME | 57 | 1.31e-01 | 4.91e-01 | 0.3810 | 2.00e-01 | 1.85e-01 | 1.53e-01 | 2.07e-01 | 6.72e-02 | 8.94e-03 | 1.57e-02 | 4.57e-02 | 6.88e-03 | 3.80e-01 |
| URINARY BLADDER SMOOTH MUSCLE CONTRACTION | 7 | 6.17e-01 | 9.06e-01 | 0.3810 | -1.43e-01 | -1.35e-01 | -1.83e-01 | -2.40e-01 | 1.23e-01 | 5.14e-01 | 5.36e-01 | 4.02e-01 | 2.71e-01 | 5.73e-01 |
| BLASTOCYST FORMATION | 45 | 2.82e-01 | 6.93e-01 | 0.3810 | 1.66e-01 | 1.65e-01 | 1.71e-01 | 1.87e-01 | 1.60e-01 | 5.33e-02 | 5.56e-02 | 4.66e-02 | 3.01e-02 | 6.29e-02 |
| REGULATION OF FLAGELLATED SPERM MOTILITY | 18 | 1.50e-01 | 5.19e-01 | 0.3810 | -1.55e-01 | -1.19e-01 | -1.87e-01 | -2.54e-01 | 8.30e-02 | 2.54e-01 | 3.81e-01 | 1.69e-01 | 6.21e-02 | 5.42e-01 |
| POSITIVE REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 6 | 4.85e-01 | 8.38e-01 | 0.3800 | 1.51e-01 | 2.72e-01 | 1.68e-01 | -3.33e-02 | 1.38e-01 | 5.23e-01 | 2.49e-01 | 4.77e-01 | 8.88e-01 | 5.59e-01 |
| EMBRYONIC ORGAN DEVELOPMENT | 446 | 1.09e-14 | 1.49e-12 | 0.3800 | 9.43e-02 | 1.47e-01 | 2.08e-01 | 1.69e-01 | 2.05e-01 | 6.40e-04 | 9.69e-08 | 4.59e-14 | 9.15e-10 | 1.03e-13 |
| RNA TEMPLATED DNA BIOSYNTHETIC PROCESS | 68 | 4.27e-03 | 5.50e-02 | 0.3800 | 1.42e-01 | 1.05e-01 | 1.77e-01 | 2.57e-01 | 1.26e-01 | 4.27e-02 | 1.33e-01 | 1.15e-02 | 2.48e-04 | 7.19e-02 |
| NEGATIVE REGULATION OF RESPONSE TO FOOD | 10 | 1.05e-01 | 4.43e-01 | 0.3800 | 2.58e-01 | 1.59e-01 | 1.42e-01 | 1.35e-02 | 1.79e-01 | 1.57e-01 | 3.83e-01 | 4.38e-01 | 9.41e-01 | 3.26e-01 |
| REGULATION OF TYPE I INTERFERON MEDIATED SIGNALING PATHWAY | 43 | 1.55e-01 | 5.26e-01 | 0.3800 | 1.01e-01 | 1.53e-01 | 1.81e-01 | 1.68e-01 | 2.23e-01 | 2.50e-01 | 8.18e-02 | 3.98e-02 | 5.64e-02 | 1.15e-02 |
| RENAL VESICLE FORMATION | 8 | 5.97e-01 | 8.98e-01 | 0.3800 | 1.96e-01 | 3.96e-02 | 1.40e-01 | 1.86e-01 | 2.24e-01 | 3.37e-01 | 8.46e-01 | 4.92e-01 | 3.61e-01 | 2.73e-01 |
| AUTOPHAGY OF MITOCHONDRION | 90 | 5.42e-03 | 6.53e-02 | 0.3800 | 2.23e-01 | 1.57e-01 | 1.36e-01 | 2.13e-01 | 7.49e-02 | 2.59e-04 | 9.84e-03 | 2.54e-02 | 4.66e-04 | 2.19e-01 |
| REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 50 | 2.50e-01 | 6.57e-01 | 0.3800 | 1.78e-01 | 1.69e-01 | 1.94e-01 | 1.71e-01 | 1.30e-01 | 2.98e-02 | 3.87e-02 | 1.75e-02 | 3.63e-02 | 1.11e-01 |
| NEURAL PLATE REGIONALIZATION | 6 | 2.19e-01 | 6.16e-01 | 0.3790 | -2.28e-01 | -6.78e-02 | 1.51e-01 | 1.56e-01 | 2.00e-01 | 3.34e-01 | 7.74e-01 | 5.21e-01 | 5.07e-01 | 3.95e-01 |
| BONE MORPHOGENESIS | 98 | 1.12e-03 | 1.92e-02 | 0.3790 | 7.79e-02 | 1.76e-01 | 2.14e-01 | 1.45e-01 | 2.00e-01 | 1.83e-01 | 2.63e-03 | 2.56e-04 | 1.28e-02 | 6.07e-04 |
| ENDOSOME ORGANIZATION | 93 | 1.18e-02 | 1.14e-01 | 0.3790 | 1.44e-01 | 1.31e-01 | 2.12e-01 | 2.03e-01 | 1.41e-01 | 1.67e-02 | 2.85e-02 | 4.15e-04 | 7.27e-04 | 1.85e-02 |
| REGULATION OF ASTROCYTE ACTIVATION | 8 | 6.50e-01 | 9.18e-01 | 0.3790 | 1.82e-01 | 2.59e-01 | 1.79e-01 | 4.55e-02 | 9.88e-02 | 3.73e-01 | 2.05e-01 | 3.81e-01 | 8.24e-01 | 6.29e-01 |
| PROGESTERONE RECEPTOR SIGNALING PATHWAY | 11 | 6.78e-01 | 9.28e-01 | 0.3790 | -1.84e-01 | -1.05e-01 | -2.11e-01 | -1.65e-01 | -1.65e-01 | 2.91e-01 | 5.47e-01 | 2.26e-01 | 3.42e-01 | 3.44e-01 |
| NEGATIVE REGULATION OF CELL CELL ADHESION MEDIATED BY CADHERIN | 9 | 8.51e-01 | 9.76e-01 | 0.3790 | 1.96e-01 | 1.48e-01 | 1.28e-01 | 2.09e-01 | 1.51e-01 | 3.08e-01 | 4.42e-01 | 5.05e-01 | 2.76e-01 | 4.31e-01 |
| CELLULAR RESPONSE TO DECREASED OXYGEN LEVELS | 146 | 3.56e-04 | 7.67e-03 | 0.3790 | 1.60e-01 | 1.61e-01 | 1.76e-01 | 1.57e-01 | 1.92e-01 | 8.74e-04 | 8.08e-04 | 2.36e-04 | 1.09e-03 | 6.35e-05 |
| RESPONSE TO BLUE LIGHT | 6 | 6.69e-01 | 9.25e-01 | 0.3790 | -8.43e-03 | -1.59e-01 | -1.84e-01 | 6.68e-03 | -2.90e-01 | 9.71e-01 | 5.00e-01 | 4.34e-01 | 9.77e-01 | 2.19e-01 |
| COPII COATED VESICLE BUDDING | 42 | 9.42e-02 | 4.16e-01 | 0.3790 | 1.95e-01 | 1.46e-01 | 2.10e-01 | 1.98e-01 | 3.10e-02 | 2.89e-02 | 1.03e-01 | 1.84e-02 | 2.67e-02 | 7.28e-01 |
| RIG I SIGNALING PATHWAY | 28 | 5.42e-01 | 8.69e-01 | 0.3790 | 1.70e-01 | 1.88e-01 | 2.09e-01 | 1.72e-01 | 7.57e-02 | 1.19e-01 | 8.46e-02 | 5.61e-02 | 1.14e-01 | 4.88e-01 |
| REGULATION OF FEMALE RECEPTIVITY | 7 | 2.07e-01 | 6.01e-01 | 0.3790 | 2.77e-01 | 9.07e-02 | -1.23e-01 | -6.56e-02 | -1.97e-01 | 2.04e-01 | 6.78e-01 | 5.74e-01 | 7.64e-01 | 3.66e-01 |
| REGULATION OF COMPLEMENT ACTIVATION ALTERNATIVE PATHWAY | 5 | 9.88e-02 | 4.28e-01 | 0.3790 | -6.13e-02 | 1.69e-03 | -3.40e-01 | -1.41e-01 | 6.13e-02 | 8.12e-01 | 9.95e-01 | 1.88e-01 | 5.84e-01 | 8.12e-01 |
| EQUILIBRIOCEPTION | 7 | 4.71e-01 | 8.30e-01 | 0.3780 | 7.50e-02 | 8.49e-02 | -2.44e-03 | -4.20e-02 | -3.59e-01 | 7.31e-01 | 6.97e-01 | 9.91e-01 | 8.47e-01 | 1.00e-01 |
| HYDROCARBON METABOLIC PROCESS | 7 | 5.04e-01 | 8.50e-01 | 0.3780 | -1.40e-01 | 4.98e-02 | 1.97e-01 | 1.09e-03 | 2.87e-01 | 5.22e-01 | 8.19e-01 | 3.66e-01 | 9.96e-01 | 1.89e-01 |
| POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 12 | 8.75e-01 | 9.78e-01 | 0.3780 | -1.44e-01 | -1.49e-01 | -2.18e-01 | -1.91e-01 | -1.28e-01 | 3.89e-01 | 3.73e-01 | 1.91e-01 | 2.53e-01 | 4.41e-01 |
| NUCLEOTIDE SUGAR TRANSMEMBRANE TRANSPORT | 11 | 5.76e-01 | 8.84e-01 | 0.3780 | 7.60e-02 | 9.49e-02 | 1.84e-01 | 2.55e-01 | 1.71e-01 | 6.63e-01 | 5.86e-01 | 2.91e-01 | 1.42e-01 | 3.26e-01 |
| CELLULAR RESPONSE TO LEUCINE | 12 | 3.58e-01 | 7.57e-01 | 0.3780 | 2.58e-01 | 9.63e-02 | 6.69e-02 | 2.48e-01 | 3.58e-02 | 1.22e-01 | 5.64e-01 | 6.88e-01 | 1.37e-01 | 8.30e-01 |
| REGULATION OF PHOSPHATIDYLCHOLINE BIOSYNTHETIC PROCESS | 5 | 8.39e-01 | 9.73e-01 | 0.3780 | 2.67e-01 | 2.24e-01 | 5.17e-02 | 1.32e-01 | 3.51e-02 | 3.01e-01 | 3.86e-01 | 8.41e-01 | 6.09e-01 | 8.92e-01 |
| REGULATION OF RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 78 | 1.13e-02 | 1.11e-01 | 0.3780 | 8.40e-02 | 1.43e-01 | 1.95e-01 | 1.46e-01 | 2.37e-01 | 1.99e-01 | 2.93e-02 | 2.86e-03 | 2.59e-02 | 3.02e-04 |
| EMBRYONIC CLEAVAGE | 8 | 7.56e-01 | 9.51e-01 | 0.3780 | 2.20e-01 | 2.48e-01 | 1.03e-01 | 9.69e-02 | -1.12e-01 | 2.80e-01 | 2.24e-01 | 6.13e-01 | 6.35e-01 | 5.83e-01 |
| EMBRYONIC ORGAN MORPHOGENESIS | 292 | 8.31e-11 | 6.95e-09 | 0.3780 | 7.40e-02 | 1.37e-01 | 2.02e-01 | 1.67e-01 | 2.23e-01 | 2.96e-02 | 5.81e-05 | 2.74e-09 | 9.45e-07 | 4.92e-11 |
| CATECHOL CONTAINING COMPOUND CATABOLIC PROCESS | 5 | 8.40e-01 | 9.73e-01 | 0.3780 | -2.38e-01 | -1.06e-01 | -7.86e-02 | -2.48e-01 | -8.46e-02 | 3.57e-01 | 6.80e-01 | 7.61e-01 | 3.37e-01 | 7.43e-01 |
| REGULATION OF TOLL LIKE RECEPTOR 3 SIGNALING PATHWAY | 12 | 4.00e-01 | 7.88e-01 | 0.3780 | 2.61e-01 | 1.41e-01 | 8.97e-02 | 1.51e-01 | 1.53e-01 | 1.17e-01 | 3.97e-01 | 5.91e-01 | 3.64e-01 | 3.58e-01 |
| NEGATIVE REGULATION OF TRANSCRIPTION BY COMPETITIVE PROMOTER BINDING | 12 | 3.72e-01 | 7.71e-01 | 0.3780 | 1.18e-01 | 1.67e-01 | 1.17e-01 | 2.35e-01 | 1.78e-01 | 4.78e-01 | 3.17e-01 | 4.84e-01 | 1.58e-01 | 2.86e-01 |
| SPERM MITOCHONDRIAL SHEATH ASSEMBLY | 6 | 2.72e-01 | 6.81e-01 | 0.3770 | -2.96e-02 | 5.00e-02 | -1.08e-01 | -3.28e-01 | -1.40e-01 | 9.00e-01 | 8.32e-01 | 6.46e-01 | 1.64e-01 | 5.52e-01 |
| SODIUM INDEPENDENT ORGANIC ANION TRANSPORT | 15 | 6.64e-01 | 9.23e-01 | 0.3770 | -8.85e-02 | -8.36e-02 | -1.98e-01 | -1.93e-01 | -2.26e-01 | 5.53e-01 | 5.75e-01 | 1.85e-01 | 1.95e-01 | 1.30e-01 |
| SOMATIC DIVERSIFICATION OF IMMUNE RECEPTORS | 77 | 2.18e-02 | 1.77e-01 | 0.3770 | 1.29e-01 | 1.47e-01 | 1.80e-01 | 2.15e-01 | 1.60e-01 | 5.04e-02 | 2.60e-02 | 6.38e-03 | 1.09e-03 | 1.54e-02 |
| POSITIVE REGULATION OF ACTIN NUCLEATION | 14 | 1.87e-01 | 5.72e-01 | 0.3770 | 2.55e-01 | 1.64e-01 | -4.91e-02 | 1.07e-01 | -1.91e-01 | 9.88e-02 | 2.89e-01 | 7.50e-01 | 4.86e-01 | 2.17e-01 |
| NADPH REGENERATION | 21 | 5.40e-01 | 8.67e-01 | 0.3770 | 2.00e-01 | 1.23e-01 | 1.60e-01 | 1.99e-01 | 1.48e-01 | 1.13e-01 | 3.29e-01 | 2.05e-01 | 1.15e-01 | 2.41e-01 |
| PIGMENT CATABOLIC PROCESS | 11 | 3.88e-01 | 7.81e-01 | 0.3770 | -2.04e-01 | -1.81e-01 | -6.23e-02 | -2.00e-01 | -1.53e-01 | 2.41e-01 | 2.99e-01 | 7.21e-01 | 2.50e-01 | 3.78e-01 |
| T HELPER 2 CELL CYTOKINE PRODUCTION | 13 | 2.45e-01 | 6.50e-01 | 0.3770 | 1.25e-01 | 2.92e-02 | -6.25e-02 | 1.74e-02 | -3.48e-01 | 4.34e-01 | 8.55e-01 | 6.96e-01 | 9.14e-01 | 2.98e-02 |
| CELL REDOX HOMEOSTASIS | 38 | 3.08e-01 | 7.19e-01 | 0.3770 | 1.20e-01 | 1.80e-01 | 1.88e-01 | 1.61e-01 | 1.83e-01 | 2.00e-01 | 5.47e-02 | 4.45e-02 | 8.53e-02 | 5.07e-02 |
| REGULATION OF NEURON DIFFERENTIATION | 192 | 2.55e-05 | 8.81e-04 | 0.3770 | 1.17e-01 | 1.37e-01 | 2.01e-01 | 1.73e-01 | 1.98e-01 | 5.36e-03 | 1.05e-03 | 1.60e-06 | 3.58e-05 | 2.17e-06 |
| NEGATIVE REGULATION OF NITRIC OXIDE METABOLIC PROCESS | 14 | 5.16e-01 | 8.56e-01 | 0.3770 | 1.68e-01 | 6.39e-02 | 1.56e-01 | 1.96e-01 | 2.16e-01 | 2.77e-01 | 6.79e-01 | 3.12e-01 | 2.04e-01 | 1.61e-01 |
| SHORT TERM MEMORY | 10 | 7.17e-01 | 9.37e-01 | 0.3770 | 1.74e-01 | 2.46e-01 | 1.92e-01 | 1.15e-01 | -2.93e-02 | 3.41e-01 | 1.78e-01 | 2.93e-01 | 5.28e-01 | 8.73e-01 |
| NEGATIVE REGULATION OF CHOLESTEROL STORAGE | 11 | 3.69e-01 | 7.69e-01 | 0.3760 | -6.16e-02 | -1.68e-01 | -2.77e-01 | -1.78e-01 | -3.61e-02 | 7.23e-01 | 3.35e-01 | 1.12e-01 | 3.06e-01 | 8.36e-01 |
| RESPONSE TO VITAMIN E | 8 | 8.83e-01 | 9.80e-01 | 0.3760 | 1.95e-01 | 1.95e-01 | 1.29e-01 | 1.56e-01 | 1.56e-01 | 3.40e-01 | 3.39e-01 | 5.29e-01 | 4.44e-01 | 4.44e-01 |
| REGULATION OF RETINAL GANGLION CELL AXON GUIDANCE | 6 | 8.77e-01 | 9.78e-01 | 0.3760 | -4.23e-02 | -9.29e-02 | -1.72e-01 | -1.95e-01 | -2.51e-01 | 8.58e-01 | 6.94e-01 | 4.65e-01 | 4.07e-01 | 2.87e-01 |
| SYNAPTIC VESICLE MATURATION | 23 | 4.10e-01 | 7.95e-01 | 0.3760 | 6.15e-02 | 1.56e-01 | 2.19e-01 | 1.35e-01 | 2.16e-01 | 6.10e-01 | 1.95e-01 | 6.87e-02 | 2.62e-01 | 7.25e-02 |
| NEGATIVE REGULATION OF NEUROTRANSMITTER SECRETION | 6 | 7.83e-01 | 9.61e-01 | 0.3760 | 2.12e-01 | 1.30e-01 | 2.30e-01 | 1.61e-01 | 3.04e-02 | 3.69e-01 | 5.81e-01 | 3.30e-01 | 4.95e-01 | 8.97e-01 |
| NEGATIVE REGULATION OF PROTEIN POLYUBIQUITINATION | 8 | 4.71e-01 | 8.30e-01 | 0.3760 | 6.20e-02 | -3.51e-02 | 1.86e-01 | 1.12e-01 | 2.98e-01 | 7.62e-01 | 8.63e-01 | 3.62e-01 | 5.84e-01 | 1.44e-01 |
| ASYMMETRIC NEUROBLAST DIVISION | 5 | 6.53e-01 | 9.19e-01 | 0.3760 | 1.99e-01 | 6.81e-02 | -1.05e-01 | 1.29e-01 | -2.63e-01 | 4.40e-01 | 7.92e-01 | 6.84e-01 | 6.18e-01 | 3.09e-01 |
| HISTIDINE CATABOLIC PROCESS | 8 | 6.31e-01 | 9.11e-01 | 0.3760 | -2.05e-01 | -4.84e-02 | -1.85e-01 | -2.37e-01 | -7.94e-02 | 3.16e-01 | 8.13e-01 | 3.64e-01 | 2.46e-01 | 6.97e-01 |
| PLASMA MEMBRANE FUSION | 30 | 8.66e-03 | 9.22e-02 | 0.3760 | -2.64e-01 | -6.78e-02 | -1.22e-01 | -1.87e-01 | -1.29e-01 | 1.24e-02 | 5.20e-01 | 2.46e-01 | 7.56e-02 | 2.20e-01 |
| DNA TEMPLATED TRANSCRIPTION TERMINATION | 24 | 1.79e-01 | 5.63e-01 | 0.3760 | 2.19e-02 | 3.43e-02 | 1.84e-01 | 1.78e-01 | 2.72e-01 | 8.52e-01 | 7.71e-01 | 1.19e-01 | 1.31e-01 | 2.11e-02 |
| NEGATIVE REGULATION OF MRNA METABOLIC PROCESS | 90 | 5.82e-03 | 6.85e-02 | 0.3750 | 2.05e-01 | 1.37e-01 | 1.48e-01 | 1.99e-01 | 1.37e-01 | 7.87e-04 | 2.44e-02 | 1.50e-02 | 1.11e-03 | 2.49e-02 |
| ENDOCANNABINOID SIGNALING PATHWAY | 5 | 2.26e-01 | 6.28e-01 | 0.3750 | -2.00e-01 | 1.49e-01 | -2.45e-02 | -2.52e-01 | -1.22e-01 | 4.38e-01 | 5.65e-01 | 9.24e-01 | 3.30e-01 | 6.37e-01 |
| TRYPTOPHAN METABOLIC PROCESS | 10 | 7.02e-01 | 9.32e-01 | 0.3750 | -1.73e-01 | -8.95e-02 | -1.56e-01 | -2.67e-01 | -8.49e-02 | 3.43e-01 | 6.24e-01 | 3.93e-01 | 1.44e-01 | 6.42e-01 |
| AORTIC VALVE MORPHOGENESIS | 38 | 1.44e-01 | 5.11e-01 | 0.3750 | 8.22e-02 | 1.77e-01 | 2.09e-01 | 1.18e-01 | 2.13e-01 | 3.80e-01 | 5.88e-02 | 2.59e-02 | 2.10e-01 | 2.33e-02 |
| REGULATION OF GROWTH RATE | 5 | 7.88e-01 | 9.63e-01 | 0.3750 | 1.89e-01 | 2.76e-01 | 5.84e-02 | 9.55e-02 | -1.26e-01 | 4.64e-01 | 2.84e-01 | 8.21e-01 | 7.12e-01 | 6.25e-01 |
| POSITIVE REGULATION OF TRANSMISSION OF NERVE IMPULSE | 7 | 8.82e-01 | 9.79e-01 | 0.3750 | 6.18e-02 | 9.20e-02 | 2.02e-01 | 1.17e-01 | 2.72e-01 | 7.77e-01 | 6.73e-01 | 3.55e-01 | 5.91e-01 | 2.13e-01 |
| DORSAL VENTRAL PATTERN FORMATION | 97 | 6.20e-04 | 1.21e-02 | 0.3750 | 5.60e-02 | 1.15e-01 | 1.85e-01 | 1.51e-01 | 2.59e-01 | 3.40e-01 | 5.13e-02 | 1.63e-03 | 1.00e-02 | 1.01e-05 |
| REGULATION OF NK T CELL PROLIFERATION | 7 | 2.07e-01 | 6.01e-01 | 0.3750 | 3.35e-02 | 1.64e-01 | 3.73e-02 | 1.43e-01 | 3.01e-01 | 8.78e-01 | 4.53e-01 | 8.64e-01 | 5.12e-01 | 1.67e-01 |
| NEGATIVE REGULATION OF AUTOPHAGY | 86 | 9.00e-03 | 9.43e-02 | 0.3750 | 2.03e-01 | 1.88e-01 | 1.36e-01 | 1.67e-01 | 1.31e-01 | 1.12e-03 | 2.54e-03 | 2.88e-02 | 7.33e-03 | 3.51e-02 |
| RETINAL BIPOLAR NEURON DIFFERENTIATION | 7 | 6.19e-01 | 9.07e-01 | 0.3750 | -2.01e-01 | -1.67e-01 | 3.69e-02 | -1.06e-01 | 2.43e-01 | 3.56e-01 | 4.43e-01 | 8.66e-01 | 6.26e-01 | 2.65e-01 |
| REGULATION OF MITOTIC RECOMBINATION | 7 | 2.54e-01 | 6.61e-01 | 0.3750 | 8.58e-02 | -6.79e-02 | -8.37e-03 | 1.52e-01 | 3.25e-01 | 6.94e-01 | 7.56e-01 | 9.69e-01 | 4.87e-01 | 1.37e-01 |
| MITOCHONDRION MORPHOGENESIS | 20 | 3.16e-01 | 7.27e-01 | 0.3750 | 2.42e-01 | 2.06e-01 | 1.53e-01 | 1.03e-01 | 7.33e-02 | 6.07e-02 | 1.11e-01 | 2.37e-01 | 4.25e-01 | 5.71e-01 |
| HYALURONAN BIOSYNTHETIC PROCESS | 14 | 2.44e-01 | 6.48e-01 | 0.3750 | 1.81e-01 | 2.30e-01 | 3.19e-02 | 5.64e-02 | -2.24e-01 | 2.41e-01 | 1.36e-01 | 8.36e-01 | 7.15e-01 | 1.46e-01 |
| REGULATION OF RESTING MEMBRANE POTENTIAL | 10 | 6.84e-01 | 9.30e-01 | 0.3740 | -2.05e-01 | -2.02e-01 | -9.15e-02 | -2.03e-01 | 8.93e-02 | 2.62e-01 | 2.69e-01 | 6.17e-01 | 2.67e-01 | 6.25e-01 |
| COMPARTMENT PATTERN SPECIFICATION | 5 | 8.79e-01 | 9.79e-01 | 0.3740 | 1.27e-01 | 2.20e-01 | 1.44e-01 | 7.69e-02 | 2.21e-01 | 6.24e-01 | 3.94e-01 | 5.77e-01 | 7.66e-01 | 3.92e-01 |
| ANTERIOR POSTERIOR AXON GUIDANCE | 7 | 6.99e-01 | 9.31e-01 | 0.3740 | 1.21e-01 | 2.07e-01 | 1.47e-01 | 4.10e-02 | 2.43e-01 | 5.79e-01 | 3.42e-01 | 5.02e-01 | 8.51e-01 | 2.65e-01 |
| RESPONSE TO MERCURY ION | 10 | 5.07e-01 | 8.52e-01 | 0.3740 | -2.98e-01 | -1.43e-01 | -5.01e-02 | -1.49e-01 | 7.93e-02 | 1.03e-01 | 4.35e-01 | 7.84e-01 | 4.15e-01 | 6.64e-01 |
| C X C CHEMOKINE RECEPTOR CXCR4 SIGNALING PATHWAY | 5 | 1.87e-01 | 5.72e-01 | 0.3740 | 5.37e-02 | -3.67e-02 | -2.20e-01 | -2.76e-01 | 1.07e-01 | 8.35e-01 | 8.87e-01 | 3.95e-01 | 2.85e-01 | 6.79e-01 |
| REGULATION OF OOCYTE MATURATION | 7 | 5.38e-01 | 8.66e-01 | 0.3740 | -1.27e-01 | -4.77e-03 | 6.82e-02 | 3.96e-02 | 3.43e-01 | 5.60e-01 | 9.83e-01 | 7.55e-01 | 8.56e-01 | 1.16e-01 |
| PARANODAL JUNCTION ASSEMBLY | 6 | 9.06e-01 | 9.84e-01 | 0.3740 | -2.41e-01 | -2.20e-01 | -9.75e-02 | -1.30e-01 | 8.40e-02 | 3.07e-01 | 3.51e-01 | 6.79e-01 | 5.80e-01 | 7.22e-01 |
| POSITIVE REGULATION OF HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 6 | 9.72e-01 | 9.95e-01 | 0.3740 | 1.15e-01 | 1.48e-01 | 1.97e-01 | 1.72e-01 | 1.90e-01 | 6.24e-01 | 5.31e-01 | 4.03e-01 | 4.65e-01 | 4.19e-01 |
| CENTRIOLE ASSEMBLY | 47 | 1.76e-01 | 5.61e-01 | 0.3740 | 1.63e-01 | 1.34e-01 | 1.99e-01 | 2.17e-01 | 9.25e-02 | 5.33e-02 | 1.12e-01 | 1.84e-02 | 9.94e-03 | 2.73e-01 |
| ESTABLISHMENT OF MEIOTIC SPINDLE LOCALIZATION | 6 | 9.03e-01 | 9.84e-01 | 0.3740 | -1.41e-01 | -2.59e-01 | -1.86e-01 | -1.20e-01 | -6.02e-02 | 5.49e-01 | 2.72e-01 | 4.29e-01 | 6.11e-01 | 7.98e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR ESTROGEN RECEPTOR SIGNALING PATHWAY | 15 | 6.47e-01 | 9.17e-01 | 0.3740 | 2.20e-01 | 2.04e-01 | 1.75e-01 | 1.19e-01 | 7.18e-02 | 1.41e-01 | 1.71e-01 | 2.42e-01 | 4.25e-01 | 6.30e-01 |
| POSITIVE REGULATION OF HORMONE METABOLIC PROCESS | 15 | 6.77e-01 | 9.28e-01 | 0.3740 | 2.11e-01 | 2.26e-01 | 1.21e-01 | 1.56e-01 | 6.98e-02 | 1.56e-01 | 1.29e-01 | 4.19e-01 | 2.94e-01 | 6.40e-01 |
| TORC2 SIGNALING | 12 | 6.57e-01 | 9.20e-01 | 0.3740 | 2.52e-01 | 1.56e-01 | 8.79e-02 | 2.01e-01 | -6.27e-02 | 1.31e-01 | 3.49e-01 | 5.98e-01 | 2.28e-01 | 7.07e-01 |
| PROLINE METABOLIC PROCESS | 10 | 2.00e-01 | 5.90e-01 | 0.3740 | 2.41e-01 | 2.62e-01 | 1.12e-01 | -2.05e-02 | 4.58e-03 | 1.87e-01 | 1.51e-01 | 5.40e-01 | 9.11e-01 | 9.80e-01 |
| EMBRYONIC CRANIAL SKELETON MORPHOGENESIS | 44 | 1.94e-01 | 5.80e-01 | 0.3740 | 9.53e-02 | 1.67e-01 | 2.04e-01 | 1.57e-01 | 1.90e-01 | 2.74e-01 | 5.51e-02 | 1.92e-02 | 7.16e-02 | 2.88e-02 |
| INORGANIC ION IMPORT ACROSS PLASMA MEMBRANE | 132 | 4.26e-05 | 1.34e-03 | 0.3730 | -2.07e-01 | -1.45e-01 | -1.30e-01 | -2.34e-01 | -6.02e-02 | 4.00e-05 | 3.93e-03 | 9.66e-03 | 3.34e-06 | 2.32e-01 |
| REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 29 | 5.47e-01 | 8.72e-01 | 0.3730 | 1.56e-01 | 2.04e-01 | 1.97e-01 | 1.54e-01 | 1.04e-01 | 1.45e-01 | 5.74e-02 | 6.63e-02 | 1.50e-01 | 3.34e-01 |
| POSITIVE REGULATION OF ANTIBACTERIAL PEPTIDE PRODUCTION | 5 | 3.35e-01 | 7.40e-01 | 0.3730 | 1.82e-02 | 2.11e-01 | -1.42e-01 | -1.78e-01 | -2.07e-01 | 9.44e-01 | 4.14e-01 | 5.82e-01 | 4.91e-01 | 4.24e-01 |
| ACTIN FILAMENT NETWORK FORMATION | 8 | 8.72e-01 | 9.78e-01 | 0.3730 | -1.02e-01 | -1.21e-01 | -1.61e-01 | -1.29e-01 | -2.67e-01 | 6.16e-01 | 5.53e-01 | 4.29e-01 | 5.27e-01 | 1.91e-01 |
| NEGATIVE REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 35 | 1.86e-01 | 5.72e-01 | 0.3730 | 1.56e-01 | 1.08e-01 | 1.65e-01 | 2.42e-01 | 1.32e-01 | 1.10e-01 | 2.68e-01 | 9.04e-02 | 1.32e-02 | 1.77e-01 |
| INDUCTION OF POSITIVE CHEMOTAXIS | 13 | 5.70e-01 | 8.82e-01 | 0.3730 | 1.66e-01 | 2.47e-01 | 1.28e-01 | 1.79e-01 | 4.61e-02 | 3.00e-01 | 1.23e-01 | 4.26e-01 | 2.63e-01 | 7.74e-01 |
| REGULATION OF B CELL ACTIVATION | 124 | 1.05e-03 | 1.81e-02 | 0.3730 | 1.74e-01 | 1.96e-01 | 1.48e-01 | 1.96e-01 | 9.88e-02 | 8.13e-04 | 1.60e-04 | 4.35e-03 | 1.58e-04 | 5.74e-02 |
| EMBRYONIC HEART TUBE MORPHOGENESIS | 70 | 1.85e-02 | 1.59e-01 | 0.3730 | 9.21e-02 | 9.72e-02 | 1.85e-01 | 1.76e-01 | 2.37e-01 | 1.82e-01 | 1.60e-01 | 7.58e-03 | 1.10e-02 | 5.99e-04 |
| SODIUM ION IMPORT ACROSS PLASMA MEMBRANE | 23 | 6.81e-02 | 3.50e-01 | 0.3730 | -1.87e-01 | -1.11e-01 | -1.01e-01 | -2.86e-01 | -1.51e-03 | 1.20e-01 | 3.57e-01 | 4.03e-01 | 1.77e-02 | 9.90e-01 |
| METANEPHRIC RENAL VESICLE MORPHOGENESIS | 14 | 8.21e-01 | 9.71e-01 | 0.3730 | 1.44e-01 | 1.49e-01 | 1.75e-01 | 2.17e-01 | 1.36e-01 | 3.52e-01 | 3.35e-01 | 2.56e-01 | 1.60e-01 | 3.78e-01 |
| SENSORY PERCEPTION OF SWEET TASTE | 7 | 4.29e-01 | 8.05e-01 | 0.3730 | -2.86e-02 | 2.09e-02 | -3.35e-02 | -6.12e-03 | -3.70e-01 | 8.96e-01 | 9.24e-01 | 8.78e-01 | 9.78e-01 | 9.04e-02 |
| NEGATIVE REGULATION OF ORGANELLE ASSEMBLY | 42 | 1.73e-01 | 5.57e-01 | 0.3730 | 2.28e-01 | 1.73e-01 | 1.27e-01 | 1.82e-01 | 8.86e-02 | 1.07e-02 | 5.25e-02 | 1.54e-01 | 4.08e-02 | 3.20e-01 |
| DIAPHRAGM DEVELOPMENT | 8 | 3.62e-01 | 7.62e-01 | 0.3730 | -1.86e-01 | 4.24e-02 | 1.42e-01 | -2.03e-02 | 2.86e-01 | 3.62e-01 | 8.35e-01 | 4.86e-01 | 9.21e-01 | 1.61e-01 |
| REGULATION OF GLOMERULAR FILTRATION | 8 | 3.34e-01 | 7.40e-01 | 0.3730 | -1.57e-01 | -4.11e-02 | -8.67e-02 | -3.21e-01 | -4.45e-02 | 4.43e-01 | 8.40e-01 | 6.71e-01 | 1.16e-01 | 8.27e-01 |
| THYROID HORMONE TRANSPORT | 10 | 4.61e-01 | 8.24e-01 | 0.3730 | 1.69e-01 | 1.76e-01 | 5.89e-03 | 8.04e-02 | -2.70e-01 | 3.56e-01 | 3.35e-01 | 9.74e-01 | 6.60e-01 | 1.40e-01 |
| POSITIVE REGULATION OF STEROID HORMONE SECRETION | 11 | 1.27e-01 | 4.84e-01 | 0.3730 | 2.26e-01 | 2.05e-01 | -3.32e-02 | 1.95e-01 | -8.16e-02 | 1.95e-01 | 2.40e-01 | 8.49e-01 | 2.62e-01 | 6.39e-01 |
| NEGATIVE REGULATION OF GLUTAMATE SECRETION | 6 | 1.89e-01 | 5.76e-01 | 0.3720 | 5.09e-04 | 5.26e-03 | -3.16e-02 | -2.05e-01 | 3.09e-01 | 9.98e-01 | 9.82e-01 | 8.93e-01 | 3.84e-01 | 1.90e-01 |
| CYTIDINE METABOLIC PROCESS | 12 | 8.04e-01 | 9.67e-01 | 0.3720 | -1.61e-01 | -1.24e-01 | -1.57e-01 | -1.67e-01 | -2.11e-01 | 3.34e-01 | 4.56e-01 | 3.45e-01 | 3.15e-01 | 2.06e-01 |
| AUTOPHAGOSOME ORGANIZATION | 115 | 2.34e-03 | 3.45e-02 | 0.3720 | 1.75e-01 | 1.55e-01 | 1.61e-01 | 2.26e-01 | 8.08e-02 | 1.19e-03 | 4.02e-03 | 2.83e-03 | 2.75e-05 | 1.34e-01 |
| RESPONSE TO ESTRADIOL | 111 | 2.77e-03 | 3.93e-02 | 0.3720 | 9.61e-02 | 1.57e-01 | 2.00e-01 | 1.52e-01 | 2.03e-01 | 8.04e-02 | 4.25e-03 | 2.78e-04 | 5.57e-03 | 2.13e-04 |
| TRANSEPITHELIAL CHLORIDE TRANSPORT | 8 | 8.23e-01 | 9.71e-01 | 0.3720 | 1.80e-01 | 2.45e-01 | 1.33e-01 | 1.55e-01 | -6.39e-02 | 3.78e-01 | 2.30e-01 | 5.15e-01 | 4.48e-01 | 7.54e-01 |
| REGULATION OF NUCLEAR DIVISION | 146 | 2.17e-04 | 4.99e-03 | 0.3720 | 1.25e-01 | 1.14e-01 | 1.91e-01 | 2.07e-01 | 1.73e-01 | 8.93e-03 | 1.75e-02 | 6.56e-05 | 1.55e-05 | 3.16e-04 |
| REGULATION OF GRANULOCYTE DIFFERENTIATION | 16 | 2.71e-01 | 6.79e-01 | 0.3710 | 1.84e-01 | 1.82e-01 | 7.42e-02 | 1.86e-01 | -1.77e-01 | 2.03e-01 | 2.08e-01 | 6.07e-01 | 1.98e-01 | 2.21e-01 |
| DNA STRAND ELONGATION INVOLVED IN DNA REPLICATION | 14 | 5.92e-01 | 8.94e-01 | 0.3710 | 1.11e-01 | 6.19e-02 | 2.13e-01 | 1.83e-01 | 2.07e-01 | 4.72e-01 | 6.88e-01 | 1.68e-01 | 2.35e-01 | 1.80e-01 |
| NEGATIVE CHEMOTAXIS | 46 | 1.19e-01 | 4.71e-01 | 0.3710 | -1.74e-01 | -1.13e-01 | -2.00e-01 | -2.06e-01 | -1.12e-01 | 4.14e-02 | 1.84e-01 | 1.88e-02 | 1.58e-02 | 1.90e-01 |
| PIGMENT ACCUMULATION | 11 | 4.86e-01 | 8.38e-01 | 0.3710 | 2.38e-01 | 8.54e-02 | 1.56e-01 | 1.69e-01 | 1.44e-01 | 1.71e-01 | 6.24e-01 | 3.70e-01 | 3.31e-01 | 4.10e-01 |
| NERVOUS SYSTEM PROCESS | 1402 | 6.71e-32 | 3.61e-29 | 0.3710 | -1.55e-01 | -1.64e-01 | -1.86e-01 | -1.80e-01 | -1.39e-01 | 2.57e-22 | 4.85e-25 | 1.04e-31 | 8.53e-30 | 2.10e-18 |
| NEGATIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 15 | 8.73e-02 | 4.00e-01 | 0.3710 | -4.31e-02 | 1.76e-01 | 2.29e-01 | 2.82e-04 | 2.28e-01 | 7.73e-01 | 2.37e-01 | 1.24e-01 | 9.98e-01 | 1.26e-01 |
| CHROMOSOME CONDENSATION | 46 | 3.09e-02 | 2.21e-01 | 0.3710 | 1.16e-01 | 6.24e-02 | 1.95e-01 | 1.60e-01 | 2.37e-01 | 1.73e-01 | 4.64e-01 | 2.19e-02 | 6.01e-02 | 5.33e-03 |
| NEGATIVE REGULATION OF INTERLEUKIN 18 PRODUCTION | 5 | 1.83e-01 | 5.70e-01 | 0.3710 | 2.46e-01 | 5.31e-02 | -2.55e-01 | 2.54e-02 | -9.27e-02 | 3.40e-01 | 8.37e-01 | 3.24e-01 | 9.22e-01 | 7.20e-01 |
| PROTEIN MONOUBIQUITINATION | 41 | 1.48e-03 | 2.39e-02 | 0.3710 | 2.39e-01 | 1.51e-01 | 4.25e-02 | 2.20e-01 | 8.57e-02 | 8.03e-03 | 9.50e-02 | 6.37e-01 | 1.48e-02 | 3.42e-01 |
| REGULATION OF TRANSMISSION OF NERVE IMPULSE | 15 | 3.89e-01 | 7.82e-01 | 0.3710 | 1.07e-01 | 1.94e-01 | 1.79e-01 | 5.09e-02 | 2.32e-01 | 4.72e-01 | 1.92e-01 | 2.31e-01 | 7.33e-01 | 1.20e-01 |
| VITAMIN D RECEPTOR SIGNALING PATHWAY | 12 | 4.31e-01 | 8.06e-01 | 0.3710 | 1.86e-01 | 2.74e-01 | 1.19e-01 | 6.64e-02 | 9.44e-02 | 2.64e-01 | 9.98e-02 | 4.74e-01 | 6.90e-01 | 5.71e-01 |
| PARAXIAL MESODERM MORPHOGENESIS | 10 | 3.47e-01 | 7.50e-01 | 0.3710 | -2.47e-01 | -1.47e-01 | 5.56e-02 | -1.84e-02 | 2.26e-01 | 1.75e-01 | 4.20e-01 | 7.61e-01 | 9.20e-01 | 2.16e-01 |
| REGULATION OF PROTEIN MATURATION | 68 | 5.17e-03 | 6.28e-02 | 0.3710 | 2.23e-01 | 2.43e-01 | 1.22e-01 | 1.14e-01 | -2.64e-02 | 1.47e-03 | 5.30e-04 | 8.12e-02 | 1.05e-01 | 7.06e-01 |
| POSITIVE REGULATION OF HISTONE ACETYLATION | 10 | 8.21e-01 | 9.71e-01 | 0.3710 | 1.97e-01 | 1.95e-01 | 1.28e-01 | 2.05e-01 | -4.36e-02 | 2.80e-01 | 2.85e-01 | 4.84e-01 | 2.61e-01 | 8.11e-01 |
| NEURON PROJECTION EXTENSION INVOLVED IN NEURON PROJECTION GUIDANCE | 36 | 3.01e-01 | 7.14e-01 | 0.3710 | -1.99e-01 | -1.35e-01 | -1.84e-01 | -1.93e-01 | -9.32e-02 | 3.88e-02 | 1.61e-01 | 5.65e-02 | 4.53e-02 | 3.33e-01 |
| POSITIVE REGULATION OF EXOSOMAL SECRETION | 15 | 8.56e-01 | 9.77e-01 | 0.3710 | 1.92e-01 | 1.74e-01 | 1.84e-01 | 1.79e-01 | 6.74e-02 | 1.98e-01 | 2.44e-01 | 2.17e-01 | 2.31e-01 | 6.51e-01 |
| NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS | 7 | 8.58e-01 | 9.77e-01 | 0.3710 | 1.52e-01 | 1.18e-01 | 1.24e-01 | 1.59e-01 | 2.44e-01 | 4.86e-01 | 5.89e-01 | 5.71e-01 | 4.66e-01 | 2.63e-01 |
| NOREPINEPHRINE TRANSPORT | 22 | 2.17e-01 | 6.14e-01 | 0.3700 | 6.66e-02 | 8.95e-02 | 2.42e-01 | 1.14e-01 | 2.31e-01 | 5.89e-01 | 4.67e-01 | 4.99e-02 | 3.53e-01 | 6.12e-02 |
| ASTROCYTE CELL MIGRATION | 9 | 7.92e-01 | 9.63e-01 | 0.3700 | 1.73e-01 | 2.04e-01 | 1.34e-01 | 2.15e-01 | -3.42e-02 | 3.69e-01 | 2.90e-01 | 4.85e-01 | 2.64e-01 | 8.59e-01 |
| PROGRAMMED CELL DEATH IN RESPONSE TO REACTIVE OXYGEN SPECIES | 19 | 6.58e-01 | 9.20e-01 | 0.3700 | -1.50e-01 | -1.82e-01 | -1.57e-01 | -1.48e-01 | -1.86e-01 | 2.58e-01 | 1.69e-01 | 2.35e-01 | 2.65e-01 | 1.60e-01 |
| POSITIVE REGULATION OF SKELETAL MUSCLE CELL DIFFERENTIATION | 7 | 4.41e-01 | 8.12e-01 | 0.3700 | -3.69e-02 | 6.86e-02 | 2.42e-01 | -1.27e-02 | 2.68e-01 | 8.66e-01 | 7.53e-01 | 2.67e-01 | 9.53e-01 | 2.19e-01 |
| CANONICAL WNT SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 6 | 8.72e-01 | 9.78e-01 | 0.3700 | 2.13e-01 | 1.96e-01 | 8.30e-02 | 2.14e-01 | -6.38e-03 | 3.65e-01 | 4.05e-01 | 7.25e-01 | 3.64e-01 | 9.78e-01 |
| PYRIMIDINE DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS | 6 | 4.95e-01 | 8.44e-01 | 0.3700 | 1.61e-01 | -3.01e-02 | 6.86e-02 | 2.61e-01 | 1.93e-01 | 4.95e-01 | 8.98e-01 | 7.71e-01 | 2.69e-01 | 4.12e-01 |
| DNA REPLICATION | 272 | 2.27e-07 | 1.17e-05 | 0.3700 | 1.47e-01 | 1.24e-01 | 1.91e-01 | 1.87e-01 | 1.68e-01 | 2.86e-05 | 4.24e-04 | 6.19e-08 | 1.06e-07 | 1.92e-06 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY ENDOTHELIN | 6 | 4.74e-01 | 8.31e-01 | 0.3700 | -1.16e-01 | 1.55e-01 | 1.72e-01 | 2.09e-02 | 2.63e-01 | 6.24e-01 | 5.10e-01 | 4.66e-01 | 9.30e-01 | 2.65e-01 |
| PROTEIN LOCALIZATION TO EARLY ENDOSOME | 11 | 7.57e-01 | 9.51e-01 | 0.3700 | -6.60e-02 | -1.56e-01 | -2.42e-01 | -1.38e-01 | -1.74e-01 | 7.05e-01 | 3.70e-01 | 1.65e-01 | 4.27e-01 | 3.17e-01 |
| MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION | 35 | 5.23e-02 | 3.02e-01 | 0.3690 | 1.20e-02 | 8.11e-02 | 2.39e-01 | 1.39e-01 | 2.31e-01 | 9.02e-01 | 4.07e-01 | 1.46e-02 | 1.54e-01 | 1.79e-02 |
| MITOTIC CELL CYCLE PROCESS | 748 | 5.33e-22 | 1.34e-19 | 0.3690 | 1.57e-01 | 1.27e-01 | 1.78e-01 | 2.14e-01 | 1.35e-01 | 2.89e-13 | 3.44e-09 | 9.76e-17 | 1.67e-23 | 3.44e-10 |
| APPENDAGE DEVELOPMENT | 177 | 2.12e-04 | 4.88e-03 | 0.3690 | 1.19e-01 | 1.56e-01 | 1.93e-01 | 1.68e-01 | 1.79e-01 | 6.33e-03 | 3.41e-04 | 9.18e-06 | 1.15e-04 | 3.81e-05 |
| POSITIVE REGULATION OF STORE OPERATED CALCIUM CHANNEL ACTIVITY | 5 | 6.67e-01 | 9.24e-01 | 0.3690 | -5.20e-02 | 2.79e-02 | -1.45e-01 | -3.57e-02 | -3.32e-01 | 8.40e-01 | 9.14e-01 | 5.75e-01 | 8.90e-01 | 1.98e-01 |
| RESPONSE TO PROTOZOAN | 31 | 1.41e-01 | 5.06e-01 | 0.3690 | 2.65e-01 | 1.86e-01 | 8.87e-02 | 1.45e-01 | -4.63e-02 | 1.05e-02 | 7.27e-02 | 3.92e-01 | 1.62e-01 | 6.55e-01 |
| POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 52 | 2.26e-01 | 6.27e-01 | 0.3690 | 1.40e-01 | 1.59e-01 | 2.10e-01 | 1.78e-01 | 1.24e-01 | 8.07e-02 | 4.76e-02 | 8.69e-03 | 2.68e-02 | 1.21e-01 |
| DNA METABOLIC PROCESS | 986 | 1.43e-27 | 5.99e-25 | 0.3690 | 1.57e-01 | 1.36e-01 | 1.73e-01 | 2.11e-01 | 1.34e-01 | 6.72e-17 | 3.85e-13 | 3.28e-20 | 2.10e-29 | 9.39e-13 |
| LIPID PHOSPHORYLATION | 10 | 7.77e-01 | 9.58e-01 | 0.3690 | -2.34e-01 | -2.25e-01 | -1.16e-01 | -1.17e-01 | -5.79e-02 | 2.00e-01 | 2.17e-01 | 5.24e-01 | 5.23e-01 | 7.51e-01 |
| L PHENYLALANINE METABOLIC PROCESS | 8 | 4.57e-01 | 8.22e-01 | 0.3690 | 1.74e-01 | 1.63e-01 | 8.44e-02 | 3.01e-02 | -2.67e-01 | 3.95e-01 | 4.24e-01 | 6.79e-01 | 8.83e-01 | 1.92e-01 |
| COENZYME A BIOSYNTHETIC PROCESS | 11 | 1.82e-01 | 5.67e-01 | 0.3690 | 1.01e-01 | 1.03e-01 | 4.24e-02 | 1.72e-01 | 2.89e-01 | 5.62e-01 | 5.52e-01 | 8.08e-01 | 3.23e-01 | 9.71e-02 |
| NEUROFILAMENT CYTOSKELETON ORGANIZATION | 10 | 6.86e-01 | 9.31e-01 | 0.3690 | 1.88e-01 | 6.16e-02 | 1.69e-01 | 2.29e-01 | 1.26e-01 | 3.04e-01 | 7.36e-01 | 3.54e-01 | 2.10e-01 | 4.91e-01 |
| POLYADENYLATION DEPENDENT RNA CATABOLIC PROCESS | 8 | 3.71e-01 | 7.71e-01 | 0.3680 | -1.84e-01 | -3.38e-02 | -2.84e-02 | -8.15e-02 | 3.06e-01 | 3.67e-01 | 8.68e-01 | 8.89e-01 | 6.90e-01 | 1.35e-01 |
| SKELETAL SYSTEM MORPHOGENESIS | 226 | 5.77e-08 | 3.26e-06 | 0.3680 | 7.26e-02 | 1.50e-01 | 2.01e-01 | 1.61e-01 | 2.04e-01 | 5.99e-02 | 9.91e-05 | 1.86e-07 | 3.06e-05 | 1.28e-07 |
| STEROID CATABOLIC PROCESS | 24 | 2.24e-01 | 6.25e-01 | 0.3680 | -1.12e-01 | -1.27e-01 | -2.54e-01 | -1.85e-01 | -9.01e-02 | 3.44e-01 | 2.80e-01 | 3.09e-02 | 1.17e-01 | 4.45e-01 |
| POSITIVE REGULATION OF NEUROINFLAMMATORY RESPONSE | 18 | 1.25e-01 | 4.82e-01 | 0.3680 | 1.53e-01 | 5.14e-02 | -5.98e-02 | 3.86e-02 | -3.23e-01 | 2.62e-01 | 7.06e-01 | 6.61e-01 | 7.77e-01 | 1.75e-02 |
| SKELETAL MUSCLE ATROPHY | 5 | 8.17e-01 | 9.70e-01 | 0.3680 | -2.69e-01 | -1.18e-01 | -9.58e-03 | -1.52e-01 | 1.62e-01 | 2.97e-01 | 6.48e-01 | 9.70e-01 | 5.57e-01 | 5.31e-01 |
| GLYCOSYLCERAMIDE METABOLIC PROCESS | 16 | 1.94e-01 | 5.81e-01 | 0.3680 | -1.31e-01 | -8.79e-02 | -8.04e-02 | -1.25e-01 | -2.97e-01 | 3.64e-01 | 5.43e-01 | 5.77e-01 | 3.86e-01 | 3.94e-02 |
| REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION INVOLVED IN ENDOCARDIAL CUSHION FORMATION | 6 | 1.18e-01 | 4.67e-01 | 0.3680 | -7.49e-02 | 2.92e-01 | 1.55e-01 | 9.98e-02 | 1.04e-01 | 7.51e-01 | 2.16e-01 | 5.11e-01 | 6.72e-01 | 6.59e-01 |
| POSITIVE REGULATION OF MYELOID LEUKOCYTE CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 35 | 3.16e-02 | 2.25e-01 | 0.3680 | 2.51e-01 | 2.28e-01 | 6.71e-02 | 1.22e-01 | 3.65e-02 | 1.02e-02 | 1.97e-02 | 4.92e-01 | 2.13e-01 | 7.09e-01 |
| GLUCOSYLCERAMIDE METABOLIC PROCESS | 7 | 4.19e-01 | 8.00e-01 | 0.3680 | 8.41e-02 | 1.84e-01 | 1.42e-01 | 1.20e-01 | -2.44e-01 | 7.00e-01 | 3.98e-01 | 5.14e-01 | 5.83e-01 | 2.63e-01 |
| ANGIOTENSIN ACTIVATED SIGNALING PATHWAY | 18 | 1.05e-01 | 4.43e-01 | 0.3680 | 6.29e-02 | -9.99e-02 | -2.49e-01 | -9.11e-02 | -2.26e-01 | 6.44e-01 | 4.63e-01 | 6.72e-02 | 5.03e-01 | 9.74e-02 |
| POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE BIOSYNTHETIC PROCESS | 16 | 5.10e-01 | 8.53e-01 | 0.3680 | -5.64e-02 | -1.69e-01 | -2.44e-01 | -1.39e-01 | -1.57e-01 | 6.96e-01 | 2.42e-01 | 9.13e-02 | 3.36e-01 | 2.76e-01 |
| REGULATION OF STEROID HORMONE SECRETION | 22 | 6.50e-02 | 3.39e-01 | 0.3680 | 2.53e-01 | 1.61e-01 | 1.33e-02 | 2.05e-01 | -5.38e-02 | 3.97e-02 | 1.90e-01 | 9.14e-01 | 9.62e-02 | 6.62e-01 |
| REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL BY SARCOPLASMIC RETICULUM | 29 | 2.87e-01 | 6.95e-01 | 0.3680 | -2.20e-01 | -2.02e-01 | -1.32e-01 | -1.29e-01 | -1.09e-01 | 4.04e-02 | 5.95e-02 | 2.18e-01 | 2.30e-01 | 3.10e-01 |
| CYTOKINETIC PROCESS | 42 | 8.58e-02 | 3.96e-01 | 0.3680 | 1.66e-01 | 1.35e-01 | 2.18e-01 | 2.02e-01 | 3.50e-02 | 6.30e-02 | 1.30e-01 | 1.47e-02 | 2.34e-02 | 6.94e-01 |
| CELLULAR RESPONSE TO UNFOLDED PROTEIN | 88 | 5.15e-03 | 6.28e-02 | 0.3680 | 7.75e-02 | 1.43e-01 | 1.89e-01 | 1.75e-01 | 2.06e-01 | 2.09e-01 | 2.01e-02 | 2.21e-03 | 4.62e-03 | 8.31e-04 |
| MITOCHONDRIAL DNA REPLICATION | 14 | 4.14e-01 | 7.98e-01 | 0.3680 | 2.49e-02 | 5.02e-02 | 2.42e-01 | 1.34e-01 | 2.36e-01 | 8.72e-01 | 7.45e-01 | 1.17e-01 | 3.86e-01 | 1.26e-01 |
| AXIS ELONGATION | 28 | 9.78e-02 | 4.26e-01 | 0.3680 | -1.01e-02 | 1.21e-01 | 2.26e-01 | 1.12e-01 | 2.38e-01 | 9.26e-01 | 2.67e-01 | 3.86e-02 | 3.03e-01 | 2.92e-02 |
| PREPULSE INHIBITION | 13 | 7.92e-01 | 9.63e-01 | 0.3680 | -2.32e-01 | -1.84e-01 | -1.33e-01 | -1.70e-01 | 3.33e-02 | 1.48e-01 | 2.52e-01 | 4.07e-01 | 2.88e-01 | 8.35e-01 |
| POSITIVE REGULATION OF HEMATOPOIETIC STEM CELL PROLIFERATION | 9 | 4.91e-01 | 8.41e-01 | 0.3670 | 1.23e-01 | 8.89e-02 | 1.00e-01 | 2.64e-01 | 1.79e-01 | 5.23e-01 | 6.44e-01 | 6.02e-01 | 1.70e-01 | 3.52e-01 |
| REGULATION OF CHOLESTEROL STORAGE | 19 | 4.23e-01 | 8.03e-01 | 0.3670 | -7.21e-02 | -1.41e-01 | -2.51e-01 | -1.69e-01 | -1.36e-01 | 5.87e-01 | 2.88e-01 | 5.85e-02 | 2.01e-01 | 3.06e-01 |
| FIBROBLAST GROWTH FACTOR PRODUCTION | 9 | 3.59e-01 | 7.58e-01 | 0.3670 | -2.06e-01 | -1.16e-01 | -5.38e-03 | -2.40e-01 | 1.47e-01 | 2.85e-01 | 5.46e-01 | 9.78e-01 | 2.13e-01 | 4.46e-01 |
| OUTFLOW TRACT MORPHOGENESIS | 82 | 7.47e-03 | 8.28e-02 | 0.3670 | 6.43e-02 | 1.14e-01 | 2.03e-01 | 1.48e-01 | 2.33e-01 | 3.14e-01 | 7.42e-02 | 1.46e-03 | 2.04e-02 | 2.62e-04 |
| MACROMOLECULE DEPALMITOYLATION | 11 | 5.03e-02 | 2.93e-01 | 0.3670 | 9.57e-02 | -6.20e-02 | -1.84e-02 | 1.89e-01 | 2.93e-01 | 5.83e-01 | 7.22e-01 | 9.16e-01 | 2.77e-01 | 9.30e-02 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 63 | 3.32e-02 | 2.31e-01 | 0.3670 | 8.22e-02 | 1.27e-01 | 2.25e-01 | 1.83e-01 | 1.66e-01 | 2.59e-01 | 8.16e-02 | 1.99e-03 | 1.20e-02 | 2.23e-02 |
| POSITIVE REGULATION OF GOLGI TO PLASMA MEMBRANE PROTEIN TRANSPORT | 5 | 6.93e-01 | 9.31e-01 | 0.3670 | 9.23e-02 | 2.72e-01 | 1.53e-01 | 1.39e-01 | -9.67e-02 | 7.21e-01 | 2.92e-01 | 5.52e-01 | 5.91e-01 | 7.08e-01 |
| MYOBLAST MIGRATION | 13 | 5.56e-01 | 8.77e-01 | 0.3670 | 3.81e-02 | 2.29e-02 | 1.74e-01 | 1.71e-01 | 2.71e-01 | 8.12e-01 | 8.86e-01 | 2.79e-01 | 2.85e-01 | 9.12e-02 |
| REGULATION OF MONOCYTE DIFFERENTIATION | 20 | 1.42e-01 | 5.08e-01 | 0.3670 | 7.06e-02 | 1.98e-01 | 1.57e-01 | 2.03e-01 | 1.57e-01 | 5.85e-01 | 1.25e-01 | 2.23e-01 | 1.17e-01 | 2.25e-01 |
| CENTRAL NERVOUS SYSTEM MYELIN FORMATION | 8 | 8.92e-01 | 9.81e-01 | 0.3670 | -1.98e-01 | -1.60e-01 | -2.05e-01 | -1.59e-01 | -4.91e-02 | 3.33e-01 | 4.33e-01 | 3.15e-01 | 4.35e-01 | 8.10e-01 |
| VESICLE FUSION WITH GOLGI APPARATUS | 9 | 3.69e-01 | 7.69e-01 | 0.3670 | 2.19e-01 | 6.11e-02 | 4.51e-02 | 2.33e-01 | 1.63e-01 | 2.55e-01 | 7.51e-01 | 8.15e-01 | 2.27e-01 | 3.97e-01 |
| EMBRYONIC HEART TUBE DEVELOPMENT | 83 | 4.46e-03 | 5.66e-02 | 0.3670 | 6.98e-02 | 8.55e-02 | 1.88e-01 | 1.68e-01 | 2.43e-01 | 2.72e-01 | 1.78e-01 | 3.12e-03 | 8.05e-03 | 1.32e-04 |
| REGULATION OF HYDROGEN PEROXIDE MEDIATED PROGRAMMED CELL DEATH | 14 | 4.26e-01 | 8.05e-01 | 0.3670 | -8.66e-02 | -8.33e-02 | -1.18e-01 | -1.02e-01 | -3.10e-01 | 5.75e-01 | 5.90e-01 | 4.46e-01 | 5.08e-01 | 4.49e-02 |
| REGULATION OF EPIDERMAL GROWTH FACTOR ACTIVATED RECEPTOR ACTIVITY | 19 | 8.25e-02 | 3.88e-01 | 0.3670 | 4.06e-02 | -1.16e-02 | 1.35e-01 | 2.43e-01 | 2.35e-01 | 7.59e-01 | 9.30e-01 | 3.07e-01 | 6.67e-02 | 7.62e-02 |
| GLYCOSPHINGOLIPID CATABOLIC PROCESS | 13 | 5.60e-01 | 8.78e-01 | 0.3660 | 2.10e-01 | 2.04e-01 | 1.25e-01 | 1.18e-01 | -1.39e-01 | 1.90e-01 | 2.04e-01 | 4.35e-01 | 4.62e-01 | 3.86e-01 |
| REGULATION OF CD8 POSITIVE ALPHA BETA T CELL ACTIVATION | 21 | 1.73e-01 | 5.57e-01 | 0.3660 | 1.66e-02 | 2.35e-02 | 2.10e-01 | 1.99e-01 | 2.23e-01 | 8.95e-01 | 8.52e-01 | 9.58e-02 | 1.14e-01 | 7.70e-02 |
| POSITIVE REGULATION OF MYELOID CELL APOPTOTIC PROCESS | 10 | 3.73e-01 | 7.72e-01 | 0.3660 | 1.04e-01 | -6.00e-02 | -1.99e-01 | -1.15e-01 | -2.58e-01 | 5.68e-01 | 7.43e-01 | 2.76e-01 | 5.28e-01 | 1.58e-01 |
| REGULATION OF EXCITATORY SYNAPSE ASSEMBLY | 15 | 5.37e-01 | 8.66e-01 | 0.3660 | -2.18e-01 | -1.79e-01 | -8.47e-02 | -1.87e-01 | 1.11e-01 | 1.44e-01 | 2.29e-01 | 5.70e-01 | 2.11e-01 | 4.57e-01 |
| POSITIVE REGULATION OF RNA METABOLIC PROCESS | 1810 | 4.93e-46 | 5.31e-43 | 0.3660 | 1.32e-01 | 1.52e-01 | 1.79e-01 | 1.87e-01 | 1.62e-01 | 1.31e-20 | 7.94e-27 | 7.02e-37 | 4.71e-40 | 1.42e-30 |
| N TERMINAL PROTEIN LIPIDATION | 6 | 6.16e-01 | 9.06e-01 | 0.3660 | -1.56e-01 | -2.81e-02 | 5.93e-03 | -1.34e-01 | 3.01e-01 | 5.07e-01 | 9.05e-01 | 9.80e-01 | 5.69e-01 | 2.02e-01 |
| OPTIC NERVE MORPHOGENESIS | 6 | 2.82e-01 | 6.93e-01 | 0.3660 | -5.69e-02 | 9.31e-02 | 1.99e-01 | -1.32e-01 | 2.55e-01 | 8.09e-01 | 6.93e-01 | 3.99e-01 | 5.75e-01 | 2.80e-01 |
| POSITIVE REGULATION OF TORC1 SIGNALING | 50 | 1.53e-01 | 5.22e-01 | 0.3660 | 1.83e-01 | 1.50e-01 | 1.57e-01 | 2.24e-01 | 5.61e-02 | 2.53e-02 | 6.71e-02 | 5.52e-02 | 6.11e-03 | 4.93e-01 |
| REGULATION OF RESPIRATORY GASEOUS EXCHANGE BY NERVOUS SYSTEM PROCESS | 10 | 7.68e-01 | 9.55e-01 | 0.3660 | 8.76e-02 | 2.18e-01 | 2.11e-01 | 1.52e-01 | 1.04e-01 | 6.32e-01 | 2.33e-01 | 2.48e-01 | 4.04e-01 | 5.70e-01 |
| CELLULAR RESPONSE TO MINERALOCORTICOID STIMULUS | 11 | 1.83e-01 | 5.68e-01 | 0.3660 | -9.64e-02 | 1.33e-01 | 1.93e-01 | -3.78e-02 | 2.61e-01 | 5.80e-01 | 4.46e-01 | 2.67e-01 | 8.28e-01 | 1.34e-01 |
| POSITIVE REGULATION OF CD8 POSITIVE ALPHA BETA T CELL ACTIVATION | 9 | 1.38e-01 | 5.01e-01 | 0.3660 | 8.63e-02 | -1.11e-02 | 2.53e-01 | 2.49e-01 | -3.94e-03 | 6.54e-01 | 9.54e-01 | 1.89e-01 | 1.95e-01 | 9.84e-01 |
| LIPID HYDROXYLATION | 7 | 4.06e-01 | 7.93e-01 | 0.3660 | -5.73e-02 | -5.07e-02 | -2.87e-01 | -8.47e-02 | -1.96e-01 | 7.93e-01 | 8.16e-01 | 1.89e-01 | 6.98e-01 | 3.70e-01 |
| MAMMARY GLAND FORMATION | 7 | 9.35e-01 | 9.91e-01 | 0.3650 | 8.27e-02 | 1.12e-01 | 2.19e-01 | 1.62e-01 | 1.99e-01 | 7.05e-01 | 6.06e-01 | 3.16e-01 | 4.57e-01 | 3.62e-01 |
| SELECTIVE AUTOPHAGY | 92 | 1.01e-02 | 1.02e-01 | 0.3650 | 2.14e-01 | 1.62e-01 | 1.30e-01 | 2.02e-01 | 6.12e-02 | 3.83e-04 | 7.34e-03 | 3.16e-02 | 8.17e-04 | 3.10e-01 |
| RESPONSE TO IONIZING RADIATION | 136 | 3.04e-04 | 6.60e-03 | 0.3650 | 1.57e-01 | 1.17e-01 | 1.64e-01 | 2.22e-01 | 1.37e-01 | 1.57e-03 | 1.89e-02 | 9.28e-04 | 7.64e-06 | 5.92e-03 |
| LINOLEIC ACID METABOLIC PROCESS | 20 | 6.91e-01 | 9.31e-01 | 0.3650 | 1.80e-01 | 1.66e-01 | 1.53e-01 | 1.57e-01 | 1.59e-01 | 1.63e-01 | 1.99e-01 | 2.37e-01 | 2.25e-01 | 2.17e-01 |
| REGULATION OF PROTEIN LIPIDATION | 11 | 6.96e-01 | 9.31e-01 | 0.3650 | 1.10e-01 | 1.83e-01 | 2.19e-01 | 1.98e-01 | 1.88e-02 | 5.27e-01 | 2.94e-01 | 2.09e-01 | 2.55e-01 | 9.14e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS EXONUCLEOLYTIC 3 5 | 12 | 4.15e-01 | 7.98e-01 | 0.3650 | -4.33e-02 | 7.54e-02 | 1.28e-01 | 4.77e-02 | 3.27e-01 | 7.95e-01 | 6.51e-01 | 4.44e-01 | 7.75e-01 | 4.97e-02 |
| REGULATION OF RIG I SIGNALING PATHWAY | 20 | 6.90e-01 | 9.31e-01 | 0.3650 | 1.81e-01 | 2.04e-01 | 1.89e-01 | 1.38e-01 | 6.40e-02 | 1.61e-01 | 1.15e-01 | 1.44e-01 | 2.84e-01 | 6.20e-01 |
| REGULATION OF STEM CELL DIVISION | 11 | 8.71e-01 | 9.78e-01 | 0.3650 | 1.21e-01 | 1.10e-01 | 1.94e-01 | 1.61e-01 | 2.07e-01 | 4.88e-01 | 5.27e-01 | 2.65e-01 | 3.57e-01 | 2.34e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL CALCIUM ION CONCENTRATION | 10 | 8.62e-01 | 9.78e-01 | 0.3650 | 2.21e-01 | 1.56e-01 | 1.25e-01 | 2.11e-01 | -1.48e-03 | 2.27e-01 | 3.93e-01 | 4.95e-01 | 2.48e-01 | 9.94e-01 |
| MEIOTIC TELOMERE CLUSTERING | 10 | 3.53e-01 | 7.53e-01 | 0.3650 | -1.91e-01 | -2.14e-01 | -1.31e-01 | -1.42e-02 | -1.84e-01 | 2.96e-01 | 2.42e-01 | 4.73e-01 | 9.38e-01 | 3.15e-01 |
| SEROTONIN SECRETION | 9 | 8.65e-01 | 9.78e-01 | 0.3650 | 2.23e-01 | 1.42e-01 | 1.17e-01 | 2.03e-01 | 8.99e-02 | 2.47e-01 | 4.61e-01 | 5.43e-01 | 2.91e-01 | 6.40e-01 |
| REGULATION OF ASYMMETRIC CELL DIVISION | 5 | 7.08e-01 | 9.34e-01 | 0.3640 | 1.09e-01 | 2.07e-01 | 1.26e-01 | 9.68e-02 | -2.30e-01 | 6.73e-01 | 4.23e-01 | 6.25e-01 | 7.08e-01 | 3.74e-01 |
| POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 9 | 9.08e-01 | 9.85e-01 | 0.3640 | -1.42e-01 | -1.20e-01 | -1.61e-01 | -1.68e-01 | -2.10e-01 | 4.61e-01 | 5.34e-01 | 4.04e-01 | 3.82e-01 | 2.75e-01 |
| PROTEIN LOCALIZATION TO PERINUCLEAR REGION OF CYTOPLASM | 9 | 6.50e-01 | 9.18e-01 | 0.3640 | -2.29e-01 | -2.58e-01 | -8.01e-02 | -7.10e-02 | 4.71e-02 | 2.35e-01 | 1.80e-01 | 6.77e-01 | 7.12e-01 | 8.07e-01 |
| CHROMATIN REMODELING | 579 | 2.07e-15 | 2.94e-13 | 0.3640 | 1.71e-01 | 1.39e-01 | 1.62e-01 | 2.04e-01 | 1.27e-01 | 1.70e-12 | 1.09e-08 | 2.74e-11 | 4.64e-17 | 1.75e-07 |
| EXIT FROM MITOSIS | 32 | 1.63e-01 | 5.41e-01 | 0.3640 | 9.80e-02 | 5.85e-02 | 1.59e-01 | 1.80e-01 | 2.49e-01 | 3.37e-01 | 5.67e-01 | 1.19e-01 | 7.88e-02 | 1.48e-02 |
| LIPOPROTEIN LOCALIZATION | 21 | 1.16e-01 | 4.64e-01 | 0.3640 | 8.80e-02 | 1.75e-02 | -1.03e-01 | -3.31e-02 | -3.36e-01 | 4.85e-01 | 8.90e-01 | 4.15e-01 | 7.93e-01 | 7.71e-03 |
| KINETOCHORE ASSEMBLY | 16 | 2.19e-01 | 6.16e-01 | 0.3640 | 1.43e-01 | 2.58e-02 | 1.27e-01 | 2.66e-01 | 1.57e-01 | 3.23e-01 | 8.58e-01 | 3.80e-01 | 6.55e-02 | 2.78e-01 |
| NEGATIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 12 | 7.96e-01 | 9.65e-01 | 0.3640 | 6.40e-02 | 9.60e-02 | 1.89e-01 | 1.65e-01 | 2.37e-01 | 7.01e-01 | 5.65e-01 | 2.58e-01 | 3.23e-01 | 1.55e-01 |
| MESODERM DEVELOPMENT | 124 | 1.14e-04 | 3.05e-03 | 0.3640 | 7.17e-02 | 8.92e-02 | 1.73e-01 | 1.59e-01 | 2.53e-01 | 1.68e-01 | 8.64e-02 | 8.75e-04 | 2.21e-03 | 1.15e-06 |
| POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 12 | 2.36e-01 | 6.40e-01 | 0.3640 | -1.79e-01 | -1.14e-01 | 9.50e-02 | 6.40e-02 | 2.72e-01 | 2.82e-01 | 4.93e-01 | 5.69e-01 | 7.01e-01 | 1.03e-01 |
| NEGATIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS NONSENSE MEDIATED DECAY | 8 | 5.56e-01 | 8.77e-01 | 0.3640 | -5.37e-02 | -2.17e-01 | -1.60e-01 | -1.89e-01 | -1.45e-01 | 7.92e-01 | 2.87e-01 | 4.33e-01 | 3.56e-01 | 4.78e-01 |
| NEGATIVE REGULATION OF GENE EXPRESSION VIA CPG ISLAND METHYLATION | 7 | 5.75e-01 | 8.84e-01 | 0.3640 | -2.86e-02 | 2.49e-02 | 1.80e-01 | 2.29e-01 | 2.15e-01 | 8.96e-01 | 9.09e-01 | 4.11e-01 | 2.94e-01 | 3.25e-01 |
| RESPONSE TO INTERLEUKIN 12 | 12 | 2.78e-01 | 6.88e-01 | 0.3640 | 2.11e-01 | 1.52e-01 | 4.03e-02 | 2.50e-01 | 1.70e-02 | 2.06e-01 | 3.62e-01 | 8.09e-01 | 1.33e-01 | 9.19e-01 |
| REGULATION OF OLIGODENDROCYTE DIFFERENTIATION | 45 | 1.10e-01 | 4.54e-01 | 0.3630 | 7.80e-02 | 8.23e-02 | 1.96e-01 | 1.64e-01 | 2.32e-01 | 3.65e-01 | 3.39e-01 | 2.26e-02 | 5.70e-02 | 7.18e-03 |
| POSITIVE REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 6 | 7.50e-01 | 9.51e-01 | 0.3630 | -2.77e-02 | 4.99e-02 | 2.53e-01 | 1.28e-01 | 2.20e-01 | 9.07e-01 | 8.32e-01 | 2.84e-01 | 5.88e-01 | 3.51e-01 |
| LEUKOCYTE ACTIVATION INVOLVED IN INFLAMMATORY RESPONSE | 52 | 9.96e-02 | 4.29e-01 | 0.3630 | 1.83e-01 | 2.17e-01 | 1.46e-01 | 1.71e-01 | -1.31e-02 | 2.25e-02 | 6.66e-03 | 6.77e-02 | 3.24e-02 | 8.70e-01 |
| REGULATION OF OSTEOCLAST PROLIFERATION | 6 | 8.26e-01 | 9.72e-01 | 0.3630 | 2.07e-01 | 8.46e-02 | 9.37e-02 | 2.26e-01 | 1.48e-01 | 3.79e-01 | 7.20e-01 | 6.91e-01 | 3.38e-01 | 5.31e-01 |
| ANTIVIRAL INNATE IMMUNE RESPONSE | 48 | 1.35e-01 | 4.98e-01 | 0.3630 | 1.15e-01 | 1.07e-01 | 2.07e-01 | 1.61e-01 | 1.95e-01 | 1.67e-01 | 1.98e-01 | 1.29e-02 | 5.36e-02 | 1.96e-02 |
| NEGATIVE REGULATION OF HIPPO SIGNALING | 12 | 5.30e-01 | 8.63e-01 | 0.3630 | -2.07e-01 | -1.01e-01 | -2.07e-01 | -1.82e-01 | -5.29e-02 | 2.14e-01 | 5.46e-01 | 2.14e-01 | 2.75e-01 | 7.51e-01 |
| REGULATION OF VITAMIN D RECEPTOR SIGNALING PATHWAY | 10 | 4.76e-01 | 8.33e-01 | 0.3630 | 1.73e-01 | 2.93e-01 | 1.02e-01 | 6.88e-02 | 2.56e-02 | 3.42e-01 | 1.09e-01 | 5.75e-01 | 7.06e-01 | 8.89e-01 |
| POSITIVE REGULATION OF JUN KINASE ACTIVITY | 31 | 3.46e-01 | 7.50e-01 | 0.3630 | 1.87e-01 | 1.70e-01 | 1.40e-01 | 1.46e-01 | 1.63e-01 | 7.08e-02 | 1.02e-01 | 1.77e-01 | 1.59e-01 | 1.15e-01 |
| CELL CELL JUNCTION DISASSEMBLY | 5 | 5.03e-01 | 8.49e-01 | 0.3630 | -2.03e-01 | 7.99e-02 | 1.39e-01 | -8.82e-03 | 2.54e-01 | 4.31e-01 | 7.57e-01 | 5.90e-01 | 9.73e-01 | 3.25e-01 |
| TYPE B PANCREATIC CELL DIFFERENTIATION | 30 | 3.78e-01 | 7.75e-01 | 0.3630 | 9.05e-02 | 1.20e-01 | 2.19e-01 | 1.83e-01 | 1.66e-01 | 3.91e-01 | 2.55e-01 | 3.83e-02 | 8.20e-02 | 1.15e-01 |
| TETRAPYRROLE BIOSYNTHETIC PROCESS | 31 | 4.43e-02 | 2.73e-01 | 0.3630 | 8.44e-02 | 1.27e-01 | 1.13e-01 | 1.80e-01 | 2.51e-01 | 4.16e-01 | 2.22e-01 | 2.76e-01 | 8.20e-02 | 1.55e-02 |
| NEGATIVE REGULATION OF LONG TERM SYNAPTIC POTENTIATION | 13 | 5.03e-02 | 2.93e-01 | 0.3630 | 1.29e-01 | 6.30e-02 | -2.42e-01 | -4.00e-02 | -2.25e-01 | 4.19e-01 | 6.94e-01 | 1.31e-01 | 8.03e-01 | 1.59e-01 |
| RESPONSE TO OXYGEN LEVELS | 321 | 2.35e-08 | 1.43e-06 | 0.3630 | 1.30e-01 | 1.62e-01 | 1.90e-01 | 1.42e-01 | 1.80e-01 | 6.38e-05 | 6.39e-07 | 4.81e-09 | 1.21e-05 | 2.99e-08 |
| POSITIVE REGULATION OF CALCIUM ION DEPENDENT EXOCYTOSIS | 13 | 6.96e-01 | 9.31e-01 | 0.3630 | 1.26e-01 | 2.26e-01 | 2.14e-01 | 1.18e-01 | 7.18e-02 | 4.30e-01 | 1.59e-01 | 1.82e-01 | 4.63e-01 | 6.54e-01 |
| POSITIVE REGULATION OF COLLATERAL SPROUTING | 10 | 8.40e-01 | 9.73e-01 | 0.3630 | 2.29e-01 | 1.46e-01 | 1.32e-01 | 1.69e-01 | 1.08e-01 | 2.11e-01 | 4.24e-01 | 4.69e-01 | 3.54e-01 | 5.53e-01 |
| SUCCINATE METABOLIC PROCESS | 5 | 7.39e-01 | 9.49e-01 | 0.3620 | -2.13e-02 | -1.84e-01 | -1.29e-01 | -1.44e-01 | -2.45e-01 | 9.34e-01 | 4.77e-01 | 6.18e-01 | 5.76e-01 | 3.44e-01 |
| POSITIVE REGULATION OF MESENCHYMAL STEM CELL PROLIFERATION | 6 | 9.42e-01 | 9.92e-01 | 0.3620 | 1.40e-01 | 1.65e-01 | 1.53e-01 | 2.24e-01 | 1.04e-01 | 5.51e-01 | 4.85e-01 | 5.16e-01 | 3.42e-01 | 6.58e-01 |
| MITOTIC SISTER CHROMATID COHESION | 26 | 1.36e-01 | 4.99e-01 | 0.3620 | 1.77e-01 | 7.41e-02 | 1.34e-01 | 2.62e-01 | 8.73e-02 | 1.18e-01 | 5.13e-01 | 2.36e-01 | 2.06e-02 | 4.41e-01 |
| NEGATIVE REGULATION OF PEPTIDE SECRETION | 44 | 7.30e-02 | 3.66e-01 | 0.3620 | 8.09e-02 | 1.54e-01 | 1.82e-01 | 9.39e-02 | 2.43e-01 | 3.53e-01 | 7.73e-02 | 3.70e-02 | 2.81e-01 | 5.23e-03 |
| NEGATIVE REGULATION OF CHEMOTAXIS | 65 | 1.89e-02 | 1.61e-01 | 0.3620 | -1.49e-01 | -8.76e-02 | -1.82e-01 | -1.72e-01 | -1.96e-01 | 3.76e-02 | 2.22e-01 | 1.11e-02 | 1.62e-02 | 6.28e-03 |
| ASPARTATE FAMILY AMINO ACID CATABOLIC PROCESS | 17 | 3.43e-01 | 7.50e-01 | 0.3620 | -1.59e-01 | -2.03e-01 | -2.31e-01 | -1.02e-01 | -3.03e-02 | 2.56e-01 | 1.47e-01 | 9.91e-02 | 4.68e-01 | 8.29e-01 |
| MIRNA PROCESSING | 45 | 5.83e-02 | 3.19e-01 | 0.3620 | 1.14e-01 | 6.16e-02 | 1.68e-01 | 2.08e-01 | 2.07e-01 | 1.85e-01 | 4.75e-01 | 5.14e-02 | 1.56e-02 | 1.63e-02 |
| SKELETAL MUSCLE CELL DIFFERENTIATION | 71 | 7.96e-03 | 8.65e-02 | 0.3620 | 9.05e-02 | 1.32e-01 | 1.96e-01 | 1.00e-01 | 2.39e-01 | 1.87e-01 | 5.37e-02 | 4.24e-03 | 1.45e-01 | 5.08e-04 |
| ACETYL COA BIOSYNTHETIC PROCESS | 16 | 1.71e-01 | 5.56e-01 | 0.3620 | 6.18e-02 | -5.54e-03 | 8.49e-02 | 1.73e-01 | 3.00e-01 | 6.69e-01 | 9.69e-01 | 5.57e-01 | 2.30e-01 | 3.77e-02 |
| NEGATIVE REGULATION OF CENTRIOLE REPLICATION | 7 | 9.66e-01 | 9.94e-01 | 0.3620 | 2.03e-01 | 1.78e-01 | 1.65e-01 | 1.55e-01 | 8.24e-02 | 3.53e-01 | 4.14e-01 | 4.50e-01 | 4.76e-01 | 7.06e-01 |
| REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT | 25 | 2.73e-01 | 6.81e-01 | 0.3620 | 9.98e-02 | 6.96e-02 | 1.52e-01 | 1.40e-01 | 2.71e-01 | 3.88e-01 | 5.47e-01 | 1.88e-01 | 2.26e-01 | 1.89e-02 |
| BRANCHED CHAIN AMINO ACID CATABOLIC PROCESS | 20 | 3.06e-01 | 7.18e-01 | 0.3620 | 2.09e-01 | 1.06e-01 | 9.99e-02 | 2.25e-01 | 1.23e-01 | 1.05e-01 | 4.10e-01 | 4.39e-01 | 8.10e-02 | 3.40e-01 |
| RESPONSE TO SALT STRESS | 24 | 1.83e-01 | 5.68e-01 | 0.3620 | 6.62e-02 | 2.24e-01 | 1.86e-01 | 1.23e-01 | 1.64e-01 | 5.75e-01 | 5.76e-02 | 1.14e-01 | 2.99e-01 | 1.65e-01 |
| INNER CELL MASS CELL PROLIFERATION | 14 | 8.26e-01 | 9.72e-01 | 0.3620 | 2.04e-01 | 1.72e-01 | 1.33e-01 | 1.75e-01 | 1.08e-01 | 1.87e-01 | 2.65e-01 | 3.88e-01 | 2.58e-01 | 4.84e-01 |
| DICARBOXYLIC ACID BIOSYNTHETIC PROCESS | 12 | 2.47e-01 | 6.53e-01 | 0.3620 | -1.76e-01 | -2.24e-01 | -2.20e-01 | -3.92e-02 | -2.78e-03 | 2.91e-01 | 1.80e-01 | 1.87e-01 | 8.14e-01 | 9.87e-01 |
| CAVEOLIN MEDIATED ENDOCYTOSIS | 11 | 1.79e-01 | 5.63e-01 | 0.3620 | 2.55e-03 | 2.63e-01 | 1.72e-01 | 5.62e-02 | 1.70e-01 | 9.88e-01 | 1.31e-01 | 3.23e-01 | 7.47e-01 | 3.29e-01 |
| XENOBIOTIC METABOLIC PROCESS | 123 | 5.84e-03 | 6.87e-02 | 0.3620 | -1.59e-01 | -1.38e-01 | -1.64e-01 | -1.97e-01 | -1.44e-01 | 2.28e-03 | 8.01e-03 | 1.71e-03 | 1.59e-04 | 5.96e-03 |
| POSITIVE REGULATION OF FERTILIZATION | 5 | 6.56e-01 | 9.20e-01 | 0.3620 | -2.52e-02 | -6.70e-02 | -2.18e-01 | -2.73e-01 | -5.66e-02 | 9.22e-01 | 7.95e-01 | 3.98e-01 | 2.90e-01 | 8.26e-01 |
| NEGATIVE REGULATION OF BONE REMODELING | 18 | 4.57e-01 | 8.22e-01 | 0.3620 | 2.19e-01 | 2.39e-01 | 1.15e-01 | 1.02e-01 | 4.42e-02 | 1.08e-01 | 7.86e-02 | 4.00e-01 | 4.53e-01 | 7.46e-01 |
| TRNA MODIFICATION | 89 | 4.37e-02 | 2.71e-01 | 0.3620 | 1.55e-01 | 1.45e-01 | 1.77e-01 | 1.65e-01 | 1.65e-01 | 1.15e-02 | 1.84e-02 | 3.90e-03 | 7.26e-03 | 6.98e-03 |
| AUDITORY RECEPTOR CELL DEVELOPMENT | 24 | 5.98e-01 | 8.98e-01 | 0.3610 | -1.44e-01 | -1.51e-01 | -1.58e-01 | -1.57e-01 | -1.94e-01 | 2.21e-01 | 2.01e-01 | 1.81e-01 | 1.82e-01 | 1.01e-01 |
| RESPONSE TO LEAD ION | 19 | 2.63e-01 | 6.72e-01 | 0.3610 | 6.42e-02 | 3.47e-02 | 1.65e-01 | 2.30e-01 | 2.12e-01 | 6.28e-01 | 7.93e-01 | 2.12e-01 | 8.21e-02 | 1.10e-01 |
| POSITIVE REGULATION OF MAINTENANCE OF SISTER CHROMATID COHESION | 6 | 4.08e-01 | 7.94e-01 | 0.3610 | -2.40e-02 | -9.27e-02 | 1.73e-01 | 2.55e-01 | 1.62e-01 | 9.19e-01 | 6.94e-01 | 4.63e-01 | 2.79e-01 | 4.92e-01 |
| GANGLIOSIDE BIOSYNTHETIC PROCESS VIA LACTOSYLCERAMIDE | 6 | 8.65e-01 | 9.78e-01 | 0.3610 | -1.82e-01 | -1.47e-01 | -1.04e-01 | -2.51e-01 | -4.69e-02 | 4.40e-01 | 5.34e-01 | 6.60e-01 | 2.88e-01 | 8.42e-01 |
| MEMBRANE DEPOLARIZATION DURING ACTION POTENTIAL | 28 | 1.79e-01 | 5.63e-01 | 0.3610 | -2.42e-01 | -1.35e-01 | -8.64e-02 | -2.14e-01 | 1.76e-02 | 2.67e-02 | 2.15e-01 | 4.29e-01 | 5.01e-02 | 8.72e-01 |
| POSITIVE REGULATION OF SYNAPTIC VESICLE ENDOCYTOSIS | 6 | 7.82e-01 | 9.60e-01 | 0.3610 | -7.70e-02 | -1.38e-01 | -2.76e-01 | -1.21e-01 | -1.20e-01 | 7.44e-01 | 5.60e-01 | 2.41e-01 | 6.07e-01 | 6.10e-01 |
| RESPONSE TO 2 3 7 8 TETRACHLORODIBENZODIOXINE | 5 | 6.30e-01 | 9.10e-01 | 0.3610 | -8.04e-02 | -1.33e-01 | 3.09e-02 | 1.34e-01 | 2.96e-01 | 7.55e-01 | 6.07e-01 | 9.05e-01 | 6.05e-01 | 2.52e-01 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 48 | 1.66e-01 | 5.45e-01 | 0.3610 | -2.20e-01 | -1.48e-01 | -1.40e-01 | -1.89e-01 | -6.61e-02 | 8.23e-03 | 7.55e-02 | 9.37e-02 | 2.34e-02 | 4.28e-01 |
| PANCREAS DEVELOPMENT | 78 | 8.85e-03 | 9.32e-02 | 0.3610 | 6.30e-02 | 9.34e-02 | 2.06e-01 | 1.60e-01 | 2.22e-01 | 3.36e-01 | 1.54e-01 | 1.62e-03 | 1.46e-02 | 6.99e-04 |
| REGULATION OF PEPTIDYL LYSINE ACETYLATION | 28 | 2.56e-01 | 6.63e-01 | 0.3610 | 1.44e-01 | 1.26e-01 | 1.36e-01 | 2.30e-01 | 1.50e-01 | 1.87e-01 | 2.49e-01 | 2.14e-01 | 3.55e-02 | 1.69e-01 |
| CATECHOLAMINE UPTAKE INVOLVED IN SYNAPTIC TRANSMISSION | 12 | 6.24e-01 | 9.09e-01 | 0.3610 | 1.11e-01 | 1.22e-01 | 1.42e-01 | 8.95e-02 | 2.74e-01 | 5.04e-01 | 4.65e-01 | 3.95e-01 | 5.91e-01 | 1.01e-01 |
| SMALL NUCLEOLAR RIBONUCLEOPROTEIN COMPLEX ASSEMBLY | 12 | 7.64e-01 | 9.54e-01 | 0.3610 | 9.49e-02 | 1.04e-01 | 1.66e-01 | 1.22e-01 | 2.61e-01 | 5.69e-01 | 5.34e-01 | 3.20e-01 | 4.65e-01 | 1.18e-01 |
| POLYOL TRANSMEMBRANE TRANSPORT | 10 | 6.19e-02 | 3.30e-01 | 0.3600 | 6.70e-02 | 1.42e-01 | -1.10e-02 | -5.67e-02 | 3.19e-01 | 7.14e-01 | 4.35e-01 | 9.52e-01 | 7.56e-01 | 8.07e-02 |
| REGULATION OF TELOMERE MAINTENANCE IN RESPONSE TO DNA DAMAGE | 19 | 5.19e-01 | 8.57e-01 | 0.3600 | 1.39e-01 | 1.80e-01 | 1.61e-01 | 9.82e-02 | 2.07e-01 | 2.95e-01 | 1.75e-01 | 2.26e-01 | 4.58e-01 | 1.18e-01 |
| NEGATIVE REGULATION OF NOTCH SIGNALING PATHWAY | 38 | 1.57e-01 | 5.28e-01 | 0.3600 | 6.23e-02 | 1.36e-01 | 1.79e-01 | 1.17e-01 | 2.48e-01 | 5.06e-01 | 1.46e-01 | 5.65e-02 | 2.10e-01 | 8.14e-03 |
| NEUROTRANSMITTER LOADING INTO SYNAPTIC VESICLE | 7 | 4.48e-01 | 8.19e-01 | 0.3600 | -2.74e-01 | -2.08e-02 | -4.55e-02 | -2.17e-01 | 7.14e-02 | 2.10e-01 | 9.24e-01 | 8.35e-01 | 3.20e-01 | 7.44e-01 |
| NEGATIVE REGULATION OF MYOBLAST DIFFERENTIATION | 24 | 1.70e-01 | 5.54e-01 | 0.3600 | 1.37e-01 | 2.38e-01 | 1.92e-01 | 5.85e-02 | 1.18e-01 | 2.46e-01 | 4.37e-02 | 1.03e-01 | 6.20e-01 | 3.18e-01 |
| POSITIVE REGULATION OF CELL PROLIFERATION INVOLVED IN HEART MORPHOGENESIS | 5 | 9.18e-01 | 9.86e-01 | 0.3600 | 1.98e-01 | 1.15e-01 | 1.46e-01 | 1.33e-01 | 1.96e-01 | 4.44e-01 | 6.57e-01 | 5.71e-01 | 6.07e-01 | 4.49e-01 |
| NEURON RECOGNITION | 45 | 2.97e-01 | 7.08e-01 | 0.3600 | -1.70e-01 | -1.98e-01 | -1.52e-01 | -1.76e-01 | -8.51e-02 | 4.79e-02 | 2.16e-02 | 7.83e-02 | 4.10e-02 | 3.23e-01 |
| FATTY ACID BETA OXIDATION USING ACYL COA OXIDASE | 12 | 8.88e-01 | 9.80e-01 | 0.3600 | 2.14e-01 | 1.83e-01 | 1.34e-01 | 1.73e-01 | 4.74e-02 | 2.00e-01 | 2.72e-01 | 4.22e-01 | 2.98e-01 | 7.76e-01 |
| NEGATIVE REGULATION OF CELLULAR EXTRAVASATION | 9 | 9.14e-01 | 9.86e-01 | 0.3600 | -1.95e-01 | -2.18e-01 | -1.54e-01 | -1.42e-01 | 6.17e-03 | 3.11e-01 | 2.58e-01 | 4.23e-01 | 4.60e-01 | 9.74e-01 |
| NEGATIVE REGULATION OF MONONUCLEAR CELL MIGRATION | 24 | 2.42e-01 | 6.47e-01 | 0.3600 | -2.55e-02 | -1.63e-01 | -2.07e-01 | -1.29e-01 | -2.07e-01 | 8.28e-01 | 1.66e-01 | 7.97e-02 | 2.75e-01 | 7.94e-02 |
| DENDRITIC TRANSPORT OF RIBONUCLEOPROTEIN COMPLEX | 5 | 4.59e-01 | 8.23e-01 | 0.3600 | 1.34e-01 | -4.22e-02 | 2.40e-01 | 1.68e-01 | 1.53e-01 | 6.03e-01 | 8.70e-01 | 3.52e-01 | 5.15e-01 | 5.53e-01 |
| NEGATIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 44 | 4.92e-02 | 2.90e-01 | 0.3600 | 1.54e-01 | 1.01e-01 | 1.25e-01 | 2.22e-01 | 1.74e-01 | 7.77e-02 | 2.46e-01 | 1.50e-01 | 1.07e-02 | 4.59e-02 |
| REGULATION OF VACUOLE ORGANIZATION | 53 | 6.18e-02 | 3.30e-01 | 0.3600 | 1.68e-01 | 1.18e-01 | 1.59e-01 | 2.39e-01 | 7.11e-02 | 3.48e-02 | 1.37e-01 | 4.55e-02 | 2.64e-03 | 3.70e-01 |
| MITOTIC CELL CYCLE | 900 | 1.44e-23 | 4.33e-21 | 0.3600 | 1.52e-01 | 1.27e-01 | 1.75e-01 | 2.02e-01 | 1.34e-01 | 8.62e-15 | 8.50e-11 | 3.90e-19 | 5.96e-25 | 7.72e-12 |
| PLASMA MEMBRANE RAFT ASSEMBLY | 7 | 5.65e-01 | 8.81e-01 | 0.3590 | 4.26e-02 | 7.47e-02 | 1.53e-01 | -1.77e-02 | 3.13e-01 | 8.45e-01 | 7.32e-01 | 4.82e-01 | 9.35e-01 | 1.52e-01 |
| POSITIVE REGULATION OF METALLOENDOPEPTIDASE ACTIVITY | 7 | 9.62e-01 | 9.94e-01 | 0.3590 | -1.77e-01 | -1.42e-01 | -1.51e-01 | -2.08e-01 | -1.07e-01 | 4.17e-01 | 5.16e-01 | 4.89e-01 | 3.39e-01 | 6.25e-01 |
| MYELIN MAINTENANCE | 17 | 6.82e-01 | 9.30e-01 | 0.3590 | 9.22e-02 | 1.71e-01 | 1.98e-01 | 1.85e-01 | 1.35e-01 | 5.10e-01 | 2.22e-01 | 1.58e-01 | 1.88e-01 | 3.36e-01 |
| PROTEIN LOCALIZATION TO CILIARY MEMBRANE | 11 | 5.63e-01 | 8.79e-01 | 0.3590 | 8.76e-02 | 4.39e-02 | 1.89e-01 | 2.52e-01 | 1.42e-01 | 6.15e-01 | 8.01e-01 | 2.78e-01 | 1.47e-01 | 4.15e-01 |
| XENOBIOTIC TRANSPORT | 59 | 6.86e-02 | 3.52e-01 | 0.3590 | -1.32e-01 | -1.28e-01 | -1.87e-01 | -2.24e-01 | -1.00e-01 | 7.94e-02 | 8.98e-02 | 1.30e-02 | 2.88e-03 | 1.83e-01 |
| RETINAL BLOOD VESSEL MORPHOGENESIS | 5 | 5.45e-01 | 8.70e-01 | 0.3590 | 1.39e-01 | 1.43e-01 | 1.89e-01 | -3.06e-02 | 2.29e-01 | 5.89e-01 | 5.79e-01 | 4.64e-01 | 9.06e-01 | 3.76e-01 |
| PUTRESCINE BIOSYNTHETIC PROCESS | 5 | 8.91e-01 | 9.81e-01 | 0.3590 | 1.13e-01 | 1.12e-01 | 1.02e-01 | 1.58e-01 | 2.62e-01 | 6.61e-01 | 6.65e-01 | 6.94e-01 | 5.41e-01 | 3.11e-01 |
| SOMATIC DIVERSIFICATION OF IMMUNOGLOBULINS | 65 | 1.16e-01 | 4.64e-01 | 0.3590 | 1.54e-01 | 1.67e-01 | 1.58e-01 | 1.97e-01 | 1.16e-01 | 3.20e-02 | 1.98e-02 | 2.76e-02 | 5.98e-03 | 1.05e-01 |
| RESPONSE TO AMMONIUM ION | 6 | 5.12e-01 | 8.54e-01 | 0.3590 | -2.46e-02 | -3.52e-02 | -2.16e-01 | 9.01e-03 | -2.84e-01 | 9.17e-01 | 8.81e-01 | 3.61e-01 | 9.70e-01 | 2.29e-01 |
| CELL PROLIFERATION IN MIDBRAIN | 8 | 7.00e-01 | 9.31e-01 | 0.3590 | 7.81e-02 | 1.48e-01 | 1.20e-01 | 6.42e-02 | 2.87e-01 | 7.02e-01 | 4.68e-01 | 5.57e-01 | 7.53e-01 | 1.60e-01 |
| POSITIVE REGULATION OF DNA REPAIR | 124 | 1.76e-03 | 2.75e-02 | 0.3590 | 1.29e-01 | 1.27e-01 | 1.64e-01 | 2.01e-01 | 1.70e-01 | 1.34e-02 | 1.46e-02 | 1.56e-03 | 1.12e-04 | 1.09e-03 |
| ALDEHYDE BIOSYNTHETIC PROCESS | 16 | 6.61e-01 | 9.22e-01 | 0.3590 | 1.02e-01 | 1.61e-01 | 2.31e-01 | 1.74e-01 | 9.34e-02 | 4.79e-01 | 2.66e-01 | 1.09e-01 | 2.27e-01 | 5.18e-01 |
| POSITIVE REGULATION OF SYNAPTIC TRANSMISSION CHOLINERGIC | 6 | 9.39e-01 | 9.92e-01 | 0.3590 | -2.14e-01 | -2.28e-01 | -1.37e-01 | -1.10e-01 | -1.52e-02 | 3.65e-01 | 3.33e-01 | 5.62e-01 | 6.42e-01 | 9.49e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY RENIN ANGIOTENSIN | 20 | 8.67e-02 | 3.98e-01 | 0.3590 | 1.00e-01 | -2.97e-02 | -1.83e-01 | -3.96e-03 | -2.90e-01 | 4.37e-01 | 8.18e-01 | 1.56e-01 | 9.76e-01 | 2.47e-02 |
| REVERSIBLE DIFFERENTIATION | 11 | 8.36e-01 | 9.73e-01 | 0.3590 | 1.06e-01 | 1.73e-01 | 1.58e-01 | 1.54e-01 | 1.96e-01 | 5.42e-01 | 3.21e-01 | 3.63e-01 | 3.76e-01 | 2.60e-01 |
| NEGATIVE REGULATION OF CELL CYCLE | 391 | 7.55e-12 | 7.10e-10 | 0.3580 | 1.40e-01 | 1.12e-01 | 1.73e-01 | 2.13e-01 | 1.46e-01 | 2.16e-06 | 1.35e-04 | 4.33e-09 | 5.00e-13 | 7.66e-07 |
| REGULATION OF NEURON APOPTOTIC PROCESS | 224 | 7.62e-06 | 2.93e-04 | 0.3580 | 1.02e-01 | 1.33e-01 | 1.93e-01 | 1.62e-01 | 1.93e-01 | 8.83e-03 | 6.27e-04 | 6.52e-07 | 2.98e-05 | 6.54e-07 |
| NEGATIVE REGULATION OF FIBROBLAST PROLIFERATION | 34 | 8.15e-02 | 3.86e-01 | 0.3580 | 9.31e-02 | 4.12e-02 | 1.65e-01 | 2.22e-01 | 2.03e-01 | 3.47e-01 | 6.77e-01 | 9.50e-02 | 2.48e-02 | 4.06e-02 |
| TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING | 77 | 7.65e-03 | 8.45e-02 | 0.3580 | 1.44e-01 | 1.04e-01 | 1.60e-01 | 2.35e-01 | 1.26e-01 | 2.89e-02 | 1.13e-01 | 1.55e-02 | 3.53e-04 | 5.61e-02 |
| VITAMIN D BIOSYNTHETIC PROCESS | 10 | 7.75e-01 | 9.57e-01 | 0.3580 | 1.45e-01 | 8.95e-02 | 1.68e-01 | 1.34e-01 | 2.31e-01 | 4.26e-01 | 6.24e-01 | 3.59e-01 | 4.64e-01 | 2.06e-01 |
| INTRACELLULAR WATER HOMEOSTASIS | 6 | 2.83e-01 | 6.93e-01 | 0.3580 | -2.63e-01 | -2.27e-02 | -1.29e-01 | -1.25e-01 | 1.63e-01 | 2.65e-01 | 9.23e-01 | 5.85e-01 | 5.97e-01 | 4.89e-01 |
| MEMBRANE DEPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 22 | 1.71e-01 | 5.55e-01 | 0.3580 | -2.62e-01 | -1.28e-01 | -4.78e-02 | -1.94e-01 | 5.97e-02 | 3.37e-02 | 3.00e-01 | 6.98e-01 | 1.15e-01 | 6.28e-01 |
| REGULATION OF GLIAL CELL DIFFERENTIATION | 78 | 7.73e-03 | 8.50e-02 | 0.3580 | 6.91e-02 | 8.19e-02 | 1.98e-01 | 1.48e-01 | 2.36e-01 | 2.91e-01 | 2.11e-01 | 2.52e-03 | 2.41e-02 | 3.12e-04 |
| MORPHOGENESIS OF EMBRYONIC EPITHELIUM | 150 | 1.63e-04 | 3.93e-03 | 0.3580 | 8.28e-02 | 1.36e-01 | 1.87e-01 | 1.41e-01 | 2.19e-01 | 8.00e-02 | 4.04e-03 | 7.87e-05 | 2.89e-03 | 3.54e-06 |
| T CELL EXTRAVASATION | 10 | 7.14e-01 | 9.36e-01 | 0.3580 | 1.78e-01 | 1.71e-01 | 1.25e-01 | 1.87e-01 | -1.28e-01 | 3.29e-01 | 3.48e-01 | 4.95e-01 | 3.06e-01 | 4.82e-01 |
| LYTIC VACUOLE ORGANIZATION | 103 | 3.02e-03 | 4.19e-02 | 0.3580 | 1.47e-01 | 1.46e-01 | 1.89e-01 | 2.18e-01 | 4.62e-02 | 9.85e-03 | 1.03e-02 | 9.43e-04 | 1.34e-04 | 4.18e-01 |
| NUCLEAR PORE COMPLEX ASSEMBLY | 11 | 7.56e-02 | 3.72e-01 | 0.3580 | 1.67e-01 | 2.50e-02 | -2.08e-01 | 8.00e-02 | -2.23e-01 | 3.36e-01 | 8.86e-01 | 2.33e-01 | 6.46e-01 | 1.99e-01 |
| POSITIVE REGULATION OF DENDRITIC CELL ANTIGEN PROCESSING AND PRESENTATION | 7 | 1.56e-01 | 5.28e-01 | 0.3580 | 2.26e-01 | 2.59e-01 | -3.09e-02 | -9.24e-02 | 1.79e-02 | 3.00e-01 | 2.35e-01 | 8.87e-01 | 6.72e-01 | 9.35e-01 |
| REGULATION OF GLIOGENESIS | 106 | 2.15e-03 | 3.23e-02 | 0.3580 | 8.24e-02 | 1.13e-01 | 1.85e-01 | 1.35e-01 | 2.37e-01 | 1.43e-01 | 4.52e-02 | 9.91e-04 | 1.63e-02 | 2.52e-05 |
| ENDONUCLEOLYTIC CLEAVAGE IN 5 ETS OF TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 8 | 8.46e-01 | 9.76e-01 | 0.3580 | 7.83e-02 | 9.99e-02 | 2.23e-01 | 1.14e-01 | 2.22e-01 | 7.02e-01 | 6.25e-01 | 2.75e-01 | 5.78e-01 | 2.77e-01 |
| GENERAL ADAPTATION SYNDROME | 6 | 7.41e-01 | 9.49e-01 | 0.3580 | -1.67e-01 | -1.60e-01 | 4.55e-02 | -3.24e-02 | 2.67e-01 | 4.78e-01 | 4.97e-01 | 8.47e-01 | 8.91e-01 | 2.58e-01 |
| MRNA METHYLATION | 17 | 7.97e-01 | 9.66e-01 | 0.3580 | 1.69e-01 | 1.54e-01 | 1.98e-01 | 1.62e-01 | 1.02e-01 | 2.28e-01 | 2.73e-01 | 1.57e-01 | 2.48e-01 | 4.67e-01 |
| OSTEOCLAST FUSION | 6 | 9.15e-01 | 9.86e-01 | 0.3570 | 1.49e-01 | 1.42e-01 | 1.88e-01 | 2.24e-01 | -1.29e-02 | 5.28e-01 | 5.47e-01 | 4.26e-01 | 3.42e-01 | 9.56e-01 |
| ESTROUS CYCLE | 16 | 1.65e-01 | 5.45e-01 | 0.3570 | 2.76e-01 | 7.23e-02 | 8.21e-02 | 1.92e-01 | 5.40e-02 | 5.60e-02 | 6.16e-01 | 5.69e-01 | 1.85e-01 | 7.08e-01 |
| REGULATION OF MEIOTIC CELL CYCLE | 66 | 3.43e-02 | 2.36e-01 | 0.3570 | 1.39e-01 | 1.01e-01 | 1.93e-01 | 2.17e-01 | 1.18e-01 | 5.12e-02 | 1.56e-01 | 6.60e-03 | 2.31e-03 | 9.80e-02 |
| POSITIVE REGULATION OF TISSUE REMODELING | 23 | 3.33e-01 | 7.40e-01 | 0.3570 | -1.08e-01 | -1.47e-01 | -1.64e-01 | -2.32e-01 | -1.16e-01 | 3.69e-01 | 2.21e-01 | 1.74e-01 | 5.37e-02 | 3.36e-01 |
| AMINO ACID BETAINE TRANSPORT | 13 | 6.01e-01 | 8.99e-01 | 0.3570 | 1.05e-01 | 8.79e-02 | 1.81e-01 | 2.51e-01 | 1.16e-01 | 5.12e-01 | 5.83e-01 | 2.59e-01 | 1.18e-01 | 4.71e-01 |
| BRANCHING INVOLVED IN MAMMARY GLAND DUCT MORPHOGENESIS | 20 | 6.01e-02 | 3.25e-01 | 0.3570 | 7.61e-02 | 2.80e-01 | 1.78e-01 | 1.08e-01 | 3.30e-03 | 5.56e-01 | 3.01e-02 | 1.69e-01 | 4.02e-01 | 9.80e-01 |
| DNA DEAMINATION | 13 | 5.57e-01 | 8.77e-01 | 0.3570 | -2.69e-01 | -1.43e-01 | -8.18e-02 | -1.59e-01 | 5.43e-02 | 9.33e-02 | 3.73e-01 | 6.10e-01 | 3.21e-01 | 7.34e-01 |
| POSITIVE REGULATION OF VASCULAR ENDOTHELIAL CELL PROLIFERATION | 26 | 2.40e-01 | 6.44e-01 | 0.3570 | 1.21e-01 | 1.06e-01 | 1.21e-01 | 1.65e-01 | 2.44e-01 | 2.85e-01 | 3.51e-01 | 2.87e-01 | 1.45e-01 | 3.10e-02 |
| REGULATION OF NCRNA TRANSCRIPTION | 91 | 2.58e-02 | 1.97e-01 | 0.3570 | 1.22e-01 | 1.40e-01 | 1.68e-01 | 1.67e-01 | 1.93e-01 | 4.43e-02 | 2.13e-02 | 5.67e-03 | 6.02e-03 | 1.47e-03 |
| VACUOLE ORGANIZATION | 219 | 8.15e-06 | 3.10e-04 | 0.3570 | 1.58e-01 | 1.47e-01 | 1.71e-01 | 2.15e-01 | 7.22e-02 | 5.76e-05 | 1.77e-04 | 1.24e-05 | 4.10e-08 | 6.55e-02 |
| THYROID HORMONE METABOLIC PROCESS | 28 | 3.68e-01 | 7.69e-01 | 0.3570 | -1.53e-01 | -1.28e-01 | -2.14e-01 | -1.93e-01 | -6.70e-02 | 1.60e-01 | 2.43e-01 | 5.05e-02 | 7.65e-02 | 5.39e-01 |
| ESTABLISHMENT OR MAINTENANCE OF TRANSMEMBRANE ELECTROCHEMICAL GRADIENT | 11 | 9.19e-01 | 9.86e-01 | 0.3570 | 1.21e-01 | 1.49e-01 | 1.89e-01 | 1.48e-01 | 1.81e-01 | 4.87e-01 | 3.91e-01 | 2.77e-01 | 3.96e-01 | 3.00e-01 |
| CELLULAR RESPONSE TO GLUCOCORTICOID STIMULUS | 49 | 2.84e-03 | 4.01e-02 | 0.3570 | -3.18e-02 | 8.14e-02 | 1.37e-01 | 8.22e-02 | 3.07e-01 | 7.00e-01 | 3.24e-01 | 9.77e-02 | 3.19e-01 | 2.02e-04 |
| BILE ACID BIOSYNTHETIC PROCESS | 36 | 3.37e-01 | 7.43e-01 | 0.3560 | -9.81e-02 | -1.74e-01 | -2.07e-01 | -1.62e-01 | -1.35e-01 | 3.08e-01 | 7.14e-02 | 3.15e-02 | 9.34e-02 | 1.60e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE I | 33 | 3.49e-01 | 7.52e-01 | 0.3560 | 1.29e-01 | 1.32e-01 | 1.49e-01 | 1.86e-01 | 1.90e-01 | 1.99e-01 | 1.89e-01 | 1.38e-01 | 6.48e-02 | 5.87e-02 |
| MITOTIC NUCLEAR MEMBRANE DISASSEMBLY | 7 | 5.39e-01 | 8.67e-01 | 0.3560 | 1.33e-01 | -1.89e-02 | -1.94e-01 | -1.07e-01 | -2.45e-01 | 5.41e-01 | 9.31e-01 | 3.75e-01 | 6.25e-01 | 2.62e-01 |
| NEGATIVE REGULATION OF STRIATED MUSCLE CONTRACTION | 9 | 6.10e-01 | 9.04e-01 | 0.3560 | 1.71e-01 | 2.48e-01 | 7.26e-02 | 1.34e-01 | -1.14e-01 | 3.74e-01 | 1.98e-01 | 7.06e-01 | 4.87e-01 | 5.54e-01 |
| NEGATIVE REGULATION OF MYELOID LEUKOCYTE MEDIATED IMMUNITY | 10 | 2.05e-01 | 5.97e-01 | 0.3560 | 1.32e-01 | 1.00e-01 | -2.01e-01 | -9.61e-02 | -2.24e-01 | 4.71e-01 | 5.84e-01 | 2.72e-01 | 5.99e-01 | 2.21e-01 |
| GROOMING BEHAVIOR | 17 | 3.95e-01 | 7.85e-01 | 0.3560 | 1.98e-01 | 2.41e-01 | 1.43e-01 | 6.58e-02 | 6.74e-02 | 1.57e-01 | 8.56e-02 | 3.06e-01 | 6.38e-01 | 6.31e-01 |
| RESPONSE TO AMINO ACID STARVATION | 53 | 2.75e-02 | 2.05e-01 | 0.3560 | 8.81e-02 | 8.82e-02 | 1.85e-01 | 2.28e-01 | 1.58e-01 | 2.67e-01 | 2.67e-01 | 1.99e-02 | 4.08e-03 | 4.67e-02 |
| RESPONSE TO INTERLEUKIN 9 | 5 | 4.43e-01 | 8.13e-01 | 0.3560 | 8.30e-02 | 2.11e-01 | 4.61e-02 | 1.88e-01 | 1.94e-01 | 7.48e-01 | 4.14e-01 | 8.58e-01 | 4.66e-01 | 4.52e-01 |
| POSITIVE REGULATION OF DEFENSE RESPONSE TO BACTERIUM | 14 | 3.96e-02 | 2.57e-01 | 0.3560 | 1.66e-01 | 2.28e-01 | 5.91e-04 | -1.15e-01 | -1.85e-01 | 2.83e-01 | 1.40e-01 | 9.97e-01 | 4.57e-01 | 2.32e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL MATRIX ADHESION VIA FIBRONECTIN | 5 | 9.78e-01 | 9.96e-01 | 0.3560 | 2.00e-01 | 2.06e-01 | 1.53e-01 | 1.27e-01 | 6.58e-02 | 4.40e-01 | 4.24e-01 | 5.53e-01 | 6.22e-01 | 7.99e-01 |
| NEGATIVE REGULATION OF VITAMIN METABOLIC PROCESS | 7 | 8.51e-01 | 9.76e-01 | 0.3550 | 2.09e-01 | 1.50e-01 | 9.34e-02 | 1.58e-01 | 1.63e-01 | 3.39e-01 | 4.91e-01 | 6.69e-01 | 4.70e-01 | 4.55e-01 |
| ACETATE ESTER METABOLIC PROCESS | 6 | 5.24e-01 | 8.60e-01 | 0.3550 | 1.27e-01 | 2.89e-01 | 7.33e-02 | -1.89e-02 | -1.45e-01 | 5.91e-01 | 2.20e-01 | 7.56e-01 | 9.36e-01 | 5.39e-01 |
| GLYCEROL TRANSMEMBRANE TRANSPORT | 7 | 1.29e-01 | 4.87e-01 | 0.3550 | -9.48e-02 | 6.73e-02 | -1.67e-01 | -2.42e-01 | 1.62e-01 | 6.64e-01 | 7.58e-01 | 4.45e-01 | 2.68e-01 | 4.57e-01 |
| REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE | 21 | 7.75e-01 | 9.57e-01 | 0.3550 | 1.56e-01 | 1.85e-01 | 1.72e-01 | 1.81e-01 | 7.43e-02 | 2.17e-01 | 1.43e-01 | 1.72e-01 | 1.52e-01 | 5.55e-01 |
| PROSTAGLANDIN SECRETION | 17 | 1.14e-01 | 4.61e-01 | 0.3550 | -6.33e-02 | 5.49e-02 | -1.67e-01 | -2.07e-01 | -2.20e-01 | 6.51e-01 | 6.95e-01 | 2.35e-01 | 1.40e-01 | 1.16e-01 |
| PARACRINE SIGNALING | 7 | 5.51e-01 | 8.75e-01 | 0.3550 | 1.66e-01 | 1.84e-01 | -8.09e-02 | -2.11e-02 | -2.40e-01 | 4.47e-01 | 3.99e-01 | 7.11e-01 | 9.23e-01 | 2.72e-01 |
| NEGATIVE REGULATION OF FAT CELL PROLIFERATION | 5 | 6.97e-01 | 9.31e-01 | 0.3540 | 2.39e-01 | 2.57e-01 | 1.18e-02 | 4.54e-02 | 1.98e-04 | 3.54e-01 | 3.19e-01 | 9.63e-01 | 8.61e-01 | 9.99e-01 |
| LUNG CELL DIFFERENTIATION | 28 | 2.60e-01 | 6.67e-01 | 0.3540 | 1.42e-01 | 9.42e-02 | 1.27e-01 | 1.91e-01 | 2.09e-01 | 1.93e-01 | 3.88e-01 | 2.43e-01 | 7.98e-02 | 5.54e-02 |
| ANTEROGRADE AXONAL TRANSPORT OF MITOCHONDRION | 6 | 9.70e-01 | 9.95e-01 | 0.3540 | -2.16e-01 | -1.67e-01 | -1.30e-01 | -1.84e-01 | -1.33e-02 | 3.59e-01 | 4.78e-01 | 5.81e-01 | 4.36e-01 | 9.55e-01 |
| POLYADENYLATION DEPENDENT SNORNA 3 END PROCESSING | 8 | 4.24e-01 | 8.03e-01 | 0.3540 | -1.13e-01 | 1.51e-02 | 5.27e-02 | 5.28e-02 | 3.27e-01 | 5.80e-01 | 9.41e-01 | 7.96e-01 | 7.96e-01 | 1.09e-01 |
| POSITIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 21 | 2.09e-01 | 6.03e-01 | 0.3540 | -1.30e-01 | -2.17e-02 | -1.82e-01 | -2.04e-01 | -1.83e-01 | 3.03e-01 | 8.64e-01 | 1.49e-01 | 1.06e-01 | 1.46e-01 |
| CIRCADIAN SLEEP WAKE CYCLE NON REM SLEEP | 6 | 1.34e-01 | 4.96e-01 | 0.3540 | 5.52e-02 | 1.20e-01 | -2.62e-02 | -2.12e-01 | 2.50e-01 | 8.15e-01 | 6.10e-01 | 9.12e-01 | 3.70e-01 | 2.89e-01 |
| CELLULAR LIPID BIOSYNTHETIC PROCESS | 12 | 7.53e-01 | 9.51e-01 | 0.3540 | -1.20e-01 | -1.64e-01 | -1.53e-01 | -9.88e-02 | -2.26e-01 | 4.73e-01 | 3.24e-01 | 3.58e-01 | 5.54e-01 | 1.76e-01 |
| PROTEOLYSIS INVOLVED IN PROTEIN CATABOLIC PROCESS | 715 | 3.10e-21 | 7.07e-19 | 0.3540 | 1.47e-01 | 1.31e-01 | 1.56e-01 | 2.12e-01 | 1.30e-01 | 1.79e-11 | 2.07e-09 | 1.01e-12 | 3.61e-22 | 3.44e-09 |
| REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 182 | 1.96e-04 | 4.65e-03 | 0.3540 | 1.51e-01 | 1.37e-01 | 1.58e-01 | 1.98e-01 | 1.40e-01 | 4.58e-04 | 1.47e-03 | 2.26e-04 | 3.92e-06 | 1.14e-03 |
| POSITIVE REGULATION OF NEUROTRANSMITTER UPTAKE | 6 | 8.26e-01 | 9.72e-01 | 0.3540 | -1.91e-01 | -2.24e-01 | -1.00e-01 | -6.67e-02 | 1.54e-01 | 4.17e-01 | 3.41e-01 | 6.71e-01 | 7.77e-01 | 5.13e-01 |
| NEGATIVE REGULATION OF PROTEIN ACETYLATION | 8 | 4.86e-01 | 8.38e-01 | 0.3540 | -2.61e-02 | -8.81e-02 | 1.56e-01 | 1.77e-01 | 2.47e-01 | 8.98e-01 | 6.66e-01 | 4.44e-01 | 3.86e-01 | 2.27e-01 |
| POSITIVE REGULATION OF DOPAMINE SECRETION | 6 | 7.06e-01 | 9.33e-01 | 0.3540 | -1.13e-01 | -4.52e-02 | 1.32e-01 | -3.81e-02 | 3.03e-01 | 6.32e-01 | 8.48e-01 | 5.77e-01 | 8.72e-01 | 1.99e-01 |
| SENSORY PERCEPTION OF UMAMI TASTE | 7 | 5.19e-01 | 8.57e-01 | 0.3540 | -2.70e-01 | -1.14e-01 | -8.57e-02 | -9.80e-02 | -1.48e-01 | 2.15e-01 | 6.01e-01 | 6.94e-01 | 6.53e-01 | 4.97e-01 |
| MONOCYTE CHEMOTAXIS | 69 | 3.03e-06 | 1.30e-04 | 0.3540 | -2.57e-02 | 2.29e-02 | -1.60e-01 | -2.35e-01 | -2.08e-01 | 7.12e-01 | 7.43e-01 | 2.17e-02 | 7.38e-04 | 2.83e-03 |
| MITOCHONDRIAL TRNA PROCESSING | 13 | 8.28e-01 | 9.72e-01 | 0.3540 | 1.64e-01 | 1.48e-01 | 1.33e-01 | 1.84e-01 | 1.57e-01 | 3.07e-01 | 3.54e-01 | 4.06e-01 | 2.50e-01 | 3.27e-01 |
| CELLULAR RESPONSE TO UV | 87 | 5.30e-02 | 3.05e-01 | 0.3540 | 1.51e-01 | 1.66e-01 | 1.56e-01 | 1.85e-01 | 1.26e-01 | 1.47e-02 | 7.42e-03 | 1.17e-02 | 2.87e-03 | 4.16e-02 |
| REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 30 | 1.45e-01 | 5.12e-01 | 0.3540 | 6.97e-02 | 1.99e-01 | 1.74e-01 | 8.96e-02 | 2.06e-01 | 5.09e-01 | 5.94e-02 | 9.85e-02 | 3.96e-01 | 5.13e-02 |
| GLYCOSIDE TRANSPORT | 5 | 2.57e-01 | 6.63e-01 | 0.3540 | 4.25e-02 | 2.30e-01 | -8.92e-02 | -2.34e-01 | -8.66e-02 | 8.69e-01 | 3.73e-01 | 7.30e-01 | 3.64e-01 | 7.37e-01 |
| NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 241 | 1.51e-07 | 8.11e-06 | 0.3540 | 1.51e-01 | 1.13e-01 | 1.63e-01 | 2.22e-01 | 1.16e-01 | 5.23e-05 | 2.58e-03 | 1.29e-05 | 2.74e-09 | 1.92e-03 |
| GANGLION DEVELOPMENT | 17 | 5.97e-01 | 8.98e-01 | 0.3540 | 7.35e-02 | 1.39e-01 | 2.26e-01 | 1.83e-01 | 1.25e-01 | 6.00e-01 | 3.20e-01 | 1.07e-01 | 1.91e-01 | 3.73e-01 |
| BRAINSTEM DEVELOPMENT | 7 | 7.21e-01 | 9.39e-01 | 0.3540 | 1.09e-01 | 1.66e-01 | 2.19e-01 | 1.83e-01 | -6.76e-02 | 6.19e-01 | 4.48e-01 | 3.17e-01 | 4.02e-01 | 7.57e-01 |
| RESPONSE TO HYDROGEN PEROXIDE | 96 | 7.83e-03 | 8.53e-02 | 0.3540 | 1.60e-01 | 1.46e-01 | 1.60e-01 | 2.23e-01 | 5.53e-02 | 6.87e-03 | 1.31e-02 | 6.90e-03 | 1.64e-04 | 3.49e-01 |
| RESPONSE TO INTERLEUKIN 4 | 33 | 5.75e-01 | 8.84e-01 | 0.3530 | 1.72e-01 | 1.71e-01 | 1.57e-01 | 1.89e-01 | 7.41e-02 | 8.68e-02 | 8.95e-02 | 1.18e-01 | 5.96e-02 | 4.62e-01 |
| MECHANOSENSORY BEHAVIOR | 14 | 4.79e-01 | 8.34e-01 | 0.3530 | -1.67e-01 | -6.43e-02 | -1.58e-01 | -2.56e-01 | -5.18e-02 | 2.80e-01 | 6.77e-01 | 3.08e-01 | 9.76e-02 | 7.37e-01 |
| REGULATION OF DOUBLE STRAND BREAK REPAIR | 125 | 6.33e-04 | 1.22e-02 | 0.3530 | 1.41e-01 | 1.39e-01 | 1.55e-01 | 2.22e-01 | 1.13e-01 | 6.57e-03 | 7.39e-03 | 2.75e-03 | 1.88e-05 | 2.97e-02 |
| NEGATIVE REGULATION OF TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 7 | 4.75e-02 | 2.86e-01 | 0.3530 | 2.66e-01 | -8.97e-03 | -2.27e-01 | 4.95e-02 | -1.09e-02 | 2.23e-01 | 9.67e-01 | 2.99e-01 | 8.20e-01 | 9.60e-01 |
| EMBRYONIC DIGIT MORPHOGENESIS | 57 | 1.61e-01 | 5.36e-01 | 0.3530 | 9.93e-02 | 1.33e-01 | 1.84e-01 | 1.57e-01 | 1.96e-01 | 1.95e-01 | 8.17e-02 | 1.60e-02 | 4.09e-02 | 1.06e-02 |
| EXTRACELLULAR REGULATION OF SIGNAL TRANSDUCTION | 13 | 7.95e-01 | 9.65e-01 | 0.3530 | -1.11e-01 | -1.03e-01 | -1.59e-01 | -2.02e-01 | -1.89e-01 | 4.88e-01 | 5.22e-01 | 3.22e-01 | 2.08e-01 | 2.38e-01 |
| CELLULAR RESPONSE TO ETHER | 6 | 4.46e-01 | 8.17e-01 | 0.3530 | 2.31e-01 | 1.87e-01 | 1.65e-03 | 5.97e-02 | 1.81e-01 | 3.28e-01 | 4.28e-01 | 9.94e-01 | 8.00e-01 | 4.43e-01 |
| BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 151 | 8.30e-04 | 1.50e-02 | 0.3530 | 1.06e-01 | 1.71e-01 | 1.87e-01 | 1.56e-01 | 1.56e-01 | 2.51e-02 | 2.85e-04 | 7.16e-05 | 9.02e-04 | 9.19e-04 |
| STOMACH DEVELOPMENT | 5 | 9.67e-01 | 9.94e-01 | 0.3530 | 2.18e-01 | 1.62e-01 | 1.17e-01 | 1.61e-01 | 1.04e-01 | 3.98e-01 | 5.30e-01 | 6.52e-01 | 5.34e-01 | 6.86e-01 |
| PEPTIDYL PROLINE HYDROXYLATION TO 4 HYDROXY L PROLINE | 8 | 9.50e-01 | 9.94e-01 | 0.3520 | 1.76e-01 | 2.10e-01 | 1.51e-01 | 1.61e-01 | 2.43e-02 | 3.89e-01 | 3.04e-01 | 4.61e-01 | 4.29e-01 | 9.05e-01 |
| NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 22 | 3.23e-01 | 7.33e-01 | 0.3520 | 1.09e-01 | 1.12e-01 | 1.34e-01 | 2.21e-01 | 1.83e-01 | 3.75e-01 | 3.65e-01 | 2.78e-01 | 7.33e-02 | 1.38e-01 |
| HEART VALVE DEVELOPMENT | 72 | 4.27e-02 | 2.69e-01 | 0.3520 | 7.60e-02 | 1.29e-01 | 1.89e-01 | 1.48e-01 | 2.10e-01 | 2.65e-01 | 5.77e-02 | 5.65e-03 | 2.99e-02 | 2.08e-03 |
| RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 258 | 9.72e-06 | 3.68e-04 | 0.3520 | 1.38e-01 | 1.47e-01 | 1.67e-01 | 1.86e-01 | 1.45e-01 | 1.36e-04 | 4.92e-05 | 3.81e-06 | 2.73e-07 | 6.28e-05 |
| NUCLEOSIDE TRANSMEMBRANE TRANSPORT | 8 | 8.90e-01 | 9.80e-01 | 0.3520 | -9.90e-02 | -9.38e-02 | -1.72e-01 | -2.22e-01 | -1.63e-01 | 6.28e-01 | 6.46e-01 | 4.00e-01 | 2.77e-01 | 4.25e-01 |
| SMOOTH MUSCLE TISSUE DEVELOPMENT | 27 | 5.92e-01 | 8.94e-01 | 0.3520 | 1.50e-01 | 1.78e-01 | 1.53e-01 | 1.50e-01 | 1.55e-01 | 1.77e-01 | 1.10e-01 | 1.69e-01 | 1.78e-01 | 1.64e-01 |
| SYNAPTIC VESICLE PRIMING | 18 | 2.14e-01 | 6.09e-01 | 0.3520 | 4.80e-02 | 3.81e-02 | 1.96e-01 | 6.71e-02 | 2.77e-01 | 7.24e-01 | 7.79e-01 | 1.49e-01 | 6.22e-01 | 4.16e-02 |
| REGULATION OF CALCIUM ION DEPENDENT EXOCYTOSIS | 39 | 1.97e-02 | 1.65e-01 | 0.3520 | 5.74e-02 | 2.02e-01 | 2.25e-01 | 6.48e-02 | 1.59e-01 | 5.35e-01 | 2.93e-02 | 1.52e-02 | 4.84e-01 | 8.66e-02 |
| RNA MODIFICATION | 170 | 1.11e-04 | 3.01e-03 | 0.3520 | 1.40e-01 | 1.09e-01 | 1.92e-01 | 1.73e-01 | 1.60e-01 | 1.62e-03 | 1.38e-02 | 1.53e-05 | 1.02e-04 | 3.32e-04 |
| REGULATION OF MORPHOGENESIS OF AN EPITHELIUM | 62 | 5.43e-02 | 3.08e-01 | 0.3520 | 8.55e-02 | 1.21e-01 | 1.63e-01 | 1.45e-01 | 2.33e-01 | 2.44e-01 | 9.98e-02 | 2.66e-02 | 4.84e-02 | 1.51e-03 |
| REGULATION OF TERMINATION OF DNA TEMPLATED TRANSCRIPTION | 5 | 3.79e-01 | 7.75e-01 | 0.3520 | -1.39e-01 | -3.19e-01 | -2.12e-03 | -2.86e-02 | -4.17e-02 | 5.90e-01 | 2.17e-01 | 9.93e-01 | 9.12e-01 | 8.72e-01 |
| REGULATION OF PROTEIN AUTOUBIQUITINATION | 5 | 7.89e-01 | 9.63e-01 | 0.3520 | 2.44e-01 | 8.03e-02 | -1.07e-02 | 1.73e-01 | -1.66e-01 | 3.45e-01 | 7.56e-01 | 9.67e-01 | 5.03e-01 | 5.19e-01 |
| POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 59 | 1.51e-01 | 5.20e-01 | 0.3510 | 1.95e-01 | 1.48e-01 | 1.43e-01 | 1.75e-01 | 1.12e-01 | 9.75e-03 | 4.86e-02 | 5.78e-02 | 2.01e-02 | 1.36e-01 |
| REGULATION OF DNA BIOSYNTHETIC PROCESS | 117 | 8.03e-03 | 8.71e-02 | 0.3510 | 1.49e-01 | 1.21e-01 | 1.66e-01 | 1.98e-01 | 1.40e-01 | 5.22e-03 | 2.36e-02 | 1.92e-03 | 2.14e-04 | 8.99e-03 |
| MODIFICATION OF POSTSYNAPTIC ACTIN CYTOSKELETON | 11 | 4.94e-01 | 8.44e-01 | 0.3510 | 2.62e-02 | 4.51e-02 | 9.75e-02 | 1.52e-01 | 2.96e-01 | 8.80e-01 | 7.96e-01 | 5.75e-01 | 3.82e-01 | 8.86e-02 |
| POLYKETIDE METABOLIC PROCESS | 10 | 3.78e-01 | 7.75e-01 | 0.3510 | 7.63e-02 | -7.23e-02 | -1.54e-01 | 4.87e-02 | -2.93e-01 | 6.76e-01 | 6.92e-01 | 3.99e-01 | 7.90e-01 | 1.08e-01 |
| CELLULAR RESPONSE TO WATER STIMULUS | 6 | 8.95e-01 | 9.82e-01 | 0.3510 | 1.28e-01 | 5.17e-02 | 1.32e-01 | 1.77e-01 | 2.35e-01 | 5.86e-01 | 8.26e-01 | 5.75e-01 | 4.52e-01 | 3.19e-01 |
| REGULATION OF INTRACELLULAR ESTROGEN RECEPTOR SIGNALING PATHWAY | 34 | 3.53e-01 | 7.53e-01 | 0.3510 | 1.79e-01 | 2.19e-01 | 1.57e-01 | 1.18e-01 | 6.85e-02 | 7.10e-02 | 2.71e-02 | 1.13e-01 | 2.35e-01 | 4.90e-01 |
| SIGNAL COMPLEX ASSEMBLY | 8 | 7.13e-01 | 9.36e-01 | 0.3510 | -2.62e-01 | -1.08e-01 | -9.24e-02 | -1.65e-01 | 8.15e-02 | 1.99e-01 | 5.98e-01 | 6.51e-01 | 4.18e-01 | 6.90e-01 |
| URATE METABOLIC PROCESS | 12 | 6.06e-01 | 9.01e-01 | 0.3510 | -1.06e-01 | -6.39e-02 | -1.47e-01 | -2.44e-01 | -1.63e-01 | 5.25e-01 | 7.02e-01 | 3.79e-01 | 1.43e-01 | 3.27e-01 |
| NUCLEOBASE CATABOLIC PROCESS | 10 | 8.12e-01 | 9.68e-01 | 0.3510 | -1.70e-01 | -1.42e-01 | -1.27e-01 | -2.37e-01 | -4.32e-02 | 3.53e-01 | 4.37e-01 | 4.88e-01 | 1.95e-01 | 8.13e-01 |
| GLIAL CELL PROLIFERATION | 54 | 5.76e-02 | 3.16e-01 | 0.3510 | 1.46e-01 | 2.16e-01 | 1.38e-01 | 1.41e-01 | 1.27e-01 | 6.28e-02 | 6.10e-03 | 7.91e-02 | 7.38e-02 | 1.07e-01 |
| PROTOPORPHYRINOGEN IX BIOSYNTHETIC PROCESS | 8 | 3.84e-01 | 7.79e-01 | 0.3500 | 1.30e-01 | 2.43e-01 | 5.58e-02 | 1.21e-01 | 1.71e-01 | 5.24e-01 | 2.34e-01 | 7.84e-01 | 5.53e-01 | 4.04e-01 |
| ETHER BIOSYNTHETIC PROCESS | 12 | 8.33e-01 | 9.73e-01 | 0.3500 | -1.40e-01 | -1.30e-01 | -1.50e-01 | -1.36e-01 | -2.13e-01 | 4.01e-01 | 4.35e-01 | 3.69e-01 | 4.15e-01 | 2.02e-01 |
| GLUTAMATERGIC NEURON DIFFERENTIATION | 15 | 2.06e-01 | 5.99e-01 | 0.3500 | -1.64e-01 | -1.92e-01 | -1.90e-02 | -1.52e-01 | 1.88e-01 | 2.70e-01 | 1.98e-01 | 8.98e-01 | 3.10e-01 | 2.07e-01 |
| MITOCHONDRIAL PROTEIN PROCESSING | 13 | 1.02e-01 | 4.35e-01 | 0.3500 | 1.18e-01 | 5.75e-02 | 8.37e-02 | 2.49e-01 | -1.90e-01 | 4.63e-01 | 7.20e-01 | 6.01e-01 | 1.20e-01 | 2.34e-01 |
| NEGATIVE REGULATION OF CELL CYCLE PROCESS | 307 | 7.55e-10 | 5.68e-08 | 0.3500 | 1.47e-01 | 1.08e-01 | 1.58e-01 | 2.20e-01 | 1.26e-01 | 8.75e-06 | 1.09e-03 | 1.99e-06 | 3.61e-11 | 1.41e-04 |
| EMBRYONIC PLACENTA DEVELOPMENT | 86 | 1.95e-02 | 1.64e-01 | 0.3500 | 7.62e-02 | 1.38e-01 | 1.93e-01 | 1.55e-01 | 1.90e-01 | 2.22e-01 | 2.67e-02 | 1.95e-03 | 1.27e-02 | 2.31e-03 |
| NEGATIVE REGULATION OF CELL SIZE | 9 | 6.50e-01 | 9.18e-01 | 0.3500 | 1.84e-01 | 1.09e-01 | 7.24e-02 | 1.98e-01 | 1.78e-01 | 3.38e-01 | 5.69e-01 | 7.07e-01 | 3.04e-01 | 3.54e-01 |
| NUCLEOBASE CONTAINING SMALL MOLECULE INTERCONVERSION | 8 | 7.91e-01 | 9.63e-01 | 0.3490 | 6.47e-02 | 1.24e-01 | 2.52e-01 | 1.66e-01 | 1.08e-01 | 7.51e-01 | 5.42e-01 | 2.18e-01 | 4.16e-01 | 5.98e-01 |
| MAST CELL MIGRATION | 13 | 7.38e-01 | 9.49e-01 | 0.3490 | 1.14e-01 | 7.38e-02 | 1.47e-01 | 1.65e-01 | 2.33e-01 | 4.75e-01 | 6.45e-01 | 3.59e-01 | 3.03e-01 | 1.45e-01 |
| CANNABINOID SIGNALING PATHWAY | 9 | 3.30e-01 | 7.38e-01 | 0.3490 | -6.29e-02 | 9.69e-02 | -8.48e-02 | -1.77e-01 | -2.65e-01 | 7.44e-01 | 6.15e-01 | 6.60e-01 | 3.57e-01 | 1.69e-01 |
| THROMBOPOIETIN MEDIATED SIGNALING PATHWAY | 5 | 6.97e-01 | 9.31e-01 | 0.3490 | -3.91e-02 | 7.53e-02 | 1.48e-01 | -7.15e-02 | 2.96e-01 | 8.80e-01 | 7.71e-01 | 5.66e-01 | 7.82e-01 | 2.52e-01 |
| REGULATION OF CYTOPLASMIC MRNA PROCESSING BODY ASSEMBLY | 7 | 4.76e-01 | 8.33e-01 | 0.3490 | -2.63e-01 | -1.90e-01 | -1.16e-01 | -1.60e-02 | 5.24e-02 | 2.29e-01 | 3.83e-01 | 5.95e-01 | 9.41e-01 | 8.10e-01 |
| GLOMERULAR BASEMENT MEMBRANE DEVELOPMENT | 11 | 7.43e-01 | 9.50e-01 | 0.3490 | -2.20e-01 | -1.55e-01 | -1.12e-01 | -1.55e-01 | 1.13e-01 | 2.07e-01 | 3.74e-01 | 5.20e-01 | 3.74e-01 | 5.15e-01 |
| REGULATION OF CELL COMMUNICATION BY ELECTRICAL COUPLING INVOLVED IN CARDIAC CONDUCTION | 12 | 3.04e-01 | 7.17e-01 | 0.3490 | -1.18e-01 | -6.55e-02 | 8.05e-02 | 9.61e-02 | 2.96e-01 | 4.81e-01 | 6.94e-01 | 6.29e-01 | 5.64e-01 | 7.56e-02 |
| DNA REPAIR DEPENDENT CHROMATIN REMODELING | 19 | 3.07e-01 | 7.19e-01 | 0.3490 | -8.89e-04 | 4.85e-02 | 1.93e-01 | 1.81e-01 | 2.22e-01 | 9.95e-01 | 7.14e-01 | 1.45e-01 | 1.72e-01 | 9.41e-02 |
| THYROID GLAND DEVELOPMENT | 31 | 1.94e-01 | 5.80e-01 | 0.3490 | 1.08e-01 | 1.60e-01 | 1.47e-01 | 2.10e-01 | 1.37e-01 | 2.99e-01 | 1.23e-01 | 1.57e-01 | 4.31e-02 | 1.87e-01 |
| RISC COMPLEX ASSEMBLY | 10 | 2.84e-01 | 6.93e-01 | 0.3480 | -1.17e-01 | -5.24e-02 | 1.14e-02 | 6.01e-02 | 3.18e-01 | 5.21e-01 | 7.74e-01 | 9.50e-01 | 7.42e-01 | 8.15e-02 |
| IMPORT INTO NUCLEUS | 163 | 1.45e-03 | 2.35e-02 | 0.3480 | 1.88e-01 | 1.48e-01 | 1.52e-01 | 1.90e-01 | 6.98e-02 | 3.39e-05 | 1.10e-03 | 7.94e-04 | 2.90e-05 | 1.24e-01 |
| REGULATION OF DENDRITIC CELL ANTIGEN PROCESSING AND PRESENTATION | 11 | 1.47e-01 | 5.14e-01 | 0.3480 | 3.05e-02 | 6.24e-02 | -2.26e-01 | -2.05e-01 | -1.53e-01 | 8.61e-01 | 7.20e-01 | 1.94e-01 | 2.39e-01 | 3.80e-01 |
| REGULATION OF FIBROBLAST PROLIFERATION | 87 | 2.47e-02 | 1.92e-01 | 0.3480 | 1.19e-01 | 1.04e-01 | 1.88e-01 | 1.94e-01 | 1.53e-01 | 5.44e-02 | 9.29e-02 | 2.49e-03 | 1.76e-03 | 1.36e-02 |
| POSITIVE REGULATION OF INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY | 11 | 4.29e-01 | 8.05e-01 | 0.3480 | -9.72e-04 | 1.51e-01 | 1.45e-01 | 7.79e-03 | 2.78e-01 | 9.96e-01 | 3.85e-01 | 4.05e-01 | 9.64e-01 | 1.10e-01 |
| POSITIVE REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT | 19 | 3.91e-01 | 7.82e-01 | 0.3480 | 1.25e-01 | 8.03e-02 | 1.26e-01 | 1.26e-01 | 2.60e-01 | 3.46e-01 | 5.45e-01 | 3.42e-01 | 3.41e-01 | 5.00e-02 |
| REGULATION OF CELL CELL ADHESION MEDIATED BY CADHERIN | 20 | 6.22e-01 | 9.08e-01 | 0.3480 | 1.68e-01 | 1.23e-01 | 1.36e-01 | 2.20e-01 | 1.04e-01 | 1.93e-01 | 3.42e-01 | 2.91e-01 | 8.84e-02 | 4.19e-01 |
| POSITIVE REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 26 | 5.00e-01 | 8.48e-01 | 0.3480 | -2.08e-01 | -1.31e-01 | -1.59e-01 | -1.78e-01 | -6.05e-02 | 6.61e-02 | 2.47e-01 | 1.61e-01 | 1.16e-01 | 5.94e-01 |
| REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNITY | 52 | 1.36e-03 | 2.25e-02 | 0.3480 | -1.73e-01 | -2.64e-01 | -1.07e-01 | -5.99e-02 | -8.21e-02 | 3.08e-02 | 1.01e-03 | 1.81e-01 | 4.55e-01 | 3.05e-01 |
| REGULATION OF HEPATIC STELLATE CELL ACTIVATION | 7 | 5.34e-01 | 8.65e-01 | 0.3480 | 1.65e-01 | 1.79e-01 | -8.74e-02 | -4.93e-02 | -2.28e-01 | 4.51e-01 | 4.12e-01 | 6.89e-01 | 8.21e-01 | 2.97e-01 |
| REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 135 | 3.00e-03 | 4.18e-02 | 0.3480 | 1.53e-01 | 1.30e-01 | 1.66e-01 | 2.08e-01 | 9.96e-02 | 2.17e-03 | 9.05e-03 | 8.62e-04 | 2.98e-05 | 4.57e-02 |
| SERTOLI CELL DEVELOPMENT | 12 | 7.52e-01 | 9.51e-01 | 0.3480 | 1.12e-01 | 7.94e-02 | 1.84e-01 | 1.30e-01 | 2.27e-01 | 5.03e-01 | 6.34e-01 | 2.70e-01 | 4.35e-01 | 1.73e-01 |
| NEGATIVE REGULATION OF NATURAL KILLER CELL ACTIVATION | 10 | 8.66e-01 | 9.78e-01 | 0.3480 | 2.24e-01 | 2.00e-01 | 1.01e-01 | 1.42e-01 | 2.16e-02 | 2.20e-01 | 2.73e-01 | 5.79e-01 | 4.37e-01 | 9.06e-01 |
| LEUKOTRIENE B4 METABOLIC PROCESS | 5 | 2.10e-01 | 6.05e-01 | 0.3480 | 2.79e-01 | 1.39e-02 | 1.24e-01 | 4.42e-02 | 1.60e-01 | 2.80e-01 | 9.57e-01 | 6.31e-01 | 8.64e-01 | 5.37e-01 |
| REGULATION OF NK T CELL DIFFERENTIATION | 6 | 7.93e-01 | 9.65e-01 | 0.3480 | 1.26e-02 | 1.13e-01 | 2.32e-01 | 1.99e-01 | 1.21e-01 | 9.57e-01 | 6.31e-01 | 3.25e-01 | 3.98e-01 | 6.09e-01 |
| POSITIVE REGULATION OF MONOCYTE EXTRAVASATION | 5 | 8.49e-01 | 9.76e-01 | 0.3480 | -1.19e-01 | -1.67e-01 | -1.60e-01 | -2.36e-02 | -2.30e-01 | 6.46e-01 | 5.18e-01 | 5.34e-01 | 9.27e-01 | 3.74e-01 |
| PROCESS UTILIZING AUTOPHAGIC MECHANISM | 552 | 7.89e-12 | 7.33e-10 | 0.3480 | 1.70e-01 | 1.48e-01 | 1.55e-01 | 1.81e-01 | 1.15e-01 | 8.71e-12 | 2.40e-09 | 4.82e-10 | 3.03e-13 | 3.75e-06 |
| POSITIVE REGULATION OF GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR PRODUCTION | 15 | 2.59e-02 | 1.97e-01 | 0.3480 | 1.77e-01 | 2.86e-01 | 2.18e-02 | -7.09e-02 | -4.44e-02 | 2.35e-01 | 5.47e-02 | 8.84e-01 | 6.35e-01 | 7.66e-01 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE TISSUE GROWTH | 27 | 2.74e-01 | 6.83e-01 | 0.3480 | 1.58e-01 | 2.25e-01 | 1.70e-01 | 7.85e-02 | 1.00e-01 | 1.56e-01 | 4.26e-02 | 1.26e-01 | 4.80e-01 | 3.69e-01 |
| REGULATION OF EXCRETION | 11 | 8.99e-01 | 9.83e-01 | 0.3480 | 1.04e-01 | 1.61e-01 | 2.10e-01 | 1.59e-01 | 1.22e-01 | 5.52e-01 | 3.56e-01 | 2.27e-01 | 3.61e-01 | 4.85e-01 |
| PROTEIN LOCALIZATION TO PHAGOPHORE ASSEMBLY SITE | 15 | 2.90e-01 | 6.99e-01 | 0.3470 | 2.08e-01 | 4.84e-02 | 1.58e-01 | 2.23e-01 | 1.51e-02 | 1.62e-01 | 7.45e-01 | 2.89e-01 | 1.36e-01 | 9.19e-01 |
| REGULATION OF DNA RECOMBINATION | 128 | 3.64e-03 | 4.86e-02 | 0.3470 | 1.45e-01 | 1.52e-01 | 1.53e-01 | 2.00e-01 | 1.15e-01 | 4.67e-03 | 3.07e-03 | 2.82e-03 | 9.23e-05 | 2.42e-02 |
| NEGATIVE REGULATION OF MUSCLE ADAPTATION | 10 | 9.01e-01 | 9.83e-01 | 0.3470 | -1.27e-01 | -1.12e-01 | -1.72e-01 | -1.40e-01 | -2.06e-01 | 4.85e-01 | 5.38e-01 | 3.45e-01 | 4.44e-01 | 2.60e-01 |
| REGULATION OF REMOVAL OF SUPEROXIDE RADICALS | 9 | 8.99e-01 | 9.83e-01 | 0.3470 | -1.64e-01 | -1.22e-01 | -1.89e-01 | -1.44e-01 | -1.49e-01 | 3.93e-01 | 5.25e-01 | 3.26e-01 | 4.55e-01 | 4.39e-01 |
| SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE SIGNAL SEQUENCE RECOGNITION | 6 | 7.46e-01 | 9.50e-01 | 0.3470 | -2.10e-01 | -9.49e-02 | 3.21e-02 | -3.61e-02 | 2.55e-01 | 3.73e-01 | 6.87e-01 | 8.92e-01 | 8.78e-01 | 2.79e-01 |
| HYPOTHALAMUS DEVELOPMENT | 24 | 1.24e-01 | 4.80e-01 | 0.3470 | 2.85e-02 | 3.66e-02 | 9.58e-02 | 1.17e-01 | 3.09e-01 | 8.09e-01 | 7.56e-01 | 4.17e-01 | 3.19e-01 | 8.84e-03 |
| REGULATION OF DOUBLE STRAND BREAK REPAIR VIA HOMOLOGOUS RECOMBINATION | 66 | 4.53e-02 | 2.77e-01 | 0.3470 | 1.36e-01 | 1.61e-01 | 1.55e-01 | 2.12e-01 | 8.35e-02 | 5.62e-02 | 2.39e-02 | 2.95e-02 | 2.84e-03 | 2.41e-01 |
| NEGATIVE REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION | 21 | 2.35e-01 | 6.37e-01 | 0.3470 | -1.57e-01 | -2.47e-01 | -1.51e-01 | -8.20e-02 | 7.22e-02 | 2.14e-01 | 4.99e-02 | 2.31e-01 | 5.16e-01 | 5.67e-01 |
| AUTONOMIC NERVOUS SYSTEM DEVELOPMENT | 45 | 1.21e-01 | 4.75e-01 | 0.3470 | 5.00e-02 | 1.18e-01 | 1.76e-01 | 1.48e-01 | 2.26e-01 | 5.61e-01 | 1.70e-01 | 4.13e-02 | 8.56e-02 | 8.78e-03 |
| ADENYLATE CYCLASE INHIBITING G PROTEIN COUPLED ACETYLCHOLINE RECEPTOR SIGNALING PATHWAY | 8 | 5.47e-01 | 8.72e-01 | 0.3470 | 4.84e-02 | -9.53e-02 | -2.57e-01 | -1.13e-01 | -1.74e-01 | 8.12e-01 | 6.41e-01 | 2.09e-01 | 5.80e-01 | 3.94e-01 |
| POSITIVE REGULATION OF HEMOGLOBIN BIOSYNTHETIC PROCESS | 6 | 5.17e-01 | 8.56e-01 | 0.3470 | 2.73e-01 | 1.38e-01 | 1.50e-05 | 1.04e-01 | 1.25e-01 | 2.47e-01 | 5.58e-01 | 1.00e+00 | 6.60e-01 | 5.95e-01 |
| PEPTIDE BIOSYNTHETIC PROCESS | 806 | 9.60e-17 | 1.57e-14 | 0.3470 | 1.45e-01 | 1.40e-01 | 1.73e-01 | 1.80e-01 | 1.32e-01 | 2.37e-12 | 1.29e-11 | 7.60e-17 | 3.66e-18 | 2.03e-10 |
| CELLULAR SENESCENCE | 106 | 1.51e-02 | 1.36e-01 | 0.3470 | 1.64e-01 | 1.26e-01 | 1.51e-01 | 1.87e-01 | 1.41e-01 | 3.48e-03 | 2.48e-02 | 7.36e-03 | 9.06e-04 | 1.23e-02 |
| SCF DEPENDENT PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 47 | 3.86e-01 | 7.80e-01 | 0.3470 | 1.39e-01 | 1.42e-01 | 1.87e-01 | 1.63e-01 | 1.40e-01 | 9.95e-02 | 9.32e-02 | 2.69e-02 | 5.36e-02 | 9.75e-02 |
| MANNOSYLATION | 23 | 4.00e-01 | 7.88e-01 | 0.3470 | 2.26e-01 | 1.55e-01 | 1.17e-01 | 1.38e-01 | 1.11e-01 | 6.11e-02 | 1.98e-01 | 3.29e-01 | 2.52e-01 | 3.57e-01 |
| VOCALIZATION BEHAVIOR | 15 | 2.74e-01 | 6.83e-01 | 0.3460 | -1.75e-01 | -3.92e-02 | -1.04e-01 | -2.65e-01 | -8.34e-02 | 2.42e-01 | 7.92e-01 | 4.86e-01 | 7.58e-02 | 5.76e-01 |
| CELLULAR RESPONSE TO EPINEPHRINE STIMULUS | 11 | 5.51e-01 | 8.75e-01 | 0.3460 | -2.17e-01 | -1.07e-01 | -5.11e-02 | -2.11e-01 | 1.19e-01 | 2.13e-01 | 5.37e-01 | 7.69e-01 | 2.25e-01 | 4.95e-01 |
| KETONE BODY BIOSYNTHETIC PROCESS | 6 | 7.56e-01 | 9.51e-01 | 0.3460 | -9.77e-02 | -1.06e-01 | -2.66e-01 | -1.57e-01 | -5.94e-02 | 6.78e-01 | 6.52e-01 | 2.59e-01 | 5.07e-01 | 8.01e-01 |
| DNA RECOMBINATION | 318 | 1.60e-08 | 9.96e-07 | 0.3460 | 1.35e-01 | 1.23e-01 | 1.66e-01 | 2.08e-01 | 1.24e-01 | 3.37e-05 | 1.67e-04 | 3.47e-07 | 1.61e-10 | 1.39e-04 |
| N TERMINAL PROTEIN AMINO ACID MODIFICATION | 27 | 3.12e-01 | 7.23e-01 | 0.3460 | 9.92e-02 | 1.62e-01 | 1.48e-01 | 9.89e-02 | 2.28e-01 | 3.72e-01 | 1.44e-01 | 1.84e-01 | 3.74e-01 | 4.03e-02 |
| POSITIVE REGULATION OF DENDRITIC SPINE MORPHOGENESIS | 15 | 7.40e-01 | 9.49e-01 | 0.3460 | -2.17e-01 | -1.32e-01 | -1.51e-01 | -1.69e-01 | -6.19e-02 | 1.45e-01 | 3.77e-01 | 3.10e-01 | 2.58e-01 | 6.78e-01 |
| SECONDARY METABOLIC PROCESS | 55 | 3.20e-01 | 7.31e-01 | 0.3460 | -1.53e-01 | -1.51e-01 | -1.79e-01 | -1.81e-01 | -9.30e-02 | 5.03e-02 | 5.29e-02 | 2.17e-02 | 2.01e-02 | 2.33e-01 |
| LUNG MORPHOGENESIS | 54 | 7.32e-02 | 3.66e-01 | 0.3450 | 7.37e-02 | 1.45e-01 | 1.77e-01 | 1.78e-01 | 1.73e-01 | 3.49e-01 | 6.54e-02 | 2.47e-02 | 2.37e-02 | 2.77e-02 |
| TRAIL ACTIVATED APOPTOTIC SIGNALING PATHWAY | 11 | 7.36e-01 | 9.48e-01 | 0.3450 | 2.13e-01 | 9.12e-02 | 1.35e-01 | 1.84e-01 | 1.15e-01 | 2.20e-01 | 6.00e-01 | 4.39e-01 | 2.90e-01 | 5.07e-01 |
| POSITIVE REGULATION OF I KAPPAB PHOSPHORYLATION | 6 | 8.22e-01 | 9.71e-01 | 0.3450 | 1.76e-01 | 2.51e-01 | 8.29e-02 | 6.67e-02 | -1.18e-01 | 4.56e-01 | 2.87e-01 | 7.25e-01 | 7.77e-01 | 6.16e-01 |
| REGULATION OF SUPEROXIDE DISMUTASE ACTIVITY | 7 | 9.34e-01 | 9.91e-01 | 0.3450 | -2.27e-01 | -1.67e-01 | -9.78e-02 | -1.70e-01 | 3.89e-02 | 2.99e-01 | 4.45e-01 | 6.54e-01 | 4.35e-01 | 8.59e-01 |
| MANGANESE ION TRANSPORT | 11 | 8.55e-01 | 9.76e-01 | 0.3450 | 2.20e-01 | 1.85e-01 | 1.00e-01 | 1.59e-01 | -3.83e-02 | 2.07e-01 | 2.88e-01 | 5.65e-01 | 3.63e-01 | 8.26e-01 |
| REGULATION OF MACROAUTOPHAGY | 150 | 1.53e-03 | 2.46e-02 | 0.3450 | 1.70e-01 | 1.38e-01 | 1.42e-01 | 1.82e-01 | 1.33e-01 | 3.21e-04 | 3.51e-03 | 2.59e-03 | 1.19e-04 | 4.91e-03 |
| PROTEIN HYDROXYLATION | 23 | 3.89e-01 | 7.82e-01 | 0.3450 | 9.76e-02 | 1.40e-01 | 1.97e-01 | 2.16e-01 | 6.68e-02 | 4.18e-01 | 2.44e-01 | 1.02e-01 | 7.29e-02 | 5.79e-01 |
| NUCLEOSIDE DIPHOSPHATE BIOSYNTHETIC PROCESS | 13 | 8.87e-01 | 9.80e-01 | 0.3450 | 9.85e-02 | 1.44e-01 | 1.99e-01 | 1.61e-01 | 1.52e-01 | 5.38e-01 | 3.70e-01 | 2.14e-01 | 3.14e-01 | 3.43e-01 |
| INNER CELL MASS CELL DIFFERENTIATION | 8 | 8.50e-01 | 9.76e-01 | 0.3450 | 2.01e-01 | 2.13e-01 | 1.53e-01 | 7.93e-02 | 6.31e-02 | 3.26e-01 | 2.98e-01 | 4.55e-01 | 6.98e-01 | 7.57e-01 |
| NEGATIVE REGULATION OF ATP METABOLIC PROCESS | 7 | 7.76e-01 | 9.58e-01 | 0.3450 | -2.05e-01 | -9.54e-02 | -9.40e-02 | -1.96e-01 | 1.43e-01 | 3.47e-01 | 6.62e-01 | 6.67e-01 | 3.68e-01 | 5.13e-01 |
| PHASIC SMOOTH MUSCLE CONTRACTION | 24 | 1.02e-01 | 4.35e-01 | 0.3450 | 1.05e-01 | 1.43e-01 | 8.80e-02 | 9.40e-02 | 2.66e-01 | 3.75e-01 | 2.25e-01 | 4.56e-01 | 4.25e-01 | 2.38e-02 |
| REGULATION OF CAVEOLIN MEDIATED ENDOCYTOSIS | 6 | 1.40e-01 | 5.04e-01 | 0.3450 | -1.21e-01 | 2.34e-01 | 1.22e-01 | -1.69e-01 | 7.74e-02 | 6.07e-01 | 3.20e-01 | 6.04e-01 | 4.74e-01 | 7.43e-01 |
| PLATELET MORPHOGENESIS | 22 | 1.68e-01 | 5.48e-01 | 0.3450 | 3.38e-02 | 1.86e-01 | 2.15e-01 | 5.22e-02 | 1.86e-01 | 7.84e-01 | 1.31e-01 | 8.15e-02 | 6.72e-01 | 1.32e-01 |
| REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION | 21 | 4.64e-01 | 8.25e-01 | 0.3450 | 1.10e-01 | 1.46e-01 | 2.19e-01 | 1.02e-01 | 1.65e-01 | 3.82e-01 | 2.46e-01 | 8.30e-02 | 4.20e-01 | 1.91e-01 |
| PROTEIN LOCALIZATION TO ORGANELLE | 917 | 7.11e-21 | 1.53e-18 | 0.3450 | 1.63e-01 | 1.38e-01 | 1.62e-01 | 1.97e-01 | 8.85e-02 | 4.65e-17 | 1.25e-12 | 7.24e-17 | 3.99e-24 | 5.43e-06 |
| REGULATION OF CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 12 | 9.55e-02 | 4.19e-01 | 0.3440 | -1.27e-01 | 9.04e-02 | 1.44e-01 | 1.26e-01 | 2.40e-01 | 4.45e-01 | 5.87e-01 | 3.87e-01 | 4.51e-01 | 1.50e-01 |
| POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 10 | 4.19e-01 | 8.00e-01 | 0.3440 | -1.87e-02 | -2.25e-01 | -1.55e-01 | -8.84e-02 | -1.90e-01 | 9.18e-01 | 2.18e-01 | 3.98e-01 | 6.28e-01 | 2.99e-01 |
| PROTEIN K11 LINKED DEUBIQUITINATION | 9 | 1.02e-01 | 4.35e-01 | 0.3440 | 5.73e-02 | -1.32e-01 | 2.13e-02 | 2.57e-01 | 1.77e-01 | 7.66e-01 | 4.92e-01 | 9.12e-01 | 1.82e-01 | 3.58e-01 |
| POSITIVE REGULATION OF CHROMOSOME ORGANIZATION | 104 | 4.70e-04 | 9.65e-03 | 0.3440 | 1.49e-01 | 1.20e-01 | 1.29e-01 | 2.28e-01 | 1.15e-01 | 8.57e-03 | 3.47e-02 | 2.35e-02 | 5.76e-05 | 4.20e-02 |
| NEGATIVE REGULATION OF COAGULATION | 52 | 9.87e-03 | 1.01e-01 | 0.3440 | -3.23e-02 | -1.23e-02 | -1.40e-01 | -1.49e-01 | -2.75e-01 | 6.87e-01 | 8.78e-01 | 8.08e-02 | 6.23e-02 | 6.13e-04 |
| IRON IMPORT INTO CELL | 10 | 6.80e-01 | 9.28e-01 | 0.3440 | -1.38e-01 | -1.99e-01 | -1.94e-01 | -1.31e-01 | 7.33e-02 | 4.51e-01 | 2.75e-01 | 2.89e-01 | 4.74e-01 | 6.88e-01 |
| REGULATION OF EXOSOMAL SECRETION | 19 | 8.27e-01 | 9.72e-01 | 0.3440 | 1.91e-01 | 1.77e-01 | 1.47e-01 | 1.58e-01 | 6.21e-02 | 1.49e-01 | 1.81e-01 | 2.67e-01 | 2.34e-01 | 6.39e-01 |
| POSITIVE REGULATION OF NEUTROPHIL MIGRATION | 30 | 2.44e-01 | 6.48e-01 | 0.3440 | 2.18e-01 | 2.22e-01 | 1.02e-01 | 1.06e-01 | 1.16e-02 | 3.91e-02 | 3.52e-02 | 3.34e-01 | 3.15e-01 | 9.13e-01 |
| ACTIN NUCLEATION | 55 | 1.02e-01 | 4.35e-01 | 0.3440 | 2.10e-01 | 1.65e-01 | 1.36e-01 | 1.64e-01 | -3.95e-02 | 7.11e-03 | 3.39e-02 | 8.06e-02 | 3.51e-02 | 6.13e-01 |
| REGULATION OF PROTEIN STABILITY | 305 | 5.03e-08 | 2.89e-06 | 0.3440 | 1.46e-01 | 1.06e-01 | 1.65e-01 | 1.79e-01 | 1.62e-01 | 1.18e-05 | 1.44e-03 | 6.75e-07 | 7.12e-08 | 1.09e-06 |
| SYNAPTIC VESICLE DOCKING | 10 | 7.04e-01 | 9.32e-01 | 0.3440 | 4.80e-02 | 1.00e-01 | 2.21e-01 | 7.75e-02 | 2.25e-01 | 7.93e-01 | 5.82e-01 | 2.25e-01 | 6.71e-01 | 2.17e-01 |
| FC RECEPTOR MEDIATED INHIBITORY SIGNALING PATHWAY | 5 | 4.12e-01 | 7.98e-01 | 0.3440 | 7.85e-03 | -1.97e-01 | -1.77e-01 | -1.89e-01 | 1.11e-01 | 9.76e-01 | 4.45e-01 | 4.94e-01 | 4.65e-01 | 6.67e-01 |
| REGULATION OF DNA REPLICATION | 121 | 2.14e-03 | 3.22e-02 | 0.3430 | 1.29e-01 | 9.17e-02 | 1.73e-01 | 1.73e-01 | 1.81e-01 | 1.43e-02 | 8.13e-02 | 1.00e-03 | 9.92e-04 | 5.64e-04 |
| REGULATION OF POTASSIUM ION IMPORT | 5 | 5.42e-01 | 8.69e-01 | 0.3430 | -1.10e-01 | -8.39e-02 | -2.89e-01 | -9.07e-02 | -8.31e-02 | 6.71e-01 | 7.45e-01 | 2.62e-01 | 7.25e-01 | 7.48e-01 |
| FACE MORPHOGENESIS | 30 | 1.75e-01 | 5.60e-01 | 0.3430 | 4.34e-02 | 8.95e-02 | 1.71e-01 | 1.99e-01 | 1.98e-01 | 6.81e-01 | 3.96e-01 | 1.05e-01 | 5.96e-02 | 6.03e-02 |
| GAMMA DELTA T CELL DIFFERENTIATION | 13 | 1.93e-01 | 5.80e-01 | 0.3430 | -1.02e-01 | -3.41e-02 | 2.11e-01 | 1.23e-01 | 2.16e-01 | 5.25e-01 | 8.32e-01 | 1.87e-01 | 4.43e-01 | 1.78e-01 |
| MAMMARY GLAND EPITHELIUM DEVELOPMENT | 65 | 6.52e-03 | 7.48e-02 | 0.3430 | 9.73e-02 | 1.98e-01 | 1.45e-01 | 1.59e-01 | 1.51e-01 | 1.75e-01 | 5.72e-03 | 4.33e-02 | 2.69e-02 | 3.54e-02 |
| ANIMAL ORGAN REGENERATION | 60 | 3.00e-01 | 7.13e-01 | 0.3430 | 1.67e-01 | 1.57e-01 | 1.60e-01 | 1.71e-01 | 1.03e-01 | 2.53e-02 | 3.60e-02 | 3.20e-02 | 2.21e-02 | 1.69e-01 |
| REGULATION OF HIPPOCAMPAL NEURON APOPTOTIC PROCESS | 5 | 3.87e-01 | 7.80e-01 | 0.3430 | 2.67e-01 | 1.90e-01 | -4.84e-02 | -1.34e-02 | 8.91e-02 | 3.02e-01 | 4.62e-01 | 8.51e-01 | 9.58e-01 | 7.30e-01 |
| RESPONSE TO HUMAN CHORIONIC GONADOTROPIN | 5 | 5.01e-01 | 8.48e-01 | 0.3430 | -1.88e-01 | -8.53e-02 | 1.21e-01 | 1.48e-01 | 1.96e-01 | 4.67e-01 | 7.41e-01 | 6.39e-01 | 5.66e-01 | 4.48e-01 |
| LIPID DROPLET ORGANIZATION | 34 | 4.74e-01 | 8.31e-01 | 0.3430 | 1.35e-01 | 1.28e-01 | 1.54e-01 | 1.90e-01 | 1.52e-01 | 1.74e-01 | 1.97e-01 | 1.21e-01 | 5.47e-02 | 1.24e-01 |
| NEUROTRANSMITTER RECEPTOR TRANSPORT POSTSYNAPTIC ENDOSOME TO LYSOSOME | 7 | 4.82e-01 | 8.37e-01 | 0.3430 | -9.58e-02 | 6.82e-02 | 1.04e-01 | -1.12e-01 | 2.84e-01 | 6.61e-01 | 7.55e-01 | 6.34e-01 | 6.09e-01 | 1.94e-01 |
| POSITIVE REGULATION OF GLIAL CELL DIFFERENTIATION | 45 | 5.62e-02 | 3.14e-01 | 0.3430 | 4.15e-02 | 7.83e-02 | 2.19e-01 | 1.27e-01 | 2.14e-01 | 6.30e-01 | 3.63e-01 | 1.11e-02 | 1.41e-01 | 1.31e-02 |
| PROGRAMMED NECROTIC CELL DEATH | 56 | 4.15e-02 | 2.64e-01 | 0.3430 | 2.10e-01 | 1.23e-01 | 1.20e-01 | 1.65e-01 | 1.28e-01 | 6.66e-03 | 1.11e-01 | 1.19e-01 | 3.23e-02 | 9.64e-02 |
| CORTISOL BIOSYNTHETIC PROCESS | 10 | 4.77e-01 | 8.33e-01 | 0.3430 | 8.23e-02 | 9.25e-02 | 2.69e-01 | 1.50e-01 | 8.56e-02 | 6.52e-01 | 6.12e-01 | 1.41e-01 | 4.12e-01 | 6.39e-01 |
| REGULATION OF KILLING OF CELLS OF ANOTHER ORGANISM | 11 | 2.84e-01 | 6.93e-01 | 0.3420 | 2.03e-01 | 9.89e-03 | -7.03e-02 | 3.70e-02 | -2.63e-01 | 2.43e-01 | 9.55e-01 | 6.87e-01 | 8.32e-01 | 1.31e-01 |
| POSITIVE REGULATION OF TOR SIGNALING | 65 | 1.32e-01 | 4.92e-01 | 0.3420 | 1.95e-01 | 1.53e-01 | 1.32e-01 | 1.89e-01 | 4.86e-02 | 6.47e-03 | 3.26e-02 | 6.67e-02 | 8.34e-03 | 4.98e-01 |
| DNA BIOSYNTHETIC PROCESS | 188 | 1.38e-04 | 3.51e-03 | 0.3420 | 1.38e-01 | 1.08e-01 | 1.68e-01 | 1.90e-01 | 1.48e-01 | 1.06e-03 | 1.09e-02 | 6.99e-05 | 6.92e-06 | 4.62e-04 |
| ENAMEL MINERALIZATION | 19 | 7.37e-01 | 9.48e-01 | 0.3420 | -1.13e-01 | -1.28e-01 | -1.64e-01 | -1.34e-01 | -2.08e-01 | 3.94e-01 | 3.33e-01 | 2.16e-01 | 3.13e-01 | 1.17e-01 |
| POSITIVE REGULATION OF PROTEIN KINASE C SIGNALING | 9 | 8.05e-01 | 9.67e-01 | 0.3420 | -2.36e-01 | -1.18e-01 | -8.60e-02 | -1.98e-01 | 3.28e-02 | 2.21e-01 | 5.41e-01 | 6.55e-01 | 3.04e-01 | 8.65e-01 |
| IMMUNE SYSTEM DEVELOPMENT | 198 | 7.38e-08 | 4.05e-06 | 0.3420 | 7.62e-02 | 8.63e-02 | 1.69e-01 | 2.07e-01 | 1.80e-01 | 6.46e-02 | 3.62e-02 | 4.22e-05 | 5.30e-07 | 1.21e-05 |
| EMBRYONIC APPENDAGE MORPHOGENESIS | 119 | 4.44e-03 | 5.66e-02 | 0.3420 | 8.24e-02 | 1.17e-01 | 1.87e-01 | 1.47e-01 | 2.00e-01 | 1.20e-01 | 2.79e-02 | 4.31e-04 | 5.72e-03 | 1.63e-04 |
| REGULATION OF CENTROSOME CYCLE | 54 | 3.28e-01 | 7.37e-01 | 0.3420 | 1.56e-01 | 1.44e-01 | 1.71e-01 | 1.86e-01 | 8.95e-02 | 4.72e-02 | 6.79e-02 | 2.97e-02 | 1.81e-02 | 2.55e-01 |
| REGULATION OF MITOTIC CELL CYCLE | 509 | 4.77e-13 | 5.36e-11 | 0.3410 | 1.34e-01 | 1.12e-01 | 1.65e-01 | 1.96e-01 | 1.44e-01 | 2.34e-07 | 1.61e-05 | 1.70e-10 | 3.90e-14 | 2.88e-08 |
| REGULATION OF ATTACHMENT OF SPINDLE MICROTUBULES TO KINETOCHORE | 21 | 7.91e-01 | 9.63e-01 | 0.3410 | 1.44e-01 | 1.28e-01 | 1.80e-01 | 1.81e-01 | 1.18e-01 | 2.52e-01 | 3.10e-01 | 1.53e-01 | 1.50e-01 | 3.50e-01 |
| LYMPHOCYTE CHEMOTAXIS | 62 | 5.66e-03 | 6.73e-02 | 0.3410 | -8.87e-02 | -4.39e-02 | -1.62e-01 | -2.21e-01 | -1.78e-01 | 2.27e-01 | 5.50e-01 | 2.73e-02 | 2.62e-03 | 1.53e-02 |
| RENAL WATER TRANSPORT | 9 | 7.41e-02 | 3.68e-01 | 0.3410 | -1.74e-01 | 1.71e-01 | 1.75e-01 | -6.45e-02 | 1.49e-01 | 3.67e-01 | 3.75e-01 | 3.62e-01 | 7.38e-01 | 4.38e-01 |
| AGGRESSIVE BEHAVIOR | 7 | 6.15e-01 | 9.06e-01 | 0.3410 | -3.21e-03 | -3.38e-02 | 9.45e-02 | -7.11e-03 | 3.26e-01 | 9.88e-01 | 8.77e-01 | 6.65e-01 | 9.74e-01 | 1.35e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO ORGANELLE | 437 | 1.66e-09 | 1.15e-07 | 0.3410 | 1.62e-01 | 1.31e-01 | 1.63e-01 | 1.91e-01 | 9.82e-02 | 5.64e-09 | 2.51e-06 | 4.81e-09 | 7.31e-12 | 4.33e-04 |
| DNA TEMPLATED DNA REPLICATION MAINTENANCE OF FIDELITY | 54 | 7.47e-02 | 3.70e-01 | 0.3410 | 1.72e-01 | 1.21e-01 | 1.24e-01 | 2.20e-01 | 9.13e-02 | 2.86e-02 | 1.23e-01 | 1.15e-01 | 5.26e-03 | 2.46e-01 |
| TRANSLATIONAL INITIATION | 109 | 1.68e-02 | 1.49e-01 | 0.3410 | 1.37e-01 | 1.22e-01 | 1.70e-01 | 1.54e-01 | 1.73e-01 | 1.31e-02 | 2.79e-02 | 2.21e-03 | 5.62e-03 | 1.75e-03 |
| MALE MATING BEHAVIOR | 6 | 8.76e-02 | 4.00e-01 | 0.3410 | 1.82e-01 | -5.22e-02 | -1.64e-01 | 4.36e-02 | 2.27e-01 | 4.41e-01 | 8.25e-01 | 4.86e-01 | 8.53e-01 | 3.35e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE CHEMOTAXIS | 21 | 4.55e-01 | 8.22e-01 | 0.3410 | -6.59e-02 | -7.86e-02 | -1.36e-01 | -1.46e-01 | -2.57e-01 | 6.01e-01 | 5.33e-01 | 2.81e-01 | 2.47e-01 | 4.18e-02 |
| REGULATION OF T CIRCLE FORMATION | 5 | 5.08e-01 | 8.53e-01 | 0.3410 | 2.19e-01 | 1.90e-01 | 1.29e-02 | -7.55e-03 | 1.79e-01 | 3.97e-01 | 4.63e-01 | 9.60e-01 | 9.77e-01 | 4.89e-01 |
| RRNA 5 END PROCESSING | 5 | 7.74e-01 | 9.57e-01 | 0.3400 | 3.71e-02 | 1.10e-01 | 2.76e-01 | 9.08e-02 | 1.35e-01 | 8.86e-01 | 6.71e-01 | 2.86e-01 | 7.25e-01 | 6.02e-01 |
| PLACENTA DEVELOPMENT | 146 | 9.45e-04 | 1.67e-02 | 0.3400 | 8.43e-02 | 1.45e-01 | 1.88e-01 | 1.61e-01 | 1.61e-01 | 7.87e-02 | 2.45e-03 | 8.49e-05 | 7.56e-04 | 7.62e-04 |
| POSITIVE REGULATION OF GAP JUNCTION ASSEMBLY | 6 | 5.68e-01 | 8.81e-01 | 0.3400 | 1.53e-01 | 4.15e-02 | 1.75e-02 | 1.49e-01 | 2.61e-01 | 5.17e-01 | 8.60e-01 | 9.41e-01 | 5.27e-01 | 2.68e-01 |
| REGULATION OF TELOMERE MAINTENANCE | 98 | 3.30e-03 | 4.49e-02 | 0.3400 | 1.30e-01 | 1.04e-01 | 1.47e-01 | 2.18e-01 | 1.37e-01 | 2.57e-02 | 7.39e-02 | 1.17e-02 | 1.92e-04 | 1.95e-02 |
| OVULATION | 15 | 2.11e-01 | 6.06e-01 | 0.3400 | -4.54e-02 | -3.89e-02 | -1.31e-01 | -2.54e-01 | -1.75e-01 | 7.61e-01 | 7.94e-01 | 3.79e-01 | 8.88e-02 | 2.42e-01 |
| NEGATIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 22 | 4.72e-01 | 8.30e-01 | 0.3400 | 1.68e-01 | 9.48e-02 | 1.30e-01 | 2.25e-01 | 1.03e-01 | 1.71e-01 | 4.42e-01 | 2.91e-01 | 6.72e-02 | 4.03e-01 |
| REGULATION OF ODONTOBLAST DIFFERENTIATION | 5 | 4.85e-01 | 8.38e-01 | 0.3400 | -1.88e-01 | 6.85e-02 | -1.86e-02 | -2.05e-01 | -1.82e-01 | 4.66e-01 | 7.91e-01 | 9.42e-01 | 4.27e-01 | 4.81e-01 |
| VENOUS BLOOD VESSEL MORPHOGENESIS | 9 | 5.51e-01 | 8.75e-01 | 0.3400 | 1.32e-01 | 2.72e-01 | 1.18e-01 | 3.99e-02 | 9.41e-02 | 4.92e-01 | 1.58e-01 | 5.40e-01 | 8.36e-01 | 6.25e-01 |
| NEGATIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 38 | 3.24e-02 | 2.29e-01 | 0.3400 | 4.43e-03 | 5.48e-03 | 1.23e-01 | 1.43e-01 | 2.83e-01 | 9.62e-01 | 9.53e-01 | 1.88e-01 | 1.27e-01 | 2.56e-03 |
| REGULATION OF AUTOPHAGOSOME MATURATION | 16 | 2.65e-01 | 6.73e-01 | 0.3400 | -2.15e-02 | 6.02e-02 | 1.38e-01 | 1.72e-01 | 2.51e-01 | 8.81e-01 | 6.77e-01 | 3.39e-01 | 2.34e-01 | 8.23e-02 |
| RESPONSE TO SORBITOL | 6 | 9.18e-01 | 9.86e-01 | 0.3400 | -1.30e-01 | -1.65e-01 | -2.18e-01 | -1.55e-01 | -3.34e-03 | 5.83e-01 | 4.84e-01 | 3.56e-01 | 5.10e-01 | 9.89e-01 |
| DIENCEPHALON DEVELOPMENT | 73 | 6.23e-03 | 7.23e-02 | 0.3400 | 1.95e-02 | 7.27e-02 | 1.64e-01 | 1.27e-01 | 2.58e-01 | 7.73e-01 | 2.83e-01 | 1.51e-02 | 6.00e-02 | 1.36e-04 |
| AMINOACYL TRNA METABOLISM INVOLVED IN TRANSLATIONAL FIDELITY | 13 | 7.54e-01 | 9.51e-01 | 0.3400 | 2.28e-01 | 1.77e-01 | 8.73e-02 | 1.40e-01 | -6.95e-02 | 1.54e-01 | 2.69e-01 | 5.86e-01 | 3.83e-01 | 6.65e-01 |
| COLLAGEN CATABOLIC PROCESS | 44 | 2.39e-01 | 6.44e-01 | 0.3400 | -1.95e-01 | -1.27e-01 | -1.54e-01 | -1.64e-01 | -1.03e-01 | 2.52e-02 | 1.46e-01 | 7.78e-02 | 5.95e-02 | 2.35e-01 |
| REGULATION OF MUCUS SECRETION | 8 | 5.13e-01 | 8.55e-01 | 0.3400 | 1.09e-01 | 1.61e-01 | 2.37e-01 | 2.43e-02 | 1.45e-01 | 5.95e-01 | 4.31e-01 | 2.46e-01 | 9.05e-01 | 4.79e-01 |
| INTERSTRAND CROSS LINK REPAIR | 37 | 2.04e-01 | 5.96e-01 | 0.3400 | 1.77e-01 | 1.15e-01 | 1.19e-01 | 2.20e-01 | 8.99e-02 | 6.27e-02 | 2.26e-01 | 2.09e-01 | 2.04e-02 | 3.44e-01 |
| POSITIVE REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 16 | 5.98e-01 | 8.98e-01 | 0.3400 | 1.59e-01 | 2.42e-01 | 1.29e-01 | 1.08e-01 | 5.44e-02 | 2.70e-01 | 9.31e-02 | 3.73e-01 | 4.54e-01 | 7.06e-01 |
| TRANSPOSITION | 38 | 4.86e-01 | 8.38e-01 | 0.3400 | -1.73e-01 | -1.58e-01 | -1.76e-01 | -1.63e-01 | -5.52e-02 | 6.54e-02 | 9.20e-02 | 6.01e-02 | 8.28e-02 | 5.56e-01 |
| REGULATION OF SYNAPTIC VESICLE TRANSPORT | 5 | 6.14e-01 | 9.06e-01 | 0.3400 | 3.24e-02 | -2.24e-01 | -1.87e-01 | 2.42e-02 | -1.69e-01 | 9.00e-01 | 3.85e-01 | 4.70e-01 | 9.25e-01 | 5.13e-01 |
| SERTOLI CELL PROLIFERATION | 5 | 1.15e-01 | 4.63e-01 | 0.3400 | 1.75e-01 | 1.19e-01 | -1.73e-01 | 2.93e-02 | 1.99e-01 | 4.97e-01 | 6.44e-01 | 5.03e-01 | 9.10e-01 | 4.41e-01 |
| NEGATIVE REGULATION OF MITOTIC CELL CYCLE PHASE TRANSITION | 189 | 8.34e-07 | 4.00e-05 | 0.3390 | 1.46e-01 | 1.06e-01 | 1.45e-01 | 2.30e-01 | 9.31e-02 | 5.17e-04 | 1.19e-02 | 5.78e-04 | 4.98e-08 | 2.73e-02 |
| NEGATIVE REGULATION OF TELOMERE CAPPING | 8 | 3.96e-01 | 7.85e-01 | 0.3390 | 1.83e-01 | 1.18e-01 | 1.01e-02 | 1.32e-01 | 2.24e-01 | 3.70e-01 | 5.62e-01 | 9.60e-01 | 5.19e-01 | 2.72e-01 |
| CRANIOFACIAL SUTURE MORPHOGENESIS | 18 | 6.02e-01 | 9.00e-01 | 0.3390 | 4.99e-02 | 1.18e-01 | 2.15e-01 | 1.19e-01 | 1.96e-01 | 7.14e-01 | 3.87e-01 | 1.14e-01 | 3.81e-01 | 1.51e-01 |
| NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 24 | 3.88e-01 | 7.81e-01 | 0.3390 | 1.30e-01 | 1.60e-01 | 1.20e-01 | 1.86e-01 | 1.54e-01 | 2.71e-01 | 1.74e-01 | 3.09e-01 | 1.15e-01 | 1.93e-01 |
| CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 175 | 7.43e-04 | 1.37e-02 | 0.3390 | 1.13e-01 | 1.36e-01 | 1.82e-01 | 1.40e-01 | 1.76e-01 | 9.59e-03 | 1.88e-03 | 3.37e-05 | 1.37e-03 | 5.84e-05 |
| INTRACILIARY ANTEROGRADE TRANSPORT | 17 | 4.44e-01 | 8.14e-01 | 0.3390 | -1.65e-02 | 8.68e-02 | 1.61e-01 | 7.74e-02 | 2.75e-01 | 9.06e-01 | 5.35e-01 | 2.52e-01 | 5.80e-01 | 4.99e-02 |
| RNA STABILIZATION | 66 | 1.90e-02 | 1.61e-01 | 0.3390 | 2.18e-01 | 1.31e-01 | 9.89e-02 | 1.85e-01 | 7.71e-02 | 2.15e-03 | 6.59e-02 | 1.65e-01 | 9.27e-03 | 2.79e-01 |
| POSITIVE REGULATION OF EPITHELIAL TUBE FORMATION | 8 | 6.79e-01 | 9.28e-01 | 0.3390 | -3.53e-02 | 1.14e-01 | 2.31e-01 | 1.11e-01 | 1.87e-01 | 8.63e-01 | 5.77e-01 | 2.58e-01 | 5.86e-01 | 3.60e-01 |
| NEURON APOPTOTIC PROCESS | 265 | 1.48e-06 | 6.70e-05 | 0.3390 | 9.24e-02 | 1.13e-01 | 1.82e-01 | 1.58e-01 | 1.88e-01 | 9.57e-03 | 1.60e-03 | 3.31e-07 | 8.99e-06 | 1.36e-07 |
| PYRIMIDINE NUCLEOSIDE CATABOLIC PROCESS | 16 | 7.52e-01 | 9.51e-01 | 0.3390 | -7.62e-02 | -8.28e-02 | -1.78e-01 | -1.49e-01 | -2.19e-01 | 5.98e-01 | 5.66e-01 | 2.17e-01 | 3.02e-01 | 1.29e-01 |
| LIVER MORPHOGENESIS | 25 | 2.12e-01 | 6.07e-01 | 0.3390 | 2.20e-01 | 1.78e-01 | 5.33e-02 | 9.37e-02 | -1.51e-01 | 5.64e-02 | 1.23e-01 | 6.44e-01 | 4.17e-01 | 1.92e-01 |
| GLUTATHIONE METABOLIC PROCESS | 52 | 1.85e-01 | 5.72e-01 | 0.3390 | 1.23e-01 | 9.85e-02 | 1.88e-01 | 1.82e-01 | 1.47e-01 | 1.25e-01 | 2.19e-01 | 1.90e-02 | 2.35e-02 | 6.75e-02 |
| NITRIC OXIDE MEDIATED SIGNAL TRANSDUCTION | 28 | 5.83e-01 | 8.89e-01 | 0.3390 | -1.81e-01 | -1.22e-01 | -1.46e-01 | -1.94e-01 | -8.91e-02 | 9.81e-02 | 2.62e-01 | 1.80e-01 | 7.55e-02 | 4.15e-01 |
| GALACTOSE TRANSMEMBRANE TRANSPORT | 5 | 8.34e-01 | 9.73e-01 | 0.3380 | -1.42e-01 | -1.14e-01 | 6.66e-02 | -5.15e-02 | 2.73e-01 | 5.82e-01 | 6.60e-01 | 7.97e-01 | 8.42e-01 | 2.91e-01 |
| NEGATIVE REGULATION OF MYELINATION | 9 | 6.09e-01 | 9.03e-01 | 0.3380 | 2.11e-01 | 1.05e-01 | -4.27e-02 | 7.32e-02 | -2.28e-01 | 2.74e-01 | 5.85e-01 | 8.24e-01 | 7.04e-01 | 2.37e-01 |
| ACUTE PHASE RESPONSE | 47 | 2.46e-01 | 6.51e-01 | 0.3380 | -9.43e-02 | -1.04e-01 | -1.90e-01 | -1.53e-01 | -1.88e-01 | 2.64e-01 | 2.18e-01 | 2.42e-02 | 6.95e-02 | 2.59e-02 |
| REGULATION OF CELL CYCLE | 1070 | 1.92e-24 | 6.89e-22 | 0.3380 | 1.29e-01 | 1.20e-01 | 1.69e-01 | 1.85e-01 | 1.43e-01 | 8.72e-13 | 2.78e-11 | 9.44e-21 | 1.34e-24 | 2.36e-15 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CONTRACTION | 30 | 5.26e-01 | 8.60e-01 | 0.3380 | 1.09e-01 | 1.64e-01 | 1.85e-01 | 1.18e-01 | 1.66e-01 | 2.99e-01 | 1.19e-01 | 8.02e-02 | 2.64e-01 | 1.16e-01 |
| POST EMBRYONIC EYE MORPHOGENESIS | 7 | 3.96e-01 | 7.85e-01 | 0.3380 | 2.97e-01 | 1.18e-01 | 4.57e-02 | 6.65e-02 | 7.67e-02 | 1.74e-01 | 5.90e-01 | 8.34e-01 | 7.61e-01 | 7.25e-01 |
| NEGATIVE REGULATION OF MAST CELL DEGRANULATION | 5 | 7.44e-01 | 9.50e-01 | 0.3380 | 2.17e-01 | 1.91e-01 | -6.39e-02 | 5.37e-02 | -1.54e-01 | 4.02e-01 | 4.59e-01 | 8.05e-01 | 8.35e-01 | 5.50e-01 |
| PROTEIN STABILIZATION | 202 | 1.04e-05 | 3.87e-04 | 0.3380 | 1.21e-01 | 8.63e-02 | 1.70e-01 | 1.78e-01 | 1.77e-01 | 2.92e-03 | 3.45e-02 | 3.06e-05 | 1.35e-05 | 1.37e-05 |
| REGULATION OF CELL PROLIFERATION IN BONE MARROW | 8 | 8.49e-01 | 9.76e-01 | 0.3380 | -1.64e-01 | -2.33e-01 | -1.44e-01 | -7.06e-02 | -8.50e-02 | 4.22e-01 | 2.53e-01 | 4.81e-01 | 7.30e-01 | 6.77e-01 |
| CELLULAR RESPONSE TO ESTRADIOL STIMULUS | 37 | 4.74e-01 | 8.31e-01 | 0.3380 | 1.26e-01 | 1.73e-01 | 1.60e-01 | 1.45e-01 | 1.48e-01 | 1.85e-01 | 6.92e-02 | 9.30e-02 | 1.26e-01 | 1.20e-01 |
| NEGATIVE REGULATION OF DNA BIOSYNTHETIC PROCESS | 36 | 5.20e-01 | 8.58e-01 | 0.3380 | 1.53e-01 | 1.49e-01 | 1.46e-01 | 1.86e-01 | 1.12e-01 | 1.13e-01 | 1.23e-01 | 1.30e-01 | 5.30e-02 | 2.45e-01 |
| PEPTIDYL LYSINE TRIMETHYLATION | 9 | 5.60e-01 | 8.78e-01 | 0.3380 | -1.09e-02 | -2.31e-02 | 2.02e-01 | 9.11e-02 | 2.53e-01 | 9.55e-01 | 9.04e-01 | 2.93e-01 | 6.36e-01 | 1.89e-01 |
| KIDNEY MORPHOGENESIS | 94 | 4.10e-02 | 2.62e-01 | 0.3370 | 1.00e-01 | 1.22e-01 | 1.80e-01 | 1.67e-01 | 1.69e-01 | 9.28e-02 | 4.14e-02 | 2.50e-03 | 5.21e-03 | 4.55e-03 |
| ONE CARBON COMPOUND TRANSPORT | 60 | 2.04e-01 | 5.96e-01 | 0.3370 | -1.78e-01 | -1.35e-01 | -1.60e-01 | -1.86e-01 | -6.30e-02 | 1.69e-02 | 7.13e-02 | 3.23e-02 | 1.29e-02 | 3.99e-01 |
| PHOTORECEPTOR CELL MORPHOGENESIS | 5 | 6.90e-01 | 9.31e-01 | 0.3370 | 1.15e-01 | 2.53e-01 | 1.90e-01 | -1.53e-02 | 1.76e-02 | 6.57e-01 | 3.27e-01 | 4.62e-01 | 9.53e-01 | 9.46e-01 |
| PHAGOSOME LYSOSOME FUSION | 13 | 3.68e-01 | 7.69e-01 | 0.3370 | 1.17e-01 | 1.56e-01 | 1.36e-01 | 1.91e-01 | -1.43e-01 | 4.63e-01 | 3.29e-01 | 3.94e-01 | 2.33e-01 | 3.72e-01 |
| POSITIVE REGULATION OF PROTEIN IMPORT INTO NUCLEUS | 39 | 4.44e-01 | 8.14e-01 | 0.3370 | 1.65e-01 | 1.26e-01 | 1.52e-01 | 1.95e-01 | 9.72e-02 | 7.53e-02 | 1.74e-01 | 9.97e-02 | 3.47e-02 | 2.94e-01 |
| REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO OXIDATIVE STRESS | 7 | 7.97e-01 | 9.66e-01 | 0.3370 | 1.22e-01 | 1.01e-01 | 2.04e-01 | 7.82e-02 | 2.01e-01 | 5.75e-01 | 6.43e-01 | 3.49e-01 | 7.20e-01 | 3.56e-01 |
| REGULATION OF IMMUNOGLOBULIN PRODUCTION | 72 | 4.77e-03 | 5.91e-02 | 0.3370 | 1.06e-01 | 2.11e-01 | 1.51e-01 | 1.64e-01 | 9.09e-02 | 1.20e-01 | 2.00e-03 | 2.64e-02 | 1.60e-02 | 1.82e-01 |
| SNO S RNA METABOLIC PROCESS | 15 | 2.30e-01 | 6.32e-01 | 0.3370 | -5.76e-03 | -1.52e-03 | 4.76e-02 | 7.15e-02 | 3.26e-01 | 9.69e-01 | 9.92e-01 | 7.49e-01 | 6.32e-01 | 2.89e-02 |
| VASCULAR WOUND HEALING | 22 | 2.19e-01 | 6.16e-01 | 0.3370 | 7.37e-02 | 2.09e-01 | 1.83e-01 | 4.62e-02 | 1.69e-01 | 5.50e-01 | 8.91e-02 | 1.37e-01 | 7.08e-01 | 1.69e-01 |
| REGULATION OF CELLULAR AMINO ACID METABOLIC PROCESS | 13 | 7.59e-01 | 9.52e-01 | 0.3370 | -2.22e-01 | -1.83e-01 | -8.16e-02 | -1.39e-01 | 6.85e-02 | 1.65e-01 | 2.54e-01 | 6.11e-01 | 3.86e-01 | 6.69e-01 |
| RENAL TUBULAR SECRETION | 19 | 4.13e-01 | 7.98e-01 | 0.3370 | 2.88e-03 | 1.11e-01 | 1.72e-01 | 1.35e-01 | 2.31e-01 | 9.83e-01 | 4.02e-01 | 1.93e-01 | 3.09e-01 | 8.16e-02 |
| ETHER METABOLIC PROCESS | 26 | 6.11e-01 | 9.04e-01 | 0.3370 | -1.72e-01 | -1.17e-01 | -1.48e-01 | -2.01e-01 | -8.82e-02 | 1.30e-01 | 3.01e-01 | 1.90e-01 | 7.59e-02 | 4.37e-01 |
| ACINAR CELL DIFFERENTIATION | 5 | 3.34e-01 | 7.40e-01 | 0.3370 | 6.29e-02 | -1.99e-01 | -2.50e-02 | 2.02e-01 | 1.68e-01 | 8.08e-01 | 4.41e-01 | 9.23e-01 | 4.33e-01 | 5.16e-01 |
| NEGATIVE REGULATION OF STRIATED MUSCLE CELL APOPTOTIC PROCESS | 33 | 5.81e-01 | 8.88e-01 | 0.3370 | 1.64e-01 | 1.79e-01 | 1.57e-01 | 1.69e-01 | 2.94e-02 | 1.03e-01 | 7.44e-02 | 1.18e-01 | 9.26e-02 | 7.70e-01 |
| REGULATION OF ATRIAL CARDIAC MUSCLE CELL MEMBRANE DEPOLARIZATION | 9 | 4.56e-01 | 8.22e-01 | 0.3370 | -2.31e-01 | -5.06e-02 | -3.54e-02 | -2.25e-01 | -7.19e-02 | 2.30e-01 | 7.93e-01 | 8.54e-01 | 2.42e-01 | 7.09e-01 |
| ENTERIC NERVOUS SYSTEM DEVELOPMENT | 12 | 5.81e-01 | 8.88e-01 | 0.3370 | -4.89e-02 | 4.69e-02 | 1.44e-01 | 5.11e-02 | 2.92e-01 | 7.69e-01 | 7.79e-01 | 3.87e-01 | 7.59e-01 | 8.00e-02 |
| REGULATION OF TRANSCRIPTION OF NUCLEOLAR LARGE RRNA BY RNA POLYMERASE I | 15 | 3.85e-01 | 7.79e-01 | 0.3360 | -5.46e-02 | -7.29e-03 | 9.82e-02 | 7.14e-02 | 3.09e-01 | 7.14e-01 | 9.61e-01 | 5.10e-01 | 6.32e-01 | 3.83e-02 |
| NEGATIVE REGULATION OF NEUROTRANSMITTER TRANSPORT | 8 | 7.39e-01 | 9.49e-01 | 0.3360 | 1.73e-01 | 1.58e-01 | 2.11e-01 | 8.33e-02 | 8.23e-02 | 3.98e-01 | 4.38e-01 | 3.01e-01 | 6.83e-01 | 6.87e-01 |
| POSITIVE REGULATION OF MITOTIC CELL CYCLE | 122 | 2.22e-03 | 3.31e-02 | 0.3360 | 1.35e-01 | 1.07e-01 | 1.42e-01 | 1.93e-01 | 1.60e-01 | 9.79e-03 | 4.13e-02 | 6.68e-03 | 2.24e-04 | 2.21e-03 |
| REGULATION OF ANIMAL ORGAN MORPHOGENESIS | 121 | 7.99e-04 | 1.46e-02 | 0.3360 | 7.90e-02 | 1.11e-01 | 1.48e-01 | 1.41e-01 | 2.30e-01 | 1.33e-01 | 3.53e-02 | 4.91e-03 | 7.33e-03 | 1.28e-05 |
| CHONDROITIN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS | 23 | 2.62e-01 | 6.70e-01 | 0.3360 | 1.79e-01 | 2.41e-01 | 9.33e-02 | 1.03e-01 | 5.84e-02 | 1.36e-01 | 4.52e-02 | 4.39e-01 | 3.93e-01 | 6.28e-01 |
| NEGATIVE REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 9 | 8.81e-01 | 9.79e-01 | 0.3360 | -4.53e-02 | -1.42e-01 | -1.97e-01 | -1.10e-01 | -2.00e-01 | 8.14e-01 | 4.60e-01 | 3.06e-01 | 5.67e-01 | 3.00e-01 |
| L ASPARTATE IMPORT ACROSS PLASMA MEMBRANE | 6 | 8.79e-01 | 9.79e-01 | 0.3360 | 2.11e-01 | 1.45e-01 | 9.68e-02 | 1.14e-01 | 1.59e-01 | 3.71e-01 | 5.40e-01 | 6.81e-01 | 6.29e-01 | 5.00e-01 |
| REGULATION OF NAD P H OXIDASE ACTIVITY | 7 | 7.64e-01 | 9.54e-01 | 0.3360 | 2.63e-01 | 1.16e-01 | 2.90e-02 | 1.32e-01 | -1.12e-01 | 2.29e-01 | 5.96e-01 | 8.94e-01 | 5.45e-01 | 6.09e-01 |
| WNT SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 12 | 8.68e-01 | 9.78e-01 | 0.3360 | 9.48e-02 | 1.31e-01 | 1.51e-01 | 1.43e-01 | 2.09e-01 | 5.70e-01 | 4.32e-01 | 3.66e-01 | 3.91e-01 | 2.10e-01 |
| CYCLIC NUCLEOTIDE METABOLIC PROCESS | 40 | 4.63e-01 | 8.25e-01 | 0.3360 | -1.84e-01 | -1.39e-01 | -1.48e-01 | -1.79e-01 | -7.75e-02 | 4.45e-02 | 1.29e-01 | 1.05e-01 | 4.97e-02 | 3.96e-01 |
| POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 37 | 3.84e-01 | 7.79e-01 | 0.3360 | 1.52e-01 | 1.43e-01 | 1.72e-01 | 1.24e-01 | 1.56e-01 | 1.09e-01 | 1.31e-01 | 7.05e-02 | 1.91e-01 | 1.01e-01 |
| POSITIVE REGULATION OF MACROPHAGE CYTOKINE PRODUCTION | 23 | 3.08e-02 | 2.21e-01 | 0.3360 | 2.24e-01 | 2.35e-01 | 2.49e-02 | 5.44e-02 | 6.27e-02 | 6.31e-02 | 5.10e-02 | 8.36e-01 | 6.52e-01 | 6.03e-01 |
| REGULATION OF PEPTIDYL CYSTEINE S NITROSYLATION | 10 | 2.58e-01 | 6.64e-01 | 0.3360 | -1.88e-01 | -2.75e-01 | -5.98e-03 | -4.50e-02 | 6.13e-03 | 3.04e-01 | 1.33e-01 | 9.74e-01 | 8.05e-01 | 9.73e-01 |
| TOOTH ERUPTION | 5 | 6.44e-01 | 9.16e-01 | 0.3360 | 1.38e-01 | 1.96e-01 | -7.12e-02 | 6.95e-02 | -2.12e-01 | 5.92e-01 | 4.47e-01 | 7.83e-01 | 7.88e-01 | 4.11e-01 |
| NEGATIVE REGULATION OF ASTROCYTE ACTIVATION | 5 | 3.23e-01 | 7.33e-01 | 0.3360 | 1.04e-01 | 1.20e-01 | -1.46e-03 | -1.39e-01 | 2.61e-01 | 6.88e-01 | 6.41e-01 | 9.96e-01 | 5.90e-01 | 3.13e-01 |
| OVULATION FROM OVARIAN FOLLICLE | 8 | 5.50e-01 | 8.74e-01 | 0.3350 | -1.39e-01 | -8.36e-03 | -1.03e-01 | -2.73e-01 | -9.10e-02 | 4.96e-01 | 9.67e-01 | 6.14e-01 | 1.82e-01 | 6.56e-01 |
| TRANSLESION SYNTHESIS | 25 | 8.93e-02 | 4.04e-01 | 0.3350 | 1.25e-01 | -7.11e-03 | 1.41e-01 | 1.87e-01 | 2.05e-01 | 2.80e-01 | 9.51e-01 | 2.22e-01 | 1.05e-01 | 7.60e-02 |
| B CELL HOMEOSTASIS | 31 | 2.24e-01 | 6.24e-01 | 0.3350 | 2.26e-01 | 1.15e-01 | 9.70e-02 | 1.91e-01 | 4.61e-02 | 2.92e-02 | 2.68e-01 | 3.50e-01 | 6.55e-02 | 6.57e-01 |
| TELOMERE CAPPING | 39 | 2.78e-01 | 6.88e-01 | 0.3350 | 1.30e-01 | 1.22e-01 | 1.33e-01 | 1.85e-01 | 1.69e-01 | 1.60e-01 | 1.87e-01 | 1.50e-01 | 4.57e-02 | 6.71e-02 |
| CARDIAC ATRIUM MORPHOGENESIS | 29 | 3.85e-01 | 7.79e-01 | 0.3350 | 5.43e-02 | 1.18e-01 | 1.62e-01 | 1.21e-01 | 2.33e-01 | 6.13e-01 | 2.70e-01 | 1.31e-01 | 2.58e-01 | 3.00e-02 |
| SYNAPSE MATURATION | 33 | 5.67e-01 | 8.81e-01 | 0.3350 | 1.33e-01 | 1.77e-01 | 1.65e-01 | 1.31e-01 | 1.36e-01 | 1.85e-01 | 7.81e-02 | 1.01e-01 | 1.93e-01 | 1.75e-01 |
| BILE ACID METABOLIC PROCESS | 49 | 1.09e-01 | 4.52e-01 | 0.3350 | -5.87e-02 | -1.50e-01 | -2.07e-01 | -1.21e-01 | -1.69e-01 | 4.77e-01 | 6.89e-02 | 1.23e-02 | 1.44e-01 | 4.04e-02 |
| POSTSYNAPTIC DENSITY PROTEIN 95 CLUSTERING | 9 | 8.69e-01 | 9.78e-01 | 0.3340 | -1.62e-01 | -7.70e-02 | -1.40e-01 | -2.17e-01 | -1.15e-01 | 4.01e-01 | 6.89e-01 | 4.68e-01 | 2.60e-01 | 5.50e-01 |
| REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 15 | 8.52e-01 | 9.76e-01 | 0.3340 | -1.19e-01 | -1.22e-01 | -1.96e-01 | -1.47e-01 | -1.51e-01 | 4.23e-01 | 4.14e-01 | 1.89e-01 | 3.23e-01 | 3.13e-01 |
| REGULATION OF DNA METABOLIC PROCESS | 506 | 4.36e-13 | 5.05e-11 | 0.3340 | 1.38e-01 | 1.19e-01 | 1.46e-01 | 1.94e-01 | 1.40e-01 | 1.06e-07 | 4.94e-06 | 1.68e-08 | 8.12e-14 | 6.41e-08 |
| INTESTINAL ABSORPTION | 41 | 4.94e-02 | 2.90e-01 | 0.3340 | -4.21e-02 | -4.82e-02 | -1.83e-01 | -2.04e-01 | -1.80e-01 | 6.41e-01 | 5.93e-01 | 4.25e-02 | 2.37e-02 | 4.60e-02 |
| POSITIVE REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 6 | 6.64e-01 | 9.22e-01 | 0.3340 | -2.67e-01 | -9.45e-02 | 3.57e-02 | -6.28e-02 | 1.61e-01 | 2.57e-01 | 6.89e-01 | 8.80e-01 | 7.90e-01 | 4.94e-01 |
| CELLULAR RESPONSE TO FOLLICLE STIMULATING HORMONE STIMULUS | 9 | 8.87e-01 | 9.80e-01 | 0.3340 | -2.09e-01 | -1.08e-01 | -1.25e-01 | -1.85e-01 | -8.05e-02 | 2.79e-01 | 5.76e-01 | 5.15e-01 | 3.37e-01 | 6.76e-01 |
| ACETATE ESTER TRANSPORT | 9 | 1.82e-01 | 5.67e-01 | 0.3340 | -2.94e-01 | -8.91e-02 | -4.04e-03 | -1.37e-02 | 1.30e-01 | 1.27e-01 | 6.44e-01 | 9.83e-01 | 9.43e-01 | 5.00e-01 |
| T CELL APOPTOTIC PROCESS | 57 | 7.10e-02 | 3.61e-01 | 0.3340 | 6.19e-02 | 7.42e-02 | 1.63e-01 | 1.57e-01 | 2.25e-01 | 4.19e-01 | 3.32e-01 | 3.27e-02 | 4.09e-02 | 3.24e-03 |
| REGULATION OF GLUTAMATE RECEPTOR SIGNALING PATHWAY | 6 | 5.38e-01 | 8.66e-01 | 0.3340 | 7.79e-02 | 2.94e-01 | 1.09e-01 | 8.52e-03 | 8.48e-02 | 7.41e-01 | 2.13e-01 | 6.45e-01 | 9.71e-01 | 7.19e-01 |
| PROTEIN MATURATION | 517 | 4.40e-09 | 2.93e-07 | 0.3340 | 1.49e-01 | 1.51e-01 | 1.68e-01 | 1.67e-01 | 1.01e-01 | 6.44e-09 | 3.98e-09 | 6.11e-11 | 8.70e-11 | 7.81e-05 |
| NEGATIVE REGULATION OF PROTEIN TARGETING TO MITOCHONDRION | 5 | 8.75e-01 | 9.78e-01 | 0.3340 | 2.08e-01 | 1.17e-01 | 5.03e-02 | 2.26e-01 | 3.06e-02 | 4.21e-01 | 6.50e-01 | 8.46e-01 | 3.82e-01 | 9.06e-01 |
| PERIPHERAL NERVOUS SYSTEM DEVELOPMENT | 80 | 1.26e-02 | 1.20e-01 | 0.3340 | 7.12e-02 | 9.17e-02 | 1.63e-01 | 1.11e-01 | 2.43e-01 | 2.71e-01 | 1.56e-01 | 1.16e-02 | 8.64e-02 | 1.75e-04 |
| REGULATION OF SKELETAL MUSCLE CONTRACTION BY CALCIUM ION SIGNALING | 6 | 6.03e-01 | 9.00e-01 | 0.3340 | -1.61e-01 | 3.71e-02 | -7.20e-02 | -2.26e-01 | -1.67e-01 | 4.94e-01 | 8.75e-01 | 7.60e-01 | 3.38e-01 | 4.79e-01 |
| SPERM CAPACITATION | 30 | 3.75e-01 | 7.74e-01 | 0.3340 | -1.58e-01 | -1.27e-01 | -1.81e-01 | -1.93e-01 | -9.81e-03 | 1.33e-01 | 2.28e-01 | 8.63e-02 | 6.74e-02 | 9.26e-01 |
| NUCLEOBASE CONTAINING COMPOUND TRANSPORT | 206 | 8.46e-05 | 2.44e-03 | 0.3340 | 1.75e-01 | 1.29e-01 | 1.46e-01 | 1.98e-01 | 6.04e-02 | 1.57e-05 | 1.40e-03 | 3.01e-04 | 9.69e-07 | 1.35e-01 |
| TRIF DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 11 | 3.46e-01 | 7.50e-01 | 0.3330 | 2.34e-01 | 2.10e-01 | -2.49e-02 | 8.76e-02 | -6.38e-02 | 1.80e-01 | 2.27e-01 | 8.86e-01 | 6.15e-01 | 7.14e-01 |
| SEMAPHORIN PLEXIN SIGNALING PATHWAY INVOLVED IN NEURON PROJECTION GUIDANCE | 14 | 4.93e-01 | 8.43e-01 | 0.3330 | -1.77e-01 | -4.00e-02 | -1.29e-01 | -1.89e-01 | -1.62e-01 | 2.52e-01 | 7.95e-01 | 4.03e-01 | 2.22e-01 | 2.95e-01 |
| DICHOTOMOUS SUBDIVISION OF AN EPITHELIAL TERMINAL UNIT | 8 | 6.38e-01 | 9.14e-01 | 0.3330 | 1.06e-01 | 1.63e-01 | 1.73e-01 | 1.59e-01 | -1.34e-01 | 6.04e-01 | 4.24e-01 | 3.96e-01 | 4.36e-01 | 5.12e-01 |
| PROTEIN DESTABILIZATION | 46 | 2.33e-01 | 6.36e-01 | 0.3330 | 1.94e-01 | 1.30e-01 | 1.36e-01 | 1.95e-01 | 1.78e-02 | 2.30e-02 | 1.28e-01 | 1.10e-01 | 2.24e-02 | 8.34e-01 |
| EMBRYONIC PLACENTA MORPHOGENESIS | 27 | 4.36e-01 | 8.09e-01 | 0.3330 | 5.36e-02 | 1.04e-01 | 1.76e-01 | 1.69e-01 | 1.94e-01 | 6.30e-01 | 3.49e-01 | 1.13e-01 | 1.28e-01 | 8.12e-02 |
| POSITIVE REGULATION OF CALCIUM ION TRANSPORT INTO CYTOSOL | 13 | 4.70e-01 | 8.29e-01 | 0.3330 | 1.86e-01 | 2.13e-01 | 1.15e-01 | 4.33e-02 | 1.25e-01 | 2.44e-01 | 1.83e-01 | 4.75e-01 | 7.87e-01 | 4.35e-01 |
| AMINOGLYCAN CATABOLIC PROCESS | 33 | 2.12e-01 | 6.08e-01 | 0.3330 | -1.27e-01 | -1.18e-01 | -2.10e-01 | -1.16e-01 | -1.53e-01 | 2.07e-01 | 2.40e-01 | 3.70e-02 | 2.50e-01 | 1.28e-01 |
| NEGATIVE REGULATION OF RETINOIC ACID RECEPTOR SIGNALING PATHWAY | 9 | 9.12e-01 | 9.85e-01 | 0.3330 | 1.04e-01 | 9.22e-02 | 1.42e-01 | 1.70e-01 | 2.06e-01 | 5.88e-01 | 6.32e-01 | 4.61e-01 | 3.76e-01 | 2.86e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CONTRACTION | 26 | 6.90e-01 | 9.31e-01 | 0.3330 | -1.03e-01 | -1.56e-01 | -1.81e-01 | -1.58e-01 | -1.34e-01 | 3.61e-01 | 1.68e-01 | 1.11e-01 | 1.63e-01 | 2.36e-01 |
| REGULATION OF PANCREATIC JUICE SECRETION | 7 | 7.83e-01 | 9.61e-01 | 0.3330 | -7.74e-02 | -2.45e-01 | -1.84e-01 | -7.61e-02 | -7.11e-02 | 7.23e-01 | 2.61e-01 | 4.00e-01 | 7.27e-01 | 7.45e-01 |
| POSITIVE REGULATION OF MUSCLE CONTRACTION | 46 | 4.77e-02 | 2.86e-01 | 0.3330 | 3.98e-02 | 1.55e-01 | 2.01e-01 | 7.76e-02 | 1.96e-01 | 6.40e-01 | 6.86e-02 | 1.82e-02 | 3.63e-01 | 2.14e-02 |
| CARDIAC MUSCLE CELL ACTION POTENTIAL INVOLVED IN CONTRACTION | 51 | 6.38e-02 | 3.36e-01 | 0.3330 | -1.44e-01 | -9.87e-02 | -1.52e-01 | -2.31e-01 | -5.86e-02 | 7.59e-02 | 2.23e-01 | 5.96e-02 | 4.25e-03 | 4.69e-01 |
| CGMP METABOLIC PROCESS | 16 | 6.33e-01 | 9.11e-01 | 0.3320 | -2.17e-01 | -2.01e-01 | -1.19e-01 | -9.37e-02 | 9.71e-03 | 1.33e-01 | 1.64e-01 | 4.11e-01 | 5.17e-01 | 9.46e-01 |
| PORE COMPLEX ASSEMBLY | 19 | 6.06e-02 | 3.26e-01 | 0.3320 | 1.17e-01 | -4.40e-03 | -2.12e-01 | -2.49e-02 | -2.26e-01 | 3.76e-01 | 9.74e-01 | 1.09e-01 | 8.51e-01 | 8.83e-02 |
| DIAPEDESIS | 6 | 6.25e-01 | 9.09e-01 | 0.3320 | -7.36e-02 | -1.54e-01 | -2.51e-01 | -1.87e-02 | -1.33e-01 | 7.55e-01 | 5.13e-01 | 2.87e-01 | 9.37e-01 | 5.72e-01 |
| PIECEMEAL MICROAUTOPHAGY OF THE NUCLEUS | 10 | 6.52e-01 | 9.19e-01 | 0.3320 | 3.34e-02 | -4.50e-02 | -1.80e-01 | -3.85e-02 | -2.70e-01 | 8.55e-01 | 8.05e-01 | 3.24e-01 | 8.33e-01 | 1.39e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 6 | 7.93e-01 | 9.65e-01 | 0.3320 | 2.35e-02 | 9.55e-02 | 9.43e-02 | 1.91e-02 | 3.02e-01 | 9.21e-01 | 6.85e-01 | 6.89e-01 | 9.35e-01 | 2.00e-01 |
| POSITIVE REGULATION OF ATP DEPENDENT ACTIVITY | 39 | 4.36e-01 | 8.09e-01 | 0.3320 | 1.31e-01 | 1.63e-01 | 1.65e-01 | 1.85e-01 | 6.96e-02 | 1.56e-01 | 7.83e-02 | 7.39e-02 | 4.56e-02 | 4.52e-01 |
| PHOSPHOLIPASE C ACTIVATING G PROTEIN COUPLED ACETYLCHOLINE RECEPTOR SIGNALING PATHWAY | 8 | 6.29e-01 | 9.10e-01 | 0.3320 | 8.74e-02 | 3.79e-02 | -1.83e-01 | -6.71e-02 | -2.51e-01 | 6.68e-01 | 8.53e-01 | 3.71e-01 | 7.42e-01 | 2.18e-01 |
| REGULATION OF AUTOPHAGY OF MITOCHONDRION | 38 | 3.51e-01 | 7.52e-01 | 0.3320 | 2.10e-01 | 1.42e-01 | 1.18e-01 | 1.75e-01 | 3.86e-02 | 2.52e-02 | 1.31e-01 | 2.10e-01 | 6.18e-02 | 6.80e-01 |
| TRNA 3 END PROCESSING | 6 | 7.41e-01 | 9.49e-01 | 0.3320 | -2.74e-01 | -1.62e-01 | -1.15e-02 | -7.18e-02 | 5.76e-02 | 2.45e-01 | 4.92e-01 | 9.61e-01 | 7.61e-01 | 8.07e-01 |
| HEPATICOBILIARY SYSTEM DEVELOPMENT | 140 | 4.72e-03 | 5.88e-02 | 0.3320 | 1.76e-01 | 1.29e-01 | 1.46e-01 | 1.66e-01 | 1.17e-01 | 3.36e-04 | 8.36e-03 | 2.83e-03 | 7.01e-04 | 1.68e-02 |
| ZYGOTIC DETERMINATION OF ANTERIOR POSTERIOR AXIS EMBRYO | 6 | 1.95e-01 | 5.82e-01 | 0.3320 | 6.21e-02 | 2.72e-01 | 4.58e-03 | -1.41e-01 | 1.10e-01 | 7.92e-01 | 2.49e-01 | 9.84e-01 | 5.49e-01 | 6.40e-01 |
| CELLULAR RESPONSE TO LUTEINIZING HORMONE STIMULUS | 5 | 9.31e-01 | 9.90e-01 | 0.3320 | -1.94e-02 | 2.70e-02 | 1.46e-01 | 1.05e-01 | 2.76e-01 | 9.40e-01 | 9.17e-01 | 5.71e-01 | 6.85e-01 | 2.84e-01 |
| SMOOTH MUSCLE CELL DIFFERENTIATION | 72 | 6.00e-02 | 3.25e-01 | 0.3320 | 1.11e-01 | 1.62e-01 | 1.46e-01 | 1.42e-01 | 1.73e-01 | 1.04e-01 | 1.75e-02 | 3.26e-02 | 3.77e-02 | 1.09e-02 |
| PEPTIDYL TYROSINE DEPHOSPHORYLATION INVOLVED IN INACTIVATION OF PROTEIN KINASE ACTIVITY | 8 | 8.18e-01 | 9.70e-01 | 0.3310 | -7.11e-02 | -2.06e-02 | -1.61e-01 | -2.04e-01 | -1.92e-01 | 7.28e-01 | 9.20e-01 | 4.31e-01 | 3.18e-01 | 3.47e-01 |
| RIBOSE PHOSPHATE BIOSYNTHETIC PROCESS | 211 | 5.31e-04 | 1.06e-02 | 0.3310 | 1.56e-01 | 1.51e-01 | 1.52e-01 | 1.49e-01 | 1.33e-01 | 9.16e-05 | 1.61e-04 | 1.46e-04 | 1.99e-04 | 8.77e-04 |
| REGULATION OF DEFENSE RESPONSE TO BACTERIUM | 20 | 1.54e-02 | 1.39e-01 | 0.3310 | 1.24e-01 | 1.09e-01 | -6.24e-02 | -1.56e-01 | -2.33e-01 | 3.35e-01 | 3.98e-01 | 6.29e-01 | 2.26e-01 | 7.18e-02 |
| DETERMINATION OF ADULT LIFESPAN | 35 | 3.49e-01 | 7.52e-01 | 0.3310 | 9.97e-02 | 1.77e-01 | 1.75e-01 | 1.70e-01 | 9.38e-02 | 3.07e-01 | 7.01e-02 | 7.30e-02 | 8.14e-02 | 3.37e-01 |
| REGULATION OF XENOPHAGY | 9 | 2.23e-01 | 6.22e-01 | 0.3310 | 1.99e-01 | 2.14e-01 | -2.98e-02 | 1.47e-01 | 4.06e-02 | 3.02e-01 | 2.65e-01 | 8.77e-01 | 4.45e-01 | 8.33e-01 |
| EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 659 | 2.66e-16 | 4.01e-14 | 0.3310 | 8.92e-02 | 1.25e-01 | 1.70e-01 | 1.60e-01 | 1.78e-01 | 9.35e-05 | 4.65e-08 | 9.58e-14 | 2.11e-12 | 7.12e-15 |
| RENAL WATER ABSORPTION | 6 | 2.12e-01 | 6.07e-01 | 0.3310 | -1.02e-01 | 2.57e-01 | 1.56e-01 | -3.62e-02 | 8.53e-02 | 6.64e-01 | 2.76e-01 | 5.07e-01 | 8.78e-01 | 7.17e-01 |
| SARCOMERE ORGANIZATION | 45 | 1.98e-02 | 1.65e-01 | 0.3310 | -2.28e-01 | -1.16e-01 | -5.35e-02 | -2.03e-01 | 1.01e-02 | 8.19e-03 | 1.77e-01 | 5.34e-01 | 1.85e-02 | 9.07e-01 |
| POSITIVE REGULATION OF SYNAPTIC VESICLE RECYCLING | 8 | 6.86e-01 | 9.31e-01 | 0.3310 | -3.03e-02 | -1.49e-01 | -2.54e-01 | -1.14e-01 | -9.52e-02 | 8.82e-01 | 4.66e-01 | 2.14e-01 | 5.77e-01 | 6.41e-01 |
| GRANULOCYTE DIFFERENTIATION | 40 | 1.77e-01 | 5.62e-01 | 0.3310 | 1.54e-01 | 2.14e-01 | 1.38e-01 | 1.39e-01 | -3.66e-02 | 9.14e-02 | 1.90e-02 | 1.31e-01 | 1.28e-01 | 6.89e-01 |
| SINGLE STRAND BREAK REPAIR | 11 | 4.39e-01 | 8.11e-01 | 0.3310 | 5.93e-02 | 2.59e-02 | 9.90e-02 | 2.71e-02 | 3.08e-01 | 7.33e-01 | 8.82e-01 | 5.70e-01 | 8.76e-01 | 7.72e-02 |
| WATER TRANSPORT | 28 | 4.86e-02 | 2.89e-01 | 0.3310 | -1.76e-01 | -4.60e-02 | -1.17e-01 | -2.48e-01 | 3.37e-02 | 1.07e-01 | 6.74e-01 | 2.83e-01 | 2.33e-02 | 7.58e-01 |
| NEGATIVE REGULATION OF VIRAL LIFE CYCLE | 26 | 7.17e-01 | 9.37e-01 | 0.3310 | 1.57e-01 | 1.86e-01 | 1.43e-01 | 1.56e-01 | 7.22e-02 | 1.66e-01 | 1.01e-01 | 2.06e-01 | 1.68e-01 | 5.24e-01 |
| HYPEROSMOTIC SALINITY RESPONSE | 10 | 6.95e-01 | 9.31e-01 | 0.3310 | -5.65e-03 | 1.01e-01 | 1.49e-01 | 1.37e-01 | 2.41e-01 | 9.75e-01 | 5.81e-01 | 4.15e-01 | 4.52e-01 | 1.87e-01 |
| PROTEIN TARGETING TO VACUOLE | 46 | 4.90e-02 | 2.89e-01 | 0.3300 | 2.03e-01 | 1.40e-01 | 7.35e-02 | 2.03e-01 | -4.48e-02 | 1.73e-02 | 1.02e-01 | 3.88e-01 | 1.72e-02 | 5.99e-01 |
| RESPONSE TO PHEROMONE | 7 | 7.54e-01 | 9.51e-01 | 0.3300 | 9.75e-03 | -1.55e-01 | -1.45e-01 | -7.67e-02 | -2.41e-01 | 9.64e-01 | 4.76e-01 | 5.06e-01 | 7.25e-01 | 2.70e-01 |
| OSTEOBLAST DEVELOPMENT | 17 | 1.50e-01 | 5.19e-01 | 0.3300 | 4.51e-02 | 2.01e-01 | 1.79e-01 | -1.21e-02 | 1.85e-01 | 7.48e-01 | 1.52e-01 | 2.01e-01 | 9.31e-01 | 1.86e-01 |
| REGULATION OF TRANSFORMING GROWTH FACTOR BETA ACTIVATION | 10 | 5.67e-01 | 8.81e-01 | 0.3300 | 6.00e-02 | 1.67e-02 | -1.21e-01 | 1.04e-02 | -3.00e-01 | 7.42e-01 | 9.27e-01 | 5.08e-01 | 9.55e-01 | 1.00e-01 |
| NADP METABOLIC PROCESS | 41 | 4.62e-01 | 8.24e-01 | 0.3300 | 1.56e-01 | 1.74e-01 | 1.38e-01 | 1.69e-01 | 8.09e-02 | 8.39e-02 | 5.42e-02 | 1.26e-01 | 6.09e-02 | 3.70e-01 |
| ASTROCYTE DEVELOPMENT | 42 | 1.46e-01 | 5.12e-01 | 0.3300 | 2.00e-01 | 2.15e-01 | 1.01e-01 | 1.07e-01 | -3.12e-02 | 2.53e-02 | 1.57e-02 | 2.58e-01 | 2.32e-01 | 7.26e-01 |
| REGULATION OF GTP BINDING | 11 | 3.66e-01 | 7.66e-01 | 0.3300 | 1.49e-01 | 4.81e-02 | 6.28e-02 | 2.56e-01 | 1.22e-01 | 3.93e-01 | 7.82e-01 | 7.18e-01 | 1.42e-01 | 4.85e-01 |
| DENSE CORE GRANULE EXOCYTOSIS | 10 | 3.96e-01 | 7.85e-01 | 0.3300 | -1.27e-01 | -1.24e-01 | -7.65e-02 | -2.63e-01 | -4.68e-02 | 4.85e-01 | 4.98e-01 | 6.75e-01 | 1.50e-01 | 7.98e-01 |
| REGULATION OF CGMP MEDIATED SIGNALING | 11 | 6.94e-01 | 9.31e-01 | 0.3300 | -2.14e-01 | -1.82e-01 | -4.12e-02 | -1.58e-01 | 5.61e-02 | 2.18e-01 | 2.97e-01 | 8.13e-01 | 3.65e-01 | 7.47e-01 |
| REGULATION OF ENDOPLASMIC RETICULUM TUBULAR NETWORK ORGANIZATION | 6 | 6.02e-01 | 9.00e-01 | 0.3290 | 1.75e-01 | -1.44e-02 | -1.71e-01 | 2.67e-02 | -2.18e-01 | 4.57e-01 | 9.51e-01 | 4.68e-01 | 9.10e-01 | 3.55e-01 |
| REGULATION OF GENERATION OF PRECURSOR METABOLITES AND ENERGY | 132 | 6.08e-03 | 7.10e-02 | 0.3290 | 1.19e-01 | 1.24e-01 | 1.60e-01 | 1.37e-01 | 1.86e-01 | 1.85e-02 | 1.42e-02 | 1.51e-03 | 6.42e-03 | 2.18e-04 |
| BRANCHED CHAIN AMINO ACID METABOLIC PROCESS | 26 | 3.33e-02 | 2.32e-01 | 0.3290 | 1.79e-01 | 9.49e-02 | 4.12e-02 | 2.26e-01 | 1.22e-01 | 1.15e-01 | 4.02e-01 | 7.16e-01 | 4.62e-02 | 2.82e-01 |
| PREASSEMBLY OF GPI ANCHOR IN ER MEMBRANE | 7 | 9.51e-01 | 9.94e-01 | 0.3290 | 1.01e-01 | 1.03e-01 | 1.85e-01 | 1.20e-01 | 1.98e-01 | 6.44e-01 | 6.37e-01 | 3.96e-01 | 5.82e-01 | 3.65e-01 |
| ISOPRENOID TRANSPORT | 5 | 9.51e-01 | 9.94e-01 | 0.3290 | -1.93e-01 | -1.92e-01 | -7.29e-02 | -1.66e-01 | 3.42e-02 | 4.54e-01 | 4.57e-01 | 7.78e-01 | 5.20e-01 | 8.95e-01 |
| POSITIVE REGULATION OF CELL CELL ADHESION MEDIATED BY CADHERIN | 11 | 8.28e-01 | 9.72e-01 | 0.3290 | 1.45e-01 | 1.02e-01 | 1.43e-01 | 2.29e-01 | 6.59e-02 | 4.05e-01 | 5.59e-01 | 4.12e-01 | 1.89e-01 | 7.05e-01 |
| MAINTENANCE OF POSTSYNAPTIC SPECIALIZATION STRUCTURE | 7 | 6.99e-01 | 9.31e-01 | 0.3290 | -5.53e-02 | 5.84e-02 | 1.84e-01 | 1.65e-01 | 2.02e-01 | 8.00e-01 | 7.89e-01 | 3.99e-01 | 4.50e-01 | 3.55e-01 |
| REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 5 | 6.79e-01 | 9.28e-01 | 0.3290 | 1.98e-01 | -6.83e-04 | 2.70e-02 | 2.44e-01 | -9.51e-02 | 4.44e-01 | 9.98e-01 | 9.17e-01 | 3.45e-01 | 7.13e-01 |
| ENTRY OF BACTERIUM INTO HOST CELL | 9 | 3.99e-01 | 7.87e-01 | 0.3290 | -3.80e-02 | -3.04e-02 | -2.08e-01 | -2.47e-01 | -3.60e-02 | 8.43e-01 | 8.74e-01 | 2.79e-01 | 1.99e-01 | 8.51e-01 |
| CO TRANSCRIPTIONAL MRNA 3 END PROCESSING CLEAVAGE AND POLYADENYLATION PATHWAY | 5 | 4.15e-01 | 7.98e-01 | 0.3290 | -4.37e-02 | -8.99e-02 | 1.33e-01 | 2.73e-01 | 7.73e-02 | 8.66e-01 | 7.28e-01 | 6.06e-01 | 2.91e-01 | 7.65e-01 |
| HISTONE MODIFICATION | 106 | 5.10e-03 | 6.23e-02 | 0.3290 | 1.33e-01 | 1.52e-01 | 1.38e-01 | 2.00e-01 | 9.22e-02 | 1.83e-02 | 6.85e-03 | 1.44e-02 | 3.81e-04 | 1.01e-01 |
| POSITIVE REGULATION OF MEMBRANE DEPOLARIZATION | 11 | 6.30e-01 | 9.10e-01 | 0.3290 | -1.04e-01 | -4.50e-02 | -1.63e-01 | -2.44e-01 | -9.33e-02 | 5.51e-01 | 7.96e-01 | 3.48e-01 | 1.61e-01 | 5.92e-01 |
| PROTEIN LOCALIZATION TO NUCLEUS | 305 | 5.58e-06 | 2.21e-04 | 0.3290 | 1.52e-01 | 1.31e-01 | 1.56e-01 | 1.88e-01 | 9.03e-02 | 4.80e-06 | 8.16e-05 | 2.87e-06 | 1.74e-08 | 6.66e-03 |
| NEGATIVE REGULATION OF LIPOPROTEIN PARTICLE CLEARANCE | 20 | 2.86e-02 | 2.10e-01 | 0.3290 | 4.10e-02 | 1.31e-01 | 1.85e-01 | 2.22e-01 | -7.55e-02 | 7.51e-01 | 3.09e-01 | 1.53e-01 | 8.57e-02 | 5.59e-01 |
| NEGATIVE REGULATION OF DEFENSE RESPONSE TO VIRUS | 49 | 3.59e-02 | 2.43e-01 | 0.3290 | 1.11e-01 | 1.41e-01 | 1.07e-01 | 1.18e-01 | 2.25e-01 | 1.78e-01 | 8.84e-02 | 1.97e-01 | 1.52e-01 | 6.54e-03 |
| SUCCINYL COA METABOLIC PROCESS | 10 | 8.86e-01 | 9.80e-01 | 0.3280 | 1.24e-01 | 1.65e-01 | 1.56e-01 | 9.10e-02 | 1.81e-01 | 4.98e-01 | 3.67e-01 | 3.94e-01 | 6.18e-01 | 3.20e-01 |
| REGULATION OF COMPLEMENT ACTIVATION | 22 | 4.49e-02 | 2.76e-01 | 0.3280 | 3.19e-02 | -9.81e-04 | -2.27e-01 | -1.78e-01 | -1.53e-01 | 7.96e-01 | 9.94e-01 | 6.48e-02 | 1.48e-01 | 2.15e-01 |
| REGULATION OF NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 10 | 6.63e-01 | 9.22e-01 | 0.3280 | 1.32e-01 | 1.78e-01 | 9.08e-02 | 1.92e-01 | 1.17e-01 | 4.68e-01 | 3.31e-01 | 6.19e-01 | 2.94e-01 | 5.23e-01 |
| POSITIVE REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 12 | 8.26e-01 | 9.72e-01 | 0.3280 | 1.81e-01 | 2.19e-01 | 1.10e-01 | 1.18e-01 | 3.15e-02 | 2.78e-01 | 1.89e-01 | 5.10e-01 | 4.81e-01 | 8.50e-01 |
| REGULATION OF VENTRICULAR CARDIAC MUSCLE CELL MEMBRANE DEPOLARIZATION | 7 | 3.98e-01 | 7.86e-01 | 0.3280 | -1.68e-01 | -8.16e-02 | 6.45e-02 | -2.05e-01 | 1.63e-01 | 4.41e-01 | 7.09e-01 | 7.67e-01 | 3.49e-01 | 4.55e-01 |
| POSITIVE REGULATION OF CARDIAC MUSCLE CONTRACTION | 8 | 2.36e-01 | 6.39e-01 | 0.3280 | -2.59e-01 | -4.17e-02 | 1.38e-01 | -8.69e-02 | 1.10e-01 | 2.05e-01 | 8.38e-01 | 4.98e-01 | 6.70e-01 | 5.89e-01 |
| VESTIBULOCOCHLEAR NERVE FORMATION | 5 | 2.85e-01 | 6.93e-01 | 0.3280 | 1.63e-01 | 1.83e-01 | -1.07e-02 | -1.41e-01 | 1.65e-01 | 5.29e-01 | 4.78e-01 | 9.67e-01 | 5.85e-01 | 5.22e-01 |
| NEGATIVE REGULATION OF RESPONSE TO TUMOR CELL | 5 | 8.74e-01 | 9.78e-01 | 0.3280 | 1.49e-01 | 1.77e-01 | 1.06e-01 | 7.71e-02 | -1.92e-01 | 5.64e-01 | 4.94e-01 | 6.82e-01 | 7.65e-01 | 4.58e-01 |
| NEURAL FOLD FORMATION | 7 | 9.24e-01 | 9.89e-01 | 0.3280 | -1.71e-01 | -9.02e-02 | -1.67e-01 | -2.01e-01 | -4.30e-02 | 4.35e-01 | 6.80e-01 | 4.44e-01 | 3.57e-01 | 8.44e-01 |
| VITAMIN CATABOLIC PROCESS | 14 | 6.56e-01 | 9.20e-01 | 0.3280 | 1.00e-01 | 1.94e-01 | 1.72e-01 | 6.20e-02 | 1.62e-01 | 5.15e-01 | 2.09e-01 | 2.66e-01 | 6.88e-01 | 2.94e-01 |
| NEGATIVE REGULATION OF PROTEIN IMPORT INTO NUCLEUS | 15 | 6.13e-01 | 9.05e-01 | 0.3280 | -1.56e-02 | -1.37e-01 | -2.00e-01 | -1.02e-01 | -1.95e-01 | 9.17e-01 | 3.59e-01 | 1.81e-01 | 4.95e-01 | 1.90e-01 |
| NEGATIVE REGULATION OF MAST CELL ACTIVATION | 12 | 5.18e-01 | 8.57e-01 | 0.3270 | 3.39e-02 | -2.50e-02 | -2.14e-01 | -1.14e-01 | -2.16e-01 | 8.39e-01 | 8.81e-01 | 2.00e-01 | 4.93e-01 | 1.95e-01 |
| ENDOCARDIAL CUSHION FORMATION | 31 | 1.66e-01 | 5.46e-01 | 0.3270 | 2.97e-03 | 9.58e-02 | 2.02e-01 | 1.46e-01 | 1.89e-01 | 9.77e-01 | 3.56e-01 | 5.14e-02 | 1.59e-01 | 6.90e-02 |
| POSITIVE REGULATION OF T HELPER CELL DIFFERENTIATION | 22 | 4.42e-02 | 2.72e-01 | 0.3270 | 2.32e-01 | 2.21e-01 | -1.03e-02 | 5.68e-02 | -2.37e-02 | 5.92e-02 | 7.25e-02 | 9.33e-01 | 6.45e-01 | 8.47e-01 |
| IRON ION IMPORT ACROSS PLASMA MEMBRANE | 5 | 6.50e-01 | 9.18e-01 | 0.3270 | -5.89e-02 | -2.20e-01 | -9.97e-02 | -1.21e-01 | 1.73e-01 | 8.19e-01 | 3.93e-01 | 6.99e-01 | 6.40e-01 | 5.02e-01 |
| COPPER ION TRANSMEMBRANE TRANSPORT | 7 | 6.96e-01 | 9.31e-01 | 0.3260 | 2.00e-01 | 9.24e-02 | 3.87e-02 | 1.82e-01 | 1.53e-01 | 3.60e-01 | 6.72e-01 | 8.59e-01 | 4.04e-01 | 4.82e-01 |
| RESPONSE TO INTERLEUKIN 2 | 9 | 6.25e-01 | 9.09e-01 | 0.3260 | -1.58e-01 | -1.04e-01 | 5.89e-04 | -2.19e-02 | 2.65e-01 | 4.12e-01 | 5.90e-01 | 9.98e-01 | 9.09e-01 | 1.68e-01 |
| NEGATIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL PROLIFERATION | 10 | 3.26e-01 | 7.35e-01 | 0.3260 | -6.02e-03 | -2.42e-01 | -1.68e-01 | -9.59e-02 | -1.01e-01 | 9.74e-01 | 1.85e-01 | 3.57e-01 | 5.99e-01 | 5.79e-01 |
| MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 18 | 5.76e-01 | 8.84e-01 | 0.3260 | 1.32e-01 | 1.95e-01 | 1.38e-01 | 7.88e-02 | 1.60e-01 | 3.33e-01 | 1.52e-01 | 3.10e-01 | 5.63e-01 | 2.39e-01 |
| RESPONSE TO NITROSATIVE STRESS | 10 | 2.53e-01 | 6.59e-01 | 0.3260 | -5.01e-02 | -4.32e-02 | 1.37e-01 | 2.30e-01 | 1.75e-01 | 7.84e-01 | 8.13e-01 | 4.53e-01 | 2.09e-01 | 3.39e-01 |
| FIBROBLAST PROLIFERATION | 104 | 2.17e-02 | 1.76e-01 | 0.3260 | 1.16e-01 | 9.78e-02 | 1.75e-01 | 1.78e-01 | 1.45e-01 | 4.06e-02 | 8.48e-02 | 2.02e-03 | 1.72e-03 | 1.08e-02 |
| INTRACELLULAR OXYGEN HOMEOSTASIS | 7 | 9.50e-01 | 9.94e-01 | 0.3260 | 1.43e-01 | 1.34e-01 | 2.02e-01 | 1.49e-01 | 6.83e-02 | 5.11e-01 | 5.39e-01 | 3.54e-01 | 4.94e-01 | 7.54e-01 |
| POSITIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 17 | 4.94e-01 | 8.44e-01 | 0.3260 | 2.19e-01 | 2.02e-01 | 8.17e-02 | 9.06e-02 | 5.16e-02 | 1.18e-01 | 1.49e-01 | 5.60e-01 | 5.18e-01 | 7.13e-01 |
| VESICLE BUDDING FROM MEMBRANE | 81 | 1.00e-01 | 4.30e-01 | 0.3260 | 1.64e-01 | 1.25e-01 | 1.65e-01 | 1.75e-01 | 7.57e-02 | 1.07e-02 | 5.14e-02 | 1.01e-02 | 6.55e-03 | 2.39e-01 |
| LYMPHOCYTE APOPTOTIC PROCESS | 80 | 2.70e-02 | 2.03e-01 | 0.3260 | 9.07e-02 | 8.74e-02 | 1.46e-01 | 1.67e-01 | 2.02e-01 | 1.61e-01 | 1.77e-01 | 2.40e-02 | 9.66e-03 | 1.76e-03 |
| ADHESION OF SYMBIONT TO HOST | 12 | 8.59e-01 | 9.78e-01 | 0.3260 | 1.11e-01 | 1.06e-01 | 1.36e-01 | 1.34e-01 | 2.15e-01 | 5.04e-01 | 5.25e-01 | 4.14e-01 | 4.23e-01 | 1.98e-01 |
| DUMP CATABOLIC PROCESS | 6 | 8.90e-01 | 9.80e-01 | 0.3260 | 2.48e-01 | 1.31e-01 | 7.37e-02 | 1.41e-01 | 4.55e-02 | 2.93e-01 | 5.77e-01 | 7.55e-01 | 5.51e-01 | 8.47e-01 |
| PROTEIN LOCALIZATION TO VACUOLE | 85 | 3.26e-02 | 2.29e-01 | 0.3260 | 1.82e-01 | 1.28e-01 | 1.19e-01 | 1.97e-01 | 5.87e-02 | 3.63e-03 | 4.15e-02 | 5.75e-02 | 1.72e-03 | 3.50e-01 |
| LIMBIC SYSTEM DEVELOPMENT | 117 | 1.21e-03 | 2.04e-02 | 0.3250 | 9.05e-02 | 7.94e-02 | 1.53e-01 | 1.25e-01 | 2.29e-01 | 9.07e-02 | 1.38e-01 | 4.36e-03 | 1.99e-02 | 1.85e-05 |
| CELL PROLIFERATION IN BONE MARROW | 10 | 6.78e-01 | 9.28e-01 | 0.3250 | -1.83e-01 | -2.39e-01 | -8.71e-02 | -6.48e-02 | -5.81e-02 | 3.16e-01 | 1.91e-01 | 6.33e-01 | 7.23e-01 | 7.50e-01 |
| PURINE NUCLEOSIDE DIPHOSPHATE CATABOLIC PROCESS | 5 | 4.71e-01 | 8.30e-01 | 0.3250 | -2.91e-01 | -1.41e-01 | 2.24e-02 | 4.94e-03 | -2.66e-02 | 2.60e-01 | 5.85e-01 | 9.31e-01 | 9.85e-01 | 9.18e-01 |
| POSITIVE REGULATION OF HUMORAL IMMUNE RESPONSE | 24 | 1.38e-01 | 5.01e-01 | 0.3250 | -1.52e-01 | -2.96e-02 | -1.81e-01 | -1.74e-01 | -1.36e-01 | 1.97e-01 | 8.02e-01 | 1.24e-01 | 1.41e-01 | 2.47e-01 |
| GLYCOLIPID CATABOLIC PROCESS | 16 | 5.43e-01 | 8.69e-01 | 0.3250 | 1.84e-01 | 2.09e-01 | 1.17e-01 | 7.77e-02 | -9.18e-02 | 2.03e-01 | 1.47e-01 | 4.20e-01 | 5.91e-01 | 5.25e-01 |
| REGULATION OF CELLULAR RESPONSE TO OXIDATIVE STRESS | 22 | 6.73e-01 | 9.27e-01 | 0.3250 | -9.97e-02 | -1.70e-01 | -1.95e-01 | -1.46e-01 | -8.55e-02 | 4.18e-01 | 1.68e-01 | 1.13e-01 | 2.35e-01 | 4.88e-01 |
| CARNITINE METABOLIC PROCESS | 11 | 8.62e-01 | 9.78e-01 | 0.3250 | 2.22e-01 | 1.54e-01 | 9.59e-02 | 1.48e-01 | -3.60e-02 | 2.03e-01 | 3.75e-01 | 5.82e-01 | 3.94e-01 | 8.36e-01 |
| PROTEIN K63 LINKED UBIQUITINATION | 56 | 1.75e-01 | 5.60e-01 | 0.3240 | 1.43e-01 | 1.24e-01 | 1.32e-01 | 1.95e-01 | 1.19e-01 | 6.39e-02 | 1.08e-01 | 8.65e-02 | 1.18e-02 | 1.25e-01 |
| POSITIVE REGULATION OF MRNA 3 END PROCESSING | 6 | 6.19e-01 | 9.07e-01 | 0.3240 | -8.32e-02 | -6.07e-02 | 6.85e-02 | 1.59e-01 | 2.55e-01 | 7.24e-01 | 7.97e-01 | 7.71e-01 | 5.01e-01 | 2.80e-01 |
| BLOOD VESSEL MATURATION | 8 | 4.10e-01 | 7.95e-01 | 0.3240 | -2.17e-01 | -1.13e-03 | 4.24e-02 | -1.86e-01 | 1.47e-01 | 2.88e-01 | 9.96e-01 | 8.35e-01 | 3.62e-01 | 4.71e-01 |
| LATERAL SPROUTING FROM AN EPITHELIUM | 10 | 2.13e-01 | 6.08e-01 | 0.3240 | -2.34e-01 | -2.31e-02 | 1.21e-01 | 1.24e-02 | 1.88e-01 | 2.01e-01 | 8.99e-01 | 5.07e-01 | 9.46e-01 | 3.04e-01 |
| PEPTIDYL SERINE DEPHOSPHORYLATION | 14 | 4.15e-01 | 7.98e-01 | 0.3240 | 1.75e-01 | 3.32e-02 | 1.53e-01 | 1.62e-01 | 1.54e-01 | 2.56e-01 | 8.30e-01 | 3.21e-01 | 2.94e-01 | 3.19e-01 |
| T CELL PROLIFERATION INVOLVED IN IMMUNE RESPONSE | 5 | 7.82e-01 | 9.60e-01 | 0.3240 | 2.37e-01 | 2.01e-01 | 1.48e-02 | 2.91e-03 | -8.95e-02 | 3.58e-01 | 4.36e-01 | 9.54e-01 | 9.91e-01 | 7.29e-01 |
| RESPONSE TO OZONE | 5 | 8.70e-01 | 9.78e-01 | 0.3240 | 6.47e-02 | 6.16e-02 | 1.24e-01 | 2.38e-01 | 1.59e-01 | 8.02e-01 | 8.11e-01 | 6.31e-01 | 3.58e-01 | 5.38e-01 |
| POSITIVE REGULATION OF VACUOLE ORGANIZATION | 23 | 5.33e-01 | 8.64e-01 | 0.3240 | 1.81e-01 | 1.17e-01 | 1.23e-01 | 2.09e-01 | -1.70e-03 | 1.34e-01 | 3.33e-01 | 3.09e-01 | 8.23e-02 | 9.89e-01 |
| REGULATION OF BINDING | 253 | 7.78e-05 | 2.26e-03 | 0.3240 | 1.50e-01 | 1.32e-01 | 1.47e-01 | 1.85e-01 | 9.71e-02 | 3.90e-05 | 3.06e-04 | 5.88e-05 | 4.26e-07 | 7.79e-03 |
| L ASCORBIC ACID METABOLIC PROCESS | 9 | 8.83e-01 | 9.80e-01 | 0.3240 | 7.74e-02 | 1.18e-01 | 2.21e-01 | 1.46e-01 | 1.21e-01 | 6.88e-01 | 5.39e-01 | 2.50e-01 | 4.49e-01 | 5.30e-01 |
| L SERINE METABOLIC PROCESS | 12 | 3.80e-01 | 7.78e-01 | 0.3240 | 1.26e-01 | 9.70e-02 | 1.05e-01 | 2.44e-01 | -9.57e-02 | 4.50e-01 | 5.61e-01 | 5.27e-01 | 1.44e-01 | 5.66e-01 |
| ARACHIDONIC ACID SECRETION | 31 | 2.73e-01 | 6.81e-01 | 0.3240 | -1.87e-01 | -1.70e-01 | -8.09e-02 | -1.82e-01 | 3.76e-02 | 7.12e-02 | 1.02e-01 | 4.36e-01 | 8.02e-02 | 7.17e-01 |
| T CELL SELECTION | 52 | 7.94e-04 | 1.45e-02 | 0.3240 | -4.09e-02 | 2.03e-02 | 1.84e-01 | 1.79e-01 | 1.92e-01 | 6.10e-01 | 8.00e-01 | 2.17e-02 | 2.58e-02 | 1.65e-02 |
| REGULATION OF INOSITOL 1 4 5 TRISPHOSPHATE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 5 | 9.61e-01 | 9.94e-01 | 0.3240 | -1.03e-01 | -1.65e-01 | -2.08e-01 | -8.92e-02 | -1.26e-01 | 6.90e-01 | 5.22e-01 | 4.22e-01 | 7.30e-01 | 6.27e-01 |
| POSITIVE REGULATION OF VIRAL GENOME REPLICATION | 30 | 6.62e-01 | 9.22e-01 | 0.3240 | 1.40e-01 | 1.27e-01 | 1.63e-01 | 1.87e-01 | 8.47e-02 | 1.83e-01 | 2.28e-01 | 1.22e-01 | 7.59e-02 | 4.22e-01 |
| PERIPHERAL NERVOUS SYSTEM MYELIN MAINTENANCE | 9 | 9.01e-01 | 9.83e-01 | 0.3240 | 9.83e-02 | 1.67e-01 | 1.37e-01 | 1.19e-01 | 1.85e-01 | 6.10e-01 | 3.84e-01 | 4.77e-01 | 5.38e-01 | 3.36e-01 |
| INTERMEDIATE FILAMENT ORGANIZATION | 72 | 1.53e-02 | 1.38e-01 | 0.3240 | -1.21e-01 | -1.19e-01 | -1.39e-01 | -2.21e-01 | -8.89e-02 | 7.65e-02 | 8.18e-02 | 4.11e-02 | 1.19e-03 | 1.92e-01 |
| INHIBITORY SYNAPSE ASSEMBLY | 19 | 5.74e-01 | 8.84e-01 | 0.3240 | 1.56e-01 | 2.28e-01 | 1.42e-01 | 8.90e-02 | 1.48e-02 | 2.39e-01 | 8.53e-02 | 2.84e-01 | 5.02e-01 | 9.11e-01 |
| NEGATIVE REGULATION OF PROTEOLYSIS INVOLVED IN PROTEIN CATABOLIC PROCESS | 59 | 1.13e-02 | 1.11e-01 | 0.3240 | 1.29e-01 | 8.19e-02 | 1.04e-01 | 2.09e-01 | 1.63e-01 | 8.59e-02 | 2.77e-01 | 1.66e-01 | 5.41e-03 | 3.03e-02 |
| NEGATIVE REGULATION OF CHEMOKINE MEDIATED SIGNALING PATHWAY | 6 | 8.86e-01 | 9.80e-01 | 0.3240 | -9.84e-02 | -1.59e-02 | -1.71e-01 | -1.99e-01 | -1.61e-01 | 6.76e-01 | 9.46e-01 | 4.69e-01 | 3.99e-01 | 4.94e-01 |
| POSITIVE REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 62 | 6.90e-02 | 3.54e-01 | 0.3240 | 4.42e-02 | 8.96e-02 | 1.70e-01 | 1.38e-01 | 2.16e-01 | 5.47e-01 | 2.23e-01 | 2.06e-02 | 6.03e-02 | 3.23e-03 |
| ENDOSOME TO PLASMA MEMBRANE PROTEIN TRANSPORT | 15 | 2.42e-01 | 6.46e-01 | 0.3230 | 9.76e-02 | 1.65e-01 | 2.33e-02 | 1.48e-02 | -2.59e-01 | 5.13e-01 | 2.68e-01 | 8.76e-01 | 9.21e-01 | 8.26e-02 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION | 20 | 4.79e-01 | 8.34e-01 | 0.3230 | 1.55e-01 | 1.64e-01 | 9.26e-02 | 1.39e-01 | 1.60e-01 | 2.30e-01 | 2.03e-01 | 4.74e-01 | 2.82e-01 | 2.15e-01 |
| POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 27 | 5.88e-01 | 8.92e-01 | 0.3230 | 1.39e-01 | 1.19e-01 | 1.35e-01 | 1.42e-01 | 1.80e-01 | 2.11e-01 | 2.84e-01 | 2.23e-01 | 2.01e-01 | 1.05e-01 |
| CERAMIDE 1 PHOSPHATE TRANSPORT | 7 | 9.51e-01 | 9.94e-01 | 0.3230 | 1.21e-01 | 1.54e-01 | 1.77e-01 | 1.85e-01 | 2.30e-02 | 5.80e-01 | 4.80e-01 | 4.16e-01 | 3.98e-01 | 9.16e-01 |
| NEGATIVE REGULATION OF REGULATED SECRETORY PATHWAY | 22 | 5.91e-01 | 8.94e-01 | 0.3230 | 1.93e-01 | 1.87e-01 | 8.88e-02 | 1.54e-01 | -1.99e-02 | 1.17e-01 | 1.29e-01 | 4.71e-01 | 2.10e-01 | 8.72e-01 |
| REGULATION OF STEM CELL POPULATION MAINTENANCE | 71 | 4.04e-02 | 2.59e-01 | 0.3230 | 8.66e-02 | 1.21e-01 | 1.36e-01 | 1.47e-01 | 2.06e-01 | 2.07e-01 | 7.89e-02 | 4.74e-02 | 3.27e-02 | 2.70e-03 |
| EOSINOPHIL DIFFERENTIATION | 6 | 3.45e-01 | 7.50e-01 | 0.3230 | -4.46e-02 | 1.91e-01 | 1.36e-01 | -1.41e-01 | 1.66e-01 | 8.50e-01 | 4.17e-01 | 5.63e-01 | 5.50e-01 | 4.82e-01 |
| SPHINGOSINE 1 PHOSPHATE RECEPTOR SIGNALING PATHWAY | 15 | 7.29e-01 | 9.44e-01 | 0.3230 | 6.44e-02 | 1.52e-01 | 2.08e-01 | 1.04e-01 | 1.53e-01 | 6.66e-01 | 3.09e-01 | 1.64e-01 | 4.86e-01 | 3.05e-01 |
| NEURONAL ACTION POTENTIAL PROPAGATION | 9 | 6.46e-01 | 9.16e-01 | 0.3230 | -2.53e-01 | -8.48e-02 | -6.52e-02 | -1.63e-01 | -4.97e-02 | 1.90e-01 | 6.60e-01 | 7.35e-01 | 3.96e-01 | 7.96e-01 |
| SPINDLE ELONGATION | 13 | 3.58e-01 | 7.57e-01 | 0.3230 | 2.33e-01 | 4.20e-02 | 7.23e-02 | 2.04e-01 | -3.38e-02 | 1.45e-01 | 7.93e-01 | 6.52e-01 | 2.02e-01 | 8.33e-01 |
| REGULATION OF ADIPOSE TISSUE DEVELOPMENT | 16 | 2.39e-01 | 6.43e-01 | 0.3230 | 2.48e-02 | 5.68e-03 | -1.95e-01 | -1.84e-01 | -1.78e-01 | 8.64e-01 | 9.69e-01 | 1.77e-01 | 2.02e-01 | 2.18e-01 |
| RECEPTOR GUANYLYL CYCLASE SIGNALING PATHWAY | 10 | 4.13e-01 | 7.98e-01 | 0.3230 | -2.82e-01 | -1.28e-01 | -4.50e-02 | -7.48e-02 | 3.01e-02 | 1.23e-01 | 4.83e-01 | 8.05e-01 | 6.82e-01 | 8.69e-01 |
| CARBOHYDRATE IMPORT ACROSS PLASMA MEMBRANE | 6 | 3.60e-01 | 7.58e-01 | 0.3230 | -1.34e-02 | 8.27e-02 | 1.36e-01 | -1.48e-01 | 2.39e-01 | 9.55e-01 | 7.26e-01 | 5.65e-01 | 5.31e-01 | 3.12e-01 |
| CATECHOLAMINE UPTAKE | 18 | 5.09e-01 | 8.53e-01 | 0.3230 | 1.05e-01 | 2.04e-01 | 1.27e-01 | 1.06e-01 | 1.55e-01 | 4.42e-01 | 1.33e-01 | 3.50e-01 | 4.38e-01 | 2.54e-01 |
| TELOMERE LOCALIZATION | 12 | 3.50e-01 | 7.52e-01 | 0.3230 | -1.43e-01 | -1.75e-01 | -1.01e-01 | -5.05e-03 | -2.06e-01 | 3.90e-01 | 2.93e-01 | 5.44e-01 | 9.76e-01 | 2.16e-01 |
| POSITIVE REGULATION OF TELOMERE MAINTENANCE | 66 | 8.18e-02 | 3.87e-01 | 0.3230 | 1.48e-01 | 1.30e-01 | 1.20e-01 | 1.87e-01 | 1.26e-01 | 3.75e-02 | 6.83e-02 | 9.21e-02 | 8.51e-03 | 7.67e-02 |
| FAT CELL DIFFERENTIATION | 243 | 2.74e-04 | 6.06e-03 | 0.3230 | 1.24e-01 | 1.53e-01 | 1.65e-01 | 1.38e-01 | 1.37e-01 | 8.84e-04 | 3.78e-05 | 9.28e-06 | 2.09e-04 | 2.26e-04 |
| CEREBELLAR GRANULAR LAYER DEVELOPMENT | 12 | 6.54e-01 | 9.20e-01 | 0.3230 | -1.33e-01 | -1.98e-01 | -1.15e-01 | -1.73e-01 | 6.28e-02 | 4.24e-01 | 2.35e-01 | 4.90e-01 | 3.00e-01 | 7.07e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 6 PRODUCTION | 63 | 2.84e-02 | 2.09e-01 | 0.3220 | 1.84e-01 | 1.42e-01 | 1.02e-01 | 1.81e-01 | -8.34e-02 | 1.17e-02 | 5.09e-02 | 1.62e-01 | 1.31e-02 | 2.52e-01 |
| UV PROTECTION | 12 | 3.87e-01 | 7.80e-01 | 0.3220 | 1.75e-01 | 2.72e-02 | 8.31e-02 | 1.40e-01 | 2.15e-01 | 2.93e-01 | 8.71e-01 | 6.18e-01 | 4.02e-01 | 1.98e-01 |
| RESPONSE TO AMPHETAMINE | 29 | 5.67e-01 | 8.81e-01 | 0.3220 | 1.55e-01 | 1.76e-01 | 1.21e-01 | 1.48e-01 | 1.12e-01 | 1.49e-01 | 1.02e-01 | 2.58e-01 | 1.67e-01 | 2.97e-01 |
| RESPONSE TO VASOPRESSIN | 8 | 1.52e-01 | 5.20e-01 | 0.3220 | -6.15e-02 | 1.65e-01 | 1.48e-01 | -1.63e-01 | 1.57e-01 | 7.63e-01 | 4.19e-01 | 4.69e-01 | 4.26e-01 | 4.42e-01 |
| RNA 3 URIDYLATION | 5 | 8.72e-01 | 9.78e-01 | 0.3220 | 1.36e-01 | 4.85e-03 | 1.01e-01 | 1.99e-01 | 1.88e-01 | 5.98e-01 | 9.85e-01 | 6.95e-01 | 4.40e-01 | 4.67e-01 |
| GLUTAMATE SECRETION NEUROTRANSMISSION | 8 | 8.17e-01 | 9.70e-01 | 0.3220 | 1.64e-01 | 2.36e-01 | 8.23e-02 | 1.05e-01 | -5.91e-02 | 4.22e-01 | 2.48e-01 | 6.87e-01 | 6.06e-01 | 7.72e-01 |
| CELL CYCLE | 1738 | 4.35e-34 | 2.73e-31 | 0.3220 | 1.34e-01 | 1.20e-01 | 1.56e-01 | 1.77e-01 | 1.26e-01 | 1.09e-20 | 8.39e-17 | 2.94e-27 | 1.17e-34 | 2.22e-18 |
| CRD MEDIATED MRNA STABILIZATION | 11 | 7.59e-01 | 9.52e-01 | 0.3220 | 2.17e-01 | 9.22e-02 | 1.22e-01 | 1.82e-01 | 4.13e-03 | 2.13e-01 | 5.96e-01 | 4.82e-01 | 2.95e-01 | 9.81e-01 |
| NEGATIVE REGULATION OF T CELL RECEPTOR SIGNALING PATHWAY | 24 | 5.71e-01 | 8.83e-01 | 0.3220 | 1.51e-01 | 1.85e-01 | 1.39e-01 | 1.63e-01 | -3.12e-02 | 1.99e-01 | 1.17e-01 | 2.40e-01 | 1.68e-01 | 7.92e-01 |
| ORGANELLE FISSION | 480 | 1.09e-10 | 9.00e-09 | 0.3220 | 1.36e-01 | 1.08e-01 | 1.65e-01 | 1.87e-01 | 1.06e-01 | 3.63e-07 | 4.65e-05 | 5.63e-10 | 2.01e-12 | 6.92e-05 |
| CRANIAL GANGLION DEVELOPMENT | 5 | 6.33e-01 | 9.12e-01 | 0.3220 | -2.55e-01 | -1.61e-01 | 4.18e-02 | 3.00e-02 | 1.00e-01 | 3.24e-01 | 5.32e-01 | 8.71e-01 | 9.08e-01 | 6.98e-01 |
| NEGATIVE REGULATION OF PROTEIN TYROSINE KINASE ACTIVITY | 24 | 3.79e-01 | 7.75e-01 | 0.3220 | 2.73e-02 | 1.20e-01 | 1.50e-01 | 8.42e-02 | 2.43e-01 | 8.17e-01 | 3.09e-01 | 2.04e-01 | 4.75e-01 | 3.95e-02 |
| AMIDE BIOSYNTHETIC PROCESS | 938 | 3.63e-17 | 6.20e-15 | 0.3220 | 1.37e-01 | 1.25e-01 | 1.59e-01 | 1.66e-01 | 1.28e-01 | 1.34e-12 | 7.36e-11 | 1.26e-16 | 6.71e-18 | 3.24e-11 |
| SERINE FAMILY AMINO ACID BIOSYNTHETIC PROCESS | 19 | 3.33e-01 | 7.40e-01 | 0.3220 | 1.61e-01 | 1.76e-01 | 7.22e-02 | 1.92e-01 | -6.78e-02 | 2.24e-01 | 1.84e-01 | 5.86e-01 | 1.47e-01 | 6.09e-01 |
| EMBRYONIC VISCEROCRANIUM MORPHOGENESIS | 10 | 8.85e-01 | 9.80e-01 | 0.3220 | 1.90e-01 | 1.67e-01 | 1.21e-01 | 1.09e-01 | 1.14e-01 | 2.98e-01 | 3.60e-01 | 5.08e-01 | 5.51e-01 | 5.32e-01 |
| REGULATION OF MULTICELLULAR ORGANISM GROWTH | 63 | 1.16e-01 | 4.64e-01 | 0.3220 | 1.27e-01 | 1.26e-01 | 1.58e-01 | 1.14e-01 | 1.83e-01 | 8.10e-02 | 8.31e-02 | 3.05e-02 | 1.18e-01 | 1.19e-02 |
| MELANIN METABOLIC PROCESS | 24 | 7.74e-01 | 9.57e-01 | 0.3210 | -1.56e-01 | -1.85e-01 | -1.46e-01 | -1.47e-01 | -4.45e-02 | 1.86e-01 | 1.18e-01 | 2.15e-01 | 2.12e-01 | 7.06e-01 |
| AMINO ACID NEUROTRANSMITTER REUPTAKE | 10 | 6.00e-01 | 8.98e-01 | 0.3210 | -2.06e-01 | -8.08e-02 | 1.29e-02 | -9.09e-02 | 2.15e-01 | 2.60e-01 | 6.58e-01 | 9.44e-01 | 6.19e-01 | 2.40e-01 |
| NEGATIVE REGULATION OF INFLAMMATORY RESPONSE TO WOUNDING | 9 | 3.23e-01 | 7.33e-01 | 0.3210 | -2.55e-01 | -1.35e-01 | -9.49e-02 | -2.31e-02 | 1.03e-01 | 1.86e-01 | 4.83e-01 | 6.22e-01 | 9.05e-01 | 5.92e-01 |
| MRNA POLYADENYLATION | 24 | 1.65e-01 | 5.44e-01 | 0.3210 | 1.63e-01 | 4.88e-02 | 1.15e-01 | 2.45e-01 | 3.21e-02 | 1.66e-01 | 6.79e-01 | 3.29e-01 | 3.78e-02 | 7.86e-01 |
| PROTEIN LOCALIZATION TO ADHERENS JUNCTION | 6 | 9.65e-01 | 9.94e-01 | 0.3210 | -1.23e-01 | -1.26e-01 | -2.01e-01 | -1.24e-01 | -1.27e-01 | 6.00e-01 | 5.93e-01 | 3.94e-01 | 5.98e-01 | 5.90e-01 |
| MHC CLASS I BIOSYNTHETIC PROCESS | 8 | 8.29e-01 | 9.72e-01 | 0.3210 | -2.04e-01 | -2.04e-01 | -9.62e-02 | -6.34e-02 | 8.30e-02 | 3.18e-01 | 3.18e-01 | 6.38e-01 | 7.56e-01 | 6.84e-01 |
| REGULATION OF DNA DEMETHYLATION | 11 | 6.36e-01 | 9.13e-01 | 0.3210 | -1.35e-01 | -2.31e-01 | -1.53e-01 | -3.59e-02 | -8.34e-02 | 4.38e-01 | 1.85e-01 | 3.81e-01 | 8.37e-01 | 6.32e-01 |
| REGULATION OF MIRNA TRANSCRIPTION | 69 | 1.71e-01 | 5.55e-01 | 0.3210 | 1.20e-01 | 1.43e-01 | 1.45e-01 | 1.59e-01 | 1.49e-01 | 8.60e-02 | 4.05e-02 | 3.72e-02 | 2.24e-02 | 3.24e-02 |
| RESPONSE TO GLYCOPROTEIN | 11 | 6.05e-01 | 9.01e-01 | 0.3210 | 1.49e-02 | 1.16e-01 | 1.82e-01 | 1.93e-01 | 1.38e-01 | 9.32e-01 | 5.04e-01 | 2.97e-01 | 2.68e-01 | 4.27e-01 |
| D AMINO ACID TRANSPORT | 6 | 8.61e-01 | 9.78e-01 | 0.3210 | 8.52e-02 | 2.69e-02 | 8.79e-02 | 1.26e-01 | 2.67e-01 | 7.18e-01 | 9.09e-01 | 7.09e-01 | 5.93e-01 | 2.57e-01 |
| DORSAL AORTA MORPHOGENESIS | 8 | 4.18e-01 | 8.00e-01 | 0.3210 | -7.99e-02 | 3.61e-02 | 1.44e-01 | -1.01e-01 | 2.53e-01 | 6.95e-01 | 8.60e-01 | 4.80e-01 | 6.19e-01 | 2.15e-01 |
| MICROTUBULE ANCHORING AT MICROTUBULE ORGANIZING CENTER | 13 | 5.04e-01 | 8.50e-01 | 0.3210 | -8.43e-02 | -1.83e-01 | -2.28e-01 | -9.72e-02 | -2.60e-02 | 5.99e-01 | 2.53e-01 | 1.54e-01 | 5.44e-01 | 8.71e-01 |
| MAINTENANCE OF BLOOD BRAIN BARRIER | 36 | 5.18e-01 | 8.57e-01 | 0.3210 | 1.68e-01 | 1.37e-01 | 1.25e-01 | 1.69e-01 | 1.09e-01 | 8.08e-02 | 1.56e-01 | 1.96e-01 | 7.95e-02 | 2.57e-01 |
| REGULATION OF PODOSOME ASSEMBLY | 13 | 4.78e-01 | 8.34e-01 | 0.3210 | 2.35e-01 | 1.89e-01 | 5.20e-02 | 4.69e-02 | -8.19e-02 | 1.42e-01 | 2.37e-01 | 7.45e-01 | 7.70e-01 | 6.09e-01 |
| INTERLEUKIN 18 PRODUCTION | 14 | 4.93e-01 | 8.42e-01 | 0.3210 | -1.87e-02 | -1.25e-01 | -2.38e-01 | -1.11e-01 | -1.33e-01 | 9.04e-01 | 4.17e-01 | 1.23e-01 | 4.71e-01 | 3.89e-01 |
| LIPID TRANSPORT ACROSS BLOOD BRAIN BARRIER | 6 | 1.99e-01 | 5.89e-01 | 0.3210 | -2.51e-01 | -2.36e-02 | -1.67e-01 | -7.65e-02 | 7.43e-02 | 2.87e-01 | 9.20e-01 | 4.80e-01 | 7.46e-01 | 7.53e-01 |
| NEGATIVE REGULATION OF EXECUTION PHASE OF APOPTOSIS | 9 | 1.16e-01 | 4.64e-01 | 0.3210 | -6.29e-02 | -2.60e-01 | -9.47e-02 | 1.34e-01 | 6.53e-02 | 7.44e-01 | 1.77e-01 | 6.23e-01 | 4.86e-01 | 7.34e-01 |
| IMMUNOGLOBULIN PRODUCTION | 104 | 7.29e-03 | 8.16e-02 | 0.3210 | 1.21e-01 | 1.89e-01 | 1.43e-01 | 1.60e-01 | 7.82e-02 | 3.26e-02 | 8.69e-04 | 1.16e-02 | 4.70e-03 | 1.68e-01 |
| POSITIVE REGULATION OF MIRNA METABOLIC PROCESS | 60 | 2.34e-01 | 6.36e-01 | 0.3210 | 9.74e-02 | 1.35e-01 | 1.60e-01 | 1.56e-01 | 1.59e-01 | 1.92e-01 | 7.12e-02 | 3.21e-02 | 3.71e-02 | 3.30e-02 |
| RAP PROTEIN SIGNAL TRANSDUCTION | 12 | 6.02e-01 | 9.00e-01 | 0.3200 | 2.25e-01 | 9.32e-02 | 8.45e-02 | 1.53e-01 | 1.14e-01 | 1.78e-01 | 5.76e-01 | 6.12e-01 | 3.59e-01 | 4.95e-01 |
| UDP N ACETYLGLUCOSAMINE BIOSYNTHETIC PROCESS | 9 | 9.15e-01 | 9.86e-01 | 0.3200 | 6.67e-02 | 7.58e-02 | 1.91e-01 | 1.50e-01 | 1.83e-01 | 7.29e-01 | 6.94e-01 | 3.20e-01 | 4.37e-01 | 3.43e-01 |
| PROTON TRANSMEMBRANE TRANSPORT | 141 | 1.96e-03 | 2.98e-02 | 0.3200 | 1.29e-01 | 1.16e-01 | 1.70e-01 | 1.24e-01 | 1.69e-01 | 8.31e-03 | 1.73e-02 | 5.10e-04 | 1.12e-02 | 5.35e-04 |
| NEGATIVE REGULATION OF CELL SUBSTRATE JUNCTION ORGANIZATION | 15 | 8.60e-01 | 9.78e-01 | 0.3200 | -1.38e-01 | -1.53e-01 | -1.63e-01 | -1.82e-01 | -2.62e-02 | 3.56e-01 | 3.06e-01 | 2.75e-01 | 2.22e-01 | 8.61e-01 |
| PEPTIDYL LYSINE MODIFICATION | 204 | 3.84e-05 | 1.25e-03 | 0.3200 | 1.30e-01 | 1.27e-01 | 1.39e-01 | 1.98e-01 | 1.05e-01 | 1.40e-03 | 1.74e-03 | 6.32e-04 | 1.11e-06 | 9.39e-03 |
| REGULATION OF PROTEIN TARGETING | 76 | 1.07e-01 | 4.47e-01 | 0.3200 | 1.20e-01 | 1.62e-01 | 1.71e-01 | 1.12e-01 | 1.42e-01 | 7.07e-02 | 1.44e-02 | 1.01e-02 | 9.25e-02 | 3.29e-02 |
| POSITIVE REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 35 | 4.20e-01 | 8.00e-01 | 0.3200 | 1.55e-01 | 1.86e-01 | 1.19e-01 | 1.63e-01 | 5.42e-02 | 1.13e-01 | 5.69e-02 | 2.23e-01 | 9.50e-02 | 5.79e-01 |
| POSITIVE REGULATION OF FEVER GENERATION | 7 | 5.68e-01 | 8.82e-01 | 0.3200 | 2.13e-01 | 1.82e-01 | -1.27e-02 | -4.19e-02 | -1.48e-01 | 3.29e-01 | 4.05e-01 | 9.54e-01 | 8.48e-01 | 4.98e-01 |
| AXIS SPECIFICATION | 91 | 8.75e-03 | 9.25e-02 | 0.3200 | 5.20e-02 | 1.35e-01 | 1.63e-01 | 1.09e-01 | 2.07e-01 | 3.91e-01 | 2.58e-02 | 7.24e-03 | 7.26e-02 | 6.46e-04 |
| POSITIVE T CELL SELECTION | 39 | 7.82e-03 | 8.53e-02 | 0.3200 | -5.93e-02 | 2.45e-02 | 1.73e-01 | 1.60e-01 | 2.07e-01 | 5.21e-01 | 7.91e-01 | 6.23e-02 | 8.39e-02 | 2.56e-02 |
| HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 132 | 8.46e-03 | 9.08e-02 | 0.3200 | 1.15e-01 | 1.28e-01 | 1.49e-01 | 1.79e-01 | 1.34e-01 | 2.26e-02 | 1.08e-02 | 3.08e-03 | 3.75e-04 | 7.70e-03 |
| PROTEIN KINASE C ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 26 | 7.94e-02 | 3.82e-01 | 0.3190 | -1.98e-01 | -2.01e-01 | -1.09e-01 | -2.90e-02 | -9.72e-02 | 8.01e-02 | 7.65e-02 | 3.34e-01 | 7.98e-01 | 3.91e-01 |
| UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 49 | 2.48e-01 | 6.54e-01 | 0.3190 | 1.72e-01 | 1.22e-01 | 1.67e-01 | 1.63e-01 | 5.33e-02 | 3.70e-02 | 1.40e-01 | 4.33e-02 | 4.83e-02 | 5.18e-01 |
| CD4 POSITIVE ALPHA BETA T CELL CYTOKINE PRODUCTION | 19 | 2.70e-01 | 6.79e-01 | 0.3190 | 6.06e-02 | -5.57e-03 | -1.16e-01 | -1.09e-01 | -2.70e-01 | 6.47e-01 | 9.66e-01 | 3.80e-01 | 4.11e-01 | 4.19e-02 |
| CELL CYCLE PHASE TRANSITION | 551 | 1.04e-13 | 1.30e-11 | 0.3190 | 1.28e-01 | 1.03e-01 | 1.47e-01 | 1.93e-01 | 1.25e-01 | 2.49e-07 | 3.60e-05 | 3.53e-09 | 7.66e-15 | 5.32e-07 |
| PROTEIN LOCALIZATION TO CHROMOSOME TELOMERIC REGION | 28 | 5.24e-01 | 8.60e-01 | 0.3190 | 1.55e-01 | 1.14e-01 | 1.29e-01 | 2.07e-01 | 7.07e-02 | 1.57e-01 | 2.94e-01 | 2.38e-01 | 5.75e-02 | 5.17e-01 |
| CENTRAL NERVOUS SYSTEM MYELIN MAINTENANCE | 5 | 2.85e-01 | 6.93e-01 | 0.3190 | -2.06e-01 | 1.08e-01 | -3.04e-03 | -9.35e-02 | -1.96e-01 | 4.24e-01 | 6.75e-01 | 9.91e-01 | 7.17e-01 | 4.47e-01 |
| RIBONUCLEOSIDE DIPHOSPHATE BIOSYNTHETIC PROCESS | 9 | 9.73e-01 | 9.95e-01 | 0.3190 | 1.68e-01 | 1.59e-01 | 1.34e-01 | 1.65e-01 | 5.62e-02 | 3.84e-01 | 4.08e-01 | 4.87e-01 | 3.93e-01 | 7.70e-01 |
| GAMMA DELTA T CELL ACTIVATION | 23 | 3.33e-02 | 2.32e-01 | 0.3180 | -1.64e-01 | -9.41e-02 | 1.44e-01 | 4.92e-02 | 2.06e-01 | 1.74e-01 | 4.35e-01 | 2.32e-01 | 6.83e-01 | 8.73e-02 |
| POSITIVE REGULATION OF GLIAL CELL MIGRATION | 11 | 2.21e-01 | 6.19e-01 | 0.3180 | 1.59e-01 | 1.88e-01 | -1.04e-01 | -1.81e-02 | -1.72e-01 | 3.62e-01 | 2.80e-01 | 5.49e-01 | 9.17e-01 | 3.24e-01 |
| AMINE BIOSYNTHETIC PROCESS | 37 | 3.31e-01 | 7.39e-01 | 0.3180 | 7.13e-02 | 1.18e-01 | 2.05e-01 | 1.29e-01 | 1.54e-01 | 4.53e-01 | 2.14e-01 | 3.13e-02 | 1.75e-01 | 1.04e-01 |
| COMPLEMENT DEPENDENT CYTOTOXICITY | 13 | 2.08e-01 | 6.03e-01 | 0.3180 | 1.86e-01 | 2.04e-01 | -6.03e-02 | 5.01e-02 | -1.38e-01 | 2.46e-01 | 2.03e-01 | 7.07e-01 | 7.54e-01 | 3.90e-01 |
| NEGATIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 71 | 1.36e-01 | 4.98e-01 | 0.3180 | -1.46e-01 | -1.38e-01 | -1.71e-01 | -1.75e-01 | -3.65e-02 | 3.35e-02 | 4.47e-02 | 1.30e-02 | 1.08e-02 | 5.95e-01 |
| CORTICOTROPIN SECRETION | 7 | 8.74e-01 | 9.78e-01 | 0.3180 | -2.08e-01 | -9.55e-02 | -1.50e-01 | -1.42e-01 | -7.86e-02 | 3.41e-01 | 6.62e-01 | 4.91e-01 | 5.15e-01 | 7.19e-01 |
| RESPONSE TO ACIDIC PH | 28 | 5.81e-03 | 6.85e-02 | 0.3180 | -1.75e-01 | 4.72e-04 | -2.70e-02 | -2.30e-01 | 1.30e-01 | 1.08e-01 | 9.97e-01 | 8.05e-01 | 3.53e-02 | 2.35e-01 |
| POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 5.75e-01 | 8.84e-01 | 0.3180 | 2.53e-01 | 7.42e-02 | 9.54e-02 | 1.04e-01 | 1.08e-01 | 2.46e-01 | 7.34e-01 | 6.62e-01 | 6.35e-01 | 6.21e-01 |
| POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 113 | 1.44e-02 | 1.32e-01 | 0.3180 | 1.35e-01 | 1.01e-01 | 1.41e-01 | 1.81e-01 | 1.42e-01 | 1.34e-02 | 6.48e-02 | 9.68e-03 | 8.91e-04 | 9.04e-03 |
| LYSOSOMAL TRANSPORT | 128 | 1.88e-02 | 1.60e-01 | 0.3180 | 1.54e-01 | 1.49e-01 | 1.60e-01 | 1.69e-01 | 2.99e-02 | 2.57e-03 | 3.57e-03 | 1.76e-03 | 9.84e-04 | 5.59e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 17 PRODUCTION | 21 | 6.00e-01 | 8.98e-01 | 0.3180 | 8.54e-02 | 1.87e-01 | 1.58e-01 | 1.11e-01 | 1.47e-01 | 4.98e-01 | 1.39e-01 | 2.11e-01 | 3.78e-01 | 2.43e-01 |
| STEM CELL PROLIFERATION | 120 | 3.59e-03 | 4.81e-02 | 0.3180 | 9.54e-02 | 1.28e-01 | 1.55e-01 | 1.89e-01 | 1.26e-01 | 7.10e-02 | 1.54e-02 | 3.32e-03 | 3.60e-04 | 1.75e-02 |
| RESCUE OF STALLED RIBOSOME | 29 | 4.98e-01 | 8.46e-01 | 0.3180 | 1.74e-01 | 1.67e-01 | 1.06e-01 | 1.77e-01 | -1.49e-02 | 1.05e-01 | 1.19e-01 | 3.23e-01 | 9.99e-02 | 8.90e-01 |
| POSITIVE REGULATION OF GLIOGENESIS | 68 | 7.13e-02 | 3.61e-01 | 0.3180 | 6.15e-02 | 1.12e-01 | 1.84e-01 | 1.10e-01 | 1.96e-01 | 3.81e-01 | 1.09e-01 | 8.77e-03 | 1.15e-01 | 5.16e-03 |
| ZINC ION TRANSPORT | 28 | 4.58e-01 | 8.23e-01 | 0.3180 | 6.56e-02 | 1.46e-01 | 1.57e-01 | 1.02e-01 | 2.01e-01 | 5.48e-01 | 1.80e-01 | 1.51e-01 | 3.52e-01 | 6.62e-02 |
| RESPONSE TO UV B | 21 | 8.16e-01 | 9.70e-01 | 0.3170 | 1.67e-01 | 1.79e-01 | 1.47e-01 | 1.25e-01 | 6.13e-02 | 1.86e-01 | 1.55e-01 | 2.45e-01 | 3.23e-01 | 6.27e-01 |
| INTERLEUKIN 5 MEDIATED SIGNALING PATHWAY | 6 | 8.53e-01 | 9.76e-01 | 0.3170 | 4.96e-02 | -9.07e-02 | -1.88e-01 | -1.01e-01 | -2.11e-01 | 8.33e-01 | 7.00e-01 | 4.26e-01 | 6.68e-01 | 3.70e-01 |
| NEUROTRANSMITTER CATABOLIC PROCESS | 8 | 9.46e-01 | 9.94e-01 | 0.3170 | -1.47e-01 | -1.31e-01 | -1.52e-01 | -1.97e-01 | -9.40e-03 | 4.71e-01 | 5.21e-01 | 4.56e-01 | 3.35e-01 | 9.63e-01 |
| NEGATIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 44 | 5.41e-02 | 3.07e-01 | 0.3170 | 2.08e-01 | 2.02e-01 | 9.11e-02 | 7.60e-02 | 5.00e-02 | 1.70e-02 | 2.02e-02 | 2.96e-01 | 3.83e-01 | 5.66e-01 |
| GLYCOLYTIC PROCESS THROUGH FRUCTOSE 6 PHOSPHATE | 22 | 1.18e-02 | 1.14e-01 | 0.3170 | 7.12e-02 | 2.67e-01 | 1.48e-01 | -4.26e-02 | 1.96e-02 | 5.63e-01 | 2.99e-02 | 2.29e-01 | 7.30e-01 | 8.73e-01 |
| CELLULAR RESPONSE TO STRESS | 1871 | 1.55e-34 | 1.06e-31 | 0.3170 | 1.39e-01 | 1.32e-01 | 1.43e-01 | 1.66e-01 | 1.26e-01 | 1.72e-23 | 3.52e-21 | 1.04e-24 | 7.52e-33 | 1.33e-19 |
| TRANSLATIONAL ELONGATION | 68 | 2.93e-01 | 7.04e-01 | 0.3170 | 1.48e-01 | 1.52e-01 | 1.42e-01 | 1.61e-01 | 9.73e-02 | 3.50e-02 | 2.98e-02 | 4.25e-02 | 2.18e-02 | 1.65e-01 |
| RNA 3 END PROCESSING | 90 | 3.82e-02 | 2.53e-01 | 0.3170 | 1.22e-01 | 8.87e-02 | 1.49e-01 | 1.77e-01 | 1.56e-01 | 4.57e-02 | 1.46e-01 | 1.46e-02 | 3.72e-03 | 1.04e-02 |
| EOSINOPHIL ACTIVATION | 8 | 3.28e-01 | 7.37e-01 | 0.3170 | 5.63e-02 | 2.53e-01 | 1.66e-01 | -3.00e-02 | -7.02e-02 | 7.83e-01 | 2.15e-01 | 4.16e-01 | 8.83e-01 | 7.31e-01 |
| EXCITATORY CHEMICAL SYNAPTIC TRANSMISSION | 10 | 2.04e-01 | 5.96e-01 | 0.3170 | 1.09e-01 | 8.94e-02 | 1.97e-01 | -1.86e-02 | 2.04e-01 | 5.52e-01 | 6.24e-01 | 2.81e-01 | 9.19e-01 | 2.64e-01 |
| REGULATION OF FAT CELL DIFFERENTIATION | 140 | 1.18e-02 | 1.15e-01 | 0.3170 | 1.07e-01 | 1.35e-01 | 1.54e-01 | 1.43e-01 | 1.63e-01 | 2.89e-02 | 5.66e-03 | 1.60e-03 | 3.49e-03 | 8.98e-04 |
| NEGATIVE REGULATION OF ADIPOSE TISSUE DEVELOPMENT | 5 | 5.33e-01 | 8.64e-01 | 0.3170 | 5.95e-02 | 2.38e-01 | 3.76e-02 | -1.22e-01 | -1.55e-01 | 8.18e-01 | 3.58e-01 | 8.84e-01 | 6.37e-01 | 5.47e-01 |
| RESPONSE TO LEUCINE | 15 | 5.57e-01 | 8.77e-01 | 0.3170 | 1.86e-01 | 5.97e-02 | 1.15e-01 | 1.72e-01 | 1.40e-01 | 2.12e-01 | 6.89e-01 | 4.43e-01 | 2.49e-01 | 3.49e-01 |
| REGULATION OF SKELETAL MUSCLE TISSUE REGENERATION | 8 | 3.57e-01 | 7.57e-01 | 0.3170 | -1.23e-01 | 6.02e-02 | 1.04e-01 | 1.15e-01 | 2.40e-01 | 5.46e-01 | 7.68e-01 | 6.11e-01 | 5.75e-01 | 2.40e-01 |
| HETEROPHILIC CELL CELL ADHESION VIA PLASMA MEMBRANE CELL ADHESION MOLECULES | 51 | 3.04e-01 | 7.17e-01 | 0.3170 | -1.61e-01 | -1.41e-01 | -1.28e-01 | -1.89e-01 | -4.95e-02 | 4.72e-02 | 8.23e-02 | 1.13e-01 | 1.95e-02 | 5.41e-01 |
| CELLULAR RESPONSE TO CORTICOSTEROID STIMULUS | 58 | 3.16e-03 | 4.34e-02 | 0.3160 | -5.05e-02 | 6.04e-02 | 1.24e-01 | 3.76e-02 | 2.78e-01 | 5.06e-01 | 4.26e-01 | 1.03e-01 | 6.21e-01 | 2.52e-04 |
| RIBONUCLEOSIDE DIPHOSPHATE CATABOLIC PROCESS | 8 | 3.39e-01 | 7.44e-01 | 0.3160 | -2.06e-01 | -1.04e-01 | 3.50e-02 | 8.52e-02 | 1.96e-01 | 3.13e-01 | 6.09e-01 | 8.64e-01 | 6.77e-01 | 3.37e-01 |
| NEGATIVE REGULATION OF MYELOID CELL APOPTOTIC PROCESS | 18 | 6.61e-01 | 9.22e-01 | 0.3160 | 6.36e-02 | 1.21e-01 | 1.49e-01 | 1.70e-01 | 1.74e-01 | 6.41e-01 | 3.76e-01 | 2.73e-01 | 2.11e-01 | 2.01e-01 |
| PROSTATE GLAND MORPHOGENESIS | 27 | 1.51e-01 | 5.20e-01 | 0.3160 | -5.20e-02 | 6.19e-02 | 1.79e-01 | 6.15e-02 | 2.40e-01 | 6.40e-01 | 5.78e-01 | 1.07e-01 | 5.80e-01 | 3.09e-02 |
| NEGATIVE REGULATION OF CALCIUM ION IMPORT ACROSS PLASMA MEMBRANE | 8 | 9.28e-01 | 9.89e-01 | 0.3160 | -1.71e-01 | -9.82e-02 | -1.69e-01 | -1.66e-01 | -7.18e-02 | 4.03e-01 | 6.31e-01 | 4.08e-01 | 4.17e-01 | 7.25e-01 |
| GLYCEROL 3 PHOSPHATE METABOLIC PROCESS | 7 | 4.87e-01 | 8.38e-01 | 0.3160 | -3.12e-02 | -1.11e-01 | -2.22e-01 | -1.75e-01 | 8.13e-02 | 8.86e-01 | 6.09e-01 | 3.09e-01 | 4.24e-01 | 7.09e-01 |
| REGULATION OF DNA METHYLATION DEPENDENT HETEROCHROMATIN FORMATION | 18 | 1.36e-02 | 1.27e-01 | 0.3160 | 9.33e-03 | -1.59e-01 | -1.99e-01 | 9.00e-02 | -1.64e-01 | 9.45e-01 | 2.43e-01 | 1.45e-01 | 5.08e-01 | 2.30e-01 |
| FAT SOLUBLE VITAMIN CATABOLIC PROCESS | 11 | 4.23e-01 | 8.03e-01 | 0.3160 | -1.75e-02 | 1.29e-01 | 1.11e-01 | -2.65e-02 | 2.64e-01 | 9.20e-01 | 4.57e-01 | 5.25e-01 | 8.79e-01 | 1.30e-01 |
| REGULATION OF TRIGLYCERIDE CATABOLIC PROCESS | 13 | 8.38e-02 | 3.92e-01 | 0.3160 | 1.76e-02 | 1.34e-01 | -3.36e-03 | 8.87e-02 | -2.71e-01 | 9.12e-01 | 4.02e-01 | 9.83e-01 | 5.80e-01 | 9.10e-02 |
| NEGATIVE REGULATION OF CHEMOKINE PRODUCTION | 29 | 2.10e-02 | 1.72e-01 | 0.3150 | 6.70e-02 | -3.59e-02 | -2.20e-01 | -1.32e-01 | -1.68e-01 | 5.32e-01 | 7.38e-01 | 4.05e-02 | 2.20e-01 | 1.18e-01 |
| REGULATION OF HUMORAL IMMUNE RESPONSE MEDIATED BY CIRCULATING IMMUNOGLOBULIN | 18 | 8.24e-01 | 9.71e-01 | 0.3150 | -1.88e-01 | -1.53e-01 | -1.37e-01 | -1.31e-01 | -6.94e-02 | 1.68e-01 | 2.61e-01 | 3.13e-01 | 3.37e-01 | 6.10e-01 |
| MITOTIC CELL CYCLE PHASE TRANSITION | 452 | 6.59e-12 | 6.30e-10 | 0.3150 | 1.31e-01 | 1.01e-01 | 1.39e-01 | 1.98e-01 | 1.17e-01 | 1.77e-06 | 2.19e-04 | 4.31e-07 | 5.83e-13 | 2.07e-05 |
| PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 21 | 3.83e-01 | 7.79e-01 | 0.3150 | -5.13e-02 | -1.14e-01 | -1.52e-01 | -4.15e-02 | -2.43e-01 | 6.84e-01 | 3.67e-01 | 2.28e-01 | 7.42e-01 | 5.43e-02 |
| ESTABLISHMENT OF SPINDLE ORIENTATION | 42 | 1.29e-01 | 4.87e-01 | 0.3150 | 1.09e-01 | 7.20e-02 | 1.74e-01 | 2.11e-01 | 8.51e-02 | 2.23e-01 | 4.19e-01 | 5.11e-02 | 1.79e-02 | 3.40e-01 |
| ASTROCYTE ACTIVATION | 25 | 3.46e-01 | 7.50e-01 | 0.3150 | 1.77e-01 | 1.72e-01 | 1.32e-01 | 1.05e-01 | -9.80e-02 | 1.26e-01 | 1.37e-01 | 2.52e-01 | 3.61e-01 | 3.96e-01 |
| NEGATIVE REGULATION OF PROTEIN BINDING | 77 | 2.41e-01 | 6.45e-01 | 0.3150 | 1.27e-01 | 1.36e-01 | 1.60e-01 | 1.63e-01 | 1.11e-01 | 5.47e-02 | 3.86e-02 | 1.51e-02 | 1.37e-02 | 9.35e-02 |
| PROTEIN PALMITOYLATION | 28 | 5.23e-01 | 8.60e-01 | 0.3150 | 1.67e-01 | 1.30e-01 | 1.18e-01 | 2.00e-01 | 1.53e-02 | 1.26e-01 | 2.33e-01 | 2.81e-01 | 6.71e-02 | 8.89e-01 |
| POSITIVE REGULATION OF MYOBLAST PROLIFERATION | 14 | 4.92e-01 | 8.42e-01 | 0.3140 | 6.41e-02 | 2.17e-01 | 1.57e-01 | 1.34e-01 | 7.16e-02 | 6.78e-01 | 1.60e-01 | 3.10e-01 | 3.85e-01 | 6.43e-01 |
| CHORION DEVELOPMENT | 10 | 9.16e-01 | 9.86e-01 | 0.3140 | 1.23e-01 | 7.79e-02 | 1.69e-01 | 1.82e-01 | 1.27e-01 | 5.02e-01 | 6.70e-01 | 3.54e-01 | 3.20e-01 | 4.85e-01 |
| NUCLEOBASE TRANSPORT | 12 | 3.83e-01 | 7.79e-01 | 0.3140 | 2.46e-02 | -1.55e-02 | -1.51e-01 | -2.06e-01 | -1.81e-01 | 8.83e-01 | 9.26e-01 | 3.67e-01 | 2.16e-01 | 2.77e-01 |
| RETINAL PIGMENT EPITHELIUM DEVELOPMENT | 6 | 9.40e-01 | 9.92e-01 | 0.3140 | 1.79e-01 | 2.04e-01 | 9.01e-02 | 1.05e-01 | 7.92e-02 | 4.48e-01 | 3.88e-01 | 7.02e-01 | 6.57e-01 | 7.37e-01 |
| WATER SOLUBLE VITAMIN BIOSYNTHETIC PROCESS | 11 | 8.15e-01 | 9.69e-01 | 0.3140 | 5.07e-02 | 1.08e-01 | 1.76e-01 | 1.87e-01 | 1.37e-01 | 7.71e-01 | 5.35e-01 | 3.13e-01 | 2.82e-01 | 4.32e-01 |
| REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 34 | 8.40e-02 | 3.92e-01 | 0.3140 | -1.57e-02 | 7.66e-02 | 1.82e-01 | 1.56e-01 | 1.88e-01 | 8.74e-01 | 4.40e-01 | 6.65e-02 | 1.16e-01 | 5.80e-02 |
| ALDITOL CATABOLIC PROCESS | 6 | 9.75e-01 | 9.95e-01 | 0.3140 | 1.63e-01 | 1.67e-01 | 1.34e-01 | 1.58e-01 | -3.92e-02 | 4.90e-01 | 4.79e-01 | 5.70e-01 | 5.03e-01 | 8.68e-01 |
| NUCLEAR PORE ORGANIZATION | 15 | 2.35e-01 | 6.37e-01 | 0.3140 | 2.16e-01 | 1.08e-01 | -1.81e-02 | 1.87e-01 | -7.17e-02 | 1.48e-01 | 4.67e-01 | 9.04e-01 | 2.11e-01 | 6.31e-01 |
| BLOOD COAGULATION FIBRIN CLOT FORMATION | 14 | 9.05e-01 | 9.84e-01 | 0.3140 | -1.40e-01 | -1.84e-01 | -1.43e-01 | -1.49e-01 | -5.09e-02 | 3.65e-01 | 2.33e-01 | 3.53e-01 | 3.36e-01 | 7.42e-01 |
| POSITIVE REGULATION OF VASCULAR WOUND HEALING | 5 | 6.93e-01 | 9.31e-01 | 0.3140 | -3.90e-02 | 1.60e-01 | 2.20e-01 | -1.90e-02 | 1.51e-01 | 8.80e-01 | 5.37e-01 | 3.94e-01 | 9.41e-01 | 5.59e-01 |
| SPONTANEOUS NEUROTRANSMITTER SECRETION | 8 | 4.24e-01 | 8.03e-01 | 0.3140 | -1.84e-01 | -5.15e-03 | -1.63e-02 | -2.36e-01 | -9.31e-02 | 3.69e-01 | 9.80e-01 | 9.36e-01 | 2.47e-01 | 6.48e-01 |
| NEGATIVE REGULATION OF LYMPHOCYTE DIFFERENTIATION | 59 | 2.68e-01 | 6.75e-01 | 0.3140 | 1.04e-01 | 1.02e-01 | 1.64e-01 | 1.61e-01 | 1.57e-01 | 1.66e-01 | 1.76e-01 | 2.98e-02 | 3.29e-02 | 3.69e-02 |
| LUTEINIZING HORMONE SECRETION | 10 | 8.84e-01 | 9.80e-01 | 0.3140 | 2.11e-01 | 1.72e-01 | 7.39e-02 | 1.32e-01 | -4.01e-02 | 2.47e-01 | 3.48e-01 | 6.86e-01 | 4.71e-01 | 8.26e-01 |
| T CELL LINEAGE COMMITMENT | 31 | 4.13e-01 | 7.98e-01 | 0.3140 | 9.08e-02 | 1.21e-01 | 1.44e-01 | 1.88e-01 | 1.39e-01 | 3.82e-01 | 2.43e-01 | 1.66e-01 | 6.94e-02 | 1.81e-01 |
| AMELOGENESIS | 24 | 5.66e-01 | 8.81e-01 | 0.3140 | -1.17e-01 | -8.25e-02 | -1.88e-01 | -1.54e-01 | -1.37e-01 | 3.20e-01 | 4.84e-01 | 1.11e-01 | 1.92e-01 | 2.45e-01 |
| ACTIVATION OF JANUS KINASE ACTIVITY | 13 | 2.45e-01 | 6.49e-01 | 0.3140 | -1.22e-01 | -1.48e-02 | -2.15e-01 | -1.29e-01 | -1.42e-01 | 4.45e-01 | 9.26e-01 | 1.80e-01 | 4.19e-01 | 3.74e-01 |
| THYROID HORMONE MEDIATED SIGNALING PATHWAY | 8 | 9.27e-01 | 9.89e-01 | 0.3140 | -2.02e-01 | -1.27e-01 | -1.42e-01 | -1.45e-01 | -1.35e-02 | 3.22e-01 | 5.35e-01 | 4.86e-01 | 4.77e-01 | 9.47e-01 |
| RESPONSE TO FOLLICLE STIMULATING HORMONE | 15 | 8.04e-01 | 9.67e-01 | 0.3140 | -2.08e-01 | -1.41e-01 | -1.01e-01 | -1.53e-01 | 3.26e-02 | 1.62e-01 | 3.43e-01 | 4.97e-01 | 3.04e-01 | 8.27e-01 |
| UROGENITAL SYSTEM DEVELOPMENT | 66 | 7.38e-02 | 3.68e-01 | 0.3130 | 7.20e-02 | 1.53e-01 | 1.91e-01 | 1.06e-01 | 1.48e-01 | 3.12e-01 | 3.20e-02 | 7.14e-03 | 1.36e-01 | 3.78e-02 |
| EYE PIGMENTATION | 5 | 7.50e-01 | 9.51e-01 | 0.3130 | -1.58e-01 | -2.53e-01 | -3.40e-02 | 2.74e-02 | 8.69e-02 | 5.40e-01 | 3.28e-01 | 8.95e-01 | 9.15e-01 | 7.37e-01 |
| POSITIVE REGULATION OF AMINE METABOLIC PROCESS | 6 | 5.48e-01 | 8.73e-01 | 0.3130 | -1.87e-01 | -2.34e-01 | -2.20e-02 | 6.84e-02 | 5.87e-02 | 4.28e-01 | 3.21e-01 | 9.26e-01 | 7.72e-01 | 8.03e-01 |
| PEPTIDE METABOLIC PROCESS | 930 | 1.52e-15 | 2.20e-13 | 0.3130 | 1.35e-01 | 1.28e-01 | 1.53e-01 | 1.63e-01 | 1.17e-01 | 2.84e-12 | 3.29e-11 | 2.42e-15 | 3.94e-17 | 1.56e-09 |
| NEUROTRANSMITTER BIOSYNTHETIC PROCESS | 14 | 4.90e-02 | 2.89e-01 | 0.3130 | -3.93e-02 | 2.29e-01 | 1.74e-01 | -5.38e-02 | 1.04e-01 | 7.99e-01 | 1.37e-01 | 2.59e-01 | 7.28e-01 | 5.01e-01 |
| POSITIVE REGULATION OF TRANSLATION | 127 | 4.38e-02 | 2.71e-01 | 0.3130 | 1.68e-01 | 1.49e-01 | 1.40e-01 | 1.48e-01 | 7.77e-02 | 1.08e-03 | 3.62e-03 | 6.37e-03 | 4.01e-03 | 1.30e-01 |
| REGULATION OF MIRNA METABOLIC PROCESS | 83 | 1.22e-01 | 4.75e-01 | 0.3130 | 1.18e-01 | 1.40e-01 | 1.44e-01 | 1.65e-01 | 1.28e-01 | 6.34e-02 | 2.77e-02 | 2.29e-02 | 9.22e-03 | 4.38e-02 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION | 10 | 6.67e-01 | 9.24e-01 | 0.3130 | -5.80e-02 | -5.56e-02 | 9.36e-02 | 6.86e-02 | 2.79e-01 | 7.51e-01 | 7.61e-01 | 6.08e-01 | 7.07e-01 | 1.26e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO TELOMERE | 17 | 4.44e-01 | 8.14e-01 | 0.3130 | 1.26e-01 | 7.71e-02 | 1.59e-01 | 2.26e-01 | -7.06e-03 | 3.68e-01 | 5.82e-01 | 2.58e-01 | 1.07e-01 | 9.60e-01 |
| INTRACELLULAR MONOATOMIC ANION HOMEOSTASIS | 10 | 6.17e-01 | 9.06e-01 | 0.3130 | -2.72e-02 | -1.86e-01 | -2.05e-01 | -1.29e-01 | -6.04e-02 | 8.81e-01 | 3.07e-01 | 2.61e-01 | 4.80e-01 | 7.41e-01 |
| MYELOID DENDRITIC CELL CHEMOTAXIS | 5 | 6.12e-01 | 9.04e-01 | 0.3130 | -1.17e-02 | -8.47e-02 | -2.10e-01 | -2.01e-01 | 7.91e-02 | 9.64e-01 | 7.43e-01 | 4.16e-01 | 4.37e-01 | 7.59e-01 |
| EATING BEHAVIOR | 37 | 4.24e-01 | 8.03e-01 | 0.3130 | 9.63e-02 | 1.44e-01 | 1.43e-01 | 1.19e-01 | 1.83e-01 | 3.11e-01 | 1.30e-01 | 1.34e-01 | 2.12e-01 | 5.42e-02 |
| RENAL TUBULE DEVELOPMENT | 99 | 3.97e-02 | 2.57e-01 | 0.3130 | 9.05e-02 | 1.23e-01 | 1.50e-01 | 1.35e-01 | 1.84e-01 | 1.20e-01 | 3.42e-02 | 9.86e-03 | 2.04e-02 | 1.60e-03 |
| CILIARY BASAL BODY ORGANIZATION | 5 | 8.16e-01 | 9.70e-01 | 0.3130 | -2.63e-01 | -1.45e-01 | -2.14e-02 | -5.03e-02 | 6.94e-02 | 3.09e-01 | 5.75e-01 | 9.34e-01 | 8.46e-01 | 7.88e-01 |
| HYPEROSMOTIC RESPONSE | 26 | 7.22e-01 | 9.40e-01 | 0.3130 | 9.96e-02 | 1.40e-01 | 1.51e-01 | 1.39e-01 | 1.61e-01 | 3.80e-01 | 2.16e-01 | 1.82e-01 | 2.18e-01 | 1.56e-01 |
| PROTEIN KINASE A SIGNALING | 37 | 4.17e-01 | 7.99e-01 | 0.3130 | -1.69e-01 | -1.58e-01 | -1.40e-01 | -1.08e-01 | -1.14e-01 | 7.53e-02 | 9.66e-02 | 1.41e-01 | 2.56e-01 | 2.29e-01 |
| REGULATION OF ENDODERMAL CELL DIFFERENTIATION | 7 | 9.23e-01 | 9.88e-01 | 0.3120 | 1.72e-01 | 1.51e-01 | 1.34e-01 | 8.45e-02 | 1.42e-01 | 4.32e-01 | 4.89e-01 | 5.40e-01 | 6.99e-01 | 5.15e-01 |
| HIPPOCAMPUS DEVELOPMENT | 90 | 6.84e-03 | 7.77e-02 | 0.3120 | 9.45e-02 | 6.84e-02 | 1.51e-01 | 1.14e-01 | 2.19e-01 | 1.21e-01 | 2.62e-01 | 1.34e-02 | 6.09e-02 | 3.24e-04 |
| RESPONSE TO THYROXINE | 5 | 7.00e-01 | 9.31e-01 | 0.3120 | 6.99e-02 | -5.00e-02 | 2.04e-01 | 1.49e-01 | 1.62e-01 | 7.87e-01 | 8.46e-01 | 4.30e-01 | 5.63e-01 | 5.31e-01 |
| EXTRACELLULAR MATRIX CONSTITUENT SECRETION | 13 | 8.66e-01 | 9.78e-01 | 0.3120 | 1.49e-01 | 1.78e-01 | 1.39e-01 | 9.39e-02 | 1.24e-01 | 3.53e-01 | 2.67e-01 | 3.85e-01 | 5.58e-01 | 4.38e-01 |
| REGULATION OF CELL CYCLE PROCESS | 713 | 7.91e-17 | 1.32e-14 | 0.3120 | 1.15e-01 | 9.69e-02 | 1.51e-01 | 1.84e-01 | 1.34e-01 | 1.77e-07 | 1.04e-05 | 7.22e-12 | 4.63e-17 | 9.26e-10 |
| NEGATIVE REGULATION OF PLASMINOGEN ACTIVATION | 8 | 6.96e-01 | 9.31e-01 | 0.3120 | 1.70e-01 | 2.06e-01 | -4.27e-03 | 4.29e-02 | -1.56e-01 | 4.06e-01 | 3.14e-01 | 9.83e-01 | 8.34e-01 | 4.45e-01 |
| DITERPENOID BIOSYNTHETIC PROCESS | 10 | 1.31e-01 | 4.90e-01 | 0.3120 | 2.57e-01 | 1.59e-01 | -4.96e-02 | -4.87e-02 | -2.99e-02 | 1.59e-01 | 3.85e-01 | 7.86e-01 | 7.90e-01 | 8.70e-01 |
| REGULATION OF INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY | 68 | 1.75e-01 | 5.60e-01 | 0.3120 | 1.73e-01 | 1.81e-01 | 1.22e-01 | 1.27e-01 | 6.28e-02 | 1.39e-02 | 1.00e-02 | 8.29e-02 | 7.09e-02 | 3.71e-01 |
| SATELLITE CELL ACTIVATION INVOLVED IN SKELETAL MUSCLE REGENERATION | 5 | 6.55e-01 | 9.20e-01 | 0.3120 | -4.03e-02 | -4.31e-04 | -1.89e-01 | -2.44e-01 | 1.04e-02 | 8.76e-01 | 9.99e-01 | 4.63e-01 | 3.45e-01 | 9.68e-01 |
| REGULATION OF NEURON MATURATION | 8 | 6.97e-01 | 9.31e-01 | 0.3110 | 1.39e-01 | 2.36e-02 | 8.67e-02 | 2.38e-01 | 1.13e-01 | 4.95e-01 | 9.08e-01 | 6.71e-01 | 2.43e-01 | 5.81e-01 |
| ENDOCARDIAL CUSHION FUSION | 5 | 8.35e-01 | 9.73e-01 | 0.3110 | -2.53e-03 | 2.02e-01 | 1.80e-01 | 8.44e-02 | 1.30e-01 | 9.92e-01 | 4.34e-01 | 4.87e-01 | 7.44e-01 | 6.15e-01 |
| NEGATIVE REGULATION OF VIRAL TRANSCRIPTION | 14 | 4.63e-01 | 8.25e-01 | 0.3110 | 1.48e-01 | 1.47e-01 | 6.18e-02 | 1.06e-01 | 1.95e-01 | 3.36e-01 | 3.40e-01 | 6.89e-01 | 4.93e-01 | 2.06e-01 |
| REGULATION OF BILE ACID METABOLIC PROCESS | 15 | 7.10e-01 | 9.35e-01 | 0.3110 | -1.10e-01 | -2.17e-01 | -1.57e-01 | -9.97e-02 | -5.32e-02 | 4.62e-01 | 1.45e-01 | 2.92e-01 | 5.04e-01 | 7.21e-01 |
| CO TRANSCRIPTIONAL RNA 3 END PROCESSING CLEAVAGE AND POLYADENYLATION PATHWAY | 6 | 5.15e-01 | 8.56e-01 | 0.3110 | -3.57e-02 | -6.14e-02 | 1.42e-01 | 2.40e-01 | 1.18e-01 | 8.80e-01 | 7.94e-01 | 5.46e-01 | 3.09e-01 | 6.17e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 8 PRODUCTION | 32 | 2.55e-02 | 1.96e-01 | 0.3110 | 1.00e-01 | -5.03e-02 | -1.16e-01 | 3.21e-02 | -2.64e-01 | 3.26e-01 | 6.22e-01 | 2.54e-01 | 7.54e-01 | 9.79e-03 |
| POSITIVE REGULATION OF DOUBLE STRAND BREAK REPAIR | 82 | 3.66e-02 | 2.46e-01 | 0.3110 | 1.08e-01 | 9.01e-02 | 1.43e-01 | 1.93e-01 | 1.39e-01 | 9.12e-02 | 1.58e-01 | 2.54e-02 | 2.56e-03 | 2.93e-02 |
| DETECTION OF VISIBLE LIGHT | 46 | 5.62e-01 | 8.79e-01 | 0.3110 | -1.49e-01 | -1.39e-01 | -1.57e-01 | -1.50e-01 | -9.02e-02 | 7.95e-02 | 1.03e-01 | 6.62e-02 | 7.93e-02 | 2.90e-01 |
| PROTEIN CATABOLIC PROCESS | 930 | 1.22e-20 | 2.55e-18 | 0.3110 | 1.29e-01 | 1.19e-01 | 1.37e-01 | 1.84e-01 | 1.15e-01 | 2.26e-11 | 8.45e-10 | 1.59e-12 | 1.71e-21 | 2.55e-09 |
| CELLULAR RESPONSE TO PH | 26 | 1.18e-01 | 4.67e-01 | 0.3110 | -2.04e-01 | -8.19e-02 | -2.18e-02 | -1.82e-01 | 1.20e-01 | 7.15e-02 | 4.70e-01 | 8.48e-01 | 1.07e-01 | 2.91e-01 |
| CELL FATE SPECIFICATION INVOLVED IN PATTERN SPECIFICATION | 7 | 8.19e-01 | 9.70e-01 | 0.3110 | 2.15e-02 | 3.38e-02 | 1.66e-01 | 3.93e-02 | 2.56e-01 | 9.22e-01 | 8.77e-01 | 4.46e-01 | 8.57e-01 | 2.41e-01 |
| CELL DIFFERENTIATION INVOLVED IN METANEPHROS DEVELOPMENT | 23 | 6.46e-01 | 9.16e-01 | 0.3110 | 8.58e-02 | 1.62e-01 | 1.47e-01 | 1.22e-01 | 1.62e-01 | 4.76e-01 | 1.78e-01 | 2.23e-01 | 3.11e-01 | 1.78e-01 |
| REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY INVOLVED IN APOPTOTIC PROCESS | 46 | 9.98e-02 | 4.30e-01 | 0.3100 | 3.68e-02 | 9.75e-02 | 2.04e-01 | 1.55e-01 | 1.41e-01 | 6.66e-01 | 2.52e-01 | 1.68e-02 | 6.83e-02 | 9.80e-02 |
| UREA METABOLIC PROCESS | 12 | 3.32e-01 | 7.39e-01 | 0.3100 | 8.95e-02 | 7.06e-03 | -1.65e-01 | -1.54e-01 | -1.93e-01 | 5.91e-01 | 9.66e-01 | 3.21e-01 | 3.56e-01 | 2.47e-01 |
| NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 158 | 3.49e-03 | 4.70e-02 | 0.3100 | 8.19e-02 | 1.07e-01 | 1.71e-01 | 1.43e-01 | 1.68e-01 | 7.56e-02 | 2.00e-02 | 2.01e-04 | 1.95e-03 | 2.61e-04 |
| DEOXYRIBONUCLEOSIDE METABOLIC PROCESS | 11 | 7.91e-01 | 9.63e-01 | 0.3100 | 1.99e-01 | 1.57e-01 | 5.80e-02 | 1.06e-01 | -1.32e-01 | 2.54e-01 | 3.67e-01 | 7.39e-01 | 5.43e-01 | 4.47e-01 |
| PARAXIAL MESODERM DEVELOPMENT | 17 | 2.69e-01 | 6.78e-01 | 0.3100 | -1.09e-01 | -7.60e-02 | 1.24e-01 | 6.76e-02 | 2.42e-01 | 4.36e-01 | 5.88e-01 | 3.75e-01 | 6.30e-01 | 8.42e-02 |
| PYRIMIDINE NUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 14 | 7.35e-01 | 9.47e-01 | 0.3100 | 2.04e-01 | 1.81e-01 | 5.91e-02 | 1.33e-01 | -2.61e-02 | 1.86e-01 | 2.42e-01 | 7.02e-01 | 3.90e-01 | 8.66e-01 |
| ATRIAL CARDIAC MUSCLE CELL TO AV NODE CELL COMMUNICATION | 17 | 1.50e-01 | 5.19e-01 | 0.3100 | -1.02e-01 | 4.84e-02 | -7.50e-02 | -1.87e-01 | -2.07e-01 | 4.66e-01 | 7.30e-01 | 5.92e-01 | 1.82e-01 | 1.40e-01 |
| POSITIVE REGULATION OF DNA BIOSYNTHETIC PROCESS | 68 | 8.16e-02 | 3.86e-01 | 0.3100 | 1.09e-01 | 7.22e-02 | 1.54e-01 | 1.82e-01 | 1.48e-01 | 1.20e-01 | 3.03e-01 | 2.80e-02 | 9.29e-03 | 3.47e-02 |
| REGULATION OF HEART GROWTH | 68 | 1.33e-01 | 4.94e-01 | 0.3100 | 1.46e-01 | 1.95e-01 | 1.49e-01 | 1.10e-01 | 4.81e-02 | 3.73e-02 | 5.32e-03 | 3.42e-02 | 1.16e-01 | 4.93e-01 |
| CATECHOLAMINE SECRETION | 60 | 3.14e-02 | 2.24e-01 | 0.3100 | 3.91e-02 | 7.61e-02 | 1.73e-01 | 7.45e-02 | 2.31e-01 | 6.00e-01 | 3.08e-01 | 2.05e-02 | 3.18e-01 | 1.99e-03 |
| VASCULOGENESIS INVOLVED IN CORONARY VASCULAR MORPHOGENESIS | 5 | 5.20e-01 | 8.57e-01 | 0.3100 | -2.05e-01 | -6.58e-02 | 1.59e-01 | -1.03e-01 | 1.18e-01 | 4.28e-01 | 7.99e-01 | 5.38e-01 | 6.90e-01 | 6.47e-01 |
| EMBRYONIC HEMOPOIESIS | 23 | 6.89e-01 | 9.31e-01 | 0.3100 | 7.44e-02 | 1.24e-01 | 1.93e-01 | 1.46e-01 | 1.28e-01 | 5.37e-01 | 3.02e-01 | 1.08e-01 | 2.26e-01 | 2.90e-01 |
| REGULATION OF TRANSLATIONAL FIDELITY | 18 | 8.03e-01 | 9.67e-01 | 0.3100 | 1.81e-01 | 1.41e-01 | 1.48e-01 | 1.26e-01 | 7.41e-02 | 1.84e-01 | 3.01e-01 | 2.78e-01 | 3.54e-01 | 5.86e-01 |
| BICARBONATE TRANSPORT | 35 | 4.89e-01 | 8.39e-01 | 0.3100 | -1.72e-01 | -1.17e-01 | -1.18e-01 | -1.64e-01 | -1.09e-01 | 7.75e-02 | 2.32e-01 | 2.28e-01 | 9.37e-02 | 2.66e-01 |
| NEGATIVE REGULATION OF BINDING | 119 | 1.16e-02 | 1.13e-01 | 0.3100 | 1.20e-01 | 1.03e-01 | 1.42e-01 | 1.89e-01 | 1.22e-01 | 2.37e-02 | 5.22e-02 | 7.36e-03 | 3.80e-04 | 2.10e-02 |
| POSITIVE REGULATION OF LONG TERM SYNAPTIC DEPRESSION | 6 | 8.69e-01 | 9.78e-01 | 0.3100 | -1.03e-01 | -8.52e-02 | -1.48e-01 | -2.37e-01 | -5.26e-03 | 6.63e-01 | 7.18e-01 | 5.29e-01 | 3.16e-01 | 9.82e-01 |
| EAR MORPHOGENESIS | 124 | 2.18e-03 | 3.28e-02 | 0.3100 | 4.88e-02 | 1.29e-01 | 1.67e-01 | 1.18e-01 | 1.87e-01 | 3.48e-01 | 1.28e-02 | 1.35e-03 | 2.37e-02 | 3.17e-04 |
| S ADENOSYLMETHIONINE METABOLIC PROCESS | 15 | 5.59e-01 | 8.78e-01 | 0.3090 | 6.94e-02 | 5.30e-02 | 1.44e-01 | 6.41e-02 | 2.51e-01 | 6.41e-01 | 7.22e-01 | 3.33e-01 | 6.67e-01 | 9.18e-02 |
| REGULATION OF PROTEIN LOCALIZATION TO CHROMOSOME TELOMERIC REGION | 12 | 7.11e-01 | 9.35e-01 | 0.3090 | 5.37e-02 | 5.53e-02 | 1.57e-01 | 2.07e-01 | 1.49e-01 | 7.48e-01 | 7.40e-01 | 3.48e-01 | 2.14e-01 | 3.70e-01 |
| REGULATION OF SMOOTH MUSCLE CELL CHEMOTAXIS | 7 | 9.72e-01 | 9.95e-01 | 0.3090 | -1.66e-01 | -1.26e-01 | -1.29e-01 | -1.36e-01 | -1.32e-01 | 4.48e-01 | 5.63e-01 | 5.56e-01 | 5.34e-01 | 5.46e-01 |
| POSITIVE REGULATION OF NON MOTILE CILIUM ASSEMBLY | 8 | 6.31e-01 | 9.10e-01 | 0.3090 | 8.77e-02 | 1.32e-01 | 8.59e-02 | 2.21e-01 | 1.21e-01 | 6.67e-01 | 5.19e-01 | 6.74e-01 | 2.80e-01 | 5.53e-01 |
| REGULATION OF GLYCOLYTIC PROCESS | 50 | 2.53e-01 | 6.59e-01 | 0.3090 | 1.33e-01 | 1.44e-01 | 1.18e-01 | 1.42e-01 | 1.52e-01 | 1.03e-01 | 7.81e-02 | 1.49e-01 | 8.32e-02 | 6.22e-02 |
| MACROPHAGE PROLIFERATION | 12 | 3.71e-02 | 2.49e-01 | 0.3090 | -1.34e-01 | 9.77e-02 | -1.47e-01 | -1.04e-01 | -1.88e-01 | 4.20e-01 | 5.58e-01 | 3.77e-01 | 5.32e-01 | 2.58e-01 |
| CELLULAR RESPONSE TO CADMIUM ION | 35 | 3.79e-02 | 2.52e-01 | 0.3090 | -6.06e-02 | -2.38e-02 | 1.38e-01 | 1.39e-02 | 2.69e-01 | 5.35e-01 | 8.08e-01 | 1.59e-01 | 8.87e-01 | 5.92e-03 |
| SNRNA PROCESSING | 25 | 5.04e-01 | 8.50e-01 | 0.3090 | 4.25e-02 | 1.12e-01 | 1.58e-01 | 8.42e-02 | 2.22e-01 | 7.13e-01 | 3.31e-01 | 1.71e-01 | 4.66e-01 | 5.52e-02 |
| INTERLEUKIN 2 MEDIATED SIGNALING PATHWAY | 8 | 6.82e-01 | 9.29e-01 | 0.3090 | -1.88e-01 | -8.40e-02 | -3.12e-02 | -5.66e-02 | 2.21e-01 | 3.57e-01 | 6.81e-01 | 8.79e-01 | 7.82e-01 | 2.78e-01 |
| REGULATION OF EPITHELIAL CELL PROLIFERATION INVOLVED IN LUNG MORPHOGENESIS | 7 | 8.67e-01 | 9.78e-01 | 0.3090 | 1.78e-01 | 1.90e-01 | 1.48e-01 | 6.45e-02 | -4.22e-02 | 4.15e-01 | 3.84e-01 | 4.98e-01 | 7.68e-01 | 8.47e-01 |
| RESPONSE TO LITHIUM ION | 15 | 8.57e-01 | 9.77e-01 | 0.3090 | 9.46e-02 | 1.16e-01 | 1.54e-01 | 1.07e-01 | 1.94e-01 | 5.26e-01 | 4.36e-01 | 3.00e-01 | 4.72e-01 | 1.93e-01 |
| NEGATIVE REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 39 | 3.97e-01 | 7.85e-01 | 0.3090 | 7.07e-02 | 1.04e-01 | 1.59e-01 | 1.13e-01 | 2.04e-01 | 4.45e-01 | 2.63e-01 | 8.65e-02 | 2.23e-01 | 2.72e-02 |
| POSITIVE REGULATION OF SYNAPTIC VESICLE FUSION TO PRESYNAPTIC ACTIVE ZONE MEMBRANE | 6 | 8.88e-01 | 9.80e-01 | 0.3090 | -3.33e-02 | -1.46e-02 | -1.12e-01 | -1.73e-01 | -2.27e-01 | 8.88e-01 | 9.51e-01 | 6.34e-01 | 4.64e-01 | 3.36e-01 |
| AORTA MORPHOGENESIS | 38 | 3.78e-01 | 7.75e-01 | 0.3080 | 7.52e-02 | 1.14e-01 | 1.59e-01 | 9.87e-02 | 2.03e-01 | 4.23e-01 | 2.24e-01 | 8.92e-02 | 2.92e-01 | 3.00e-02 |
| PARTURITION | 14 | 3.00e-01 | 7.13e-01 | 0.3080 | -5.03e-02 | 1.29e-01 | 1.49e-01 | -1.86e-02 | 2.31e-01 | 7.45e-01 | 4.04e-01 | 3.33e-01 | 9.04e-01 | 1.35e-01 |
| ATRIAL SEPTUM DEVELOPMENT | 23 | 5.18e-01 | 8.57e-01 | 0.3080 | 3.93e-02 | 9.90e-02 | 1.49e-01 | 1.54e-01 | 1.95e-01 | 7.44e-01 | 4.11e-01 | 2.16e-01 | 2.01e-01 | 1.06e-01 |
| GLUTAMINE FAMILY AMINO ACID BIOSYNTHETIC PROCESS | 15 | 7.09e-01 | 9.34e-01 | 0.3080 | 1.83e-01 | 1.43e-01 | 8.01e-02 | 1.43e-01 | 1.18e-01 | 2.19e-01 | 3.36e-01 | 5.91e-01 | 3.38e-01 | 4.28e-01 |
| REGULATION OF ACTIVIN RECEPTOR SIGNALING PATHWAY | 26 | 3.63e-02 | 2.45e-01 | 0.3080 | -9.50e-02 | -2.06e-02 | 1.01e-01 | 1.31e-01 | 2.41e-01 | 4.02e-01 | 8.56e-01 | 3.75e-01 | 2.48e-01 | 3.32e-02 |
| NEGATIVE REGULATION OF DIGESTIVE SYSTEM PROCESS | 14 | 6.86e-01 | 9.31e-01 | 0.3080 | -3.71e-02 | -5.46e-02 | -1.82e-01 | -1.81e-01 | -1.57e-01 | 8.10e-01 | 7.23e-01 | 2.39e-01 | 2.41e-01 | 3.09e-01 |
| DIET INDUCED THERMOGENESIS | 13 | 5.44e-01 | 8.70e-01 | 0.3080 | 9.00e-02 | 1.62e-01 | 1.12e-01 | 3.04e-02 | 2.17e-01 | 5.74e-01 | 3.10e-01 | 4.86e-01 | 8.49e-01 | 1.76e-01 |
| REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 21 | 5.36e-01 | 8.65e-01 | 0.3080 | -1.80e-01 | -1.60e-01 | -7.75e-02 | -1.42e-01 | -1.01e-01 | 1.52e-01 | 2.03e-01 | 5.39e-01 | 2.59e-01 | 4.22e-01 |
| REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 19 | 2.64e-01 | 6.72e-01 | 0.3080 | -2.83e-03 | -1.99e-02 | 1.48e-01 | 1.80e-01 | 2.00e-01 | 9.83e-01 | 8.81e-01 | 2.65e-01 | 1.75e-01 | 1.30e-01 |
| DETECTION OF LIPOPOLYSACCHARIDE | 5 | 7.31e-01 | 9.44e-01 | 0.3080 | -2.34e-04 | -9.28e-02 | -2.27e-01 | -1.86e-01 | -6.68e-03 | 9.99e-01 | 7.19e-01 | 3.79e-01 | 4.72e-01 | 9.79e-01 |
| PHOSPHOLIPID HOMEOSTASIS | 16 | 8.69e-01 | 9.78e-01 | 0.3080 | -1.71e-01 | -1.15e-01 | -1.38e-01 | -1.75e-01 | -4.91e-02 | 2.36e-01 | 4.27e-01 | 3.38e-01 | 2.25e-01 | 7.34e-01 |
| POSITIVE REGULATION OF UTERINE SMOOTH MUSCLE CONTRACTION | 7 | 9.05e-01 | 9.84e-01 | 0.3080 | 1.55e-01 | 6.15e-02 | 1.06e-01 | 2.07e-01 | 1.14e-01 | 4.78e-01 | 7.78e-01 | 6.28e-01 | 3.43e-01 | 6.02e-01 |
| SNARE COMPLEX ASSEMBLY | 22 | 3.52e-01 | 7.53e-01 | 0.3080 | 1.91e-01 | 2.08e-01 | 9.62e-02 | 5.75e-02 | 4.56e-02 | 1.20e-01 | 9.08e-02 | 4.35e-01 | 6.41e-01 | 7.11e-01 |
| AMINO SUGAR BIOSYNTHETIC PROCESS | 11 | 9.06e-01 | 9.84e-01 | 0.3080 | 7.19e-02 | 7.03e-02 | 1.61e-01 | 1.59e-01 | 1.83e-01 | 6.80e-01 | 6.86e-01 | 3.55e-01 | 3.61e-01 | 2.95e-01 |
| NEGATIVE REGULATION OF CATECHOLAMINE SECRETION | 13 | 4.19e-01 | 8.00e-01 | 0.3080 | 3.04e-04 | -3.40e-02 | 1.81e-01 | 9.69e-02 | 2.26e-01 | 9.98e-01 | 8.32e-01 | 2.58e-01 | 5.45e-01 | 1.58e-01 |
| REGULATION OF MITOPHAGY | 15 | 6.74e-01 | 9.27e-01 | 0.3070 | 2.27e-01 | 1.52e-01 | 6.21e-02 | 1.15e-01 | -5.22e-02 | 1.27e-01 | 3.09e-01 | 6.77e-01 | 4.40e-01 | 7.26e-01 |
| REGULATION OF EATING BEHAVIOR | 7 | 6.72e-01 | 9.26e-01 | 0.3070 | -1.18e-01 | 3.12e-02 | -1.58e-01 | -1.89e-01 | -1.36e-01 | 5.87e-01 | 8.86e-01 | 4.68e-01 | 3.86e-01 | 5.32e-01 |
| GENERATION OF PRECURSOR METABOLITES AND ENERGY | 470 | 3.67e-07 | 1.83e-05 | 0.3070 | 1.30e-01 | 1.32e-01 | 1.54e-01 | 1.46e-01 | 1.21e-01 | 1.30e-06 | 8.65e-07 | 1.01e-08 | 6.17e-08 | 6.41e-06 |
| PYROPTOSIS | 36 | 1.97e-01 | 5.86e-01 | 0.3070 | -2.19e-02 | -8.59e-02 | -1.93e-01 | -1.52e-01 | -1.61e-01 | 8.20e-01 | 3.73e-01 | 4.49e-02 | 1.15e-01 | 9.45e-02 |
| CELLULAR RESPONSE TO ACID CHEMICAL | 86 | 3.20e-02 | 2.27e-01 | 0.3070 | 9.26e-02 | 8.32e-02 | 1.57e-01 | 1.88e-01 | 1.38e-01 | 1.38e-01 | 1.82e-01 | 1.21e-02 | 2.65e-03 | 2.73e-02 |
| GLOMERULAR MESANGIUM DEVELOPMENT | 18 | 6.79e-01 | 9.28e-01 | 0.3070 | 1.05e-01 | 1.97e-01 | 1.74e-01 | 8.80e-02 | 7.94e-02 | 4.43e-01 | 1.48e-01 | 2.00e-01 | 5.18e-01 | 5.60e-01 |
| NEGATIVE REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 7 | 6.24e-01 | 9.09e-01 | 0.3070 | -1.78e-01 | -1.71e-01 | -1.63e-01 | -2.54e-02 | 7.53e-02 | 4.14e-01 | 4.32e-01 | 4.56e-01 | 9.07e-01 | 7.30e-01 |
| TONIC SMOOTH MUSCLE CONTRACTION | 11 | 4.89e-01 | 8.39e-01 | 0.3060 | -2.06e-01 | -5.75e-02 | -2.16e-02 | -2.10e-01 | 5.80e-02 | 2.36e-01 | 7.41e-01 | 9.01e-01 | 2.27e-01 | 7.39e-01 |
| PROSTAGLANDIN TRANSPORT | 28 | 2.29e-02 | 1.83e-01 | 0.3060 | -1.63e-01 | 2.45e-02 | -1.05e-01 | -2.02e-01 | -1.22e-01 | 1.36e-01 | 8.23e-01 | 3.38e-01 | 6.42e-02 | 2.63e-01 |
| POSITIVE REGULATION OF DNA METHYLATION DEPENDENT HETEROCHROMATIN FORMATION | 11 | 7.84e-02 | 3.80e-01 | 0.3060 | 1.04e-01 | -5.48e-02 | -1.35e-01 | 1.78e-01 | -1.73e-01 | 5.49e-01 | 7.53e-01 | 4.38e-01 | 3.06e-01 | 3.22e-01 |
| REGULATION OF PLATELET AGGREGATION | 27 | 1.77e-01 | 5.62e-01 | 0.3060 | 1.89e-01 | 1.39e-01 | -6.38e-03 | 8.28e-02 | -1.78e-01 | 8.85e-02 | 2.12e-01 | 9.54e-01 | 4.57e-01 | 1.10e-01 |
| REGULATION OF NEUROTRANSMITTER UPTAKE | 18 | 5.02e-01 | 8.48e-01 | 0.3060 | 7.87e-03 | 7.48e-02 | 1.12e-01 | 8.52e-02 | 2.61e-01 | 9.54e-01 | 5.83e-01 | 4.09e-01 | 5.31e-01 | 5.55e-02 |
| MELANOSOME ASSEMBLY | 18 | 4.34e-01 | 8.08e-01 | 0.3060 | 2.23e-01 | 1.14e-01 | 7.58e-02 | 1.27e-01 | 9.45e-02 | 1.02e-01 | 4.02e-01 | 5.78e-01 | 3.51e-01 | 4.87e-01 |
| STRIATED MUSCLE CELL DEVELOPMENT | 73 | 2.24e-02 | 1.80e-01 | 0.3060 | -2.02e-01 | -1.09e-01 | -8.65e-02 | -1.82e-01 | -1.99e-02 | 2.87e-03 | 1.09e-01 | 2.02e-01 | 7.23e-03 | 7.69e-01 |
| REGULATION OF MICROTUBULE NUCLEATION | 17 | 4.49e-01 | 8.19e-01 | 0.3060 | -1.22e-02 | 7.74e-02 | 1.16e-01 | 2.99e-02 | 2.70e-01 | 9.31e-01 | 5.81e-01 | 4.08e-01 | 8.31e-01 | 5.39e-02 |
| DEOXYRIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 23 | 5.79e-01 | 8.86e-01 | 0.3050 | 2.12e-01 | 1.62e-01 | 8.38e-02 | 1.18e-01 | -3.59e-02 | 7.87e-02 | 1.80e-01 | 4.87e-01 | 3.26e-01 | 7.65e-01 |
| ANTEROGRADE DENDRITIC TRANSPORT | 9 | 5.18e-01 | 8.57e-01 | 0.3050 | 2.07e-01 | 1.50e-02 | 1.03e-01 | 1.93e-01 | -4.66e-02 | 2.82e-01 | 9.38e-01 | 5.91e-01 | 3.17e-01 | 8.09e-01 |
| PROTEIN TARGETING | 316 | 6.49e-05 | 1.93e-03 | 0.3050 | 1.32e-01 | 1.20e-01 | 1.54e-01 | 1.59e-01 | 1.11e-01 | 5.21e-05 | 2.47e-04 | 2.39e-06 | 1.18e-06 | 7.24e-04 |
| POSITIVE REGULATION OF B CELL PROLIFERATION | 43 | 2.44e-01 | 6.48e-01 | 0.3050 | 1.74e-01 | 1.41e-01 | 9.30e-02 | 1.84e-01 | -1.15e-02 | 4.78e-02 | 1.09e-01 | 2.91e-01 | 3.70e-02 | 8.96e-01 |
| PROLINE TRANSPORT | 11 | 4.23e-01 | 8.03e-01 | 0.3050 | -1.60e-02 | 1.92e-01 | 1.98e-01 | 7.14e-02 | 1.07e-01 | 9.27e-01 | 2.70e-01 | 2.56e-01 | 6.82e-01 | 5.38e-01 |
| REGULATION OF SYNAPSE STRUCTURAL PLASTICITY | 7 | 5.49e-01 | 8.73e-01 | 0.3050 | -1.32e-01 | -6.78e-03 | -3.79e-02 | -2.51e-01 | -1.04e-01 | 5.46e-01 | 9.75e-01 | 8.62e-01 | 2.49e-01 | 6.34e-01 |
| REGULATION OF CELL CYCLE PHASE TRANSITION | 439 | 6.62e-11 | 5.66e-09 | 0.3050 | 1.16e-01 | 8.97e-02 | 1.39e-01 | 1.87e-01 | 1.31e-01 | 3.25e-05 | 1.27e-03 | 5.76e-07 | 1.85e-11 | 2.54e-06 |
| POSITIVE REGULATION OF MICROGLIAL CELL ACTIVATION | 10 | 4.28e-01 | 8.05e-01 | 0.3040 | 9.11e-02 | 7.01e-02 | 8.39e-02 | 1.56e-01 | -2.19e-01 | 6.18e-01 | 7.01e-01 | 6.46e-01 | 3.93e-01 | 2.29e-01 |
| VESICLE MEDIATED CHOLESTEROL TRANSPORT | 9 | 7.38e-01 | 9.49e-01 | 0.3040 | 2.18e-01 | 9.44e-02 | 2.24e-02 | 1.74e-01 | -7.29e-02 | 2.56e-01 | 6.24e-01 | 9.08e-01 | 3.66e-01 | 7.05e-01 |
| METANEPHRIC NEPHRON TUBULE EPITHELIAL CELL DIFFERENTIATION | 6 | 9.11e-01 | 9.85e-01 | 0.3040 | -2.11e-01 | -8.13e-02 | -1.19e-01 | -1.65e-01 | 1.10e-02 | 3.71e-01 | 7.30e-01 | 6.13e-01 | 4.84e-01 | 9.63e-01 |
| NEGATIVE REGULATION OF MONOCYTE DIFFERENTIATION | 8 | 1.90e-01 | 5.76e-01 | 0.3040 | -1.74e-01 | -1.18e-01 | -1.64e-02 | 1.34e-01 | 1.73e-01 | 3.94e-01 | 5.62e-01 | 9.36e-01 | 5.12e-01 | 3.95e-01 |
| POSITIVE REGULATION OF BINDING | 121 | 2.13e-02 | 1.73e-01 | 0.3040 | 1.54e-01 | 1.12e-01 | 1.28e-01 | 1.81e-01 | 8.49e-02 | 3.48e-03 | 3.28e-02 | 1.53e-02 | 5.84e-04 | 1.07e-01 |
| POSITIVE REGULATION OF DEVELOPMENTAL PIGMENTATION | 9 | 6.16e-01 | 9.06e-01 | 0.3040 | -6.28e-02 | -1.63e-01 | -2.09e-01 | -1.26e-01 | 4.79e-02 | 7.44e-01 | 3.98e-01 | 2.77e-01 | 5.13e-01 | 8.03e-01 |
| POST TRANSLATIONAL PROTEIN TARGETING TO MEMBRANE TRANSLOCATION | 8 | 8.60e-01 | 9.78e-01 | 0.3040 | 8.55e-02 | 1.30e-01 | 2.22e-01 | 1.06e-01 | 8.79e-02 | 6.75e-01 | 5.24e-01 | 2.77e-01 | 6.04e-01 | 6.67e-01 |
| THIAMINE CONTAINING COMPOUND METABOLIC PROCESS | 6 | 9.12e-01 | 9.85e-01 | 0.3040 | -8.04e-02 | -1.70e-01 | -2.10e-01 | -7.46e-02 | -8.57e-02 | 7.33e-01 | 4.71e-01 | 3.73e-01 | 7.52e-01 | 7.16e-01 |
| STABILIZATION OF MEMBRANE POTENTIAL | 17 | 8.48e-02 | 3.94e-01 | 0.3040 | -1.72e-02 | 1.09e-01 | 1.12e-01 | -9.23e-02 | 2.43e-01 | 9.02e-01 | 4.36e-01 | 4.25e-01 | 5.10e-01 | 8.26e-02 |
| NEGATIVE REGULATION OF PLATELET ACTIVATION | 17 | 5.33e-01 | 8.64e-01 | 0.3040 | 1.71e-01 | 2.11e-01 | 6.67e-02 | 7.39e-02 | -9.30e-02 | 2.22e-01 | 1.33e-01 | 6.34e-01 | 5.98e-01 | 5.07e-01 |
| BONE TRABECULA MORPHOGENESIS | 13 | 2.11e-01 | 6.06e-01 | 0.3040 | 3.52e-02 | 2.54e-01 | 1.60e-01 | 2.18e-02 | 1.89e-02 | 8.26e-01 | 1.13e-01 | 3.18e-01 | 8.92e-01 | 9.06e-01 |
| REGULATION OF MYELOID DENDRITIC CELL ACTIVATION | 5 | 8.74e-01 | 9.78e-01 | 0.3040 | 2.26e-01 | 6.26e-02 | 3.65e-02 | 1.89e-01 | 6.04e-03 | 3.81e-01 | 8.09e-01 | 8.87e-01 | 4.64e-01 | 9.81e-01 |
| NEGATIVE REGULATION OF RECEPTOR BINDING | 12 | 6.82e-01 | 9.30e-01 | 0.3040 | 4.38e-02 | 1.31e-01 | 1.58e-01 | 1.87e-01 | 1.14e-01 | 7.93e-01 | 4.31e-01 | 3.44e-01 | 2.61e-01 | 4.93e-01 |
| AMP CATABOLIC PROCESS | 5 | 7.51e-01 | 9.51e-01 | 0.3030 | 2.81e-02 | 2.69e-02 | 2.50e-01 | 1.42e-01 | 8.98e-02 | 9.13e-01 | 9.17e-01 | 3.33e-01 | 5.83e-01 | 7.28e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 12 PRODUCTION | 42 | 5.31e-02 | 3.05e-01 | 0.3030 | 1.99e-01 | 1.90e-01 | 5.53e-02 | 9.78e-02 | 6.03e-02 | 2.54e-02 | 3.31e-02 | 5.35e-01 | 2.73e-01 | 4.99e-01 |
| CELL ADHESION MOLECULE PRODUCTION | 18 | 4.27e-01 | 8.05e-01 | 0.3030 | 6.09e-02 | 4.73e-03 | -1.26e-01 | -8.18e-02 | -2.56e-01 | 6.55e-01 | 9.72e-01 | 3.54e-01 | 5.48e-01 | 5.97e-02 |
| PODOCYTE CELL MIGRATION | 7 | 9.18e-01 | 9.86e-01 | 0.3030 | 2.15e-01 | 1.42e-01 | 1.14e-01 | 1.04e-01 | 4.12e-02 | 3.24e-01 | 5.15e-01 | 6.00e-01 | 6.35e-01 | 8.50e-01 |
| REGULATION OF CELLULAR RESPONSE TO HYPOXIA | 20 | 5.09e-01 | 8.53e-01 | 0.3030 | 2.26e-01 | 1.21e-01 | 9.63e-02 | 1.30e-01 | -1.77e-02 | 8.07e-02 | 3.49e-01 | 4.56e-01 | 3.15e-01 | 8.91e-01 |
| POSITIVE REGULATION OF DNA DAMAGE CHECKPOINT | 5 | 9.55e-01 | 9.94e-01 | 0.3030 | 1.33e-01 | 9.55e-02 | 9.16e-02 | 1.20e-01 | 2.05e-01 | 6.06e-01 | 7.12e-01 | 7.23e-01 | 6.41e-01 | 4.27e-01 |
| REGULATION OF ENDOPLASMIC RETICULUM STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 32 | 3.58e-01 | 7.57e-01 | 0.3030 | 2.69e-02 | 5.94e-02 | 1.70e-01 | 1.38e-01 | 1.99e-01 | 7.92e-01 | 5.61e-01 | 9.60e-02 | 1.77e-01 | 5.13e-02 |
| CELLULAR RESPONSE TO PARATHYROID HORMONE STIMULUS | 8 | 3.43e-01 | 7.50e-01 | 0.3030 | -4.57e-02 | 8.57e-02 | -1.64e-02 | -7.16e-02 | 2.77e-01 | 8.23e-01 | 6.75e-01 | 9.36e-01 | 7.26e-01 | 1.74e-01 |
| NEGATIVE REGULATION OF GRANULOCYTE DIFFERENTIATION | 8 | 4.20e-01 | 8.00e-01 | 0.3030 | 8.33e-02 | 2.59e-01 | 5.72e-02 | 9.02e-02 | -8.08e-02 | 6.83e-01 | 2.05e-01 | 7.79e-01 | 6.59e-01 | 6.92e-01 |
| STEM CELL DIFFERENTIATION | 240 | 7.01e-08 | 3.88e-06 | 0.3030 | 3.27e-02 | 7.97e-02 | 1.38e-01 | 1.31e-01 | 2.19e-01 | 3.82e-01 | 3.35e-02 | 2.31e-04 | 4.49e-04 | 4.96e-09 |
| POSITIVE REGULATION OF CALCINEURIN MEDIATED SIGNALING | 21 | 6.46e-01 | 9.16e-01 | 0.3030 | -5.78e-02 | -5.16e-02 | -1.48e-01 | -1.43e-01 | -2.08e-01 | 6.47e-01 | 6.82e-01 | 2.41e-01 | 2.55e-01 | 9.88e-02 |
| CHEMOKINE C X C MOTIF LIGAND 12 SIGNALING PATHWAY | 7 | 4.91e-02 | 2.89e-01 | 0.3030 | 2.38e-01 | 7.04e-02 | -4.61e-02 | -1.49e-01 | 7.44e-02 | 2.75e-01 | 7.47e-01 | 8.33e-01 | 4.94e-01 | 7.33e-01 |
| ANGIOGENESIS INVOLVED IN WOUND HEALING | 31 | 3.01e-01 | 7.13e-01 | 0.3030 | 8.19e-02 | 1.83e-01 | 1.50e-01 | 6.87e-02 | 1.56e-01 | 4.30e-01 | 7.82e-02 | 1.48e-01 | 5.08e-01 | 1.34e-01 |
| NEGATIVE REGULATION OF MUSCLE CELL APOPTOTIC PROCESS | 50 | 5.17e-01 | 8.56e-01 | 0.3030 | 1.43e-01 | 1.65e-01 | 1.48e-01 | 1.35e-01 | 5.99e-02 | 7.95e-02 | 4.29e-02 | 7.09e-02 | 9.82e-02 | 4.64e-01 |
| MITOCHONDRIAL FUSION | 32 | 3.76e-01 | 7.75e-01 | 0.3030 | 2.07e-01 | 1.20e-01 | 8.30e-02 | 1.65e-01 | 1.20e-02 | 4.28e-02 | 2.39e-01 | 4.16e-01 | 1.06e-01 | 9.06e-01 |
| REGULATION OF RESPONSE TO EXTRACELLULAR STIMULUS | 28 | 4.78e-02 | 2.86e-01 | 0.3020 | 1.78e-01 | 1.71e-01 | 8.13e-02 | 2.42e-02 | 1.53e-01 | 1.04e-01 | 1.17e-01 | 4.57e-01 | 8.25e-01 | 1.60e-01 |
| FORMATE METABOLIC PROCESS | 6 | 4.29e-01 | 8.05e-01 | 0.3020 | 5.43e-02 | 1.01e-01 | -2.17e-01 | -9.15e-02 | -1.52e-01 | 8.18e-01 | 6.68e-01 | 3.58e-01 | 6.98e-01 | 5.20e-01 |
| NEGATIVE REGULATION OF HEPATOCYTE APOPTOTIC PROCESS | 7 | 6.29e-01 | 9.10e-01 | 0.3020 | 1.81e-01 | 1.22e-01 | 5.17e-03 | 1.56e-01 | 1.39e-01 | 4.06e-01 | 5.76e-01 | 9.81e-01 | 4.74e-01 | 5.26e-01 |
| NEGATIVE REGULATION OF TOR SIGNALING | 72 | 2.18e-02 | 1.77e-01 | 0.3020 | 7.59e-02 | 5.09e-02 | 1.47e-01 | 1.88e-01 | 1.62e-01 | 2.65e-01 | 4.55e-01 | 3.14e-02 | 5.74e-03 | 1.78e-02 |
| REGULATION OF ICOSANOID SECRETION | 20 | 5.69e-01 | 8.82e-01 | 0.3020 | -9.93e-02 | -6.08e-02 | -1.63e-01 | -2.04e-01 | -9.77e-02 | 4.42e-01 | 6.38e-01 | 2.06e-01 | 1.15e-01 | 4.50e-01 |
| RESPONSE TO UV | 147 | 1.28e-02 | 1.21e-01 | 0.3020 | 1.42e-01 | 1.18e-01 | 1.29e-01 | 1.69e-01 | 1.11e-01 | 3.01e-03 | 1.35e-02 | 6.99e-03 | 4.06e-04 | 2.07e-02 |
| ACTOMYOSIN CONTRACTILE RING ORGANIZATION | 10 | 9.48e-01 | 9.94e-01 | 0.3020 | -8.84e-02 | -1.59e-01 | -1.74e-01 | -1.25e-01 | -1.10e-01 | 6.29e-01 | 3.83e-01 | 3.40e-01 | 4.95e-01 | 5.47e-01 |
| SODIUM ION TRANSMEMBRANE TRANSPORT | 169 | 1.43e-04 | 3.60e-03 | 0.3020 | -1.57e-01 | -1.13e-01 | -1.11e-01 | -1.99e-01 | -4.15e-02 | 4.25e-04 | 1.14e-02 | 1.26e-02 | 7.80e-06 | 3.52e-01 |
| SULFUR AMINO ACID CATABOLIC PROCESS | 10 | 5.89e-01 | 8.92e-01 | 0.3020 | 1.20e-01 | 1.59e-01 | 8.51e-02 | 2.07e-02 | 2.10e-01 | 5.11e-01 | 3.85e-01 | 6.41e-01 | 9.10e-01 | 2.51e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 7 | 9.44e-01 | 9.93e-01 | 0.3020 | -5.74e-02 | -5.35e-02 | -1.46e-01 | -1.05e-01 | -2.30e-01 | 7.93e-01 | 8.06e-01 | 5.04e-01 | 6.30e-01 | 2.93e-01 |
| GENITALIA MORPHOGENESIS | 11 | 1.59e-01 | 5.33e-01 | 0.3020 | -1.52e-01 | -3.25e-02 | -2.11e-01 | -1.39e-01 | 5.65e-02 | 3.83e-01 | 8.52e-01 | 2.25e-01 | 4.26e-01 | 7.46e-01 |
| MAINTENANCE OF CELL POLARITY | 17 | 7.06e-01 | 9.33e-01 | 0.3020 | 7.38e-02 | 8.97e-02 | 1.47e-01 | 1.93e-01 | 1.37e-01 | 5.99e-01 | 5.22e-01 | 2.94e-01 | 1.68e-01 | 3.29e-01 |
| NEGATIVE REGULATION OF MOTOR NEURON APOPTOTIC PROCESS | 11 | 9.14e-01 | 9.86e-01 | 0.3020 | 1.60e-01 | 1.53e-01 | 1.56e-01 | 1.00e-01 | 8.63e-02 | 3.57e-01 | 3.78e-01 | 3.70e-01 | 5.66e-01 | 6.20e-01 |
| TRANSCYTOSIS | 20 | 3.61e-01 | 7.60e-01 | 0.3020 | 1.14e-01 | 2.14e-01 | 1.04e-01 | 1.44e-01 | 2.20e-02 | 3.76e-01 | 9.72e-02 | 4.22e-01 | 2.64e-01 | 8.65e-01 |
| FACE DEVELOPMENT | 49 | 2.56e-01 | 6.63e-01 | 0.3020 | 8.01e-02 | 1.13e-01 | 1.50e-01 | 1.73e-01 | 1.39e-01 | 3.32e-01 | 1.70e-01 | 6.99e-02 | 3.61e-02 | 9.12e-02 |
| REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 139 | 2.85e-03 | 4.01e-02 | 0.3020 | 1.82e-01 | 1.46e-01 | 9.53e-02 | 1.47e-01 | 7.67e-02 | 2.11e-04 | 2.94e-03 | 5.23e-02 | 2.78e-03 | 1.18e-01 |
| POSITIVE REGULATION OF COA TRANSFERASE ACTIVITY | 8 | 3.39e-01 | 7.44e-01 | 0.3020 | -1.28e-01 | 9.86e-02 | -9.74e-02 | -1.65e-01 | -1.67e-01 | 5.29e-01 | 6.29e-01 | 6.33e-01 | 4.18e-01 | 4.13e-01 |
| COLLATERAL SPROUTING IN ABSENCE OF INJURY | 5 | 8.48e-01 | 9.76e-01 | 0.3010 | 5.55e-02 | -4.44e-02 | -1.72e-01 | 1.79e-02 | -2.36e-01 | 8.30e-01 | 8.63e-01 | 5.05e-01 | 9.45e-01 | 3.60e-01 |
| PROTEIN CONTAINING COMPLEX ASSEMBLY | 1523 | 1.81e-22 | 4.71e-20 | 0.3010 | 1.35e-01 | 1.32e-01 | 1.47e-01 | 1.46e-01 | 1.11e-01 | 1.54e-18 | 5.76e-18 | 6.74e-22 | 1.48e-21 | 5.22e-13 |
| RESPONSE TO POTASSIUM ION | 17 | 3.79e-01 | 7.75e-01 | 0.3010 | -1.88e-01 | -1.72e-01 | -3.32e-02 | -1.51e-01 | -4.57e-02 | 1.81e-01 | 2.19e-01 | 8.13e-01 | 2.81e-01 | 7.44e-01 |
| NEGATIVE REGULATION OF DENDRITIC CELL DIFFERENTIATION | 6 | 9.84e-01 | 9.96e-01 | 0.3010 | -1.65e-01 | -1.57e-01 | -1.24e-01 | -1.51e-01 | 2.26e-02 | 4.83e-01 | 5.05e-01 | 5.98e-01 | 5.23e-01 | 9.24e-01 |
| APOPTOTIC SIGNALING PATHWAY | 600 | 4.65e-10 | 3.57e-08 | 0.3010 | 1.15e-01 | 1.20e-01 | 1.57e-01 | 1.66e-01 | 1.05e-01 | 1.41e-06 | 5.28e-07 | 5.58e-11 | 3.68e-12 | 1.07e-05 |
| REGULATION OF OVARIAN FOLLICLE DEVELOPMENT | 6 | 8.30e-01 | 9.73e-01 | 0.3010 | 1.32e-01 | 2.12e-01 | 4.06e-02 | 8.95e-02 | -1.37e-01 | 5.75e-01 | 3.70e-01 | 8.63e-01 | 7.04e-01 | 5.60e-01 |
| RESPONSE TO HEPATOCYTE GROWTH FACTOR | 17 | 4.87e-01 | 8.39e-01 | 0.3010 | -3.26e-02 | -1.51e-01 | -2.15e-01 | -9.55e-02 | -1.07e-01 | 8.16e-01 | 2.82e-01 | 1.24e-01 | 4.95e-01 | 4.45e-01 |
| MEIOTIC CYTOKINESIS | 8 | 9.31e-01 | 9.90e-01 | 0.3010 | -2.26e-02 | -7.06e-02 | -1.51e-01 | -1.01e-01 | -2.28e-01 | 9.12e-01 | 7.30e-01 | 4.59e-01 | 6.20e-01 | 2.63e-01 |
| EPITHELIAL TO MESENCHYMAL TRANSITION | 176 | 7.16e-03 | 8.05e-02 | 0.3010 | 1.04e-01 | 1.27e-01 | 1.50e-01 | 1.50e-01 | 1.37e-01 | 1.73e-02 | 3.75e-03 | 6.15e-04 | 5.76e-04 | 1.66e-03 |
| OLFACTORY NERVE DEVELOPMENT | 6 | 8.12e-01 | 9.68e-01 | 0.3010 | -1.70e-01 | -8.19e-02 | 7.75e-02 | -7.74e-02 | 2.08e-01 | 4.72e-01 | 7.28e-01 | 7.42e-01 | 7.43e-01 | 3.78e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY | 45 | 1.88e-01 | 5.73e-01 | 0.3010 | 3.59e-02 | 9.21e-02 | 1.89e-01 | 1.41e-01 | 1.58e-01 | 6.77e-01 | 2.85e-01 | 2.81e-02 | 1.01e-01 | 6.61e-02 |
| LEUCINE METABOLIC PROCESS | 8 | 5.22e-02 | 3.02e-01 | 0.3010 | 1.08e-01 | 1.00e-01 | -9.93e-02 | 1.67e-01 | 1.76e-01 | 5.96e-01 | 6.23e-01 | 6.27e-01 | 4.13e-01 | 3.88e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION INVOLVED IN WOUND HEALING | 10 | 4.03e-01 | 7.90e-01 | 0.3010 | 1.32e-01 | 2.15e-01 | -2.27e-02 | -4.19e-02 | -1.58e-01 | 4.71e-01 | 2.40e-01 | 9.01e-01 | 8.19e-01 | 3.88e-01 |
| CRANIAL NERVE MORPHOGENESIS | 29 | 3.23e-01 | 7.33e-01 | 0.3010 | 7.82e-02 | 1.55e-01 | 1.61e-01 | 5.26e-02 | 1.77e-01 | 4.66e-01 | 1.48e-01 | 1.33e-01 | 6.24e-01 | 9.82e-02 |
| MITOCHONDRION LOCALIZATION | 46 | 4.08e-01 | 7.94e-01 | 0.3000 | 1.06e-01 | 8.82e-02 | 1.46e-01 | 1.56e-01 | 1.60e-01 | 2.12e-01 | 3.01e-01 | 8.74e-02 | 6.72e-02 | 6.01e-02 |
| POSITIVE REGULATION OF BLOOD CIRCULATION | 38 | 1.75e-01 | 5.60e-01 | 0.3000 | 4.63e-03 | 9.51e-02 | 1.80e-01 | 7.93e-02 | 2.06e-01 | 9.61e-01 | 3.11e-01 | 5.50e-02 | 3.98e-01 | 2.78e-02 |
| RESPONSE TO INTERLEUKIN 15 | 11 | 9.10e-01 | 9.85e-01 | 0.3000 | 7.80e-02 | 1.15e-01 | 1.40e-01 | 1.65e-01 | 1.56e-01 | 6.54e-01 | 5.09e-01 | 4.23e-01 | 3.44e-01 | 3.71e-01 |
| DETECTION OF LIGHT STIMULUS | 61 | 4.13e-01 | 7.98e-01 | 0.3000 | -1.61e-01 | -1.39e-01 | -1.35e-01 | -1.53e-01 | -5.86e-02 | 2.99e-02 | 5.98e-02 | 6.91e-02 | 3.88e-02 | 4.29e-01 |
| INTRACELLULAR PROTEIN TRANSPORT | 838 | 9.75e-13 | 1.03e-10 | 0.3000 | 1.37e-01 | 1.25e-01 | 1.50e-01 | 1.60e-01 | 8.93e-02 | 1.68e-11 | 7.65e-10 | 1.83e-13 | 3.92e-15 | 1.12e-05 |
| PHOTOTRANSDUCTION VISIBLE LIGHT | 18 | 1.96e-01 | 5.84e-01 | 0.3000 | -1.78e-01 | -7.65e-02 | -1.68e-01 | -8.44e-02 | -1.31e-01 | 1.91e-01 | 5.74e-01 | 2.16e-01 | 5.35e-01 | 3.37e-01 |
| NEGATIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 20 | 7.42e-01 | 9.50e-01 | 0.3000 | 1.36e-01 | 1.73e-01 | 1.45e-01 | 1.42e-01 | -2.24e-02 | 2.92e-01 | 1.80e-01 | 2.63e-01 | 2.70e-01 | 8.62e-01 |
| PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION | 777 | 2.11e-17 | 3.77e-15 | 0.3000 | 1.37e-01 | 1.02e-01 | 1.26e-01 | 1.80e-01 | 1.12e-01 | 7.89e-11 | 1.24e-06 | 2.28e-09 | 1.11e-17 | 1.16e-07 |
| POSITIVE REGULATION OF PEPTIDYL LYSINE ACETYLATION | 16 | 8.49e-01 | 9.76e-01 | 0.3000 | 1.57e-01 | 1.40e-01 | 1.04e-01 | 1.74e-01 | 6.78e-02 | 2.75e-01 | 3.33e-01 | 4.72e-01 | 2.27e-01 | 6.39e-01 |
| NEGATIVE REGULATION OF ACTIVATED T CELL PROLIFERATION | 14 | 4.35e-01 | 8.09e-01 | 0.3000 | -1.59e-02 | -1.17e-01 | -2.29e-01 | -1.36e-01 | -7.13e-02 | 9.18e-01 | 4.48e-01 | 1.38e-01 | 3.77e-01 | 6.44e-01 |
| N ACETYLNEURAMINATE CATABOLIC PROCESS | 6 | 7.85e-01 | 9.61e-01 | 0.3000 | 2.12e-01 | 1.16e-01 | 1.56e-01 | 8.41e-02 | -1.58e-02 | 3.69e-01 | 6.24e-01 | 5.07e-01 | 7.21e-01 | 9.47e-01 |
| LUNG LOBE DEVELOPMENT | 7 | 7.36e-01 | 9.48e-01 | 0.3000 | -2.07e-01 | -1.07e-01 | 7.06e-02 | -4.50e-02 | 1.69e-01 | 3.43e-01 | 6.24e-01 | 7.46e-01 | 8.37e-01 | 4.38e-01 |
| REGULATION OF MITOTIC CENTROSOME SEPARATION | 9 | 4.65e-01 | 8.26e-01 | 0.3000 | 1.48e-01 | 7.46e-03 | 4.50e-02 | 2.49e-01 | 6.10e-02 | 4.41e-01 | 9.69e-01 | 8.15e-01 | 1.95e-01 | 7.51e-01 |
| CELL CYCLE PROCESS | 1248 | 4.74e-24 | 1.49e-21 | 0.3000 | 1.25e-01 | 1.04e-01 | 1.45e-01 | 1.76e-01 | 1.09e-01 | 1.15e-13 | 7.36e-10 | 7.83e-18 | 1.22e-25 | 1.07e-10 |
| HYDROGEN PEROXIDE BIOSYNTHETIC PROCESS | 14 | 5.60e-01 | 8.78e-01 | 0.3000 | -5.41e-02 | 6.30e-02 | 1.49e-01 | 8.78e-02 | 2.31e-01 | 7.26e-01 | 6.83e-01 | 3.35e-01 | 5.69e-01 | 1.35e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO MICROTUBULE | 5 | 4.09e-01 | 7.94e-01 | 0.3000 | -7.91e-02 | -7.44e-02 | -7.94e-02 | 1.24e-01 | 2.38e-01 | 7.59e-01 | 7.73e-01 | 7.59e-01 | 6.32e-01 | 3.57e-01 |
| REGULATION OF TOLERANCE INDUCTION | 19 | 2.09e-01 | 6.03e-01 | 0.3000 | -1.41e-01 | -1.99e-01 | -7.11e-02 | -2.96e-03 | 1.58e-01 | 2.87e-01 | 1.32e-01 | 5.91e-01 | 9.82e-01 | 2.32e-01 |
| MOTOR NEURON MIGRATION | 13 | 9.11e-01 | 9.85e-01 | 0.3000 | 9.39e-02 | 9.82e-02 | 1.64e-01 | 1.18e-01 | 1.75e-01 | 5.58e-01 | 5.40e-01 | 3.06e-01 | 4.61e-01 | 2.75e-01 |
| NEGATIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 93 | 1.70e-01 | 5.55e-01 | 0.3000 | 1.40e-01 | 1.18e-01 | 1.46e-01 | 1.56e-01 | 1.01e-01 | 1.93e-02 | 4.83e-02 | 1.46e-02 | 9.28e-03 | 9.28e-02 |
| PROTEIN LOCALIZATION TO ENDOSOME | 26 | 2.29e-01 | 6.32e-01 | 0.3000 | 1.78e-01 | 8.64e-02 | 6.65e-02 | 1.87e-01 | -1.05e-01 | 1.16e-01 | 4.46e-01 | 5.57e-01 | 9.85e-02 | 3.54e-01 |
| TOR SIGNALING | 158 | 5.23e-03 | 6.33e-02 | 0.2990 | 1.46e-01 | 1.02e-01 | 1.36e-01 | 1.77e-01 | 9.03e-02 | 1.58e-03 | 2.70e-02 | 3.07e-03 | 1.23e-04 | 5.01e-02 |
| REGULATION OF SISTER CHROMATID COHESION | 15 | 3.39e-02 | 2.34e-01 | 0.2990 | -3.34e-02 | -1.14e-01 | 2.36e-02 | 2.16e-01 | 1.68e-01 | 8.23e-01 | 4.43e-01 | 8.74e-01 | 1.48e-01 | 2.60e-01 |
| STEROID HORMONE MEDIATED SIGNALING PATHWAY | 132 | 2.97e-02 | 2.16e-01 | 0.2990 | 1.57e-01 | 1.67e-01 | 1.20e-01 | 1.37e-01 | 6.47e-02 | 1.89e-03 | 9.09e-04 | 1.76e-02 | 6.72e-03 | 1.99e-01 |
| NATURAL KILLER CELL PROLIFERATION | 14 | 2.31e-01 | 6.33e-01 | 0.2990 | -1.40e-01 | -1.01e-01 | 5.33e-02 | -1.42e-01 | 1.91e-01 | 3.63e-01 | 5.13e-01 | 7.30e-01 | 3.56e-01 | 2.15e-01 |
| ANTIBACTERIAL INNATE IMMUNE RESPONSE | 6 | 2.81e-01 | 6.93e-01 | 0.2990 | -9.24e-02 | -1.07e-01 | -9.64e-03 | 2.08e-01 | 1.62e-01 | 6.95e-01 | 6.49e-01 | 9.67e-01 | 3.78e-01 | 4.91e-01 |
| NEGATIVE REGULATION OF ACTIVIN RECEPTOR SIGNALING PATHWAY | 14 | 2.10e-01 | 6.05e-01 | 0.2990 | -2.46e-01 | -1.31e-01 | -4.33e-02 | -1.59e-02 | 9.72e-02 | 1.11e-01 | 3.94e-01 | 7.79e-01 | 9.18e-01 | 5.29e-01 |
| CELL CELL ADHESION MEDIATED BY CADHERIN | 47 | 4.46e-01 | 8.17e-01 | 0.2990 | -1.15e-01 | -1.15e-01 | -1.57e-01 | -1.20e-01 | -1.54e-01 | 1.74e-01 | 1.72e-01 | 6.25e-02 | 1.53e-01 | 6.72e-02 |
| REGULATION OF ESTABLISHMENT OF T CELL POLARITY | 6 | 4.72e-01 | 8.30e-01 | 0.2990 | 2.44e-01 | 2.07e-02 | -7.20e-02 | 1.56e-01 | 6.75e-03 | 3.01e-01 | 9.30e-01 | 7.60e-01 | 5.08e-01 | 9.77e-01 |
| TYPE B PANCREATIC CELL APOPTOTIC PROCESS | 10 | 7.54e-01 | 9.51e-01 | 0.2990 | 1.04e-01 | 1.73e-01 | 1.44e-01 | 2.79e-02 | 1.65e-01 | 5.69e-01 | 3.44e-01 | 4.30e-01 | 8.79e-01 | 3.68e-01 |
| POSITIVE REGULATION OF PROGRAMMED NECROTIC CELL DEATH | 10 | 1.82e-01 | 5.67e-01 | 0.2990 | 1.64e-01 | -6.96e-02 | -7.90e-02 | 1.83e-01 | -1.34e-01 | 3.69e-01 | 7.03e-01 | 6.65e-01 | 3.17e-01 | 4.64e-01 |
| REGULATION OF TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 12 | 1.29e-01 | 4.87e-01 | 0.2990 | 2.50e-01 | 1.26e-01 | -5.15e-02 | 6.09e-02 | 6.72e-02 | 1.33e-01 | 4.51e-01 | 7.57e-01 | 7.15e-01 | 6.87e-01 |
| NEGATIVE REGULATION OF PERK MEDIATED UNFOLDED PROTEIN RESPONSE | 6 | 7.11e-01 | 9.35e-01 | 0.2990 | -1.85e-01 | -5.77e-02 | 8.03e-02 | -1.34e-01 | 1.65e-01 | 4.32e-01 | 8.07e-01 | 7.33e-01 | 5.71e-01 | 4.84e-01 |
| RESPONSE TO MANGANESE ION | 17 | 3.07e-01 | 7.19e-01 | 0.2990 | 1.28e-01 | 1.87e-01 | 4.69e-02 | 1.36e-01 | -1.31e-01 | 3.61e-01 | 1.81e-01 | 7.38e-01 | 3.33e-01 | 3.50e-01 |
| OLFACTORY LOBE DEVELOPMENT | 36 | 6.05e-01 | 9.01e-01 | 0.2990 | 8.16e-02 | 1.20e-01 | 1.68e-01 | 1.45e-01 | 1.38e-01 | 3.97e-01 | 2.15e-01 | 8.12e-02 | 1.33e-01 | 1.51e-01 |
| NEGATIVE REGULATION OF PROTEIN DEPHOSPHORYLATION | 28 | 5.38e-01 | 8.66e-01 | 0.2990 | 1.37e-01 | 9.15e-02 | 1.35e-01 | 2.01e-01 | 5.96e-02 | 2.10e-01 | 4.02e-01 | 2.17e-01 | 6.58e-02 | 5.85e-01 |
| PYRIMIDINE DEOXYRIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 11 | 4.68e-01 | 8.28e-01 | 0.2980 | 2.37e-01 | 1.63e-01 | -1.97e-02 | 6.52e-02 | -4.11e-02 | 1.73e-01 | 3.50e-01 | 9.10e-01 | 7.08e-01 | 8.14e-01 |
| RESPONSE TO ANTIBIOTIC | 36 | 2.93e-01 | 7.04e-01 | 0.2980 | 1.33e-01 | 1.30e-01 | 1.15e-01 | 2.01e-01 | 2.81e-02 | 1.67e-01 | 1.79e-01 | 2.32e-01 | 3.65e-02 | 7.70e-01 |
| NEURON PROJECTION MAINTENANCE | 11 | 8.95e-01 | 9.82e-01 | 0.2980 | 1.30e-01 | 1.35e-01 | 1.47e-01 | 1.79e-01 | -1.49e-02 | 4.54e-01 | 4.37e-01 | 4.00e-01 | 3.04e-01 | 9.32e-01 |
| REGULATION OF L GLUTAMATE IMPORT ACROSS PLASMA MEMBRANE | 8 | 6.10e-01 | 9.03e-01 | 0.2980 | 7.45e-02 | 8.32e-02 | 1.88e-01 | 1.87e-01 | -7.96e-02 | 7.15e-01 | 6.84e-01 | 3.58e-01 | 3.60e-01 | 6.97e-01 |
| POSITIVE REGULATION OF T CELL CYTOKINE PRODUCTION | 25 | 8.45e-01 | 9.76e-01 | 0.2980 | 1.39e-01 | 1.35e-01 | 1.56e-01 | 1.36e-01 | 9.21e-02 | 2.28e-01 | 2.42e-01 | 1.78e-01 | 2.39e-01 | 4.25e-01 |
| NEGATIVE REGULATION OF UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 48 | 9.28e-02 | 4.13e-01 | 0.2980 | 1.05e-01 | 6.50e-02 | 1.18e-01 | 2.03e-01 | 1.36e-01 | 2.10e-01 | 4.36e-01 | 1.56e-01 | 1.50e-02 | 1.04e-01 |
| NEGATIVE REGULATION OF CAMP MEDIATED SIGNALING | 11 | 7.76e-01 | 9.58e-01 | 0.2980 | 1.52e-01 | 6.60e-02 | 1.03e-01 | 2.19e-01 | 5.41e-02 | 3.84e-01 | 7.05e-01 | 5.55e-01 | 2.09e-01 | 7.56e-01 |
| PROTEIN LOCALIZATION TO CYTOPLASMIC STRESS GRANULE | 7 | 7.21e-01 | 9.40e-01 | 0.2980 | -8.82e-02 | -2.30e-01 | -1.62e-01 | -2.44e-02 | 3.28e-02 | 6.86e-01 | 2.92e-01 | 4.58e-01 | 9.11e-01 | 8.81e-01 |
| IN UTERO EMBRYONIC DEVELOPMENT | 383 | 1.34e-06 | 6.10e-05 | 0.2980 | 9.51e-02 | 1.12e-01 | 1.51e-01 | 1.48e-01 | 1.49e-01 | 1.40e-03 | 1.73e-04 | 3.85e-07 | 6.36e-07 | 5.27e-07 |
| HEMATOPOIETIC STEM CELL DIFFERENTIATION | 36 | 3.88e-01 | 7.81e-01 | 0.2980 | 5.23e-02 | 7.25e-02 | 1.43e-01 | 1.45e-01 | 1.98e-01 | 5.87e-01 | 4.52e-01 | 1.38e-01 | 1.33e-01 | 3.98e-02 |
| POSITIVE REGULATION OF NUCLEAR DIVISION | 60 | 3.03e-01 | 7.15e-01 | 0.2970 | 9.70e-02 | 9.92e-02 | 1.45e-01 | 1.49e-01 | 1.61e-01 | 1.94e-01 | 1.84e-01 | 5.13e-02 | 4.65e-02 | 3.07e-02 |
| REGULATION OF MONOATOMIC ANION TRANSPORT | 16 | 4.50e-01 | 8.20e-01 | 0.2970 | -8.55e-02 | -1.88e-01 | -1.61e-01 | -1.24e-01 | 6.54e-02 | 5.54e-01 | 1.93e-01 | 2.63e-01 | 3.89e-01 | 6.50e-01 |
| NEGATIVE REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 25 | 1.63e-01 | 5.41e-01 | 0.2970 | 1.28e-01 | 1.03e-01 | 9.00e-03 | 1.00e-01 | -2.27e-01 | 2.68e-01 | 3.73e-01 | 9.38e-01 | 3.84e-01 | 4.99e-02 |
| REGULATION OF COLLATERAL SPROUTING | 20 | 5.37e-01 | 8.66e-01 | 0.2970 | 1.99e-01 | 1.36e-01 | 5.46e-02 | 1.65e-01 | 2.14e-02 | 1.24e-01 | 2.94e-01 | 6.72e-01 | 2.02e-01 | 8.69e-01 |
| REGULATION OF MITOTIC CELL CYCLE PHASE TRANSITION | 343 | 5.43e-09 | 3.58e-07 | 0.2970 | 1.19e-01 | 8.74e-02 | 1.28e-01 | 1.91e-01 | 1.18e-01 | 1.55e-04 | 5.40e-03 | 4.79e-05 | 1.24e-09 | 1.67e-04 |
| RESPONSE TO BILE ACID | 7 | 6.33e-01 | 9.12e-01 | 0.2970 | -4.88e-03 | -9.93e-02 | -2.21e-01 | 8.34e-04 | -1.72e-01 | 9.82e-01 | 6.49e-01 | 3.11e-01 | 9.97e-01 | 4.30e-01 |
| REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 215 | 4.64e-03 | 5.84e-02 | 0.2970 | 1.52e-01 | 1.34e-01 | 1.43e-01 | 1.50e-01 | 6.72e-02 | 1.23e-04 | 7.39e-04 | 3.04e-04 | 1.46e-04 | 8.96e-02 |
| GLUTAMATE REUPTAKE | 6 | 5.24e-01 | 8.60e-01 | 0.2970 | -2.30e-01 | -1.13e-01 | 3.92e-02 | 6.36e-02 | 1.31e-01 | 3.30e-01 | 6.32e-01 | 8.68e-01 | 7.87e-01 | 5.77e-01 |
| MYELOID CELL HOMEOSTASIS | 166 | 1.30e-02 | 1.23e-01 | 0.2970 | 1.38e-01 | 1.32e-01 | 1.28e-01 | 1.51e-01 | 1.14e-01 | 2.13e-03 | 3.44e-03 | 4.58e-03 | 8.06e-04 | 1.12e-02 |
| INNER DYNEIN ARM ASSEMBLY | 16 | 4.18e-01 | 8.00e-01 | 0.2970 | -5.53e-02 | -3.51e-02 | 5.55e-02 | 4.66e-02 | 2.81e-01 | 7.02e-01 | 8.08e-01 | 7.01e-01 | 7.47e-01 | 5.19e-02 |
| PYRIMIDINE NUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 9 | 6.43e-01 | 9.15e-01 | 0.2970 | -6.96e-02 | -1.26e-01 | 3.36e-02 | 2.93e-02 | 2.56e-01 | 7.18e-01 | 5.12e-01 | 8.62e-01 | 8.79e-01 | 1.84e-01 |
| POSITIVE REGULATION OF BLOOD PRESSURE BY EPINEPHRINE NOREPINEPHRINE | 6 | 5.70e-01 | 8.83e-01 | 0.2970 | 1.96e-01 | 1.20e-01 | 3.92e-02 | -2.25e-04 | 1.84e-01 | 4.06e-01 | 6.09e-01 | 8.68e-01 | 9.99e-01 | 4.35e-01 |
| RESPONSE TO STIMULUS INVOLVED IN REGULATION OF MUSCLE ADAPTATION | 13 | 2.45e-01 | 6.50e-01 | 0.2970 | -1.23e-01 | -6.33e-03 | -7.30e-02 | -2.60e-01 | 6.24e-03 | 4.43e-01 | 9.69e-01 | 6.48e-01 | 1.04e-01 | 9.69e-01 |
| CHOLINE TRANSPORT | 9 | 9.48e-01 | 9.94e-01 | 0.2970 | -1.13e-01 | -1.15e-01 | -1.85e-01 | -1.20e-01 | -1.16e-01 | 5.57e-01 | 5.51e-01 | 3.37e-01 | 5.32e-01 | 5.47e-01 |
| AROMATIC AMINO ACID FAMILY CATABOLIC PROCESS | 16 | 5.65e-01 | 8.80e-01 | 0.2970 | -3.50e-02 | -3.28e-02 | -1.16e-01 | -1.71e-01 | -2.07e-01 | 8.08e-01 | 8.20e-01 | 4.22e-01 | 2.36e-01 | 1.51e-01 |
| CEREBRAL CORTEX DEVELOPMENT | 121 | 4.75e-02 | 2.86e-01 | 0.2970 | 1.41e-01 | 1.11e-01 | 1.48e-01 | 1.42e-01 | 1.16e-01 | 7.49e-03 | 3.45e-02 | 4.83e-03 | 6.88e-03 | 2.71e-02 |
| SYNAPTIC MEMBRANE ADHESION | 25 | 7.19e-02 | 3.63e-01 | 0.2970 | -2.31e-01 | -4.19e-02 | -4.91e-02 | -1.52e-01 | 8.44e-02 | 4.52e-02 | 7.17e-01 | 6.71e-01 | 1.88e-01 | 4.65e-01 |
| REGULATION OF INWARD RECTIFIER POTASSIUM CHANNEL ACTIVITY | 7 | 6.55e-01 | 9.20e-01 | 0.2970 | -6.91e-02 | -1.97e-01 | -1.30e-01 | -5.10e-02 | 1.57e-01 | 7.51e-01 | 3.66e-01 | 5.50e-01 | 8.15e-01 | 4.72e-01 |
| RESPONSE TO ACID CHEMICAL | 132 | 5.59e-03 | 6.68e-02 | 0.2970 | 6.64e-02 | 7.61e-02 | 1.54e-01 | 1.48e-01 | 1.78e-01 | 1.88e-01 | 1.31e-01 | 2.18e-03 | 3.22e-03 | 4.01e-04 |
| MRNA PSEUDOURIDINE SYNTHESIS | 8 | 7.73e-01 | 9.57e-01 | 0.2960 | -5.38e-02 | -7.33e-02 | 8.83e-02 | 4.01e-02 | 2.65e-01 | 7.92e-01 | 7.20e-01 | 6.65e-01 | 8.44e-01 | 1.94e-01 |
| KYNURENINE METABOLIC PROCESS | 11 | 6.22e-01 | 9.08e-01 | 0.2960 | 8.34e-03 | -1.28e-02 | -1.95e-01 | -1.57e-01 | -1.59e-01 | 9.62e-01 | 9.41e-01 | 2.63e-01 | 3.68e-01 | 3.63e-01 |
| REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 106 | 2.86e-02 | 2.10e-01 | 0.2960 | 1.85e-01 | 1.20e-01 | 1.08e-01 | 1.59e-01 | 4.84e-02 | 1.01e-03 | 3.23e-02 | 5.52e-02 | 4.74e-03 | 3.89e-01 |
| REGULATION OF SYNAPSE PRUNING | 6 | 4.49e-01 | 8.19e-01 | 0.2960 | 2.24e-01 | 1.45e-01 | -8.46e-02 | 8.67e-02 | 4.51e-02 | 3.43e-01 | 5.39e-01 | 7.20e-01 | 7.13e-01 | 8.48e-01 |
| CELLULAR RESPONSE TO PROSTAGLANDIN E STIMULUS | 15 | 8.44e-01 | 9.75e-01 | 0.2960 | 1.82e-01 | 1.32e-01 | 9.88e-02 | 1.34e-01 | 9.69e-02 | 2.24e-01 | 3.75e-01 | 5.08e-01 | 3.67e-01 | 5.16e-01 |
| DISACCHARIDE METABOLIC PROCESS | 11 | 5.81e-01 | 8.88e-01 | 0.2960 | -4.39e-02 | -6.85e-03 | -2.06e-01 | -1.37e-01 | -1.56e-01 | 8.01e-01 | 9.69e-01 | 2.36e-01 | 4.31e-01 | 3.71e-01 |
| SEMI LUNAR VALVE DEVELOPMENT | 47 | 2.53e-01 | 6.59e-01 | 0.2960 | 6.40e-02 | 1.31e-01 | 1.73e-01 | 8.77e-02 | 1.70e-01 | 4.48e-01 | 1.21e-01 | 4.04e-02 | 2.98e-01 | 4.41e-02 |
| MEMBRANE BIOGENESIS | 59 | 1.09e-01 | 4.51e-01 | 0.2960 | 6.30e-02 | 8.70e-02 | 1.85e-01 | 1.63e-01 | 1.23e-01 | 4.02e-01 | 2.48e-01 | 1.38e-02 | 3.02e-02 | 1.03e-01 |
| SKELETAL MYOFIBRIL ASSEMBLY | 10 | 8.44e-01 | 9.75e-01 | 0.2960 | -1.18e-01 | -1.06e-01 | -8.96e-02 | -1.75e-01 | -1.54e-01 | 5.17e-01 | 5.62e-01 | 6.24e-01 | 3.38e-01 | 3.99e-01 |
| FRUCTOSE METABOLIC PROCESS | 13 | 8.79e-01 | 9.79e-01 | 0.2960 | 7.63e-02 | 1.36e-01 | 1.37e-01 | 1.46e-01 | 1.52e-01 | 6.34e-01 | 3.97e-01 | 3.91e-01 | 3.61e-01 | 3.43e-01 |
| CELLULAR RESPONSE TO TESTOSTERONE STIMULUS | 9 | 5.69e-01 | 8.82e-01 | 0.2960 | 2.26e-01 | 9.47e-02 | -1.50e-02 | 1.65e-01 | -3.70e-03 | 2.40e-01 | 6.23e-01 | 9.38e-01 | 3.92e-01 | 9.85e-01 |
| UBIQUITIN INDEPENDENT PROTEIN CATABOLIC PROCESS VIA THE MULTIVESICULAR BODY SORTING PATHWAY | 5 | 8.88e-01 | 9.80e-01 | 0.2960 | 2.31e-01 | 6.90e-02 | 1.01e-01 | 1.39e-01 | 1.10e-02 | 3.72e-01 | 7.89e-01 | 6.95e-01 | 5.91e-01 | 9.66e-01 |
| OLIGODENDROCYTE DIFFERENTIATION | 102 | 1.77e-02 | 1.54e-01 | 0.2960 | 4.39e-02 | 1.09e-01 | 1.59e-01 | 1.17e-01 | 1.86e-01 | 4.44e-01 | 5.67e-02 | 5.47e-03 | 4.05e-02 | 1.19e-03 |
| REGULATION OF SREBP SIGNALING PATHWAY | 8 | 8.28e-01 | 9.72e-01 | 0.2960 | 8.88e-02 | 7.21e-02 | 2.01e-01 | 1.81e-01 | 3.74e-02 | 6.64e-01 | 7.24e-01 | 3.25e-01 | 3.76e-01 | 8.55e-01 |
| TOLL LIKE RECEPTOR 3 SIGNALING PATHWAY | 26 | 2.94e-01 | 7.05e-01 | 0.2960 | 2.16e-01 | 1.48e-01 | 8.04e-02 | 9.04e-02 | 6.22e-02 | 5.61e-02 | 1.90e-01 | 4.78e-01 | 4.25e-01 | 5.83e-01 |
| REGULATION OF CORE PROMOTER BINDING | 5 | 9.42e-01 | 9.92e-01 | 0.2960 | 1.30e-01 | 4.59e-02 | 1.59e-01 | 2.02e-01 | 4.72e-02 | 6.15e-01 | 8.59e-01 | 5.37e-01 | 4.34e-01 | 8.55e-01 |
| MRNA MODIFICATION | 31 | 4.78e-01 | 8.33e-01 | 0.2960 | 1.43e-01 | 9.48e-02 | 1.68e-01 | 1.35e-01 | 1.06e-01 | 1.67e-01 | 3.61e-01 | 1.05e-01 | 1.94e-01 | 3.06e-01 |
| PROTEIN LOCALIZATION TO CELL LEADING EDGE | 5 | 4.68e-01 | 8.28e-01 | 0.2950 | -2.20e-02 | 7.83e-02 | 1.06e-01 | 2.59e-01 | 4.59e-02 | 9.32e-01 | 7.62e-01 | 6.81e-01 | 3.15e-01 | 8.59e-01 |
| TOXIN TRANSPORT | 11 | 7.95e-01 | 9.65e-01 | 0.2950 | -1.15e-01 | -6.30e-02 | -1.85e-01 | -1.27e-01 | -1.40e-01 | 5.10e-01 | 7.17e-01 | 2.87e-01 | 4.67e-01 | 4.20e-01 |
| 10 FORMYLTETRAHYDROFOLATE METABOLIC PROCESS | 6 | 6.96e-01 | 9.31e-01 | 0.2950 | 1.97e-01 | 4.26e-02 | -9.59e-02 | 1.13e-01 | -1.58e-01 | 4.04e-01 | 8.57e-01 | 6.84e-01 | 6.32e-01 | 5.04e-01 |
| TAURINE METABOLIC PROCESS | 9 | 8.88e-01 | 9.80e-01 | 0.2950 | -1.16e-01 | -1.53e-01 | -1.55e-01 | -1.55e-01 | 4.76e-02 | 5.45e-01 | 4.27e-01 | 4.20e-01 | 4.22e-01 | 8.04e-01 |
| MHC CLASS II BIOSYNTHETIC PROCESS | 20 | 3.58e-02 | 2.43e-01 | 0.2950 | 1.90e-01 | 1.93e-01 | -6.59e-02 | 7.01e-02 | -6.58e-02 | 1.40e-01 | 1.35e-01 | 6.10e-01 | 5.87e-01 | 6.10e-01 |
| CRANIAL NERVE STRUCTURAL ORGANIZATION | 9 | 8.78e-01 | 9.79e-01 | 0.2950 | 1.23e-01 | 1.74e-01 | 1.75e-01 | 6.26e-02 | 8.59e-02 | 5.24e-01 | 3.67e-01 | 3.64e-01 | 7.45e-01 | 6.55e-01 |
| ACROSOMAL VESICLE EXOCYTOSIS | 9 | 9.40e-01 | 9.92e-01 | 0.2950 | -1.53e-01 | -1.24e-01 | -1.11e-01 | -1.89e-01 | -5.50e-03 | 4.27e-01 | 5.21e-01 | 5.63e-01 | 3.25e-01 | 9.77e-01 |
| MITOTIC CYTOKINESIS | 85 | 5.38e-02 | 3.07e-01 | 0.2950 | 1.73e-01 | 1.00e-01 | 1.28e-01 | 1.70e-01 | 3.79e-02 | 5.79e-03 | 1.09e-01 | 4.08e-02 | 6.62e-03 | 5.46e-01 |
| PROGRAMMED CELL DEATH INVOLVED IN CELL DEVELOPMENT | 24 | 7.55e-01 | 9.51e-01 | 0.2950 | -1.19e-01 | -1.19e-01 | -1.74e-01 | -1.21e-01 | -1.16e-01 | 3.11e-01 | 3.12e-01 | 1.39e-01 | 3.05e-01 | 3.27e-01 |
| POSITIVE REGULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR ACTIVITY | 5 | 4.10e-01 | 7.95e-01 | 0.2950 | -8.95e-03 | -8.18e-02 | -8.40e-02 | 1.90e-01 | -1.92e-01 | 9.72e-01 | 7.52e-01 | 7.45e-01 | 4.62e-01 | 4.56e-01 |
| ENDOPLASMIC RETICULUM CALCIUM ION HOMEOSTASIS | 25 | 7.02e-01 | 9.32e-01 | 0.2950 | 1.57e-01 | 1.51e-01 | 1.47e-01 | 1.32e-01 | -1.30e-02 | 1.73e-01 | 1.91e-01 | 2.03e-01 | 2.54e-01 | 9.10e-01 |
| REGULATION OF PROTEOLYSIS INVOLVED IN PROTEIN CATABOLIC PROCESS | 219 | 6.24e-04 | 1.21e-02 | 0.2950 | 1.28e-01 | 1.14e-01 | 1.28e-01 | 1.72e-01 | 1.07e-01 | 1.09e-03 | 3.74e-03 | 1.08e-03 | 1.14e-05 | 6.43e-03 |
| REGULATION OF PROTEIN LOCALIZATION TO SYNAPSE | 18 | 5.26e-01 | 8.60e-01 | 0.2950 | -1.64e-01 | -1.08e-01 | -7.13e-02 | -1.81e-01 | 1.01e-01 | 2.28e-01 | 4.28e-01 | 6.00e-01 | 1.84e-01 | 4.57e-01 |
| REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 18 | 7.99e-02 | 3.82e-01 | 0.2940 | 2.14e-01 | 1.57e-01 | -6.76e-02 | -2.19e-02 | -1.04e-01 | 1.15e-01 | 2.48e-01 | 6.20e-01 | 8.72e-01 | 4.43e-01 |
| REGULATION OF GLUCOCORTICOID BIOSYNTHETIC PROCESS | 9 | 9.36e-01 | 9.91e-01 | 0.2940 | 1.12e-01 | 6.04e-02 | 1.55e-01 | 1.63e-01 | 1.42e-01 | 5.62e-01 | 7.54e-01 | 4.22e-01 | 3.98e-01 | 4.61e-01 |
| POSITIVE REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 90 | 1.26e-01 | 4.82e-01 | 0.2940 | 1.20e-01 | 1.09e-01 | 1.47e-01 | 1.75e-01 | 9.08e-02 | 4.90e-02 | 7.38e-02 | 1.60e-02 | 4.18e-03 | 1.37e-01 |
| POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 62 | 2.75e-01 | 6.84e-01 | 0.2940 | 1.02e-01 | 1.22e-01 | 1.54e-01 | 1.70e-01 | 9.17e-02 | 1.67e-01 | 9.57e-02 | 3.55e-02 | 2.03e-02 | 2.12e-01 |
| CONNECTIVE TISSUE REPLACEMENT INVOLVED IN INFLAMMATORY RESPONSE WOUND HEALING | 6 | 9.33e-01 | 9.91e-01 | 0.2940 | -2.10e-01 | -1.29e-01 | -3.42e-02 | -1.44e-01 | 6.16e-02 | 3.72e-01 | 5.84e-01 | 8.85e-01 | 5.41e-01 | 7.94e-01 |
| TAURINE TRANSPORT | 8 | 8.68e-01 | 9.78e-01 | 0.2940 | 1.59e-01 | 1.28e-01 | 1.01e-01 | 7.51e-02 | 1.71e-01 | 4.38e-01 | 5.32e-01 | 6.22e-01 | 7.13e-01 | 4.01e-01 |
| REGULATION OF NEURON MIGRATION | 45 | 4.42e-01 | 8.13e-01 | 0.2940 | -1.16e-01 | -9.20e-02 | -1.40e-01 | -1.73e-01 | -1.22e-01 | 1.80e-01 | 2.86e-01 | 1.04e-01 | 4.41e-02 | 1.56e-01 |
| LENS FIBER CELL DIFFERENTIATION | 37 | 4.24e-01 | 8.03e-01 | 0.2940 | 1.35e-01 | 8.34e-02 | 1.18e-01 | 1.76e-01 | 1.27e-01 | 1.55e-01 | 3.80e-01 | 2.14e-01 | 6.34e-02 | 1.81e-01 |
| RESPONSE TO EPINEPHRINE | 14 | 7.48e-01 | 9.51e-01 | 0.2940 | -1.65e-01 | -1.24e-01 | -8.13e-02 | -1.71e-01 | 8.83e-02 | 2.84e-01 | 4.24e-01 | 5.98e-01 | 2.67e-01 | 5.67e-01 |
| RESPONSE TO GONADOTROPIN RELEASING HORMONE | 7 | 8.28e-01 | 9.72e-01 | 0.2940 | 2.02e-01 | 1.14e-01 | -2.94e-02 | 9.11e-02 | -1.52e-01 | 3.54e-01 | 6.01e-01 | 8.93e-01 | 6.76e-01 | 4.85e-01 |
| NUCLEOLAR CHROMATIN ORGANIZATION | 9 | 5.74e-01 | 8.84e-01 | 0.2940 | 2.79e-02 | -6.05e-03 | 4.24e-02 | 1.51e-01 | 2.47e-01 | 8.85e-01 | 9.75e-01 | 8.26e-01 | 4.32e-01 | 2.00e-01 |
| POSITIVE REGULATION OF MITOTIC CELL CYCLE PHASE TRANSITION | 93 | 1.98e-02 | 1.65e-01 | 0.2940 | 1.36e-01 | 8.10e-02 | 1.12e-01 | 1.76e-01 | 1.33e-01 | 2.35e-02 | 1.77e-01 | 6.23e-02 | 3.33e-03 | 2.64e-02 |
| REGULATION OF INFLAMMATORY RESPONSE TO WOUNDING | 12 | 5.59e-01 | 8.78e-01 | 0.2940 | -2.32e-01 | -1.11e-01 | -1.07e-01 | -9.33e-02 | 1.33e-02 | 1.65e-01 | 5.04e-01 | 5.23e-01 | 5.76e-01 | 9.36e-01 |
| POSITIVE REGULATION OF DNA METABOLIC PROCESS | 286 | 1.47e-05 | 5.28e-04 | 0.2940 | 1.11e-01 | 9.38e-02 | 1.35e-01 | 1.66e-01 | 1.39e-01 | 1.29e-03 | 6.31e-03 | 8.67e-05 | 1.35e-06 | 4.96e-05 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO VACUOLE | 63 | 1.25e-01 | 4.80e-01 | 0.2930 | 1.72e-01 | 1.24e-01 | 9.10e-02 | 1.79e-01 | 2.64e-02 | 1.79e-02 | 8.81e-02 | 2.11e-01 | 1.41e-02 | 7.17e-01 |
| NODAL SIGNALING PATHWAY | 16 | 3.53e-01 | 7.53e-01 | 0.2930 | -1.13e-01 | 2.26e-03 | 1.08e-01 | 5.94e-02 | 2.41e-01 | 4.33e-01 | 9.87e-01 | 4.54e-01 | 6.81e-01 | 9.53e-02 |
| DEADENYLATION DEPENDENT DECAPPING OF NUCLEAR TRANSCRIBED MRNA | 11 | 5.54e-02 | 3.12e-01 | 0.2930 | -1.07e-02 | -9.77e-02 | -3.71e-02 | 2.14e-01 | 1.71e-01 | 9.51e-01 | 5.75e-01 | 8.31e-01 | 2.20e-01 | 3.25e-01 |
| STEROID HORMONE SECRETION | 27 | 1.99e-01 | 5.88e-01 | 0.2930 | 2.17e-01 | 1.25e-01 | 2.21e-02 | 1.50e-01 | -1.13e-02 | 5.07e-02 | 2.63e-01 | 8.42e-01 | 1.76e-01 | 9.19e-01 |
| POSITIVE REGULATION OF TYPE I INTERFERON MEDIATED SIGNALING PATHWAY | 19 | 6.62e-01 | 9.22e-01 | 0.2930 | 4.34e-02 | 1.31e-01 | 1.36e-01 | 9.82e-02 | 1.96e-01 | 7.43e-01 | 3.22e-01 | 3.04e-01 | 4.58e-01 | 1.38e-01 |
| DIGESTION | 128 | 8.68e-04 | 1.56e-02 | 0.2930 | -8.36e-02 | -6.22e-02 | -1.69e-01 | -1.82e-01 | -1.15e-01 | 1.02e-01 | 2.24e-01 | 9.72e-04 | 3.69e-04 | 2.44e-02 |
| MEMBRANE FISSION | 42 | 1.58e-01 | 5.30e-01 | 0.2930 | 1.73e-01 | 6.96e-02 | 1.34e-01 | 1.56e-01 | 9.40e-02 | 5.20e-02 | 4.35e-01 | 1.33e-01 | 8.11e-02 | 2.92e-01 |
| VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL | 34 | 9.53e-02 | 4.19e-01 | 0.2930 | -8.78e-02 | -9.28e-02 | -1.39e-01 | -2.23e-01 | -1.91e-02 | 3.76e-01 | 3.49e-01 | 1.59e-01 | 2.45e-02 | 8.47e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE MIGRATION | 53 | 3.34e-01 | 7.40e-01 | 0.2930 | -7.70e-02 | -1.40e-01 | -1.70e-01 | -1.30e-01 | -1.19e-01 | 3.32e-01 | 7.71e-02 | 3.21e-02 | 1.00e-01 | 1.34e-01 |
| REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 98 | 7.54e-03 | 8.33e-02 | 0.2930 | 3.00e-02 | 4.66e-02 | 1.55e-01 | 1.30e-01 | 2.04e-01 | 6.07e-01 | 4.25e-01 | 8.03e-03 | 2.58e-02 | 4.77e-04 |
| HISTONE H3 ACETYLATION | 6 | 6.68e-01 | 9.24e-01 | 0.2930 | -9.49e-03 | 1.60e-03 | 3.72e-02 | 1.63e-01 | 2.40e-01 | 9.68e-01 | 9.95e-01 | 8.74e-01 | 4.89e-01 | 3.09e-01 |
| LUNG ASSOCIATED MESENCHYME DEVELOPMENT | 8 | 3.08e-01 | 7.19e-01 | 0.2930 | 1.20e-01 | 2.42e-02 | -1.43e-02 | 2.32e-01 | 1.30e-01 | 5.56e-01 | 9.06e-01 | 9.44e-01 | 2.57e-01 | 5.26e-01 |
| L SERINE CATABOLIC PROCESS | 5 | 1.31e-01 | 4.91e-01 | 0.2930 | -7.91e-02 | 2.06e-02 | 7.10e-03 | 2.62e-01 | -1.01e-01 | 7.59e-01 | 9.36e-01 | 9.78e-01 | 3.10e-01 | 6.96e-01 |
| REGULATION OF GAMMA DELTA T CELL ACTIVATION | 11 | 8.98e-01 | 9.82e-01 | 0.2930 | 7.84e-02 | 1.33e-01 | 1.94e-01 | 1.05e-01 | 1.13e-01 | 6.53e-01 | 4.43e-01 | 2.64e-01 | 5.47e-01 | 5.15e-01 |
| PROSTHETIC GROUP METABOLIC PROCESS | 6 | 4.83e-01 | 8.37e-01 | 0.2930 | 1.32e-01 | 6.06e-02 | 1.34e-01 | -3.27e-02 | 2.13e-01 | 5.75e-01 | 7.97e-01 | 5.68e-01 | 8.90e-01 | 3.67e-01 |
| REGULATION OF RENAL SODIUM EXCRETION | 8 | 9.50e-01 | 9.94e-01 | 0.2930 | 1.23e-01 | 9.35e-02 | 1.80e-01 | 1.54e-01 | 7.43e-02 | 5.49e-01 | 6.47e-01 | 3.77e-01 | 4.50e-01 | 7.16e-01 |
| THYROID HORMONE GENERATION | 22 | 4.90e-01 | 8.41e-01 | 0.2930 | -1.54e-01 | -8.29e-02 | -1.65e-01 | -1.67e-01 | -1.35e-02 | 2.12e-01 | 5.01e-01 | 1.81e-01 | 1.76e-01 | 9.13e-01 |
| HEART FIELD SPECIFICATION | 17 | 3.62e-01 | 7.62e-01 | 0.2930 | -5.89e-02 | -6.64e-02 | 7.77e-02 | -1.19e-03 | 2.68e-01 | 6.74e-01 | 6.36e-01 | 5.79e-01 | 9.93e-01 | 5.60e-02 |
| APICAL PROTEIN LOCALIZATION | 14 | 4.70e-01 | 8.30e-01 | 0.2920 | -1.14e-01 | -1.31e-01 | -1.25e-01 | -1.16e-01 | 1.62e-01 | 4.61e-01 | 3.97e-01 | 4.17e-01 | 4.53e-01 | 2.93e-01 |
| PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA SIGNALING PATHWAY | 14 | 1.47e-01 | 5.15e-01 | 0.2920 | 1.02e-01 | 2.67e-01 | 5.50e-02 | -1.18e-02 | 2.36e-02 | 5.09e-01 | 8.37e-02 | 7.22e-01 | 9.39e-01 | 8.79e-01 |
| POSITIVE REGULATION OF CATECHOLAMINE SECRETION | 12 | 2.62e-01 | 6.70e-01 | 0.2920 | -3.55e-02 | -9.64e-03 | 9.77e-02 | -9.20e-02 | 2.57e-01 | 8.32e-01 | 9.54e-01 | 5.58e-01 | 5.81e-01 | 1.23e-01 |
| VENTRICULAR CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 27 | 1.63e-01 | 5.40e-01 | 0.2920 | -1.57e-01 | -7.80e-02 | -6.92e-02 | -2.15e-01 | 5.77e-02 | 1.57e-01 | 4.83e-01 | 5.34e-01 | 5.28e-02 | 6.04e-01 |
| FUCOSE METABOLIC PROCESS | 16 | 8.04e-01 | 9.67e-01 | 0.2920 | -1.71e-01 | -1.62e-01 | -1.33e-01 | -8.67e-02 | -6.76e-02 | 2.36e-01 | 2.61e-01 | 3.58e-01 | 5.48e-01 | 6.40e-01 |
| OXYGEN METABOLIC PROCESS | 5 | 6.33e-01 | 9.12e-01 | 0.2920 | -9.09e-02 | -2.44e-01 | -3.53e-02 | -1.27e-01 | -3.81e-03 | 7.25e-01 | 3.44e-01 | 8.91e-01 | 6.24e-01 | 9.88e-01 |
| HEAD MORPHOGENESIS | 35 | 1.83e-01 | 5.70e-01 | 0.2920 | 4.51e-02 | 8.16e-02 | 1.31e-01 | 1.82e-01 | 1.62e-01 | 6.44e-01 | 4.04e-01 | 1.79e-01 | 6.23e-02 | 9.74e-02 |
| REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 24 | 1.80e-01 | 5.63e-01 | 0.2920 | -8.18e-02 | -2.33e-02 | 1.47e-01 | 9.35e-02 | 2.18e-01 | 4.88e-01 | 8.43e-01 | 2.13e-01 | 4.28e-01 | 6.42e-02 |
| RESPONSE TO OSMOTIC STRESS | 79 | 2.11e-01 | 6.06e-01 | 0.2920 | 1.58e-01 | 1.58e-01 | 1.21e-01 | 1.22e-01 | 7.60e-02 | 1.50e-02 | 1.51e-02 | 6.35e-02 | 6.16e-02 | 2.43e-01 |
| EXPLORATION BEHAVIOR | 28 | 6.02e-01 | 9.00e-01 | 0.2920 | -1.74e-01 | -1.40e-01 | -8.79e-02 | -1.66e-01 | 3.32e-03 | 1.12e-01 | 2.00e-01 | 4.21e-01 | 1.27e-01 | 9.76e-01 |
| REGULATION OF DNA CATABOLIC PROCESS | 11 | 6.23e-01 | 9.08e-01 | 0.2920 | 1.35e-02 | 3.90e-02 | 1.02e-01 | 1.77e-01 | 2.04e-01 | 9.38e-01 | 8.23e-01 | 5.58e-01 | 3.09e-01 | 2.41e-01 |
| LATERAL VENTRICLE DEVELOPMENT | 12 | 8.49e-01 | 9.76e-01 | 0.2920 | 1.32e-01 | 1.85e-01 | 1.27e-01 | 6.83e-02 | 1.12e-01 | 4.28e-01 | 2.67e-01 | 4.46e-01 | 6.82e-01 | 5.00e-01 |
| POSITIVE REGULATION OF MEMBRANE PERMEABILITY | 49 | 2.26e-01 | 6.28e-01 | 0.2920 | 5.26e-02 | 9.62e-02 | 1.83e-01 | 1.48e-01 | 1.33e-01 | 5.24e-01 | 2.44e-01 | 2.68e-02 | 7.37e-02 | 1.07e-01 |
| REGULATION OF PROTEIN CATABOLIC PROCESS | 340 | 3.97e-06 | 1.64e-04 | 0.2920 | 1.25e-01 | 1.14e-01 | 1.25e-01 | 1.67e-01 | 1.14e-01 | 7.56e-05 | 3.14e-04 | 7.26e-05 | 1.26e-07 | 3.00e-04 |
| ERK5 CASCADE | 5 | 7.93e-01 | 9.65e-01 | 0.2910 | -6.79e-02 | -1.29e-01 | -1.38e-01 | -9.94e-02 | 1.86e-01 | 7.93e-01 | 6.17e-01 | 5.93e-01 | 7.00e-01 | 4.71e-01 |
| TETRAHYDROFOLATE METABOLIC PROCESS | 15 | 2.10e-01 | 6.05e-01 | 0.2910 | 1.77e-01 | 3.78e-02 | 1.45e-02 | 2.27e-01 | 2.44e-02 | 2.36e-01 | 8.00e-01 | 9.22e-01 | 1.29e-01 | 8.70e-01 |
| SKELETAL MUSCLE ORGAN DEVELOPMENT | 169 | 9.92e-04 | 1.75e-02 | 0.2910 | 5.76e-02 | 8.56e-02 | 1.56e-01 | 1.11e-01 | 1.93e-01 | 1.97e-01 | 5.47e-02 | 4.49e-04 | 1.27e-02 | 1.46e-05 |
| CENTROSOME DUPLICATION | 74 | 1.78e-01 | 5.63e-01 | 0.2910 | 1.67e-01 | 1.17e-01 | 1.21e-01 | 1.67e-01 | 2.84e-02 | 1.31e-02 | 8.24e-02 | 7.18e-02 | 1.31e-02 | 6.73e-01 |
| REGULATION OF NUCLEOTIDE BIOSYNTHETIC PROCESS | 28 | 2.75e-01 | 6.84e-01 | 0.2910 | -1.68e-01 | -1.21e-01 | -3.92e-02 | -1.15e-01 | 1.64e-01 | 1.23e-01 | 2.67e-01 | 7.20e-01 | 2.92e-01 | 1.34e-01 |
| PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 124 | 3.21e-02 | 2.27e-01 | 0.2910 | 8.72e-02 | 9.32e-02 | 1.56e-01 | 1.53e-01 | 1.43e-01 | 9.34e-02 | 7.31e-02 | 2.63e-03 | 3.31e-03 | 5.82e-03 |
| MIRNA CATABOLIC PROCESS | 18 | 8.98e-01 | 9.82e-01 | 0.2910 | 1.07e-01 | 1.20e-01 | 1.63e-01 | 1.58e-01 | 8.49e-02 | 4.32e-01 | 3.80e-01 | 2.32e-01 | 2.45e-01 | 5.33e-01 |
| POSITIVE REGULATION OF MONOCYTE CHEMOTAXIS | 20 | 1.91e-03 | 2.93e-02 | 0.2910 | -2.58e-02 | 1.99e-01 | -2.35e-02 | -2.01e-01 | -5.73e-02 | 8.42e-01 | 1.24e-01 | 8.56e-01 | 1.19e-01 | 6.57e-01 |
| VESICLE ORGANIZATION | 351 | 6.70e-05 | 1.99e-03 | 0.2910 | 1.35e-01 | 1.22e-01 | 1.43e-01 | 1.57e-01 | 7.76e-02 | 1.38e-05 | 8.53e-05 | 3.85e-06 | 3.94e-07 | 1.25e-02 |
| CELLULAR RESPONSE TO STARVATION | 171 | 1.95e-03 | 2.98e-02 | 0.2900 | 1.10e-01 | 1.06e-01 | 1.35e-01 | 1.80e-01 | 1.02e-01 | 1.33e-02 | 1.64e-02 | 2.31e-03 | 4.84e-05 | 2.17e-02 |
| RESPONSE TO LEPTIN | 21 | 6.49e-01 | 9.17e-01 | 0.2900 | 1.24e-01 | 1.15e-01 | 1.37e-01 | 8.23e-02 | 1.74e-01 | 3.24e-01 | 3.63e-01 | 2.79e-01 | 5.14e-01 | 1.68e-01 |
| POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 149 | 5.93e-02 | 3.22e-01 | 0.2900 | 1.35e-01 | 1.32e-01 | 1.41e-01 | 1.39e-01 | 9.57e-02 | 4.37e-03 | 5.29e-03 | 2.89e-03 | 3.46e-03 | 4.37e-02 |
| DIACYLGLYCEROL BIOSYNTHETIC PROCESS | 9 | 3.44e-01 | 7.50e-01 | 0.2900 | -1.55e-02 | 1.54e-01 | -7.08e-02 | -1.42e-01 | -1.87e-01 | 9.36e-01 | 4.24e-01 | 7.13e-01 | 4.61e-01 | 3.30e-01 |
| HARD PALATE DEVELOPMENT | 8 | 7.33e-01 | 9.46e-01 | 0.2900 | -8.49e-02 | -4.78e-02 | 2.02e-02 | -7.22e-02 | 2.63e-01 | 6.77e-01 | 8.15e-01 | 9.21e-01 | 7.24e-01 | 1.98e-01 |
| CHIASMA ASSEMBLY | 6 | 8.19e-01 | 9.70e-01 | 0.2900 | 2.14e-01 | 1.73e-01 | 6.46e-02 | 1.53e-02 | -6.24e-02 | 3.63e-01 | 4.64e-01 | 7.84e-01 | 9.48e-01 | 7.91e-01 |
| DNA METHYLATION | 47 | 1.91e-01 | 5.78e-01 | 0.2900 | 1.31e-01 | 9.84e-02 | 9.47e-02 | 1.64e-01 | 1.46e-01 | 1.20e-01 | 2.43e-01 | 2.61e-01 | 5.17e-02 | 8.25e-02 |
| POSITIVE REGULATION OF ORGANELLE ASSEMBLY | 82 | 7.73e-02 | 3.77e-01 | 0.2900 | 1.34e-01 | 1.34e-01 | 1.18e-01 | 1.81e-01 | 3.93e-02 | 3.57e-02 | 3.60e-02 | 6.58e-02 | 4.56e-03 | 5.39e-01 |
| REGULATION OF I KAPPAB PHOSPHORYLATION | 8 | 5.99e-01 | 8.98e-01 | 0.2900 | 1.20e-01 | 1.68e-01 | -7.11e-02 | -5.24e-02 | -1.84e-01 | 5.58e-01 | 4.10e-01 | 7.27e-01 | 7.97e-01 | 3.68e-01 |
| REGULATION OF LIPOPROTEIN METABOLIC PROCESS | 17 | 7.98e-01 | 9.66e-01 | 0.2900 | 1.59e-01 | 1.81e-01 | 1.04e-01 | 1.12e-01 | -5.07e-02 | 2.57e-01 | 1.95e-01 | 4.59e-01 | 4.23e-01 | 7.18e-01 |
| RRNA CATABOLIC PROCESS | 21 | 8.76e-01 | 9.78e-01 | 0.2900 | 1.09e-01 | 1.16e-01 | 1.36e-01 | 1.47e-01 | 1.36e-01 | 3.88e-01 | 3.59e-01 | 2.79e-01 | 2.43e-01 | 2.79e-01 |
| REGULATION OF ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 64 | 1.12e-01 | 4.55e-01 | 0.2900 | 8.93e-02 | 1.07e-01 | 1.66e-01 | 1.80e-01 | 6.74e-02 | 2.17e-01 | 1.38e-01 | 2.15e-02 | 1.27e-02 | 3.51e-01 |
| GLOMERULAR EPITHELIUM DEVELOPMENT | 24 | 2.87e-01 | 6.95e-01 | 0.2900 | -1.30e-01 | -1.21e-01 | -1.47e-01 | -1.40e-01 | 1.06e-01 | 2.69e-01 | 3.03e-01 | 2.13e-01 | 2.36e-01 | 3.70e-01 |
| CELLULAR PIGMENTATION | 60 | 3.92e-01 | 7.83e-01 | 0.2900 | 1.60e-01 | 1.47e-01 | 1.29e-01 | 1.42e-01 | 1.29e-02 | 3.22e-02 | 4.93e-02 | 8.51e-02 | 5.65e-02 | 8.63e-01 |
| HEPATOCYTE DIFFERENTIATION | 15 | 1.26e-01 | 4.82e-01 | 0.2900 | 1.17e-01 | -6.31e-02 | 2.28e-02 | 1.54e-01 | 2.05e-01 | 4.32e-01 | 6.72e-01 | 8.78e-01 | 3.01e-01 | 1.69e-01 |
| REGULATION OF BILE ACID SECRETION | 6 | 7.96e-01 | 9.65e-01 | 0.2900 | 2.02e-01 | 9.64e-02 | -7.32e-02 | 1.62e-02 | -1.69e-01 | 3.92e-01 | 6.83e-01 | 7.56e-01 | 9.45e-01 | 4.75e-01 |
| GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR PRODUCTION | 18 | 4.65e-02 | 2.82e-01 | 0.2900 | 1.20e-01 | 1.87e-01 | -6.73e-02 | -1.12e-01 | -1.33e-01 | 3.80e-01 | 1.71e-01 | 6.21e-01 | 4.12e-01 | 3.27e-01 |
| MISMATCH REPAIR | 34 | 5.26e-01 | 8.60e-01 | 0.2900 | 5.99e-02 | 7.79e-02 | 1.61e-01 | 1.48e-01 | 1.62e-01 | 5.45e-01 | 4.32e-01 | 1.04e-01 | 1.34e-01 | 1.02e-01 |
| GERM CELL MIGRATION | 8 | 8.04e-01 | 9.67e-01 | 0.2890 | 1.87e-01 | 5.15e-02 | 6.19e-02 | 1.99e-01 | 5.38e-02 | 3.60e-01 | 8.01e-01 | 7.62e-01 | 3.30e-01 | 7.92e-01 |
| RIBOFLAVIN TRANSPORT | 6 | 4.60e-01 | 8.23e-01 | 0.2890 | -1.70e-01 | -2.67e-02 | 4.94e-02 | -2.15e-01 | -7.37e-02 | 4.70e-01 | 9.10e-01 | 8.34e-01 | 3.62e-01 | 7.55e-01 |
| NUCLEOLAR LARGE RRNA TRANSCRIPTION BY RNA POLYMERASE I | 21 | 5.16e-01 | 8.56e-01 | 0.2890 | -1.19e-02 | 2.60e-02 | 1.23e-01 | 9.17e-02 | 2.44e-01 | 9.25e-01 | 8.37e-01 | 3.30e-01 | 4.67e-01 | 5.32e-02 |
| RESPONSE TO RETINOIC ACID | 105 | 5.85e-02 | 3.19e-01 | 0.2890 | 9.93e-02 | 1.27e-01 | 1.32e-01 | 1.17e-01 | 1.63e-01 | 7.88e-02 | 2.49e-02 | 1.94e-02 | 3.86e-02 | 3.80e-03 |
| DNA METHYLATION ON CYTOSINE | 6 | 9.47e-01 | 9.94e-01 | 0.2890 | 4.52e-02 | 1.17e-01 | 1.12e-01 | 9.69e-02 | 2.15e-01 | 8.48e-01 | 6.19e-01 | 6.36e-01 | 6.81e-01 | 3.62e-01 |
| LIPOPROTEIN BIOSYNTHETIC PROCESS | 91 | 1.48e-01 | 5.15e-01 | 0.2890 | 1.28e-01 | 1.21e-01 | 1.35e-01 | 1.71e-01 | 7.23e-02 | 3.54e-02 | 4.68e-02 | 2.62e-02 | 4.69e-03 | 2.33e-01 |
| EMBRYONIC MORPHOGENESIS | 604 | 6.61e-12 | 6.30e-10 | 0.2890 | 6.90e-02 | 1.04e-01 | 1.49e-01 | 1.30e-01 | 1.70e-01 | 3.75e-03 | 1.32e-05 | 3.98e-10 | 4.41e-08 | 1.02e-12 |
| MEMBRANE DISASSEMBLY | 11 | 4.11e-01 | 7.95e-01 | 0.2890 | 1.90e-01 | 4.79e-02 | -6.46e-02 | -2.21e-02 | -2.01e-01 | 2.75e-01 | 7.83e-01 | 7.11e-01 | 8.99e-01 | 2.48e-01 |
| BRANCHING INVOLVED IN LABYRINTHINE LAYER MORPHOGENESIS | 13 | 8.97e-01 | 9.82e-01 | 0.2890 | 6.91e-02 | 1.35e-01 | 1.38e-01 | 1.14e-01 | 1.68e-01 | 6.66e-01 | 3.98e-01 | 3.88e-01 | 4.77e-01 | 2.94e-01 |
| SEBACEOUS GLAND DEVELOPMENT | 10 | 8.54e-01 | 9.76e-01 | 0.2890 | -7.75e-02 | -8.75e-02 | -1.45e-01 | -5.87e-02 | -2.13e-01 | 6.71e-01 | 6.32e-01 | 4.27e-01 | 7.48e-01 | 2.44e-01 |
| NADH OXIDATION | 6 | 3.09e-01 | 7.21e-01 | 0.2890 | 4.51e-02 | 5.96e-02 | -1.13e-01 | -1.26e-01 | 2.22e-01 | 8.48e-01 | 8.01e-01 | 6.32e-01 | 5.94e-01 | 3.46e-01 |
| MEMBRANE REPOLARIZATION | 52 | 3.90e-02 | 2.55e-01 | 0.2890 | -1.46e-01 | -4.69e-02 | -1.28e-01 | -2.04e-01 | -3.95e-02 | 6.77e-02 | 5.59e-01 | 1.11e-01 | 1.08e-02 | 6.22e-01 |
| NEGATIVE REGULATION OF ADENYLATE CYCLASE ACTIVATING ADRENERGIC RECEPTOR SIGNALING PATHWAY | 6 | 8.05e-01 | 9.67e-01 | 0.2890 | -2.29e-01 | -9.03e-02 | -1.04e-01 | -9.44e-02 | 5.64e-02 | 3.32e-01 | 7.02e-01 | 6.60e-01 | 6.89e-01 | 8.11e-01 |
| REGULATION OF POSTSYNAPTIC DENSITY ORGANIZATION | 14 | 8.80e-01 | 9.79e-01 | 0.2880 | -1.80e-01 | -1.27e-01 | -9.02e-02 | -1.62e-01 | 1.56e-02 | 2.43e-01 | 4.10e-01 | 5.59e-01 | 2.95e-01 | 9.19e-01 |
| POSITIVE REGULATION OF NON CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 65 | 4.66e-03 | 5.84e-02 | 0.2880 | 2.03e-01 | 1.73e-01 | 2.82e-02 | 1.06e-01 | 1.16e-02 | 4.70e-03 | 1.58e-02 | 6.94e-01 | 1.41e-01 | 8.72e-01 |
| REGULATION OF ORGANELLE ASSEMBLY | 232 | 2.70e-03 | 3.88e-02 | 0.2880 | 1.41e-01 | 1.20e-01 | 1.30e-01 | 1.58e-01 | 8.38e-02 | 2.06e-04 | 1.61e-03 | 6.75e-04 | 3.38e-05 | 2.79e-02 |
| REGULATION OF ASTROCYTE DIFFERENTIATION | 31 | 6.91e-01 | 9.31e-01 | 0.2880 | 7.17e-02 | 1.13e-01 | 1.58e-01 | 1.21e-01 | 1.60e-01 | 4.89e-01 | 2.76e-01 | 1.27e-01 | 2.44e-01 | 1.23e-01 |
| NEGATIVE REGULATION OF RNA CATABOLIC PROCESS | 78 | 3.47e-02 | 2.37e-01 | 0.2880 | 1.89e-01 | 9.91e-02 | 9.19e-02 | 1.59e-01 | 6.24e-02 | 3.90e-03 | 1.30e-01 | 1.61e-01 | 1.54e-02 | 3.41e-01 |
| REGULATION OF MATRIX METALLOPEPTIDASE SECRETION | 10 | 6.41e-01 | 9.14e-01 | 0.2880 | 2.35e-01 | 1.26e-01 | 1.01e-02 | 1.08e-01 | 1.31e-02 | 1.98e-01 | 4.91e-01 | 9.56e-01 | 5.53e-01 | 9.43e-01 |
| D ASPARTATE IMPORT ACROSS PLASMA MEMBRANE | 5 | 8.86e-01 | 9.80e-01 | 0.2880 | 8.95e-03 | 6.34e-02 | 1.14e-01 | 1.88e-01 | 1.75e-01 | 9.72e-01 | 8.06e-01 | 6.60e-01 | 4.66e-01 | 4.98e-01 |
| NEGATIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 12 | 7.26e-01 | 9.43e-01 | 0.2880 | 1.19e-01 | 6.52e-02 | 1.80e-01 | 1.77e-01 | 2.66e-02 | 4.74e-01 | 6.96e-01 | 2.81e-01 | 2.87e-01 | 8.73e-01 |
| RESPONSE TO WATER DEPRIVATION | 5 | 9.48e-01 | 9.94e-01 | 0.2880 | 2.99e-02 | 1.07e-02 | 1.16e-01 | 1.61e-01 | 2.06e-01 | 9.08e-01 | 9.67e-01 | 6.53e-01 | 5.33e-01 | 4.24e-01 |
| RETROGRADE VESICLE MEDIATED TRANSPORT GOLGI TO ENDOPLASMIC RETICULUM | 51 | 1.81e-01 | 5.66e-01 | 0.2880 | 8.93e-02 | 1.05e-01 | 1.41e-01 | 1.90e-01 | 8.89e-02 | 2.70e-01 | 1.95e-01 | 8.19e-02 | 1.88e-02 | 2.72e-01 |
| REGULATION OF TRANSLATIONAL INITIATION | 76 | 1.72e-01 | 5.56e-01 | 0.2880 | 1.39e-01 | 1.07e-01 | 1.18e-01 | 1.43e-01 | 1.33e-01 | 3.61e-02 | 1.05e-01 | 7.61e-02 | 3.12e-02 | 4.51e-02 |
| CHRONIC INFLAMMATORY RESPONSE | 18 | 3.09e-01 | 7.20e-01 | 0.2880 | -1.55e-02 | -5.36e-02 | -1.63e-01 | -5.27e-03 | -2.30e-01 | 9.09e-01 | 6.94e-01 | 2.31e-01 | 9.69e-01 | 9.05e-02 |
| PLATELET DENSE GRANULE ORGANIZATION | 24 | 7.69e-01 | 9.55e-01 | 0.2880 | 1.36e-01 | 1.55e-01 | 1.11e-01 | 1.22e-01 | 1.14e-01 | 2.50e-01 | 1.90e-01 | 3.45e-01 | 3.00e-01 | 3.33e-01 |
| DOPAMINE BIOSYNTHETIC PROCESS | 12 | 7.08e-01 | 9.34e-01 | 0.2880 | 4.68e-02 | 1.09e-01 | 1.98e-01 | 1.64e-01 | 4.97e-02 | 7.79e-01 | 5.12e-01 | 2.35e-01 | 3.25e-01 | 7.66e-01 |
| REGULATION OF TELOMERASE ACTIVITY | 48 | 1.52e-01 | 5.21e-01 | 0.2880 | 1.04e-01 | 1.11e-01 | 1.28e-01 | 1.99e-01 | 5.77e-02 | 2.12e-01 | 1.82e-01 | 1.26e-01 | 1.68e-02 | 4.89e-01 |
| NONRIBOSOMAL PEPTIDE BIOSYNTHETIC PROCESS | 17 | 5.29e-01 | 8.62e-01 | 0.2880 | 1.23e-01 | 5.66e-02 | 1.18e-01 | 2.22e-01 | 3.22e-02 | 3.78e-01 | 6.86e-01 | 3.99e-01 | 1.13e-01 | 8.18e-01 |
| INTERLEUKIN 4 MEDIATED SIGNALING PATHWAY | 9 | 5.33e-01 | 8.64e-01 | 0.2870 | 8.26e-02 | 7.76e-02 | -1.62e-01 | -3.74e-02 | -2.05e-01 | 6.68e-01 | 6.87e-01 | 4.01e-01 | 8.46e-01 | 2.86e-01 |
| NEGATIVE REGULATION OF LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 14 | 7.40e-01 | 9.49e-01 | 0.2870 | 3.80e-02 | 1.44e-01 | 1.61e-01 | 1.43e-01 | 1.18e-01 | 8.06e-01 | 3.50e-01 | 2.97e-01 | 3.55e-01 | 4.44e-01 |
| GLIAL CELL ACTIVATION | 57 | 1.70e-01 | 5.54e-01 | 0.2870 | 1.45e-01 | 1.71e-01 | 1.05e-01 | 1.39e-01 | -4.17e-02 | 5.75e-02 | 2.57e-02 | 1.69e-01 | 6.86e-02 | 5.86e-01 |
| PYRIMIDINE NUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 20 | 5.90e-01 | 8.93e-01 | 0.2870 | 2.00e-01 | 1.74e-01 | 5.57e-02 | 9.64e-02 | -1.20e-02 | 1.22e-01 | 1.79e-01 | 6.66e-01 | 4.56e-01 | 9.26e-01 |
| MAINTENANCE OF CELL NUMBER | 179 | 5.18e-04 | 1.04e-02 | 0.2870 | 8.34e-02 | 9.55e-02 | 1.21e-01 | 1.29e-01 | 1.87e-01 | 5.41e-02 | 2.75e-02 | 5.31e-03 | 2.95e-03 | 1.51e-05 |
| PYRIMIDINE NUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 8 | 4.44e-01 | 8.14e-01 | 0.2870 | 2.29e-01 | 1.49e-01 | -5.21e-02 | -2.78e-02 | -6.62e-02 | 2.63e-01 | 4.66e-01 | 7.98e-01 | 8.92e-01 | 7.46e-01 |
| APPENDAGE MORPHOGENESIS | 142 | 3.02e-02 | 2.18e-01 | 0.2870 | 8.97e-02 | 1.14e-01 | 1.48e-01 | 1.24e-01 | 1.54e-01 | 6.49e-02 | 1.91e-02 | 2.31e-03 | 1.05e-02 | 1.48e-03 |
| POSITIVE REGULATION OF INTERLEUKIN 6 PRODUCTION | 97 | 8.17e-04 | 1.49e-02 | 0.2870 | 1.80e-01 | 1.98e-01 | 8.12e-02 | 5.24e-02 | -3.74e-02 | 2.17e-03 | 7.67e-04 | 1.67e-01 | 3.73e-01 | 5.25e-01 |
| PYRIDINE CONTAINING COMPOUND METABOLIC PROCESS | 83 | 1.81e-01 | 5.65e-01 | 0.2870 | 1.23e-01 | 1.61e-01 | 1.26e-01 | 1.30e-01 | 9.23e-02 | 5.34e-02 | 1.14e-02 | 4.70e-02 | 4.00e-02 | 1.46e-01 |
| REGULATION OF HYPERSENSITIVITY | 9 | 7.72e-02 | 3.77e-01 | 0.2870 | -2.38e-01 | -1.43e-02 | -2.58e-02 | 4.02e-02 | 1.52e-01 | 2.17e-01 | 9.41e-01 | 8.93e-01 | 8.35e-01 | 4.28e-01 |
| REGULATION OF CHROMATIN BINDING | 11 | 3.37e-01 | 7.43e-01 | 0.2870 | 1.38e-01 | -3.82e-02 | 5.76e-02 | 2.31e-01 | 6.98e-02 | 4.29e-01 | 8.26e-01 | 7.41e-01 | 1.84e-01 | 6.89e-01 |
| FIBROBLAST ACTIVATION | 15 | 5.31e-01 | 8.63e-01 | 0.2870 | 1.57e-01 | 1.85e-01 | 1.57e-02 | 5.34e-02 | -1.42e-01 | 2.92e-01 | 2.15e-01 | 9.16e-01 | 7.20e-01 | 3.41e-01 |
| CELLULAR RESPONSE TO RETINOIC ACID | 67 | 3.21e-01 | 7.32e-01 | 0.2860 | 9.86e-02 | 1.31e-01 | 1.45e-01 | 1.14e-01 | 1.45e-01 | 1.63e-01 | 6.29e-02 | 3.97e-02 | 1.07e-01 | 4.04e-02 |
| SYNAPTIC VESICLE BUDDING | 10 | 7.51e-01 | 9.51e-01 | 0.2860 | 1.90e-01 | 1.12e-01 | 7.23e-02 | 9.36e-02 | 1.39e-01 | 2.98e-01 | 5.38e-01 | 6.92e-01 | 6.08e-01 | 4.48e-01 |
| PYRAMIDAL NEURON DEVELOPMENT | 9 | 7.43e-01 | 9.50e-01 | 0.2860 | 1.52e-01 | 1.26e-01 | -4.85e-02 | 3.78e-02 | -1.98e-01 | 4.30e-01 | 5.11e-01 | 8.01e-01 | 8.44e-01 | 3.04e-01 |
| INTERNEURON MIGRATION FROM THE SUBPALLIUM TO THE CORTEX | 7 | 9.83e-01 | 9.96e-01 | 0.2860 | 1.39e-01 | 1.47e-01 | 1.30e-01 | 1.02e-01 | 1.19e-01 | 5.25e-01 | 5.02e-01 | 5.51e-01 | 6.42e-01 | 5.87e-01 |
| PRENYLATION | 11 | 1.50e-01 | 5.19e-01 | 0.2860 | -3.99e-02 | 1.13e-01 | 5.89e-02 | 1.48e-01 | 2.06e-01 | 8.19e-01 | 5.18e-01 | 7.35e-01 | 3.96e-01 | 2.37e-01 |
| ICOSANOID TRANSPORT | 63 | 5.32e-02 | 3.05e-01 | 0.2860 | -1.65e-01 | -8.47e-02 | -9.64e-02 | -1.95e-01 | -1.32e-02 | 2.38e-02 | 2.45e-01 | 1.86e-01 | 7.28e-03 | 8.56e-01 |
| L LYSINE TRANSPORT | 7 | 5.46e-01 | 8.72e-01 | 0.2860 | 2.72e-02 | 1.65e-01 | 8.72e-02 | 8.86e-02 | -1.96e-01 | 9.01e-01 | 4.49e-01 | 6.90e-01 | 6.85e-01 | 3.69e-01 |
| METENCEPHALON DEVELOPMENT | 107 | 4.32e-02 | 2.70e-01 | 0.2860 | 1.05e-01 | 8.96e-02 | 1.35e-01 | 1.22e-01 | 1.72e-01 | 6.15e-02 | 1.09e-01 | 1.55e-02 | 2.87e-02 | 2.16e-03 |
| RENAL SODIUM EXCRETION | 11 | 7.33e-01 | 9.46e-01 | 0.2860 | 1.06e-02 | -1.53e-02 | 1.57e-01 | 1.17e-01 | 2.07e-01 | 9.51e-01 | 9.30e-01 | 3.68e-01 | 5.00e-01 | 2.34e-01 |
| NEGATIVE REGULATION OF PROGRAMMED CELL DEATH | 881 | 2.42e-13 | 2.90e-11 | 0.2860 | 1.01e-01 | 1.11e-01 | 1.44e-01 | 1.36e-01 | 1.40e-01 | 3.65e-07 | 2.10e-08 | 3.29e-13 | 6.62e-12 | 1.54e-12 |
| HYALURONAN CATABOLIC PROCESS | 16 | 7.44e-01 | 9.50e-01 | 0.2860 | -1.55e-01 | -1.04e-01 | -1.54e-01 | -1.05e-01 | -1.10e-01 | 2.82e-01 | 4.73e-01 | 2.87e-01 | 4.69e-01 | 4.48e-01 |
| CELLULAR RESPONSE TO VIRUS | 80 | 2.73e-01 | 6.81e-01 | 0.2850 | -1.03e-01 | -1.19e-01 | -1.62e-01 | -1.37e-01 | -1.08e-01 | 1.10e-01 | 6.64e-02 | 1.24e-02 | 3.42e-02 | 9.41e-02 |
| REGULATION OF COA TRANSFERASE ACTIVITY | 10 | 4.65e-01 | 8.25e-01 | 0.2850 | -1.25e-01 | 3.74e-02 | -1.30e-01 | -1.34e-01 | -1.72e-01 | 4.94e-01 | 8.38e-01 | 4.78e-01 | 4.62e-01 | 3.47e-01 |
| QUINONE METABOLIC PROCESS | 39 | 6.09e-01 | 9.03e-01 | 0.2850 | 1.61e-01 | 1.27e-01 | 1.08e-01 | 1.58e-01 | 5.31e-02 | 8.11e-02 | 1.70e-01 | 2.45e-01 | 8.87e-02 | 5.66e-01 |
| LACTATE METABOLIC PROCESS | 18 | 4.93e-01 | 8.43e-01 | 0.2850 | -6.73e-03 | -1.93e-02 | 1.23e-01 | 1.29e-01 | 2.22e-01 | 9.61e-01 | 8.87e-01 | 3.67e-01 | 3.43e-01 | 1.03e-01 |
| LATE NUCLEOPHAGY | 8 | 8.91e-01 | 9.81e-01 | 0.2850 | 9.97e-02 | 1.46e-01 | 1.51e-01 | 1.57e-01 | -5.11e-02 | 6.25e-01 | 4.75e-01 | 4.60e-01 | 4.42e-01 | 8.03e-01 |
| RESPONSE TO HYDROSTATIC PRESSURE | 7 | 8.68e-01 | 9.78e-01 | 0.2850 | -1.81e-01 | -1.14e-01 | -2.58e-02 | -5.35e-02 | 1.78e-01 | 4.06e-01 | 6.00e-01 | 9.06e-01 | 8.06e-01 | 4.16e-01 |
| CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 118 | 4.38e-03 | 5.61e-02 | 0.2850 | 1.84e-01 | 1.74e-01 | 7.90e-02 | 1.01e-01 | 1.74e-02 | 5.40e-04 | 1.06e-03 | 1.38e-01 | 5.85e-02 | 7.44e-01 |
| REGULATION OF RETINOIC ACID RECEPTOR SIGNALING PATHWAY | 16 | 4.29e-01 | 8.05e-01 | 0.2850 | 9.33e-02 | 5.93e-02 | 6.99e-02 | 1.95e-01 | 1.61e-01 | 5.18e-01 | 6.81e-01 | 6.28e-01 | 1.77e-01 | 2.64e-01 |
| DIGESTIVE TRACT MORPHOGENESIS | 48 | 6.06e-02 | 3.26e-01 | 0.2850 | -3.09e-02 | 6.34e-02 | 1.51e-01 | 1.01e-01 | 2.07e-01 | 7.11e-01 | 4.48e-01 | 6.94e-02 | 2.28e-01 | 1.29e-02 |
| REGULATION OF JUN KINASE ACTIVITY | 44 | 4.26e-01 | 8.05e-01 | 0.2850 | 1.64e-01 | 1.25e-01 | 1.12e-01 | 1.20e-01 | 1.07e-01 | 6.04e-02 | 1.50e-01 | 1.98e-01 | 1.67e-01 | 2.20e-01 |
| POSITIVE REGULATION OF MYOBLAST FUSION | 16 | 4.88e-01 | 8.39e-01 | 0.2850 | 1.48e-01 | 8.07e-02 | 7.04e-02 | 2.12e-01 | -5.07e-02 | 3.06e-01 | 5.76e-01 | 6.26e-01 | 1.42e-01 | 7.25e-01 |
| PINOCYTOSIS | 22 | 2.87e-01 | 6.95e-01 | 0.2850 | 6.62e-02 | 1.81e-01 | 1.25e-01 | 1.98e-02 | 1.67e-01 | 5.91e-01 | 1.41e-01 | 3.10e-01 | 8.72e-01 | 1.76e-01 |
| ANTERIOR POSTERIOR AXIS SPECIFICATION | 54 | 8.55e-02 | 3.95e-01 | 0.2840 | 4.80e-02 | 1.53e-01 | 1.37e-01 | 8.08e-02 | 1.73e-01 | 5.41e-01 | 5.13e-02 | 8.17e-02 | 3.05e-01 | 2.81e-02 |
| REGULATION OF ISOMERASE ACTIVITY | 8 | 6.87e-01 | 9.31e-01 | 0.2840 | 7.63e-02 | 4.45e-02 | 3.12e-02 | 1.20e-01 | 2.40e-01 | 7.09e-01 | 8.27e-01 | 8.78e-01 | 5.58e-01 | 2.39e-01 |
| TOLERANCE INDUCTION | 29 | 2.44e-02 | 1.90e-01 | 0.2840 | -1.03e-01 | -2.05e-01 | -5.08e-02 | 3.65e-02 | 1.56e-01 | 3.35e-01 | 5.60e-02 | 6.36e-01 | 7.34e-01 | 1.47e-01 |
| DE NOVO NAD BIOSYNTHETIC PROCESS | 8 | 9.49e-01 | 9.94e-01 | 0.2840 | -1.01e-01 | -8.86e-02 | -1.57e-01 | -1.87e-01 | -5.72e-02 | 6.20e-01 | 6.64e-01 | 4.41e-01 | 3.61e-01 | 7.79e-01 |
| POSITIVE REGULATION OF STEM CELL PROLIFERATION | 53 | 9.79e-02 | 4.26e-01 | 0.2840 | 9.96e-02 | 1.04e-01 | 1.13e-01 | 1.95e-01 | 9.72e-02 | 2.10e-01 | 1.91e-01 | 1.54e-01 | 1.42e-02 | 2.21e-01 |
| MACROMOLECULE CATABOLIC PROCESS | 1346 | 1.92e-26 | 7.62e-24 | 0.2840 | 1.21e-01 | 9.91e-02 | 1.25e-01 | 1.74e-01 | 1.01e-01 | 7.45e-14 | 1.03e-09 | 1.33e-14 | 6.57e-27 | 5.41e-10 |
| NATURAL KILLER CELL CYTOKINE PRODUCTION | 9 | 3.56e-01 | 7.56e-01 | 0.2840 | -2.23e-01 | -1.71e-01 | 3.75e-02 | 1.44e-02 | -1.58e-03 | 2.47e-01 | 3.75e-01 | 8.45e-01 | 9.40e-01 | 9.93e-01 |
| REGULATION OF GENE EXPRESSION BY GENOMIC IMPRINTING | 10 | 6.02e-01 | 9.00e-01 | 0.2840 | -4.94e-02 | 6.90e-02 | 1.68e-01 | 1.48e-01 | 1.51e-01 | 7.87e-01 | 7.06e-01 | 3.56e-01 | 4.16e-01 | 4.07e-01 |
| NON MEMBRANE BOUNDED ORGANELLE ASSEMBLY | 389 | 4.31e-05 | 1.35e-03 | 0.2840 | 1.18e-01 | 1.19e-01 | 1.40e-01 | 1.50e-01 | 1.01e-01 | 6.02e-05 | 5.90e-05 | 1.96e-06 | 3.91e-07 | 6.48e-04 |
| NEGATIVE REGULATION OF RECEPTOR SIGNALING PATHWAY VIA JAK STAT | 24 | 1.87e-01 | 5.72e-01 | 0.2840 | -5.89e-02 | -6.73e-02 | 1.23e-01 | 9.20e-02 | 2.21e-01 | 6.17e-01 | 5.68e-01 | 2.99e-01 | 4.35e-01 | 6.07e-02 |
| ASTROCYTE DIFFERENTIATION | 84 | 2.73e-01 | 6.81e-01 | 0.2840 | 1.28e-01 | 1.47e-01 | 1.29e-01 | 1.26e-01 | 1.00e-01 | 4.34e-02 | 2.02e-02 | 4.06e-02 | 4.54e-02 | 1.13e-01 |
| BASOLATERAL PROTEIN SECRETION | 5 | 9.91e-01 | 9.98e-01 | 0.2830 | 1.20e-01 | 1.28e-01 | 1.67e-01 | 1.42e-01 | 3.78e-02 | 6.41e-01 | 6.20e-01 | 5.18e-01 | 5.82e-01 | 8.84e-01 |
| PALLIUM DEVELOPMENT | 183 | 1.85e-03 | 2.86e-02 | 0.2830 | 1.19e-01 | 9.51e-02 | 1.39e-01 | 1.19e-01 | 1.54e-01 | 5.48e-03 | 2.65e-02 | 1.16e-03 | 5.49e-03 | 3.39e-04 |
| NEGATIVE REGULATION OF KIDNEY DEVELOPMENT | 5 | 7.15e-01 | 9.36e-01 | 0.2830 | -1.24e-01 | 4.06e-02 | 1.18e-01 | 1.19e-01 | 1.87e-01 | 6.30e-01 | 8.75e-01 | 6.48e-01 | 6.45e-01 | 4.68e-01 |
| METANEPHRIC EPITHELIUM DEVELOPMENT | 29 | 6.60e-01 | 9.21e-01 | 0.2830 | 1.07e-01 | 1.65e-01 | 1.41e-01 | 8.93e-02 | 1.17e-01 | 3.18e-01 | 1.23e-01 | 1.89e-01 | 4.05e-01 | 2.77e-01 |
| SYMPATHETIC NERVOUS SYSTEM DEVELOPMENT | 22 | 7.57e-01 | 9.51e-01 | 0.2830 | 4.96e-02 | 8.99e-02 | 1.41e-01 | 1.15e-01 | 1.91e-01 | 6.87e-01 | 4.65e-01 | 2.51e-01 | 3.50e-01 | 1.21e-01 |
| REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT | 83 | 1.07e-01 | 4.48e-01 | 0.2830 | -1.10e-01 | -1.08e-01 | -1.59e-01 | -1.68e-01 | -5.24e-02 | 8.24e-02 | 8.93e-02 | 1.24e-02 | 7.99e-03 | 4.09e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CILIUM | 11 | 7.35e-01 | 9.47e-01 | 0.2830 | -1.47e-04 | 5.36e-02 | 8.67e-02 | 9.89e-02 | 2.45e-01 | 9.99e-01 | 7.58e-01 | 6.19e-01 | 5.70e-01 | 1.60e-01 |
| POSITIVE REGULATION OF NEUROTRANSMITTER TRANSPORT | 23 | 5.23e-01 | 8.59e-01 | 0.2830 | -1.79e-01 | -1.71e-01 | -4.65e-02 | -1.14e-01 | 5.82e-02 | 1.37e-01 | 1.55e-01 | 6.99e-01 | 3.43e-01 | 6.29e-01 |
| REGULATION OF INCLUSION BODY ASSEMBLY | 17 | 7.42e-01 | 9.50e-01 | 0.2830 | 7.08e-02 | 7.89e-02 | 1.91e-01 | 1.42e-01 | 1.10e-01 | 6.13e-01 | 5.73e-01 | 1.72e-01 | 3.11e-01 | 4.32e-01 |
| REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING | 57 | 6.59e-02 | 3.42e-01 | 0.2830 | 1.32e-01 | 7.35e-02 | 1.03e-01 | 2.04e-01 | 6.96e-02 | 8.39e-02 | 3.37e-01 | 1.78e-01 | 7.70e-03 | 3.64e-01 |
| REGULATION OF CILIUM BEAT FREQUENCY INVOLVED IN CILIARY MOTILITY | 9 | 1.77e-01 | 5.63e-01 | 0.2830 | 5.32e-02 | 5.52e-02 | 7.94e-02 | -9.61e-02 | -2.42e-01 | 7.82e-01 | 7.74e-01 | 6.80e-01 | 6.17e-01 | 2.09e-01 |
| REGULATION OF RETROGRADE TRANSPORT ENDOSOME TO GOLGI | 7 | 8.04e-01 | 9.67e-01 | 0.2830 | -1.48e-02 | -1.73e-01 | -1.69e-01 | -1.29e-02 | -1.46e-01 | 9.46e-01 | 4.29e-01 | 4.38e-01 | 9.53e-01 | 5.05e-01 |
| VIRAL GENE EXPRESSION | 99 | 2.45e-02 | 1.91e-01 | 0.2830 | 1.02e-01 | 7.44e-02 | 1.14e-01 | 1.59e-01 | 1.60e-01 | 7.88e-02 | 2.01e-01 | 4.91e-02 | 6.27e-03 | 5.96e-03 |
| ISOPENTENYL DIPHOSPHATE BIOSYNTHETIC PROCESS | 5 | 9.45e-01 | 9.93e-01 | 0.2830 | -9.99e-03 | 3.84e-02 | 1.84e-01 | 1.34e-01 | 1.63e-01 | 9.69e-01 | 8.82e-01 | 4.75e-01 | 6.04e-01 | 5.29e-01 |
| ORGANELLE MEMBRANE FUSION | 118 | 1.33e-01 | 4.94e-01 | 0.2830 | 1.12e-01 | 1.29e-01 | 1.54e-01 | 1.36e-01 | 9.18e-02 | 3.51e-02 | 1.56e-02 | 3.88e-03 | 1.06e-02 | 8.48e-02 |
| NEGATIVE REGULATION OF OXIDATIVE STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 33 | 3.51e-01 | 7.52e-01 | 0.2830 | 5.37e-02 | 8.13e-02 | 1.91e-01 | 1.47e-01 | 1.10e-01 | 5.93e-01 | 4.19e-01 | 5.69e-02 | 1.44e-01 | 2.75e-01 |
| MEDIUM CHAIN FATTY ACID METABOLIC PROCESS | 15 | 5.99e-01 | 8.98e-01 | 0.2820 | 1.36e-01 | 3.46e-02 | 1.39e-01 | 1.27e-01 | 1.57e-01 | 3.60e-01 | 8.16e-01 | 3.53e-01 | 3.95e-01 | 2.92e-01 |
| PYRIMIDINE RIBONUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 7 | 8.61e-01 | 9.78e-01 | 0.2820 | -1.24e-01 | -1.07e-01 | 1.24e-02 | -1.81e-02 | 2.29e-01 | 5.71e-01 | 6.23e-01 | 9.55e-01 | 9.34e-01 | 2.94e-01 |
| LIMB JOINT MORPHOGENESIS | 5 | 6.94e-01 | 9.31e-01 | 0.2820 | -1.27e-01 | -1.79e-01 | -1.74e-01 | 3.16e-02 | 7.40e-03 | 6.22e-01 | 4.88e-01 | 5.01e-01 | 9.03e-01 | 9.77e-01 |
| REGULATION OF GLIAL CELL MIGRATION | 19 | 5.41e-01 | 8.68e-01 | 0.2820 | 1.85e-01 | 1.77e-01 | 3.37e-02 | 1.06e-01 | -4.00e-02 | 1.62e-01 | 1.83e-01 | 7.99e-01 | 4.24e-01 | 7.63e-01 |
| EPIDERMAL CELL FATE SPECIFICATION | 5 | 9.80e-01 | 9.96e-01 | 0.2820 | 1.15e-01 | 1.85e-01 | 1.10e-01 | 1.01e-01 | 9.87e-02 | 6.56e-01 | 4.73e-01 | 6.71e-01 | 6.97e-01 | 7.02e-01 |
| HORMONE CATABOLIC PROCESS | 11 | 9.19e-01 | 9.86e-01 | 0.2820 | -8.00e-02 | -1.04e-01 | -1.68e-01 | -8.71e-02 | -1.63e-01 | 6.46e-01 | 5.52e-01 | 3.36e-01 | 6.17e-01 | 3.48e-01 |
| IRON ION TRANSMEMBRANE TRANSPORT | 27 | 7.55e-01 | 9.51e-01 | 0.2820 | 1.74e-01 | 1.30e-01 | 1.01e-01 | 1.48e-01 | 1.51e-02 | 1.17e-01 | 2.44e-01 | 3.63e-01 | 1.84e-01 | 8.92e-01 |
| NEGATIVE REGULATION OF PLATELET AGGREGATION | 10 | 5.85e-01 | 8.91e-01 | 0.2820 | 1.59e-01 | 1.33e-01 | -2.63e-02 | -4.26e-02 | -1.84e-01 | 3.84e-01 | 4.66e-01 | 8.85e-01 | 8.16e-01 | 3.14e-01 |
| NEGATIVE REGULATION OF T HELPER CELL DIFFERENTIATION | 18 | 7.76e-01 | 9.58e-01 | 0.2820 | 1.50e-01 | 1.08e-01 | 9.10e-02 | 1.81e-01 | 6.54e-02 | 2.69e-01 | 4.29e-01 | 5.04e-01 | 1.85e-01 | 6.31e-01 |
| POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 112 | 1.03e-01 | 4.37e-01 | 0.2820 | 1.03e-01 | 1.08e-01 | 1.39e-01 | 1.54e-01 | 1.19e-01 | 6.01e-02 | 4.88e-02 | 1.10e-02 | 4.89e-03 | 2.97e-02 |
| REGULATION OF RAB PROTEIN SIGNAL TRANSDUCTION | 7 | 6.84e-01 | 9.30e-01 | 0.2820 | 6.84e-02 | -4.08e-02 | -9.02e-02 | 9.75e-02 | -2.35e-01 | 7.54e-01 | 8.52e-01 | 6.79e-01 | 6.55e-01 | 2.81e-01 |
| REGULATION OF AMPA RECEPTOR ACTIVITY | 23 | 2.64e-02 | 1.99e-01 | 0.2820 | -5.91e-02 | 1.44e-01 | 1.23e-01 | -7.96e-02 | 1.83e-01 | 6.24e-01 | 2.32e-01 | 3.07e-01 | 5.09e-01 | 1.28e-01 |
| CELLULAR RESPONSE TO CGMP | 7 | 7.78e-01 | 9.58e-01 | 0.2820 | -1.50e-01 | -6.97e-02 | 6.32e-02 | 4.32e-02 | 2.15e-01 | 4.92e-01 | 7.49e-01 | 7.72e-01 | 8.43e-01 | 3.25e-01 |
| NOREPINEPHRINE UPTAKE | 8 | 3.45e-01 | 7.50e-01 | 0.2820 | 4.95e-02 | 2.66e-01 | 5.85e-02 | 5.28e-02 | 5.51e-03 | 8.08e-01 | 1.93e-01 | 7.75e-01 | 7.96e-01 | 9.78e-01 |
| TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 17 | 1.26e-01 | 4.82e-01 | 0.2810 | 2.41e-01 | 9.97e-02 | -5.93e-02 | 7.75e-02 | -4.28e-02 | 8.57e-02 | 4.77e-01 | 6.72e-01 | 5.80e-01 | 7.60e-01 |
| DNA SYNTHESIS INVOLVED IN DNA REPAIR | 39 | 1.39e-01 | 5.03e-01 | 0.2810 | 1.24e-01 | 2.59e-02 | 1.24e-01 | 1.47e-01 | 1.62e-01 | 1.81e-01 | 7.79e-01 | 1.81e-01 | 1.12e-01 | 7.98e-02 |
| MICROTUBULE ANCHORING | 23 | 1.92e-01 | 5.80e-01 | 0.2810 | -3.91e-02 | -1.60e-01 | -2.09e-01 | -5.23e-02 | -7.33e-02 | 7.46e-01 | 1.84e-01 | 8.20e-02 | 6.64e-01 | 5.43e-01 |
| POSITIVE REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 16 | 2.40e-01 | 6.44e-01 | 0.2810 | -4.45e-02 | 7.78e-02 | -7.06e-02 | -1.62e-01 | -2.00e-01 | 7.58e-01 | 5.90e-01 | 6.25e-01 | 2.62e-01 | 1.67e-01 |
| REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 109 | 1.15e-02 | 1.13e-01 | 0.2810 | 6.91e-02 | 1.18e-01 | 1.30e-01 | 1.54e-01 | 1.41e-01 | 2.12e-01 | 3.34e-02 | 1.91e-02 | 5.45e-03 | 1.12e-02 |
| DIOL BIOSYNTHETIC PROCESS | 21 | 4.48e-01 | 8.19e-01 | 0.2810 | 9.93e-02 | 8.33e-02 | 7.71e-02 | 1.67e-01 | 1.69e-01 | 4.31e-01 | 5.09e-01 | 5.41e-01 | 1.86e-01 | 1.80e-01 |
| LYMPHATIC ENDOTHELIAL CELL DIFFERENTIATION | 8 | 9.54e-01 | 9.94e-01 | 0.2810 | 5.08e-02 | 4.65e-02 | 1.42e-01 | 1.26e-01 | 1.96e-01 | 8.04e-01 | 8.20e-01 | 4.88e-01 | 5.37e-01 | 3.38e-01 |
| PROSTATE GLAND DEVELOPMENT | 49 | 1.99e-01 | 5.88e-01 | 0.2810 | 7.57e-02 | 1.48e-01 | 1.84e-01 | 8.95e-02 | 9.75e-02 | 3.59e-01 | 7.38e-02 | 2.56e-02 | 2.79e-01 | 2.38e-01 |
| REGULATION PROTEIN CATABOLIC PROCESS AT SYNAPSE | 6 | 5.92e-01 | 8.94e-01 | 0.2810 | 1.19e-01 | -4.99e-02 | 3.89e-04 | 2.07e-01 | -1.39e-01 | 6.13e-01 | 8.32e-01 | 9.99e-01 | 3.79e-01 | 5.56e-01 |
| DEFINITIVE HEMOPOIESIS | 19 | 9.29e-01 | 9.90e-01 | 0.2810 | 1.43e-01 | 1.37e-01 | 1.38e-01 | 1.27e-01 | 6.97e-02 | 2.82e-01 | 3.02e-01 | 2.99e-01 | 3.38e-01 | 5.99e-01 |
| POSITIVE REGULATION OF RESPIRATORY BURST | 7 | 7.47e-01 | 9.51e-01 | 0.2810 | -5.59e-02 | -1.60e-01 | -1.42e-01 | -1.45e-01 | 9.57e-02 | 7.98e-01 | 4.63e-01 | 5.16e-01 | 5.07e-01 | 6.61e-01 |
| REGULATION OF MEMBRANE PERMEABILITY | 72 | 1.29e-01 | 4.87e-01 | 0.2810 | 6.57e-02 | 7.52e-02 | 1.63e-01 | 1.52e-01 | 1.39e-01 | 3.35e-01 | 2.70e-01 | 1.67e-02 | 2.56e-02 | 4.20e-02 |
| ORGANELLE FUSION | 156 | 6.34e-02 | 3.35e-01 | 0.2810 | 1.26e-01 | 1.22e-01 | 1.40e-01 | 1.42e-01 | 9.23e-02 | 6.82e-03 | 8.29e-03 | 2.59e-03 | 2.25e-03 | 4.67e-02 |
| POLYAMINE TRANSPORT | 16 | 7.73e-01 | 9.57e-01 | 0.2810 | 1.36e-01 | 1.38e-01 | 8.95e-02 | 1.78e-01 | 4.19e-02 | 3.47e-01 | 3.39e-01 | 5.35e-01 | 2.19e-01 | 7.71e-01 |
| RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL BY ENDOPLASMIC RETICULUM | 35 | 3.42e-01 | 7.48e-01 | 0.2810 | -1.62e-01 | -1.78e-01 | -9.66e-02 | -7.47e-02 | -7.80e-02 | 9.73e-02 | 6.86e-02 | 3.23e-01 | 4.45e-01 | 4.24e-01 |
| ASPARTATE METABOLIC PROCESS | 8 | 2.96e-01 | 7.07e-01 | 0.2810 | -1.51e-01 | -6.41e-02 | -2.19e-01 | -6.38e-02 | 5.88e-03 | 4.61e-01 | 7.54e-01 | 2.84e-01 | 7.55e-01 | 9.77e-01 |
| G PROTEIN COUPLED PURINERGIC RECEPTOR SIGNALING PATHWAY | 12 | 7.90e-01 | 9.63e-01 | 0.2810 | 4.21e-02 | 5.03e-02 | 1.93e-01 | 1.31e-01 | 1.42e-01 | 8.01e-01 | 7.63e-01 | 2.47e-01 | 4.33e-01 | 3.93e-01 |
| INTERLEUKIN 6 PRODUCTION | 165 | 1.46e-03 | 2.36e-02 | 0.2810 | 1.69e-01 | 1.69e-01 | 9.58e-02 | 1.06e-01 | -3.44e-02 | 1.76e-04 | 1.75e-04 | 3.37e-02 | 1.92e-02 | 4.46e-01 |
| PRIMARY ALCOHOL CATABOLIC PROCESS | 13 | 6.10e-01 | 9.04e-01 | 0.2800 | 1.45e-01 | 7.93e-02 | -5.64e-02 | 1.68e-02 | -2.19e-01 | 3.67e-01 | 6.21e-01 | 7.25e-01 | 9.16e-01 | 1.71e-01 |
| UREA CYCLE | 10 | 1.47e-01 | 5.14e-01 | 0.2800 | 1.34e-01 | 1.16e-01 | -8.23e-02 | -1.79e-01 | -9.15e-02 | 4.63e-01 | 5.25e-01 | 6.52e-01 | 3.27e-01 | 6.16e-01 |
| NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE ACTIVITY | 24 | 7.91e-01 | 9.63e-01 | 0.2800 | 1.07e-01 | 1.09e-01 | 1.46e-01 | 1.71e-01 | 6.62e-02 | 3.64e-01 | 3.54e-01 | 2.14e-01 | 1.46e-01 | 5.75e-01 |
| POSITIVE REGULATION OF G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 27 | 2.31e-01 | 6.33e-01 | 0.2800 | 9.02e-02 | 1.60e-01 | 1.37e-01 | 1.38e-01 | -8.20e-02 | 4.17e-01 | 1.49e-01 | 2.16e-01 | 2.13e-01 | 4.61e-01 |
| MORPHOGENESIS OF A BRANCHING STRUCTURE | 195 | 2.71e-03 | 3.88e-02 | 0.2800 | 7.37e-02 | 1.26e-01 | 1.49e-01 | 1.27e-01 | 1.38e-01 | 7.59e-02 | 2.50e-03 | 3.33e-04 | 2.24e-03 | 8.77e-04 |
| REGULATION OF MICROVILLUS LENGTH | 7 | 3.90e-01 | 7.82e-01 | 0.2800 | -1.57e-01 | -1.13e-01 | 5.28e-02 | -9.34e-02 | -1.73e-01 | 4.73e-01 | 6.06e-01 | 8.09e-01 | 6.69e-01 | 4.28e-01 |
| COPPER ION IMPORT | 6 | 9.05e-01 | 9.84e-01 | 0.2800 | -1.37e-01 | -1.73e-01 | -2.49e-02 | -7.12e-02 | 1.56e-01 | 5.61e-01 | 4.64e-01 | 9.16e-01 | 7.63e-01 | 5.09e-01 |
| REGULATION OF GASTRIC ACID SECRETION | 6 | 8.52e-01 | 9.76e-01 | 0.2800 | -2.11e-01 | -4.77e-02 | -4.98e-02 | -1.40e-01 | 9.86e-02 | 3.72e-01 | 8.40e-01 | 8.33e-01 | 5.52e-01 | 6.76e-01 |
| REGULATION OF HAIR CYCLE | 28 | 1.08e-01 | 4.51e-01 | 0.2800 | 5.05e-02 | 1.62e-01 | 1.47e-01 | 1.68e-01 | -4.32e-03 | 6.44e-01 | 1.38e-01 | 1.79e-01 | 1.24e-01 | 9.68e-01 |
| UMP CATABOLIC PROCESS | 5 | 8.95e-01 | 9.82e-01 | 0.2800 | 1.94e-01 | 9.29e-02 | 2.83e-02 | 1.30e-01 | 1.20e-01 | 4.52e-01 | 7.19e-01 | 9.13e-01 | 6.16e-01 | 6.42e-01 |
| REGULATION OF PLATELET ACTIVATION | 47 | 2.11e-02 | 1.72e-01 | 0.2800 | 1.53e-01 | 1.43e-01 | -1.87e-02 | 8.11e-02 | -1.66e-01 | 6.98e-02 | 9.01e-02 | 8.25e-01 | 3.36e-01 | 4.83e-02 |
| VACUOLAR LOCALIZATION | 82 | 1.95e-01 | 5.82e-01 | 0.2800 | 9.84e-02 | 1.27e-01 | 1.65e-01 | 1.41e-01 | 7.41e-02 | 1.24e-01 | 4.66e-02 | 9.72e-03 | 2.76e-02 | 2.46e-01 |
| GLYCOLIPID BIOSYNTHETIC PROCESS | 72 | 1.78e-01 | 5.63e-01 | 0.2800 | 8.24e-02 | 1.14e-01 | 1.77e-01 | 1.18e-01 | 1.16e-01 | 2.26e-01 | 9.45e-02 | 9.35e-03 | 8.44e-02 | 8.90e-02 |
| MAST CELL PROLIFERATION | 7 | 6.99e-01 | 9.31e-01 | 0.2800 | -9.75e-04 | -3.05e-02 | -2.14e-01 | -4.11e-02 | -1.73e-01 | 9.96e-01 | 8.89e-01 | 3.26e-01 | 8.51e-01 | 4.28e-01 |
| REGULATION OF AMINO ACID TRANSPORT | 41 | 7.03e-01 | 9.32e-01 | 0.2800 | 1.21e-01 | 1.50e-01 | 1.41e-01 | 1.20e-01 | 8.35e-02 | 1.80e-01 | 9.61e-02 | 1.19e-01 | 1.83e-01 | 3.55e-01 |
| PYRIMIDINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 11 | 8.58e-01 | 9.77e-01 | 0.2800 | 1.89e-01 | 1.75e-01 | 5.69e-02 | 8.34e-02 | -4.03e-02 | 2.78e-01 | 3.14e-01 | 7.44e-01 | 6.32e-01 | 8.17e-01 |
| G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART PROCESS | 18 | 6.96e-01 | 9.31e-01 | 0.2800 | -1.74e-01 | -1.42e-01 | -7.66e-02 | -9.98e-02 | 1.10e-01 | 2.02e-01 | 2.97e-01 | 5.74e-01 | 4.63e-01 | 4.19e-01 |
| REGULATION OF SKELETAL MUSCLE CONTRACTION | 15 | 3.51e-02 | 2.39e-01 | 0.2800 | -1.70e-01 | 1.03e-01 | 1.06e-01 | -1.38e-01 | 9.15e-02 | 2.55e-01 | 4.88e-01 | 4.76e-01 | 3.54e-01 | 5.39e-01 |
| NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 231 | 7.02e-03 | 7.92e-02 | 0.2800 | 1.16e-01 | 1.15e-01 | 1.42e-01 | 1.39e-01 | 1.10e-01 | 2.29e-03 | 2.66e-03 | 1.91e-04 | 2.85e-04 | 4.06e-03 |
| CELLULAR DETOXIFICATION OF ALDEHYDE | 9 | 4.25e-01 | 8.04e-01 | 0.2800 | 6.71e-02 | -8.25e-02 | -8.36e-02 | 1.25e-01 | -2.10e-01 | 7.27e-01 | 6.68e-01 | 6.64e-01 | 5.16e-01 | 2.74e-01 |
| PYRIMIDINE NUCLEOSIDE TRANSPORT | 6 | 9.67e-01 | 9.94e-01 | 0.2800 | -1.07e-01 | -1.07e-01 | -1.37e-01 | -1.90e-01 | -1.66e-02 | 6.50e-01 | 6.49e-01 | 5.62e-01 | 4.19e-01 | 9.44e-01 |
| MATERNAL PROCESS INVOLVED IN FEMALE PREGNANCY | 54 | 1.77e-01 | 5.63e-01 | 0.2800 | 8.62e-02 | 1.70e-01 | 1.28e-01 | 1.25e-01 | 9.95e-02 | 2.73e-01 | 3.09e-02 | 1.03e-01 | 1.12e-01 | 2.06e-01 |
| SULFATION | 20 | 5.85e-01 | 8.90e-01 | 0.2800 | -6.75e-03 | -5.69e-02 | -1.68e-01 | -6.90e-02 | -2.05e-01 | 9.58e-01 | 6.60e-01 | 1.93e-01 | 5.93e-01 | 1.13e-01 |
| PROTEIN CONTAINING COMPLEX DISASSEMBLY | 241 | 1.39e-03 | 2.29e-02 | 0.2790 | 1.15e-01 | 9.87e-02 | 1.51e-01 | 1.50e-01 | 9.91e-02 | 2.16e-03 | 8.33e-03 | 5.25e-05 | 5.93e-05 | 8.05e-03 |
| C 5 METHYLATION OF CYTOSINE | 5 | 9.19e-01 | 9.86e-01 | 0.2790 | 9.13e-03 | 5.94e-02 | 6.25e-02 | 3.68e-02 | 2.63e-01 | 9.72e-01 | 8.18e-01 | 8.09e-01 | 8.87e-01 | 3.08e-01 |
| REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 58 | 1.97e-01 | 5.85e-01 | 0.2790 | -1.85e-01 | -1.26e-01 | -1.07e-01 | -1.15e-01 | -5.68e-02 | 1.51e-02 | 9.59e-02 | 1.57e-01 | 1.29e-01 | 4.54e-01 |
| SYNAPTIC SIGNALING VIA NEUROPEPTIDE | 6 | 5.26e-01 | 8.60e-01 | 0.2790 | -1.18e-01 | -3.21e-02 | 6.24e-02 | -2.02e-01 | 1.35e-01 | 6.16e-01 | 8.92e-01 | 7.91e-01 | 3.91e-01 | 5.67e-01 |
| PIGMENT GRANULE ORGANIZATION | 37 | 6.46e-01 | 9.16e-01 | 0.2790 | 1.64e-01 | 1.20e-01 | 1.13e-01 | 1.36e-01 | 7.26e-02 | 8.39e-02 | 2.06e-01 | 2.33e-01 | 1.52e-01 | 4.45e-01 |
| CANONICAL WNT SIGNALING PATHWAY INVOLVED IN REGULATION OF CELL PROLIFERATION | 6 | 6.52e-01 | 9.19e-01 | 0.2790 | 7.52e-02 | -1.40e-02 | 2.17e-02 | 2.12e-01 | 1.64e-01 | 7.50e-01 | 9.53e-01 | 9.27e-01 | 3.69e-01 | 4.87e-01 |
| TRANSPORT OF VIRUS | 21 | 7.46e-01 | 9.50e-01 | 0.2790 | 1.46e-01 | 1.27e-01 | 9.56e-02 | 1.15e-01 | 1.35e-01 | 2.48e-01 | 3.15e-01 | 4.48e-01 | 3.60e-01 | 2.83e-01 |
| ISG15 PROTEIN CONJUGATION | 6 | 7.10e-01 | 9.35e-01 | 0.2790 | 1.69e-01 | 8.59e-02 | -1.57e-02 | 2.04e-01 | -1.96e-02 | 4.74e-01 | 7.16e-01 | 9.47e-01 | 3.88e-01 | 9.34e-01 |
| HISTIDINE METABOLIC PROCESS | 10 | 7.00e-01 | 9.31e-01 | 0.2790 | -7.81e-02 | -5.09e-03 | -1.80e-01 | -1.31e-01 | -1.50e-01 | 6.69e-01 | 9.78e-01 | 3.25e-01 | 4.72e-01 | 4.13e-01 |
| VESICLE TARGETING | 65 | 3.63e-01 | 7.62e-01 | 0.2790 | 1.30e-01 | 1.01e-01 | 1.42e-01 | 1.38e-01 | 1.07e-01 | 6.90e-02 | 1.61e-01 | 4.72e-02 | 5.47e-02 | 1.34e-01 |
| DENDRITE EXTENSION | 35 | 7.90e-01 | 9.63e-01 | 0.2790 | -1.15e-01 | -1.20e-01 | -1.49e-01 | -1.39e-01 | -9.43e-02 | 2.39e-01 | 2.21e-01 | 1.28e-01 | 1.54e-01 | 3.34e-01 |
| REGULATION OF SULFUR METABOLIC PROCESS | 12 | 6.47e-01 | 9.17e-01 | 0.2790 | -1.23e-01 | -1.83e-01 | -1.18e-01 | -4.78e-02 | 1.14e-01 | 4.61e-01 | 2.73e-01 | 4.77e-01 | 7.74e-01 | 4.95e-01 |
| REGULATION OF CELLULAR SENESCENCE | 52 | 1.34e-01 | 4.94e-01 | 0.2790 | 1.18e-01 | 4.22e-02 | 1.22e-01 | 1.63e-01 | 1.45e-01 | 1.42e-01 | 5.99e-01 | 1.29e-01 | 4.26e-02 | 7.14e-02 |
| NEURAL TUBE DEVELOPMENT | 160 | 1.16e-03 | 1.97e-02 | 0.2790 | 4.45e-02 | 9.61e-02 | 1.40e-01 | 1.31e-01 | 1.72e-01 | 3.31e-01 | 3.59e-02 | 2.31e-03 | 4.11e-03 | 1.67e-04 |
| RESPONSE TO CADMIUM ION | 57 | 4.24e-02 | 2.68e-01 | 0.2790 | 2.98e-03 | 1.05e-02 | 1.23e-01 | 6.38e-02 | 2.41e-01 | 9.69e-01 | 8.91e-01 | 1.07e-01 | 4.04e-01 | 1.61e-03 |
| CELL DIVISION | 614 | 1.32e-10 | 1.05e-08 | 0.2790 | 1.09e-01 | 8.49e-02 | 1.42e-01 | 1.58e-01 | 1.17e-01 | 3.98e-06 | 3.25e-04 | 2.06e-09 | 2.44e-11 | 7.90e-07 |
| RESPONSE TO INTERFERON ALPHA | 17 | 7.28e-01 | 9.43e-01 | 0.2780 | 6.62e-02 | 1.08e-01 | 1.22e-01 | 5.93e-02 | 2.08e-01 | 6.37e-01 | 4.43e-01 | 3.84e-01 | 6.72e-01 | 1.38e-01 |
| POSITIVE REGULATION OF TRIGLYCERIDE CATABOLIC PROCESS | 8 | 5.86e-02 | 3.20e-01 | 0.2780 | -1.67e-01 | 3.62e-02 | 3.80e-02 | 1.04e-01 | -1.90e-01 | 4.14e-01 | 8.59e-01 | 8.52e-01 | 6.09e-01 | 3.53e-01 |
| REGULATION OF BLOOD VESSEL REMODELING | 12 | 3.87e-01 | 7.80e-01 | 0.2780 | 5.53e-02 | 1.68e-01 | 8.19e-02 | 3.35e-02 | -1.96e-01 | 7.40e-01 | 3.14e-01 | 6.23e-01 | 8.41e-01 | 2.40e-01 |
| REGULATION OF STEM CELL PROLIFERATION | 91 | 2.20e-02 | 1.77e-01 | 0.2780 | 6.89e-02 | 9.14e-02 | 1.33e-01 | 1.75e-01 | 1.27e-01 | 2.56e-01 | 1.32e-01 | 2.79e-02 | 3.91e-03 | 3.69e-02 |
| DNA CATABOLIC PROCESS | 29 | 6.97e-02 | 3.57e-01 | 0.2780 | -1.85e-02 | -5.54e-03 | 1.24e-01 | 1.84e-01 | 1.67e-01 | 8.63e-01 | 9.59e-01 | 2.47e-01 | 8.61e-02 | 1.20e-01 |
| REGULATION OF MICROTUBULE BINDING | 7 | 5.89e-01 | 8.92e-01 | 0.2780 | 2.00e-01 | -2.36e-02 | 5.70e-03 | 1.83e-01 | -5.76e-02 | 3.60e-01 | 9.14e-01 | 9.79e-01 | 4.01e-01 | 7.92e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DIFFERENTIATION | 38 | 6.16e-01 | 9.06e-01 | 0.2780 | 6.81e-02 | 1.17e-01 | 1.51e-01 | 1.21e-01 | 1.48e-01 | 4.68e-01 | 2.14e-01 | 1.07e-01 | 1.97e-01 | 1.15e-01 |
| BONE TRABECULA FORMATION | 10 | 3.96e-01 | 7.85e-01 | 0.2780 | -4.46e-02 | 1.80e-01 | 1.45e-01 | -2.66e-02 | 1.47e-01 | 8.07e-01 | 3.25e-01 | 4.29e-01 | 8.84e-01 | 4.21e-01 |
| MYELOID DENDRITIC CELL CYTOKINE PRODUCTION | 8 | 8.94e-01 | 9.82e-01 | 0.2780 | 2.02e-01 | 1.00e-01 | 3.94e-02 | 1.29e-01 | -9.08e-02 | 3.23e-01 | 6.23e-01 | 8.47e-01 | 5.29e-01 | 6.56e-01 |
| SA NODE CELL TO ATRIAL CARDIAC MUSCLE CELL SIGNALING | 9 | 4.75e-01 | 8.32e-01 | 0.2780 | -1.79e-01 | -2.66e-02 | 5.91e-03 | -1.98e-01 | -7.19e-02 | 3.53e-01 | 8.90e-01 | 9.76e-01 | 3.03e-01 | 7.09e-01 |
| GAMMA AMINOBUTYRIC ACID IMPORT | 6 | 7.72e-01 | 9.57e-01 | 0.2770 | -9.14e-02 | 1.04e-01 | 1.56e-01 | -5.36e-03 | 1.83e-01 | 6.98e-01 | 6.60e-01 | 5.08e-01 | 9.82e-01 | 4.37e-01 |
| POSITIVE REGULATION OF PHAGOCYTOSIS | 68 | 1.71e-03 | 2.69e-02 | 0.2770 | 2.24e-02 | 2.01e-02 | -1.32e-01 | -1.52e-01 | -1.89e-01 | 7.49e-01 | 7.75e-01 | 5.97e-02 | 3.07e-02 | 7.11e-03 |
| RESPONSE TO COCAINE | 47 | 4.55e-01 | 8.22e-01 | 0.2770 | 1.09e-01 | 1.31e-01 | 1.27e-01 | 9.67e-02 | 1.49e-01 | 1.96e-01 | 1.19e-01 | 1.31e-01 | 2.51e-01 | 7.71e-02 |
| PLASMA MEMBRANE RAFT ORGANIZATION | 11 | 6.45e-01 | 9.16e-01 | 0.2770 | -5.03e-02 | 9.83e-02 | 1.13e-01 | 2.56e-02 | 2.26e-01 | 7.73e-01 | 5.73e-01 | 5.16e-01 | 8.83e-01 | 1.94e-01 |
| POST TRANSLATIONAL PROTEIN MODIFICATION | 999 | 6.27e-21 | 1.39e-18 | 0.2770 | 1.31e-01 | 9.42e-02 | 1.11e-01 | 1.73e-01 | 9.32e-02 | 2.51e-12 | 4.66e-07 | 3.02e-09 | 2.22e-20 | 6.18e-07 |
| COCHLEA DEVELOPMENT | 46 | 4.31e-01 | 8.06e-01 | 0.2770 | 7.01e-02 | 1.16e-01 | 1.39e-01 | 9.55e-02 | 1.73e-01 | 4.11e-01 | 1.72e-01 | 1.03e-01 | 2.62e-01 | 4.27e-02 |
| INFLAMMATORY CELL APOPTOTIC PROCESS | 24 | 7.82e-01 | 9.60e-01 | 0.2770 | 1.35e-01 | 1.35e-01 | 1.00e-01 | 1.51e-01 | 8.59e-02 | 2.51e-01 | 2.52e-01 | 3.96e-01 | 2.01e-01 | 4.66e-01 |
| POSITIVE REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 21 | 4.29e-01 | 8.05e-01 | 0.2770 | 5.79e-02 | 1.30e-01 | 2.07e-01 | 8.31e-02 | 8.14e-02 | 6.46e-01 | 3.03e-01 | 1.00e-01 | 5.10e-01 | 5.19e-01 |
| TERMINATION OF RNA POLYMERASE II TRANSCRIPTION | 10 | 1.26e-01 | 4.83e-01 | 0.2770 | -1.06e-01 | -1.26e-01 | 1.35e-01 | 1.73e-01 | 3.60e-02 | 5.60e-01 | 4.90e-01 | 4.60e-01 | 3.43e-01 | 8.44e-01 |
| ORGANONITROGEN COMPOUND BIOSYNTHETIC PROCESS | 1764 | 1.03e-22 | 2.77e-20 | 0.2770 | 1.26e-01 | 1.23e-01 | 1.26e-01 | 1.39e-01 | 1.01e-01 | 1.05e-18 | 7.46e-18 | 1.16e-18 | 2.34e-22 | 1.67e-12 |
| ENUCLEATE ERYTHROCYTE DIFFERENTIATION | 10 | 4.95e-01 | 8.44e-01 | 0.2770 | 1.23e-02 | 8.01e-02 | 8.34e-02 | -6.64e-02 | 2.42e-01 | 9.46e-01 | 6.61e-01 | 6.48e-01 | 7.16e-01 | 1.85e-01 |
| LYMPHOCYTE HOMEOSTASIS | 72 | 1.27e-01 | 4.84e-01 | 0.2770 | 1.31e-01 | 8.94e-02 | 1.12e-01 | 1.81e-01 | 7.82e-02 | 5.42e-02 | 1.90e-01 | 1.01e-01 | 7.83e-03 | 2.51e-01 |
| RETINOIC ACID RECEPTOR SIGNALING PATHWAY | 32 | 1.54e-01 | 5.24e-01 | 0.2770 | 1.07e-01 | 8.24e-02 | 6.62e-02 | 1.75e-01 | 1.53e-01 | 2.94e-01 | 4.20e-01 | 5.17e-01 | 8.74e-02 | 1.33e-01 |
| NEGATIVE REGULATION OF LIPID TRANSPORT | 48 | 1.61e-02 | 1.43e-01 | 0.2770 | 5.23e-02 | 4.21e-02 | -5.05e-02 | 1.95e-02 | -2.63e-01 | 5.31e-01 | 6.14e-01 | 5.45e-01 | 8.15e-01 | 1.62e-03 |
| REGULATION OF CELL COMMUNICATION BY ELECTRICAL COUPLING | 16 | 7.74e-01 | 9.57e-01 | 0.2770 | -1.52e-01 | -1.81e-01 | -1.18e-01 | -7.33e-02 | 3.35e-02 | 2.91e-01 | 2.10e-01 | 4.12e-01 | 6.12e-01 | 8.16e-01 |
| NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 223 | 8.71e-03 | 9.22e-02 | 0.2770 | 1.20e-01 | 1.28e-01 | 1.28e-01 | 1.33e-01 | 1.09e-01 | 2.07e-03 | 1.03e-03 | 9.89e-04 | 6.43e-04 | 4.89e-03 |
| NEGATIVE REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 24 | 2.79e-01 | 6.89e-01 | 0.2770 | -1.68e-02 | 6.93e-03 | 1.78e-01 | 8.13e-02 | 1.95e-01 | 8.86e-01 | 9.53e-01 | 1.32e-01 | 4.90e-01 | 9.86e-02 |
| NEGATIVE REGULATION OF T HELPER 1 TYPE IMMUNE RESPONSE | 8 | 8.97e-01 | 9.82e-01 | 0.2760 | 1.90e-02 | -7.77e-02 | -1.24e-01 | -7.20e-02 | -2.22e-01 | 9.26e-01 | 7.03e-01 | 5.43e-01 | 7.24e-01 | 2.77e-01 |
| POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 101 | 2.59e-01 | 6.66e-01 | 0.2760 | 1.22e-01 | 1.31e-01 | 1.42e-01 | 1.29e-01 | 8.62e-02 | 3.44e-02 | 2.26e-02 | 1.39e-02 | 2.47e-02 | 1.34e-01 |
| B CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 85 | 7.19e-02 | 3.63e-01 | 0.2760 | 1.33e-01 | 1.54e-01 | 9.51e-02 | 1.41e-01 | 7.72e-02 | 3.47e-02 | 1.40e-02 | 1.30e-01 | 2.44e-02 | 2.18e-01 |
| INTRACELLULAR TRANSPORT | 1513 | 9.48e-20 | 1.93e-17 | 0.2760 | 1.23e-01 | 1.11e-01 | 1.38e-01 | 1.48e-01 | 9.05e-02 | 1.37e-15 | 5.93e-13 | 3.52e-19 | 6.22e-22 | 3.91e-09 |
| REGULATION OF GLUTAMINE FAMILY AMINO ACID METABOLIC PROCESS | 8 | 8.50e-01 | 9.76e-01 | 0.2760 | -1.08e-01 | -7.31e-02 | -1.43e-01 | -5.48e-02 | -1.90e-01 | 5.98e-01 | 7.20e-01 | 4.84e-01 | 7.89e-01 | 3.53e-01 |
| REGULATION OF PROGRAMMED NECROTIC CELL DEATH | 36 | 7.18e-02 | 3.63e-01 | 0.2760 | 1.95e-01 | 7.56e-02 | 3.72e-02 | 1.57e-01 | 7.91e-02 | 4.29e-02 | 4.32e-01 | 7.00e-01 | 1.02e-01 | 4.11e-01 |
| TOOTH MINERALIZATION | 28 | 6.99e-01 | 9.31e-01 | 0.2760 | -1.40e-01 | -1.05e-01 | -9.96e-02 | -1.52e-01 | -1.11e-01 | 2.00e-01 | 3.34e-01 | 3.62e-01 | 1.63e-01 | 3.09e-01 |
| REGULATION OF MYOBLAST FUSION | 21 | 4.59e-01 | 8.23e-01 | 0.2760 | 1.53e-01 | 1.01e-01 | 5.70e-02 | 1.75e-01 | -9.27e-02 | 2.24e-01 | 4.25e-01 | 6.51e-01 | 1.64e-01 | 4.62e-01 |
| POSITIVE REGULATION OF PROTEIN CONTAINING COMPLEX DISASSEMBLY | 36 | 4.68e-01 | 8.28e-01 | 0.2760 | 1.15e-01 | 1.53e-01 | 1.39e-01 | 1.40e-01 | -2.00e-02 | 2.31e-01 | 1.11e-01 | 1.49e-01 | 1.46e-01 | 8.35e-01 |
| NEURAL PRECURSOR CELL PROLIFERATION | 163 | 5.62e-03 | 6.71e-02 | 0.2760 | 6.44e-02 | 8.16e-02 | 1.44e-01 | 1.39e-01 | 1.59e-01 | 1.56e-01 | 7.22e-02 | 1.46e-03 | 2.24e-03 | 4.68e-04 |
| NEGATIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 6 | 8.84e-01 | 9.80e-01 | 0.2760 | -1.65e-01 | -5.97e-02 | 4.08e-02 | -3.49e-02 | 2.06e-01 | 4.83e-01 | 8.00e-01 | 8.62e-01 | 8.82e-01 | 3.83e-01 |
| POSITIVE REGULATION OF HEART RATE | 27 | 2.26e-01 | 6.28e-01 | 0.2760 | -8.10e-03 | 7.11e-02 | 1.56e-01 | 1.20e-02 | 2.16e-01 | 9.42e-01 | 5.23e-01 | 1.61e-01 | 9.14e-01 | 5.24e-02 |
| OXALATE TRANSPORT | 12 | 3.34e-01 | 7.40e-01 | 0.2760 | -3.82e-02 | 6.12e-02 | -3.89e-02 | -1.84e-01 | -1.89e-01 | 8.19e-01 | 7.14e-01 | 8.16e-01 | 2.71e-01 | 2.58e-01 |
| EPITHELIAL CILIUM MOVEMENT INVOLVED IN DETERMINATION OF LEFT RIGHT ASYMMETRY | 12 | 5.77e-02 | 3.16e-01 | 0.2760 | 2.29e-01 | 4.02e-02 | 5.44e-02 | 2.92e-03 | 1.38e-01 | 1.69e-01 | 8.10e-01 | 7.44e-01 | 9.86e-01 | 4.08e-01 |
| REGULATION OF MITOCHONDRIAL FUSION | 11 | 4.33e-01 | 8.08e-01 | 0.2760 | 1.84e-01 | 8.14e-02 | -1.24e-02 | 1.86e-01 | 2.71e-02 | 2.91e-01 | 6.40e-01 | 9.43e-01 | 2.84e-01 | 8.76e-01 |
| MICROTUBULE NUCLEATION | 43 | 4.96e-01 | 8.45e-01 | 0.2760 | 1.45e-01 | 1.07e-01 | 1.01e-01 | 1.58e-01 | 9.05e-02 | 9.94e-02 | 2.25e-01 | 2.52e-01 | 7.24e-02 | 3.04e-01 |
| C21 STEROID HORMONE METABOLIC PROCESS | 36 | 7.45e-01 | 9.50e-01 | 0.2760 | -1.43e-01 | -1.37e-01 | -1.12e-01 | -1.38e-01 | -7.43e-02 | 1.39e-01 | 1.56e-01 | 2.47e-01 | 1.52e-01 | 4.40e-01 |
| POSITIVE REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 14 | 8.92e-01 | 9.81e-01 | 0.2760 | -1.39e-01 | -1.79e-01 | -1.25e-01 | -7.99e-02 | -5.20e-02 | 3.68e-01 | 2.47e-01 | 4.18e-01 | 6.05e-01 | 7.36e-01 |
| REGULATION OF NATURAL KILLER CELL PROLIFERATION | 12 | 6.77e-01 | 9.28e-01 | 0.2760 | -1.36e-01 | -1.21e-01 | -4.73e-02 | -1.69e-01 | 1.10e-01 | 4.14e-01 | 4.68e-01 | 7.77e-01 | 3.11e-01 | 5.11e-01 |
| REGULATION OF CARBOHYDRATE CATABOLIC PROCESS | 61 | 2.35e-01 | 6.37e-01 | 0.2760 | 1.10e-01 | 9.93e-02 | 1.07e-01 | 1.31e-01 | 1.60e-01 | 1.36e-01 | 1.80e-01 | 1.50e-01 | 7.78e-02 | 3.09e-02 |
| GLAND DEVELOPMENT | 429 | 2.82e-06 | 1.22e-04 | 0.2750 | 8.48e-02 | 1.09e-01 | 1.43e-01 | 1.35e-01 | 1.35e-01 | 2.59e-03 | 1.13e-04 | 3.74e-07 | 1.53e-06 | 1.73e-06 |
| CARNITINE TRANSPORT | 8 | 8.53e-01 | 9.76e-01 | 0.2750 | 1.78e-01 | 4.41e-02 | 7.62e-02 | 1.88e-01 | 3.09e-02 | 3.83e-01 | 8.29e-01 | 7.09e-01 | 3.56e-01 | 8.80e-01 |
| NEGATIVE REGULATION OF AXON EXTENSION INVOLVED IN AXON GUIDANCE | 26 | 2.13e-01 | 6.08e-01 | 0.2750 | -1.76e-01 | -5.74e-02 | -1.45e-01 | -1.38e-01 | -3.32e-02 | 1.20e-01 | 6.12e-01 | 2.00e-01 | 2.22e-01 | 7.69e-01 |
| PLASMINOGEN ACTIVATION | 26 | 1.62e-01 | 5.38e-01 | 0.2750 | 5.71e-02 | 2.12e-02 | -9.42e-02 | -1.21e-01 | -2.20e-01 | 6.14e-01 | 8.52e-01 | 4.06e-01 | 2.85e-01 | 5.25e-02 |
| GLANDULAR EPITHELIAL CELL DIFFERENTIATION | 72 | 3.15e-01 | 7.26e-01 | 0.2750 | 8.51e-02 | 9.82e-02 | 1.54e-01 | 1.27e-01 | 1.37e-01 | 2.12e-01 | 1.50e-01 | 2.39e-02 | 6.30e-02 | 4.38e-02 |
| POSITIVE REGULATION OF GLUCONEOGENESIS | 21 | 2.77e-01 | 6.88e-01 | 0.2750 | -9.06e-03 | -6.19e-02 | -2.11e-01 | -6.92e-02 | -1.50e-01 | 9.43e-01 | 6.23e-01 | 9.49e-02 | 5.83e-01 | 2.35e-01 |
| CORTICOSTEROID RECEPTOR SIGNALING PATHWAY | 14 | 3.97e-01 | 7.86e-01 | 0.2750 | 1.80e-01 | 1.12e-01 | 8.20e-03 | 1.37e-01 | 1.08e-01 | 2.43e-01 | 4.68e-01 | 9.58e-01 | 3.77e-01 | 4.83e-01 |
| NEUROMUSCULAR PROCESS CONTROLLING BALANCE | 51 | 3.82e-01 | 7.78e-01 | 0.2750 | 1.11e-01 | 1.65e-01 | 1.52e-01 | 1.06e-01 | 3.85e-02 | 1.71e-01 | 4.16e-02 | 6.08e-02 | 1.88e-01 | 6.34e-01 |
| MYOSIN FILAMENT ORGANIZATION | 6 | 9.63e-01 | 9.94e-01 | 0.2740 | -1.61e-01 | -1.45e-01 | -1.42e-01 | -8.89e-02 | 1.69e-02 | 4.95e-01 | 5.38e-01 | 5.47e-01 | 7.06e-01 | 9.43e-01 |
| MACROMOLECULE METHYLATION | 197 | 5.48e-04 | 1.09e-02 | 0.2740 | 1.21e-01 | 7.00e-02 | 1.22e-01 | 1.57e-01 | 1.27e-01 | 3.42e-03 | 9.03e-02 | 3.04e-03 | 1.45e-04 | 2.09e-03 |
| REGULATION OF T CELL APOPTOTIC PROCESS | 39 | 8.56e-02 | 3.95e-01 | 0.2740 | -4.04e-02 | -2.52e-02 | 8.18e-02 | 8.71e-02 | 2.42e-01 | 6.62e-01 | 7.85e-01 | 3.77e-01 | 3.47e-01 | 8.80e-03 |
| REGULATION OF ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 27 | 7.48e-01 | 9.51e-01 | 0.2740 | -1.04e-01 | -1.13e-01 | -1.60e-01 | -1.53e-01 | -5.16e-02 | 3.51e-01 | 3.10e-01 | 1.49e-01 | 1.69e-01 | 6.42e-01 |
| APOPTOTIC PROCESS | 1856 | 9.54e-25 | 3.59e-22 | 0.2740 | 1.01e-01 | 1.08e-01 | 1.39e-01 | 1.41e-01 | 1.18e-01 | 4.28e-13 | 8.96e-15 | 2.67e-23 | 5.19e-24 | 4.08e-17 |
| HEART VALVE MORPHOGENESIS | 60 | 1.56e-01 | 5.28e-01 | 0.2740 | 3.97e-02 | 1.10e-01 | 1.43e-01 | 7.78e-02 | 1.87e-01 | 5.94e-01 | 1.40e-01 | 5.54e-02 | 2.97e-01 | 1.23e-02 |
| NECROPTOTIC PROCESS | 45 | 1.50e-01 | 5.19e-01 | 0.2740 | 1.88e-01 | 9.35e-02 | 7.19e-02 | 1.39e-01 | 7.97e-02 | 2.88e-02 | 2.78e-01 | 4.04e-01 | 1.06e-01 | 3.55e-01 |
| EPIGENETIC REGULATION OF GENE EXPRESSION | 210 | 1.71e-03 | 2.69e-02 | 0.2740 | 1.40e-01 | 1.10e-01 | 1.11e-01 | 1.68e-01 | 5.56e-02 | 4.91e-04 | 6.11e-03 | 5.44e-03 | 2.80e-05 | 1.65e-01 |
| MUSCLE CELL CELLULAR HOMEOSTASIS | 21 | 3.94e-01 | 7.85e-01 | 0.2740 | -1.28e-01 | -1.16e-01 | -8.59e-02 | -1.01e-01 | 1.67e-01 | 3.11e-01 | 3.58e-01 | 4.96e-01 | 4.21e-01 | 1.87e-01 |
| BLOOD VESSEL ENDOTHELIAL CELL DIFFERENTIATION | 14 | 5.63e-01 | 8.79e-01 | 0.2740 | 4.69e-02 | -3.08e-02 | 8.36e-02 | 9.79e-02 | 2.35e-01 | 7.61e-01 | 8.42e-01 | 5.88e-01 | 5.26e-01 | 1.28e-01 |
| REGULATION OF HETEROCHROMATIN ORGANIZATION | 23 | 3.47e-02 | 2.37e-01 | 0.2740 | 3.49e-02 | -7.92e-02 | -1.90e-01 | 4.63e-02 | -1.71e-01 | 7.72e-01 | 5.11e-01 | 1.14e-01 | 7.00e-01 | 1.56e-01 |
| RIBOSOME ASSOCIATED UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 7 | 7.69e-01 | 9.55e-01 | 0.2740 | 1.74e-01 | 1.22e-01 | -3.59e-02 | 1.32e-01 | -1.04e-01 | 4.24e-01 | 5.75e-01 | 8.69e-01 | 5.46e-01 | 6.32e-01 |
| REGULATION OF MRNA 3 END PROCESSING | 12 | 3.36e-01 | 7.43e-01 | 0.2740 | 6.62e-02 | -4.91e-02 | 6.53e-02 | 2.21e-01 | 1.23e-01 | 6.91e-01 | 7.69e-01 | 6.95e-01 | 1.86e-01 | 4.59e-01 |
| NEGATIVE REGULATION OF MEIOTIC NUCLEAR DIVISION | 9 | 3.89e-01 | 7.81e-01 | 0.2740 | 1.97e-01 | 5.37e-02 | 1.42e-01 | 8.36e-02 | -7.65e-02 | 3.06e-01 | 7.80e-01 | 4.60e-01 | 6.64e-01 | 6.91e-01 |
| INTESTINAL EPITHELIAL CELL DIFFERENTIATION | 27 | 2.06e-01 | 6.00e-01 | 0.2740 | 1.96e-02 | 1.19e-01 | 8.71e-02 | 5.10e-02 | 2.24e-01 | 8.60e-01 | 2.84e-01 | 4.33e-01 | 6.46e-01 | 4.41e-02 |
| NEURAL PLATE PATTERN SPECIFICATION | 8 | 4.55e-01 | 8.22e-01 | 0.2740 | -1.96e-01 | -7.31e-02 | 8.41e-02 | 7.26e-02 | 1.37e-01 | 3.38e-01 | 7.20e-01 | 6.81e-01 | 7.22e-01 | 5.01e-01 |
| CYCLIC GMP AMP TRANSMEMBRANE IMPORT ACROSS PLASMA MEMBRANE | 6 | 8.71e-01 | 9.78e-01 | 0.2740 | 7.10e-02 | 1.71e-01 | 1.13e-01 | -1.59e-03 | 1.67e-01 | 7.63e-01 | 4.68e-01 | 6.33e-01 | 9.95e-01 | 4.79e-01 |
| RESPONSE TO ISCHEMIA | 62 | 1.28e-01 | 4.85e-01 | 0.2730 | 1.41e-01 | 1.73e-01 | 8.45e-02 | 1.16e-01 | 6.56e-02 | 5.40e-02 | 1.86e-02 | 2.50e-01 | 1.14e-01 | 3.71e-01 |
| PROTEIN O LINKED GLYCOSYLATION VIA SERINE | 10 | 2.63e-01 | 6.71e-01 | 0.2730 | 1.31e-01 | -8.29e-02 | 5.55e-02 | 2.18e-01 | -9.62e-03 | 4.74e-01 | 6.50e-01 | 7.61e-01 | 2.32e-01 | 9.58e-01 |
| STORE OPERATED CALCIUM ENTRY | 21 | 4.19e-01 | 8.00e-01 | 0.2730 | 9.60e-02 | 1.57e-01 | 1.07e-01 | 1.66e-01 | -4.19e-02 | 4.46e-01 | 2.13e-01 | 3.97e-01 | 1.87e-01 | 7.39e-01 |
| PROTEIN AUTOPROCESSING | 28 | 3.96e-01 | 7.85e-01 | 0.2730 | 3.93e-02 | 2.08e-02 | 1.63e-01 | 1.32e-01 | 1.70e-01 | 7.19e-01 | 8.49e-01 | 1.35e-01 | 2.28e-01 | 1.20e-01 |
| NEGATIVE REGULATION OF GLUCOCORTICOID METABOLIC PROCESS | 5 | 9.41e-01 | 9.92e-01 | 0.2730 | -1.85e-02 | -2.97e-02 | 1.40e-01 | 1.05e-01 | 2.07e-01 | 9.43e-01 | 9.09e-01 | 5.87e-01 | 6.84e-01 | 4.23e-01 |
| DEFENSE RESPONSE TO FUNGUS | 52 | 5.93e-02 | 3.22e-01 | 0.2730 | 1.92e-02 | -1.18e-02 | -1.54e-01 | -1.06e-01 | -1.98e-01 | 8.10e-01 | 8.83e-01 | 5.52e-02 | 1.87e-01 | 1.34e-02 |
| NUCLEOSIDE PHOSPHATE BIOSYNTHETIC PROCESS | 272 | 1.99e-03 | 3.02e-02 | 0.2730 | 1.27e-01 | 1.28e-01 | 1.22e-01 | 1.25e-01 | 1.06e-01 | 3.01e-04 | 2.78e-04 | 5.13e-04 | 3.77e-04 | 2.54e-03 |
| NEGATIVE REGULATION OF COLLATERAL SPROUTING | 10 | 5.45e-01 | 8.70e-01 | 0.2730 | 1.69e-01 | 1.25e-01 | -2.31e-02 | 1.60e-01 | -6.55e-02 | 3.55e-01 | 4.94e-01 | 9.00e-01 | 3.81e-01 | 7.20e-01 |
| POSITIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DIFFERENTIATION | 12 | 8.76e-01 | 9.78e-01 | 0.2730 | 1.36e-01 | 1.83e-01 | 8.50e-02 | 1.23e-01 | 1.69e-02 | 4.14e-01 | 2.73e-01 | 6.10e-01 | 4.62e-01 | 9.19e-01 |
| REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT | 5 | 9.71e-01 | 9.95e-01 | 0.2730 | 8.55e-02 | 4.37e-02 | 1.60e-01 | 1.08e-01 | 1.67e-01 | 7.41e-01 | 8.66e-01 | 5.36e-01 | 6.76e-01 | 5.17e-01 |
| NEGATIVE REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNITY | 21 | 3.86e-02 | 2.54e-01 | 0.2730 | -1.80e-01 | -1.80e-01 | 7.49e-02 | 1.01e-02 | 6.42e-02 | 1.54e-01 | 1.54e-01 | 5.52e-01 | 9.36e-01 | 6.11e-01 |
| NEGATIVE REGULATION OF INFLAMMASOME MEDIATED SIGNALING PATHWAY | 15 | 2.73e-01 | 6.81e-01 | 0.2730 | -3.22e-03 | -5.99e-03 | 2.26e-02 | -5.84e-02 | 2.65e-01 | 9.83e-01 | 9.68e-01 | 8.79e-01 | 6.95e-01 | 7.52e-02 |
| SYNAPTONEMAL COMPLEX ORGANIZATION | 25 | 1.01e-01 | 4.34e-01 | 0.2730 | -4.62e-02 | -1.51e-01 | -6.79e-02 | -1.10e-01 | -1.81e-01 | 6.89e-01 | 1.92e-01 | 5.57e-01 | 3.41e-01 | 1.17e-01 |
| VESICLE UNCOATING | 8 | 8.04e-01 | 9.67e-01 | 0.2730 | -2.34e-02 | -1.17e-02 | 1.75e-01 | 1.21e-01 | 1.69e-01 | 9.09e-01 | 9.54e-01 | 3.92e-01 | 5.54e-01 | 4.08e-01 |
| REGULATION OF HISTONE METHYLATION | 16 | 3.74e-01 | 7.73e-01 | 0.2730 | 7.80e-02 | 5.63e-02 | -3.02e-02 | 8.39e-02 | -2.39e-01 | 5.89e-01 | 6.97e-01 | 8.34e-01 | 5.61e-01 | 9.80e-02 |
| MEMBRANE REPOLARIZATION DURING VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL | 15 | 3.34e-01 | 7.40e-01 | 0.2720 | -8.68e-02 | -7.27e-02 | -9.47e-02 | -2.06e-01 | 9.97e-02 | 5.61e-01 | 6.26e-01 | 5.26e-01 | 1.67e-01 | 5.04e-01 |
| REGULATION OF IRON ION TRANSPORT | 7 | 5.74e-01 | 8.84e-01 | 0.2720 | 1.34e-01 | -8.18e-03 | 4.90e-02 | 3.94e-02 | 2.29e-01 | 5.40e-01 | 9.70e-01 | 8.22e-01 | 8.57e-01 | 2.95e-01 |
| ACYLGLYCEROL HOMEOSTASIS | 42 | 7.90e-04 | 1.45e-02 | 0.2720 | -1.45e-01 | 3.72e-02 | -3.08e-02 | -2.07e-01 | -8.98e-02 | 1.04e-01 | 6.76e-01 | 7.29e-01 | 2.04e-02 | 3.14e-01 |
| NEGATIVE REGULATION OF EXOCYTOSIS | 32 | 3.27e-01 | 7.35e-01 | 0.2720 | 1.99e-01 | 1.38e-01 | 3.79e-02 | 1.17e-01 | -2.03e-02 | 5.12e-02 | 1.77e-01 | 7.10e-01 | 2.53e-01 | 8.43e-01 |
| POSITIVE REGULATION OF RECEPTOR RECYCLING | 14 | 8.55e-01 | 9.76e-01 | 0.2720 | -1.75e-01 | -1.34e-01 | -1.04e-01 | -1.07e-01 | 5.92e-02 | 2.58e-01 | 3.85e-01 | 5.02e-01 | 4.89e-01 | 7.01e-01 |
| REGULATION OF CORTICOSTEROID HORMONE SECRETION | 16 | 4.51e-01 | 8.21e-01 | 0.2720 | 1.80e-01 | 1.11e-01 | 1.84e-02 | 1.63e-01 | 4.92e-02 | 2.12e-01 | 4.40e-01 | 8.99e-01 | 2.60e-01 | 7.33e-01 |
| EPITHELIAL TUBE FORMATION | 136 | 6.72e-03 | 7.65e-02 | 0.2720 | 3.68e-02 | 9.09e-02 | 1.40e-01 | 1.05e-01 | 1.84e-01 | 4.59e-01 | 6.73e-02 | 4.73e-03 | 3.39e-02 | 2.17e-04 |
| TOLL SIGNALING PATHWAY | 10 | 9.70e-01 | 9.95e-01 | 0.2720 | 1.15e-01 | 8.19e-02 | 1.37e-01 | 1.41e-01 | 1.25e-01 | 5.28e-01 | 6.54e-01 | 4.53e-01 | 4.42e-01 | 4.95e-01 |
| NEGATIVE REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 21 | 1.54e-01 | 5.25e-01 | 0.2720 | -3.01e-03 | 3.98e-02 | 2.23e-01 | 1.02e-01 | 1.11e-01 | 9.81e-01 | 7.52e-01 | 7.66e-02 | 4.20e-01 | 3.79e-01 |
| VITAMIN BIOSYNTHETIC PROCESS | 24 | 7.70e-01 | 9.55e-01 | 0.2720 | 5.13e-02 | 8.57e-02 | 1.47e-01 | 1.33e-01 | 1.57e-01 | 6.64e-01 | 4.67e-01 | 2.12e-01 | 2.59e-01 | 1.83e-01 |
| RESPONSE TO ZINC ION | 48 | 1.92e-02 | 1.62e-01 | 0.2720 | -1.43e-02 | 7.51e-02 | 1.47e-01 | -6.81e-03 | 2.15e-01 | 8.64e-01 | 3.68e-01 | 7.72e-02 | 9.35e-01 | 9.87e-03 |
| NEUROTRANSMITTER RECEPTOR TRANSPORT ENDOSOME TO POSTSYNAPTIC MEMBRANE | 10 | 3.84e-01 | 7.79e-01 | 0.2720 | -1.86e-01 | -1.09e-03 | -9.10e-03 | -1.29e-01 | -1.50e-01 | 3.08e-01 | 9.95e-01 | 9.60e-01 | 4.81e-01 | 4.10e-01 |
| POSITIVE REGULATION OF MULTICELLULAR ORGANISM GROWTH | 31 | 4.19e-01 | 8.00e-01 | 0.2720 | 1.49e-01 | 1.93e-01 | 8.70e-02 | 7.53e-02 | 3.68e-02 | 1.51e-01 | 6.33e-02 | 4.02e-01 | 4.68e-01 | 7.23e-01 |
| GLUTAMINE TRANSPORT | 9 | 8.28e-01 | 9.72e-01 | 0.2720 | 1.33e-01 | 1.14e-01 | 6.67e-02 | 7.33e-02 | 1.83e-01 | 4.90e-01 | 5.52e-01 | 7.29e-01 | 7.04e-01 | 3.43e-01 |
| REGULATION OF VITAMIN METABOLIC PROCESS | 12 | 9.30e-01 | 9.90e-01 | 0.2720 | 1.77e-01 | 1.35e-01 | 7.60e-02 | 1.36e-01 | 1.24e-02 | 2.89e-01 | 4.17e-01 | 6.48e-01 | 4.16e-01 | 9.41e-01 |
| G QUADRUPLEX DNA UNWINDING | 7 | 6.30e-01 | 9.10e-01 | 0.2720 | -1.39e-01 | -1.43e-01 | -1.60e-01 | -1.51e-02 | 9.01e-02 | 5.23e-01 | 5.12e-01 | 4.64e-01 | 9.45e-01 | 6.80e-01 |
| CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 31 | 2.64e-01 | 6.72e-01 | 0.2720 | -1.25e-04 | 1.18e-02 | 1.21e-01 | 1.40e-01 | 1.99e-01 | 9.99e-01 | 9.10e-01 | 2.45e-01 | 1.77e-01 | 5.53e-02 |
| NEGATIVE REGULATION OF ALPHA BETA T CELL ACTIVATION | 44 | 2.07e-01 | 6.02e-01 | 0.2720 | 1.00e-01 | 3.54e-02 | 1.27e-01 | 1.75e-01 | 1.25e-01 | 2.50e-01 | 6.84e-01 | 1.44e-01 | 4.47e-02 | 1.50e-01 |
| CDC42 PROTEIN SIGNAL TRANSDUCTION | 16 | 5.05e-01 | 8.50e-01 | 0.2720 | -7.99e-02 | -2.99e-02 | -1.72e-01 | -1.85e-01 | -5.09e-02 | 5.80e-01 | 8.36e-01 | 2.33e-01 | 2.00e-01 | 7.25e-01 |
| UREA TRANSMEMBRANE TRANSPORT | 9 | 2.18e-01 | 6.15e-01 | 0.2720 | 2.46e-02 | 6.86e-02 | -7.46e-02 | -1.06e-01 | 2.27e-01 | 8.98e-01 | 7.21e-01 | 6.98e-01 | 5.83e-01 | 2.37e-01 |
| CAMERA TYPE EYE PHOTORECEPTOR CELL DIFFERENTIATION | 29 | 1.96e-01 | 5.84e-01 | 0.2720 | -1.34e-01 | -8.02e-02 | -7.33e-02 | -1.50e-01 | 1.46e-01 | 2.12e-01 | 4.55e-01 | 4.95e-01 | 1.61e-01 | 1.73e-01 |
| REGULATION OF SUPEROXIDE ANION GENERATION | 19 | 4.85e-01 | 8.38e-01 | 0.2710 | 1.44e-01 | 1.88e-01 | 4.12e-02 | 1.04e-01 | -7.02e-02 | 2.77e-01 | 1.55e-01 | 7.56e-01 | 4.34e-01 | 5.96e-01 |
| PROTEIN LOCALIZATION TO ENDOPLASMIC RETICULUM | 68 | 4.00e-02 | 2.58e-01 | 0.2710 | 8.09e-02 | 9.62e-02 | 1.78e-01 | 1.58e-01 | 3.27e-02 | 2.48e-01 | 1.70e-01 | 1.10e-02 | 2.42e-02 | 6.41e-01 |
| REGULATION OF CARDIAC MUSCLE CELL ACTION POTENTIAL INVOLVED IN REGULATION OF CONTRACTION | 7 | 6.13e-01 | 9.05e-01 | 0.2710 | 8.43e-02 | 6.66e-02 | 3.67e-02 | -3.79e-02 | 2.44e-01 | 6.99e-01 | 7.60e-01 | 8.66e-01 | 8.62e-01 | 2.64e-01 |
| NEURON REMODELING | 15 | 5.00e-01 | 8.48e-01 | 0.2710 | 1.31e-01 | 2.24e-01 | 6.60e-02 | 4.21e-02 | 8.24e-03 | 3.81e-01 | 1.32e-01 | 6.58e-01 | 7.78e-01 | 9.56e-01 |
| CELLULAR RESPONSE TO RADIATION | 170 | 1.32e-02 | 1.24e-01 | 0.2710 | 1.04e-01 | 1.13e-01 | 1.20e-01 | 1.48e-01 | 1.17e-01 | 1.91e-02 | 1.08e-02 | 7.12e-03 | 8.46e-04 | 8.74e-03 |
| REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 24 | 5.27e-01 | 8.60e-01 | 0.2710 | 1.04e-02 | 1.18e-01 | 1.59e-01 | 7.10e-02 | 1.71e-01 | 9.30e-01 | 3.18e-01 | 1.77e-01 | 5.47e-01 | 1.47e-01 |
| UTERINE SMOOTH MUSCLE CONTRACTION | 9 | 6.60e-01 | 9.21e-01 | 0.2710 | 7.52e-02 | -5.60e-02 | 1.03e-01 | 1.55e-01 | 1.73e-01 | 6.96e-01 | 7.71e-01 | 5.93e-01 | 4.20e-01 | 3.68e-01 |
| SELF PROTEOLYSIS | 12 | 5.55e-01 | 8.77e-01 | 0.2710 | 4.48e-02 | 1.35e-01 | 1.73e-01 | 1.45e-01 | -4.58e-02 | 7.88e-01 | 4.17e-01 | 2.99e-01 | 3.84e-01 | 7.84e-01 |
| MESODERM MORPHOGENESIS | 76 | 1.13e-01 | 4.57e-01 | 0.2710 | 4.67e-02 | 7.69e-02 | 1.30e-01 | 9.90e-02 | 1.97e-01 | 4.82e-01 | 2.46e-01 | 4.99e-02 | 1.36e-01 | 3.05e-03 |
| REGULATION OF DENDRITIC SPINE DEVELOPMENT | 52 | 4.44e-01 | 8.14e-01 | 0.2710 | -1.26e-01 | -9.46e-02 | -1.36e-01 | -1.20e-01 | -1.25e-01 | 1.17e-01 | 2.38e-01 | 9.02e-02 | 1.34e-01 | 1.17e-01 |
| LOBAR BRONCHUS DEVELOPMENT | 6 | 7.31e-01 | 9.44e-01 | 0.2710 | 1.65e-01 | 1.32e-01 | -3.10e-03 | 6.90e-02 | 1.55e-01 | 4.85e-01 | 5.76e-01 | 9.90e-01 | 7.70e-01 | 5.10e-01 |
| POSITIVE REGULATION OF ATP METABOLIC PROCESS | 10 | 6.34e-02 | 3.35e-01 | 0.2710 | 1.77e-01 | 2.27e-02 | -1.68e-01 | -1.13e-01 | 2.26e-02 | 3.32e-01 | 9.01e-01 | 3.58e-01 | 5.37e-01 | 9.01e-01 |
| ENDOPLASMIC RETICULUM ORGANIZATION | 96 | 4.93e-02 | 2.90e-01 | 0.2710 | 1.55e-01 | 8.63e-02 | 1.23e-01 | 1.59e-01 | 3.44e-02 | 8.53e-03 | 1.44e-01 | 3.72e-02 | 6.98e-03 | 5.61e-01 |
| MATURE B CELL DIFFERENTIATION | 35 | 3.07e-01 | 7.19e-01 | 0.2710 | 1.47e-01 | 1.39e-01 | 6.49e-02 | 1.54e-01 | 6.71e-02 | 1.33e-01 | 1.53e-01 | 5.06e-01 | 1.16e-01 | 4.92e-01 |
| REGULATION OF STORE OPERATED CALCIUM CHANNEL ACTIVITY | 6 | 7.70e-01 | 9.55e-01 | 0.2710 | 1.01e-01 | 1.63e-01 | -6.00e-03 | 1.08e-01 | -1.58e-01 | 6.69e-01 | 4.89e-01 | 9.80e-01 | 6.48e-01 | 5.04e-01 |
| THIAMINE DIPHOSPHATE METABOLIC PROCESS | 5 | 9.52e-01 | 9.94e-01 | 0.2710 | -1.47e-01 | -1.39e-01 | -1.45e-01 | -8.17e-02 | 6.68e-02 | 5.68e-01 | 5.90e-01 | 5.75e-01 | 7.52e-01 | 7.96e-01 |
| NEGATIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 19 | 8.46e-02 | 3.94e-01 | 0.2700 | -1.59e-01 | -1.06e-01 | 5.12e-02 | 9.56e-02 | 1.58e-01 | 2.30e-01 | 4.23e-01 | 6.99e-01 | 4.71e-01 | 2.34e-01 |
| CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS | 267 | 6.57e-04 | 1.25e-02 | 0.2700 | 1.13e-01 | 1.18e-01 | 1.18e-01 | 1.52e-01 | 9.63e-02 | 1.51e-03 | 8.71e-04 | 8.69e-04 | 1.87e-05 | 6.73e-03 |
| REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA SIGNALING PATHWAY | 8 | 4.75e-01 | 8.32e-01 | 0.2700 | 4.75e-02 | 2.50e-01 | 8.03e-02 | -2.21e-02 | -3.84e-02 | 8.16e-01 | 2.21e-01 | 6.94e-01 | 9.14e-01 | 8.51e-01 |
| FRUCTOSE TRANSMEMBRANE TRANSPORT | 10 | 1.90e-01 | 5.78e-01 | 0.2700 | 1.08e-01 | 2.36e-01 | -2.32e-02 | -6.09e-02 | 3.80e-02 | 5.54e-01 | 1.96e-01 | 8.99e-01 | 7.39e-01 | 8.35e-01 |
| REGULATION OF CARDIOCYTE DIFFERENTIATION | 32 | 5.99e-01 | 8.98e-01 | 0.2700 | 9.29e-02 | 1.31e-01 | 1.71e-01 | 9.21e-02 | 9.70e-02 | 3.63e-01 | 1.99e-01 | 9.40e-02 | 3.67e-01 | 3.42e-01 |
| NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 28 | 2.51e-01 | 6.58e-01 | 0.2700 | 2.12e-01 | 1.02e-01 | 5.03e-02 | 1.14e-01 | 4.84e-02 | 5.27e-02 | 3.50e-01 | 6.45e-01 | 2.97e-01 | 6.58e-01 |
| REGULATION OF NEUTROPHIL MIGRATION | 40 | 6.55e-02 | 3.41e-01 | 0.2700 | 2.06e-01 | 1.61e-01 | 2.49e-02 | 5.48e-02 | -2.74e-02 | 2.40e-02 | 7.73e-02 | 7.85e-01 | 5.48e-01 | 7.64e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 57 | 5.52e-02 | 3.11e-01 | 0.2700 | 2.56e-02 | 1.15e-02 | 1.04e-01 | 1.30e-01 | 2.11e-01 | 7.38e-01 | 8.80e-01 | 1.74e-01 | 8.94e-02 | 5.93e-03 |
| ENDOPLASMIC RETICULUM TUBULAR NETWORK ORGANIZATION | 20 | 2.52e-01 | 6.58e-01 | 0.2700 | 2.12e-01 | 5.73e-02 | 1.75e-02 | 1.55e-01 | 2.00e-02 | 1.01e-01 | 6.57e-01 | 8.92e-01 | 2.31e-01 | 8.77e-01 |
| REGULATION OF CD40 SIGNALING PATHWAY | 6 | 8.79e-01 | 9.79e-01 | 0.2700 | 1.48e-01 | 9.83e-02 | 1.65e-01 | 6.15e-02 | 1.01e-01 | 5.31e-01 | 6.77e-01 | 4.83e-01 | 7.94e-01 | 6.67e-01 |
| POSITIVE REGULATION OF IMMUNOGLOBULIN PRODUCTION | 52 | 4.71e-02 | 2.85e-01 | 0.2700 | 7.20e-02 | 1.65e-01 | 1.19e-01 | 1.54e-01 | 5.22e-02 | 3.69e-01 | 3.99e-02 | 1.38e-01 | 5.48e-02 | 5.15e-01 |
| RESPONSE TO CHEMOKINE | 96 | 5.63e-03 | 6.71e-02 | 0.2700 | -9.84e-02 | -1.01e-01 | -1.35e-01 | -1.86e-01 | -3.74e-04 | 9.58e-02 | 8.66e-02 | 2.22e-02 | 1.61e-03 | 9.95e-01 |
| BLOOD VESSEL ENDOTHELIAL CELL PROLIFERATION INVOLVED IN SPROUTING ANGIOGENESIS | 51 | 1.50e-01 | 5.19e-01 | 0.2700 | -1.79e-01 | -1.69e-01 | -8.60e-02 | -6.76e-02 | 3.53e-03 | 2.67e-02 | 3.65e-02 | 2.88e-01 | 4.04e-01 | 9.65e-01 |
| HEPATOCYTE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 12 | 6.90e-01 | 9.31e-01 | 0.2700 | 9.93e-03 | -1.26e-01 | -1.70e-01 | -3.28e-02 | -1.64e-01 | 9.53e-01 | 4.50e-01 | 3.08e-01 | 8.44e-01 | 3.25e-01 |
| DOUBLE STRAND BREAK REPAIR VIA CLASSICAL NONHOMOLOGOUS END JOINING | 6 | 9.80e-01 | 9.96e-01 | 0.2700 | 1.60e-01 | 1.31e-01 | 9.08e-02 | 1.29e-01 | -7.23e-02 | 4.98e-01 | 5.79e-01 | 7.00e-01 | 5.85e-01 | 7.59e-01 |
| REGULATION OF LEUKOCYTE TETHERING OR ROLLING | 18 | 7.69e-01 | 9.55e-01 | 0.2690 | -1.00e-01 | -4.87e-02 | -1.53e-01 | -1.44e-01 | -1.27e-01 | 4.63e-01 | 7.20e-01 | 2.62e-01 | 2.89e-01 | 3.52e-01 |
| REGULATION OF ORGAN GROWTH | 93 | 1.89e-01 | 5.74e-01 | 0.2690 | 1.27e-01 | 1.60e-01 | 1.32e-01 | 1.03e-01 | 5.32e-02 | 3.43e-02 | 7.64e-03 | 2.83e-02 | 8.46e-02 | 3.75e-01 |
| EPITHELIAL TUBE MORPHOGENESIS | 326 | 6.87e-05 | 2.03e-03 | 0.2690 | 7.66e-02 | 1.13e-01 | 1.36e-01 | 1.21e-01 | 1.44e-01 | 1.74e-02 | 4.62e-04 | 2.28e-05 | 1.71e-04 | 7.84e-06 |
| NAD TRANSPORT | 5 | 8.44e-01 | 9.75e-01 | 0.2690 | 3.23e-03 | -1.61e-02 | -1.95e-01 | -2.69e-02 | -1.83e-01 | 9.90e-01 | 9.50e-01 | 4.50e-01 | 9.17e-01 | 4.78e-01 |
| SYNAPTIC VESICLE COATING | 5 | 8.72e-01 | 9.78e-01 | 0.2690 | 1.77e-01 | 4.16e-02 | 6.20e-02 | 9.43e-02 | 1.63e-01 | 4.92e-01 | 8.72e-01 | 8.10e-01 | 7.15e-01 | 5.27e-01 |
| TUBE FORMATION | 149 | 3.25e-03 | 4.44e-02 | 0.2690 | 3.10e-02 | 8.15e-02 | 1.40e-01 | 1.05e-01 | 1.86e-01 | 5.14e-01 | 8.61e-02 | 3.22e-03 | 2.74e-02 | 9.20e-05 |
| RESPONSE TO ATP | 31 | 5.37e-01 | 8.66e-01 | 0.2690 | 1.09e-01 | 1.64e-01 | 1.57e-01 | 9.42e-02 | 1.42e-02 | 2.94e-01 | 1.13e-01 | 1.31e-01 | 3.64e-01 | 8.91e-01 |
| REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA SIGNALING PATHWAY | 5 | 6.37e-01 | 9.13e-01 | 0.2690 | -7.91e-04 | -2.04e-01 | -1.64e-01 | 5.34e-02 | 2.90e-02 | 9.98e-01 | 4.29e-01 | 5.24e-01 | 8.36e-01 | 9.10e-01 |
| POSITIVE REGULATION OF NEURON PROJECTION REGENERATION | 10 | 7.55e-01 | 9.51e-01 | 0.2690 | -1.07e-02 | -8.42e-02 | -2.06e-01 | -6.95e-02 | -1.34e-01 | 9.53e-01 | 6.45e-01 | 2.60e-01 | 7.03e-01 | 4.62e-01 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR PRODUCTION | 57 | 3.81e-02 | 2.52e-01 | 0.2690 | -3.28e-02 | 1.27e-02 | -1.16e-01 | -1.20e-01 | -2.08e-01 | 6.68e-01 | 8.68e-01 | 1.30e-01 | 1.16e-01 | 6.62e-03 |
| STEM CELL DIVISION | 30 | 6.68e-01 | 9.24e-01 | 0.2690 | 5.23e-02 | 9.30e-02 | 1.36e-01 | 1.31e-01 | 1.59e-01 | 6.20e-01 | 3.78e-01 | 1.98e-01 | 2.15e-01 | 1.31e-01 |
| POSITIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 79 | 8.54e-02 | 3.95e-01 | 0.2690 | 1.76e-01 | 1.50e-01 | 8.61e-02 | 9.67e-02 | 4.68e-02 | 6.83e-03 | 2.15e-02 | 1.86e-01 | 1.37e-01 | 4.72e-01 |
| RELAXATION OF SMOOTH MUSCLE | 9 | 9.76e-01 | 9.96e-01 | 0.2690 | 8.62e-02 | 1.05e-01 | 1.22e-01 | 1.40e-01 | 1.39e-01 | 6.54e-01 | 5.86e-01 | 5.26e-01 | 4.66e-01 | 4.70e-01 |
| PEPTIDE ANTIGEN ASSEMBLY WITH MHC CLASS II PROTEIN COMPLEX | 14 | 6.34e-01 | 9.12e-01 | 0.2690 | 4.67e-02 | 4.43e-02 | -5.97e-02 | -3.70e-02 | -2.52e-01 | 7.62e-01 | 7.74e-01 | 6.99e-01 | 8.11e-01 | 1.03e-01 |
| POSITIVE REGULATION OF NEUROTRANSMITTER SECRETION | 17 | 6.09e-01 | 9.03e-01 | 0.2690 | -1.75e-01 | -1.53e-01 | -2.75e-02 | -1.31e-01 | 2.42e-02 | 2.13e-01 | 2.76e-01 | 8.44e-01 | 3.50e-01 | 8.63e-01 |
| NEGATIVE REGULATION OF SKELETAL MUSCLE CELL PROLIFERATION | 5 | 8.68e-01 | 9.78e-01 | 0.2690 | -1.87e-01 | -1.35e-01 | -1.90e-02 | 1.67e-02 | 1.36e-01 | 4.69e-01 | 6.02e-01 | 9.41e-01 | 9.48e-01 | 5.98e-01 |
| POSITIVE REGULATION OF NUCLEOTIDE BIOSYNTHETIC PROCESS | 13 | 5.60e-01 | 8.78e-01 | 0.2690 | -3.39e-02 | -4.77e-02 | -1.67e-01 | -1.96e-01 | -5.06e-02 | 8.32e-01 | 7.66e-01 | 2.96e-01 | 2.22e-01 | 7.52e-01 |
| MARGINAL ZONE B CELL DIFFERENTIATION | 8 | 6.30e-01 | 9.10e-01 | 0.2690 | -9.66e-02 | -3.31e-02 | -5.82e-02 | -4.99e-02 | 2.36e-01 | 6.36e-01 | 8.71e-01 | 7.75e-01 | 8.07e-01 | 2.47e-01 |
| RESPONSE TO LIPOTEICHOIC ACID | 10 | 1.61e-01 | 5.36e-01 | 0.2690 | 2.39e-01 | 4.86e-02 | -1.10e-01 | 2.34e-02 | -2.41e-03 | 1.90e-01 | 7.90e-01 | 5.49e-01 | 8.98e-01 | 9.89e-01 |
| MITOTIC SPINDLE ELONGATION | 11 | 3.85e-01 | 7.79e-01 | 0.2690 | 2.22e-01 | 2.05e-03 | 1.40e-02 | 1.33e-01 | -7.20e-02 | 2.03e-01 | 9.91e-01 | 9.36e-01 | 4.46e-01 | 6.79e-01 |
| REGULATION OF TRANSFORMING GROWTH FACTOR BETA1 PRODUCTION | 12 | 4.20e-01 | 8.00e-01 | 0.2690 | 6.38e-02 | 8.84e-02 | -1.31e-01 | -1.29e-02 | -2.07e-01 | 7.02e-01 | 5.96e-01 | 4.32e-01 | 9.38e-01 | 2.14e-01 |
| RNA CATABOLIC PROCESS | 349 | 1.08e-07 | 5.87e-06 | 0.2690 | 1.15e-01 | 6.36e-02 | 1.24e-01 | 1.70e-01 | 1.02e-01 | 2.18e-04 | 4.12e-02 | 6.78e-05 | 4.76e-08 | 1.01e-03 |
| TOLL LIKE RECEPTOR SIGNALING PATHWAY | 67 | 4.70e-01 | 8.29e-01 | 0.2680 | 1.37e-01 | 1.47e-01 | 1.16e-01 | 1.26e-01 | 4.81e-02 | 5.21e-02 | 3.70e-02 | 9.99e-02 | 7.56e-02 | 4.96e-01 |
| POTASSIUM ION EXPORT ACROSS PLASMA MEMBRANE | 19 | 3.97e-01 | 7.86e-01 | 0.2680 | -4.86e-02 | -2.88e-02 | -1.51e-01 | -2.01e-01 | -7.45e-02 | 7.14e-01 | 8.28e-01 | 2.55e-01 | 1.29e-01 | 5.74e-01 |
| OOCYTE MATURATION | 33 | 4.72e-01 | 8.30e-01 | 0.2680 | 8.91e-02 | 4.24e-02 | 1.29e-01 | 1.63e-01 | 1.38e-01 | 3.76e-01 | 6.74e-01 | 2.01e-01 | 1.05e-01 | 1.70e-01 |
| POSITIVE REGULATION OF MIRNA TRANSCRIPTION | 50 | 5.04e-01 | 8.50e-01 | 0.2680 | 7.88e-02 | 1.04e-01 | 1.29e-01 | 1.32e-01 | 1.44e-01 | 3.35e-01 | 2.01e-01 | 1.15e-01 | 1.05e-01 | 7.83e-02 |
| REGULATION OF T HELPER 17 CELL DIFFERENTIATION | 21 | 7.22e-01 | 9.40e-01 | 0.2680 | 3.97e-02 | 4.85e-02 | 1.28e-01 | 1.37e-01 | 1.81e-01 | 7.53e-01 | 7.00e-01 | 3.10e-01 | 2.76e-01 | 1.51e-01 |
| NEUROTRANSMITTER RECEPTOR TRANSPORT TO PLASMA MEMBRANE | 16 | 4.60e-01 | 8.23e-01 | 0.2680 | -2.14e-01 | -5.67e-02 | -2.93e-02 | -1.41e-01 | 4.91e-02 | 1.39e-01 | 6.94e-01 | 8.39e-01 | 3.30e-01 | 7.34e-01 |
| TOLL LIKE RECEPTOR 7 SIGNALING PATHWAY | 9 | 5.19e-01 | 8.57e-01 | 0.2680 | 1.98e-01 | 6.23e-02 | -6.36e-02 | -2.94e-02 | -1.54e-01 | 3.03e-01 | 7.46e-01 | 7.41e-01 | 8.79e-01 | 4.24e-01 |
| NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 193 | 9.07e-04 | 1.62e-02 | 0.2680 | 1.66e-01 | 1.22e-01 | 8.48e-02 | 1.31e-01 | 7.20e-02 | 6.91e-05 | 3.60e-03 | 4.21e-02 | 1.77e-03 | 8.45e-02 |
| PROTOPORPHYRINOGEN IX METABOLIC PROCESS | 10 | 4.06e-01 | 7.93e-01 | 0.2680 | 8.47e-02 | 1.67e-01 | 3.05e-02 | 1.44e-01 | 1.23e-01 | 6.43e-01 | 3.61e-01 | 8.67e-01 | 4.31e-01 | 4.99e-01 |
| NEGATIVE REGULATION OF CYTOPLASMIC TRANSLATION | 8 | 7.88e-01 | 9.63e-01 | 0.2680 | 1.04e-01 | -1.80e-02 | 9.53e-02 | 1.21e-01 | 1.92e-01 | 6.12e-01 | 9.30e-01 | 6.41e-01 | 5.53e-01 | 3.47e-01 |
| POSITIVE REGULATION OF CHONDROCYTE DIFFERENTIATION | 20 | 8.13e-01 | 9.68e-01 | 0.2680 | -1.81e-01 | -1.19e-01 | -8.91e-02 | -1.29e-01 | 1.47e-02 | 1.62e-01 | 3.56e-01 | 4.90e-01 | 3.18e-01 | 9.10e-01 |
| MODIFICATION OF SYNAPTIC STRUCTURE | 27 | 5.84e-01 | 8.90e-01 | 0.2680 | 6.06e-02 | 8.75e-02 | 1.13e-01 | 1.49e-01 | 1.59e-01 | 5.86e-01 | 4.31e-01 | 3.10e-01 | 1.80e-01 | 1.52e-01 |
| POSITIVE REGULATION OF AMIDE METABOLIC PROCESS | 155 | 3.39e-02 | 2.34e-01 | 0.2670 | 1.58e-01 | 1.30e-01 | 1.11e-01 | 1.20e-01 | 5.32e-02 | 6.68e-04 | 5.17e-03 | 1.70e-02 | 9.99e-03 | 2.53e-01 |
| MACROPHAGE ACTIVATION INVOLVED IN IMMUNE RESPONSE | 19 | 1.03e-01 | 4.37e-01 | 0.2670 | 1.76e-01 | 4.49e-02 | -1.30e-01 | -3.29e-02 | -1.43e-01 | 1.84e-01 | 7.35e-01 | 3.25e-01 | 8.04e-01 | 2.82e-01 |
| RESPONSE TO INACTIVITY | 12 | 7.45e-01 | 9.50e-01 | 0.2670 | -1.85e-02 | -1.02e-02 | -1.35e-01 | -1.69e-01 | -1.55e-01 | 9.11e-01 | 9.51e-01 | 4.18e-01 | 3.10e-01 | 3.52e-01 |
| FATTY ACID CATABOLIC PROCESS | 104 | 2.92e-02 | 2.13e-01 | 0.2670 | 1.53e-01 | 1.22e-01 | 8.52e-02 | 1.18e-01 | 1.10e-01 | 7.06e-03 | 3.12e-02 | 1.33e-01 | 3.83e-02 | 5.35e-02 |
| TYPE III INTERFERON PRODUCTION | 5 | 9.46e-01 | 9.94e-01 | 0.2670 | 1.63e-01 | 1.14e-01 | -1.06e-02 | 1.06e-01 | -1.43e-01 | 5.27e-01 | 6.60e-01 | 9.67e-01 | 6.82e-01 | 5.80e-01 |
| URINARY TRACT SMOOTH MUSCLE CONTRACTION | 9 | 6.18e-01 | 9.07e-01 | 0.2670 | -2.23e-02 | -1.10e-02 | 6.10e-03 | -6.26e-02 | 2.58e-01 | 9.08e-01 | 9.55e-01 | 9.75e-01 | 7.45e-01 | 1.80e-01 |
| RESPONSE TO FOLIC ACID | 10 | 4.41e-01 | 8.12e-01 | 0.2670 | -2.33e-02 | 2.85e-02 | -2.48e-02 | -4.04e-02 | 2.60e-01 | 8.98e-01 | 8.76e-01 | 8.92e-01 | 8.25e-01 | 1.55e-01 |
| VOLUNTARY MUSCULOSKELETAL MOVEMENT | 7 | 8.41e-01 | 9.74e-01 | 0.2670 | 1.71e-01 | 4.19e-02 | 2.03e-02 | 1.62e-01 | -1.16e-01 | 4.33e-01 | 8.48e-01 | 9.26e-01 | 4.59e-01 | 5.94e-01 |
| TERPENOID BIOSYNTHETIC PROCESS | 16 | 1.71e-01 | 5.55e-01 | 0.2670 | 2.30e-01 | 1.02e-01 | 3.06e-02 | 3.79e-02 | 7.48e-02 | 1.12e-01 | 4.80e-01 | 8.32e-01 | 7.93e-01 | 6.04e-01 |
| ALDEHYDE CATABOLIC PROCESS | 14 | 4.19e-01 | 8.00e-01 | 0.2670 | 5.42e-02 | 8.15e-02 | 1.72e-01 | 1.70e-01 | -5.50e-02 | 7.25e-01 | 5.97e-01 | 2.66e-01 | 2.70e-01 | 7.22e-01 |
| MESENCHYME DEVELOPMENT | 311 | 1.52e-06 | 6.84e-05 | 0.2660 | 5.07e-02 | 9.07e-02 | 1.24e-01 | 1.22e-01 | 1.73e-01 | 1.24e-01 | 5.94e-03 | 1.69e-04 | 2.06e-04 | 1.59e-07 |
| NEUROTRANSMITTER UPTAKE | 44 | 1.27e-01 | 4.84e-01 | 0.2660 | 2.05e-02 | 1.03e-01 | 1.01e-01 | 5.83e-02 | 2.15e-01 | 8.14e-01 | 2.38e-01 | 2.45e-01 | 5.04e-01 | 1.36e-02 |
| REGULATION OF DENDRITIC SPINE MAINTENANCE | 13 | 3.28e-01 | 7.37e-01 | 0.2660 | -3.69e-02 | -7.91e-03 | -2.16e-01 | -9.89e-02 | -1.13e-01 | 8.18e-01 | 9.61e-01 | 1.77e-01 | 5.37e-01 | 4.79e-01 |
| HYALURONAN METABOLIC PROCESS | 33 | 2.28e-01 | 6.31e-01 | 0.2660 | -3.47e-02 | 1.48e-02 | -1.14e-01 | -1.29e-01 | -2.00e-01 | 7.30e-01 | 8.83e-01 | 2.58e-01 | 1.99e-01 | 4.72e-02 |
| NK T CELL DIFFERENTIATION | 11 | 8.21e-01 | 9.71e-01 | 0.2660 | 2.07e-02 | 8.28e-02 | 1.94e-01 | 8.86e-02 | 1.34e-01 | 9.06e-01 | 6.34e-01 | 2.65e-01 | 6.11e-01 | 4.42e-01 |
| CELLULAR RESPONSE TO ESTROGEN STIMULUS | 18 | 1.40e-01 | 5.04e-01 | 0.2660 | 1.82e-01 | 2.37e-02 | -2.03e-03 | 1.51e-01 | 1.20e-01 | 1.82e-01 | 8.62e-01 | 9.88e-01 | 2.66e-01 | 3.80e-01 |
| PTERIDINE CONTAINING COMPOUND METABOLIC PROCESS | 32 | 2.03e-01 | 5.96e-01 | 0.2660 | 1.69e-01 | 1.07e-01 | 3.82e-02 | 1.54e-01 | 7.61e-02 | 9.87e-02 | 2.97e-01 | 7.09e-01 | 1.33e-01 | 4.56e-01 |
| REGULATION OF GONADOTROPIN SECRETION | 11 | 6.79e-01 | 9.28e-01 | 0.2660 | -8.72e-02 | -7.05e-02 | -1.41e-01 | -1.87e-01 | 5.80e-02 | 6.16e-01 | 6.86e-01 | 4.19e-01 | 2.83e-01 | 7.39e-01 |
| VAGINA DEVELOPMENT | 10 | 5.68e-01 | 8.81e-01 | 0.2660 | 1.25e-01 | 1.71e-01 | 3.35e-02 | 3.01e-02 | 1.54e-01 | 4.95e-01 | 3.48e-01 | 8.54e-01 | 8.69e-01 | 3.99e-01 |
| MAINTENANCE OF PROTEIN LOCATION | 85 | 5.75e-02 | 3.16e-01 | 0.2660 | 1.07e-01 | 9.90e-02 | 1.51e-01 | 1.62e-01 | 1.58e-02 | 8.95e-02 | 1.15e-01 | 1.58e-02 | 9.84e-03 | 8.01e-01 |
| REGULATION OF MITOCHONDRION ORGANIZATION | 147 | 3.94e-02 | 2.56e-01 | 0.2660 | 1.27e-01 | 9.67e-02 | 1.15e-01 | 1.37e-01 | 1.15e-01 | 7.94e-03 | 4.30e-02 | 1.60e-02 | 4.15e-03 | 1.65e-02 |
| PEPTIDYL PROLINE HYDROXYLATION | 11 | 9.69e-01 | 9.95e-01 | 0.2660 | 1.29e-01 | 1.15e-01 | 1.15e-01 | 1.61e-01 | 3.92e-02 | 4.59e-01 | 5.08e-01 | 5.09e-01 | 3.55e-01 | 8.22e-01 |
| MONOAMINE TRANSPORT | 86 | 7.84e-02 | 3.80e-01 | 0.2660 | 4.51e-02 | 1.03e-01 | 1.50e-01 | 8.02e-02 | 1.70e-01 | 4.70e-01 | 9.88e-02 | 1.58e-02 | 1.99e-01 | 6.49e-03 |
| POSITIVE REGULATION OF ACTION POTENTIAL | 8 | 8.02e-01 | 9.67e-01 | 0.2650 | -1.16e-01 | -2.77e-02 | -4.81e-02 | -1.15e-01 | -2.02e-01 | 5.70e-01 | 8.92e-01 | 8.14e-01 | 5.75e-01 | 3.23e-01 |
| REGULATION OF AMYLOID BETA CLEARANCE | 20 | 8.70e-01 | 9.78e-01 | 0.2650 | 9.59e-02 | 1.53e-01 | 1.49e-01 | 9.47e-02 | 8.10e-02 | 4.58e-01 | 2.35e-01 | 2.49e-01 | 4.64e-01 | 5.31e-01 |
| POSITIVE REGULATION OF ALPHA BETA T CELL DIFFERENTIATION | 48 | 5.32e-01 | 8.63e-01 | 0.2650 | 1.51e-01 | 1.52e-01 | 9.38e-02 | 1.24e-01 | 1.17e-02 | 6.97e-02 | 6.76e-02 | 2.61e-01 | 1.38e-01 | 8.88e-01 |
| NEGATIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 7 | 4.57e-01 | 8.22e-01 | 0.2650 | -8.94e-02 | -9.72e-02 | 6.65e-03 | -2.14e-01 | 8.49e-02 | 6.82e-01 | 6.56e-01 | 9.76e-01 | 3.27e-01 | 6.97e-01 |
| REGULATION OF AXON GUIDANCE | 13 | 8.78e-01 | 9.79e-01 | 0.2650 | 4.72e-02 | 3.94e-02 | 1.48e-01 | 1.07e-01 | 1.82e-01 | 7.68e-01 | 8.06e-01 | 3.54e-01 | 5.02e-01 | 2.56e-01 |
| POSITIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL MIGRATION | 22 | 4.27e-01 | 8.05e-01 | 0.2650 | -3.88e-02 | -3.31e-02 | -6.56e-02 | -8.20e-02 | -2.38e-01 | 7.53e-01 | 7.88e-01 | 5.94e-01 | 5.05e-01 | 5.32e-02 |
| DNA REPLICATION SYNTHESIS OF RNA PRIMER | 6 | 8.20e-01 | 9.71e-01 | 0.2650 | 3.91e-02 | -8.05e-02 | 8.54e-02 | 1.23e-01 | 2.00e-01 | 8.68e-01 | 7.33e-01 | 7.17e-01 | 6.03e-01 | 3.97e-01 |
| RESPONSE TO IMMOBILIZATION STRESS | 21 | 5.88e-01 | 8.92e-01 | 0.2650 | 6.01e-02 | 1.16e-01 | 1.03e-01 | 4.95e-02 | 2.00e-01 | 6.34e-01 | 3.55e-01 | 4.14e-01 | 6.95e-01 | 1.13e-01 |
| PROTEIN HETEROOLIGOMERIZATION | 28 | 5.37e-01 | 8.66e-01 | 0.2650 | 1.45e-01 | 9.41e-02 | 8.28e-02 | 1.82e-01 | 1.56e-02 | 1.84e-01 | 3.89e-01 | 4.48e-01 | 9.58e-02 | 8.86e-01 |
| UREA TRANSPORT | 11 | 1.36e-01 | 4.99e-01 | 0.2650 | 4.53e-02 | 9.52e-02 | -5.31e-02 | -1.11e-01 | 2.09e-01 | 7.95e-01 | 5.85e-01 | 7.60e-01 | 5.24e-01 | 2.29e-01 |
| MAMMARY GLAND DUCT MORPHOGENESIS | 28 | 5.59e-02 | 3.13e-01 | 0.2650 | 5.38e-02 | 2.27e-01 | 1.09e-01 | 5.71e-02 | -1.97e-02 | 6.22e-01 | 3.74e-02 | 3.19e-01 | 6.01e-01 | 8.57e-01 |
| NEGATIVE REGULATION OF CYTOKINESIS | 7 | 7.72e-01 | 9.57e-01 | 0.2650 | 5.12e-02 | -7.15e-02 | 9.31e-02 | 1.39e-01 | 1.85e-01 | 8.15e-01 | 7.43e-01 | 6.70e-01 | 5.24e-01 | 3.96e-01 |
| POSITIVE REGULATION OF WNT SIGNALING PATHWAY PLANAR CELL POLARITY PATHWAY | 8 | 2.50e-01 | 6.57e-01 | 0.2650 | -1.02e-01 | -1.27e-01 | -1.47e-01 | 6.62e-02 | 1.32e-01 | 6.18e-01 | 5.34e-01 | 4.71e-01 | 7.46e-01 | 5.17e-01 |
| NEGATIVE REGULATION OF TISSUE REMODELING | 21 | 5.61e-01 | 8.79e-01 | 0.2640 | 1.76e-01 | 1.79e-01 | 5.57e-02 | 6.27e-02 | -3.33e-03 | 1.63e-01 | 1.56e-01 | 6.59e-01 | 6.19e-01 | 9.79e-01 |
| RESPONSE TO LUTEINIZING HORMONE | 7 | 6.50e-01 | 9.18e-01 | 0.2640 | -1.30e-01 | -7.28e-02 | -3.30e-02 | 4.18e-02 | 2.12e-01 | 5.50e-01 | 7.39e-01 | 8.80e-01 | 8.48e-01 | 3.32e-01 |
| GLYCOLYTIC PROCESS THROUGH GLUCOSE 6 PHOSPHATE | 19 | 1.13e-02 | 1.12e-01 | 0.2640 | -1.22e-02 | 2.24e-01 | 6.95e-02 | -1.18e-01 | -3.04e-02 | 9.27e-01 | 9.15e-02 | 6.00e-01 | 3.71e-01 | 8.18e-01 |
| RESPONSE TO INTERLEUKIN 6 | 41 | 1.86e-01 | 5.72e-01 | 0.2640 | -7.60e-02 | -3.97e-02 | -1.68e-01 | -1.60e-01 | -9.35e-02 | 4.00e-01 | 6.60e-01 | 6.32e-02 | 7.57e-02 | 3.00e-01 |
| PURINE NUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 40 | 6.25e-01 | 9.09e-01 | 0.2640 | 1.46e-01 | 1.16e-01 | 1.36e-01 | 1.17e-01 | 5.56e-02 | 1.11e-01 | 2.05e-01 | 1.37e-01 | 2.02e-01 | 5.43e-01 |
| REGULATION OF GLUCOCORTICOID METABOLIC PROCESS | 11 | 8.54e-01 | 9.76e-01 | 0.2640 | 2.41e-02 | 5.04e-02 | 1.82e-01 | 1.12e-01 | 1.45e-01 | 8.90e-01 | 7.72e-01 | 2.97e-01 | 5.21e-01 | 4.04e-01 |
| POSITIVE REGULATION OF CIRCADIAN RHYTHM | 18 | 7.85e-01 | 9.61e-01 | 0.2640 | -1.17e-01 | -9.64e-02 | -1.62e-01 | -9.62e-02 | -1.06e-01 | 3.90e-01 | 4.79e-01 | 2.35e-01 | 4.80e-01 | 4.35e-01 |
| DNA STRAND RESECTION INVOLVED IN REPLICATION FORK PROCESSING | 8 | 4.94e-01 | 8.44e-01 | 0.2640 | 8.02e-02 | 6.36e-02 | -1.30e-01 | 7.33e-02 | -1.92e-01 | 6.94e-01 | 7.55e-01 | 5.23e-01 | 7.20e-01 | 3.47e-01 |
| SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE | 19 | 3.33e-01 | 7.40e-01 | 0.2640 | -1.57e-01 | -1.50e-01 | 5.54e-03 | 1.64e-02 | 1.49e-01 | 2.37e-01 | 2.58e-01 | 9.67e-01 | 9.01e-01 | 2.59e-01 |
| ANATOMICAL STRUCTURE ARRANGEMENT | 15 | 5.84e-01 | 8.90e-01 | 0.2640 | 1.00e-01 | 1.28e-01 | 1.25e-01 | 1.38e-02 | 1.65e-01 | 5.02e-01 | 3.90e-01 | 4.00e-01 | 9.26e-01 | 2.69e-01 |
| NEGATIVE REGULATION OF LIPID LOCALIZATION | 66 | 8.11e-03 | 8.77e-02 | 0.2640 | 6.63e-02 | 2.22e-02 | -9.73e-02 | 1.73e-03 | -2.35e-01 | 3.52e-01 | 7.55e-01 | 1.72e-01 | 9.81e-01 | 9.62e-04 |
| DNA STRAND ELONGATION | 36 | 6.83e-01 | 9.30e-01 | 0.2640 | 1.00e-01 | 9.30e-02 | 1.18e-01 | 1.17e-01 | 1.53e-01 | 2.97e-01 | 3.34e-01 | 2.21e-01 | 2.26e-01 | 1.13e-01 |
| N TERMINAL PEPTIDYL METHIONINE ACETYLATION | 6 | 9.12e-01 | 9.85e-01 | 0.2640 | -1.38e-02 | -1.40e-02 | 9.62e-02 | 1.39e-01 | 2.02e-01 | 9.53e-01 | 9.53e-01 | 6.83e-01 | 5.57e-01 | 3.92e-01 |
| NEGATIVE REGULATION OF TYROSINE PHOSPHORYLATION OF STAT PROTEIN | 12 | 5.92e-01 | 8.94e-01 | 0.2640 | -1.28e-01 | -1.59e-01 | 7.13e-03 | 2.50e-02 | 1.64e-01 | 4.41e-01 | 3.40e-01 | 9.66e-01 | 8.81e-01 | 3.25e-01 |
| REGULATION OF SENSORY PERCEPTION | 17 | 7.01e-01 | 9.32e-01 | 0.2640 | -1.68e-01 | -1.83e-01 | -6.09e-02 | -6.38e-02 | 8.70e-03 | 2.31e-01 | 1.91e-01 | 6.64e-01 | 6.49e-01 | 9.50e-01 |
| GLYCINE TRANSPORT | 14 | 6.01e-01 | 9.00e-01 | 0.2640 | 8.06e-02 | 1.18e-01 | 1.13e-01 | 5.92e-03 | 1.91e-01 | 6.01e-01 | 4.45e-01 | 4.66e-01 | 9.69e-01 | 2.17e-01 |
| DOPAMINE RECEPTOR SIGNALING PATHWAY | 37 | 5.92e-01 | 8.94e-01 | 0.2640 | 1.57e-01 | 1.26e-01 | 8.18e-02 | 1.36e-01 | 6.07e-02 | 9.81e-02 | 1.84e-01 | 3.89e-01 | 1.53e-01 | 5.23e-01 |
| CDP CHOLINE PATHWAY | 6 | 9.72e-01 | 9.95e-01 | 0.2630 | 1.48e-01 | 7.10e-02 | 1.39e-01 | 1.41e-01 | 5.65e-02 | 5.31e-01 | 7.63e-01 | 5.54e-01 | 5.49e-01 | 8.11e-01 |
| LEUCINE CATABOLIC PROCESS | 6 | 1.49e-01 | 5.17e-01 | 0.2630 | 1.12e-01 | 1.05e-01 | -1.50e-01 | 1.10e-01 | 1.07e-01 | 6.35e-01 | 6.55e-01 | 5.25e-01 | 6.42e-01 | 6.51e-01 |
| MESENCHYMAL CELL PROLIFERATION INVOLVED IN LUNG DEVELOPMENT | 6 | 4.34e-01 | 8.08e-01 | 0.2630 | 2.16e-02 | -1.37e-01 | -8.92e-03 | 2.19e-01 | 4.64e-02 | 9.27e-01 | 5.60e-01 | 9.70e-01 | 3.53e-01 | 8.44e-01 |
| REGULATION OF MEMBRANE INVAGINATION | 15 | 5.20e-01 | 8.57e-01 | 0.2630 | 1.38e-01 | 1.21e-01 | -5.16e-02 | -1.07e-02 | -1.81e-01 | 3.55e-01 | 4.16e-01 | 7.30e-01 | 9.43e-01 | 2.24e-01 |
| POSITIVE REGULATION OF MUSCLE ADAPTATION | 13 | 3.24e-01 | 7.34e-01 | 0.2630 | -8.42e-03 | 3.82e-02 | 1.62e-01 | -3.98e-02 | 2.00e-01 | 9.58e-01 | 8.11e-01 | 3.12e-01 | 8.04e-01 | 2.12e-01 |
| ISOTYPE SWITCHING TO IGG ISOTYPES | 15 | 2.93e-01 | 7.04e-01 | 0.2630 | -4.93e-02 | 5.29e-02 | 2.00e-01 | 1.29e-01 | 8.59e-02 | 7.41e-01 | 7.23e-01 | 1.79e-01 | 3.88e-01 | 5.65e-01 |
| PLATELET AGGREGATION | 71 | 1.62e-01 | 5.37e-01 | 0.2630 | 1.50e-01 | 1.46e-01 | 9.19e-02 | 1.16e-01 | -6.10e-02 | 2.88e-02 | 3.39e-02 | 1.81e-01 | 9.14e-02 | 3.74e-01 |
| REGULATION OF HUMORAL IMMUNE RESPONSE | 47 | 4.02e-01 | 7.89e-01 | 0.2630 | -1.14e-01 | -7.09e-02 | -1.49e-01 | -1.37e-01 | -1.02e-01 | 1.77e-01 | 4.00e-01 | 7.75e-02 | 1.05e-01 | 2.25e-01 |
| RESPONSE TO SODIUM PHOSPHATE | 7 | 5.46e-01 | 8.71e-01 | 0.2630 | -6.27e-02 | 4.31e-02 | -4.47e-02 | -4.36e-02 | 2.44e-01 | 7.74e-01 | 8.43e-01 | 8.38e-01 | 8.41e-01 | 2.64e-01 |
| REGULATION OF MITOTIC CYTOKINESIS | 11 | 8.77e-01 | 9.79e-01 | 0.2630 | 1.85e-01 | 8.86e-02 | 5.92e-02 | 1.53e-01 | -6.89e-03 | 2.87e-01 | 6.11e-01 | 7.34e-01 | 3.81e-01 | 9.68e-01 |
| CELLULAR RESPONSE TO DEXAMETHASONE STIMULUS | 24 | 3.26e-01 | 7.35e-01 | 0.2630 | -1.53e-01 | -6.96e-02 | -4.87e-02 | -1.04e-01 | 1.66e-01 | 1.96e-01 | 5.55e-01 | 6.80e-01 | 3.79e-01 | 1.58e-01 |
| EMBRYO DEVELOPMENT | 1094 | 2.17e-15 | 3.02e-13 | 0.2630 | 7.58e-02 | 1.04e-01 | 1.38e-01 | 1.23e-01 | 1.35e-01 | 2.30e-05 | 5.75e-09 | 1.31e-14 | 6.47e-12 | 4.24e-14 |
| REGULATION OF COAGULATION | 73 | 1.73e-02 | 1.51e-01 | 0.2630 | -3.79e-02 | -7.16e-03 | -9.30e-02 | -1.26e-01 | -2.07e-01 | 5.76e-01 | 9.16e-01 | 1.69e-01 | 6.31e-02 | 2.19e-03 |
| REGULATION OF HORMONE BIOSYNTHETIC PROCESS | 24 | 2.21e-01 | 6.18e-01 | 0.2630 | 1.16e-01 | 2.43e-02 | 4.39e-02 | 1.38e-01 | 1.84e-01 | 3.25e-01 | 8.37e-01 | 7.09e-01 | 2.43e-01 | 1.18e-01 |
| CARDIOLIPIN ACYL CHAIN REMODELING | 5 | 5.67e-01 | 8.81e-01 | 0.2630 | 1.03e-02 | 7.91e-02 | 7.59e-02 | -1.63e-01 | 1.73e-01 | 9.68e-01 | 7.59e-01 | 7.69e-01 | 5.27e-01 | 5.02e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS PEPTIDE ANTIGEN VIA MHC CLASS II | 29 | 2.98e-01 | 7.10e-01 | 0.2620 | 1.20e-01 | 1.65e-01 | 6.69e-02 | 6.63e-02 | -1.35e-01 | 2.62e-01 | 1.23e-01 | 5.33e-01 | 5.37e-01 | 2.10e-01 |
| ACTIVATION OF PROTEIN KINASE ACTIVITY | 86 | 2.19e-01 | 6.16e-01 | 0.2620 | 1.56e-01 | 1.30e-01 | 9.99e-02 | 1.16e-01 | 6.44e-02 | 1.23e-02 | 3.73e-02 | 1.09e-01 | 6.38e-02 | 3.02e-01 |
| EPITHELIAL CELL MORPHOGENESIS | 29 | 3.78e-01 | 7.75e-01 | 0.2620 | -1.97e-01 | -1.11e-01 | -2.90e-02 | -1.15e-01 | 5.83e-02 | 6.60e-02 | 3.00e-01 | 7.87e-01 | 2.84e-01 | 5.87e-01 |
| CELL DIFFERENTIATION IN HINDBRAIN | 21 | 4.77e-01 | 8.33e-01 | 0.2620 | -1.44e-01 | -1.60e-01 | -2.23e-02 | -9.70e-02 | 1.12e-01 | 2.53e-01 | 2.04e-01 | 8.59e-01 | 4.41e-01 | 3.76e-01 |
| UTP METABOLIC PROCESS | 12 | 4.69e-01 | 8.28e-01 | 0.2620 | -1.33e-01 | 1.36e-02 | 2.19e-02 | -2.92e-02 | 2.22e-01 | 4.24e-01 | 9.35e-01 | 8.96e-01 | 8.61e-01 | 1.83e-01 |
| LYSOSOMAL MICROAUTOPHAGY | 13 | 6.22e-01 | 9.08e-01 | 0.2620 | 8.91e-03 | -2.40e-02 | -1.28e-01 | 4.02e-03 | -2.27e-01 | 9.56e-01 | 8.81e-01 | 4.23e-01 | 9.80e-01 | 1.57e-01 |
| CARDIAC MUSCLE CELL CONTRACTION | 72 | 1.33e-01 | 4.93e-01 | 0.2620 | -1.20e-01 | -7.06e-02 | -1.26e-01 | -1.73e-01 | -5.52e-02 | 7.78e-02 | 3.00e-01 | 6.38e-02 | 1.09e-02 | 4.18e-01 |
| INDOLALKYLAMINE METABOLIC PROCESS | 11 | 7.20e-01 | 9.39e-01 | 0.2620 | -1.23e-01 | -3.03e-02 | -9.19e-02 | -2.09e-01 | -1.23e-02 | 4.79e-01 | 8.62e-01 | 5.98e-01 | 2.29e-01 | 9.44e-01 |
| NEGATIVE REGULATION OF CATABOLIC PROCESS | 323 | 3.31e-05 | 1.10e-03 | 0.2620 | 1.31e-01 | 1.04e-01 | 9.85e-02 | 1.38e-01 | 1.08e-01 | 4.93e-05 | 1.30e-03 | 2.34e-03 | 1.93e-05 | 8.65e-04 |
| POSITIVE REGULATION OF OLIGODENDROCYTE DIFFERENTIATION | 27 | 6.37e-01 | 9.13e-01 | 0.2620 | 4.90e-02 | 5.21e-02 | 1.56e-01 | 1.05e-01 | 1.67e-01 | 6.59e-01 | 6.39e-01 | 1.61e-01 | 3.44e-01 | 1.33e-01 |
| ADENOSINE TO INOSINE EDITING | 7 | 8.51e-01 | 9.76e-01 | 0.2620 | -1.46e-01 | -1.31e-01 | -7.23e-02 | -2.37e-02 | 1.56e-01 | 5.03e-01 | 5.49e-01 | 7.41e-01 | 9.13e-01 | 4.76e-01 |
| PEPTIDYL TYROSINE DEPHOSPHORYLATION | 30 | 3.86e-01 | 7.80e-01 | 0.2620 | 1.41e-01 | 1.92e-01 | 8.57e-02 | 5.45e-02 | -3.97e-02 | 1.82e-01 | 6.93e-02 | 4.16e-01 | 6.05e-01 | 7.06e-01 |
| NEGATIVE REGULATION OF HOMOTYPIC CELL CELL ADHESION | 12 | 5.75e-01 | 8.84e-01 | 0.2610 | 2.06e-01 | 1.55e-01 | 9.16e-03 | 2.64e-02 | -3.24e-02 | 2.16e-01 | 3.54e-01 | 9.56e-01 | 8.74e-01 | 8.46e-01 |
| NEPHRON EPITHELIUM DEVELOPMENT | 115 | 2.60e-02 | 1.98e-01 | 0.2610 | 5.93e-02 | 9.54e-02 | 1.14e-01 | 1.00e-01 | 1.81e-01 | 2.72e-01 | 7.70e-02 | 3.53e-02 | 6.36e-02 | 8.03e-04 |
| VIRAL PROCESS | 414 | 1.76e-05 | 6.26e-04 | 0.2610 | 1.32e-01 | 1.02e-01 | 1.11e-01 | 1.39e-01 | 9.21e-02 | 3.93e-06 | 3.60e-04 | 1.06e-04 | 1.11e-06 | 1.30e-03 |
| DNA DEALKYLATION INVOLVED IN DNA REPAIR | 9 | 7.64e-01 | 9.54e-01 | 0.2610 | 1.77e-01 | 5.67e-02 | -5.15e-02 | 6.80e-02 | -1.62e-01 | 3.58e-01 | 7.68e-01 | 7.89e-01 | 7.24e-01 | 3.99e-01 |
| NEGATIVE REGULATION OF EXCITATORY POSTSYNAPTIC POTENTIAL | 10 | 9.58e-01 | 9.94e-01 | 0.2610 | -6.21e-02 | -1.36e-01 | -1.51e-01 | -8.73e-02 | -1.23e-01 | 7.34e-01 | 4.55e-01 | 4.07e-01 | 6.33e-01 | 5.01e-01 |
| MONOCARBOXYLIC ACID CATABOLIC PROCESS | 128 | 6.46e-02 | 3.38e-01 | 0.2610 | 1.45e-01 | 1.27e-01 | 1.01e-01 | 1.13e-01 | 8.92e-02 | 4.70e-03 | 1.29e-02 | 4.86e-02 | 2.67e-02 | 8.14e-02 |
| NUCLEOBASE BIOSYNTHETIC PROCESS | 16 | 6.38e-01 | 9.13e-01 | 0.2610 | 1.89e-01 | 6.43e-02 | 9.53e-02 | 1.38e-01 | -1.17e-02 | 1.91e-01 | 6.56e-01 | 5.09e-01 | 3.40e-01 | 9.36e-01 |
| RESPONSE TO ANGIOTENSIN | 35 | 9.93e-02 | 4.28e-01 | 0.2610 | 7.36e-02 | -5.74e-02 | -1.32e-01 | -5.94e-02 | -1.96e-01 | 4.51e-01 | 5.57e-01 | 1.77e-01 | 5.43e-01 | 4.49e-02 |
| INHIBITORY POSTSYNAPTIC POTENTIAL | 16 | 5.24e-01 | 8.60e-01 | 0.2610 | -2.02e-01 | -1.35e-01 | -2.96e-02 | -3.66e-02 | 8.16e-02 | 1.61e-01 | 3.49e-01 | 8.38e-01 | 8.00e-01 | 5.72e-01 |
| GLYCOSYLATION | 215 | 2.45e-03 | 3.58e-02 | 0.2610 | 1.63e-01 | 1.22e-01 | 8.85e-02 | 1.34e-01 | 3.05e-02 | 3.90e-05 | 2.04e-03 | 2.53e-02 | 7.31e-04 | 4.41e-01 |
| ACTIVIN RECEPTOR SIGNALING PATHWAY | 44 | 9.78e-03 | 9.98e-02 | 0.2610 | -9.81e-02 | -1.60e-02 | 9.20e-02 | 1.02e-01 | 1.98e-01 | 2.60e-01 | 8.54e-01 | 2.91e-01 | 2.42e-01 | 2.31e-02 |
| STARTLE RESPONSE | 26 | 6.60e-01 | 9.21e-01 | 0.2600 | -1.81e-01 | -1.44e-01 | -6.64e-02 | -9.63e-02 | 2.40e-02 | 1.10e-01 | 2.03e-01 | 5.58e-01 | 3.95e-01 | 8.32e-01 |
| COLLAGEN ACTIVATED SIGNALING PATHWAY | 13 | 6.72e-01 | 9.26e-01 | 0.2600 | 2.86e-02 | 1.35e-02 | -1.04e-01 | -4.20e-03 | -2.37e-01 | 8.58e-01 | 9.33e-01 | 5.17e-01 | 9.79e-01 | 1.39e-01 |
| REGULATION OF MYOSIN LIGHT CHAIN PHOSPHATASE ACTIVITY | 7 | 9.16e-01 | 9.86e-01 | 0.2600 | 1.52e-01 | 8.64e-02 | 3.45e-03 | 9.02e-02 | -1.70e-01 | 4.85e-01 | 6.92e-01 | 9.87e-01 | 6.80e-01 | 4.36e-01 |
| REGULATION OF PERK MEDIATED UNFOLDED PROTEIN RESPONSE | 11 | 5.39e-01 | 8.67e-01 | 0.2600 | -1.00e-01 | -2.66e-02 | -5.21e-02 | -1.65e-01 | 1.64e-01 | 5.66e-01 | 8.78e-01 | 7.65e-01 | 3.43e-01 | 3.45e-01 |
| ERYTHROCYTE DEVELOPMENT | 37 | 5.33e-01 | 8.64e-01 | 0.2600 | 6.00e-02 | 1.26e-01 | 1.31e-01 | 1.30e-01 | 1.18e-01 | 5.28e-01 | 1.86e-01 | 1.66e-01 | 1.70e-01 | 2.13e-01 |
| MONOUBIQUITINATED PROTEIN DEUBIQUITINATION | 7 | 7.02e-01 | 9.32e-01 | 0.2600 | -5.80e-02 | -2.61e-02 | -2.32e-02 | 2.06e-02 | -2.50e-01 | 7.90e-01 | 9.05e-01 | 9.15e-01 | 9.25e-01 | 2.51e-01 |
| G PROTEIN COUPLED OPIOID RECEPTOR SIGNALING PATHWAY | 10 | 9.57e-01 | 9.94e-01 | 0.2600 | 7.85e-02 | 8.86e-02 | 1.06e-01 | 1.28e-01 | 1.61e-01 | 6.67e-01 | 6.27e-01 | 5.62e-01 | 4.83e-01 | 3.77e-01 |
| CELL MIGRATION INVOLVED IN METANEPHROS DEVELOPMENT | 5 | 9.31e-01 | 9.90e-01 | 0.2600 | 6.89e-02 | 2.12e-01 | 1.12e-01 | 5.20e-02 | 5.39e-02 | 7.90e-01 | 4.12e-01 | 6.66e-01 | 8.40e-01 | 8.35e-01 |
| MAINTENANCE OF LENS TRANSPARENCY | 7 | 7.67e-01 | 9.55e-01 | 0.2600 | -4.45e-02 | -1.89e-01 | -1.16e-01 | 2.48e-02 | -1.26e-01 | 8.39e-01 | 3.87e-01 | 5.94e-01 | 9.10e-01 | 5.65e-01 |
| NEGATIVE REGULATION OF CARBOHYDRATE METABOLIC PROCESS | 54 | 2.99e-01 | 7.12e-01 | 0.2600 | 7.46e-02 | 1.14e-01 | 1.07e-01 | 1.20e-01 | 1.52e-01 | 3.43e-01 | 1.47e-01 | 1.75e-01 | 1.26e-01 | 5.38e-02 |
| ACTIN CROSSLINK FORMATION | 12 | 5.40e-01 | 8.67e-01 | 0.2600 | -1.31e-01 | -9.08e-02 | -2.12e-02 | -1.61e-01 | -1.25e-01 | 4.32e-01 | 5.86e-01 | 8.99e-01 | 3.33e-01 | 4.55e-01 |
| PROSTANOID BIOSYNTHETIC PROCESS | 31 | 4.58e-01 | 8.23e-01 | 0.2600 | 1.70e-01 | 1.05e-01 | 1.24e-01 | 1.11e-01 | -6.17e-03 | 1.01e-01 | 3.14e-01 | 2.33e-01 | 2.87e-01 | 9.53e-01 |
| AMIDE METABOLIC PROCESS | 1223 | 4.23e-14 | 5.40e-12 | 0.2600 | 1.15e-01 | 1.05e-01 | 1.23e-01 | 1.33e-01 | 1.01e-01 | 1.08e-11 | 5.65e-10 | 3.86e-13 | 4.05e-15 | 3.11e-09 |
| AMINO ACID BETAINE BIOSYNTHETIC PROCESS | 5 | 5.80e-01 | 8.87e-01 | 0.2600 | 2.44e-01 | 2.43e-02 | 1.76e-02 | 1.45e-02 | -8.29e-02 | 3.45e-01 | 9.25e-01 | 9.46e-01 | 9.55e-01 | 7.48e-01 |
| POSITIVE REGULATION OF EXCITATORY POSTSYNAPTIC POTENTIAL | 31 | 1.35e-01 | 4.97e-01 | 0.2600 | -1.95e-01 | -8.91e-02 | 1.89e-02 | -1.18e-01 | 8.35e-02 | 5.98e-02 | 3.91e-01 | 8.56e-01 | 2.54e-01 | 4.21e-01 |
| REGULATION OF ALPHA BETA T CELL DIFFERENTIATION | 70 | 5.06e-01 | 8.52e-01 | 0.2600 | 1.16e-01 | 1.34e-01 | 1.26e-01 | 1.31e-01 | 5.50e-02 | 9.27e-02 | 5.32e-02 | 6.89e-02 | 5.79e-02 | 4.26e-01 |
| CD4 POSITIVE OR CD8 POSITIVE ALPHA BETA T CELL LINEAGE COMMITMENT | 25 | 7.06e-01 | 9.33e-01 | 0.2600 | 7.84e-02 | 8.60e-02 | 1.16e-01 | 1.64e-01 | 1.16e-01 | 4.97e-01 | 4.57e-01 | 3.17e-01 | 1.55e-01 | 3.14e-01 |
| POSITIVE REGULATION OF INTEGRIN MEDIATED SIGNALING PATHWAY | 11 | 6.64e-01 | 9.23e-01 | 0.2590 | -1.21e-02 | -1.12e-01 | -1.60e-01 | -1.63e-01 | -4.71e-02 | 9.44e-01 | 5.19e-01 | 3.57e-01 | 3.49e-01 | 7.87e-01 |
| MITOCHONDRIAL TRANSLATIONAL ELONGATION | 5 | 7.64e-01 | 9.54e-01 | 0.2590 | 2.13e-01 | 4.22e-02 | -1.52e-02 | 9.79e-02 | 1.01e-01 | 4.09e-01 | 8.70e-01 | 9.53e-01 | 7.05e-01 | 6.95e-01 |
| EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 82 | 1.51e-01 | 5.19e-01 | 0.2590 | 9.90e-02 | 7.45e-02 | 1.38e-01 | 1.62e-01 | 8.06e-02 | 1.21e-01 | 2.43e-01 | 3.09e-02 | 1.10e-02 | 2.07e-01 |
| REGULATION OF T HELPER CELL DIFFERENTIATION | 42 | 3.36e-01 | 7.42e-01 | 0.2590 | 1.51e-01 | 1.69e-01 | 6.95e-02 | 9.64e-02 | 4.13e-02 | 8.96e-02 | 5.84e-02 | 4.36e-01 | 2.80e-01 | 6.43e-01 |
| PROTEIN TARGETING TO MEMBRANE | 120 | 6.29e-02 | 3.34e-01 | 0.2590 | 5.56e-02 | 9.75e-02 | 1.37e-01 | 1.08e-01 | 1.55e-01 | 2.92e-01 | 6.51e-02 | 9.37e-03 | 4.17e-02 | 3.26e-03 |
| TRICUSPID VALVE DEVELOPMENT | 6 | 8.31e-01 | 9.73e-01 | 0.2590 | -2.16e-01 | -1.25e-01 | 2.72e-02 | -5.75e-02 | 3.20e-02 | 3.60e-01 | 5.96e-01 | 9.08e-01 | 8.07e-01 | 8.92e-01 |
| TRANSFORMING GROWTH FACTOR BETA1 PRODUCTION | 15 | 4.56e-01 | 8.22e-01 | 0.2590 | 3.39e-02 | 4.32e-02 | -1.47e-01 | -4.41e-02 | -2.01e-01 | 8.20e-01 | 7.72e-01 | 3.23e-01 | 7.67e-01 | 1.77e-01 |
| BILE ACID SECRETION | 12 | 2.62e-01 | 6.70e-01 | 0.2590 | 1.08e-01 | 1.05e-01 | -1.53e-01 | -8.09e-02 | -1.21e-01 | 5.19e-01 | 5.29e-01 | 3.59e-01 | 6.27e-01 | 4.69e-01 |
| PEPTIDYL LYSINE ACETYLATION | 64 | 1.27e-01 | 4.84e-01 | 0.2590 | 1.14e-01 | 1.09e-01 | 8.35e-02 | 1.57e-01 | 1.03e-01 | 1.15e-01 | 1.31e-01 | 2.48e-01 | 2.96e-02 | 1.56e-01 |
| ASPARTATE FAMILY AMINO ACID BIOSYNTHETIC PROCESS | 21 | 8.78e-02 | 4.00e-01 | 0.2590 | -5.54e-02 | -1.08e-01 | -4.45e-02 | 6.86e-02 | 2.14e-01 | 6.60e-01 | 3.92e-01 | 7.24e-01 | 5.86e-01 | 9.01e-02 |
| UTP BIOSYNTHETIC PROCESS | 10 | 6.55e-01 | 9.20e-01 | 0.2590 | -1.35e-01 | -8.40e-03 | 9.07e-04 | -1.28e-01 | 1.80e-01 | 4.60e-01 | 9.63e-01 | 9.96e-01 | 4.82e-01 | 3.25e-01 |
| REGULATION OF MAINTENANCE OF SISTER CHROMATID COHESION | 7 | 4.03e-01 | 7.90e-01 | 0.2590 | -9.88e-02 | -1.73e-01 | 4.26e-02 | 1.56e-01 | 3.54e-02 | 6.51e-01 | 4.28e-01 | 8.45e-01 | 4.76e-01 | 8.71e-01 |
| REGULATION OF T HELPER 1 TYPE IMMUNE RESPONSE | 31 | 2.34e-02 | 1.86e-01 | 0.2590 | 1.32e-01 | 8.26e-02 | -1.01e-01 | -9.53e-02 | -1.53e-01 | 2.03e-01 | 4.26e-01 | 3.29e-01 | 3.58e-01 | 1.40e-01 |
| RESPONSE TO INTERLEUKIN 3 | 6 | 9.12e-01 | 9.85e-01 | 0.2590 | 1.69e-03 | 1.71e-02 | 1.73e-01 | 1.49e-01 | 1.21e-01 | 9.94e-01 | 9.42e-01 | 4.64e-01 | 5.27e-01 | 6.07e-01 |
| RESPONSE TO DISACCHARIDE | 7 | 3.13e-01 | 7.25e-01 | 0.2590 | -1.22e-02 | 2.27e-02 | 3.70e-02 | -2.04e-01 | 1.53e-01 | 9.55e-01 | 9.17e-01 | 8.65e-01 | 3.50e-01 | 4.84e-01 |
| ANTERIOR HEAD DEVELOPMENT | 7 | 9.47e-01 | 9.94e-01 | 0.2590 | 1.06e-01 | 1.27e-01 | 1.75e-01 | 8.05e-02 | 4.79e-02 | 6.28e-01 | 5.59e-01 | 4.22e-01 | 7.12e-01 | 8.26e-01 |
| OMEGA HYDROXYLASE P450 PATHWAY | 11 | 7.52e-01 | 9.51e-01 | 0.2590 | -1.33e-01 | -1.83e-01 | -1.15e-01 | -2.36e-02 | 4.47e-02 | 4.44e-01 | 2.94e-01 | 5.10e-01 | 8.92e-01 | 7.97e-01 |
| REGULATION OF LYMPHANGIOGENESIS | 6 | 8.86e-01 | 9.80e-01 | 0.2590 | -3.41e-02 | -5.08e-03 | 1.75e-01 | 1.10e-01 | 1.52e-01 | 8.85e-01 | 9.83e-01 | 4.57e-01 | 6.42e-01 | 5.20e-01 |
| FLUID TRANSPORT | 37 | 8.18e-02 | 3.87e-01 | 0.2590 | -1.28e-01 | -2.80e-02 | -1.02e-01 | -1.97e-01 | 2.35e-02 | 1.80e-01 | 7.68e-01 | 2.83e-01 | 3.79e-02 | 8.04e-01 |
| MONOATOMIC ANION HOMEOSTASIS | 20 | 5.64e-01 | 8.80e-01 | 0.2580 | -7.41e-02 | -1.71e-01 | -1.30e-01 | -1.23e-01 | 1.38e-02 | 5.66e-01 | 1.85e-01 | 3.16e-01 | 3.42e-01 | 9.15e-01 |
| REGULATION OF OXIDATIVE STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 44 | 5.08e-01 | 8.53e-01 | 0.2580 | 8.74e-02 | 1.05e-01 | 1.63e-01 | 1.32e-01 | 6.22e-02 | 3.16e-01 | 2.27e-01 | 6.10e-02 | 1.29e-01 | 4.75e-01 |
| POSITIVE REGULATION OF CHROMATIN ORGANIZATION | 14 | 1.02e-01 | 4.35e-01 | 0.2580 | 1.45e-01 | 1.66e-02 | -8.18e-02 | 1.85e-01 | -6.73e-02 | 3.48e-01 | 9.14e-01 | 5.96e-01 | 2.30e-01 | 6.63e-01 |
| IMMUNOLOGICAL MEMORY FORMATION PROCESS | 14 | 6.66e-01 | 9.23e-01 | 0.2580 | -2.72e-02 | -7.50e-03 | 5.78e-02 | 1.51e-02 | 2.50e-01 | 8.60e-01 | 9.61e-01 | 7.08e-01 | 9.22e-01 | 1.06e-01 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 16 | 1.44e-01 | 5.11e-01 | 0.2580 | 3.87e-02 | 1.84e-01 | 8.02e-02 | -7.60e-02 | 1.38e-01 | 7.89e-01 | 2.02e-01 | 5.79e-01 | 5.99e-01 | 3.39e-01 |
| REGULATION OF SYNAPTIC TRANSMISSION CHOLINERGIC | 8 | 8.91e-01 | 9.81e-01 | 0.2580 | -1.47e-01 | -9.91e-02 | 6.13e-03 | -4.57e-02 | 1.82e-01 | 4.71e-01 | 6.27e-01 | 9.76e-01 | 8.23e-01 | 3.74e-01 |
| POSITIVE REGULATION OF GONADOTROPIN SECRETION | 7 | 3.26e-01 | 7.35e-01 | 0.2580 | 9.73e-02 | 5.60e-02 | -4.78e-02 | -1.18e-01 | 1.94e-01 | 6.56e-01 | 7.98e-01 | 8.27e-01 | 5.88e-01 | 3.74e-01 |
| POSITIVE REGULATION OF T CELL MIGRATION | 33 | 1.93e-01 | 5.80e-01 | 0.2580 | 3.83e-02 | 4.84e-02 | -7.10e-02 | -4.01e-02 | -2.37e-01 | 7.03e-01 | 6.30e-01 | 4.80e-01 | 6.90e-01 | 1.86e-02 |
| CARDIAC LEFT VENTRICLE MORPHOGENESIS | 16 | 5.61e-01 | 8.79e-01 | 0.2580 | -7.91e-02 | 2.15e-02 | 1.37e-01 | 2.54e-02 | 2.01e-01 | 5.84e-01 | 8.82e-01 | 3.43e-01 | 8.60e-01 | 1.64e-01 |
| REGULATION OF COLLAGEN FIBRIL ORGANIZATION | 8 | 9.38e-01 | 9.92e-01 | 0.2580 | -1.81e-01 | -1.29e-01 | -3.62e-02 | -1.24e-01 | 2.15e-02 | 3.74e-01 | 5.29e-01 | 8.59e-01 | 5.45e-01 | 9.16e-01 |
| POSITIVE REGULATION OF T CELL MEDIATED CYTOTOXICITY | 40 | 6.44e-02 | 3.38e-01 | 0.2580 | -1.72e-02 | 3.16e-02 | 1.41e-01 | 1.60e-01 | 1.40e-01 | 8.51e-01 | 7.30e-01 | 1.22e-01 | 7.92e-02 | 1.26e-01 |
| CHOLESTEROL STORAGE | 25 | 7.30e-01 | 9.44e-01 | 0.2580 | -5.97e-02 | -1.38e-01 | -1.59e-01 | -1.03e-01 | -8.85e-02 | 6.05e-01 | 2.31e-01 | 1.68e-01 | 3.74e-01 | 4.44e-01 |
| GLUTATHIONE TRANSMEMBRANE TRANSPORT | 7 | 8.76e-01 | 9.78e-01 | 0.2580 | -1.00e-01 | -8.96e-02 | -1.73e-01 | -4.89e-02 | -1.27e-01 | 6.47e-01 | 6.81e-01 | 4.29e-01 | 8.23e-01 | 5.60e-01 |
| STEROID HORMONE BIOSYNTHETIC PROCESS | 44 | 5.33e-01 | 8.64e-01 | 0.2580 | -1.62e-01 | -1.04e-01 | -9.00e-02 | -1.41e-01 | -3.85e-02 | 6.26e-02 | 2.34e-01 | 3.01e-01 | 1.06e-01 | 6.59e-01 |
| MEMBRANE PROTEIN INTRACELLULAR DOMAIN PROTEOLYSIS | 13 | 7.46e-01 | 9.51e-01 | 0.2580 | -5.91e-02 | 1.11e-02 | 8.60e-02 | 2.96e-02 | 2.33e-01 | 7.12e-01 | 9.45e-01 | 5.91e-01 | 8.53e-01 | 1.45e-01 |
| ODONTOBLAST DIFFERENTIATION | 11 | 4.03e-01 | 7.90e-01 | 0.2580 | -1.80e-01 | 1.45e-02 | 9.59e-02 | -8.48e-02 | 1.32e-01 | 3.01e-01 | 9.34e-01 | 5.82e-01 | 6.26e-01 | 4.49e-01 |
| POSITIVE REGULATION OF INOSITOL PHOSPHATE BIOSYNTHETIC PROCESS | 14 | 6.35e-01 | 9.12e-01 | 0.2580 | -1.01e-01 | -1.21e-01 | -9.95e-02 | -9.64e-02 | 1.50e-01 | 5.14e-01 | 4.33e-01 | 5.19e-01 | 5.32e-01 | 3.32e-01 |
| ACTIVATION OF MEIOSIS | 6 | 5.01e-01 | 8.48e-01 | 0.2580 | -3.00e-02 | 1.95e-01 | 7.12e-02 | 8.83e-02 | 1.21e-01 | 8.99e-01 | 4.09e-01 | 7.63e-01 | 7.08e-01 | 6.07e-01 |
| DNA LIGATION INVOLVED IN DNA REPAIR | 5 | 9.79e-01 | 9.96e-01 | 0.2580 | -1.05e-01 | -1.35e-01 | -7.84e-02 | -9.83e-02 | -1.45e-01 | 6.85e-01 | 6.00e-01 | 7.61e-01 | 7.03e-01 | 5.73e-01 |
| NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 107 | 1.36e-01 | 4.99e-01 | 0.2570 | 8.98e-02 | 8.17e-02 | 1.31e-01 | 1.47e-01 | 1.13e-01 | 1.08e-01 | 1.44e-01 | 1.94e-02 | 8.65e-03 | 4.34e-02 |
| COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION | 121 | 8.66e-03 | 9.22e-02 | 0.2570 | 1.31e-02 | 7.91e-02 | 1.41e-01 | 7.83e-02 | 1.84e-01 | 8.04e-01 | 1.33e-01 | 7.52e-03 | 1.37e-01 | 4.76e-04 |
| POSITIVE REGULATION OF INTERLEUKIN 1 PRODUCTION | 71 | 4.03e-03 | 5.27e-02 | 0.2570 | 1.74e-01 | 9.19e-02 | -3.58e-02 | 6.01e-02 | -1.50e-01 | 1.13e-02 | 1.80e-01 | 6.02e-01 | 3.81e-01 | 2.85e-02 |
| REGULATION OF AUTOPHAGY | 338 | 1.61e-04 | 3.91e-03 | 0.2570 | 1.21e-01 | 9.97e-02 | 1.08e-01 | 1.32e-01 | 1.11e-01 | 1.25e-04 | 1.63e-03 | 6.61e-04 | 2.92e-05 | 4.55e-04 |
| INTERLEUKIN 4 PRODUCTION | 32 | 5.85e-01 | 8.90e-01 | 0.2570 | 4.38e-02 | 1.01e-01 | 1.46e-01 | 1.38e-01 | 1.15e-01 | 6.68e-01 | 3.21e-01 | 1.52e-01 | 1.76e-01 | 2.59e-01 |
| CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 200 | 7.17e-03 | 8.05e-02 | 0.2570 | 8.99e-02 | 1.33e-01 | 1.21e-01 | 1.00e-01 | 1.25e-01 | 2.84e-02 | 1.22e-03 | 3.09e-03 | 1.48e-02 | 2.32e-03 |
| T CELL RECEPTOR SIGNALING PATHWAY | 133 | 4.16e-05 | 1.32e-03 | 0.2570 | -2.95e-03 | 3.50e-02 | 1.52e-01 | 1.50e-01 | 1.38e-01 | 9.53e-01 | 4.85e-01 | 2.42e-03 | 2.83e-03 | 5.96e-03 |
| CD8 POSITIVE ALPHA BETA T CELL ACTIVATION | 29 | 2.85e-01 | 6.94e-01 | 0.2570 | -1.33e-02 | -1.31e-02 | 1.17e-01 | 1.31e-01 | 1.87e-01 | 9.02e-01 | 9.03e-01 | 2.77e-01 | 2.22e-01 | 8.18e-02 |
| VESTIBULOCOCHLEAR NERVE MORPHOGENESIS | 7 | 5.65e-01 | 8.81e-01 | 0.2570 | -4.34e-03 | 1.42e-02 | -1.38e-01 | -2.16e-01 | 1.33e-02 | 9.84e-01 | 9.48e-01 | 5.28e-01 | 3.23e-01 | 9.51e-01 |
| REGULATION OF METANEPHROS DEVELOPMENT | 5 | 9.72e-01 | 9.95e-01 | 0.2570 | 1.17e-01 | 1.84e-01 | 1.23e-01 | 5.43e-02 | -2.45e-02 | 6.51e-01 | 4.77e-01 | 6.35e-01 | 8.33e-01 | 9.24e-01 |
| POSITIVE REGULATION OF MONOOXYGENASE ACTIVITY | 26 | 3.57e-01 | 7.57e-01 | 0.2570 | 1.51e-01 | 1.66e-01 | 1.45e-02 | 7.38e-02 | -9.94e-02 | 1.82e-01 | 1.44e-01 | 8.98e-01 | 5.15e-01 | 3.80e-01 |
| HEPATOCYTE APOPTOTIC PROCESS | 21 | 7.55e-01 | 9.51e-01 | 0.2570 | 1.11e-01 | 5.91e-02 | 1.08e-01 | 1.74e-01 | 9.00e-02 | 3.77e-01 | 6.39e-01 | 3.90e-01 | 1.69e-01 | 4.75e-01 |
| OSTEOBLAST PROLIFERATION | 36 | 6.06e-01 | 9.01e-01 | 0.2570 | 9.63e-02 | 1.31e-01 | 1.59e-01 | 8.68e-02 | 8.14e-02 | 3.17e-01 | 1.73e-01 | 9.93e-02 | 3.67e-01 | 3.98e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO ENDOPLASMIC RETICULUM | 42 | 1.40e-01 | 5.04e-01 | 0.2570 | 3.11e-02 | 2.95e-02 | 1.58e-01 | 1.63e-01 | 1.11e-01 | 7.27e-01 | 7.41e-01 | 7.57e-02 | 6.82e-02 | 2.11e-01 |
| CELL RECOGNITION | 153 | 6.65e-02 | 3.45e-01 | 0.2560 | -1.42e-01 | -1.35e-01 | -1.00e-01 | -1.28e-01 | -2.98e-02 | 2.52e-03 | 3.84e-03 | 3.22e-02 | 6.26e-03 | 5.24e-01 |
| REGULATION OF INTRACELLULAR TRANSPORT | 321 | 2.57e-03 | 3.71e-02 | 0.2560 | 1.23e-01 | 1.10e-01 | 1.22e-01 | 1.34e-01 | 7.47e-02 | 1.56e-04 | 6.91e-04 | 1.62e-04 | 3.72e-05 | 2.14e-02 |
| ESTABLISHMENT OF EPITHELIAL CELL APICAL BASAL POLARITY | 17 | 4.74e-01 | 8.31e-01 | 0.2560 | -8.14e-02 | 5.12e-03 | 1.44e-01 | 1.59e-02 | 1.95e-01 | 5.61e-01 | 9.71e-01 | 3.05e-01 | 9.10e-01 | 1.63e-01 |
| ISOPRENOID BIOSYNTHETIC PROCESS | 29 | 1.07e-01 | 4.48e-01 | 0.2560 | 2.10e-01 | 7.75e-02 | 4.92e-02 | 8.87e-02 | 7.16e-02 | 5.00e-02 | 4.70e-01 | 6.46e-01 | 4.08e-01 | 5.04e-01 |
| GLYCOSAMINOGLYCAN CATABOLIC PROCESS | 27 | 7.55e-01 | 9.51e-01 | 0.2560 | -1.29e-01 | -9.78e-02 | -1.47e-01 | -1.18e-01 | -6.37e-02 | 2.46e-01 | 3.79e-01 | 1.87e-01 | 2.90e-01 | 5.67e-01 |
| FOAM CELL DIFFERENTIATION | 41 | 4.13e-01 | 7.98e-01 | 0.2560 | -1.24e-01 | -6.89e-02 | -1.26e-01 | -1.10e-01 | -1.33e-01 | 1.69e-01 | 4.45e-01 | 1.64e-01 | 2.24e-01 | 1.42e-01 |
| REGULATION OF APOPTOTIC SIGNALING PATHWAY | 381 | 3.04e-04 | 6.60e-03 | 0.2560 | 1.10e-01 | 1.04e-01 | 1.26e-01 | 1.42e-01 | 8.19e-02 | 2.25e-04 | 5.01e-04 | 2.52e-05 | 1.89e-06 | 6.05e-03 |
| FEVER GENERATION | 11 | 4.17e-01 | 7.99e-01 | 0.2560 | -4.34e-02 | 8.26e-02 | -1.22e-01 | -1.74e-01 | -1.08e-01 | 8.03e-01 | 6.35e-01 | 4.84e-01 | 3.16e-01 | 5.36e-01 |
| RESPONSE TO HYDROXYUREA | 11 | 1.73e-01 | 5.57e-01 | 0.2560 | 4.23e-03 | -9.55e-02 | -8.73e-02 | 1.04e-01 | 1.95e-01 | 9.81e-01 | 5.83e-01 | 6.16e-01 | 5.50e-01 | 2.63e-01 |
| AXON ENSHEATHMENT IN CENTRAL NERVOUS SYSTEM | 25 | 3.11e-01 | 7.22e-01 | 0.2560 | -2.09e-01 | -7.80e-02 | -2.49e-02 | -1.15e-01 | 4.69e-02 | 7.10e-02 | 4.99e-01 | 8.30e-01 | 3.21e-01 | 6.84e-01 |
| RETINAL METABOLIC PROCESS | 18 | 1.95e-01 | 5.82e-01 | 0.2560 | 1.27e-01 | -7.06e-02 | -9.96e-02 | 2.04e-02 | -1.84e-01 | 3.50e-01 | 6.04e-01 | 4.64e-01 | 8.81e-01 | 1.76e-01 |
| REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 55 | 2.42e-01 | 6.46e-01 | 0.2560 | -8.05e-02 | -1.01e-01 | -1.57e-01 | -1.51e-01 | -3.59e-02 | 3.02e-01 | 1.94e-01 | 4.40e-02 | 5.28e-02 | 6.45e-01 |
| REGULATION OF T CELL DIFFERENTIATION IN THYMUS | 26 | 4.03e-01 | 7.90e-01 | 0.2560 | 3.07e-03 | 5.78e-02 | 1.49e-01 | 1.51e-01 | 1.31e-01 | 9.78e-01 | 6.10e-01 | 1.88e-01 | 1.83e-01 | 2.49e-01 |
| T CELL CYTOKINE PRODUCTION | 36 | 8.45e-01 | 9.75e-01 | 0.2560 | 1.18e-01 | 1.22e-01 | 1.32e-01 | 1.19e-01 | 7.09e-02 | 2.21e-01 | 2.05e-01 | 1.72e-01 | 2.15e-01 | 4.62e-01 |
| POSITIVE REGULATION OF T HELPER 2 CELL CYTOKINE PRODUCTION | 9 | 8.08e-01 | 9.67e-01 | 0.2560 | 6.81e-03 | -2.02e-02 | -5.62e-02 | 3.30e-03 | -2.49e-01 | 9.72e-01 | 9.16e-01 | 7.70e-01 | 9.86e-01 | 1.97e-01 |
| ANTIBACTERIAL HUMORAL RESPONSE | 60 | 1.43e-01 | 5.09e-01 | 0.2560 | 1.45e-01 | 1.74e-01 | 9.74e-02 | 5.85e-02 | 3.01e-02 | 5.15e-02 | 1.94e-02 | 1.92e-01 | 4.33e-01 | 6.87e-01 |
| POSITIVE REGULATION OF CELL CYCLE PROCESS | 251 | 2.11e-04 | 4.88e-03 | 0.2560 | 7.64e-02 | 6.11e-02 | 1.24e-01 | 1.43e-01 | 1.41e-01 | 3.70e-02 | 9.57e-02 | 7.05e-04 | 9.16e-05 | 1.22e-04 |
| CARDIAC ATRIUM DEVELOPMENT | 37 | 4.92e-01 | 8.42e-01 | 0.2560 | 3.57e-02 | 7.18e-02 | 1.17e-01 | 1.19e-01 | 1.76e-01 | 7.07e-01 | 4.50e-01 | 2.17e-01 | 2.10e-01 | 6.38e-02 |
| EYE PHOTORECEPTOR CELL DIFFERENTIATION | 47 | 5.89e-02 | 3.20e-01 | 0.2560 | -1.51e-01 | -4.81e-02 | -8.06e-02 | -1.68e-01 | 7.39e-02 | 7.29e-02 | 5.68e-01 | 3.39e-01 | 4.66e-02 | 3.81e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 1 BETA PRODUCTION | 61 | 2.87e-03 | 4.03e-02 | 0.2550 | 1.60e-01 | 8.51e-02 | -7.82e-02 | 3.77e-02 | -1.58e-01 | 3.11e-02 | 2.50e-01 | 2.91e-01 | 6.10e-01 | 3.26e-02 |
| MICROTUBULE SEVERING | 8 | 8.10e-01 | 9.68e-01 | 0.2550 | -1.98e-01 | -1.16e-01 | -1.59e-02 | -9.04e-02 | -6.55e-02 | 3.33e-01 | 5.71e-01 | 9.38e-01 | 6.58e-01 | 7.48e-01 |
| CELLULAR RESPONSE TO PROGESTERONE STIMULUS | 7 | 8.45e-01 | 9.75e-01 | 0.2550 | 1.65e-01 | 3.98e-02 | -6.69e-02 | 4.20e-02 | -1.74e-01 | 4.49e-01 | 8.55e-01 | 7.59e-01 | 8.47e-01 | 4.26e-01 |
| SPHINGOID METABOLIC PROCESS | 22 | 6.65e-01 | 9.23e-01 | 0.2550 | -1.57e-01 | -1.59e-01 | -1.06e-01 | -6.02e-02 | 1.67e-02 | 2.01e-01 | 1.97e-01 | 3.90e-01 | 6.25e-01 | 8.92e-01 |
| PROTEIN CONTAINING COMPLEX REMODELING | 36 | 3.83e-03 | 5.06e-02 | 0.2550 | -1.04e-01 | 8.22e-02 | -5.17e-02 | -1.35e-01 | -1.64e-01 | 2.82e-01 | 3.94e-01 | 5.91e-01 | 1.62e-01 | 8.85e-02 |
| REGULATION OF MONOCYTE CHEMOTAXIS | 27 | 3.69e-03 | 4.91e-02 | 0.2550 | 4.60e-02 | 1.96e-01 | 4.86e-03 | -1.39e-01 | -7.33e-02 | 6.79e-01 | 7.80e-02 | 9.65e-01 | 2.12e-01 | 5.10e-01 |
| POSITIVE REGULATION OF CELL CYCLE | 319 | 9.11e-05 | 2.58e-03 | 0.2550 | 8.51e-02 | 7.78e-02 | 1.22e-01 | 1.41e-01 | 1.31e-01 | 8.96e-03 | 1.69e-02 | 1.89e-04 | 1.40e-05 | 5.93e-05 |
| T CELL DIFFERENTIATION | 301 | 2.37e-06 | 1.03e-04 | 0.2550 | 5.55e-02 | 6.35e-02 | 1.32e-01 | 1.53e-01 | 1.32e-01 | 9.78e-02 | 5.80e-02 | 8.56e-05 | 5.25e-06 | 8.34e-05 |
| POSITIVE REGULATION OF T CELL MEDIATED IMMUNITY | 66 | 1.43e-01 | 5.09e-01 | 0.2550 | 4.13e-02 | 6.77e-02 | 1.42e-01 | 1.50e-01 | 1.27e-01 | 5.62e-01 | 3.42e-01 | 4.54e-02 | 3.56e-02 | 7.48e-02 |
| NUCLEUS ORGANIZATION | 142 | 3.95e-02 | 2.56e-01 | 0.2550 | 1.04e-01 | 8.08e-02 | 1.37e-01 | 1.51e-01 | 7.79e-02 | 3.17e-02 | 9.65e-02 | 4.91e-03 | 1.91e-03 | 1.09e-01 |
| PODOSOME ASSEMBLY | 19 | 4.55e-01 | 8.22e-01 | 0.2550 | 1.83e-01 | 1.59e-01 | 1.17e-02 | 2.91e-02 | -7.22e-02 | 1.68e-01 | 2.29e-01 | 9.30e-01 | 8.26e-01 | 5.86e-01 |
| DETECTION OF MECHANICAL STIMULUS | 53 | 5.07e-01 | 8.52e-01 | 0.2550 | -1.36e-01 | -9.71e-02 | -1.04e-01 | -1.55e-01 | -4.74e-02 | 8.72e-02 | 2.21e-01 | 1.92e-01 | 5.09e-02 | 5.50e-01 |
| FOLIC ACID METABOLIC PROCESS | 15 | 7.46e-01 | 9.50e-01 | 0.2550 | 1.93e-01 | 1.42e-01 | 4.46e-02 | 7.35e-02 | -9.81e-03 | 1.95e-01 | 3.43e-01 | 7.65e-01 | 6.22e-01 | 9.48e-01 |
| OLFACTORY BEHAVIOR | 10 | 9.29e-01 | 9.89e-01 | 0.2550 | 4.63e-02 | 1.35e-01 | 1.64e-01 | 7.45e-02 | 1.11e-01 | 8.00e-01 | 4.61e-01 | 3.70e-01 | 6.83e-01 | 5.45e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO MEMBRANE | 260 | 4.26e-03 | 5.50e-02 | 0.2550 | 8.48e-02 | 9.53e-02 | 1.30e-01 | 1.23e-01 | 1.29e-01 | 1.85e-02 | 8.15e-03 | 3.22e-04 | 6.53e-04 | 3.28e-04 |
| POSITIVE REGULATION OF MYOTUBE DIFFERENTIATION | 17 | 9.32e-01 | 9.90e-01 | 0.2550 | -1.54e-01 | -1.26e-01 | -9.07e-02 | -1.20e-01 | -5.07e-02 | 2.72e-01 | 3.70e-01 | 5.17e-01 | 3.90e-01 | 7.18e-01 |
| METANEPHRIC PROXIMAL TUBULE DEVELOPMENT | 5 | 3.99e-01 | 7.87e-01 | 0.2550 | -2.09e-01 | 2.39e-02 | -1.31e-01 | -5.60e-02 | -1.51e-02 | 4.18e-01 | 9.26e-01 | 6.13e-01 | 8.28e-01 | 9.53e-01 |
| INTRACILIARY RETROGRADE TRANSPORT | 14 | 8.36e-01 | 9.73e-01 | 0.2550 | -1.36e-01 | -1.08e-01 | -8.39e-02 | -1.36e-01 | 9.57e-02 | 3.77e-01 | 4.85e-01 | 5.87e-01 | 3.79e-01 | 5.35e-01 |
| NEGATIVE REGULATION OF ACTIN FILAMENT DEPOLYMERIZATION | 44 | 6.36e-01 | 9.13e-01 | 0.2550 | -1.37e-01 | -1.22e-01 | -1.31e-01 | -1.04e-01 | -5.45e-02 | 1.16e-01 | 1.61e-01 | 1.31e-01 | 2.33e-01 | 5.32e-01 |
| POSITIVE REGULATION OF EXECUTION PHASE OF APOPTOSIS | 8 | 8.83e-01 | 9.79e-01 | 0.2550 | -1.38e-01 | -1.06e-01 | 2.92e-02 | -4.59e-02 | 1.77e-01 | 4.99e-01 | 6.03e-01 | 8.86e-01 | 8.22e-01 | 3.85e-01 |
| RESPONSE TO ZINC ION STARVATION | 9 | 4.47e-01 | 8.17e-01 | 0.2540 | 1.21e-01 | 2.17e-01 | 6.36e-03 | -4.57e-02 | 2.93e-02 | 5.31e-01 | 2.59e-01 | 9.74e-01 | 8.12e-01 | 8.79e-01 |
| NEGATIVE REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 7 | 5.24e-01 | 8.60e-01 | 0.2540 | 1.54e-01 | 1.75e-01 | -3.48e-02 | -7.37e-03 | 9.54e-02 | 4.80e-01 | 4.23e-01 | 8.73e-01 | 9.73e-01 | 6.62e-01 |
| B CELL ACTIVATION | 262 | 6.49e-04 | 1.24e-02 | 0.2540 | 1.09e-01 | 1.10e-01 | 1.06e-01 | 1.52e-01 | 8.19e-02 | 2.42e-03 | 2.26e-03 | 3.18e-03 | 2.39e-05 | 2.25e-02 |
| INTRACELLULAR PH REDUCTION | 51 | 6.18e-01 | 9.07e-01 | 0.2540 | 1.16e-01 | 8.92e-02 | 1.27e-01 | 1.28e-01 | 1.03e-01 | 1.50e-01 | 2.70e-01 | 1.16e-01 | 1.13e-01 | 2.04e-01 |
| REGULATION OF NUCLEOTIDE EXCISION REPAIR | 28 | 2.95e-01 | 7.07e-01 | 0.2540 | 8.71e-02 | 9.25e-02 | 6.96e-02 | 1.69e-01 | 1.23e-01 | 4.25e-01 | 3.97e-01 | 5.24e-01 | 1.22e-01 | 2.60e-01 |
| NEGATIVE REGULATION OF TROPHOBLAST CELL MIGRATION | 7 | 7.54e-01 | 9.51e-01 | 0.2540 | -9.42e-02 | 2.98e-03 | -1.13e-01 | -2.03e-01 | 4.09e-02 | 6.66e-01 | 9.89e-01 | 6.05e-01 | 3.52e-01 | 8.51e-01 |
| SARCOPLASMIC RETICULUM CALCIUM ION TRANSPORT | 40 | 5.14e-01 | 8.56e-01 | 0.2540 | -1.35e-01 | -1.58e-01 | -8.77e-02 | -9.11e-02 | -7.36e-02 | 1.39e-01 | 8.43e-02 | 3.37e-01 | 3.19e-01 | 4.20e-01 |
| REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 58 | 1.15e-01 | 4.62e-01 | 0.2540 | 3.43e-02 | 3.58e-02 | 9.56e-02 | 1.22e-01 | 1.95e-01 | 6.51e-01 | 6.38e-01 | 2.08e-01 | 1.07e-01 | 1.03e-02 |
| POSITIVE REGULATION OF VESICLE FUSION | 11 | 7.88e-01 | 9.63e-01 | 0.2540 | 5.46e-02 | -5.45e-02 | -1.49e-01 | -6.23e-02 | -1.80e-01 | 7.54e-01 | 7.54e-01 | 3.93e-01 | 7.20e-01 | 3.01e-01 |
| RESPONSE TO STARVATION | 208 | 2.87e-03 | 4.03e-02 | 0.2540 | 9.38e-02 | 8.44e-02 | 1.15e-01 | 1.55e-01 | 1.07e-01 | 1.97e-02 | 3.59e-02 | 4.20e-03 | 1.22e-04 | 8.00e-03 |
| T HELPER 2 CELL DIFFERENTIATION | 19 | 8.28e-01 | 9.72e-01 | 0.2540 | 1.30e-01 | 1.65e-01 | 8.34e-02 | 1.04e-01 | 5.21e-02 | 3.28e-01 | 2.14e-01 | 5.29e-01 | 4.34e-01 | 6.94e-01 |
| SYNAPTIC TRANSMISSION GLYCINERGIC | 5 | 9.35e-01 | 9.91e-01 | 0.2540 | 1.07e-02 | 3.05e-02 | 7.01e-02 | -8.32e-03 | 2.42e-01 | 9.67e-01 | 9.06e-01 | 7.86e-01 | 9.74e-01 | 3.50e-01 |
| RESPONSE TO NICOTINE | 49 | 2.37e-01 | 6.40e-01 | 0.2540 | -4.03e-03 | 4.62e-02 | 1.35e-01 | 8.75e-02 | 1.90e-01 | 9.61e-01 | 5.76e-01 | 1.02e-01 | 2.89e-01 | 2.11e-02 |
| NEGATIVE REGULATION OF OXIDOREDUCTASE ACTIVITY | 27 | 1.17e-01 | 4.65e-01 | 0.2540 | -9.84e-02 | 8.94e-03 | -7.65e-02 | -2.11e-01 | -6.65e-02 | 3.76e-01 | 9.36e-01 | 4.92e-01 | 5.83e-02 | 5.50e-01 |
| NEGATIVE REGULATION OF TELOMERASE ACTIVITY | 10 | 5.86e-01 | 8.91e-01 | 0.2530 | 6.17e-02 | 1.38e-01 | 7.12e-02 | 1.80e-01 | 6.16e-02 | 7.36e-01 | 4.50e-01 | 6.97e-01 | 3.23e-01 | 7.36e-01 |
| EXCRETION | 29 | 1.72e-01 | 5.57e-01 | 0.2530 | -8.05e-02 | 4.09e-02 | 1.08e-01 | 6.19e-02 | 2.02e-01 | 4.53e-01 | 7.03e-01 | 3.14e-01 | 5.64e-01 | 6.03e-02 |
| PROTEIN POLYUBIQUITINATION | 219 | 2.04e-04 | 4.80e-03 | 0.2530 | 1.37e-01 | 7.80e-02 | 8.91e-02 | 1.59e-01 | 7.76e-02 | 4.68e-04 | 4.67e-02 | 2.30e-02 | 4.83e-05 | 4.78e-02 |
| DNA MODIFICATION | 99 | 8.30e-02 | 3.90e-01 | 0.2530 | 1.03e-01 | 7.95e-02 | 9.96e-02 | 1.48e-01 | 1.25e-01 | 7.54e-02 | 1.72e-01 | 8.68e-02 | 1.12e-02 | 3.22e-02 |
| EXTRAEMBRYONIC MEMBRANE DEVELOPMENT | 13 | 8.81e-01 | 9.79e-01 | 0.2530 | 9.12e-02 | 6.00e-02 | 1.61e-01 | 1.43e-01 | 7.67e-02 | 5.69e-01 | 7.08e-01 | 3.15e-01 | 3.71e-01 | 6.32e-01 |
| MITOTIC RECOMBINATION | 25 | 3.57e-01 | 7.57e-01 | 0.2530 | 1.08e-01 | 2.53e-02 | 6.29e-02 | 1.52e-01 | 1.57e-01 | 3.48e-01 | 8.27e-01 | 5.86e-01 | 1.89e-01 | 1.73e-01 |
| LYSINE METABOLIC PROCESS | 8 | 6.72e-01 | 9.26e-01 | 0.2530 | -2.76e-03 | -5.49e-02 | -1.87e-01 | -1.62e-01 | -4.56e-03 | 9.89e-01 | 7.88e-01 | 3.61e-01 | 4.28e-01 | 9.82e-01 |
| REGULATION OF COMPLEMENT DEPENDENT CYTOTOXICITY | 11 | 5.18e-01 | 8.57e-01 | 0.2530 | 1.38e-01 | 1.43e-01 | -7.27e-02 | 4.19e-02 | -1.32e-01 | 4.30e-01 | 4.10e-01 | 6.76e-01 | 8.10e-01 | 4.47e-01 |
| NEGATIVE REGULATION OF PROTEIN TARGETING TO MEMBRANE | 5 | 5.99e-01 | 8.98e-01 | 0.2530 | 1.81e-02 | 1.41e-01 | 1.99e-01 | -3.78e-02 | -5.07e-02 | 9.44e-01 | 5.85e-01 | 4.40e-01 | 8.84e-01 | 8.44e-01 |
| MONOACYLGLYCEROL METABOLIC PROCESS | 12 | 2.88e-01 | 6.96e-01 | 0.2530 | -2.59e-02 | 1.10e-01 | 4.87e-02 | -5.97e-02 | -2.13e-01 | 8.77e-01 | 5.11e-01 | 7.70e-01 | 7.20e-01 | 2.01e-01 |
| CELLULAR RESPONSE TO EXTERNAL STIMULUS | 329 | 1.56e-04 | 3.85e-03 | 0.2530 | 1.17e-01 | 1.20e-01 | 1.02e-01 | 1.44e-01 | 6.97e-02 | 2.63e-04 | 1.89e-04 | 1.51e-03 | 7.19e-06 | 2.97e-02 |
| POSITIVE REGULATION OF LYMPHOCYTE DIFFERENTIATION | 124 | 8.76e-02 | 4.00e-01 | 0.2530 | 1.04e-01 | 1.03e-01 | 1.12e-01 | 1.52e-01 | 8.29e-02 | 4.55e-02 | 4.67e-02 | 3.14e-02 | 3.53e-03 | 1.11e-01 |
| NEGATIVE REGULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR ACTIVITY | 10 | 6.13e-01 | 9.05e-01 | 0.2530 | 1.36e-01 | 8.84e-02 | -2.47e-02 | 1.54e-01 | -1.15e-01 | 4.58e-01 | 6.28e-01 | 8.92e-01 | 3.98e-01 | 5.29e-01 |
| NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 102 | 4.43e-02 | 2.73e-01 | 0.2530 | 7.10e-02 | 7.72e-02 | 1.05e-01 | 1.43e-01 | 1.46e-01 | 2.16e-01 | 1.78e-01 | 6.75e-02 | 1.24e-02 | 1.08e-02 |
| PERICARDIUM DEVELOPMENT | 19 | 8.38e-01 | 9.73e-01 | 0.2520 | 3.44e-02 | 5.98e-02 | 1.46e-01 | 1.23e-01 | 1.50e-01 | 7.95e-01 | 6.52e-01 | 2.71e-01 | 3.53e-01 | 2.57e-01 |
| REGULATION OF HISTONE MODIFICATION | 36 | 1.20e-01 | 4.73e-01 | 0.2520 | 9.77e-02 | 1.06e-01 | 7.91e-02 | 1.91e-01 | -2.08e-02 | 3.10e-01 | 2.73e-01 | 4.12e-01 | 4.77e-02 | 8.29e-01 |
| REGULATION OF SALIVA SECRETION | 7 | 5.95e-01 | 8.97e-01 | 0.2520 | -1.10e-01 | 3.85e-02 | -1.46e-01 | -1.69e-01 | 1.28e-02 | 6.13e-01 | 8.60e-01 | 5.03e-01 | 4.39e-01 | 9.53e-01 |
| POSITIVE REGULATION OF NOTCH SIGNALING PATHWAY | 45 | 1.61e-01 | 5.36e-01 | 0.2520 | 6.33e-02 | 1.04e-01 | 8.82e-02 | 1.45e-01 | 1.41e-01 | 4.62e-01 | 2.26e-01 | 3.06e-01 | 9.29e-02 | 1.01e-01 |
| MYOTUBE DIFFERENTIATION INVOLVED IN SKELETAL MUSCLE REGENERATION | 8 | 9.84e-01 | 9.96e-01 | 0.2520 | 1.14e-01 | 1.13e-01 | 1.51e-01 | 1.13e-01 | 5.03e-02 | 5.77e-01 | 5.79e-01 | 4.61e-01 | 5.81e-01 | 8.05e-01 |
| HISTONE H4 K16 ACETYLATION | 6 | 8.91e-01 | 9.81e-01 | 0.2520 | 1.56e-01 | 3.09e-02 | 2.64e-02 | 1.64e-01 | -1.04e-01 | 5.09e-01 | 8.96e-01 | 9.11e-01 | 4.88e-01 | 6.58e-01 |
| NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 34 | 2.18e-01 | 6.15e-01 | 0.2520 | 1.48e-01 | 1.63e-01 | 1.74e-02 | 4.04e-02 | -1.14e-01 | 1.35e-01 | 9.92e-02 | 8.61e-01 | 6.83e-01 | 2.50e-01 |
| NEGATIVE REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 9 | 5.91e-01 | 8.94e-01 | 0.2520 | -5.10e-02 | 7.29e-02 | 1.24e-01 | -7.93e-02 | 1.84e-01 | 7.91e-01 | 7.05e-01 | 5.19e-01 | 6.80e-01 | 3.38e-01 |
| REGULATION OF CELLULAR PH REDUCTION | 7 | 6.62e-01 | 9.22e-01 | 0.2520 | 2.05e-01 | 2.31e-02 | 6.65e-02 | 8.78e-02 | -9.31e-02 | 3.47e-01 | 9.16e-01 | 7.60e-01 | 6.88e-01 | 6.70e-01 |
| NUCLEOTIDE EXCISION REPAIR | 83 | 8.57e-03 | 9.16e-02 | 0.2520 | 8.50e-02 | 1.19e-01 | 9.88e-02 | 1.77e-01 | 3.08e-02 | 1.80e-01 | 6.08e-02 | 1.20e-01 | 5.33e-03 | 6.27e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE OR POLYSACCHARIDE ANTIGEN VIA MHC CLASS II | 35 | 1.87e-01 | 5.72e-01 | 0.2520 | 1.25e-01 | 1.36e-01 | 5.08e-03 | 2.78e-02 | -1.68e-01 | 1.99e-01 | 1.64e-01 | 9.59e-01 | 7.76e-01 | 8.46e-02 |
| POSITIVE REGULATION OF ISOTYPE SWITCHING TO IGG ISOTYPES | 11 | 7.78e-01 | 9.58e-01 | 0.2520 | 1.60e-02 | 1.04e-01 | 1.85e-01 | 1.22e-01 | 5.86e-02 | 9.27e-01 | 5.52e-01 | 2.89e-01 | 4.84e-01 | 7.36e-01 |
| CHOLESTEROL CATABOLIC PROCESS | 9 | 8.54e-01 | 9.76e-01 | 0.2520 | -8.51e-02 | -1.44e-02 | -1.51e-01 | -1.64e-01 | -7.91e-02 | 6.59e-01 | 9.40e-01 | 4.33e-01 | 3.95e-01 | 6.81e-01 |
| RESPONSE TO WATER | 13 | 6.56e-01 | 9.20e-01 | 0.2520 | -1.28e-01 | -1.00e-01 | 3.40e-02 | 2.43e-02 | 1.88e-01 | 4.26e-01 | 5.32e-01 | 8.32e-01 | 8.80e-01 | 2.41e-01 |
| RESPONSE TO GROWTH HORMONE | 36 | 5.95e-02 | 3.23e-01 | 0.2520 | -1.26e-01 | -3.36e-02 | 4.75e-05 | -2.00e-02 | 2.14e-01 | 1.91e-01 | 7.27e-01 | 1.00e+00 | 8.35e-01 | 2.62e-02 |
| METHYLATION | 262 | 1.02e-04 | 2.84e-03 | 0.2510 | 9.90e-02 | 5.69e-02 | 1.14e-01 | 1.42e-01 | 1.30e-01 | 5.80e-03 | 1.13e-01 | 1.46e-03 | 7.53e-05 | 2.79e-04 |
| PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 9.22e-01 | 9.88e-01 | 0.2510 | -1.22e-01 | -1.12e-01 | -8.60e-02 | -6.36e-02 | 1.56e-01 | 6.05e-01 | 6.33e-01 | 7.15e-01 | 7.87e-01 | 5.09e-01 |
| LOCOMOTORY EXPLORATION BEHAVIOR | 14 | 9.46e-01 | 9.94e-01 | 0.2510 | -1.20e-01 | -7.74e-02 | -1.08e-01 | -1.36e-01 | -1.13e-01 | 4.37e-01 | 6.16e-01 | 4.86e-01 | 3.80e-01 | 4.63e-01 |
| REGULATION OF GASTRULATION | 16 | 3.98e-01 | 7.86e-01 | 0.2510 | 3.73e-02 | 1.89e-01 | 1.02e-01 | 1.01e-01 | 7.30e-02 | 7.96e-01 | 1.90e-01 | 4.81e-01 | 4.84e-01 | 6.13e-01 |
| PROTEIN K48 LINKED UBIQUITINATION | 64 | 1.36e-02 | 1.27e-01 | 0.2510 | 1.16e-01 | 2.12e-02 | 7.28e-02 | 1.83e-01 | 1.02e-01 | 1.08e-01 | 7.69e-01 | 3.14e-01 | 1.13e-02 | 1.59e-01 |
| REGULATION OF PROGRAMMED CELL DEATH | 1469 | 2.39e-16 | 3.67e-14 | 0.2510 | 9.57e-02 | 1.01e-01 | 1.23e-01 | 1.27e-01 | 1.11e-01 | 8.05e-10 | 1.00e-10 | 2.44e-15 | 3.45e-16 | 8.43e-13 |
| ANTEROGRADE AXONAL TRANSPORT | 49 | 3.02e-01 | 7.14e-01 | 0.2510 | 1.04e-01 | 4.33e-02 | 1.07e-01 | 1.45e-01 | 1.34e-01 | 2.07e-01 | 6.00e-01 | 1.96e-01 | 7.89e-02 | 1.05e-01 |
| PENETRATION OF ZONA PELLUCIDA | 9 | 9.00e-01 | 9.83e-01 | 0.2510 | 1.08e-01 | 1.68e-01 | 7.72e-02 | 1.30e-01 | -1.39e-02 | 5.76e-01 | 3.82e-01 | 6.88e-01 | 5.01e-01 | 9.43e-01 |
| RESPONSE TO STEROL DEPLETION | 18 | 7.53e-01 | 9.51e-01 | 0.2510 | 1.02e-01 | 1.56e-01 | 1.29e-01 | 9.46e-02 | -4.84e-02 | 4.54e-01 | 2.51e-01 | 3.42e-01 | 4.87e-01 | 7.22e-01 |
| EMBRYONIC BODY MORPHOGENESIS | 11 | 8.33e-01 | 9.73e-01 | 0.2510 | -1.26e-01 | -1.51e-01 | -1.46e-01 | -4.36e-02 | -3.11e-02 | 4.70e-01 | 3.86e-01 | 4.01e-01 | 8.02e-01 | 8.58e-01 |
| KERATINOCYTE DIFFERENTIATION | 174 | 2.43e-04 | 5.45e-03 | 0.2510 | -9.34e-02 | -5.77e-02 | -1.14e-01 | -1.80e-01 | -7.40e-02 | 3.36e-02 | 1.89e-01 | 9.44e-03 | 4.34e-05 | 9.23e-02 |
| HEPATIC STELLATE CELL ACTIVATION | 9 | 7.99e-01 | 9.66e-01 | 0.2510 | 5.58e-02 | 8.20e-02 | -9.16e-02 | -6.58e-02 | -2.01e-01 | 7.72e-01 | 6.70e-01 | 6.34e-01 | 7.33e-01 | 2.97e-01 |
| POSITIVE REGULATION OF ORGAN GROWTH | 47 | 6.20e-01 | 9.07e-01 | 0.2510 | 1.11e-01 | 1.45e-01 | 1.35e-01 | 9.83e-02 | 4.00e-02 | 1.90e-01 | 8.48e-02 | 1.10e-01 | 2.44e-01 | 6.36e-01 |
| POSITIVE REGULATION OF MACROAUTOPHAGY | 71 | 3.52e-01 | 7.53e-01 | 0.2510 | 1.52e-01 | 1.28e-01 | 8.42e-02 | 1.20e-01 | 3.89e-02 | 2.65e-02 | 6.15e-02 | 2.20e-01 | 7.91e-02 | 5.71e-01 |
| RESPONSE TO TESTOSTERONE | 42 | 6.32e-01 | 9.11e-01 | 0.2500 | 1.17e-01 | 1.40e-01 | 1.02e-01 | 9.60e-02 | 9.96e-02 | 1.91e-01 | 1.16e-01 | 2.55e-01 | 2.82e-01 | 2.64e-01 |
| GAMMA AMINOBUTYRIC ACID SECRETION | 12 | 5.25e-01 | 8.60e-01 | 0.2500 | -7.54e-02 | -9.38e-02 | -2.05e-01 | -5.80e-02 | -5.21e-02 | 6.51e-01 | 5.74e-01 | 2.18e-01 | 7.28e-01 | 7.55e-01 |
| LIPOPROTEIN CATABOLIC PROCESS | 15 | 1.92e-01 | 5.80e-01 | 0.2500 | -7.68e-02 | -5.79e-02 | -3.22e-02 | 7.71e-02 | 2.16e-01 | 6.07e-01 | 6.98e-01 | 8.29e-01 | 6.05e-01 | 1.48e-01 |
| CLATHRIN COATED VESICLE CARGO LOADING | 7 | 9.40e-01 | 9.92e-01 | 0.2500 | 1.79e-01 | 6.62e-02 | 5.71e-02 | 1.50e-01 | 2.45e-02 | 4.13e-01 | 7.62e-01 | 7.94e-01 | 4.91e-01 | 9.11e-01 |
| PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA SIGNALING PATHWAY | 7 | 6.41e-01 | 9.14e-01 | 0.2500 | 1.13e-01 | -4.33e-02 | 2.94e-03 | 1.77e-01 | 1.29e-01 | 6.04e-01 | 8.43e-01 | 9.89e-01 | 4.17e-01 | 5.54e-01 |
| REACTIVE GLIOSIS | 6 | 6.11e-01 | 9.04e-01 | 0.2500 | -1.51e-02 | 2.40e-03 | -1.09e-01 | -1.31e-01 | 1.83e-01 | 9.49e-01 | 9.92e-01 | 6.43e-01 | 5.78e-01 | 4.39e-01 |
| INTRACELLULAR MRNA LOCALIZATION | 13 | 9.56e-01 | 9.94e-01 | 0.2500 | -1.26e-01 | -1.51e-01 | -1.12e-01 | -8.27e-02 | -6.84e-02 | 4.32e-01 | 3.45e-01 | 4.86e-01 | 6.06e-01 | 6.70e-01 |
| SCHWANN CELL DIFFERENTIATION | 38 | 4.77e-01 | 8.33e-01 | 0.2500 | 7.30e-02 | 4.39e-02 | 1.06e-01 | 1.10e-01 | 1.79e-01 | 4.36e-01 | 6.39e-01 | 2.58e-01 | 2.41e-01 | 5.60e-02 |
| PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 221 | 3.77e-04 | 8.05e-03 | 0.2500 | 1.41e-01 | 1.62e-01 | 7.69e-02 | 1.02e-01 | 1.18e-02 | 2.99e-04 | 3.36e-05 | 4.88e-02 | 8.77e-03 | 7.63e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CONTRACTION | 13 | 6.83e-01 | 9.30e-01 | 0.2500 | -2.04e-02 | -1.53e-02 | 1.41e-01 | 1.34e-01 | 1.55e-01 | 8.99e-01 | 9.24e-01 | 3.77e-01 | 4.04e-01 | 3.32e-01 |
| REGULATION OF EXECUTION PHASE OF APOPTOSIS | 17 | 2.68e-01 | 6.75e-01 | 0.2500 | -9.83e-02 | -1.88e-01 | -3.64e-02 | 4.94e-02 | 1.18e-01 | 4.83e-01 | 1.80e-01 | 7.95e-01 | 7.25e-01 | 3.99e-01 |
| POSITIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 32 | 5.42e-01 | 8.69e-01 | 0.2500 | 1.75e-01 | 1.12e-01 | 7.95e-02 | 1.04e-01 | -4.81e-02 | 8.61e-02 | 2.73e-01 | 4.36e-01 | 3.11e-01 | 6.38e-01 |
| REGULATION OF CARDIAC MUSCLE CONTRACTION BY REGULATION OF THE RELEASE OF SEQUESTERED CALCIUM ION | 20 | 4.54e-01 | 8.22e-01 | 0.2500 | -1.71e-01 | -1.60e-01 | -8.72e-04 | -3.91e-02 | 7.77e-02 | 1.85e-01 | 2.15e-01 | 9.95e-01 | 7.62e-01 | 5.47e-01 |
| RETINA VASCULATURE DEVELOPMENT IN CAMERA TYPE EYE | 18 | 4.54e-01 | 8.22e-01 | 0.2500 | -1.24e-01 | -8.41e-02 | -4.15e-03 | -1.39e-01 | 1.44e-01 | 3.61e-01 | 5.37e-01 | 9.76e-01 | 3.09e-01 | 2.90e-01 |
| POSITIVE REGULATION OF NEUROBLAST PROLIFERATION | 37 | 3.34e-01 | 7.40e-01 | 0.2500 | 9.33e-03 | 5.44e-02 | 1.11e-01 | 1.22e-01 | 1.79e-01 | 9.22e-01 | 5.67e-01 | 2.42e-01 | 1.98e-01 | 5.95e-02 |
| POSITIVE REGULATION OF SKELETAL MUSCLE FIBER DEVELOPMENT | 9 | 9.30e-01 | 9.90e-01 | 0.2500 | 1.04e-01 | 1.20e-01 | 1.21e-01 | 4.54e-02 | 1.43e-01 | 5.88e-01 | 5.33e-01 | 5.31e-01 | 8.14e-01 | 4.57e-01 |
| RESPONSE TO GONADOTROPIN | 27 | 1.66e-01 | 5.46e-01 | 0.2500 | -1.61e-01 | -5.05e-02 | -2.80e-02 | -5.54e-02 | 1.74e-01 | 1.49e-01 | 6.50e-01 | 8.01e-01 | 6.18e-01 | 1.18e-01 |
| NEGATIVE REGULATION OF PROTEIN SUMOYLATION | 8 | 5.40e-01 | 8.67e-01 | 0.2500 | -8.22e-02 | -1.59e-01 | 2.24e-02 | 1.26e-01 | 1.17e-01 | 6.87e-01 | 4.35e-01 | 9.13e-01 | 5.36e-01 | 5.66e-01 |
| REGULATION OF HEMOGLOBIN BIOSYNTHETIC PROCESS | 8 | 6.76e-01 | 9.28e-01 | 0.2500 | 1.81e-01 | 6.92e-02 | -1.77e-02 | 1.36e-01 | 7.77e-02 | 3.76e-01 | 7.34e-01 | 9.31e-01 | 5.05e-01 | 7.03e-01 |
| CALCIUM ION IMPORT INTO SARCOPLASMIC RETICULUM | 5 | 6.37e-01 | 9.13e-01 | 0.2500 | 1.44e-01 | -1.08e-01 | 1.71e-02 | 1.38e-01 | 1.04e-01 | 5.78e-01 | 6.77e-01 | 9.47e-01 | 5.93e-01 | 6.88e-01 |
| POSITIVE REGULATION OF HISTONE METHYLATION | 14 | 5.57e-01 | 8.77e-01 | 0.2500 | 4.61e-02 | 2.62e-02 | -5.47e-02 | 5.24e-02 | -2.32e-01 | 7.65e-01 | 8.65e-01 | 7.23e-01 | 7.34e-01 | 1.33e-01 |
| POSITIVE REGULATION OF PODOSOME ASSEMBLY | 10 | 7.20e-01 | 9.39e-01 | 0.2500 | 1.33e-01 | 6.44e-02 | -6.99e-02 | -4.50e-02 | -1.83e-01 | 4.66e-01 | 7.24e-01 | 7.02e-01 | 8.06e-01 | 3.16e-01 |
| ARGININE METABOLIC PROCESS | 19 | 2.27e-01 | 6.28e-01 | 0.2500 | -5.34e-02 | 2.09e-02 | -1.37e-01 | -1.97e-01 | -3.83e-02 | 6.87e-01 | 8.75e-01 | 3.01e-01 | 1.37e-01 | 7.73e-01 |
| POSITIVE REGULATION OF FIBROBLAST MIGRATION | 15 | 7.47e-01 | 9.51e-01 | 0.2500 | -1.53e-01 | -1.08e-01 | -1.39e-01 | -7.49e-02 | -4.69e-02 | 3.05e-01 | 4.67e-01 | 3.52e-01 | 6.16e-01 | 7.53e-01 |
| AMINO ACID SALVAGE | 7 | 8.39e-01 | 9.73e-01 | 0.2490 | -8.99e-02 | -4.54e-02 | 6.60e-02 | -7.76e-02 | 2.04e-01 | 6.80e-01 | 8.35e-01 | 7.62e-01 | 7.22e-01 | 3.49e-01 |
| NEGATIVE REGULATION OF TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 14 | 5.45e-01 | 8.70e-01 | 0.2490 | 1.86e-01 | 5.72e-02 | 2.11e-02 | 1.34e-01 | 7.64e-02 | 2.27e-01 | 7.11e-01 | 8.91e-01 | 3.87e-01 | 6.21e-01 |
| REGULATION OF UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 169 | 1.48e-02 | 1.34e-01 | 0.2490 | 1.10e-01 | 8.76e-02 | 1.15e-01 | 1.60e-01 | 5.90e-02 | 1.32e-02 | 4.93e-02 | 1.02e-02 | 3.29e-04 | 1.85e-01 |
| REGULATION OF HEPATOCYTE PROLIFERATION | 16 | 5.91e-01 | 8.94e-01 | 0.2490 | 1.28e-01 | 1.23e-01 | 4.82e-02 | 2.32e-02 | -1.67e-01 | 3.77e-01 | 3.95e-01 | 7.38e-01 | 8.73e-01 | 2.48e-01 |
| MEDIUM CHAIN FATTY ACID BIOSYNTHETIC PROCESS | 6 | 9.59e-01 | 9.94e-01 | 0.2490 | 1.10e-01 | 8.71e-02 | 1.45e-01 | 1.41e-01 | -3.92e-02 | 6.42e-01 | 7.12e-01 | 5.39e-01 | 5.49e-01 | 8.68e-01 |
| REGULATION OF CILIUM DEPENDENT CELL MOTILITY | 27 | 3.02e-01 | 7.14e-01 | 0.2490 | -8.59e-02 | -6.12e-02 | -9.84e-02 | -2.01e-01 | -2.54e-02 | 4.40e-01 | 5.82e-01 | 3.76e-01 | 7.00e-02 | 8.19e-01 |
| CELLULAR RESPONSE TO SALT STRESS | 14 | 4.17e-01 | 7.99e-01 | 0.2490 | -9.67e-02 | 6.36e-02 | 1.09e-01 | 6.37e-02 | 1.81e-01 | 5.31e-01 | 6.81e-01 | 4.80e-01 | 6.80e-01 | 2.41e-01 |
| PIGMENT CELL DIFFERENTIATION | 35 | 5.59e-01 | 8.78e-01 | 0.2490 | -7.91e-02 | -1.33e-01 | -1.47e-01 | -1.27e-01 | -2.01e-02 | 4.18e-01 | 1.73e-01 | 1.33e-01 | 1.95e-01 | 8.37e-01 |
| CELLULAR RESPONSE TO MACROPHAGE COLONY STIMULATING FACTOR STIMULUS | 13 | 1.41e-01 | 5.07e-01 | 0.2490 | 1.00e-01 | 2.13e-01 | -2.06e-02 | -6.39e-02 | 4.49e-02 | 5.32e-01 | 1.84e-01 | 8.98e-01 | 6.90e-01 | 7.79e-01 |
| POSITIVE REGULATION OF BONE RESORPTION | 18 | 6.39e-02 | 3.37e-01 | 0.2490 | 3.31e-02 | 1.09e-01 | -1.43e-01 | -1.74e-02 | -1.69e-01 | 8.08e-01 | 4.25e-01 | 2.95e-01 | 8.98e-01 | 2.16e-01 |
| DENDRITIC CELL CHEMOTAXIS | 25 | 4.66e-01 | 8.26e-01 | 0.2490 | 1.83e-01 | 1.21e-01 | 3.10e-02 | 1.08e-01 | 3.25e-02 | 1.13e-01 | 2.93e-01 | 7.89e-01 | 3.52e-01 | 7.79e-01 |
| T HELPER 1 TYPE IMMUNE RESPONSE | 48 | 2.51e-02 | 1.93e-01 | 0.2490 | 1.67e-01 | 1.78e-01 | 7.92e-03 | 3.81e-02 | -2.69e-02 | 4.55e-02 | 3.26e-02 | 9.24e-01 | 6.48e-01 | 7.47e-01 |
| FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 81 | 2.42e-02 | 1.89e-01 | 0.2490 | -5.76e-04 | 3.27e-02 | 1.20e-01 | 1.26e-01 | 1.75e-01 | 9.93e-01 | 6.11e-01 | 6.10e-02 | 5.03e-02 | 6.62e-03 |
| ATRIAL CARDIAC MUSCLE TISSUE MORPHOGENESIS | 6 | 9.15e-01 | 9.86e-01 | 0.2490 | -1.61e-01 | -4.17e-02 | -9.01e-02 | -1.44e-01 | 7.41e-02 | 4.95e-01 | 8.60e-01 | 7.02e-01 | 5.42e-01 | 7.53e-01 |
| PROTEIN IMPORT INTO PEROXISOME MATRIX | 14 | 8.85e-01 | 9.80e-01 | 0.2490 | 3.73e-02 | 9.67e-02 | 1.26e-01 | 1.33e-01 | 1.32e-01 | 8.09e-01 | 5.31e-01 | 4.14e-01 | 3.89e-01 | 3.92e-01 |
| MESENCHYMAL CELL DIFFERENTIATION | 256 | 1.06e-04 | 2.90e-03 | 0.2490 | 4.71e-02 | 8.65e-02 | 1.15e-01 | 1.14e-01 | 1.61e-01 | 1.94e-01 | 1.71e-02 | 1.58e-03 | 1.69e-03 | 9.06e-06 |
| PURINE NUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 10 | 8.74e-01 | 9.78e-01 | 0.2490 | 1.09e-01 | 5.75e-02 | 1.53e-01 | 1.52e-01 | 1.21e-02 | 5.49e-01 | 7.53e-01 | 4.02e-01 | 4.07e-01 | 9.47e-01 |
| AXONAL TRANSPORT OF MITOCHONDRION | 16 | 6.30e-01 | 9.10e-01 | 0.2490 | -6.94e-03 | -1.67e-02 | 6.64e-02 | 1.01e-01 | 2.16e-01 | 9.62e-01 | 9.08e-01 | 6.46e-01 | 4.85e-01 | 1.34e-01 |
| HEPARIN METABOLIC PROCESS | 17 | 4.43e-01 | 8.13e-01 | 0.2480 | 9.09e-02 | 4.98e-02 | -1.31e-01 | -4.71e-02 | -1.78e-01 | 5.17e-01 | 7.22e-01 | 3.51e-01 | 7.37e-01 | 2.04e-01 |
| SYNAPSE PRUNING | 14 | 3.26e-01 | 7.35e-01 | 0.2480 | 1.09e-01 | 2.22e-01 | 2.30e-02 | 3.21e-03 | 9.38e-03 | 4.81e-01 | 1.50e-01 | 8.82e-01 | 9.83e-01 | 9.52e-01 |
| TELENCEPHALON DEVELOPMENT | 268 | 1.30e-03 | 2.17e-02 | 0.2480 | 9.63e-02 | 8.86e-02 | 1.32e-01 | 1.01e-01 | 1.30e-01 | 6.67e-03 | 1.25e-02 | 1.96e-04 | 4.24e-03 | 2.56e-04 |
| PYRIMIDINE NUCLEOSIDE DIPHOSPHATE BIOSYNTHETIC PROCESS | 6 | 8.35e-01 | 9.73e-01 | 0.2480 | 5.60e-02 | -3.25e-02 | 1.41e-01 | 7.17e-02 | 1.80e-01 | 8.12e-01 | 8.90e-01 | 5.50e-01 | 7.61e-01 | 4.44e-01 |
| PYRIMIDINE RIBONUCLEOTIDE CATABOLIC PROCESS | 8 | 5.73e-01 | 8.84e-01 | 0.2480 | 1.21e-03 | -5.96e-02 | -5.02e-02 | 6.01e-02 | 2.28e-01 | 9.95e-01 | 7.70e-01 | 8.06e-01 | 7.68e-01 | 2.64e-01 |
| POSITIVE REGULATION OF AXON EXTENSION | 33 | 7.98e-01 | 9.66e-01 | 0.2480 | -1.28e-01 | -9.98e-02 | -9.77e-02 | -1.38e-01 | -8.16e-02 | 2.03e-01 | 3.21e-01 | 3.31e-01 | 1.71e-01 | 4.17e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS PEPTIDE ANTIGEN VIA MHC CLASS I | 8 | 4.93e-01 | 8.43e-01 | 0.2480 | 4.32e-02 | 2.00e-01 | 5.50e-02 | 1.27e-01 | 2.18e-02 | 8.33e-01 | 3.27e-01 | 7.88e-01 | 5.34e-01 | 9.15e-01 |
| REGULATION OF HORMONE METABOLIC PROCESS | 39 | 6.43e-01 | 9.15e-01 | 0.2480 | 9.18e-02 | 8.56e-02 | 1.09e-01 | 9.94e-02 | 1.55e-01 | 3.21e-01 | 3.55e-01 | 2.41e-01 | 2.83e-01 | 9.36e-02 |
| HUMORAL IMMUNE RESPONSE MEDIATED BY CIRCULATING IMMUNOGLOBULIN | 47 | 4.85e-01 | 8.38e-01 | 0.2480 | -1.26e-01 | -9.22e-02 | -8.59e-02 | -1.33e-01 | -1.10e-01 | 1.34e-01 | 2.74e-01 | 3.08e-01 | 1.16e-01 | 1.92e-01 |
| HISTONE H4 ACETYLATION | 11 | 6.64e-01 | 9.22e-01 | 0.2480 | 1.33e-01 | 7.25e-02 | -2.82e-02 | 1.31e-01 | -1.43e-01 | 4.45e-01 | 6.77e-01 | 8.71e-01 | 4.52e-01 | 4.10e-01 |
| POSITIVE REGULATION OF FEEDING BEHAVIOR | 10 | 2.58e-01 | 6.65e-01 | 0.2480 | 1.13e-01 | 1.62e-01 | -1.14e-01 | -7.63e-02 | -5.89e-02 | 5.37e-01 | 3.74e-01 | 5.31e-01 | 6.76e-01 | 7.47e-01 |
| CEREBRAL CORTEX TANGENTIAL MIGRATION | 5 | 9.28e-01 | 9.89e-01 | 0.2480 | 4.06e-02 | -4.34e-02 | -1.74e-01 | -1.15e-01 | -1.20e-01 | 8.75e-01 | 8.66e-01 | 5.00e-01 | 6.56e-01 | 6.43e-01 |
| SULFUR COMPOUND CATABOLIC PROCESS | 35 | 6.75e-01 | 9.28e-01 | 0.2480 | 9.49e-02 | 9.52e-02 | 1.30e-01 | 8.26e-02 | 1.40e-01 | 3.31e-01 | 3.30e-01 | 1.83e-01 | 3.98e-01 | 1.51e-01 |
| REGULATION OF RHODOPSIN MEDIATED SIGNALING PATHWAY | 9 | 3.51e-02 | 2.39e-01 | 0.2480 | -2.02e-01 | 8.32e-02 | -2.11e-03 | 5.22e-02 | 1.04e-01 | 2.93e-01 | 6.66e-01 | 9.91e-01 | 7.86e-01 | 5.88e-01 |
| PROTEIN LOCALIZATION TO PHOTORECEPTOR OUTER SEGMENT | 7 | 8.55e-01 | 9.77e-01 | 0.2480 | -9.45e-02 | -4.33e-02 | -7.17e-03 | -1.14e-01 | 1.94e-01 | 6.65e-01 | 8.43e-01 | 9.74e-01 | 6.03e-01 | 3.74e-01 |
| ALLANTOIN METABOLIC PROCESS | 9 | 7.62e-01 | 9.54e-01 | 0.2480 | 1.92e-02 | -2.48e-03 | 1.66e-01 | 1.60e-01 | 8.82e-02 | 9.21e-01 | 9.90e-01 | 3.88e-01 | 4.06e-01 | 6.47e-01 |
| L GLUTAMATE TRANSMEMBRANE TRANSPORT | 28 | 6.84e-01 | 9.30e-01 | 0.2480 | -1.58e-01 | -1.50e-01 | -7.96e-02 | -7.84e-02 | -3.54e-02 | 1.48e-01 | 1.68e-01 | 4.66e-01 | 4.73e-01 | 7.46e-01 |
| SPINAL CORD OLIGODENDROCYTE CELL DIFFERENTIATION | 5 | 7.58e-01 | 9.52e-01 | 0.2480 | -8.62e-02 | -3.97e-02 | 1.52e-01 | -5.81e-02 | 1.61e-01 | 7.39e-01 | 8.78e-01 | 5.56e-01 | 8.22e-01 | 5.33e-01 |
| ESTABLISHMENT OR MAINTENANCE OF MONOPOLAR CELL POLARITY | 25 | 2.99e-01 | 7.12e-01 | 0.2480 | -1.33e-01 | -3.28e-02 | 7.09e-02 | -1.39e-02 | 1.93e-01 | 2.49e-01 | 7.77e-01 | 5.40e-01 | 9.04e-01 | 9.47e-02 |
| POST EMBRYONIC ANIMAL ORGAN DEVELOPMENT | 18 | 4.48e-01 | 8.19e-01 | 0.2480 | 1.80e-01 | 1.29e-01 | 6.70e-02 | 3.59e-02 | 7.94e-02 | 1.85e-01 | 3.43e-01 | 6.22e-01 | 7.92e-01 | 5.60e-01 |
| IRES DEPENDENT VIRAL TRANSLATIONAL INITIATION | 10 | 8.75e-01 | 9.78e-01 | 0.2480 | -1.38e-02 | 1.44e-04 | 9.62e-02 | 1.08e-01 | 2.01e-01 | 9.40e-01 | 9.99e-01 | 5.98e-01 | 5.56e-01 | 2.72e-01 |
| INSULIN METABOLIC PROCESS | 16 | 9.37e-01 | 9.92e-01 | 0.2480 | 1.40e-01 | 1.53e-01 | 9.82e-02 | 9.42e-02 | 3.16e-03 | 3.34e-01 | 2.91e-01 | 4.97e-01 | 5.14e-01 | 9.83e-01 |
| RESPONSE TO THYROID HORMONE | 28 | 8.48e-01 | 9.76e-01 | 0.2480 | 7.85e-02 | 9.21e-02 | 1.48e-01 | 1.12e-01 | 1.10e-01 | 4.72e-01 | 3.99e-01 | 1.76e-01 | 3.04e-01 | 3.12e-01 |
| NEGATIVE REGULATION OF KINASE ACTIVITY | 190 | 4.54e-02 | 2.77e-01 | 0.2470 | 1.26e-01 | 1.29e-01 | 1.06e-01 | 1.08e-01 | 7.56e-02 | 2.69e-03 | 2.17e-03 | 1.15e-02 | 1.02e-02 | 7.25e-02 |
| POSITIVE REGULATION OF B CELL MEDIATED IMMUNITY | 41 | 5.44e-01 | 8.70e-01 | 0.2470 | 9.35e-02 | 1.32e-01 | 1.01e-01 | 1.33e-01 | 8.47e-02 | 3.00e-01 | 1.43e-01 | 2.65e-01 | 1.40e-01 | 3.48e-01 |
| REGULATION OF CELLULAR RESPONSE TO STRESS | 629 | 2.78e-07 | 1.43e-05 | 0.2470 | 1.06e-01 | 1.07e-01 | 1.08e-01 | 1.24e-01 | 1.07e-01 | 5.31e-06 | 4.18e-06 | 3.98e-06 | 1.18e-07 | 4.32e-06 |
| CELLULAR RESPONSE TO INSULIN LIKE GROWTH FACTOR STIMULUS | 7 | 8.73e-01 | 9.78e-01 | 0.2470 | 1.45e-01 | 1.11e-01 | 8.46e-03 | 1.55e-01 | -6.12e-02 | 5.08e-01 | 6.10e-01 | 9.69e-01 | 4.77e-01 | 7.79e-01 |
| PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR SIGNALING PATHWAY | 23 | 1.65e-01 | 5.45e-01 | 0.2470 | 1.45e-01 | 2.76e-02 | 4.87e-02 | 7.13e-02 | 1.78e-01 | 2.28e-01 | 8.19e-01 | 6.86e-01 | 5.54e-01 | 1.38e-01 |
| HINDBRAIN DEVELOPMENT | 149 | 5.46e-02 | 3.09e-01 | 0.2470 | 8.05e-02 | 8.54e-02 | 1.26e-01 | 1.01e-01 | 1.46e-01 | 8.97e-02 | 7.18e-02 | 7.97e-03 | 3.29e-02 | 2.15e-03 |
| ACTIN FILAMENT BASED MOVEMENT | 128 | 1.50e-02 | 1.36e-01 | 0.2470 | -1.29e-01 | -7.20e-02 | -1.00e-01 | -1.67e-01 | -3.59e-02 | 1.16e-02 | 1.60e-01 | 5.07e-02 | 1.09e-03 | 4.83e-01 |
| CEREBROSPINAL FLUID CIRCULATION | 15 | 1.20e-01 | 4.73e-01 | 0.2470 | 7.07e-02 | -6.99e-02 | -1.19e-01 | -1.69e-01 | -9.15e-02 | 6.36e-01 | 6.39e-01 | 4.23e-01 | 2.57e-01 | 5.40e-01 |
| CELLULAR RESPONSE TO INDOLE 3 METHANOL | 5 | 3.94e-01 | 7.85e-01 | 0.2470 | -7.12e-02 | -2.82e-02 | -2.34e-02 | 1.86e-01 | -1.42e-01 | 7.83e-01 | 9.13e-01 | 9.28e-01 | 4.71e-01 | 5.84e-01 |
| GLIOGENESIS | 329 | 1.23e-03 | 2.07e-02 | 0.2470 | 8.46e-02 | 1.09e-01 | 1.22e-01 | 1.21e-01 | 1.11e-01 | 8.34e-03 | 6.51e-04 | 1.35e-04 | 1.66e-04 | 5.49e-04 |
| GLIAL CELL DIFFERENTIATION | 246 | 5.50e-03 | 6.61e-02 | 0.2470 | 6.75e-02 | 9.53e-02 | 1.32e-01 | 1.12e-01 | 1.31e-01 | 6.83e-02 | 1.01e-02 | 3.49e-04 | 2.41e-03 | 4.04e-04 |
| T HELPER 17 CELL LINEAGE COMMITMENT | 16 | 9.04e-01 | 9.84e-01 | 0.2470 | 4.44e-02 | 8.42e-02 | 1.48e-01 | 1.29e-01 | 1.15e-01 | 7.58e-01 | 5.60e-01 | 3.06e-01 | 3.71e-01 | 4.25e-01 |
| PROTEIN LOCALIZATION TO MICROTUBULE ORGANIZING CENTER | 35 | 2.09e-02 | 1.71e-01 | 0.2470 | 1.11e-01 | 2.39e-03 | 1.41e-02 | 1.78e-01 | -1.29e-01 | 2.58e-01 | 9.81e-01 | 8.85e-01 | 6.81e-02 | 1.86e-01 |
| POSITIVE REGULATION OF MACROPHAGE MIGRATION | 26 | 3.79e-02 | 2.52e-01 | 0.2470 | 1.12e-01 | 2.04e-01 | -2.95e-02 | -1.39e-02 | -7.37e-02 | 3.23e-01 | 7.13e-02 | 7.95e-01 | 9.02e-01 | 5.15e-01 |
| PEPTIDYL CYSTEINE MODIFICATION | 41 | 2.13e-01 | 6.08e-01 | 0.2460 | 1.12e-01 | 9.79e-02 | 8.04e-02 | 1.78e-01 | -2.12e-02 | 2.15e-01 | 2.78e-01 | 3.73e-01 | 4.83e-02 | 8.15e-01 |
| POSITIVE REGULATION OF DOPAMINE RECEPTOR SIGNALING PATHWAY | 5 | 8.67e-01 | 9.78e-01 | 0.2460 | 9.27e-03 | -8.48e-02 | 1.07e-01 | 1.53e-01 | 1.36e-01 | 9.71e-01 | 7.43e-01 | 6.79e-01 | 5.54e-01 | 5.97e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO CELL SURFACE | 11 | 7.52e-01 | 9.51e-01 | 0.2460 | 8.41e-02 | 8.39e-02 | 1.04e-01 | 1.16e-02 | 1.88e-01 | 6.29e-01 | 6.30e-01 | 5.49e-01 | 9.47e-01 | 2.79e-01 |
| FOREBRAIN DEVELOPMENT | 392 | 5.02e-05 | 1.55e-03 | 0.2460 | 8.20e-02 | 8.68e-02 | 1.32e-01 | 1.01e-01 | 1.37e-01 | 5.31e-03 | 3.17e-03 | 7.48e-06 | 5.64e-04 | 3.32e-06 |
| POSITIVE REGULATION OF STEROL TRANSPORT | 38 | 4.31e-01 | 8.06e-01 | 0.2460 | -8.09e-02 | -7.34e-02 | -1.35e-01 | -1.69e-01 | -4.47e-02 | 3.88e-01 | 4.34e-01 | 1.51e-01 | 7.14e-02 | 6.34e-01 |
| RESPONSE TO FLUID SHEAR STRESS | 34 | 7.26e-01 | 9.42e-01 | 0.2460 | 1.16e-01 | 1.60e-01 | 1.07e-01 | 9.44e-02 | 3.22e-02 | 2.42e-01 | 1.05e-01 | 2.80e-01 | 3.41e-01 | 7.46e-01 |
| NEUTROPHIL HOMEOSTASIS | 20 | 5.10e-01 | 8.53e-01 | 0.2460 | 4.17e-02 | 2.69e-02 | -1.31e-01 | -8.39e-02 | -1.84e-01 | 7.47e-01 | 8.35e-01 | 3.11e-01 | 5.16e-01 | 1.54e-01 |
| REGULATION OF CALCIUM ION IMPORT ACROSS PLASMA MEMBRANE | 16 | 8.79e-01 | 9.79e-01 | 0.2460 | -1.42e-01 | -1.33e-01 | -1.10e-01 | -6.89e-02 | -7.53e-02 | 3.25e-01 | 3.56e-01 | 4.46e-01 | 6.33e-01 | 6.02e-01 |
| METANEPHRIC LOOP OF HENLE DEVELOPMENT | 6 | 9.79e-01 | 9.96e-01 | 0.2460 | 9.94e-02 | 1.49e-01 | 8.71e-02 | 8.00e-02 | 1.20e-01 | 6.73e-01 | 5.28e-01 | 7.12e-01 | 7.34e-01 | 6.09e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL MIGRATION | 44 | 6.11e-01 | 9.04e-01 | 0.2460 | -8.46e-02 | -8.65e-02 | -1.28e-01 | -8.98e-02 | -1.46e-01 | 3.32e-01 | 3.21e-01 | 1.42e-01 | 3.02e-01 | 9.28e-02 |
| PRE MIRNA PROCESSING | 17 | 6.22e-01 | 9.08e-01 | 0.2460 | 1.04e-01 | 1.53e-02 | 6.74e-02 | 1.35e-01 | 1.64e-01 | 4.59e-01 | 9.13e-01 | 6.31e-01 | 3.35e-01 | 2.43e-01 |
| NEGATIVE REGULATION OF TRANSLATIONAL INITIATION | 21 | 5.31e-01 | 8.63e-01 | 0.2460 | 1.75e-01 | 1.03e-01 | 2.27e-02 | 1.35e-01 | 1.87e-02 | 1.64e-01 | 4.14e-01 | 8.57e-01 | 2.83e-01 | 8.82e-01 |
| RETROGRADE TRANSPORT ENDOSOME TO GOLGI | 95 | 2.18e-01 | 6.16e-01 | 0.2460 | 1.53e-01 | 1.11e-01 | 9.06e-02 | 1.28e-01 | 1.72e-02 | 1.02e-02 | 6.18e-02 | 1.27e-01 | 3.11e-02 | 7.72e-01 |
| LIPOSACCHARIDE METABOLIC PROCESS | 106 | 1.45e-01 | 5.11e-01 | 0.2460 | 1.01e-01 | 1.20e-01 | 1.48e-01 | 9.54e-02 | 7.01e-02 | 7.21e-02 | 3.27e-02 | 8.68e-03 | 8.95e-02 | 2.13e-01 |
| REGULATION OF B CELL RECEPTOR SIGNALING PATHWAY | 23 | 6.11e-01 | 9.04e-01 | 0.2460 | 1.34e-01 | 1.10e-01 | 1.04e-01 | 1.03e-01 | -9.51e-02 | 2.66e-01 | 3.63e-01 | 3.89e-01 | 3.92e-01 | 4.30e-01 |
| FATTY ACID ELONGATION SATURATED FATTY ACID | 7 | 9.57e-01 | 9.94e-01 | 0.2460 | 3.29e-02 | 6.98e-02 | 9.38e-02 | 1.25e-01 | 1.73e-01 | 8.80e-01 | 7.49e-01 | 6.67e-01 | 5.68e-01 | 4.27e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS | 127 | 4.34e-03 | 5.58e-02 | 0.2460 | 6.13e-02 | 3.14e-02 | 1.23e-01 | 1.57e-01 | 1.26e-01 | 2.33e-01 | 5.41e-01 | 1.65e-02 | 2.27e-03 | 1.45e-02 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 19 | 6.50e-01 | 9.18e-01 | 0.2450 | -1.70e-01 | -8.85e-02 | -8.72e-02 | -1.02e-01 | 7.46e-02 | 1.99e-01 | 5.04e-01 | 5.10e-01 | 4.43e-01 | 5.74e-01 |
| LABYRINTHINE LAYER DEVELOPMENT | 43 | 4.53e-01 | 8.21e-01 | 0.2450 | 2.76e-02 | 1.00e-01 | 1.36e-01 | 1.04e-01 | 1.42e-01 | 7.54e-01 | 2.56e-01 | 1.24e-01 | 2.38e-01 | 1.07e-01 |
| OLIGODENDROCYTE DEVELOPMENT | 44 | 1.11e-01 | 4.55e-01 | 0.2450 | -5.80e-02 | 4.13e-02 | 1.38e-01 | 5.40e-02 | 1.82e-01 | 5.05e-01 | 6.36e-01 | 1.14e-01 | 5.35e-01 | 3.63e-02 |
| RADIAL GLIA GUIDED PYRAMIDAL NEURON MIGRATION | 6 | 8.64e-01 | 9.78e-01 | 0.2450 | 6.31e-02 | -2.96e-02 | -3.97e-02 | 8.15e-02 | -2.17e-01 | 7.89e-01 | 9.00e-01 | 8.66e-01 | 7.30e-01 | 3.57e-01 |
| REGULATION OF SNARE COMPLEX ASSEMBLY | 14 | 4.55e-01 | 8.22e-01 | 0.2450 | 1.64e-01 | 1.50e-01 | -2.00e-02 | -2.97e-02 | -9.87e-02 | 2.88e-01 | 3.33e-01 | 8.97e-01 | 8.47e-01 | 5.22e-01 |
| TRANSITION METAL ION TRANSPORT | 93 | 3.25e-01 | 7.34e-01 | 0.2450 | 1.14e-01 | 1.19e-01 | 1.03e-01 | 1.32e-01 | 7.04e-02 | 5.70e-02 | 4.81e-02 | 8.58e-02 | 2.72e-02 | 2.41e-01 |
| LONG CHAIN FATTY ACID CATABOLIC PROCESS | 8 | 9.80e-02 | 4.26e-01 | 0.2450 | 1.58e-01 | -1.18e-01 | -9.45e-02 | -1.08e-01 | -2.74e-02 | 4.39e-01 | 5.63e-01 | 6.44e-01 | 5.98e-01 | 8.93e-01 |
| FAT SOLUBLE VITAMIN BIOSYNTHETIC PROCESS | 13 | 9.43e-01 | 9.93e-01 | 0.2450 | 5.17e-02 | 6.68e-02 | 1.23e-01 | 8.75e-02 | 1.74e-01 | 7.47e-01 | 6.77e-01 | 4.42e-01 | 5.85e-01 | 2.78e-01 |
| T HELPER 17 CELL DIFFERENTIATION | 32 | 1.82e-01 | 5.68e-01 | 0.2450 | -3.80e-02 | -1.49e-02 | 1.03e-01 | 1.26e-01 | 1.79e-01 | 7.10e-01 | 8.84e-01 | 3.13e-01 | 2.17e-01 | 8.02e-02 |
| DORSAL ROOT GANGLION DEVELOPMENT | 7 | 8.78e-01 | 9.79e-01 | 0.2450 | 9.74e-02 | 8.96e-02 | 4.91e-02 | 1.48e-01 | -1.35e-01 | 6.55e-01 | 6.81e-01 | 8.22e-01 | 4.99e-01 | 5.36e-01 |
| REGULATION OF HYDROGEN PEROXIDE BIOSYNTHETIC PROCESS | 7 | 7.38e-01 | 9.49e-01 | 0.2450 | -1.41e-01 | -2.99e-02 | 1.09e-01 | 7.44e-02 | 1.48e-01 | 5.20e-01 | 8.91e-01 | 6.16e-01 | 7.33e-01 | 4.99e-01 |
| MULTICELLULAR ORGANISM GROWTH | 144 | 1.24e-01 | 4.80e-01 | 0.2450 | 9.44e-02 | 9.64e-02 | 1.20e-01 | 1.10e-01 | 1.23e-01 | 5.06e-02 | 4.57e-02 | 1.27e-02 | 2.27e-02 | 1.08e-02 |
| REGULATION OF POTASSIUM ION TRANSPORT | 99 | 9.65e-02 | 4.22e-01 | 0.2450 | -1.09e-01 | -8.57e-02 | -1.24e-01 | -1.56e-01 | -2.33e-02 | 6.05e-02 | 1.40e-01 | 3.23e-02 | 7.14e-03 | 6.89e-01 |
| PROTEIN OXIDATION | 13 | 7.01e-02 | 3.57e-01 | 0.2440 | -4.10e-02 | 2.26e-01 | 5.19e-02 | -4.32e-02 | -4.87e-02 | 7.98e-01 | 1.58e-01 | 7.46e-01 | 7.88e-01 | 7.61e-01 |
| CRANIAL SKELETAL SYSTEM DEVELOPMENT | 70 | 2.30e-01 | 6.32e-01 | 0.2440 | 2.99e-02 | 8.54e-02 | 1.35e-01 | 1.06e-01 | 1.49e-01 | 6.66e-01 | 2.17e-01 | 5.10e-02 | 1.25e-01 | 3.16e-02 |
| REGULATION OF CORTICOTROPIN SECRETION | 5 | 7.45e-01 | 9.50e-01 | 0.2440 | -3.93e-02 | -1.24e-01 | -2.03e-01 | 1.76e-02 | -3.72e-02 | 8.79e-01 | 6.32e-01 | 4.32e-01 | 9.46e-01 | 8.85e-01 |
| DETECTION OF TEMPERATURE STIMULUS | 24 | 3.09e-01 | 7.21e-01 | 0.2440 | -1.25e-01 | -6.08e-02 | 2.13e-02 | -1.13e-01 | 1.65e-01 | 2.89e-01 | 6.06e-01 | 8.56e-01 | 3.39e-01 | 1.62e-01 |
| GOLGI VESICLE TRANSPORT | 284 | 4.51e-04 | 9.31e-03 | 0.2440 | 1.33e-01 | 1.01e-01 | 9.34e-02 | 1.50e-01 | 2.39e-02 | 1.13e-04 | 3.50e-03 | 6.78e-03 | 1.38e-05 | 4.88e-01 |
| COBALAMIN METABOLIC PROCESS | 9 | 3.00e-01 | 7.13e-01 | 0.2440 | -1.36e-01 | -1.73e-01 | 6.46e-02 | 7.45e-02 | -3.66e-02 | 4.78e-01 | 3.69e-01 | 7.37e-01 | 6.99e-01 | 8.49e-01 |
| MITOCHONDRIAL ATP TRANSMEMBRANE TRANSPORT | 6 | 4.68e-01 | 8.28e-01 | 0.2440 | 6.68e-03 | -8.55e-02 | -3.93e-02 | -2.08e-01 | -8.69e-02 | 9.77e-01 | 7.17e-01 | 8.68e-01 | 3.79e-01 | 7.12e-01 |
| POSITIVE REGULATION OF IRE1 MEDIATED UNFOLDED PROTEIN RESPONSE | 7 | 3.49e-01 | 7.51e-01 | 0.2440 | 1.41e-01 | 1.08e-01 | -8.06e-02 | -8.27e-02 | 1.21e-01 | 5.17e-01 | 6.21e-01 | 7.12e-01 | 7.05e-01 | 5.80e-01 |
| POSITIVE REGULATION OF RUFFLE ASSEMBLY | 15 | 6.36e-01 | 9.13e-01 | 0.2440 | 2.88e-02 | 8.90e-03 | 8.58e-02 | 1.65e-01 | 1.55e-01 | 8.47e-01 | 9.52e-01 | 5.65e-01 | 2.69e-01 | 2.98e-01 |
| KIDNEY EPITHELIUM DEVELOPMENT | 145 | 4.59e-02 | 2.79e-01 | 0.2440 | 7.38e-02 | 9.70e-02 | 1.10e-01 | 1.02e-01 | 1.49e-01 | 1.25e-01 | 4.37e-02 | 2.24e-02 | 3.46e-02 | 1.95e-03 |
| CARDIAC MUSCLE CELL PROLIFERATION | 57 | 3.21e-01 | 7.32e-01 | 0.2440 | 1.24e-01 | 1.65e-01 | 1.04e-01 | 6.83e-02 | 3.72e-02 | 1.07e-01 | 3.09e-02 | 1.74e-01 | 3.73e-01 | 6.27e-01 |
| CARBOHYDRATE DERIVATIVE BIOSYNTHETIC PROCESS | 614 | 6.41e-06 | 2.53e-04 | 0.2440 | 1.20e-01 | 1.18e-01 | 1.07e-01 | 1.20e-01 | 7.27e-02 | 3.71e-07 | 6.49e-07 | 5.56e-06 | 3.76e-07 | 2.09e-03 |
| NEGATIVE REGULATION OF VIRAL ENTRY INTO HOST CELL | 22 | 8.33e-01 | 9.73e-01 | 0.2440 | 9.68e-02 | 1.51e-01 | 1.09e-01 | 1.21e-01 | 2.66e-02 | 4.32e-01 | 2.21e-01 | 3.75e-01 | 3.25e-01 | 8.29e-01 |
| REGULATION OF SPONTANEOUS SYNAPTIC TRANSMISSION | 6 | 9.77e-01 | 9.96e-01 | 0.2440 | -1.51e-01 | -1.57e-01 | -6.49e-02 | -6.31e-02 | 6.18e-02 | 5.22e-01 | 5.06e-01 | 7.83e-01 | 7.89e-01 | 7.93e-01 |
| REGULATION OF LONG TERM SYNAPTIC DEPRESSION | 12 | 3.32e-01 | 7.40e-01 | 0.2440 | -1.13e-01 | 6.68e-02 | -8.06e-02 | -1.88e-01 | -1.56e-02 | 5.00e-01 | 6.89e-01 | 6.29e-01 | 2.58e-01 | 9.26e-01 |
| SPINDLE LOCALIZATION | 62 | 2.96e-01 | 7.07e-01 | 0.2440 | 9.14e-02 | 6.77e-02 | 1.38e-01 | 1.52e-01 | 6.51e-02 | 2.13e-01 | 3.57e-01 | 5.95e-02 | 3.89e-02 | 3.75e-01 |
| RETINAL ROD CELL DIFFERENTIATION | 14 | 5.54e-01 | 8.76e-01 | 0.2440 | -4.48e-02 | 7.54e-03 | 1.17e-02 | -2.13e-02 | 2.38e-01 | 7.72e-01 | 9.61e-01 | 9.39e-01 | 8.90e-01 | 1.23e-01 |
| REGULATION OF MUSCLE ORGAN DEVELOPMENT | 23 | 5.09e-01 | 8.53e-01 | 0.2430 | -1.98e-02 | 7.47e-02 | 9.50e-02 | 3.76e-02 | 2.07e-01 | 8.69e-01 | 5.35e-01 | 4.30e-01 | 7.55e-01 | 8.56e-02 |
| POSITIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT | 35 | 2.70e-01 | 6.79e-01 | 0.2430 | -1.22e-01 | -3.24e-02 | -1.14e-01 | -1.72e-01 | -2.44e-02 | 2.11e-01 | 7.40e-01 | 2.45e-01 | 7.74e-02 | 8.03e-01 |
| REGULATION OF HEAT GENERATION | 12 | 4.89e-01 | 8.40e-01 | 0.2430 | 1.06e-01 | 1.73e-01 | 2.61e-02 | 1.72e-02 | 1.31e-01 | 5.26e-01 | 3.00e-01 | 8.76e-01 | 9.18e-01 | 4.32e-01 |
| NEGATIVE REGULATION OF CELL KILLING | 29 | 4.49e-02 | 2.76e-01 | 0.2430 | -1.54e-01 | -1.76e-01 | 2.28e-02 | 3.15e-02 | 5.23e-02 | 1.51e-01 | 1.00e-01 | 8.31e-01 | 7.69e-01 | 6.26e-01 |
| POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 189 | 6.43e-02 | 3.38e-01 | 0.2430 | 1.17e-01 | 1.04e-01 | 1.15e-01 | 1.13e-01 | 9.24e-02 | 5.62e-03 | 1.33e-02 | 6.54e-03 | 7.16e-03 | 2.85e-02 |
| FOREBRAIN NEUROBLAST DIVISION | 5 | 6.41e-01 | 9.14e-01 | 0.2430 | -4.88e-02 | -3.84e-03 | 8.95e-02 | 1.12e-01 | -1.90e-01 | 8.50e-01 | 9.88e-01 | 7.29e-01 | 6.66e-01 | 4.61e-01 |
| INTERMEDIATE FILAMENT BASED PROCESS | 94 | 6.40e-02 | 3.37e-01 | 0.2430 | -7.73e-02 | -9.16e-02 | -1.04e-01 | -1.56e-01 | -9.76e-02 | 1.95e-01 | 1.25e-01 | 8.22e-02 | 8.92e-03 | 1.02e-01 |
| GLYOXYLATE METABOLIC PROCESS | 8 | 5.74e-01 | 8.84e-01 | 0.2430 | -4.96e-02 | 1.61e-01 | 1.42e-01 | 8.15e-02 | 6.28e-02 | 8.08e-01 | 4.32e-01 | 4.87e-01 | 6.90e-01 | 7.58e-01 |
| NEGATIVE REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 13 | 6.93e-01 | 9.31e-01 | 0.2430 | 1.61e-01 | 1.67e-01 | 1.92e-02 | 6.55e-02 | 2.38e-02 | 3.14e-01 | 2.98e-01 | 9.05e-01 | 6.83e-01 | 8.82e-01 |
| GLANDULAR EPITHELIAL CELL DEVELOPMENT | 36 | 3.10e-01 | 7.22e-01 | 0.2430 | -5.27e-04 | 9.53e-02 | 1.52e-01 | 1.10e-01 | 1.22e-01 | 9.96e-01 | 3.23e-01 | 1.14e-01 | 2.55e-01 | 2.07e-01 |
| POSITIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 27 | 2.20e-01 | 6.18e-01 | 0.2430 | -1.23e-01 | -7.94e-02 | -1.65e-01 | -6.46e-02 | -7.85e-02 | 2.67e-01 | 4.75e-01 | 1.39e-01 | 5.61e-01 | 4.80e-01 |
| ADHERENS JUNCTION ORGANIZATION | 57 | 6.51e-01 | 9.18e-01 | 0.2430 | -9.29e-02 | -1.17e-01 | -1.38e-01 | -1.11e-01 | -7.24e-02 | 2.25e-01 | 1.26e-01 | 7.19e-02 | 1.46e-01 | 3.45e-01 |
| OTIC VESICLE DEVELOPMENT | 15 | 9.26e-01 | 9.89e-01 | 0.2430 | 9.54e-02 | 1.38e-01 | 9.63e-02 | 1.12e-01 | 9.49e-02 | 5.22e-01 | 3.54e-01 | 5.18e-01 | 4.54e-01 | 5.25e-01 |
| REGULATION OF CELLULAR RESPONSE TO HEAT | 16 | 9.36e-01 | 9.91e-01 | 0.2430 | 1.12e-01 | 7.43e-02 | 1.28e-01 | 1.18e-01 | 1.03e-01 | 4.38e-01 | 6.07e-01 | 3.76e-01 | 4.15e-01 | 4.75e-01 |
| NEGATIVE REGULATION OF HORMONE BIOSYNTHETIC PROCESS | 10 | 9.59e-01 | 9.94e-01 | 0.2430 | 1.23e-01 | 7.66e-02 | 8.21e-02 | 1.35e-01 | 1.14e-01 | 5.01e-01 | 6.75e-01 | 6.53e-01 | 4.61e-01 | 5.32e-01 |
| URETERIC BUD ELONGATION | 8 | 7.08e-01 | 9.34e-01 | 0.2430 | 1.70e-02 | 5.69e-02 | 2.05e-01 | 4.05e-02 | 1.08e-01 | 9.34e-01 | 7.81e-01 | 3.15e-01 | 8.43e-01 | 5.98e-01 |
| REGULATION OF VIRAL TRANSCRIPTION | 18 | 3.26e-01 | 7.35e-01 | 0.2420 | 1.23e-01 | 7.47e-02 | 1.04e-02 | 9.41e-02 | 1.71e-01 | 3.68e-01 | 5.83e-01 | 9.39e-01 | 4.89e-01 | 2.09e-01 |
| REGULATION OF MICROTUBULE DEPOLYMERIZATION | 26 | 8.33e-01 | 9.73e-01 | 0.2420 | 1.19e-01 | 1.36e-01 | 1.05e-01 | 1.21e-01 | -1.99e-02 | 2.92e-01 | 2.30e-01 | 3.52e-01 | 2.87e-01 | 8.61e-01 |
| CELLULAR COMPONENT DISASSEMBLY | 480 | 9.86e-05 | 2.76e-03 | 0.2420 | 1.09e-01 | 9.85e-02 | 1.22e-01 | 1.33e-01 | 6.95e-02 | 4.60e-05 | 2.16e-04 | 4.85e-06 | 6.21e-07 | 9.12e-03 |
| SUBSTRATE DEPENDENT CELL MIGRATION | 25 | 7.11e-01 | 9.35e-01 | 0.2420 | -7.81e-02 | -8.71e-02 | -8.41e-02 | -1.19e-01 | -1.54e-01 | 4.99e-01 | 4.51e-01 | 4.67e-01 | 3.03e-01 | 1.81e-01 |
| POSITIVE REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 30 | 2.33e-01 | 6.36e-01 | 0.2420 | 7.50e-02 | 1.72e-01 | 1.45e-01 | 4.32e-02 | -2.40e-02 | 4.77e-01 | 1.02e-01 | 1.70e-01 | 6.82e-01 | 8.20e-01 |
| DOPAMINE SECRETION | 41 | 4.07e-01 | 7.93e-01 | 0.2420 | 3.72e-02 | 1.26e-01 | 1.30e-01 | 6.10e-02 | 1.44e-01 | 6.81e-01 | 1.64e-01 | 1.50e-01 | 4.99e-01 | 1.10e-01 |
| ENDOCHONDRAL BONE MORPHOGENESIS | 59 | 1.37e-01 | 5.00e-01 | 0.2420 | 5.62e-03 | 1.02e-01 | 1.26e-01 | 6.84e-02 | 1.66e-01 | 9.40e-01 | 1.74e-01 | 9.36e-02 | 3.64e-01 | 2.75e-02 |
| AXIAL MESODERM DEVELOPMENT | 8 | 7.77e-01 | 9.58e-01 | 0.2420 | -8.45e-03 | 3.86e-02 | 9.23e-02 | 1.70e-01 | 1.41e-01 | 9.67e-01 | 8.50e-01 | 6.51e-01 | 4.06e-01 | 4.91e-01 |
| FOLLICLE STIMULATING HORMONE SECRETION | 8 | 3.53e-01 | 7.53e-01 | 0.2420 | 8.28e-02 | 3.75e-02 | -7.18e-03 | -1.10e-01 | 1.95e-01 | 6.85e-01 | 8.54e-01 | 9.72e-01 | 5.89e-01 | 3.39e-01 |
| MYOBLAST FATE COMMITMENT | 6 | 8.31e-01 | 9.73e-01 | 0.2420 | 8.64e-02 | -4.75e-02 | 3.44e-02 | 1.00e-01 | 1.94e-01 | 7.14e-01 | 8.40e-01 | 8.84e-01 | 6.70e-01 | 4.12e-01 |
| INTERNAL PROTEIN AMINO ACID ACETYLATION | 53 | 1.95e-01 | 5.82e-01 | 0.2420 | 1.12e-01 | 9.91e-02 | 7.00e-02 | 1.57e-01 | 8.05e-02 | 1.59e-01 | 2.12e-01 | 3.78e-01 | 4.77e-02 | 3.10e-01 |
| VACUOLAR TRANSPORT | 163 | 8.06e-02 | 3.84e-01 | 0.2420 | 1.19e-01 | 1.01e-01 | 1.15e-01 | 1.39e-01 | 3.95e-02 | 8.76e-03 | 2.54e-02 | 1.14e-02 | 2.26e-03 | 3.84e-01 |
| REGULATION OF NK T CELL ACTIVATION | 11 | 4.61e-01 | 8.24e-01 | 0.2420 | 4.84e-02 | 7.41e-02 | 2.91e-02 | 1.66e-01 | 1.48e-01 | 7.81e-01 | 6.70e-01 | 8.67e-01 | 3.39e-01 | 3.94e-01 |
| EXOCRINE SYSTEM DEVELOPMENT | 45 | 5.81e-01 | 8.88e-01 | 0.2420 | 4.54e-02 | 1.04e-01 | 1.39e-01 | 9.51e-02 | 1.31e-01 | 5.98e-01 | 2.28e-01 | 1.07e-01 | 2.70e-01 | 1.28e-01 |
| MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 16 | 3.88e-01 | 7.81e-01 | 0.2410 | 1.69e-01 | 1.42e-01 | -5.13e-02 | 3.30e-02 | -7.70e-02 | 2.41e-01 | 3.27e-01 | 7.22e-01 | 8.19e-01 | 5.94e-01 |
| REGULATION OF AMINE METABOLIC PROCESS | 31 | 5.00e-01 | 8.48e-01 | 0.2410 | -1.76e-02 | 4.33e-02 | 1.15e-01 | 6.05e-02 | 1.98e-01 | 8.66e-01 | 6.76e-01 | 2.69e-01 | 5.60e-01 | 5.62e-02 |
| POSITIVE REGULATION OF PSEUDOPODIUM ASSEMBLY | 12 | 5.94e-01 | 8.95e-01 | 0.2410 | 1.59e-02 | 1.46e-01 | 1.50e-01 | 1.18e-01 | -1.38e-02 | 9.24e-01 | 3.81e-01 | 3.69e-01 | 4.78e-01 | 9.34e-01 |
| RETINAL CELL APOPTOTIC PROCESS | 7 | 9.60e-01 | 9.94e-01 | 0.2410 | 6.12e-02 | 6.38e-02 | 8.20e-02 | 6.25e-02 | 1.99e-01 | 7.79e-01 | 7.70e-01 | 7.07e-01 | 7.75e-01 | 3.61e-01 |
| METANEPHRIC NEPHRON EPITHELIUM DEVELOPMENT | 25 | 6.47e-01 | 9.17e-01 | 0.2410 | 3.27e-02 | 9.24e-02 | 9.76e-02 | 6.24e-02 | 1.88e-01 | 7.77e-01 | 4.24e-01 | 3.98e-01 | 5.89e-01 | 1.05e-01 |
| REGULATION OF MYELOID CELL DIFFERENTIATION | 206 | 4.45e-03 | 5.66e-02 | 0.2410 | 1.16e-01 | 1.42e-01 | 8.78e-02 | 1.11e-01 | 6.73e-02 | 4.05e-03 | 4.59e-04 | 2.98e-02 | 5.83e-03 | 9.57e-02 |
| NEGATIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 65 | 3.76e-01 | 7.75e-01 | 0.2410 | 4.59e-02 | 7.97e-02 | 1.26e-01 | 9.36e-02 | 1.59e-01 | 5.22e-01 | 2.66e-01 | 7.98e-02 | 1.92e-01 | 2.69e-02 |
| FATTY ACID TRANSMEMBRANE TRANSPORT | 19 | 3.89e-01 | 7.82e-01 | 0.2410 | 1.44e-01 | 1.92e-02 | 3.66e-02 | 1.64e-01 | -9.41e-02 | 2.78e-01 | 8.85e-01 | 7.82e-01 | 2.15e-01 | 4.78e-01 |
| MAMMARY GLAND ALVEOLUS DEVELOPMENT | 19 | 8.51e-01 | 9.76e-01 | 0.2410 | 4.21e-02 | 6.30e-02 | 1.54e-01 | 1.17e-01 | 1.22e-01 | 7.51e-01 | 6.34e-01 | 2.45e-01 | 3.75e-01 | 3.57e-01 |
| REGULATION OF HIGH VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 11 | 8.52e-01 | 9.76e-01 | 0.2410 | -1.56e-01 | -1.35e-01 | -6.64e-02 | -5.20e-02 | -9.19e-02 | 3.71e-01 | 4.37e-01 | 7.03e-01 | 7.65e-01 | 5.98e-01 |
| REGULATION OF GLUCOCORTICOID RECEPTOR SIGNALING PATHWAY | 7 | 8.42e-01 | 9.75e-01 | 0.2410 | 1.44e-01 | 1.78e-01 | -9.21e-03 | 5.25e-02 | -5.08e-02 | 5.08e-01 | 4.14e-01 | 9.66e-01 | 8.10e-01 | 8.16e-01 |
| POSITIVE REGULATION OF FATTY ACID OXIDATION | 14 | 6.97e-01 | 9.31e-01 | 0.2410 | 7.37e-02 | 1.36e-01 | 6.10e-02 | 9.12e-02 | 1.49e-01 | 6.33e-01 | 3.79e-01 | 6.93e-01 | 5.54e-01 | 3.35e-01 |
| HEMOGLOBIN BIOSYNTHETIC PROCESS | 13 | 4.09e-01 | 7.94e-01 | 0.2410 | 1.50e-01 | 8.98e-02 | -4.11e-03 | 5.81e-02 | 1.55e-01 | 3.49e-01 | 5.75e-01 | 9.80e-01 | 7.17e-01 | 3.32e-01 |
| POSITIVE REGULATION OF CYTOPLASMIC MRNA PROCESSING BODY ASSEMBLY | 6 | 5.87e-01 | 8.91e-01 | 0.2410 | -1.58e-01 | -7.39e-02 | -1.43e-01 | 1.02e-02 | -8.52e-02 | 5.02e-01 | 7.54e-01 | 5.46e-01 | 9.65e-01 | 7.18e-01 |
| NEURON MATURATION | 47 | 6.63e-01 | 9.22e-01 | 0.2410 | 9.16e-02 | 1.31e-01 | 1.09e-01 | 1.06e-01 | 9.64e-02 | 2.77e-01 | 1.20e-01 | 1.95e-01 | 2.07e-01 | 2.53e-01 |
| HEART MORPHOGENESIS | 262 | 1.34e-04 | 3.45e-03 | 0.2410 | 2.78e-02 | 7.01e-02 | 1.28e-01 | 8.39e-02 | 1.70e-01 | 4.38e-01 | 5.07e-02 | 3.59e-04 | 1.93e-02 | 2.11e-06 |
| POSITIVE REGULATION OF ENDOPLASMIC RETICULUM STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 7.66e-01 | 9.55e-01 | 0.2410 | -1.64e-01 | -7.28e-02 | 5.92e-03 | -1.59e-02 | 1.60e-01 | 3.70e-01 | 6.90e-01 | 9.74e-01 | 9.31e-01 | 3.80e-01 |
| NEGATIVE REGULATION OF MACROPHAGE DERIVED FOAM CELL DIFFERENTIATION | 14 | 9.57e-01 | 9.94e-01 | 0.2410 | -9.05e-02 | -7.94e-02 | -1.10e-01 | -1.03e-01 | -1.44e-01 | 5.58e-01 | 6.07e-01 | 4.76e-01 | 5.04e-01 | 3.50e-01 |
| MESENCHYMAL STEM CELL DIFFERENTIATION | 12 | 6.66e-01 | 9.23e-01 | 0.2410 | -1.10e-01 | -8.39e-02 | 3.87e-02 | 5.65e-02 | 1.85e-01 | 5.11e-01 | 6.15e-01 | 8.17e-01 | 7.35e-01 | 2.67e-01 |
| NEGATIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION | 7 | 8.04e-01 | 9.67e-01 | 0.2410 | -1.30e-01 | -3.59e-02 | 2.45e-02 | 3.64e-02 | 1.94e-01 | 5.51e-01 | 8.69e-01 | 9.11e-01 | 8.68e-01 | 3.73e-01 |
| TRANSITION BETWEEN FAST AND SLOW FIBER | 9 | 4.73e-01 | 8.31e-01 | 0.2410 | 3.33e-02 | 1.81e-01 | 1.28e-01 | -7.50e-02 | 4.67e-02 | 8.63e-01 | 3.48e-01 | 5.06e-01 | 6.97e-01 | 8.08e-01 |
| LABYRINTHINE LAYER MORPHOGENESIS | 22 | 7.63e-01 | 9.54e-01 | 0.2410 | 2.50e-02 | 1.03e-01 | 1.25e-01 | 1.02e-01 | 1.44e-01 | 8.39e-01 | 4.01e-01 | 3.09e-01 | 4.09e-01 | 2.44e-01 |
| I KAPPAB PHOSPHORYLATION | 15 | 5.25e-01 | 8.60e-01 | 0.2410 | 1.69e-01 | 1.41e-01 | -3.60e-02 | 3.53e-02 | -8.37e-02 | 2.57e-01 | 3.45e-01 | 8.09e-01 | 8.13e-01 | 5.74e-01 |
| NEGATIVE REGULATION OF MAP KINASE ACTIVITY | 50 | 4.32e-01 | 8.07e-01 | 0.2410 | 1.40e-01 | 1.42e-01 | 1.04e-01 | 8.20e-02 | -2.85e-02 | 8.73e-02 | 8.32e-02 | 2.03e-01 | 3.16e-01 | 7.27e-01 |
| KETONE CATABOLIC PROCESS | 14 | 9.25e-01 | 9.89e-01 | 0.2410 | 9.12e-02 | 9.95e-02 | 1.30e-01 | 1.50e-01 | 1.59e-02 | 5.55e-01 | 5.19e-01 | 3.99e-01 | 3.31e-01 | 9.18e-01 |
| POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 100 | 4.17e-03 | 5.43e-02 | 0.2410 | 1.15e-01 | 1.67e-01 | 5.98e-02 | 1.01e-01 | 5.65e-02 | 4.72e-02 | 3.99e-03 | 3.01e-01 | 8.11e-02 | 3.29e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO EARLY ENDOSOME | 8 | 7.29e-01 | 9.44e-01 | 0.2410 | 5.02e-02 | -1.00e-01 | -1.87e-01 | -4.68e-02 | -9.09e-02 | 8.06e-01 | 6.23e-01 | 3.61e-01 | 8.19e-01 | 6.56e-01 |
| NEGATIVE REGULATION OF LIPID STORAGE | 22 | 1.27e-01 | 4.83e-01 | 0.2410 | 9.42e-02 | -2.40e-02 | -1.75e-01 | -7.65e-03 | -1.33e-01 | 4.44e-01 | 8.46e-01 | 1.56e-01 | 9.50e-01 | 2.79e-01 |
| EMBRYONIC RETINA MORPHOGENESIS IN CAMERA TYPE EYE | 6 | 6.41e-01 | 9.14e-01 | 0.2400 | 9.33e-02 | -6.19e-02 | -4.32e-02 | 4.25e-02 | 2.04e-01 | 6.92e-01 | 7.93e-01 | 8.55e-01 | 8.57e-01 | 3.87e-01 |
| POSITIVE REGULATION OF CELLULAR PH REDUCTION | 5 | 7.14e-01 | 9.36e-01 | 0.2400 | 2.09e-01 | 4.45e-02 | 5.23e-02 | 1.27e-02 | -9.64e-02 | 4.19e-01 | 8.63e-01 | 8.39e-01 | 9.61e-01 | 7.09e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CELL SURFACE | 20 | 8.97e-01 | 9.82e-01 | 0.2400 | 1.23e-01 | 1.41e-01 | 9.22e-02 | 8.76e-02 | 8.21e-02 | 3.43e-01 | 2.75e-01 | 4.75e-01 | 4.98e-01 | 5.25e-01 |
| REGULATION OF PROTEIN BINDING | 140 | 1.29e-01 | 4.87e-01 | 0.2400 | 1.27e-01 | 1.06e-01 | 9.82e-02 | 1.37e-01 | 4.42e-02 | 9.39e-03 | 2.96e-02 | 4.48e-02 | 5.25e-03 | 3.67e-01 |
| NEGATIVE REGULATION OF B CELL ACTIVATION | 31 | 2.17e-01 | 6.14e-01 | 0.2400 | 1.31e-01 | 1.06e-01 | 3.02e-02 | 1.19e-01 | 1.19e-01 | 2.07e-01 | 3.07e-01 | 7.71e-01 | 2.52e-01 | 2.50e-01 |
| PHOTOPERIODISM | 28 | 2.84e-01 | 6.93e-01 | 0.2400 | 8.40e-02 | 6.94e-02 | 4.62e-02 | 1.36e-01 | 1.58e-01 | 4.42e-01 | 5.25e-01 | 6.72e-01 | 2.12e-01 | 1.47e-01 |
| POSITIVE REGULATION OF NEURON MIGRATION | 18 | 8.86e-01 | 9.80e-01 | 0.2400 | -3.21e-02 | -7.27e-02 | -1.18e-01 | -1.01e-01 | -1.64e-01 | 8.14e-01 | 5.93e-01 | 3.85e-01 | 4.56e-01 | 2.27e-01 |
| ERROR PRONE TRANSLESION SYNTHESIS | 11 | 1.93e-01 | 5.80e-01 | 0.2400 | 2.27e-02 | -2.10e-01 | -4.13e-02 | 9.01e-02 | 5.54e-02 | 8.96e-01 | 2.27e-01 | 8.12e-01 | 6.05e-01 | 7.50e-01 |
| NEGATIVE REGULATION OF CARDIOCYTE DIFFERENTIATION | 13 | 7.24e-01 | 9.41e-01 | 0.2400 | -1.10e-01 | -8.01e-02 | 6.92e-02 | -7.33e-04 | 1.85e-01 | 4.91e-01 | 6.17e-01 | 6.66e-01 | 9.96e-01 | 2.48e-01 |
| NEGATIVE REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 11 | 8.59e-01 | 9.78e-01 | 0.2400 | -1.80e-01 | -6.49e-02 | -7.51e-02 | -1.23e-01 | 1.86e-02 | 3.02e-01 | 7.09e-01 | 6.66e-01 | 4.80e-01 | 9.15e-01 |
| TYPE II INTERFERON MEDIATED SIGNALING PATHWAY | 26 | 7.46e-01 | 9.50e-01 | 0.2400 | -8.18e-02 | -1.09e-01 | -1.59e-01 | -8.42e-02 | -8.10e-02 | 4.70e-01 | 3.36e-01 | 1.60e-01 | 4.57e-01 | 4.75e-01 |
| NEGATIVE REGULATION OF RYANODINE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 11 | 8.18e-01 | 9.70e-01 | 0.2400 | 7.40e-02 | 2.41e-02 | 7.52e-02 | 1.73e-01 | 1.27e-01 | 6.71e-01 | 8.90e-01 | 6.66e-01 | 3.22e-01 | 4.67e-01 |
| PLACENTA BLOOD VESSEL DEVELOPMENT | 30 | 7.31e-01 | 9.45e-01 | 0.2400 | 4.01e-02 | 8.24e-02 | 1.45e-01 | 8.21e-02 | 1.46e-01 | 7.04e-01 | 4.34e-01 | 1.69e-01 | 4.36e-01 | 1.66e-01 |
| PHOSPHOLIPID TRANSLOCATION | 50 | 5.76e-01 | 8.84e-01 | 0.2400 | -7.47e-02 | -8.48e-02 | -1.26e-01 | -1.43e-01 | -9.12e-02 | 3.61e-01 | 2.99e-01 | 1.24e-01 | 7.94e-02 | 2.64e-01 |
| INTRACELLULAR POTASSIUM ION HOMEOSTASIS | 15 | 6.57e-01 | 9.20e-01 | 0.2400 | -7.60e-03 | 6.78e-02 | 1.56e-01 | 1.52e-02 | 1.68e-01 | 9.59e-01 | 6.50e-01 | 2.94e-01 | 9.19e-01 | 2.61e-01 |
| GLIAL CELL MIGRATION | 58 | 1.16e-01 | 4.63e-01 | 0.2400 | 1.43e-01 | 1.40e-01 | 3.20e-02 | 1.11e-01 | -6.54e-02 | 6.00e-02 | 6.58e-02 | 6.73e-01 | 1.45e-01 | 3.89e-01 |
| GTP BIOSYNTHETIC PROCESS | 11 | 7.22e-01 | 9.40e-01 | 0.2400 | -5.23e-02 | 5.19e-02 | 5.84e-02 | -3.17e-02 | 2.18e-01 | 7.64e-01 | 7.66e-01 | 7.37e-01 | 8.56e-01 | 2.10e-01 |
| NEGATIVE REGULATION OF EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 27 | 6.87e-01 | 9.31e-01 | 0.2400 | 4.12e-02 | 1.12e-01 | 1.09e-01 | 9.21e-02 | 1.51e-01 | 7.11e-01 | 3.15e-01 | 3.26e-01 | 4.08e-01 | 1.74e-01 |
| REGULATION OF FAT CELL PROLIFERATION | 10 | 2.24e-01 | 6.24e-01 | 0.2400 | 1.45e-01 | 1.63e-01 | -8.78e-02 | -3.83e-03 | 4.86e-02 | 4.29e-01 | 3.73e-01 | 6.31e-01 | 9.83e-01 | 7.90e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 2 PRODUCTION | 26 | 8.92e-01 | 9.81e-01 | 0.2390 | 1.43e-01 | 1.16e-01 | 9.35e-02 | 1.21e-01 | 7.75e-03 | 2.08e-01 | 3.05e-01 | 4.09e-01 | 2.87e-01 | 9.45e-01 |
| ERBB2 EGFR SIGNALING PATHWAY | 8 | 6.95e-01 | 9.31e-01 | 0.2390 | 6.17e-02 | 1.95e-02 | -3.69e-02 | -1.18e-01 | -1.94e-01 | 7.63e-01 | 9.24e-01 | 8.57e-01 | 5.64e-01 | 3.41e-01 |
| MYELOID CELL DIFFERENTIATION | 413 | 2.95e-04 | 6.45e-03 | 0.2390 | 1.07e-01 | 1.28e-01 | 1.06e-01 | 1.17e-01 | 6.71e-02 | 1.99e-04 | 8.26e-06 | 2.19e-04 | 4.33e-05 | 1.93e-02 |
| REGULATION OF TRANSFERASE ACTIVITY | 673 | 1.02e-06 | 4.76e-05 | 0.2390 | 1.08e-01 | 1.10e-01 | 1.05e-01 | 1.22e-01 | 8.62e-02 | 1.77e-06 | 1.07e-06 | 3.44e-06 | 6.24e-08 | 1.36e-04 |
| POSITIVE REGULATION OF CELL MORPHOGENESIS | 31 | 8.89e-01 | 9.80e-01 | 0.2390 | -1.08e-01 | -9.77e-02 | -1.24e-01 | -1.30e-01 | -6.13e-02 | 2.98e-01 | 3.46e-01 | 2.32e-01 | 2.11e-01 | 5.55e-01 |
| STRIATED MUSCLE CELL PROLIFERATION | 80 | 1.40e-01 | 5.04e-01 | 0.2390 | 1.23e-01 | 1.63e-01 | 9.92e-02 | 6.34e-02 | 4.08e-02 | 5.73e-02 | 1.19e-02 | 1.25e-01 | 3.27e-01 | 5.29e-01 |
| REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 26 | 4.78e-01 | 8.34e-01 | 0.2390 | 6.40e-02 | 3.66e-02 | 1.22e-01 | 1.79e-01 | 6.88e-02 | 5.72e-01 | 7.46e-01 | 2.83e-01 | 1.14e-01 | 5.44e-01 |
| REGULATION OF RESPIRATORY SYSTEM PROCESS | 13 | 9.82e-01 | 9.96e-01 | 0.2390 | 1.12e-01 | 1.24e-01 | 1.26e-01 | 1.07e-01 | 4.19e-02 | 4.83e-01 | 4.40e-01 | 4.32e-01 | 5.03e-01 | 7.94e-01 |
| UDP GLUCOSE METABOLIC PROCESS | 6 | 9.62e-01 | 9.94e-01 | 0.2390 | 1.24e-01 | 5.61e-02 | 6.11e-02 | 1.10e-01 | 1.50e-01 | 6.00e-01 | 8.12e-01 | 7.95e-01 | 6.39e-01 | 5.24e-01 |
| ADP METABOLIC PROCESS | 8 | 9.34e-01 | 9.91e-01 | 0.2390 | 7.20e-02 | 7.95e-02 | 9.56e-02 | 1.76e-01 | 7.40e-02 | 7.24e-01 | 6.97e-01 | 6.40e-01 | 3.90e-01 | 7.17e-01 |
| SUBPALLIUM DEVELOPMENT | 26 | 8.43e-01 | 9.75e-01 | 0.2390 | 1.33e-01 | 1.24e-01 | 1.21e-01 | 9.45e-02 | 1.31e-02 | 2.39e-01 | 2.72e-01 | 2.86e-01 | 4.04e-01 | 9.08e-01 |
| REGULATION OF RESPONSE TO TUMOR CELL | 22 | 8.76e-01 | 9.78e-01 | 0.2390 | -1.18e-01 | -8.94e-02 | -1.15e-01 | -9.46e-02 | -1.13e-01 | 3.38e-01 | 4.68e-01 | 3.49e-01 | 4.43e-01 | 3.59e-01 |
| L ARGININE TRANSMEMBRANE TRANSPORT | 14 | 6.17e-01 | 9.06e-01 | 0.2390 | 1.11e-01 | 1.80e-01 | 1.76e-02 | 4.88e-02 | -9.71e-02 | 4.73e-01 | 2.42e-01 | 9.09e-01 | 7.52e-01 | 5.29e-01 |
| MORPHOGENESIS OF AN EPITHELIAL BUD | 14 | 5.25e-01 | 8.60e-01 | 0.2390 | -4.93e-02 | 2.49e-02 | 1.01e-01 | 1.36e-01 | 1.59e-01 | 7.50e-01 | 8.72e-01 | 5.14e-01 | 3.79e-01 | 3.02e-01 |
| ENDOTHELIAL CELL FATE COMMITMENT | 8 | 7.16e-01 | 9.37e-01 | 0.2390 | -5.00e-02 | -1.65e-01 | -1.52e-02 | -3.39e-02 | 1.61e-01 | 8.07e-01 | 4.20e-01 | 9.41e-01 | 8.68e-01 | 4.31e-01 |
| REGULATION OF LYMPHOCYTE DIFFERENTIATION | 206 | 1.23e-02 | 1.18e-01 | 0.2380 | 7.12e-02 | 8.85e-02 | 1.18e-01 | 1.32e-01 | 1.13e-01 | 7.82e-02 | 2.85e-02 | 3.64e-03 | 1.09e-03 | 5.22e-03 |
| SENSORY PERCEPTION OF TEMPERATURE STIMULUS | 27 | 3.78e-01 | 7.75e-01 | 0.2380 | -1.27e-01 | -1.05e-01 | 1.32e-02 | -7.91e-02 | 1.53e-01 | 2.54e-01 | 3.45e-01 | 9.06e-01 | 4.77e-01 | 1.70e-01 |
| REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION | 41 | 4.05e-01 | 7.92e-01 | 0.2380 | 9.09e-02 | 1.42e-01 | 8.67e-02 | 7.20e-02 | 1.25e-01 | 3.14e-01 | 1.15e-01 | 3.37e-01 | 4.25e-01 | 1.67e-01 |
| OTOLITH MORPHOGENESIS | 5 | 9.76e-01 | 9.96e-01 | 0.2380 | 8.98e-05 | -1.09e-01 | -1.40e-01 | -9.46e-02 | -1.28e-01 | 1.00e+00 | 6.74e-01 | 5.88e-01 | 7.14e-01 | 6.19e-01 |
| CELLULAR MODIFIED AMINO ACID CATABOLIC PROCESS | 22 | 3.46e-01 | 7.50e-01 | 0.2380 | 3.44e-02 | 1.39e-01 | 1.22e-01 | -1.54e-02 | 1.45e-01 | 7.80e-01 | 2.60e-01 | 3.21e-01 | 9.01e-01 | 2.38e-01 |
| CALCIUM ION IMPORT | 46 | 6.21e-01 | 9.08e-01 | 0.2380 | -1.46e-01 | -1.05e-01 | -1.00e-01 | -1.20e-01 | 5.58e-03 | 8.73e-02 | 2.17e-01 | 2.39e-01 | 1.61e-01 | 9.48e-01 |
| POSITIVE REGULATION OF CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 9 | 4.37e-01 | 8.10e-01 | 0.2380 | -3.97e-02 | 1.55e-01 | 9.86e-02 | 1.12e-01 | 9.38e-02 | 8.37e-01 | 4.22e-01 | 6.08e-01 | 5.60e-01 | 6.26e-01 |
| POSITIVE REGULATION OF LEUKOCYTE TETHERING OR ROLLING | 13 | 4.49e-01 | 8.19e-01 | 0.2380 | 5.83e-02 | 1.29e-01 | -7.75e-02 | -1.33e-02 | -1.74e-01 | 7.16e-01 | 4.21e-01 | 6.28e-01 | 9.34e-01 | 2.77e-01 |
| SULFUR AMINO ACID BIOSYNTHETIC PROCESS | 16 | 3.51e-01 | 7.52e-01 | 0.2380 | 3.41e-02 | 2.12e-02 | -3.60e-03 | 5.24e-02 | 2.28e-01 | 8.13e-01 | 8.84e-01 | 9.80e-01 | 7.17e-01 | 1.14e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO HYDROGEN PEROXIDE | 6 | 5.69e-01 | 8.82e-01 | 0.2380 | -4.60e-02 | 5.69e-02 | 1.08e-01 | -2.74e-02 | -1.97e-01 | 8.45e-01 | 8.09e-01 | 6.48e-01 | 9.07e-01 | 4.03e-01 |
| XENOBIOTIC CATABOLIC PROCESS | 25 | 1.07e-01 | 4.47e-01 | 0.2380 | -1.15e-01 | 3.05e-02 | -1.18e-01 | -1.12e-01 | -1.26e-01 | 3.21e-01 | 7.92e-01 | 3.08e-01 | 3.31e-01 | 2.75e-01 |
| INTERCELLULAR TRANSPORT | 10 | 2.73e-01 | 6.81e-01 | 0.2380 | -5.62e-02 | 1.34e-01 | 2.05e-02 | -1.76e-01 | -6.14e-02 | 7.58e-01 | 4.62e-01 | 9.11e-01 | 3.34e-01 | 7.37e-01 |
| NEUROTRANSMITTER RECEPTOR TRANSPORT | 25 | 2.51e-01 | 6.57e-01 | 0.2380 | -1.67e-01 | -2.38e-02 | -5.61e-03 | -1.31e-01 | 1.04e-01 | 1.49e-01 | 8.37e-01 | 9.61e-01 | 2.56e-01 | 3.69e-01 |
| LENS FIBER CELL MORPHOGENESIS | 6 | 8.23e-01 | 9.71e-01 | 0.2380 | -3.96e-02 | -1.72e-01 | -1.22e-01 | 4.33e-02 | -9.18e-02 | 8.67e-01 | 4.65e-01 | 6.04e-01 | 8.54e-01 | 6.97e-01 |
| MICROTUBULE NUCLEATION BY MICROTUBULE ORGANIZING CENTER | 5 | 6.92e-01 | 9.31e-01 | 0.2370 | 5.19e-02 | -1.18e-01 | -5.22e-02 | 1.41e-01 | 1.31e-01 | 8.41e-01 | 6.48e-01 | 8.40e-01 | 5.85e-01 | 6.11e-01 |
| SYNAPTIC VESICLE LOCALIZATION | 53 | 4.34e-01 | 8.08e-01 | 0.2370 | 1.28e-01 | 7.56e-02 | 8.49e-02 | 1.44e-01 | 7.98e-02 | 1.08e-01 | 3.41e-01 | 2.85e-01 | 6.93e-02 | 3.15e-01 |
| REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 185 | 2.52e-03 | 3.65e-02 | 0.2370 | 1.32e-01 | 1.59e-01 | 7.30e-02 | 9.19e-02 | 1.06e-02 | 2.02e-03 | 1.98e-04 | 8.67e-02 | 3.11e-02 | 8.04e-01 |
| MIRNA METABOLIC PROCESS | 101 | 1.98e-01 | 5.87e-01 | 0.2370 | 8.61e-02 | 8.82e-02 | 1.04e-01 | 1.34e-01 | 1.12e-01 | 1.35e-01 | 1.25e-01 | 7.15e-02 | 2.01e-02 | 5.24e-02 |
| NEGATIVE REGULATION OF INTERLEUKIN 13 PRODUCTION | 7 | 8.86e-01 | 9.80e-01 | 0.2370 | 2.46e-02 | 5.47e-02 | 1.93e-01 | 9.47e-02 | 8.15e-02 | 9.10e-01 | 8.02e-01 | 3.77e-01 | 6.64e-01 | 7.09e-01 |
| LYMPHOCYTE ANERGY | 7 | 6.99e-01 | 9.31e-01 | 0.2370 | -6.86e-02 | -1.32e-01 | -1.20e-01 | 1.38e-02 | 1.40e-01 | 7.53e-01 | 5.45e-01 | 5.84e-01 | 9.50e-01 | 5.20e-01 |
| POSITIVE REGULATION OF CELL MATURATION | 7 | 9.63e-01 | 9.94e-01 | 0.2370 | 1.74e-01 | 1.04e-01 | 5.33e-02 | 9.95e-02 | 5.00e-02 | 4.26e-01 | 6.32e-01 | 8.07e-01 | 6.48e-01 | 8.19e-01 |
| ER NUCLEUS SIGNALING PATHWAY | 45 | 6.42e-01 | 9.14e-01 | 0.2370 | 6.63e-02 | 1.28e-01 | 1.31e-01 | 9.85e-02 | 9.28e-02 | 4.41e-01 | 1.38e-01 | 1.28e-01 | 2.53e-01 | 2.81e-01 |
| POSITIVE REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN | 22 | 3.51e-01 | 7.52e-01 | 0.2370 | -1.91e-01 | -5.30e-02 | -1.91e-02 | -1.27e-01 | -1.98e-02 | 1.20e-01 | 6.67e-01 | 8.77e-01 | 3.04e-01 | 8.72e-01 |
| SALIVA SECRETION | 13 | 7.99e-01 | 9.66e-01 | 0.2370 | -1.28e-01 | -4.84e-02 | -1.42e-01 | -1.20e-01 | -5.51e-02 | 4.26e-01 | 7.62e-01 | 3.75e-01 | 4.55e-01 | 7.31e-01 |
| INSULIN PROCESSING | 8 | 8.04e-01 | 9.67e-01 | 0.2370 | 2.53e-02 | -5.48e-02 | 1.18e-01 | 1.46e-01 | 1.32e-01 | 9.01e-01 | 7.88e-01 | 5.64e-01 | 4.74e-01 | 5.19e-01 |
| REGULATION OF ACTIVATION OF JANUS KINASE ACTIVITY | 8 | 2.12e-01 | 6.07e-01 | 0.2370 | -8.46e-02 | 1.04e-01 | -1.58e-01 | -8.71e-02 | -7.40e-02 | 6.78e-01 | 6.09e-01 | 4.38e-01 | 6.70e-01 | 7.17e-01 |
| MIRNA MEDIATED GENE SILENCING BY INHIBITION OF TRANSLATION | 91 | 3.34e-01 | 7.40e-01 | 0.2370 | -7.64e-02 | -8.86e-02 | -1.30e-01 | -9.78e-02 | -1.26e-01 | 2.08e-01 | 1.44e-01 | 3.14e-02 | 1.07e-01 | 3.76e-02 |
| NEGATIVE REGULATION OF CIRCADIAN RHYTHM | 11 | 8.69e-01 | 9.78e-01 | 0.2370 | 9.47e-02 | 6.26e-02 | 6.37e-02 | 7.65e-02 | 1.83e-01 | 5.86e-01 | 7.19e-01 | 7.14e-01 | 6.60e-01 | 2.95e-01 |
| CLATHRIN COAT ASSEMBLY | 17 | 6.24e-01 | 9.09e-01 | 0.2370 | 3.90e-02 | 6.02e-02 | -5.84e-02 | -2.67e-02 | -2.16e-01 | 7.81e-01 | 6.67e-01 | 6.77e-01 | 8.49e-01 | 1.23e-01 |
| REGULATION OF NEUROTRANSMITTER RECEPTOR ACTIVITY | 45 | 1.55e-02 | 1.39e-01 | 0.2370 | -1.62e-01 | -2.88e-04 | -3.00e-02 | -1.69e-01 | 8.33e-03 | 5.97e-02 | 9.97e-01 | 7.27e-01 | 4.92e-02 | 9.23e-01 |
| NEGATIVE REGULATION OF T CELL MEDIATED IMMUNITY | 28 | 8.43e-01 | 9.75e-01 | 0.2370 | -8.86e-02 | -1.22e-01 | -1.01e-01 | -1.03e-01 | -1.11e-01 | 4.17e-01 | 2.63e-01 | 3.54e-01 | 3.44e-01 | 3.10e-01 |
| MITOCHONDRIAL DEPOLARIZATION | 22 | 6.58e-01 | 9.20e-01 | 0.2370 | 1.48e-01 | 1.20e-01 | 4.05e-02 | 1.25e-01 | 4.73e-02 | 2.28e-01 | 3.28e-01 | 7.42e-01 | 3.11e-01 | 7.01e-01 |
| GLYCOLYTIC PROCESS | 85 | 1.31e-01 | 4.90e-01 | 0.2370 | 7.27e-02 | 1.39e-01 | 1.11e-01 | 6.86e-02 | 1.20e-01 | 2.47e-01 | 2.69e-02 | 7.65e-02 | 2.75e-01 | 5.65e-02 |
| GLIAL CELL DERIVED NEUROTROPHIC FACTOR RECEPTOR SIGNALING PATHWAY | 9 | 5.88e-01 | 8.92e-01 | 0.2360 | -2.15e-01 | -5.51e-02 | -2.47e-02 | -5.96e-02 | -5.09e-02 | 2.65e-01 | 7.75e-01 | 8.98e-01 | 7.57e-01 | 7.92e-01 |
| INNER EAR MORPHOGENESIS | 104 | 5.03e-02 | 2.93e-01 | 0.2360 | 2.40e-02 | 1.03e-01 | 1.31e-01 | 7.93e-02 | 1.46e-01 | 6.72e-01 | 6.99e-02 | 2.07e-02 | 1.63e-01 | 1.03e-02 |
| ALPHA BETA T CELL DIFFERENTIATION | 119 | 7.54e-02 | 3.72e-01 | 0.2360 | 7.63e-02 | 8.47e-02 | 1.08e-01 | 1.44e-01 | 1.02e-01 | 1.50e-01 | 1.11e-01 | 4.23e-02 | 6.53e-03 | 5.50e-02 |
| ACTIN MEDIATED CELL CONTRACTION | 101 | 7.11e-02 | 3.61e-01 | 0.2360 | -1.17e-01 | -6.96e-02 | -9.73e-02 | -1.62e-01 | -3.88e-02 | 4.15e-02 | 2.27e-01 | 9.11e-02 | 4.95e-03 | 5.00e-01 |
| IMPORT ACROSS PLASMA MEMBRANE | 202 | 2.14e-03 | 3.23e-02 | 0.2360 | -1.41e-01 | -8.98e-02 | -7.74e-02 | -1.48e-01 | -6.00e-03 | 5.72e-04 | 2.78e-02 | 5.79e-02 | 2.85e-04 | 8.83e-01 |
| LEARNED VOCALIZATION BEHAVIOR OR VOCAL LEARNING | 10 | 3.51e-01 | 7.52e-01 | 0.2360 | -6.10e-02 | 8.53e-02 | -2.68e-02 | -1.82e-01 | 1.05e-01 | 7.38e-01 | 6.40e-01 | 8.83e-01 | 3.20e-01 | 5.67e-01 |
| LEPTIN MEDIATED SIGNALING PATHWAY | 10 | 5.97e-01 | 8.98e-01 | 0.2360 | 1.68e-01 | 5.99e-02 | 1.21e-01 | 5.09e-02 | 7.99e-02 | 3.56e-01 | 7.43e-01 | 5.06e-01 | 7.81e-01 | 6.62e-01 |
| PYRIMIDINE NUCLEOBASE CATABOLIC PROCESS | 8 | 7.75e-01 | 9.57e-01 | 0.2360 | -1.05e-01 | -7.34e-02 | -1.06e-02 | -1.67e-01 | 1.05e-01 | 6.07e-01 | 7.19e-01 | 9.59e-01 | 4.12e-01 | 6.05e-01 |
| REGULATION OF EOSINOPHIL MIGRATION | 6 | 4.88e-01 | 8.39e-01 | 0.2360 | -3.87e-02 | 2.13e-01 | 3.40e-02 | -5.19e-02 | 7.11e-02 | 8.70e-01 | 3.67e-01 | 8.85e-01 | 8.26e-01 | 7.63e-01 |
| NEURAL TUBE FORMATION | 103 | 1.59e-02 | 1.42e-01 | 0.2360 | -8.72e-03 | 4.44e-02 | 1.03e-01 | 8.45e-02 | 1.89e-01 | 8.78e-01 | 4.36e-01 | 6.98e-02 | 1.38e-01 | 9.20e-04 |
| POSITIVE REGULATION OF MYELOID LEUKOCYTE MEDIATED IMMUNITY | 21 | 6.35e-01 | 9.12e-01 | 0.2360 | 1.28e-01 | 1.49e-01 | 4.35e-02 | 1.22e-01 | -1.37e-02 | 3.09e-01 | 2.38e-01 | 7.30e-01 | 3.34e-01 | 9.13e-01 |
| PYRIMIDINE NUCLEOTIDE METABOLIC PROCESS | 50 | 3.25e-01 | 7.35e-01 | 0.2360 | 1.05e-01 | 9.78e-02 | 7.02e-02 | 1.27e-01 | 1.18e-01 | 2.00e-01 | 2.32e-01 | 3.90e-01 | 1.22e-01 | 1.47e-01 |
| REGULATION OF STRIATED MUSCLE TISSUE DEVELOPMENT | 18 | 6.19e-01 | 9.07e-01 | 0.2350 | -7.83e-02 | 1.77e-02 | 9.31e-02 | 1.62e-02 | 2.00e-01 | 5.65e-01 | 8.96e-01 | 4.94e-01 | 9.05e-01 | 1.41e-01 |
| REGULATION OF HEMOPOIESIS | 406 | 4.20e-05 | 1.33e-03 | 0.2350 | 8.99e-02 | 1.16e-01 | 1.02e-01 | 1.23e-01 | 9.29e-02 | 1.87e-03 | 6.26e-05 | 4.42e-04 | 2.26e-05 | 1.32e-03 |
| CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 37 | 4.82e-02 | 2.88e-01 | 0.2350 | -1.24e-01 | 3.39e-03 | -6.30e-02 | -1.86e-01 | 3.81e-02 | 1.90e-01 | 9.72e-01 | 5.07e-01 | 5.05e-02 | 6.88e-01 |
| RESPONSE TO INDOLE 3 METHANOL | 6 | 6.08e-01 | 9.03e-01 | 0.2350 | -4.51e-03 | 2.94e-02 | 8.31e-02 | 2.11e-01 | -5.57e-02 | 9.85e-01 | 9.01e-01 | 7.25e-01 | 3.71e-01 | 8.13e-01 |
| RESPONSE TO THYROGLOBULIN TRIIODOTHYRONINE | 5 | 6.78e-01 | 9.28e-01 | 0.2350 | 1.66e-02 | -2.11e-01 | -5.69e-02 | 1.69e-03 | 8.68e-02 | 9.49e-01 | 4.15e-01 | 8.26e-01 | 9.95e-01 | 7.37e-01 |
| PHENOTYPIC SWITCHING | 16 | 5.77e-01 | 8.85e-01 | 0.2350 | 1.11e-01 | 1.96e-01 | 4.46e-02 | 3.82e-02 | -3.43e-02 | 4.44e-01 | 1.74e-01 | 7.57e-01 | 7.91e-01 | 8.12e-01 |
| RELAXATION OF CARDIAC MUSCLE | 17 | 7.30e-01 | 9.44e-01 | 0.2350 | -1.41e-01 | -1.09e-01 | -1.35e-01 | -7.43e-02 | 1.41e-03 | 3.14e-01 | 4.38e-01 | 3.36e-01 | 5.96e-01 | 9.92e-01 |
| MYOBLAST DIFFERENTIATION | 109 | 1.29e-01 | 4.87e-01 | 0.2350 | 7.39e-02 | 1.06e-01 | 1.10e-01 | 7.81e-02 | 1.43e-01 | 1.82e-01 | 5.70e-02 | 4.72e-02 | 1.59e-01 | 9.75e-03 |
| EPOXYGENASE P450 PATHWAY | 18 | 6.05e-02 | 3.25e-01 | 0.2350 | -4.38e-02 | -1.32e-01 | -2.84e-02 | -1.78e-01 | -5.83e-02 | 7.48e-01 | 3.31e-01 | 8.35e-01 | 1.91e-01 | 6.69e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 42 | 5.28e-01 | 8.60e-01 | 0.2350 | 1.33e-01 | 7.80e-02 | 1.23e-01 | 1.25e-01 | 2.68e-02 | 1.37e-01 | 3.82e-01 | 1.66e-01 | 1.61e-01 | 7.64e-01 |
| NEGATIVE REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 38 | 4.94e-01 | 8.44e-01 | 0.2350 | 1.35e-01 | 9.08e-02 | 7.91e-02 | 1.36e-01 | -6.37e-02 | 1.49e-01 | 3.33e-01 | 3.99e-01 | 1.48e-01 | 4.97e-01 |
| PROTEOGLYCAN CATABOLIC PROCESS | 9 | 8.30e-01 | 9.73e-01 | 0.2350 | -3.55e-03 | 8.97e-02 | 1.85e-01 | 5.61e-02 | 9.94e-02 | 9.85e-01 | 6.41e-01 | 3.37e-01 | 7.71e-01 | 6.06e-01 |
| NEGATIVE REGULATION OF ORGANELLE ORGANIZATION | 337 | 2.05e-03 | 3.11e-02 | 0.2350 | 1.15e-01 | 9.98e-02 | 9.82e-02 | 1.24e-01 | 8.33e-02 | 2.80e-04 | 1.63e-03 | 1.93e-03 | 8.92e-05 | 8.56e-03 |
| VIRAL LIFE CYCLE | 309 | 1.76e-03 | 2.75e-02 | 0.2350 | 1.28e-01 | 1.01e-01 | 9.16e-02 | 1.19e-01 | 7.77e-02 | 1.02e-04 | 2.29e-03 | 5.60e-03 | 3.33e-04 | 1.88e-02 |
| BONE RESORPTION | 65 | 1.26e-03 | 2.11e-02 | 0.2350 | 1.06e-01 | 1.98e-01 | 2.05e-02 | 5.51e-02 | -3.78e-02 | 1.40e-01 | 5.82e-03 | 7.75e-01 | 4.42e-01 | 5.98e-01 |
| HEAT GENERATION | 17 | 5.15e-01 | 8.56e-01 | 0.2350 | 5.90e-02 | 1.10e-01 | 6.60e-02 | -3.38e-03 | 1.87e-01 | 6.74e-01 | 4.31e-01 | 6.38e-01 | 9.81e-01 | 1.81e-01 |
| SECONDARY PALATE DEVELOPMENT | 26 | 3.10e-01 | 7.21e-01 | 0.2350 | -1.12e-01 | -4.35e-02 | 4.05e-03 | -1.58e-02 | 2.01e-01 | 3.23e-01 | 7.01e-01 | 9.72e-01 | 8.89e-01 | 7.59e-02 |
| INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 338 | 4.35e-04 | 9.04e-03 | 0.2350 | 1.27e-01 | 1.12e-01 | 9.05e-02 | 1.03e-01 | 8.70e-02 | 5.62e-05 | 3.91e-04 | 4.26e-03 | 1.16e-03 | 5.97e-03 |
| POSITIVE REGULATION OF RNA EXPORT FROM NUCLEUS | 5 | 7.47e-01 | 9.51e-01 | 0.2350 | 1.38e-01 | -4.93e-02 | 6.63e-03 | 6.53e-02 | 1.71e-01 | 5.93e-01 | 8.49e-01 | 9.80e-01 | 8.00e-01 | 5.07e-01 |
| REGULATION OF DIGESTIVE SYSTEM PROCESS | 37 | 3.86e-02 | 2.54e-01 | 0.2350 | -1.23e-02 | 4.88e-02 | -1.29e-01 | -1.60e-01 | -1.02e-01 | 8.97e-01 | 6.08e-01 | 1.76e-01 | 9.16e-02 | 2.84e-01 |
| POSITIVE REGULATION OF AUTOPHAGOSOME MATURATION | 7 | 8.95e-01 | 9.82e-01 | 0.2350 | -2.01e-01 | -9.60e-02 | -3.03e-02 | -6.52e-02 | 1.22e-02 | 3.56e-01 | 6.60e-01 | 8.90e-01 | 7.65e-01 | 9.55e-01 |
| EMBRYONIC AXIS SPECIFICATION | 39 | 6.52e-01 | 9.19e-01 | 0.2350 | 7.58e-02 | 9.48e-02 | 1.04e-01 | 7.69e-02 | 1.53e-01 | 4.13e-01 | 3.06e-01 | 2.62e-01 | 4.06e-01 | 9.71e-02 |
| PROTEIN LOCALIZATION TO CELL CELL JUNCTION | 21 | 7.94e-01 | 9.65e-01 | 0.2340 | -5.04e-02 | -5.95e-02 | -1.46e-01 | -7.51e-02 | -1.48e-01 | 6.90e-01 | 6.37e-01 | 2.48e-01 | 5.51e-01 | 2.39e-01 |
| VENTRICULAR COMPACT MYOCARDIUM MORPHOGENESIS | 8 | 7.99e-01 | 9.66e-01 | 0.2340 | -9.90e-02 | -1.91e-01 | -9.02e-02 | 1.91e-02 | 1.63e-02 | 6.28e-01 | 3.50e-01 | 6.59e-01 | 9.25e-01 | 9.36e-01 |
| REGULATION OF TELOMERE CAPPING | 26 | 5.58e-01 | 8.77e-01 | 0.2340 | 9.17e-02 | 9.17e-02 | 6.18e-02 | 1.30e-01 | 1.32e-01 | 4.18e-01 | 4.18e-01 | 5.85e-01 | 2.53e-01 | 2.43e-01 |
| POSITIVE REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL | 41 | 1.71e-01 | 5.55e-01 | 0.2340 | -1.69e-01 | -1.01e-01 | -8.93e-02 | -6.72e-02 | 6.07e-02 | 6.18e-02 | 2.62e-01 | 3.23e-01 | 4.56e-01 | 5.02e-01 |
| BEHAVIORAL RESPONSE TO COCAINE | 14 | 4.57e-01 | 8.22e-01 | 0.2340 | 5.23e-02 | 3.44e-02 | 9.60e-03 | 1.56e-03 | 2.25e-01 | 7.35e-01 | 8.24e-01 | 9.50e-01 | 9.92e-01 | 1.44e-01 |
| ACETYL COA METABOLIC PROCESS | 31 | 2.03e-01 | 5.96e-01 | 0.2340 | -2.70e-02 | -4.31e-02 | 1.73e-02 | 3.33e-02 | 2.25e-01 | 7.95e-01 | 6.78e-01 | 8.67e-01 | 7.48e-01 | 3.00e-02 |
| PYRUVATE METABOLIC PROCESS | 112 | 1.42e-01 | 5.08e-01 | 0.2340 | 8.23e-02 | 1.23e-01 | 1.05e-01 | 8.89e-02 | 1.18e-01 | 1.32e-01 | 2.45e-02 | 5.54e-02 | 1.04e-01 | 3.09e-02 |
| REGULATION OF MRNA METABOLIC PROCESS | 339 | 1.39e-05 | 5.03e-04 | 0.2340 | 9.25e-02 | 5.04e-02 | 1.10e-01 | 1.42e-01 | 1.06e-01 | 3.43e-03 | 1.10e-01 | 4.71e-04 | 6.70e-06 | 8.36e-04 |
| PRIMARY AMINO COMPOUND METABOLIC PROCESS | 13 | 9.55e-01 | 9.94e-01 | 0.2340 | -1.27e-01 | -1.44e-01 | -1.04e-01 | -8.23e-02 | 1.71e-02 | 4.28e-01 | 3.69e-01 | 5.17e-01 | 6.07e-01 | 9.15e-01 |
| DIGESTIVE SYSTEM DEVELOPMENT | 142 | 7.70e-03 | 8.48e-02 | 0.2340 | 7.34e-03 | 7.02e-02 | 1.21e-01 | 6.73e-02 | 1.74e-01 | 8.80e-01 | 1.49e-01 | 1.27e-02 | 1.66e-01 | 3.37e-04 |
| POSITIVE REGULATION OF VASOCONSTRICTION | 30 | 5.26e-01 | 8.60e-01 | 0.2340 | -5.68e-02 | -1.11e-01 | -1.16e-01 | -1.50e-01 | -5.45e-02 | 5.90e-01 | 2.91e-01 | 2.73e-01 | 1.54e-01 | 6.05e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO HYDROGEN PEROXIDE | 9 | 7.26e-01 | 9.43e-01 | 0.2340 | -1.17e-01 | -1.06e-01 | -7.97e-03 | -7.84e-02 | -1.53e-01 | 5.43e-01 | 5.83e-01 | 9.67e-01 | 6.84e-01 | 4.26e-01 |
| NEGATIVE REGULATION OF ACTION POTENTIAL | 6 | 8.07e-01 | 9.67e-01 | 0.2330 | -2.87e-02 | 1.41e-01 | 1.07e-01 | -5.70e-02 | 1.38e-01 | 9.03e-01 | 5.49e-01 | 6.51e-01 | 8.09e-01 | 5.58e-01 |
| CHEMOREPULSION OF AXON | 6 | 6.66e-01 | 9.23e-01 | 0.2330 | -6.93e-02 | 1.14e-01 | 2.96e-02 | -1.45e-01 | 1.22e-01 | 7.69e-01 | 6.30e-01 | 9.00e-01 | 5.39e-01 | 6.05e-01 |
| LEUKOCYTE APOPTOTIC PROCESS | 118 | 5.96e-02 | 3.23e-01 | 0.2330 | 7.46e-02 | 5.64e-02 | 9.62e-02 | 1.22e-01 | 1.46e-01 | 1.62e-01 | 2.90e-01 | 7.11e-02 | 2.18e-02 | 6.09e-03 |
| NEGATIVE REGULATION OF HORMONE SECRETION | 65 | 1.37e-01 | 4.99e-01 | 0.2330 | 6.77e-02 | 1.16e-01 | 1.05e-01 | 3.88e-02 | 1.54e-01 | 3.46e-01 | 1.05e-01 | 1.43e-01 | 5.88e-01 | 3.19e-02 |
| NUCLEOSIDE MONOPHOSPHATE PHOSPHORYLATION | 11 | 8.62e-01 | 9.78e-01 | 0.2330 | 1.49e-01 | 4.80e-02 | 5.24e-02 | 1.47e-01 | 7.29e-02 | 3.91e-01 | 7.83e-01 | 7.64e-01 | 3.99e-01 | 6.76e-01 |
| PHENOL CONTAINING COMPOUND CATABOLIC PROCESS | 7 | 3.58e-01 | 7.57e-01 | 0.2330 | -5.23e-02 | 7.99e-02 | 7.97e-02 | -1.87e-01 | -6.18e-02 | 8.11e-01 | 7.14e-01 | 7.15e-01 | 3.92e-01 | 7.77e-01 |
| PURINE NUCLEOBASE TRANSMEMBRANE TRANSPORT | 8 | 8.25e-01 | 9.72e-01 | 0.2330 | 4.64e-02 | -6.00e-02 | -1.25e-01 | -1.23e-01 | -1.33e-01 | 8.20e-01 | 7.69e-01 | 5.41e-01 | 5.48e-01 | 5.14e-01 |
| PRIMARY ALCOHOL BIOSYNTHETIC PROCESS | 14 | 4.32e-01 | 8.06e-01 | 0.2330 | 1.26e-02 | -1.34e-02 | 1.77e-01 | 1.33e-01 | 6.80e-02 | 9.35e-01 | 9.31e-01 | 2.51e-01 | 3.88e-01 | 6.59e-01 |
| BIOLOGICAL PROCESS INVOLVED IN INTERACTION WITH HOST | 206 | 2.47e-02 | 1.92e-01 | 0.2330 | 1.35e-01 | 1.10e-01 | 9.16e-02 | 1.05e-01 | 6.67e-02 | 8.29e-04 | 6.67e-03 | 2.34e-02 | 9.46e-03 | 9.88e-02 |
| PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 147 | 1.13e-01 | 4.58e-01 | 0.2320 | 6.93e-02 | 7.86e-02 | 1.20e-01 | 1.12e-01 | 1.27e-01 | 1.47e-01 | 1.00e-01 | 1.21e-02 | 1.91e-02 | 7.77e-03 |
| REGULATION OF EPIDERMIS DEVELOPMENT | 66 | 2.95e-01 | 7.07e-01 | 0.2320 | 6.23e-02 | 1.26e-01 | 1.08e-01 | 7.70e-02 | 1.30e-01 | 3.81e-01 | 7.78e-02 | 1.29e-01 | 2.79e-01 | 6.87e-02 |
| REGULATION OF CALCIUM ION IMPORT | 31 | 8.20e-01 | 9.71e-01 | 0.2320 | -1.27e-01 | -1.19e-01 | -1.08e-01 | -1.08e-01 | 1.59e-02 | 2.20e-01 | 2.52e-01 | 2.97e-01 | 2.98e-01 | 8.78e-01 |
| REGULATION OF TRANSLATION AT SYNAPSE | 6 | 9.71e-01 | 9.95e-01 | 0.2320 | -1.29e-01 | -6.48e-02 | -1.16e-01 | -1.36e-01 | 3.29e-02 | 5.83e-01 | 7.83e-01 | 6.23e-01 | 5.64e-01 | 8.89e-01 |
| REGULATION OF PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 138 | 3.39e-02 | 2.34e-01 | 0.2320 | 1.34e-01 | 1.14e-01 | 8.16e-02 | 8.84e-02 | 9.16e-02 | 6.38e-03 | 2.09e-02 | 9.80e-02 | 7.29e-02 | 6.32e-02 |
| NK T CELL PROLIFERATION | 8 | 4.42e-01 | 8.13e-01 | 0.2320 | -8.38e-03 | 7.64e-02 | -2.26e-02 | 7.38e-02 | 2.05e-01 | 9.67e-01 | 7.08e-01 | 9.12e-01 | 7.18e-01 | 3.15e-01 |
| FOREBRAIN NEURON DEVELOPMENT | 23 | 6.78e-01 | 9.28e-01 | 0.2320 | 1.51e-01 | 1.50e-01 | 4.81e-02 | 7.31e-02 | 3.17e-02 | 2.10e-01 | 2.14e-01 | 6.90e-01 | 5.44e-01 | 7.92e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OXIDATIVE STRESS | 61 | 5.62e-01 | 8.79e-01 | 0.2320 | 8.80e-02 | 8.76e-02 | 1.30e-01 | 1.34e-01 | 6.14e-02 | 2.34e-01 | 2.37e-01 | 7.96e-02 | 7.13e-02 | 4.07e-01 |
| NEGATIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 31 | 6.44e-01 | 9.15e-01 | 0.2320 | 2.04e-02 | 8.51e-02 | 1.39e-01 | 1.10e-01 | 1.20e-01 | 8.44e-01 | 4.12e-01 | 1.79e-01 | 2.87e-01 | 2.46e-01 |
| NEGATIVE REGULATION OF ORGANIC ACID TRANSPORT | 24 | 8.62e-02 | 3.98e-01 | 0.2320 | 1.02e-01 | 1.57e-01 | 1.93e-02 | -2.53e-02 | 1.32e-01 | 3.86e-01 | 1.82e-01 | 8.70e-01 | 8.30e-01 | 2.61e-01 |
| REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 159 | 1.47e-01 | 5.15e-01 | 0.2320 | 1.03e-01 | 9.32e-02 | 1.08e-01 | 1.29e-01 | 7.74e-02 | 2.46e-02 | 4.25e-02 | 1.84e-02 | 5.06e-03 | 9.21e-02 |
| PARKIN MEDIATED STIMULATION OF MITOPHAGY IN RESPONSE TO MITOCHONDRIAL DEPOLARIZATION | 5 | 8.88e-01 | 9.80e-01 | 0.2320 | 1.65e-01 | -5.82e-03 | 7.38e-03 | 1.62e-01 | -1.44e-02 | 5.23e-01 | 9.82e-01 | 9.77e-01 | 5.31e-01 | 9.55e-01 |
| EOSINOPHIL MEDIATED IMMUNITY | 8 | 6.05e-01 | 9.01e-01 | 0.2320 | 1.58e-02 | 1.93e-01 | 1.15e-01 | -3.66e-02 | -4.15e-02 | 9.38e-01 | 3.46e-01 | 5.73e-01 | 8.58e-01 | 8.39e-01 |
| CARDIAC SEPTUM MORPHOGENESIS | 72 | 1.38e-01 | 5.01e-01 | 0.2310 | 5.03e-03 | 6.78e-02 | 1.29e-01 | 1.02e-01 | 1.48e-01 | 9.41e-01 | 3.20e-01 | 5.84e-02 | 1.35e-01 | 3.01e-02 |
| BERGMANN GLIAL CELL DIFFERENTIATION | 11 | 4.57e-01 | 8.22e-01 | 0.2310 | -4.08e-02 | 1.67e-02 | 6.76e-02 | 1.65e-01 | 1.40e-01 | 8.15e-01 | 9.24e-01 | 6.98e-01 | 3.43e-01 | 4.21e-01 |
| HORMONE METABOLIC PROCESS | 233 | 3.97e-02 | 2.57e-01 | 0.2310 | -9.25e-02 | -9.86e-02 | -1.28e-01 | -1.16e-01 | -7.28e-02 | 1.50e-02 | 9.50e-03 | 7.40e-04 | 2.32e-03 | 5.57e-02 |
| LEUKOTRIENE METABOLIC PROCESS | 30 | 3.15e-01 | 7.26e-01 | 0.2310 | 1.13e-01 | 1.28e-01 | 1.43e-01 | 5.39e-02 | -3.13e-02 | 2.84e-01 | 2.25e-01 | 1.76e-01 | 6.09e-01 | 7.67e-01 |
| REGULATION OF 3 UTR MEDIATED MRNA STABILIZATION | 6 | 7.69e-01 | 9.55e-01 | 0.2310 | 1.24e-01 | 1.69e-01 | -2.12e-02 | 9.29e-02 | 1.59e-02 | 5.99e-01 | 4.73e-01 | 9.28e-01 | 6.94e-01 | 9.46e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY BARORECEPTOR FEEDBACK | 5 | 6.55e-01 | 9.20e-01 | 0.2310 | -8.29e-02 | -1.37e-02 | 5.26e-02 | -1.70e-01 | -1.21e-01 | 7.48e-01 | 9.58e-01 | 8.39e-01 | 5.10e-01 | 6.40e-01 |
| REGULATION OF BONE DEVELOPMENT | 9 | 7.37e-01 | 9.48e-01 | 0.2310 | -6.10e-02 | -2.99e-02 | -1.12e-01 | -1.81e-01 | 5.82e-02 | 7.51e-01 | 8.77e-01 | 5.60e-01 | 3.47e-01 | 7.62e-01 |
| PYRAMIDAL NEURON DIFFERENTIATION | 12 | 8.36e-01 | 9.73e-01 | 0.2310 | 1.19e-01 | 1.40e-01 | 1.89e-02 | 7.74e-02 | -1.15e-01 | 4.76e-01 | 4.01e-01 | 9.10e-01 | 6.43e-01 | 4.89e-01 |
| RESPONSE TO L ASCORBIC ACID | 6 | 9.87e-01 | 9.97e-01 | 0.2310 | -1.44e-02 | -7.53e-02 | -1.37e-01 | -9.31e-02 | -1.41e-01 | 9.51e-01 | 7.50e-01 | 5.61e-01 | 6.93e-01 | 5.49e-01 |
| POSITIVE REGULATION OF DIGESTIVE SYSTEM PROCESS | 12 | 3.49e-01 | 7.52e-01 | 0.2310 | 5.69e-04 | 4.49e-02 | -1.51e-01 | -1.67e-01 | -1.93e-02 | 9.97e-01 | 7.88e-01 | 3.64e-01 | 3.15e-01 | 9.08e-01 |
| T CELL HOMEOSTASIS | 44 | 5.20e-01 | 8.57e-01 | 0.2310 | 4.58e-02 | 6.33e-02 | 1.14e-01 | 1.35e-01 | 1.27e-01 | 5.99e-01 | 4.68e-01 | 1.90e-01 | 1.23e-01 | 1.46e-01 |
| TOXIN METABOLIC PROCESS | 14 | 6.88e-01 | 9.31e-01 | 0.2310 | -1.63e-01 | -3.61e-02 | -2.31e-02 | -1.43e-01 | 6.56e-02 | 2.90e-01 | 8.15e-01 | 8.81e-01 | 3.55e-01 | 6.71e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION | 1622 | 1.29e-13 | 1.57e-11 | 0.2310 | 1.13e-01 | 1.07e-01 | 1.08e-01 | 1.20e-01 | 5.66e-02 | 3.58e-14 | 7.32e-13 | 4.76e-13 | 7.78e-16 | 1.42e-04 |
| RESPONSE TO PARATHYROID HORMONE | 10 | 6.18e-01 | 9.07e-01 | 0.2310 | -1.04e-01 | -9.47e-03 | -9.16e-02 | -1.22e-01 | 1.38e-01 | 5.70e-01 | 9.59e-01 | 6.16e-01 | 5.05e-01 | 4.48e-01 |
| NEGATIVE REGULATION OF CELL GROWTH | 177 | 2.74e-02 | 2.05e-01 | 0.2310 | 8.05e-02 | 1.32e-01 | 1.07e-01 | 9.42e-02 | 9.48e-02 | 6.46e-02 | 2.53e-03 | 1.37e-02 | 3.07e-02 | 2.95e-02 |
| POSITIVE REGULATION OF ANOIKIS | 6 | 9.19e-01 | 9.86e-01 | 0.2310 | -1.13e-01 | -1.43e-01 | 2.53e-02 | -3.83e-02 | 1.34e-01 | 6.31e-01 | 5.45e-01 | 9.15e-01 | 8.71e-01 | 5.70e-01 |
| HEMATOPOIETIC STEM CELL MIGRATION | 8 | 9.06e-01 | 9.84e-01 | 0.2310 | -3.56e-02 | -1.03e-01 | -1.00e-01 | 1.01e-03 | -1.77e-01 | 8.62e-01 | 6.14e-01 | 6.24e-01 | 9.96e-01 | 3.86e-01 |
| REGULATION OF CARDIAC MUSCLE CELL ACTION POTENTIAL | 28 | 8.53e-01 | 9.76e-01 | 0.2310 | -9.43e-02 | -1.34e-01 | -1.04e-01 | -1.17e-01 | -4.33e-02 | 3.88e-01 | 2.19e-01 | 3.42e-01 | 2.85e-01 | 6.91e-01 |
| THIOESTER BIOSYNTHETIC PROCESS | 43 | 8.03e-02 | 3.83e-01 | 0.2310 | 2.46e-02 | -2.01e-02 | 3.31e-02 | 7.21e-02 | 2.14e-01 | 7.80e-01 | 8.20e-01 | 7.07e-01 | 4.13e-01 | 1.51e-02 |
| EPIGENETIC PROGRAMMING IN THE ZYGOTIC PRONUCLEI | 8 | 7.93e-01 | 9.65e-01 | 0.2300 | 7.93e-03 | -9.07e-02 | 4.54e-02 | 1.02e-01 | 1.80e-01 | 9.69e-01 | 6.57e-01 | 8.24e-01 | 6.17e-01 | 3.79e-01 |
| WOUND HEALING INVOLVED IN INFLAMMATORY RESPONSE | 8 | 8.40e-01 | 9.73e-01 | 0.2300 | -9.85e-02 | -6.30e-02 | -2.21e-02 | -1.50e-01 | 1.28e-01 | 6.30e-01 | 7.58e-01 | 9.14e-01 | 4.63e-01 | 5.32e-01 |
| POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 57 | 3.48e-01 | 7.50e-01 | 0.2300 | 6.79e-02 | 7.58e-02 | 9.33e-02 | 1.37e-01 | 1.23e-01 | 3.76e-01 | 3.22e-01 | 2.23e-01 | 7.44e-02 | 1.08e-01 |
| CATECHOL CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 22 | 2.54e-01 | 6.60e-01 | 0.2300 | -1.75e-02 | 7.77e-02 | 1.92e-01 | 5.22e-02 | 8.26e-02 | 8.87e-01 | 5.28e-01 | 1.19e-01 | 6.72e-01 | 5.02e-01 |
| CALCIUM DEPENDENT CELL CELL ADHESION VIA PLASMA MEMBRANE CELL ADHESION MOLECULES | 47 | 1.26e-01 | 4.83e-01 | 0.2300 | -1.18e-01 | -3.57e-02 | -5.07e-02 | -1.34e-01 | -1.30e-01 | 1.60e-01 | 6.72e-01 | 5.48e-01 | 1.12e-01 | 1.22e-01 |
| DETECTION OF ABIOTIC STIMULUS | 133 | 1.27e-01 | 4.83e-01 | 0.2300 | -1.35e-01 | -9.46e-02 | -9.32e-02 | -1.29e-01 | -1.72e-02 | 7.17e-03 | 5.95e-02 | 6.35e-02 | 1.03e-02 | 7.33e-01 |
| COMMISSURAL NEURON AXON GUIDANCE | 12 | 9.39e-01 | 9.92e-01 | 0.2300 | -1.52e-01 | -1.33e-01 | -8.45e-02 | -6.70e-02 | 1.58e-02 | 3.61e-01 | 4.26e-01 | 6.12e-01 | 6.88e-01 | 9.24e-01 |
| IMMUNOLOGICAL MEMORY PROCESS | 17 | 8.61e-01 | 9.78e-01 | 0.2300 | 1.77e-02 | 2.80e-02 | 9.83e-02 | 8.11e-02 | 1.88e-01 | 9.00e-01 | 8.41e-01 | 4.83e-01 | 5.62e-01 | 1.80e-01 |
| POSITIVE REGULATION OF OXIDOREDUCTASE ACTIVITY | 44 | 1.73e-01 | 5.57e-01 | 0.2290 | 1.47e-01 | 1.48e-01 | 1.73e-02 | 9.09e-02 | -2.47e-02 | 9.19e-02 | 8.92e-02 | 8.42e-01 | 2.97e-01 | 7.77e-01 |
| R LOOP PROCESSING | 6 | 9.34e-01 | 9.91e-01 | 0.2290 | -1.08e-01 | -2.45e-02 | 2.30e-02 | -1.42e-02 | 1.99e-01 | 6.46e-01 | 9.17e-01 | 9.22e-01 | 9.52e-01 | 3.99e-01 |
| SURFACTANT HOMEOSTASIS | 17 | 3.16e-01 | 7.27e-01 | 0.2290 | -4.15e-02 | -1.39e-01 | -5.53e-02 | -1.32e-01 | -1.05e-01 | 7.67e-01 | 3.20e-01 | 6.93e-01 | 3.46e-01 | 4.55e-01 |
| BONE GROWTH | 32 | 5.49e-01 | 8.73e-01 | 0.2290 | 4.78e-02 | 1.32e-01 | 1.40e-01 | 4.76e-02 | 1.05e-01 | 6.40e-01 | 1.98e-01 | 1.70e-01 | 6.41e-01 | 3.03e-01 |
| VERY LOW DENSITY LIPOPROTEIN PARTICLE ASSEMBLY | 12 | 5.22e-01 | 8.59e-01 | 0.2290 | 5.57e-02 | 1.82e-01 | 3.63e-02 | 5.71e-02 | -1.08e-01 | 7.38e-01 | 2.76e-01 | 8.27e-01 | 7.32e-01 | 5.15e-01 |
| NOREPINEPHRINE METABOLIC PROCESS | 12 | 6.60e-01 | 9.21e-01 | 0.2290 | -1.55e-01 | -4.83e-02 | 2.82e-02 | -1.34e-01 | 8.53e-02 | 3.53e-01 | 7.72e-01 | 8.66e-01 | 4.20e-01 | 6.09e-01 |
| REGULATION OF TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 31 | 1.00e-01 | 4.30e-01 | 0.2290 | 1.94e-01 | 4.79e-02 | 4.99e-03 | 1.06e-01 | 3.52e-02 | 6.13e-02 | 6.45e-01 | 9.62e-01 | 3.09e-01 | 7.34e-01 |
| CALCIUM INDEPENDENT CELL CELL ADHESION VIA PLASMA MEMBRANE CELL ADHESION MOLECULES | 22 | 1.39e-01 | 5.03e-01 | 0.2290 | -1.91e-01 | -1.83e-02 | 1.98e-02 | -1.21e-01 | -2.55e-02 | 1.22e-01 | 8.82e-01 | 8.72e-01 | 3.25e-01 | 8.36e-01 |
| ICOSANOID SECRETION | 46 | 2.98e-01 | 7.10e-01 | 0.2290 | -1.07e-01 | -7.89e-02 | -8.05e-02 | -1.68e-01 | 1.03e-03 | 2.07e-01 | 3.54e-01 | 3.45e-01 | 4.93e-02 | 9.90e-01 |
| HEXOSE PHOSPHATE TRANSPORT | 7 | 8.39e-01 | 9.73e-01 | 0.2290 | -3.17e-03 | 1.53e-02 | -1.41e-01 | -1.64e-01 | -7.26e-02 | 9.88e-01 | 9.44e-01 | 5.19e-01 | 4.52e-01 | 7.39e-01 |
| REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT | 17 | 7.64e-01 | 9.54e-01 | 0.2290 | 1.36e-01 | 9.00e-02 | 4.18e-02 | 1.54e-01 | 1.05e-02 | 3.31e-01 | 5.21e-01 | 7.65e-01 | 2.71e-01 | 9.40e-01 |
| GLOMERULUS MORPHOGENESIS | 9 | 7.84e-01 | 9.61e-01 | 0.2290 | -2.52e-02 | 4.86e-02 | 4.35e-02 | -5.28e-02 | 2.11e-01 | 8.96e-01 | 8.01e-01 | 8.21e-01 | 7.84e-01 | 2.73e-01 |
| N ACETYLNEURAMINATE METABOLIC PROCESS | 11 | 9.66e-01 | 9.94e-01 | 0.2280 | 1.49e-01 | 9.15e-02 | 9.87e-02 | 1.06e-01 | 2.60e-02 | 3.92e-01 | 5.99e-01 | 5.71e-01 | 5.43e-01 | 8.81e-01 |
| ECTODERMAL PLACODE DEVELOPMENT | 13 | 5.64e-01 | 8.80e-01 | 0.2280 | 2.01e-02 | 8.59e-03 | 1.03e-01 | 1.92e-01 | 6.54e-02 | 9.00e-01 | 9.57e-01 | 5.21e-01 | 2.31e-01 | 6.83e-01 |
| EAR DEVELOPMENT | 218 | 4.84e-03 | 5.97e-02 | 0.2280 | 3.58e-02 | 8.39e-02 | 1.26e-01 | 8.98e-02 | 1.41e-01 | 3.63e-01 | 3.27e-02 | 1.38e-03 | 2.23e-02 | 3.21e-04 |
| REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO CHROMOSOME | 11 | 7.69e-01 | 9.55e-01 | 0.2280 | 8.61e-02 | -1.26e-02 | 1.04e-01 | 1.71e-01 | 6.69e-02 | 6.21e-01 | 9.42e-01 | 5.49e-01 | 3.26e-01 | 7.01e-01 |
| RNA PROCESSING | 1257 | 1.23e-12 | 1.29e-10 | 0.2280 | 1.02e-01 | 8.44e-02 | 1.20e-01 | 1.26e-01 | 6.60e-02 | 1.16e-09 | 4.84e-07 | 8.25e-13 | 5.64e-14 | 8.18e-05 |
| POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 16 | 6.31e-01 | 9.10e-01 | 0.2280 | 1.29e-01 | 1.16e-01 | 1.72e-02 | 1.43e-01 | -3.78e-02 | 3.73e-01 | 4.22e-01 | 9.05e-01 | 3.22e-01 | 7.93e-01 |
| ESTABLISHMENT OF EPITHELIAL CELL POLARITY | 33 | 7.00e-01 | 9.31e-01 | 0.2280 | 3.63e-02 | 7.77e-02 | 1.49e-01 | 9.95e-02 | 1.13e-01 | 7.19e-01 | 4.40e-01 | 1.39e-01 | 3.23e-01 | 2.62e-01 |
| REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 45 | 4.47e-01 | 8.17e-01 | 0.2280 | 1.29e-01 | 1.58e-01 | 8.11e-02 | 5.83e-02 | 2.41e-02 | 1.35e-01 | 6.66e-02 | 3.46e-01 | 4.99e-01 | 7.79e-01 |
| RESPONSE TO ALDOSTERONE | 16 | 3.94e-01 | 7.85e-01 | 0.2280 | -1.14e-01 | -6.72e-02 | -1.17e-02 | -1.79e-01 | -4.68e-02 | 4.28e-01 | 6.42e-01 | 9.36e-01 | 2.14e-01 | 7.46e-01 |
| EXPORT ACROSS PLASMA MEMBRANE | 78 | 2.60e-01 | 6.67e-01 | 0.2280 | -1.18e-01 | -9.32e-02 | -8.88e-02 | -1.47e-01 | 3.97e-04 | 7.08e-02 | 1.55e-01 | 1.75e-01 | 2.52e-02 | 9.95e-01 |
| GLUTAMINE METABOLIC PROCESS | 25 | 7.12e-01 | 9.35e-01 | 0.2280 | 6.40e-02 | 2.13e-02 | 1.09e-01 | 1.35e-01 | 1.32e-01 | 5.80e-01 | 8.54e-01 | 3.47e-01 | 2.42e-01 | 2.53e-01 |
| CALCIUM MEDIATED SIGNALING USING INTRACELLULAR CALCIUM SOURCE | 20 | 1.87e-01 | 5.72e-01 | 0.2280 | 8.67e-02 | -1.12e-02 | -1.55e-01 | -1.08e-01 | -9.42e-02 | 5.02e-01 | 9.31e-01 | 2.31e-01 | 4.05e-01 | 4.66e-01 |
| NEGATIVE REGULATION OF SINGLE STRANDED VIRAL RNA REPLICATION VIA DOUBLE STRANDED DNA INTERMEDIATE | 16 | 7.77e-01 | 9.58e-01 | 0.2280 | -9.92e-02 | -1.07e-01 | -1.30e-01 | -3.58e-02 | -1.11e-01 | 4.92e-01 | 4.57e-01 | 3.66e-01 | 8.04e-01 | 4.42e-01 |
| GDP METABOLIC PROCESS | 9 | 9.79e-01 | 9.96e-01 | 0.2280 | -1.22e-01 | -1.07e-01 | -7.47e-02 | -1.00e-01 | -1.00e-01 | 5.27e-01 | 5.77e-01 | 6.98e-01 | 6.03e-01 | 6.03e-01 |
| INTERLEUKIN 12 MEDIATED SIGNALING PATHWAY | 9 | 6.08e-01 | 9.03e-01 | 0.2280 | 1.10e-01 | 8.56e-02 | -3.46e-03 | 1.77e-01 | 3.11e-02 | 5.67e-01 | 6.57e-01 | 9.86e-01 | 3.57e-01 | 8.72e-01 |
| NEGATIVE REGULATION OF GROWTH | 233 | 8.42e-03 | 9.05e-02 | 0.2280 | 6.58e-02 | 1.14e-01 | 1.19e-01 | 8.17e-02 | 1.18e-01 | 8.37e-02 | 2.71e-03 | 1.80e-03 | 3.16e-02 | 1.95e-03 |
| CYTOSOLIC TRANSPORT | 176 | 8.11e-03 | 8.77e-02 | 0.2280 | 1.39e-01 | 8.60e-02 | 7.32e-02 | 1.41e-01 | -3.89e-03 | 1.50e-03 | 4.92e-02 | 9.39e-02 | 1.28e-03 | 9.29e-01 |
| HEMOPOIESIS | 913 | 3.16e-09 | 2.14e-07 | 0.2270 | 9.07e-02 | 9.98e-02 | 1.06e-01 | 1.28e-01 | 7.70e-02 | 3.36e-06 | 3.13e-07 | 5.74e-08 | 5.14e-11 | 7.85e-05 |
| POSITIVE REGULATION OF CEREBELLAR GRANULE CELL PRECURSOR PROLIFERATION | 8 | 9.50e-01 | 9.94e-01 | 0.2270 | -1.85e-02 | 2.32e-02 | 1.30e-01 | 5.12e-02 | 1.77e-01 | 9.28e-01 | 9.09e-01 | 5.23e-01 | 8.02e-01 | 3.87e-01 |
| GTP METABOLIC PROCESS | 24 | 7.15e-01 | 9.36e-01 | 0.2270 | 2.01e-02 | 7.17e-02 | 1.25e-01 | 3.95e-02 | 1.70e-01 | 8.65e-01 | 5.43e-01 | 2.90e-01 | 7.38e-01 | 1.48e-01 |
| RHODOPSIN MEDIATED SIGNALING PATHWAY | 12 | 1.09e-01 | 4.51e-01 | 0.2270 | -1.92e-01 | -2.93e-02 | -1.10e-01 | -6.34e-03 | -4.20e-02 | 2.50e-01 | 8.60e-01 | 5.08e-01 | 9.70e-01 | 8.01e-01 |
| CELLULAR RESPONSE TO STEROL DEPLETION | 16 | 7.42e-01 | 9.50e-01 | 0.2270 | 7.13e-02 | 1.43e-01 | 1.29e-01 | 8.26e-02 | -5.25e-02 | 6.22e-01 | 3.23e-01 | 3.71e-01 | 5.68e-01 | 7.16e-01 |
| REGULATION OF LIPOPROTEIN PARTICLE CLEARANCE | 35 | 1.26e-02 | 1.20e-01 | 0.2270 | -1.64e-02 | 3.85e-02 | -6.40e-03 | 7.23e-02 | -2.11e-01 | 8.67e-01 | 6.93e-01 | 9.48e-01 | 4.59e-01 | 3.06e-02 |
| GLUCOSAMINE CONTAINING COMPOUND METABOLIC PROCESS | 23 | 6.83e-01 | 9.30e-01 | 0.2270 | 1.03e-01 | 1.10e-01 | 7.21e-02 | 1.54e-01 | -7.78e-03 | 3.93e-01 | 3.59e-01 | 5.50e-01 | 2.02e-01 | 9.49e-01 |
| GAP JUNCTION MEDIATED INTERCELLULAR TRANSPORT | 6 | 7.57e-01 | 9.52e-01 | 0.2270 | -9.49e-02 | 5.80e-02 | -2.91e-02 | -1.96e-01 | -1.59e-03 | 6.87e-01 | 8.06e-01 | 9.02e-01 | 4.06e-01 | 9.95e-01 |
| TRNA CATABOLIC PROCESS | 16 | 2.81e-01 | 6.92e-01 | 0.2270 | 5.23e-02 | -2.89e-02 | -2.86e-02 | 5.00e-02 | 2.11e-01 | 7.17e-01 | 8.41e-01 | 8.43e-01 | 7.29e-01 | 1.43e-01 |
| CELL MIGRATION INVOLVED IN GASTRULATION | 13 | 7.99e-01 | 9.66e-01 | 0.2270 | -7.37e-02 | 2.21e-03 | 6.92e-02 | 2.37e-02 | 2.02e-01 | 6.45e-01 | 9.89e-01 | 6.66e-01 | 8.82e-01 | 2.08e-01 |
| AUTOPHAGY OF PEROXISOME | 10 | 7.51e-01 | 9.51e-01 | 0.2270 | 7.65e-02 | -1.04e-02 | 1.03e-01 | 1.85e-01 | 2.83e-02 | 6.75e-01 | 9.55e-01 | 5.73e-01 | 3.11e-01 | 8.77e-01 |
| POSITIVE REGULATION OF TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 6 | 9.47e-01 | 9.94e-01 | 0.2270 | 1.06e-01 | 1.09e-01 | 4.27e-02 | 1.46e-01 | 7.44e-02 | 6.54e-01 | 6.45e-01 | 8.56e-01 | 5.37e-01 | 7.52e-01 |
| LIPID EXPORT FROM CELL | 47 | 9.65e-02 | 4.22e-01 | 0.2270 | 1.53e-01 | 1.30e-01 | -1.84e-02 | 5.13e-02 | -9.06e-02 | 6.95e-02 | 1.23e-01 | 8.28e-01 | 5.43e-01 | 2.82e-01 |
| NEGATIVE REGULATION OF CYCLASE ACTIVITY | 15 | 2.93e-01 | 7.04e-01 | 0.2270 | 3.35e-02 | 2.03e-01 | 5.75e-02 | 2.40e-02 | -7.12e-02 | 8.22e-01 | 1.73e-01 | 7.00e-01 | 8.72e-01 | 6.33e-01 |
| REGULATION OF EPITHELIAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 14 | 7.84e-01 | 9.61e-01 | 0.2270 | 8.60e-03 | 1.66e-02 | 6.43e-02 | 1.06e-01 | 1.89e-01 | 9.56e-01 | 9.14e-01 | 6.77e-01 | 4.94e-01 | 2.20e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 4 PRODUCTION | 24 | 7.48e-01 | 9.51e-01 | 0.2270 | 6.42e-02 | 6.23e-02 | 9.94e-02 | 1.54e-01 | 9.90e-02 | 5.86e-01 | 5.97e-01 | 3.99e-01 | 1.92e-01 | 4.01e-01 |
| CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 72 | 1.11e-01 | 4.54e-01 | 0.2270 | -1.65e-01 | -1.20e-01 | -2.98e-02 | -8.26e-02 | 4.78e-02 | 1.57e-02 | 7.94e-02 | 6.62e-01 | 2.26e-01 | 4.84e-01 |
| NEGATIVE REGULATION OF ENDOPLASMIC RETICULUM STRESS INDUCED EIF2 ALPHA PHOSPHORYLATION | 5 | 9.96e-01 | 1.00e+00 | 0.2270 | 9.64e-02 | 7.99e-02 | 9.79e-02 | 9.12e-02 | 1.33e-01 | 7.09e-01 | 7.57e-01 | 7.05e-01 | 7.24e-01 | 6.06e-01 |
| REGULATION OF ANDROGEN RECEPTOR SIGNALING PATHWAY | 26 | 9.28e-01 | 9.89e-01 | 0.2260 | 1.13e-01 | 9.02e-02 | 9.76e-02 | 1.22e-01 | 7.73e-02 | 3.20e-01 | 4.26e-01 | 3.89e-01 | 2.81e-01 | 4.95e-01 |
| TRANSFORMING GROWTH FACTOR BETA ACTIVATION | 13 | 7.44e-01 | 9.50e-01 | 0.2260 | 1.01e-01 | 6.89e-02 | -2.48e-02 | 8.41e-02 | -1.69e-01 | 5.28e-01 | 6.67e-01 | 8.77e-01 | 6.00e-01 | 2.91e-01 |
| POSITIVE REGULATION OF OSTEOBLAST PROLIFERATION | 12 | 9.87e-01 | 9.97e-01 | 0.2260 | 1.14e-01 | 8.81e-02 | 1.03e-01 | 1.27e-01 | 6.16e-02 | 4.95e-01 | 5.97e-01 | 5.37e-01 | 4.48e-01 | 7.12e-01 |
| POSITIVE REGULATION OF CELL SIZE | 10 | 9.53e-01 | 9.94e-01 | 0.2260 | -1.46e-01 | -1.46e-01 | -7.19e-02 | -5.56e-02 | 1.68e-02 | 4.24e-01 | 4.24e-01 | 6.94e-01 | 7.61e-01 | 9.27e-01 |
| T HELPER CELL LINEAGE COMMITMENT | 20 | 8.63e-01 | 9.78e-01 | 0.2260 | 4.44e-02 | 8.91e-02 | 1.27e-01 | 1.31e-01 | 8.91e-02 | 7.31e-01 | 4.90e-01 | 3.27e-01 | 3.09e-01 | 4.90e-01 |
| NEGATIVE REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 14 | 8.12e-01 | 9.68e-01 | 0.2260 | -6.18e-02 | -1.49e-01 | -1.47e-01 | -4.53e-02 | -3.69e-02 | 6.89e-01 | 3.35e-01 | 3.40e-01 | 7.69e-01 | 8.11e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CENTROSOME | 12 | 1.40e-01 | 5.04e-01 | 0.2260 | -3.87e-02 | -5.26e-02 | 1.85e-02 | 1.77e-01 | -1.22e-01 | 8.17e-01 | 7.53e-01 | 9.12e-01 | 2.87e-01 | 4.63e-01 |
| CEREBELLAR PURKINJE CELL LAYER DEVELOPMENT | 27 | 7.62e-01 | 9.54e-01 | 0.2260 | 5.18e-02 | 8.83e-02 | 1.21e-01 | 5.24e-02 | 1.52e-01 | 6.41e-01 | 4.27e-01 | 2.75e-01 | 6.37e-01 | 1.72e-01 |
| CELLULAR RESPONSE TO ABIOTIC STIMULUS | 318 | 1.36e-03 | 2.25e-02 | 0.2260 | 9.77e-02 | 1.12e-01 | 9.08e-02 | 1.19e-01 | 8.16e-02 | 2.72e-03 | 6.21e-04 | 5.35e-03 | 2.70e-04 | 1.24e-02 |
| REGULATION OF DEFENSE RESPONSE TO VIRUS | 93 | 2.95e-01 | 7.07e-01 | 0.2260 | 1.15e-01 | 1.17e-01 | 8.90e-02 | 8.83e-02 | 9.16e-02 | 5.47e-02 | 5.18e-02 | 1.38e-01 | 1.41e-01 | 1.27e-01 |
| LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 57 | 4.68e-01 | 8.28e-01 | 0.2260 | 8.38e-02 | 1.11e-01 | 8.81e-02 | 1.16e-01 | 1.02e-01 | 2.74e-01 | 1.48e-01 | 2.50e-01 | 1.31e-01 | 1.81e-01 |
| CELL SUBSTRATE JUNCTION DISASSEMBLY | 8 | 5.84e-01 | 8.90e-01 | 0.2260 | -1.98e-01 | -9.48e-02 | -3.34e-03 | 9.06e-03 | -5.31e-02 | 3.33e-01 | 6.43e-01 | 9.87e-01 | 9.65e-01 | 7.95e-01 |
| CELL CYCLE G1 S PHASE TRANSITION | 264 | 7.36e-04 | 1.36e-02 | 0.2250 | 8.61e-02 | 6.25e-02 | 9.74e-02 | 1.42e-01 | 9.89e-02 | 1.60e-02 | 8.06e-02 | 6.43e-03 | 6.82e-05 | 5.64e-03 |
| NEGATIVE REGULATION OF CELL MATURATION | 8 | 4.27e-01 | 8.05e-01 | 0.2250 | 7.55e-02 | 8.70e-02 | -6.50e-02 | 2.28e-02 | 1.81e-01 | 7.11e-01 | 6.70e-01 | 7.50e-01 | 9.11e-01 | 3.75e-01 |
| FATTY ACID BETA OXIDATION | 74 | 2.57e-01 | 6.63e-01 | 0.2250 | 1.15e-01 | 1.17e-01 | 7.03e-02 | 1.01e-01 | 9.34e-02 | 8.67e-02 | 8.22e-02 | 2.96e-01 | 1.33e-01 | 1.65e-01 |
| FORMATION OF CYTOPLASMIC TRANSLATION INITIATION COMPLEX | 14 | 6.23e-01 | 9.08e-01 | 0.2250 | 6.57e-02 | -2.79e-02 | 1.22e-01 | 1.51e-01 | 8.97e-02 | 6.70e-01 | 8.57e-01 | 4.30e-01 | 3.28e-01 | 5.61e-01 |
| ADENOSINE METABOLIC PROCESS | 10 | 9.20e-01 | 9.86e-01 | 0.2250 | -4.70e-02 | -1.34e-01 | -9.74e-02 | -1.07e-01 | -9.84e-02 | 7.97e-01 | 4.63e-01 | 5.94e-01 | 5.58e-01 | 5.90e-01 |
| REGULATION OF ORGANELLE ORGANIZATION | 1151 | 4.01e-11 | 3.55e-09 | 0.2250 | 1.01e-01 | 8.99e-02 | 1.00e-01 | 1.27e-01 | 7.94e-02 | 7.99e-09 | 2.69e-07 | 9.51e-09 | 3.40e-13 | 5.50e-06 |
| PHOSPHATIDYLGLYCEROL ACYL CHAIN REMODELING | 9 | 5.95e-01 | 8.96e-01 | 0.2250 | 1.24e-01 | 1.14e-01 | 1.26e-01 | -5.82e-03 | -7.92e-02 | 5.18e-01 | 5.54e-01 | 5.11e-01 | 9.76e-01 | 6.81e-01 |
| CARDIAC CHAMBER MORPHOGENESIS | 127 | 7.95e-03 | 8.65e-02 | 0.2250 | -1.25e-02 | 5.98e-02 | 1.25e-01 | 5.40e-02 | 1.69e-01 | 8.08e-01 | 2.44e-01 | 1.52e-02 | 2.93e-01 | 1.02e-03 |
| ADENYLATE CYCLASE ACTIVATING DOPAMINE RECEPTOR SIGNALING PATHWAY | 9 | 4.54e-01 | 8.22e-01 | 0.2250 | 1.97e-01 | 8.10e-02 | -6.90e-02 | 3.14e-03 | 2.15e-02 | 3.06e-01 | 6.74e-01 | 7.20e-01 | 9.87e-01 | 9.11e-01 |
| SECRETION BY TISSUE | 44 | 4.91e-01 | 8.42e-01 | 0.2250 | -1.25e-01 | -7.05e-02 | -7.35e-02 | -1.52e-01 | -4.12e-02 | 1.52e-01 | 4.19e-01 | 3.99e-01 | 8.15e-02 | 6.36e-01 |
| REGULATION OF BONE MINERALIZATION INVOLVED IN BONE MATURATION | 7 | 5.01e-01 | 8.48e-01 | 0.2250 | -9.05e-02 | 1.14e-01 | 7.65e-02 | -5.99e-02 | -1.42e-01 | 6.79e-01 | 6.02e-01 | 7.26e-01 | 7.84e-01 | 5.17e-01 |
| MEIOTIC CELL CYCLE | 276 | 2.41e-03 | 3.53e-02 | 0.2250 | 1.03e-01 | 8.39e-02 | 1.11e-01 | 1.40e-01 | 3.11e-02 | 3.32e-03 | 1.64e-02 | 1.44e-03 | 6.12e-05 | 3.74e-01 |
| POSITIVE REGULATION OF MHC CLASS II BIOSYNTHETIC PROCESS | 14 | 1.47e-01 | 5.14e-01 | 0.2250 | 9.22e-02 | 1.63e-01 | -1.01e-01 | -3.84e-03 | -7.36e-02 | 5.50e-01 | 2.92e-01 | 5.14e-01 | 9.80e-01 | 6.33e-01 |
| POSITIVE REGULATION OF LYMPHOCYTE MIGRATION | 40 | 2.84e-01 | 6.93e-01 | 0.2250 | 3.08e-02 | 2.35e-02 | -6.72e-02 | -4.63e-02 | -2.06e-01 | 7.36e-01 | 7.97e-01 | 4.62e-01 | 6.12e-01 | 2.44e-02 |
| PRESYNAPTIC MODULATION OF CHEMICAL SYNAPTIC TRANSMISSION | 32 | 4.60e-01 | 8.23e-01 | 0.2250 | -1.54e-02 | 5.67e-02 | 1.06e-01 | 9.39e-02 | 1.64e-01 | 8.80e-01 | 5.79e-01 | 2.98e-01 | 3.58e-01 | 1.08e-01 |
| EPIBOLY | 37 | 7.49e-01 | 9.51e-01 | 0.2250 | -8.45e-02 | -1.08e-01 | -1.42e-01 | -9.04e-02 | -5.88e-02 | 3.74e-01 | 2.56e-01 | 1.36e-01 | 3.41e-01 | 5.36e-01 |
| REGULATION OF MYOFIBROBLAST DIFFERENTIATION | 9 | 6.95e-01 | 9.31e-01 | 0.2250 | -3.44e-02 | -3.84e-02 | 1.04e-01 | -4.27e-02 | 1.88e-01 | 8.58e-01 | 8.42e-01 | 5.90e-01 | 8.24e-01 | 3.30e-01 |
| ADHERENS JUNCTION ASSEMBLY | 13 | 4.62e-01 | 8.24e-01 | 0.2250 | -4.44e-02 | -1.33e-01 | -2.63e-03 | 9.52e-02 | 1.47e-01 | 7.82e-01 | 4.07e-01 | 9.87e-01 | 5.52e-01 | 3.57e-01 |
| POSITIVE REGULATION OF LIPID KINASE ACTIVITY | 26 | 1.77e-01 | 5.62e-01 | 0.2240 | -1.10e-01 | 1.89e-02 | -1.21e-01 | -1.22e-01 | -9.18e-02 | 3.32e-01 | 8.67e-01 | 2.85e-01 | 2.82e-01 | 4.18e-01 |
| REGULATION OF CARDIAC CONDUCTION | 26 | 6.73e-01 | 9.27e-01 | 0.2240 | -1.51e-01 | -8.15e-02 | -4.68e-02 | -1.33e-01 | -3.32e-02 | 1.83e-01 | 4.72e-01 | 6.79e-01 | 2.40e-01 | 7.70e-01 |
| REGULATION OF APOPTOTIC DNA FRAGMENTATION | 10 | 7.92e-01 | 9.64e-01 | 0.2240 | 5.39e-05 | 2.82e-02 | 5.25e-02 | 1.20e-01 | 1.80e-01 | 1.00e+00 | 8.77e-01 | 7.74e-01 | 5.13e-01 | 3.24e-01 |
| PYRIMIDINE RIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 15 | 8.93e-01 | 9.81e-01 | 0.2240 | 1.58e-01 | 1.29e-01 | 4.59e-02 | 8.04e-02 | 5.29e-03 | 2.89e-01 | 3.85e-01 | 7.58e-01 | 5.90e-01 | 9.72e-01 |
| POSITIVE REGULATION OF CARTILAGE DEVELOPMENT | 31 | 5.00e-01 | 8.48e-01 | 0.2240 | -1.71e-01 | -7.92e-02 | -4.73e-02 | -9.87e-02 | 5.18e-02 | 9.85e-02 | 4.45e-01 | 6.48e-01 | 3.42e-01 | 6.17e-01 |
| REGULATION OF NEUROBLAST PROLIFERATION | 53 | 1.54e-01 | 5.25e-01 | 0.2240 | -1.99e-02 | -1.38e-03 | 9.77e-02 | 1.01e-01 | 1.74e-01 | 8.02e-01 | 9.86e-01 | 2.19e-01 | 2.05e-01 | 2.85e-02 |
| PEPTIDE ANTIGEN ASSEMBLY WITH MHC PROTEIN COMPLEX | 18 | 6.54e-01 | 9.20e-01 | 0.2240 | 1.13e-01 | 1.44e-01 | 8.76e-03 | 5.63e-02 | -1.16e-01 | 4.06e-01 | 2.89e-01 | 9.49e-01 | 6.79e-01 | 3.96e-01 |
| POSITIVE REGULATION OF PROTEOLYSIS INVOLVED IN PROTEIN CATABOLIC PROCESS | 132 | 2.83e-01 | 6.93e-01 | 0.2240 | 8.75e-02 | 9.29e-02 | 1.14e-01 | 1.21e-01 | 7.91e-02 | 8.25e-02 | 6.52e-02 | 2.41e-02 | 1.60e-02 | 1.16e-01 |
| MITOCHONDRIAL CALCIUM ION HOMEOSTASIS | 24 | 8.58e-01 | 9.77e-01 | 0.2240 | 1.24e-01 | 9.54e-02 | 6.98e-02 | 1.23e-01 | 7.60e-02 | 2.92e-01 | 4.19e-01 | 5.54e-01 | 2.99e-01 | 5.19e-01 |
| DEFENSE RESPONSE TO SYMBIONT | 324 | 4.20e-03 | 5.46e-02 | 0.2240 | 1.23e-01 | 1.12e-01 | 8.47e-02 | 1.15e-01 | 4.56e-02 | 1.36e-04 | 5.22e-04 | 8.74e-03 | 3.77e-04 | 1.58e-01 |
| NEGATIVE REGULATION OF WOUND HEALING | 72 | 9.15e-02 | 4.11e-01 | 0.2240 | -7.99e-03 | 4.48e-03 | -9.52e-02 | -8.16e-02 | -1.85e-01 | 9.07e-01 | 9.48e-01 | 1.62e-01 | 2.31e-01 | 6.50e-03 |
| NEGATIVE REGULATION OF AMYLOID BETA CLEARANCE | 11 | 9.43e-01 | 9.93e-01 | 0.2240 | 1.18e-01 | 9.27e-02 | 1.22e-01 | 6.74e-02 | 9.10e-02 | 4.97e-01 | 5.95e-01 | 4.85e-01 | 6.99e-01 | 6.01e-01 |
| ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 564 | 7.09e-05 | 2.08e-03 | 0.2240 | 1.00e-01 | 9.43e-02 | 1.01e-01 | 1.12e-01 | 9.18e-02 | 4.53e-05 | 1.29e-04 | 4.25e-05 | 5.00e-06 | 1.93e-04 |
| POSITIVE REGULATION OF INSULIN SECRETION | 83 | 2.08e-01 | 6.03e-01 | 0.2240 | 8.96e-02 | 1.42e-01 | 8.97e-02 | 9.32e-02 | 7.16e-02 | 1.58e-01 | 2.50e-02 | 1.58e-01 | 1.42e-01 | 2.59e-01 |
| NEGATIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 44 | 5.01e-01 | 8.48e-01 | 0.2240 | 1.16e-01 | 7.94e-02 | 7.49e-02 | 1.54e-01 | 3.39e-02 | 1.84e-01 | 3.62e-01 | 3.90e-01 | 7.74e-02 | 6.98e-01 |
| PLASMA LIPOPROTEIN PARTICLE CLEARANCE | 54 | 8.38e-03 | 9.02e-02 | 0.2240 | -8.56e-02 | 2.17e-03 | -5.37e-02 | -3.53e-02 | -1.97e-01 | 2.76e-01 | 9.78e-01 | 4.95e-01 | 6.53e-01 | 1.25e-02 |
| SHORT CHAIN FATTY ACID METABOLIC PROCESS | 16 | 2.03e-01 | 5.96e-01 | 0.2240 | 1.28e-02 | 3.32e-02 | -4.96e-02 | -1.64e-02 | 2.15e-01 | 9.29e-01 | 8.18e-01 | 7.31e-01 | 9.10e-01 | 1.37e-01 |
| CELL AGGREGATION | 23 | 6.08e-01 | 9.02e-01 | 0.2240 | -1.53e-01 | -1.06e-01 | -2.42e-03 | -9.78e-02 | 7.53e-02 | 2.04e-01 | 3.77e-01 | 9.84e-01 | 4.17e-01 | 5.32e-01 |
| HAIR CYCLE PHASE | 9 | 5.48e-01 | 8.73e-01 | 0.2240 | -1.98e-01 | -1.00e-01 | 2.40e-02 | 1.48e-02 | -3.82e-03 | 3.04e-01 | 6.03e-01 | 9.01e-01 | 9.39e-01 | 9.84e-01 |
| EPINEPHRINE TRANSPORT | 11 | 9.38e-01 | 9.92e-01 | 0.2230 | -1.16e-01 | -1.51e-01 | -8.45e-02 | -5.95e-02 | 5.59e-02 | 5.05e-01 | 3.87e-01 | 6.27e-01 | 7.32e-01 | 7.48e-01 |
| MAINTENANCE OF SISTER CHROMATID COHESION | 11 | 4.78e-01 | 8.34e-01 | 0.2230 | 8.62e-02 | -5.39e-02 | 3.88e-02 | 1.95e-01 | 5.69e-03 | 6.21e-01 | 7.57e-01 | 8.24e-01 | 2.63e-01 | 9.74e-01 |
| PURINE NUCLEOSIDE TRANSMEMBRANE TRANSPORT | 5 | 9.61e-01 | 9.94e-01 | 0.2230 | -5.95e-02 | -1.49e-01 | -9.82e-02 | -1.02e-01 | 6.41e-02 | 8.18e-01 | 5.64e-01 | 7.04e-01 | 6.92e-01 | 8.04e-01 |
| POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 21 | 6.53e-01 | 9.19e-01 | 0.2230 | 4.55e-02 | 9.01e-03 | -6.19e-02 | -3.33e-02 | -2.07e-01 | 7.18e-01 | 9.43e-01 | 6.23e-01 | 7.92e-01 | 1.01e-01 |
| ESTABLISHMENT OF ORGANELLE LOCALIZATION | 454 | 6.40e-04 | 1.23e-02 | 0.2230 | 9.49e-02 | 8.52e-02 | 1.16e-01 | 1.21e-01 | 7.37e-02 | 5.28e-04 | 1.85e-03 | 2.18e-05 | 9.62e-06 | 7.09e-03 |
| MESENCHYMAL STEM CELL PROLIFERATION | 10 | 3.65e-01 | 7.65e-01 | 0.2230 | -7.98e-02 | -9.63e-02 | -9.23e-02 | 8.97e-02 | -1.33e-01 | 6.62e-01 | 5.98e-01 | 6.13e-01 | 6.23e-01 | 4.67e-01 |
| CARDIAC VENTRICLE MORPHOGENESIS | 72 | 6.75e-02 | 3.48e-01 | 0.2230 | -3.37e-02 | 4.71e-02 | 1.15e-01 | 3.77e-02 | 1.78e-01 | 6.21e-01 | 4.89e-01 | 9.16e-02 | 5.80e-01 | 8.85e-03 |
| DGMP METABOLIC PROCESS | 5 | 7.58e-01 | 9.52e-01 | 0.2230 | -2.75e-02 | -1.89e-01 | -2.31e-02 | 8.04e-02 | -7.97e-02 | 9.15e-01 | 4.64e-01 | 9.29e-01 | 7.56e-01 | 7.58e-01 |
| ENDOCARDIAL CELL DIFFERENTIATION | 6 | 9.56e-01 | 9.94e-01 | 0.2230 | 9.43e-02 | 9.70e-02 | 5.49e-02 | 1.59e-01 | 5.53e-02 | 6.89e-01 | 6.81e-01 | 8.16e-01 | 4.99e-01 | 8.14e-01 |
| REGULATION OF EXTRACELLULAR MATRIX ASSEMBLY | 20 | 6.88e-01 | 9.31e-01 | 0.2230 | -9.10e-02 | -7.61e-03 | -8.67e-02 | -1.18e-01 | -1.41e-01 | 4.81e-01 | 9.53e-01 | 5.02e-01 | 3.60e-01 | 2.76e-01 |
| TRNA METHYLATION | 40 | 7.75e-01 | 9.58e-01 | 0.2230 | 7.74e-02 | 9.10e-02 | 9.60e-02 | 1.06e-01 | 1.22e-01 | 3.97e-01 | 3.19e-01 | 2.93e-01 | 2.45e-01 | 1.83e-01 |
| NEGATIVE REGULATION OF OSTEOCLAST DIFFERENTIATION | 33 | 1.71e-01 | 5.55e-01 | 0.2230 | 1.81e-01 | 6.45e-02 | 2.58e-02 | 5.52e-02 | -9.40e-02 | 7.15e-02 | 5.21e-01 | 7.98e-01 | 5.83e-01 | 3.50e-01 |
| POSITIVE REGULATION OF HEART RATE BY EPINEPHRINE NOREPINEPHRINE | 5 | 9.41e-01 | 9.92e-01 | 0.2230 | 7.99e-02 | -2.13e-02 | 1.03e-01 | 8.36e-02 | 1.59e-01 | 7.57e-01 | 9.34e-01 | 6.91e-01 | 7.46e-01 | 5.39e-01 |
| POSITIVE REGULATION OF MEIOTIC CELL CYCLE | 27 | 4.91e-01 | 8.42e-01 | 0.2220 | -7.26e-02 | -3.11e-02 | 5.85e-02 | 2.05e-02 | 1.99e-01 | 5.14e-01 | 7.80e-01 | 5.99e-01 | 8.54e-01 | 7.41e-02 |
| NEUTRAL LIPID CATABOLIC PROCESS | 37 | 1.15e-02 | 1.12e-01 | 0.2220 | 2.30e-02 | 1.62e-01 | -2.11e-02 | -4.96e-02 | -1.41e-01 | 8.09e-01 | 8.81e-02 | 8.24e-01 | 6.01e-01 | 1.39e-01 |
| POSITIVE REGULATION OF CILIUM MOVEMENT | 11 | 3.34e-01 | 7.40e-01 | 0.2220 | 4.37e-02 | 1.11e-01 | -3.43e-02 | -2.09e-02 | 1.83e-01 | 8.02e-01 | 5.25e-01 | 8.44e-01 | 9.04e-01 | 2.92e-01 |
| NUCLEOSIDE BISPHOSPHATE BIOSYNTHETIC PROCESS | 54 | 3.49e-02 | 2.38e-01 | 0.2220 | 2.32e-02 | 6.65e-03 | 2.75e-02 | 7.86e-02 | 2.05e-01 | 7.68e-01 | 9.33e-01 | 7.27e-01 | 3.18e-01 | 9.25e-03 |
| GOLGI LOCALIZATION | 14 | 8.60e-01 | 9.78e-01 | 0.2220 | -7.48e-02 | -1.22e-01 | -6.93e-02 | -1.06e-01 | -1.13e-01 | 6.28e-01 | 4.29e-01 | 6.54e-01 | 4.91e-01 | 4.64e-01 |
| TERPENOID METABOLIC PROCESS | 96 | 3.60e-01 | 7.59e-01 | 0.2220 | -6.51e-02 | -9.77e-02 | -1.12e-01 | -1.09e-01 | -1.06e-01 | 2.70e-01 | 9.80e-02 | 5.77e-02 | 6.55e-02 | 7.34e-02 |
| NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 419 | 2.05e-04 | 4.80e-03 | 0.2220 | 8.19e-02 | 7.97e-02 | 9.85e-02 | 1.14e-01 | 1.16e-01 | 4.04e-03 | 5.12e-03 | 5.41e-04 | 6.04e-05 | 4.41e-05 |
| REGULATION OF ANTIGEN PROCESSING AND PRESENTATION | 19 | 1.93e-01 | 5.80e-01 | 0.2220 | 1.09e-02 | 2.24e-02 | -1.79e-01 | -1.12e-01 | -6.33e-02 | 9.34e-01 | 8.66e-01 | 1.77e-01 | 3.98e-01 | 6.33e-01 |
| AMINO SUGAR METABOLIC PROCESS | 40 | 4.07e-01 | 7.93e-01 | 0.2220 | 8.62e-02 | 8.87e-02 | 7.68e-02 | 1.56e-01 | 6.05e-02 | 3.46e-01 | 3.31e-01 | 4.01e-01 | 8.73e-02 | 5.08e-01 |
| IODIDE TRANSPORT | 9 | 8.57e-01 | 9.77e-01 | 0.2220 | -2.94e-02 | 2.10e-02 | -7.62e-02 | -1.53e-01 | -1.37e-01 | 8.79e-01 | 9.13e-01 | 6.92e-01 | 4.26e-01 | 4.78e-01 |
| RESPONSE TO ELECTRICAL STIMULUS | 44 | 2.41e-01 | 6.45e-01 | 0.2220 | 1.11e-01 | 1.74e-01 | 5.68e-02 | 5.60e-02 | -1.08e-02 | 2.01e-01 | 4.56e-02 | 5.14e-01 | 5.20e-01 | 9.02e-01 |
| POSITIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 31 | 2.35e-01 | 6.37e-01 | 0.2220 | 1.42e-01 | 1.51e-01 | -1.28e-02 | 3.28e-02 | -6.97e-02 | 1.70e-01 | 1.45e-01 | 9.02e-01 | 7.52e-01 | 5.02e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 10 PRODUCTION | 20 | 4.01e-01 | 7.89e-01 | 0.2220 | 2.68e-02 | -1.22e-02 | -1.72e-01 | -7.01e-02 | -1.17e-01 | 8.36e-01 | 9.25e-01 | 1.83e-01 | 5.88e-01 | 3.63e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION | 61 | 5.79e-02 | 3.17e-01 | 0.2220 | 1.35e-01 | 1.56e-01 | 5.98e-02 | 2.48e-02 | 4.96e-02 | 6.75e-02 | 3.54e-02 | 4.19e-01 | 7.38e-01 | 5.03e-01 |
| NEURON NEURON SYNAPTIC TRANSMISSION | 6 | 9.68e-01 | 9.94e-01 | 0.2220 | -7.23e-02 | -1.48e-01 | -1.40e-01 | -4.57e-02 | -1.44e-02 | 7.59e-01 | 5.29e-01 | 5.52e-01 | 8.46e-01 | 9.51e-01 |
| CALCIUM ION REGULATED EXOCYTOSIS OF NEUROTRANSMITTER | 21 | 3.66e-01 | 7.67e-01 | 0.2220 | -1.42e-01 | -2.89e-02 | -1.30e-02 | -1.67e-01 | -1.18e-02 | 2.59e-01 | 8.19e-01 | 9.18e-01 | 1.86e-01 | 9.25e-01 |
| RESPONSE TO EXTRACELLULAR STIMULUS | 501 | 1.20e-04 | 3.18e-03 | 0.2220 | 8.34e-02 | 1.02e-01 | 1.04e-01 | 1.16e-01 | 8.61e-02 | 1.39e-03 | 8.97e-05 | 6.85e-05 | 8.35e-06 | 9.64e-04 |
| NEGATIVE REGULATION OF RELAXATION OF MUSCLE | 7 | 4.72e-01 | 8.30e-01 | 0.2220 | 9.06e-03 | 1.44e-01 | -8.87e-02 | -1.42e-01 | 1.45e-02 | 9.67e-01 | 5.10e-01 | 6.84e-01 | 5.15e-01 | 9.47e-01 |
| CYTOSKELETON DEPENDENT CYTOKINESIS | 113 | 1.50e-01 | 5.19e-01 | 0.2220 | 1.29e-01 | 7.58e-02 | 9.65e-02 | 1.29e-01 | 2.56e-02 | 1.80e-02 | 1.64e-01 | 7.63e-02 | 1.75e-02 | 6.38e-01 |
| MACROMOLECULE DEACYLATION | 63 | 3.06e-02 | 2.20e-01 | 0.2210 | 5.87e-02 | 2.72e-02 | 3.95e-02 | 1.07e-01 | 1.79e-01 | 4.20e-01 | 7.09e-01 | 5.88e-01 | 1.43e-01 | 1.42e-02 |
| PROGESTERONE BIOSYNTHETIC PROCESS | 6 | 9.58e-01 | 9.94e-01 | 0.2210 | 5.31e-02 | 1.28e-01 | 1.60e-01 | 6.23e-02 | 1.77e-02 | 8.22e-01 | 5.88e-01 | 4.96e-01 | 7.92e-01 | 9.40e-01 |
| POSITIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 133 | 7.73e-02 | 3.77e-01 | 0.2210 | 1.21e-01 | 1.41e-01 | 7.36e-02 | 9.22e-02 | 2.44e-02 | 1.61e-02 | 4.97e-03 | 1.43e-01 | 6.64e-02 | 6.27e-01 |
| REGULATION OF HETEROTYPIC CELL CELL ADHESION | 24 | 3.67e-01 | 7.68e-01 | 0.2210 | 5.86e-02 | 2.74e-02 | -1.14e-01 | -1.04e-01 | -1.45e-01 | 6.19e-01 | 8.16e-01 | 3.34e-01 | 3.80e-01 | 2.18e-01 |
| REGULATION OF MITOCHONDRIAL DNA METABOLIC PROCESS | 8 | 6.56e-01 | 9.20e-01 | 0.2210 | -1.12e-01 | -9.49e-02 | 1.00e-01 | 9.79e-02 | 8.79e-02 | 5.82e-01 | 6.42e-01 | 6.24e-01 | 6.32e-01 | 6.67e-01 |
| NEGATIVE REGULATION OF DENDRITIC CELL APOPTOTIC PROCESS | 8 | 6.56e-01 | 9.20e-01 | 0.2210 | -1.10e-01 | -1.25e-01 | 5.91e-02 | -9.58e-02 | 9.19e-02 | 5.89e-01 | 5.40e-01 | 7.72e-01 | 6.39e-01 | 6.53e-01 |
| CENTRAL NERVOUS SYSTEM DEVELOPMENT | 972 | 1.45e-08 | 9.12e-07 | 0.2210 | 7.61e-02 | 9.84e-02 | 1.19e-01 | 9.38e-02 | 1.03e-01 | 5.80e-05 | 2.02e-07 | 3.47e-10 | 7.19e-07 | 5.97e-08 |
| NEGATIVE REGULATION OF CALCINEURIN MEDIATED SIGNALING | 15 | 3.13e-01 | 7.25e-01 | 0.2210 | -9.86e-02 | -6.90e-02 | -4.37e-02 | 5.12e-02 | 1.73e-01 | 5.09e-01 | 6.44e-01 | 7.70e-01 | 7.31e-01 | 2.46e-01 |
| MAMMARY GLAND DEVELOPMENT | 126 | 9.26e-02 | 4.13e-01 | 0.2210 | 5.63e-02 | 1.18e-01 | 1.11e-01 | 9.45e-02 | 1.03e-01 | 2.75e-01 | 2.24e-02 | 3.11e-02 | 6.68e-02 | 4.65e-02 |
| SKELETAL SYSTEM DEVELOPMENT | 509 | 3.50e-07 | 1.76e-05 | 0.2210 | 3.62e-02 | 9.44e-02 | 1.22e-01 | 9.36e-02 | 1.22e-01 | 1.62e-01 | 2.65e-04 | 2.29e-06 | 2.98e-04 | 2.45e-06 |
| REGULATION OF CATABOLIC PROCESS | 1028 | 3.00e-11 | 2.69e-09 | 0.2210 | 1.02e-01 | 8.05e-02 | 9.19e-02 | 1.28e-01 | 8.47e-02 | 3.33e-08 | 1.27e-05 | 6.23e-07 | 4.03e-12 | 4.30e-06 |
| CYTOPLASMIC SEQUESTERING OF NF KAPPAB | 5 | 9.19e-01 | 9.86e-01 | 0.2210 | 1.41e-01 | -1.45e-02 | 5.52e-02 | 1.22e-01 | 1.04e-01 | 5.86e-01 | 9.55e-01 | 8.31e-01 | 6.37e-01 | 6.87e-01 |
| DOPAMINE TRANSPORT | 55 | 2.78e-01 | 6.88e-01 | 0.2210 | 5.28e-02 | 1.44e-01 | 1.11e-01 | 5.85e-02 | 9.75e-02 | 4.98e-01 | 6.51e-02 | 1.54e-01 | 4.53e-01 | 2.11e-01 |
| LYMPHOCYTE MIGRATION INTO LYMPHOID ORGANS | 9 | 5.45e-01 | 8.70e-01 | 0.2210 | 7.64e-02 | 7.62e-02 | -2.90e-02 | 1.55e-01 | -1.10e-01 | 6.91e-01 | 6.92e-01 | 8.80e-01 | 4.21e-01 | 5.67e-01 |
| CHEMOKINE C X C MOTIF LIGAND 1 PRODUCTION | 6 | 8.40e-01 | 9.73e-01 | 0.2210 | -1.11e-01 | 1.83e-02 | -2.61e-03 | -1.02e-01 | -1.60e-01 | 6.36e-01 | 9.38e-01 | 9.91e-01 | 6.64e-01 | 4.99e-01 |
| VESTIBULOCOCHLEAR NERVE DEVELOPMENT | 11 | 7.18e-01 | 9.38e-01 | 0.2210 | -7.57e-02 | 2.65e-02 | -1.04e-01 | -1.69e-01 | -5.44e-02 | 6.64e-01 | 8.79e-01 | 5.50e-01 | 3.33e-01 | 7.55e-01 |
| AROMATIC AMINO ACID METABOLIC PROCESS | 31 | 8.44e-01 | 9.75e-01 | 0.2200 | -7.86e-02 | -9.97e-02 | -9.74e-02 | -1.25e-01 | -8.63e-02 | 4.49e-01 | 3.37e-01 | 3.48e-01 | 2.30e-01 | 4.05e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 71 | 6.16e-02 | 3.29e-01 | 0.2200 | -8.41e-03 | 9.70e-02 | 1.11e-01 | 3.89e-02 | 1.59e-01 | 9.03e-01 | 1.58e-01 | 1.05e-01 | 5.71e-01 | 2.09e-02 |
| CELLULAR HYPEROSMOTIC RESPONSE | 19 | 9.59e-01 | 9.94e-01 | 0.2200 | 9.60e-02 | 1.00e-01 | 9.08e-02 | 1.13e-01 | 9.10e-02 | 4.69e-01 | 4.50e-01 | 4.93e-01 | 3.95e-01 | 4.92e-01 |
| CD4 POSITIVE ALPHA BETA T CELL PROLIFERATION | 20 | 4.41e-01 | 8.13e-01 | 0.2200 | -8.96e-02 | -1.89e-01 | -5.04e-02 | -1.30e-02 | 4.30e-02 | 4.88e-01 | 1.42e-01 | 6.96e-01 | 9.20e-01 | 7.39e-01 |
| NEURAL CREST CELL DIFFERENTIATION | 93 | 1.84e-03 | 2.85e-02 | 0.2200 | -5.52e-02 | 2.51e-02 | 5.44e-02 | 4.45e-02 | 2.00e-01 | 3.58e-01 | 6.76e-01 | 3.65e-01 | 4.58e-01 | 8.81e-04 |
| REGULATION OF LYSOSOME ORGANIZATION | 12 | 4.15e-01 | 7.98e-01 | 0.2200 | 8.26e-02 | -7.37e-02 | 6.75e-02 | 1.77e-01 | 1.86e-02 | 6.20e-01 | 6.59e-01 | 6.86e-01 | 2.89e-01 | 9.11e-01 |
| LOCOMOTOR RHYTHM | 15 | 9.64e-01 | 9.94e-01 | 0.2200 | 1.03e-01 | 7.34e-02 | 9.31e-02 | 1.05e-01 | 1.12e-01 | 4.89e-01 | 6.23e-01 | 5.32e-01 | 4.80e-01 | 4.51e-01 |
| PROTEIN LOCALIZATION TO CYTOSKELETON | 57 | 1.88e-02 | 1.60e-01 | 0.2200 | 9.15e-02 | 3.75e-02 | 5.85e-02 | 1.87e-01 | -1.88e-02 | 2.32e-01 | 6.25e-01 | 4.45e-01 | 1.48e-02 | 8.06e-01 |
| NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 7 | 8.51e-01 | 9.76e-01 | 0.2200 | 4.41e-02 | 9.37e-03 | 8.09e-02 | 1.94e-01 | 4.66e-02 | 8.40e-01 | 9.66e-01 | 7.11e-01 | 3.75e-01 | 8.31e-01 |
| NEGATIVE REGULATION OF GTPASE ACTIVITY | 21 | 7.87e-01 | 9.63e-01 | 0.2200 | -9.29e-02 | -4.12e-02 | -1.30e-01 | -1.32e-01 | -6.04e-02 | 4.61e-01 | 7.44e-01 | 3.02e-01 | 2.96e-01 | 6.32e-01 |
| UTERUS MORPHOGENESIS | 6 | 8.01e-01 | 9.66e-01 | 0.2200 | -9.96e-02 | -8.38e-02 | 2.06e-02 | -6.17e-02 | -1.64e-01 | 6.73e-01 | 7.22e-01 | 9.30e-01 | 7.93e-01 | 4.85e-01 |
| NEGATIVE REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN | 11 | 7.56e-01 | 9.51e-01 | 0.2200 | 6.63e-02 | 1.72e-01 | 7.43e-02 | 7.68e-04 | 9.27e-02 | 7.03e-01 | 3.22e-01 | 6.69e-01 | 9.96e-01 | 5.94e-01 |
| G0 TO G1 TRANSITION | 36 | 4.36e-01 | 8.09e-01 | 0.2200 | 4.51e-02 | 8.30e-02 | 7.73e-02 | 1.19e-01 | 1.38e-01 | 6.39e-01 | 3.89e-01 | 4.22e-01 | 2.16e-01 | 1.51e-01 |
| NEGATIVE REGULATION OF ERBB SIGNALING PATHWAY | 32 | 6.99e-01 | 9.31e-01 | 0.2200 | 3.92e-02 | 9.82e-02 | 9.73e-02 | 8.03e-02 | 1.45e-01 | 7.01e-01 | 3.36e-01 | 3.41e-01 | 4.32e-01 | 1.55e-01 |
| ADENYLATE CYCLASE ACTIVATING ADRENERGIC RECEPTOR SIGNALING PATHWAY | 26 | 7.71e-02 | 3.77e-01 | 0.2200 | -3.79e-02 | -9.11e-02 | 5.94e-02 | -6.17e-02 | 1.76e-01 | 7.38e-01 | 4.21e-01 | 6.00e-01 | 5.86e-01 | 1.19e-01 |
| MONOCYTE DIFFERENTIATION | 34 | 1.80e-01 | 5.65e-01 | 0.2190 | -2.75e-02 | 1.08e-01 | 1.12e-01 | 7.70e-02 | 1.31e-01 | 7.82e-01 | 2.74e-01 | 2.59e-01 | 4.37e-01 | 1.85e-01 |
| NEGATIVE REGULATION OF B CELL MEDIATED IMMUNITY | 15 | 7.66e-01 | 9.54e-01 | 0.2190 | -1.53e-01 | -1.01e-01 | -6.78e-02 | -4.75e-02 | 8.79e-02 | 3.06e-01 | 4.96e-01 | 6.49e-01 | 7.50e-01 | 5.56e-01 |
| INTRACELLULAR SODIUM ION HOMEOSTASIS | 22 | 3.15e-01 | 7.26e-01 | 0.2190 | -1.00e-01 | 4.83e-03 | 8.98e-02 | -7.02e-02 | 1.58e-01 | 4.16e-01 | 9.69e-01 | 4.66e-01 | 5.69e-01 | 1.99e-01 |
| HEAD DEVELOPMENT | 726 | 1.64e-06 | 7.31e-05 | 0.2190 | 7.22e-02 | 8.66e-02 | 1.20e-01 | 9.60e-02 | 1.08e-01 | 9.22e-04 | 7.03e-05 | 3.36e-08 | 1.04e-05 | 6.62e-07 |
| REGULATION OF SYNAPTIC VESICLE CYCLE | 12 | 7.57e-01 | 9.51e-01 | 0.2190 | -2.79e-02 | -1.68e-01 | -1.03e-01 | -6.16e-02 | -6.82e-02 | 8.67e-01 | 3.13e-01 | 5.37e-01 | 7.12e-01 | 6.83e-01 |
| NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 46 | 7.14e-01 | 9.36e-01 | 0.2190 | 9.71e-02 | 8.73e-02 | 8.90e-02 | 9.62e-02 | 1.18e-01 | 2.55e-01 | 3.06e-01 | 2.96e-01 | 2.59e-01 | 1.67e-01 |
| INCLUSION BODY ASSEMBLY | 23 | 7.70e-01 | 9.55e-01 | 0.2190 | 3.25e-02 | 4.60e-02 | 1.49e-01 | 9.76e-02 | 1.15e-01 | 7.88e-01 | 7.03e-01 | 2.17e-01 | 4.18e-01 | 3.38e-01 |
| POSITIVE REGULATION OF METALLOPEPTIDASE ACTIVITY | 10 | 6.96e-01 | 9.31e-01 | 0.2190 | -1.62e-01 | -4.50e-02 | 1.02e-02 | -1.20e-01 | -7.26e-02 | 3.75e-01 | 8.05e-01 | 9.56e-01 | 5.11e-01 | 6.91e-01 |
| ESTABLISHMENT OF MITOCHONDRION LOCALIZATION | 27 | 8.18e-01 | 9.70e-01 | 0.2190 | 6.88e-02 | 4.97e-02 | 9.18e-02 | 9.88e-02 | 1.51e-01 | 5.36e-01 | 6.55e-01 | 4.09e-01 | 3.74e-01 | 1.76e-01 |
| REGULATION OF GROWTH HORMONE RECEPTOR SIGNALING PATHWAY | 6 | 8.77e-01 | 9.79e-01 | 0.2190 | 6.46e-02 | 3.52e-02 | 5.99e-03 | 1.08e-01 | 1.75e-01 | 7.84e-01 | 8.81e-01 | 9.80e-01 | 6.46e-01 | 4.57e-01 |
| POSITIVE REGULATION OF PROGRAMMED CELL DEATH | 546 | 8.93e-05 | 2.54e-03 | 0.2190 | 1.03e-01 | 8.31e-02 | 1.06e-01 | 1.24e-01 | 6.06e-02 | 4.01e-05 | 8.94e-04 | 2.12e-05 | 6.57e-07 | 1.55e-02 |
| NUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 71 | 5.18e-01 | 8.57e-01 | 0.2190 | 1.36e-01 | 1.20e-01 | 8.11e-02 | 9.16e-02 | 9.59e-03 | 4.73e-02 | 8.15e-02 | 2.37e-01 | 1.82e-01 | 8.89e-01 |
| CYTOKINESIS | 178 | 1.07e-02 | 1.07e-01 | 0.2190 | 9.72e-02 | 5.50e-02 | 1.14e-01 | 1.40e-01 | 5.21e-02 | 2.53e-02 | 2.06e-01 | 8.58e-03 | 1.27e-03 | 2.30e-01 |
| NEGATIVE REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 32 | 7.75e-01 | 9.57e-01 | 0.2190 | -1.00e-01 | -5.06e-02 | -1.06e-01 | -1.19e-01 | -9.88e-02 | 3.26e-01 | 6.21e-01 | 2.99e-01 | 2.43e-01 | 3.33e-01 |
| POLYOL BIOSYNTHETIC PROCESS | 62 | 3.68e-02 | 2.47e-01 | 0.2190 | 2.31e-02 | 1.66e-02 | 3.48e-02 | 5.98e-02 | 2.05e-01 | 7.53e-01 | 8.21e-01 | 6.36e-01 | 4.15e-01 | 5.13e-03 |
| ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN | 70 | 3.08e-01 | 7.19e-01 | 0.2190 | 7.60e-02 | 1.41e-01 | 9.93e-02 | 9.45e-02 | 5.77e-02 | 2.71e-01 | 4.12e-02 | 1.51e-01 | 1.71e-01 | 4.03e-01 |
| POSITIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND TRANSPORT | 6 | 8.33e-01 | 9.73e-01 | 0.2190 | 5.73e-02 | 4.70e-03 | 3.02e-02 | -3.00e-02 | 2.07e-01 | 8.08e-01 | 9.84e-01 | 8.98e-01 | 8.99e-01 | 3.81e-01 |
| XENOBIOTIC TRANSMEMBRANE TRANSPORT | 16 | 2.14e-01 | 6.09e-01 | 0.2190 | 6.89e-02 | -3.02e-02 | -1.13e-01 | -1.54e-01 | -7.36e-02 | 6.33e-01 | 8.35e-01 | 4.32e-01 | 2.85e-01 | 6.10e-01 |
| POSITIVE REGULATION OF FATTY ACID TRANSPORT | 23 | 5.31e-01 | 8.63e-01 | 0.2180 | -7.81e-02 | -1.97e-02 | -1.09e-01 | -1.69e-01 | -2.69e-02 | 5.17e-01 | 8.70e-01 | 3.67e-01 | 1.60e-01 | 8.23e-01 |
| POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 198 | 8.42e-02 | 3.92e-01 | 0.2180 | 9.98e-02 | 9.04e-02 | 9.47e-02 | 1.22e-01 | 7.59e-02 | 1.54e-02 | 2.82e-02 | 2.15e-02 | 3.13e-03 | 6.57e-02 |
| REGULATION OF NEUTROPHIL MEDIATED CYTOTOXICITY | 5 | 9.66e-01 | 9.94e-01 | 0.2180 | 4.74e-03 | -8.05e-02 | -6.41e-02 | -5.13e-02 | -1.86e-01 | 9.85e-01 | 7.55e-01 | 8.04e-01 | 8.43e-01 | 4.72e-01 |
| RESPONSE TO INTERLEUKIN 18 | 11 | 8.26e-01 | 9.72e-01 | 0.2180 | -4.91e-02 | -9.42e-02 | -1.61e-01 | -1.02e-01 | 1.60e-02 | 7.78e-01 | 5.89e-01 | 3.56e-01 | 5.60e-01 | 9.27e-01 |
| POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 67 | 1.21e-01 | 4.75e-01 | 0.2180 | 1.42e-01 | 1.18e-01 | 3.91e-02 | 8.99e-02 | 6.19e-02 | 4.39e-02 | 9.42e-02 | 5.80e-01 | 2.03e-01 | 3.81e-01 |
| POSITIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 13 | 5.38e-01 | 8.66e-01 | 0.2180 | 1.38e-01 | 1.40e-01 | -1.23e-02 | 6.44e-02 | 6.79e-02 | 3.89e-01 | 3.82e-01 | 9.39e-01 | 6.88e-01 | 6.72e-01 |
| POSITIVE REGULATION OF NEURON PROJECTION ARBORIZATION | 8 | 9.27e-01 | 9.89e-01 | 0.2180 | -1.12e-01 | -3.90e-02 | 3.00e-02 | -3.38e-02 | 1.78e-01 | 5.84e-01 | 8.49e-01 | 8.83e-01 | 8.69e-01 | 3.85e-01 |
| REGULATION OF PROTEIN K63 LINKED UBIQUITINATION | 13 | 8.68e-01 | 9.78e-01 | 0.2180 | 1.39e-01 | 9.00e-02 | 6.70e-02 | 6.31e-02 | 1.08e-01 | 3.87e-01 | 5.74e-01 | 6.76e-01 | 6.93e-01 | 4.98e-01 |
| NEGATIVE REGULATION OF GLUCOSE TRANSMEMBRANE TRANSPORT | 21 | 5.99e-01 | 8.98e-01 | 0.2180 | 1.58e-02 | -9.74e-02 | -1.41e-01 | -3.03e-02 | -1.30e-01 | 9.00e-01 | 4.40e-01 | 2.62e-01 | 8.10e-01 | 3.03e-01 |
| CELLULAR RESPONSE TO VITAMIN | 28 | 6.05e-02 | 3.25e-01 | 0.2180 | -3.35e-02 | 5.42e-02 | -1.06e-01 | -1.78e-01 | -2.47e-02 | 7.59e-01 | 6.20e-01 | 3.31e-01 | 1.04e-01 | 8.21e-01 |
| LIPID OXIDATION | 112 | 5.35e-02 | 3.06e-01 | 0.2180 | 9.43e-02 | 1.15e-01 | 6.84e-02 | 1.05e-01 | 9.86e-02 | 8.48e-02 | 3.55e-02 | 2.11e-01 | 5.48e-02 | 7.15e-02 |
| REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 35 | 4.07e-01 | 7.93e-01 | 0.2180 | 1.27e-01 | 1.41e-01 | 4.94e-02 | 5.67e-02 | 7.69e-02 | 1.95e-01 | 1.48e-01 | 6.13e-01 | 5.62e-01 | 4.31e-01 |
| POSITIVE REGULATION OF HIPPO SIGNALING | 10 | 8.09e-01 | 9.68e-01 | 0.2180 | -5.61e-02 | 4.36e-02 | -9.08e-02 | -1.22e-01 | -1.39e-01 | 7.59e-01 | 8.11e-01 | 6.19e-01 | 5.04e-01 | 4.47e-01 |
| POSITIVE REGULATION OF HORMONE BIOSYNTHETIC PROCESS | 9 | 5.70e-01 | 8.82e-01 | 0.2180 | 1.45e-01 | 1.54e-02 | -4.05e-02 | 1.31e-01 | 8.51e-02 | 4.51e-01 | 9.36e-01 | 8.33e-01 | 4.95e-01 | 6.58e-01 |
| TYPE B PANCREATIC CELL DEVELOPMENT | 24 | 6.23e-01 | 9.08e-01 | 0.2180 | -1.26e-02 | 3.42e-02 | 1.25e-01 | 1.15e-01 | 1.31e-01 | 9.15e-01 | 7.72e-01 | 2.88e-01 | 3.28e-01 | 2.68e-01 |
| NEGATIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 16 | 2.19e-01 | 6.16e-01 | 0.2180 | -1.05e-01 | -9.57e-02 | -5.78e-02 | 6.08e-02 | -1.42e-01 | 4.68e-01 | 5.08e-01 | 6.89e-01 | 6.74e-01 | 3.24e-01 |
| CARDIAC MUSCLE CELL ACTION POTENTIAL | 72 | 4.31e-01 | 8.06e-01 | 0.2180 | -1.06e-01 | -8.16e-02 | -9.87e-02 | -1.39e-01 | -1.97e-02 | 1.19e-01 | 2.31e-01 | 1.47e-01 | 4.13e-02 | 7.73e-01 |
| REGULATION OF ATP BIOSYNTHETIC PROCESS | 17 | 5.90e-01 | 8.93e-01 | 0.2180 | -8.20e-02 | -9.17e-02 | 3.94e-03 | -8.94e-02 | 1.56e-01 | 5.58e-01 | 5.13e-01 | 9.78e-01 | 5.24e-01 | 2.66e-01 |
| REGULATION OF RELAXATION OF MUSCLE | 14 | 5.40e-01 | 8.67e-01 | 0.2180 | -1.32e-01 | -1.10e-02 | -5.07e-02 | -8.43e-02 | 1.42e-01 | 3.93e-01 | 9.43e-01 | 7.43e-01 | 5.85e-01 | 3.56e-01 |
| REGULATION OF GAMMA AMINOBUTYRIC ACID SECRETION | 8 | 3.58e-01 | 7.57e-01 | 0.2180 | 3.32e-02 | 1.07e-01 | -3.30e-02 | 1.15e-01 | 1.44e-01 | 8.71e-01 | 6.02e-01 | 8.71e-01 | 5.74e-01 | 4.81e-01 |
| POSITIVE REGULATION OF HEMOPOIESIS | 181 | 2.35e-02 | 1.86e-01 | 0.2180 | 9.99e-02 | 1.20e-01 | 8.04e-02 | 1.20e-01 | 4.75e-02 | 2.04e-02 | 5.42e-03 | 6.20e-02 | 5.48e-03 | 2.70e-01 |
| PIGMENT METABOLIC PROCESS | 74 | 4.38e-01 | 8.10e-01 | 0.2170 | -1.30e-01 | -1.06e-01 | -9.73e-02 | -9.75e-02 | 9.53e-03 | 5.23e-02 | 1.15e-01 | 1.48e-01 | 1.47e-01 | 8.87e-01 |
| MORPHOGENESIS OF AN ENDOTHELIUM | 17 | 8.03e-01 | 9.67e-01 | 0.2170 | 3.00e-02 | 7.05e-03 | 9.51e-02 | 1.34e-01 | 1.39e-01 | 8.30e-01 | 9.60e-01 | 4.97e-01 | 3.40e-01 | 3.19e-01 |
| NEGATIVE REGULATION OF CELL DIFFERENTIATION | 686 | 6.25e-08 | 3.51e-06 | 0.2170 | 5.30e-02 | 7.05e-02 | 1.06e-01 | 1.02e-01 | 1.34e-01 | 1.80e-02 | 1.65e-03 | 2.29e-06 | 4.93e-06 | 2.37e-09 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 93 | 1.35e-01 | 4.97e-01 | 0.2170 | 8.55e-02 | 1.53e-01 | 1.04e-01 | 6.71e-02 | 3.65e-02 | 1.54e-01 | 1.08e-02 | 8.43e-02 | 2.63e-01 | 5.43e-01 |
| PRONEPHROS DEVELOPMENT | 9 | 8.64e-01 | 9.78e-01 | 0.2170 | 6.40e-02 | 1.52e-01 | 6.11e-02 | 2.77e-02 | 1.24e-01 | 7.39e-01 | 4.29e-01 | 7.51e-01 | 8.86e-01 | 5.20e-01 |
| ESTABLISHMENT OF SISTER CHROMATID COHESION | 9 | 4.94e-01 | 8.43e-01 | 0.2170 | 1.25e-02 | -5.19e-02 | -1.94e-02 | 1.57e-01 | 1.39e-01 | 9.48e-01 | 7.88e-01 | 9.20e-01 | 4.15e-01 | 4.71e-01 |
| AMINE TRANSPORT | 106 | 6.04e-02 | 3.25e-01 | 0.2170 | 4.44e-02 | 7.89e-02 | 1.09e-01 | 4.25e-02 | 1.59e-01 | 4.30e-01 | 1.60e-01 | 5.18e-02 | 4.50e-01 | 4.78e-03 |
| POST EMBRYONIC DEVELOPMENT | 91 | 4.27e-01 | 8.05e-01 | 0.2170 | 1.09e-01 | 9.71e-02 | 8.44e-02 | 1.23e-01 | 5.90e-02 | 7.17e-02 | 1.10e-01 | 1.64e-01 | 4.25e-02 | 3.31e-01 |
| BLASTOCYST DEVELOPMENT | 114 | 1.30e-01 | 4.87e-01 | 0.2170 | 9.55e-02 | 8.54e-02 | 7.66e-02 | 1.06e-01 | 1.17e-01 | 7.81e-02 | 1.15e-01 | 1.58e-01 | 5.11e-02 | 3.16e-02 |
| EPOXIDE METABOLIC PROCESS | 5 | 8.75e-01 | 9.78e-01 | 0.2170 | -5.01e-02 | 1.29e-01 | 6.74e-02 | -3.70e-02 | 1.48e-01 | 8.46e-01 | 6.18e-01 | 7.94e-01 | 8.86e-01 | 5.66e-01 |
| HUMORAL IMMUNE RESPONSE | 237 | 4.71e-03 | 5.88e-02 | 0.2170 | -6.66e-02 | -4.94e-02 | -1.03e-01 | -1.22e-01 | -1.21e-01 | 7.71e-02 | 1.90e-01 | 6.16e-03 | 1.20e-03 | 1.37e-03 |
| NEGATIVE REGULATION OF CILIUM ASSEMBLY | 18 | 6.28e-01 | 9.09e-01 | 0.2170 | 1.80e-01 | 7.17e-02 | 8.00e-03 | 9.62e-02 | -1.31e-02 | 1.86e-01 | 5.99e-01 | 9.53e-01 | 4.80e-01 | 9.23e-01 |
| PROTEIN ACETYLATION | 97 | 4.88e-02 | 2.89e-01 | 0.2170 | 7.45e-02 | 6.47e-02 | 7.39e-02 | 1.42e-01 | 1.08e-01 | 2.05e-01 | 2.71e-01 | 2.09e-01 | 1.56e-02 | 6.65e-02 |
| NEGATIVE REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 5 | 7.03e-01 | 9.32e-01 | 0.2170 | 8.01e-02 | -4.67e-02 | -1.28e-01 | -1.48e-01 | 1.25e-02 | 7.56e-01 | 8.56e-01 | 6.20e-01 | 5.67e-01 | 9.62e-01 |
| NEGATIVE REGULATION OF MAST CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 8 | 8.75e-01 | 9.78e-01 | 0.2170 | 4.93e-02 | 3.69e-02 | -1.32e-01 | -7.12e-02 | -1.43e-01 | 8.09e-01 | 8.56e-01 | 5.16e-01 | 7.27e-01 | 4.83e-01 |
| POSITIVE REGULATION OF DENDRITIC SPINE DEVELOPMENT | 34 | 6.76e-01 | 9.28e-01 | 0.2170 | -1.36e-01 | -6.81e-02 | -9.04e-02 | -1.03e-01 | -7.00e-02 | 1.70e-01 | 4.92e-01 | 3.61e-01 | 2.97e-01 | 4.80e-01 |
| ORGANELLE LOCALIZATION | 588 | 1.23e-04 | 3.24e-03 | 0.2170 | 9.41e-02 | 8.60e-02 | 1.13e-01 | 1.15e-01 | 6.74e-02 | 9.60e-05 | 3.66e-04 | 2.82e-06 | 1.71e-06 | 5.19e-03 |
| INTEGRIN ACTIVATION | 26 | 6.77e-01 | 9.28e-01 | 0.2170 | -5.47e-02 | -1.28e-02 | -8.06e-02 | -1.13e-01 | -1.56e-01 | 6.29e-01 | 9.10e-01 | 4.77e-01 | 3.17e-01 | 1.68e-01 |
| DOPAMINE METABOLIC PROCESS | 35 | 4.44e-01 | 8.14e-01 | 0.2170 | -3.34e-03 | 8.77e-02 | 1.31e-01 | 3.37e-02 | 1.45e-01 | 9.73e-01 | 3.69e-01 | 1.81e-01 | 7.30e-01 | 1.38e-01 |
| NEGATIVE REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS | 37 | 8.91e-01 | 9.81e-01 | 0.2160 | -8.93e-02 | -8.44e-02 | -1.18e-01 | -1.07e-01 | -8.01e-02 | 3.47e-01 | 3.74e-01 | 2.14e-01 | 2.61e-01 | 3.99e-01 |
| CRANIAL NERVE DEVELOPMENT | 61 | 3.91e-01 | 7.83e-01 | 0.2160 | 5.12e-02 | 1.18e-01 | 1.22e-01 | 5.71e-02 | 1.10e-01 | 4.90e-01 | 1.11e-01 | 9.99e-02 | 4.40e-01 | 1.36e-01 |
| PYRIMIDINE CONTAINING COMPOUND CATABOLIC PROCESS | 42 | 7.66e-01 | 9.55e-01 | 0.2160 | 1.27e-01 | 1.12e-01 | 7.99e-02 | 8.87e-02 | 6.19e-02 | 1.54e-01 | 2.09e-01 | 3.70e-01 | 3.20e-01 | 4.88e-01 |
| PENTOSE METABOLIC PROCESS | 11 | 7.58e-01 | 9.52e-01 | 0.2160 | -5.41e-02 | -1.05e-01 | 4.12e-02 | -1.04e-02 | 1.76e-01 | 7.56e-01 | 5.45e-01 | 8.13e-01 | 9.52e-01 | 3.12e-01 |
| AUDITORY RECEPTOR CELL MORPHOGENESIS | 20 | 9.56e-01 | 9.94e-01 | 0.2160 | -9.12e-02 | -8.56e-02 | -9.49e-02 | -9.71e-02 | -1.13e-01 | 4.80e-01 | 5.07e-01 | 4.63e-01 | 4.52e-01 | 3.83e-01 |
| POSITIVE REGULATION OF T HELPER 1 TYPE IMMUNE RESPONSE | 18 | 4.33e-01 | 8.08e-01 | 0.2160 | 6.03e-02 | 4.73e-02 | -9.42e-02 | -1.21e-01 | -1.32e-01 | 6.58e-01 | 7.28e-01 | 4.89e-01 | 3.73e-01 | 3.34e-01 |
| REGULATION OF METALLOPEPTIDASE ACTIVITY | 22 | 7.35e-01 | 9.47e-01 | 0.2160 | -1.33e-01 | -7.09e-02 | -4.57e-02 | -1.43e-01 | -3.92e-02 | 2.80e-01 | 5.65e-01 | 7.10e-01 | 2.46e-01 | 7.51e-01 |
| ZYMOGEN ACTIVATION | 57 | 2.61e-01 | 6.68e-01 | 0.2160 | 1.57e-01 | 1.14e-01 | 3.30e-02 | 6.90e-02 | -5.68e-02 | 4.03e-02 | 1.37e-01 | 6.67e-01 | 3.67e-01 | 4.58e-01 |
| RUFFLE ASSEMBLY | 45 | 5.58e-01 | 8.78e-01 | 0.2160 | 6.39e-02 | 8.46e-02 | 1.11e-01 | 1.41e-01 | 5.52e-02 | 4.58e-01 | 3.26e-01 | 1.97e-01 | 1.01e-01 | 5.22e-01 |
| COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE | 24 | 3.44e-01 | 7.50e-01 | 0.2160 | -1.13e-01 | -1.34e-01 | 2.41e-02 | 2.93e-02 | 1.20e-01 | 3.38e-01 | 2.55e-01 | 8.38e-01 | 8.04e-01 | 3.09e-01 |
| REGULATION OF FC RECEPTOR MEDIATED STIMULATORY SIGNALING PATHWAY | 10 | 5.04e-01 | 8.50e-01 | 0.2160 | 1.06e-01 | -4.93e-02 | -1.49e-02 | 1.67e-01 | 7.04e-02 | 5.62e-01 | 7.87e-01 | 9.35e-01 | 3.61e-01 | 7.00e-01 |
| VESICLE MEDIATED TRANSPORT BETWEEN ENDOSOMAL COMPARTMENTS | 46 | 3.96e-01 | 7.85e-01 | 0.2160 | 1.15e-01 | 8.32e-02 | 6.35e-02 | 1.45e-01 | -3.59e-02 | 1.76e-01 | 3.29e-01 | 4.56e-01 | 8.87e-02 | 6.74e-01 |
| FORMATION OF EXTRACHROMOSOMAL CIRCULAR DNA | 13 | 6.42e-01 | 9.14e-01 | 0.2160 | 1.45e-01 | 1.50e-01 | 3.07e-03 | 3.21e-02 | 4.55e-02 | 3.65e-01 | 3.50e-01 | 9.85e-01 | 8.41e-01 | 7.76e-01 |
| EARLY ENDOSOME TO RECYCLING ENDOSOME TRANSPORT | 6 | 7.45e-01 | 9.50e-01 | 0.2160 | 3.76e-02 | -6.03e-03 | -1.90e-02 | 1.58e-01 | -1.41e-01 | 8.73e-01 | 9.80e-01 | 9.36e-01 | 5.02e-01 | 5.51e-01 |
| GOLGI TO LYSOSOME TRANSPORT | 12 | 7.77e-01 | 9.58e-01 | 0.2160 | 1.01e-01 | 5.96e-02 | 4.21e-02 | 1.65e-01 | -6.22e-02 | 5.45e-01 | 7.21e-01 | 8.01e-01 | 3.22e-01 | 7.09e-01 |
| NEGATIVE REGULATION OF WNT SIGNALING PATHWAY | 167 | 2.26e-02 | 1.81e-01 | 0.2160 | 2.86e-02 | 6.24e-02 | 1.09e-01 | 1.01e-01 | 1.41e-01 | 5.24e-01 | 1.64e-01 | 1.54e-02 | 2.50e-02 | 1.63e-03 |
| GASTRIC ACID SECRETION | 13 | 8.33e-01 | 9.73e-01 | 0.2160 | -7.71e-02 | -3.27e-02 | -1.49e-01 | -1.15e-01 | -6.26e-02 | 6.30e-01 | 8.38e-01 | 3.51e-01 | 4.72e-01 | 6.96e-01 |
| REGULATION OF MUSCLE TISSUE DEVELOPMENT | 45 | 4.13e-01 | 7.98e-01 | 0.2160 | 3.42e-03 | 1.43e-02 | 9.49e-02 | 5.73e-02 | 1.84e-01 | 9.68e-01 | 8.68e-01 | 2.71e-01 | 5.06e-01 | 3.23e-02 |
| STEM CELL DEVELOPMENT | 87 | 6.49e-03 | 7.47e-02 | 0.2160 | -7.21e-02 | 8.20e-03 | 5.48e-02 | 2.76e-02 | 1.94e-01 | 2.45e-01 | 8.95e-01 | 3.77e-01 | 6.56e-01 | 1.80e-03 |
| TRIGLYCERIDE CATABOLIC PROCESS | 27 | 1.04e-01 | 4.41e-01 | 0.2160 | 2.83e-02 | 1.47e-01 | -1.55e-02 | -1.33e-02 | -1.54e-01 | 7.99e-01 | 1.85e-01 | 8.89e-01 | 9.05e-01 | 1.67e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 1 ALPHA PRODUCTION | 5 | 4.79e-01 | 8.34e-01 | 0.2160 | -1.37e-01 | 1.24e-01 | 8.53e-02 | 5.38e-02 | -4.47e-02 | 5.95e-01 | 6.30e-01 | 7.41e-01 | 8.35e-01 | 8.62e-01 |
| PURINE NUCLEOSIDE METABOLIC PROCESS | 25 | 3.94e-01 | 7.85e-01 | 0.2160 | 1.86e-01 | 8.35e-02 | 3.68e-02 | 5.76e-02 | -1.84e-02 | 1.08e-01 | 4.70e-01 | 7.50e-01 | 6.18e-01 | 8.73e-01 |
| REGULATION OF INSULIN SECRETION | 161 | 3.15e-02 | 2.24e-01 | 0.2150 | 7.71e-02 | 1.41e-01 | 1.08e-01 | 7.14e-02 | 6.25e-02 | 9.15e-02 | 2.06e-03 | 1.80e-02 | 1.18e-01 | 1.71e-01 |
| POSITIVE REGULATION OF RIG I SIGNALING PATHWAY | 10 | 9.29e-01 | 9.89e-01 | 0.2150 | 1.15e-01 | 8.65e-02 | 3.31e-02 | 7.12e-02 | -1.40e-01 | 5.28e-01 | 6.36e-01 | 8.56e-01 | 6.97e-01 | 4.45e-01 |
| HISTAMINE SECRETION | 12 | 2.46e-01 | 6.51e-01 | 0.2150 | -4.88e-02 | 1.85e-01 | 7.60e-02 | 1.63e-02 | 6.05e-02 | 7.70e-01 | 2.67e-01 | 6.49e-01 | 9.22e-01 | 7.17e-01 |
| SIGNALING RECEPTOR LIGAND PRECURSOR PROCESSING | 36 | 7.25e-01 | 9.42e-01 | 0.2150 | -3.31e-02 | -9.41e-02 | -1.21e-01 | -6.71e-02 | -1.31e-01 | 7.31e-01 | 3.29e-01 | 2.10e-01 | 4.86e-01 | 1.72e-01 |
| POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 496 | 2.26e-05 | 7.87e-04 | 0.2150 | 1.01e-01 | 8.45e-02 | 8.41e-02 | 1.26e-01 | 7.87e-02 | 1.23e-04 | 1.26e-03 | 1.34e-03 | 1.67e-06 | 2.69e-03 |
| NEURONAL DENSE CORE VESICLE EXOCYTOSIS | 7 | 6.80e-01 | 9.28e-01 | 0.2150 | -6.79e-02 | -6.32e-02 | 2.58e-02 | -1.59e-01 | 1.08e-01 | 7.56e-01 | 7.72e-01 | 9.06e-01 | 4.66e-01 | 6.20e-01 |
| PROTEIN DESUMOYLATION | 8 | 7.56e-01 | 9.51e-01 | 0.2150 | 4.06e-02 | -3.47e-02 | 6.81e-02 | 1.90e-01 | 5.27e-02 | 8.42e-01 | 8.65e-01 | 7.39e-01 | 3.53e-01 | 7.96e-01 |
| DISRUPTION OF ANATOMICAL STRUCTURE IN ANOTHER ORGANISM | 98 | 1.11e-01 | 4.55e-01 | 0.2150 | -1.05e-02 | -6.34e-02 | -1.17e-01 | -9.21e-02 | -1.41e-01 | 8.58e-01 | 2.78e-01 | 4.62e-02 | 1.15e-01 | 1.55e-02 |
| RESPONSE TO COLD | 43 | 7.09e-01 | 9.34e-01 | 0.2150 | 6.41e-02 | 6.98e-02 | 1.00e-01 | 7.71e-02 | 1.45e-01 | 4.67e-01 | 4.28e-01 | 2.55e-01 | 3.82e-01 | 9.88e-02 |
| REGULATION OF ACTION POTENTIAL | 55 | 4.70e-01 | 8.30e-01 | 0.2150 | -1.09e-01 | -6.89e-02 | -8.15e-02 | -1.47e-01 | -3.62e-02 | 1.62e-01 | 3.77e-01 | 2.96e-01 | 5.95e-02 | 6.42e-01 |
| POSITIVE REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING | 36 | 3.73e-01 | 7.72e-01 | 0.2150 | 9.96e-02 | 4.10e-02 | 7.15e-02 | 1.69e-01 | 3.03e-02 | 3.01e-01 | 6.70e-01 | 4.58e-01 | 7.96e-02 | 7.53e-01 |
| REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 51 | 2.73e-01 | 6.81e-01 | 0.2150 | 8.28e-02 | 1.21e-01 | 1.04e-01 | 9.77e-02 | -6.48e-02 | 3.06e-01 | 1.34e-01 | 1.99e-01 | 2.28e-01 | 4.23e-01 |
| POSITIVE REGULATION OF VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 7 | 9.07e-01 | 9.84e-01 | 0.2150 | 1.46e-01 | 3.47e-02 | 4.54e-02 | 8.27e-02 | -1.21e-01 | 5.03e-01 | 8.74e-01 | 8.35e-01 | 7.05e-01 | 5.80e-01 |
| REGULATION OF B CELL PROLIFERATION | 63 | 1.25e-01 | 4.82e-01 | 0.2150 | 1.25e-01 | 1.08e-01 | 3.43e-02 | 1.32e-01 | -1.38e-02 | 8.69e-02 | 1.37e-01 | 6.38e-01 | 6.98e-02 | 8.50e-01 |
| INTERKINETIC NUCLEAR MIGRATION | 5 | 8.64e-01 | 9.78e-01 | 0.2150 | 1.37e-01 | -2.94e-02 | -8.68e-02 | 9.90e-02 | -9.53e-02 | 5.96e-01 | 9.09e-01 | 7.37e-01 | 7.01e-01 | 7.12e-01 |
| CELLULAR RESPONSE TO BRAIN DERIVED NEUROTROPHIC FACTOR STIMULUS | 8 | 9.89e-01 | 9.98e-01 | 0.2150 | -1.26e-01 | -1.24e-01 | -6.19e-02 | -1.03e-01 | -7.89e-03 | 5.36e-01 | 5.42e-01 | 7.62e-01 | 6.13e-01 | 9.69e-01 |
| GROWTH HORMONE RECEPTOR SIGNALING PATHWAY VIA JAK STAT | 10 | 5.37e-01 | 8.66e-01 | 0.2150 | -1.03e-02 | 2.89e-02 | -4.04e-02 | 1.05e-02 | 2.08e-01 | 9.55e-01 | 8.74e-01 | 8.25e-01 | 9.54e-01 | 2.54e-01 |
| NATURAL KILLER CELL MEDIATED IMMUNITY | 78 | 9.17e-03 | 9.56e-02 | 0.2150 | -1.11e-01 | -1.69e-01 | -4.67e-02 | -2.35e-02 | -4.96e-02 | 8.96e-02 | 9.99e-03 | 4.76e-01 | 7.20e-01 | 4.49e-01 |
| PHOSPHOLIPID BIOSYNTHETIC PROCESS | 244 | 4.39e-02 | 2.71e-01 | 0.2140 | 8.83e-02 | 7.88e-02 | 1.02e-01 | 1.18e-01 | 8.88e-02 | 1.75e-02 | 3.39e-02 | 6.31e-03 | 1.57e-03 | 1.69e-02 |
| RESPONSE TO FUNGUS | 62 | 6.98e-02 | 3.57e-01 | 0.2140 | 4.10e-02 | 4.35e-03 | -1.23e-01 | -8.38e-02 | -1.49e-01 | 5.77e-01 | 9.53e-01 | 9.41e-02 | 2.54e-01 | 4.27e-02 |
| INTRACELLULAR IRON ION HOMEOSTASIS | 66 | 2.80e-01 | 6.90e-01 | 0.2140 | 3.98e-02 | 5.83e-02 | 8.14e-02 | 7.27e-02 | 1.71e-01 | 5.76e-01 | 4.13e-01 | 2.53e-01 | 3.07e-01 | 1.66e-02 |
| NEGATIVE REGULATION OF OSTEOBLAST PROLIFERATION | 15 | 2.84e-01 | 6.93e-01 | 0.2140 | -9.72e-02 | -1.68e-02 | 3.46e-02 | -1.73e-01 | 7.24e-02 | 5.14e-01 | 9.11e-01 | 8.17e-01 | 2.47e-01 | 6.27e-01 |
| REGULATION OF CELL CELL ADHESION MEDIATED BY INTEGRIN | 11 | 9.70e-01 | 9.95e-01 | 0.2140 | -9.15e-02 | -6.43e-02 | -1.27e-01 | -9.18e-02 | -9.38e-02 | 5.99e-01 | 7.12e-01 | 4.65e-01 | 5.98e-01 | 5.90e-01 |
| POSITIVE REGULATION OF MEIOTIC NUCLEAR DIVISION | 17 | 7.13e-01 | 9.36e-01 | 0.2140 | -9.37e-02 | -3.28e-02 | 1.56e-02 | -3.38e-02 | 1.86e-01 | 5.04e-01 | 8.15e-01 | 9.11e-01 | 8.09e-01 | 1.84e-01 |
| VESICLE LOCALIZATION | 208 | 1.00e-01 | 4.30e-01 | 0.2140 | 1.14e-01 | 9.09e-02 | 9.71e-02 | 1.15e-01 | 4.43e-02 | 4.63e-03 | 2.39e-02 | 1.57e-02 | 4.17e-03 | 2.71e-01 |
| LOBAR BRONCHUS EPITHELIUM DEVELOPMENT | 5 | 6.93e-01 | 9.31e-01 | 0.2140 | 9.65e-02 | 2.89e-02 | -9.16e-02 | 3.12e-02 | 1.62e-01 | 7.09e-01 | 9.11e-01 | 7.23e-01 | 9.04e-01 | 5.29e-01 |
| CELL ADHESION INVOLVED IN HEART MORPHOGENESIS | 6 | 8.31e-01 | 9.73e-01 | 0.2140 | -4.15e-02 | 1.52e-01 | 1.14e-01 | 3.65e-02 | 8.20e-02 | 8.60e-01 | 5.19e-01 | 6.29e-01 | 8.77e-01 | 7.28e-01 |
| POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 28 | 2.23e-01 | 6.22e-01 | 0.2140 | 4.54e-02 | -2.41e-02 | -1.53e-01 | -1.06e-01 | -9.22e-02 | 6.77e-01 | 8.25e-01 | 1.61e-01 | 3.30e-01 | 3.99e-01 |
| COBALT ION TRANSPORT | 6 | 5.92e-01 | 8.94e-01 | 0.2140 | 6.48e-02 | -4.11e-02 | -2.00e-01 | -6.95e-03 | -2.80e-03 | 7.83e-01 | 8.62e-01 | 3.97e-01 | 9.76e-01 | 9.91e-01 |
| RESPONSE TO PH | 41 | 2.93e-02 | 2.14e-01 | 0.2140 | -1.38e-01 | 1.74e-02 | -6.65e-03 | -1.51e-01 | 5.85e-02 | 1.26e-01 | 8.47e-01 | 9.41e-01 | 9.33e-02 | 5.17e-01 |
| CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 149 | 5.61e-02 | 3.13e-01 | 0.2140 | 9.89e-02 | 7.95e-02 | 8.48e-02 | 1.42e-01 | 4.91e-02 | 3.72e-02 | 9.40e-02 | 7.39e-02 | 2.83e-03 | 3.01e-01 |
| NEURON INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OXIDATIVE STRESS | 20 | 9.53e-01 | 9.94e-01 | 0.2140 | 7.91e-02 | 6.31e-02 | 1.05e-01 | 1.18e-01 | 1.04e-01 | 5.41e-01 | 6.25e-01 | 4.18e-01 | 3.63e-01 | 4.21e-01 |
| ENDOSOMAL TRANSPORT | 242 | 3.84e-02 | 2.54e-01 | 0.2140 | 1.12e-01 | 9.76e-02 | 8.81e-02 | 1.22e-01 | 3.17e-02 | 2.71e-03 | 8.91e-03 | 1.82e-02 | 1.05e-03 | 3.96e-01 |
| REGULATION OF COLLAGEN METABOLIC PROCESS | 41 | 4.54e-01 | 8.22e-01 | 0.2140 | 1.09e-01 | 9.82e-02 | 6.06e-02 | 1.05e-01 | -9.72e-02 | 2.25e-01 | 2.77e-01 | 5.02e-01 | 2.46e-01 | 2.82e-01 |
| REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 218 | 9.91e-03 | 1.01e-01 | 0.2140 | 1.30e-01 | 9.87e-02 | 6.40e-02 | 1.13e-01 | 4.83e-02 | 9.56e-04 | 1.20e-02 | 1.04e-01 | 4.16e-03 | 2.19e-01 |
| REGULATION OF SYNCYTIUM FORMATION BY PLASMA MEMBRANE FUSION | 30 | 2.17e-01 | 6.13e-01 | 0.2140 | 1.27e-01 | 2.63e-02 | -8.04e-02 | 5.39e-02 | -1.40e-01 | 2.29e-01 | 8.03e-01 | 4.46e-01 | 6.09e-01 | 1.85e-01 |
| POSITIVE REGULATION OF SEQUESTERING OF CALCIUM ION | 15 | 5.80e-01 | 8.87e-01 | 0.2140 | -1.13e-01 | -1.64e-01 | -6.83e-02 | 2.43e-02 | 2.59e-02 | 4.48e-01 | 2.71e-01 | 6.47e-01 | 8.71e-01 | 8.62e-01 |
| RENAL SYSTEM VASCULATURE MORPHOGENESIS | 8 | 9.11e-01 | 9.85e-01 | 0.2140 | 8.16e-02 | 3.51e-02 | 7.14e-02 | 3.51e-02 | 1.77e-01 | 6.89e-01 | 8.63e-01 | 7.26e-01 | 8.64e-01 | 3.85e-01 |
| NEGATIVE REGULATION OF RUFFLE ASSEMBLY | 7 | 4.06e-01 | 7.93e-01 | 0.2140 | -1.29e-01 | -4.04e-02 | 8.43e-02 | 1.37e-01 | -3.93e-02 | 5.53e-01 | 8.53e-01 | 6.99e-01 | 5.31e-01 | 8.57e-01 |
| POSITIVE REGULATION OF PROTEIN TARGETING TO MEMBRANE | 27 | 3.27e-01 | 7.35e-01 | 0.2140 | -8.61e-02 | 3.42e-02 | 5.83e-02 | -2.25e-02 | 1.82e-01 | 4.39e-01 | 7.58e-01 | 6.00e-01 | 8.40e-01 | 1.01e-01 |
| RESPIRATORY SYSTEM DEVELOPMENT | 207 | 1.45e-02 | 1.33e-01 | 0.2140 | 3.49e-02 | 6.30e-02 | 1.11e-01 | 9.78e-02 | 1.36e-01 | 3.86e-01 | 1.18e-01 | 5.85e-03 | 1.53e-02 | 7.21e-04 |
| REGULATION OF GLYCOGEN CATABOLIC PROCESS | 7 | 9.64e-01 | 9.94e-01 | 0.2140 | 4.97e-02 | 3.03e-02 | 1.38e-01 | 1.39e-01 | 6.32e-02 | 8.20e-01 | 8.90e-01 | 5.28e-01 | 5.25e-01 | 7.72e-01 |
| NEGATIVE REGULATION OF FIBRINOLYSIS | 13 | 8.55e-01 | 9.76e-01 | 0.2140 | 9.21e-02 | 1.34e-01 | 4.52e-02 | 6.02e-02 | -1.16e-01 | 5.65e-01 | 4.02e-01 | 7.78e-01 | 7.07e-01 | 4.69e-01 |
| AMINO ACID BIOSYNTHETIC PROCESS | 74 | 1.33e-02 | 1.24e-01 | 0.2140 | 5.02e-02 | 4.34e-02 | 4.56e-02 | 1.31e-01 | 1.48e-01 | 4.55e-01 | 5.19e-01 | 4.97e-01 | 5.06e-02 | 2.79e-02 |
| REGULATION OF PROTEIN IMPORT INTO NUCLEUS | 57 | 3.46e-01 | 7.50e-01 | 0.2130 | 1.28e-01 | 5.31e-02 | 8.16e-02 | 1.39e-01 | 2.17e-02 | 9.57e-02 | 4.88e-01 | 2.87e-01 | 6.92e-02 | 7.77e-01 |
| NEGATIVE REGULATION OF LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 15 | 3.74e-01 | 7.73e-01 | 0.2130 | -4.43e-02 | 6.52e-02 | 1.20e-01 | 1.44e-01 | 6.43e-02 | 7.66e-01 | 6.62e-01 | 4.21e-01 | 3.34e-01 | 6.66e-01 |
| REGULATION OF GLYCOGEN BIOSYNTHETIC PROCESS | 30 | 5.51e-01 | 8.75e-01 | 0.2130 | -1.22e-01 | -9.09e-02 | -4.01e-02 | -6.01e-02 | 1.31e-01 | 2.47e-01 | 3.89e-01 | 7.04e-01 | 5.69e-01 | 2.15e-01 |
| NEGATIVE REGULATION OF DOPAMINE SECRETION | 5 | 9.71e-01 | 9.95e-01 | 0.2130 | -1.08e-01 | -6.80e-02 | -7.22e-02 | -8.21e-02 | 1.31e-01 | 6.76e-01 | 7.92e-01 | 7.80e-01 | 7.51e-01 | 6.11e-01 |
| MALATE METABOLIC PROCESS | 9 | 9.83e-01 | 9.96e-01 | 0.2130 | 1.10e-01 | 1.32e-01 | 7.34e-02 | 9.85e-02 | -3.06e-02 | 5.69e-01 | 4.92e-01 | 7.03e-01 | 6.09e-01 | 8.74e-01 |
| POSITIVE REGULATION OF PLATELET ACTIVATION | 9 | 5.86e-01 | 8.91e-01 | 0.2130 | 1.19e-02 | -1.41e-03 | -1.92e-01 | -5.98e-02 | -6.93e-02 | 9.51e-01 | 9.94e-01 | 3.18e-01 | 7.56e-01 | 7.19e-01 |
| REGULATION OF ALPHA BETA T CELL ACTIVATION | 109 | 1.10e-01 | 4.53e-01 | 0.2130 | 5.10e-02 | 6.68e-02 | 1.15e-01 | 1.35e-01 | 8.32e-02 | 3.57e-01 | 2.28e-01 | 3.72e-02 | 1.51e-02 | 1.33e-01 |
| NEGATIVE REGULATION OF HEMOPOIESIS | 115 | 4.32e-01 | 8.06e-01 | 0.2130 | 1.01e-01 | 8.48e-02 | 1.03e-01 | 1.10e-01 | 7.25e-02 | 6.03e-02 | 1.16e-01 | 5.52e-02 | 4.25e-02 | 1.79e-01 |
| C21 STEROID HORMONE BIOSYNTHETIC PROCESS | 20 | 6.64e-01 | 9.23e-01 | 0.2130 | 1.79e-02 | 9.35e-02 | 1.63e-01 | 5.46e-02 | 8.30e-02 | 8.90e-01 | 4.69e-01 | 2.08e-01 | 6.72e-01 | 5.21e-01 |
| DETECTION OF TEMPERATURE STIMULUS INVOLVED IN SENSORY PERCEPTION OF PAIN | 17 | 4.92e-01 | 8.42e-01 | 0.2130 | -8.13e-02 | 4.83e-02 | 1.05e-01 | -4.71e-02 | 1.52e-01 | 5.62e-01 | 7.30e-01 | 4.53e-01 | 7.36e-01 | 2.77e-01 |
| CYCLIC NUCLEOTIDE BIOSYNTHETIC PROCESS | 20 | 8.53e-01 | 9.76e-01 | 0.2130 | -1.01e-01 | -3.63e-02 | -8.45e-02 | -1.30e-01 | -9.87e-02 | 4.35e-01 | 7.79e-01 | 5.13e-01 | 3.13e-01 | 4.45e-01 |
| T CELL MEDIATED IMMUNITY | 123 | 5.32e-02 | 3.05e-01 | 0.2130 | 5.79e-02 | 8.19e-02 | 1.08e-01 | 1.39e-01 | 6.52e-02 | 2.67e-01 | 1.17e-01 | 3.89e-02 | 7.62e-03 | 2.12e-01 |
| POSITIVE REGULATION OF T CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 5 | 8.21e-01 | 9.71e-01 | 0.2130 | -1.18e-01 | -5.08e-02 | 4.32e-02 | -1.09e-01 | -1.22e-01 | 6.47e-01 | 8.44e-01 | 8.67e-01 | 6.73e-01 | 6.35e-01 |
| PHOSPHATIDYLETHANOLAMINE ACYL CHAIN REMODELING | 11 | 7.85e-01 | 9.61e-01 | 0.2130 | 5.01e-02 | -1.11e-03 | -1.11e-02 | -1.36e-02 | -2.06e-01 | 7.73e-01 | 9.95e-01 | 9.49e-01 | 9.38e-01 | 2.37e-01 |
| REGULATION OF EXTRACELLULAR MATRIX DISASSEMBLY | 15 | 5.01e-01 | 8.48e-01 | 0.2130 | -1.67e-01 | -1.04e-01 | -1.91e-02 | -1.93e-02 | -7.81e-02 | 2.64e-01 | 4.88e-01 | 8.98e-01 | 8.97e-01 | 6.00e-01 |
| PYRIMIDINE NUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 23 | 4.99e-01 | 8.47e-01 | 0.2130 | 8.89e-03 | 3.83e-02 | 4.00e-02 | 7.20e-02 | 1.92e-01 | 9.41e-01 | 7.50e-01 | 7.40e-01 | 5.50e-01 | 1.10e-01 |
| NEGATIVE REGULATION OF NEUROBLAST PROLIFERATION | 11 | 7.74e-01 | 9.57e-01 | 0.2130 | -1.05e-01 | -1.13e-01 | 6.00e-02 | 1.47e-02 | 1.33e-01 | 5.45e-01 | 5.18e-01 | 7.30e-01 | 9.33e-01 | 4.46e-01 |
| STEROL TRANSPORT | 141 | 5.73e-02 | 3.16e-01 | 0.2130 | -5.68e-02 | -6.07e-02 | -1.01e-01 | -6.86e-02 | -1.53e-01 | 2.45e-01 | 2.13e-01 | 3.79e-02 | 1.59e-01 | 1.74e-03 |
| REGULATION OF WNT SIGNALING PATHWAY PLANAR CELL POLARITY PATHWAY | 15 | 1.85e-01 | 5.72e-01 | 0.2130 | 2.98e-02 | 6.04e-03 | -2.32e-02 | 1.49e-01 | 1.46e-01 | 8.42e-01 | 9.68e-01 | 8.76e-01 | 3.16e-01 | 3.27e-01 |
| CELLULAR RESPONSE TO LIPOPROTEIN PARTICLE STIMULUS | 41 | 3.69e-01 | 7.69e-01 | 0.2130 | 1.33e-01 | 1.40e-01 | 2.07e-02 | 5.87e-02 | -6.43e-02 | 1.41e-01 | 1.22e-01 | 8.19e-01 | 5.16e-01 | 4.76e-01 |
| PHOSPHATIDYLSERINE EXPOSURE ON APOPTOTIC CELL SURFACE | 8 | 9.78e-01 | 9.96e-01 | 0.2120 | 2.18e-02 | 6.87e-02 | 1.44e-01 | 9.24e-02 | 1.03e-01 | 9.15e-01 | 7.37e-01 | 4.80e-01 | 6.51e-01 | 6.14e-01 |
| PROTEIN DEACETYLATION | 51 | 2.44e-01 | 6.48e-01 | 0.2120 | 6.18e-02 | 5.32e-02 | 5.53e-02 | 9.70e-02 | 1.61e-01 | 4.45e-01 | 5.11e-01 | 4.95e-01 | 2.31e-01 | 4.62e-02 |
| CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 54 | 1.18e-01 | 4.69e-01 | 0.2120 | -1.57e-02 | 4.15e-02 | 5.45e-02 | 3.98e-02 | 1.97e-01 | 8.42e-01 | 5.98e-01 | 4.89e-01 | 6.13e-01 | 1.25e-02 |
| KERATINOCYTE DEVELOPMENT | 13 | 6.30e-01 | 9.10e-01 | 0.2120 | -1.66e-01 | -1.24e-02 | -5.79e-02 | -1.06e-01 | -5.07e-02 | 2.99e-01 | 9.38e-01 | 7.18e-01 | 5.06e-01 | 7.52e-01 |
| POSITIVE REGULATION OF DNA REPLICATION | 37 | 3.21e-01 | 7.32e-01 | 0.2120 | 3.56e-02 | -1.74e-02 | 1.13e-01 | 1.01e-01 | 1.44e-01 | 7.08e-01 | 8.54e-01 | 2.36e-01 | 2.89e-01 | 1.30e-01 |
| MODULATION BY HOST OF VIRAL GENOME REPLICATION | 23 | 3.45e-01 | 7.50e-01 | 0.2120 | 1.42e-03 | -6.68e-02 | 6.08e-03 | 2.04e-02 | 2.00e-01 | 9.91e-01 | 5.79e-01 | 9.60e-01 | 8.65e-01 | 9.61e-02 |
| EPITHELIAL CELL DIFFERENTIATION INVOLVED IN PROSTATE GLAND DEVELOPMENT | 10 | 6.02e-01 | 9.00e-01 | 0.2120 | -7.39e-03 | 9.50e-02 | 1.59e-01 | 8.63e-02 | -5.84e-02 | 9.68e-01 | 6.03e-01 | 3.85e-01 | 6.37e-01 | 7.49e-01 |
| POTASSIUM ION IMPORT ACROSS PLASMA MEMBRANE | 46 | 1.38e-01 | 5.02e-01 | 0.2120 | -1.35e-01 | -6.43e-02 | -1.33e-02 | -1.45e-01 | 3.68e-02 | 1.13e-01 | 4.50e-01 | 8.76e-01 | 8.84e-02 | 6.66e-01 |
| MRNA CATABOLIC PROCESS | 295 | 6.43e-05 | 1.92e-03 | 0.2120 | 7.98e-02 | 3.58e-02 | 9.21e-02 | 1.36e-01 | 1.01e-01 | 1.83e-02 | 2.90e-01 | 6.51e-03 | 5.64e-05 | 2.79e-03 |
| CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 85 | 5.56e-01 | 8.77e-01 | 0.2120 | 1.01e-01 | 1.12e-01 | 9.82e-02 | 8.24e-02 | 7.46e-02 | 1.06e-01 | 7.34e-02 | 1.18e-01 | 1.89e-01 | 2.34e-01 |
| POSITIVE REGULATION OF STRESS FIBER ASSEMBLY | 51 | 2.19e-01 | 6.16e-01 | 0.2120 | 1.20e-01 | 4.83e-02 | 4.76e-02 | 1.25e-01 | 1.01e-01 | 1.39e-01 | 5.51e-01 | 5.57e-01 | 1.22e-01 | 2.12e-01 |
| INTERLEUKIN 17 PRODUCTION | 46 | 2.95e-01 | 7.07e-01 | 0.2120 | 3.37e-02 | 1.28e-01 | 9.99e-02 | 9.36e-02 | 9.23e-02 | 6.93e-01 | 1.33e-01 | 2.41e-01 | 2.72e-01 | 2.79e-01 |
| AORTA DEVELOPMENT | 65 | 4.59e-01 | 8.23e-01 | 0.2110 | 4.47e-02 | 6.92e-02 | 1.03e-01 | 6.67e-02 | 1.51e-01 | 5.33e-01 | 3.35e-01 | 1.51e-01 | 3.52e-01 | 3.50e-02 |
| POSITIVE REGULATION OF SMOOTHENED SIGNALING PATHWAY | 36 | 7.18e-01 | 9.38e-01 | 0.2110 | 6.77e-02 | 1.37e-01 | 1.03e-01 | 7.37e-02 | 7.18e-02 | 4.82e-01 | 1.54e-01 | 2.84e-01 | 4.44e-01 | 4.56e-01 |
| POSITIVE REGULATION OF SYNAPSE ASSEMBLY | 56 | 2.08e-01 | 6.03e-01 | 0.2110 | -1.33e-01 | -5.51e-02 | -4.91e-02 | -1.45e-01 | 2.08e-02 | 8.44e-02 | 4.75e-01 | 5.25e-01 | 6.10e-02 | 7.87e-01 |
| GLIAL CELL DEVELOPMENT | 118 | 2.88e-01 | 6.96e-01 | 0.2110 | 6.57e-02 | 1.10e-01 | 1.14e-01 | 8.31e-02 | 8.99e-02 | 2.18e-01 | 3.83e-02 | 3.17e-02 | 1.19e-01 | 9.16e-02 |
| REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 278 | 3.41e-02 | 2.35e-01 | 0.2110 | 1.09e-01 | 1.06e-01 | 8.57e-02 | 1.07e-01 | 5.19e-02 | 1.78e-03 | 2.44e-03 | 1.39e-02 | 2.10e-03 | 1.36e-01 |
| POSITIVE REGULATION OF CELLULAR SENESCENCE | 17 | 2.40e-01 | 6.44e-01 | 0.2110 | 4.77e-02 | -1.16e-01 | 2.93e-02 | 1.06e-01 | 1.30e-01 | 7.34e-01 | 4.10e-01 | 8.34e-01 | 4.50e-01 | 3.54e-01 |
| ICOSANOID BIOSYNTHETIC PROCESS | 56 | 1.95e-01 | 5.82e-01 | 0.2110 | 1.42e-01 | 9.31e-02 | 8.61e-02 | 6.92e-02 | -5.84e-02 | 6.59e-02 | 2.28e-01 | 2.65e-01 | 3.70e-01 | 4.49e-01 |
| REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 32 | 7.88e-01 | 9.63e-01 | 0.2110 | 1.36e-01 | 1.12e-01 | 5.31e-02 | 1.02e-01 | 1.87e-02 | 1.84e-01 | 2.73e-01 | 6.03e-01 | 3.19e-01 | 8.55e-01 |
| POSITIVE REGULATION OF CHOLESTEROL EFFLUX | 27 | 7.87e-01 | 9.63e-01 | 0.2110 | -7.91e-02 | -8.73e-02 | -1.04e-01 | -1.40e-01 | -7.96e-03 | 4.77e-01 | 4.32e-01 | 3.51e-01 | 2.06e-01 | 9.43e-01 |
| TELOMERE MAINTENANCE VIA RECOMBINATION | 14 | 6.63e-01 | 9.22e-01 | 0.2110 | 6.75e-02 | 4.62e-03 | 2.40e-02 | 1.24e-01 | 1.55e-01 | 6.62e-01 | 9.76e-01 | 8.77e-01 | 4.22e-01 | 3.17e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO CHROMATIN | 9 | 8.22e-01 | 9.71e-01 | 0.2110 | -2.42e-02 | 6.73e-02 | 1.23e-01 | -3.41e-02 | 1.51e-01 | 9.00e-01 | 7.27e-01 | 5.21e-01 | 8.59e-01 | 4.31e-01 |
| REGULATION OF CYTOKINESIS | 87 | 5.99e-02 | 3.24e-01 | 0.2110 | 6.68e-02 | 2.17e-02 | 1.09e-01 | 1.48e-01 | 7.63e-02 | 2.82e-01 | 7.27e-01 | 7.96e-02 | 1.71e-02 | 2.19e-01 |
| REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 43 | 1.01e-01 | 4.32e-01 | 0.2110 | -1.42e-01 | -9.65e-02 | -1.13e-01 | -3.48e-02 | -2.93e-02 | 1.07e-01 | 2.73e-01 | 1.99e-01 | 6.93e-01 | 7.40e-01 |
| INTRACELLULAR TRIGLYCERIDE HOMEOSTASIS | 7 | 8.82e-01 | 9.79e-01 | 0.2100 | -1.90e-02 | -1.67e-02 | -7.66e-02 | 3.12e-02 | -1.92e-01 | 9.31e-01 | 9.39e-01 | 7.26e-01 | 8.86e-01 | 3.80e-01 |
| MATURE B CELL DIFFERENTIATION INVOLVED IN IMMUNE RESPONSE | 30 | 3.35e-01 | 7.40e-01 | 0.2100 | 1.28e-01 | 1.27e-01 | 1.55e-02 | 9.31e-02 | 5.47e-02 | 2.27e-01 | 2.30e-01 | 8.83e-01 | 3.78e-01 | 6.04e-01 |
| PURINE RIBONUCLEOSIDE METABOLIC PROCESS | 20 | 4.73e-01 | 8.31e-01 | 0.2100 | 1.87e-01 | 6.90e-02 | 2.57e-02 | 5.75e-02 | -2.58e-02 | 1.49e-01 | 5.93e-01 | 8.42e-01 | 6.56e-01 | 8.41e-01 |
| EXTRACELLULAR TRANSPORT | 45 | 2.04e-02 | 1.69e-01 | 0.2100 | -3.25e-02 | -7.57e-02 | -8.54e-02 | -1.70e-01 | 3.42e-02 | 7.06e-01 | 3.79e-01 | 3.22e-01 | 4.86e-02 | 6.91e-01 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE CONTRACTION | 7 | 9.53e-01 | 9.94e-01 | 0.2100 | 1.37e-01 | 1.25e-01 | 8.09e-04 | 8.29e-02 | -5.33e-02 | 5.31e-01 | 5.66e-01 | 9.97e-01 | 7.04e-01 | 8.07e-01 |
| ORGANONITROGEN COMPOUND CATABOLIC PROCESS | 1269 | 4.72e-13 | 5.36e-11 | 0.2100 | 9.34e-02 | 8.28e-02 | 8.51e-02 | 1.23e-01 | 7.85e-02 | 2.19e-08 | 6.90e-07 | 3.40e-07 | 1.74e-13 | 2.51e-06 |
| POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 140 | 1.00e-01 | 4.30e-01 | 0.2100 | 9.36e-02 | 6.54e-02 | 9.69e-02 | 1.38e-01 | 5.13e-02 | 5.58e-02 | 1.82e-01 | 4.78e-02 | 4.83e-03 | 2.95e-01 |
| REGULATION OF SKELETAL MUSCLE ADAPTATION | 14 | 2.34e-01 | 6.36e-01 | 0.2100 | -3.81e-02 | 1.17e-01 | 1.07e-01 | -1.11e-01 | 7.14e-02 | 8.05e-01 | 4.49e-01 | 4.88e-01 | 4.70e-01 | 6.44e-01 |
| ENDOMEMBRANE SYSTEM ORGANIZATION | 568 | 1.19e-04 | 3.15e-03 | 0.2100 | 8.14e-02 | 8.67e-02 | 1.07e-01 | 1.20e-01 | 6.44e-02 | 9.07e-04 | 4.10e-04 | 1.38e-05 | 1.03e-06 | 8.72e-03 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS | 23 | 4.72e-01 | 8.30e-01 | 0.2100 | -1.72e-01 | -1.10e-01 | -3.78e-02 | -2.98e-02 | 5.90e-03 | 1.53e-01 | 3.61e-01 | 7.54e-01 | 8.05e-01 | 9.61e-01 |
| POSITIVE REGULATION OF CORTICOSTEROID HORMONE SECRETION | 7 | 4.50e-01 | 8.20e-01 | 0.2100 | 3.09e-02 | 8.04e-02 | -3.26e-02 | 1.44e-01 | 1.22e-01 | 8.87e-01 | 7.13e-01 | 8.81e-01 | 5.10e-01 | 5.77e-01 |
| CATECHOL CONTAINING COMPOUND METABOLIC PROCESS | 50 | 1.97e-01 | 5.85e-01 | 0.2100 | 1.85e-02 | 7.16e-02 | 1.33e-01 | 1.89e-02 | 1.43e-01 | 8.21e-01 | 3.81e-01 | 1.04e-01 | 8.17e-01 | 8.03e-02 |
| SODIUM ION TRANSPORT | 235 | 4.67e-03 | 5.84e-02 | 0.2100 | -9.82e-02 | -6.88e-02 | -9.23e-02 | -1.42e-01 | -3.14e-02 | 9.51e-03 | 6.92e-02 | 1.48e-02 | 1.84e-04 | 4.07e-01 |
| GASTRULATION | 188 | 2.19e-02 | 1.77e-01 | 0.2100 | 3.83e-02 | 6.86e-02 | 9.93e-02 | 9.86e-02 | 1.35e-01 | 3.65e-01 | 1.05e-01 | 1.89e-02 | 1.97e-02 | 1.43e-03 |
| BIOLOGICAL PROCESS INVOLVED IN SYMBIOTIC INTERACTION | 310 | 2.93e-03 | 4.10e-02 | 0.2100 | 1.30e-01 | 9.61e-02 | 8.23e-02 | 9.12e-02 | 5.19e-02 | 8.23e-05 | 3.62e-03 | 1.27e-02 | 5.75e-03 | 1.16e-01 |
| REGULATION OF GLYCOGEN METABOLIC PROCESS | 36 | 4.17e-01 | 7.99e-01 | 0.2100 | -1.09e-01 | -7.77e-02 | -1.39e-02 | -4.83e-02 | 1.53e-01 | 2.57e-01 | 4.20e-01 | 8.85e-01 | 6.16e-01 | 1.12e-01 |
| SEMAPHORIN PLEXIN SIGNALING PATHWAY | 41 | 5.28e-01 | 8.60e-01 | 0.2100 | -1.35e-01 | -5.77e-02 | -9.37e-02 | -1.15e-01 | -2.08e-02 | 1.34e-01 | 5.23e-01 | 2.99e-01 | 2.04e-01 | 8.18e-01 |
| RESPONSE TO CGMP | 8 | 8.71e-01 | 9.78e-01 | 0.2100 | -6.14e-02 | -9.31e-02 | 4.60e-02 | 7.95e-02 | 1.52e-01 | 7.64e-01 | 6.49e-01 | 8.22e-01 | 6.97e-01 | 4.57e-01 |
| GLUCOSE CATABOLIC PROCESS | 25 | 5.46e-02 | 3.09e-01 | 0.2090 | -3.17e-03 | 1.74e-01 | 7.75e-02 | -7.63e-02 | 4.00e-02 | 9.78e-01 | 1.31e-01 | 5.02e-01 | 5.09e-01 | 7.29e-01 |
| CARDIOLIPIN BIOSYNTHETIC PROCESS | 7 | 8.53e-01 | 9.76e-01 | 0.2090 | 1.04e-01 | 4.10e-02 | 4.67e-02 | 8.84e-03 | 1.71e-01 | 6.35e-01 | 8.51e-01 | 8.31e-01 | 9.68e-01 | 4.34e-01 |
| REGULATION OF THE FORCE OF HEART CONTRACTION BY CHEMICAL SIGNAL | 6 | 9.04e-01 | 9.84e-01 | 0.2090 | -9.17e-02 | 1.20e-04 | -1.52e-02 | -1.40e-01 | 1.25e-01 | 6.97e-01 | 1.00e+00 | 9.49e-01 | 5.52e-01 | 5.97e-01 |
| REGULATION OF PIGMENTATION | 17 | 6.58e-01 | 9.20e-01 | 0.2090 | -5.40e-02 | -6.19e-02 | -1.68e-02 | -2.60e-02 | 1.90e-01 | 7.00e-01 | 6.59e-01 | 9.04e-01 | 8.53e-01 | 1.75e-01 |
| NEGATIVE REGULATION OF GENE EXPRESSION EPIGENETIC | 107 | 1.81e-02 | 1.57e-01 | 0.2090 | 1.24e-01 | 4.74e-02 | 5.04e-02 | 1.36e-01 | 7.22e-02 | 2.68e-02 | 3.97e-01 | 3.67e-01 | 1.52e-02 | 1.97e-01 |
| DENDRITIC CELL DIFFERENTIATION | 45 | 4.34e-01 | 8.08e-01 | 0.2090 | -8.45e-02 | -3.98e-02 | -1.18e-01 | -1.40e-01 | -4.04e-02 | 3.27e-01 | 6.45e-01 | 1.72e-01 | 1.05e-01 | 6.39e-01 |
| INTERLEUKIN 17A MEDIATED SIGNALING PATHWAY | 6 | 8.35e-01 | 9.73e-01 | 0.2090 | -1.72e-02 | 5.97e-02 | -1.04e-01 | -1.65e-01 | -4.21e-02 | 9.42e-01 | 8.00e-01 | 6.60e-01 | 4.83e-01 | 8.58e-01 |
| POST EMBRYONIC ANIMAL MORPHOGENESIS | 16 | 4.79e-01 | 8.34e-01 | 0.2090 | 5.72e-02 | 1.84e-03 | -7.87e-02 | -1.27e-01 | -1.35e-01 | 6.92e-01 | 9.90e-01 | 5.86e-01 | 3.80e-01 | 3.51e-01 |
| CELLULAR RESPONSE TO POTASSIUM ION | 12 | 4.37e-01 | 8.10e-01 | 0.2090 | -1.30e-01 | -1.11e-01 | 4.12e-02 | -9.16e-02 | -6.75e-02 | 4.36e-01 | 5.07e-01 | 8.05e-01 | 5.83e-01 | 6.86e-01 |
| REGULATION OF CELL MATURATION | 20 | 4.88e-01 | 8.39e-01 | 0.2090 | 8.20e-02 | 4.11e-02 | 1.64e-02 | 8.19e-02 | 1.68e-01 | 5.25e-01 | 7.51e-01 | 8.99e-01 | 5.26e-01 | 1.93e-01 |
| REGULATION OF MICROTUBULE CYTOSKELETON ORGANIZATION | 155 | 2.31e-01 | 6.33e-01 | 0.2090 | 7.67e-02 | 7.81e-02 | 1.02e-01 | 1.06e-01 | 1.01e-01 | 9.95e-02 | 9.32e-02 | 2.91e-02 | 2.32e-02 | 2.96e-02 |
| REGULATION OF PROTEIN LOCALIZATION TO ENDOSOME | 12 | 4.60e-01 | 8.23e-01 | 0.2090 | 7.87e-03 | -1.37e-01 | -1.56e-01 | 3.72e-03 | 1.84e-02 | 9.62e-01 | 4.11e-01 | 3.48e-01 | 9.82e-01 | 9.12e-01 |
| DEVELOPMENTAL PIGMENTATION | 47 | 4.68e-01 | 8.28e-01 | 0.2090 | -5.89e-02 | -1.20e-01 | -1.22e-01 | -1.04e-01 | -1.00e-02 | 4.84e-01 | 1.56e-01 | 1.48e-01 | 2.16e-01 | 9.06e-01 |
| LONG TERM SYNAPTIC DEPRESSION | 30 | 5.73e-02 | 3.16e-01 | 0.2090 | 5.56e-03 | 1.71e-01 | 5.85e-02 | -2.07e-02 | 1.03e-01 | 9.58e-01 | 1.05e-01 | 5.79e-01 | 8.45e-01 | 3.30e-01 |
| CELLULAR RESPONSE TO GONADOTROPIN RELEASING HORMONE | 5 | 9.54e-01 | 9.94e-01 | 0.2090 | 1.74e-01 | 1.06e-01 | -9.83e-03 | 3.06e-02 | -3.56e-02 | 5.01e-01 | 6.82e-01 | 9.70e-01 | 9.06e-01 | 8.90e-01 |
| NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 11 | 9.37e-01 | 9.92e-01 | 0.2090 | 1.48e-01 | 9.10e-02 | 1.96e-02 | 1.03e-01 | -5.09e-02 | 3.97e-01 | 6.01e-01 | 9.10e-01 | 5.55e-01 | 7.70e-01 |
| AXONAL FASCICULATION | 21 | 9.54e-01 | 9.94e-01 | 0.2090 | -1.03e-01 | -1.15e-01 | -9.77e-02 | -7.26e-02 | -6.99e-02 | 4.12e-01 | 3.62e-01 | 4.38e-01 | 5.64e-01 | 5.79e-01 |
| NON MOTILE CILIUM ASSEMBLY | 63 | 2.52e-01 | 6.58e-01 | 0.2090 | 1.06e-01 | 9.07e-02 | 6.16e-02 | 1.42e-01 | -1.29e-02 | 1.46e-01 | 2.13e-01 | 3.98e-01 | 5.11e-02 | 8.59e-01 |
| EMBRYONIC PATTERN SPECIFICATION | 69 | 5.91e-01 | 8.94e-01 | 0.2090 | 7.65e-02 | 1.23e-01 | 1.09e-01 | 7.99e-02 | 6.48e-02 | 2.72e-01 | 7.72e-02 | 1.16e-01 | 2.51e-01 | 3.52e-01 |
| RESPONSE TO AUDITORY STIMULUS | 31 | 9.01e-01 | 9.83e-01 | 0.2090 | -1.24e-01 | -9.10e-02 | -9.33e-02 | -1.04e-01 | -1.97e-02 | 2.33e-01 | 3.81e-01 | 3.69e-01 | 3.16e-01 | 8.49e-01 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 45 | 2.13e-01 | 6.08e-01 | 0.2090 | -1.85e-02 | 2.21e-02 | -5.33e-02 | -8.40e-02 | -1.81e-01 | 8.30e-01 | 7.97e-01 | 5.36e-01 | 3.30e-01 | 3.56e-02 |
| POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL PROLIFERATION INVOLVED IN SPROUTING ANGIOGENESIS | 21 | 3.85e-01 | 7.79e-01 | 0.2080 | -1.30e-01 | -1.45e-01 | 7.77e-03 | 2.75e-02 | 6.87e-02 | 3.04e-01 | 2.49e-01 | 9.51e-01 | 8.27e-01 | 5.86e-01 |
| HINDBRAIN TANGENTIAL CELL MIGRATION | 5 | 8.06e-01 | 9.67e-01 | 0.2080 | -1.15e-01 | 7.69e-02 | 2.55e-02 | -1.50e-01 | -3.46e-02 | 6.56e-01 | 7.66e-01 | 9.21e-01 | 5.62e-01 | 8.93e-01 |
| DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS | 217 | 3.28e-02 | 2.30e-01 | 0.2080 | 9.66e-02 | 1.05e-01 | 8.60e-02 | 7.87e-02 | 9.70e-02 | 1.42e-02 | 7.48e-03 | 2.89e-02 | 4.57e-02 | 1.38e-02 |
| VIRAL TRANSLATIONAL TERMINATION REINITIATION | 5 | 6.78e-01 | 9.28e-01 | 0.2080 | -6.78e-02 | -8.02e-02 | 1.68e-01 | 6.06e-02 | 2.16e-02 | 7.93e-01 | 7.56e-01 | 5.15e-01 | 8.15e-01 | 9.33e-01 |
| POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 74 | 3.22e-01 | 7.33e-01 | 0.2080 | 7.54e-02 | 4.85e-02 | 9.39e-02 | 8.23e-02 | 1.41e-01 | 2.62e-01 | 4.71e-01 | 1.63e-01 | 2.21e-01 | 3.65e-02 |
| NEGATIVE REGULATION OF PHOSPHORYLATION | 321 | 8.69e-03 | 9.22e-02 | 0.2080 | 8.82e-02 | 8.19e-02 | 9.01e-02 | 1.00e-01 | 1.04e-01 | 6.58e-03 | 1.17e-02 | 5.49e-03 | 2.07e-03 | 1.37e-03 |
| POSITIVE REGULATION OF CELL PROLIFERATION INVOLVED IN KIDNEY DEVELOPMENT | 9 | 9.86e-01 | 9.97e-01 | 0.2080 | 6.92e-02 | 6.49e-02 | 1.15e-01 | 1.34e-01 | 5.68e-02 | 7.19e-01 | 7.36e-01 | 5.50e-01 | 4.87e-01 | 7.68e-01 |
| EPITHELIAL CELL FATE COMMITMENT | 14 | 9.13e-01 | 9.85e-01 | 0.2080 | 1.75e-02 | 1.48e-02 | 1.23e-01 | 9.54e-02 | 1.37e-01 | 9.10e-01 | 9.24e-01 | 4.26e-01 | 5.37e-01 | 3.76e-01 |
| REGULATION OF ENDOSOME ORGANIZATION | 5 | 9.25e-01 | 9.89e-01 | 0.2080 | 1.41e-02 | -1.12e-01 | -1.48e-01 | -9.33e-02 | -4.76e-03 | 9.57e-01 | 6.64e-01 | 5.67e-01 | 7.18e-01 | 9.85e-01 |
| REGULATION OF FIBRINOLYSIS | 18 | 6.73e-01 | 9.27e-01 | 0.2080 | -1.30e-02 | 3.03e-02 | -3.88e-02 | -4.98e-02 | -1.95e-01 | 9.24e-01 | 8.24e-01 | 7.76e-01 | 7.14e-01 | 1.51e-01 |
| REGULATION OF EMBRYONIC DEVELOPMENT | 89 | 1.12e-01 | 4.56e-01 | 0.2080 | 9.48e-02 | 1.20e-01 | 6.02e-02 | 1.04e-01 | 7.36e-02 | 1.22e-01 | 4.97e-02 | 3.26e-01 | 9.07e-02 | 2.30e-01 |
| POSITIVE REGULATION OF FILOPODIUM ASSEMBLY | 28 | 8.18e-01 | 9.70e-01 | 0.2080 | -1.15e-01 | -1.26e-01 | -9.28e-02 | -5.28e-02 | -5.22e-02 | 2.92e-01 | 2.50e-01 | 3.96e-01 | 6.29e-01 | 6.33e-01 |
| NEGATIVE REGULATION OF ASTROCYTE DIFFERENTIATION | 15 | 8.59e-01 | 9.78e-01 | 0.2080 | 4.00e-02 | 2.81e-02 | 5.87e-02 | 5.68e-02 | 1.84e-01 | 7.88e-01 | 8.51e-01 | 6.94e-01 | 7.03e-01 | 2.16e-01 |
| POSITIVE REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT | 8 | 5.38e-01 | 8.66e-01 | 0.2070 | 1.56e-01 | -1.90e-02 | -9.21e-03 | 3.23e-02 | 1.30e-01 | 4.45e-01 | 9.26e-01 | 9.64e-01 | 8.74e-01 | 5.23e-01 |
| NEGATIVE REGULATION OF CHOLESTEROL METABOLIC PROCESS | 10 | 4.66e-01 | 8.26e-01 | 0.2070 | 4.91e-02 | 1.65e-01 | -5.73e-02 | -1.46e-03 | -9.99e-02 | 7.88e-01 | 3.67e-01 | 7.54e-01 | 9.94e-01 | 5.84e-01 |
| NUCLEOSIDE DIPHOSPHATE CATABOLIC PROCESS | 12 | 6.60e-01 | 9.21e-01 | 0.2070 | -1.73e-01 | -6.69e-02 | -2.19e-02 | -1.62e-02 | 8.75e-02 | 2.99e-01 | 6.88e-01 | 8.96e-01 | 9.22e-01 | 6.00e-01 |
| MICROTUBULE ORGANIZING CENTER ORGANIZATION | 150 | 5.03e-02 | 2.93e-01 | 0.2070 | 1.11e-01 | 6.80e-02 | 8.73e-02 | 1.35e-01 | 5.75e-03 | 1.86e-02 | 1.51e-01 | 6.49e-02 | 4.41e-03 | 9.03e-01 |
| GLOMERULAR MESANGIAL CELL PROLIFERATION | 13 | 9.23e-01 | 9.88e-01 | 0.2070 | 6.87e-02 | 1.17e-01 | 1.28e-01 | 8.80e-02 | -1.73e-02 | 6.68e-01 | 4.64e-01 | 4.26e-01 | 5.83e-01 | 9.14e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 33 | 7.03e-01 | 9.32e-01 | 0.2070 | -1.13e-01 | -5.22e-02 | -8.27e-02 | -9.77e-02 | -1.04e-01 | 2.59e-01 | 6.04e-01 | 4.11e-01 | 3.31e-01 | 3.03e-01 |
| MEIOTIC CHROMOSOME SEGREGATION | 90 | 4.07e-02 | 2.61e-01 | 0.2070 | 9.00e-02 | 6.20e-02 | 1.06e-01 | 1.33e-01 | -4.27e-02 | 1.40e-01 | 3.09e-01 | 8.14e-02 | 2.96e-02 | 4.84e-01 |
| GOLGI TO ENDOSOME TRANSPORT | 17 | 2.98e-01 | 7.10e-01 | 0.2070 | 9.84e-02 | 2.06e-02 | -6.62e-02 | 1.29e-01 | -1.07e-01 | 4.82e-01 | 8.83e-01 | 6.36e-01 | 3.57e-01 | 4.45e-01 |
| APOPTOTIC DNA FRAGMENTATION | 19 | 4.92e-01 | 8.42e-01 | 0.2060 | -1.18e-01 | -1.28e-01 | -5.54e-02 | 1.90e-02 | 9.38e-02 | 3.71e-01 | 3.34e-01 | 6.76e-01 | 8.86e-01 | 4.79e-01 |
| MAMMARY GLAND MORPHOGENESIS | 42 | 1.01e-01 | 4.31e-01 | 0.2060 | 3.71e-02 | 1.71e-01 | 9.56e-02 | 5.15e-02 | -4.38e-03 | 6.77e-01 | 5.45e-02 | 2.84e-01 | 5.63e-01 | 9.61e-01 |
| XENOPHAGY | 14 | 3.13e-01 | 7.25e-01 | 0.2060 | 1.02e-01 | 9.35e-02 | -1.03e-01 | 5.98e-02 | -9.71e-02 | 5.10e-01 | 5.45e-01 | 5.07e-01 | 6.98e-01 | 5.29e-01 |
| CELL CELL ADHESION MEDIATED BY INTEGRIN | 17 | 8.29e-01 | 9.72e-01 | 0.2060 | -4.65e-02 | -7.28e-02 | -1.42e-01 | -4.30e-02 | -1.15e-01 | 7.40e-01 | 6.03e-01 | 3.12e-01 | 7.59e-01 | 4.12e-01 |
| PROTEIN ACYLATION | 134 | 2.50e-02 | 1.93e-01 | 0.2060 | 8.18e-02 | 7.50e-02 | 6.87e-02 | 1.35e-01 | 8.51e-02 | 1.02e-01 | 1.34e-01 | 1.69e-01 | 7.02e-03 | 8.89e-02 |
| MYELOID CELL DEVELOPMENT | 80 | 2.15e-01 | 6.11e-01 | 0.2060 | 8.92e-02 | 1.39e-01 | 7.82e-02 | 9.53e-02 | -4.39e-03 | 1.68e-01 | 3.16e-02 | 2.27e-01 | 1.41e-01 | 9.46e-01 |
| POSITIVE REGULATION OF MITOTIC CELL CYCLE SPINDLE ASSEMBLY CHECKPOINT | 12 | 9.19e-01 | 9.86e-01 | 0.2060 | 1.34e-02 | 9.06e-04 | 1.17e-01 | 1.03e-01 | 1.35e-01 | 9.36e-01 | 9.96e-01 | 4.84e-01 | 5.38e-01 | 4.20e-01 |
| REGULATION OF PHOSPHOLIPASE C ACTIVITY | 39 | 4.59e-01 | 8.23e-01 | 0.2060 | 4.00e-03 | -6.75e-02 | -1.42e-01 | -7.28e-02 | -1.12e-01 | 9.66e-01 | 4.66e-01 | 1.25e-01 | 4.32e-01 | 2.28e-01 |
| MONOACYLGLYCEROL CATABOLIC PROCESS | 7 | 8.65e-01 | 9.78e-01 | 0.2060 | 7.32e-02 | 1.56e-01 | 2.78e-02 | -4.52e-02 | -9.90e-02 | 7.37e-01 | 4.74e-01 | 8.99e-01 | 8.36e-01 | 6.50e-01 |
| ADAPTIVE THERMOGENESIS | 165 | 1.42e-01 | 5.08e-01 | 0.2050 | 1.13e-01 | 1.19e-01 | 7.51e-02 | 9.22e-02 | 3.25e-02 | 1.21e-02 | 8.22e-03 | 9.62e-02 | 4.10e-02 | 4.71e-01 |
| POSITIVE REGULATION OF SODIUM ION TRANSPORT | 29 | 7.75e-01 | 9.57e-01 | 0.2050 | 1.16e-01 | 1.34e-01 | 5.33e-02 | 8.63e-02 | 1.77e-02 | 2.79e-01 | 2.10e-01 | 6.20e-01 | 4.21e-01 | 8.69e-01 |
| APOLIPOPROTEIN A I MEDIATED SIGNALING PATHWAY | 7 | 7.55e-01 | 9.51e-01 | 0.2050 | 3.74e-02 | 1.11e-01 | 2.09e-02 | 1.26e-01 | -1.10e-01 | 8.64e-01 | 6.10e-01 | 9.24e-01 | 5.65e-01 | 6.13e-01 |
| POSITIVE REGULATION OF SUPEROXIDE ANION GENERATION | 16 | 6.84e-01 | 9.30e-01 | 0.2050 | 1.03e-01 | 1.64e-01 | 1.66e-02 | 3.16e-02 | -5.87e-02 | 4.77e-01 | 2.56e-01 | 9.09e-01 | 8.27e-01 | 6.84e-01 |
| GLYCOSPHINGOLIPID BIOSYNTHETIC PROCESS | 34 | 4.56e-01 | 8.22e-01 | 0.2050 | -1.15e-01 | -8.05e-02 | -3.46e-02 | -1.25e-01 | -7.48e-02 | 2.44e-01 | 4.16e-01 | 7.27e-01 | 2.08e-01 | 4.50e-01 |
| REGULATION OF SYNAPTIC ASSEMBLY AT NEUROMUSCULAR JUNCTION | 6 | 8.42e-01 | 9.75e-01 | 0.2050 | -1.67e-01 | -3.32e-02 | 5.27e-02 | 1.81e-02 | 9.91e-02 | 4.78e-01 | 8.88e-01 | 8.23e-01 | 9.39e-01 | 6.74e-01 |
| REGULATION OF NEUTROPHIL CHEMOTAXIS | 31 | 2.06e-02 | 1.70e-01 | 0.2050 | 1.76e-01 | 9.19e-02 | -3.71e-02 | -2.42e-02 | 2.59e-02 | 8.99e-02 | 3.76e-01 | 7.21e-01 | 8.15e-01 | 8.03e-01 |
| NEGATIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL ACTIVATION | 33 | 2.52e-01 | 6.58e-01 | 0.2050 | 1.39e-01 | 1.28e-02 | 3.39e-02 | 1.44e-01 | 2.67e-02 | 1.67e-01 | 8.99e-01 | 7.36e-01 | 1.53e-01 | 7.90e-01 |
| LEUKOTRIENE BIOSYNTHETIC PROCESS | 17 | 3.21e-01 | 7.32e-01 | 0.2050 | 4.78e-02 | 9.88e-02 | 1.16e-01 | 5.63e-03 | -1.28e-01 | 7.33e-01 | 4.81e-01 | 4.08e-01 | 9.68e-01 | 3.59e-01 |
| NEGATIVE REGULATION OF CELL MATRIX ADHESION | 37 | 6.37e-01 | 9.13e-01 | 0.2050 | -1.33e-01 | -8.02e-02 | -9.54e-02 | -9.24e-02 | 1.50e-02 | 1.62e-01 | 3.99e-01 | 3.15e-01 | 3.31e-01 | 8.74e-01 |
| REGULATION OF VIRAL PROCESS | 164 | 1.44e-01 | 5.11e-01 | 0.2050 | 1.20e-01 | 9.43e-02 | 7.94e-02 | 9.35e-02 | 5.88e-02 | 7.80e-03 | 3.72e-02 | 7.95e-02 | 3.89e-02 | 1.93e-01 |
| ONE CARBON METABOLIC PROCESS | 37 | 7.02e-01 | 9.32e-01 | 0.2050 | 1.46e-01 | 9.74e-02 | 5.96e-02 | 8.34e-02 | 2.45e-02 | 1.25e-01 | 3.05e-01 | 5.31e-01 | 3.80e-01 | 7.96e-01 |
| ALPHA BETA T CELL ACTIVATION | 169 | 1.31e-03 | 2.18e-02 | 0.2050 | 2.57e-02 | 4.39e-02 | 1.04e-01 | 1.37e-01 | 9.85e-02 | 5.64e-01 | 3.24e-01 | 2.01e-02 | 2.08e-03 | 2.72e-02 |
| NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 134 | 1.03e-01 | 4.37e-01 | 0.2050 | 2.86e-02 | 6.45e-02 | 1.05e-01 | 9.47e-02 | 1.30e-01 | 5.67e-01 | 1.97e-01 | 3.57e-02 | 5.84e-02 | 9.42e-03 |
| ENTRAINMENT OF CIRCADIAN CLOCK | 30 | 3.42e-01 | 7.48e-01 | 0.2050 | 7.96e-02 | 2.59e-02 | 3.43e-02 | 1.37e-01 | 1.22e-01 | 4.51e-01 | 8.06e-01 | 7.45e-01 | 1.94e-01 | 2.47e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL DEPOLARIZATION | 9 | 6.75e-01 | 9.28e-01 | 0.2050 | 1.21e-02 | 4.49e-02 | -1.08e-01 | -1.63e-01 | -3.63e-02 | 9.50e-01 | 8.16e-01 | 5.74e-01 | 3.96e-01 | 8.51e-01 |
| RESPONSE TO MACROPHAGE COLONY STIMULATING FACTOR | 17 | 1.72e-01 | 5.56e-01 | 0.2040 | 7.02e-02 | 1.60e-01 | -5.07e-02 | -8.92e-02 | -2.58e-02 | 6.17e-01 | 2.52e-01 | 7.18e-01 | 5.24e-01 | 8.54e-01 |
| INTERLEUKIN 27 MEDIATED SIGNALING PATHWAY | 7 | 8.00e-01 | 9.66e-01 | 0.2040 | -1.44e-01 | -8.66e-02 | 7.16e-02 | 5.12e-02 | 7.61e-02 | 5.09e-01 | 6.92e-01 | 7.43e-01 | 8.15e-01 | 7.27e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS NONSENSE MEDIATED DECAY | 42 | 7.76e-02 | 3.78e-01 | 0.2040 | 4.57e-02 | -4.53e-02 | 6.63e-02 | 1.50e-01 | 1.03e-01 | 6.08e-01 | 6.12e-01 | 4.57e-01 | 9.20e-02 | 2.46e-01 |
| HISTAMINE TRANSPORT | 15 | 1.08e-01 | 4.51e-01 | 0.2040 | -3.07e-02 | 1.98e-01 | 3.01e-02 | -2.32e-02 | -1.72e-02 | 8.37e-01 | 1.85e-01 | 8.40e-01 | 8.76e-01 | 9.08e-01 |
| OSTEOBLAST DIFFERENTIATION | 249 | 1.01e-02 | 1.02e-01 | 0.2040 | 3.75e-02 | 8.13e-02 | 1.16e-01 | 7.28e-02 | 1.22e-01 | 3.08e-01 | 2.71e-02 | 1.58e-03 | 4.79e-02 | 8.92e-04 |
| POSITIVE REGULATION OF HOMOTYPIC CELL CELL ADHESION | 16 | 6.23e-01 | 9.08e-01 | 0.2040 | 8.94e-02 | 1.26e-01 | 1.74e-02 | 1.14e-01 | -6.76e-02 | 5.36e-01 | 3.84e-01 | 9.04e-01 | 4.28e-01 | 6.39e-01 |
| CELL SURFACE PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 70 | 4.91e-02 | 2.90e-01 | 0.2040 | 1.63e-01 | 7.44e-02 | 4.54e-02 | 7.20e-02 | 5.03e-02 | 1.86e-02 | 2.82e-01 | 5.11e-01 | 2.98e-01 | 4.67e-01 |
| ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 179 | 1.50e-04 | 3.73e-03 | 0.2040 | 1.44e-02 | 2.94e-02 | 1.15e-01 | 1.38e-01 | 9.07e-02 | 7.39e-01 | 4.98e-01 | 7.69e-03 | 1.42e-03 | 3.63e-02 |
| METHIONINE BIOSYNTHETIC PROCESS | 12 | 7.19e-01 | 9.38e-01 | 0.2040 | -6.27e-02 | -9.25e-02 | -7.00e-02 | -1.05e-02 | 1.56e-01 | 7.07e-01 | 5.79e-01 | 6.75e-01 | 9.50e-01 | 3.51e-01 |
| GASTRULATION WITH MOUTH FORMING SECOND | 26 | 8.75e-01 | 9.78e-01 | 0.2040 | 3.78e-02 | 7.55e-02 | 9.77e-02 | 6.39e-02 | 1.45e-01 | 7.38e-01 | 5.05e-01 | 3.88e-01 | 5.73e-01 | 2.02e-01 |
| REGULATION OF FOCAL ADHESION DISASSEMBLY | 6 | 7.46e-01 | 9.50e-01 | 0.2040 | -1.48e-01 | -5.00e-02 | 1.32e-02 | 7.38e-02 | 1.08e-01 | 5.31e-01 | 8.32e-01 | 9.55e-01 | 7.54e-01 | 6.46e-01 |
| RESPONSE TO GLUCAGON | 20 | 8.56e-01 | 9.77e-01 | 0.2040 | 7.85e-02 | 1.21e-01 | 6.89e-02 | 1.03e-01 | 7.48e-02 | 5.43e-01 | 3.51e-01 | 5.94e-01 | 4.25e-01 | 5.62e-01 |
| LIPID GLYCOSYLATION | 12 | 3.54e-01 | 7.54e-01 | 0.2040 | -1.39e-02 | 1.79e-01 | 7.21e-02 | 5.07e-02 | -4.22e-02 | 9.34e-01 | 2.84e-01 | 6.65e-01 | 7.61e-01 | 8.00e-01 |
| FREE UBIQUITIN CHAIN POLYMERIZATION | 9 | 9.07e-01 | 9.84e-01 | 0.2040 | -6.55e-02 | -8.46e-02 | 4.79e-02 | 1.09e-03 | 1.67e-01 | 7.34e-01 | 6.60e-01 | 8.04e-01 | 9.95e-01 | 3.86e-01 |
| REGULATION OF RESPONSE TO OXIDATIVE STRESS | 31 | 7.29e-01 | 9.44e-01 | 0.2040 | -9.33e-02 | -9.46e-02 | -1.03e-01 | -1.06e-01 | 4.55e-02 | 3.69e-01 | 3.62e-01 | 3.20e-01 | 3.08e-01 | 6.61e-01 |
| NON CANONICAL WNT SIGNALING PATHWAY | 66 | 2.48e-01 | 6.54e-01 | 0.2040 | 2.18e-02 | 3.38e-02 | 7.17e-02 | 7.98e-02 | 1.69e-01 | 7.59e-01 | 6.35e-01 | 3.14e-01 | 2.62e-01 | 1.78e-02 |
| CYTOPLASM ORGANIZATION | 15 | 8.42e-01 | 9.75e-01 | 0.2040 | 1.14e-01 | 8.64e-02 | -8.81e-03 | 6.90e-02 | -1.27e-01 | 4.44e-01 | 5.62e-01 | 9.53e-01 | 6.44e-01 | 3.93e-01 |
| CUT CATABOLIC PROCESS | 5 | 6.97e-01 | 9.31e-01 | 0.2040 | 3.16e-02 | -6.88e-02 | -1.59e-01 | 1.91e-02 | 1.01e-01 | 9.03e-01 | 7.90e-01 | 5.39e-01 | 9.41e-01 | 6.95e-01 |
| EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 221 | 9.91e-02 | 4.28e-01 | 0.2040 | 8.19e-02 | 7.52e-02 | 1.02e-01 | 1.15e-01 | 7.43e-02 | 3.59e-02 | 5.41e-02 | 8.76e-03 | 3.31e-03 | 5.69e-02 |
| DIGESTIVE SYSTEM PROCESS | 102 | 1.32e-02 | 1.24e-01 | 0.2040 | -3.87e-02 | -2.20e-02 | -1.31e-01 | -1.35e-01 | -6.38e-02 | 4.99e-01 | 7.00e-01 | 2.21e-02 | 1.84e-02 | 2.66e-01 |
| RESPONSE TO AMINE | 45 | 6.64e-01 | 9.22e-01 | 0.2040 | 8.50e-02 | 1.19e-01 | 7.50e-02 | 8.39e-02 | 8.59e-02 | 3.24e-01 | 1.66e-01 | 3.84e-01 | 3.30e-01 | 3.19e-01 |
| EXCITATORY SYNAPSE ASSEMBLY | 32 | 6.69e-01 | 9.25e-01 | 0.2040 | -1.22e-01 | -6.02e-02 | -6.47e-02 | -1.33e-01 | 3.30e-02 | 2.34e-01 | 5.56e-01 | 5.27e-01 | 1.92e-01 | 7.47e-01 |
| SECRETORY GRANULE LOCALIZATION | 13 | 8.95e-01 | 9.82e-01 | 0.2040 | 1.17e-01 | 5.41e-02 | 7.74e-02 | 1.19e-01 | -6.79e-02 | 4.66e-01 | 7.35e-01 | 6.29e-01 | 4.56e-01 | 6.72e-01 |
| POSITIVE REGULATION OF TYPE 2 IMMUNE RESPONSE | 18 | 5.78e-01 | 8.86e-01 | 0.2040 | 8.69e-02 | 8.35e-02 | -8.27e-02 | -2.63e-02 | -1.39e-01 | 5.23e-01 | 5.40e-01 | 5.44e-01 | 8.47e-01 | 3.06e-01 |
| ANIMAL ORGAN MATURATION | 30 | 2.24e-01 | 6.24e-01 | 0.2040 | 4.37e-02 | 1.74e-01 | 9.06e-02 | 1.82e-02 | -2.95e-02 | 6.79e-01 | 9.99e-02 | 3.91e-01 | 8.63e-01 | 7.80e-01 |
| NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION | 60 | 2.86e-01 | 6.94e-01 | 0.2030 | 1.73e-02 | 3.48e-03 | 8.86e-02 | 9.38e-02 | 1.56e-01 | 8.17e-01 | 9.63e-01 | 2.35e-01 | 2.09e-01 | 3.63e-02 |
| LOW DENSITY LIPOPROTEIN RECEPTOR PARTICLE METABOLIC PROCESS | 6 | 3.58e-01 | 7.57e-01 | 0.2030 | -1.91e-01 | 3.70e-02 | -2.46e-02 | 2.44e-02 | -4.76e-02 | 4.18e-01 | 8.75e-01 | 9.17e-01 | 9.18e-01 | 8.40e-01 |
| POSITIVE REGULATION OF MACROPHAGE CHEMOTAXIS | 19 | 6.66e-02 | 3.45e-01 | 0.2030 | 1.85e-02 | 1.76e-01 | -5.06e-02 | -7.84e-02 | -3.64e-02 | 8.89e-01 | 1.84e-01 | 7.02e-01 | 5.54e-01 | 7.83e-01 |
| VASCULOGENESIS | 81 | 1.91e-01 | 5.78e-01 | 0.2030 | 1.44e-02 | 8.21e-02 | 9.97e-02 | 4.98e-02 | 1.48e-01 | 8.22e-01 | 2.01e-01 | 1.21e-01 | 4.38e-01 | 2.11e-02 |
| ORGANISM EMERGENCE FROM PROTECTIVE STRUCTURE | 24 | 9.26e-01 | 9.89e-01 | 0.2030 | 1.12e-01 | 6.55e-02 | 8.98e-02 | 1.08e-01 | 6.89e-02 | 3.43e-01 | 5.78e-01 | 4.47e-01 | 3.59e-01 | 5.59e-01 |
| SPECIFICATION OF SYMMETRY | 136 | 9.51e-02 | 4.19e-01 | 0.2030 | 4.00e-02 | 4.90e-02 | 9.12e-02 | 8.04e-02 | 1.50e-01 | 4.20e-01 | 3.23e-01 | 6.64e-02 | 1.06e-01 | 2.50e-03 |
| TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 55 | 3.42e-02 | 2.35e-01 | 0.2030 | 1.66e-01 | 4.25e-02 | 3.77e-02 | 8.06e-02 | 6.35e-02 | 3.32e-02 | 5.85e-01 | 6.29e-01 | 3.01e-01 | 4.15e-01 |
| CELLULAR COMPONENT ASSEMBLY INVOLVED IN MORPHOGENESIS | 128 | 2.34e-01 | 6.37e-01 | 0.2030 | -1.26e-01 | -8.69e-02 | -8.65e-02 | -9.78e-02 | -2.80e-02 | 1.36e-02 | 8.97e-02 | 9.10e-02 | 5.61e-02 | 5.84e-01 |
| REGULATION OF CENTROMERE COMPLEX ASSEMBLY | 6 | 9.65e-01 | 9.94e-01 | 0.2030 | 1.50e-02 | 9.72e-02 | 9.93e-02 | -6.68e-03 | 1.47e-01 | 9.49e-01 | 6.80e-01 | 6.74e-01 | 9.77e-01 | 5.33e-01 |
| REGULATION OF LEUKOCYTE DEGRANULATION | 43 | 2.13e-01 | 6.08e-01 | 0.2030 | 8.59e-02 | 1.42e-01 | 2.56e-02 | 2.83e-02 | -1.10e-01 | 3.30e-01 | 1.06e-01 | 7.72e-01 | 7.48e-01 | 2.13e-01 |
| POSITIVE REGULATION OF SYNAPTIC TRANSMISSION GABAERGIC | 15 | 9.30e-01 | 9.90e-01 | 0.2030 | -1.08e-01 | -1.42e-01 | -5.64e-02 | -7.85e-02 | -4.55e-04 | 4.67e-01 | 3.42e-01 | 7.06e-01 | 5.99e-01 | 9.98e-01 |
| REGULATION OF VASCULOGENESIS | 16 | 2.73e-01 | 6.81e-01 | 0.2030 | 1.72e-01 | 5.00e-02 | 4.11e-02 | 1.15e-02 | 8.45e-02 | 2.33e-01 | 7.29e-01 | 7.76e-01 | 9.37e-01 | 5.58e-01 |
| TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 105 | 2.09e-01 | 6.03e-01 | 0.2030 | 6.03e-02 | 4.73e-02 | 9.81e-02 | 7.84e-02 | 1.39e-01 | 2.86e-01 | 4.02e-01 | 8.25e-02 | 1.65e-01 | 1.35e-02 |
| REGULATION OF T CELL ACTIVATION VIA T CELL RECEPTOR CONTACT WITH ANTIGEN BOUND TO MHC MOLECULE ON ANTIGEN PRESENTING CELL | 6 | 9.11e-01 | 9.85e-01 | 0.2030 | 1.28e-01 | -2.13e-02 | -4.68e-02 | 3.45e-02 | -1.44e-01 | 5.87e-01 | 9.28e-01 | 8.43e-01 | 8.84e-01 | 5.40e-01 |
| DCMP CATABOLIC PROCESS | 6 | 7.43e-01 | 9.50e-01 | 0.2030 | 1.65e-01 | 4.35e-02 | -1.07e-01 | -7.79e-04 | -2.20e-02 | 4.84e-01 | 8.54e-01 | 6.50e-01 | 9.97e-01 | 9.26e-01 |
| ACTIN FILAMENT SEVERING | 16 | 8.26e-01 | 9.72e-01 | 0.2030 | 6.76e-02 | 1.42e-01 | 7.47e-02 | 3.14e-02 | 9.91e-02 | 6.40e-01 | 3.27e-01 | 6.05e-01 | 8.28e-01 | 4.93e-01 |
| POSITIVE REGULATION OF AMYLOID PRECURSOR PROTEIN CATABOLIC PROCESS | 25 | 4.81e-01 | 8.35e-01 | 0.2020 | 1.59e-01 | 4.06e-02 | 4.06e-03 | 7.87e-02 | -8.89e-02 | 1.69e-01 | 7.25e-01 | 9.72e-01 | 4.96e-01 | 4.42e-01 |
| MODULATION OF EXCITATORY POSTSYNAPTIC POTENTIAL | 47 | 4.27e-01 | 8.05e-01 | 0.2020 | -1.31e-01 | -7.99e-02 | -3.65e-02 | -1.27e-01 | 1.01e-03 | 1.19e-01 | 3.43e-01 | 6.65e-01 | 1.33e-01 | 9.90e-01 |
| CELLULAR RESPONSE TO GROWTH HORMONE STIMULUS | 25 | 3.29e-01 | 7.37e-01 | 0.2020 | -5.40e-02 | 5.32e-03 | 4.48e-03 | 1.82e-02 | 1.94e-01 | 6.40e-01 | 9.63e-01 | 9.69e-01 | 8.75e-01 | 9.30e-02 |
| POSITIVE REGULATION OF SYNCYTIUM FORMATION BY PLASMA MEMBRANE FUSION | 24 | 4.01e-01 | 7.88e-01 | 0.2020 | 1.19e-01 | 3.22e-02 | -7.49e-02 | 5.64e-02 | -1.30e-01 | 3.13e-01 | 7.85e-01 | 5.25e-01 | 6.32e-01 | 2.70e-01 |
| MONOATOMIC ANION TRANSPORT | 161 | 1.36e-01 | 4.99e-01 | 0.2020 | -8.61e-02 | -6.99e-02 | -8.76e-02 | -1.22e-01 | -7.70e-02 | 5.94e-02 | 1.26e-01 | 5.50e-02 | 7.34e-03 | 9.16e-02 |
| NEGATIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 49 | 2.34e-01 | 6.36e-01 | 0.2020 | -3.84e-02 | 4.29e-02 | 9.65e-02 | 6.84e-02 | 1.53e-01 | 6.42e-01 | 6.03e-01 | 2.43e-01 | 4.08e-01 | 6.34e-02 |
| BLOOD COAGULATION INTRINSIC PATHWAY | 6 | 9.56e-01 | 9.94e-01 | 0.2020 | -5.57e-02 | 1.04e-02 | 6.07e-02 | 6.74e-02 | 1.71e-01 | 8.13e-01 | 9.65e-01 | 7.97e-01 | 7.75e-01 | 4.68e-01 |
| NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 371 | 7.36e-03 | 8.21e-02 | 0.2020 | 8.85e-02 | 8.22e-02 | 8.69e-02 | 1.05e-01 | 8.73e-02 | 3.41e-03 | 6.53e-03 | 4.06e-03 | 5.21e-04 | 3.89e-03 |
| RENAL SYSTEM PROCESS INVOLVED IN REGULATION OF BLOOD VOLUME | 13 | 2.37e-01 | 6.41e-01 | 0.2020 | 3.41e-02 | 4.85e-02 | 1.45e-01 | -6.47e-02 | 1.10e-01 | 8.31e-01 | 7.62e-01 | 3.66e-01 | 6.86e-01 | 4.94e-01 |
| NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 945 | 6.92e-08 | 3.86e-06 | 0.2020 | 6.29e-02 | 8.12e-02 | 9.71e-02 | 9.47e-02 | 1.08e-01 | 1.04e-03 | 2.32e-05 | 4.16e-07 | 8.03e-07 | 1.59e-08 |
| REGULATION OF FEVER GENERATION | 9 | 6.75e-01 | 9.28e-01 | 0.2020 | 9.26e-02 | 1.55e-01 | -4.19e-02 | -5.84e-02 | -5.36e-02 | 6.30e-01 | 4.20e-01 | 8.28e-01 | 7.61e-01 | 7.81e-01 |
| HINDBRAIN MORPHOGENESIS | 44 | 3.90e-01 | 7.82e-01 | 0.2020 | 1.23e-02 | 1.53e-02 | 9.33e-02 | 3.18e-02 | 1.75e-01 | 8.88e-01 | 8.61e-01 | 2.84e-01 | 7.15e-01 | 4.47e-02 |
| VENOUS BLOOD VESSEL DEVELOPMENT | 16 | 7.99e-01 | 9.66e-01 | 0.2020 | -3.03e-02 | 5.94e-02 | 1.19e-01 | 8.30e-02 | 1.23e-01 | 8.34e-01 | 6.81e-01 | 4.10e-01 | 5.65e-01 | 3.93e-01 |
| REGULATION OF BONE REMODELING | 49 | 3.48e-02 | 2.38e-01 | 0.2020 | 1.01e-01 | 1.66e-01 | 5.49e-03 | 5.33e-02 | -1.46e-02 | 2.23e-01 | 4.47e-02 | 9.47e-01 | 5.18e-01 | 8.60e-01 |
| ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 67 | 5.37e-01 | 8.66e-01 | 0.2020 | 3.37e-02 | 7.59e-02 | 1.09e-01 | 9.17e-02 | 1.16e-01 | 6.33e-01 | 2.82e-01 | 1.21e-01 | 1.94e-01 | 1.02e-01 |
| REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 23 | 2.16e-01 | 6.12e-01 | 0.2020 | 1.60e-02 | 1.07e-01 | -5.98e-02 | -1.15e-01 | -1.10e-01 | 8.94e-01 | 3.72e-01 | 6.20e-01 | 3.40e-01 | 3.62e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION | 208 | 1.06e-01 | 4.44e-01 | 0.2020 | 9.85e-02 | 7.69e-02 | 9.60e-02 | 1.18e-01 | 4.38e-02 | 1.43e-02 | 5.58e-02 | 1.70e-02 | 3.39e-03 | 2.76e-01 |
| PROTEIN POLYGLUTAMYLATION | 12 | 9.68e-01 | 9.94e-01 | 0.2020 | -1.36e-01 | -9.38e-02 | -4.85e-02 | -1.01e-01 | -2.94e-02 | 4.16e-01 | 5.74e-01 | 7.71e-01 | 5.45e-01 | 8.60e-01 |
| REGULATION OF TRANSLATION IN RESPONSE TO STRESS | 19 | 9.24e-01 | 9.89e-01 | 0.2020 | 8.29e-02 | 1.31e-01 | 8.14e-02 | 9.62e-02 | 2.85e-02 | 5.31e-01 | 3.24e-01 | 5.39e-01 | 4.68e-01 | 8.30e-01 |
| MAMMALIAN OOGENESIS STAGE | 12 | 7.27e-01 | 9.43e-01 | 0.2010 | -1.27e-02 | -1.31e-01 | -1.39e-01 | -5.72e-02 | 2.12e-02 | 9.39e-01 | 4.31e-01 | 4.03e-01 | 7.32e-01 | 8.99e-01 |
| FORMATION OF PRIMARY GERM LAYER | 126 | 7.49e-02 | 3.70e-01 | 0.2010 | 1.44e-02 | 5.05e-02 | 9.15e-02 | 7.31e-02 | 1.55e-01 | 7.80e-01 | 3.28e-01 | 7.59e-02 | 1.56e-01 | 2.65e-03 |
| HEART GROWTH | 94 | 3.19e-01 | 7.30e-01 | 0.2010 | 8.05e-02 | 1.31e-01 | 1.03e-01 | 6.70e-02 | 4.01e-02 | 1.78e-01 | 2.78e-02 | 8.32e-02 | 2.61e-01 | 5.02e-01 |
| NEGATIVE REGULATION OF FATTY ACID TRANSPORT | 7 | 8.97e-01 | 9.82e-01 | 0.2010 | -1.22e-01 | -1.17e-02 | -9.08e-02 | -1.18e-01 | 5.68e-02 | 5.76e-01 | 9.57e-01 | 6.77e-01 | 5.88e-01 | 7.95e-01 |
| RESPONSE TO REDOX STATE | 14 | 3.41e-01 | 7.47e-01 | 0.2010 | 3.09e-02 | 1.39e-01 | 6.91e-03 | 8.91e-02 | -1.10e-01 | 8.41e-01 | 3.67e-01 | 9.64e-01 | 5.64e-01 | 4.76e-01 |
| GLYCINE METABOLIC PROCESS | 15 | 5.54e-01 | 8.76e-01 | 0.2010 | 7.79e-05 | -6.95e-04 | -7.86e-02 | 4.67e-02 | -1.79e-01 | 1.00e+00 | 9.96e-01 | 5.98e-01 | 7.54e-01 | 2.30e-01 |
| CELLULAR RESPONSE TO MECHANICAL STIMULUS | 69 | 3.06e-01 | 7.18e-01 | 0.2010 | 1.13e-01 | 1.17e-01 | 4.85e-02 | 1.09e-01 | -1.35e-04 | 1.06e-01 | 9.33e-02 | 4.86e-01 | 1.19e-01 | 9.98e-01 |
| TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 42 | 5.32e-01 | 8.63e-01 | 0.2010 | 8.99e-03 | -3.88e-02 | -1.08e-01 | -4.25e-02 | -1.59e-01 | 9.20e-01 | 6.63e-01 | 2.26e-01 | 6.33e-01 | 7.39e-02 |
| RESPONSE TO VIRUS | 421 | 4.44e-03 | 5.66e-02 | 0.2010 | 1.06e-01 | 9.71e-02 | 8.15e-02 | 9.56e-02 | 6.35e-02 | 1.99e-04 | 6.33e-04 | 4.14e-03 | 7.60e-04 | 2.53e-02 |
| REGULATION OF MESENCHYMAL TO EPITHELIAL TRANSITION INVOLVED IN METANEPHROS MORPHOGENESIS | 7 | 9.04e-01 | 9.84e-01 | 0.2010 | 6.70e-03 | 1.06e-01 | 1.04e-01 | 1.29e-01 | 4.12e-02 | 9.76e-01 | 6.26e-01 | 6.35e-01 | 5.55e-01 | 8.50e-01 |
| POSITIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN INFLAMMATORY RESPONSE | 31 | 6.34e-02 | 3.35e-01 | 0.2010 | 8.40e-02 | 1.76e-01 | -9.43e-03 | -3.92e-02 | -2.87e-02 | 4.18e-01 | 9.03e-02 | 9.28e-01 | 7.05e-01 | 7.82e-01 |
| ENDOLYSOSOMAL TOLL LIKE RECEPTOR SIGNALING PATHWAY | 41 | 5.88e-01 | 8.92e-01 | 0.2010 | 1.34e-01 | 1.08e-01 | 5.45e-02 | 6.73e-02 | 5.69e-02 | 1.38e-01 | 2.30e-01 | 5.46e-01 | 4.56e-01 | 5.29e-01 |
| RESPONSE TO DEXAMETHASONE | 38 | 1.80e-01 | 5.63e-01 | 0.2010 | -9.93e-02 | 1.01e-02 | 4.09e-02 | -4.83e-03 | 1.69e-01 | 2.89e-01 | 9.14e-01 | 6.63e-01 | 9.59e-01 | 7.06e-02 |
| LYMPHOCYTE ACTIVATION | 758 | 1.53e-07 | 8.14e-06 | 0.2010 | 7.15e-02 | 7.05e-02 | 9.71e-02 | 1.25e-01 | 7.27e-02 | 8.02e-04 | 9.58e-04 | 5.36e-06 | 5.04e-09 | 6.55e-04 |
| NEGATIVE REGULATION OF TYPE I INTERFERON MEDIATED SIGNALING PATHWAY | 22 | 8.61e-01 | 9.78e-01 | 0.2010 | 1.87e-02 | 4.02e-02 | 1.04e-01 | 1.10e-01 | 1.24e-01 | 8.79e-01 | 7.44e-01 | 4.00e-01 | 3.71e-01 | 3.13e-01 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 60 | 4.71e-01 | 8.30e-01 | 0.2010 | 6.66e-02 | 1.10e-01 | 9.34e-02 | 4.79e-02 | 1.12e-01 | 3.72e-01 | 1.39e-01 | 2.11e-01 | 5.21e-01 | 1.32e-01 |
| REGULATION OF DNA STRAND ELONGATION | 17 | 8.99e-01 | 9.83e-01 | 0.2010 | 9.06e-02 | 1.01e-01 | 6.42e-02 | 5.79e-02 | 1.20e-01 | 5.18e-01 | 4.73e-01 | 6.47e-01 | 6.79e-01 | 3.90e-01 |
| HOMEOSTASIS OF NUMBER OF CELLS | 299 | 2.06e-02 | 1.70e-01 | 0.2010 | 9.57e-02 | 7.54e-02 | 8.49e-02 | 1.12e-01 | 7.58e-02 | 4.40e-03 | 2.48e-02 | 1.15e-02 | 8.98e-04 | 2.41e-02 |
| CELLULAR RESPONSE TO CHEMICAL STRESS | 307 | 1.38e-02 | 1.28e-01 | 0.2010 | 9.01e-02 | 8.21e-02 | 8.18e-02 | 1.00e-01 | 9.33e-02 | 6.61e-03 | 1.34e-02 | 1.37e-02 | 2.55e-03 | 4.94e-03 |
| SKELETAL MUSCLE CELL PROLIFERATION | 24 | 7.98e-01 | 9.66e-01 | 0.2010 | 1.17e-01 | 1.40e-01 | 6.17e-02 | 4.53e-02 | 3.27e-02 | 3.22e-01 | 2.34e-01 | 6.01e-01 | 7.01e-01 | 7.81e-01 |
| CARBOHYDRATE CATABOLIC PROCESS | 155 | 3.16e-01 | 7.27e-01 | 0.2000 | 8.98e-02 | 1.10e-01 | 9.62e-02 | 9.46e-02 | 4.17e-02 | 5.35e-02 | 1.80e-02 | 3.87e-02 | 4.21e-02 | 3.70e-01 |
| PHOSPHATIDYLGLYCEROL BIOSYNTHETIC PROCESS | 9 | 7.16e-01 | 9.37e-01 | 0.2000 | 1.52e-01 | 2.18e-02 | 1.76e-02 | 5.04e-02 | 1.17e-01 | 4.30e-01 | 9.10e-01 | 9.27e-01 | 7.93e-01 | 5.43e-01 |
| PROTEIN REPAIR | 7 | 8.52e-01 | 9.76e-01 | 0.2000 | 4.19e-02 | -9.88e-02 | -7.40e-02 | 6.35e-02 | -1.38e-01 | 8.48e-01 | 6.51e-01 | 7.35e-01 | 7.71e-01 | 5.27e-01 |
| VENTRICULAR CARDIAC MUSCLE CELL DEVELOPMENT | 10 | 5.31e-01 | 8.63e-01 | 0.2000 | 1.33e-01 | -6.74e-02 | 1.78e-02 | 1.17e-01 | 5.97e-02 | 4.65e-01 | 7.12e-01 | 9.22e-01 | 5.20e-01 | 7.44e-01 |
| POSITIVE REGULATION OF UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 109 | 3.78e-01 | 7.75e-01 | 0.2000 | 8.77e-02 | 7.63e-02 | 1.02e-01 | 1.21e-01 | 3.63e-02 | 1.14e-01 | 1.69e-01 | 6.55e-02 | 2.87e-02 | 5.12e-01 |
| OVULATION CYCLE | 72 | 2.81e-02 | 2.08e-01 | 0.2000 | 1.76e-02 | -5.38e-02 | -1.18e-01 | -1.20e-01 | -9.07e-02 | 7.96e-01 | 4.30e-01 | 8.22e-02 | 7.76e-02 | 1.83e-01 |
| GRANULOCYTE CHEMOTAXIS | 125 | 1.45e-04 | 3.61e-03 | 0.2000 | 2.25e-02 | 4.85e-02 | -8.58e-02 | -1.16e-01 | -1.27e-01 | 6.64e-01 | 3.49e-01 | 9.76e-02 | 2.45e-02 | 1.43e-02 |
| POSITIVE REGULATION OF CELL DIFFERENTIATION | 854 | 1.71e-07 | 8.94e-06 | 0.2000 | 7.96e-02 | 9.59e-02 | 8.67e-02 | 8.08e-02 | 1.01e-01 | 7.73e-05 | 1.92e-06 | 1.67e-05 | 6.04e-05 | 4.75e-07 |
| GLUCOCORTICOID METABOLIC PROCESS | 24 | 4.63e-01 | 8.25e-01 | 0.2000 | -9.03e-02 | 5.87e-03 | 1.03e-01 | -1.20e-02 | 1.45e-01 | 4.44e-01 | 9.60e-01 | 3.82e-01 | 9.19e-01 | 2.20e-01 |
| POSITIVE REGULATION OF VASCULOGENESIS | 12 | 1.53e-01 | 5.22e-01 | 0.2000 | 1.74e-01 | -9.77e-03 | -2.04e-02 | -2.42e-02 | 9.22e-02 | 2.97e-01 | 9.53e-01 | 9.03e-01 | 8.85e-01 | 5.80e-01 |
| NEGATIVE REGULATION OF LYASE ACTIVITY | 18 | 6.38e-01 | 9.13e-01 | 0.2000 | 6.57e-02 | 1.72e-01 | 6.48e-02 | 3.19e-02 | -2.87e-02 | 6.29e-01 | 2.07e-01 | 6.34e-01 | 8.15e-01 | 8.33e-01 |
| PSEUDOPODIUM ORGANIZATION | 16 | 8.14e-01 | 9.69e-01 | 0.2000 | -9.92e-02 | -1.95e-02 | -6.49e-02 | -8.63e-02 | -1.34e-01 | 4.92e-01 | 8.93e-01 | 6.53e-01 | 5.50e-01 | 3.53e-01 |
| CORTICOSTEROID HORMONE SECRETION | 19 | 6.04e-01 | 9.01e-01 | 0.2000 | 1.08e-01 | 4.61e-02 | 2.00e-02 | 1.40e-01 | 7.72e-02 | 4.14e-01 | 7.28e-01 | 8.80e-01 | 2.91e-01 | 5.60e-01 |
| POSITIVE REGULATION OF ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 8 | 8.28e-01 | 9.72e-01 | 0.1990 | 1.25e-01 | 5.19e-02 | -1.03e-01 | 8.70e-03 | -1.04e-01 | 5.40e-01 | 7.99e-01 | 6.14e-01 | 9.66e-01 | 6.12e-01 |
| POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 312 | 2.72e-02 | 2.04e-01 | 0.1990 | 9.98e-02 | 1.16e-01 | 8.98e-02 | 8.11e-02 | 4.25e-02 | 2.42e-03 | 4.47e-04 | 6.36e-03 | 1.37e-02 | 1.97e-01 |
| RESPONSE TO OXIDATIVE STRESS | 384 | 9.61e-03 | 9.89e-02 | 0.1990 | 9.50e-02 | 8.66e-02 | 8.47e-02 | 1.09e-01 | 6.45e-02 | 1.39e-03 | 3.57e-03 | 4.38e-03 | 2.42e-04 | 3.00e-02 |
| SECRETORY GRANULE ORGANIZATION | 63 | 3.17e-01 | 7.27e-01 | 0.1990 | 1.16e-01 | 9.95e-02 | 4.19e-02 | 1.20e-01 | -1.46e-02 | 1.10e-01 | 1.72e-01 | 5.65e-01 | 1.00e-01 | 8.41e-01 |
| REGULATION OF INFLAMMASOME MEDIATED SIGNALING PATHWAY | 34 | 1.98e-01 | 5.87e-01 | 0.1990 | -1.45e-02 | -1.16e-01 | -1.05e-01 | -1.22e-01 | -1.70e-02 | 8.84e-01 | 2.43e-01 | 2.90e-01 | 2.18e-01 | 8.64e-01 |
| NUCLEIC ACID PHOSPHODIESTER BOND HYDROLYSIS | 24 | 5.82e-01 | 8.88e-01 | 0.1990 | 1.06e-01 | 1.16e-02 | 7.26e-02 | 8.96e-02 | 1.23e-01 | 3.70e-01 | 9.22e-01 | 5.38e-01 | 4.47e-01 | 2.97e-01 |
| REGULATION OF CILIUM ASSEMBLY | 93 | 5.10e-01 | 8.53e-01 | 0.1990 | 1.15e-01 | 9.49e-02 | 7.34e-02 | 1.09e-01 | 1.49e-02 | 5.59e-02 | 1.14e-01 | 2.21e-01 | 6.87e-02 | 8.03e-01 |
| SYNAPTIC TRANSMISSION CHOLINERGIC | 31 | 5.86e-01 | 8.91e-01 | 0.1990 | 2.36e-02 | 1.23e-01 | 1.21e-01 | 7.74e-02 | 5.74e-02 | 8.20e-01 | 2.35e-01 | 2.44e-01 | 4.56e-01 | 5.80e-01 |
| DENDRITIC SPINE MAINTENANCE | 22 | 6.20e-01 | 9.08e-01 | 0.1990 | -3.53e-02 | -2.18e-02 | -1.46e-01 | -1.12e-01 | -6.27e-02 | 7.74e-01 | 8.59e-01 | 2.35e-01 | 3.62e-01 | 6.11e-01 |
| ACTIN POLYMERIZATION DEPENDENT CELL MOTILITY | 7 | 3.29e-01 | 7.37e-01 | 0.1990 | 8.20e-02 | -1.66e-01 | 3.05e-02 | 4.73e-02 | -4.84e-02 | 7.07e-01 | 4.48e-01 | 8.89e-01 | 8.29e-01 | 8.25e-01 |
| REGULATION OF PHOSPHOLIPASE A2 ACTIVITY | 9 | 3.26e-01 | 7.35e-01 | 0.1990 | 1.72e-01 | -7.86e-02 | -3.31e-02 | 2.64e-02 | -4.63e-02 | 3.72e-01 | 6.83e-01 | 8.63e-01 | 8.91e-01 | 8.10e-01 |
| POSITIVE REGULATION OF HORMONE SECRETION | 139 | 5.77e-02 | 3.16e-01 | 0.1990 | 1.10e-01 | 1.23e-01 | 5.73e-02 | 7.71e-02 | 5.55e-02 | 2.48e-02 | 1.22e-02 | 2.43e-01 | 1.17e-01 | 2.58e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CELL SURFACE | 40 | 5.89e-01 | 8.92e-01 | 0.1990 | 6.93e-02 | 8.77e-02 | 6.16e-02 | 7.60e-02 | 1.32e-01 | 4.49e-01 | 3.37e-01 | 5.00e-01 | 4.05e-01 | 1.48e-01 |
| NEGATIVE REGULATION OF GLUCOSE IMPORT | 16 | 6.81e-01 | 9.29e-01 | 0.1990 | 6.99e-03 | -1.22e-01 | -1.37e-01 | -2.51e-02 | -7.24e-02 | 9.61e-01 | 3.98e-01 | 3.44e-01 | 8.62e-01 | 6.16e-01 |
| HYDROGEN PEROXIDE CATABOLIC PROCESS | 30 | 8.39e-01 | 9.73e-01 | 0.1990 | -4.25e-02 | -1.06e-01 | -1.19e-01 | -8.65e-02 | -6.93e-02 | 6.87e-01 | 3.13e-01 | 2.61e-01 | 4.12e-01 | 5.11e-01 |
| CELLULAR RESPONSE TO OSMOTIC STRESS | 51 | 5.59e-01 | 8.78e-01 | 0.1990 | 1.19e-01 | 1.15e-01 | 5.05e-02 | 8.61e-02 | 4.47e-02 | 1.41e-01 | 1.54e-01 | 5.33e-01 | 2.88e-01 | 5.81e-01 |
| PERK MEDIATED UNFOLDED PROTEIN RESPONSE | 18 | 7.12e-01 | 9.35e-01 | 0.1990 | 9.47e-03 | 1.11e-01 | 8.79e-02 | 1.86e-03 | 1.39e-01 | 9.45e-01 | 4.13e-01 | 5.19e-01 | 9.89e-01 | 3.09e-01 |
| REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 53 | 2.18e-01 | 6.15e-01 | 0.1980 | 4.74e-02 | 1.13e-01 | 1.37e-01 | 7.42e-02 | -4.21e-03 | 5.51e-01 | 1.55e-01 | 8.37e-02 | 3.50e-01 | 9.58e-01 |
| NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN INFLAMMATORY RESPONSE | 37 | 6.44e-01 | 9.15e-01 | 0.1980 | -7.76e-03 | -1.82e-02 | -9.14e-02 | -9.12e-02 | -1.49e-01 | 9.35e-01 | 8.48e-01 | 3.36e-01 | 3.37e-01 | 1.16e-01 |
| REGULATION OF HOMOTYPIC CELL CELL ADHESION | 34 | 3.33e-01 | 7.40e-01 | 0.1980 | 1.24e-01 | 1.04e-01 | -3.42e-02 | 3.95e-02 | -1.01e-01 | 2.10e-01 | 2.93e-01 | 7.30e-01 | 6.90e-01 | 3.07e-01 |
| NEGATIVE REGULATION OF MACROPHAGE CHEMOTAXIS | 7 | 8.24e-01 | 9.71e-01 | 0.1980 | -7.18e-02 | -9.53e-02 | 9.16e-03 | -3.03e-02 | -1.55e-01 | 7.42e-01 | 6.62e-01 | 9.67e-01 | 8.90e-01 | 4.78e-01 |
| HINDBRAIN RADIAL GLIA GUIDED CELL MIGRATION | 8 | 9.17e-01 | 9.86e-01 | 0.1980 | -3.97e-02 | -1.58e-01 | -9.23e-02 | -1.13e-02 | -6.31e-02 | 8.46e-01 | 4.39e-01 | 6.51e-01 | 9.56e-01 | 7.57e-01 |
| REGULATION OF STORE OPERATED CALCIUM ENTRY | 15 | 8.37e-01 | 9.73e-01 | 0.1980 | 7.03e-02 | 1.44e-01 | 6.82e-02 | 8.94e-02 | -3.09e-02 | 6.37e-01 | 3.35e-01 | 6.47e-01 | 5.49e-01 | 8.36e-01 |
| MITRAL VALVE DEVELOPMENT | 13 | 8.17e-01 | 9.70e-01 | 0.1980 | -1.12e-01 | -3.64e-02 | 7.28e-02 | -1.38e-02 | 1.41e-01 | 4.85e-01 | 8.20e-01 | 6.50e-01 | 9.31e-01 | 3.79e-01 |
| POSITIVE REGULATION OF AMINE TRANSPORT | 39 | 5.22e-01 | 8.59e-01 | 0.1980 | -2.49e-02 | 2.36e-02 | 1.02e-01 | 3.40e-02 | 1.63e-01 | 7.87e-01 | 7.99e-01 | 2.71e-01 | 7.14e-01 | 7.87e-02 |
| SKELETAL MUSCLE ADAPTATION | 25 | 2.06e-01 | 5.99e-01 | 0.1980 | -1.29e-01 | 5.39e-03 | 4.16e-02 | -1.27e-01 | 6.82e-02 | 2.63e-01 | 9.63e-01 | 7.19e-01 | 2.73e-01 | 5.55e-01 |
| BONE MATURATION | 26 | 1.09e-01 | 4.51e-01 | 0.1980 | 1.62e-02 | 1.66e-01 | 2.24e-02 | -2.61e-02 | -1.00e-01 | 8.86e-01 | 1.42e-01 | 8.43e-01 | 8.18e-01 | 3.77e-01 |
| POSITIVE REGULATION OF CILIUM ASSEMBLY | 28 | 4.57e-01 | 8.22e-01 | 0.1980 | 8.40e-03 | 1.00e-01 | 8.49e-02 | 1.02e-01 | 1.07e-01 | 9.39e-01 | 3.58e-01 | 4.37e-01 | 3.52e-01 | 3.28e-01 |
| PROTEIN LOCALIZATION TO CILIUM | 70 | 5.55e-01 | 8.77e-01 | 0.1980 | 8.80e-02 | 8.49e-02 | 7.38e-02 | 1.15e-01 | 7.47e-02 | 2.03e-01 | 2.19e-01 | 2.86e-01 | 9.75e-02 | 2.80e-01 |
| SULFATE TRANSPORT | 17 | 8.12e-01 | 9.68e-01 | 0.1980 | -1.19e-01 | -4.60e-02 | -4.00e-02 | -1.04e-01 | -1.02e-01 | 3.97e-01 | 7.43e-01 | 7.75e-01 | 4.58e-01 | 4.65e-01 |
| SPINDLE MIDZONE ASSEMBLY | 13 | 5.96e-01 | 8.97e-01 | 0.1970 | 1.50e-01 | -1.67e-02 | 3.91e-02 | 1.15e-01 | 3.90e-02 | 3.48e-01 | 9.17e-01 | 8.07e-01 | 4.75e-01 | 8.08e-01 |
| PRIMARY ALCOHOL METABOLIC PROCESS | 101 | 4.97e-01 | 8.45e-01 | 0.1970 | -5.64e-02 | -7.24e-02 | -1.06e-01 | -8.63e-02 | -1.09e-01 | 3.27e-01 | 2.08e-01 | 6.49e-02 | 1.34e-01 | 5.89e-02 |
| ENDOCYTIC RECYCLING | 83 | 3.26e-02 | 2.29e-01 | 0.1970 | 8.28e-02 | 1.00e-01 | 3.90e-02 | 1.08e-01 | -9.34e-02 | 1.92e-01 | 1.15e-01 | 5.39e-01 | 8.85e-02 | 1.41e-01 |
| KERATINOCYTE MIGRATION | 20 | 4.73e-01 | 8.31e-01 | 0.1970 | 1.19e-02 | 4.97e-02 | -1.22e-01 | -6.62e-02 | -1.30e-01 | 9.26e-01 | 7.00e-01 | 3.45e-01 | 6.08e-01 | 3.15e-01 |
| SEQUESTERING OF TRIGLYCERIDE | 18 | 7.35e-01 | 9.47e-01 | 0.1970 | 1.38e-01 | 1.20e-01 | -7.17e-03 | 2.57e-02 | -6.85e-02 | 3.12e-01 | 3.78e-01 | 9.58e-01 | 8.50e-01 | 6.15e-01 |
| RESPONSE TO REACTIVE OXYGEN SPECIES | 196 | 3.78e-02 | 2.52e-01 | 0.1970 | 7.41e-02 | 7.53e-02 | 8.93e-02 | 1.28e-01 | 5.56e-02 | 7.35e-02 | 6.89e-02 | 3.11e-02 | 1.92e-03 | 1.80e-01 |
| RIBONUCLEOSIDE CATABOLIC PROCESS | 20 | 8.25e-01 | 9.72e-01 | 0.1970 | 2.84e-02 | 4.05e-03 | -9.08e-02 | -5.31e-02 | -1.64e-01 | 8.26e-01 | 9.75e-01 | 4.82e-01 | 6.81e-01 | 2.05e-01 |
| POSITIVE REGULATION OF MITOTIC CYTOKINESIS | 8 | 7.15e-01 | 9.36e-01 | 0.1970 | 1.08e-02 | -1.53e-01 | -4.08e-02 | 2.40e-02 | -1.13e-01 | 9.58e-01 | 4.52e-01 | 8.42e-01 | 9.06e-01 | 5.79e-01 |
| INTRACELLULAR PH ELEVATION | 7 | 9.40e-01 | 9.92e-01 | 0.1970 | -1.65e-01 | -6.19e-02 | -4.90e-02 | -6.18e-02 | 3.54e-02 | 4.48e-01 | 7.77e-01 | 8.22e-01 | 7.77e-01 | 8.71e-01 |
| SEROTONIN UPTAKE | 12 | 3.25e-01 | 7.35e-01 | 0.1970 | 1.10e-02 | 1.81e-01 | 2.78e-02 | 6.12e-02 | -3.54e-02 | 9.47e-01 | 2.77e-01 | 8.67e-01 | 7.14e-01 | 8.32e-01 |
| PML BODY ORGANIZATION | 7 | 6.44e-01 | 9.15e-01 | 0.1970 | -2.52e-02 | -6.00e-02 | 6.67e-02 | 1.58e-01 | -7.00e-02 | 9.08e-01 | 7.83e-01 | 7.60e-01 | 4.68e-01 | 7.49e-01 |
| REGULATION OF CHOLESTEROL EFFLUX | 54 | 2.73e-01 | 6.81e-01 | 0.1970 | -1.34e-02 | -6.17e-03 | -5.57e-02 | -4.69e-02 | -1.82e-01 | 8.65e-01 | 9.37e-01 | 4.79e-01 | 5.51e-01 | 2.06e-02 |
| ACTIVATION OF ADENYLATE CYCLASE ACTIVITY | 25 | 8.62e-01 | 9.78e-01 | 0.1970 | -8.87e-02 | -5.02e-02 | -7.29e-02 | -1.31e-01 | -7.67e-02 | 4.43e-01 | 6.64e-01 | 5.28e-01 | 2.59e-01 | 5.07e-01 |
| ORGANELLE ASSEMBLY | 961 | 4.01e-07 | 1.98e-05 | 0.1960 | 9.09e-02 | 8.02e-02 | 8.42e-02 | 1.11e-01 | 6.67e-02 | 1.81e-06 | 2.51e-05 | 9.83e-06 | 5.24e-09 | 4.56e-04 |
| SMOOTHENED SIGNALING PATHWAY INVOLVED IN VENTRAL SPINAL CORD PATTERNING | 8 | 9.66e-01 | 9.94e-01 | 0.1960 | -3.65e-02 | -1.91e-02 | 8.44e-02 | 5.53e-02 | 1.63e-01 | 8.58e-01 | 9.26e-01 | 6.79e-01 | 7.87e-01 | 4.23e-01 |
| REGULATION OF AMIDE METABOLIC PROCESS | 570 | 5.16e-04 | 1.04e-02 | 0.1960 | 9.58e-02 | 7.45e-02 | 8.98e-02 | 1.11e-01 | 5.93e-02 | 9.15e-05 | 2.36e-03 | 2.47e-04 | 6.39e-06 | 1.55e-02 |
| REGULATION OF CHRONIC INFLAMMATORY RESPONSE | 9 | 8.98e-01 | 9.82e-01 | 0.1960 | -1.30e-01 | -1.27e-01 | -5.76e-02 | -4.49e-03 | -4.75e-02 | 5.00e-01 | 5.10e-01 | 7.65e-01 | 9.81e-01 | 8.05e-01 |
| REGULATION OF PROTEIN KINASE C SIGNALING | 18 | 7.77e-01 | 9.58e-01 | 0.1960 | -1.35e-01 | -3.58e-02 | -7.22e-02 | -1.14e-01 | 2.56e-02 | 3.20e-01 | 7.92e-01 | 5.96e-01 | 4.02e-01 | 8.51e-01 |
| EYE PHOTORECEPTOR CELL DEVELOPMENT | 34 | 1.61e-01 | 5.36e-01 | 0.1960 | -1.03e-01 | 8.02e-03 | -6.51e-02 | -1.41e-01 | 6.11e-02 | 2.97e-01 | 9.35e-01 | 5.11e-01 | 1.56e-01 | 5.37e-01 |
| NATURAL KILLER CELL DIFFERENTIATION | 24 | 7.68e-01 | 9.55e-01 | 0.1960 | 1.44e-03 | 9.99e-03 | 1.09e-01 | 1.02e-01 | 1.27e-01 | 9.90e-01 | 9.32e-01 | 3.56e-01 | 3.88e-01 | 2.81e-01 |
| TNFSF11 MEDIATED SIGNALING PATHWAY | 5 | 8.40e-01 | 9.73e-01 | 0.1960 | 6.14e-02 | 7.34e-02 | -7.86e-02 | -1.47e-01 | -3.76e-02 | 8.12e-01 | 7.76e-01 | 7.61e-01 | 5.68e-01 | 8.84e-01 |
| MITOCHONDRIAL GENOME MAINTENANCE | 31 | 7.09e-01 | 9.34e-01 | 0.1960 | -3.42e-03 | 1.19e-02 | 1.03e-01 | 5.85e-02 | 1.55e-01 | 9.74e-01 | 9.09e-01 | 3.19e-01 | 5.73e-01 | 1.34e-01 |
| STRIATUM DEVELOPMENT | 20 | 7.20e-01 | 9.38e-01 | 0.1960 | 4.62e-02 | 1.30e-02 | -5.50e-02 | -6.17e-02 | -1.71e-01 | 7.20e-01 | 9.20e-01 | 6.70e-01 | 6.33e-01 | 1.85e-01 |
| CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 528 | 1.42e-04 | 3.60e-03 | 0.1960 | 9.25e-02 | 1.02e-01 | 7.64e-02 | 8.42e-02 | 8.13e-02 | 2.77e-04 | 6.47e-05 | 2.67e-03 | 9.22e-04 | 1.38e-03 |
| NEGATIVE REGULATION OF FATTY ACID METABOLIC PROCESS | 41 | 3.49e-01 | 7.52e-01 | 0.1960 | 4.12e-02 | 3.63e-02 | -4.89e-02 | 1.34e-03 | -1.82e-01 | 6.48e-01 | 6.87e-01 | 5.88e-01 | 9.88e-01 | 4.42e-02 |
| REGULATION OF RECEPTOR SIGNALING PATHWAY VIA STAT | 112 | 3.72e-01 | 7.71e-01 | 0.1960 | -1.15e-01 | -9.75e-02 | -7.94e-02 | -7.89e-02 | -5.51e-02 | 3.50e-02 | 7.47e-02 | 1.47e-01 | 1.49e-01 | 3.14e-01 |
| GLIAL CELL APOPTOTIC PROCESS | 15 | 6.16e-01 | 9.06e-01 | 0.1960 | -5.27e-04 | 6.42e-02 | 3.53e-02 | -5.22e-02 | 1.74e-01 | 9.97e-01 | 6.67e-01 | 8.13e-01 | 7.27e-01 | 2.43e-01 |
| REGULATION OF HISTAMINE SECRETION BY MAST CELL | 6 | 8.74e-01 | 9.78e-01 | 0.1960 | -1.16e-01 | 4.43e-02 | 4.51e-02 | -1.08e-01 | 9.66e-02 | 6.24e-01 | 8.51e-01 | 8.48e-01 | 6.47e-01 | 6.82e-01 |
| REPRODUCTIVE SYSTEM DEVELOPMENT | 289 | 3.88e-02 | 2.54e-01 | 0.1960 | 9.31e-02 | 9.90e-02 | 9.10e-02 | 7.55e-02 | 7.67e-02 | 6.43e-03 | 3.76e-03 | 7.78e-03 | 2.73e-02 | 2.49e-02 |
| REGULATION OF HEPATOCYTE APOPTOTIC PROCESS | 10 | 6.40e-01 | 9.14e-01 | 0.1960 | 2.29e-02 | 3.26e-02 | -2.92e-02 | 4.39e-02 | 1.84e-01 | 9.00e-01 | 8.58e-01 | 8.73e-01 | 8.10e-01 | 3.13e-01 |
| POSITIVE REGULATION OF CAMP MEDIATED SIGNALING | 15 | 6.27e-01 | 9.09e-01 | 0.1960 | -6.00e-02 | 4.02e-02 | -2.05e-02 | -1.03e-01 | -1.49e-01 | 6.88e-01 | 7.87e-01 | 8.91e-01 | 4.92e-01 | 3.19e-01 |
| MAINTENANCE OF GASTROINTESTINAL EPITHELIUM | 23 | 5.40e-02 | 3.07e-01 | 0.1950 | 2.77e-03 | 8.69e-02 | -7.70e-02 | -1.43e-01 | 6.49e-02 | 9.82e-01 | 4.71e-01 | 5.23e-01 | 2.34e-01 | 5.90e-01 |
| POSITIVE REGULATION OF PROTEIN DEACETYLATION | 10 | 6.52e-01 | 9.19e-01 | 0.1950 | 4.35e-02 | -7.61e-02 | -1.48e-01 | 3.73e-02 | -8.56e-02 | 8.12e-01 | 6.77e-01 | 4.19e-01 | 8.38e-01 | 6.39e-01 |
| MALONYL COA METABOLIC PROCESS | 6 | 9.84e-01 | 9.96e-01 | 0.1950 | 9.31e-02 | 4.80e-02 | 1.27e-01 | 8.83e-02 | 5.76e-02 | 6.93e-01 | 8.39e-01 | 5.91e-01 | 7.08e-01 | 8.07e-01 |
| CORONARY VASCULATURE MORPHOGENESIS | 19 | 7.98e-01 | 9.66e-01 | 0.1950 | -1.07e-01 | -7.04e-02 | -3.84e-02 | -1.39e-01 | -2.95e-02 | 4.20e-01 | 5.95e-01 | 7.72e-01 | 2.93e-01 | 8.24e-01 |
| LUNG GROWTH | 6 | 9.94e-01 | 9.99e-01 | 0.1950 | 3.76e-02 | 3.96e-02 | 1.12e-01 | 1.18e-01 | 9.40e-02 | 8.73e-01 | 8.67e-01 | 6.35e-01 | 6.18e-01 | 6.90e-01 |
| PROTEIN LIPID COMPLEX ORGANIZATION | 54 | 1.15e-02 | 1.12e-01 | 0.1950 | -9.06e-02 | 5.28e-02 | -5.33e-02 | -1.06e-01 | -1.13e-01 | 2.49e-01 | 5.02e-01 | 4.98e-01 | 1.76e-01 | 1.51e-01 |
| RESPONSE TO LEUKEMIA INHIBITORY FACTOR | 101 | 3.81e-01 | 7.78e-01 | 0.1950 | 8.71e-02 | 6.31e-02 | 8.07e-02 | 9.41e-02 | 1.05e-01 | 1.30e-01 | 2.73e-01 | 1.61e-01 | 1.02e-01 | 6.90e-02 |
| POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 17 | 8.61e-01 | 9.78e-01 | 0.1950 | -4.33e-02 | 4.93e-03 | 7.89e-02 | 3.91e-02 | 1.68e-01 | 7.57e-01 | 9.72e-01 | 5.73e-01 | 7.80e-01 | 2.30e-01 |
| MYELOID LEUKOCYTE MEDIATED IMMUNITY | 107 | 3.68e-01 | 7.69e-01 | 0.1950 | 9.72e-02 | 1.20e-01 | 8.34e-02 | 8.34e-02 | -4.37e-03 | 8.23e-02 | 3.14e-02 | 1.36e-01 | 1.36e-01 | 9.38e-01 |
| DIACYLGLYCEROL METABOLIC PROCESS | 26 | 1.20e-01 | 4.73e-01 | 0.1950 | -8.15e-02 | 8.03e-02 | -4.35e-02 | -1.09e-01 | -1.05e-01 | 4.72e-01 | 4.78e-01 | 7.01e-01 | 3.38e-01 | 3.53e-01 |
| NEGATIVE REGULATION OF SPROUTING ANGIOGENESIS | 27 | 4.50e-01 | 8.20e-01 | 0.1950 | 1.41e-01 | 5.74e-02 | 7.09e-02 | 5.36e-02 | 8.21e-02 | 2.04e-01 | 6.06e-01 | 5.24e-01 | 6.30e-01 | 4.60e-01 |
| ALDITOL PHOSPHATE METABOLIC PROCESS | 10 | 3.37e-01 | 7.43e-01 | 0.1950 | 9.36e-02 | 4.70e-02 | -1.09e-01 | -6.28e-02 | 1.05e-01 | 6.08e-01 | 7.97e-01 | 5.51e-01 | 7.31e-01 | 5.65e-01 |
| REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 94 | 4.84e-01 | 8.38e-01 | 0.1950 | 4.83e-02 | 7.18e-02 | 1.11e-01 | 7.64e-02 | 1.10e-01 | 4.18e-01 | 2.29e-01 | 6.23e-02 | 2.01e-01 | 6.49e-02 |
| REGULATION OF RUFFLE ASSEMBLY | 32 | 6.07e-01 | 9.02e-01 | 0.1940 | 6.93e-02 | 5.07e-02 | 6.53e-02 | 1.43e-01 | 7.47e-02 | 4.97e-01 | 6.19e-01 | 5.22e-01 | 1.60e-01 | 4.64e-01 |
| ATP TRANSPORT | 17 | 8.82e-01 | 9.79e-01 | 0.1940 | 9.98e-02 | 1.10e-01 | 3.37e-02 | 7.47e-02 | -9.55e-02 | 4.76e-01 | 4.34e-01 | 8.10e-01 | 5.94e-01 | 4.95e-01 |
| POSITIVE REGULATION OF TRIGLYCERIDE BIOSYNTHETIC PROCESS | 13 | 9.73e-01 | 9.95e-01 | 0.1940 | 4.43e-02 | 9.64e-02 | 1.27e-01 | 7.65e-02 | 6.68e-02 | 7.82e-01 | 5.47e-01 | 4.27e-01 | 6.33e-01 | 6.77e-01 |
| GERMINAL CENTER B CELL DIFFERENTIATION | 9 | 9.28e-01 | 9.89e-01 | 0.1940 | 1.05e-01 | 7.82e-02 | -2.54e-02 | 7.01e-02 | -1.23e-01 | 5.85e-01 | 6.85e-01 | 8.95e-01 | 7.16e-01 | 5.24e-01 |
| PENILE ERECTION | 7 | 9.34e-01 | 9.91e-01 | 0.1940 | 2.08e-03 | -5.18e-02 | 1.39e-02 | 3.83e-02 | 1.83e-01 | 9.92e-01 | 8.12e-01 | 9.49e-01 | 8.61e-01 | 4.02e-01 |
| GLYCOSIDE CATABOLIC PROCESS | 8 | 8.93e-01 | 9.81e-01 | 0.1940 | -1.75e-02 | 2.07e-02 | 1.22e-01 | 1.34e-01 | 6.49e-02 | 9.32e-01 | 9.19e-01 | 5.52e-01 | 5.10e-01 | 7.50e-01 |
| PROTEIN TRIMERIZATION | 17 | 3.11e-01 | 7.22e-01 | 0.1940 | 4.64e-02 | 1.82e-02 | -1.16e-01 | -1.45e-01 | -3.12e-02 | 7.41e-01 | 8.97e-01 | 4.09e-01 | 3.02e-01 | 8.24e-01 |
| POSITIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL PROLIFERATION | 10 | 8.06e-01 | 9.67e-01 | 0.1940 | -1.18e-01 | -1.49e-01 | -3.22e-02 | 2.35e-02 | -9.16e-03 | 5.20e-01 | 4.14e-01 | 8.60e-01 | 8.98e-01 | 9.60e-01 |
| NUCLEOBASE CONTAINING SMALL MOLECULE METABOLIC PROCESS | 567 | 6.55e-04 | 1.25e-02 | 0.1940 | 8.52e-02 | 8.92e-02 | 8.83e-02 | 8.28e-02 | 8.88e-02 | 5.22e-04 | 2.82e-04 | 3.24e-04 | 7.53e-04 | 2.99e-04 |
| T CELL ACTIVATION VIA T CELL RECEPTOR CONTACT WITH ANTIGEN BOUND TO MHC MOLECULE ON ANTIGEN PRESENTING CELL | 10 | 8.47e-01 | 9.76e-01 | 0.1940 | 1.16e-01 | 3.07e-03 | -1.79e-02 | 1.05e-01 | -1.14e-01 | 5.25e-01 | 9.87e-01 | 9.22e-01 | 5.66e-01 | 5.34e-01 |
| CARTILAGE CONDENSATION | 19 | 5.57e-01 | 8.77e-01 | 0.1940 | -9.59e-02 | -6.48e-02 | 9.14e-02 | 3.38e-03 | 1.26e-01 | 4.69e-01 | 6.25e-01 | 4.90e-01 | 9.80e-01 | 3.41e-01 |
| NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 55 | 1.74e-01 | 5.59e-01 | 0.1940 | -5.16e-02 | -5.70e-03 | 6.10e-02 | 5.80e-02 | 1.67e-01 | 5.08e-01 | 9.42e-01 | 4.34e-01 | 4.57e-01 | 3.21e-02 |
| DNA METHYLATION DEPENDENT HETEROCHROMATIN FORMATION | 28 | 3.90e-02 | 2.55e-01 | 0.1940 | 2.35e-02 | -1.29e-01 | -7.01e-02 | 1.11e-01 | -5.78e-02 | 8.30e-01 | 2.39e-01 | 5.21e-01 | 3.09e-01 | 5.96e-01 |
| POSITIVE REGULATION OF TELOMERE CAPPING | 17 | 9.37e-01 | 9.92e-01 | 0.1940 | 5.62e-02 | 8.49e-02 | 8.09e-02 | 1.15e-01 | 8.71e-02 | 6.88e-01 | 5.45e-01 | 5.64e-01 | 4.13e-01 | 5.34e-01 |
| RESPONSE TO MINERALOCORTICOID | 33 | 3.63e-01 | 7.63e-01 | 0.1940 | 1.39e-02 | 1.08e-01 | 1.32e-01 | 7.54e-03 | 9.16e-02 | 8.90e-01 | 2.84e-01 | 1.90e-01 | 9.40e-01 | 3.62e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 69 | 1.17e-01 | 4.66e-01 | 0.1940 | -1.63e-03 | -1.02e-02 | 7.82e-02 | 1.06e-01 | 1.42e-01 | 9.81e-01 | 8.83e-01 | 2.61e-01 | 1.27e-01 | 4.18e-02 |
| PROTEIN LIPID COMPLEX ASSEMBLY | 30 | 2.50e-02 | 1.93e-01 | 0.1940 | -9.48e-02 | 8.71e-02 | -4.13e-02 | -7.13e-02 | -1.19e-01 | 3.69e-01 | 4.09e-01 | 6.95e-01 | 4.99e-01 | 2.59e-01 |
| ADENOSINE TRANSPORT | 5 | 8.53e-01 | 9.76e-01 | 0.1940 | 2.23e-02 | 1.42e-01 | 1.07e-01 | -7.45e-02 | -2.82e-03 | 9.31e-01 | 5.83e-01 | 6.80e-01 | 7.73e-01 | 9.91e-01 |
| POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 19 | 6.41e-01 | 9.14e-01 | 0.1940 | -6.59e-02 | -8.23e-02 | -8.81e-02 | -6.54e-02 | 1.20e-01 | 6.19e-01 | 5.35e-01 | 5.06e-01 | 6.21e-01 | 3.66e-01 |
| POSITIVE REGULATION OF GRANULOCYTE CHEMOTAXIS | 27 | 4.70e-01 | 8.30e-01 | 0.1940 | 1.04e-01 | 1.39e-01 | 6.96e-02 | -2.99e-03 | 5.03e-02 | 3.49e-01 | 2.12e-01 | 5.32e-01 | 9.79e-01 | 6.51e-01 |
| REGULATION OF SYNAPTIC VESICLE MEMBRANE ORGANIZATION | 12 | 4.58e-01 | 8.23e-01 | 0.1940 | 2.26e-02 | 1.09e-01 | 8.60e-02 | -6.42e-02 | -1.16e-01 | 8.92e-01 | 5.13e-01 | 6.06e-01 | 7.00e-01 | 4.85e-01 |
| POSITIVE REGULATION OF POTASSIUM ION TRANSPORT | 41 | 2.70e-01 | 6.79e-01 | 0.1940 | -9.48e-02 | -1.56e-02 | -7.79e-02 | -1.48e-01 | 1.36e-02 | 2.94e-01 | 8.62e-01 | 3.88e-01 | 1.00e-01 | 8.80e-01 |
| CARDIAC SEPTUM DEVELOPMENT | 108 | 7.92e-02 | 3.82e-01 | 0.1940 | -8.96e-03 | 3.12e-02 | 9.97e-02 | 8.18e-02 | 1.41e-01 | 8.72e-01 | 5.75e-01 | 7.36e-02 | 1.42e-01 | 1.15e-02 |
| POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 14 | 2.40e-01 | 6.44e-01 | 0.1940 | -6.62e-02 | -1.17e-01 | 2.73e-02 | 1.34e-01 | -2.95e-02 | 6.68e-01 | 4.50e-01 | 8.60e-01 | 3.86e-01 | 8.48e-01 |
| REGULATION OF OSSIFICATION | 116 | 1.22e-02 | 1.18e-01 | 0.1930 | 3.74e-03 | 9.24e-02 | 1.00e-01 | 9.21e-02 | 1.02e-01 | 9.45e-01 | 8.55e-02 | 6.26e-02 | 8.66e-02 | 5.81e-02 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO CHROMOSOME | 27 | 8.24e-01 | 9.71e-01 | 0.1930 | 7.68e-02 | 5.64e-02 | 1.18e-01 | 1.18e-01 | 2.33e-02 | 4.90e-01 | 6.12e-01 | 2.88e-01 | 2.90e-01 | 8.34e-01 |
| T CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 9 | 5.84e-01 | 8.90e-01 | 0.1930 | -8.96e-02 | 8.15e-03 | 1.52e-01 | 7.66e-02 | 1.94e-02 | 6.41e-01 | 9.66e-01 | 4.31e-01 | 6.91e-01 | 9.20e-01 |
| VERY LONG CHAIN FATTY ACID CATABOLIC PROCESS | 6 | 8.78e-01 | 9.79e-01 | 0.1930 | 3.39e-02 | -2.93e-02 | 1.30e-01 | 1.35e-01 | 1.29e-02 | 8.86e-01 | 9.01e-01 | 5.82e-01 | 5.66e-01 | 9.56e-01 |
| PROTEIN MODIFICATION BY SMALL PROTEIN REMOVAL | 107 | 3.29e-02 | 2.30e-01 | 0.1930 | 1.07e-01 | 3.24e-02 | 5.51e-02 | 1.39e-01 | 5.13e-02 | 5.65e-02 | 5.62e-01 | 3.25e-01 | 1.33e-02 | 3.59e-01 |
| REGULATION OF CELLULAR CATABOLIC PROCESS | 686 | 3.97e-06 | 1.64e-04 | 0.1930 | 9.14e-02 | 6.38e-02 | 7.86e-02 | 1.10e-01 | 8.06e-02 | 4.44e-05 | 4.40e-03 | 4.51e-04 | 8.38e-07 | 3.18e-04 |
| REGULATION OF KINASE ACTIVITY | 565 | 4.75e-04 | 9.73e-03 | 0.1930 | 9.83e-02 | 1.01e-01 | 7.55e-02 | 9.27e-02 | 5.62e-02 | 6.46e-05 | 4.24e-05 | 2.16e-03 | 1.65e-04 | 2.23e-02 |
| ELASTIC FIBER ASSEMBLY | 9 | 9.22e-01 | 9.88e-01 | 0.1930 | 7.79e-02 | 6.16e-02 | -7.49e-02 | -2.62e-02 | -1.45e-01 | 6.86e-01 | 7.49e-01 | 6.97e-01 | 8.92e-01 | 4.51e-01 |
| REGULATION OF MICROVILLUS ORGANIZATION | 13 | 7.65e-01 | 9.54e-01 | 0.1930 | -7.90e-02 | -9.87e-02 | -2.04e-02 | -9.38e-02 | -1.10e-01 | 6.22e-01 | 5.38e-01 | 8.99e-01 | 5.58e-01 | 4.94e-01 |
| POSITIVE REGULATION OF OSTEOCLAST DIFFERENTIATION | 27 | 2.38e-02 | 1.88e-01 | 0.1930 | 3.72e-02 | 1.47e-01 | -8.74e-02 | -4.72e-02 | -6.61e-02 | 7.38e-01 | 1.87e-01 | 4.32e-01 | 6.71e-01 | 5.52e-01 |
| INTERLEUKIN 12 PRODUCTION | 62 | 2.67e-01 | 6.74e-01 | 0.1930 | 1.23e-01 | 1.09e-01 | 3.52e-02 | 7.42e-02 | 5.76e-02 | 9.46e-02 | 1.37e-01 | 6.32e-01 | 3.12e-01 | 4.32e-01 |
| POSITIVE REGULATION OF SPROUTING ANGIOGENESIS | 28 | 2.97e-01 | 7.08e-01 | 0.1920 | 6.15e-02 | 4.01e-02 | -7.53e-02 | -1.04e-01 | -1.23e-01 | 5.73e-01 | 7.13e-01 | 4.90e-01 | 3.40e-01 | 2.60e-01 |
| REGULATION OF CHEMOKINE MEDIATED SIGNALING PATHWAY | 9 | 7.35e-01 | 9.47e-01 | 0.1920 | -6.29e-02 | 2.13e-02 | -9.77e-02 | -1.36e-01 | 6.87e-02 | 7.44e-01 | 9.12e-01 | 6.12e-01 | 4.81e-01 | 7.21e-01 |
| POSITIVE REGULATION OF GAMMA DELTA T CELL ACTIVATION | 9 | 9.53e-01 | 9.94e-01 | 0.1920 | 1.35e-01 | 1.10e-01 | 7.44e-02 | 3.35e-02 | -1.21e-02 | 4.83e-01 | 5.69e-01 | 6.99e-01 | 8.62e-01 | 9.50e-01 |
| HOMOPHILIC CELL ADHESION VIA PLASMA MEMBRANE ADHESION MOLECULES | 164 | 8.96e-07 | 4.24e-05 | 0.1920 | -8.39e-02 | 5.87e-03 | -1.20e-02 | -1.09e-01 | -1.34e-01 | 6.39e-02 | 8.97e-01 | 7.91e-01 | 1.55e-02 | 3.15e-03 |
| NEGATIVE REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 18 | 4.34e-01 | 8.08e-01 | 0.1920 | 8.98e-02 | 1.09e-01 | -4.44e-02 | 7.37e-02 | -9.77e-02 | 5.09e-01 | 4.21e-01 | 7.44e-01 | 5.88e-01 | 4.73e-01 |
| NUCLEOSIDE TRIPHOSPHATE CATABOLIC PROCESS | 12 | 7.68e-01 | 9.55e-01 | 0.1920 | 6.37e-02 | 1.40e-02 | 2.14e-02 | 2.03e-02 | 1.79e-01 | 7.03e-01 | 9.33e-01 | 8.98e-01 | 9.03e-01 | 2.84e-01 |
| NAD METABOLIC PROCESS | 42 | 7.94e-01 | 9.65e-01 | 0.1920 | 8.03e-02 | 1.12e-01 | 7.63e-02 | 7.42e-02 | 8.14e-02 | 3.68e-01 | 2.08e-01 | 3.92e-01 | 4.05e-01 | 3.62e-01 |
| CELLULAR RESPONSE TO OXIDATIVE STRESS | 248 | 7.31e-02 | 3.66e-01 | 0.1920 | 8.24e-02 | 7.52e-02 | 8.26e-02 | 9.79e-02 | 9.02e-02 | 2.54e-02 | 4.13e-02 | 2.51e-02 | 7.90e-03 | 1.44e-02 |
| GLAND MORPHOGENESIS | 120 | 1.39e-01 | 5.03e-01 | 0.1920 | 6.24e-02 | 1.27e-01 | 1.06e-01 | 6.22e-02 | 4.25e-02 | 2.38e-01 | 1.64e-02 | 4.42e-02 | 2.39e-01 | 4.22e-01 |
| NEGATIVE REGULATION OF ORGAN GROWTH | 35 | 6.79e-01 | 9.28e-01 | 0.1920 | 9.24e-02 | 1.38e-01 | 8.62e-02 | 3.58e-02 | 2.26e-02 | 3.44e-01 | 1.57e-01 | 3.77e-01 | 7.14e-01 | 8.17e-01 |
| MESENCHYMAL CELL MIGRATION | 61 | 3.06e-02 | 2.20e-01 | 0.1920 | -1.06e-01 | -1.36e-02 | 5.36e-03 | -8.98e-03 | 1.59e-01 | 1.53e-01 | 8.54e-01 | 9.42e-01 | 9.03e-01 | 3.12e-02 |
| CELLULAR CATABOLIC PROCESS | 1537 | 1.28e-10 | 1.04e-08 | 0.1920 | 9.83e-02 | 8.06e-02 | 7.95e-02 | 1.04e-01 | 6.06e-02 | 1.17e-10 | 1.29e-07 | 1.92e-07 | 1.03e-11 | 7.22e-05 |
| POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 60 | 6.67e-02 | 3.45e-01 | 0.1920 | 8.92e-02 | 1.53e-01 | 2.09e-02 | 5.17e-02 | -5.04e-02 | 2.32e-01 | 4.08e-02 | 7.80e-01 | 4.89e-01 | 5.00e-01 |
| ESTABLISHMENT OR MAINTENANCE OF CYTOSKELETON POLARITY | 7 | 9.86e-01 | 9.97e-01 | 0.1920 | -7.87e-02 | -3.67e-02 | -6.81e-02 | -1.32e-01 | -8.56e-02 | 7.18e-01 | 8.66e-01 | 7.55e-01 | 5.46e-01 | 6.95e-01 |
| CHEMOKINE C X C MOTIF LIGAND 2 PRODUCTION | 19 | 8.12e-01 | 9.68e-01 | 0.1920 | 1.42e-01 | 8.76e-02 | 4.17e-02 | 6.22e-02 | 5.95e-02 | 2.85e-01 | 5.08e-01 | 7.53e-01 | 6.39e-01 | 6.53e-01 |
| RESPONSE TO FIBROBLAST GROWTH FACTOR | 116 | 1.27e-02 | 1.21e-01 | 0.1920 | -2.89e-02 | 2.07e-02 | 8.71e-02 | 8.64e-02 | 1.43e-01 | 5.91e-01 | 7.00e-01 | 1.05e-01 | 1.08e-01 | 7.74e-03 |
| NEGATIVE REGULATION OF BONE MINERALIZATION | 18 | 4.80e-01 | 8.35e-01 | 0.1920 | -9.25e-03 | 1.50e-01 | 1.06e-01 | 3.77e-02 | 3.91e-02 | 9.46e-01 | 2.71e-01 | 4.36e-01 | 7.82e-01 | 7.74e-01 |
| FEEDING BEHAVIOR | 102 | 3.24e-01 | 7.33e-01 | 0.1920 | 6.38e-02 | 1.13e-01 | 1.12e-01 | 6.29e-02 | 5.78e-02 | 2.66e-01 | 4.86e-02 | 4.97e-02 | 2.72e-01 | 3.13e-01 |
| HORMONE BIOSYNTHETIC PROCESS | 65 | 4.76e-01 | 8.33e-01 | 0.1920 | -1.14e-01 | -6.96e-02 | -7.67e-02 | -1.10e-01 | 2.95e-02 | 1.12e-01 | 3.32e-01 | 2.85e-01 | 1.24e-01 | 6.81e-01 |
| NEURONAL ION CHANNEL CLUSTERING | 12 | 7.67e-01 | 9.55e-01 | 0.1920 | -1.32e-01 | -8.19e-02 | 6.42e-02 | 7.04e-04 | 9.20e-02 | 4.28e-01 | 6.23e-01 | 7.00e-01 | 9.97e-01 | 5.81e-01 |
| MALE GENITALIA DEVELOPMENT | 23 | 7.48e-01 | 9.51e-01 | 0.1920 | -1.49e-01 | -8.78e-02 | -1.09e-02 | -5.66e-02 | 5.94e-02 | 2.17e-01 | 4.66e-01 | 9.28e-01 | 6.38e-01 | 6.22e-01 |
| NAD BIOSYNTHESIS VIA NICOTINAMIDE RIBOSIDE SALVAGE PATHWAY | 10 | 7.37e-01 | 9.48e-01 | 0.1920 | -2.94e-02 | -9.89e-02 | -2.85e-02 | 7.26e-02 | 1.41e-01 | 8.72e-01 | 5.88e-01 | 8.76e-01 | 6.91e-01 | 4.39e-01 |
| REGULATION OF SKELETAL MUSCLE CELL PROLIFERATION | 15 | 9.08e-01 | 9.85e-01 | 0.1920 | 1.53e-02 | 7.44e-02 | 7.41e-02 | 7.33e-02 | 1.42e-01 | 9.18e-01 | 6.18e-01 | 6.19e-01 | 6.23e-01 | 3.42e-01 |
| FACULTATIVE HETEROCHROMATIN FORMATION | 40 | 1.03e-02 | 1.03e-01 | 0.1920 | 8.76e-02 | -6.15e-02 | -5.25e-02 | 1.37e-01 | -6.16e-02 | 3.38e-01 | 5.01e-01 | 5.66e-01 | 1.35e-01 | 5.00e-01 |
| POSITIVE REGULATION OF CYTOSKELETON ORGANIZATION | 180 | 1.32e-01 | 4.92e-01 | 0.1910 | 1.06e-01 | 9.74e-02 | 6.47e-02 | 9.95e-02 | 4.27e-02 | 1.43e-02 | 2.41e-02 | 1.34e-01 | 2.13e-02 | 3.23e-01 |
| REGULATION OF PLASMA MEMBRANE REPAIR | 6 | 9.58e-01 | 9.94e-01 | 0.1910 | -1.54e-01 | -9.68e-02 | -7.02e-03 | -1.32e-02 | 5.72e-02 | 5.13e-01 | 6.81e-01 | 9.76e-01 | 9.55e-01 | 8.08e-01 |
| PROTEIN COMPLEX OLIGOMERIZATION | 249 | 9.88e-02 | 4.28e-01 | 0.1910 | 9.12e-02 | 8.78e-02 | 8.88e-02 | 7.98e-02 | 7.94e-02 | 1.32e-02 | 1.71e-02 | 1.57e-02 | 3.01e-02 | 3.09e-02 |
| AMIDE CATABOLIC PROCESS | 20 | 1.66e-01 | 5.46e-01 | 0.1910 | -9.09e-03 | 1.03e-01 | -6.17e-02 | -1.47e-01 | -2.29e-02 | 9.44e-01 | 4.25e-01 | 6.33e-01 | 2.56e-01 | 8.59e-01 |
| POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 23 | 6.06e-01 | 9.01e-01 | 0.1910 | 8.54e-02 | 2.51e-02 | 3.52e-02 | 6.55e-02 | 1.52e-01 | 4.78e-01 | 8.35e-01 | 7.70e-01 | 5.87e-01 | 2.07e-01 |
| CELL CELL SIGNALING INVOLVED IN CARDIAC CONDUCTION | 32 | 2.09e-01 | 6.03e-01 | 0.1910 | -1.13e-01 | 3.83e-03 | -1.49e-02 | -1.38e-01 | -6.71e-02 | 2.68e-01 | 9.70e-01 | 8.84e-01 | 1.77e-01 | 5.12e-01 |
| CYSTEINE METABOLIC PROCESS | 11 | 9.55e-01 | 9.94e-01 | 0.1910 | 6.85e-02 | 8.40e-02 | 5.21e-02 | 8.01e-02 | 1.25e-01 | 6.94e-01 | 6.30e-01 | 7.65e-01 | 6.46e-01 | 4.74e-01 |
| CARDIAC VENTRICLE DEVELOPMENT | 127 | 3.90e-03 | 5.13e-02 | 0.1910 | -8.04e-02 | -1.27e-02 | 7.72e-02 | 7.61e-04 | 1.54e-01 | 1.18e-01 | 8.04e-01 | 1.33e-01 | 9.88e-01 | 2.65e-03 |
| REGULATION OF CALCINEURIN MEDIATED SIGNALING | 41 | 7.43e-01 | 9.50e-01 | 0.1910 | -6.06e-02 | -7.78e-02 | -1.27e-01 | -6.83e-02 | -7.65e-02 | 5.02e-01 | 3.89e-01 | 1.59e-01 | 4.49e-01 | 3.97e-01 |
| REGULATION OF SYNAPTIC VESICLE CLUSTERING | 6 | 9.49e-01 | 9.94e-01 | 0.1910 | -1.30e-01 | -6.73e-02 | -6.01e-02 | -2.75e-02 | -1.03e-01 | 5.82e-01 | 7.75e-01 | 7.99e-01 | 9.07e-01 | 6.63e-01 |
| ARTERY MORPHOGENESIS | 81 | 1.08e-01 | 4.51e-01 | 0.1900 | -4.37e-02 | 1.27e-02 | 7.97e-02 | 1.63e-02 | 1.66e-01 | 4.96e-01 | 8.43e-01 | 2.15e-01 | 8.00e-01 | 9.74e-03 |
| MUSCLE ATROPHY | 10 | 9.53e-01 | 9.94e-01 | 0.1900 | -8.58e-02 | -2.07e-02 | -5.52e-02 | -1.13e-01 | -1.12e-01 | 6.39e-01 | 9.10e-01 | 7.62e-01 | 5.36e-01 | 5.38e-01 |
| REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 25 | 5.39e-01 | 8.67e-01 | 0.1900 | 7.74e-02 | 7.19e-02 | 3.00e-02 | 1.19e-01 | 9.98e-02 | 5.03e-01 | 5.34e-01 | 7.95e-01 | 3.01e-01 | 3.88e-01 |
| NEUROTRANSMITTER METABOLIC PROCESS | 25 | 1.07e-01 | 4.48e-01 | 0.1900 | -9.73e-02 | 9.99e-02 | 7.34e-02 | -6.02e-02 | 8.82e-02 | 4.00e-01 | 3.87e-01 | 5.25e-01 | 6.03e-01 | 4.45e-01 |
| POSITIVE REGULATION OF FATTY ACID METABOLIC PROCESS | 38 | 7.10e-01 | 9.35e-01 | 0.1900 | 4.24e-02 | 1.13e-01 | 1.03e-01 | 4.60e-02 | 9.42e-02 | 6.51e-01 | 2.28e-01 | 2.71e-01 | 6.23e-01 | 3.15e-01 |
| PROXIMAL TUBULE DEVELOPMENT | 10 | 5.99e-01 | 8.98e-01 | 0.1900 | -5.27e-02 | 5.11e-02 | -6.39e-02 | -1.13e-01 | 1.18e-01 | 7.73e-01 | 7.80e-01 | 7.26e-01 | 5.36e-01 | 5.18e-01 |
| NEGATIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 45 | 1.83e-01 | 5.69e-01 | 0.1900 | 1.05e-01 | 1.23e-01 | -2.29e-02 | 1.53e-02 | -9.51e-02 | 2.21e-01 | 1.52e-01 | 7.91e-01 | 8.59e-01 | 2.70e-01 |
| PROSTATE GLANDULAR ACINUS MORPHOGENESIS | 6 | 9.40e-01 | 9.92e-01 | 0.1900 | -3.12e-02 | -5.43e-02 | 1.06e-01 | 3.03e-02 | 1.42e-01 | 8.95e-01 | 8.18e-01 | 6.53e-01 | 8.98e-01 | 5.47e-01 |
| ENDOTHELIAL CELL CHEMOTAXIS | 27 | 4.22e-01 | 8.03e-01 | 0.1900 | -1.45e-01 | -8.97e-02 | 8.82e-03 | -7.89e-02 | -2.66e-02 | 1.92e-01 | 4.20e-01 | 9.37e-01 | 4.78e-01 | 8.11e-01 |
| SMOOTHENED SIGNALING PATHWAY | 140 | 7.21e-02 | 3.64e-01 | 0.1900 | 1.88e-02 | 6.92e-02 | 8.95e-02 | 7.61e-02 | 1.31e-01 | 7.01e-01 | 1.57e-01 | 6.76e-02 | 1.20e-01 | 7.42e-03 |
| MUSCLE CELL PROLIFERATION | 230 | 3.35e-02 | 2.33e-01 | 0.1900 | 8.31e-02 | 1.25e-01 | 8.67e-02 | 6.62e-02 | 4.05e-02 | 2.99e-02 | 1.09e-03 | 2.34e-02 | 8.35e-02 | 2.90e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 13 | 9.14e-01 | 9.86e-01 | 0.1900 | -9.07e-02 | -1.14e-01 | -4.11e-02 | -8.25e-02 | -7.91e-02 | 5.71e-01 | 4.76e-01 | 7.98e-01 | 6.07e-01 | 6.22e-01 |
| REGULATION OF CLATHRIN DEPENDENT ENDOCYTOSIS | 18 | 9.74e-01 | 9.95e-01 | 0.1900 | -5.73e-02 | -7.17e-02 | -8.71e-02 | -7.82e-02 | -1.18e-01 | 6.74e-01 | 5.99e-01 | 5.22e-01 | 5.66e-01 | 3.86e-01 |
| ACTIVATION OF PHOSPHOLIPASE C ACTIVITY | 27 | 5.43e-01 | 8.69e-01 | 0.1900 | 6.51e-02 | -2.68e-02 | -9.96e-02 | -4.34e-02 | -1.39e-01 | 5.58e-01 | 8.09e-01 | 3.70e-01 | 6.96e-01 | 2.12e-01 |
| POSITIVE REGULATION OF RECEPTOR INTERNALIZATION | 26 | 9.01e-01 | 9.83e-01 | 0.1900 | -6.35e-02 | -4.55e-02 | -1.15e-01 | -9.58e-02 | -8.63e-02 | 5.75e-01 | 6.88e-01 | 3.09e-01 | 3.98e-01 | 4.46e-01 |
| L KYNURENINE METABOLIC PROCESS | 7 | 8.25e-01 | 9.72e-01 | 0.1900 | 1.02e-01 | 1.35e-01 | -6.21e-02 | -1.91e-02 | -5.53e-02 | 6.40e-01 | 5.35e-01 | 7.76e-01 | 9.30e-01 | 8.00e-01 |
| TUBULIN DEACETYLATION | 19 | 4.12e-01 | 7.97e-01 | 0.1900 | -2.16e-02 | -5.30e-02 | -6.95e-02 | -3.12e-02 | 1.64e-01 | 8.70e-01 | 6.89e-01 | 6.00e-01 | 8.14e-01 | 2.16e-01 |
| NOTCH SIGNALING PATHWAY | 174 | 1.25e-02 | 1.20e-01 | 0.1900 | 6.62e-03 | 3.71e-02 | 7.65e-02 | 7.25e-02 | 1.53e-01 | 8.80e-01 | 3.98e-01 | 8.18e-02 | 9.91e-02 | 4.96e-04 |
| NEGATIVE REGULATION OF IMMUNOGLOBULIN PRODUCTION | 11 | 5.76e-01 | 8.84e-01 | 0.1900 | 4.68e-02 | 1.18e-01 | -3.49e-03 | 6.20e-02 | 1.27e-01 | 7.88e-01 | 4.99e-01 | 9.84e-01 | 7.22e-01 | 4.67e-01 |
| STRIATED MUSCLE CELL APOPTOTIC PROCESS | 58 | 6.37e-01 | 9.13e-01 | 0.1890 | 9.26e-02 | 1.12e-01 | 8.24e-02 | 8.45e-02 | -3.12e-02 | 2.23e-01 | 1.42e-01 | 2.78e-01 | 2.65e-01 | 6.81e-01 |
| POSITIVE REGULATION OF SMAD PROTEIN SIGNAL TRANSDUCTION | 26 | 7.96e-01 | 9.65e-01 | 0.1890 | -1.16e-01 | -1.33e-01 | -5.79e-02 | -3.63e-02 | 9.26e-03 | 3.04e-01 | 2.42e-01 | 6.10e-01 | 7.48e-01 | 9.35e-01 |
| G PROTEIN COUPLED ACETYLCHOLINE RECEPTOR SIGNALING PATHWAY | 21 | 4.62e-01 | 8.25e-01 | 0.1890 | 1.28e-01 | 3.76e-02 | -6.20e-02 | 7.86e-02 | -8.97e-02 | 3.10e-01 | 7.65e-01 | 6.23e-01 | 5.33e-01 | 4.77e-01 |
| NEGATIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 75 | 1.71e-01 | 5.55e-01 | 0.1890 | 1.35e-01 | 1.13e-01 | 1.57e-02 | 5.78e-02 | -3.63e-02 | 4.39e-02 | 9.02e-02 | 8.14e-01 | 3.87e-01 | 5.86e-01 |
| CILIUM DISASSEMBLY | 5 | 8.38e-01 | 9.73e-01 | 0.1890 | -2.62e-02 | 3.74e-02 | -3.95e-04 | -1.70e-01 | 6.96e-02 | 9.19e-01 | 8.85e-01 | 9.99e-01 | 5.10e-01 | 7.88e-01 |
| LONG CHAIN FATTY ACID TRANSPORT | 66 | 5.56e-01 | 8.77e-01 | 0.1890 | -1.08e-01 | -8.07e-02 | -6.29e-02 | -1.16e-01 | 1.57e-02 | 1.30e-01 | 2.57e-01 | 3.77e-01 | 1.03e-01 | 8.26e-01 |
| CIRCADIAN REGULATION OF GENE EXPRESSION | 66 | 2.29e-01 | 6.32e-01 | 0.1890 | 3.35e-02 | 2.32e-02 | 5.28e-02 | 6.07e-02 | 1.66e-01 | 6.37e-01 | 7.44e-01 | 4.59e-01 | 3.94e-01 | 1.95e-02 |
| NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 28 | 7.99e-01 | 9.66e-01 | 0.1890 | 9.21e-02 | 2.94e-02 | 9.36e-02 | 1.14e-01 | 6.75e-02 | 3.99e-01 | 7.88e-01 | 3.91e-01 | 2.95e-01 | 5.36e-01 |
| NUCLEOSIDE BISPHOSPHATE CATABOLIC PROCESS | 11 | 5.63e-01 | 8.79e-01 | 0.1890 | 1.44e-01 | -1.31e-03 | 8.41e-02 | 5.58e-02 | 6.94e-02 | 4.08e-01 | 9.94e-01 | 6.29e-01 | 7.49e-01 | 6.90e-01 |
| NEUROTROPHIN SIGNALING PATHWAY | 38 | 6.72e-01 | 9.26e-01 | 0.1890 | 5.91e-02 | 7.41e-02 | 6.28e-02 | 1.03e-01 | 1.11e-01 | 5.29e-01 | 4.29e-01 | 5.03e-01 | 2.73e-01 | 2.38e-01 |
| SENSORY PERCEPTION OF LIGHT STIMULUS | 208 | 6.99e-02 | 3.57e-01 | 0.1890 | -9.68e-02 | -5.90e-02 | -8.68e-02 | -9.57e-02 | -7.86e-02 | 1.61e-02 | 1.42e-01 | 3.08e-02 | 1.73e-02 | 5.08e-02 |
| NEGATIVE REGULATION OF MUSCLE CONTRACTION | 23 | 8.43e-01 | 9.75e-01 | 0.1890 | 3.38e-02 | 6.91e-02 | 1.17e-01 | 1.17e-01 | 4.82e-02 | 7.79e-01 | 5.66e-01 | 3.31e-01 | 3.30e-01 | 6.89e-01 |
| REGULATION OF WOUND HEALING | 129 | 1.47e-01 | 5.14e-01 | 0.1890 | -5.69e-02 | -3.03e-02 | -9.62e-02 | -9.70e-02 | -1.13e-01 | 2.65e-01 | 5.52e-01 | 5.93e-02 | 5.72e-02 | 2.61e-02 |
| S ADENOSYLMETHIONINE CYCLE | 7 | 9.69e-01 | 9.95e-01 | 0.1890 | 1.02e-01 | 1.83e-02 | 4.56e-02 | 1.23e-01 | 8.81e-02 | 6.39e-01 | 9.33e-01 | 8.34e-01 | 5.74e-01 | 6.86e-01 |
| CELL VOLUME HOMEOSTASIS | 34 | 1.54e-01 | 5.25e-01 | 0.1890 | 4.55e-02 | 1.59e-01 | 8.18e-02 | -2.90e-02 | 2.49e-02 | 6.46e-01 | 1.08e-01 | 4.09e-01 | 7.70e-01 | 8.02e-01 |
| REGULATION OF MUSCLE CELL DIFFERENTIATION | 155 | 2.11e-01 | 6.06e-01 | 0.1890 | 7.14e-02 | 8.34e-02 | 8.48e-02 | 6.92e-02 | 1.08e-01 | 1.25e-01 | 7.31e-02 | 6.85e-02 | 1.37e-01 | 2.08e-02 |
| GLYCOPROTEIN CATABOLIC PROCESS | 33 | 7.44e-01 | 9.50e-01 | 0.1890 | 4.78e-02 | 1.10e-01 | 1.11e-01 | 9.26e-02 | 1.93e-02 | 6.35e-01 | 2.74e-01 | 2.72e-01 | 3.57e-01 | 8.48e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO LYSOSOME | 5 | 9.67e-01 | 9.94e-01 | 0.1890 | 1.23e-01 | 1.31e-01 | -1.21e-02 | 5.36e-02 | -1.78e-02 | 6.35e-01 | 6.11e-01 | 9.63e-01 | 8.35e-01 | 9.45e-01 |
| REGULATION OF PROTEIN MODIFICATION PROCESS | 1250 | 1.10e-09 | 8.05e-08 | 0.1880 | 9.11e-02 | 7.89e-02 | 7.34e-02 | 1.05e-01 | 6.69e-02 | 5.97e-08 | 2.64e-06 | 1.27e-05 | 3.55e-10 | 6.84e-05 |
| MUCOSA ASSOCIATED LYMPHOID TISSUE DEVELOPMENT | 8 | 8.03e-01 | 9.67e-01 | 0.1880 | 8.69e-02 | 5.56e-02 | 1.33e-01 | 5.71e-03 | 8.45e-02 | 6.71e-01 | 7.85e-01 | 5.15e-01 | 9.78e-01 | 6.79e-01 |
| POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR PRODUCTION | 29 | 5.58e-01 | 8.78e-01 | 0.1880 | 8.94e-02 | 1.53e-01 | 5.33e-02 | 1.86e-02 | -2.77e-02 | 4.05e-01 | 1.53e-01 | 6.19e-01 | 8.62e-01 | 7.96e-01 |
| BONE MINERALIZATION INVOLVED IN BONE MATURATION | 13 | 5.78e-01 | 8.86e-01 | 0.1880 | 2.22e-02 | 1.54e-01 | 4.82e-02 | -4.14e-02 | -8.46e-02 | 8.90e-01 | 3.36e-01 | 7.64e-01 | 7.96e-01 | 5.97e-01 |
| PROSTANOID METABOLIC PROCESS | 50 | 5.58e-01 | 8.77e-01 | 0.1880 | 1.24e-01 | 7.58e-02 | 9.02e-02 | 7.68e-02 | 1.23e-02 | 1.28e-01 | 3.54e-01 | 2.70e-01 | 3.47e-01 | 8.80e-01 |
| REGULATION OF PROTEIN DEPHOSPHORYLATION | 75 | 4.12e-01 | 7.97e-01 | 0.1880 | 5.60e-02 | 7.13e-02 | 8.24e-02 | 1.20e-01 | 7.79e-02 | 4.01e-01 | 2.86e-01 | 2.17e-01 | 7.32e-02 | 2.44e-01 |
| POSITIVE REGULATION OF P38MAPK CASCADE | 31 | 9.19e-01 | 9.86e-01 | 0.1880 | 7.39e-02 | 5.97e-02 | 1.03e-01 | 8.21e-02 | 9.48e-02 | 4.76e-01 | 5.65e-01 | 3.21e-01 | 4.29e-01 | 3.61e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CILIUM | 7 | 8.94e-01 | 9.82e-01 | 0.1880 | -1.25e-01 | -5.73e-02 | -8.83e-02 | -4.02e-02 | 8.31e-02 | 5.65e-01 | 7.93e-01 | 6.86e-01 | 8.54e-01 | 7.03e-01 |
| NEGATIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 26 | 2.71e-01 | 6.79e-01 | 0.1880 | -3.59e-03 | 1.49e-01 | 1.08e-01 | 3.80e-02 | 9.88e-03 | 9.75e-01 | 1.89e-01 | 3.41e-01 | 7.38e-01 | 9.31e-01 |
| POSTSYNAPTIC SIGNAL TRANSDUCTION | 38 | 2.79e-01 | 6.90e-01 | 0.1880 | 1.20e-01 | 6.10e-02 | 1.78e-02 | 7.29e-02 | 1.08e-01 | 2.01e-01 | 5.15e-01 | 8.49e-01 | 4.36e-01 | 2.50e-01 |
| NEGATIVE REGULATION OF RECEPTOR INTERNALIZATION | 16 | 6.88e-01 | 9.31e-01 | 0.1880 | 8.66e-02 | 1.09e-02 | 1.05e-01 | 1.26e-01 | -3.15e-02 | 5.49e-01 | 9.40e-01 | 4.69e-01 | 3.84e-01 | 8.27e-01 |
| NEGATIVE REGULATION OF NEURON PROJECTION REGENERATION | 14 | 3.08e-01 | 7.19e-01 | 0.1880 | -5.72e-02 | 1.19e-01 | -1.75e-03 | -1.29e-01 | 3.85e-02 | 7.11e-01 | 4.43e-01 | 9.91e-01 | 4.05e-01 | 8.03e-01 |
| CALCIUM IMPORT INTO THE MITOCHONDRION | 12 | 8.33e-01 | 9.73e-01 | 0.1880 | 8.95e-02 | 1.97e-02 | 1.98e-02 | 1.13e-01 | 1.18e-01 | 5.92e-01 | 9.06e-01 | 9.05e-01 | 5.00e-01 | 4.80e-01 |
| POSITIVE REGULATION OF EPIDERMIS DEVELOPMENT | 32 | 2.18e-01 | 6.15e-01 | 0.1880 | 6.77e-03 | 1.39e-01 | 6.59e-02 | 3.62e-02 | 1.01e-01 | 9.47e-01 | 1.73e-01 | 5.19e-01 | 7.23e-01 | 3.21e-01 |
| CELLULAR RESPONSE TO UV A | 10 | 6.84e-01 | 9.30e-01 | 0.1880 | 2.73e-02 | -8.54e-02 | -2.52e-02 | 9.79e-02 | -1.30e-01 | 8.81e-01 | 6.40e-01 | 8.90e-01 | 5.92e-01 | 4.75e-01 |
| NEUROBLAST DIVISION | 13 | 5.22e-01 | 8.59e-01 | 0.1880 | 9.37e-03 | 5.25e-03 | 2.93e-02 | 1.21e-01 | -1.40e-01 | 9.53e-01 | 9.74e-01 | 8.55e-01 | 4.49e-01 | 3.82e-01 |
| AXO DENDRITIC TRANSPORT | 74 | 1.24e-01 | 4.80e-01 | 0.1880 | 7.28e-02 | 2.38e-03 | 6.71e-02 | 1.21e-01 | 1.04e-01 | 2.79e-01 | 9.72e-01 | 3.19e-01 | 7.19e-02 | 1.22e-01 |
| ASPARTATE TRANSMEMBRANE TRANSPORT | 19 | 9.15e-01 | 9.86e-01 | 0.1880 | -1.37e-01 | -9.00e-02 | -3.61e-02 | -7.33e-02 | 4.19e-02 | 3.02e-01 | 4.97e-01 | 7.85e-01 | 5.80e-01 | 7.52e-01 |
| POSITIVE REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 60 | 3.32e-01 | 7.39e-01 | 0.1880 | 1.09e-01 | 5.45e-02 | 4.33e-02 | 1.15e-01 | 7.31e-02 | 1.43e-01 | 4.65e-01 | 5.62e-01 | 1.25e-01 | 3.27e-01 |
| POSITIVE REGULATION OF STRIATED MUSCLE CELL APOPTOTIC PROCESS | 19 | 8.01e-01 | 9.66e-01 | 0.1880 | 8.49e-02 | 1.04e-01 | 3.68e-02 | 2.67e-02 | -1.23e-01 | 5.22e-01 | 4.33e-01 | 7.81e-01 | 8.40e-01 | 3.53e-01 |
| AMPA GLUTAMATE RECEPTOR CLUSTERING | 10 | 8.36e-01 | 9.73e-01 | 0.1870 | 5.57e-02 | 1.16e-01 | -3.82e-02 | -6.36e-03 | -1.31e-01 | 7.60e-01 | 5.25e-01 | 8.34e-01 | 9.72e-01 | 4.74e-01 |
| CHEMOKINE PRODUCTION | 101 | 6.81e-04 | 1.27e-02 | 0.1870 | 1.15e-01 | 7.62e-02 | -5.96e-02 | -4.27e-02 | -1.03e-01 | 4.57e-02 | 1.86e-01 | 3.00e-01 | 4.59e-01 | 7.23e-02 |
| REGULATION OF CELL DIFFERENTIATION | 1558 | 1.93e-11 | 1.75e-09 | 0.1870 | 6.44e-02 | 7.94e-02 | 8.55e-02 | 8.30e-02 | 1.02e-01 | 2.19e-05 | 1.66e-07 | 1.72e-08 | 4.47e-08 | 1.57e-11 |
| RENAL ABSORPTION | 32 | 1.60e-01 | 5.34e-01 | 0.1870 | -5.59e-02 | 6.86e-02 | -4.14e-02 | -1.08e-01 | -1.18e-01 | 5.84e-01 | 5.02e-01 | 6.85e-01 | 2.90e-01 | 2.49e-01 |
| HISTONE METHYLATION | 35 | 6.13e-01 | 9.05e-01 | 0.1870 | 1.06e-01 | 8.97e-02 | 2.07e-02 | 9.42e-02 | -8.03e-02 | 2.78e-01 | 3.58e-01 | 8.32e-01 | 3.35e-01 | 4.11e-01 |
| REGULATION OF SMOOTHENED SIGNALING PATHWAY | 84 | 3.33e-01 | 7.40e-01 | 0.1870 | 6.79e-02 | 1.10e-01 | 7.05e-02 | 7.36e-02 | 8.92e-02 | 2.82e-01 | 8.23e-02 | 2.64e-01 | 2.43e-01 | 1.58e-01 |
| PLATELET ACTIVATION | 128 | 8.20e-02 | 3.87e-01 | 0.1870 | 9.62e-02 | 9.82e-02 | 5.81e-02 | 8.70e-02 | -7.12e-02 | 6.01e-02 | 5.49e-02 | 2.56e-01 | 8.92e-02 | 1.64e-01 |
| RESPONSE TO ESTROGEN | 66 | 7.37e-01 | 9.49e-01 | 0.1870 | 6.62e-02 | 7.41e-02 | 8.39e-02 | 1.00e-01 | 8.89e-02 | 3.52e-01 | 2.98e-01 | 2.39e-01 | 1.58e-01 | 2.12e-01 |
| TRANSCRIPTION INITIATION COUPLED CHROMATIN REMODELING | 38 | 5.16e-01 | 8.56e-01 | 0.1870 | 5.05e-02 | 1.40e-01 | 1.03e-01 | 3.98e-02 | 2.47e-02 | 5.90e-01 | 1.36e-01 | 2.72e-01 | 6.71e-01 | 7.93e-01 |
| NEGATIVE REGULATION OF COLD INDUCED THERMOGENESIS | 46 | 8.69e-01 | 9.78e-01 | 0.1870 | 1.03e-01 | 1.09e-01 | 7.41e-02 | 7.47e-02 | 3.49e-02 | 2.27e-01 | 1.99e-01 | 3.84e-01 | 3.81e-01 | 6.82e-01 |
| MONONUCLEAR CELL DIFFERENTIATION | 463 | 1.32e-04 | 3.42e-03 | 0.1870 | 4.49e-02 | 5.84e-02 | 9.33e-02 | 1.09e-01 | 9.38e-02 | 9.75e-02 | 3.14e-02 | 5.82e-04 | 5.66e-05 | 5.39e-04 |
| EMBRYO IMPLANTATION | 58 | 3.22e-01 | 7.32e-01 | 0.1870 | -7.05e-04 | 8.68e-02 | 1.10e-01 | 3.63e-02 | 1.17e-01 | 9.93e-01 | 2.53e-01 | 1.46e-01 | 6.33e-01 | 1.22e-01 |
| MAINTENANCE OF DNA REPEAT ELEMENTS | 7 | 9.40e-01 | 9.92e-01 | 0.1870 | 1.21e-02 | 1.28e-01 | 1.09e-01 | -4.41e-03 | 7.96e-02 | 9.56e-01 | 5.56e-01 | 6.18e-01 | 9.84e-01 | 7.15e-01 |
| POSITIVE REGULATION OF PROTEIN BINDING | 59 | 7.45e-02 | 3.69e-01 | 0.1870 | 1.20e-01 | 3.17e-02 | 1.14e-02 | 1.38e-01 | -7.87e-03 | 1.10e-01 | 6.73e-01 | 8.80e-01 | 6.61e-02 | 9.17e-01 |
| CELLULAR RESPONSE TO SALT | 192 | 1.65e-01 | 5.45e-01 | 0.1860 | 6.96e-02 | 1.01e-01 | 9.26e-02 | 6.73e-02 | 8.18e-02 | 9.61e-02 | 1.61e-02 | 2.70e-02 | 1.08e-01 | 5.05e-02 |
| REGULATION OF FILOPODIUM ASSEMBLY | 48 | 6.30e-01 | 9.10e-01 | 0.1860 | -1.33e-01 | -8.40e-02 | -6.39e-02 | -7.20e-02 | -2.73e-02 | 1.11e-01 | 3.14e-01 | 4.44e-01 | 3.88e-01 | 7.43e-01 |
| BODY MORPHOGENESIS | 46 | 1.78e-01 | 5.63e-01 | 0.1860 | 4.15e-03 | 2.60e-02 | 6.49e-02 | 1.28e-01 | 1.16e-01 | 9.61e-01 | 7.61e-01 | 4.46e-01 | 1.33e-01 | 1.74e-01 |
| BENZENE CONTAINING COMPOUND METABOLIC PROCESS | 26 | 2.50e-01 | 6.57e-01 | 0.1860 | -1.02e-01 | 3.67e-02 | -3.39e-02 | -1.48e-01 | -9.52e-03 | 3.70e-01 | 7.46e-01 | 7.65e-01 | 1.92e-01 | 9.33e-01 |
| MUCUS SECRETION | 18 | 9.16e-02 | 4.11e-01 | 0.1860 | 7.79e-04 | 9.77e-02 | 1.19e-01 | -1.04e-01 | 4.54e-04 | 9.95e-01 | 4.73e-01 | 3.81e-01 | 4.43e-01 | 9.97e-01 |
| CARDIAC MUSCLE TISSUE REGENERATION | 8 | 8.49e-01 | 9.76e-01 | 0.1860 | -1.21e-01 | 1.91e-02 | -1.74e-02 | -7.73e-02 | 1.16e-01 | 5.54e-01 | 9.25e-01 | 9.32e-01 | 7.05e-01 | 5.71e-01 |
| REGULATION OF NOTCH SIGNALING PATHWAY | 94 | 2.51e-01 | 6.57e-01 | 0.1860 | 3.07e-02 | 6.19e-02 | 7.66e-02 | 8.46e-02 | 1.30e-01 | 6.07e-01 | 3.00e-01 | 1.99e-01 | 1.56e-01 | 2.97e-02 |
| CELLULAR RESPONSE TO LIGHT STIMULUS | 114 | 3.07e-01 | 7.19e-01 | 0.1860 | 7.17e-02 | 9.16e-02 | 7.25e-02 | 9.61e-02 | 8.09e-02 | 1.86e-01 | 9.10e-02 | 1.81e-01 | 7.62e-02 | 1.36e-01 |
| ANDROGEN RECEPTOR SIGNALING PATHWAY | 45 | 8.50e-01 | 9.76e-01 | 0.1860 | 8.37e-02 | 9.24e-02 | 8.52e-02 | 1.08e-01 | 1.23e-02 | 3.31e-01 | 2.83e-01 | 3.23e-01 | 2.11e-01 | 8.86e-01 |
| REGULATION OF NUCLEOBASE CONTAINING COMPOUND TRANSPORT | 16 | 5.59e-01 | 8.78e-01 | 0.1860 | 4.38e-04 | -1.11e-01 | -1.24e-01 | -6.90e-02 | 4.47e-02 | 9.98e-01 | 4.42e-01 | 3.89e-01 | 6.33e-01 | 7.57e-01 |
| NEURON PROJECTION ARBORIZATION | 31 | 9.00e-01 | 9.83e-01 | 0.1860 | -1.05e-01 | -8.56e-02 | -6.03e-02 | -1.12e-01 | -1.28e-02 | 3.13e-01 | 4.09e-01 | 5.61e-01 | 2.82e-01 | 9.02e-01 |
| LACTATE TRANSMEMBRANE TRANSPORT | 7 | 9.43e-01 | 9.93e-01 | 0.1860 | 1.50e-01 | 6.99e-02 | -3.20e-02 | 3.40e-02 | -7.04e-02 | 4.92e-01 | 7.49e-01 | 8.83e-01 | 8.76e-01 | 7.47e-01 |
| IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN PHAGOCYTOSIS | 26 | 5.22e-01 | 8.58e-01 | 0.1860 | 8.71e-02 | 1.47e-02 | -8.87e-02 | -3.77e-02 | -1.32e-01 | 4.42e-01 | 8.97e-01 | 4.33e-01 | 7.39e-01 | 2.45e-01 |
| SULFUR AMINO ACID TRANSPORT | 12 | 8.61e-01 | 9.78e-01 | 0.1860 | -1.03e-01 | -5.87e-03 | -9.53e-02 | -1.20e-01 | -2.29e-02 | 5.39e-01 | 9.72e-01 | 5.68e-01 | 4.73e-01 | 8.91e-01 |
| NEPHRON TUBULE EPITHELIAL CELL DIFFERENTIATION | 13 | 5.72e-01 | 8.83e-01 | 0.1860 | -8.99e-02 | -6.03e-02 | -7.89e-02 | 3.38e-03 | 1.28e-01 | 5.75e-01 | 7.07e-01 | 6.22e-01 | 9.83e-01 | 4.23e-01 |
| POSITIVE REGULATION OF AMYLOID BETA CLEARANCE | 8 | 8.79e-01 | 9.79e-01 | 0.1860 | 2.33e-02 | 1.52e-01 | 8.01e-02 | 6.12e-02 | -2.70e-02 | 9.09e-01 | 4.58e-01 | 6.95e-01 | 7.64e-01 | 8.95e-01 |
| NEGATIVE REGULATION OF OSSIFICATION | 37 | 2.77e-01 | 6.86e-01 | 0.1860 | 1.27e-02 | 1.38e-01 | 9.08e-02 | 5.67e-02 | 6.06e-02 | 8.94e-01 | 1.45e-01 | 3.39e-01 | 5.51e-01 | 5.24e-01 |
| REGULATION OF FEAR RESPONSE | 9 | 8.45e-01 | 9.76e-01 | 0.1860 | -1.63e-01 | -2.70e-02 | -3.37e-03 | -8.18e-02 | -2.33e-02 | 3.98e-01 | 8.89e-01 | 9.86e-01 | 6.71e-01 | 9.04e-01 |
| CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 220 | 5.56e-02 | 3.12e-01 | 0.1850 | 4.72e-02 | 7.50e-02 | 9.67e-02 | 5.89e-02 | 1.17e-01 | 2.27e-01 | 5.53e-02 | 1.35e-02 | 1.32e-01 | 2.74e-03 |
| VENTRICULAR SEPTUM DEVELOPMENT | 74 | 7.39e-02 | 3.68e-01 | 0.1850 | -8.39e-02 | -3.02e-02 | 7.13e-02 | 2.49e-02 | 1.44e-01 | 2.12e-01 | 6.54e-01 | 2.89e-01 | 7.11e-01 | 3.23e-02 |
| REGULATION OF MICROTUBULE BASED PROCESS | 248 | 1.40e-01 | 5.04e-01 | 0.1850 | 7.26e-02 | 7.16e-02 | 8.96e-02 | 8.95e-02 | 8.90e-02 | 4.89e-02 | 5.21e-02 | 1.51e-02 | 1.52e-02 | 1.58e-02 |
| CELLULAR RESPONSE TO OXYGEN RADICAL | 23 | 8.37e-01 | 9.73e-01 | 0.1850 | 7.80e-02 | 1.40e-01 | 7.01e-02 | 5.94e-02 | -1.74e-02 | 5.17e-01 | 2.46e-01 | 5.60e-01 | 6.22e-01 | 8.85e-01 |
| BIOLOGICAL PROCESS INVOLVED IN INTRASPECIES INTERACTION BETWEEN ORGANISMS | 48 | 3.93e-01 | 7.85e-01 | 0.1850 | 3.18e-02 | 1.07e-01 | 1.12e-01 | 1.91e-02 | 9.45e-02 | 7.03e-01 | 1.98e-01 | 1.81e-01 | 8.19e-01 | 2.57e-01 |
| GOLGI ORGANIZATION | 141 | 1.63e-02 | 1.45e-01 | 0.1850 | 5.05e-02 | 5.50e-02 | 8.04e-02 | 1.37e-01 | 5.77e-02 | 3.01e-01 | 2.60e-01 | 9.94e-02 | 4.82e-03 | 2.37e-01 |
| LYMPHANGIOGENESIS | 18 | 8.20e-01 | 9.70e-01 | 0.1850 | -8.89e-02 | -3.79e-02 | 5.08e-02 | -4.50e-03 | 1.49e-01 | 5.14e-01 | 7.81e-01 | 7.09e-01 | 9.74e-01 | 2.73e-01 |
| POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 51 | 2.04e-01 | 5.96e-01 | 0.1850 | 1.01e-01 | 1.73e-03 | 6.44e-02 | 1.33e-01 | 4.59e-02 | 2.13e-01 | 9.83e-01 | 4.26e-01 | 9.96e-02 | 5.71e-01 |
| NEGATIVE REGULATION OF SODIUM ION TRANSPORT | 17 | 6.90e-01 | 9.31e-01 | 0.1850 | -5.00e-02 | -1.33e-01 | -1.09e-01 | -1.73e-02 | 4.43e-02 | 7.21e-01 | 3.44e-01 | 4.37e-01 | 9.02e-01 | 7.52e-01 |
| ENDOTHELIAL CELL APOPTOTIC PROCESS | 67 | 5.72e-01 | 8.83e-01 | 0.1850 | -1.10e-01 | -9.08e-02 | -7.98e-02 | -6.15e-02 | -6.04e-02 | 1.19e-01 | 1.99e-01 | 2.59e-01 | 3.84e-01 | 3.92e-01 |
| REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 515 | 5.70e-03 | 6.77e-02 | 0.1850 | 9.40e-02 | 1.01e-01 | 8.48e-02 | 8.59e-02 | 2.27e-02 | 2.60e-04 | 8.36e-05 | 9.89e-04 | 8.48e-04 | 3.77e-01 |
| FEMALE MEIOTIC NUCLEAR DIVISION | 38 | 4.51e-01 | 8.21e-01 | 0.1850 | 7.74e-03 | 3.85e-02 | 1.20e-01 | 1.19e-01 | 6.41e-02 | 9.34e-01 | 6.81e-01 | 2.00e-01 | 2.05e-01 | 4.94e-01 |
| REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 10 | 7.94e-01 | 9.65e-01 | 0.1850 | -7.33e-02 | -7.25e-02 | -1.47e-01 | -2.41e-02 | -3.54e-02 | 6.88e-01 | 6.92e-01 | 4.20e-01 | 8.95e-01 | 8.46e-01 |
| REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 45 | 3.25e-01 | 7.34e-01 | 0.1850 | 8.15e-02 | 6.32e-02 | 4.58e-02 | 3.54e-02 | 1.42e-01 | 3.44e-01 | 4.63e-01 | 5.95e-01 | 6.81e-01 | 9.96e-02 |
| DEFENSE RESPONSE TO TUMOR CELL | 13 | 9.33e-01 | 9.90e-01 | 0.1850 | 9.55e-02 | 1.12e-01 | 1.01e-01 | 4.09e-02 | -2.40e-02 | 5.51e-01 | 4.83e-01 | 5.30e-01 | 7.99e-01 | 8.81e-01 |
| POSITIVE REGULATION OF LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL | 25 | 9.05e-01 | 9.84e-01 | 0.1850 | 7.49e-02 | 1.21e-01 | 8.70e-02 | 7.86e-02 | -5.58e-03 | 5.17e-01 | 2.94e-01 | 4.51e-01 | 4.96e-01 | 9.61e-01 |
| POSITIVE REGULATION OF COLD INDUCED THERMOGENESIS | 100 | 6.65e-01 | 9.23e-01 | 0.1850 | 9.73e-02 | 9.34e-02 | 7.62e-02 | 9.10e-02 | 4.24e-02 | 9.28e-02 | 1.07e-01 | 1.88e-01 | 1.16e-01 | 4.64e-01 |
| REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 169 | 4.85e-02 | 2.89e-01 | 0.1850 | 2.22e-02 | 7.41e-02 | 8.79e-02 | 5.66e-02 | 1.31e-01 | 6.18e-01 | 9.66e-02 | 4.85e-02 | 2.04e-01 | 3.33e-03 |
| MODULATION BY HOST OF VIRAL PROCESS | 45 | 2.49e-01 | 6.56e-01 | 0.1840 | -6.96e-02 | -8.31e-02 | 2.65e-02 | 3.64e-02 | 1.42e-01 | 4.19e-01 | 3.35e-01 | 7.59e-01 | 6.73e-01 | 9.85e-02 |
| LIPID IMPORT INTO CELL | 20 | 8.12e-01 | 9.68e-01 | 0.1840 | -1.00e-01 | -6.19e-02 | -3.65e-03 | -7.91e-02 | 1.18e-01 | 4.38e-01 | 6.32e-01 | 9.77e-01 | 5.40e-01 | 3.61e-01 |
| RENAL SYSTEM PROCESS INVOLVED IN REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 22 | 5.26e-01 | 8.60e-01 | 0.1840 | 1.48e-01 | 4.64e-02 | 3.08e-02 | 4.02e-02 | -8.62e-02 | 2.30e-01 | 7.06e-01 | 8.03e-01 | 7.44e-01 | 4.84e-01 |
| RETINAL ROD CELL DEVELOPMENT | 8 | 9.32e-01 | 9.90e-01 | 0.1840 | 8.94e-02 | 9.95e-02 | 2.84e-02 | 2.44e-02 | 1.21e-01 | 6.62e-01 | 6.26e-01 | 8.89e-01 | 9.05e-01 | 5.53e-01 |
| POSITIVE REGULATION OF NK T CELL ACTIVATION | 9 | 4.09e-01 | 7.94e-01 | 0.1840 | -8.83e-02 | -4.34e-02 | -7.85e-02 | 7.23e-02 | 1.14e-01 | 6.46e-01 | 8.22e-01 | 6.84e-01 | 7.07e-01 | 5.55e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY | 36 | 6.72e-01 | 9.26e-01 | 0.1840 | 1.23e-01 | 1.24e-01 | 3.65e-02 | 4.52e-02 | -1.54e-02 | 2.03e-01 | 1.98e-01 | 7.04e-01 | 6.39e-01 | 8.73e-01 |
| OVIDUCT DEVELOPMENT | 5 | 9.13e-01 | 9.85e-01 | 0.1840 | -5.81e-02 | -1.03e-02 | -6.17e-02 | -1.90e-02 | 1.62e-01 | 8.22e-01 | 9.68e-01 | 8.11e-01 | 9.41e-01 | 5.30e-01 |
| MEIOTIC CELL CYCLE PROCESS | 210 | 1.37e-02 | 1.28e-01 | 0.1840 | 6.61e-02 | 6.31e-02 | 1.05e-01 | 1.20e-01 | 1.69e-02 | 9.87e-02 | 1.15e-01 | 8.90e-03 | 2.76e-03 | 6.72e-01 |
| CARDIAC CHAMBER DEVELOPMENT | 168 | 9.17e-03 | 9.56e-02 | 0.1840 | -2.54e-02 | 2.86e-02 | 9.60e-02 | 3.94e-02 | 1.47e-01 | 5.71e-01 | 5.22e-01 | 3.18e-02 | 3.78e-01 | 9.81e-04 |
| REGULATION OF TRANSLATION INITIATION IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 8 | 9.54e-01 | 9.94e-01 | 0.1840 | -9.07e-02 | -2.98e-02 | -4.30e-02 | -1.47e-01 | -3.73e-02 | 6.57e-01 | 8.84e-01 | 8.33e-01 | 4.72e-01 | 8.55e-01 |
| CENTRIOLE CENTRIOLE COHESION | 15 | 1.19e-01 | 4.69e-01 | 0.1840 | 4.50e-02 | -5.26e-02 | -1.12e-01 | 1.08e-01 | 6.91e-02 | 7.63e-01 | 7.24e-01 | 4.52e-01 | 4.67e-01 | 6.43e-01 |
| EPITHELIAL FLUID TRANSPORT | 11 | 8.58e-01 | 9.77e-01 | 0.1840 | -6.46e-02 | 7.28e-03 | -7.62e-02 | -1.53e-01 | -2.20e-02 | 7.11e-01 | 9.67e-01 | 6.62e-01 | 3.80e-01 | 8.99e-01 |
| REGULATION OF ACTIN FILAMENT BASED MOVEMENT | 39 | 5.98e-01 | 8.98e-01 | 0.1840 | -8.32e-02 | -3.60e-02 | -9.51e-02 | -1.28e-01 | -8.98e-03 | 3.68e-01 | 6.97e-01 | 3.04e-01 | 1.65e-01 | 9.23e-01 |
| INFLAMMASOME MEDIATED SIGNALING PATHWAY | 39 | 7.62e-02 | 3.74e-01 | 0.1840 | -1.11e-02 | -8.52e-02 | -8.23e-02 | -1.39e-01 | 1.47e-02 | 9.05e-01 | 3.57e-01 | 3.74e-01 | 1.32e-01 | 8.74e-01 |
| DENDRITIC SPINE MORPHOGENESIS | 51 | 7.00e-01 | 9.31e-01 | 0.1840 | -1.27e-01 | -8.91e-02 | -5.08e-02 | -8.20e-02 | -2.20e-02 | 1.17e-01 | 2.71e-01 | 5.30e-01 | 3.11e-01 | 7.86e-01 |
| HETEROCYCLE CATABOLIC PROCESS | 518 | 3.35e-05 | 1.10e-03 | 0.1840 | 7.68e-02 | 4.14e-02 | 8.61e-02 | 1.14e-01 | 7.57e-02 | 2.75e-03 | 1.07e-01 | 7.95e-04 | 8.85e-06 | 3.18e-03 |
| RESPONSE TO ABIOTIC STIMULUS | 1079 | 3.15e-07 | 1.59e-05 | 0.1840 | 6.72e-02 | 7.93e-02 | 8.47e-02 | 7.87e-02 | 9.76e-02 | 1.90e-04 | 1.07e-05 | 2.56e-06 | 1.26e-05 | 6.08e-08 |
| POSITIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 15 | 8.06e-01 | 9.67e-01 | 0.1840 | 1.06e-02 | -1.66e-03 | 7.76e-02 | 1.36e-01 | 9.58e-02 | 9.43e-01 | 9.91e-01 | 6.03e-01 | 3.63e-01 | 5.21e-01 |
| NEGATIVE REGULATION OF MACROPHAGE ACTIVATION | 18 | 9.56e-01 | 9.94e-01 | 0.1830 | 5.59e-02 | 5.00e-02 | 1.14e-01 | 1.07e-01 | 5.99e-02 | 6.81e-01 | 7.14e-01 | 4.03e-01 | 4.32e-01 | 6.60e-01 |
| COBALAMIN TRANSPORT | 8 | 8.56e-01 | 9.77e-01 | 0.1830 | -4.28e-02 | 6.04e-02 | 1.09e-03 | -4.98e-02 | -1.60e-01 | 8.34e-01 | 7.67e-01 | 9.96e-01 | 8.07e-01 | 4.33e-01 |
| CHROMOSOME MOVEMENT TOWARDS SPINDLE POLE | 7 | 9.07e-01 | 9.84e-01 | 0.1830 | 1.13e-01 | 1.04e-01 | 9.11e-02 | -3.71e-03 | -4.09e-02 | 6.05e-01 | 6.33e-01 | 6.76e-01 | 9.86e-01 | 8.51e-01 |
| POSITIVE REGULATION OF PROTEIN TYROSINE KINASE ACTIVITY | 29 | 8.36e-01 | 9.73e-01 | 0.1830 | -1.52e-02 | -4.19e-02 | -1.08e-01 | -4.95e-02 | -1.32e-01 | 8.88e-01 | 6.96e-01 | 3.12e-01 | 6.44e-01 | 2.20e-01 |
| REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 60 | 1.04e-01 | 4.41e-01 | 0.1830 | 1.49e-01 | 3.51e-02 | 9.59e-03 | 9.69e-02 | -2.71e-02 | 4.65e-02 | 6.38e-01 | 8.98e-01 | 1.94e-01 | 7.17e-01 |
| POSITIVE REGULATION OF TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 13 | 4.57e-01 | 8.22e-01 | 0.1830 | 1.65e-01 | 2.23e-02 | -6.38e-02 | -8.84e-03 | -4.07e-02 | 3.03e-01 | 8.89e-01 | 6.90e-01 | 9.56e-01 | 8.00e-01 |
| PROTEIN O LINKED MANNOSYLATION | 17 | 9.50e-01 | 9.94e-01 | 0.1830 | 1.08e-01 | 1.17e-01 | 7.19e-02 | 4.43e-02 | 3.12e-02 | 4.40e-01 | 4.03e-01 | 6.08e-01 | 7.52e-01 | 8.24e-01 |
| DETECTION OF LIGHT STIMULUS INVOLVED IN SENSORY PERCEPTION | 20 | 9.49e-01 | 9.94e-01 | 0.1830 | -4.05e-02 | -4.69e-02 | -1.07e-01 | -1.07e-01 | -8.32e-02 | 7.54e-01 | 7.17e-01 | 4.09e-01 | 4.08e-01 | 5.20e-01 |
| INTERLEUKIN 17 MEDIATED SIGNALING PATHWAY | 11 | 7.66e-01 | 9.55e-01 | 0.1830 | -1.54e-01 | -1.03e-02 | 3.31e-02 | -7.56e-02 | 5.23e-02 | 3.75e-01 | 9.53e-01 | 8.49e-01 | 6.64e-01 | 7.64e-01 |
| MEMBRANE RAFT ASSEMBLY | 11 | 9.41e-01 | 9.92e-01 | 0.1830 | 5.41e-03 | 7.59e-02 | 7.10e-02 | 1.43e-02 | 1.50e-01 | 9.75e-01 | 6.63e-01 | 6.83e-01 | 9.35e-01 | 3.90e-01 |
| METHIONINE METABOLIC PROCESS | 15 | 9.14e-01 | 9.86e-01 | 0.1830 | -7.92e-02 | -9.98e-02 | -7.58e-02 | -6.73e-02 | 8.34e-02 | 5.95e-01 | 5.03e-01 | 6.11e-01 | 6.52e-01 | 5.76e-01 |
| POSITIVE REGULATION OF NERVOUS SYSTEM PROCESS | 31 | 7.84e-01 | 9.61e-01 | 0.1830 | -1.07e-01 | -8.13e-02 | -3.89e-02 | -8.15e-02 | 8.54e-02 | 3.03e-01 | 4.33e-01 | 7.08e-01 | 4.33e-01 | 4.11e-01 |
| REGULATION OF MYELOID LEUKOCYTE MEDIATED IMMUNITY | 55 | 3.32e-01 | 7.40e-01 | 0.1830 | 9.74e-02 | 1.29e-01 | 2.77e-02 | 4.80e-02 | -6.48e-02 | 2.11e-01 | 9.74e-02 | 7.23e-01 | 5.38e-01 | 4.06e-01 |
| NEGATIVE REGULATION OF CELL DIVISION | 17 | 6.21e-01 | 9.08e-01 | 0.1830 | -1.66e-02 | -7.76e-02 | 7.34e-02 | 9.30e-02 | 1.14e-01 | 9.06e-01 | 5.79e-01 | 6.00e-01 | 5.07e-01 | 4.14e-01 |
| POSITIVE REGULATION OF INFLAMMATORY RESPONSE | 149 | 2.88e-01 | 6.97e-01 | 0.1830 | 9.75e-02 | 8.19e-02 | 6.64e-02 | 9.28e-02 | 6.46e-02 | 3.99e-02 | 8.46e-02 | 1.62e-01 | 5.06e-02 | 1.73e-01 |
| RENAL SYSTEM DEVELOPMENT | 316 | 2.09e-02 | 1.71e-01 | 0.1830 | 6.06e-02 | 7.06e-02 | 8.28e-02 | 7.36e-02 | 1.11e-01 | 6.37e-02 | 3.08e-02 | 1.14e-02 | 2.44e-02 | 6.71e-04 |
| RESPONSE TO OXYGEN RADICAL | 27 | 6.89e-01 | 9.31e-01 | 0.1830 | 3.99e-02 | 1.32e-01 | 8.96e-02 | 7.52e-02 | 2.64e-02 | 7.19e-01 | 2.36e-01 | 4.20e-01 | 4.99e-01 | 8.12e-01 |
| ADAPTIVE IMMUNE RESPONSE BASED ON SOMATIC RECOMBINATION OF IMMUNE RECEPTORS BUILT FROM IMMUNOGLOBULIN SUPERFAMILY DOMAINS | 297 | 1.93e-02 | 1.62e-01 | 0.1820 | 6.36e-02 | 9.16e-02 | 8.97e-02 | 1.04e-01 | 4.54e-02 | 5.93e-02 | 6.63e-03 | 7.82e-03 | 2.13e-03 | 1.78e-01 |
| NEUROBLAST PROLIFERATION | 80 | 1.62e-01 | 5.38e-01 | 0.1820 | 6.08e-03 | 4.92e-02 | 9.72e-02 | 1.09e-01 | 9.71e-02 | 9.25e-01 | 4.47e-01 | 1.33e-01 | 9.16e-02 | 1.33e-01 |
| PHOSPHATIDYLINOSITOL PHOSPHATE BIOSYNTHETIC PROCESS | 64 | 4.56e-01 | 8.22e-01 | 0.1820 | 1.83e-02 | 3.30e-02 | 1.11e-01 | 9.68e-02 | 1.00e-01 | 8.00e-01 | 6.48e-01 | 1.24e-01 | 1.80e-01 | 1.65e-01 |
| POSITIVE REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 34 | 4.04e-01 | 7.91e-01 | 0.1820 | -5.19e-02 | -1.00e-01 | -2.74e-02 | -2.42e-02 | 1.38e-01 | 6.01e-01 | 3.12e-01 | 7.82e-01 | 8.07e-01 | 1.63e-01 |
| ORGAN GROWTH | 168 | 2.30e-01 | 6.32e-01 | 0.1820 | 6.76e-02 | 1.06e-01 | 9.91e-02 | 6.65e-02 | 5.70e-02 | 1.30e-01 | 1.83e-02 | 2.66e-02 | 1.37e-01 | 2.03e-01 |
| SPERM MOTILITY | 127 | 2.57e-01 | 6.63e-01 | 0.1820 | -7.96e-02 | -7.79e-02 | -8.87e-02 | -1.14e-01 | -4.60e-03 | 1.22e-01 | 1.29e-01 | 8.44e-02 | 2.70e-02 | 9.29e-01 |
| CELL CELL JUNCTION ASSEMBLY | 152 | 8.54e-02 | 3.95e-01 | 0.1820 | -1.04e-01 | -7.42e-02 | -7.70e-02 | -6.29e-02 | -8.40e-02 | 2.74e-02 | 1.14e-01 | 1.01e-01 | 1.81e-01 | 7.38e-02 |
| PHOSPHATIDIC ACID METABOLIC PROCESS | 35 | 9.53e-01 | 9.94e-01 | 0.1820 | -1.00e-01 | -9.26e-02 | -7.75e-02 | -8.32e-02 | -4.05e-02 | 3.05e-01 | 3.43e-01 | 4.28e-01 | 3.94e-01 | 6.78e-01 |
| IP 10 PRODUCTION | 5 | 7.57e-01 | 9.51e-01 | 0.1820 | 2.26e-02 | -1.67e-01 | -8.80e-03 | -4.22e-03 | -6.73e-02 | 9.30e-01 | 5.17e-01 | 9.73e-01 | 9.87e-01 | 7.94e-01 |
| CELLULAR RESPONSE TO HEAT | 62 | 6.18e-01 | 9.07e-01 | 0.1820 | 4.82e-02 | 7.18e-02 | 1.02e-01 | 4.82e-02 | 1.14e-01 | 5.11e-01 | 3.28e-01 | 1.67e-01 | 5.11e-01 | 1.20e-01 |
| TRANSCRIPTION INITIATION AT RNA POLYMERASE I PROMOTER | 12 | 8.53e-01 | 9.76e-01 | 0.1820 | -1.05e-02 | 1.19e-01 | 1.05e-01 | 4.40e-02 | 7.73e-02 | 9.50e-01 | 4.75e-01 | 5.30e-01 | 7.92e-01 | 6.43e-01 |
| MAINTENANCE OF SYNAPSE STRUCTURE | 25 | 9.26e-01 | 9.89e-01 | 0.1820 | 3.90e-02 | 3.59e-02 | 1.02e-01 | 7.93e-02 | 1.17e-01 | 7.36e-01 | 7.56e-01 | 3.80e-01 | 4.93e-01 | 3.11e-01 |
| MEMBRANE LIPID BIOSYNTHETIC PROCESS | 148 | 3.19e-01 | 7.30e-01 | 0.1820 | 6.11e-02 | 6.03e-02 | 1.06e-01 | 8.67e-02 | 8.29e-02 | 2.00e-01 | 2.05e-01 | 2.54e-02 | 6.85e-02 | 8.15e-02 |
| CHOLESTEROL EFFLUX | 73 | 6.21e-02 | 3.30e-01 | 0.1820 | -5.15e-02 | -8.88e-03 | -3.58e-02 | -3.91e-02 | -1.66e-01 | 4.47e-01 | 8.96e-01 | 5.97e-01 | 5.63e-01 | 1.42e-02 |
| REGULATION OF VASOCONSTRICTION | 61 | 6.49e-01 | 9.17e-01 | 0.1820 | -7.39e-02 | -8.09e-02 | -7.40e-02 | -1.16e-01 | -4.58e-02 | 3.18e-01 | 2.74e-01 | 3.17e-01 | 1.17e-01 | 5.36e-01 |
| REGULATION OF NATURAL KILLER CELL DIFFERENTIATION | 12 | 9.46e-01 | 9.94e-01 | 0.1820 | 3.33e-02 | 2.35e-02 | 1.26e-01 | 8.39e-02 | 9.18e-02 | 8.42e-01 | 8.88e-01 | 4.49e-01 | 6.15e-01 | 5.82e-01 |
| REGULATION OF PEPTIDE TRANSPORT | 195 | 6.98e-02 | 3.57e-01 | 0.1820 | 7.74e-02 | 1.18e-01 | 7.87e-02 | 5.98e-02 | 5.76e-02 | 6.24e-02 | 4.50e-03 | 5.81e-02 | 1.50e-01 | 1.65e-01 |
| NEGATIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DIFFERENTIATION | 12 | 9.71e-01 | 9.95e-01 | 0.1820 | -1.19e-01 | -9.04e-02 | -3.95e-02 | -8.25e-02 | -4.70e-02 | 4.74e-01 | 5.88e-01 | 8.13e-01 | 6.21e-01 | 7.78e-01 |
| ASSOCIATIVE LEARNING | 84 | 1.91e-01 | 5.79e-01 | 0.1820 | 1.73e-02 | 4.58e-02 | 6.40e-02 | 3.27e-02 | 1.59e-01 | 7.84e-01 | 4.68e-01 | 3.11e-01 | 6.05e-01 | 1.16e-02 |
| PHOSPHATIDYLSERINE METABOLIC PROCESS | 23 | 2.85e-01 | 6.93e-01 | 0.1820 | 1.24e-02 | 5.10e-02 | -8.99e-02 | -1.41e-01 | -4.68e-02 | 9.18e-01 | 6.72e-01 | 4.55e-01 | 2.41e-01 | 6.97e-01 |
| T CELL MEDIATED CYTOTOXICITY | 59 | 2.50e-02 | 1.93e-01 | 0.1820 | -6.08e-03 | 9.02e-03 | 9.34e-02 | 1.48e-01 | 4.74e-02 | 9.36e-01 | 9.05e-01 | 2.15e-01 | 4.94e-02 | 5.29e-01 |
| REGULATION OF LYMPHOCYTE ACTIVATION | 491 | 1.21e-03 | 2.05e-02 | 0.1810 | 6.44e-02 | 7.03e-02 | 8.24e-02 | 1.05e-01 | 7.81e-02 | 1.45e-02 | 7.64e-03 | 1.76e-03 | 7.07e-05 | 3.04e-03 |
| DE NOVO PYRIMIDINE NUCLEOBASE BIOSYNTHETIC PROCESS | 6 | 9.93e-01 | 9.99e-01 | 0.1810 | -4.36e-02 | -1.17e-01 | -8.63e-02 | -4.95e-02 | -8.59e-02 | 8.53e-01 | 6.19e-01 | 7.14e-01 | 8.34e-01 | 7.15e-01 |
| L GLUTAMATE IMPORT ACROSS PLASMA MEMBRANE | 17 | 4.68e-01 | 8.28e-01 | 0.1810 | -2.08e-02 | -3.27e-02 | 9.15e-02 | 1.45e-01 | 4.41e-02 | 8.82e-01 | 8.15e-01 | 5.14e-01 | 3.00e-01 | 7.53e-01 |
| REGULATION OF CHROMATIN ORGANIZATION | 44 | 7.94e-02 | 3.82e-01 | 0.1810 | 1.10e-01 | 1.03e-02 | -5.03e-02 | 1.03e-01 | -8.71e-02 | 2.07e-01 | 9.06e-01 | 5.63e-01 | 2.38e-01 | 3.18e-01 |
| MONOSACCHARIDE CATABOLIC PROCESS | 49 | 3.03e-01 | 7.16e-01 | 0.1810 | 6.21e-02 | 1.50e-01 | 7.17e-02 | 3.37e-02 | 1.10e-02 | 4.52e-01 | 6.93e-02 | 3.85e-01 | 6.83e-01 | 8.94e-01 |
| MONOSACCHARIDE METABOLIC PROCESS | 249 | 4.38e-02 | 2.71e-01 | 0.1810 | 4.66e-02 | 7.23e-02 | 8.26e-02 | 7.56e-02 | 1.13e-01 | 2.06e-01 | 4.95e-02 | 2.47e-02 | 3.99e-02 | 2.14e-03 |
| PROTEIN K63 LINKED DEUBIQUITINATION | 27 | 4.82e-01 | 8.37e-01 | 0.1810 | 3.70e-02 | -8.08e-02 | -9.53e-02 | 1.23e-02 | -1.25e-01 | 7.39e-01 | 4.67e-01 | 3.91e-01 | 9.12e-01 | 2.62e-01 |
| SYNAPTIC VESICLE CLUSTERING | 15 | 9.60e-01 | 9.94e-01 | 0.1810 | -8.32e-02 | -8.55e-02 | -1.03e-01 | -4.58e-02 | -7.53e-02 | 5.77e-01 | 5.66e-01 | 4.90e-01 | 7.59e-01 | 6.14e-01 |
| POSITIVE REGULATION OF SIGNALING RECEPTOR ACTIVITY | 28 | 6.50e-01 | 9.18e-01 | 0.1810 | -1.28e-01 | -1.21e-01 | -2.97e-02 | -2.10e-02 | 1.76e-02 | 2.41e-01 | 2.68e-01 | 7.85e-01 | 8.48e-01 | 8.72e-01 |
| ARF PROTEIN SIGNAL TRANSDUCTION | 21 | 5.14e-01 | 8.56e-01 | 0.1810 | -8.94e-02 | -1.99e-02 | -2.11e-02 | -9.21e-03 | 1.54e-01 | 4.78e-01 | 8.74e-01 | 8.67e-01 | 9.42e-01 | 2.22e-01 |
| PHOSPHATIDYLCHOLINE CATABOLIC PROCESS | 16 | 5.77e-01 | 8.85e-01 | 0.1810 | -3.51e-02 | 2.09e-02 | -8.08e-02 | -1.56e-01 | 2.00e-03 | 8.08e-01 | 8.85e-01 | 5.76e-01 | 2.79e-01 | 9.89e-01 |
| REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 45 | 2.28e-01 | 6.31e-01 | 0.1800 | 6.79e-02 | 9.79e-02 | 4.39e-02 | 1.27e-01 | -1.58e-02 | 4.31e-01 | 2.56e-01 | 6.10e-01 | 1.40e-01 | 8.55e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 61 | 2.62e-01 | 6.70e-01 | 0.1800 | 9.11e-02 | 8.92e-02 | 1.50e-02 | 7.83e-02 | -9.98e-02 | 2.19e-01 | 2.28e-01 | 8.39e-01 | 2.90e-01 | 1.78e-01 |
| FATTY ACID BIOSYNTHETIC PROCESS | 160 | 2.33e-01 | 6.36e-01 | 0.1800 | 7.62e-02 | 9.73e-02 | 9.19e-02 | 9.36e-02 | 7.24e-03 | 9.61e-02 | 3.37e-02 | 4.48e-02 | 4.10e-02 | 8.74e-01 |
| CELLULAR RESPONSE TO TEMPERATURE STIMULUS | 5 | 4.36e-01 | 8.09e-01 | 0.1800 | -2.47e-02 | 1.42e-01 | -8.13e-02 | 6.40e-02 | -3.24e-02 | 9.24e-01 | 5.83e-01 | 7.53e-01 | 8.04e-01 | 9.00e-01 |
| POSITIVE REGULATION OF DEFENSE RESPONSE TO VIRUS BY HOST | 31 | 8.02e-01 | 9.67e-01 | 0.1800 | 1.12e-01 | 8.87e-02 | 7.95e-02 | 6.34e-02 | -4.04e-02 | 2.79e-01 | 3.93e-01 | 4.44e-01 | 5.41e-01 | 6.97e-01 |
| REGULATION OF DENDRITIC CELL DIFFERENTIATION | 14 | 8.64e-01 | 9.78e-01 | 0.1800 | 4.18e-02 | 7.92e-02 | 4.36e-02 | 9.11e-02 | 1.19e-01 | 7.87e-01 | 6.08e-01 | 7.78e-01 | 5.55e-01 | 4.40e-01 |
| DENTATE GYRUS DEVELOPMENT | 23 | 9.25e-01 | 9.89e-01 | 0.1800 | 5.25e-02 | 3.54e-02 | 9.23e-02 | 6.87e-02 | 1.23e-01 | 6.63e-01 | 7.69e-01 | 4.44e-01 | 5.68e-01 | 3.07e-01 |
| REGULATION OF NEUROTRANSMITTER RECEPTOR LOCALIZATION TO POSTSYNAPTIC SPECIALIZATION MEMBRANE | 8 | 6.90e-01 | 9.31e-01 | 0.1800 | -3.82e-04 | -1.47e-01 | -4.07e-02 | -7.40e-02 | 5.98e-02 | 9.99e-01 | 4.71e-01 | 8.42e-01 | 7.17e-01 | 7.70e-01 |
| N ACYLPHOSPHATIDYLETHANOLAMINE METABOLIC PROCESS | 9 | 9.09e-01 | 9.85e-01 | 0.1800 | 3.45e-02 | -4.24e-02 | -2.48e-02 | 2.23e-02 | -1.68e-01 | 8.58e-01 | 8.26e-01 | 8.97e-01 | 9.08e-01 | 3.83e-01 |
| SPERM FLAGELLUM ASSEMBLY | 39 | 6.28e-01 | 9.10e-01 | 0.1800 | -2.72e-02 | -5.22e-02 | -8.47e-02 | -1.19e-01 | -8.74e-02 | 7.69e-01 | 5.73e-01 | 3.60e-01 | 2.00e-01 | 3.45e-01 |
| CELLULAR RESPONSE TO GLUCAGON STIMULUS | 11 | 6.68e-01 | 9.25e-01 | 0.1800 | -1.49e-01 | -2.56e-02 | -7.20e-02 | -4.69e-02 | 4.46e-02 | 3.91e-01 | 8.83e-01 | 6.79e-01 | 7.88e-01 | 7.98e-01 |
| NEGATIVE REGULATION OF BEHAVIOR | 12 | 5.83e-01 | 8.90e-01 | 0.1800 | 2.76e-02 | 1.60e-01 | 2.95e-02 | 5.63e-02 | -4.30e-02 | 8.68e-01 | 3.37e-01 | 8.59e-01 | 7.36e-01 | 7.97e-01 |
| HEME TRANSPORT | 9 | 5.19e-01 | 8.57e-01 | 0.1800 | -9.12e-02 | -3.18e-03 | -1.44e-01 | -2.11e-02 | -5.23e-02 | 6.36e-01 | 9.87e-01 | 4.54e-01 | 9.13e-01 | 7.86e-01 |
| VIRAL GENOME REPLICATION | 124 | 1.94e-01 | 5.81e-01 | 0.1800 | 7.78e-02 | 6.41e-02 | 6.01e-02 | 1.04e-01 | 8.77e-02 | 1.35e-01 | 2.17e-01 | 2.48e-01 | 4.55e-02 | 9.17e-02 |
| POSITIVE REGULATION OF RECEPTOR CATABOLIC PROCESS | 7 | 7.19e-01 | 9.38e-01 | 0.1800 | -1.78e-02 | 1.11e-01 | 2.70e-04 | 5.44e-02 | -1.29e-01 | 9.35e-01 | 6.10e-01 | 9.99e-01 | 8.03e-01 | 5.55e-01 |
| CERAMIDE BIOSYNTHETIC PROCESS | 68 | 4.49e-01 | 8.19e-01 | 0.1800 | 6.89e-02 | 5.29e-02 | 1.18e-01 | 7.53e-02 | 7.18e-02 | 3.26e-01 | 4.50e-01 | 9.30e-02 | 2.83e-01 | 3.06e-01 |
| POSITIVE REGULATION OF TRANSLATIONAL INITIATION | 24 | 3.36e-01 | 7.42e-01 | 0.1790 | 4.32e-02 | 1.82e-02 | 3.11e-04 | -2.37e-02 | 1.72e-01 | 7.14e-01 | 8.77e-01 | 9.98e-01 | 8.41e-01 | 1.46e-01 |
| ARTERY DEVELOPMENT | 111 | 6.24e-02 | 3.32e-01 | 0.1790 | -3.58e-02 | 1.85e-02 | 8.06e-02 | 2.31e-02 | 1.53e-01 | 5.15e-01 | 7.36e-01 | 1.43e-01 | 6.75e-01 | 5.23e-03 |
| ANTIGEN PROCESSING AND PRESENTATION | 112 | 2.14e-01 | 6.09e-01 | 0.1790 | 7.67e-02 | 1.01e-01 | 6.14e-02 | 9.85e-02 | 5.12e-02 | 1.61e-01 | 6.54e-02 | 2.61e-01 | 7.17e-02 | 3.50e-01 |
| REGULATION OF PIGMENT CELL DIFFERENTIATION | 8 | 9.21e-01 | 9.86e-01 | 0.1790 | -4.19e-02 | -1.11e-01 | -1.29e-01 | -1.73e-03 | -3.86e-02 | 8.38e-01 | 5.87e-01 | 5.29e-01 | 9.93e-01 | 8.50e-01 |
| REGULATION OF FEEDING BEHAVIOR | 27 | 5.43e-01 | 8.69e-01 | 0.1790 | 3.40e-02 | 7.73e-02 | -3.83e-02 | -1.64e-02 | -1.52e-01 | 7.60e-01 | 4.87e-01 | 7.31e-01 | 8.83e-01 | 1.70e-01 |
| POSITIVE REGULATION OF HEAT GENERATION | 9 | 6.87e-01 | 9.31e-01 | 0.1790 | 1.15e-01 | 1.16e-01 | -4.02e-02 | -5.82e-02 | 1.56e-02 | 5.49e-01 | 5.46e-01 | 8.35e-01 | 7.62e-01 | 9.36e-01 |
| NEGATIVE REGULATION OF RESPONSE TO BIOTIC STIMULUS | 145 | 2.64e-01 | 6.72e-01 | 0.1790 | 4.10e-02 | 5.64e-02 | 8.55e-02 | 7.91e-02 | 1.17e-01 | 3.94e-01 | 2.41e-01 | 7.56e-02 | 1.00e-01 | 1.53e-02 |
| REGULATION OF VIRAL GENOME REPLICATION | 84 | 5.96e-01 | 8.97e-01 | 0.1790 | 7.62e-02 | 8.30e-02 | 7.32e-02 | 1.07e-01 | 5.06e-02 | 2.27e-01 | 1.88e-01 | 2.46e-01 | 9.06e-02 | 4.22e-01 |
| RESPONSE TO AMYLOID BETA | 55 | 7.66e-01 | 9.55e-01 | 0.1790 | -5.76e-02 | -8.23e-02 | -1.06e-01 | -9.79e-02 | -3.45e-02 | 4.60e-01 | 2.91e-01 | 1.75e-01 | 2.09e-01 | 6.58e-01 |
| MONOCARBOXYLIC ACID TRANSPORT | 174 | 1.73e-02 | 1.51e-01 | 0.1790 | -5.44e-02 | -4.60e-02 | -9.41e-02 | -1.29e-01 | -3.73e-02 | 2.15e-01 | 2.96e-01 | 3.23e-02 | 3.27e-03 | 3.95e-01 |
| PYRIMIDINE RIBONUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 17 | 4.89e-01 | 8.39e-01 | 0.1790 | -8.36e-02 | 2.54e-02 | -1.67e-02 | -2.64e-02 | 1.53e-01 | 5.51e-01 | 8.56e-01 | 9.05e-01 | 8.50e-01 | 2.75e-01 |
| REGULATION OF TOLL LIKE RECEPTOR 7 SIGNALING PATHWAY | 5 | 9.96e-01 | 1.00e+00 | 0.1790 | -5.09e-02 | -7.36e-02 | -1.06e-01 | -1.12e-01 | -1.39e-02 | 8.44e-01 | 7.76e-01 | 6.80e-01 | 6.65e-01 | 9.57e-01 |
| INTRACELLULAR AMINO ACID HOMEOSTASIS | 8 | 8.85e-01 | 9.80e-01 | 0.1790 | 8.07e-02 | 7.61e-02 | -1.10e-02 | 1.17e-01 | -7.60e-02 | 6.92e-01 | 7.09e-01 | 9.57e-01 | 5.66e-01 | 7.10e-01 |
| LEUKOCYTE HOMEOSTASIS | 103 | 1.51e-01 | 5.19e-01 | 0.1790 | 1.04e-01 | 5.84e-02 | 4.76e-02 | 1.25e-01 | -1.95e-03 | 6.94e-02 | 3.06e-01 | 4.04e-01 | 2.88e-02 | 9.73e-01 |
| REGULATION OF MAP KINASE ACTIVITY | 140 | 1.33e-01 | 4.94e-01 | 0.1790 | 1.06e-01 | 1.12e-01 | 4.44e-02 | 7.76e-02 | -3.22e-03 | 3.00e-02 | 2.16e-02 | 3.65e-01 | 1.13e-01 | 9.48e-01 |
| NEGATIVE REGULATION OF RESPONSE TO WOUNDING | 94 | 8.41e-02 | 3.92e-01 | 0.1790 | -3.10e-02 | 1.39e-02 | -7.89e-02 | -7.69e-02 | -1.36e-01 | 6.04e-01 | 8.16e-01 | 1.86e-01 | 1.97e-01 | 2.22e-02 |
| ACUTE INFLAMMATORY RESPONSE | 104 | 6.45e-01 | 9.16e-01 | 0.1780 | -6.92e-02 | -8.36e-02 | -1.02e-01 | -8.54e-02 | -4.81e-02 | 2.23e-01 | 1.41e-01 | 7.16e-02 | 1.32e-01 | 3.97e-01 |
| REGULATION OF MYOTUBE DIFFERENTIATION | 48 | 4.85e-01 | 8.38e-01 | 0.1780 | -3.63e-02 | 1.25e-03 | 8.25e-02 | 4.21e-02 | 1.48e-01 | 6.64e-01 | 9.88e-01 | 3.23e-01 | 6.14e-01 | 7.59e-02 |
| RIBOSE PHOSPHATE METABOLIC PROCESS | 361 | 2.34e-02 | 1.86e-01 | 0.1780 | 8.19e-02 | 8.11e-02 | 8.31e-02 | 6.88e-02 | 8.30e-02 | 7.49e-03 | 8.08e-03 | 6.70e-03 | 2.47e-02 | 6.76e-03 |
| MYELOID CELL APOPTOTIC PROCESS | 38 | 6.31e-01 | 9.10e-01 | 0.1780 | 6.10e-02 | 6.44e-02 | 6.66e-02 | 1.31e-01 | 4.76e-02 | 5.15e-01 | 4.92e-01 | 4.77e-01 | 1.62e-01 | 6.11e-01 |
| NEGATIVE REGULATION OF STEROID HORMONE BIOSYNTHETIC PROCESS | 6 | 9.80e-01 | 9.96e-01 | 0.1780 | -8.80e-02 | -9.42e-02 | 2.23e-02 | 1.53e-03 | 1.21e-01 | 7.09e-01 | 6.89e-01 | 9.25e-01 | 9.95e-01 | 6.07e-01 |
| CEREBELLAR PURKINJE CELL LAYER MORPHOGENESIS | 18 | 8.55e-01 | 9.76e-01 | 0.1780 | -1.43e-02 | -1.32e-02 | 9.23e-02 | 3.50e-02 | 1.47e-01 | 9.16e-01 | 9.22e-01 | 4.98e-01 | 7.97e-01 | 2.80e-01 |
| AXONEMAL DYNEIN COMPLEX ASSEMBLY | 39 | 2.49e-01 | 6.56e-01 | 0.1780 | -4.77e-02 | -1.77e-02 | -9.70e-03 | -7.68e-02 | 1.52e-01 | 6.06e-01 | 8.48e-01 | 9.17e-01 | 4.06e-01 | 1.00e-01 |
| ENDODERM FORMATION | 57 | 4.80e-01 | 8.35e-01 | 0.1780 | 2.19e-02 | 3.92e-02 | 6.24e-02 | 7.69e-02 | 1.41e-01 | 7.74e-01 | 6.08e-01 | 4.15e-01 | 3.15e-01 | 6.53e-02 |
| PYRIMIDINE NUCLEOSIDE TRIPHOSPHATE BIOSYNTHETIC PROCESS | 18 | 6.83e-01 | 9.30e-01 | 0.1780 | -3.41e-03 | 2.19e-03 | -1.03e-03 | 8.67e-03 | 1.78e-01 | 9.80e-01 | 9.87e-01 | 9.94e-01 | 9.49e-01 | 1.92e-01 |
| REGULATION OF BMP SIGNALING PATHWAY | 115 | 8.26e-02 | 3.88e-01 | 0.1780 | -1.97e-02 | 4.41e-02 | 8.94e-02 | 3.91e-02 | 1.41e-01 | 7.15e-01 | 4.14e-01 | 9.76e-02 | 4.68e-01 | 9.08e-03 |
| EXECUTION PHASE OF APOPTOSIS | 74 | 5.18e-02 | 3.00e-01 | 0.1780 | -4.17e-02 | -5.88e-02 | 4.01e-02 | 7.05e-02 | 1.41e-01 | 5.35e-01 | 3.81e-01 | 5.50e-01 | 2.94e-01 | 3.59e-02 |
| NEGATIVE REGULATION OF PROTEIN SECRETION | 71 | 6.47e-01 | 9.17e-01 | 0.1780 | 4.52e-02 | 9.49e-02 | 1.01e-01 | 6.08e-02 | 8.24e-02 | 5.10e-01 | 1.67e-01 | 1.42e-01 | 3.76e-01 | 2.30e-01 |
| NEUROTRANSMITTER GATED ION CHANNEL CLUSTERING | 16 | 8.11e-01 | 9.68e-01 | 0.1780 | 7.91e-02 | 1.13e-01 | -7.62e-03 | 3.68e-02 | -1.06e-01 | 5.84e-01 | 4.34e-01 | 9.58e-01 | 7.99e-01 | 4.63e-01 |
| SCHWANN CELL PROLIFERATION | 9 | 8.14e-01 | 9.69e-01 | 0.1780 | -6.28e-02 | -2.10e-02 | -4.12e-02 | 7.23e-03 | 1.60e-01 | 7.44e-01 | 9.13e-01 | 8.31e-01 | 9.70e-01 | 4.06e-01 |
| NEGATIVE REGULATION OF B CELL PROLIFERATION | 16 | 2.85e-01 | 6.93e-01 | 0.1780 | 1.09e-01 | 2.35e-02 | -1.18e-01 | 5.90e-02 | -4.28e-02 | 4.52e-01 | 8.71e-01 | 4.12e-01 | 6.83e-01 | 7.67e-01 |
| FOREBRAIN VENTRICULAR ZONE PROGENITOR CELL DIVISION | 5 | 9.98e-01 | 1.00e+00 | 0.1780 | 7.57e-02 | 7.98e-02 | 8.38e-02 | 4.86e-02 | 1.01e-01 | 7.69e-01 | 7.57e-01 | 7.46e-01 | 8.51e-01 | 6.96e-01 |
| LAYER FORMATION IN CEREBRAL CORTEX | 14 | 8.56e-01 | 9.77e-01 | 0.1780 | 5.76e-02 | 2.27e-02 | 1.25e-01 | 1.08e-01 | 2.07e-02 | 7.09e-01 | 8.83e-01 | 4.18e-01 | 4.83e-01 | 8.93e-01 |
| REGULATION OF PROTEIN TARGETING TO MEMBRANE | 32 | 3.34e-01 | 7.40e-01 | 0.1780 | -6.39e-02 | 6.18e-02 | 7.16e-02 | -2.54e-02 | 1.34e-01 | 5.31e-01 | 5.45e-01 | 4.83e-01 | 8.04e-01 | 1.90e-01 |
| RESPONSE TO STEROID HORMONE | 318 | 2.01e-02 | 1.67e-01 | 0.1780 | 5.92e-02 | 1.03e-01 | 8.82e-02 | 6.85e-02 | 7.11e-02 | 6.93e-02 | 1.61e-03 | 6.82e-03 | 3.56e-02 | 2.93e-02 |
| SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 65 | 7.81e-01 | 9.60e-01 | 0.1780 | 1.09e-01 | 8.40e-02 | 7.01e-02 | 8.06e-02 | 3.41e-02 | 1.27e-01 | 2.41e-01 | 3.29e-01 | 2.61e-01 | 6.34e-01 |
| POLARIZED EPITHELIAL CELL DIFFERENTIATION | 25 | 7.34e-01 | 9.46e-01 | 0.1780 | -1.27e-01 | -7.70e-02 | 1.36e-02 | -4.15e-02 | 8.79e-02 | 2.73e-01 | 5.05e-01 | 9.06e-01 | 7.19e-01 | 4.47e-01 |
| REGULATION OF GRANULOCYTE CHEMOTAXIS | 50 | 1.41e-02 | 1.30e-01 | 0.1780 | 3.75e-02 | 8.88e-02 | -7.47e-02 | -1.14e-01 | -6.11e-02 | 6.46e-01 | 2.77e-01 | 3.61e-01 | 1.64e-01 | 4.55e-01 |
| CELL MIGRATION INVOLVED IN KIDNEY DEVELOPMENT | 6 | 9.75e-01 | 9.95e-01 | 0.1780 | 2.54e-02 | 1.20e-01 | 6.44e-02 | 2.52e-02 | 1.08e-01 | 9.14e-01 | 6.09e-01 | 7.85e-01 | 9.15e-01 | 6.47e-01 |
| REGULATION OF LYMPHOCYTE MIGRATION | 66 | 3.51e-01 | 7.52e-01 | 0.1780 | 4.17e-03 | -1.58e-02 | -6.17e-02 | -3.74e-02 | -1.62e-01 | 9.53e-01 | 8.24e-01 | 3.86e-01 | 5.99e-01 | 2.33e-02 |
| REGULATION OF NUCLEAR TRANSCRIBED MRNA POLY A TAIL SHORTENING | 15 | 7.59e-01 | 9.52e-01 | 0.1780 | -9.82e-02 | -1.27e-01 | -6.51e-02 | 1.62e-02 | 3.50e-02 | 5.10e-01 | 3.94e-01 | 6.62e-01 | 9.13e-01 | 8.15e-01 |
| TRUNK SEGMENTATION | 5 | 8.87e-01 | 9.80e-01 | 0.1780 | -5.87e-02 | 1.14e-01 | 8.89e-02 | 6.33e-02 | 5.70e-02 | 8.20e-01 | 6.60e-01 | 7.31e-01 | 8.06e-01 | 8.25e-01 |
| NEGATIVE REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 39 | 8.11e-01 | 9.68e-01 | 0.1770 | -5.95e-02 | -4.87e-02 | -8.99e-02 | -5.79e-02 | -1.19e-01 | 5.20e-01 | 5.98e-01 | 3.31e-01 | 5.32e-01 | 1.99e-01 |
| FC RECEPTOR MEDIATED STIMULATORY SIGNALING PATHWAY | 32 | 4.85e-01 | 8.38e-01 | 0.1770 | 1.25e-01 | 6.35e-02 | -4.06e-02 | 3.73e-02 | -9.42e-02 | 2.23e-01 | 5.34e-01 | 6.91e-01 | 7.15e-01 | 3.56e-01 |
| REGULATION OF LIPID CATABOLIC PROCESS | 60 | 5.07e-01 | 8.52e-01 | 0.1770 | 9.86e-02 | 1.28e-01 | 5.18e-02 | 4.84e-02 | -1.97e-02 | 1.86e-01 | 8.74e-02 | 4.88e-01 | 5.16e-01 | 7.92e-01 |
| POSITIVE REGULATION OF VOLTAGE GATED POTASSIUM CHANNEL ACTIVITY | 12 | 6.20e-01 | 9.07e-01 | 0.1770 | -4.82e-02 | 1.08e-01 | 5.30e-02 | -7.35e-02 | 9.57e-02 | 7.73e-01 | 5.16e-01 | 7.51e-01 | 6.59e-01 | 5.66e-01 |
| MACROPHAGE MIGRATION | 61 | 3.88e-02 | 2.54e-01 | 0.1770 | 7.84e-02 | 1.14e-01 | -4.27e-02 | 1.02e-02 | -1.01e-01 | 2.90e-01 | 1.23e-01 | 5.64e-01 | 8.90e-01 | 1.71e-01 |
| NEGATIVE REGULATION OF AMYLOID PRECURSOR PROTEIN BIOSYNTHETIC PROCESS | 18 | 2.16e-01 | 6.12e-01 | 0.1770 | -6.32e-02 | -3.75e-03 | 5.20e-02 | 6.95e-02 | -1.41e-01 | 6.43e-01 | 9.78e-01 | 7.02e-01 | 6.10e-01 | 3.01e-01 |
| PROTEIN O LINKED GLYCOSYLATION VIA THREONINE | 10 | 6.41e-01 | 9.14e-01 | 0.1770 | 1.09e-01 | -5.46e-02 | -5.48e-02 | 1.14e-01 | -2.16e-02 | 5.49e-01 | 7.65e-01 | 7.64e-01 | 5.33e-01 | 9.06e-01 |
| VESICLE TETHERING | 31 | 6.73e-01 | 9.27e-01 | 0.1770 | 9.63e-02 | 1.92e-02 | 7.89e-02 | 8.90e-02 | 8.68e-02 | 3.53e-01 | 8.54e-01 | 4.47e-01 | 3.91e-01 | 4.03e-01 |
| VENTRICULAR CARDIAC MUSCLE TISSUE DEVELOPMENT | 58 | 3.74e-01 | 7.73e-01 | 0.1770 | -1.06e-02 | 5.34e-02 | 9.59e-02 | 1.77e-02 | 1.37e-01 | 8.89e-01 | 4.82e-01 | 2.06e-01 | 8.15e-01 | 7.08e-02 |
| NEGATIVE REGULATION OF MONOOXYGENASE ACTIVITY | 14 | 4.02e-01 | 7.89e-01 | 0.1770 | -1.15e-01 | 6.35e-02 | 8.61e-02 | -7.64e-02 | 2.82e-02 | 4.57e-01 | 6.81e-01 | 5.77e-01 | 6.21e-01 | 8.55e-01 |
| MIRNA MEDIATED GENE SILENCING BY MRNA DESTABILIZATION | 62 | 7.27e-02 | 3.65e-01 | 0.1770 | -4.15e-02 | -1.36e-01 | -6.01e-02 | -6.54e-04 | -8.53e-02 | 5.72e-01 | 6.32e-02 | 4.13e-01 | 9.93e-01 | 2.46e-01 |
| FOLIC ACID CONTAINING COMPOUND METABOLIC PROCESS | 26 | 3.95e-01 | 7.85e-01 | 0.1770 | 1.32e-01 | 6.31e-02 | -2.67e-02 | 9.54e-02 | 4.24e-03 | 2.44e-01 | 5.78e-01 | 8.13e-01 | 4.00e-01 | 9.70e-01 |
| CERAMIDE TRANSPORT | 17 | 6.18e-01 | 9.07e-01 | 0.1760 | 6.79e-02 | 3.81e-04 | 4.49e-02 | 6.89e-02 | -1.40e-01 | 6.28e-01 | 9.98e-01 | 7.49e-01 | 6.23e-01 | 3.16e-01 |
| REGULATION OF KERATINOCYTE MIGRATION | 14 | 5.77e-01 | 8.85e-01 | 0.1760 | -8.29e-02 | -1.02e-01 | -1.15e-01 | 1.81e-02 | 2.00e-02 | 5.91e-01 | 5.10e-01 | 4.57e-01 | 9.07e-01 | 8.97e-01 |
| POSITIVE REGULATION OF GLYCOGEN METABOLIC PROCESS | 17 | 8.18e-01 | 9.70e-01 | 0.1760 | -1.28e-01 | -2.87e-02 | -1.37e-02 | -8.20e-02 | 8.28e-02 | 3.59e-01 | 8.38e-01 | 9.22e-01 | 5.58e-01 | 5.55e-01 |
| GOLGI TO PLASMA MEMBRANE PROTEIN TRANSPORT | 39 | 5.24e-01 | 8.60e-01 | 0.1760 | 8.84e-02 | 6.52e-02 | 2.16e-02 | 9.57e-02 | -9.69e-02 | 3.39e-01 | 4.81e-01 | 8.15e-01 | 3.01e-01 | 2.95e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL DIFFERENTIATION | 7 | 7.64e-01 | 9.54e-01 | 0.1760 | 1.62e-02 | -1.14e-01 | 6.42e-02 | 1.11e-01 | 3.54e-02 | 9.41e-01 | 6.02e-01 | 7.68e-01 | 6.10e-01 | 8.71e-01 |
| POSITIVE REGULATION OF LIPID STORAGE | 27 | 6.60e-01 | 9.21e-01 | 0.1760 | -1.34e-01 | -5.53e-02 | -2.01e-02 | -4.85e-02 | 8.55e-02 | 2.28e-01 | 6.19e-01 | 8.56e-01 | 6.63e-01 | 4.42e-01 |
| REGULATION OF MEMBRANE DEPOLARIZATION | 45 | 4.31e-01 | 8.06e-01 | 0.1760 | -1.17e-01 | -4.52e-02 | 2.79e-03 | -6.94e-02 | 1.02e-01 | 1.74e-01 | 6.00e-01 | 9.74e-01 | 4.21e-01 | 2.37e-01 |
| MORPHOGENESIS OF AN EPITHELIAL FOLD | 23 | 6.92e-01 | 9.31e-01 | 0.1760 | -5.47e-02 | -2.02e-02 | 3.86e-02 | 5.05e-02 | 1.54e-01 | 6.50e-01 | 8.67e-01 | 7.49e-01 | 6.75e-01 | 2.02e-01 |
| REGULATION OF FATTY ACID TRANSPORT | 31 | 4.74e-01 | 8.31e-01 | 0.1760 | -5.29e-02 | 2.24e-03 | -9.31e-02 | -1.37e-01 | -2.90e-02 | 6.10e-01 | 9.83e-01 | 3.70e-01 | 1.88e-01 | 7.80e-01 |
| REGULATION OF GLUTAMATE SECRETION | 20 | 9.67e-01 | 9.94e-01 | 0.1760 | 5.87e-02 | 9.56e-02 | 1.04e-01 | 5.37e-02 | 6.88e-02 | 6.50e-01 | 4.59e-01 | 4.22e-01 | 6.77e-01 | 5.94e-01 |
| SCHWANN CELL DEVELOPMENT | 30 | 7.39e-01 | 9.49e-01 | 0.1760 | 5.43e-03 | 5.55e-03 | 5.06e-02 | 5.05e-02 | 1.61e-01 | 9.59e-01 | 9.58e-01 | 6.32e-01 | 6.32e-01 | 1.28e-01 |
| RETINA HOMEOSTASIS | 75 | 5.35e-01 | 8.65e-01 | 0.1760 | -1.18e-01 | -8.61e-02 | -6.87e-02 | -6.45e-02 | -2.54e-02 | 7.62e-02 | 1.97e-01 | 3.03e-01 | 3.34e-01 | 7.04e-01 |
| POSITIVE REGULATION OF RESPONSE TO WOUNDING | 73 | 7.82e-01 | 9.60e-01 | 0.1760 | -7.07e-02 | -6.90e-02 | -9.82e-02 | -7.57e-02 | -7.61e-02 | 2.96e-01 | 3.08e-01 | 1.47e-01 | 2.63e-01 | 2.61e-01 |
| RETINA LAYER FORMATION | 23 | 9.16e-01 | 9.86e-01 | 0.1760 | -8.20e-02 | -1.17e-01 | -5.87e-02 | -8.30e-02 | -1.08e-02 | 4.96e-01 | 3.30e-01 | 6.26e-01 | 4.91e-01 | 9.28e-01 |
| FACIAL NERVE STRUCTURAL ORGANIZATION | 7 | 8.74e-01 | 9.78e-01 | 0.1760 | 1.79e-02 | 1.47e-01 | 4.30e-02 | -3.31e-02 | -7.69e-02 | 9.35e-01 | 4.99e-01 | 8.44e-01 | 8.80e-01 | 7.24e-01 |
| INTRACILIARY TRANSPORT | 45 | 4.41e-01 | 8.13e-01 | 0.1760 | -5.67e-02 | -3.60e-02 | 2.84e-02 | 7.01e-03 | 1.60e-01 | 5.11e-01 | 6.76e-01 | 7.42e-01 | 9.35e-01 | 6.36e-02 |
| CAMERA TYPE EYE MORPHOGENESIS | 130 | 6.36e-02 | 3.36e-01 | 0.1760 | 2.21e-02 | 2.59e-02 | 5.87e-02 | 4.53e-02 | 1.56e-01 | 6.63e-01 | 6.10e-01 | 2.48e-01 | 3.73e-01 | 2.17e-03 |
| GLYCEROPHOSPHOLIPID BIOSYNTHETIC PROCESS | 200 | 2.29e-01 | 6.32e-01 | 0.1760 | 5.53e-02 | 6.30e-02 | 8.80e-02 | 9.26e-02 | 8.68e-02 | 1.77e-01 | 1.25e-01 | 3.19e-02 | 2.40e-02 | 3.44e-02 |
| POSITIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 14 | 6.37e-01 | 9.13e-01 | 0.1760 | 2.62e-02 | 4.88e-02 | 6.96e-03 | 9.71e-02 | 1.35e-01 | 8.65e-01 | 7.52e-01 | 9.64e-01 | 5.29e-01 | 3.81e-01 |
| BLEB ASSEMBLY | 11 | 5.63e-01 | 8.79e-01 | 0.1760 | 9.99e-02 | -1.51e-02 | -1.20e-01 | -7.34e-02 | -2.94e-02 | 5.66e-01 | 9.31e-01 | 4.91e-01 | 6.73e-01 | 8.66e-01 |
| REGULATION OF INOSITOL PHOSPHATE BIOSYNTHETIC PROCESS | 17 | 6.84e-01 | 9.30e-01 | 0.1760 | -4.54e-02 | -8.10e-02 | -1.16e-01 | -5.65e-02 | 7.43e-02 | 7.46e-01 | 5.63e-01 | 4.07e-01 | 6.86e-01 | 5.96e-01 |
| REGULATION OF RECEPTOR BINDING | 17 | 8.17e-01 | 9.70e-01 | 0.1760 | 2.45e-02 | 5.00e-02 | 6.83e-02 | 1.29e-01 | 7.96e-02 | 8.61e-01 | 7.21e-01 | 6.26e-01 | 3.56e-01 | 5.70e-01 |
| MALE SEX DIFFERENTIATION | 163 | 2.16e-01 | 6.13e-01 | 0.1760 | 7.40e-02 | 8.09e-02 | 7.22e-02 | 6.51e-02 | 9.66e-02 | 1.03e-01 | 7.46e-02 | 1.12e-01 | 1.51e-01 | 3.32e-02 |
| HEMOGLOBIN METABOLIC PROCESS | 17 | 4.17e-01 | 7.99e-01 | 0.1760 | 8.78e-02 | -9.73e-04 | -3.48e-02 | 6.27e-02 | 1.34e-01 | 5.31e-01 | 9.94e-01 | 8.04e-01 | 6.54e-01 | 3.39e-01 |
| NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 128 | 5.73e-01 | 8.84e-01 | 0.1750 | 7.44e-02 | 8.24e-02 | 9.49e-02 | 9.03e-02 | 3.61e-02 | 1.46e-01 | 1.08e-01 | 6.36e-02 | 7.78e-02 | 4.81e-01 |
| DEFENSE RESPONSE TO BACTERIUM | 301 | 3.74e-06 | 1.57e-04 | 0.1750 | 4.47e-02 | 2.13e-02 | -7.86e-02 | -6.01e-02 | -1.36e-01 | 1.82e-01 | 5.25e-01 | 1.90e-02 | 7.30e-02 | 4.80e-05 |
| MICROTUBULE CYTOSKELETON ORGANIZATION | 628 | 6.79e-04 | 1.27e-02 | 0.1750 | 7.32e-02 | 5.66e-02 | 8.28e-02 | 9.55e-02 | 7.90e-02 | 1.74e-03 | 1.54e-02 | 3.96e-04 | 4.40e-05 | 7.21e-04 |
| POSITIVE REGULATION OF ADAPTIVE IMMUNE RESPONSE | 125 | 4.66e-01 | 8.26e-01 | 0.1750 | 6.48e-02 | 7.46e-02 | 8.17e-02 | 1.02e-01 | 6.28e-02 | 2.11e-01 | 1.50e-01 | 1.14e-01 | 4.92e-02 | 2.26e-01 |
| SEX DIFFERENTIATION | 266 | 6.13e-02 | 3.28e-01 | 0.1750 | 7.89e-02 | 9.45e-02 | 7.76e-02 | 6.02e-02 | 7.71e-02 | 2.67e-02 | 7.98e-03 | 2.93e-02 | 9.10e-02 | 3.03e-02 |
| PROTEIN AUTOUBIQUITINATION | 67 | 7.76e-01 | 9.58e-01 | 0.1750 | 9.58e-02 | 7.98e-02 | 6.32e-02 | 9.79e-02 | 4.02e-02 | 1.75e-01 | 2.59e-01 | 3.71e-01 | 1.66e-01 | 5.69e-01 |
| COLLAGEN FIBRIL ORGANIZATION | 63 | 3.75e-02 | 2.50e-01 | 0.1750 | -1.41e-01 | -7.92e-03 | -1.03e-02 | -1.03e-01 | -5.87e-03 | 5.22e-02 | 9.13e-01 | 8.88e-01 | 1.59e-01 | 9.36e-01 |
| C4 DICARBOXYLATE TRANSPORT | 27 | 6.85e-01 | 9.30e-01 | 0.1750 | -1.09e-01 | -4.87e-02 | 3.21e-02 | -3.25e-02 | 1.20e-01 | 3.25e-01 | 6.61e-01 | 7.73e-01 | 7.70e-01 | 2.82e-01 |
| REGULATION OF RECEPTOR LOCALIZATION TO SYNAPSE | 17 | 9.67e-01 | 9.94e-01 | 0.1750 | -6.66e-02 | -9.61e-02 | -8.96e-02 | -9.47e-02 | 5.37e-03 | 6.34e-01 | 4.93e-01 | 5.22e-01 | 4.99e-01 | 9.69e-01 |
| POSITIVE REGULATION OF CELL KILLING | 75 | 1.91e-02 | 1.61e-01 | 0.1750 | -7.90e-02 | -1.32e-01 | -5.67e-02 | 2.29e-02 | -5.65e-02 | 2.37e-01 | 4.77e-02 | 3.96e-01 | 7.32e-01 | 3.98e-01 |
| POSITIVE REGULATION OF MACROPHAGE ACTIVATION | 30 | 5.39e-01 | 8.67e-01 | 0.1750 | 4.23e-02 | -5.58e-02 | -7.02e-02 | 1.11e-02 | -1.44e-01 | 6.89e-01 | 5.97e-01 | 5.06e-01 | 9.16e-01 | 1.73e-01 |
| PYRIMIDINE NUCLEOBASE BIOSYNTHETIC PROCESS | 7 | 9.63e-01 | 9.94e-01 | 0.1750 | 2.54e-02 | -7.73e-02 | -8.59e-02 | 1.17e-02 | -1.28e-01 | 9.08e-01 | 7.23e-01 | 6.94e-01 | 9.57e-01 | 5.56e-01 |
| REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 47 | 2.53e-01 | 6.59e-01 | 0.1750 | 3.95e-02 | 2.93e-03 | 8.12e-02 | 1.42e-01 | 4.66e-02 | 6.39e-01 | 9.72e-01 | 3.35e-01 | 9.10e-02 | 5.81e-01 |
| HAIR FOLLICLE MATURATION | 15 | 4.41e-01 | 8.12e-01 | 0.1750 | -9.43e-02 | -1.08e-01 | -3.01e-03 | 9.05e-02 | 4.38e-02 | 5.27e-01 | 4.70e-01 | 9.84e-01 | 5.44e-01 | 7.69e-01 |
| RESPONSE TO HEAT | 99 | 3.24e-01 | 7.34e-01 | 0.1750 | 2.72e-02 | 6.58e-02 | 1.14e-01 | 5.57e-02 | 9.66e-02 | 6.40e-01 | 2.58e-01 | 4.90e-02 | 3.38e-01 | 9.66e-02 |
| FUCOSYLATION | 17 | 9.11e-01 | 9.85e-01 | 0.1750 | -9.37e-02 | -6.90e-02 | -6.83e-02 | -4.01e-02 | -1.04e-01 | 5.04e-01 | 6.22e-01 | 6.26e-01 | 7.75e-01 | 4.59e-01 |
| PROTEIN LOCALIZATION TO MICROTUBULE | 17 | 5.30e-01 | 8.63e-01 | 0.1750 | 1.70e-02 | 4.21e-02 | 4.43e-02 | 1.49e-01 | 6.53e-02 | 9.03e-01 | 7.64e-01 | 7.52e-01 | 2.87e-01 | 6.41e-01 |
| PRESYNAPSE ORGANIZATION | 44 | 1.72e-01 | 5.56e-01 | 0.1750 | -8.00e-02 | -2.50e-02 | 3.63e-02 | -9.12e-02 | 1.18e-01 | 3.58e-01 | 7.74e-01 | 6.77e-01 | 2.95e-01 | 1.77e-01 |
| NEGATIVE REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 89 | 6.56e-01 | 9.20e-01 | 0.1750 | -9.54e-02 | -9.00e-02 | -6.23e-02 | -9.45e-02 | -2.18e-02 | 1.20e-01 | 1.42e-01 | 3.09e-01 | 1.23e-01 | 7.22e-01 |
| REGULATION OF CYTOPLASMIC TRANSLATION | 30 | 8.48e-01 | 9.76e-01 | 0.1750 | 1.06e-01 | 4.67e-02 | 7.29e-02 | 8.44e-02 | 6.89e-02 | 3.17e-01 | 6.58e-01 | 4.90e-01 | 4.24e-01 | 5.14e-01 |
| REGULATION OF MACROPHAGE MIGRATION | 45 | 1.39e-01 | 5.03e-01 | 0.1750 | 8.79e-02 | 1.21e-01 | -3.48e-02 | 1.22e-02 | -8.29e-02 | 3.08e-01 | 1.62e-01 | 6.86e-01 | 8.87e-01 | 3.36e-01 |
| POSITIVE REGULATION OF CELL CYCLE CHECKPOINT | 18 | 9.30e-01 | 9.90e-01 | 0.1750 | 3.37e-02 | 6.04e-03 | 7.53e-02 | 7.98e-02 | 1.31e-01 | 8.05e-01 | 9.65e-01 | 5.80e-01 | 5.58e-01 | 3.34e-01 |
| INTESTINE SMOOTH MUSCLE CONTRACTION | 8 | 4.10e-01 | 7.95e-01 | 0.1750 | -2.60e-02 | -6.01e-02 | -9.92e-02 | 1.26e-01 | 2.31e-02 | 8.99e-01 | 7.69e-01 | 6.27e-01 | 5.38e-01 | 9.10e-01 |
| CORONARY ARTERY MORPHOGENESIS | 9 | 9.72e-01 | 9.95e-01 | 0.1740 | 9.49e-02 | 1.20e-01 | 3.83e-02 | 4.91e-02 | 5.68e-02 | 6.22e-01 | 5.34e-01 | 8.42e-01 | 7.99e-01 | 7.68e-01 |
| REGULATION OF MYOBLAST PROLIFERATION | 25 | 3.70e-01 | 7.70e-01 | 0.1740 | -5.66e-02 | 2.40e-02 | 6.08e-03 | -7.64e-02 | -1.44e-01 | 6.24e-01 | 8.35e-01 | 9.58e-01 | 5.09e-01 | 2.12e-01 |
| VESICLE TRANSPORT ALONG MICROTUBULE | 45 | 6.45e-01 | 9.16e-01 | 0.1740 | 7.62e-02 | 2.75e-02 | 7.20e-02 | 1.23e-01 | 5.87e-02 | 3.77e-01 | 7.50e-01 | 4.04e-01 | 1.52e-01 | 4.96e-01 |
| CALCIUM ION TRANSMEMBRANE IMPORT INTO CYTOSOL | 198 | 1.36e-01 | 4.99e-01 | 0.1740 | -1.13e-01 | -7.82e-02 | -6.86e-02 | -7.93e-02 | -2.19e-02 | 5.97e-03 | 5.78e-02 | 9.62e-02 | 5.44e-02 | 5.96e-01 |
| CELLULAR RESPONSE TO CHOLESTEROL | 20 | 6.59e-01 | 9.21e-01 | 0.1740 | -4.55e-02 | -5.53e-02 | -1.41e-01 | -7.36e-02 | 1.95e-03 | 7.24e-01 | 6.69e-01 | 2.75e-01 | 5.69e-01 | 9.88e-01 |
| MUSCLE ORGAN DEVELOPMENT | 342 | 1.42e-04 | 3.60e-03 | 0.1740 | -6.58e-04 | 3.77e-02 | 9.19e-02 | 3.14e-02 | 1.40e-01 | 9.83e-01 | 2.31e-01 | 3.48e-03 | 3.19e-01 | 8.86e-06 |
| REGULATION OF ATP METABOLIC PROCESS | 22 | 2.36e-01 | 6.39e-01 | 0.1740 | 4.82e-02 | 1.23e-02 | 2.33e-02 | -6.27e-02 | 1.53e-01 | 6.96e-01 | 9.20e-01 | 8.50e-01 | 6.10e-01 | 2.14e-01 |
| RIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 54 | 7.73e-01 | 9.57e-01 | 0.1740 | 1.14e-01 | 9.20e-02 | 6.69e-02 | 6.52e-02 | 4.66e-03 | 1.46e-01 | 2.42e-01 | 3.95e-01 | 4.07e-01 | 9.53e-01 |
| CANONICAL WNT SIGNALING PATHWAY | 302 | 9.98e-03 | 1.01e-01 | 0.1740 | 3.27e-02 | 5.24e-02 | 8.30e-02 | 9.04e-02 | 1.07e-01 | 3.29e-01 | 1.18e-01 | 1.31e-02 | 6.87e-03 | 1.41e-03 |
| RESPONSE TO LAMINAR FLUID SHEAR STRESS | 14 | 8.90e-01 | 9.80e-01 | 0.1740 | -5.31e-02 | 2.49e-02 | 6.58e-02 | 3.75e-02 | 1.45e-01 | 7.31e-01 | 8.72e-01 | 6.70e-01 | 8.08e-01 | 3.47e-01 |
| CYTOSOLIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 138 | 4.29e-02 | 2.69e-01 | 0.1740 | 1.22e-01 | 7.96e-02 | 4.62e-02 | 5.84e-02 | 5.91e-02 | 1.33e-02 | 1.07e-01 | 3.49e-01 | 2.36e-01 | 2.30e-01 |
| WATER SOLUBLE VITAMIN METABOLIC PROCESS | 58 | 7.39e-01 | 9.49e-01 | 0.1740 | 8.97e-02 | 8.32e-02 | 8.02e-02 | 9.08e-02 | -2.49e-02 | 2.37e-01 | 2.73e-01 | 2.91e-01 | 2.32e-01 | 7.43e-01 |
| AXONAL TRANSPORT | 62 | 2.21e-01 | 6.19e-01 | 0.1740 | 5.76e-02 | -7.15e-03 | 5.50e-02 | 1.08e-01 | 1.10e-01 | 4.33e-01 | 9.22e-01 | 4.54e-01 | 1.41e-01 | 1.33e-01 |
| STEROL HOMEOSTASIS | 99 | 2.02e-02 | 1.68e-01 | 0.1740 | -9.39e-02 | -2.48e-03 | -6.99e-02 | -8.11e-02 | -9.98e-02 | 1.06e-01 | 9.66e-01 | 2.29e-01 | 1.63e-01 | 8.62e-02 |
| RENAL WATER HOMEOSTASIS | 24 | 6.10e-01 | 9.04e-01 | 0.1740 | -1.82e-02 | 5.68e-02 | 1.17e-01 | -5.50e-03 | 1.14e-01 | 8.77e-01 | 6.30e-01 | 3.21e-01 | 9.63e-01 | 3.35e-01 |
| EPITHELIAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 45 | 2.02e-01 | 5.96e-01 | 0.1740 | -2.71e-02 | 1.54e-02 | 6.25e-03 | 6.15e-03 | 1.71e-01 | 7.53e-01 | 8.58e-01 | 9.42e-01 | 9.43e-01 | 4.75e-02 |
| MACROPHAGE ACTIVATION | 109 | 4.16e-01 | 7.99e-01 | 0.1740 | 1.05e-01 | 1.02e-01 | 5.02e-02 | 7.80e-02 | 1.12e-02 | 5.71e-02 | 6.68e-02 | 3.65e-01 | 1.59e-01 | 8.40e-01 |
| SERINE FAMILY AMINO ACID CATABOLIC PROCESS | 14 | 5.10e-01 | 8.53e-01 | 0.1740 | 3.62e-02 | 6.78e-02 | 1.10e-02 | 1.37e-01 | -7.34e-02 | 8.15e-01 | 6.60e-01 | 9.43e-01 | 3.75e-01 | 6.34e-01 |
| NEGATIVE REGULATION OF LYMPHOCYTE ACTIVATION | 164 | 2.36e-01 | 6.40e-01 | 0.1740 | 1.00e-01 | 6.70e-02 | 6.20e-02 | 9.53e-02 | 5.18e-02 | 2.70e-02 | 1.39e-01 | 1.71e-01 | 3.51e-02 | 2.52e-01 |
| DENDRITE MORPHOGENESIS | 129 | 4.30e-01 | 8.06e-01 | 0.1730 | -9.92e-02 | -6.32e-02 | -7.58e-02 | -9.69e-02 | -3.37e-02 | 5.17e-02 | 2.15e-01 | 1.37e-01 | 5.73e-02 | 5.09e-01 |
| NEUROINFLAMMATORY RESPONSE | 82 | 4.36e-01 | 8.09e-01 | 0.1730 | 1.07e-01 | 9.73e-02 | 3.66e-02 | 7.19e-02 | -4.96e-02 | 9.25e-02 | 1.28e-01 | 5.67e-01 | 2.61e-01 | 4.38e-01 |
| CELLULAR MODIFIED AMINO ACID BIOSYNTHETIC PROCESS | 26 | 6.77e-01 | 9.28e-01 | 0.1730 | 1.40e-01 | 3.75e-02 | 3.12e-02 | 8.86e-02 | -5.00e-03 | 2.16e-01 | 7.40e-01 | 7.83e-01 | 4.34e-01 | 9.65e-01 |
| RETINA VASCULATURE MORPHOGENESIS IN CAMERA TYPE EYE | 9 | 9.25e-01 | 9.89e-01 | 0.1730 | 5.94e-02 | 6.27e-02 | 8.46e-02 | -6.98e-03 | 1.23e-01 | 7.58e-01 | 7.45e-01 | 6.60e-01 | 9.71e-01 | 5.21e-01 |
| MEMBRANE LIPID METABOLIC PROCESS | 208 | 2.51e-01 | 6.57e-01 | 0.1730 | 7.27e-02 | 6.55e-02 | 9.66e-02 | 8.15e-02 | 6.60e-02 | 7.08e-02 | 1.04e-01 | 1.63e-02 | 4.27e-02 | 1.01e-01 |
| REGULATION OF NEUROMUSCULAR JUNCTION DEVELOPMENT | 8 | 8.39e-01 | 9.73e-01 | 0.1730 | -1.37e-01 | -5.12e-03 | 2.87e-02 | 6.60e-03 | 1.01e-01 | 5.02e-01 | 9.80e-01 | 8.88e-01 | 9.74e-01 | 6.20e-01 |
| REGULATION OF CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 53 | 7.57e-01 | 9.51e-01 | 0.1730 | 1.04e-01 | 1.06e-01 | 4.79e-02 | 7.49e-02 | 9.03e-03 | 1.92e-01 | 1.84e-01 | 5.46e-01 | 3.46e-01 | 9.09e-01 |
| GENOMIC IMPRINTING | 18 | 6.80e-01 | 9.28e-01 | 0.1730 | 3.78e-02 | 4.79e-02 | 2.07e-03 | 7.51e-02 | -1.43e-01 | 7.81e-01 | 7.25e-01 | 9.88e-01 | 5.81e-01 | 2.93e-01 |
| SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 32 | 6.26e-01 | 9.09e-01 | 0.1730 | -2.55e-02 | -7.56e-02 | -8.22e-02 | -1.17e-01 | -5.59e-02 | 8.03e-01 | 4.59e-01 | 4.21e-01 | 2.53e-01 | 5.84e-01 |
| MORPHOGENESIS OF AN EPITHELIUM | 505 | 3.82e-04 | 8.14e-03 | 0.1730 | 3.26e-02 | 6.10e-02 | 8.19e-02 | 6.95e-02 | 1.16e-01 | 2.10e-01 | 1.89e-02 | 1.63e-03 | 7.51e-03 | 7.82e-06 |
| FATTY ACYL COA METABOLIC PROCESS | 37 | 8.61e-01 | 9.78e-01 | 0.1730 | 5.10e-02 | 5.33e-02 | 6.80e-02 | 6.77e-02 | 1.23e-01 | 5.92e-01 | 5.75e-01 | 4.74e-01 | 4.76e-01 | 1.95e-01 |
| NEGATIVE REGULATION OF DENDRITIC SPINE MORPHOGENESIS | 6 | 9.50e-01 | 9.94e-01 | 0.1730 | 4.34e-02 | -5.54e-02 | -1.26e-01 | 6.80e-03 | -9.39e-02 | 8.54e-01 | 8.14e-01 | 5.92e-01 | 9.77e-01 | 6.90e-01 |
| POSITIVE REGULATION OF REGULATED SECRETORY PATHWAY | 42 | 6.48e-01 | 9.17e-01 | 0.1730 | 4.24e-02 | 1.12e-01 | 1.04e-01 | 6.84e-02 | 1.16e-02 | 6.34e-01 | 2.11e-01 | 2.46e-01 | 4.43e-01 | 8.96e-01 |
| POSITIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 10 | 6.18e-01 | 9.07e-01 | 0.1720 | 1.07e-01 | 5.47e-02 | 7.34e-03 | -8.19e-02 | -9.27e-02 | 5.59e-01 | 7.65e-01 | 9.68e-01 | 6.54e-01 | 6.12e-01 |
| REGULATION OF ESTABLISHMENT OF PLANAR POLARITY | 51 | 2.53e-01 | 6.59e-01 | 0.1720 | -4.83e-02 | -3.75e-02 | 1.11e-02 | 2.90e-02 | 1.58e-01 | 5.51e-01 | 6.43e-01 | 8.91e-01 | 7.20e-01 | 5.07e-02 |
| SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE TRANSLOCATION | 8 | 5.80e-01 | 8.87e-01 | 0.1720 | -1.24e-01 | 3.14e-04 | 8.04e-02 | 8.84e-02 | 7.41e-04 | 5.43e-01 | 9.99e-01 | 6.94e-01 | 6.65e-01 | 9.97e-01 |
| VASOCONSTRICTION | 80 | 6.77e-01 | 9.28e-01 | 0.1720 | -6.06e-02 | -7.26e-02 | -8.21e-02 | -1.04e-01 | -5.71e-02 | 3.49e-01 | 2.62e-01 | 2.04e-01 | 1.09e-01 | 3.78e-01 |
| PYRIMIDINE NUCLEOSIDE METABOLIC PROCESS | 24 | 4.64e-01 | 8.25e-01 | 0.1720 | 1.01e-01 | 1.17e-01 | -3.93e-02 | -1.07e-02 | -6.45e-02 | 3.93e-01 | 3.21e-01 | 7.39e-01 | 9.27e-01 | 5.84e-01 |
| ECTODERM DEVELOPMENT | 21 | 8.98e-01 | 9.82e-01 | 0.1720 | 6.62e-02 | 2.83e-02 | 5.27e-02 | 8.46e-02 | 1.21e-01 | 5.99e-01 | 8.22e-01 | 6.76e-01 | 5.02e-01 | 3.39e-01 |
| RESPONSE TO TEMPERATURE STIMULUS | 165 | 8.79e-02 | 4.00e-01 | 0.1720 | 1.37e-02 | 3.93e-02 | 9.49e-02 | 4.92e-02 | 1.28e-01 | 7.61e-01 | 3.84e-01 | 3.54e-02 | 2.75e-01 | 4.41e-03 |
| CAMKK AMPK SIGNALING CASCADE | 9 | 9.75e-01 | 9.96e-01 | 0.1720 | -6.26e-02 | -5.03e-02 | -1.01e-01 | -1.13e-01 | 1.49e-02 | 7.45e-01 | 7.94e-01 | 5.99e-01 | 5.58e-01 | 9.38e-01 |
| PERIPHERAL NERVOUS SYSTEM AXON REGENERATION | 8 | 9.41e-01 | 9.92e-01 | 0.1720 | -4.11e-02 | -8.68e-03 | 3.09e-03 | -6.29e-02 | 1.55e-01 | 8.41e-01 | 9.66e-01 | 9.88e-01 | 7.58e-01 | 4.49e-01 |
| EXTRACELLULAR MATRIX DISASSEMBLY | 61 | 3.58e-01 | 7.57e-01 | 0.1720 | -1.06e-02 | 1.39e-02 | -6.16e-02 | -6.25e-02 | -1.47e-01 | 8.86e-01 | 8.51e-01 | 4.05e-01 | 3.99e-01 | 4.70e-02 |
| HORMONE MEDIATED SIGNALING PATHWAY | 185 | 1.79e-01 | 5.63e-01 | 0.1720 | 9.62e-02 | 1.00e-01 | 5.64e-02 | 7.84e-02 | 3.06e-02 | 2.40e-02 | 1.85e-02 | 1.86e-01 | 6.60e-02 | 4.72e-01 |
| DENDRITIC SPINE DEVELOPMENT | 86 | 5.73e-01 | 8.84e-01 | 0.1720 | -1.10e-01 | -8.36e-02 | -5.79e-02 | -7.33e-02 | -4.11e-02 | 7.68e-02 | 1.80e-01 | 3.54e-01 | 2.40e-01 | 5.10e-01 |
| RESPONSE TO ORGANIC CYCLIC COMPOUND | 875 | 5.79e-05 | 1.76e-03 | 0.1720 | 7.07e-02 | 8.54e-02 | 7.60e-02 | 7.49e-02 | 7.66e-02 | 3.82e-04 | 1.80e-05 | 1.35e-04 | 1.67e-04 | 1.21e-04 |
| POSITIVE REGULATION OF PROTEIN POLYMERIZATION | 89 | 5.45e-01 | 8.70e-01 | 0.1720 | 8.93e-02 | 9.39e-02 | 5.58e-02 | 8.44e-02 | 5.00e-02 | 1.45e-01 | 1.26e-01 | 3.63e-01 | 1.69e-01 | 4.15e-01 |
| VENTRICULAR TRABECULA MYOCARDIUM MORPHOGENESIS | 14 | 9.64e-01 | 9.94e-01 | 0.1720 | -5.98e-02 | -3.74e-02 | -5.55e-02 | -9.80e-02 | -1.09e-01 | 6.98e-01 | 8.09e-01 | 7.19e-01 | 5.25e-01 | 4.80e-01 |
| MODULATION BY HOST OF SYMBIONT PROCESS | 81 | 3.15e-01 | 7.26e-01 | 0.1720 | 2.13e-02 | 1.25e-02 | 9.51e-02 | 9.64e-02 | 1.03e-01 | 7.41e-01 | 8.46e-01 | 1.39e-01 | 1.34e-01 | 1.10e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 558 | 5.92e-04 | 1.16e-02 | 0.1710 | 6.72e-02 | 5.41e-02 | 7.40e-02 | 1.00e-01 | 8.04e-02 | 6.61e-03 | 2.89e-02 | 2.78e-03 | 5.27e-05 | 1.15e-03 |
| ECTOPIC GERM CELL PROGRAMMED CELL DEATH | 17 | 8.34e-01 | 9.73e-01 | 0.1710 | 5.41e-02 | 4.15e-02 | -8.16e-02 | -3.58e-02 | -1.30e-01 | 6.99e-01 | 7.67e-01 | 5.60e-01 | 7.98e-01 | 3.55e-01 |
| TRABECULA FORMATION | 26 | 6.31e-01 | 9.10e-01 | 0.1710 | 3.30e-02 | 1.19e-01 | 8.06e-02 | -4.69e-03 | 8.77e-02 | 7.71e-01 | 2.95e-01 | 4.77e-01 | 9.67e-01 | 4.39e-01 |
| ODONTOGENESIS | 126 | 4.90e-02 | 2.89e-01 | 0.1710 | -1.40e-02 | 6.72e-02 | 1.01e-01 | 4.79e-02 | 1.10e-01 | 7.86e-01 | 1.92e-01 | 4.92e-02 | 3.53e-01 | 3.32e-02 |
| POSITIVE REGULATION OF MEMORY T CELL DIFFERENTIATION | 9 | 9.83e-01 | 9.96e-01 | 0.1710 | 9.57e-02 | 8.91e-02 | 5.48e-02 | 4.14e-02 | 8.69e-02 | 6.19e-01 | 6.43e-01 | 7.76e-01 | 8.30e-01 | 6.52e-01 |
| B CELL DIFFERENTIATION | 143 | 1.50e-01 | 5.19e-01 | 0.1710 | 8.26e-02 | 5.39e-02 | 6.46e-02 | 1.20e-01 | 3.27e-02 | 8.82e-02 | 2.65e-01 | 1.82e-01 | 1.33e-02 | 5.00e-01 |
| LUTEINIZATION | 12 | 8.78e-01 | 9.79e-01 | 0.1710 | 1.47e-01 | 5.88e-02 | -3.93e-03 | 3.45e-02 | -5.54e-02 | 3.78e-01 | 7.24e-01 | 9.81e-01 | 8.36e-01 | 7.40e-01 |
| POSITIVE REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 27 | 9.05e-01 | 9.84e-01 | 0.1710 | -9.58e-02 | -7.50e-02 | -8.29e-02 | -8.17e-02 | 3.17e-02 | 3.89e-01 | 5.00e-01 | 4.56e-01 | 4.63e-01 | 7.76e-01 |
| RIBONUCLEOPROTEIN COMPLEX LOCALIZATION | 9 | 8.90e-01 | 9.80e-01 | 0.1710 | 9.30e-02 | 1.99e-02 | 1.20e-02 | 4.26e-02 | 1.35e-01 | 6.29e-01 | 9.18e-01 | 9.50e-01 | 8.25e-01 | 4.82e-01 |
| ADRENERGIC RECEPTOR SIGNALING PATHWAY | 32 | 1.45e-01 | 5.11e-01 | 0.1710 | -3.14e-02 | -8.11e-02 | 4.86e-02 | -4.86e-02 | 1.30e-01 | 7.58e-01 | 4.27e-01 | 6.34e-01 | 6.34e-01 | 2.02e-01 |
| REGULATION OF RECEPTOR RECYCLING | 25 | 6.84e-01 | 9.30e-01 | 0.1710 | -9.76e-02 | -7.15e-02 | 1.19e-02 | 1.33e-02 | 1.20e-01 | 3.98e-01 | 5.36e-01 | 9.18e-01 | 9.08e-01 | 3.00e-01 |
| REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 286 | 8.77e-02 | 4.00e-01 | 0.1710 | 4.64e-02 | 5.95e-02 | 8.93e-02 | 8.05e-02 | 9.56e-02 | 1.77e-01 | 8.35e-02 | 9.32e-03 | 1.92e-02 | 5.38e-03 |
| SYNAPTIC TRANSMISSION GLUTAMATERGIC | 106 | 4.88e-01 | 8.39e-01 | 0.1710 | -1.00e-01 | -6.03e-02 | -6.51e-02 | -1.01e-01 | -3.29e-02 | 7.39e-02 | 2.84e-01 | 2.47e-01 | 7.17e-02 | 5.59e-01 |
| MESODERMAL CELL MIGRATION | 5 | 9.81e-01 | 9.96e-01 | 0.1710 | 1.01e-01 | -3.56e-03 | 4.05e-02 | 1.27e-01 | 3.61e-02 | 6.95e-01 | 9.89e-01 | 8.75e-01 | 6.24e-01 | 8.89e-01 |
| REGULATION OF VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 33 | 3.87e-01 | 7.80e-01 | 0.1710 | -6.44e-02 | 4.65e-02 | 9.21e-02 | -1.74e-02 | 1.19e-01 | 5.22e-01 | 6.44e-01 | 3.60e-01 | 8.63e-01 | 2.36e-01 |
| RESPONSE TO VITAMIN | 82 | 4.42e-01 | 8.13e-01 | 0.1710 | 3.73e-02 | 8.09e-02 | 7.50e-02 | 4.73e-02 | 1.16e-01 | 5.59e-01 | 2.05e-01 | 2.40e-01 | 4.59e-01 | 6.91e-02 |
| POSITIVE REGULATION OF CHEMOKINE PRODUCTION | 70 | 9.25e-02 | 4.13e-01 | 0.1710 | 1.11e-01 | 8.87e-02 | -1.06e-02 | -1.21e-02 | -9.43e-02 | 1.09e-01 | 1.99e-01 | 8.79e-01 | 8.61e-01 | 1.73e-01 |
| REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 24 | 7.10e-01 | 9.35e-01 | 0.1710 | 6.00e-02 | 9.49e-02 | 3.50e-02 | 3.89e-02 | 1.18e-01 | 6.11e-01 | 4.21e-01 | 7.67e-01 | 7.41e-01 | 3.17e-01 |
| POSITIVE REGULATION OF POST TRANSCRIPTIONAL GENE SILENCING | 14 | 5.14e-01 | 8.55e-01 | 0.1710 | 1.16e-01 | -5.78e-03 | -4.74e-02 | 1.10e-01 | 3.88e-02 | 4.54e-01 | 9.70e-01 | 7.59e-01 | 4.76e-01 | 8.02e-01 |
| CELLULAR RESPONSE TO LIPID | 592 | 7.50e-06 | 2.89e-04 | 0.1710 | 9.17e-02 | 1.03e-01 | 5.44e-02 | 6.04e-02 | 5.99e-02 | 1.37e-04 | 1.87e-05 | 2.36e-02 | 1.20e-02 | 1.27e-02 |
| 2 OXOGLUTARATE METABOLIC PROCESS | 15 | 4.38e-01 | 8.10e-01 | 0.1710 | -3.60e-02 | 6.25e-02 | 1.13e-03 | 4.90e-02 | 1.47e-01 | 8.09e-01 | 6.75e-01 | 9.94e-01 | 7.43e-01 | 3.24e-01 |
| NEGATIVE REGULATION OF BLOOD CIRCULATION | 24 | 5.19e-01 | 8.57e-01 | 0.1710 | 3.45e-02 | 1.35e-01 | 5.93e-02 | 5.98e-02 | -5.07e-02 | 7.70e-01 | 2.51e-01 | 6.15e-01 | 6.12e-01 | 6.67e-01 |
| SKELETAL MUSCLE CONTRACTION | 43 | 1.58e-02 | 1.42e-01 | 0.1710 | -9.13e-02 | 6.33e-02 | 8.55e-02 | -8.72e-02 | 4.39e-02 | 3.00e-01 | 4.73e-01 | 3.32e-01 | 3.23e-01 | 6.19e-01 |
| REACTIVE NITROGEN SPECIES METABOLIC PROCESS | 76 | 5.48e-01 | 8.73e-01 | 0.1710 | 9.68e-02 | 9.21e-02 | 4.62e-02 | 9.29e-02 | 2.32e-02 | 1.45e-01 | 1.65e-01 | 4.86e-01 | 1.61e-01 | 7.27e-01 |
| ENDOPLASMIC RETICULUM PLASMA MEMBRANE TETHERING | 6 | 7.26e-01 | 9.42e-01 | 0.1710 | -4.91e-03 | 2.44e-02 | 1.45e-01 | -5.83e-02 | 6.30e-02 | 9.83e-01 | 9.17e-01 | 5.37e-01 | 8.05e-01 | 7.89e-01 |
| NEGATIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 65 | 8.42e-01 | 9.75e-01 | 0.1710 | 6.89e-02 | 7.32e-02 | 8.49e-02 | 9.96e-02 | 4.31e-02 | 3.36e-01 | 3.07e-01 | 2.37e-01 | 1.65e-01 | 5.48e-01 |
| POSITIVE REGULATION OF ALPHA BETA T CELL ACTIVATION | 67 | 4.66e-01 | 8.26e-01 | 0.1710 | 5.07e-02 | 7.32e-02 | 8.60e-02 | 1.15e-01 | 2.17e-02 | 4.73e-01 | 3.00e-01 | 2.23e-01 | 1.03e-01 | 7.59e-01 |
| COLLAGEN BIOSYNTHETIC PROCESS | 46 | 2.59e-01 | 6.66e-01 | 0.1700 | 3.86e-02 | 1.22e-01 | 7.33e-02 | 6.03e-02 | -6.08e-02 | 6.51e-01 | 1.52e-01 | 3.90e-01 | 4.79e-01 | 4.76e-01 |
| CELLULAR RESPONSE TO XENOBIOTIC STIMULUS | 189 | 1.13e-01 | 4.59e-01 | 0.1700 | -7.17e-02 | -3.98e-02 | -8.86e-02 | -1.04e-01 | -6.11e-02 | 8.90e-02 | 3.45e-01 | 3.57e-02 | 1.40e-02 | 1.48e-01 |
| RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 354 | 6.39e-04 | 1.23e-02 | 0.1700 | 1.00e-01 | 1.16e-01 | 4.59e-02 | 5.58e-02 | 1.66e-02 | 1.19e-03 | 1.74e-04 | 1.38e-01 | 7.14e-02 | 5.91e-01 |
| REGULATION OF POSTSYNAPTIC CYTOSOLIC CALCIUM ION CONCENTRATION | 10 | 8.52e-01 | 9.76e-01 | 0.1700 | 9.27e-02 | 1.94e-02 | 6.72e-02 | 6.18e-02 | -1.08e-01 | 6.12e-01 | 9.16e-01 | 7.13e-01 | 7.35e-01 | 5.54e-01 |
| REGULATION OF SKELETAL MUSCLE CELL DIFFERENTIATION | 20 | 5.26e-01 | 8.60e-01 | 0.1700 | -5.93e-02 | -1.88e-02 | 9.51e-02 | -4.18e-02 | 1.20e-01 | 6.46e-01 | 8.84e-01 | 4.62e-01 | 7.46e-01 | 3.54e-01 |
| NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 34 | 7.23e-01 | 9.41e-01 | 0.1700 | 8.58e-02 | 1.32e-01 | 4.77e-02 | 4.37e-02 | 2.21e-03 | 3.86e-01 | 1.83e-01 | 6.30e-01 | 6.59e-01 | 9.82e-01 |
| NEGATIVE REGULATION OF SIGNALING RECEPTOR ACTIVITY | 26 | 8.91e-01 | 9.81e-01 | 0.1700 | 4.54e-02 | 6.27e-02 | 5.90e-02 | 8.23e-02 | 1.13e-01 | 6.89e-01 | 5.80e-01 | 6.02e-01 | 4.68e-01 | 3.19e-01 |
| MYELOID CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 95 | 3.76e-01 | 7.75e-01 | 0.1700 | 9.14e-02 | 1.17e-01 | 6.41e-02 | 4.97e-02 | -2.04e-02 | 1.23e-01 | 4.94e-02 | 2.80e-01 | 4.02e-01 | 7.31e-01 |
| POSITIVE REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 8 | 7.77e-01 | 9.58e-01 | 0.1700 | -9.77e-02 | -1.09e-01 | -5.61e-02 | 6.54e-02 | -7.47e-03 | 6.32e-01 | 5.93e-01 | 7.84e-01 | 7.49e-01 | 9.71e-01 |
| PHENOL CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 46 | 4.39e-01 | 8.11e-01 | 0.1700 | -1.18e-01 | -7.88e-02 | -1.29e-02 | -8.71e-02 | -3.09e-02 | 1.65e-01 | 3.55e-01 | 8.79e-01 | 3.07e-01 | 7.17e-01 |
| REGULATION OF PHOSPHATASE ACTIVITY | 59 | 1.22e-01 | 4.75e-01 | 0.1700 | 6.90e-02 | 7.42e-02 | -2.73e-03 | 8.58e-02 | -1.06e-01 | 3.60e-01 | 3.24e-01 | 9.71e-01 | 2.54e-01 | 1.59e-01 |
| SLEEP | 22 | 3.11e-01 | 7.23e-01 | 0.1700 | -3.95e-02 | 2.90e-02 | -2.31e-02 | -1.46e-01 | 6.84e-02 | 7.48e-01 | 8.14e-01 | 8.52e-01 | 2.36e-01 | 5.79e-01 |
| REGULATION OF STEROL TRANSPORT | 80 | 1.47e-01 | 5.15e-01 | 0.1700 | -1.89e-03 | 2.30e-02 | -5.20e-02 | -3.34e-02 | -1.57e-01 | 9.77e-01 | 7.23e-01 | 4.22e-01 | 6.06e-01 | 1.54e-02 |
| LENS FIBER CELL DEVELOPMENT | 14 | 9.41e-01 | 9.92e-01 | 0.1700 | 1.06e-01 | 3.39e-02 | 4.35e-02 | 1.20e-01 | 1.70e-02 | 4.94e-01 | 8.26e-01 | 7.78e-01 | 4.38e-01 | 9.12e-01 |
| NEUTROPHIL CHEMOTAXIS | 102 | 4.80e-03 | 5.93e-02 | 0.1700 | 4.79e-02 | 3.85e-02 | -8.03e-02 | -9.23e-02 | -1.00e-01 | 4.03e-01 | 5.02e-01 | 1.61e-01 | 1.07e-01 | 7.99e-02 |
| MEMBRANE ORGANIZATION | 777 | 1.88e-03 | 2.90e-02 | 0.1700 | 7.03e-02 | 7.44e-02 | 8.91e-02 | 8.68e-02 | 5.34e-02 | 8.51e-04 | 4.15e-04 | 2.35e-05 | 3.86e-05 | 1.14e-02 |
| SULFUR AMINO ACID METABOLIC PROCESS | 32 | 2.91e-01 | 7.02e-01 | 0.1700 | -5.42e-02 | -2.73e-02 | -7.80e-02 | -7.58e-02 | 1.15e-01 | 5.95e-01 | 7.89e-01 | 4.45e-01 | 4.58e-01 | 2.59e-01 |
| NEGATIVE REGULATION OF PHAGOCYTOSIS | 21 | 4.83e-01 | 8.37e-01 | 0.1700 | 1.25e-01 | 6.88e-02 | -3.80e-02 | 8.42e-02 | -5.14e-05 | 3.23e-01 | 5.85e-01 | 7.63e-01 | 5.04e-01 | 1.00e+00 |
| AMINO SUGAR CATABOLIC PROCESS | 14 | 8.00e-01 | 9.66e-01 | 0.1700 | 4.56e-02 | -2.21e-02 | -7.66e-02 | 5.08e-02 | -1.33e-01 | 7.68e-01 | 8.86e-01 | 6.20e-01 | 7.42e-01 | 3.88e-01 |
| DETECTION OF BIOTIC STIMULUS | 37 | 1.34e-01 | 4.94e-01 | 0.1700 | 9.87e-02 | 7.05e-02 | -8.97e-02 | -2.56e-02 | -7.31e-02 | 2.99e-01 | 4.58e-01 | 3.45e-01 | 7.88e-01 | 4.41e-01 |
| DEVELOPMENTAL MATURATION | 318 | 6.02e-02 | 3.25e-01 | 0.1700 | 5.36e-02 | 8.53e-02 | 8.94e-02 | 6.38e-02 | 8.10e-02 | 1.00e-01 | 8.88e-03 | 6.11e-03 | 5.05e-02 | 1.30e-02 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEOLUS | 6 | 9.06e-01 | 9.84e-01 | 0.1700 | 4.16e-02 | 1.53e-01 | 2.26e-02 | 5.50e-02 | 1.51e-03 | 8.60e-01 | 5.16e-01 | 9.24e-01 | 8.15e-01 | 9.95e-01 |
| CELL PROLIFERATION IN FOREBRAIN | 26 | 8.48e-01 | 9.76e-01 | 0.1700 | 1.97e-02 | 2.62e-02 | 1.08e-01 | 4.94e-02 | 1.16e-01 | 8.62e-01 | 8.17e-01 | 3.40e-01 | 6.63e-01 | 3.04e-01 |
| NEGATIVE REGULATION OF SYNAPTIC TRANSMISSION | 52 | 2.35e-02 | 1.86e-01 | 0.1690 | 2.02e-02 | 1.36e-01 | 3.20e-02 | -3.73e-02 | 8.55e-02 | 8.01e-01 | 8.91e-02 | 6.90e-01 | 6.42e-01 | 2.86e-01 |
| NEGATIVE REGULATION OF PHOSPHATASE ACTIVITY | 24 | 7.97e-01 | 9.66e-01 | 0.1690 | 5.73e-02 | 1.11e-01 | 7.05e-02 | 6.64e-02 | -6.11e-02 | 6.27e-01 | 3.47e-01 | 5.50e-01 | 5.74e-01 | 6.05e-01 |
| REGULATION OF CELLULAR LOCALIZATION | 946 | 2.10e-04 | 4.87e-03 | 0.1690 | 8.63e-02 | 8.19e-02 | 7.21e-02 | 8.41e-02 | 4.75e-02 | 6.74e-06 | 1.98e-05 | 1.70e-04 | 1.16e-05 | 1.33e-02 |
| RNA POLYMERASE I PREINITIATION COMPLEX ASSEMBLY | 9 | 6.95e-01 | 9.31e-01 | 0.1690 | -1.52e-01 | 3.15e-02 | 1.18e-02 | -6.56e-02 | -1.55e-02 | 4.31e-01 | 8.70e-01 | 9.51e-01 | 7.33e-01 | 9.36e-01 |
| POSITIVE REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 41 | 1.78e-01 | 5.63e-01 | 0.1690 | 1.48e-01 | 2.53e-02 | -2.31e-02 | 6.30e-02 | -3.91e-02 | 1.00e-01 | 7.80e-01 | 7.98e-01 | 4.85e-01 | 6.65e-01 |
| CEREBELLAR CORTEX DEVELOPMENT | 49 | 5.06e-01 | 8.51e-01 | 0.1690 | 4.77e-03 | 6.55e-03 | 7.14e-02 | 2.19e-02 | 1.52e-01 | 9.54e-01 | 9.37e-01 | 3.87e-01 | 7.91e-01 | 6.61e-02 |
| POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 107 | 1.20e-01 | 4.73e-01 | 0.1690 | 1.12e-01 | 9.28e-02 | 8.31e-03 | 4.27e-02 | -7.53e-02 | 4.57e-02 | 9.71e-02 | 8.82e-01 | 4.45e-01 | 1.79e-01 |
| CALMODULIN DEPENDENT KINASE SIGNALING PATHWAY | 11 | 9.10e-01 | 9.85e-01 | 0.1690 | -4.99e-02 | -3.91e-02 | -2.93e-02 | -4.37e-02 | 1.48e-01 | 7.74e-01 | 8.23e-01 | 8.66e-01 | 8.02e-01 | 3.96e-01 |
| NEGATIVE REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 14 | 9.63e-01 | 9.94e-01 | 0.1690 | 7.14e-02 | 2.54e-02 | 5.86e-02 | 1.04e-01 | 9.26e-02 | 6.44e-01 | 8.69e-01 | 7.04e-01 | 4.99e-01 | 5.49e-01 |
| NEGATIVE REGULATION OF MORPHOGENESIS OF AN EPITHELIUM | 9 | 7.82e-01 | 9.60e-01 | 0.1690 | -9.94e-02 | 4.49e-02 | 1.12e-01 | -1.90e-02 | 6.25e-02 | 6.06e-01 | 8.16e-01 | 5.62e-01 | 9.21e-01 | 7.46e-01 |
| CELLULAR RESPONSE TO BIOTIC STIMULUS | 255 | 3.09e-03 | 4.27e-02 | 0.1690 | 1.15e-01 | 1.09e-01 | 3.81e-02 | 4.55e-02 | 7.55e-03 | 1.57e-03 | 2.78e-03 | 2.94e-01 | 2.11e-01 | 8.36e-01 |
| DETECTION OF CELL DENSITY | 9 | 8.68e-01 | 9.78e-01 | 0.1690 | 7.26e-02 | 4.66e-02 | -1.09e-01 | -3.08e-02 | -9.19e-02 | 7.06e-01 | 8.09e-01 | 5.73e-01 | 8.73e-01 | 6.33e-01 |
| GLUCOSE METABOLIC PROCESS | 183 | 1.29e-01 | 4.87e-01 | 0.1690 | 4.49e-02 | 7.41e-02 | 7.20e-02 | 6.52e-02 | 1.08e-01 | 2.94e-01 | 8.37e-02 | 9.31e-02 | 1.28e-01 | 1.17e-02 |
| CELL CELL ADHESION VIA PLASMA MEMBRANE ADHESION MOLECULES | 269 | 4.09e-07 | 2.01e-05 | 0.1690 | -1.04e-01 | -1.30e-02 | -2.09e-02 | -1.15e-01 | -6.34e-02 | 3.42e-03 | 7.13e-01 | 5.55e-01 | 1.16e-03 | 7.33e-02 |
| EPITHELIAL STRUCTURE MAINTENANCE | 33 | 3.38e-02 | 2.34e-01 | 0.1690 | 1.39e-02 | 8.35e-02 | -7.80e-02 | -1.19e-01 | 3.39e-02 | 8.90e-01 | 4.07e-01 | 4.38e-01 | 2.36e-01 | 7.36e-01 |
| RECEPTOR MEDIATED ENDOCYTOSIS OF VIRUS BY HOST CELL | 10 | 9.94e-01 | 9.99e-01 | 0.1690 | 4.60e-02 | 6.12e-02 | 7.12e-02 | 6.74e-02 | 1.14e-01 | 8.01e-01 | 7.38e-01 | 6.97e-01 | 7.12e-01 | 5.31e-01 |
| TEMPERATURE HOMEOSTASIS | 181 | 2.01e-01 | 5.92e-01 | 0.1690 | 9.15e-02 | 9.93e-02 | 5.78e-02 | 7.14e-02 | 4.28e-02 | 3.38e-02 | 2.12e-02 | 1.80e-01 | 9.75e-02 | 3.21e-01 |
| STEROL BIOSYNTHETIC PROCESS | 63 | 5.15e-01 | 8.56e-01 | 0.1690 | 1.11e-02 | 6.85e-02 | 7.72e-02 | 5.83e-02 | 1.20e-01 | 8.79e-01 | 3.47e-01 | 2.89e-01 | 4.23e-01 | 1.01e-01 |
| RESPONSE TO CAMP | 82 | 4.95e-01 | 8.44e-01 | 0.1690 | 3.91e-02 | 8.38e-02 | 7.37e-02 | 6.73e-02 | 9.98e-02 | 5.40e-01 | 1.89e-01 | 2.49e-01 | 2.92e-01 | 1.18e-01 |
| POSITIVE REGULATION OF AMINO ACID TRANSPORT | 22 | 7.53e-01 | 9.51e-01 | 0.1690 | -2.24e-02 | 2.34e-02 | 9.34e-02 | 9.84e-02 | 9.47e-02 | 8.56e-01 | 8.49e-01 | 4.48e-01 | 4.24e-01 | 4.42e-01 |
| MORPHOGENESIS OF A POLARIZED EPITHELIUM | 89 | 9.02e-02 | 4.07e-01 | 0.1690 | -7.71e-02 | -4.30e-02 | 2.54e-02 | 1.21e-02 | 1.41e-01 | 2.09e-01 | 4.83e-01 | 6.79e-01 | 8.44e-01 | 2.16e-02 |
| FATTY ACYL COA BIOSYNTHETIC PROCESS | 25 | 5.56e-01 | 8.77e-01 | 0.1690 | 2.02e-02 | -4.53e-02 | 1.18e-02 | 4.49e-02 | 1.54e-01 | 8.62e-01 | 6.95e-01 | 9.19e-01 | 6.98e-01 | 1.82e-01 |
| RESPONSE TO RADIATION | 410 | 3.96e-03 | 5.20e-02 | 0.1690 | 6.06e-02 | 4.76e-02 | 7.01e-02 | 9.27e-02 | 9.46e-02 | 3.54e-02 | 9.81e-02 | 1.48e-02 | 1.27e-03 | 1.01e-03 |
| REGULATION OF PLASMA MEMBRANE ORGANIZATION | 16 | 9.39e-01 | 9.92e-01 | 0.1690 | -3.54e-02 | -7.85e-02 | -6.09e-02 | -8.10e-02 | -1.04e-01 | 8.06e-01 | 5.87e-01 | 6.73e-01 | 5.75e-01 | 4.73e-01 |
| POSITIVE REGULATION OF WOUND HEALING | 61 | 8.59e-01 | 9.78e-01 | 0.1680 | -7.93e-02 | -6.22e-02 | -8.42e-02 | -7.79e-02 | -7.11e-02 | 2.84e-01 | 4.01e-01 | 2.55e-01 | 2.93e-01 | 3.37e-01 |
| PEPTIDYL TYROSINE AUTOPHOSPHORYLATION | 18 | 7.09e-01 | 9.34e-01 | 0.1680 | -2.28e-02 | 4.93e-02 | 1.37e-01 | 2.78e-02 | 7.57e-02 | 8.67e-01 | 7.18e-01 | 3.13e-01 | 8.38e-01 | 5.78e-01 |
| CHONDROCYTE DIFFERENTIATION | 113 | 1.25e-01 | 4.80e-01 | 0.1680 | 1.61e-02 | 7.62e-02 | 8.07e-02 | 8.31e-02 | 9.41e-02 | 7.68e-01 | 1.62e-01 | 1.39e-01 | 1.27e-01 | 8.38e-02 |
| REGULATION OF CELL DEVELOPMENT | 815 | 6.81e-06 | 2.66e-04 | 0.1680 | 4.58e-02 | 6.80e-02 | 7.51e-02 | 7.69e-02 | 1.00e-01 | 2.63e-02 | 9.73e-04 | 2.66e-04 | 1.91e-04 | 1.19e-06 |
| PHOSPHOLIPID METABOLIC PROCESS | 364 | 8.99e-02 | 4.06e-01 | 0.1680 | 6.74e-02 | 7.72e-02 | 8.96e-02 | 7.12e-02 | 6.83e-02 | 2.73e-02 | 1.14e-02 | 3.30e-03 | 1.97e-02 | 2.52e-02 |
| POSITIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 28 | 9.67e-01 | 9.94e-01 | 0.1680 | 9.82e-02 | 7.74e-02 | 5.99e-02 | 8.89e-02 | 3.36e-02 | 3.68e-01 | 4.78e-01 | 5.84e-01 | 4.15e-01 | 7.59e-01 |
| REGULATION OF MICROVILLUS ASSEMBLY | 6 | 9.65e-01 | 9.94e-01 | 0.1680 | 1.15e-02 | -8.24e-02 | -1.06e-01 | -9.42e-02 | -3.58e-02 | 9.61e-01 | 7.27e-01 | 6.54e-01 | 6.90e-01 | 8.79e-01 |
| NEURON PROJECTION REGENERATION | 54 | 3.34e-01 | 7.40e-01 | 0.1680 | -6.30e-02 | -2.67e-02 | -1.07e-01 | -1.10e-01 | -8.20e-03 | 4.24e-01 | 7.34e-01 | 1.74e-01 | 1.63e-01 | 9.17e-01 |
| NEURONAL ACTION POTENTIAL | 32 | 8.22e-01 | 9.71e-01 | 0.1680 | -1.08e-01 | -6.67e-02 | -5.25e-02 | -6.27e-02 | -7.40e-02 | 2.92e-01 | 5.14e-01 | 6.07e-01 | 5.39e-01 | 4.68e-01 |
| PHOSPHATIDYLETHANOLAMINE METABOLIC PROCESS | 28 | 5.40e-01 | 8.67e-01 | 0.1680 | 3.59e-02 | 1.06e-01 | 5.73e-02 | -1.41e-02 | 1.10e-01 | 7.43e-01 | 3.30e-01 | 6.00e-01 | 8.98e-01 | 3.13e-01 |
| NEGATIVE REGULATION OF RECEPTOR SIGNALING PATHWAY VIA STAT | 33 | 5.77e-01 | 8.85e-01 | 0.1680 | -9.76e-02 | -1.18e-01 | -1.06e-04 | -2.27e-02 | 6.46e-02 | 3.32e-01 | 2.39e-01 | 9.99e-01 | 8.22e-01 | 5.21e-01 |
| SYNAPTIC ASSEMBLY AT NEUROMUSCULAR JUNCTION | 10 | 6.98e-01 | 9.31e-01 | 0.1680 | -1.03e-01 | 4.97e-02 | -5.94e-02 | -1.04e-01 | 2.56e-02 | 5.71e-01 | 7.86e-01 | 7.45e-01 | 5.68e-01 | 8.89e-01 |
| PHOSPHATE ION TRANSMEMBRANE TRANSPORT | 17 | 8.80e-01 | 9.79e-01 | 0.1680 | -3.37e-03 | 2.70e-02 | 1.24e-01 | 5.31e-02 | 9.57e-02 | 9.81e-01 | 8.47e-01 | 3.76e-01 | 7.05e-01 | 4.94e-01 |
| REGULATION OF T CELL MIGRATION | 47 | 5.11e-01 | 8.54e-01 | 0.1680 | -4.27e-03 | -1.08e-02 | -4.60e-02 | -2.14e-02 | -1.59e-01 | 9.60e-01 | 8.98e-01 | 5.86e-01 | 7.99e-01 | 5.87e-02 |
| POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 26 | 6.75e-01 | 9.28e-01 | 0.1680 | 5.01e-02 | 1.31e-01 | 7.00e-02 | 5.27e-03 | 5.90e-02 | 6.58e-01 | 2.47e-01 | 5.37e-01 | 9.63e-01 | 6.02e-01 |
| TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 183 | 3.39e-02 | 2.34e-01 | 0.1680 | 1.12e-01 | 9.75e-02 | 2.30e-02 | 5.62e-02 | -4.85e-02 | 9.03e-03 | 2.29e-02 | 5.92e-01 | 1.90e-01 | 2.58e-01 |
| REGULATION OF LEUKOCYTE DIFFERENTIATION | 315 | 4.20e-02 | 2.66e-01 | 0.1670 | 6.86e-02 | 8.94e-02 | 7.04e-02 | 8.90e-02 | 4.97e-02 | 3.62e-02 | 6.36e-03 | 3.17e-02 | 6.58e-03 | 1.30e-01 |
| MITOCHONDRION DISTRIBUTION | 16 | 9.43e-01 | 9.93e-01 | 0.1670 | 1.12e-02 | 1.79e-02 | 7.55e-02 | 9.69e-02 | 1.12e-01 | 9.38e-01 | 9.01e-01 | 6.01e-01 | 5.02e-01 | 4.39e-01 |
| REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 89 | 6.69e-01 | 9.25e-01 | 0.1670 | 5.22e-02 | 7.41e-02 | 7.64e-02 | 8.23e-02 | 8.48e-02 | 3.94e-01 | 2.27e-01 | 2.13e-01 | 1.79e-01 | 1.67e-01 |
| ACTIN MYOSIN FILAMENT SLIDING | 16 | 6.45e-01 | 9.16e-01 | 0.1670 | -1.20e-01 | -3.76e-02 | 3.99e-02 | -1.00e-01 | 2.07e-02 | 4.04e-01 | 7.94e-01 | 7.82e-01 | 4.87e-01 | 8.86e-01 |
| INSULIN SECRETION | 193 | 6.55e-02 | 3.41e-01 | 0.1670 | 5.13e-02 | 1.11e-01 | 8.62e-02 | 5.15e-02 | 5.53e-02 | 2.19e-01 | 8.11e-03 | 3.90e-02 | 2.18e-01 | 1.85e-01 |
| NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 147 | 1.20e-01 | 4.73e-01 | 0.1670 | 3.25e-02 | 4.25e-02 | 6.45e-02 | 4.88e-02 | 1.36e-01 | 4.97e-01 | 3.74e-01 | 1.77e-01 | 3.07e-01 | 4.37e-03 |
| NEGATIVE REGULATION OF CYTOSOLIC CALCIUM ION CONCENTRATION | 13 | 5.74e-01 | 8.84e-01 | 0.1670 | -9.32e-02 | 7.07e-02 | 1.51e-02 | -1.14e-01 | 3.13e-02 | 5.61e-01 | 6.59e-01 | 9.25e-01 | 4.76e-01 | 8.45e-01 |
| REGULATION OF PROTEIN GLYCOSYLATION | 12 | 7.91e-01 | 9.63e-01 | 0.1670 | -7.35e-02 | 2.02e-02 | -3.59e-02 | -1.05e-01 | 9.91e-02 | 6.59e-01 | 9.03e-01 | 8.30e-01 | 5.29e-01 | 5.52e-01 |
| POSITIVE REGULATION OF DENDRITIC CELL CHEMOTAXIS | 9 | 9.44e-01 | 9.93e-01 | 0.1670 | -8.04e-02 | -6.54e-02 | 5.36e-02 | 3.69e-02 | 1.14e-01 | 6.76e-01 | 7.34e-01 | 7.81e-01 | 8.48e-01 | 5.55e-01 |
| POSITIVE REGULATION OF LIPID CATABOLIC PROCESS | 26 | 1.98e-01 | 5.87e-01 | 0.1670 | 8.69e-03 | 1.40e-01 | -7.88e-04 | -1.18e-02 | -9.04e-02 | 9.39e-01 | 2.18e-01 | 9.94e-01 | 9.17e-01 | 4.25e-01 |
| AMYLOID FIBRIL FORMATION | 38 | 5.07e-01 | 8.52e-01 | 0.1670 | 1.13e-01 | 1.11e-01 | -3.61e-03 | 3.55e-02 | -3.98e-02 | 2.28e-01 | 2.38e-01 | 9.69e-01 | 7.05e-01 | 6.71e-01 |
| ALCOHOL BIOSYNTHETIC PROCESS | 139 | 8.73e-02 | 4.00e-01 | 0.1670 | 1.40e-02 | 2.99e-02 | 5.80e-02 | 6.19e-02 | 1.40e-01 | 7.76e-01 | 5.43e-01 | 2.37e-01 | 2.08e-01 | 4.44e-03 |
| LAMELLIPODIUM MORPHOGENESIS | 18 | 9.31e-01 | 9.90e-01 | 0.1670 | 8.82e-02 | 1.05e-01 | 3.66e-02 | 8.69e-02 | -7.63e-03 | 5.17e-01 | 4.40e-01 | 7.88e-01 | 5.23e-01 | 9.55e-01 |
| FOLIC ACID TRANSPORT | 10 | 9.22e-01 | 9.87e-01 | 0.1670 | 3.38e-02 | 1.80e-02 | -1.12e-01 | -6.41e-02 | -9.80e-02 | 8.53e-01 | 9.22e-01 | 5.39e-01 | 7.26e-01 | 5.91e-01 |
| LONG TERM MEMORY | 36 | 6.07e-01 | 9.02e-01 | 0.1670 | 3.08e-02 | 1.08e-01 | 6.26e-02 | 5.22e-02 | 9.19e-02 | 7.49e-01 | 2.61e-01 | 5.16e-01 | 5.88e-01 | 3.40e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR TRANSPORT | 58 | 4.97e-01 | 8.45e-01 | 0.1670 | 8.84e-02 | 4.10e-02 | 8.32e-02 | 1.06e-01 | -1.36e-02 | 2.44e-01 | 5.89e-01 | 2.73e-01 | 1.65e-01 | 8.58e-01 |
| ENERGY HOMEOSTASIS | 76 | 5.30e-01 | 8.63e-01 | 0.1660 | 4.13e-02 | 9.80e-02 | 7.83e-02 | 6.34e-02 | 7.89e-02 | 5.34e-01 | 1.40e-01 | 2.38e-01 | 3.39e-01 | 2.35e-01 |
| CELLULAR HYPOTONIC RESPONSE | 11 | 5.82e-01 | 8.88e-01 | 0.1660 | 3.18e-02 | -1.08e-02 | -1.13e-01 | -8.11e-02 | 8.51e-02 | 8.55e-01 | 9.51e-01 | 5.17e-01 | 6.41e-01 | 6.25e-01 |
| NUCLEOBASE CONTAINING SMALL MOLECULE CATABOLIC PROCESS | 30 | 8.81e-01 | 9.79e-01 | 0.1660 | -1.36e-02 | -4.46e-02 | -9.77e-02 | -4.16e-02 | -1.19e-01 | 8.98e-01 | 6.72e-01 | 3.54e-01 | 6.93e-01 | 2.58e-01 |
| INTESTINAL EPITHELIAL CELL DEVELOPMENT | 17 | 6.42e-01 | 9.14e-01 | 0.1660 | -4.94e-02 | 2.31e-02 | 2.05e-02 | 5.15e-02 | 1.47e-01 | 7.24e-01 | 8.69e-01 | 8.84e-01 | 7.13e-01 | 2.94e-01 |
| POSITIVE REGULATION OF OXIDATIVE STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 7 | 8.37e-01 | 9.73e-01 | 0.1660 | -6.46e-03 | -9.79e-02 | 1.21e-02 | 6.81e-02 | -1.15e-01 | 9.76e-01 | 6.54e-01 | 9.56e-01 | 7.55e-01 | 5.99e-01 |
| RECOGNITION OF APOPTOTIC CELL | 7 | 6.78e-01 | 9.28e-01 | 0.1660 | 6.37e-02 | 6.40e-02 | 1.04e-01 | -5.73e-02 | -7.28e-02 | 7.70e-01 | 7.69e-01 | 6.33e-01 | 7.93e-01 | 7.39e-01 |
| NEGATIVE REGULATION OF KERATINOCYTE PROLIFERATION | 23 | 5.42e-01 | 8.69e-01 | 0.1660 | -5.36e-02 | 8.00e-02 | 8.47e-02 | -1.04e-02 | 1.05e-01 | 6.56e-01 | 5.06e-01 | 4.82e-01 | 9.31e-01 | 3.83e-01 |
| PROTEIN LOCALIZATION TO PRESYNAPSE | 11 | 9.49e-01 | 9.94e-01 | 0.1660 | -1.03e-01 | -5.59e-02 | 2.67e-02 | -5.26e-02 | 1.02e-01 | 5.56e-01 | 7.48e-01 | 8.78e-01 | 7.62e-01 | 5.57e-01 |
| CLATHRIN DEPENDENT ENDOCYTOSIS | 47 | 4.22e-01 | 8.02e-01 | 0.1660 | 4.24e-02 | 1.17e-03 | -9.88e-02 | -4.82e-02 | -1.17e-01 | 6.15e-01 | 9.89e-01 | 2.41e-01 | 5.68e-01 | 1.65e-01 |
| AMINOGLYCAN BIOSYNTHETIC PROCESS | 73 | 1.59e-01 | 5.34e-01 | 0.1660 | 9.84e-02 | 1.07e-01 | -8.14e-03 | 2.24e-02 | -7.72e-02 | 1.46e-01 | 1.15e-01 | 9.04e-01 | 7.40e-01 | 2.54e-01 |
| POSITIVE REGULATION OF TOLL LIKE RECEPTOR 3 SIGNALING PATHWAY | 8 | 6.29e-01 | 9.10e-01 | 0.1660 | 1.16e-01 | -2.06e-02 | -6.86e-02 | -2.33e-02 | 9.22e-02 | 5.71e-01 | 9.20e-01 | 7.37e-01 | 9.09e-01 | 6.51e-01 |
| LEARNING | 145 | 1.02e-01 | 4.35e-01 | 0.1660 | 2.50e-02 | 7.09e-02 | 6.88e-02 | 4.25e-02 | 1.24e-01 | 6.04e-01 | 1.40e-01 | 1.53e-01 | 3.77e-01 | 9.94e-03 |
| SPHINGOSINE BIOSYNTHETIC PROCESS | 14 | 8.94e-01 | 9.82e-01 | 0.1660 | -1.03e-01 | -9.00e-02 | -6.92e-02 | -2.08e-02 | 6.05e-02 | 5.06e-01 | 5.60e-01 | 6.54e-01 | 8.93e-01 | 6.95e-01 |
| HOMOLOGOUS RECOMBINATION | 65 | 3.35e-01 | 7.40e-01 | 0.1660 | 7.11e-02 | 1.31e-02 | 7.34e-02 | 1.23e-01 | 4.34e-02 | 3.21e-01 | 8.55e-01 | 3.06e-01 | 8.74e-02 | 5.45e-01 |
| LENS MORPHOGENESIS IN CAMERA TYPE EYE | 21 | 6.92e-01 | 9.31e-01 | 0.1660 | 8.19e-02 | 4.04e-02 | 1.27e-02 | 1.10e-01 | 8.38e-02 | 5.16e-01 | 7.49e-01 | 9.20e-01 | 3.85e-01 | 5.06e-01 |
| DETECTION OF EXTERNAL BIOTIC STIMULUS | 26 | 4.39e-01 | 8.11e-01 | 0.1660 | 1.11e-01 | 9.07e-02 | -5.30e-02 | -1.35e-02 | -6.34e-02 | 3.28e-01 | 4.23e-01 | 6.40e-01 | 9.05e-01 | 5.76e-01 |
| MUSCLE TISSUE DEVELOPMENT | 422 | 8.50e-03 | 9.10e-02 | 0.1660 | 4.27e-02 | 6.91e-02 | 9.20e-02 | 5.55e-02 | 9.67e-02 | 1.33e-01 | 1.49e-02 | 1.18e-03 | 5.03e-02 | 6.56e-04 |
| NEGATIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 28 | 7.13e-01 | 9.36e-01 | 0.1660 | 8.42e-02 | 4.43e-02 | 3.83e-02 | 4.83e-02 | 1.21e-01 | 4.40e-01 | 6.85e-01 | 7.26e-01 | 6.58e-01 | 2.68e-01 |
| NEGATIVE REGULATION OF TRANSPORTER ACTIVITY | 93 | 6.23e-01 | 9.08e-01 | 0.1660 | -7.67e-02 | -1.05e-01 | -8.29e-02 | -5.68e-02 | -2.28e-02 | 2.01e-01 | 8.14e-02 | 1.67e-01 | 3.44e-01 | 7.03e-01 |
| DENSE CORE GRANULE LOCALIZATION | 10 | 8.32e-01 | 9.73e-01 | 0.1660 | 4.42e-02 | -5.09e-02 | -3.98e-03 | 1.11e-02 | -1.51e-01 | 8.09e-01 | 7.80e-01 | 9.83e-01 | 9.52e-01 | 4.09e-01 |
| RETINA MORPHOGENESIS IN CAMERA TYPE EYE | 63 | 3.55e-01 | 7.55e-01 | 0.1660 | -7.16e-02 | -7.16e-02 | -5.04e-02 | -8.83e-02 | 8.26e-02 | 3.26e-01 | 3.26e-01 | 4.89e-01 | 2.26e-01 | 2.57e-01 |
| PERICARDIUM MORPHOGENESIS | 8 | 9.37e-01 | 9.92e-01 | 0.1660 | -1.40e-01 | -7.38e-02 | 6.26e-03 | -4.21e-02 | -2.60e-02 | 4.94e-01 | 7.18e-01 | 9.76e-01 | 8.37e-01 | 8.99e-01 |
| REGULATION OF GROWTH | 589 | 3.76e-03 | 4.99e-02 | 0.1660 | 5.80e-02 | 8.42e-02 | 8.57e-02 | 6.27e-02 | 7.54e-02 | 1.62e-02 | 4.79e-04 | 3.80e-04 | 9.33e-03 | 1.77e-03 |
| POSITIVE CHEMOTAXIS | 63 | 1.12e-01 | 4.56e-01 | 0.1660 | 1.10e-01 | 7.17e-02 | -5.00e-02 | 2.29e-02 | -8.41e-02 | 1.30e-01 | 3.25e-01 | 4.92e-01 | 7.53e-01 | 2.48e-01 |
| CONNECTIVE TISSUE DEVELOPMENT | 278 | 4.73e-03 | 5.88e-02 | 0.1650 | 4.19e-02 | 8.99e-02 | 7.14e-02 | 8.41e-02 | 7.33e-02 | 2.29e-01 | 9.89e-03 | 4.05e-02 | 1.57e-02 | 3.54e-02 |
| CHORIONIC TROPHOBLAST CELL DIFFERENTIATION | 7 | 9.09e-01 | 9.85e-01 | 0.1650 | -7.81e-02 | -4.83e-02 | 1.04e-01 | 5.19e-02 | 7.31e-02 | 7.20e-01 | 8.25e-01 | 6.33e-01 | 8.12e-01 | 7.38e-01 |
| REGULATION OF LIPASE ACTIVITY | 77 | 7.55e-01 | 9.51e-01 | 0.1650 | -4.24e-02 | -5.32e-02 | -9.19e-02 | -6.98e-02 | -9.70e-02 | 5.20e-01 | 4.20e-01 | 1.63e-01 | 2.89e-01 | 1.41e-01 |
| REGULATION OF B CELL MEDIATED IMMUNITY | 61 | 3.76e-01 | 7.75e-01 | 0.1650 | 3.72e-02 | 9.10e-02 | 6.21e-02 | 8.78e-02 | 7.82e-02 | 6.15e-01 | 2.19e-01 | 4.02e-01 | 2.36e-01 | 2.91e-01 |
| RIGHTING REFLEX | 8 | 8.75e-01 | 9.78e-01 | 0.1650 | -1.74e-02 | 9.00e-02 | 6.92e-02 | 9.95e-02 | 6.51e-02 | 9.32e-01 | 6.60e-01 | 7.35e-01 | 6.26e-01 | 7.50e-01 |
| EPITHELIAL CELL CELL ADHESION | 15 | 9.03e-01 | 9.84e-01 | 0.1650 | -6.79e-02 | -1.57e-02 | 1.83e-02 | -3.84e-02 | 1.43e-01 | 6.49e-01 | 9.16e-01 | 9.03e-01 | 7.97e-01 | 3.36e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CENTROSOME | 7 | 8.24e-01 | 9.71e-01 | 0.1650 | -5.09e-03 | -5.78e-05 | 2.11e-02 | 1.24e-01 | -1.07e-01 | 9.81e-01 | 1.00e+00 | 9.23e-01 | 5.70e-01 | 6.25e-01 |
| PROTEIN HOMOOLIGOMERIZATION | 188 | 9.62e-02 | 4.22e-01 | 0.1650 | 8.62e-02 | 8.11e-02 | 7.33e-02 | 4.64e-02 | 7.55e-02 | 4.15e-02 | 5.53e-02 | 8.32e-02 | 2.72e-01 | 7.44e-02 |
| CELLULAR RESPONSE TO NUTRIENT | 45 | 2.61e-01 | 6.67e-01 | 0.1650 | 7.51e-02 | 1.33e-01 | 3.62e-02 | 1.31e-03 | 4.96e-02 | 3.84e-01 | 1.21e-01 | 6.74e-01 | 9.88e-01 | 5.65e-01 |
| FATTY ACID TRANSPORT | 115 | 1.56e-01 | 5.26e-01 | 0.1650 | -8.66e-02 | -4.63e-02 | -5.74e-02 | -1.19e-01 | 1.06e-02 | 1.09e-01 | 3.91e-01 | 2.87e-01 | 2.75e-02 | 8.45e-01 |
| POSITIVE REGULATION OF MRNA METABOLIC PROCESS | 190 | 5.19e-04 | 1.04e-02 | 0.1650 | 1.49e-02 | -2.01e-02 | 6.50e-02 | 1.11e-01 | 1.01e-01 | 7.23e-01 | 6.34e-01 | 1.22e-01 | 8.61e-03 | 1.67e-02 |
| POSITIVE REGULATION OF NATURAL KILLER CELL ACTIVATION | 25 | 6.63e-01 | 9.22e-01 | 0.1650 | -6.98e-03 | -4.11e-02 | 8.27e-02 | 8.40e-02 | 1.07e-01 | 9.52e-01 | 7.22e-01 | 4.74e-01 | 4.67e-01 | 3.52e-01 |
| LEUKOCYTE MEDIATED IMMUNITY | 380 | 2.04e-02 | 1.69e-01 | 0.1650 | 7.04e-02 | 7.84e-02 | 7.95e-02 | 9.77e-02 | 1.52e-02 | 1.85e-02 | 8.72e-03 | 7.78e-03 | 1.08e-03 | 6.10e-01 |
| ENDODERM DEVELOPMENT | 81 | 3.98e-01 | 7.86e-01 | 0.1650 | 2.20e-02 | 5.91e-02 | 7.24e-02 | 8.58e-02 | 1.03e-01 | 7.32e-01 | 3.58e-01 | 2.60e-01 | 1.82e-01 | 1.10e-01 |
| NEGATIVE REGULATION OF CELL DEVELOPMENT | 275 | 5.00e-02 | 2.92e-01 | 0.1650 | 5.01e-02 | 5.98e-02 | 7.20e-02 | 6.02e-02 | 1.11e-01 | 1.53e-01 | 8.78e-02 | 3.99e-02 | 8.56e-02 | 1.59e-03 |
| ALCOHOL CATABOLIC PROCESS | 33 | 7.03e-01 | 9.32e-01 | 0.1640 | 7.55e-03 | 1.22e-02 | -9.17e-02 | -7.06e-02 | -1.16e-01 | 9.40e-01 | 9.03e-01 | 3.62e-01 | 4.82e-01 | 2.49e-01 |
| CILIUM OR FLAGELLUM DEPENDENT CELL MOTILITY | 155 | 2.72e-01 | 6.80e-01 | 0.1640 | -6.78e-02 | -6.57e-02 | -7.86e-02 | -1.07e-01 | -2.27e-02 | 1.45e-01 | 1.58e-01 | 9.11e-02 | 2.15e-02 | 6.26e-01 |
| PROTEIN METHYLATION | 75 | 3.32e-01 | 7.39e-01 | 0.1640 | 9.50e-02 | 2.92e-02 | 4.90e-02 | 9.61e-02 | 7.44e-02 | 1.55e-01 | 6.62e-01 | 4.63e-01 | 1.50e-01 | 2.65e-01 |
| ACTIVATED T CELL PROLIFERATION | 47 | 5.40e-01 | 8.67e-01 | 0.1640 | -3.85e-02 | -1.06e-01 | -1.01e-01 | -6.50e-02 | 6.41e-03 | 6.48e-01 | 2.11e-01 | 2.32e-01 | 4.41e-01 | 9.39e-01 |
| MYOBLAST PROLIFERATION | 34 | 3.20e-01 | 7.31e-01 | 0.1640 | 2.59e-02 | 8.32e-02 | 1.26e-02 | -5.22e-02 | -1.29e-01 | 7.94e-01 | 4.01e-01 | 8.99e-01 | 5.99e-01 | 1.94e-01 |
| REGULATION OF HIPPO SIGNALING | 25 | 5.63e-01 | 8.79e-01 | 0.1640 | -8.48e-02 | 1.02e-02 | -8.97e-02 | -9.58e-02 | -5.00e-02 | 4.63e-01 | 9.29e-01 | 4.38e-01 | 4.07e-01 | 6.65e-01 |
| REGULATION OF PHAGOCYTOSIS | 96 | 1.37e-02 | 1.27e-01 | 0.1640 | 7.74e-02 | 6.69e-02 | -5.73e-02 | -5.03e-02 | -1.03e-01 | 1.90e-01 | 2.57e-01 | 3.32e-01 | 3.94e-01 | 7.98e-02 |
| RESPONSE TO ISOQUINOLINE ALKALOID | 11 | 8.93e-01 | 9.81e-01 | 0.1640 | -3.68e-02 | -1.12e-01 | -9.92e-02 | -2.35e-02 | 5.28e-02 | 8.33e-01 | 5.22e-01 | 5.69e-01 | 8.92e-01 | 7.62e-01 |
| NEGATIVE REGULATION OF SIGNALING | 1399 | 1.34e-07 | 7.27e-06 | 0.1640 | 5.27e-02 | 6.36e-02 | 7.78e-02 | 7.90e-02 | 8.86e-02 | 9.41e-04 | 6.66e-05 | 1.07e-06 | 7.13e-07 | 2.75e-08 |
| AMYLOID PRECURSOR PROTEIN BIOSYNTHETIC PROCESS | 25 | 3.30e-01 | 7.38e-01 | 0.1640 | -1.26e-01 | -5.94e-02 | -2.45e-04 | -6.91e-03 | -8.70e-02 | 2.77e-01 | 6.07e-01 | 9.98e-01 | 9.52e-01 | 4.52e-01 |
| REGULATION OF MAST CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 28 | 6.69e-01 | 9.25e-01 | 0.1640 | 8.39e-02 | 1.21e-01 | 3.36e-02 | -8.96e-04 | -6.39e-02 | 4.42e-01 | 2.67e-01 | 7.58e-01 | 9.93e-01 | 5.59e-01 |
| REGULATION OF NEUROINFLAMMATORY RESPONSE | 41 | 5.05e-01 | 8.50e-01 | 0.1640 | 6.59e-02 | 4.57e-02 | 1.07e-02 | 2.00e-02 | -1.41e-01 | 4.65e-01 | 6.13e-01 | 9.06e-01 | 8.25e-01 | 1.18e-01 |
| REGULATION OF LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL | 38 | 8.93e-01 | 9.81e-01 | 0.1640 | -4.54e-02 | -4.29e-02 | -6.86e-02 | -7.90e-02 | -1.10e-01 | 6.28e-01 | 6.47e-01 | 4.64e-01 | 3.99e-01 | 2.42e-01 |
| NEGATIVE REGULATION OF CHONDROCYTE DIFFERENTIATION | 24 | 6.19e-01 | 9.07e-01 | 0.1640 | -2.07e-02 | 8.39e-02 | 1.13e-01 | 6.61e-02 | 4.83e-02 | 8.60e-01 | 4.77e-01 | 3.39e-01 | 5.75e-01 | 6.82e-01 |
| MATING BEHAVIOR | 36 | 2.48e-01 | 6.54e-01 | 0.1640 | 1.18e-01 | 6.75e-02 | -1.20e-02 | 5.02e-02 | 7.64e-02 | 2.22e-01 | 4.83e-01 | 9.01e-01 | 6.02e-01 | 4.28e-01 |
| B CELL MEDIATED IMMUNITY | 130 | 1.84e-01 | 5.71e-01 | 0.1640 | 2.97e-02 | 9.33e-02 | 9.69e-02 | 7.07e-02 | 5.37e-02 | 5.59e-01 | 6.63e-02 | 5.64e-02 | 1.64e-01 | 2.90e-01 |
| POSITIVE REGULATION OF DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 231 | 1.19e-01 | 4.69e-01 | 0.1640 | 1.02e-01 | 8.32e-02 | 5.20e-02 | 7.43e-02 | 3.46e-02 | 7.37e-03 | 2.93e-02 | 1.73e-01 | 5.15e-02 | 3.65e-01 |
| CILIUM MOVEMENT | 194 | 8.07e-02 | 3.84e-01 | 0.1640 | -6.55e-02 | -5.96e-02 | -8.10e-02 | -1.11e-01 | -1.14e-02 | 1.15e-01 | 1.52e-01 | 5.18e-02 | 7.81e-03 | 7.84e-01 |
| REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 45 | 4.95e-01 | 8.44e-01 | 0.1640 | 3.13e-02 | 4.40e-02 | 4.72e-02 | 1.24e-02 | 1.47e-01 | 7.16e-01 | 6.09e-01 | 5.84e-01 | 8.86e-01 | 8.88e-02 |
| NEGATIVE REGULATION OF EPITHELIAL CELL MIGRATION | 108 | 7.40e-01 | 9.49e-01 | 0.1640 | -8.11e-02 | -8.03e-02 | -6.96e-02 | -8.62e-02 | -3.82e-02 | 1.45e-01 | 1.49e-01 | 2.11e-01 | 1.22e-01 | 4.93e-01 |
| CARTILAGE DEVELOPMENT | 199 | 1.39e-02 | 1.28e-01 | 0.1640 | 2.12e-02 | 8.04e-02 | 7.47e-02 | 7.84e-02 | 9.01e-02 | 6.06e-01 | 5.04e-02 | 6.91e-02 | 5.66e-02 | 2.85e-02 |
| DEFENSE RESPONSE TO GRAM NEGATIVE BACTERIUM | 85 | 5.21e-03 | 6.32e-02 | 0.1640 | 9.51e-02 | 1.22e-01 | -3.25e-02 | -1.13e-02 | -3.97e-02 | 1.30e-01 | 5.14e-02 | 6.05e-01 | 8.57e-01 | 5.27e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION OF NOTCH RECEPTOR TARGET | 7 | 9.50e-01 | 9.94e-01 | 0.1630 | 3.30e-02 | 5.98e-02 | 5.52e-02 | 9.56e-02 | -9.94e-02 | 8.80e-01 | 7.84e-01 | 8.00e-01 | 6.61e-01 | 6.49e-01 |
| ALANINE TRANSPORT | 16 | 9.36e-01 | 9.92e-01 | 0.1630 | 5.25e-02 | 1.24e-01 | 7.64e-02 | 2.96e-02 | 4.35e-02 | 7.16e-01 | 3.91e-01 | 5.97e-01 | 8.38e-01 | 7.63e-01 |
| LONG CHAIN FATTY ACID BIOSYNTHETIC PROCESS | 26 | 7.19e-01 | 9.38e-01 | 0.1630 | 3.32e-02 | 9.98e-02 | 5.59e-02 | 8.11e-02 | 7.71e-02 | 7.70e-01 | 3.79e-01 | 6.22e-01 | 4.74e-01 | 4.96e-01 |
| PEPTIDYL LYSINE DEACETYLATION | 6 | 9.95e-01 | 9.99e-01 | 0.1630 | -6.89e-03 | 3.68e-02 | 1.00e-01 | 3.66e-02 | 1.18e-01 | 9.77e-01 | 8.76e-01 | 6.70e-01 | 8.77e-01 | 6.17e-01 |
| CELLULAR RESPONSE TO CAMP | 49 | 2.03e-01 | 5.96e-01 | 0.1630 | -3.72e-02 | -3.44e-03 | -8.37e-03 | -4.63e-03 | 1.59e-01 | 6.53e-01 | 9.67e-01 | 9.19e-01 | 9.55e-01 | 5.45e-02 |
| ESTABLISHMENT OR MAINTENANCE OF BIPOLAR CELL POLARITY | 55 | 2.69e-01 | 6.78e-01 | 0.1630 | -9.04e-02 | -4.82e-02 | 5.38e-02 | 1.25e-02 | 1.15e-01 | 2.46e-01 | 5.37e-01 | 4.90e-01 | 8.73e-01 | 1.42e-01 |
| PEPTIDYL METHIONINE MODIFICATION | 12 | 6.06e-01 | 9.01e-01 | 0.1630 | -2.43e-03 | 1.14e-01 | -1.50e-03 | -6.87e-02 | 9.40e-02 | 9.88e-01 | 4.92e-01 | 9.93e-01 | 6.80e-01 | 5.73e-01 |
| POSITIVE REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 52 | 4.64e-01 | 8.25e-01 | 0.1630 | -5.24e-02 | -1.94e-02 | -1.06e-01 | -1.03e-01 | -4.16e-02 | 5.13e-01 | 8.09e-01 | 1.87e-01 | 1.99e-01 | 6.03e-01 |
| NEGATIVE REGULATION OF MICROTUBULE POLYMERIZATION | 13 | 9.57e-01 | 9.94e-01 | 0.1630 | -9.40e-02 | -1.08e-01 | -5.19e-02 | -2.29e-02 | 5.47e-02 | 5.57e-01 | 5.01e-01 | 7.46e-01 | 8.86e-01 | 7.33e-01 |
| NEGATIVE REGULATION OF INNATE IMMUNE RESPONSE | 89 | 3.72e-01 | 7.71e-01 | 0.1630 | 3.58e-02 | 1.35e-02 | 8.19e-02 | 9.42e-02 | 9.80e-02 | 5.59e-01 | 8.26e-01 | 1.82e-01 | 1.25e-01 | 1.10e-01 |
| MYELOID LEUKOCYTE MIGRATION | 233 | 4.77e-06 | 1.93e-04 | 0.1630 | 7.69e-02 | 7.72e-02 | -4.82e-02 | -4.03e-02 | -1.04e-01 | 4.32e-02 | 4.23e-02 | 2.05e-01 | 2.90e-01 | 6.29e-03 |
| REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 198 | 3.00e-02 | 2.17e-01 | 0.1630 | 4.62e-02 | 2.93e-02 | 6.91e-02 | 1.10e-01 | 8.14e-02 | 2.62e-01 | 4.78e-01 | 9.35e-02 | 7.37e-03 | 4.82e-02 |
| POSITIVE REGULATION OF LAMELLIPODIUM MORPHOGENESIS | 7 | 9.68e-01 | 9.94e-01 | 0.1630 | -3.91e-02 | 3.18e-02 | -3.68e-02 | -5.65e-02 | -1.40e-01 | 8.58e-01 | 8.84e-01 | 8.66e-01 | 7.96e-01 | 5.22e-01 |
| REGULATION OF MODIFICATION OF SYNAPTIC STRUCTURE | 12 | 7.34e-01 | 9.46e-01 | 0.1630 | 3.89e-02 | 7.36e-02 | 2.39e-02 | 1.32e-01 | 4.18e-02 | 8.16e-01 | 6.59e-01 | 8.86e-01 | 4.30e-01 | 8.02e-01 |
| PURINE CONTAINING COMPOUND TRANSMEMBRANE TRANSPORT | 35 | 6.25e-01 | 9.09e-01 | 0.1630 | 4.06e-02 | -1.36e-02 | -9.64e-02 | -5.56e-02 | -1.11e-01 | 6.78e-01 | 8.89e-01 | 3.23e-01 | 5.69e-01 | 2.57e-01 |
| NEGATIVE REGULATION OF NERVOUS SYSTEM PROCESS | 15 | 9.13e-01 | 9.85e-01 | 0.1630 | 1.15e-01 | 9.70e-02 | 5.02e-02 | 2.03e-02 | 2.85e-02 | 4.40e-01 | 5.15e-01 | 7.37e-01 | 8.92e-01 | 8.49e-01 |
| POSITIVE REGULATION OF CYCLASE ACTIVITY | 38 | 7.57e-01 | 9.51e-01 | 0.1620 | -1.09e-01 | -4.32e-02 | -4.97e-02 | -8.45e-02 | -5.46e-02 | 2.44e-01 | 6.45e-01 | 5.96e-01 | 3.68e-01 | 5.60e-01 |
| REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL | 80 | 5.31e-01 | 8.63e-01 | 0.1620 | -9.95e-02 | -7.97e-02 | -8.08e-02 | -5.30e-02 | -2.78e-02 | 1.24e-01 | 2.18e-01 | 2.11e-01 | 4.13e-01 | 6.67e-01 |
| KETONE BIOSYNTHETIC PROCESS | 48 | 8.93e-01 | 9.81e-01 | 0.1620 | 5.59e-02 | 6.24e-02 | 9.32e-02 | 9.43e-02 | 4.22e-02 | 5.03e-01 | 4.54e-01 | 2.64e-01 | 2.58e-01 | 6.13e-01 |
| B CELL RECEPTOR SIGNALING PATHWAY | 61 | 2.86e-01 | 6.94e-01 | 0.1620 | 6.47e-02 | 3.30e-02 | 5.89e-02 | 1.33e-01 | -7.29e-04 | 3.82e-01 | 6.56e-01 | 4.26e-01 | 7.30e-02 | 9.92e-01 |
| REGULATION OF FATTY ACID OXIDATION | 33 | 4.69e-01 | 8.29e-01 | 0.1620 | 8.10e-02 | 1.03e-01 | 1.37e-02 | 5.52e-02 | 7.78e-02 | 4.21e-01 | 3.08e-01 | 8.91e-01 | 5.83e-01 | 4.39e-01 |
| FRUCTOSE 6 PHOSPHATE METABOLIC PROCESS | 11 | 7.39e-01 | 9.49e-01 | 0.1620 | -1.00e-01 | 2.39e-02 | -4.67e-02 | -7.01e-02 | 9.31e-02 | 5.66e-01 | 8.91e-01 | 7.88e-01 | 6.87e-01 | 5.93e-01 |
| P38MAPK CASCADE | 58 | 5.26e-01 | 8.60e-01 | 0.1620 | 8.19e-02 | 8.20e-02 | 6.25e-02 | 3.01e-02 | 8.99e-02 | 2.81e-01 | 2.80e-01 | 4.10e-01 | 6.91e-01 | 2.36e-01 |
| POSITIVE REGULATION OF GLOMERULAR MESANGIAL CELL PROLIFERATION | 7 | 9.78e-01 | 9.96e-01 | 0.1620 | 1.75e-02 | -1.88e-02 | -6.10e-02 | 2.33e-02 | -1.46e-01 | 9.36e-01 | 9.31e-01 | 7.80e-01 | 9.15e-01 | 5.03e-01 |
| RESPONSE TO VITAMIN D | 36 | 8.04e-01 | 9.67e-01 | 0.1620 | 4.55e-02 | 9.17e-02 | 6.48e-02 | 3.71e-02 | 1.01e-01 | 6.36e-01 | 3.41e-01 | 5.01e-01 | 7.00e-01 | 2.94e-01 |
| HETEROCHROMATIN ORGANIZATION | 89 | 3.38e-02 | 2.34e-01 | 0.1620 | 1.03e-01 | 3.25e-02 | 7.89e-03 | 1.02e-01 | 6.44e-02 | 9.20e-02 | 5.96e-01 | 8.98e-01 | 9.72e-02 | 2.94e-01 |
| GRANULOCYTE MIGRATION | 148 | 4.12e-04 | 8.67e-03 | 0.1620 | 4.84e-02 | 7.58e-02 | -4.87e-02 | -6.85e-02 | -1.05e-01 | 3.10e-01 | 1.11e-01 | 3.06e-01 | 1.50e-01 | 2.68e-02 |
| REGULATION OF CELL ACTIVATION | 630 | 1.68e-03 | 2.65e-02 | 0.1620 | 7.10e-02 | 7.84e-02 | 6.83e-02 | 9.26e-02 | 4.28e-02 | 2.36e-03 | 7.79e-04 | 3.41e-03 | 7.20e-05 | 6.69e-02 |
| L GLUTAMATE IMPORT | 38 | 8.69e-01 | 9.78e-01 | 0.1620 | -9.68e-02 | -8.07e-02 | -6.11e-02 | -5.25e-02 | -6.23e-02 | 3.02e-01 | 3.90e-01 | 5.14e-01 | 5.76e-01 | 5.06e-01 |
| HISTONE H3 K4 METHYLATION | 18 | 8.62e-01 | 9.78e-01 | 0.1620 | 7.26e-02 | 7.89e-02 | 7.15e-03 | 7.33e-02 | -9.65e-02 | 5.94e-01 | 5.62e-01 | 9.58e-01 | 5.90e-01 | 4.78e-01 |
| POSITIVE REGULATION OF CELL FATE COMMITMENT | 13 | 8.64e-01 | 9.78e-01 | 0.1620 | -5.07e-02 | 2.64e-02 | 1.18e-01 | 2.27e-02 | 9.29e-02 | 7.52e-01 | 8.69e-01 | 4.63e-01 | 8.87e-01 | 5.62e-01 |
| GLYCOPROTEIN BIOSYNTHETIC PROCESS | 291 | 5.31e-02 | 3.05e-01 | 0.1620 | 9.25e-02 | 8.72e-02 | 5.02e-02 | 8.58e-02 | 1.35e-02 | 6.64e-03 | 1.05e-02 | 1.41e-01 | 1.18e-02 | 6.91e-01 |
| IRON COORDINATION ENTITY TRANSPORT | 12 | 2.46e-01 | 6.52e-01 | 0.1620 | -3.95e-02 | 8.93e-02 | -5.19e-02 | 5.78e-02 | -1.03e-01 | 8.13e-01 | 5.92e-01 | 7.55e-01 | 7.29e-01 | 5.36e-01 |
| N ACYLETHANOLAMINE METABOLIC PROCESS | 5 | 9.82e-01 | 9.96e-01 | 0.1620 | 8.91e-02 | -1.79e-02 | -6.67e-02 | 1.95e-02 | -1.14e-01 | 7.30e-01 | 9.45e-01 | 7.96e-01 | 9.40e-01 | 6.58e-01 |
| ANIMAL ORGAN MORPHOGENESIS | 1014 | 1.10e-08 | 6.99e-07 | 0.1620 | 1.69e-02 | 6.36e-02 | 8.66e-02 | 5.93e-02 | 1.04e-01 | 3.61e-01 | 6.14e-04 | 3.05e-06 | 1.41e-03 | 1.98e-08 |
| REGULATION OF SYNAPTIC VESICLE RECYCLING | 24 | 8.20e-01 | 9.70e-01 | 0.1620 | -2.14e-02 | 4.28e-02 | 6.65e-02 | -6.52e-04 | 1.40e-01 | 8.56e-01 | 7.17e-01 | 5.73e-01 | 9.96e-01 | 2.37e-01 |
| CENTRAL NERVOUS SYSTEM PROJECTION NEURON AXONOGENESIS | 29 | 9.64e-01 | 9.94e-01 | 0.1620 | 4.64e-02 | 8.26e-02 | 9.63e-02 | 6.68e-02 | 5.87e-02 | 6.66e-01 | 4.41e-01 | 3.69e-01 | 5.33e-01 | 5.84e-01 |
| MEMBRANE REPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 23 | 2.24e-01 | 6.24e-01 | 0.1620 | -8.15e-03 | 7.21e-02 | -3.56e-02 | -1.15e-01 | 7.98e-02 | 9.46e-01 | 5.49e-01 | 7.68e-01 | 3.39e-01 | 5.07e-01 |
| LEUKOCYTE DIFFERENTIATION | 596 | 1.82e-03 | 2.83e-02 | 0.1620 | 6.15e-02 | 6.91e-02 | 7.53e-02 | 9.71e-02 | 5.00e-02 | 1.04e-02 | 3.96e-03 | 1.67e-03 | 5.06e-05 | 3.70e-02 |
| O GLYCAN PROCESSING | 42 | 4.59e-01 | 8.23e-01 | 0.1620 | 1.28e-01 | 6.44e-02 | -1.65e-02 | 5.29e-02 | -5.13e-02 | 1.52e-01 | 4.70e-01 | 8.53e-01 | 5.53e-01 | 5.65e-01 |
| NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 99 | 6.27e-01 | 9.09e-01 | 0.1620 | 1.03e-01 | 8.50e-02 | 6.09e-02 | 6.73e-02 | -2.52e-03 | 7.60e-02 | 1.44e-01 | 2.95e-01 | 2.47e-01 | 9.65e-01 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 15 | 6.26e-01 | 9.09e-01 | 0.1620 | 1.20e-01 | -1.25e-02 | -5.07e-02 | -1.34e-02 | -9.36e-02 | 4.20e-01 | 9.33e-01 | 7.34e-01 | 9.28e-01 | 5.30e-01 |
| REGULATION OF AMYLOID PRECURSOR PROTEIN CATABOLIC PROCESS | 54 | 3.68e-01 | 7.68e-01 | 0.1620 | 1.12e-01 | 3.48e-02 | -6.10e-03 | 6.43e-02 | -9.04e-02 | 1.54e-01 | 6.59e-01 | 9.38e-01 | 4.14e-01 | 2.50e-01 |
| WALKING BEHAVIOR | 35 | 5.90e-01 | 8.93e-01 | 0.1620 | 5.49e-02 | -1.65e-02 | 6.37e-02 | 8.88e-02 | 1.04e-01 | 5.74e-01 | 8.66e-01 | 5.14e-01 | 3.63e-01 | 2.86e-01 |
| POSITIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 28 | 9.18e-01 | 9.86e-01 | 0.1620 | 9.51e-02 | 8.94e-02 | 5.03e-02 | 5.81e-02 | -5.63e-02 | 3.84e-01 | 4.13e-01 | 6.45e-01 | 5.95e-01 | 6.06e-01 |
| ISOPRENOID CATABOLIC PROCESS | 10 | 8.49e-01 | 9.76e-01 | 0.1620 | -4.59e-02 | 9.00e-02 | 1.14e-01 | 1.65e-02 | 5.17e-02 | 8.02e-01 | 6.22e-01 | 5.33e-01 | 9.28e-01 | 7.77e-01 |
| PROTEIN PROCESSING | 233 | 2.03e-01 | 5.96e-01 | 0.1620 | 8.87e-02 | 8.97e-02 | 7.70e-02 | 6.47e-02 | 8.13e-03 | 1.97e-02 | 1.84e-02 | 4.28e-02 | 8.89e-02 | 8.31e-01 |
| POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 74 | 2.27e-01 | 6.28e-01 | 0.1610 | -3.83e-02 | -2.22e-02 | 3.67e-02 | -1.23e-02 | 1.50e-01 | 5.69e-01 | 7.41e-01 | 5.85e-01 | 8.55e-01 | 2.53e-02 |
| GUANINE NUCLEOTIDE TRANSPORT | 9 | 9.63e-01 | 9.94e-01 | 0.1610 | 8.93e-02 | 8.94e-02 | -1.82e-02 | 4.70e-02 | -8.70e-02 | 6.43e-01 | 6.42e-01 | 9.25e-01 | 8.07e-01 | 6.51e-01 |
| NEPHRON DEVELOPMENT | 152 | 1.78e-01 | 5.63e-01 | 0.1610 | 3.85e-02 | 6.30e-02 | 6.35e-02 | 5.46e-02 | 1.17e-01 | 4.13e-01 | 1.80e-01 | 1.77e-01 | 2.45e-01 | 1.31e-02 |
| POSITIVE REGULATION OF MUSCLE CELL APOPTOTIC PROCESS | 33 | 6.76e-01 | 9.28e-01 | 0.1610 | 1.05e-01 | 6.43e-02 | 2.02e-02 | 2.42e-02 | -9.97e-02 | 2.97e-01 | 5.22e-01 | 8.40e-01 | 8.10e-01 | 3.22e-01 |
| GANGLIOSIDE METABOLIC PROCESS | 28 | 7.73e-01 | 9.57e-01 | 0.1610 | 5.48e-02 | 8.24e-02 | 1.17e-01 | 3.87e-02 | 3.12e-02 | 6.16e-01 | 4.50e-01 | 2.82e-01 | 7.23e-01 | 7.75e-01 |
| ACTIVATION OF TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY | 6 | 9.67e-01 | 9.94e-01 | 0.1610 | -6.96e-02 | -8.56e-03 | -1.16e-01 | -7.51e-02 | -4.51e-02 | 7.68e-01 | 9.71e-01 | 6.23e-01 | 7.50e-01 | 8.48e-01 |
| FEMALE GENITALIA DEVELOPMENT | 19 | 4.21e-01 | 8.00e-01 | 0.1610 | -6.06e-02 | 6.24e-03 | -5.80e-02 | -2.80e-02 | 1.35e-01 | 6.48e-01 | 9.62e-01 | 6.62e-01 | 8.32e-01 | 3.10e-01 |
| PHOSPHOLIPID TRANSPORT | 101 | 3.90e-01 | 7.82e-01 | 0.1610 | -7.54e-02 | -4.03e-02 | -5.54e-02 | -9.00e-02 | -8.67e-02 | 1.91e-01 | 4.84e-01 | 3.36e-01 | 1.18e-01 | 1.32e-01 |
| REGULATION OF GAP JUNCTION ASSEMBLY | 9 | 9.91e-01 | 9.98e-01 | 0.1610 | 9.41e-02 | 4.13e-02 | 6.27e-02 | 7.56e-02 | 7.58e-02 | 6.25e-01 | 8.30e-01 | 7.45e-01 | 6.95e-01 | 6.94e-01 |
| ORGANIC ACID CATABOLIC PROCESS | 246 | 4.07e-02 | 2.61e-01 | 0.1610 | 9.53e-02 | 8.22e-02 | 4.43e-02 | 7.39e-02 | 5.19e-02 | 1.00e-02 | 2.63e-02 | 2.32e-01 | 4.59e-02 | 1.61e-01 |
| INOSITOL PHOSPHATE METABOLIC PROCESS | 42 | 7.88e-01 | 9.63e-01 | 0.1610 | -6.09e-02 | -8.53e-02 | -8.51e-02 | -8.45e-02 | 2.41e-02 | 4.94e-01 | 3.39e-01 | 3.40e-01 | 3.43e-01 | 7.87e-01 |
| CELLULAR RESPONSE TO TOXIC SUBSTANCE | 124 | 2.79e-01 | 6.90e-01 | 0.1610 | 8.37e-02 | 1.06e-01 | 4.80e-02 | 7.26e-02 | 1.02e-02 | 1.07e-01 | 4.13e-02 | 3.56e-01 | 1.63e-01 | 8.44e-01 |
| PROTEIN LOCALIZATION TO GOLGI APPARATUS | 29 | 8.04e-01 | 9.67e-01 | 0.1610 | 8.02e-02 | 8.67e-02 | 3.51e-02 | 9.94e-02 | 2.84e-02 | 4.55e-01 | 4.19e-01 | 7.44e-01 | 3.54e-01 | 7.91e-01 |
| REGULATION OF NON CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 106 | 1.12e-01 | 4.56e-01 | 0.1610 | 1.25e-01 | 8.02e-02 | 6.61e-03 | 5.45e-02 | -2.77e-02 | 2.62e-02 | 1.54e-01 | 9.06e-01 | 3.32e-01 | 6.22e-01 |
| MEIOSIS I CELL CYCLE PROCESS | 133 | 8.49e-02 | 3.94e-01 | 0.1610 | 7.75e-02 | 4.50e-02 | 8.70e-02 | 9.89e-02 | -2.07e-02 | 1.23e-01 | 3.70e-01 | 8.33e-02 | 4.88e-02 | 6.81e-01 |
| POSITIVE REGULATION OF RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 34 | 6.62e-01 | 9.22e-01 | 0.1610 | 3.90e-02 | 6.81e-02 | 4.13e-02 | 7.89e-02 | 1.08e-01 | 6.94e-01 | 4.92e-01 | 6.77e-01 | 4.26e-01 | 2.74e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CELL PERIPHERY | 70 | 5.67e-01 | 8.81e-01 | 0.1610 | 7.64e-02 | 7.64e-02 | 5.23e-02 | 1.06e-01 | 1.17e-02 | 2.69e-01 | 2.69e-01 | 4.49e-01 | 1.25e-01 | 8.66e-01 |
| TERMINAL BUTTON ORGANIZATION | 6 | 8.80e-01 | 9.79e-01 | 0.1610 | -1.04e-01 | -4.92e-02 | 1.07e-01 | -2.72e-03 | 3.46e-02 | 6.61e-01 | 8.35e-01 | 6.50e-01 | 9.91e-01 | 8.83e-01 |
| MUSCLE STRUCTURE DEVELOPMENT | 677 | 1.16e-04 | 3.09e-03 | 0.1610 | 3.63e-02 | 6.56e-02 | 8.59e-02 | 4.94e-02 | 1.02e-01 | 1.07e-01 | 3.61e-03 | 1.37e-04 | 2.82e-02 | 6.50e-06 |
| OLFACTORY BULB INTERNEURON DIFFERENTIATION | 12 | 9.73e-01 | 9.95e-01 | 0.1610 | 7.40e-02 | 6.78e-02 | 1.04e-01 | 6.93e-02 | -8.11e-03 | 6.57e-01 | 6.84e-01 | 5.33e-01 | 6.78e-01 | 9.61e-01 |
| ODONTOGENESIS OF DENTIN CONTAINING TOOTH | 90 | 1.61e-01 | 5.36e-01 | 0.1600 | -3.58e-02 | 3.09e-02 | 9.26e-02 | 4.32e-02 | 1.14e-01 | 5.57e-01 | 6.12e-01 | 1.29e-01 | 4.79e-01 | 6.10e-02 |
| NEURON PROJECTION ORGANIZATION | 85 | 8.19e-01 | 9.70e-01 | 0.1600 | -8.73e-02 | -7.06e-02 | -7.00e-02 | -7.66e-02 | -4.84e-02 | 1.64e-01 | 2.61e-01 | 2.64e-01 | 2.22e-01 | 4.40e-01 |
| CELL COMMUNICATION BY ELECTRICAL COUPLING INVOLVED IN CARDIAC CONDUCTION | 27 | 7.63e-01 | 9.54e-01 | 0.1600 | -4.11e-02 | -9.78e-03 | 5.56e-02 | 5.62e-02 | 1.33e-01 | 7.12e-01 | 9.30e-01 | 6.17e-01 | 6.14e-01 | 2.32e-01 |
| REGULATION OF PROTEIN ACETYLATION | 38 | 2.82e-01 | 6.93e-01 | 0.1600 | 1.27e-02 | -6.74e-03 | 5.10e-02 | 1.34e-01 | 6.99e-02 | 8.92e-01 | 9.43e-01 | 5.87e-01 | 1.53e-01 | 4.56e-01 |
| POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 96 | 2.58e-01 | 6.65e-01 | 0.1600 | 3.76e-05 | -6.58e-02 | -8.69e-02 | -6.36e-02 | -9.85e-02 | 9.99e-01 | 2.65e-01 | 1.41e-01 | 2.81e-01 | 9.53e-02 |
| CELL CELL SIGNALING BY WNT | 441 | 9.01e-04 | 1.62e-02 | 0.1600 | 3.09e-02 | 3.58e-02 | 7.17e-02 | 8.68e-02 | 1.04e-01 | 2.65e-01 | 1.97e-01 | 9.87e-03 | 1.78e-03 | 1.90e-04 |
| SEROTONIN RECEPTOR SIGNALING PATHWAY | 27 | 3.26e-01 | 7.35e-01 | 0.1600 | -5.24e-02 | -9.50e-02 | -1.16e-01 | 1.65e-02 | -7.62e-03 | 6.37e-01 | 3.93e-01 | 2.96e-01 | 8.82e-01 | 9.45e-01 |
| POSITIVE REGULATION OF STEROID METABOLIC PROCESS | 27 | 8.06e-01 | 9.67e-01 | 0.1600 | -4.74e-02 | -1.78e-03 | -5.67e-02 | -1.06e-01 | -9.43e-02 | 6.70e-01 | 9.87e-01 | 6.10e-01 | 3.40e-01 | 3.96e-01 |
| STRIATED MUSCLE CONTRACTION | 175 | 5.59e-03 | 6.68e-02 | 0.1600 | -1.03e-01 | -2.58e-02 | -3.29e-02 | -1.16e-01 | 1.39e-04 | 1.92e-02 | 5.56e-01 | 4.52e-01 | 8.35e-03 | 9.97e-01 |
| VENTRICULAR SYSTEM DEVELOPMENT | 32 | 8.98e-01 | 9.82e-01 | 0.1600 | 1.04e-01 | 7.97e-02 | 4.57e-02 | 6.10e-02 | -5.12e-02 | 3.08e-01 | 4.35e-01 | 6.54e-01 | 5.50e-01 | 6.16e-01 |
| SUPEROXIDE ANION GENERATION | 37 | 4.31e-01 | 8.06e-01 | 0.1600 | 7.72e-02 | 1.18e-01 | -9.22e-03 | 1.57e-02 | -7.35e-02 | 4.16e-01 | 2.16e-01 | 9.23e-01 | 8.69e-01 | 4.39e-01 |
| REGULATION OF NEURONAL SYNAPTIC PLASTICITY | 53 | 3.86e-01 | 7.80e-01 | 0.1600 | 1.10e-02 | 1.09e-01 | 9.35e-02 | 4.00e-02 | 5.58e-02 | 8.90e-01 | 1.69e-01 | 2.39e-01 | 6.14e-01 | 4.82e-01 |
| CALCIUM ION TRANSMEMBRANE TRANSPORT | 338 | 2.99e-02 | 2.16e-01 | 0.1600 | -9.89e-02 | -5.85e-02 | -6.70e-02 | -8.44e-02 | -2.57e-02 | 1.77e-03 | 6.45e-02 | 3.43e-02 | 7.61e-03 | 4.16e-01 |
| POSITIVE REGULATION OF TELOMERASE ACTIVITY | 33 | 5.49e-01 | 8.73e-01 | 0.1600 | 3.96e-02 | 3.64e-02 | 6.66e-02 | 1.34e-01 | 1.16e-02 | 6.94e-01 | 7.17e-01 | 5.08e-01 | 1.82e-01 | 9.09e-01 |
| FAT SOLUBLE VITAMIN METABOLIC PROCESS | 45 | 1.84e-01 | 5.71e-01 | 0.1600 | -1.89e-02 | 1.87e-02 | 2.91e-02 | -6.67e-02 | 1.40e-01 | 8.27e-01 | 8.28e-01 | 7.35e-01 | 4.39e-01 | 1.05e-01 |
| REGULATION OF ANOIKIS | 24 | 5.48e-01 | 8.73e-01 | 0.1590 | -7.11e-02 | 2.45e-02 | -3.35e-03 | -5.24e-02 | 1.30e-01 | 5.46e-01 | 8.35e-01 | 9.77e-01 | 6.56e-01 | 2.69e-01 |
| GLYCOSYL COMPOUND CATABOLIC PROCESS | 34 | 7.77e-01 | 9.58e-01 | 0.1590 | 1.45e-02 | -1.10e-02 | -7.08e-02 | -1.64e-02 | -1.41e-01 | 8.84e-01 | 9.12e-01 | 4.75e-01 | 8.68e-01 | 1.56e-01 |
| DENDRITIC CELL MIGRATION | 32 | 5.23e-01 | 8.59e-01 | 0.1590 | 1.21e-01 | 6.31e-02 | -2.54e-03 | 7.06e-02 | 4.18e-02 | 2.35e-01 | 5.37e-01 | 9.80e-01 | 4.89e-01 | 6.82e-01 |
| CELLULAR ALDEHYDE METABOLIC PROCESS | 70 | 4.63e-01 | 8.25e-01 | 0.1590 | 5.26e-02 | 3.15e-02 | 9.60e-02 | 1.06e-01 | 3.30e-02 | 4.46e-01 | 6.49e-01 | 1.65e-01 | 1.24e-01 | 6.33e-01 |
| SALIVARY GLAND DEVELOPMENT | 33 | 9.49e-01 | 9.94e-01 | 0.1590 | 4.33e-02 | 7.75e-02 | 9.54e-02 | 7.68e-02 | 5.02e-02 | 6.67e-01 | 4.41e-01 | 3.43e-01 | 4.45e-01 | 6.18e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 14 | 7.53e-01 | 9.51e-01 | 0.1590 | -6.70e-02 | -6.65e-03 | 1.69e-02 | -1.17e-01 | 8.29e-02 | 6.64e-01 | 9.66e-01 | 9.13e-01 | 4.50e-01 | 5.91e-01 |
| NEGATIVE REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 26 | 2.28e-01 | 6.31e-01 | 0.1590 | -1.27e-01 | -6.15e-02 | 4.81e-04 | 1.82e-02 | -7.11e-02 | 2.62e-01 | 5.88e-01 | 9.97e-01 | 8.73e-01 | 5.31e-01 |
| REGULATION OF CELL DIVISION | 177 | 1.11e-01 | 4.54e-01 | 0.1590 | 2.96e-02 | 1.73e-02 | 8.34e-02 | 7.65e-02 | 1.06e-01 | 4.97e-01 | 6.91e-01 | 5.56e-02 | 7.93e-02 | 1.47e-02 |
| MESONEPHRIC DUCT DEVELOPMENT | 8 | 9.90e-01 | 9.98e-01 | 0.1590 | -9.10e-03 | 5.42e-02 | 9.28e-02 | 2.89e-02 | 1.13e-01 | 9.64e-01 | 7.91e-01 | 6.49e-01 | 8.88e-01 | 5.79e-01 |
| POSITIVE REGULATION OF PROTEIN DEPOLYMERIZATION | 19 | 7.00e-01 | 9.31e-01 | 0.1590 | 2.28e-02 | 8.52e-02 | 5.47e-02 | 2.41e-02 | -1.18e-01 | 8.63e-01 | 5.20e-01 | 6.80e-01 | 8.56e-01 | 3.74e-01 |
| PURINERGIC NUCLEOTIDE RECEPTOR SIGNALING PATHWAY | 29 | 7.91e-01 | 9.63e-01 | 0.1590 | 5.21e-02 | 6.04e-02 | 1.06e-01 | 8.63e-02 | -1.67e-02 | 6.27e-01 | 5.74e-01 | 3.25e-01 | 4.21e-01 | 8.76e-01 |
| REGULATION OF HEART RATE BY CARDIAC CONDUCTION | 37 | 5.36e-01 | 8.65e-01 | 0.1590 | -5.55e-02 | -4.93e-02 | -5.64e-02 | -1.23e-01 | 3.66e-02 | 5.59e-01 | 6.04e-01 | 5.53e-01 | 1.95e-01 | 7.00e-01 |
| EPIDERMIS MORPHOGENESIS | 36 | 7.10e-01 | 9.35e-01 | 0.1590 | -1.15e-01 | -4.06e-02 | -5.95e-02 | -7.35e-02 | -3.54e-02 | 2.31e-01 | 6.73e-01 | 5.37e-01 | 4.45e-01 | 7.13e-01 |
| TERTIARY ALCOHOL METABOLIC PROCESS | 22 | 8.15e-01 | 9.69e-01 | 0.1590 | 5.49e-02 | 5.07e-02 | 8.74e-02 | 9.62e-02 | -5.16e-02 | 6.56e-01 | 6.80e-01 | 4.78e-01 | 4.35e-01 | 6.75e-01 |
| POSITIVE REGULATION OF TROPHOBLAST CELL MIGRATION | 7 | 9.94e-01 | 9.99e-01 | 0.1590 | -9.97e-02 | -8.86e-02 | -1.66e-02 | -5.01e-02 | 6.77e-02 | 6.48e-01 | 6.85e-01 | 9.39e-01 | 8.18e-01 | 7.57e-01 |
| REGULATION OF RAC PROTEIN SIGNAL TRANSDUCTION | 19 | 1.97e-01 | 5.85e-01 | 0.1590 | -4.82e-02 | -2.24e-02 | 3.85e-02 | 1.32e-01 | -5.91e-02 | 7.16e-01 | 8.66e-01 | 7.71e-01 | 3.21e-01 | 6.55e-01 |
| REGULATION OF OSTEOBLAST PROLIFERATION | 30 | 7.58e-01 | 9.52e-01 | 0.1590 | 6.29e-02 | 8.52e-02 | 1.05e-01 | 2.37e-02 | 4.84e-02 | 5.51e-01 | 4.19e-01 | 3.20e-01 | 8.22e-01 | 6.46e-01 |
| INTERLEUKIN 1 PRODUCTION | 123 | 1.07e-02 | 1.07e-01 | 0.1590 | 1.04e-01 | 5.27e-02 | -4.96e-02 | 4.49e-03 | -9.46e-02 | 4.54e-02 | 3.13e-01 | 3.42e-01 | 9.31e-01 | 6.98e-02 |
| NEGATIVE REGULATION OF SECRETION | 164 | 4.96e-02 | 2.91e-01 | 0.1580 | 9.35e-02 | 9.24e-02 | 5.07e-02 | 3.40e-02 | 6.41e-02 | 3.87e-02 | 4.11e-02 | 2.63e-01 | 4.53e-01 | 1.57e-01 |
| EPHRIN RECEPTOR SIGNALING PATHWAY | 49 | 6.62e-01 | 9.22e-01 | 0.1580 | -7.80e-02 | -8.89e-02 | -7.12e-02 | -5.22e-02 | 5.77e-02 | 3.45e-01 | 2.82e-01 | 3.89e-01 | 5.27e-01 | 4.84e-01 |
| NEGATIVE REGULATION OF ACTIN FILAMENT POLYMERIZATION | 61 | 8.10e-01 | 9.68e-01 | 0.1580 | -8.72e-02 | -6.08e-02 | -8.27e-02 | -8.22e-02 | -1.39e-02 | 2.39e-01 | 4.11e-01 | 2.64e-01 | 2.67e-01 | 8.51e-01 |
| REGULATION OF RESPONSE TO WOUNDING | 166 | 6.50e-02 | 3.39e-01 | 0.1580 | -4.37e-02 | -9.66e-03 | -8.47e-02 | -7.97e-02 | -9.78e-02 | 3.32e-01 | 8.30e-01 | 5.97e-02 | 7.63e-02 | 2.97e-02 |
| INTERLEUKIN 11 MEDIATED SIGNALING PATHWAY | 6 | 9.12e-01 | 9.85e-01 | 0.1580 | -1.26e-01 | -6.91e-02 | 5.79e-03 | 4.71e-02 | 4.58e-02 | 5.92e-01 | 7.69e-01 | 9.80e-01 | 8.42e-01 | 8.46e-01 |
| POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 151 | 2.93e-01 | 7.04e-01 | 0.1580 | -9.93e-02 | -5.70e-02 | -6.74e-02 | -8.60e-02 | -6.82e-03 | 3.52e-02 | 2.27e-01 | 1.53e-01 | 6.82e-02 | 8.85e-01 |
| POSTSYNAPSE ASSEMBLY | 35 | 3.29e-01 | 7.37e-01 | 0.1580 | -1.22e-01 | 4.93e-03 | 1.18e-02 | -8.03e-02 | 5.93e-02 | 2.11e-01 | 9.60e-01 | 9.03e-01 | 4.11e-01 | 5.44e-01 |
| IMMUNOLOGICAL SYNAPSE FORMATION | 15 | 7.42e-01 | 9.50e-01 | 0.1580 | -1.17e-01 | -9.34e-02 | 3.57e-02 | -3.59e-02 | 4.79e-03 | 4.32e-01 | 5.31e-01 | 8.11e-01 | 8.10e-01 | 9.74e-01 |
| INTERLEUKIN 13 PRODUCTION | 21 | 6.23e-01 | 9.08e-01 | 0.1580 | 5.36e-03 | 1.90e-02 | 1.35e-01 | 7.38e-02 | 3.15e-02 | 9.66e-01 | 8.80e-01 | 2.84e-01 | 5.58e-01 | 8.03e-01 |
| POSITIVE REGULATION OF FOCAL ADHESION ASSEMBLY | 26 | 2.53e-01 | 6.60e-01 | 0.1580 | 1.12e-01 | 6.21e-03 | -8.67e-02 | -4.25e-02 | -5.51e-02 | 3.21e-01 | 9.56e-01 | 4.44e-01 | 7.08e-01 | 6.27e-01 |
| PHENOL CONTAINING COMPOUND METABOLIC PROCESS | 105 | 4.33e-01 | 8.07e-01 | 0.1580 | -8.57e-02 | -6.23e-02 | -5.37e-02 | -1.04e-01 | 3.31e-03 | 1.29e-01 | 2.70e-01 | 3.42e-01 | 6.44e-02 | 9.53e-01 |
| POSITIVE REGULATION OF LYASE ACTIVITY | 39 | 8.31e-01 | 9.73e-01 | 0.1580 | -8.87e-02 | -4.85e-02 | -4.49e-02 | -9.32e-02 | -6.38e-02 | 3.38e-01 | 6.00e-01 | 6.28e-01 | 3.14e-01 | 4.91e-01 |
| MALE MEIOSIS I | 27 | 9.00e-01 | 9.83e-01 | 0.1580 | 7.43e-02 | 6.36e-02 | 9.97e-02 | 7.41e-02 | -9.66e-04 | 5.04e-01 | 5.67e-01 | 3.70e-01 | 5.05e-01 | 9.93e-01 |
| EPIDERMAL CELL DIFFERENTIATION | 242 | 2.82e-03 | 3.99e-02 | 0.1580 | -5.26e-02 | -2.63e-02 | -6.60e-02 | -1.21e-01 | -4.91e-02 | 1.59e-01 | 4.82e-01 | 7.68e-02 | 1.13e-03 | 1.88e-01 |
| HEXOSE CATABOLIC PROCESS | 42 | 1.23e-01 | 4.77e-01 | 0.1580 | 2.44e-02 | 1.40e-01 | 3.01e-02 | -2.38e-02 | -5.76e-02 | 7.84e-01 | 1.17e-01 | 7.35e-01 | 7.90e-01 | 5.18e-01 |
| P BODY ASSEMBLY | 20 | 9.32e-02 | 4.14e-01 | 0.1580 | -6.79e-02 | -1.09e-02 | 9.65e-03 | 1.36e-01 | 3.88e-02 | 5.99e-01 | 9.33e-01 | 9.40e-01 | 2.91e-01 | 7.64e-01 |
| ORGANOPHOSPHATE METABOLIC PROCESS | 917 | 4.16e-04 | 8.71e-03 | 0.1580 | 6.90e-02 | 7.61e-02 | 7.26e-02 | 6.49e-02 | 6.97e-02 | 3.94e-04 | 9.32e-05 | 1.91e-04 | 8.65e-04 | 3.44e-04 |
| REGULATION OF LEUKOCYTE MEDIATED CYTOTOXICITY | 95 | 2.78e-03 | 3.95e-02 | 0.1580 | -6.24e-02 | -1.25e-01 | -3.20e-02 | 3.79e-02 | -5.30e-02 | 2.93e-01 | 3.48e-02 | 5.90e-01 | 5.23e-01 | 3.72e-01 |
| CELLULAR RESPONSE TO VITAMIN D | 21 | 2.58e-01 | 6.64e-01 | 0.1580 | 1.80e-02 | 9.06e-02 | -3.33e-02 | -9.36e-02 | 8.03e-02 | 8.87e-01 | 4.72e-01 | 7.92e-01 | 4.58e-01 | 5.24e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 91 | 5.64e-01 | 8.80e-01 | 0.1580 | 5.23e-02 | 3.28e-02 | 8.25e-02 | 9.80e-02 | 6.78e-02 | 3.88e-01 | 5.89e-01 | 1.74e-01 | 1.06e-01 | 2.63e-01 |
| ORGANIC CYCLIC COMPOUND CATABOLIC PROCESS | 560 | 5.31e-04 | 1.06e-02 | 0.1580 | 6.89e-02 | 3.70e-02 | 7.15e-02 | 9.70e-02 | 6.47e-02 | 5.29e-03 | 1.34e-01 | 3.82e-03 | 8.68e-05 | 8.88e-03 |
| REGULATION OF CYTOPLASMIC TRANSPORT | 29 | 5.55e-01 | 8.77e-01 | 0.1570 | 9.86e-02 | 2.89e-02 | -5.43e-03 | 1.13e-01 | -3.77e-02 | 3.58e-01 | 7.88e-01 | 9.60e-01 | 2.93e-01 | 7.25e-01 |
| RESPONSE TO MUSCLE ACTIVITY | 28 | 6.56e-01 | 9.20e-01 | 0.1570 | -1.01e-01 | -1.87e-02 | 2.55e-02 | -7.02e-02 | 9.24e-02 | 3.54e-01 | 8.64e-01 | 8.16e-01 | 5.20e-01 | 3.97e-01 |
| NEGATIVE REGULATION OF MUSCLE HYPERTROPHY | 36 | 7.51e-01 | 9.51e-01 | 0.1570 | 9.47e-03 | 1.53e-02 | -5.67e-02 | -5.07e-02 | -1.36e-01 | 9.22e-01 | 8.74e-01 | 5.56e-01 | 5.98e-01 | 1.57e-01 |
| SENSORY ORGAN MORPHOGENESIS | 272 | 4.39e-03 | 5.61e-02 | 0.1570 | -1.01e-02 | 3.17e-02 | 6.55e-02 | 4.14e-02 | 1.33e-01 | 7.75e-01 | 3.68e-01 | 6.30e-02 | 2.40e-01 | 1.65e-04 |
| CEREBELLAR CORTEX MORPHOGENESIS | 34 | 5.87e-01 | 8.91e-01 | 0.1570 | -5.44e-02 | -5.99e-02 | 3.35e-02 | -2.89e-02 | 1.27e-01 | 5.83e-01 | 5.46e-01 | 7.35e-01 | 7.70e-01 | 1.99e-01 |
| REGULATION OF T CELL MEDIATED IMMUNITY | 95 | 3.81e-01 | 7.78e-01 | 0.1570 | 4.77e-02 | 6.11e-02 | 7.92e-02 | 1.08e-01 | 2.60e-02 | 4.21e-01 | 3.03e-01 | 1.82e-01 | 6.81e-02 | 6.61e-01 |
| FOREBRAIN CELL MIGRATION | 64 | 8.32e-01 | 9.73e-01 | 0.1570 | 7.99e-02 | 5.86e-02 | 8.48e-02 | 7.15e-02 | 5.01e-02 | 2.69e-01 | 4.17e-01 | 2.41e-01 | 3.22e-01 | 4.88e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL PROLIFERATION | 84 | 6.87e-01 | 9.31e-01 | 0.1570 | 3.35e-02 | 7.56e-02 | 9.20e-02 | 6.93e-02 | 6.70e-02 | 5.96e-01 | 2.31e-01 | 1.45e-01 | 2.72e-01 | 2.89e-01 |
| CD4 POSITIVE ALPHA BETA T CELL ACTIVATION | 113 | 1.22e-01 | 4.76e-01 | 0.1570 | 6.83e-02 | 5.13e-02 | 4.33e-02 | 1.16e-01 | 4.56e-02 | 2.10e-01 | 3.46e-01 | 4.26e-01 | 3.38e-02 | 4.03e-01 |
| ADIPOSE TISSUE DEVELOPMENT | 57 | 4.02e-01 | 7.89e-01 | 0.1570 | 9.79e-02 | 8.74e-02 | 1.07e-02 | 8.46e-02 | -8.99e-03 | 2.01e-01 | 2.54e-01 | 8.88e-01 | 2.69e-01 | 9.06e-01 |
| CELLULAR RESPONSE TO ALDEHYDE | 16 | 9.68e-01 | 9.94e-01 | 0.1570 | -5.64e-02 | -8.06e-02 | -4.99e-02 | -6.05e-02 | -9.34e-02 | 6.96e-01 | 5.77e-01 | 7.30e-01 | 6.75e-01 | 5.18e-01 |
| REGULATION OF CELL PROJECTION SIZE | 12 | 4.96e-01 | 8.45e-01 | 0.1570 | -9.02e-02 | 9.25e-03 | 1.19e-01 | -4.71e-02 | 2.28e-03 | 5.89e-01 | 9.56e-01 | 4.76e-01 | 7.78e-01 | 9.89e-01 |
| POSITIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL PROLIFERATION | 49 | 8.72e-01 | 9.78e-01 | 0.1570 | 5.90e-02 | 9.62e-02 | 8.88e-02 | 5.53e-02 | 2.88e-02 | 4.75e-01 | 2.44e-01 | 2.82e-01 | 5.03e-01 | 7.28e-01 |
| POSITIVE REGULATION OF LYMPHOCYTE ACTIVATION | 316 | 2.87e-02 | 2.10e-01 | 0.1560 | 6.22e-02 | 6.08e-02 | 6.29e-02 | 9.99e-02 | 5.46e-02 | 5.71e-02 | 6.32e-02 | 5.44e-02 | 2.26e-03 | 9.51e-02 |
| SERINE FAMILY AMINO ACID METABOLIC PROCESS | 37 | 8.95e-02 | 4.05e-01 | 0.1560 | 4.70e-02 | 2.20e-02 | -1.18e-02 | 1.36e-01 | -5.67e-02 | 6.21e-01 | 8.17e-01 | 9.01e-01 | 1.53e-01 | 5.51e-01 |
| ECTODERMAL CELL DIFFERENTIATION | 6 | 9.96e-01 | 1.00e+00 | 0.1560 | 1.04e-01 | 5.12e-02 | 7.29e-02 | 7.50e-02 | -5.32e-03 | 6.58e-01 | 8.28e-01 | 7.57e-01 | 7.51e-01 | 9.82e-01 |
| NK T CELL ACTIVATION | 12 | 6.27e-01 | 9.09e-01 | 0.1560 | 1.92e-02 | 2.32e-02 | -1.01e-02 | 1.18e-01 | 9.70e-02 | 9.08e-01 | 8.89e-01 | 9.52e-01 | 4.78e-01 | 5.61e-01 |
| OLIGOSACCHARIDE CATABOLIC PROCESS | 17 | 9.56e-01 | 9.94e-01 | 0.1560 | 8.03e-02 | 9.11e-02 | 3.49e-02 | 4.97e-02 | -7.70e-02 | 5.66e-01 | 5.16e-01 | 8.03e-01 | 7.23e-01 | 5.83e-01 |
| POST EMBRYONIC ANIMAL ORGAN MORPHOGENESIS | 11 | 7.55e-01 | 9.51e-01 | 0.1560 | 1.22e-01 | 6.58e-02 | -9.68e-03 | -4.91e-02 | -5.21e-02 | 4.85e-01 | 7.05e-01 | 9.56e-01 | 7.78e-01 | 7.65e-01 |
| NITRIC OXIDE SYNTHASE BIOSYNTHETIC PROCESS | 20 | 6.63e-01 | 9.22e-01 | 0.1560 | 2.63e-03 | -8.13e-02 | -1.23e-01 | -5.00e-02 | 7.03e-03 | 9.84e-01 | 5.29e-01 | 3.40e-01 | 6.99e-01 | 9.57e-01 |
| FC EPSILON RECEPTOR SIGNALING PATHWAY | 24 | 6.97e-01 | 9.31e-01 | 0.1560 | 8.65e-02 | -9.29e-03 | -6.13e-02 | 2.44e-02 | -1.11e-01 | 4.63e-01 | 9.37e-01 | 6.03e-01 | 8.36e-01 | 3.45e-01 |
| REGULATION OF TYPE 2 IMMUNE RESPONSE | 34 | 6.19e-01 | 9.07e-01 | 0.1560 | 9.09e-02 | 8.48e-02 | -7.88e-03 | -1.01e-02 | -9.31e-02 | 3.59e-01 | 3.92e-01 | 9.37e-01 | 9.19e-01 | 3.48e-01 |
| SYNAPTIC VESICLE ENDOSOMAL PROCESSING | 8 | 8.76e-01 | 9.78e-01 | 0.1560 | 1.19e-01 | -2.11e-02 | 2.90e-02 | 6.79e-02 | -6.51e-02 | 5.61e-01 | 9.18e-01 | 8.87e-01 | 7.40e-01 | 7.50e-01 |
| COPPER ION TRANSPORT | 15 | 6.92e-01 | 9.31e-01 | 0.1560 | 1.07e-01 | -2.17e-02 | -5.42e-02 | 7.60e-02 | -5.90e-02 | 4.71e-01 | 8.84e-01 | 7.16e-01 | 6.10e-01 | 6.92e-01 |
| NEGATIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 23 | 5.85e-01 | 8.90e-01 | 0.1560 | 7.91e-02 | -3.85e-02 | -4.51e-02 | 5.99e-02 | -1.04e-01 | 5.11e-01 | 7.49e-01 | 7.08e-01 | 6.19e-01 | 3.87e-01 |
| MITOCHONDRIAL FRAGMENTATION INVOLVED IN APOPTOTIC PROCESS | 10 | 6.27e-01 | 9.09e-01 | 0.1560 | 1.20e-01 | 6.56e-02 | 4.45e-02 | -5.59e-02 | -2.12e-02 | 5.12e-01 | 7.20e-01 | 8.07e-01 | 7.59e-01 | 9.08e-01 |
| REGULATION OF REGULATED SECRETORY PATHWAY | 117 | 1.46e-01 | 5.14e-01 | 0.1550 | 4.52e-02 | 1.12e-01 | 7.90e-02 | 2.56e-02 | 5.18e-02 | 3.98e-01 | 3.66e-02 | 1.40e-01 | 6.32e-01 | 3.33e-01 |
| POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 18 | 8.06e-01 | 9.67e-01 | 0.1550 | 5.35e-02 | 1.72e-02 | 1.52e-02 | 9.22e-02 | 1.11e-01 | 6.94e-01 | 9.00e-01 | 9.11e-01 | 4.98e-01 | 4.16e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 107 | 6.17e-02 | 3.30e-01 | 0.1550 | -6.12e-02 | -3.44e-02 | -3.73e-03 | -1.08e-02 | 1.38e-01 | 2.74e-01 | 5.38e-01 | 9.47e-01 | 8.47e-01 | 1.36e-02 |
| POSTSYNAPTIC SPECIALIZATION ASSEMBLY | 26 | 7.01e-01 | 9.32e-01 | 0.1550 | -9.61e-02 | -5.76e-03 | 3.28e-02 | -3.05e-02 | 1.13e-01 | 3.96e-01 | 9.59e-01 | 7.73e-01 | 7.87e-01 | 3.17e-01 |
| RUFFLE ORGANIZATION | 57 | 3.21e-01 | 7.32e-01 | 0.1550 | 2.64e-02 | 6.39e-02 | 7.73e-02 | 1.14e-01 | 1.63e-02 | 7.30e-01 | 4.04e-01 | 3.13e-01 | 1.36e-01 | 8.32e-01 |
| RESPONSE TO NITROGEN COMPOUND | 1082 | 3.19e-06 | 1.37e-04 | 0.1550 | 6.83e-02 | 7.54e-02 | 5.90e-02 | 7.81e-02 | 6.45e-02 | 1.48e-04 | 2.80e-05 | 1.05e-03 | 1.42e-05 | 3.37e-04 |
| VESICLE CARGO LOADING | 29 | 5.98e-01 | 8.98e-01 | 0.1550 | 1.24e-01 | 1.30e-02 | 1.77e-02 | 8.98e-02 | -1.50e-02 | 2.49e-01 | 9.03e-01 | 8.69e-01 | 4.03e-01 | 8.89e-01 |
| REGULATION OF GOLGI TO PLASMA MEMBRANE PROTEIN TRANSPORT | 9 | 7.64e-01 | 9.54e-01 | 0.1550 | -2.09e-02 | 8.24e-02 | 2.58e-02 | 5.97e-02 | -1.12e-01 | 9.14e-01 | 6.69e-01 | 8.93e-01 | 7.57e-01 | 5.60e-01 |
| REGULATION OF PLASMA LIPOPROTEIN PARTICLE LEVELS | 91 | 1.38e-02 | 1.28e-01 | 0.1550 | -6.63e-02 | 2.77e-02 | -3.59e-02 | -5.27e-02 | -1.22e-01 | 2.75e-01 | 6.48e-01 | 5.54e-01 | 3.85e-01 | 4.48e-02 |
| CELL ACTIVATION | 1063 | 8.15e-06 | 3.10e-04 | 0.1550 | 6.33e-02 | 6.81e-02 | 7.16e-02 | 9.51e-02 | 3.49e-02 | 4.86e-04 | 1.73e-04 | 8.01e-05 | 1.60e-07 | 5.47e-02 |
| POSITIVE REGULATION OF KERATINOCYTE DIFFERENTIATION | 19 | 2.83e-01 | 6.93e-01 | 0.1550 | -1.43e-02 | 1.50e-01 | 2.45e-02 | -6.19e-03 | 2.40e-02 | 9.14e-01 | 2.57e-01 | 8.53e-01 | 9.63e-01 | 8.56e-01 |
| PHOTORECEPTOR CELL DIFFERENTIATION | 63 | 1.12e-01 | 4.56e-01 | 0.1550 | -8.60e-02 | 4.82e-03 | -3.39e-03 | -1.02e-01 | 7.89e-02 | 2.38e-01 | 9.47e-01 | 9.63e-01 | 1.63e-01 | 2.79e-01 |
| POSITIVE REGULATION OF TRIGLYCERIDE METABOLIC PROCESS | 21 | 3.45e-01 | 7.50e-01 | 0.1550 | -3.62e-02 | 7.35e-02 | 9.34e-02 | 8.72e-02 | -3.10e-02 | 7.74e-01 | 5.60e-01 | 4.59e-01 | 4.89e-01 | 8.06e-01 |
| OLIGOSACCHARIDE BIOSYNTHETIC PROCESS | 29 | 4.39e-01 | 8.11e-01 | 0.1550 | -6.95e-02 | -2.29e-02 | -8.78e-02 | -1.33e-02 | -1.04e-01 | 5.17e-01 | 8.31e-01 | 4.13e-01 | 9.01e-01 | 3.33e-01 |
| CARBOHYDRATE DERIVATIVE METABOLIC PROCESS | 983 | 1.95e-04 | 4.64e-03 | 0.1550 | 8.03e-02 | 7.80e-02 | 6.21e-02 | 6.96e-02 | 5.23e-02 | 2.00e-05 | 3.46e-05 | 9.82e-04 | 2.18e-04 | 5.45e-03 |
| POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 1310 | 4.97e-08 | 2.89e-06 | 0.1550 | 6.02e-02 | 8.36e-02 | 6.61e-02 | 5.53e-02 | 7.68e-02 | 2.49e-04 | 3.69e-07 | 5.82e-05 | 7.70e-04 | 2.96e-06 |
| G PROTEIN COUPLED RECEPTOR INTERNALIZATION | 10 | 9.78e-01 | 9.96e-01 | 0.1540 | 9.95e-03 | 2.78e-02 | 6.00e-02 | 9.21e-02 | 1.04e-01 | 9.57e-01 | 8.79e-01 | 7.43e-01 | 6.14e-01 | 5.67e-01 |
| RECEPTOR DIFFUSION TRAPPING | 10 | 9.28e-01 | 9.89e-01 | 0.1540 | -5.08e-02 | 5.01e-02 | 6.77e-02 | -3.45e-02 | 1.14e-01 | 7.81e-01 | 7.84e-01 | 7.11e-01 | 8.50e-01 | 5.33e-01 |
| REGULATION OF PHOSPHOLIPID TRANSPORT | 15 | 4.27e-01 | 8.05e-01 | 0.1540 | -8.10e-02 | 9.35e-02 | 7.72e-02 | -4.71e-02 | -1.87e-02 | 5.87e-01 | 5.31e-01 | 6.05e-01 | 7.52e-01 | 9.00e-01 |
| PYRIMIDINE RIBONUCLEOTIDE METABOLIC PROCESS | 30 | 6.13e-01 | 9.05e-01 | 0.1540 | 3.48e-02 | 7.07e-02 | 2.64e-02 | 5.99e-02 | 1.15e-01 | 7.41e-01 | 5.03e-01 | 8.03e-01 | 5.70e-01 | 2.74e-01 |
| REGULATION OF ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN | 6 | 9.23e-01 | 9.88e-01 | 0.1540 | -2.09e-02 | -1.50e-02 | -1.22e-01 | -7.51e-02 | 5.21e-02 | 9.29e-01 | 9.49e-01 | 6.06e-01 | 7.50e-01 | 8.25e-01 |
| COLUMNAR CUBOIDAL EPITHELIAL CELL DEVELOPMENT | 51 | 2.82e-01 | 6.93e-01 | 0.1540 | -5.13e-02 | 3.69e-02 | 8.19e-02 | 5.27e-02 | 1.01e-01 | 5.26e-01 | 6.48e-01 | 3.12e-01 | 5.15e-01 | 2.11e-01 |
| NEGATIVE REGULATION OF ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 69 | 6.25e-01 | 9.09e-01 | 0.1540 | -8.61e-02 | -9.99e-02 | -4.48e-02 | -4.76e-02 | 4.53e-02 | 2.16e-01 | 1.51e-01 | 5.20e-01 | 4.94e-01 | 5.15e-01 |
| POSITIVE REGULATION OF PEPTIDE SECRETION | 110 | 3.05e-01 | 7.18e-01 | 0.1540 | 7.03e-02 | 9.91e-02 | 4.68e-02 | 6.30e-02 | 5.24e-02 | 2.03e-01 | 7.24e-02 | 3.97e-01 | 2.54e-01 | 3.42e-01 |
| NEUROTRANSMITTER REUPTAKE | 34 | 4.84e-01 | 8.38e-01 | 0.1540 | -1.97e-02 | 7.49e-02 | 4.63e-02 | 1.83e-02 | 1.23e-01 | 8.43e-01 | 4.50e-01 | 6.40e-01 | 8.54e-01 | 2.14e-01 |
| NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 692 | 1.14e-02 | 1.12e-01 | 0.1540 | 6.75e-02 | 7.25e-02 | 6.99e-02 | 7.25e-02 | 6.05e-02 | 2.46e-03 | 1.14e-03 | 1.73e-03 | 1.15e-03 | 6.63e-03 |
| ENDOTHELIUM DEVELOPMENT | 143 | 3.95e-01 | 7.85e-01 | 0.1540 | 5.07e-02 | 4.44e-02 | 7.71e-02 | 5.67e-02 | 9.94e-02 | 2.95e-01 | 3.59e-01 | 1.12e-01 | 2.41e-01 | 4.01e-02 |
| POSITIVE REGULATION OF 3 UTR MEDIATED MRNA STABILIZATION | 5 | 8.49e-01 | 9.76e-01 | 0.1540 | 7.04e-02 | 1.01e-01 | -7.06e-02 | 5.65e-02 | 1.65e-02 | 7.85e-01 | 6.96e-01 | 7.85e-01 | 8.27e-01 | 9.49e-01 |
| RIBONUCLEOTIDE CATABOLIC PROCESS | 48 | 5.96e-01 | 8.97e-01 | 0.1530 | -3.96e-02 | -1.11e-01 | -7.76e-02 | -6.05e-02 | 7.35e-04 | 6.35e-01 | 1.84e-01 | 3.52e-01 | 4.69e-01 | 9.93e-01 |
| ASPARTATE FAMILY AMINO ACID METABOLIC PROCESS | 47 | 3.19e-01 | 7.30e-01 | 0.1530 | -7.73e-02 | -8.73e-02 | -6.78e-02 | -6.41e-03 | 7.29e-02 | 3.59e-01 | 3.01e-01 | 4.21e-01 | 9.39e-01 | 3.87e-01 |
| DELAMINATION | 7 | 9.24e-01 | 9.89e-01 | 0.1530 | -1.25e-01 | 6.15e-03 | 3.21e-04 | -3.40e-02 | 8.24e-02 | 5.68e-01 | 9.78e-01 | 9.99e-01 | 8.76e-01 | 7.06e-01 |
| COPII COATED VESICLE CARGO LOADING | 16 | 5.98e-01 | 8.98e-01 | 0.1530 | 8.81e-02 | -5.40e-02 | 7.18e-03 | 8.56e-02 | -7.39e-02 | 5.42e-01 | 7.08e-01 | 9.60e-01 | 5.53e-01 | 6.09e-01 |
| REGULATION OF TYPE B PANCREATIC CELL DEVELOPMENT | 9 | 8.86e-01 | 9.80e-01 | 0.1530 | 4.24e-02 | -6.91e-02 | 1.67e-02 | 6.29e-02 | 1.13e-01 | 8.26e-01 | 7.20e-01 | 9.31e-01 | 7.44e-01 | 5.58e-01 |
| MODIFICATION OF POSTSYNAPTIC STRUCTURE | 21 | 9.20e-01 | 9.86e-01 | 0.1530 | -1.74e-02 | -4.02e-03 | 5.00e-02 | 3.86e-02 | 1.38e-01 | 8.90e-01 | 9.75e-01 | 6.92e-01 | 7.59e-01 | 2.72e-01 |
| REGULATION OF TRANSLATIONAL INITIATION IN RESPONSE TO STRESS | 14 | 9.72e-01 | 9.95e-01 | 0.1530 | 1.10e-02 | 3.36e-02 | 6.22e-02 | 7.97e-02 | 1.10e-01 | 9.43e-01 | 8.28e-01 | 6.87e-01 | 6.06e-01 | 4.78e-01 |
| REGULATION OF DOPAMINE RECEPTOR SIGNALING PATHWAY | 11 | 9.54e-01 | 9.94e-01 | 0.1530 | 9.44e-02 | 1.41e-02 | 4.32e-02 | 1.06e-01 | -3.49e-02 | 5.88e-01 | 9.35e-01 | 8.04e-01 | 5.42e-01 | 8.41e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS PEPTIDE ANTIGEN | 38 | 4.88e-01 | 8.39e-01 | 0.1530 | 4.07e-02 | 1.16e-01 | 5.17e-02 | 5.73e-02 | -4.99e-02 | 6.64e-01 | 2.18e-01 | 5.81e-01 | 5.41e-01 | 5.95e-01 |
| OLEFINIC COMPOUND BIOSYNTHETIC PROCESS | 28 | 7.59e-01 | 9.52e-01 | 0.1530 | -6.55e-02 | -4.57e-02 | -2.47e-02 | -5.30e-02 | -1.17e-01 | 5.49e-01 | 6.75e-01 | 8.21e-01 | 6.27e-01 | 2.85e-01 |
| NEGATIVE REGULATION OF SCHWANN CELL PROLIFERATION | 8 | 9.12e-01 | 9.85e-01 | 0.1530 | 2.95e-02 | -5.50e-03 | -1.61e-02 | 6.85e-02 | 1.33e-01 | 8.85e-01 | 9.78e-01 | 9.37e-01 | 7.37e-01 | 5.16e-01 |
| RENAL PROTEIN ABSORPTION | 7 | 8.73e-01 | 9.78e-01 | 0.1530 | -4.05e-02 | 4.76e-02 | -5.30e-02 | 9.52e-03 | -1.29e-01 | 8.53e-01 | 8.28e-01 | 8.08e-01 | 9.65e-01 | 5.55e-01 |
| POSITIVE REGULATION OF HEART GROWTH | 38 | 7.76e-01 | 9.58e-01 | 0.1530 | 5.50e-02 | 1.05e-01 | 7.80e-02 | 4.96e-02 | -2.73e-02 | 5.57e-01 | 2.61e-01 | 4.05e-01 | 5.96e-01 | 7.71e-01 |
| MULTICELLULAR ORGANISMAL LEVEL WATER HOMEOSTASIS | 33 | 1.78e-01 | 5.63e-01 | 0.1530 | -5.70e-02 | 2.46e-02 | 3.37e-02 | -1.18e-01 | 6.67e-02 | 5.71e-01 | 8.07e-01 | 7.37e-01 | 2.40e-01 | 5.07e-01 |
| NERVE DEVELOPMENT | 94 | 1.72e-01 | 5.56e-01 | 0.1530 | -4.81e-03 | 7.18e-02 | 8.53e-02 | 1.09e-02 | 1.04e-01 | 9.36e-01 | 2.29e-01 | 1.53e-01 | 8.56e-01 | 8.09e-02 |
| REGULATION OF OSTEOCLAST DIFFERENTIATION | 68 | 1.59e-01 | 5.34e-01 | 0.1530 | 6.90e-02 | 6.64e-02 | -5.53e-02 | -2.52e-02 | -1.03e-01 | 3.25e-01 | 3.44e-01 | 4.30e-01 | 7.19e-01 | 1.43e-01 |
| NEGATIVE REGULATION OF PROTEIN POLYMERIZATION | 75 | 7.74e-01 | 9.57e-01 | 0.1530 | -8.84e-02 | -6.69e-02 | -7.47e-02 | -7.40e-02 | -3.72e-04 | 1.86e-01 | 3.16e-01 | 2.63e-01 | 2.68e-01 | 9.96e-01 |
| CELLULAR RESPONSE TO MANGANESE ION | 10 | 8.44e-01 | 9.75e-01 | 0.1530 | 1.62e-02 | 1.07e-01 | 8.10e-03 | 3.67e-02 | -1.01e-01 | 9.29e-01 | 5.56e-01 | 9.65e-01 | 8.41e-01 | 5.82e-01 |
| ESTABLISHMENT OF GOLGI LOCALIZATION | 8 | 9.24e-01 | 9.89e-01 | 0.1530 | -2.05e-02 | -7.50e-02 | 5.33e-02 | -2.85e-03 | 1.20e-01 | 9.20e-01 | 7.13e-01 | 7.94e-01 | 9.89e-01 | 5.56e-01 |
| NEGATIVE REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 24 | 7.07e-01 | 9.34e-01 | 0.1530 | -4.25e-02 | -8.11e-02 | -4.19e-02 | -8.75e-02 | 7.45e-02 | 7.19e-01 | 4.92e-01 | 7.22e-01 | 4.58e-01 | 5.27e-01 |
| REGULATION OF CELL GROWTH | 399 | 7.15e-02 | 3.61e-01 | 0.1530 | 5.61e-02 | 8.40e-02 | 7.54e-02 | 6.57e-02 | 5.60e-02 | 5.45e-02 | 3.99e-03 | 9.74e-03 | 2.43e-02 | 5.48e-02 |
| AXONOGENESIS INVOLVED IN INNERVATION | 9 | 6.35e-01 | 9.12e-01 | 0.1530 | -1.52e-01 | -6.02e-03 | -2.52e-03 | 1.17e-02 | -1.13e-02 | 4.31e-01 | 9.75e-01 | 9.90e-01 | 9.51e-01 | 9.53e-01 |
| NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS | 27 | 4.97e-01 | 8.45e-01 | 0.1530 | 7.77e-02 | 1.18e-01 | 3.00e-02 | -3.81e-02 | -3.24e-02 | 4.85e-01 | 2.89e-01 | 7.87e-01 | 7.32e-01 | 7.71e-01 |
| RESPONSE TO ORGANOPHOSPHORUS | 121 | 4.79e-01 | 8.34e-01 | 0.1530 | 5.60e-02 | 9.12e-02 | 6.48e-02 | 6.85e-02 | 5.44e-02 | 2.88e-01 | 8.31e-02 | 2.18e-01 | 1.93e-01 | 3.01e-01 |
| THIAMINE TRANSPORT | 8 | 8.08e-01 | 9.67e-01 | 0.1530 | 3.73e-03 | 2.66e-02 | -3.73e-02 | 5.03e-02 | 1.37e-01 | 9.85e-01 | 8.96e-01 | 8.55e-01 | 8.05e-01 | 5.04e-01 |
| REGULATION OF LAMELLIPODIUM ASSEMBLY | 37 | 3.91e-01 | 7.82e-01 | 0.1530 | -8.44e-02 | -1.20e-01 | -3.43e-02 | 2.34e-02 | 9.98e-03 | 3.74e-01 | 2.08e-01 | 7.18e-01 | 8.05e-01 | 9.16e-01 |
| POSITIVE REGULATION OF AUTOPHAGY OF MITOCHONDRION | 14 | 8.84e-01 | 9.80e-01 | 0.1520 | 2.79e-02 | -5.47e-02 | -1.13e-01 | -1.28e-02 | -8.02e-02 | 8.56e-01 | 7.23e-01 | 4.62e-01 | 9.34e-01 | 6.03e-01 |
| POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 1246 | 5.03e-06 | 2.01e-04 | 0.1520 | 8.58e-02 | 6.83e-02 | 5.58e-02 | 7.94e-02 | 4.21e-02 | 3.46e-07 | 4.91e-05 | 9.13e-04 | 2.38e-06 | 1.24e-02 |
| OSSIFICATION | 425 | 2.53e-03 | 3.66e-02 | 0.1520 | 2.71e-02 | 8.00e-02 | 7.83e-02 | 5.43e-02 | 8.35e-02 | 3.37e-01 | 4.67e-03 | 5.65e-03 | 5.47e-02 | 3.14e-03 |
| REGULATION OF BLOOD BRAIN BARRIER PERMEABILITY | 9 | 9.83e-01 | 9.96e-01 | 0.1520 | -7.31e-02 | -4.29e-02 | -3.12e-02 | -9.51e-02 | -7.74e-02 | 7.04e-01 | 8.24e-01 | 8.71e-01 | 6.21e-01 | 6.88e-01 |
| PYRIMIDINE CONTAINING COMPOUND TRANSMEMBRANE TRANSPORT | 16 | 8.10e-01 | 9.68e-01 | 0.1520 | -4.58e-03 | -4.35e-02 | -1.31e-01 | -6.16e-02 | -2.07e-02 | 9.75e-01 | 7.63e-01 | 3.66e-01 | 6.70e-01 | 8.86e-01 |
| REGULATION OF SEQUESTERING OF TRIGLYCERIDE | 15 | 9.27e-01 | 9.89e-01 | 0.1520 | 8.97e-02 | 9.06e-02 | 9.45e-03 | 8.02e-02 | -1.73e-02 | 5.48e-01 | 5.44e-01 | 9.49e-01 | 5.90e-01 | 9.08e-01 |
| CELL MATRIX ADHESION | 232 | 1.96e-01 | 5.84e-01 | 0.1520 | -6.77e-02 | -5.82e-02 | -8.94e-02 | -6.53e-02 | -5.34e-02 | 7.58e-02 | 1.27e-01 | 1.89e-02 | 8.67e-02 | 1.61e-01 |
| CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 89 | 2.46e-01 | 6.51e-01 | 0.1520 | 6.53e-02 | 5.63e-02 | 3.83e-02 | 1.07e-01 | 5.31e-02 | 2.87e-01 | 3.58e-01 | 5.32e-01 | 8.24e-02 | 3.86e-01 |
| STEROID METABOLIC PROCESS | 315 | 1.48e-01 | 5.15e-01 | 0.1520 | -8.35e-02 | -6.37e-02 | -7.51e-02 | -7.18e-02 | -3.49e-02 | 1.08e-02 | 5.18e-02 | 2.19e-02 | 2.83e-02 | 2.87e-01 |
| REGULATION OF SYNAPTIC VESICLE EXOCYTOSIS | 38 | 6.23e-01 | 9.09e-01 | 0.1520 | -5.10e-02 | -7.93e-02 | -7.58e-02 | -5.66e-02 | 7.22e-02 | 5.86e-01 | 3.98e-01 | 4.19e-01 | 5.46e-01 | 4.41e-01 |
| TISSUE MORPHOGENESIS | 620 | 6.24e-04 | 1.21e-02 | 0.1520 | 3.04e-02 | 5.73e-02 | 7.10e-02 | 6.02e-02 | 1.01e-01 | 1.96e-01 | 1.49e-02 | 2.54e-03 | 1.05e-02 | 1.79e-05 |
| NEGATIVE REGULATION OF ALPHA BETA T CELL PROLIFERATION | 13 | 6.03e-01 | 9.01e-01 | 0.1520 | 5.96e-02 | -8.61e-02 | 3.98e-02 | 6.65e-02 | 7.75e-02 | 7.10e-01 | 5.91e-01 | 8.04e-01 | 6.78e-01 | 6.29e-01 |
| VISUAL BEHAVIOR | 55 | 4.36e-01 | 8.09e-01 | 0.1520 | -3.23e-02 | -3.10e-02 | 1.40e-02 | 2.57e-03 | 1.44e-01 | 6.78e-01 | 6.91e-01 | 8.57e-01 | 9.74e-01 | 6.45e-02 |
| NEGATIVE REGULATION OF BMP SIGNALING PATHWAY | 67 | 3.84e-01 | 7.79e-01 | 0.1520 | -1.16e-01 | -7.38e-02 | -1.35e-02 | -2.96e-02 | 5.53e-02 | 1.01e-01 | 2.96e-01 | 8.48e-01 | 6.75e-01 | 4.34e-01 |
| GLUTATHIONE TRANSPORT | 9 | 8.81e-01 | 9.79e-01 | 0.1510 | -1.27e-02 | -9.32e-03 | -1.14e-01 | 4.24e-03 | -9.83e-02 | 9.47e-01 | 9.61e-01 | 5.54e-01 | 9.82e-01 | 6.10e-01 |
| POSITIVE REGULATION OF ENDOCYTOSIS | 149 | 1.24e-02 | 1.19e-01 | 0.1510 | -7.32e-03 | 1.07e-02 | -8.32e-02 | -1.01e-01 | -7.45e-02 | 8.77e-01 | 8.22e-01 | 7.97e-02 | 3.27e-02 | 1.16e-01 |
| ETHANOL CATABOLIC PROCESS | 10 | 9.82e-01 | 9.96e-01 | 0.1510 | 9.92e-02 | 4.74e-02 | 3.55e-02 | 6.15e-02 | -7.56e-02 | 5.87e-01 | 7.95e-01 | 8.46e-01 | 7.36e-01 | 6.79e-01 |
| REGULATION OF ADAPTIVE IMMUNE RESPONSE | 201 | 2.93e-01 | 7.04e-01 | 0.1510 | 7.82e-02 | 7.63e-02 | 5.51e-02 | 8.75e-02 | 1.44e-02 | 5.59e-02 | 6.21e-02 | 1.78e-01 | 3.24e-02 | 7.25e-01 |
| CARDIAC MUSCLE CONTRACTION | 131 | 5.51e-02 | 3.11e-01 | 0.1510 | -9.59e-02 | -2.25e-02 | -3.88e-02 | -1.06e-01 | 1.91e-02 | 5.79e-02 | 6.57e-01 | 4.44e-01 | 3.61e-02 | 7.06e-01 |
| NEGATIVE REGULATION OF INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 32 | 2.00e-01 | 5.91e-01 | 0.1510 | 4.20e-02 | 8.59e-02 | -5.55e-02 | -9.47e-02 | -4.01e-02 | 6.81e-01 | 4.00e-01 | 5.87e-01 | 3.54e-01 | 6.94e-01 |
| OSTEOCLAST DIFFERENTIATION | 103 | 5.03e-02 | 2.93e-01 | 0.1510 | 7.00e-02 | 6.77e-02 | -4.88e-02 | -6.82e-04 | -1.04e-01 | 2.19e-01 | 2.35e-01 | 3.92e-01 | 9.90e-01 | 6.70e-02 |
| MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 129 | 6.20e-01 | 9.07e-01 | 0.1510 | 4.82e-02 | 4.88e-02 | 7.69e-02 | 8.46e-02 | 7.07e-02 | 3.45e-01 | 3.39e-01 | 1.31e-01 | 9.71e-02 | 1.66e-01 |
| MACROPHAGE DIFFERENTIATION | 61 | 4.84e-01 | 8.38e-01 | 0.1510 | 8.43e-02 | 1.06e-01 | 4.15e-02 | 1.71e-02 | -4.91e-02 | 2.55e-01 | 1.53e-01 | 5.75e-01 | 8.17e-01 | 5.07e-01 |
| PROTEIN TARGETING TO VACUOLE INVOLVED IN AUTOPHAGY | 5 | 8.78e-01 | 9.79e-01 | 0.1510 | -4.19e-02 | -6.11e-04 | 4.17e-02 | 1.36e-01 | -2.93e-02 | 8.71e-01 | 9.98e-01 | 8.72e-01 | 5.99e-01 | 9.10e-01 |
| PHAGOCYTOSIS | 230 | 2.59e-03 | 3.74e-02 | 0.1510 | 9.28e-02 | 8.31e-02 | -9.07e-03 | 2.09e-02 | -8.19e-02 | 1.53e-02 | 2.99e-02 | 8.13e-01 | 5.86e-01 | 3.23e-02 |
| POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 401 | 7.33e-02 | 3.66e-01 | 0.1510 | 7.20e-02 | 7.93e-02 | 5.99e-02 | 7.54e-02 | 4.43e-02 | 1.33e-02 | 6.38e-03 | 3.95e-02 | 9.57e-03 | 1.27e-01 |
| REGULATION OF THE FORCE OF HEART CONTRACTION | 26 | 8.18e-01 | 9.70e-01 | 0.1510 | -1.06e-01 | -4.50e-02 | 2.73e-03 | -7.99e-02 | 5.58e-02 | 3.51e-01 | 6.91e-01 | 9.81e-01 | 4.80e-01 | 6.22e-01 |
| RESPONSE TO LIPID | 893 | 2.61e-05 | 8.93e-04 | 0.1510 | 6.86e-02 | 8.96e-02 | 5.80e-02 | 5.98e-02 | 5.51e-02 | 5.05e-04 | 5.55e-06 | 3.25e-03 | 2.41e-03 | 5.21e-03 |
| POTASSIUM ION TRANSPORT | 234 | 1.07e-03 | 1.85e-02 | 0.1510 | -7.35e-02 | -3.98e-02 | -3.53e-02 | -1.20e-01 | -5.22e-03 | 5.26e-02 | 2.95e-01 | 3.52e-01 | 1.55e-03 | 8.90e-01 |
| OTIC VESICLE FORMATION | 8 | 9.63e-01 | 9.94e-01 | 0.1510 | 9.34e-02 | 1.10e-01 | -1.36e-02 | 2.49e-02 | -3.23e-02 | 6.47e-01 | 5.90e-01 | 9.47e-01 | 9.03e-01 | 8.74e-01 |
| CELLULAR EXTRAVASATION | 71 | 1.21e-01 | 4.75e-01 | 0.1510 | 9.38e-02 | 6.95e-02 | -4.56e-02 | 3.10e-02 | -7.75e-02 | 1.72e-01 | 3.11e-01 | 5.06e-01 | 6.52e-01 | 2.59e-01 |
| VESICLE FUSION TO PLASMA MEMBRANE | 24 | 3.17e-01 | 7.27e-01 | 0.1510 | 1.10e-02 | 8.94e-02 | 1.11e-01 | -4.24e-02 | 1.82e-02 | 9.26e-01 | 4.48e-01 | 3.45e-01 | 7.19e-01 | 8.78e-01 |
| POSITIVE REGULATION OF SYNAPSE MATURATION | 9 | 9.87e-01 | 9.97e-01 | 0.1500 | 9.96e-02 | 5.41e-02 | 7.35e-02 | 5.14e-02 | 4.15e-02 | 6.05e-01 | 7.79e-01 | 7.02e-01 | 7.89e-01 | 8.29e-01 |
| RESPONSE TO PLATELET DERIVED GROWTH FACTOR | 21 | 3.75e-01 | 7.74e-01 | 0.1500 | 5.57e-02 | 1.20e-01 | -3.41e-02 | 4.45e-02 | -4.58e-02 | 6.59e-01 | 3.43e-01 | 7.87e-01 | 7.24e-01 | 7.16e-01 |
| VIRAL PROTEIN PROCESSING | 31 | 6.20e-01 | 9.07e-01 | 0.1500 | 1.58e-03 | -2.81e-02 | 2.90e-02 | 8.31e-02 | 1.18e-01 | 9.88e-01 | 7.87e-01 | 7.80e-01 | 4.23e-01 | 2.54e-01 |
| REGULATION OF DENDRITIC SPINE MORPHOGENESIS | 39 | 8.82e-01 | 9.79e-01 | 0.1500 | -8.91e-02 | -6.31e-02 | -5.75e-02 | -5.28e-02 | -6.75e-02 | 3.36e-01 | 4.95e-01 | 5.34e-01 | 5.68e-01 | 4.66e-01 |
| G PROTEIN COUPLED PURINERGIC NUCLEOTIDE RECEPTOR SIGNALING PATHWAY | 10 | 8.46e-01 | 9.76e-01 | 0.1500 | -7.26e-02 | -8.75e-02 | 2.08e-03 | 2.60e-02 | -9.46e-02 | 6.91e-01 | 6.32e-01 | 9.91e-01 | 8.87e-01 | 6.04e-01 |
| REGULATION OF NEURON PROJECTION ARBORIZATION | 14 | 8.88e-01 | 9.80e-01 | 0.1500 | -8.62e-02 | -2.79e-03 | -2.88e-03 | -3.81e-02 | 1.17e-01 | 5.77e-01 | 9.86e-01 | 9.85e-01 | 8.05e-01 | 4.49e-01 |
| IRON ION TRANSPORT | 53 | 6.12e-01 | 9.04e-01 | 0.1500 | 8.47e-02 | 6.93e-02 | 2.70e-02 | 9.86e-02 | -1.04e-02 | 2.86e-01 | 3.83e-01 | 7.34e-01 | 2.14e-01 | 8.96e-01 |
| INORGANIC ANION TRANSPORT | 162 | 1.76e-01 | 5.61e-01 | 0.1500 | -8.18e-02 | -4.16e-02 | -4.84e-02 | -1.00e-01 | -4.11e-02 | 7.24e-02 | 3.60e-01 | 2.88e-01 | 2.75e-02 | 3.66e-01 |
| STRESS FIBER ASSEMBLY | 108 | 4.52e-01 | 8.21e-01 | 0.1500 | 9.04e-02 | 6.05e-02 | 4.20e-02 | 7.60e-02 | 5.62e-02 | 1.05e-01 | 2.78e-01 | 4.51e-01 | 1.72e-01 | 3.13e-01 |
| REGULATION OF SMOOTH MUSCLE CONTRACTION | 61 | 8.37e-01 | 9.73e-01 | 0.1500 | 3.64e-02 | 6.05e-02 | 9.76e-02 | 6.52e-02 | 6.13e-02 | 6.23e-01 | 4.14e-01 | 1.87e-01 | 3.79e-01 | 4.07e-01 |
| FACIAL NERVE MORPHOGENESIS | 9 | 8.83e-01 | 9.80e-01 | 0.1500 | -3.77e-02 | 1.02e-01 | 9.64e-02 | 1.21e-02 | 3.38e-02 | 8.45e-01 | 5.95e-01 | 6.16e-01 | 9.50e-01 | 8.61e-01 |
| REGULATION OF CYCLASE ACTIVITY | 53 | 3.07e-01 | 7.19e-01 | 0.1500 | -1.01e-01 | -2.46e-03 | -4.81e-02 | -8.63e-02 | -4.93e-02 | 2.01e-01 | 9.75e-01 | 5.44e-01 | 2.77e-01 | 5.34e-01 |
| NEUTROPHIL MIGRATION | 121 | 7.07e-03 | 7.96e-02 | 0.1500 | 7.63e-02 | 7.34e-02 | -4.34e-02 | -4.27e-02 | -8.70e-02 | 1.47e-01 | 1.63e-01 | 4.09e-01 | 4.17e-01 | 9.85e-02 |
| MUSCLE CELL APOPTOTIC PROCESS | 91 | 6.00e-01 | 8.98e-01 | 0.1500 | 8.95e-02 | 8.30e-02 | 5.79e-02 | 5.50e-02 | -3.47e-02 | 1.40e-01 | 1.71e-01 | 3.39e-01 | 3.65e-01 | 5.67e-01 |
| SKIN EPIDERMIS DEVELOPMENT | 125 | 3.41e-01 | 7.48e-01 | 0.1500 | 4.85e-02 | 7.65e-02 | 6.39e-02 | 8.97e-02 | 4.60e-02 | 3.49e-01 | 1.39e-01 | 2.17e-01 | 8.32e-02 | 3.74e-01 |
| CEREBRAL CORTEX CELL MIGRATION | 46 | 8.11e-01 | 9.68e-01 | 0.1500 | 9.80e-02 | 4.06e-02 | 5.51e-02 | 8.93e-02 | 1.18e-02 | 2.50e-01 | 6.34e-01 | 5.18e-01 | 2.94e-01 | 8.90e-01 |
| ESTABLISHMENT OF ENDOTHELIAL BARRIER | 51 | 3.65e-01 | 7.65e-01 | 0.1500 | 1.20e-01 | 5.96e-02 | 2.70e-02 | 3.82e-02 | 4.77e-02 | 1.38e-01 | 4.62e-01 | 7.39e-01 | 6.37e-01 | 5.55e-01 |
| POSITIVE REGULATION OF COAGULATION | 30 | 6.94e-01 | 9.31e-01 | 0.1500 | 5.78e-02 | 8.34e-02 | 6.06e-02 | 2.27e-02 | -8.90e-02 | 5.84e-01 | 4.29e-01 | 5.66e-01 | 8.30e-01 | 3.99e-01 |
| NEURON CELLULAR HOMEOSTASIS | 59 | 6.06e-01 | 9.01e-01 | 0.1500 | 5.17e-02 | 8.72e-02 | 6.97e-02 | 8.05e-02 | -2.77e-02 | 4.92e-01 | 2.46e-01 | 3.54e-01 | 2.85e-01 | 7.13e-01 |
| CELLULAR RESPONSE TO LEPTIN STIMULUS | 17 | 7.44e-01 | 9.50e-01 | 0.1500 | 9.52e-02 | 4.17e-02 | 5.01e-02 | 6.05e-03 | 9.51e-02 | 4.97e-01 | 7.66e-01 | 7.20e-01 | 9.66e-01 | 4.97e-01 |
| HEPARAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS | 32 | 5.13e-01 | 8.55e-01 | 0.1500 | -4.12e-02 | 2.92e-04 | -1.11e-01 | -6.00e-02 | -6.90e-02 | 6.87e-01 | 9.98e-01 | 2.77e-01 | 5.57e-01 | 4.99e-01 |
| NEGATIVE REGULATION OF ADAPTIVE IMMUNE RESPONSE | 62 | 8.29e-01 | 9.72e-01 | 0.1500 | -5.48e-02 | -8.59e-02 | -7.25e-02 | -4.32e-02 | -6.98e-02 | 4.55e-01 | 2.42e-01 | 3.23e-01 | 5.56e-01 | 3.42e-01 |
| AMINO ACID IMPORT ACROSS PLASMA MEMBRANE | 44 | 8.28e-01 | 9.72e-01 | 0.1490 | 1.48e-02 | 5.29e-02 | 8.85e-02 | 8.05e-02 | 7.08e-02 | 8.65e-01 | 5.44e-01 | 3.10e-01 | 3.56e-01 | 4.17e-01 |
| POSITIVE REGULATION OF FEAR RESPONSE | 6 | 9.51e-01 | 9.94e-01 | 0.1490 | 3.37e-02 | -3.99e-02 | 8.65e-02 | 1.09e-01 | 1.76e-02 | 8.86e-01 | 8.66e-01 | 7.14e-01 | 6.45e-01 | 9.40e-01 |
| REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 155 | 5.79e-01 | 8.86e-01 | 0.1490 | 5.47e-02 | 6.25e-02 | 7.64e-02 | 5.79e-02 | 7.87e-02 | 2.40e-01 | 1.79e-01 | 1.01e-01 | 2.14e-01 | 9.09e-02 |
| APOPTOTIC CELL CLEARANCE | 47 | 6.47e-01 | 9.17e-01 | 0.1490 | 6.89e-02 | 7.47e-02 | 4.97e-02 | 4.56e-02 | -8.59e-02 | 4.14e-01 | 3.76e-01 | 5.56e-01 | 5.89e-01 | 3.08e-01 |
| REGULATION OF RNA EXPORT FROM NUCLEUS | 13 | 5.62e-01 | 8.79e-01 | 0.1490 | 8.86e-02 | -4.63e-02 | -5.07e-02 | 2.17e-02 | 9.58e-02 | 5.80e-01 | 7.73e-01 | 7.52e-01 | 8.92e-01 | 5.50e-01 |
| MORPHOGENESIS OF AN EPITHELIAL SHEET | 59 | 4.24e-01 | 8.03e-01 | 0.1490 | -6.24e-02 | -7.93e-02 | -7.90e-02 | -4.48e-02 | 6.16e-02 | 4.07e-01 | 2.92e-01 | 2.94e-01 | 5.52e-01 | 4.13e-01 |
| RIBONUCLEOSIDE METABOLIC PROCESS | 34 | 5.75e-01 | 8.84e-01 | 0.1490 | 7.35e-02 | 4.02e-03 | -6.12e-02 | -3.39e-02 | -1.09e-01 | 4.58e-01 | 9.68e-01 | 5.37e-01 | 7.32e-01 | 2.71e-01 |
| L METHIONINE SALVAGE FROM METHYLTHIOADENOSINE | 5 | 9.77e-01 | 9.96e-01 | 0.1490 | -8.30e-02 | 3.95e-02 | 5.14e-02 | -5.16e-02 | 9.19e-02 | 7.48e-01 | 8.79e-01 | 8.42e-01 | 8.42e-01 | 7.22e-01 |
| REGULATION OF NEUROGENESIS | 373 | 1.11e-02 | 1.09e-01 | 0.1490 | 1.60e-02 | 3.52e-02 | 7.11e-02 | 4.89e-02 | 1.15e-01 | 5.95e-01 | 2.43e-01 | 1.83e-02 | 1.05e-01 | 1.36e-04 |
| MICROTUBULE POLYMERIZATION | 91 | 6.60e-01 | 9.21e-01 | 0.1490 | 6.86e-02 | 5.76e-02 | 5.32e-02 | 9.17e-02 | 5.38e-02 | 2.58e-01 | 3.42e-01 | 3.80e-01 | 1.31e-01 | 3.75e-01 |
| VESICLE DOCKING | 64 | 7.58e-01 | 9.52e-01 | 0.1490 | 4.35e-02 | 7.98e-02 | 6.43e-02 | 4.55e-02 | 8.76e-02 | 5.47e-01 | 2.69e-01 | 3.74e-01 | 5.29e-01 | 2.26e-01 |
| GONADOTROPIN SECRETION | 17 | 6.70e-01 | 9.25e-01 | 0.1490 | 4.07e-02 | 2.59e-02 | -7.30e-02 | -1.09e-01 | -5.18e-02 | 7.72e-01 | 8.53e-01 | 6.02e-01 | 4.38e-01 | 7.11e-01 |
| NEGATIVE REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 57 | 2.79e-01 | 6.89e-01 | 0.1490 | -1.05e-01 | -1.02e-01 | 5.14e-03 | -1.25e-02 | 2.23e-02 | 1.70e-01 | 1.83e-01 | 9.47e-01 | 8.70e-01 | 7.71e-01 |
| POLYSACCHARIDE CATABOLIC PROCESS | 21 | 6.68e-01 | 9.25e-01 | 0.1490 | 4.81e-02 | 4.67e-03 | 4.38e-02 | 5.59e-02 | -1.21e-01 | 7.03e-01 | 9.70e-01 | 7.28e-01 | 6.57e-01 | 3.36e-01 |
| GROWTH | 887 | 2.05e-03 | 3.11e-02 | 0.1480 | 5.17e-02 | 6.97e-02 | 7.73e-02 | 6.19e-02 | 6.86e-02 | 9.01e-03 | 4.26e-04 | 9.30e-05 | 1.75e-03 | 5.22e-04 |
| POSITIVE REGULATION OF CHOLESTEROL METABOLIC PROCESS | 15 | 5.48e-01 | 8.73e-01 | 0.1480 | -4.74e-02 | 9.45e-02 | 5.97e-02 | -8.40e-02 | 1.51e-02 | 7.51e-01 | 5.26e-01 | 6.89e-01 | 5.73e-01 | 9.20e-01 |
| INOSITOL TRISPHOSPHATE METABOLIC PROCESS | 12 | 9.29e-01 | 9.89e-01 | 0.1480 | 4.12e-02 | -1.33e-02 | 5.77e-02 | 1.21e-01 | 4.78e-02 | 8.05e-01 | 9.36e-01 | 7.29e-01 | 4.69e-01 | 7.74e-01 |
| NOTCH RECEPTOR PROCESSING | 9 | 9.51e-01 | 9.94e-01 | 0.1480 | -3.51e-02 | -9.56e-02 | -3.46e-02 | 7.81e-03 | 1.02e-01 | 8.55e-01 | 6.20e-01 | 8.57e-01 | 9.68e-01 | 5.96e-01 |
| POSITIVE REGULATION OF MAST CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 13 | 9.47e-01 | 9.94e-01 | 0.1480 | 7.97e-02 | 8.92e-02 | 3.44e-02 | 2.59e-03 | -8.08e-02 | 6.19e-01 | 5.78e-01 | 8.30e-01 | 9.87e-01 | 6.14e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO MEMBRANE | 34 | 6.08e-01 | 9.03e-01 | 0.1480 | 6.13e-02 | 4.59e-02 | 6.26e-02 | 5.69e-02 | -9.48e-02 | 5.36e-01 | 6.43e-01 | 5.28e-01 | 5.66e-01 | 3.39e-01 |
| SMOOTH MUSCLE CELL PROLIFERATION | 160 | 3.71e-01 | 7.71e-01 | 0.1480 | 5.84e-02 | 9.75e-02 | 7.08e-02 | 5.73e-02 | 2.79e-02 | 2.03e-01 | 3.34e-02 | 1.22e-01 | 2.11e-01 | 5.43e-01 |
| SKIN MORPHOGENESIS | 13 | 7.78e-01 | 9.58e-01 | 0.1480 | -8.01e-02 | 1.67e-02 | 1.61e-02 | -7.61e-02 | -9.61e-02 | 6.17e-01 | 9.17e-01 | 9.20e-01 | 6.35e-01 | 5.48e-01 |
| LOCALIZATION WITHIN MEMBRANE | 657 | 1.90e-02 | 1.61e-01 | 0.1480 | 6.29e-02 | 6.05e-02 | 7.13e-02 | 8.29e-02 | 4.88e-02 | 5.92e-03 | 8.12e-03 | 1.83e-03 | 2.88e-04 | 3.30e-02 |
| POSITIVE REGULATION OF GLUCOSE TRANSMEMBRANE TRANSPORT | 42 | 6.64e-02 | 3.44e-01 | 0.1480 | -1.29e-01 | 2.77e-03 | -5.45e-02 | -4.77e-02 | 1.09e-02 | 1.49e-01 | 9.75e-01 | 5.41e-01 | 5.92e-01 | 9.03e-01 |
| NEGATIVE REGULATION OF ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 32 | 9.30e-01 | 9.90e-01 | 0.1480 | 7.20e-02 | 9.03e-02 | 5.42e-02 | 6.79e-02 | -3.25e-02 | 4.81e-01 | 3.77e-01 | 5.96e-01 | 5.06e-01 | 7.51e-01 |
| ESTABLISHMENT OF TISSUE POLARITY | 67 | 3.18e-01 | 7.30e-01 | 0.1480 | -5.49e-02 | -4.67e-02 | 5.68e-03 | 1.25e-02 | 1.28e-01 | 4.37e-01 | 5.09e-01 | 9.36e-01 | 8.60e-01 | 6.93e-02 |
| NON CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 140 | 1.17e-01 | 4.66e-01 | 0.1480 | 1.13e-01 | 7.76e-02 | 1.75e-02 | 5.30e-02 | -2.80e-03 | 2.13e-02 | 1.13e-01 | 7.20e-01 | 2.79e-01 | 9.54e-01 |
| ESTABLISHMENT OF SKIN BARRIER | 33 | 3.08e-01 | 7.19e-01 | 0.1480 | 6.67e-03 | 1.30e-01 | 6.67e-02 | -1.37e-02 | -1.20e-02 | 9.47e-01 | 1.95e-01 | 5.07e-01 | 8.92e-01 | 9.05e-01 |
| GLUTAMATE RECEPTOR SIGNALING PATHWAY | 47 | 6.05e-01 | 9.01e-01 | 0.1480 | -9.34e-02 | -1.88e-02 | -5.20e-02 | -1.00e-01 | 1.21e-03 | 2.68e-01 | 8.24e-01 | 5.37e-01 | 2.34e-01 | 9.89e-01 |
| REGULATION OF CATION CHANNEL ACTIVITY | 115 | 1.84e-01 | 5.71e-01 | 0.1480 | -8.96e-02 | -4.84e-02 | -3.28e-02 | -6.14e-02 | 8.13e-02 | 9.70e-02 | 3.70e-01 | 5.43e-01 | 2.56e-01 | 1.32e-01 |
| PROTEIN K48 LINKED DEUBIQUITINATION | 25 | 4.77e-01 | 8.33e-01 | 0.1480 | -5.78e-02 | -9.30e-02 | 2.01e-02 | 7.37e-02 | 6.31e-02 | 6.17e-01 | 4.21e-01 | 8.62e-01 | 5.23e-01 | 5.85e-01 |
| POTASSIUM ION HOMEOSTASIS | 34 | 3.73e-01 | 7.72e-01 | 0.1480 | -6.13e-03 | 4.65e-02 | 1.19e-01 | -5.34e-03 | 7.29e-02 | 9.51e-01 | 6.39e-01 | 2.28e-01 | 9.57e-01 | 4.62e-01 |
| POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE ACTIVITY | 14 | 9.68e-01 | 9.94e-01 | 0.1480 | -2.76e-02 | -6.09e-03 | 4.59e-02 | 3.15e-02 | 1.34e-01 | 8.58e-01 | 9.69e-01 | 7.66e-01 | 8.38e-01 | 3.86e-01 |
| POSITIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 30 | 9.55e-01 | 9.94e-01 | 0.1480 | -5.85e-02 | -8.14e-02 | -7.17e-02 | -3.82e-02 | -7.18e-02 | 5.79e-01 | 4.40e-01 | 4.97e-01 | 7.18e-01 | 4.96e-01 |
| CELL CELL JUNCTION ORGANIZATION | 208 | 2.04e-01 | 5.96e-01 | 0.1480 | -7.75e-02 | -5.21e-02 | -7.51e-02 | -6.13e-02 | -6.06e-02 | 5.39e-02 | 1.95e-01 | 6.19e-02 | 1.28e-01 | 1.32e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 37 | 2.07e-01 | 6.02e-01 | 0.1480 | 3.99e-02 | -7.67e-02 | -9.11e-02 | 4.50e-02 | -6.30e-02 | 6.74e-01 | 4.19e-01 | 3.37e-01 | 6.36e-01 | 5.07e-01 |
| LUNG ALVEOLUS DEVELOPMENT | 47 | 4.14e-01 | 7.98e-01 | 0.1480 | -7.10e-02 | -4.22e-02 | 6.52e-02 | 2.72e-02 | 9.98e-02 | 4.00e-01 | 6.17e-01 | 4.39e-01 | 7.47e-01 | 2.36e-01 |
| VIRAL TRANSLATION | 20 | 8.81e-01 | 9.79e-01 | 0.1470 | 1.05e-02 | -2.94e-02 | 3.66e-02 | 5.21e-02 | 1.29e-01 | 9.35e-01 | 8.20e-01 | 7.77e-01 | 6.86e-01 | 3.17e-01 |
| POSTSYNAPTIC SPECIALIZATION ORGANIZATION | 41 | 5.18e-01 | 8.57e-01 | 0.1470 | -8.90e-02 | -5.68e-03 | 2.77e-02 | -2.30e-02 | 1.12e-01 | 3.24e-01 | 9.50e-01 | 7.59e-01 | 7.99e-01 | 2.16e-01 |
| REGULATION OF HORMONE SECRETION | 248 | 1.08e-01 | 4.51e-01 | 0.1470 | 7.73e-02 | 9.72e-02 | 5.34e-02 | 4.86e-02 | 3.31e-02 | 3.60e-02 | 8.41e-03 | 1.48e-01 | 1.88e-01 | 3.70e-01 |
| CELL CELL JUNCTION MAINTENANCE | 18 | 5.06e-01 | 8.52e-01 | 0.1470 | -3.64e-02 | 7.45e-02 | -2.54e-02 | -1.18e-01 | 1.56e-02 | 7.89e-01 | 5.84e-01 | 8.52e-01 | 3.87e-01 | 9.09e-01 |
| PARENTAL BEHAVIOR | 10 | 7.91e-01 | 9.63e-01 | 0.1470 | 5.66e-02 | 2.41e-02 | 1.08e-01 | -8.05e-03 | 7.82e-02 | 7.57e-01 | 8.95e-01 | 5.55e-01 | 9.65e-01 | 6.69e-01 |
| REGULATION OF MRNA CATABOLIC PROCESS | 240 | 5.42e-03 | 6.53e-02 | 0.1470 | 4.42e-02 | -1.86e-03 | 5.62e-02 | 9.19e-02 | 8.95e-02 | 2.38e-01 | 9.60e-01 | 1.34e-01 | 1.42e-02 | 1.69e-02 |
| POSITIVE REGULATION OF NITRIC OXIDE METABOLIC PROCESS | 38 | 4.16e-01 | 7.99e-01 | 0.1470 | 6.44e-02 | 8.43e-02 | -4.92e-02 | -1.47e-02 | -8.74e-02 | 4.92e-01 | 3.68e-01 | 6.00e-01 | 8.75e-01 | 3.51e-01 |
| PURINE CONTAINING COMPOUND METABOLIC PROCESS | 460 | 3.19e-02 | 2.26e-01 | 0.1470 | 6.62e-02 | 6.94e-02 | 6.54e-02 | 5.36e-02 | 7.20e-02 | 1.50e-02 | 1.07e-02 | 1.63e-02 | 4.89e-02 | 8.10e-03 |
| FEAR RESPONSE | 43 | 7.82e-01 | 9.60e-01 | 0.1460 | -1.07e-02 | 4.73e-02 | 8.49e-02 | 4.60e-02 | 9.88e-02 | 9.03e-01 | 5.92e-01 | 3.35e-01 | 6.02e-01 | 2.62e-01 |
| REGULATION OF T CELL MEDIATED CYTOTOXICITY | 50 | 6.46e-02 | 3.38e-01 | 0.1460 | -2.90e-02 | -8.99e-03 | 7.12e-02 | 1.22e-01 | 2.41e-02 | 7.23e-01 | 9.12e-01 | 3.84e-01 | 1.36e-01 | 7.68e-01 |
| CELLULAR LIPID CATABOLIC PROCESS | 220 | 9.76e-02 | 4.26e-01 | 0.1460 | 8.30e-02 | 9.05e-02 | 4.79e-02 | 4.33e-02 | 4.61e-02 | 3.38e-02 | 2.07e-02 | 2.21e-01 | 2.68e-01 | 2.39e-01 |
| NEGATIVE REGULATION OF CELL ACTIVATION | 217 | 1.57e-01 | 5.28e-01 | 0.1460 | 9.73e-02 | 7.19e-02 | 3.62e-02 | 7.23e-02 | 1.13e-02 | 1.35e-02 | 6.78e-02 | 3.58e-01 | 6.65e-02 | 7.75e-01 |
| RETROGRADE TRANSPORT VESICLE RECYCLING WITHIN GOLGI | 9 | 8.85e-01 | 9.80e-01 | 0.1460 | 9.13e-02 | -3.74e-02 | 6.62e-03 | 6.05e-02 | -8.86e-02 | 6.35e-01 | 8.46e-01 | 9.73e-01 | 7.53e-01 | 6.45e-01 |
| REGULATION OF DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 382 | 4.30e-02 | 2.69e-01 | 0.1460 | 9.02e-02 | 6.15e-02 | 5.17e-02 | 7.07e-02 | 4.10e-02 | 2.45e-03 | 3.92e-02 | 8.30e-02 | 1.76e-02 | 1.69e-01 |
| ACTIN FILAMENT DEPOLYMERIZATION | 58 | 7.73e-01 | 9.57e-01 | 0.1460 | -9.26e-02 | -6.30e-02 | -7.29e-02 | -5.66e-02 | -1.49e-02 | 2.23e-01 | 4.06e-01 | 3.37e-01 | 4.56e-01 | 8.45e-01 |
| REGULATION OF LAMELLIPODIUM ORGANIZATION | 49 | 5.19e-01 | 8.57e-01 | 0.1460 | -8.04e-02 | -1.05e-01 | -5.44e-02 | -3.14e-03 | -2.66e-02 | 3.30e-01 | 2.02e-01 | 5.10e-01 | 9.70e-01 | 7.47e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CELL PERIPHERY | 129 | 6.03e-01 | 9.01e-01 | 0.1460 | 6.48e-02 | 6.09e-02 | 6.47e-02 | 9.21e-02 | 2.57e-02 | 2.03e-01 | 2.32e-01 | 2.04e-01 | 7.09e-02 | 6.14e-01 |
| ACTIVATION OF INNATE IMMUNE RESPONSE | 263 | 9.20e-03 | 9.57e-02 | 0.1460 | 1.14e-01 | 6.31e-02 | 2.72e-02 | 5.87e-02 | 3.28e-03 | 1.42e-03 | 7.80e-02 | 4.48e-01 | 1.01e-01 | 9.27e-01 |
| INTERMEMBRANE LIPID TRANSFER | 54 | 2.83e-01 | 6.93e-01 | 0.1460 | -1.20e-01 | -4.14e-02 | 2.09e-02 | -6.19e-02 | 2.71e-02 | 1.26e-01 | 5.99e-01 | 7.91e-01 | 4.31e-01 | 7.31e-01 |
| POSITIVE REGULATION OF CATABOLIC PROCESS | 575 | 5.23e-03 | 6.33e-02 | 0.1460 | 6.59e-02 | 4.76e-02 | 6.18e-02 | 9.20e-02 | 4.79e-02 | 6.88e-03 | 5.09e-02 | 1.13e-02 | 1.62e-04 | 4.94e-02 |
| POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 142 | 1.37e-01 | 4.99e-01 | 0.1460 | 1.01e-01 | 8.05e-02 | 8.36e-03 | 4.65e-02 | -4.76e-02 | 3.78e-02 | 9.78e-02 | 8.63e-01 | 3.38e-01 | 3.27e-01 |
| POSITIVE REGULATION OF CALCIUM ION IMPORT | 14 | 8.36e-01 | 9.73e-01 | 0.1450 | -3.45e-02 | 7.10e-02 | 8.36e-02 | -3.30e-02 | 8.28e-02 | 8.23e-01 | 6.46e-01 | 5.88e-01 | 8.30e-01 | 5.92e-01 |
| NEGATIVE REGULATION OF TYPE 2 IMMUNE RESPONSE | 15 | 8.95e-01 | 9.82e-01 | 0.1450 | 9.63e-02 | 8.98e-02 | 3.58e-02 | -7.76e-03 | -4.96e-02 | 5.19e-01 | 5.47e-01 | 8.10e-01 | 9.58e-01 | 7.39e-01 |
| REGULATION OF ALDOSTERONE METABOLIC PROCESS | 8 | 9.95e-01 | 9.99e-01 | 0.1450 | 7.55e-02 | 2.93e-02 | 6.59e-02 | 1.01e-01 | 1.07e-02 | 7.12e-01 | 8.86e-01 | 7.47e-01 | 6.22e-01 | 9.58e-01 |
| POSITIVE REGULATION OF PROTEIN DEPHOSPHORYLATION | 41 | 6.76e-01 | 9.28e-01 | 0.1450 | -2.47e-02 | 4.48e-02 | 8.21e-02 | 8.94e-03 | 1.08e-01 | 7.84e-01 | 6.19e-01 | 3.63e-01 | 9.21e-01 | 2.31e-01 |
| REGULATION OF LAMELLIPODIUM MORPHOGENESIS | 11 | 9.92e-01 | 9.98e-01 | 0.1450 | -4.28e-02 | -3.53e-02 | -7.85e-02 | -4.19e-02 | -1.00e-01 | 8.06e-01 | 8.39e-01 | 6.52e-01 | 8.10e-01 | 5.64e-01 |
| RESPONSE TO BMP | 170 | 9.32e-02 | 4.14e-01 | 0.1450 | -1.80e-02 | 2.60e-02 | 7.80e-02 | 3.61e-02 | 1.13e-01 | 6.85e-01 | 5.58e-01 | 7.92e-02 | 4.16e-01 | 1.13e-02 |
| POSITIVE REGULATION OF GENE EXPRESSION | 1130 | 1.30e-04 | 3.39e-03 | 0.1450 | 6.16e-02 | 7.00e-02 | 6.12e-02 | 7.21e-02 | 5.87e-02 | 4.70e-04 | 7.19e-05 | 5.17e-04 | 4.34e-05 | 8.72e-04 |
| PROSTATE GLANDULAR ACINUS DEVELOPMENT | 10 | 9.56e-01 | 9.94e-01 | 0.1450 | -3.04e-02 | 5.76e-02 | 1.05e-01 | 3.58e-02 | 6.77e-02 | 8.68e-01 | 7.53e-01 | 5.67e-01 | 8.44e-01 | 7.11e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 5 PRODUCTION | 10 | 8.65e-01 | 9.78e-01 | 0.1450 | -5.11e-02 | -1.27e-01 | -9.67e-03 | 3.25e-02 | -3.23e-02 | 7.80e-01 | 4.86e-01 | 9.58e-01 | 8.59e-01 | 8.60e-01 |
| VITAMIN TRANSMEMBRANE TRANSPORT | 21 | 9.06e-01 | 9.84e-01 | 0.1450 | -5.52e-02 | 2.29e-03 | -6.94e-02 | -9.38e-02 | -6.59e-02 | 6.62e-01 | 9.86e-01 | 5.82e-01 | 4.57e-01 | 6.01e-01 |
| CELLULAR RESPONSE TO COLD | 13 | 7.54e-01 | 9.51e-01 | 0.1450 | -8.09e-03 | -6.45e-03 | -7.41e-02 | -7.21e-02 | 1.01e-01 | 9.60e-01 | 9.68e-01 | 6.44e-01 | 6.53e-01 | 5.28e-01 |
| POSITIVE REGULATION OF SYNAPTIC TRANSMISSION GLUTAMATERGIC | 32 | 4.51e-01 | 8.21e-01 | 0.1450 | -8.40e-02 | -7.94e-03 | 2.52e-03 | -1.17e-01 | -1.01e-02 | 4.11e-01 | 9.38e-01 | 9.80e-01 | 2.51e-01 | 9.22e-01 |
| REGULATION OF RECEPTOR CATABOLIC PROCESS | 11 | 6.22e-01 | 9.08e-01 | 0.1450 | -4.48e-02 | -7.31e-03 | -5.38e-02 | 6.95e-02 | -1.06e-01 | 7.97e-01 | 9.67e-01 | 7.57e-01 | 6.90e-01 | 5.44e-01 |
| NEGATIVE REGULATION OF ENDOCYTOSIS | 76 | 8.70e-01 | 9.78e-01 | 0.1450 | 8.09e-02 | 7.01e-02 | 5.45e-02 | 8.02e-02 | 8.42e-03 | 2.23e-01 | 2.91e-01 | 4.11e-01 | 2.27e-01 | 8.99e-01 |
| CIRCADIAN SLEEP WAKE CYCLE SLEEP | 16 | 7.58e-01 | 9.52e-01 | 0.1450 | 2.77e-02 | 8.54e-02 | 4.45e-02 | -4.90e-02 | 9.20e-02 | 8.48e-01 | 5.54e-01 | 7.58e-01 | 7.35e-01 | 5.24e-01 |
| BARBED END ACTIN FILAMENT CAPPING | 25 | 8.58e-01 | 9.77e-01 | 0.1450 | -7.86e-02 | -3.87e-02 | -7.42e-02 | -3.87e-02 | -7.89e-02 | 4.96e-01 | 7.38e-01 | 5.21e-01 | 7.38e-01 | 4.95e-01 |
| VASCULAR ENDOTHELIAL CELL PROLIFERATION | 49 | 2.15e-01 | 6.11e-01 | 0.1440 | -1.91e-02 | -3.31e-02 | -8.44e-02 | -9.64e-02 | 5.48e-02 | 8.17e-01 | 6.89e-01 | 3.07e-01 | 2.43e-01 | 5.07e-01 |
| REGULATION OF FATTY ACID BETA OXIDATION | 19 | 6.82e-01 | 9.30e-01 | 0.1440 | 8.96e-02 | 7.00e-02 | -1.68e-02 | 4.56e-02 | 7.46e-02 | 4.99e-01 | 5.97e-01 | 8.99e-01 | 7.31e-01 | 5.73e-01 |
| REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN | 48 | 6.16e-01 | 9.06e-01 | 0.1440 | 2.06e-02 | 1.02e-01 | 7.82e-02 | 4.76e-02 | 4.00e-02 | 8.05e-01 | 2.20e-01 | 3.48e-01 | 5.69e-01 | 6.32e-01 |
| RHYTHMIC BEHAVIOR | 44 | 7.29e-01 | 9.44e-01 | 0.1440 | 4.54e-02 | 6.36e-02 | 6.02e-02 | 1.41e-02 | 1.04e-01 | 6.03e-01 | 4.65e-01 | 4.89e-01 | 8.71e-01 | 2.31e-01 |
| ESTABLISHMENT OF MITOTIC SISTER CHROMATID COHESION | 5 | 9.72e-01 | 9.95e-01 | 0.1440 | 5.12e-03 | -1.01e-01 | -9.61e-02 | 2.55e-02 | -2.61e-02 | 9.84e-01 | 6.96e-01 | 7.10e-01 | 9.21e-01 | 9.19e-01 |
| ADULT LOCOMOTORY BEHAVIOR | 80 | 5.58e-01 | 8.78e-01 | 0.1440 | 3.55e-02 | 2.48e-02 | 9.46e-02 | 6.67e-02 | 7.42e-02 | 5.83e-01 | 7.01e-01 | 1.43e-01 | 3.02e-01 | 2.51e-01 |
| POSITIVE REGULATION OF GLYCOLYTIC PROCESS | 22 | 7.23e-01 | 9.40e-01 | 0.1440 | -1.59e-02 | -6.78e-02 | -1.11e-01 | -5.25e-02 | 2.67e-02 | 8.97e-01 | 5.82e-01 | 3.65e-01 | 6.70e-01 | 8.29e-01 |
| RIBONUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 14 | 9.72e-01 | 9.95e-01 | 0.1440 | 9.46e-02 | 2.66e-02 | 5.48e-02 | 8.96e-02 | 5.48e-03 | 5.40e-01 | 8.63e-01 | 7.23e-01 | 5.61e-01 | 9.72e-01 |
| MOTOR NEURON AXON GUIDANCE | 23 | 9.62e-01 | 9.94e-01 | 0.1440 | 6.50e-02 | 2.96e-02 | 8.09e-02 | 8.46e-02 | 4.38e-02 | 5.90e-01 | 8.06e-01 | 5.02e-01 | 4.82e-01 | 7.16e-01 |
| REGULATION OF PH | 96 | 3.68e-01 | 7.68e-01 | 0.1440 | 2.68e-02 | 1.07e-02 | 8.70e-02 | 8.41e-02 | 7.24e-02 | 6.50e-01 | 8.56e-01 | 1.41e-01 | 1.54e-01 | 2.20e-01 |
| DETECTION OF MECHANICAL STIMULUS INVOLVED IN SENSORY PERCEPTION OF PAIN | 15 | 8.70e-01 | 9.78e-01 | 0.1440 | -7.60e-02 | -4.19e-02 | 3.89e-02 | -6.61e-02 | 8.55e-02 | 6.10e-01 | 7.79e-01 | 7.94e-01 | 6.58e-01 | 5.67e-01 |
| POLYOL CATABOLIC PROCESS | 9 | 9.96e-01 | 1.00e+00 | 0.1440 | 3.33e-02 | 8.49e-02 | 7.26e-02 | 5.31e-02 | 6.56e-02 | 8.63e-01 | 6.59e-01 | 7.06e-01 | 7.83e-01 | 7.33e-01 |
| POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY | 274 | 1.33e-01 | 4.94e-01 | 0.1440 | 8.35e-02 | 7.95e-02 | 4.35e-02 | 6.77e-02 | 2.99e-02 | 1.74e-02 | 2.35e-02 | 2.15e-01 | 5.39e-02 | 3.94e-01 |
| POSITIVE REGULATION OF GLUCOSE IMPORT | 35 | 2.00e-01 | 5.91e-01 | 0.1440 | -1.29e-01 | -1.49e-02 | -3.46e-02 | -2.61e-02 | 4.44e-02 | 1.87e-01 | 8.78e-01 | 7.23e-01 | 7.90e-01 | 6.50e-01 |
| BRADYKININ CATABOLIC PROCESS | 7 | 9.90e-01 | 9.98e-01 | 0.1440 | -9.57e-02 | -4.40e-02 | -3.22e-02 | -4.47e-02 | 8.06e-02 | 6.61e-01 | 8.40e-01 | 8.83e-01 | 8.38e-01 | 7.12e-01 |
| REGULATION OF CARDIAC MUSCLE CONTRACTION BY CALCIUM ION SIGNALING | 24 | 9.40e-01 | 9.92e-01 | 0.1440 | -1.03e-01 | -7.45e-02 | -1.53e-02 | -5.90e-02 | 2.66e-02 | 3.82e-01 | 5.27e-01 | 8.97e-01 | 6.17e-01 | 8.22e-01 |
| DNA DOUBLE STRAND BREAK PROCESSING | 19 | 3.23e-01 | 7.33e-01 | 0.1440 | 6.24e-02 | -2.36e-02 | -1.17e-01 | 4.81e-02 | -1.66e-02 | 6.38e-01 | 8.59e-01 | 3.79e-01 | 7.16e-01 | 9.00e-01 |
| POSITIVE REGULATION OF ADENYLATE CYCLASE ACTIVITY | 31 | 8.98e-01 | 9.82e-01 | 0.1440 | -4.41e-02 | -2.24e-02 | -4.84e-02 | -8.55e-02 | -9.23e-02 | 6.71e-01 | 8.29e-01 | 6.41e-01 | 4.10e-01 | 3.74e-01 |
| T CELL ACTIVATION | 541 | 3.35e-05 | 1.10e-03 | 0.1430 | 3.31e-02 | 3.21e-02 | 6.96e-02 | 1.02e-01 | 5.67e-02 | 1.88e-01 | 2.02e-01 | 5.64e-03 | 4.97e-05 | 2.41e-02 |
| CELL COMMUNICATION BY ELECTRICAL COUPLING | 34 | 8.64e-01 | 9.78e-01 | 0.1430 | 5.12e-03 | 3.00e-02 | 7.35e-02 | 8.26e-02 | 8.60e-02 | 9.59e-01 | 7.62e-01 | 4.58e-01 | 4.04e-01 | 3.85e-01 |
| REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS INVOLVED IN CHOLESTEROL TRANSPORT | 6 | 8.64e-01 | 9.78e-01 | 0.1430 | -1.21e-01 | 4.45e-02 | 5.44e-02 | -2.20e-02 | -2.12e-02 | 6.07e-01 | 8.50e-01 | 8.18e-01 | 9.26e-01 | 9.28e-01 |
| PURINE NUCLEOBASE METABOLIC PROCESS | 19 | 8.72e-01 | 9.78e-01 | 0.1430 | 2.05e-02 | -7.09e-02 | -8.38e-02 | -2.40e-03 | -8.93e-02 | 8.77e-01 | 5.93e-01 | 5.27e-01 | 9.86e-01 | 5.00e-01 |
| POSITIVE REGULATION OF PHOSPHATASE ACTIVITY | 27 | 8.53e-01 | 9.76e-01 | 0.1430 | 4.11e-02 | 3.68e-02 | -3.35e-02 | 4.13e-03 | -1.28e-01 | 7.12e-01 | 7.41e-01 | 7.63e-01 | 9.70e-01 | 2.51e-01 |
| PYRIMIDINE RIBONUCLEOTIDE BIOSYNTHETIC PROCESS | 22 | 9.08e-01 | 9.85e-01 | 0.1430 | 7.34e-02 | 1.00e-01 | 3.09e-02 | 3.96e-02 | 4.99e-02 | 5.51e-01 | 4.16e-01 | 8.02e-01 | 7.48e-01 | 6.85e-01 |
| CELL JUNCTION MAINTENANCE | 45 | 8.61e-01 | 9.78e-01 | 0.1430 | 1.91e-02 | 4.78e-02 | 7.39e-02 | 2.96e-02 | 1.07e-01 | 8.25e-01 | 5.79e-01 | 3.91e-01 | 7.31e-01 | 2.15e-01 |
| CELLULAR RESPONSE TO INTERFERON BETA | 26 | 9.62e-01 | 9.94e-01 | 0.1430 | -9.23e-02 | -8.50e-02 | -3.12e-02 | -5.79e-02 | 1.77e-02 | 4.15e-01 | 4.53e-01 | 7.83e-01 | 6.09e-01 | 8.76e-01 |
| SIALYLATION | 8 | 9.92e-01 | 9.98e-01 | 0.1430 | 3.03e-03 | 6.38e-02 | 8.84e-02 | 1.66e-02 | 9.04e-02 | 9.88e-01 | 7.55e-01 | 6.65e-01 | 9.35e-01 | 6.58e-01 |
| NATURAL KILLER CELL ACTIVATION | 92 | 1.35e-01 | 4.96e-01 | 0.1430 | -4.47e-02 | -9.95e-02 | -3.57e-02 | -2.78e-02 | -8.00e-02 | 4.58e-01 | 9.91e-02 | 5.54e-01 | 6.45e-01 | 1.85e-01 |
| STRIATED MUSCLE ATROPHY | 7 | 9.28e-01 | 9.89e-01 | 0.1430 | -7.83e-02 | 4.15e-02 | 1.06e-02 | -1.11e-01 | 1.57e-03 | 7.20e-01 | 8.49e-01 | 9.61e-01 | 6.11e-01 | 9.94e-01 |
| NEGATIVE REGULATION OF SMAD PROTEIN SIGNAL TRANSDUCTION | 22 | 8.81e-01 | 9.79e-01 | 0.1420 | -4.85e-03 | 5.24e-02 | 4.23e-02 | 1.81e-02 | 1.24e-01 | 9.69e-01 | 6.70e-01 | 7.31e-01 | 8.83e-01 | 3.14e-01 |
| LIPOPROTEIN METABOLIC PROCESS | 129 | 2.64e-01 | 6.72e-01 | 0.1420 | 4.09e-02 | 5.50e-02 | 6.02e-02 | 9.77e-02 | 4.92e-02 | 4.22e-01 | 2.81e-01 | 2.38e-01 | 5.53e-02 | 3.35e-01 |
| T CELL CHEMOTAXIS | 27 | 8.45e-01 | 9.76e-01 | 0.1420 | 5.90e-03 | 2.62e-02 | -4.80e-02 | -2.43e-02 | -1.29e-01 | 9.58e-01 | 8.13e-01 | 6.66e-01 | 8.27e-01 | 2.46e-01 |
| POSITIVE REGULATION OF MAP KINASE ACTIVITY | 86 | 1.16e-01 | 4.64e-01 | 0.1420 | 9.03e-02 | 9.53e-02 | -1.06e-02 | 4.61e-02 | -2.74e-02 | 1.48e-01 | 1.26e-01 | 8.65e-01 | 4.59e-01 | 6.61e-01 |
| OOCYTE DIFFERENTIATION | 64 | 7.21e-01 | 9.39e-01 | 0.1420 | 2.44e-02 | 1.97e-02 | 8.45e-02 | 8.03e-02 | 7.51e-02 | 7.35e-01 | 7.85e-01 | 2.43e-01 | 2.67e-01 | 2.99e-01 |
| REGULATION OF SUPEROXIDE METABOLIC PROCESS | 30 | 5.54e-01 | 8.77e-01 | 0.1420 | 2.87e-02 | 5.08e-02 | -7.11e-02 | -5.34e-03 | -1.08e-01 | 7.86e-01 | 6.30e-01 | 5.00e-01 | 9.60e-01 | 3.05e-01 |
| POST GOLGI VESICLE MEDIATED TRANSPORT | 101 | 2.40e-02 | 1.88e-01 | 0.1420 | 6.11e-02 | -5.24e-03 | -6.27e-02 | 5.23e-02 | -9.87e-02 | 2.88e-01 | 9.27e-01 | 2.76e-01 | 3.64e-01 | 8.66e-02 |
| POSITIVE REGULATION OF CATION CHANNEL ACTIVITY | 47 | 7.01e-01 | 9.32e-01 | 0.1420 | -1.03e-01 | -5.56e-02 | -6.17e-03 | -3.99e-02 | 6.96e-02 | 2.22e-01 | 5.10e-01 | 9.42e-01 | 6.36e-01 | 4.09e-01 |
| SYNAPTIC VESICLE MEMBRANE ORGANIZATION | 27 | 2.71e-01 | 6.79e-01 | 0.1420 | -2.43e-03 | 7.78e-02 | 7.94e-02 | -7.39e-02 | 4.80e-02 | 9.83e-01 | 4.84e-01 | 4.75e-01 | 5.06e-01 | 6.66e-01 |
| LEUKOCYTE DEGRANULATION | 78 | 6.99e-01 | 9.31e-01 | 0.1420 | 6.87e-02 | 9.60e-02 | 5.98e-02 | 4.77e-02 | -1.89e-02 | 2.94e-01 | 1.43e-01 | 3.61e-01 | 4.67e-01 | 7.73e-01 |
| NEGATIVE REGULATION OF PLASMA MEMBRANE BOUNDED CELL PROJECTION ASSEMBLY | 36 | 9.47e-01 | 9.94e-01 | 0.1420 | -3.84e-02 | -6.88e-02 | -7.38e-02 | -3.84e-02 | -8.36e-02 | 6.90e-01 | 4.75e-01 | 4.44e-01 | 6.90e-01 | 3.85e-01 |
| POSITIVE REGULATION OF VASCULAR PERMEABILITY | 18 | 2.88e-01 | 6.97e-01 | 0.1420 | -8.14e-02 | 8.44e-02 | 2.84e-02 | -3.86e-03 | -7.44e-02 | 5.50e-01 | 5.35e-01 | 8.35e-01 | 9.77e-01 | 5.85e-01 |
| NEGATIVE REGULATION OF G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 50 | 9.15e-01 | 9.86e-01 | 0.1420 | 7.21e-02 | 8.25e-02 | 5.23e-02 | 7.30e-02 | -6.21e-03 | 3.77e-01 | 3.13e-01 | 5.22e-01 | 3.72e-01 | 9.39e-01 |
| REGULATION OF MESENCHYMAL STEM CELL DIFFERENTIATION | 8 | 9.63e-01 | 9.94e-01 | 0.1420 | -9.70e-02 | -7.42e-02 | 4.29e-02 | 3.82e-03 | 5.77e-02 | 6.35e-01 | 7.16e-01 | 8.34e-01 | 9.85e-01 | 7.77e-01 |
| CELL MATURATION | 191 | 5.18e-01 | 8.57e-01 | 0.1420 | 5.18e-02 | 6.67e-02 | 6.48e-02 | 6.20e-02 | 6.97e-02 | 2.17e-01 | 1.12e-01 | 1.22e-01 | 1.39e-01 | 9.66e-02 |
| REGULATION OF TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 10 | 9.10e-01 | 9.85e-01 | 0.1420 | 4.54e-02 | 7.79e-02 | 9.13e-03 | 7.87e-02 | 7.50e-02 | 8.04e-01 | 6.70e-01 | 9.60e-01 | 6.66e-01 | 6.81e-01 |
| NEGATIVE REGULATION OF MATRIX METALLOPEPTIDASE SECRETION | 6 | 9.96e-01 | 1.00e+00 | 0.1410 | 1.47e-02 | -3.10e-02 | -5.59e-02 | -1.36e-02 | -1.25e-01 | 9.50e-01 | 8.95e-01 | 8.13e-01 | 9.54e-01 | 5.97e-01 |
| RENAL SYSTEM VASCULATURE DEVELOPMENT | 32 | 9.01e-01 | 9.83e-01 | 0.1410 | 9.65e-02 | 8.83e-02 | 3.99e-02 | 3.32e-02 | 1.35e-02 | 3.45e-01 | 3.87e-01 | 6.96e-01 | 7.45e-01 | 8.95e-01 |
| ENDOCRINE HORMONE SECRETION | 56 | 2.24e-01 | 6.24e-01 | 0.1410 | 1.06e-01 | 5.75e-02 | -4.38e-02 | -4.68e-04 | -5.89e-02 | 1.69e-01 | 4.57e-01 | 5.71e-01 | 9.95e-01 | 4.46e-01 |
| REGULATION OF GLIAL CELL APOPTOTIC PROCESS | 10 | 7.83e-01 | 9.61e-01 | 0.1410 | 1.69e-02 | 4.98e-02 | -5.44e-02 | -1.11e-01 | 4.26e-02 | 9.26e-01 | 7.85e-01 | 7.66e-01 | 5.42e-01 | 8.16e-01 |
| PROTEIN LOCALIZATION TO CELL SURFACE | 65 | 6.41e-01 | 9.14e-01 | 0.1410 | 8.68e-02 | 6.69e-02 | 2.61e-02 | 7.81e-02 | 3.39e-02 | 2.26e-01 | 3.51e-01 | 7.16e-01 | 2.76e-01 | 6.37e-01 |
| RETINAL GANGLION CELL AXON GUIDANCE | 22 | 8.38e-01 | 9.73e-01 | 0.1410 | 3.49e-02 | 3.63e-02 | -2.59e-02 | -5.47e-02 | -1.17e-01 | 7.77e-01 | 7.68e-01 | 8.33e-01 | 6.57e-01 | 3.42e-01 |
| POSITIVE REGULATION OF PROTEOLYSIS | 340 | 2.70e-01 | 6.79e-01 | 0.1410 | 5.47e-02 | 6.77e-02 | 6.75e-02 | 6.58e-02 | 5.84e-02 | 8.31e-02 | 3.18e-02 | 3.25e-02 | 3.72e-02 | 6.42e-02 |
| POSITIVE REGULATION OF ACTIN FILAMENT DEPOLYMERIZATION | 13 | 9.77e-01 | 9.96e-01 | 0.1410 | 3.36e-02 | 3.62e-03 | -5.53e-02 | -1.08e-02 | -1.25e-01 | 8.34e-01 | 9.82e-01 | 7.30e-01 | 9.46e-01 | 4.37e-01 |
| REGULATION OF ORGANELLE TRANSPORT ALONG MICROTUBULE | 9 | 9.93e-01 | 9.99e-01 | 0.1410 | 7.19e-03 | 9.36e-03 | 6.19e-02 | 2.94e-02 | 1.22e-01 | 9.70e-01 | 9.61e-01 | 7.48e-01 | 8.78e-01 | 5.25e-01 |
| POSITIVE REGULATION OF INOSITOL TRISPHOSPHATE BIOSYNTHETIC PROCESS | 5 | 9.61e-01 | 9.94e-01 | 0.1410 | -1.91e-02 | -1.33e-01 | -1.25e-02 | 3.39e-02 | 2.16e-02 | 9.41e-01 | 6.07e-01 | 9.61e-01 | 8.96e-01 | 9.33e-01 |
| VENTRICULAR SEPTUM MORPHOGENESIS | 43 | 5.68e-01 | 8.81e-01 | 0.1410 | -4.81e-02 | 1.07e-02 | 8.57e-02 | 3.99e-02 | 9.19e-02 | 5.85e-01 | 9.04e-01 | 3.31e-01 | 6.50e-01 | 2.97e-01 |
| RESPONSE TO PROSTAGLANDIN | 31 | 9.12e-01 | 9.85e-01 | 0.1410 | -6.60e-02 | -5.72e-02 | -5.72e-02 | -8.53e-02 | 4.02e-02 | 5.25e-01 | 5.82e-01 | 5.81e-01 | 4.11e-01 | 6.98e-01 |
| PROTEIN IMPORT INTO PEROXISOME MATRIX SUBSTRATE RELEASE | 5 | 7.70e-01 | 9.55e-01 | 0.1410 | -3.22e-02 | -8.03e-03 | -1.16e-01 | 4.90e-02 | 5.25e-02 | 9.01e-01 | 9.75e-01 | 6.52e-01 | 8.50e-01 | 8.39e-01 |
| VESICLE DOCKING INVOLVED IN EXOCYTOSIS | 42 | 8.06e-01 | 9.67e-01 | 0.1410 | 7.65e-02 | 8.61e-02 | 5.83e-02 | 2.12e-02 | 5.15e-02 | 3.91e-01 | 3.34e-01 | 5.13e-01 | 8.12e-01 | 5.64e-01 |
| CALCIUM ION REGULATED EXOCYTOSIS | 64 | 6.16e-02 | 3.29e-01 | 0.1410 | -7.04e-02 | 3.15e-02 | 4.21e-02 | -8.39e-02 | 7.08e-02 | 3.30e-01 | 6.63e-01 | 5.60e-01 | 2.46e-01 | 3.28e-01 |
| REGULATION OF INTEGRIN MEDIATED SIGNALING PATHWAY | 19 | 3.01e-01 | 7.13e-01 | 0.1410 | 6.27e-02 | -8.33e-02 | -6.63e-02 | -6.71e-02 | 1.35e-03 | 6.36e-01 | 5.30e-01 | 6.17e-01 | 6.13e-01 | 9.92e-01 |
| CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 284 | 4.30e-02 | 2.69e-01 | 0.1410 | 8.88e-02 | 5.23e-02 | 4.76e-02 | 6.02e-02 | 5.70e-02 | 1.00e-02 | 1.29e-01 | 1.67e-01 | 8.06e-02 | 9.83e-02 |
| POSITIVE REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 18 | 4.07e-01 | 7.93e-01 | 0.1410 | 9.55e-02 | 3.63e-02 | -7.77e-02 | -5.25e-02 | 2.30e-02 | 4.83e-01 | 7.90e-01 | 5.68e-01 | 7.00e-01 | 8.66e-01 |
| POSITIVE REGULATION OF ACTIVATED T CELL PROLIFERATION | 26 | 7.55e-01 | 9.51e-01 | 0.1410 | -4.90e-02 | -8.82e-02 | 1.05e-02 | -1.90e-02 | 9.54e-02 | 6.65e-01 | 4.36e-01 | 9.26e-01 | 8.67e-01 | 4.00e-01 |
| ENDOCARDIUM DEVELOPMENT | 12 | 9.37e-01 | 9.92e-01 | 0.1410 | 9.71e-02 | 1.09e-03 | 2.20e-02 | 9.74e-02 | 1.84e-02 | 5.60e-01 | 9.95e-01 | 8.95e-01 | 5.59e-01 | 9.12e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 17 | 2.38e-01 | 6.41e-01 | 0.1410 | 2.59e-02 | -7.86e-03 | 7.06e-03 | -1.36e-01 | -1.96e-02 | 8.53e-01 | 9.55e-01 | 9.60e-01 | 3.31e-01 | 8.89e-01 |
| TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 17 | 9.81e-01 | 9.96e-01 | 0.1400 | 9.85e-02 | 5.41e-02 | 3.00e-02 | 7.34e-02 | -2.83e-02 | 4.82e-01 | 6.99e-01 | 8.30e-01 | 6.00e-01 | 8.40e-01 |
| HOMOTYPIC CELL CELL ADHESION | 93 | 5.08e-01 | 8.53e-01 | 0.1400 | 8.65e-02 | 7.21e-02 | 2.68e-02 | 4.53e-02 | -6.54e-02 | 1.50e-01 | 2.29e-01 | 6.55e-01 | 4.50e-01 | 2.76e-01 |
| KERATAN SULFATE METABOLIC PROCESS | 18 | 9.50e-01 | 9.94e-01 | 0.1400 | 5.46e-02 | 3.13e-02 | 3.68e-02 | 4.36e-02 | 1.12e-01 | 6.88e-01 | 8.18e-01 | 7.87e-01 | 7.49e-01 | 4.12e-01 |
| MEMBRANE REPOLARIZATION DURING ACTION POTENTIAL | 29 | 2.65e-01 | 6.73e-01 | 0.1400 | -2.01e-02 | 6.62e-02 | -2.64e-02 | -9.66e-02 | 6.97e-02 | 8.51e-01 | 5.37e-01 | 8.06e-01 | 3.68e-01 | 5.16e-01 |
| NUCLEOTIDE TRANSPORT | 40 | 6.02e-01 | 9.00e-01 | 0.1400 | 6.53e-02 | 7.06e-02 | -1.00e-02 | 5.61e-02 | -8.47e-02 | 4.75e-01 | 4.40e-01 | 9.13e-01 | 5.39e-01 | 3.54e-01 |
| BIOLOGICAL PROCESS INVOLVED IN INTERACTION WITH SYMBIONT | 115 | 5.96e-01 | 8.97e-01 | 0.1400 | 8.73e-02 | 4.93e-02 | 5.99e-02 | 6.88e-02 | 3.60e-02 | 1.06e-01 | 3.61e-01 | 2.67e-01 | 2.03e-01 | 5.04e-01 |
| ACROSOME ASSEMBLY | 27 | 2.53e-01 | 6.59e-01 | 0.1400 | 4.52e-02 | -1.23e-02 | -2.27e-02 | 1.30e-01 | 7.79e-04 | 6.84e-01 | 9.12e-01 | 8.38e-01 | 2.42e-01 | 9.94e-01 |
| REGULATION OF POSTSYNAPSE ORGANIZATION | 97 | 6.66e-01 | 9.23e-01 | 0.1400 | -8.46e-02 | -4.85e-02 | -6.78e-02 | -7.08e-02 | -2.23e-02 | 1.50e-01 | 4.09e-01 | 2.48e-01 | 2.28e-01 | 7.04e-01 |
| POSITIVE REGULATION OF AMYLOID BETA FORMATION | 20 | 5.81e-01 | 8.88e-01 | 0.1400 | 1.18e-01 | -1.52e-02 | -5.42e-03 | 3.49e-02 | -6.45e-02 | 3.61e-01 | 9.06e-01 | 9.66e-01 | 7.87e-01 | 6.18e-01 |
| ACTION POTENTIAL | 139 | 3.11e-01 | 7.22e-01 | 0.1400 | -8.77e-02 | -3.45e-02 | -5.10e-02 | -8.29e-02 | -3.50e-02 | 7.41e-02 | 4.83e-01 | 2.99e-01 | 9.17e-02 | 4.76e-01 |
| DETECTION OF MOLECULE OF BACTERIAL ORIGIN | 13 | 6.44e-01 | 9.15e-01 | 0.1400 | 9.39e-02 | 5.84e-02 | -4.19e-02 | -4.24e-02 | 6.17e-02 | 5.58e-01 | 7.15e-01 | 7.94e-01 | 7.91e-01 | 7.00e-01 |
| NEUROMUSCULAR PROCESS CONTROLLING POSTURE | 18 | 9.42e-01 | 9.92e-01 | 0.1400 | 9.85e-02 | 5.98e-02 | 6.65e-02 | 3.81e-02 | 2.06e-02 | 4.69e-01 | 6.60e-01 | 6.25e-01 | 7.79e-01 | 8.80e-01 |
| TYPE 2 IMMUNE RESPONSE | 42 | 6.39e-01 | 9.14e-01 | 0.1400 | 7.89e-02 | 6.77e-02 | -2.42e-02 | -4.42e-03 | -9.03e-02 | 3.76e-01 | 4.47e-01 | 7.86e-01 | 9.60e-01 | 3.11e-01 |
| REGULATION OF CELL KILLING | 113 | 4.65e-03 | 5.84e-02 | 0.1400 | -3.37e-02 | -1.01e-01 | -3.84e-02 | 3.94e-02 | -7.20e-02 | 5.36e-01 | 6.38e-02 | 4.80e-01 | 4.70e-01 | 1.86e-01 |
| BIOGENIC AMINE METABOLIC PROCESS | 87 | 4.85e-01 | 8.38e-01 | 0.1400 | 2.90e-02 | 6.40e-02 | 8.74e-02 | 2.20e-02 | 8.04e-02 | 6.41e-01 | 3.02e-01 | 1.59e-01 | 7.23e-01 | 1.95e-01 |
| POSITIVE REGULATION OF CELL DEVELOPMENT | 426 | 5.40e-02 | 3.07e-01 | 0.1400 | 5.38e-02 | 7.06e-02 | 5.77e-02 | 6.58e-02 | 6.30e-02 | 5.69e-02 | 1.24e-02 | 4.12e-02 | 1.98e-02 | 2.57e-02 |
| REGULATION OF STRIATED MUSCLE CONTRACTION | 92 | 7.58e-02 | 3.72e-01 | 0.1390 | -9.96e-02 | -4.88e-03 | -9.50e-03 | -9.67e-02 | 6.19e-03 | 9.86e-02 | 9.36e-01 | 8.75e-01 | 1.09e-01 | 9.18e-01 |
| POSITIVE REGULATION OF CHOLESTEROL BIOSYNTHETIC PROCESS | 10 | 9.41e-01 | 9.92e-01 | 0.1390 | -1.06e-01 | 1.21e-03 | -1.88e-02 | -8.14e-02 | -3.50e-02 | 5.62e-01 | 9.95e-01 | 9.18e-01 | 6.56e-01 | 8.48e-01 |
| TRANSLATIONAL READTHROUGH | 9 | 9.68e-01 | 9.94e-01 | 0.1390 | 9.53e-02 | 8.53e-02 | 1.37e-02 | -1.30e-02 | -5.21e-02 | 6.20e-01 | 6.58e-01 | 9.43e-01 | 9.46e-01 | 7.87e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY HORMONE | 33 | 6.92e-01 | 9.31e-01 | 0.1390 | 8.25e-02 | 3.17e-02 | -5.47e-02 | 7.06e-03 | -9.26e-02 | 4.12e-01 | 7.52e-01 | 5.87e-01 | 9.44e-01 | 3.57e-01 |
| GLUCOCORTICOID BIOSYNTHETIC PROCESS | 16 | 8.28e-01 | 9.72e-01 | 0.1390 | -9.29e-02 | -2.85e-02 | 6.90e-02 | -2.18e-02 | 6.90e-02 | 5.20e-01 | 8.44e-01 | 6.33e-01 | 8.80e-01 | 6.33e-01 |
| CHONDROITIN SULFATE PROTEOGLYCAN METABOLIC PROCESS | 31 | 4.29e-01 | 8.05e-01 | 0.1390 | 5.09e-02 | 1.14e-01 | 7.22e-03 | 3.70e-02 | 4.89e-02 | 6.24e-01 | 2.71e-01 | 9.45e-01 | 7.21e-01 | 6.38e-01 |
| RENAL SODIUM ION ABSORPTION | 12 | 9.21e-01 | 9.87e-01 | 0.1390 | 3.90e-03 | -1.30e-02 | -1.08e-01 | -8.22e-02 | -2.76e-02 | 9.81e-01 | 9.38e-01 | 5.17e-01 | 6.22e-01 | 8.69e-01 |
| AMYLOID BETA CLEARANCE | 39 | 9.05e-01 | 9.84e-01 | 0.1390 | 5.34e-02 | 9.70e-02 | 5.76e-02 | 5.49e-02 | 2.82e-02 | 5.64e-01 | 2.95e-01 | 5.34e-01 | 5.53e-01 | 7.61e-01 |
| ORGANELLE TRANSPORT ALONG MICROTUBULE | 84 | 4.29e-01 | 8.05e-01 | 0.1390 | 2.31e-02 | -6.06e-03 | 6.65e-02 | 7.57e-02 | 9.30e-02 | 7.14e-01 | 9.24e-01 | 2.92e-01 | 2.31e-01 | 1.41e-01 |
| REGULATION OF MYOBLAST DIFFERENTIATION | 72 | 6.04e-01 | 9.01e-01 | 0.1390 | 3.64e-02 | 8.65e-02 | 5.82e-02 | 3.17e-02 | 7.80e-02 | 5.94e-01 | 2.04e-01 | 3.93e-01 | 6.42e-01 | 2.52e-01 |
| RESPONSE TO INORGANIC SUBSTANCE | 510 | 1.72e-02 | 1.51e-01 | 0.1390 | 2.80e-02 | 5.00e-02 | 6.84e-02 | 5.97e-02 | 8.80e-02 | 2.80e-01 | 5.34e-02 | 8.15e-03 | 2.10e-02 | 6.69e-04 |
| POSITIVE REGULATION OF ALPHA BETA T CELL PROLIFERATION | 25 | 3.39e-01 | 7.45e-01 | 0.1390 | -9.83e-02 | -1.71e-02 | 5.00e-02 | 6.42e-02 | 5.19e-02 | 3.95e-01 | 8.82e-01 | 6.65e-01 | 5.79e-01 | 6.53e-01 |
| REGULATION OF GTPASE ACTIVITY | 288 | 5.61e-02 | 3.13e-01 | 0.1390 | -4.52e-02 | -4.43e-02 | -9.37e-02 | -6.85e-02 | -4.22e-02 | 1.87e-01 | 1.96e-01 | 6.23e-03 | 4.55e-02 | 2.18e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 140 | 1.27e-01 | 4.85e-01 | 0.1390 | 6.17e-02 | 1.31e-02 | 5.25e-02 | 1.04e-01 | 4.08e-02 | 2.08e-01 | 7.90e-01 | 2.83e-01 | 3.36e-02 | 4.05e-01 |
| REPRODUCTIVE BEHAVIOR | 42 | 4.22e-01 | 8.02e-01 | 0.1390 | 9.57e-02 | 4.74e-02 | -2.46e-03 | 5.07e-02 | 7.23e-02 | 2.83e-01 | 5.95e-01 | 9.78e-01 | 5.69e-01 | 4.18e-01 |
| ALPHA BETA T CELL PROLIFERATION | 43 | 3.85e-01 | 7.79e-01 | 0.1380 | -7.29e-02 | -4.93e-02 | 5.12e-02 | 4.97e-02 | 7.96e-02 | 4.08e-01 | 5.76e-01 | 5.61e-01 | 5.73e-01 | 3.66e-01 |
| MOLTING CYCLE PROCESS | 93 | 3.53e-01 | 7.53e-01 | 0.1380 | 4.59e-02 | 4.32e-02 | 4.65e-02 | 1.01e-01 | 5.16e-02 | 4.44e-01 | 4.71e-01 | 4.38e-01 | 9.08e-02 | 3.90e-01 |
| CELLULAR RESPONSE TO ALKALOID | 35 | 7.11e-01 | 9.35e-01 | 0.1380 | -2.77e-02 | -7.47e-02 | -4.73e-02 | -8.40e-02 | -5.87e-02 | 7.77e-01 | 4.44e-01 | 6.28e-01 | 3.90e-01 | 5.48e-01 |
| NEGATIVE REGULATION OF OSTEOBLAST DIFFERENTIATION | 62 | 3.13e-01 | 7.25e-01 | 0.1380 | -3.71e-02 | 2.77e-02 | 5.26e-02 | -3.46e-02 | 1.14e-01 | 6.13e-01 | 7.06e-01 | 4.74e-01 | 6.38e-01 | 1.21e-01 |
| NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 954 | 4.12e-05 | 1.32e-03 | 0.1380 | 5.46e-02 | 4.99e-02 | 5.18e-02 | 7.75e-02 | 6.99e-02 | 4.27e-03 | 8.97e-03 | 6.74e-03 | 4.97e-05 | 2.56e-04 |
| GAMMA AMINOBUTYRIC ACID TRANSPORT | 19 | 8.32e-01 | 9.73e-01 | 0.1380 | -7.52e-02 | -3.33e-02 | -6.13e-02 | -4.48e-02 | 8.05e-02 | 5.70e-01 | 8.02e-01 | 6.44e-01 | 7.35e-01 | 5.43e-01 |
| GLYCOPROTEIN METABOLIC PROCESS | 358 | 8.63e-02 | 3.98e-01 | 0.1380 | 6.75e-02 | 7.49e-02 | 4.96e-02 | 7.58e-02 | 2.54e-02 | 2.83e-02 | 1.49e-02 | 1.07e-01 | 1.37e-02 | 4.10e-01 |
| NEURAL RETINA DEVELOPMENT | 78 | 4.14e-01 | 7.98e-01 | 0.1380 | -4.17e-02 | -2.44e-03 | 5.46e-02 | 1.73e-05 | 1.19e-01 | 5.24e-01 | 9.70e-01 | 4.04e-01 | 1.00e+00 | 6.82e-02 |
| NEUROMUSCULAR PROCESS | 159 | 1.22e-01 | 4.75e-01 | 0.1380 | 2.30e-02 | 8.20e-02 | 9.01e-02 | 2.76e-02 | 5.35e-02 | 6.17e-01 | 7.44e-02 | 4.99e-02 | 5.47e-01 | 2.44e-01 |
| DENDRITE DEVELOPMENT | 219 | 1.80e-01 | 5.64e-01 | 0.1380 | -8.10e-02 | -4.10e-02 | -6.72e-02 | -7.43e-02 | -2.69e-02 | 3.89e-02 | 2.96e-01 | 8.67e-02 | 5.80e-02 | 4.92e-01 |
| UTERUS DEVELOPMENT | 23 | 8.24e-01 | 9.71e-01 | 0.1380 | -5.05e-03 | 5.39e-02 | 1.09e-01 | 1.92e-02 | 6.18e-02 | 9.67e-01 | 6.55e-01 | 3.66e-01 | 8.74e-01 | 6.08e-01 |
| DEOXYRIBONUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 14 | 9.05e-01 | 9.84e-01 | 0.1380 | 9.04e-02 | 7.26e-02 | 7.01e-02 | 4.24e-03 | 2.40e-02 | 5.58e-01 | 6.38e-01 | 6.50e-01 | 9.78e-01 | 8.76e-01 |
| NEGATIVE REGULATION OF INCLUSION BODY ASSEMBLY | 12 | 8.87e-01 | 9.80e-01 | 0.1380 | -2.76e-02 | 4.87e-02 | 1.16e-01 | 1.19e-02 | 4.72e-02 | 8.69e-01 | 7.70e-01 | 4.86e-01 | 9.43e-01 | 7.77e-01 |
| DETECTION OF MECHANICAL STIMULUS INVOLVED IN SENSORY PERCEPTION OF SOUND | 15 | 7.02e-01 | 9.32e-01 | 0.1380 | -8.71e-03 | 1.05e-01 | 2.43e-02 | 1.25e-02 | -8.41e-02 | 9.53e-01 | 4.81e-01 | 8.71e-01 | 9.33e-01 | 5.73e-01 |
| RESPONSE TO METAL ION | 346 | 3.52e-02 | 2.39e-01 | 0.1380 | 2.21e-02 | 4.95e-02 | 6.64e-02 | 3.61e-02 | 1.02e-01 | 4.80e-01 | 1.14e-01 | 3.39e-02 | 2.48e-01 | 1.17e-03 |
| PYRIMIDINE RIBONUCLEOSIDE TRIPHOSPHATE BIOSYNTHETIC PROCESS | 14 | 7.84e-01 | 9.61e-01 | 0.1380 | -4.54e-02 | 3.99e-02 | -2.51e-02 | -6.46e-02 | 1.02e-01 | 7.69e-01 | 7.96e-01 | 8.71e-01 | 6.75e-01 | 5.07e-01 |
| POSITIVE REGULATION OF PROTEIN GLYCOSYLATION | 8 | 9.28e-01 | 9.89e-01 | 0.1370 | 4.52e-02 | 1.15e-01 | 7.11e-03 | 5.98e-02 | -1.93e-03 | 8.25e-01 | 5.73e-01 | 9.72e-01 | 7.70e-01 | 9.92e-01 |
| MICROTUBULE ORGANIZING CENTER LOCALIZATION | 32 | 4.28e-01 | 8.05e-01 | 0.1370 | 7.91e-02 | -4.16e-02 | -2.09e-02 | 6.14e-02 | -8.18e-02 | 4.39e-01 | 6.84e-01 | 8.38e-01 | 5.48e-01 | 4.23e-01 |
| MULTICELLULAR ORGANISMAL MOVEMENT | 57 | 2.33e-01 | 6.36e-01 | 0.1370 | -8.62e-03 | 7.34e-02 | 9.80e-02 | -1.06e-02 | 6.04e-02 | 9.10e-01 | 3.38e-01 | 2.01e-01 | 8.90e-01 | 4.30e-01 |
| INOSITOL PHOSPHATE BIOSYNTHETIC PROCESS | 29 | 8.49e-01 | 9.76e-01 | 0.1370 | -7.47e-02 | -6.30e-02 | -2.38e-02 | -1.51e-02 | 9.21e-02 | 4.86e-01 | 5.57e-01 | 8.25e-01 | 8.88e-01 | 3.90e-01 |
| TELOMERIC D LOOP DISASSEMBLY | 7 | 9.67e-01 | 9.94e-01 | 0.1370 | -7.74e-02 | -8.20e-02 | -6.67e-02 | 1.14e-02 | 3.88e-02 | 7.23e-01 | 7.07e-01 | 7.60e-01 | 9.58e-01 | 8.59e-01 |
| REGULATION OF PHOSPHOLIPID BIOSYNTHETIC PROCESS | 16 | 4.27e-01 | 8.05e-01 | 0.1370 | 6.61e-02 | 1.16e-02 | -8.24e-02 | 8.61e-02 | -8.27e-03 | 6.47e-01 | 9.36e-01 | 5.68e-01 | 5.51e-01 | 9.54e-01 |
| GASTRO INTESTINAL SYSTEM SMOOTH MUSCLE CONTRACTION | 12 | 6.40e-01 | 9.14e-01 | 0.1370 | -8.07e-02 | 1.85e-02 | -5.63e-02 | -1.62e-02 | 9.22e-02 | 6.28e-01 | 9.12e-01 | 7.36e-01 | 9.22e-01 | 5.80e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION | 458 | 6.37e-02 | 3.36e-01 | 0.1370 | 6.70e-02 | 8.04e-02 | 5.41e-02 | 5.77e-02 | 3.97e-02 | 1.40e-02 | 3.19e-03 | 4.72e-02 | 3.43e-02 | 1.45e-01 |
| NEGATIVE REGULATION OF VIRAL PROCESS | 91 | 7.15e-01 | 9.36e-01 | 0.1370 | 6.61e-02 | 7.60e-02 | 4.58e-02 | 7.57e-02 | 2.80e-02 | 2.76e-01 | 2.10e-01 | 4.50e-01 | 2.12e-01 | 6.44e-01 |
| GOLGI TO VACUOLE TRANSPORT | 20 | 7.52e-01 | 9.51e-01 | 0.1370 | 8.42e-02 | 2.82e-02 | -3.57e-02 | 8.20e-02 | -5.37e-02 | 5.14e-01 | 8.27e-01 | 7.82e-01 | 5.26e-01 | 6.77e-01 |
| HOMOLOGOUS CHROMOSOME PAIRING AT MEIOSIS | 52 | 1.97e-01 | 5.85e-01 | 0.1370 | 9.23e-03 | -7.23e-02 | -1.95e-02 | -1.12e-02 | -1.14e-01 | 9.08e-01 | 3.67e-01 | 8.08e-01 | 8.89e-01 | 1.56e-01 |
| GLUTAMATE SECRETION | 28 | 7.90e-01 | 9.63e-01 | 0.1370 | -1.94e-03 | 7.41e-02 | 5.92e-02 | -5.97e-03 | 9.85e-02 | 9.86e-01 | 4.98e-01 | 5.87e-01 | 9.56e-01 | 3.67e-01 |
| ORGANIC HYDROXY COMPOUND CATABOLIC PROCESS | 52 | 3.84e-01 | 7.79e-01 | 0.1370 | 2.99e-03 | 1.51e-02 | -6.57e-02 | -1.00e-01 | -6.40e-02 | 9.70e-01 | 8.51e-01 | 4.12e-01 | 2.10e-01 | 4.25e-01 |
| REGULATION OF LIPID TRANSPORT | 153 | 4.22e-02 | 2.67e-01 | 0.1370 | 5.28e-02 | 5.32e-02 | -3.49e-02 | 8.52e-03 | -1.08e-01 | 2.60e-01 | 2.56e-01 | 4.56e-01 | 8.56e-01 | 2.06e-02 |
| HYPOTONIC RESPONSE | 13 | 6.39e-01 | 9.14e-01 | 0.1370 | 6.31e-02 | 3.67e-02 | -5.23e-02 | -6.00e-02 | 8.35e-02 | 6.93e-01 | 8.19e-01 | 7.44e-01 | 7.08e-01 | 6.02e-01 |
| TRANSFORMING GROWTH FACTOR BETA2 PRODUCTION | 9 | 7.52e-01 | 9.51e-01 | 0.1360 | -1.17e-01 | -1.24e-02 | 3.63e-02 | 2.94e-02 | -5.13e-02 | 5.44e-01 | 9.48e-01 | 8.50e-01 | 8.79e-01 | 7.90e-01 |
| NEURON GLIAL CELL SIGNALING | 5 | 9.61e-01 | 9.94e-01 | 0.1360 | -2.05e-02 | 3.83e-02 | 8.13e-02 | -6.64e-02 | 7.54e-02 | 9.37e-01 | 8.82e-01 | 7.53e-01 | 7.97e-01 | 7.70e-01 |
| POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 777 | 1.49e-03 | 2.40e-02 | 0.1360 | 8.32e-02 | 6.10e-02 | 4.35e-02 | 7.41e-02 | 2.39e-02 | 7.99e-05 | 3.81e-03 | 3.92e-02 | 4.38e-04 | 2.57e-01 |
| REGULATION OF CARBOHYDRATE METABOLIC PROCESS | 181 | 5.49e-02 | 3.11e-01 | 0.1360 | 4.44e-02 | 4.68e-02 | 3.14e-02 | 4.67e-02 | 1.06e-01 | 3.03e-01 | 2.78e-01 | 4.67e-01 | 2.78e-01 | 1.38e-02 |
| REGULATION OF TISSUE REMODELING | 86 | 2.69e-02 | 2.03e-01 | 0.1360 | 1.71e-02 | 5.77e-02 | -7.62e-02 | -7.18e-02 | -6.32e-02 | 7.84e-01 | 3.55e-01 | 2.22e-01 | 2.50e-01 | 3.11e-01 |
| NEGATIVE REGULATION OF PEPTIDASE ACTIVITY | 126 | 4.59e-01 | 8.23e-01 | 0.1360 | -4.27e-02 | -2.24e-02 | -6.91e-02 | -8.71e-02 | -6.22e-02 | 4.07e-01 | 6.64e-01 | 1.80e-01 | 9.11e-02 | 2.28e-01 |
| T CELL MIGRATION | 68 | 6.98e-01 | 9.31e-01 | 0.1360 | 6.64e-02 | 6.51e-02 | 4.43e-02 | 7.68e-02 | -4.53e-02 | 3.44e-01 | 3.53e-01 | 5.28e-01 | 2.73e-01 | 5.18e-01 |
| PHOTORECEPTOR CELL OUTER SEGMENT ORGANIZATION | 13 | 7.99e-01 | 9.66e-01 | 0.1360 | -5.04e-02 | -2.03e-02 | 2.62e-03 | -1.25e-01 | -4.33e-03 | 7.53e-01 | 8.99e-01 | 9.87e-01 | 4.36e-01 | 9.78e-01 |
| REGULATION OF MEMBRANE LIPID DISTRIBUTION | 60 | 9.13e-01 | 9.85e-01 | 0.1360 | -5.22e-02 | -4.86e-02 | -6.98e-02 | -8.57e-02 | -3.46e-02 | 4.84e-01 | 5.15e-01 | 3.50e-01 | 2.51e-01 | 6.43e-01 |
| EXTERNAL ENCAPSULATING STRUCTURE ORGANIZATION | 312 | 2.66e-02 | 2.00e-01 | 0.1360 | -7.11e-02 | -2.64e-02 | -5.39e-02 | -9.10e-02 | -3.90e-02 | 3.09e-02 | 4.23e-01 | 1.02e-01 | 5.71e-03 | 2.37e-01 |
| GLYCEROPHOSPHOLIPID CATABOLIC PROCESS | 34 | 2.79e-01 | 6.89e-01 | 0.1360 | -7.86e-03 | 3.55e-02 | -3.81e-02 | -1.25e-01 | -2.87e-03 | 9.37e-01 | 7.20e-01 | 7.01e-01 | 2.07e-01 | 9.77e-01 |
| NEGATIVE REGULATION OF SERINE TYPE PEPTIDASE ACTIVITY | 5 | 9.63e-01 | 9.94e-01 | 0.1360 | 2.97e-02 | 2.70e-02 | -3.09e-02 | -5.60e-02 | 1.13e-01 | 9.09e-01 | 9.17e-01 | 9.05e-01 | 8.28e-01 | 6.62e-01 |
| POSITIVE REGULATION OF CELL ACTIVATION | 378 | 5.50e-02 | 3.11e-01 | 0.1360 | 5.50e-02 | 6.01e-02 | 5.60e-02 | 8.56e-02 | 3.66e-02 | 6.66e-02 | 4.48e-02 | 6.17e-02 | 4.26e-03 | 2.22e-01 |
| TETRAHYDROFOLATE INTERCONVERSION | 9 | 8.31e-01 | 9.73e-01 | 0.1360 | 7.11e-02 | -4.85e-02 | -8.31e-02 | 6.28e-02 | -1.32e-02 | 7.12e-01 | 8.01e-01 | 6.66e-01 | 7.44e-01 | 9.45e-01 |
| CYTOKINE PRODUCTION INVOLVED IN INFLAMMATORY RESPONSE | 77 | 4.99e-02 | 2.92e-01 | 0.1360 | 3.35e-02 | 8.08e-02 | -5.16e-02 | -5.51e-02 | -7.12e-02 | 6.12e-01 | 2.20e-01 | 4.33e-01 | 4.03e-01 | 2.80e-01 |
| GLUCOSE 6 PHOSPHATE METABOLIC PROCESS | 27 | 9.30e-01 | 9.90e-01 | 0.1360 | 6.79e-02 | 4.30e-02 | 3.21e-02 | 7.52e-02 | 7.24e-02 | 5.41e-01 | 6.99e-01 | 7.73e-01 | 4.99e-01 | 5.15e-01 |
| REGULATION OF ACTIN FILAMENT ORGANIZATION | 259 | 3.69e-01 | 7.69e-01 | 0.1350 | 7.92e-02 | 7.20e-02 | 4.85e-02 | 6.38e-02 | 2.13e-02 | 2.81e-02 | 4.59e-02 | 1.79e-01 | 7.69e-02 | 5.55e-01 |
| AMINOGLYCAN METABOLIC PROCESS | 118 | 5.77e-02 | 3.16e-01 | 0.1350 | 1.45e-02 | 2.74e-02 | -8.20e-02 | -4.30e-02 | -9.37e-02 | 7.86e-01 | 6.07e-01 | 1.24e-01 | 4.20e-01 | 7.87e-02 |
| EPITHELIAL CELL APOPTOTIC PROCESS | 143 | 3.50e-01 | 7.52e-01 | 0.1350 | 8.47e-03 | 1.76e-02 | 6.03e-02 | 5.73e-02 | 1.05e-01 | 8.61e-01 | 7.17e-01 | 2.13e-01 | 2.37e-01 | 3.03e-02 |
| ZINC ION IMPORT ACROSS PLASMA MEMBRANE | 9 | 9.73e-01 | 9.95e-01 | 0.1350 | 1.03e-02 | 1.84e-02 | -2.79e-02 | -7.51e-02 | -1.07e-01 | 9.57e-01 | 9.24e-01 | 8.85e-01 | 6.97e-01 | 5.79e-01 |
| REGULATION OF REPRODUCTIVE PROCESS | 201 | 6.20e-01 | 9.07e-01 | 0.1350 | 4.93e-02 | 5.94e-02 | 6.77e-02 | 5.97e-02 | 6.44e-02 | 2.28e-01 | 1.46e-01 | 9.79e-02 | 1.44e-01 | 1.15e-01 |
| NEUTRAL LIPID BIOSYNTHETIC PROCESS | 46 | 8.91e-01 | 9.81e-01 | 0.1350 | -5.66e-02 | -2.70e-02 | -6.78e-02 | -8.99e-02 | -4.07e-02 | 5.07e-01 | 7.52e-01 | 4.26e-01 | 2.92e-01 | 6.33e-01 |
| POSITIVE REGULATION OF REPRODUCTIVE PROCESS | 83 | 3.30e-01 | 7.38e-01 | 0.1350 | 6.67e-03 | 4.64e-02 | 3.74e-02 | 9.14e-03 | 1.21e-01 | 9.16e-01 | 4.65e-01 | 5.56e-01 | 8.86e-01 | 5.72e-02 |
| MEMBRANE FUSION | 174 | 4.06e-01 | 7.93e-01 | 0.1350 | 3.31e-02 | 6.59e-02 | 8.02e-02 | 6.90e-02 | 4.02e-02 | 4.51e-01 | 1.34e-01 | 6.78e-02 | 1.16e-01 | 3.60e-01 |
| RETROGRADE AXONAL TRANSPORT | 21 | 7.18e-01 | 9.38e-01 | 0.1350 | 1.30e-02 | -5.08e-02 | 7.06e-02 | 8.12e-02 | 6.25e-02 | 9.18e-01 | 6.87e-01 | 5.75e-01 | 5.19e-01 | 6.20e-01 |
| REGULATORY NCRNA PROCESSING | 84 | 1.43e-01 | 5.09e-01 | 0.1350 | 4.46e-02 | -2.62e-02 | 3.54e-02 | 8.92e-02 | 7.97e-02 | 4.79e-01 | 6.78e-01 | 5.75e-01 | 1.58e-01 | 2.07e-01 |
| POSITIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 21 | 6.45e-01 | 9.16e-01 | 0.1350 | 1.46e-02 | 1.13e-01 | 2.67e-02 | -2.11e-02 | 6.34e-02 | 9.08e-01 | 3.69e-01 | 8.32e-01 | 8.67e-01 | 6.15e-01 |
| GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 286 | 2.86e-01 | 6.94e-01 | 0.1350 | 4.43e-02 | 5.90e-02 | 7.30e-02 | 4.78e-02 | 7.19e-02 | 1.97e-01 | 8.60e-02 | 3.37e-02 | 1.64e-01 | 3.64e-02 |
| REGULATION OF PROTEOLYSIS | 588 | 5.14e-02 | 2.99e-01 | 0.1350 | 6.41e-02 | 7.02e-02 | 5.54e-02 | 6.37e-02 | 4.48e-02 | 7.93e-03 | 3.62e-03 | 2.17e-02 | 8.26e-03 | 6.36e-02 |
| REGULATION OF FIBROBLAST MIGRATION | 38 | 8.55e-02 | 3.95e-01 | 0.1350 | 6.56e-02 | 7.30e-02 | -4.24e-02 | 7.85e-02 | 2.35e-02 | 4.84e-01 | 4.36e-01 | 6.51e-01 | 4.02e-01 | 8.02e-01 |
| SKELETAL MUSCLE ACETYLCHOLINE GATED CHANNEL CLUSTERING | 10 | 7.07e-01 | 9.34e-01 | 0.1350 | 4.34e-02 | 5.42e-02 | -7.66e-02 | -2.88e-02 | 8.13e-02 | 8.12e-01 | 7.66e-01 | 6.75e-01 | 8.75e-01 | 6.56e-01 |
| POSITIVE REGULATION OF CELLULAR EXTRAVASATION | 15 | 8.17e-01 | 9.70e-01 | 0.1350 | -5.04e-03 | -1.06e-02 | -3.96e-02 | -1.82e-02 | 1.27e-01 | 9.73e-01 | 9.43e-01 | 7.91e-01 | 9.03e-01 | 3.95e-01 |
| REGULATION OF NITRIC OXIDE METABOLIC PROCESS | 57 | 6.12e-01 | 9.05e-01 | 0.1350 | 9.23e-02 | 6.42e-02 | 1.36e-02 | 6.44e-02 | 3.38e-02 | 2.28e-01 | 4.02e-01 | 8.59e-01 | 4.01e-01 | 6.59e-01 |
| REGULATION OF LEUKOCYTE CHEMOTAXIS | 120 | 9.20e-02 | 4.12e-01 | 0.1350 | -3.80e-03 | 1.85e-02 | -6.43e-02 | -8.69e-02 | -7.79e-02 | 9.43e-01 | 7.26e-01 | 2.24e-01 | 1.00e-01 | 1.40e-01 |
| NEGATIVE REGULATION OF CALCIUM MEDIATED SIGNALING | 21 | 4.01e-01 | 7.88e-01 | 0.1350 | -7.64e-02 | -2.22e-02 | -1.02e-01 | -1.96e-02 | 3.27e-02 | 5.45e-01 | 8.60e-01 | 4.20e-01 | 8.76e-01 | 7.96e-01 |
| TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 392 | 1.43e-01 | 5.09e-01 | 0.1340 | 3.59e-02 | 4.77e-02 | 6.85e-02 | 6.24e-02 | 7.70e-02 | 2.22e-01 | 1.05e-01 | 1.99e-02 | 3.39e-02 | 8.88e-03 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 118 | 2.10e-01 | 6.05e-01 | 0.1340 | -1.10e-01 | -4.74e-02 | -2.18e-02 | -5.60e-02 | 9.35e-03 | 3.89e-02 | 3.74e-01 | 6.83e-01 | 2.94e-01 | 8.61e-01 |
| VENTRICULAR CARDIAC MUSCLE CELL DIFFERENTIATION | 14 | 6.24e-01 | 9.09e-01 | 0.1340 | 8.46e-02 | -7.34e-02 | -7.18e-02 | 1.54e-02 | -1.01e-02 | 5.84e-01 | 6.34e-01 | 6.42e-01 | 9.21e-01 | 9.48e-01 |
| BONE REMODELING | 89 | 1.85e-02 | 1.59e-01 | 0.1340 | 5.54e-02 | 1.21e-01 | -4.98e-03 | 1.08e-02 | -7.71e-03 | 3.66e-01 | 4.76e-02 | 9.35e-01 | 8.60e-01 | 9.00e-01 |
| REGULATION OF TRIGLYCERIDE METABOLIC PROCESS | 43 | 2.30e-01 | 6.33e-01 | 0.1340 | 1.41e-03 | 5.03e-02 | -2.18e-02 | 3.94e-02 | -1.16e-01 | 9.87e-01 | 5.68e-01 | 8.05e-01 | 6.55e-01 | 1.88e-01 |
| REGULATION OF POSITIVE CHEMOTAXIS | 25 | 9.37e-01 | 9.92e-01 | 0.1340 | 6.31e-02 | 6.95e-02 | 3.13e-02 | 6.63e-02 | 6.18e-02 | 5.85e-01 | 5.47e-01 | 7.86e-01 | 5.66e-01 | 5.93e-01 |
| HETEROTYPIC CELL CELL ADHESION | 61 | 1.77e-01 | 5.63e-01 | 0.1340 | 2.72e-02 | -7.03e-02 | -1.02e-01 | -1.16e-02 | -4.24e-02 | 7.13e-01 | 3.43e-01 | 1.69e-01 | 8.75e-01 | 5.67e-01 |
| CARBOHYDRATE METABOLIC PROCESS | 541 | 4.63e-02 | 2.81e-01 | 0.1340 | 5.19e-02 | 6.36e-02 | 5.74e-02 | 6.47e-02 | 6.13e-02 | 3.87e-02 | 1.14e-02 | 2.24e-02 | 1.00e-02 | 1.47e-02 |
| REGULATION OF CYTOSKELETON ORGANIZATION | 493 | 1.23e-01 | 4.77e-01 | 0.1340 | 6.47e-02 | 6.63e-02 | 5.59e-02 | 7.02e-02 | 3.65e-02 | 1.38e-02 | 1.17e-02 | 3.34e-02 | 7.59e-03 | 1.65e-01 |
| MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 45 | 2.86e-01 | 6.94e-01 | 0.1340 | 3.53e-02 | 3.49e-02 | -8.40e-02 | -7.56e-02 | -5.19e-02 | 6.82e-01 | 6.86e-01 | 3.29e-01 | 3.80e-01 | 5.47e-01 |
| CENTRAL NERVOUS SYSTEM NEURON AXONOGENESIS | 39 | 9.83e-01 | 9.96e-01 | 0.1340 | 7.16e-02 | 7.28e-02 | 6.23e-02 | 5.81e-02 | 1.52e-02 | 4.39e-01 | 4.31e-01 | 5.01e-01 | 5.30e-01 | 8.70e-01 |
| INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 62 | 3.32e-01 | 7.40e-01 | 0.1340 | 1.64e-02 | 8.97e-02 | 8.88e-02 | 3.78e-02 | -1.66e-02 | 8.24e-01 | 2.22e-01 | 2.27e-01 | 6.07e-01 | 8.21e-01 |
| COLLATERAL SPROUTING | 26 | 4.05e-01 | 7.92e-01 | 0.1340 | 8.84e-02 | 5.11e-02 | -5.11e-02 | 6.95e-02 | -3.49e-04 | 4.35e-01 | 6.52e-01 | 6.52e-01 | 5.40e-01 | 9.98e-01 |
| TYROSINE METABOLIC PROCESS | 17 | 9.71e-01 | 9.95e-01 | 0.1340 | 3.25e-03 | -2.00e-02 | -6.12e-02 | -1.07e-02 | -1.17e-01 | 9.82e-01 | 8.87e-01 | 6.62e-01 | 9.39e-01 | 4.05e-01 |
| RAC PROTEIN SIGNAL TRANSDUCTION | 41 | 4.33e-01 | 8.07e-01 | 0.1340 | 1.81e-02 | -3.72e-03 | -1.33e-02 | 6.02e-02 | -1.17e-01 | 8.41e-01 | 9.67e-01 | 8.83e-01 | 5.05e-01 | 1.95e-01 |
| ACID SECRETION | 43 | 1.42e-01 | 5.08e-01 | 0.1340 | 7.87e-03 | 1.52e-02 | -1.19e-01 | -5.39e-02 | -2.40e-02 | 9.29e-01 | 8.63e-01 | 1.78e-01 | 5.41e-01 | 7.86e-01 |
| CHONDROITIN SULFATE METABOLIC PROCESS | 26 | 6.48e-01 | 9.17e-01 | 0.1330 | 6.30e-02 | 6.14e-02 | 2.49e-04 | 8.75e-02 | 4.91e-02 | 5.78e-01 | 5.88e-01 | 9.98e-01 | 4.40e-01 | 6.65e-01 |
| G PROTEIN COUPLED SEROTONIN RECEPTOR SIGNALING PATHWAY | 22 | 6.10e-01 | 9.04e-01 | 0.1330 | 7.10e-03 | -3.75e-02 | -4.50e-02 | 1.99e-02 | 1.18e-01 | 9.54e-01 | 7.61e-01 | 7.15e-01 | 8.72e-01 | 3.38e-01 |
| HEART TRABECULA FORMATION | 15 | 8.99e-01 | 9.83e-01 | 0.1330 | 1.05e-01 | 7.86e-02 | 2.16e-02 | -1.77e-03 | 9.30e-03 | 4.81e-01 | 5.98e-01 | 8.85e-01 | 9.91e-01 | 9.50e-01 |
| SENSORY ORGAN DEVELOPMENT | 578 | 2.51e-03 | 3.65e-02 | 0.1330 | 1.34e-02 | 4.04e-02 | 7.08e-02 | 3.80e-02 | 9.75e-02 | 5.82e-01 | 9.68e-02 | 3.60e-03 | 1.19e-01 | 6.09e-05 |
| POSITIVE REGULATION OF AUTOPHAGY | 143 | 4.87e-01 | 8.38e-01 | 0.1330 | 7.92e-02 | 3.83e-02 | 5.62e-02 | 7.93e-02 | 2.47e-02 | 1.02e-01 | 4.29e-01 | 2.46e-01 | 1.02e-01 | 6.10e-01 |
| ENDOCRINE PROCESS | 87 | 1.67e-01 | 5.48e-01 | 0.1330 | 9.64e-02 | 6.55e-02 | -2.77e-02 | 7.03e-03 | -5.76e-02 | 1.20e-01 | 2.91e-01 | 6.56e-01 | 9.10e-01 | 3.53e-01 |
| G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY COUPLED TO CYCLIC NUCLEOTIDE SECOND MESSENGER | 54 | 1.30e-01 | 4.87e-01 | 0.1330 | 1.59e-02 | -2.82e-02 | -3.39e-02 | -3.53e-02 | 1.19e-01 | 8.39e-01 | 7.20e-01 | 6.67e-01 | 6.54e-01 | 1.29e-01 |
| ENDOPLASMIC RETICULUM LOCALIZATION | 10 | 6.36e-01 | 9.13e-01 | 0.1330 | -3.11e-02 | -4.38e-02 | 4.03e-02 | -1.14e-01 | -1.51e-02 | 8.65e-01 | 8.10e-01 | 8.25e-01 | 5.33e-01 | 9.34e-01 |
| ENDOCYTOSIS INVOLVED IN VIRAL ENTRY INTO HOST CELL | 12 | 9.99e-01 | 1.00e+00 | 0.1330 | 5.40e-02 | 7.82e-02 | 6.34e-02 | 5.84e-02 | 3.47e-02 | 7.46e-01 | 6.39e-01 | 7.04e-01 | 7.26e-01 | 8.35e-01 |
| MEMBRANE HYPERPOLARIZATION | 10 | 7.15e-01 | 9.36e-01 | 0.1330 | -3.77e-02 | 3.16e-02 | 1.04e-01 | -2.37e-02 | -6.24e-02 | 8.36e-01 | 8.63e-01 | 5.69e-01 | 8.97e-01 | 7.33e-01 |
| BONE DEVELOPMENT | 204 | 7.04e-02 | 3.59e-01 | 0.1330 | 7.12e-03 | 7.29e-02 | 7.31e-02 | 4.16e-02 | 7.21e-02 | 8.61e-01 | 7.26e-02 | 7.17e-02 | 3.05e-01 | 7.57e-02 |
| NATURAL KILLER CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 11 | 6.42e-01 | 9.14e-01 | 0.1330 | -1.04e-02 | -3.51e-02 | -1.24e-01 | 1.96e-02 | 2.39e-02 | 9.52e-01 | 8.40e-01 | 4.77e-01 | 9.10e-01 | 8.91e-01 |
| NEGATIVE REGULATION OF ANOIKIS | 18 | 5.34e-01 | 8.64e-01 | 0.1330 | -6.89e-03 | 9.12e-02 | -1.77e-02 | -4.91e-02 | 8.09e-02 | 9.60e-01 | 5.03e-01 | 8.96e-01 | 7.18e-01 | 5.52e-01 |
| REGULATION OF MRNA EXPORT FROM NUCLEUS | 7 | 8.88e-01 | 9.80e-01 | 0.1330 | 1.10e-01 | -8.60e-03 | -7.20e-02 | 6.37e-03 | 1.18e-02 | 6.13e-01 | 9.69e-01 | 7.41e-01 | 9.77e-01 | 9.57e-01 |
| CELLULAR DEFENSE RESPONSE | 50 | 5.74e-02 | 3.16e-01 | 0.1330 | -2.37e-03 | -1.20e-01 | -8.56e-03 | 3.03e-02 | -4.68e-02 | 9.77e-01 | 1.42e-01 | 9.17e-01 | 7.11e-01 | 5.67e-01 |
| REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 57 | 7.06e-01 | 9.33e-01 | 0.1330 | 3.92e-02 | 7.78e-03 | 6.62e-02 | 4.88e-02 | 9.61e-02 | 6.08e-01 | 9.19e-01 | 3.87e-01 | 5.24e-01 | 2.09e-01 |
| GOLGI TO PLASMA MEMBRANE TRANSPORT | 57 | 3.31e-01 | 7.39e-01 | 0.1330 | 4.61e-02 | -7.86e-03 | -5.02e-02 | 4.76e-02 | -1.03e-01 | 5.48e-01 | 9.18e-01 | 5.12e-01 | 5.34e-01 | 1.78e-01 |
| MEMBRANE DOCKING | 91 | 6.74e-01 | 9.27e-01 | 0.1320 | 6.38e-02 | 6.94e-02 | 5.42e-02 | 3.35e-02 | 6.79e-02 | 2.93e-01 | 2.53e-01 | 3.71e-01 | 5.81e-01 | 2.63e-01 |
| CORTICAL ACTIN CYTOSKELETON ORGANIZATION | 42 | 7.18e-01 | 9.38e-01 | 0.1320 | 5.27e-02 | 3.44e-03 | -4.20e-02 | 2.17e-02 | -1.12e-01 | 5.54e-01 | 9.69e-01 | 6.38e-01 | 8.08e-01 | 2.10e-01 |
| CMP METABOLIC PROCESS | 8 | 8.38e-01 | 9.73e-01 | 0.1320 | 6.67e-02 | 4.21e-02 | -6.56e-02 | 1.63e-03 | 8.35e-02 | 7.44e-01 | 8.36e-01 | 7.48e-01 | 9.94e-01 | 6.82e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS ANTIGEN | 47 | 4.07e-01 | 7.93e-01 | 0.1320 | 3.28e-02 | 5.39e-02 | 2.39e-02 | 7.78e-02 | -8.30e-02 | 6.97e-01 | 5.23e-01 | 7.77e-01 | 3.56e-01 | 3.25e-01 |
| MEMBRANE DEPOLARIZATION | 78 | 1.73e-01 | 5.57e-01 | 0.1320 | -9.26e-02 | -2.37e-03 | 3.09e-02 | -2.66e-02 | 8.51e-02 | 1.57e-01 | 9.71e-01 | 6.37e-01 | 6.85e-01 | 1.94e-01 |
| REGULATION OF SMALL MOLECULE METABOLIC PROCESS | 325 | 1.99e-02 | 1.66e-01 | 0.1320 | 5.16e-02 | 6.25e-02 | 4.11e-02 | 4.29e-02 | 8.59e-02 | 1.09e-01 | 5.27e-02 | 2.03e-01 | 1.84e-01 | 7.73e-03 |
| HOMOLOGOUS CHROMOSOME SEGREGATION | 64 | 2.40e-01 | 6.44e-01 | 0.1320 | 6.46e-03 | -5.21e-02 | -1.79e-02 | 9.81e-03 | -1.20e-01 | 9.29e-01 | 4.71e-01 | 8.04e-01 | 8.92e-01 | 9.82e-02 |
| EMBRYONIC NEUROCRANIUM MORPHOGENESIS | 8 | 9.79e-01 | 9.96e-01 | 0.1320 | 8.43e-02 | 1.90e-02 | 4.75e-03 | 9.89e-02 | 1.16e-02 | 6.80e-01 | 9.26e-01 | 9.81e-01 | 6.28e-01 | 9.55e-01 |
| CARBOHYDRATE PHOSPHORYLATION | 22 | 7.19e-01 | 9.38e-01 | 0.1320 | -1.02e-04 | 7.81e-02 | 1.94e-02 | 5.59e-03 | 1.04e-01 | 9.99e-01 | 5.26e-01 | 8.75e-01 | 9.64e-01 | 3.97e-01 |
| CARDIAC FIBROBLAST CELL DIFFERENTIATION | 5 | 9.29e-01 | 9.89e-01 | 0.1320 | 1.18e-01 | -1.47e-03 | -1.05e-02 | -3.08e-02 | -4.92e-02 | 6.48e-01 | 9.95e-01 | 9.68e-01 | 9.05e-01 | 8.49e-01 |
| REGULATION OF LIPID STORAGE | 54 | 4.45e-01 | 8.14e-01 | 0.1320 | -1.79e-02 | -4.23e-02 | -1.09e-01 | -2.96e-02 | -4.92e-02 | 8.20e-01 | 5.91e-01 | 1.65e-01 | 7.07e-01 | 5.31e-01 |
| REGULATION OF OXIDOREDUCTASE ACTIVITY | 77 | 2.09e-01 | 6.03e-01 | 0.1320 | 7.87e-02 | 9.96e-02 | -9.55e-04 | -5.32e-03 | -3.49e-02 | 2.32e-01 | 1.31e-01 | 9.88e-01 | 9.36e-01 | 5.96e-01 |
| POSITIVE REGULATION OF CELL MATRIX ADHESION | 56 | 5.86e-01 | 8.91e-01 | 0.1320 | -3.53e-02 | -4.66e-02 | -9.57e-02 | -6.87e-02 | 5.25e-03 | 6.48e-01 | 5.46e-01 | 2.15e-01 | 3.74e-01 | 9.46e-01 |
| REGULATION OF PHOSPHORYLATION | 1010 | 1.60e-03 | 2.55e-02 | 0.1310 | 6.24e-02 | 5.64e-02 | 5.18e-02 | 6.87e-02 | 5.28e-02 | 7.84e-04 | 2.43e-03 | 5.31e-03 | 2.18e-04 | 4.54e-03 |
| MYOTUBE CELL DEVELOPMENT | 40 | 7.17e-01 | 9.37e-01 | 0.1310 | -7.35e-02 | -8.50e-02 | -1.17e-03 | 2.33e-03 | 6.80e-02 | 4.21e-01 | 3.52e-01 | 9.90e-01 | 9.80e-01 | 4.57e-01 |
| REGULATION OF BIOLOGICAL PROCESS INVOLVED IN SYMBIOTIC INTERACTION | 64 | 9.49e-02 | 4.18e-01 | 0.1310 | 8.67e-02 | 5.59e-02 | -2.96e-02 | -5.05e-02 | -5.63e-02 | 2.30e-01 | 4.39e-01 | 6.82e-01 | 4.85e-01 | 4.36e-01 |
| POSITIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 82 | 8.22e-01 | 9.71e-01 | 0.1310 | -8.04e-02 | -6.25e-02 | -6.17e-02 | -4.96e-02 | -2.40e-02 | 2.08e-01 | 3.28e-01 | 3.34e-01 | 4.37e-01 | 7.07e-01 |
| REGULATION OF SYNAPTIC TRANSMISSION GABAERGIC | 35 | 9.20e-01 | 9.86e-01 | 0.1310 | -8.84e-02 | -3.40e-02 | -4.37e-02 | -7.71e-02 | -1.91e-02 | 3.65e-01 | 7.28e-01 | 6.55e-01 | 4.30e-01 | 8.45e-01 |
| REGULATION OF RESPONSE TO STRESS | 1437 | 9.82e-06 | 3.69e-04 | 0.1310 | 6.65e-02 | 6.21e-02 | 4.63e-02 | 6.73e-02 | 4.73e-02 | 2.40e-05 | 8.05e-05 | 3.27e-03 | 1.89e-05 | 2.69e-03 |
| REGULATION OF LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 22 | 3.57e-01 | 7.57e-01 | 0.1310 | -3.48e-02 | 3.45e-02 | 4.55e-02 | 1.12e-01 | 1.25e-02 | 7.78e-01 | 7.79e-01 | 7.12e-01 | 3.63e-01 | 9.19e-01 |
| RECEPTOR RECYCLING | 46 | 8.15e-01 | 9.69e-01 | 0.1310 | 1.16e-02 | 2.04e-02 | 5.67e-02 | 7.94e-02 | 8.43e-02 | 8.92e-01 | 8.11e-01 | 5.06e-01 | 3.52e-01 | 3.22e-01 |
| CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 292 | 1.16e-01 | 4.64e-01 | 0.1310 | 7.85e-02 | 7.33e-02 | 3.31e-02 | 6.72e-02 | 3.09e-03 | 2.10e-02 | 3.11e-02 | 3.30e-01 | 4.82e-02 | 9.28e-01 |
| CHONDROCYTE PROLIFERATION | 24 | 5.79e-01 | 8.86e-01 | 0.1310 | -6.94e-02 | 4.77e-02 | 5.00e-02 | 2.34e-02 | 8.37e-02 | 5.56e-01 | 6.86e-01 | 6.72e-01 | 8.43e-01 | 4.78e-01 |
| REGULATION OF LONG CHAIN FATTY ACID IMPORT INTO CELL | 8 | 9.04e-01 | 9.84e-01 | 0.1310 | -7.52e-02 | 2.39e-02 | -7.60e-03 | 7.75e-03 | 1.04e-01 | 7.13e-01 | 9.07e-01 | 9.70e-01 | 9.70e-01 | 6.11e-01 |
| ENDOTHELIAL CELL PROLIFERATION | 197 | 6.47e-02 | 3.38e-01 | 0.1310 | -6.54e-02 | -4.86e-02 | -5.64e-02 | -6.38e-02 | 5.69e-02 | 1.13e-01 | 2.39e-01 | 1.72e-01 | 1.23e-01 | 1.69e-01 |
| REGULATION OF TRANSLATION IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 11 | 9.13e-01 | 9.85e-01 | 0.1310 | -3.92e-02 | 6.36e-02 | 4.72e-02 | -5.11e-02 | 8.18e-02 | 8.22e-01 | 7.15e-01 | 7.86e-01 | 7.69e-01 | 6.39e-01 |
| POSITIVE REGULATION OF CALCIUM MEDIATED SIGNALING | 42 | 4.83e-01 | 8.37e-01 | 0.1310 | 2.56e-02 | -1.25e-02 | -6.76e-02 | -8.87e-02 | -6.21e-02 | 7.74e-01 | 8.89e-01 | 4.48e-01 | 3.20e-01 | 4.86e-01 |
| OTIC VESICLE MORPHOGENESIS | 10 | 8.58e-01 | 9.77e-01 | 0.1310 | 7.96e-02 | 8.58e-02 | -3.88e-02 | 1.25e-02 | 4.15e-02 | 6.63e-01 | 6.38e-01 | 8.32e-01 | 9.45e-01 | 8.20e-01 |
| NEGATIVE REGULATION OF AMYLOID FIBRIL FORMATION | 12 | 6.58e-01 | 9.20e-01 | 0.1310 | -6.62e-02 | 9.73e-02 | 2.32e-02 | -1.76e-02 | 4.88e-02 | 6.91e-01 | 5.59e-01 | 8.90e-01 | 9.16e-01 | 7.70e-01 |
| RESPONSE TO MAGNESIUM ION | 20 | 9.71e-01 | 9.95e-01 | 0.1310 | -3.64e-02 | -9.14e-03 | -7.51e-02 | -7.15e-02 | -7.00e-02 | 7.78e-01 | 9.44e-01 | 5.61e-01 | 5.80e-01 | 5.88e-01 |
| REGULATION OF MONONUCLEAR CELL MIGRATION | 119 | 2.44e-01 | 6.48e-01 | 0.1310 | 2.13e-02 | 2.29e-02 | -5.14e-02 | -3.62e-02 | -1.10e-01 | 6.88e-01 | 6.67e-01 | 3.33e-01 | 4.95e-01 | 3.79e-02 |
| GLYCEROLIPID BIOSYNTHETIC PROCESS | 236 | 5.14e-01 | 8.55e-01 | 0.1310 | 4.41e-02 | 5.45e-02 | 6.42e-02 | 6.83e-02 | 5.80e-02 | 2.43e-01 | 1.49e-01 | 8.91e-02 | 7.05e-02 | 1.25e-01 |
| DETECTION OF STIMULUS INVOLVED IN SENSORY PERCEPTION OF PAIN | 26 | 6.80e-01 | 9.28e-01 | 0.1310 | -3.88e-02 | 3.99e-02 | 7.89e-02 | -3.34e-02 | 8.14e-02 | 7.32e-01 | 7.25e-01 | 4.86e-01 | 7.68e-01 | 4.72e-01 |
| NEGATIVE REGULATION OF ADENYLATE CYCLASE ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 11 | 8.68e-01 | 9.78e-01 | 0.1300 | 1.28e-02 | 1.12e-01 | 1.98e-02 | 2.19e-02 | 5.94e-02 | 9.41e-01 | 5.21e-01 | 9.10e-01 | 9.00e-01 | 7.33e-01 |
| REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 90 | 2.99e-01 | 7.11e-01 | 0.1300 | 3.26e-02 | -3.05e-03 | 2.89e-02 | 6.95e-02 | 1.01e-01 | 5.93e-01 | 9.60e-01 | 6.36e-01 | 2.55e-01 | 9.64e-02 |
| PROTEIN KINASE C SIGNALING | 35 | 7.55e-01 | 9.51e-01 | 0.1300 | -6.91e-02 | -4.76e-02 | -8.90e-02 | -3.52e-02 | -2.82e-02 | 4.79e-01 | 6.26e-01 | 3.62e-01 | 7.18e-01 | 7.73e-01 |
| REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 341 | 2.05e-01 | 5.97e-01 | 0.1300 | 3.21e-02 | 5.82e-02 | 6.85e-02 | 5.61e-02 | 6.88e-02 | 3.08e-01 | 6.46e-02 | 2.98e-02 | 7.52e-02 | 2.89e-02 |
| NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 502 | 8.10e-02 | 3.85e-01 | 0.1300 | 7.01e-02 | 5.60e-02 | 5.01e-02 | 6.48e-02 | 4.69e-02 | 7.18e-03 | 3.17e-02 | 5.44e-02 | 1.29e-02 | 7.22e-02 |
| SODIUM ION EXPORT ACROSS PLASMA MEMBRANE | 15 | 8.42e-01 | 9.75e-01 | 0.1300 | -3.34e-02 | 6.08e-02 | 8.71e-02 | -2.89e-02 | 6.10e-02 | 8.23e-01 | 6.84e-01 | 5.59e-01 | 8.46e-01 | 6.82e-01 |
| REGULATION OF GLUCOSE METABOLIC PROCESS | 99 | 3.16e-01 | 7.27e-01 | 0.1300 | 2.72e-02 | 5.24e-02 | 3.24e-02 | 3.26e-02 | 1.06e-01 | 6.39e-01 | 3.68e-01 | 5.77e-01 | 5.75e-01 | 6.72e-02 |
| REGULATION OF MEMBRANE TUBULATION | 5 | 9.49e-01 | 9.94e-01 | 0.1300 | 3.58e-02 | -9.92e-02 | -4.54e-02 | -4.67e-02 | -3.94e-02 | 8.90e-01 | 7.01e-01 | 8.61e-01 | 8.56e-01 | 8.79e-01 |
| PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 57 | 5.53e-01 | 8.76e-01 | 0.1300 | 3.46e-02 | 7.90e-02 | 3.45e-02 | 2.30e-02 | 8.78e-02 | 6.51e-01 | 3.02e-01 | 6.53e-01 | 7.64e-01 | 2.52e-01 |
| QUINOLINATE METABOLIC PROCESS | 5 | 9.76e-01 | 9.96e-01 | 0.1300 | -7.35e-02 | 4.62e-02 | -3.05e-03 | -8.80e-02 | 3.97e-02 | 7.76e-01 | 8.58e-01 | 9.91e-01 | 7.33e-01 | 8.78e-01 |
| OLEFINIC COMPOUND METABOLIC PROCESS | 157 | 5.91e-01 | 8.94e-01 | 0.1300 | -5.06e-02 | -4.55e-02 | -5.17e-02 | -6.80e-02 | -7.02e-02 | 2.74e-01 | 3.26e-01 | 2.63e-01 | 1.41e-01 | 1.29e-01 |
| POSITIVE REGULATION OF T CELL APOPTOTIC PROCESS | 13 | 9.00e-01 | 9.83e-01 | 0.1300 | -8.03e-02 | 2.04e-02 | -3.14e-02 | -9.12e-02 | 2.61e-02 | 6.16e-01 | 8.99e-01 | 8.45e-01 | 5.69e-01 | 8.71e-01 |
| LEUKOCYTE CHEMOTAXIS | 233 | 1.17e-04 | 3.13e-03 | 0.1300 | 6.60e-02 | 8.15e-02 | -1.98e-02 | -3.91e-02 | -6.25e-02 | 8.27e-02 | 3.21e-02 | 6.03e-01 | 3.04e-01 | 1.00e-01 |
| PHOTORECEPTOR CELL DEVELOPMENT | 49 | 1.50e-01 | 5.19e-01 | 0.1300 | -4.56e-02 | 4.98e-02 | 7.71e-03 | -9.68e-02 | 5.30e-02 | 5.81e-01 | 5.46e-01 | 9.26e-01 | 2.41e-01 | 5.21e-01 |
| GLYCEROLIPID CATABOLIC PROCESS | 64 | 7.72e-02 | 3.77e-01 | 0.1300 | 9.72e-03 | 9.52e-02 | -1.77e-02 | -5.98e-02 | -6.11e-02 | 8.93e-01 | 1.88e-01 | 8.07e-01 | 4.08e-01 | 3.98e-01 |
| REGULATION OF DEFENSE RESPONSE TO VIRUS BY HOST | 43 | 8.24e-01 | 9.71e-01 | 0.1300 | 8.53e-02 | 6.08e-02 | 5.26e-02 | 3.83e-02 | -3.97e-02 | 3.33e-01 | 4.90e-01 | 5.51e-01 | 6.64e-01 | 6.52e-01 |
| NUCLEAR TRANSCRIBED MRNA POLY A TAIL SHORTENING | 34 | 3.99e-01 | 7.87e-01 | 0.1290 | -2.38e-02 | -6.13e-02 | 1.21e-02 | 8.87e-02 | 6.65e-02 | 8.10e-01 | 5.36e-01 | 9.03e-01 | 3.71e-01 | 5.02e-01 |
| SODIUM ION HOMEOSTASIS | 46 | 1.41e-01 | 5.07e-01 | 0.1290 | -6.54e-02 | -3.83e-02 | 5.42e-02 | -7.44e-02 | 5.01e-02 | 4.43e-01 | 6.53e-01 | 5.25e-01 | 3.82e-01 | 5.56e-01 |
| MONONUCLEAR CELL MIGRATION | 199 | 6.64e-03 | 7.59e-02 | 0.1290 | 6.46e-02 | 6.52e-02 | -3.11e-02 | -2.08e-02 | -8.30e-02 | 1.16e-01 | 1.13e-01 | 4.49e-01 | 6.12e-01 | 4.34e-02 |
| POSTSYNAPTIC MEMBRANE ORGANIZATION | 35 | 5.87e-01 | 8.91e-01 | 0.1290 | 6.05e-02 | 1.13e-01 | 6.76e-03 | 5.19e-03 | -1.10e-02 | 5.36e-01 | 2.46e-01 | 9.45e-01 | 9.58e-01 | 9.10e-01 |
| VESICLE MEDIATED TRANSPORT TO THE PLASMA MEMBRANE | 145 | 3.28e-02 | 2.30e-01 | 0.1290 | 5.40e-02 | 4.79e-02 | 1.25e-03 | 7.33e-02 | -7.81e-02 | 2.61e-01 | 3.20e-01 | 9.79e-01 | 1.28e-01 | 1.04e-01 |
| REGULATION OF T CELL ACTIVATION | 369 | 2.10e-02 | 1.72e-01 | 0.1290 | 2.72e-02 | 2.79e-02 | 6.19e-02 | 8.35e-02 | 6.60e-02 | 3.69e-01 | 3.58e-01 | 4.12e-02 | 5.85e-03 | 2.94e-02 |
| TUBE DEVELOPMENT | 1121 | 1.51e-05 | 5.41e-04 | 0.1290 | 3.22e-02 | 5.99e-02 | 5.76e-02 | 4.32e-02 | 8.26e-02 | 6.88e-02 | 7.06e-04 | 1.13e-03 | 1.47e-02 | 3.01e-06 |
| REGULATION OF MONOOXYGENASE ACTIVITY | 42 | 4.27e-01 | 8.05e-01 | 0.1290 | 2.25e-02 | 9.15e-02 | -3.08e-03 | -3.39e-02 | -8.10e-02 | 8.01e-01 | 3.05e-01 | 9.72e-01 | 7.04e-01 | 3.63e-01 |
| FOLATE TRANSMEMBRANE TRANSPORT | 5 | 9.81e-01 | 9.96e-01 | 0.1290 | 4.87e-02 | 1.16e-01 | 2.53e-03 | -2.19e-02 | 1.46e-02 | 8.50e-01 | 6.52e-01 | 9.92e-01 | 9.32e-01 | 9.55e-01 |
| RECEPTOR INTERNALIZATION | 123 | 5.16e-01 | 8.56e-01 | 0.1290 | 8.99e-02 | 6.92e-02 | 3.03e-02 | 5.01e-02 | 1.72e-02 | 8.51e-02 | 1.85e-01 | 5.61e-01 | 3.38e-01 | 7.42e-01 |
| REGULATION OF SIGNALING RECEPTOR ACTIVITY | 104 | 3.59e-01 | 7.58e-01 | 0.1290 | -9.21e-02 | -3.50e-02 | -1.74e-02 | -6.31e-02 | 5.11e-02 | 1.05e-01 | 5.37e-01 | 7.59e-01 | 2.66e-01 | 3.68e-01 |
| QUATERNARY AMMONIUM GROUP TRANSPORT | 29 | 4.23e-01 | 8.03e-01 | 0.1290 | -9.19e-02 | -5.19e-02 | 1.76e-02 | 5.36e-02 | 4.77e-02 | 3.92e-01 | 6.29e-01 | 8.70e-01 | 6.17e-01 | 6.56e-01 |
| REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 102 | 6.29e-01 | 9.10e-01 | 0.1290 | 8.45e-02 | 5.66e-02 | 3.11e-02 | 6.49e-02 | 3.25e-02 | 1.40e-01 | 3.24e-01 | 5.88e-01 | 2.57e-01 | 5.71e-01 |
| VITAMIN D METABOLIC PROCESS | 20 | 7.51e-01 | 9.51e-01 | 0.1290 | -1.67e-02 | -1.73e-02 | -4.31e-02 | -9.14e-02 | 7.60e-02 | 8.97e-01 | 8.93e-01 | 7.39e-01 | 4.79e-01 | 5.56e-01 |
| POSITIVE REGULATION OF CELL POPULATION PROLIFERATION | 1217 | 4.89e-05 | 1.51e-03 | 0.1290 | 3.58e-02 | 5.27e-02 | 5.75e-02 | 6.25e-02 | 7.27e-02 | 3.53e-02 | 1.95e-03 | 7.24e-04 | 2.41e-04 | 1.96e-05 |
| POSITIVE REGULATION OF CALCIUM ION TRANSPORT | 113 | 4.10e-01 | 7.95e-01 | 0.1290 | -9.37e-02 | -4.81e-02 | -5.22e-02 | -5.22e-02 | -3.69e-04 | 8.53e-02 | 3.77e-01 | 3.38e-01 | 3.38e-01 | 9.95e-01 |
| CELL CELL ADHESION INVOLVED IN GASTRULATION | 11 | 7.37e-01 | 9.48e-01 | 0.1290 | 3.14e-02 | 6.49e-02 | -5.85e-02 | -3.84e-02 | 8.02e-02 | 8.57e-01 | 7.09e-01 | 7.37e-01 | 8.26e-01 | 6.45e-01 |
| POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 81 | 5.89e-01 | 8.92e-01 | 0.1280 | 6.49e-02 | 7.98e-02 | 4.36e-02 | 2.30e-02 | 5.91e-02 | 3.13e-01 | 2.14e-01 | 4.98e-01 | 7.21e-01 | 3.58e-01 |
| HEART TRABECULA MORPHOGENESIS | 32 | 9.91e-01 | 9.98e-01 | 0.1280 | -5.23e-02 | -5.48e-02 | -5.77e-02 | -6.74e-02 | -5.37e-02 | 6.08e-01 | 5.92e-01 | 5.72e-01 | 5.09e-01 | 5.99e-01 |
| NERVOUS SYSTEM PROCESS INVOLVED IN REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 11 | 6.18e-01 | 9.07e-01 | 0.1280 | -4.21e-02 | -8.01e-04 | 7.31e-02 | -9.20e-02 | -2.93e-02 | 8.09e-01 | 9.96e-01 | 6.74e-01 | 5.97e-01 | 8.66e-01 |
| SENSORY PERCEPTION OF MECHANICAL STIMULUS | 179 | 8.22e-02 | 3.88e-01 | 0.1280 | -8.70e-02 | -3.09e-02 | -1.63e-02 | -7.02e-02 | 5.23e-02 | 4.47e-02 | 4.76e-01 | 7.06e-01 | 1.05e-01 | 2.27e-01 |
| FATTY ACID ELONGATION | 12 | 9.44e-01 | 9.93e-01 | 0.1280 | -2.14e-02 | -5.93e-02 | 3.81e-02 | 6.44e-02 | 8.28e-02 | 8.98e-01 | 7.22e-01 | 8.19e-01 | 6.99e-01 | 6.19e-01 |
| TRANSPORT ALONG MICROTUBULE | 164 | 8.90e-02 | 4.04e-01 | 0.1280 | -9.00e-03 | -2.30e-02 | 4.12e-02 | 5.08e-02 | 1.07e-01 | 8.42e-01 | 6.11e-01 | 3.62e-01 | 2.62e-01 | 1.76e-02 |
| COPULATION | 19 | 8.08e-01 | 9.67e-01 | 0.1280 | 1.90e-02 | -2.99e-02 | 3.31e-03 | 8.13e-02 | 9.23e-02 | 8.86e-01 | 8.21e-01 | 9.80e-01 | 5.40e-01 | 4.86e-01 |
| RNA DESTABILIZATION | 163 | 2.26e-03 | 3.37e-02 | 0.1280 | 3.99e-03 | -5.08e-02 | 2.97e-02 | 8.68e-02 | 7.32e-02 | 9.30e-01 | 2.63e-01 | 5.12e-01 | 5.57e-02 | 1.07e-01 |
| TRIGLYCERIDE BIOSYNTHETIC PROCESS | 40 | 9.73e-01 | 9.95e-01 | 0.1280 | -7.42e-02 | -4.81e-02 | -5.36e-02 | -7.43e-02 | -1.24e-02 | 4.17e-01 | 5.98e-01 | 5.57e-01 | 4.16e-01 | 8.92e-01 |
| PYRIMIDINE CONTAINING COMPOUND METABOLIC PROCESS | 85 | 5.15e-01 | 8.56e-01 | 0.1280 | 6.88e-02 | 5.31e-02 | 2.42e-02 | 6.71e-02 | 6.11e-02 | 2.73e-01 | 3.97e-01 | 7.00e-01 | 2.85e-01 | 3.30e-01 |
| REGULATION OF CELL MORPHOGENESIS | 233 | 1.60e-01 | 5.34e-01 | 0.1280 | -2.94e-02 | -4.04e-02 | -8.89e-02 | -5.11e-02 | -5.79e-02 | 4.40e-01 | 2.88e-01 | 1.94e-02 | 1.79e-01 | 1.28e-01 |
| NEGATIVE REGULATION OF MACROPHAGE MIGRATION | 14 | 9.00e-01 | 9.83e-01 | 0.1280 | 3.46e-02 | -5.27e-02 | -8.27e-02 | 2.31e-02 | -7.05e-02 | 8.23e-01 | 7.33e-01 | 5.92e-01 | 8.81e-01 | 6.48e-01 |
| POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 13 | 5.82e-01 | 8.88e-01 | 0.1280 | 9.00e-02 | -4.09e-02 | -6.38e-02 | -4.27e-02 | 2.53e-02 | 5.74e-01 | 7.98e-01 | 6.90e-01 | 7.90e-01 | 8.74e-01 |
| REGULATION OF PROTEIN DEACETYLATION | 31 | 3.22e-01 | 7.32e-01 | 0.1280 | -1.01e-02 | -5.30e-02 | -8.22e-02 | 1.16e-02 | 8.05e-02 | 9.23e-01 | 6.10e-01 | 4.28e-01 | 9.11e-01 | 4.38e-01 |
| RECEPTOR CATABOLIC PROCESS | 27 | 6.94e-01 | 9.31e-01 | 0.1280 | -6.25e-03 | 5.15e-02 | -1.59e-03 | 4.36e-03 | -1.17e-01 | 9.55e-01 | 6.43e-01 | 9.89e-01 | 9.69e-01 | 2.95e-01 |
| REGULATION OF MACROPHAGE CHEMOTAXIS | 28 | 4.72e-01 | 8.30e-01 | 0.1280 | -8.81e-03 | 8.17e-02 | -4.21e-02 | -5.71e-02 | -6.71e-02 | 9.36e-01 | 4.54e-01 | 7.00e-01 | 6.01e-01 | 5.39e-01 |
| INTERLEUKIN 8 PRODUCTION | 97 | 1.80e-01 | 5.65e-01 | 0.1280 | 8.39e-02 | 4.80e-02 | -3.22e-02 | -5.89e-03 | -7.65e-02 | 1.53e-01 | 4.14e-01 | 5.84e-01 | 9.20e-01 | 1.93e-01 |
| UBIQUITIN RECYCLING | 13 | 9.28e-01 | 9.89e-01 | 0.1280 | 2.68e-02 | -4.18e-02 | 1.04e-02 | 4.66e-02 | 1.07e-01 | 8.67e-01 | 7.94e-01 | 9.48e-01 | 7.71e-01 | 5.03e-01 |
| CALCIUM ION TRANSPORT | 427 | 1.83e-02 | 1.58e-01 | 0.1280 | -8.39e-02 | -3.85e-02 | -4.88e-02 | -7.05e-02 | -2.01e-02 | 2.94e-03 | 1.73e-01 | 8.35e-02 | 1.25e-02 | 4.76e-01 |
| NEGATIVE REGULATION OF ANDROGEN RECEPTOR SIGNALING PATHWAY | 15 | 9.82e-01 | 9.96e-01 | 0.1280 | -8.30e-02 | -2.55e-02 | -4.82e-02 | -6.67e-02 | -4.41e-02 | 5.78e-01 | 8.64e-01 | 7.47e-01 | 6.55e-01 | 7.67e-01 |
| REGULATION OF NERVOUS SYSTEM PROCESS | 114 | 5.66e-01 | 8.81e-01 | 0.1270 | -7.94e-02 | -4.84e-02 | -3.21e-02 | -8.07e-02 | 6.86e-03 | 1.43e-01 | 3.72e-01 | 5.54e-01 | 1.37e-01 | 8.99e-01 |
| REGULATION OF CELLULAR COMPONENT BIOGENESIS | 956 | 1.94e-02 | 1.63e-01 | 0.1270 | 5.99e-02 | 5.95e-02 | 5.68e-02 | 6.31e-02 | 4.35e-02 | 1.70e-03 | 1.81e-03 | 2.94e-03 | 9.46e-04 | 2.27e-02 |
| INTERLEUKIN 5 PRODUCTION | 19 | 5.22e-01 | 8.59e-01 | 0.1270 | -1.09e-02 | -1.09e-01 | 1.58e-02 | 4.42e-02 | -4.46e-02 | 9.35e-01 | 4.11e-01 | 9.05e-01 | 7.39e-01 | 7.37e-01 |
| MODIFIED AMINO ACID TRANSPORT | 47 | 8.21e-01 | 9.71e-01 | 0.1270 | -2.77e-02 | -3.22e-02 | -9.25e-02 | -4.61e-02 | -6.08e-02 | 7.43e-01 | 7.02e-01 | 2.72e-01 | 5.84e-01 | 4.71e-01 |
| REGULATION OF VASCULAR PERMEABILITY | 50 | 7.05e-01 | 9.33e-01 | 0.1270 | 4.30e-02 | 9.35e-02 | 4.60e-02 | 5.00e-02 | -3.07e-02 | 5.99e-01 | 2.53e-01 | 5.73e-01 | 5.41e-01 | 7.08e-01 |
| CARDIOCYTE DIFFERENTIATION | 163 | 3.94e-01 | 7.85e-01 | 0.1270 | 3.61e-02 | 6.36e-02 | 6.98e-02 | 2.65e-02 | 7.21e-02 | 4.26e-01 | 1.61e-01 | 1.24e-01 | 5.60e-01 | 1.12e-01 |
| POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION | 16 | 9.49e-01 | 9.94e-01 | 0.1270 | 6.96e-02 | 9.78e-02 | 1.41e-02 | 3.61e-02 | 1.40e-02 | 6.30e-01 | 4.98e-01 | 9.22e-01 | 8.02e-01 | 9.23e-01 |
| CHEMOSENSORY BEHAVIOR | 18 | 4.36e-01 | 8.09e-01 | 0.1270 | -7.69e-02 | 8.59e-02 | 5.16e-02 | -5.14e-03 | -1.13e-02 | 5.72e-01 | 5.28e-01 | 7.05e-01 | 9.70e-01 | 9.34e-01 |
| NEGATIVE REGULATION OF CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 52 | 4.55e-01 | 8.22e-01 | 0.1270 | 9.91e-02 | 1.60e-02 | -1.09e-02 | 7.12e-02 | -2.89e-02 | 2.16e-01 | 8.42e-01 | 8.92e-01 | 3.74e-01 | 7.18e-01 |
| INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 89 | 5.69e-02 | 3.15e-01 | 0.1270 | 8.74e-02 | -1.04e-02 | -6.01e-02 | 3.15e-03 | -6.88e-02 | 1.54e-01 | 8.65e-01 | 3.27e-01 | 9.59e-01 | 2.62e-01 |
| FILOPODIUM ASSEMBLY | 66 | 8.60e-01 | 9.78e-01 | 0.1270 | -8.95e-02 | -5.35e-02 | -3.82e-02 | -6.08e-02 | 5.64e-03 | 2.09e-01 | 4.53e-01 | 5.91e-01 | 3.93e-01 | 9.37e-01 |
| PROTEOLYSIS | 1554 | 1.30e-04 | 3.39e-03 | 0.1270 | 5.35e-02 | 5.89e-02 | 5.58e-02 | 7.02e-02 | 4.07e-02 | 4.23e-04 | 1.05e-04 | 2.38e-04 | 3.73e-06 | 7.37e-03 |
| NEUROTRANSMITTER RECEPTOR LOCALIZATION TO POSTSYNAPTIC SPECIALIZATION MEMBRANE | 22 | 6.92e-01 | 9.31e-01 | 0.1260 | 9.97e-02 | 6.10e-02 | 2.53e-02 | -1.25e-02 | 3.93e-02 | 4.18e-01 | 6.21e-01 | 8.37e-01 | 9.19e-01 | 7.50e-01 |
| ENTRY INTO HOST | 159 | 2.66e-01 | 6.73e-01 | 0.1260 | 8.96e-02 | 6.39e-02 | 2.42e-02 | 5.10e-02 | 2.61e-02 | 5.12e-02 | 1.64e-01 | 5.98e-01 | 2.67e-01 | 5.70e-01 |
| PEPTIDYL LYSINE METHYLATION | 48 | 8.21e-01 | 9.71e-01 | 0.1260 | 8.64e-02 | 4.12e-02 | 1.75e-02 | 7.57e-02 | -2.73e-02 | 3.00e-01 | 6.22e-01 | 8.34e-01 | 3.64e-01 | 7.43e-01 |
| PHOSPHOLIPID CATABOLIC PROCESS | 55 | 1.11e-01 | 4.54e-01 | 0.1260 | 4.69e-02 | 9.27e-02 | 1.27e-02 | -6.72e-02 | -2.22e-02 | 5.48e-01 | 2.35e-01 | 8.71e-01 | 3.89e-01 | 7.75e-01 |
| NEGATIVE REGULATION OF REPRODUCTIVE PROCESS | 72 | 6.70e-01 | 9.25e-01 | 0.1260 | 6.08e-02 | 9.48e-02 | 5.24e-02 | 1.93e-02 | 1.22e-02 | 3.73e-01 | 1.64e-01 | 4.42e-01 | 7.76e-01 | 8.58e-01 |
| SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 99 | 1.28e-01 | 4.85e-01 | 0.1260 | 1.08e-01 | 4.12e-02 | -1.17e-02 | 4.77e-02 | -9.05e-03 | 6.25e-02 | 4.78e-01 | 8.41e-01 | 4.12e-01 | 8.76e-01 |
| CORTICOSPINAL TRACT MORPHOGENESIS | 8 | 8.74e-01 | 9.78e-01 | 0.1260 | -2.95e-02 | -6.47e-02 | -9.45e-02 | 4.35e-02 | 5.33e-03 | 8.85e-01 | 7.51e-01 | 6.43e-01 | 8.31e-01 | 9.79e-01 |
| VERY LONG CHAIN FATTY ACID METABOLIC PROCESS | 34 | 5.75e-01 | 8.84e-01 | 0.1260 | -5.64e-02 | -3.06e-02 | 1.33e-02 | 5.10e-02 | 9.50e-02 | 5.69e-01 | 7.57e-01 | 8.93e-01 | 6.07e-01 | 3.38e-01 |
| REGULATION OF POLYSACCHARIDE METABOLIC PROCESS | 44 | 7.59e-01 | 9.52e-01 | 0.1260 | -5.93e-02 | -1.68e-02 | 1.66e-02 | -1.35e-02 | 1.08e-01 | 4.96e-01 | 8.47e-01 | 8.49e-01 | 8.77e-01 | 2.16e-01 |
| RESPONSE TO DSRNA | 52 | 3.37e-01 | 7.43e-01 | 0.1260 | 5.59e-02 | 1.27e-02 | -7.43e-02 | 2.30e-02 | -8.09e-02 | 4.86e-01 | 8.74e-01 | 3.54e-01 | 7.74e-01 | 3.13e-01 |
| POSITIVE REGULATION OF LONG TERM SYNAPTIC POTENTIATION | 22 | 5.12e-01 | 8.54e-01 | 0.1260 | -2.06e-02 | 3.55e-02 | 9.10e-02 | 2.83e-02 | -7.13e-02 | 8.67e-01 | 7.73e-01 | 4.60e-01 | 8.18e-01 | 5.63e-01 |
| CYTOPLASMIC SEQUESTERING OF PROTEIN | 18 | 8.04e-01 | 9.67e-01 | 0.1260 | 8.78e-02 | -1.74e-02 | -8.87e-03 | 8.79e-02 | -6.78e-03 | 5.19e-01 | 8.99e-01 | 9.48e-01 | 5.18e-01 | 9.60e-01 |
| REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 1424 | 4.28e-06 | 1.75e-04 | 0.1260 | 3.69e-02 | 6.55e-02 | 5.66e-02 | 4.96e-02 | 6.73e-02 | 1.95e-02 | 3.47e-05 | 3.44e-04 | 1.72e-03 | 2.08e-05 |
| LENS DEVELOPMENT IN CAMERA TYPE EYE | 85 | 8.12e-01 | 9.68e-01 | 0.1260 | 4.31e-02 | 4.40e-02 | 4.84e-02 | 6.94e-02 | 6.97e-02 | 4.92e-01 | 4.83e-01 | 4.41e-01 | 2.68e-01 | 2.66e-01 |
| REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS NONSENSE MEDIATED DECAY | 13 | 1.74e-01 | 5.59e-01 | 0.1260 | 5.91e-02 | -8.01e-02 | 6.05e-02 | -4.70e-02 | -2.41e-03 | 7.12e-01 | 6.17e-01 | 7.06e-01 | 7.69e-01 | 9.88e-01 |
| NUCLEOSIDE METABOLIC PROCESS | 53 | 3.65e-01 | 7.65e-01 | 0.1260 | 9.04e-02 | 7.05e-02 | -2.06e-02 | -1.82e-02 | -4.34e-02 | 2.55e-01 | 3.75e-01 | 7.95e-01 | 8.18e-01 | 5.84e-01 |
| REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DIFFERENTIATION | 23 | 9.78e-01 | 9.96e-01 | 0.1260 | 4.07e-02 | 8.14e-02 | 5.74e-02 | 6.11e-02 | 2.14e-02 | 7.35e-01 | 4.99e-01 | 6.34e-01 | 6.12e-01 | 8.59e-01 |
| CIRCADIAN SLEEP WAKE CYCLE | 21 | 6.94e-01 | 9.31e-01 | 0.1250 | -2.73e-02 | 1.97e-02 | -1.27e-02 | -1.01e-01 | 6.52e-02 | 8.29e-01 | 8.76e-01 | 9.20e-01 | 4.23e-01 | 6.05e-01 |
| REGULATION OF BRANCHING INVOLVED IN SALIVARY GLAND MORPHOGENESIS | 8 | 9.32e-01 | 9.90e-01 | 0.1250 | 8.50e-02 | 1.67e-02 | -8.03e-02 | -2.83e-02 | -3.07e-02 | 6.77e-01 | 9.35e-01 | 6.94e-01 | 8.90e-01 | 8.80e-01 |
| NEGATIVE REGULATION OF AXON EXTENSION | 43 | 6.81e-01 | 9.29e-01 | 0.1250 | -7.33e-02 | -2.27e-02 | -5.57e-02 | -6.61e-02 | 4.84e-02 | 4.06e-01 | 7.97e-01 | 5.28e-01 | 4.53e-01 | 5.83e-01 |
| REGULATION OF PROTEIN SECRETION | 261 | 1.27e-01 | 4.83e-01 | 0.1250 | 6.18e-02 | 9.11e-02 | 4.89e-02 | 3.24e-02 | 1.08e-02 | 8.57e-02 | 1.12e-02 | 1.74e-01 | 3.67e-01 | 7.64e-01 |
| HORMONE TRANSPORT | 311 | 9.40e-02 | 4.16e-01 | 0.1250 | 6.40e-02 | 8.90e-02 | 4.61e-02 | 3.67e-02 | 1.36e-02 | 5.24e-02 | 6.94e-03 | 1.62e-01 | 2.66e-01 | 6.80e-01 |
| POSITIVE REGULATION OF AXONOGENESIS | 72 | 7.44e-01 | 9.50e-01 | 0.1250 | -1.19e-02 | -1.74e-02 | -6.38e-02 | -7.29e-02 | -7.64e-02 | 8.62e-01 | 7.98e-01 | 3.49e-01 | 2.85e-01 | 2.63e-01 |
| REGULATION OF SYNAPSE ASSEMBLY | 104 | 1.25e-01 | 4.82e-01 | 0.1250 | -6.08e-02 | 9.41e-03 | 3.24e-02 | -4.72e-02 | 9.27e-02 | 2.84e-01 | 8.68e-01 | 5.68e-01 | 4.06e-01 | 1.02e-01 |
| LONG CHAIN FATTY ACYL COA BIOSYNTHETIC PROCESS | 18 | 8.46e-01 | 9.76e-01 | 0.1250 | -3.47e-02 | -3.43e-02 | -3.08e-02 | 1.44e-02 | 1.10e-01 | 7.99e-01 | 8.01e-01 | 8.21e-01 | 9.16e-01 | 4.19e-01 |
| SULFUR COMPOUND BIOSYNTHETIC PROCESS | 150 | 1.30e-01 | 4.87e-01 | 0.1250 | 2.68e-02 | 2.60e-02 | 2.47e-02 | 4.32e-02 | 1.08e-01 | 5.71e-01 | 5.82e-01 | 6.02e-01 | 3.62e-01 | 2.20e-02 |
| NEGATIVE REGULATION OF DEPHOSPHORYLATION | 35 | 7.67e-01 | 9.55e-01 | 0.1250 | 5.32e-02 | 1.36e-02 | 3.67e-02 | 1.06e-01 | 2.16e-03 | 5.86e-01 | 8.89e-01 | 7.07e-01 | 2.78e-01 | 9.82e-01 |
| REGULATION OF IMMUNE EFFECTOR PROCESS | 375 | 1.12e-01 | 4.56e-01 | 0.1250 | 7.35e-02 | 7.39e-02 | 3.62e-02 | 5.83e-02 | -3.05e-04 | 1.45e-02 | 1.40e-02 | 2.29e-01 | 5.24e-02 | 9.92e-01 |
| RESPONSE TO ENDOGENOUS STIMULUS | 1700 | 1.34e-05 | 4.87e-04 | 0.1250 | 4.11e-02 | 5.51e-02 | 5.61e-02 | 5.57e-02 | 6.77e-02 | 4.77e-03 | 1.54e-04 | 1.16e-04 | 1.31e-04 | 3.40e-06 |
| CELLULAR RESPONSE TO ALCOHOL | 99 | 1.34e-01 | 4.95e-01 | 0.1250 | -2.47e-02 | -2.75e-02 | -7.78e-02 | -8.67e-02 | 2.51e-02 | 6.71e-01 | 6.37e-01 | 1.81e-01 | 1.36e-01 | 6.67e-01 |
| T HELPER 17 TYPE IMMUNE RESPONSE | 46 | 5.41e-01 | 8.67e-01 | 0.1250 | -4.39e-02 | -1.45e-02 | 4.91e-02 | 6.22e-02 | 8.44e-02 | 6.06e-01 | 8.65e-01 | 5.65e-01 | 4.65e-01 | 3.22e-01 |
| REGULATION OF PHOSPHORUS METABOLIC PROCESS | 1135 | 6.04e-04 | 1.18e-02 | 0.1250 | 6.04e-02 | 5.41e-02 | 4.62e-02 | 6.61e-02 | 4.95e-02 | 5.90e-04 | 2.10e-03 | 8.61e-03 | 1.69e-04 | 4.90e-03 |
| POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 162 | 8.41e-02 | 3.92e-01 | 0.1250 | -3.19e-03 | -2.06e-03 | -8.48e-02 | -3.93e-02 | -8.24e-02 | 9.44e-01 | 9.64e-01 | 6.26e-02 | 3.88e-01 | 7.02e-02 |
| REGULATION OF CHOLESTEROL BIOSYNTHETIC PROCESS | 24 | 5.54e-01 | 8.76e-01 | 0.1250 | -7.25e-02 | 1.53e-02 | -8.00e-02 | -5.17e-02 | -3.11e-02 | 5.39e-01 | 8.97e-01 | 4.98e-01 | 6.61e-01 | 7.92e-01 |
| CELLULAR RESPONSE TO STEROL | 25 | 8.95e-01 | 9.82e-01 | 0.1250 | -2.37e-02 | -6.32e-02 | -9.65e-02 | -4.00e-02 | -7.21e-03 | 8.38e-01 | 5.85e-01 | 4.04e-01 | 7.29e-01 | 9.50e-01 |
| NEUROGENESIS | 1648 | 1.15e-06 | 5.36e-05 | 0.1250 | 2.24e-02 | 4.26e-02 | 6.19e-02 | 4.71e-02 | 8.45e-02 | 1.30e-01 | 3.96e-03 | 2.79e-05 | 1.45e-03 | 1.05e-08 |
| ENDOTHELIAL CELL MATRIX ADHESION | 8 | 9.86e-01 | 9.97e-01 | 0.1240 | 1.45e-02 | -2.57e-02 | -3.99e-02 | -6.57e-02 | -9.34e-02 | 9.43e-01 | 9.00e-01 | 8.45e-01 | 7.48e-01 | 6.47e-01 |
| POSITIVE REGULATION OF MYOBLAST DIFFERENTIATION | 43 | 7.83e-01 | 9.61e-01 | 0.1240 | 2.99e-02 | 4.24e-02 | 2.75e-02 | 5.40e-02 | 9.53e-02 | 7.35e-01 | 6.30e-01 | 7.55e-01 | 5.40e-01 | 2.79e-01 |
| REGULATION OF NEURON PROJECTION REGENERATION | 29 | 4.56e-01 | 8.22e-01 | 0.1240 | 2.66e-02 | 8.10e-02 | -4.93e-02 | -6.74e-02 | -3.47e-02 | 8.04e-01 | 4.50e-01 | 6.46e-01 | 5.30e-01 | 7.46e-01 |
| POSITIVE REGULATION OF MONONUCLEAR CELL MIGRATION | 69 | 5.33e-01 | 8.64e-01 | 0.1240 | 2.80e-02 | 3.88e-02 | -3.34e-02 | -3.18e-02 | -1.05e-01 | 6.87e-01 | 5.77e-01 | 6.31e-01 | 6.47e-01 | 1.32e-01 |
| RESPONSE TO DOPAMINE | 70 | 3.51e-01 | 7.52e-01 | 0.1240 | 7.61e-02 | 3.74e-02 | 4.20e-03 | 8.79e-02 | 2.17e-02 | 2.71e-01 | 5.88e-01 | 9.51e-01 | 2.03e-01 | 7.54e-01 |
| SMALL MOLECULE METABOLIC PROCESS | 1783 | 2.56e-05 | 8.81e-04 | 0.1240 | 5.60e-02 | 6.02e-02 | 5.14e-02 | 5.46e-02 | 5.49e-02 | 8.62e-05 | 2.42e-05 | 3.10e-04 | 1.27e-04 | 1.18e-04 |
| REGULATION OF LIPID LOCALIZATION | 183 | 2.79e-02 | 2.07e-01 | 0.1240 | 5.10e-02 | 5.92e-02 | -2.27e-02 | 2.27e-02 | -9.07e-02 | 2.34e-01 | 1.67e-01 | 5.96e-01 | 5.96e-01 | 3.44e-02 |
| POSITIVE REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 52 | 7.88e-01 | 9.63e-01 | 0.1240 | 3.42e-02 | 6.64e-02 | 8.39e-02 | 2.07e-02 | 4.80e-02 | 6.70e-01 | 4.07e-01 | 2.95e-01 | 7.97e-01 | 5.49e-01 |
| MACROPHAGE CHEMOTAXIS | 41 | 3.51e-01 | 7.52e-01 | 0.1240 | 2.64e-02 | 1.05e-01 | -9.36e-03 | -1.30e-02 | -5.77e-02 | 7.70e-01 | 2.44e-01 | 9.17e-01 | 8.86e-01 | 5.23e-01 |
| POSITIVE REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 123 | 8.66e-02 | 3.98e-01 | 0.1240 | 1.92e-02 | -4.90e-04 | 5.47e-02 | 1.02e-01 | 3.89e-02 | 7.13e-01 | 9.93e-01 | 2.94e-01 | 5.03e-02 | 4.56e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 13 PRODUCTION | 14 | 8.54e-01 | 9.76e-01 | 0.1240 | -4.24e-03 | 1.18e-03 | 1.06e-01 | 6.33e-02 | 6.41e-03 | 9.78e-01 | 9.94e-01 | 4.92e-01 | 6.82e-01 | 9.67e-01 |
| FIBROBLAST MIGRATION | 52 | 2.86e-01 | 6.94e-01 | 0.1240 | 5.56e-02 | 3.42e-02 | -2.47e-03 | 9.15e-02 | 5.15e-02 | 4.88e-01 | 6.69e-01 | 9.75e-01 | 2.53e-01 | 5.20e-01 |
| RESPONSE TO PROGESTERONE | 40 | 8.92e-01 | 9.81e-01 | 0.1240 | 6.58e-02 | 6.47e-02 | 2.73e-02 | 7.76e-02 | -3.45e-03 | 4.72e-01 | 4.79e-01 | 7.65e-01 | 3.96e-01 | 9.70e-01 |
| REGULATION OF LYASE ACTIVITY | 57 | 6.47e-01 | 9.17e-01 | 0.1240 | -7.02e-02 | -5.94e-03 | -3.70e-02 | -8.40e-02 | -4.35e-02 | 3.59e-01 | 9.38e-01 | 6.29e-01 | 2.73e-01 | 5.70e-01 |
| ENDOSOMAL VESICLE FUSION | 12 | 9.72e-01 | 9.95e-01 | 0.1240 | 2.32e-02 | 4.14e-02 | 3.49e-02 | 8.59e-02 | 6.64e-02 | 8.89e-01 | 8.04e-01 | 8.34e-01 | 6.06e-01 | 6.90e-01 |
| TRANSMISSION OF NERVE IMPULSE | 68 | 5.65e-01 | 8.81e-01 | 0.1240 | -7.81e-02 | -1.90e-02 | -2.92e-02 | -8.35e-02 | 3.12e-02 | 2.65e-01 | 7.86e-01 | 6.78e-01 | 2.34e-01 | 6.56e-01 |
| REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 55 | 2.46e-01 | 6.51e-01 | 0.1240 | 5.28e-02 | 5.69e-02 | 2.72e-03 | -1.39e-02 | 9.50e-02 | 4.98e-01 | 4.66e-01 | 9.72e-01 | 8.58e-01 | 2.23e-01 |
| REGULATION OF TRANSLATIONAL INITIATION BY EIF2 ALPHA PHOSPHORYLATION | 10 | 9.73e-01 | 9.95e-01 | 0.1230 | 4.15e-02 | 3.66e-03 | 2.26e-02 | 9.91e-02 | 5.61e-02 | 8.20e-01 | 9.84e-01 | 9.02e-01 | 5.87e-01 | 7.59e-01 |
| POSITIVE REGULATION OF GLUTAMATE SECRETION | 11 | 8.92e-01 | 9.81e-01 | 0.1230 | -1.39e-03 | 5.13e-03 | 6.33e-02 | 8.35e-02 | -6.49e-02 | 9.94e-01 | 9.76e-01 | 7.16e-01 | 6.32e-01 | 7.10e-01 |
| SEROTONIN TRANSPORT | 20 | 8.36e-01 | 9.73e-01 | 0.1230 | 5.22e-02 | 1.00e-01 | 2.70e-03 | 4.31e-02 | -2.43e-02 | 6.86e-01 | 4.38e-01 | 9.83e-01 | 7.39e-01 | 8.51e-01 |
| ANOIKIS | 33 | 7.13e-01 | 9.36e-01 | 0.1230 | -1.23e-03 | 7.74e-02 | 3.82e-02 | 1.46e-02 | 8.66e-02 | 9.90e-01 | 4.42e-01 | 7.04e-01 | 8.85e-01 | 3.89e-01 |
| POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 167 | 6.56e-01 | 9.20e-01 | 0.1230 | 4.42e-02 | 5.65e-02 | 5.22e-02 | 5.32e-02 | 6.66e-02 | 3.24e-01 | 2.08e-01 | 2.44e-01 | 2.36e-01 | 1.38e-01 |
| REGULATION OF IMMUNE SYSTEM PROCESS | 1465 | 6.63e-04 | 1.26e-02 | 0.1230 | 5.84e-02 | 5.74e-02 | 5.05e-02 | 6.41e-02 | 4.14e-02 | 1.84e-04 | 2.33e-04 | 1.21e-03 | 4.01e-05 | 7.92e-03 |
| NUCLEAR BODY ORGANIZATION | 15 | 8.47e-01 | 9.76e-01 | 0.1230 | -4.01e-02 | -2.36e-02 | 9.20e-02 | 5.35e-02 | 3.95e-02 | 7.88e-01 | 8.74e-01 | 5.37e-01 | 7.20e-01 | 7.91e-01 |
| REGULATION OF PROTEIN COMPLEX STABILITY | 14 | 7.43e-01 | 9.50e-01 | 0.1230 | -8.69e-02 | -4.30e-02 | -5.13e-03 | 5.65e-02 | 4.93e-02 | 5.74e-01 | 7.80e-01 | 9.73e-01 | 7.14e-01 | 7.49e-01 |
| REGULATION OF HEART RATE BY CHEMICAL SIGNAL | 7 | 8.21e-01 | 9.71e-01 | 0.1220 | -1.47e-02 | -8.46e-02 | 6.45e-02 | -3.68e-02 | 4.58e-02 | 9.46e-01 | 6.98e-01 | 7.68e-01 | 8.66e-01 | 8.34e-01 |
| ESTABLISHMENT OF ENDOTHELIAL INTESTINAL BARRIER | 14 | 9.77e-01 | 9.96e-01 | 0.1220 | -8.79e-04 | 4.23e-02 | 9.24e-02 | 5.39e-02 | 4.17e-02 | 9.95e-01 | 7.84e-01 | 5.50e-01 | 7.27e-01 | 7.87e-01 |
| NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 170 | 3.87e-01 | 7.80e-01 | 0.1220 | 8.78e-03 | 2.57e-02 | 6.30e-02 | 6.18e-02 | 8.02e-02 | 8.43e-01 | 5.64e-01 | 1.56e-01 | 1.65e-01 | 7.10e-02 |
| MULTICELLULAR ORGANISMAL LEVEL HOMEOSTASIS | 781 | 1.86e-02 | 1.59e-01 | 0.1220 | 5.89e-02 | 6.72e-02 | 4.78e-02 | 5.48e-02 | 4.11e-02 | 5.13e-03 | 1.40e-03 | 2.30e-02 | 9.19e-03 | 5.06e-02 |
| PROSTATE GLAND GROWTH | 10 | 7.71e-01 | 9.56e-01 | 0.1220 | 6.37e-02 | 2.44e-02 | 8.19e-02 | -1.41e-02 | -5.82e-02 | 7.27e-01 | 8.94e-01 | 6.54e-01 | 9.38e-01 | 7.50e-01 |
| SENSORY PERCEPTION OF PAIN | 76 | 1.84e-01 | 5.71e-01 | 0.1220 | -8.29e-02 | 4.75e-03 | 5.30e-02 | -1.03e-02 | 7.16e-02 | 2.12e-01 | 9.43e-01 | 4.24e-01 | 8.77e-01 | 2.80e-01 |
| REGULATION OF BONE MINERALIZATION | 76 | 1.71e-01 | 5.56e-01 | 0.1220 | -4.17e-02 | 4.87e-02 | 7.19e-02 | 4.22e-02 | 6.22e-02 | 5.30e-01 | 4.63e-01 | 2.78e-01 | 5.25e-01 | 3.48e-01 |
| NEGATIVE ADAPTATION OF SIGNALING PATHWAY | 18 | 9.73e-01 | 9.95e-01 | 0.1220 | 3.93e-02 | 1.62e-02 | 5.60e-02 | 9.47e-02 | 3.20e-02 | 7.73e-01 | 9.05e-01 | 6.81e-01 | 4.87e-01 | 8.14e-01 |
| POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE | 220 | 3.02e-02 | 2.18e-01 | 0.1220 | -4.06e-02 | -9.88e-03 | -6.58e-02 | -9.23e-02 | -1.81e-02 | 2.99e-01 | 8.01e-01 | 9.27e-02 | 1.83e-02 | 6.44e-01 |
| REGULATION OF MACROPHAGE DIFFERENTIATION | 24 | 6.49e-01 | 9.18e-01 | 0.1220 | 1.76e-02 | 5.95e-02 | -6.28e-02 | -7.39e-02 | -4.08e-02 | 8.81e-01 | 6.14e-01 | 5.94e-01 | 5.31e-01 | 7.30e-01 |
| MYOTUBE DIFFERENTIATION | 127 | 2.57e-01 | 6.63e-01 | 0.1220 | -1.37e-02 | 7.86e-03 | 6.24e-02 | 6.44e-02 | 8.13e-02 | 7.89e-01 | 8.78e-01 | 2.24e-01 | 2.10e-01 | 1.13e-01 |
| REGULATION OF LEUKOCYTE MEDIATED IMMUNITY | 239 | 1.57e-01 | 5.28e-01 | 0.1220 | 6.44e-02 | 5.18e-02 | 3.54e-02 | 8.24e-02 | -3.95e-03 | 8.62e-02 | 1.68e-01 | 3.45e-01 | 2.81e-02 | 9.16e-01 |
| GLOMERULUS DEVELOPMENT | 68 | 6.15e-01 | 9.06e-01 | 0.1220 | -6.13e-02 | -4.69e-02 | -5.59e-02 | -5.10e-02 | 5.67e-02 | 3.82e-01 | 5.04e-01 | 4.25e-01 | 4.67e-01 | 4.19e-01 |
| REGULATION OF FATTY ACID METABOLIC PROCESS | 95 | 6.93e-01 | 9.31e-01 | 0.1220 | 5.99e-02 | 8.83e-02 | 4.22e-02 | 4.07e-02 | -8.51e-03 | 3.13e-01 | 1.37e-01 | 4.78e-01 | 4.93e-01 | 8.86e-01 |
| CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 1249 | 5.21e-06 | 2.08e-04 | 0.1220 | 5.69e-02 | 6.83e-02 | 3.95e-02 | 5.50e-02 | 4.90e-02 | 7.14e-04 | 4.80e-05 | 1.89e-02 | 1.08e-03 | 3.58e-03 |
| DETECTION OF MECHANICAL STIMULUS INVOLVED IN SENSORY PERCEPTION | 35 | 8.68e-01 | 9.78e-01 | 0.1220 | -8.56e-02 | -2.08e-02 | -2.58e-02 | -8.01e-02 | -5.14e-03 | 3.81e-01 | 8.31e-01 | 7.91e-01 | 4.12e-01 | 9.58e-01 |
| AMYLOID PRECURSOR PROTEIN METABOLIC PROCESS | 93 | 5.87e-01 | 8.91e-01 | 0.1220 | 7.65e-02 | 4.37e-02 | 1.69e-02 | 5.61e-02 | -6.07e-02 | 2.03e-01 | 4.66e-01 | 7.78e-01 | 3.50e-01 | 3.12e-01 |
| POSITIVE REGULATION OF DEFENSE RESPONSE | 463 | 2.04e-02 | 1.69e-01 | 0.1220 | 8.47e-02 | 4.94e-02 | 2.96e-02 | 6.60e-02 | 5.31e-03 | 1.79e-03 | 6.87e-02 | 2.76e-01 | 1.49e-02 | 8.45e-01 |
| REGULATION OF T CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 8 | 9.04e-01 | 9.84e-01 | 0.1220 | -3.65e-02 | 7.19e-03 | 6.70e-02 | 1.96e-02 | -9.27e-02 | 8.58e-01 | 9.72e-01 | 7.43e-01 | 9.23e-01 | 6.50e-01 |
| NEGATIVE REGULATION OF DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 155 | 3.82e-01 | 7.78e-01 | 0.1220 | 6.36e-02 | 2.39e-02 | 4.40e-02 | 6.56e-02 | 6.30e-02 | 1.72e-01 | 6.08e-01 | 3.45e-01 | 1.59e-01 | 1.76e-01 |
| PEPTIDE CATABOLIC PROCESS | 22 | 9.15e-01 | 9.86e-01 | 0.1220 | -2.63e-02 | -1.43e-03 | -8.43e-02 | -7.37e-02 | -3.96e-02 | 8.31e-01 | 9.91e-01 | 4.94e-01 | 5.50e-01 | 7.48e-01 |
| POSTSYNAPTIC DENSITY ASSEMBLY | 21 | 8.73e-01 | 9.78e-01 | 0.1220 | -4.46e-02 | 4.51e-02 | 5.82e-02 | -1.38e-02 | 8.48e-02 | 7.23e-01 | 7.20e-01 | 6.44e-01 | 9.13e-01 | 5.01e-01 |
| INTRACELLULAR LIPID TRANSPORT | 50 | 7.90e-01 | 9.63e-01 | 0.1210 | 7.32e-02 | 2.29e-02 | 4.99e-02 | 7.77e-02 | -1.78e-02 | 3.70e-01 | 7.80e-01 | 5.41e-01 | 3.42e-01 | 8.27e-01 |
| SMALL MOLECULE CATABOLIC PROCESS | 366 | 3.10e-02 | 2.21e-01 | 0.1210 | 7.34e-02 | 7.68e-02 | 2.69e-02 | 4.82e-02 | 2.02e-02 | 1.58e-02 | 1.17e-02 | 3.77e-01 | 1.13e-01 | 5.07e-01 |
| POST TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION | 970 | 2.96e-03 | 4.14e-02 | 0.1210 | -4.56e-02 | -5.75e-02 | -6.01e-02 | -3.95e-02 | -6.46e-02 | 1.61e-02 | 2.42e-03 | 1.51e-03 | 3.70e-02 | 6.54e-04 |
| POSITIVE REGULATION OF GLUCOSE METABOLIC PROCESS | 44 | 7.70e-01 | 9.55e-01 | 0.1210 | -4.27e-02 | -2.13e-02 | -8.59e-02 | -6.94e-02 | -1.64e-02 | 6.24e-01 | 8.07e-01 | 3.24e-01 | 4.26e-01 | 8.51e-01 |
| HIPPO SIGNALING | 42 | 4.19e-01 | 8.00e-01 | 0.1210 | -6.67e-02 | 1.80e-02 | -6.68e-02 | -6.71e-02 | -3.09e-02 | 4.54e-01 | 8.40e-01 | 4.54e-01 | 4.52e-01 | 7.29e-01 |
| NEGATIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 80 | 2.03e-01 | 5.96e-01 | 0.1210 | 9.09e-02 | -2.08e-03 | 2.36e-02 | 7.09e-02 | 2.84e-02 | 1.60e-01 | 9.74e-01 | 7.15e-01 | 2.73e-01 | 6.61e-01 |
| MICROTUBULE BASED PROCESS | 901 | 2.75e-03 | 3.92e-02 | 0.1210 | 4.60e-02 | 3.10e-02 | 5.46e-02 | 6.40e-02 | 6.71e-02 | 1.91e-02 | 1.14e-01 | 5.42e-03 | 1.12e-03 | 6.35e-04 |
| CELL JUNCTION DISASSEMBLY | 27 | 3.57e-01 | 7.57e-01 | 0.1210 | -3.98e-02 | 1.02e-01 | 3.67e-02 | 2.72e-03 | 3.62e-02 | 7.20e-01 | 3.60e-01 | 7.41e-01 | 9.81e-01 | 7.45e-01 |
| PROTEIN LOCALIZATION TO SYNAPSE | 73 | 3.58e-01 | 7.57e-01 | 0.1210 | -5.76e-02 | -2.71e-03 | 1.18e-02 | -6.13e-02 | 8.61e-02 | 3.94e-01 | 9.68e-01 | 8.62e-01 | 3.65e-01 | 2.04e-01 |
| CELLULAR RESPONSE TO MAGNESIUM ION | 7 | 9.82e-01 | 9.96e-01 | 0.1210 | 2.76e-02 | 1.69e-02 | 5.91e-02 | 7.05e-02 | -7.11e-02 | 8.99e-01 | 9.38e-01 | 7.86e-01 | 7.47e-01 | 7.45e-01 |
| PHOSPHATE ION TRANSPORT | 28 | 9.31e-01 | 9.90e-01 | 0.1210 | -6.68e-02 | -4.38e-02 | 1.89e-04 | -4.92e-02 | 7.57e-02 | 5.41e-01 | 6.89e-01 | 9.99e-01 | 6.52e-01 | 4.88e-01 |
| POSITIVE REGULATION OF LEUKOCYTE MEDIATED IMMUNITY | 146 | 1.62e-01 | 5.39e-01 | 0.1210 | 4.93e-02 | 2.33e-02 | 4.11e-02 | 9.86e-02 | 1.14e-02 | 3.04e-01 | 6.28e-01 | 3.91e-01 | 3.96e-02 | 8.12e-01 |
| MONOCARBOXYLIC ACID BIOSYNTHETIC PROCESS | 217 | 6.57e-01 | 9.20e-01 | 0.1200 | 6.19e-02 | 6.75e-02 | 5.61e-02 | 5.39e-02 | 7.59e-03 | 1.16e-01 | 8.65e-02 | 1.55e-01 | 1.71e-01 | 8.47e-01 |
| CELL GROWTH | 476 | 1.57e-01 | 5.28e-01 | 0.1200 | 3.90e-02 | 6.19e-02 | 5.93e-02 | 5.42e-02 | 5.18e-02 | 1.45e-01 | 2.07e-02 | 2.67e-02 | 4.27e-02 | 5.28e-02 |
| HEART DEVELOPMENT | 598 | 5.00e-03 | 6.14e-02 | 0.1200 | 1.01e-02 | 4.05e-02 | 6.83e-02 | 3.09e-02 | 8.44e-02 | 6.74e-01 | 9.06e-02 | 4.31e-03 | 1.97e-01 | 4.23e-04 |
| POSITIVE REGULATION OF CARBOHYDRATE METABOLIC PROCESS | 80 | 2.84e-01 | 6.93e-01 | 0.1200 | -2.67e-02 | -4.17e-02 | -9.39e-02 | -5.50e-02 | 1.38e-02 | 6.80e-01 | 5.19e-01 | 1.47e-01 | 3.95e-01 | 8.31e-01 |
| CGMP BIOSYNTHETIC PROCESS | 10 | 8.79e-01 | 9.79e-01 | 0.1200 | -7.27e-02 | -3.61e-02 | 1.98e-02 | 7.23e-02 | 4.75e-02 | 6.91e-01 | 8.43e-01 | 9.14e-01 | 6.92e-01 | 7.95e-01 |
| POSITIVE REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 65 | 7.13e-01 | 9.36e-01 | 0.1200 | 4.27e-02 | 6.63e-02 | 3.50e-02 | 6.52e-02 | 5.25e-02 | 5.52e-01 | 3.55e-01 | 6.26e-01 | 3.63e-01 | 4.64e-01 |
| REGULATION OF HEART RATE | 99 | 9.21e-02 | 4.12e-01 | 0.1200 | -2.37e-02 | 2.90e-02 | 3.56e-02 | -5.08e-02 | 9.58e-02 | 6.83e-01 | 6.18e-01 | 5.41e-01 | 3.82e-01 | 9.94e-02 |
| NEGATIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 7 | 9.94e-01 | 9.99e-01 | 0.1200 | 4.47e-02 | 4.36e-02 | 3.56e-02 | 9.42e-02 | -1.93e-02 | 8.38e-01 | 8.42e-01 | 8.70e-01 | 6.66e-01 | 9.30e-01 |
| TROPHOBLAST CELL MIGRATION | 17 | 9.00e-01 | 9.83e-01 | 0.1200 | -4.82e-02 | 1.11e-02 | -1.66e-02 | -5.51e-02 | 9.30e-02 | 7.31e-01 | 9.37e-01 | 9.06e-01 | 6.94e-01 | 5.07e-01 |
| REGULATION OF MACROPHAGE ACTIVATION | 61 | 8.03e-01 | 9.67e-01 | 0.1200 | 7.59e-02 | 3.39e-02 | 3.30e-02 | 7.40e-02 | -3.01e-02 | 3.05e-01 | 6.47e-01 | 6.56e-01 | 3.17e-01 | 6.85e-01 |
| ANATOMICAL STRUCTURE MATURATION | 253 | 3.97e-01 | 7.86e-01 | 0.1200 | 3.52e-02 | 6.64e-02 | 6.18e-02 | 4.15e-02 | 5.61e-02 | 3.35e-01 | 6.88e-02 | 9.06e-02 | 2.56e-01 | 1.24e-01 |
| LYMPHOCYTE MEDIATED IMMUNITY | 282 | 3.55e-02 | 2.41e-01 | 0.1200 | 3.07e-02 | 3.64e-02 | 6.93e-02 | 8.45e-02 | 1.12e-02 | 3.76e-01 | 2.93e-01 | 4.53e-02 | 1.45e-02 | 7.47e-01 |
| REGULATION OF SKELETAL MUSCLE SATELLITE CELL PROLIFERATION | 12 | 9.80e-01 | 9.96e-01 | 0.1200 | 4.45e-02 | 7.58e-02 | 2.82e-02 | 6.82e-02 | 3.41e-02 | 7.90e-01 | 6.49e-01 | 8.66e-01 | 6.83e-01 | 8.38e-01 |
| OPTIC NERVE DEVELOPMENT | 20 | 7.17e-01 | 9.37e-01 | 0.1200 | -2.33e-02 | 6.45e-03 | 3.23e-02 | -7.98e-02 | 7.96e-02 | 8.57e-01 | 9.60e-01 | 8.03e-01 | 5.37e-01 | 5.38e-01 |
| NEGATIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 53 | 5.96e-01 | 8.97e-01 | 0.1200 | 8.77e-02 | 3.76e-02 | -1.55e-02 | 4.25e-03 | -7.04e-02 | 2.69e-01 | 6.36e-01 | 8.45e-01 | 9.57e-01 | 3.75e-01 |
| HEMOSTASIS | 220 | 3.93e-02 | 2.56e-01 | 0.1200 | 4.61e-02 | 6.31e-02 | 6.62e-03 | 1.70e-02 | -8.87e-02 | 2.38e-01 | 1.07e-01 | 8.66e-01 | 6.64e-01 | 2.33e-02 |
| RESPONSE TO DIETARY EXCESS | 34 | 6.24e-01 | 9.09e-01 | 0.1200 | 2.31e-02 | 9.61e-02 | 1.41e-02 | -1.60e-02 | -6.38e-02 | 8.16e-01 | 3.32e-01 | 8.87e-01 | 8.71e-01 | 5.20e-01 |
| NUCLEOTIDE TRANSMEMBRANE TRANSPORT | 26 | 8.40e-01 | 9.73e-01 | 0.1200 | 8.86e-02 | 3.21e-02 | -3.21e-02 | 8.23e-04 | -6.62e-02 | 4.34e-01 | 7.77e-01 | 7.77e-01 | 9.94e-01 | 5.59e-01 |
| NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 462 | 5.61e-02 | 3.13e-01 | 0.1190 | 5.27e-02 | 8.10e-02 | 4.93e-02 | 4.41e-02 | 2.31e-02 | 5.23e-02 | 2.84e-03 | 6.94e-02 | 1.04e-01 | 3.94e-01 |
| NEUROTRANSMITTER RECEPTOR INTERNALIZATION | 30 | 5.30e-01 | 8.63e-01 | 0.1190 | -1.61e-02 | 3.10e-02 | -2.88e-02 | -4.39e-02 | 1.01e-01 | 8.79e-01 | 7.69e-01 | 7.84e-01 | 6.78e-01 | 3.37e-01 |
| SUPEROXIDE METABOLIC PROCESS | 66 | 3.90e-01 | 7.82e-01 | 0.1190 | 4.92e-02 | 8.04e-02 | -1.86e-02 | -6.16e-04 | -7.05e-02 | 4.89e-01 | 2.59e-01 | 7.94e-01 | 9.93e-01 | 3.22e-01 |
| REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 445 | 2.71e-02 | 2.03e-01 | 0.1190 | 1.06e-02 | 3.03e-02 | 5.51e-02 | 3.03e-02 | 9.60e-02 | 7.01e-01 | 2.73e-01 | 4.61e-02 | 2.74e-01 | 5.17e-04 |
| ENSHEATHMENT OF NEURONS | 143 | 7.88e-01 | 9.63e-01 | 0.1190 | 6.20e-02 | 5.03e-02 | 4.51e-02 | 6.36e-02 | 4.17e-02 | 2.00e-01 | 2.99e-01 | 3.52e-01 | 1.89e-01 | 3.90e-01 |
| REGULATION OF WNT SIGNALING PATHWAY | 325 | 4.32e-02 | 2.70e-01 | 0.1190 | 9.98e-03 | 1.84e-02 | 5.36e-02 | 6.73e-02 | 7.96e-02 | 7.57e-01 | 5.68e-01 | 9.66e-02 | 3.70e-02 | 1.36e-02 |
| SEMINIFEROUS TUBULE DEVELOPMENT | 14 | 9.54e-01 | 9.94e-01 | 0.1190 | 7.65e-02 | -6.12e-03 | 2.70e-02 | 8.00e-02 | 3.39e-02 | 6.20e-01 | 9.68e-01 | 8.61e-01 | 6.04e-01 | 8.26e-01 |
| PROTEIN LOCALIZATION TO CELL PERIPHERY | 336 | 4.31e-01 | 8.06e-01 | 0.1190 | 5.94e-02 | 4.84e-02 | 5.47e-02 | 6.89e-02 | 2.33e-02 | 6.11e-02 | 1.27e-01 | 8.46e-02 | 3.00e-02 | 4.63e-01 |
| PHOSPHATIDYLCHOLINE BIOSYNTHETIC PROCESS | 28 | 8.08e-01 | 9.67e-01 | 0.1190 | 6.44e-02 | 9.45e-02 | 9.28e-03 | 1.39e-02 | 2.83e-02 | 5.55e-01 | 3.87e-01 | 9.32e-01 | 8.99e-01 | 7.95e-01 |
| NEGATIVE REGULATION OF INFLAMMATORY RESPONSE | 193 | 1.74e-02 | 1.53e-01 | 0.1190 | 3.72e-02 | 4.11e-02 | -5.53e-02 | -3.56e-02 | -8.21e-02 | 3.72e-01 | 3.25e-01 | 1.85e-01 | 3.93e-01 | 4.91e-02 |
| POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 210 | 2.28e-01 | 6.31e-01 | 0.1190 | 1.69e-02 | 2.96e-02 | 4.32e-02 | 5.15e-02 | 9.20e-02 | 6.74e-01 | 4.60e-01 | 2.81e-01 | 1.99e-01 | 2.16e-02 |
| VESICLE MEDIATED TRANSPORT | 1468 | 6.69e-04 | 1.26e-02 | 0.1190 | 6.63e-02 | 6.55e-02 | 4.49e-02 | 5.33e-02 | 2.35e-02 | 2.12e-05 | 2.62e-05 | 3.95e-03 | 6.24e-04 | 1.31e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 43 | 6.53e-01 | 9.19e-01 | 0.1190 | 5.27e-04 | -4.67e-02 | -9.94e-02 | -2.61e-02 | -3.69e-02 | 9.95e-01 | 5.96e-01 | 2.60e-01 | 7.67e-01 | 6.76e-01 |
| REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 151 | 6.76e-01 | 9.28e-01 | 0.1190 | 5.80e-02 | 3.70e-02 | 5.08e-02 | 7.69e-02 | 2.89e-02 | 2.18e-01 | 4.33e-01 | 2.81e-01 | 1.03e-01 | 5.40e-01 |
| NEGATIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL PROLIFERATION | 34 | 8.51e-01 | 9.76e-01 | 0.1190 | 1.01e-02 | 2.49e-02 | 3.61e-02 | 7.27e-02 | 8.21e-02 | 9.19e-01 | 8.01e-01 | 7.16e-01 | 4.63e-01 | 4.07e-01 |
| PYRIMIDINE NUCLEOTIDE BIOSYNTHETIC PROCESS | 29 | 8.76e-01 | 9.78e-01 | 0.1180 | 6.65e-02 | 4.77e-02 | 1.06e-02 | 6.15e-02 | 5.87e-02 | 5.36e-01 | 6.57e-01 | 9.21e-01 | 5.66e-01 | 5.84e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 103 | 6.25e-01 | 9.09e-01 | 0.1180 | 3.84e-02 | 5.16e-02 | 5.64e-02 | 8.11e-02 | 9.57e-03 | 5.00e-01 | 3.65e-01 | 3.22e-01 | 1.55e-01 | 8.67e-01 |
| REGULATION OF CATALYTIC ACTIVITY | 1430 | 1.04e-04 | 2.86e-03 | 0.1180 | 5.66e-02 | 6.74e-02 | 4.35e-02 | 5.66e-02 | 3.33e-02 | 3.34e-04 | 1.95e-05 | 5.81e-03 | 3.38e-04 | 3.51e-02 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE MEDIATED BY A CHEMICAL SIGNAL | 42 | 7.68e-01 | 9.55e-01 | 0.1180 | 9.89e-02 | 3.76e-02 | -5.98e-04 | 3.61e-02 | -3.76e-02 | 2.68e-01 | 6.73e-01 | 9.95e-01 | 6.85e-01 | 6.73e-01 |
| INORGANIC ANION TRANSMEMBRANE TRANSPORT | 125 | 1.98e-01 | 5.87e-01 | 0.1180 | -6.86e-02 | -1.89e-02 | -1.78e-02 | -8.30e-02 | -4.03e-02 | 1.86e-01 | 7.15e-01 | 7.31e-01 | 1.09e-01 | 4.37e-01 |
| NATURAL KILLER CELL DEGRANULATION | 11 | 8.24e-01 | 9.71e-01 | 0.1180 | 5.29e-03 | -1.63e-02 | 1.00e-01 | 5.14e-02 | -3.05e-02 | 9.76e-01 | 9.25e-01 | 5.66e-01 | 7.68e-01 | 8.61e-01 |
| NEGATIVE REGULATION OF T HELPER 17 TYPE IMMUNE RESPONSE | 12 | 9.59e-01 | 9.94e-01 | 0.1180 | -1.91e-02 | 1.80e-04 | 7.37e-02 | 7.93e-02 | 4.21e-02 | 9.09e-01 | 9.99e-01 | 6.58e-01 | 6.34e-01 | 8.01e-01 |
| INTERLEUKIN 10 PRODUCTION | 59 | 1.61e-01 | 5.36e-01 | 0.1180 | 7.86e-02 | 1.09e-02 | -7.72e-02 | -1.36e-02 | -3.76e-02 | 2.96e-01 | 8.84e-01 | 3.05e-01 | 8.57e-01 | 6.18e-01 |
| TRANSEPITHELIAL TRANSPORT | 34 | 8.09e-01 | 9.68e-01 | 0.1180 | 1.14e-03 | 3.95e-02 | -1.94e-02 | -2.38e-02 | -1.07e-01 | 9.91e-01 | 6.90e-01 | 8.45e-01 | 8.10e-01 | 2.82e-01 |
| CELLULAR RESPONSE TO INTERLEUKIN 1 | 107 | 1.07e-01 | 4.48e-01 | 0.1180 | 2.44e-02 | 1.52e-02 | -6.45e-02 | -7.54e-02 | -5.60e-02 | 6.62e-01 | 7.87e-01 | 2.49e-01 | 1.78e-01 | 3.17e-01 |
| REGULATION OF NATURAL KILLER CELL ACTIVATION | 42 | 8.04e-01 | 9.67e-01 | 0.1180 | 6.26e-02 | 1.37e-02 | 6.94e-02 | 6.00e-02 | 3.60e-02 | 4.83e-01 | 8.78e-01 | 4.36e-01 | 5.01e-01 | 6.87e-01 |
| RESPONSE TO PURINE CONTAINING COMPOUND | 137 | 5.69e-01 | 8.82e-01 | 0.1180 | 2.80e-02 | 7.40e-02 | 6.24e-02 | 3.84e-02 | 4.67e-02 | 5.71e-01 | 1.35e-01 | 2.07e-01 | 4.38e-01 | 3.45e-01 |
| MUSCLE HYPERTROPHY | 103 | 8.72e-01 | 9.78e-01 | 0.1180 | -3.15e-02 | -3.62e-02 | -5.71e-02 | -5.51e-02 | -7.22e-02 | 5.81e-01 | 5.25e-01 | 3.17e-01 | 3.34e-01 | 2.05e-01 |
| NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 1676 | 1.43e-04 | 3.60e-03 | 0.1170 | 4.00e-02 | 4.93e-02 | 5.35e-02 | 5.88e-02 | 5.85e-02 | 6.33e-03 | 7.68e-04 | 2.64e-04 | 6.13e-05 | 6.56e-05 |
| REGULATION OF INOSITOL TRISPHOSPHATE BIOSYNTHETIC PROCESS | 6 | 9.76e-01 | 9.96e-01 | 0.1170 | 2.16e-03 | -7.89e-02 | 1.03e-02 | 7.15e-02 | 4.81e-02 | 9.93e-01 | 7.38e-01 | 9.65e-01 | 7.62e-01 | 8.38e-01 |
| RESPONSE TO INTERLEUKIN 17 | 17 | 8.64e-01 | 9.78e-01 | 0.1170 | -4.96e-02 | 4.85e-02 | 2.74e-02 | -5.27e-03 | 9.01e-02 | 7.23e-01 | 7.29e-01 | 8.45e-01 | 9.70e-01 | 5.20e-01 |
| RESPONSE TO SALT | 352 | 1.51e-01 | 5.20e-01 | 0.1170 | 3.30e-02 | 5.23e-02 | 5.23e-02 | 3.41e-02 | 7.73e-02 | 2.88e-01 | 9.18e-02 | 9.18e-02 | 2.71e-01 | 1.28e-02 |
| PURINE NUCLEOTIDE TRANSPORT | 34 | 7.82e-01 | 9.60e-01 | 0.1170 | 5.40e-02 | 5.24e-02 | -3.34e-02 | 2.60e-02 | -7.89e-02 | 5.86e-01 | 5.97e-01 | 7.36e-01 | 7.93e-01 | 4.26e-01 |
| MYELIN ASSEMBLY | 24 | 9.72e-01 | 9.95e-01 | 0.1170 | -5.24e-02 | -4.72e-02 | -7.87e-02 | -4.91e-02 | -8.48e-03 | 6.57e-01 | 6.89e-01 | 5.04e-01 | 6.77e-01 | 9.43e-01 |
| PEPTIDYL LYSINE DIMETHYLATION | 11 | 9.55e-01 | 9.94e-01 | 0.1170 | 9.44e-02 | -1.68e-03 | -1.84e-02 | 5.87e-02 | -3.06e-02 | 5.88e-01 | 9.92e-01 | 9.16e-01 | 7.36e-01 | 8.61e-01 |
| STRESS INDUCED PREMATURE SENESCENCE | 8 | 9.71e-01 | 9.95e-01 | 0.1160 | -5.25e-02 | -2.13e-02 | 3.42e-02 | 6.56e-02 | 6.98e-02 | 7.97e-01 | 9.17e-01 | 8.67e-01 | 7.48e-01 | 7.32e-01 |
| REGULATION OF CD4 POSITIVE ALPHA BETA T CELL ACTIVATION | 73 | 8.69e-01 | 9.78e-01 | 0.1160 | 6.57e-02 | 4.91e-02 | 3.31e-02 | 7.25e-02 | 2.20e-02 | 3.32e-01 | 4.68e-01 | 6.25e-01 | 2.84e-01 | 7.45e-01 |
| REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 122 | 1.38e-01 | 5.01e-01 | 0.1160 | 6.06e-02 | 7.80e-02 | -1.62e-02 | 7.39e-03 | -5.89e-02 | 2.48e-01 | 1.37e-01 | 7.57e-01 | 8.88e-01 | 2.61e-01 |
| REGULATION OF PHOSPHOLIPASE ACTIVITY | 58 | 7.65e-01 | 9.54e-01 | 0.1160 | 4.60e-04 | -4.58e-02 | -8.37e-02 | -2.83e-02 | -6.01e-02 | 9.95e-01 | 5.46e-01 | 2.70e-01 | 7.10e-01 | 4.29e-01 |
| PHOSPHOLIPID DEPHOSPHORYLATION | 37 | 7.26e-01 | 9.43e-01 | 0.1160 | -5.44e-02 | -5.89e-02 | -7.78e-02 | -1.99e-02 | 2.52e-02 | 5.67e-01 | 5.35e-01 | 4.13e-01 | 8.34e-01 | 7.91e-01 |
| REGULATION OF ADENYLATE CYCLASE ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 14 | 8.68e-01 | 9.78e-01 | 0.1160 | -3.83e-02 | 5.35e-02 | 1.75e-02 | 1.59e-02 | 9.27e-02 | 8.04e-01 | 7.29e-01 | 9.10e-01 | 9.18e-01 | 5.48e-01 |
| NEGATIVE REGULATION OF PROTEIN CONTAINING COMPLEX DISASSEMBLY | 76 | 8.98e-01 | 9.82e-01 | 0.1160 | -5.71e-02 | -5.30e-02 | -5.81e-02 | -3.67e-02 | -5.19e-02 | 3.89e-01 | 4.25e-01 | 3.81e-01 | 5.80e-01 | 4.34e-01 |
| ENDOTHELIAL CELL DEVELOPMENT | 65 | 7.69e-01 | 9.55e-01 | 0.1160 | 6.30e-02 | 3.48e-02 | 4.41e-02 | 3.52e-02 | 7.15e-02 | 3.80e-01 | 6.28e-01 | 5.39e-01 | 6.24e-01 | 3.19e-01 |
| FATTY ACID HOMEOSTASIS | 16 | 9.20e-01 | 9.86e-01 | 0.1160 | -1.19e-02 | 7.45e-02 | 7.07e-02 | 4.78e-02 | 2.23e-02 | 9.34e-01 | 6.06e-01 | 6.25e-01 | 7.41e-01 | 8.77e-01 |
| POSITIVE REGULATION OF MYELINATION | 17 | 9.36e-01 | 9.91e-01 | 0.1160 | -2.41e-02 | 4.31e-03 | -7.66e-02 | -8.12e-02 | -1.97e-02 | 8.64e-01 | 9.75e-01 | 5.85e-01 | 5.62e-01 | 8.88e-01 |
| RESPONSE TO GROWTH FACTOR | 730 | 8.80e-03 | 9.29e-02 | 0.1160 | 2.01e-02 | 3.50e-02 | 5.37e-02 | 4.91e-02 | 8.07e-02 | 3.55e-01 | 1.07e-01 | 1.35e-02 | 2.38e-02 | 2.04e-04 |
| REGULATION OF CIRCADIAN RHYTHM | 110 | 1.45e-01 | 5.12e-01 | 0.1160 | 5.97e-02 | 1.88e-04 | 1.12e-02 | 6.87e-02 | 7.07e-02 | 2.80e-01 | 9.97e-01 | 8.39e-01 | 2.13e-01 | 2.00e-01 |
| POSITIVE REGULATION OF MAST CELL ACTIVATION | 18 | 9.80e-01 | 9.96e-01 | 0.1160 | 3.84e-02 | 9.03e-02 | 5.41e-02 | 2.32e-02 | 1.66e-02 | 7.78e-01 | 5.07e-01 | 6.91e-01 | 8.65e-01 | 9.03e-01 |
| NEGATIVE REGULATION OF HEART RATE | 11 | 8.89e-01 | 9.80e-01 | 0.1160 | -3.15e-02 | 8.19e-02 | 7.17e-02 | -1.92e-02 | -1.27e-02 | 8.56e-01 | 6.38e-01 | 6.80e-01 | 9.12e-01 | 9.42e-01 |
| NEUROMUSCULAR JUNCTION DEVELOPMENT | 50 | 7.94e-01 | 9.65e-01 | 0.1160 | -5.61e-02 | -3.63e-02 | -5.35e-02 | -6.07e-02 | 4.85e-02 | 4.92e-01 | 6.57e-01 | 5.13e-01 | 4.58e-01 | 5.53e-01 |
| CYTOPLASMIC TRANSLATIONAL INITIATION | 34 | 8.49e-01 | 9.76e-01 | 0.1160 | 5.41e-03 | -2.81e-02 | 5.03e-02 | 5.63e-02 | 8.28e-02 | 9.56e-01 | 7.77e-01 | 6.12e-01 | 5.70e-01 | 4.04e-01 |
| MYOFIBROBLAST DIFFERENTIATION | 14 | 9.98e-01 | 1.00e+00 | 0.1160 | 5.44e-02 | 5.36e-02 | 6.79e-02 | 4.27e-02 | 3.32e-02 | 7.24e-01 | 7.28e-01 | 6.60e-01 | 7.82e-01 | 8.30e-01 |
| RESPONSE TO ACTIVITY | 72 | 2.78e-01 | 6.88e-01 | 0.1160 | -3.98e-02 | 3.38e-02 | 1.43e-02 | -1.90e-02 | 1.00e-01 | 5.60e-01 | 6.20e-01 | 8.34e-01 | 7.81e-01 | 1.41e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 17 PRODUCTION | 26 | 5.57e-01 | 8.77e-01 | 0.1150 | -4.96e-03 | 8.54e-02 | 3.28e-02 | 6.25e-02 | 3.21e-02 | 9.65e-01 | 4.51e-01 | 7.72e-01 | 5.81e-01 | 7.77e-01 |
| GAP JUNCTION ASSEMBLY | 16 | 9.82e-01 | 9.96e-01 | 0.1150 | -5.94e-02 | -7.56e-02 | -4.10e-02 | -1.17e-02 | -4.76e-02 | 6.81e-01 | 6.01e-01 | 7.76e-01 | 9.36e-01 | 7.42e-01 |
| SMALL MOLECULE BIOSYNTHETIC PROCESS | 579 | 4.12e-02 | 2.63e-01 | 0.1150 | 4.28e-02 | 5.56e-02 | 4.47e-02 | 5.15e-02 | 6.09e-02 | 7.81e-02 | 2.23e-02 | 6.60e-02 | 3.40e-02 | 1.23e-02 |
| MEMBRANE RAFT ORGANIZATION | 26 | 7.02e-01 | 9.32e-01 | 0.1150 | -4.55e-02 | 4.21e-02 | 4.54e-02 | 4.37e-02 | 7.38e-02 | 6.88e-01 | 7.10e-01 | 6.88e-01 | 7.00e-01 | 5.15e-01 |
| RESPONSE TO CORTICOSTEROID | 143 | 1.06e-01 | 4.47e-01 | 0.1150 | -4.67e-02 | 2.33e-02 | 5.08e-02 | -1.02e-02 | 8.84e-02 | 3.35e-01 | 6.30e-01 | 2.95e-01 | 8.33e-01 | 6.80e-02 |
| LYMPH VESSEL DEVELOPMENT | 31 | 9.60e-01 | 9.94e-01 | 0.1150 | -1.08e-03 | 3.43e-02 | 4.94e-02 | 2.54e-02 | 9.46e-02 | 9.92e-01 | 7.41e-01 | 6.34e-01 | 8.07e-01 | 3.62e-01 |
| RESPONSE TO OXYGEN CONTAINING COMPOUND | 1742 | 3.29e-06 | 1.40e-04 | 0.1150 | 4.84e-02 | 6.34e-02 | 4.29e-02 | 5.25e-02 | 4.73e-02 | 7.89e-04 | 1.08e-05 | 2.92e-03 | 2.67e-04 | 1.02e-03 |
| NEGATIVE REGULATION OF MOLECULAR FUNCTION | 754 | 8.09e-02 | 3.85e-01 | 0.1150 | 5.29e-02 | 5.82e-02 | 4.83e-02 | 5.72e-02 | 3.67e-02 | 1.34e-02 | 6.52e-03 | 2.40e-02 | 7.52e-03 | 8.58e-02 |
| IMMUNE RESPONSE REGULATING SIGNALING PATHWAY | 461 | 7.56e-02 | 3.72e-01 | 0.1140 | 6.31e-02 | 3.67e-02 | 3.95e-02 | 6.90e-02 | 3.79e-02 | 2.01e-02 | 1.77e-01 | 1.46e-01 | 1.11e-02 | 1.63e-01 |
| MAST CELL MEDIATED IMMUNITY | 55 | 8.95e-01 | 9.82e-01 | 0.1140 | 4.65e-02 | 8.06e-02 | 5.94e-02 | 2.56e-02 | 1.46e-02 | 5.50e-01 | 3.01e-01 | 4.46e-01 | 7.42e-01 | 8.51e-01 |
| NEURON PROJECTION EXTENSION | 168 | 7.43e-01 | 9.50e-01 | 0.1140 | -6.64e-02 | -4.80e-02 | -5.39e-02 | -5.77e-02 | -1.09e-02 | 1.37e-01 | 2.83e-01 | 2.28e-01 | 1.97e-01 | 8.08e-01 |
| NEGATIVE REGULATION OF LIPOPROTEIN METABOLIC PROCESS | 5 | 9.97e-01 | 1.00e+00 | 0.1140 | 3.70e-02 | 6.67e-02 | -1.42e-02 | -5.48e-03 | -8.35e-02 | 8.86e-01 | 7.96e-01 | 9.56e-01 | 9.83e-01 | 7.47e-01 |
| POSITIVE REGULATION OF CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 185 | 9.42e-02 | 4.16e-01 | 0.1140 | 7.51e-02 | 4.02e-02 | 2.79e-02 | 3.19e-02 | 6.28e-02 | 7.83e-02 | 3.46e-01 | 5.13e-01 | 4.54e-01 | 1.40e-01 |
| NUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 18 | 9.51e-01 | 9.94e-01 | 0.1140 | 9.13e-02 | 5.37e-02 | 2.88e-02 | 1.38e-02 | -2.72e-02 | 5.03e-01 | 6.94e-01 | 8.32e-01 | 9.19e-01 | 8.42e-01 |
| ADULT BEHAVIOR | 141 | 5.00e-01 | 8.48e-01 | 0.1140 | 1.70e-02 | 4.04e-02 | 7.22e-02 | 2.39e-02 | 7.25e-02 | 7.28e-01 | 4.08e-01 | 1.39e-01 | 6.24e-01 | 1.37e-01 |
| POSITIVE REGULATION OF MONOATOMIC ION TRANSMEMBRANE TRANSPORT | 149 | 4.20e-01 | 8.00e-01 | 0.1140 | -7.59e-02 | -3.01e-02 | -4.68e-02 | -6.40e-02 | 2.65e-03 | 1.10e-01 | 5.26e-01 | 3.24e-01 | 1.78e-01 | 9.55e-01 |
| REGULATION OF MODIFICATION OF POSTSYNAPTIC ACTIN CYTOSKELETON | 5 | 9.99e-01 | 1.00e+00 | 0.1140 | -3.15e-02 | -5.73e-02 | -7.76e-02 | -5.13e-02 | 5.43e-03 | 9.03e-01 | 8.25e-01 | 7.64e-01 | 8.42e-01 | 9.83e-01 |
| REGULATION OF SUPRAMOLECULAR FIBER ORGANIZATION | 368 | 4.02e-01 | 7.89e-01 | 0.1140 | 5.28e-02 | 6.32e-02 | 4.76e-02 | 5.40e-02 | 3.15e-02 | 8.20e-02 | 3.74e-02 | 1.17e-01 | 7.50e-02 | 3.00e-01 |
| SPERM AXONEME ASSEMBLY | 27 | 7.28e-01 | 9.43e-01 | 0.1140 | 3.52e-02 | -1.47e-03 | -9.15e-03 | -4.81e-02 | -9.65e-02 | 7.51e-01 | 9.89e-01 | 9.34e-01 | 6.65e-01 | 3.86e-01 |
| REPLACEMENT OSSIFICATION | 30 | 7.11e-01 | 9.35e-01 | 0.1140 | -2.59e-02 | 6.30e-02 | 3.07e-02 | 2.12e-03 | 8.57e-02 | 8.06e-01 | 5.50e-01 | 7.71e-01 | 9.84e-01 | 4.16e-01 |
| REGULATION OF KETONE BIOSYNTHETIC PROCESS | 21 | 7.99e-01 | 9.66e-01 | 0.1140 | 6.24e-02 | -3.64e-02 | 2.61e-02 | 7.48e-02 | 3.80e-02 | 6.21e-01 | 7.73e-01 | 8.36e-01 | 5.53e-01 | 7.63e-01 |
| POLYOL METABOLIC PROCESS | 103 | 3.31e-01 | 7.39e-01 | 0.1140 | -3.84e-02 | -4.37e-02 | -3.04e-02 | -3.51e-02 | 8.60e-02 | 5.00e-01 | 4.44e-01 | 5.94e-01 | 5.38e-01 | 1.32e-01 |
| BODY FLUID SECRETION | 87 | 5.67e-01 | 8.81e-01 | 0.1140 | -7.27e-02 | -2.81e-02 | -1.67e-02 | -7.74e-02 | 2.33e-02 | 2.41e-01 | 6.51e-01 | 7.88e-01 | 2.12e-01 | 7.08e-01 |
| SYMPATHETIC GANGLION DEVELOPMENT | 9 | 9.44e-01 | 9.93e-01 | 0.1130 | -5.50e-02 | -2.54e-02 | 7.21e-03 | 6.14e-02 | 7.35e-02 | 7.75e-01 | 8.95e-01 | 9.70e-01 | 7.50e-01 | 7.03e-01 |
| CEREBELLAR PURKINJE CELL LAYER FORMATION | 14 | 8.42e-01 | 9.75e-01 | 0.1130 | -2.70e-02 | -7.24e-02 | 6.16e-02 | 3.51e-02 | 4.33e-02 | 8.61e-01 | 6.39e-01 | 6.90e-01 | 8.20e-01 | 7.79e-01 |
| CELLULAR RESPONSE TO KETONE | 97 | 4.59e-02 | 2.80e-01 | 0.1130 | -1.11e-02 | 1.75e-02 | -2.47e-02 | -6.91e-02 | 8.40e-02 | 8.50e-01 | 7.66e-01 | 6.74e-01 | 2.40e-01 | 1.53e-01 |
| INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 76 | 6.94e-01 | 9.31e-01 | 0.1130 | -7.37e-02 | -2.20e-02 | -3.39e-02 | -7.53e-02 | 1.18e-02 | 2.66e-01 | 7.41e-01 | 6.09e-01 | 2.57e-01 | 8.59e-01 |
| LYMPHOCYTE ACTIVATION INVOLVED IN IMMUNE RESPONSE | 203 | 1.76e-01 | 5.61e-01 | 0.1130 | 7.12e-02 | 5.29e-02 | 1.56e-02 | 6.90e-02 | -2.23e-06 | 8.04e-02 | 1.94e-01 | 7.02e-01 | 9.03e-02 | 1.00e+00 |
| MULTI MULTICELLULAR ORGANISM PROCESS | 203 | 2.85e-02 | 2.10e-01 | 0.1130 | -2.28e-02 | 5.45e-02 | 6.71e-02 | 1.22e-02 | 6.87e-02 | 5.75e-01 | 1.81e-01 | 9.92e-02 | 7.64e-01 | 9.16e-02 |
| POSITIVE REGULATION OF GROWTH | 240 | 3.78e-01 | 7.75e-01 | 0.1130 | 5.63e-02 | 7.36e-02 | 4.24e-02 | 3.61e-02 | 3.41e-02 | 1.33e-01 | 4.94e-02 | 2.58e-01 | 3.36e-01 | 3.62e-01 |
| CELL KILLING | 220 | 7.69e-02 | 3.76e-01 | 0.1130 | -1.21e-02 | -6.17e-02 | -4.99e-02 | -6.21e-03 | -7.97e-02 | 7.57e-01 | 1.15e-01 | 2.02e-01 | 8.74e-01 | 4.17e-02 |
| NUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 35 | 9.71e-01 | 9.95e-01 | 0.1130 | 1.83e-02 | 1.70e-02 | 4.84e-02 | 4.91e-02 | 8.62e-02 | 8.51e-01 | 8.62e-01 | 6.20e-01 | 6.15e-01 | 3.77e-01 |
| LAMELLIPODIUM ASSEMBLY | 67 | 2.14e-01 | 6.10e-01 | 0.1130 | -2.95e-03 | -7.77e-02 | -6.14e-02 | 3.46e-02 | -4.19e-02 | 9.67e-01 | 2.71e-01 | 3.85e-01 | 6.24e-01 | 5.53e-01 |
| POSITIVE REGULATION OF SECRETION | 305 | 1.49e-01 | 5.17e-01 | 0.1130 | 6.44e-02 | 7.56e-02 | 3.67e-02 | 3.01e-02 | 2.47e-02 | 5.29e-02 | 2.31e-02 | 2.70e-01 | 3.66e-01 | 4.58e-01 |
| POSITIVE REGULATION OF ERBB SIGNALING PATHWAY | 29 | 5.25e-01 | 8.60e-01 | 0.1130 | 2.13e-02 | -6.21e-02 | -7.53e-02 | 4.52e-02 | -2.68e-02 | 8.43e-01 | 5.63e-01 | 4.83e-01 | 6.73e-01 | 8.03e-01 |
| CHLORIDE TRANSPORT | 116 | 3.64e-01 | 7.63e-01 | 0.1130 | -4.71e-02 | -1.55e-02 | -2.61e-02 | -7.76e-02 | -5.96e-02 | 3.81e-01 | 7.74e-01 | 6.27e-01 | 1.49e-01 | 2.67e-01 |
| SMOOTH MUSCLE CELL MIGRATION | 86 | 4.30e-01 | 8.06e-01 | 0.1130 | -3.03e-02 | 1.39e-02 | -2.99e-02 | -3.95e-02 | -9.56e-02 | 6.27e-01 | 8.23e-01 | 6.32e-01 | 5.26e-01 | 1.25e-01 |
| MICROTUBULE BASED PROTEIN TRANSPORT | 14 | 9.60e-01 | 9.94e-01 | 0.1130 | -8.69e-02 | -5.04e-02 | 2.94e-02 | -2.01e-02 | 3.67e-02 | 5.74e-01 | 7.44e-01 | 8.49e-01 | 8.97e-01 | 8.12e-01 |
| POSITIVE REGULATION OF MOLECULAR FUNCTION | 1221 | 1.36e-03 | 2.25e-02 | 0.1130 | 5.70e-02 | 5.94e-02 | 3.97e-02 | 5.48e-02 | 3.66e-02 | 7.92e-04 | 4.77e-04 | 1.95e-02 | 1.25e-03 | 3.15e-02 |
| REGULATION OF ENDOCRINE PROCESS | 39 | 5.73e-01 | 8.84e-01 | 0.1130 | 4.43e-02 | -7.58e-03 | -8.73e-02 | -5.85e-03 | -5.49e-02 | 6.32e-01 | 9.35e-01 | 3.46e-01 | 9.50e-01 | 5.53e-01 |
| REGULATION OF CAMP MEDIATED SIGNALING | 29 | 9.36e-01 | 9.92e-01 | 0.1130 | 4.16e-02 | 6.74e-02 | 3.63e-02 | 5.41e-02 | -4.66e-02 | 6.98e-01 | 5.30e-01 | 7.35e-01 | 6.14e-01 | 6.64e-01 |
| REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 44 | 9.08e-01 | 9.85e-01 | 0.1130 | 7.51e-02 | 7.28e-02 | 2.01e-02 | 2.21e-02 | -2.89e-02 | 3.88e-01 | 4.03e-01 | 8.18e-01 | 8.00e-01 | 7.40e-01 |
| NEUROTRANSMITTER TRANSPORT | 198 | 4.71e-02 | 2.85e-01 | 0.1120 | -1.98e-02 | 4.49e-02 | 6.17e-02 | -4.31e-03 | 8.01e-02 | 6.30e-01 | 2.76e-01 | 1.34e-01 | 9.17e-01 | 5.18e-02 |
| VASCULAR TRANSPORT | 84 | 4.72e-01 | 8.30e-01 | 0.1120 | -6.37e-02 | -4.04e-03 | -5.17e-02 | -7.55e-02 | -1.39e-02 | 3.13e-01 | 9.49e-01 | 4.13e-01 | 2.31e-01 | 8.26e-01 |
| INTERLEUKIN 2 PRODUCTION | 60 | 8.17e-01 | 9.70e-01 | 0.1120 | 8.26e-02 | 5.62e-02 | 6.44e-03 | 3.11e-02 | -4.03e-02 | 2.69e-01 | 4.51e-01 | 9.31e-01 | 6.77e-01 | 5.90e-01 |
| REGULATION OF RYANODINE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 23 | 9.40e-01 | 9.92e-01 | 0.1120 | -4.93e-02 | -3.53e-02 | -1.07e-02 | -4.17e-03 | 9.38e-02 | 6.83e-01 | 7.69e-01 | 9.29e-01 | 9.72e-01 | 4.36e-01 |
| REGULATION OF LEUKOCYTE PROLIFERATION | 257 | 1.59e-01 | 5.32e-01 | 0.1120 | 7.00e-02 | 5.51e-02 | 2.07e-02 | 6.30e-02 | 1.60e-02 | 5.32e-02 | 1.28e-01 | 5.68e-01 | 8.21e-02 | 6.59e-01 |
| ORGANOPHOSPHATE ESTER TRANSPORT | 147 | 4.80e-01 | 8.35e-01 | 0.1120 | -3.92e-02 | -1.13e-02 | -4.33e-02 | -5.52e-02 | -7.74e-02 | 4.11e-01 | 8.12e-01 | 3.65e-01 | 2.48e-01 | 1.05e-01 |
| CHOLESTEROL IMPORT | 9 | 9.00e-01 | 9.83e-01 | 0.1120 | -4.63e-02 | 3.33e-02 | 6.90e-02 | -1.02e-02 | -6.65e-02 | 8.10e-01 | 8.63e-01 | 7.20e-01 | 9.58e-01 | 7.30e-01 |
| REGULATION OF DEPHOSPHORYLATION | 101 | 5.83e-01 | 8.89e-01 | 0.1120 | 5.56e-02 | 4.70e-02 | 2.86e-02 | 7.97e-02 | -6.80e-03 | 3.34e-01 | 4.14e-01 | 6.19e-01 | 1.66e-01 | 9.06e-01 |
| MINERALOCORTICOID METABOLIC PROCESS | 14 | 8.36e-01 | 9.73e-01 | 0.1120 | -6.19e-02 | -2.32e-02 | 8.62e-02 | 6.34e-03 | 2.61e-02 | 6.88e-01 | 8.81e-01 | 5.77e-01 | 9.67e-01 | 8.66e-01 |
| FATTY ACID DERIVATIVE METABOLIC PROCESS | 69 | 9.43e-01 | 9.93e-01 | 0.1120 | 4.41e-02 | 4.17e-02 | 5.63e-02 | 3.93e-02 | 6.40e-02 | 5.27e-01 | 5.49e-01 | 4.18e-01 | 5.72e-01 | 3.58e-01 |
| REGULATION OF DENDRITE DEVELOPMENT | 91 | 5.15e-01 | 8.56e-01 | 0.1120 | -7.38e-02 | -3.20e-02 | -5.46e-02 | -5.08e-02 | 2.15e-02 | 2.24e-01 | 5.97e-01 | 3.68e-01 | 4.03e-01 | 7.23e-01 |
| NEGATIVE REGULATION OF MONOATOMIC ION TRANSMEMBRANE TRANSPORT | 95 | 9.28e-01 | 9.89e-01 | 0.1120 | -4.83e-02 | -6.44e-02 | -5.57e-02 | -5.25e-02 | -1.23e-02 | 4.16e-01 | 2.78e-01 | 3.48e-01 | 3.76e-01 | 8.36e-01 |
| PROTEIN TETRAMERIZATION | 88 | 8.87e-01 | 9.80e-01 | 0.1120 | 3.20e-02 | 3.87e-02 | 5.48e-02 | 6.87e-02 | 4.74e-02 | 6.04e-01 | 5.31e-01 | 3.74e-01 | 2.65e-01 | 4.42e-01 |
| POSITIVE REGULATION OF T HELPER 17 TYPE IMMUNE RESPONSE | 16 | 8.08e-01 | 9.67e-01 | 0.1120 | 2.83e-02 | -5.49e-02 | -5.22e-02 | 1.18e-03 | 7.71e-02 | 8.45e-01 | 7.04e-01 | 7.18e-01 | 9.93e-01 | 5.93e-01 |
| RESPONSE TO TOXIC SUBSTANCE | 249 | 2.37e-01 | 6.41e-01 | 0.1120 | 3.06e-02 | 6.82e-02 | 4.81e-02 | 3.48e-02 | 5.78e-02 | 4.05e-01 | 6.37e-02 | 1.91e-01 | 3.44e-01 | 1.16e-01 |
| NEGATIVE REGULATION OF NON CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 36 | 7.50e-01 | 9.51e-01 | 0.1120 | 2.50e-02 | -5.85e-02 | -4.57e-02 | -1.04e-02 | -7.88e-02 | 7.95e-01 | 5.44e-01 | 6.35e-01 | 9.14e-01 | 4.13e-01 |
| UNSATURATED FATTY ACID METABOLIC PROCESS | 110 | 7.46e-01 | 9.50e-01 | 0.1120 | 5.00e-02 | 4.81e-02 | 7.21e-02 | 4.51e-02 | 2.00e-02 | 3.65e-01 | 3.83e-01 | 1.91e-01 | 4.14e-01 | 7.17e-01 |
| CARDIAC MUSCLE TISSUE MORPHOGENESIS | 61 | 4.29e-01 | 8.05e-01 | 0.1110 | -8.33e-02 | -1.15e-02 | 1.32e-02 | -7.08e-02 | 1.27e-02 | 2.60e-01 | 8.76e-01 | 8.58e-01 | 3.39e-01 | 8.63e-01 |
| POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 16 | 7.74e-01 | 9.57e-01 | 0.1110 | 5.47e-02 | 8.10e-02 | -4.83e-02 | -2.31e-02 | 2.75e-04 | 7.05e-01 | 5.75e-01 | 7.38e-01 | 8.73e-01 | 9.98e-01 |
| DESMOSOME ORGANIZATION | 10 | 9.02e-01 | 9.83e-01 | 0.1110 | 2.16e-02 | -7.72e-02 | -5.03e-04 | -5.24e-03 | 7.72e-02 | 9.06e-01 | 6.73e-01 | 9.98e-01 | 9.77e-01 | 6.72e-01 |
| NEGATIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 52 | 4.52e-01 | 8.21e-01 | 0.1110 | -6.28e-02 | -7.93e-02 | -3.69e-02 | 2.46e-02 | 1.44e-02 | 4.33e-01 | 3.22e-01 | 6.45e-01 | 7.59e-01 | 8.58e-01 |
| SEQUESTERING OF CALCIUM ION | 138 | 3.45e-01 | 7.50e-01 | 0.1110 | -7.69e-02 | -5.39e-02 | -5.23e-02 | -2.87e-02 | 5.54e-03 | 1.19e-01 | 2.74e-01 | 2.89e-01 | 5.61e-01 | 9.11e-01 |
| REGULATION OF MAST CELL ACTIVATION | 38 | 7.67e-01 | 9.55e-01 | 0.1110 | 5.94e-02 | 8.09e-02 | -8.85e-03 | -6.91e-03 | -4.65e-02 | 5.26e-01 | 3.88e-01 | 9.25e-01 | 9.41e-01 | 6.20e-01 |
| GLYCOSIDE METABOLIC PROCESS | 20 | 8.95e-01 | 9.82e-01 | 0.1110 | -1.67e-02 | -2.50e-02 | -3.14e-02 | 2.81e-02 | -9.84e-02 | 8.97e-01 | 8.47e-01 | 8.08e-01 | 8.28e-01 | 4.46e-01 |
| GLYCOSYL COMPOUND METABOLIC PROCESS | 79 | 5.75e-01 | 8.84e-01 | 0.1110 | 7.33e-02 | 6.50e-02 | -9.40e-03 | 1.74e-02 | -4.85e-02 | 2.60e-01 | 3.18e-01 | 8.85e-01 | 7.89e-01 | 4.57e-01 |
| RESPONSE TO TYPE III INTERFERON | 12 | 9.28e-01 | 9.89e-01 | 0.1110 | -4.00e-02 | 4.98e-02 | -3.54e-02 | -6.08e-02 | -5.73e-02 | 8.10e-01 | 7.65e-01 | 8.32e-01 | 7.15e-01 | 7.31e-01 |
| POSITIVE REGULATION OF DENDRITIC CELL DIFFERENTIATION | 6 | 9.25e-01 | 9.89e-01 | 0.1110 | 2.18e-02 | 1.34e-02 | -1.08e-01 | 1.50e-03 | -2.55e-03 | 9.26e-01 | 9.55e-01 | 6.47e-01 | 9.95e-01 | 9.91e-01 |
| MICROVILLUS ASSEMBLY | 20 | 6.06e-01 | 9.01e-01 | 0.1110 | 9.18e-02 | -6.96e-03 | 3.02e-02 | 7.74e-03 | 5.32e-02 | 4.77e-01 | 9.57e-01 | 8.15e-01 | 9.52e-01 | 6.80e-01 |
| SINGLE STRANDED VIRAL RNA REPLICATION VIA DOUBLE STRANDED DNA INTERMEDIATE | 20 | 9.33e-01 | 9.91e-01 | 0.1110 | 1.29e-03 | 2.50e-03 | -3.42e-02 | 1.87e-02 | -1.04e-01 | 9.92e-01 | 9.85e-01 | 7.91e-01 | 8.85e-01 | 4.22e-01 |
| LIPID LOCALIZATION | 496 | 1.92e-01 | 5.80e-01 | 0.1110 | -2.96e-02 | -3.42e-02 | -5.86e-02 | -4.83e-02 | -6.68e-02 | 2.59e-01 | 1.92e-01 | 2.55e-02 | 6.53e-02 | 1.09e-02 |
| ACIDIC AMINO ACID TRANSPORT | 65 | 7.40e-01 | 9.49e-01 | 0.1110 | -8.23e-02 | -2.90e-02 | -9.06e-03 | -5.68e-02 | 3.63e-02 | 2.51e-01 | 6.86e-01 | 8.99e-01 | 4.28e-01 | 6.13e-01 |
| NEGATIVE REGULATION OF TRANSMEMBRANE TRANSPORT | 138 | 7.01e-01 | 9.32e-01 | 0.1110 | -3.63e-02 | -6.59e-02 | -6.52e-02 | -4.68e-02 | -1.17e-02 | 4.62e-01 | 1.81e-01 | 1.86e-01 | 3.42e-01 | 8.12e-01 |
| RESPONSE TO INTERLEUKIN 1 | 134 | 1.81e-01 | 5.66e-01 | 0.1110 | 1.27e-02 | 6.12e-03 | -6.98e-02 | -6.16e-02 | -5.80e-02 | 8.00e-01 | 9.03e-01 | 1.63e-01 | 2.18e-01 | 2.47e-01 |
| RESPONSE TO INSULIN | 262 | 9.76e-03 | 9.98e-02 | 0.1100 | 2.49e-02 | 5.82e-02 | 2.17e-02 | 3.08e-02 | 8.23e-02 | 4.88e-01 | 1.05e-01 | 5.45e-01 | 3.90e-01 | 2.18e-02 |
| ACTIVATION OF PROTEIN KINASE B ACTIVITY | 25 | 2.82e-01 | 6.93e-01 | 0.1100 | 4.83e-03 | -9.96e-02 | 3.85e-02 | -5.07e-04 | 2.76e-02 | 9.67e-01 | 3.89e-01 | 7.39e-01 | 9.96e-01 | 8.11e-01 |
| ERYTHROCYTE MATURATION | 17 | 8.26e-01 | 9.72e-01 | 0.1100 | -4.07e-02 | 5.05e-02 | 4.86e-02 | 5.29e-02 | 5.31e-02 | 7.72e-01 | 7.18e-01 | 7.29e-01 | 7.06e-01 | 7.05e-01 |
| POSITIVE REGULATION OF LAMELLIPODIUM ASSEMBLY | 26 | 8.06e-01 | 9.67e-01 | 0.1100 | 5.60e-02 | -1.02e-02 | 7.16e-03 | 9.21e-02 | -1.99e-02 | 6.21e-01 | 9.28e-01 | 9.50e-01 | 4.16e-01 | 8.61e-01 |
| POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 1620 | 5.84e-04 | 1.15e-02 | 0.1100 | 4.15e-02 | 6.06e-02 | 5.12e-02 | 4.56e-02 | 4.56e-02 | 5.29e-03 | 4.69e-05 | 5.93e-04 | 2.20e-03 | 2.21e-03 |
| PROTEIN PHOSPHORYLATION | 1274 | 2.52e-04 | 5.61e-03 | 0.1100 | 5.40e-02 | 4.54e-02 | 3.69e-02 | 6.39e-02 | 4.17e-02 | 1.18e-03 | 6.43e-03 | 2.67e-02 | 1.24e-04 | 1.24e-02 |
| T CELL DIFFERENTIATION INVOLVED IN IMMUNE RESPONSE | 82 | 4.05e-01 | 7.92e-01 | 0.1100 | 4.59e-02 | 2.15e-02 | 1.05e-02 | 6.67e-02 | 7.07e-02 | 4.72e-01 | 7.36e-01 | 8.69e-01 | 2.96e-01 | 2.69e-01 |
| REGULATION OF PROTEIN CONTAINING COMPLEX ASSEMBLY | 403 | 4.19e-01 | 8.00e-01 | 0.1100 | 5.53e-02 | 5.70e-02 | 5.02e-02 | 4.37e-02 | 3.72e-02 | 5.68e-02 | 4.95e-02 | 8.38e-02 | 1.32e-01 | 2.00e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 10 PRODUCTION | 40 | 2.52e-01 | 6.58e-01 | 0.1100 | 8.62e-02 | 1.71e-02 | -6.38e-02 | -1.09e-02 | 1.27e-02 | 3.46e-01 | 8.51e-01 | 4.85e-01 | 9.05e-01 | 8.90e-01 |
| EPITHELIUM DEVELOPMENT | 1206 | 8.06e-04 | 1.47e-02 | 0.1100 | 2.02e-02 | 4.02e-02 | 5.45e-02 | 3.93e-02 | 7.44e-02 | 2.37e-01 | 1.87e-02 | 1.44e-03 | 2.17e-02 | 1.36e-05 |
| PROTEIN O LINKED GLYCOSYLATION | 96 | 5.59e-01 | 8.78e-01 | 0.1100 | 8.14e-02 | 3.61e-02 | 6.58e-06 | 4.78e-02 | -4.27e-02 | 1.68e-01 | 5.40e-01 | 1.00e+00 | 4.18e-01 | 4.70e-01 |
| POSITIVE REGULATION OF EXTRACELLULAR MATRIX DISASSEMBLY | 8 | 9.79e-01 | 9.96e-01 | 0.1100 | 2.89e-02 | -2.81e-02 | -4.56e-02 | 5.36e-02 | -7.39e-02 | 8.87e-01 | 8.91e-01 | 8.23e-01 | 7.93e-01 | 7.17e-01 |
| ORGANIC ACID BIOSYNTHETIC PROCESS | 321 | 5.53e-01 | 8.76e-01 | 0.1100 | 4.70e-02 | 5.49e-02 | 4.78e-02 | 5.47e-02 | 3.93e-02 | 1.48e-01 | 9.06e-02 | 1.41e-01 | 9.22e-02 | 2.25e-01 |
| POSITIVE REGULATION OF LIPID TRANSPORT | 86 | 3.03e-01 | 7.15e-01 | 0.1100 | 8.06e-03 | 1.57e-02 | -7.18e-02 | -6.60e-02 | -4.72e-02 | 8.97e-01 | 8.02e-01 | 2.50e-01 | 2.90e-01 | 4.50e-01 |
| REGULATION OF VIRAL INDUCED CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 87 | 3.79e-01 | 7.75e-01 | 0.1100 | 6.94e-02 | 3.97e-02 | 1.68e-02 | 2.27e-02 | 6.96e-02 | 2.63e-01 | 5.23e-01 | 7.87e-01 | 7.15e-01 | 2.62e-01 |
| PHOSPHORYLATION | 1527 | 2.95e-04 | 6.45e-03 | 0.1100 | 4.94e-02 | 4.83e-02 | 4.13e-02 | 6.09e-02 | 4.29e-02 | 1.26e-03 | 1.60e-03 | 6.97e-03 | 6.99e-05 | 5.09e-03 |
| SEPTUM PRIMUM DEVELOPMENT | 5 | 9.57e-01 | 9.94e-01 | 0.1100 | -6.40e-02 | 8.07e-02 | 3.67e-02 | -3.16e-03 | -6.92e-03 | 8.04e-01 | 7.55e-01 | 8.87e-01 | 9.90e-01 | 9.79e-01 |
| REGULATION OF ENDOCYTIC RECYCLING | 20 | 7.24e-01 | 9.41e-01 | 0.1100 | -4.20e-03 | 5.81e-02 | 2.63e-02 | 6.77e-02 | -5.78e-02 | 9.74e-01 | 6.53e-01 | 8.39e-01 | 6.00e-01 | 6.54e-01 |
| PROTEIN LOCALIZATION TO EXTRACELLULAR REGION | 364 | 3.72e-02 | 2.49e-01 | 0.1090 | 4.36e-02 | 8.48e-02 | 4.62e-02 | 2.50e-02 | 1.03e-02 | 1.53e-01 | 5.42e-03 | 1.30e-01 | 4.12e-01 | 7.36e-01 |
| CORNEA DEVELOPMENT IN CAMERA TYPE EYE | 12 | 9.88e-01 | 9.97e-01 | 0.1090 | 6.16e-02 | 4.74e-02 | 6.47e-02 | 3.33e-02 | -2.51e-02 | 7.12e-01 | 7.76e-01 | 6.98e-01 | 8.42e-01 | 8.80e-01 |
| REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 48 | 7.83e-01 | 9.61e-01 | 0.1090 | -3.23e-02 | -3.75e-02 | -7.64e-02 | -5.79e-02 | 1.73e-02 | 6.99e-01 | 6.53e-01 | 3.60e-01 | 4.87e-01 | 8.36e-01 |
| REGULATION OF AMYLOID FIBRIL FORMATION | 16 | 8.93e-01 | 9.81e-01 | 0.1090 | -6.83e-02 | 1.46e-02 | -3.97e-02 | -3.75e-02 | -6.40e-02 | 6.36e-01 | 9.19e-01 | 7.83e-01 | 7.95e-01 | 6.58e-01 |
| CELL COMMUNICATION INVOLVED IN CARDIAC CONDUCTION | 58 | 6.56e-01 | 9.20e-01 | 0.1090 | -8.27e-02 | -1.91e-02 | 3.39e-03 | -6.24e-02 | 2.85e-02 | 2.76e-01 | 8.01e-01 | 9.64e-01 | 4.11e-01 | 7.08e-01 |
| COLLAGEN METABOLIC PROCESS | 103 | 8.46e-02 | 3.94e-01 | 0.1090 | -5.19e-02 | 2.00e-02 | -1.60e-02 | -2.76e-02 | -8.83e-02 | 3.63e-01 | 7.26e-01 | 7.79e-01 | 6.29e-01 | 1.22e-01 |
| PIGMENT BIOSYNTHETIC PROCESS | 51 | 4.77e-01 | 8.33e-01 | 0.1090 | -4.12e-02 | -2.21e-02 | -2.58e-02 | 7.65e-03 | 9.48e-02 | 6.11e-01 | 7.85e-01 | 7.50e-01 | 9.25e-01 | 2.42e-01 |
| LOCOMOTORY BEHAVIOR | 198 | 6.71e-01 | 9.25e-01 | 0.1090 | 4.10e-02 | 5.46e-02 | 6.09e-02 | 3.42e-02 | 4.85e-02 | 3.20e-01 | 1.85e-01 | 1.40e-01 | 4.07e-01 | 2.39e-01 |
| SINGLE FERTILIZATION | 158 | 3.28e-01 | 7.37e-01 | 0.1090 | -7.50e-02 | -2.04e-02 | -3.84e-02 | -6.46e-02 | -1.47e-02 | 1.04e-01 | 6.59e-01 | 4.05e-01 | 1.61e-01 | 7.50e-01 |
| COGNITION | 304 | 1.11e-01 | 4.54e-01 | 0.1090 | 2.02e-02 | 4.05e-02 | 3.77e-02 | 3.06e-02 | 8.65e-02 | 5.44e-01 | 2.24e-01 | 2.58e-01 | 3.59e-01 | 9.49e-03 |
| PROTEIN AUTO ADP RIBOSYLATION | 11 | 9.17e-01 | 9.86e-01 | 0.1090 | -1.58e-02 | -9.06e-02 | 1.81e-02 | 5.04e-02 | 2.30e-02 | 9.28e-01 | 6.03e-01 | 9.17e-01 | 7.72e-01 | 8.95e-01 |
| CYCLIC NUCLEOTIDE MEDIATED SIGNALING | 80 | 7.07e-01 | 9.34e-01 | 0.1090 | -7.30e-02 | -2.85e-02 | -3.13e-02 | -4.91e-02 | -4.82e-02 | 2.59e-01 | 6.60e-01 | 6.29e-01 | 4.48e-01 | 4.56e-01 |
| REGULATION OF KERATINOCYTE DIFFERENTIATION | 40 | 7.31e-01 | 9.44e-01 | 0.1090 | -6.49e-02 | 2.62e-03 | 1.29e-03 | -2.44e-02 | 8.37e-02 | 4.77e-01 | 9.77e-01 | 9.89e-01 | 7.90e-01 | 3.60e-01 |
| SULFUR COMPOUND METABOLIC PROCESS | 295 | 4.64e-02 | 2.81e-01 | 0.1090 | 4.37e-02 | 4.25e-02 | 2.34e-02 | 4.04e-02 | 7.70e-02 | 1.97e-01 | 2.09e-01 | 4.89e-01 | 2.33e-01 | 2.28e-02 |
| VITAMIN METABOLIC PROCESS | 107 | 7.79e-01 | 9.59e-01 | 0.1090 | 4.76e-02 | 6.09e-02 | 5.78e-02 | 2.41e-02 | 4.39e-02 | 3.95e-01 | 2.77e-01 | 3.02e-01 | 6.66e-01 | 4.33e-01 |
| MUCOPOLYSACCHARIDE METABOLIC PROCESS | 89 | 2.46e-01 | 6.51e-01 | 0.1090 | 5.17e-02 | 5.70e-02 | -4.33e-02 | -1.62e-02 | -6.13e-02 | 4.00e-01 | 3.53e-01 | 4.80e-01 | 7.91e-01 | 3.18e-01 |
| PLASMA MEMBRANE PHOSPHOLIPID SCRAMBLING | 24 | 9.42e-01 | 9.92e-01 | 0.1090 | -5.27e-02 | -3.38e-02 | -2.03e-02 | -8.55e-02 | 1.18e-02 | 6.55e-01 | 7.75e-01 | 8.63e-01 | 4.68e-01 | 9.20e-01 |
| NEGATIVE REGULATION OF MONOATOMIC ION TRANSPORT | 125 | 7.91e-01 | 9.63e-01 | 0.1090 | -3.94e-02 | -6.38e-02 | -6.10e-02 | -4.89e-02 | -6.64e-03 | 4.47e-01 | 2.18e-01 | 2.39e-01 | 3.45e-01 | 8.98e-01 |
| REGULATION OF KERATINOCYTE PROLIFERATION | 47 | 3.55e-01 | 7.55e-01 | 0.1080 | -8.67e-02 | 2.42e-02 | 1.79e-02 | -5.61e-02 | 1.31e-02 | 3.04e-01 | 7.74e-01 | 8.32e-01 | 5.06e-01 | 8.76e-01 |
| REGULATION OF ADENYLATE CYCLASE ACTIVITY | 44 | 5.72e-01 | 8.83e-01 | 0.1080 | -2.31e-02 | 4.84e-02 | -2.23e-02 | -5.85e-02 | -7.03e-02 | 7.91e-01 | 5.78e-01 | 7.98e-01 | 5.02e-01 | 4.20e-01 |
| CEREBELLAR CORTEX FORMATION | 24 | 8.10e-01 | 9.68e-01 | 0.1080 | -1.83e-02 | -6.15e-02 | 1.51e-02 | -2.81e-02 | 8.12e-02 | 8.77e-01 | 6.02e-01 | 8.98e-01 | 8.12e-01 | 4.91e-01 |
| REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 28 | 9.37e-01 | 9.92e-01 | 0.1080 | -4.02e-02 | 5.83e-03 | -4.40e-02 | -7.44e-02 | -5.08e-02 | 7.13e-01 | 9.57e-01 | 6.87e-01 | 4.96e-01 | 6.42e-01 |
| REGULATION OF CHEMOTAXIS | 221 | 5.32e-02 | 3.05e-01 | 0.1080 | -2.85e-02 | 6.70e-03 | -6.51e-02 | -6.35e-02 | -5.06e-02 | 4.65e-01 | 8.64e-01 | 9.53e-02 | 1.04e-01 | 1.95e-01 |
| PROLINE TRANSMEMBRANE TRANSPORT | 9 | 9.76e-01 | 9.96e-01 | 0.1080 | -6.43e-02 | 1.58e-02 | -1.42e-03 | -6.54e-02 | -5.43e-02 | 7.38e-01 | 9.35e-01 | 9.94e-01 | 7.34e-01 | 7.78e-01 |
| REGULATION OF OSTEOBLAST DIFFERENTIATION | 144 | 5.76e-01 | 8.84e-01 | 0.1080 | 1.34e-02 | 4.03e-02 | 6.17e-02 | 1.94e-02 | 7.50e-02 | 7.82e-01 | 4.03e-01 | 2.02e-01 | 6.87e-01 | 1.20e-01 |
| SKELETAL MUSCLE TISSUE REGENERATION | 37 | 9.47e-01 | 9.94e-01 | 0.1080 | -4.75e-02 | -7.79e-02 | -3.79e-02 | -3.21e-02 | 2.82e-02 | 6.17e-01 | 4.12e-01 | 6.90e-01 | 7.36e-01 | 7.66e-01 |
| REGULATION OF NEUROTRANSMITTER TRANSPORT | 92 | 5.34e-01 | 8.64e-01 | 0.1080 | -5.90e-02 | -1.60e-02 | 2.68e-02 | -1.32e-02 | 8.34e-02 | 3.28e-01 | 7.91e-01 | 6.57e-01 | 8.27e-01 | 1.67e-01 |
| TYROSINE PHOSPHORYLATION OF STAT PROTEIN | 81 | 4.54e-01 | 8.22e-01 | 0.1080 | -6.45e-02 | -2.97e-02 | -6.79e-02 | -4.29e-02 | 9.01e-03 | 3.16e-01 | 6.44e-01 | 2.91e-01 | 5.04e-01 | 8.88e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 126 | 4.77e-01 | 8.33e-01 | 0.1070 | -5.14e-02 | -4.96e-02 | -1.22e-02 | -2.58e-02 | 7.50e-02 | 3.19e-01 | 3.36e-01 | 8.14e-01 | 6.17e-01 | 1.46e-01 |
| SYNAPTIC VESICLE UNCOATING | 6 | 9.83e-01 | 9.96e-01 | 0.1070 | 2.50e-02 | -1.26e-02 | 6.91e-02 | 6.76e-02 | -3.76e-02 | 9.15e-01 | 9.57e-01 | 7.69e-01 | 7.74e-01 | 8.73e-01 |
| PRODUCTION OF MOLECULAR MEDIATOR INVOLVED IN INFLAMMATORY RESPONSE | 103 | 1.38e-01 | 5.01e-01 | 0.1070 | 4.75e-02 | 8.43e-02 | -1.41e-02 | -1.65e-02 | -4.13e-02 | 4.05e-01 | 1.39e-01 | 8.05e-01 | 7.73e-01 | 4.69e-01 |
| REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 249 | 1.40e-01 | 5.04e-01 | 0.1070 | -5.91e-04 | 1.95e-02 | 5.01e-02 | 5.84e-02 | 7.23e-02 | 9.87e-01 | 5.96e-01 | 1.73e-01 | 1.13e-01 | 4.94e-02 |
| INNER EAR AUDITORY RECEPTOR CELL DIFFERENTIATION | 45 | 8.84e-01 | 9.80e-01 | 0.1070 | -6.55e-02 | -4.28e-02 | -1.68e-02 | -5.11e-02 | -5.01e-02 | 4.47e-01 | 6.19e-01 | 8.45e-01 | 5.53e-01 | 5.61e-01 |
| DIOL METABOLIC PROCESS | 30 | 7.04e-01 | 9.33e-01 | 0.1070 | -4.30e-02 | -5.14e-02 | -3.35e-02 | 2.89e-02 | 7.13e-02 | 6.84e-01 | 6.26e-01 | 7.51e-01 | 7.84e-01 | 4.99e-01 |
| NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 90 | 3.46e-01 | 7.50e-01 | 0.1070 | 4.64e-02 | 1.32e-03 | 2.92e-02 | 9.22e-02 | 1.88e-03 | 4.47e-01 | 9.83e-01 | 6.32e-01 | 1.31e-01 | 9.75e-01 |
| RECEPTOR SIGNALING PATHWAY VIA STAT | 181 | 4.30e-01 | 8.05e-01 | 0.1070 | -4.29e-02 | -3.10e-02 | -6.47e-02 | -3.55e-02 | -5.69e-02 | 3.19e-01 | 4.72e-01 | 1.33e-01 | 4.10e-01 | 1.86e-01 |
| REGULATION OF SHORT TERM NEURONAL SYNAPTIC PLASTICITY | 13 | 9.30e-01 | 9.90e-01 | 0.1070 | -6.51e-02 | 1.93e-02 | 1.99e-02 | -7.78e-02 | 2.02e-02 | 6.84e-01 | 9.04e-01 | 9.01e-01 | 6.27e-01 | 9.00e-01 |
| REGULATION OF SYNAPTIC TRANSMISSION GLUTAMATERGIC | 75 | 6.39e-01 | 9.14e-01 | 0.1070 | -7.78e-02 | -1.89e-02 | -1.88e-02 | -6.42e-02 | -2.41e-02 | 2.44e-01 | 7.77e-01 | 7.78e-01 | 3.37e-01 | 7.19e-01 |
| CORTICAL CYTOSKELETON ORGANIZATION | 50 | 7.56e-01 | 9.51e-01 | 0.1070 | 5.75e-02 | 1.13e-02 | -1.04e-02 | 5.21e-02 | -7.21e-02 | 4.82e-01 | 8.90e-01 | 8.98e-01 | 5.24e-01 | 3.78e-01 |
| POSITIVE REGULATION OF NEUROGENESIS | 228 | 5.43e-01 | 8.69e-01 | 0.1070 | 1.75e-02 | 3.60e-02 | 5.68e-02 | 3.54e-02 | 7.32e-02 | 6.48e-01 | 3.49e-01 | 1.39e-01 | 3.56e-01 | 5.68e-02 |
| MODULATION BY SYMBIONT OF ENTRY INTO HOST | 55 | 2.66e-01 | 6.73e-01 | 0.1070 | 6.94e-02 | 5.63e-02 | -1.55e-02 | -4.96e-02 | -2.72e-02 | 3.73e-01 | 4.70e-01 | 8.43e-01 | 5.24e-01 | 7.27e-01 |
| DICARBOXYLIC ACID TRANSPORT | 98 | 4.13e-01 | 7.98e-01 | 0.1070 | -7.76e-02 | -1.33e-02 | -1.19e-02 | -7.05e-02 | 1.08e-02 | 1.84e-01 | 8.20e-01 | 8.39e-01 | 2.28e-01 | 8.53e-01 |
| REGULATION OF NON MOTILE CILIUM ASSEMBLY | 11 | 8.74e-01 | 9.78e-01 | 0.1070 | 1.18e-02 | 9.92e-03 | -2.68e-03 | 1.05e-01 | 1.35e-02 | 9.46e-01 | 9.55e-01 | 9.88e-01 | 5.47e-01 | 9.38e-01 |
| RESPONSE TO LIGHT STIMULUS | 302 | 1.34e-01 | 4.94e-01 | 0.1070 | 2.99e-02 | 2.98e-02 | 3.22e-02 | 4.62e-02 | 8.01e-02 | 3.71e-01 | 3.73e-01 | 3.36e-01 | 1.68e-01 | 1.66e-02 |
| POSITIVE REGULATION OF PROTEIN SECRETION | 142 | 2.94e-01 | 7.05e-01 | 0.1070 | 5.47e-02 | 8.61e-02 | 2.38e-02 | 1.83e-02 | 8.08e-03 | 2.61e-01 | 7.65e-02 | 6.25e-01 | 7.07e-01 | 8.68e-01 |
| REGULATION OF AXONOGENESIS | 145 | 7.30e-01 | 9.44e-01 | 0.1070 | -3.14e-02 | -3.25e-02 | -6.75e-02 | -6.01e-02 | -3.42e-02 | 5.15e-01 | 4.99e-01 | 1.61e-01 | 2.12e-01 | 4.77e-01 |
| PHOSPHATIDYLINOSITOL DEPHOSPHORYLATION | 23 | 6.27e-01 | 9.09e-01 | 0.1070 | -2.34e-02 | -2.52e-02 | -9.05e-02 | -1.34e-02 | 4.25e-02 | 8.46e-01 | 8.34e-01 | 4.52e-01 | 9.12e-01 | 7.24e-01 |
| REGULATION OF RESPONSE TO REACTIVE OXYGEN SPECIES | 13 | 9.61e-01 | 9.94e-01 | 0.1070 | -5.19e-02 | 2.63e-02 | 1.24e-02 | -2.85e-02 | 8.37e-02 | 7.46e-01 | 8.70e-01 | 9.38e-01 | 8.59e-01 | 6.01e-01 |
| INSEMINATION | 12 | 9.62e-01 | 9.94e-01 | 0.1070 | -1.98e-02 | -5.10e-02 | 2.61e-02 | 6.49e-02 | 5.87e-02 | 9.05e-01 | 7.59e-01 | 8.75e-01 | 6.97e-01 | 7.25e-01 |
| REGULATION OF POLYSACCHARIDE BIOSYNTHETIC PROCESS | 38 | 8.69e-01 | 9.78e-01 | 0.1060 | -6.17e-02 | -1.77e-02 | 7.13e-04 | -1.73e-02 | 8.32e-02 | 5.11e-01 | 8.51e-01 | 9.94e-01 | 8.54e-01 | 3.75e-01 |
| EPITHELIAL CELL DEVELOPMENT | 208 | 2.47e-01 | 6.53e-01 | 0.1060 | -1.26e-02 | 2.56e-02 | 4.74e-02 | 1.69e-02 | 8.93e-02 | 7.54e-01 | 5.25e-01 | 2.39e-01 | 6.74e-01 | 2.63e-02 |
| REGULATION OF SECRETION | 603 | 1.55e-02 | 1.39e-01 | 0.1060 | 4.98e-02 | 7.46e-02 | 4.39e-02 | 2.53e-02 | 2.65e-02 | 3.65e-02 | 1.74e-03 | 6.56e-02 | 2.88e-01 | 2.66e-01 |
| MYELOID LEUKOCYTE ACTIVATION | 236 | 2.31e-01 | 6.34e-01 | 0.1060 | 6.16e-02 | 7.66e-02 | 3.10e-02 | 2.10e-02 | -1.60e-02 | 1.03e-01 | 4.26e-02 | 4.12e-01 | 5.78e-01 | 6.72e-01 |
| GLUTAMINE FAMILY AMINO ACID CATABOLIC PROCESS | 26 | 7.32e-01 | 9.45e-01 | 0.1060 | -2.02e-02 | 3.51e-02 | -6.63e-02 | -6.97e-02 | -2.07e-02 | 8.58e-01 | 7.57e-01 | 5.59e-01 | 5.39e-01 | 8.55e-01 |
| REGULATORY T CELL DIFFERENTIATION | 39 | 6.04e-01 | 9.01e-01 | 0.1060 | -1.99e-02 | -1.03e-02 | 5.09e-02 | 8.40e-02 | 3.37e-02 | 8.30e-01 | 9.11e-01 | 5.82e-01 | 3.64e-01 | 7.16e-01 |
| THIOESTER METABOLIC PROCESS | 89 | 4.42e-01 | 8.13e-01 | 0.1060 | -2.57e-02 | -1.81e-02 | -7.43e-03 | -8.50e-03 | 1.01e-01 | 6.75e-01 | 7.67e-01 | 9.04e-01 | 8.90e-01 | 1.00e-01 |
| POSITIVE REGULATION OF PROTEIN CONTAINING COMPLEX ASSEMBLY | 192 | 4.91e-01 | 8.42e-01 | 0.1060 | 7.74e-02 | 4.99e-02 | 2.28e-02 | 4.62e-02 | -1.17e-02 | 6.43e-02 | 2.33e-01 | 5.86e-01 | 2.69e-01 | 7.81e-01 |
| NEUTRAL LIPID METABOLIC PROCESS | 128 | 9.93e-02 | 4.28e-01 | 0.1060 | -1.99e-02 | 4.07e-02 | -2.71e-02 | -4.28e-02 | -8.15e-02 | 6.97e-01 | 4.27e-01 | 5.96e-01 | 4.03e-01 | 1.11e-01 |
| HEPARAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS ENZYMATIC MODIFICATION | 11 | 9.90e-01 | 9.98e-01 | 0.1060 | 1.31e-03 | 2.48e-03 | -6.31e-02 | -1.27e-02 | -8.43e-02 | 9.94e-01 | 9.89e-01 | 7.17e-01 | 9.42e-01 | 6.28e-01 |
| TUBE MORPHOGENESIS | 915 | 1.51e-03 | 2.43e-02 | 0.1060 | 2.95e-02 | 5.67e-02 | 4.50e-02 | 3.13e-02 | 6.44e-02 | 1.31e-01 | 3.60e-03 | 2.10e-02 | 1.09e-01 | 9.57e-04 |
| CARDIAC MUSCLE CELL DIFFERENTIATION | 129 | 4.39e-01 | 8.11e-01 | 0.1060 | 3.89e-02 | 5.66e-02 | 5.53e-02 | 7.24e-03 | 5.83e-02 | 4.45e-01 | 2.67e-01 | 2.78e-01 | 8.87e-01 | 2.53e-01 |
| AMYLOID BETA CLEARANCE BY CELLULAR CATABOLIC PROCESS | 8 | 9.53e-01 | 9.94e-01 | 0.1060 | -4.67e-02 | -1.35e-03 | -7.87e-02 | -3.79e-02 | 3.76e-02 | 8.19e-01 | 9.95e-01 | 7.00e-01 | 8.53e-01 | 8.54e-01 |
| GENERATION OF NEURONS | 1421 | 1.00e-04 | 2.79e-03 | 0.1060 | 1.38e-02 | 3.31e-02 | 5.14e-02 | 3.51e-02 | 7.78e-02 | 3.84e-01 | 3.67e-02 | 1.18e-03 | 2.65e-02 | 8.78e-07 |
| REGULATION OF LIPID KINASE ACTIVITY | 38 | 2.55e-01 | 6.62e-01 | 0.1060 | 1.08e-02 | 1.02e-01 | -1.91e-02 | -6.08e-03 | -1.35e-02 | 9.08e-01 | 2.74e-01 | 8.39e-01 | 9.48e-01 | 8.85e-01 |
| PEPTIDYL AMINO ACID MODIFICATION | 892 | 3.00e-05 | 1.02e-03 | 0.1060 | 5.34e-02 | 4.92e-02 | 2.44e-02 | 7.10e-02 | 1.71e-02 | 6.84e-03 | 1.27e-02 | 2.16e-01 | 3.17e-04 | 3.87e-01 |
| RESPONSE TO NUTRIENT | 147 | 5.09e-01 | 8.53e-01 | 0.1060 | 1.27e-02 | 5.78e-02 | 4.98e-02 | 3.38e-02 | 6.37e-02 | 7.90e-01 | 2.26e-01 | 2.97e-01 | 4.80e-01 | 1.82e-01 |
| EXTRACELLULAR MATRIX ASSEMBLY | 42 | 6.64e-01 | 9.23e-01 | 0.1060 | -3.71e-03 | 5.06e-02 | 7.79e-03 | -2.28e-02 | -8.96e-02 | 9.67e-01 | 5.70e-01 | 9.30e-01 | 7.98e-01 | 3.15e-01 |
| REGULATION OF SODIUM ION TRANSPORT | 80 | 3.69e-01 | 7.69e-01 | 0.1060 | 5.06e-02 | 6.03e-02 | 7.79e-03 | 1.19e-02 | 6.91e-02 | 4.34e-01 | 3.51e-01 | 9.04e-01 | 8.53e-01 | 2.85e-01 |
| LEUKOCYTE TETHERING OR ROLLING | 34 | 8.75e-01 | 9.78e-01 | 0.1060 | 7.83e-03 | -4.86e-03 | -7.00e-02 | -6.54e-02 | -4.38e-02 | 9.37e-01 | 9.61e-01 | 4.80e-01 | 5.09e-01 | 6.59e-01 |
| REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 39 | 8.61e-01 | 9.78e-01 | 0.1060 | -1.69e-02 | -3.49e-02 | 1.09e-02 | -3.04e-03 | 9.76e-02 | 8.55e-01 | 7.06e-01 | 9.06e-01 | 9.74e-01 | 2.91e-01 |
| WHITE FAT CELL DIFFERENTIATION | 17 | 9.83e-01 | 9.96e-01 | 0.1060 | -6.74e-02 | -3.47e-02 | 1.13e-03 | -1.33e-02 | 7.24e-02 | 6.30e-01 | 8.04e-01 | 9.94e-01 | 9.24e-01 | 6.05e-01 |
| POSITIVE REGULATION OF PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 60 | 4.96e-01 | 8.44e-01 | 0.1060 | 9.40e-02 | 3.80e-02 | -1.04e-02 | 2.74e-02 | 5.29e-03 | 2.08e-01 | 6.10e-01 | 8.89e-01 | 7.14e-01 | 9.44e-01 |
| POSITIVE REGULATION OF LEUKOCYTE CELL CELL ADHESION | 264 | 1.72e-01 | 5.56e-01 | 0.1050 | 2.38e-02 | 2.80e-02 | 4.94e-02 | 7.49e-02 | 4.12e-02 | 5.05e-01 | 4.33e-01 | 1.67e-01 | 3.61e-02 | 2.50e-01 |
| SPERMATID NUCLEUS DIFFERENTIATION | 27 | 8.18e-01 | 9.70e-01 | 0.1050 | -7.38e-02 | -5.99e-02 | 1.91e-02 | -3.97e-02 | -1.13e-02 | 5.07e-01 | 5.90e-01 | 8.64e-01 | 7.21e-01 | 9.19e-01 |
| REGULATION OF EPITHELIAL CELL PROLIFERATION | 395 | 3.22e-02 | 2.27e-01 | 0.1050 | 7.48e-03 | 3.71e-02 | 3.72e-02 | 2.62e-02 | 8.71e-02 | 7.99e-01 | 2.06e-01 | 2.05e-01 | 3.72e-01 | 2.96e-03 |
| SYNCYTIUM FORMATION | 65 | 6.70e-01 | 9.25e-01 | 0.1050 | 6.07e-02 | 6.55e-02 | -6.79e-03 | 3.58e-02 | -4.21e-02 | 3.97e-01 | 3.61e-01 | 9.25e-01 | 6.18e-01 | 5.57e-01 |
| PROTEIN NITROSYLATION | 15 | 8.57e-01 | 9.77e-01 | 0.1050 | -5.45e-03 | -3.56e-02 | 3.40e-02 | 6.39e-02 | -6.69e-02 | 9.71e-01 | 8.11e-01 | 8.20e-01 | 6.68e-01 | 6.53e-01 |
| CELLULAR RESPONSE TO NITROGEN COMPOUND | 662 | 6.72e-03 | 7.65e-02 | 0.1050 | 3.84e-02 | 5.15e-02 | 3.36e-02 | 5.04e-02 | 5.67e-02 | 9.16e-02 | 2.38e-02 | 1.40e-01 | 2.70e-02 | 1.28e-02 |
| RESPONSE TO INTERFERON BETA | 33 | 9.11e-01 | 9.85e-01 | 0.1050 | -4.53e-02 | -2.59e-02 | -2.09e-02 | -3.65e-02 | 8.07e-02 | 6.53e-01 | 7.97e-01 | 8.35e-01 | 7.16e-01 | 4.22e-01 |
| VITAMIN TRANSPORT | 52 | 4.53e-01 | 8.21e-01 | 0.1050 | -4.58e-02 | 3.56e-02 | -2.08e-02 | -7.86e-02 | -3.19e-02 | 5.68e-01 | 6.57e-01 | 7.95e-01 | 3.27e-01 | 6.91e-01 |
| UV DAMAGE EXCISION REPAIR | 12 | 9.02e-01 | 9.83e-01 | 0.1050 | -1.36e-02 | 4.39e-02 | -2.58e-02 | -2.50e-02 | 8.71e-02 | 9.35e-01 | 7.92e-01 | 8.77e-01 | 8.81e-01 | 6.02e-01 |
| NEGATIVE REGULATION OF AXONOGENESIS | 60 | 7.44e-01 | 9.50e-01 | 0.1050 | -6.07e-02 | -2.83e-02 | -5.97e-02 | -5.01e-02 | 2.05e-02 | 4.16e-01 | 7.04e-01 | 4.24e-01 | 5.02e-01 | 7.83e-01 |
| POSITIVE REGULATION OF IMMUNE EFFECTOR PROCESS | 259 | 2.65e-01 | 6.73e-01 | 0.1050 | 6.52e-02 | 6.70e-02 | 2.02e-02 | 4.25e-02 | -2.92e-03 | 7.06e-02 | 6.35e-02 | 5.76e-01 | 2.39e-01 | 9.35e-01 |
| CDP DIACYLGLYCEROL BIOSYNTHETIC PROCESS | 12 | 9.51e-01 | 9.94e-01 | 0.1050 | -2.90e-03 | -8.10e-02 | -5.57e-02 | 7.92e-03 | 3.51e-02 | 9.86e-01 | 6.27e-01 | 7.38e-01 | 9.62e-01 | 8.33e-01 |
| NEGATIVE REGULATION OF LIPID METABOLIC PROCESS | 108 | 8.52e-01 | 9.76e-01 | 0.1050 | 6.18e-02 | 6.46e-02 | 4.46e-02 | 3.08e-02 | 5.38e-03 | 2.67e-01 | 2.46e-01 | 4.23e-01 | 5.81e-01 | 9.23e-01 |
| PHOSPHATIDYLCHOLINE ACYL CHAIN REMODELING | 14 | 9.37e-01 | 9.92e-01 | 0.1050 | -2.95e-03 | -8.63e-03 | -4.75e-04 | -5.89e-02 | -8.60e-02 | 9.85e-01 | 9.55e-01 | 9.98e-01 | 7.03e-01 | 5.77e-01 |
| REGULATION OF INTRACELLULAR LIPID TRANSPORT | 10 | 9.38e-01 | 9.92e-01 | 0.1050 | 1.45e-03 | 7.92e-02 | 2.90e-02 | 6.17e-02 | -1.55e-03 | 9.94e-01 | 6.64e-01 | 8.74e-01 | 7.35e-01 | 9.93e-01 |
| PROTEIN CONTAINING COMPLEX LOCALIZATION | 178 | 5.44e-01 | 8.70e-01 | 0.1050 | 2.78e-02 | 3.19e-02 | 3.66e-02 | 4.09e-02 | 7.83e-02 | 5.22e-01 | 4.63e-01 | 3.99e-01 | 3.46e-01 | 7.17e-02 |
| REGULATION OF SYNAPTIC VESICLE ENDOCYTOSIS | 18 | 9.55e-01 | 9.94e-01 | 0.1040 | -3.28e-02 | 3.54e-02 | 3.04e-02 | -5.29e-03 | 8.73e-02 | 8.10e-01 | 7.95e-01 | 8.23e-01 | 9.69e-01 | 5.21e-01 |
| REGULATION OF INNATE IMMUNE RESPONSE | 407 | 3.27e-02 | 2.29e-01 | 0.1040 | 7.69e-02 | 3.63e-02 | 2.24e-02 | 5.13e-02 | 2.25e-02 | 7.73e-03 | 2.09e-01 | 4.39e-01 | 7.55e-02 | 4.37e-01 |
| STRIATED MUSCLE ADAPTATION | 55 | 3.39e-01 | 7.45e-01 | 0.1040 | -6.23e-02 | 2.70e-02 | 4.21e-02 | -5.52e-02 | 3.81e-02 | 4.24e-01 | 7.29e-01 | 5.89e-01 | 4.79e-01 | 6.25e-01 |
| REGULATION OF CELL SUBSTRATE JUNCTION ORGANIZATION | 66 | 8.00e-01 | 9.66e-01 | 0.1040 | -7.17e-03 | -4.07e-02 | -7.82e-02 | -4.43e-02 | -3.29e-02 | 9.20e-01 | 5.67e-01 | 2.72e-01 | 5.34e-01 | 6.44e-01 |
| NEUTRAL AMINO ACID TRANSPORT | 54 | 5.23e-01 | 8.60e-01 | 0.1040 | 2.52e-02 | 6.83e-02 | 3.08e-02 | -2.69e-02 | 6.23e-02 | 7.49e-01 | 3.85e-01 | 6.95e-01 | 7.32e-01 | 4.28e-01 |
| HEMATOPOIETIC STEM CELL HOMEOSTASIS | 20 | 9.89e-01 | 9.98e-01 | 0.1040 | -4.10e-02 | -4.97e-02 | -3.96e-02 | -7.14e-02 | 2.53e-03 | 7.51e-01 | 7.00e-01 | 7.59e-01 | 5.80e-01 | 9.84e-01 |
| MICROTUBULE BASED TRANSPORT | 204 | 9.26e-02 | 4.13e-01 | 0.1040 | -1.47e-02 | -3.54e-02 | 1.47e-02 | 6.77e-03 | 9.53e-02 | 7.18e-01 | 3.84e-01 | 7.17e-01 | 8.68e-01 | 1.89e-02 |
| SPROUTING ANGIOGENESIS | 183 | 6.29e-01 | 9.10e-01 | 0.1040 | -5.25e-02 | -4.88e-02 | -4.32e-02 | -5.85e-02 | 1.97e-02 | 2.21e-01 | 2.55e-01 | 3.14e-01 | 1.72e-01 | 6.46e-01 |
| REGULATION OF SECONDARY METABOLIC PROCESS | 15 | 9.58e-01 | 9.94e-01 | 0.1040 | 2.01e-02 | 1.39e-02 | 1.41e-02 | -1.28e-02 | -9.89e-02 | 8.93e-01 | 9.26e-01 | 9.25e-01 | 9.32e-01 | 5.07e-01 |
| POSITIVE REGULATION OF CELL SUBSTRATE JUNCTION ORGANIZATION | 31 | 6.27e-01 | 9.09e-01 | 0.1040 | 8.78e-02 | 1.79e-02 | -4.83e-02 | -3.85e-03 | -1.90e-02 | 3.98e-01 | 8.63e-01 | 6.42e-01 | 9.70e-01 | 8.55e-01 |
| REGULATION OF AXON EXTENSION | 85 | 7.42e-01 | 9.50e-01 | 0.1040 | -6.68e-02 | -1.97e-02 | -4.17e-02 | -6.42e-02 | -1.09e-03 | 2.87e-01 | 7.54e-01 | 5.06e-01 | 3.06e-01 | 9.86e-01 |
| NEGATIVE REGULATION OF T CELL CYTOKINE PRODUCTION | 10 | 8.61e-01 | 9.78e-01 | 0.1040 | 1.89e-02 | -6.26e-02 | 4.49e-02 | 3.78e-02 | -5.46e-02 | 9.17e-01 | 7.32e-01 | 8.06e-01 | 8.36e-01 | 7.65e-01 |
| NEGATIVE REGULATION OF CELL POPULATION PROLIFERATION | 904 | 3.20e-02 | 2.27e-01 | 0.1030 | 3.17e-02 | 5.05e-02 | 4.85e-02 | 4.13e-02 | 5.56e-02 | 1.06e-01 | 1.01e-02 | 1.34e-02 | 3.50e-02 | 4.53e-03 |
| TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 225 | 8.11e-01 | 9.68e-01 | 0.1030 | 5.03e-02 | 4.68e-02 | 4.46e-02 | 5.51e-02 | 3.08e-02 | 1.93e-01 | 2.26e-01 | 2.49e-01 | 1.54e-01 | 4.27e-01 |
| BEHAVIOR | 629 | 7.14e-02 | 3.61e-01 | 0.1030 | 3.65e-02 | 5.24e-02 | 4.51e-02 | 3.34e-02 | 5.89e-02 | 1.18e-01 | 2.49e-02 | 5.35e-02 | 1.52e-01 | 1.17e-02 |
| APICAL JUNCTION ASSEMBLY | 73 | 4.55e-01 | 8.22e-01 | 0.1030 | -3.65e-02 | -2.27e-02 | -3.76e-02 | 5.72e-03 | -8.60e-02 | 5.90e-01 | 7.37e-01 | 5.78e-01 | 9.33e-01 | 2.04e-01 |
| POSITIVE REGULATION OF GTPASE ACTIVITY | 225 | 3.27e-01 | 7.36e-01 | 0.1030 | -3.12e-02 | -2.24e-02 | -6.94e-02 | -5.65e-02 | -3.41e-02 | 4.20e-01 | 5.62e-01 | 7.30e-02 | 1.44e-01 | 3.78e-01 |
| RESPONSE TO ALKALOID | 90 | 4.76e-01 | 8.33e-01 | 0.1030 | 5.10e-03 | -2.09e-03 | 4.81e-02 | 7.64e-04 | 9.10e-02 | 9.33e-01 | 9.73e-01 | 4.30e-01 | 9.90e-01 | 1.35e-01 |
| POSITIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL ACTIVATION | 40 | 8.06e-01 | 9.67e-01 | 0.1030 | 5.64e-02 | 7.20e-02 | -1.12e-02 | 2.39e-02 | -3.96e-02 | 5.37e-01 | 4.31e-01 | 9.03e-01 | 7.94e-01 | 6.64e-01 |
| CLEAVAGE FURROW FORMATION | 7 | 9.98e-01 | 1.00e+00 | 0.1030 | 1.46e-02 | 2.53e-02 | -1.84e-02 | -2.75e-02 | -9.30e-02 | 9.47e-01 | 9.08e-01 | 9.33e-01 | 9.00e-01 | 6.70e-01 |
| LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 34 | 4.05e-01 | 7.92e-01 | 0.1030 | -8.22e-02 | -3.06e-02 | 2.58e-02 | 4.69e-02 | 6.91e-03 | 4.07e-01 | 7.58e-01 | 7.95e-01 | 6.36e-01 | 9.44e-01 |
| REGULATION OF DEVELOPMENTAL GROWTH | 311 | 2.33e-01 | 6.36e-01 | 0.1030 | 3.14e-02 | 5.82e-02 | 4.47e-02 | 2.48e-02 | 6.01e-02 | 3.42e-01 | 7.75e-02 | 1.75e-01 | 4.52e-01 | 6.84e-02 |
| TRIGLYCERIDE METABOLIC PROCESS | 102 | 2.13e-01 | 6.08e-01 | 0.1030 | -1.55e-02 | 3.99e-02 | -2.12e-02 | -2.44e-02 | -8.77e-02 | 7.87e-01 | 4.87e-01 | 7.12e-01 | 6.70e-01 | 1.26e-01 |
| AXONEME ASSEMBLY | 92 | 3.69e-01 | 7.69e-01 | 0.1030 | -5.16e-03 | 1.68e-02 | 9.78e-03 | -2.15e-02 | 9.85e-02 | 9.32e-01 | 7.81e-01 | 8.71e-01 | 7.22e-01 | 1.03e-01 |
| REGULATION OF SMAD PROTEIN SIGNAL TRANSDUCTION | 52 | 8.08e-01 | 9.67e-01 | 0.1030 | -6.81e-02 | -5.36e-02 | -5.65e-03 | -3.48e-04 | 5.49e-02 | 3.95e-01 | 5.04e-01 | 9.44e-01 | 9.97e-01 | 4.94e-01 |
| AMINO ACID METABOLIC PROCESS | 278 | 9.00e-02 | 4.06e-01 | 0.1030 | 5.51e-02 | 3.80e-02 | 1.82e-02 | 5.87e-02 | 4.79e-02 | 1.14e-01 | 2.76e-01 | 6.02e-01 | 9.18e-02 | 1.70e-01 |
| REGULATION OF LONG TERM SYNAPTIC POTENTIATION | 46 | 9.15e-01 | 9.86e-01 | 0.1030 | 5.50e-02 | 4.38e-02 | 3.57e-03 | 3.69e-02 | -6.50e-02 | 5.19e-01 | 6.07e-01 | 9.67e-01 | 6.65e-01 | 4.46e-01 |
| TETRAPYRROLE METABOLIC PROCESS | 58 | 5.43e-01 | 8.69e-01 | 0.1030 | -6.01e-02 | -3.07e-02 | 1.54e-02 | 3.11e-02 | 6.89e-02 | 4.28e-01 | 6.86e-01 | 8.39e-01 | 6.82e-01 | 3.64e-01 |
| PORPHYRIN CONTAINING COMPOUND METABOLIC PROCESS | 49 | 6.15e-01 | 9.06e-01 | 0.1020 | -4.60e-02 | -4.54e-03 | 6.32e-03 | 2.31e-02 | 8.83e-02 | 5.77e-01 | 9.56e-01 | 9.39e-01 | 7.80e-01 | 2.85e-01 |
| MINERALOCORTICOID BIOSYNTHETIC PROCESS | 12 | 8.36e-01 | 9.73e-01 | 0.1020 | -5.69e-02 | -3.94e-02 | 7.39e-02 | -2.95e-03 | -1.42e-02 | 7.33e-01 | 8.13e-01 | 6.58e-01 | 9.86e-01 | 9.32e-01 |
| REGULATION OF ORGANIC ACID TRANSPORT | 75 | 5.60e-01 | 8.78e-01 | 0.1020 | 4.86e-02 | 8.23e-02 | 2.77e-02 | -2.46e-03 | 2.35e-02 | 4.67e-01 | 2.18e-01 | 6.78e-01 | 9.71e-01 | 7.25e-01 |
| DEMETHYLATION | 51 | 5.53e-01 | 8.76e-01 | 0.1020 | 1.91e-02 | -5.42e-02 | -6.95e-02 | 1.62e-02 | -4.56e-02 | 8.14e-01 | 5.03e-01 | 3.91e-01 | 8.41e-01 | 5.73e-01 |
| CYCLIC NUCLEOTIDE TRANSPORT | 9 | 9.75e-01 | 9.95e-01 | 0.1020 | 7.17e-03 | 7.36e-02 | -1.52e-02 | -1.32e-02 | -6.77e-02 | 9.70e-01 | 7.02e-01 | 9.37e-01 | 9.45e-01 | 7.25e-01 |
| REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS | 113 | 5.86e-01 | 8.91e-01 | 0.1020 | 1.34e-02 | 2.94e-02 | 2.92e-02 | 4.21e-02 | 8.22e-02 | 8.05e-01 | 5.90e-01 | 5.92e-01 | 4.39e-01 | 1.31e-01 |
| BEHAVIORAL RESPONSE TO PAIN | 19 | 8.36e-01 | 9.73e-01 | 0.1020 | 1.41e-02 | -1.99e-02 | -5.46e-02 | -7.95e-02 | 2.25e-02 | 9.15e-01 | 8.81e-01 | 6.80e-01 | 5.49e-01 | 8.65e-01 |
| TIGHT JUNCTION ORGANIZATION | 78 | 2.82e-01 | 6.93e-01 | 0.1020 | -3.47e-02 | 3.58e-03 | -2.97e-02 | 3.77e-03 | -9.10e-02 | 5.96e-01 | 9.56e-01 | 6.50e-01 | 9.54e-01 | 1.65e-01 |
| AMYLOID PRECURSOR PROTEIN CATABOLIC PROCESS | 67 | 5.83e-01 | 8.89e-01 | 0.1020 | 7.39e-02 | 7.48e-03 | -1.48e-02 | 4.83e-02 | -4.82e-02 | 2.95e-01 | 9.16e-01 | 8.34e-01 | 4.94e-01 | 4.95e-01 |
| REGULATION OF CELL MATRIX ADHESION | 121 | 5.93e-01 | 8.94e-01 | 0.1020 | -4.93e-02 | -4.50e-02 | -6.73e-02 | -3.73e-02 | -1.77e-03 | 3.49e-01 | 3.93e-01 | 2.01e-01 | 4.78e-01 | 9.73e-01 |
| REGULATION OF NEUROTRANSMITTER SECRETION | 76 | 7.57e-01 | 9.51e-01 | 0.1020 | -7.27e-02 | -3.92e-02 | 3.00e-03 | -4.19e-02 | 4.20e-02 | 2.73e-01 | 5.54e-01 | 9.64e-01 | 5.27e-01 | 5.27e-01 |
| AMINO ACID BETAINE METABOLIC PROCESS | 16 | 9.11e-01 | 9.85e-01 | 0.1020 | 9.57e-02 | 1.85e-02 | 1.20e-02 | 1.37e-02 | -2.26e-02 | 5.07e-01 | 8.98e-01 | 9.34e-01 | 9.24e-01 | 8.75e-01 |
| SKELETAL MUSCLE SATELLITE CELL PROLIFERATION | 17 | 9.96e-01 | 1.00e+00 | 0.1020 | 6.81e-02 | 5.98e-02 | 2.11e-02 | 4.04e-02 | 6.16e-03 | 6.27e-01 | 6.69e-01 | 8.80e-01 | 7.73e-01 | 9.65e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 1 PRODUCTION | 49 | 5.02e-01 | 8.48e-01 | 0.1020 | 4.52e-02 | 2.91e-02 | -6.06e-02 | -4.86e-02 | -3.76e-02 | 5.84e-01 | 7.25e-01 | 4.63e-01 | 5.56e-01 | 6.49e-01 |
| CHROMOSOME ORGANIZATION INVOLVED IN MEIOTIC CELL CYCLE | 63 | 2.09e-01 | 6.03e-01 | 0.1020 | 1.73e-02 | -5.88e-02 | 5.12e-03 | 3.96e-02 | -7.06e-02 | 8.13e-01 | 4.20e-01 | 9.44e-01 | 5.87e-01 | 3.32e-01 |
| NEURON MIGRATION | 167 | 4.87e-01 | 8.39e-01 | 0.1020 | 9.99e-03 | 2.78e-02 | 5.40e-02 | 1.41e-02 | 7.97e-02 | 8.24e-01 | 5.36e-01 | 2.29e-01 | 7.54e-01 | 7.56e-02 |
| POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 134 | 4.27e-01 | 8.05e-01 | 0.1020 | 6.02e-02 | 7.18e-02 | 9.82e-03 | 3.64e-02 | -1.12e-02 | 2.29e-01 | 1.51e-01 | 8.44e-01 | 4.67e-01 | 8.23e-01 |
| RESPONSE TO UV A | 13 | 9.18e-01 | 9.86e-01 | 0.1020 | -1.53e-03 | -6.20e-02 | 7.33e-04 | 5.35e-02 | -6.00e-02 | 9.92e-01 | 6.99e-01 | 9.96e-01 | 7.38e-01 | 7.08e-01 |
| RIBONUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 28 | 9.59e-01 | 9.94e-01 | 0.1020 | -2.20e-03 | 7.42e-03 | 4.11e-02 | 6.01e-02 | 7.03e-02 | 9.84e-01 | 9.46e-01 | 7.07e-01 | 5.82e-01 | 5.20e-01 |
| POSITIVE REGULATION OF CYTOKINE PRODUCTION | 483 | 1.26e-01 | 4.83e-01 | 0.1010 | 5.57e-02 | 6.09e-02 | 2.96e-02 | 5.06e-02 | -7.44e-03 | 3.61e-02 | 2.19e-02 | 2.65e-01 | 5.69e-02 | 7.79e-01 |
| POSITIVE REGULATION OF TRANSMEMBRANE TRANSPORT | 204 | 6.54e-02 | 3.40e-01 | 0.1010 | -7.71e-02 | -1.79e-02 | -4.17e-02 | -4.72e-02 | 7.60e-03 | 5.76e-02 | 6.59e-01 | 3.04e-01 | 2.46e-01 | 8.52e-01 |
| CALCINEURIN MEDIATED SIGNALING | 48 | 7.25e-01 | 9.41e-01 | 0.1010 | -2.45e-02 | -3.59e-02 | -8.22e-02 | -1.44e-02 | -3.79e-02 | 7.69e-01 | 6.67e-01 | 3.25e-01 | 8.63e-01 | 6.50e-01 |
| MUSCLE ORGAN MORPHOGENESIS | 82 | 5.12e-01 | 8.54e-01 | 0.1010 | -2.50e-02 | 1.30e-02 | 6.51e-02 | -3.57e-03 | 7.23e-02 | 6.95e-01 | 8.38e-01 | 3.08e-01 | 9.55e-01 | 2.58e-01 |
| PYRIMIDINE CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 39 | 6.47e-01 | 9.17e-01 | 0.1010 | 6.51e-02 | 4.38e-02 | -1.70e-02 | 5.17e-02 | 3.39e-02 | 4.82e-01 | 6.36e-01 | 8.54e-01 | 5.77e-01 | 7.14e-01 |
| REGULATION OF LIPID BIOSYNTHETIC PROCESS | 180 | 8.30e-01 | 9.73e-01 | 0.1010 | 4.61e-02 | 5.34e-02 | 4.20e-02 | 4.26e-02 | 4.13e-02 | 2.86e-01 | 2.17e-01 | 3.31e-01 | 3.25e-01 | 3.39e-01 |
| POSITIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 382 | 7.58e-02 | 3.72e-01 | 0.1010 | 4.32e-02 | 1.73e-02 | 4.04e-02 | 7.43e-02 | 3.05e-02 | 1.47e-01 | 5.62e-01 | 1.75e-01 | 1.26e-02 | 3.06e-01 |
| NEUROMUSCULAR SYNAPTIC TRANSMISSION | 28 | 6.22e-01 | 9.08e-01 | 0.1010 | 4.94e-03 | 6.34e-02 | 1.81e-02 | -7.14e-02 | 2.81e-02 | 9.64e-01 | 5.62e-01 | 8.68e-01 | 5.13e-01 | 7.97e-01 |
| BONE MINERALIZATION | 116 | 3.00e-01 | 7.12e-01 | 0.1010 | 5.66e-03 | 7.67e-02 | 5.97e-02 | 1.89e-02 | 2.03e-02 | 9.16e-01 | 1.54e-01 | 2.67e-01 | 7.26e-01 | 7.06e-01 |
| ADENYLATE CYCLASE ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 152 | 9.00e-02 | 4.06e-01 | 0.1010 | -4.26e-02 | -2.64e-02 | -1.38e-02 | -8.62e-02 | 9.90e-03 | 3.65e-01 | 5.74e-01 | 7.69e-01 | 6.67e-02 | 8.33e-01 |
| REGULATION OF MONOATOMIC ION TRANSMEMBRANE TRANSPORT | 431 | 9.94e-03 | 1.01e-01 | 0.1010 | -5.37e-02 | -2.01e-02 | -2.84e-02 | -7.79e-02 | 7.07e-03 | 5.57e-02 | 4.74e-01 | 3.13e-01 | 5.55e-03 | 8.01e-01 |
| REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 1718 | 5.75e-04 | 1.13e-02 | 0.1010 | 5.15e-02 | 4.04e-02 | 3.68e-02 | 5.62e-02 | 3.74e-02 | 3.78e-04 | 5.31e-03 | 1.13e-02 | 1.06e-04 | 9.83e-03 |
| NEGATIVE REGULATION OF AMYLOID PRECURSOR PROTEIN CATABOLIC PROCESS | 31 | 9.35e-01 | 9.91e-01 | 0.1010 | 5.65e-02 | 1.62e-02 | -2.82e-02 | 2.17e-02 | -7.40e-02 | 5.86e-01 | 8.76e-01 | 7.86e-01 | 8.34e-01 | 4.76e-01 |
| DEVELOPMENTAL GROWTH | 633 | 1.89e-01 | 5.76e-01 | 0.1010 | 3.07e-02 | 4.58e-02 | 5.11e-02 | 3.83e-02 | 5.55e-02 | 1.87e-01 | 4.94e-02 | 2.83e-02 | 1.00e-01 | 1.72e-02 |
| REGULATION OF T HELPER 17 TYPE IMMUNE RESPONSE | 31 | 9.51e-01 | 9.94e-01 | 0.1010 | -1.13e-02 | -2.19e-02 | 3.52e-02 | 3.44e-02 | 8.46e-02 | 9.13e-01 | 8.33e-01 | 7.34e-01 | 7.40e-01 | 4.15e-01 |
| POSITIVE REGULATION OF LEUKOCYTE MIGRATION | 142 | 8.03e-02 | 3.83e-01 | 0.1010 | 2.53e-02 | 4.76e-02 | -4.70e-02 | -4.08e-02 | -5.83e-02 | 6.03e-01 | 3.28e-01 | 3.33e-01 | 4.01e-01 | 2.30e-01 |
| NEGATIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 47 | 6.58e-01 | 9.20e-01 | 0.1010 | 9.27e-02 | 3.22e-02 | 1.26e-02 | 1.66e-02 | -1.03e-02 | 2.71e-01 | 7.03e-01 | 8.81e-01 | 8.44e-01 | 9.03e-01 |
| TELENCEPHALON GLIAL CELL MIGRATION | 27 | 9.01e-01 | 9.83e-01 | 0.1010 | 2.59e-02 | -3.95e-02 | -2.76e-02 | 1.43e-02 | -8.35e-02 | 8.16e-01 | 7.22e-01 | 8.04e-01 | 8.98e-01 | 4.52e-01 |
| REGULATION OF CARDIAC MUSCLE CONTRACTION | 73 | 7.55e-01 | 9.51e-01 | 0.1010 | -6.73e-02 | -2.00e-02 | -1.72e-02 | -6.91e-02 | 1.13e-02 | 3.20e-01 | 7.68e-01 | 8.00e-01 | 3.07e-01 | 8.68e-01 |
| IMMUNE EFFECTOR PROCESS | 611 | 9.71e-02 | 4.24e-01 | 0.1010 | 5.54e-02 | 5.67e-02 | 3.21e-02 | 5.25e-02 | -6.25e-03 | 1.93e-02 | 1.66e-02 | 1.76e-01 | 2.67e-02 | 7.92e-01 |
| POSITIVE REGULATION OF LEUKOCYTE DEGRANULATION | 23 | 9.12e-01 | 9.85e-01 | 0.1000 | 6.80e-04 | 6.80e-02 | 5.95e-02 | 4.33e-02 | -6.96e-03 | 9.95e-01 | 5.72e-01 | 6.21e-01 | 7.19e-01 | 9.54e-01 |
| NEGATIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 72 | 9.56e-01 | 9.94e-01 | 0.1000 | -4.45e-02 | -5.21e-02 | -3.68e-02 | -5.21e-02 | -3.64e-02 | 5.14e-01 | 4.44e-01 | 5.89e-01 | 4.45e-01 | 5.93e-01 |
| SYNAPTIC TRANSMISSION GABAERGIC | 56 | 8.79e-01 | 9.79e-01 | 0.1000 | -8.59e-04 | 5.20e-02 | 5.91e-02 | 3.09e-02 | 5.40e-02 | 9.91e-01 | 5.01e-01 | 4.44e-01 | 6.89e-01 | 4.84e-01 |
| POSITIVE REGULATION OF KINASE ACTIVITY | 328 | 2.23e-01 | 6.22e-01 | 0.1000 | 5.55e-02 | 6.54e-02 | 2.64e-02 | 4.12e-02 | 1.75e-02 | 8.39e-02 | 4.17e-02 | 4.11e-01 | 1.99e-01 | 5.87e-01 |
| CALCIUM ION TRANSPORT INTO CYTOSOL | 28 | 7.28e-01 | 9.43e-01 | 0.1000 | 1.93e-02 | 8.65e-02 | 1.78e-02 | -4.23e-02 | 1.01e-02 | 8.60e-01 | 4.28e-01 | 8.70e-01 | 6.98e-01 | 9.26e-01 |
| B CELL PROLIFERATION | 97 | 2.33e-01 | 6.36e-01 | 0.1000 | 5.69e-04 | -2.33e-02 | -5.72e-02 | 2.44e-02 | -7.51e-02 | 9.92e-01 | 6.92e-01 | 3.31e-01 | 6.78e-01 | 2.01e-01 |
| PROTEIN POLYMERIZATION | 272 | 6.02e-01 | 9.00e-01 | 0.1000 | 5.34e-02 | 5.43e-02 | 3.66e-02 | 4.10e-02 | 3.52e-02 | 1.30e-01 | 1.23e-01 | 2.99e-01 | 2.45e-01 | 3.18e-01 |
| NUCLEOPHAGY | 18 | 8.43e-01 | 9.75e-01 | 0.1000 | 4.53e-02 | -4.55e-02 | -6.10e-02 | 3.97e-02 | -2.45e-02 | 7.39e-01 | 7.38e-01 | 6.54e-01 | 7.71e-01 | 8.57e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS | 41 | 7.59e-01 | 9.52e-01 | 0.1000 | -5.02e-02 | 5.02e-03 | 2.46e-02 | 2.20e-02 | 7.99e-02 | 5.78e-01 | 9.56e-01 | 7.85e-01 | 8.08e-01 | 3.76e-01 |
| ORGANIC ACID TRANSPORT | 341 | 2.66e-02 | 2.00e-01 | 0.1000 | -3.87e-02 | -8.84e-03 | -4.08e-02 | -8.04e-02 | -1.76e-02 | 2.20e-01 | 7.79e-01 | 1.96e-01 | 1.07e-02 | 5.76e-01 |
| REGULATION OF CHOLESTEROL METABOLIC PROCESS | 40 | 6.22e-01 | 9.08e-01 | 0.1000 | -2.00e-02 | 4.05e-02 | 1.19e-02 | 2.48e-02 | 8.49e-02 | 8.27e-01 | 6.57e-01 | 8.96e-01 | 7.86e-01 | 3.53e-01 |
| LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL | 55 | 7.95e-01 | 9.65e-01 | 0.1000 | 2.31e-02 | -3.74e-03 | -4.97e-02 | -4.97e-02 | -6.72e-02 | 7.67e-01 | 9.62e-01 | 5.24e-01 | 5.24e-01 | 3.89e-01 |
| MICROTUBULE DEPOLYMERIZATION | 42 | 9.09e-01 | 9.85e-01 | 0.0999 | -1.28e-02 | -1.25e-02 | 5.46e-02 | 3.56e-02 | 7.36e-02 | 8.86e-01 | 8.88e-01 | 5.40e-01 | 6.90e-01 | 4.09e-01 |
| STEROL METABOLIC PROCESS | 150 | 1.52e-01 | 5.21e-01 | 0.0998 | -5.34e-02 | 7.48e-03 | 3.48e-02 | 8.56e-03 | 7.60e-02 | 2.59e-01 | 8.74e-01 | 4.61e-01 | 8.56e-01 | 1.08e-01 |
| REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 128 | 3.41e-01 | 7.48e-01 | 0.0997 | 1.30e-02 | -4.53e-02 | -6.28e-02 | -3.97e-02 | -4.69e-02 | 7.99e-01 | 3.76e-01 | 2.20e-01 | 4.38e-01 | 3.59e-01 |
| NEGATIVE REGULATION OF CARTILAGE DEVELOPMENT | 31 | 7.56e-01 | 9.51e-01 | 0.0997 | -5.86e-02 | 2.31e-02 | 3.04e-02 | 1.38e-02 | 6.98e-02 | 5.72e-01 | 8.24e-01 | 7.70e-01 | 8.94e-01 | 5.01e-01 |
| LYMPHOCYTE MIGRATION | 117 | 4.22e-01 | 8.02e-01 | 0.0996 | 2.44e-02 | 4.02e-02 | -1.94e-02 | -2.33e-02 | -8.24e-02 | 6.49e-01 | 4.52e-01 | 7.17e-01 | 6.64e-01 | 1.23e-01 |
| NEGATIVE REGULATION OF HYDROLASE ACTIVITY | 204 | 2.50e-01 | 6.57e-01 | 0.0996 | -3.19e-02 | 1.91e-03 | -5.03e-02 | -5.52e-02 | -5.77e-02 | 4.32e-01 | 9.62e-01 | 2.16e-01 | 1.74e-01 | 1.56e-01 |
| ANATOMICAL STRUCTURE REGRESSION | 16 | 9.81e-01 | 9.96e-01 | 0.0995 | -5.67e-02 | -1.51e-02 | -1.44e-02 | -7.89e-02 | -4.48e-03 | 6.95e-01 | 9.16e-01 | 9.21e-01 | 5.85e-01 | 9.75e-01 |
| PEPTIDE MODIFICATION | 5 | 9.87e-01 | 9.97e-01 | 0.0995 | -1.59e-02 | 3.49e-02 | -2.56e-02 | -5.66e-03 | 8.80e-02 | 9.51e-01 | 8.92e-01 | 9.21e-01 | 9.83e-01 | 7.33e-01 |
| VENTRICULAR CARDIAC MUSCLE TISSUE MORPHOGENESIS | 47 | 6.96e-01 | 9.31e-01 | 0.0992 | -6.51e-02 | 3.51e-03 | 3.62e-02 | -3.62e-02 | 5.46e-02 | 4.40e-01 | 9.67e-01 | 6.68e-01 | 6.68e-01 | 5.17e-01 |
| LYMPHOCYTE COSTIMULATION | 46 | 6.14e-01 | 9.06e-01 | 0.0992 | -6.87e-02 | -3.50e-02 | 9.78e-05 | 2.40e-02 | 5.76e-02 | 4.20e-01 | 6.81e-01 | 9.99e-01 | 7.78e-01 | 4.99e-01 |
| GLUCAN BIOSYNTHETIC PROCESS | 44 | 7.30e-01 | 9.44e-01 | 0.0991 | -5.83e-02 | -2.62e-02 | 4.08e-02 | 2.95e-02 | 5.65e-02 | 5.04e-01 | 7.64e-01 | 6.39e-01 | 7.35e-01 | 5.17e-01 |
| POSITIVE REGULATION OF CELL DIVISION | 89 | 5.11e-01 | 8.54e-01 | 0.0988 | 1.63e-03 | -2.90e-02 | 1.14e-02 | 1.69e-02 | 9.22e-02 | 9.79e-01 | 6.36e-01 | 8.52e-01 | 7.83e-01 | 1.33e-01 |
| PROTEIN DEPHOSPHORYLATION | 194 | 2.09e-01 | 6.03e-01 | 0.0988 | 4.82e-02 | 1.95e-02 | 2.53e-02 | 7.93e-02 | 1.14e-02 | 2.47e-01 | 6.40e-01 | 5.43e-01 | 5.68e-02 | 7.84e-01 |
| CEREBRAL CORTEX RADIALLY ORIENTED CELL MIGRATION | 36 | 9.20e-01 | 9.86e-01 | 0.0987 | 6.50e-02 | 9.76e-03 | 2.63e-02 | 6.78e-02 | -1.12e-02 | 4.99e-01 | 9.19e-01 | 7.85e-01 | 4.81e-01 | 9.07e-01 |
| NUCLEOSIDE BISPHOSPHATE METABOLIC PROCESS | 116 | 2.37e-01 | 6.40e-01 | 0.0986 | -4.35e-03 | -6.68e-03 | -7.56e-03 | 1.00e-02 | 9.75e-02 | 9.35e-01 | 9.01e-01 | 8.88e-01 | 8.52e-01 | 6.96e-02 |
| RECEPTOR MEDIATED ENDOCYTOSIS | 254 | 4.73e-02 | 2.85e-01 | 0.0985 | 7.22e-02 | 6.22e-02 | -5.43e-03 | 1.60e-02 | -1.81e-02 | 4.74e-02 | 8.78e-02 | 8.81e-01 | 6.61e-01 | 6.20e-01 |
| EYE MORPHOGENESIS | 159 | 2.87e-01 | 6.94e-01 | 0.0985 | -3.55e-02 | -2.44e-02 | -7.15e-03 | -1.71e-02 | 8.66e-02 | 4.40e-01 | 5.96e-01 | 8.76e-01 | 7.10e-01 | 5.95e-02 |
| POSITIVE REGULATION OF ACTIN FILAMENT POLYMERIZATION | 51 | 9.47e-01 | 9.94e-01 | 0.0984 | 6.13e-02 | 5.78e-02 | 2.09e-02 | 3.98e-02 | 2.38e-02 | 4.49e-01 | 4.75e-01 | 7.96e-01 | 6.23e-01 | 7.69e-01 |
| REGULATION OF P38MAPK CASCADE | 47 | 7.05e-01 | 9.33e-01 | 0.0984 | 8.31e-02 | 4.49e-02 | 2.56e-02 | 6.66e-03 | 7.94e-03 | 3.24e-01 | 5.94e-01 | 7.62e-01 | 9.37e-01 | 9.25e-01 |
| TRIPARTITE REGIONAL SUBDIVISION | 19 | 8.58e-01 | 9.77e-01 | 0.0983 | 7.77e-03 | 7.15e-02 | 8.42e-04 | -6.11e-02 | -2.75e-02 | 9.53e-01 | 5.89e-01 | 9.95e-01 | 6.45e-01 | 8.35e-01 |
| SIGNAL RELEASE | 467 | 9.89e-02 | 4.28e-01 | 0.0982 | 3.38e-02 | 6.45e-02 | 4.96e-02 | 2.20e-02 | 3.75e-02 | 2.10e-01 | 1.69e-02 | 6.63e-02 | 4.15e-01 | 1.65e-01 |
| NEGATIVE REGULATION OF FATTY ACID BETA OXIDATION | 6 | 9.93e-01 | 9.99e-01 | 0.0982 | -3.72e-02 | 2.59e-02 | -5.44e-02 | -6.03e-02 | -3.15e-02 | 8.75e-01 | 9.13e-01 | 8.18e-01 | 7.98e-01 | 8.94e-01 |
| MYOBLAST FUSION | 47 | 8.39e-01 | 9.73e-01 | 0.0981 | 2.23e-02 | 7.11e-02 | 4.20e-02 | 4.69e-02 | -1.06e-02 | 7.92e-01 | 3.99e-01 | 6.19e-01 | 5.78e-01 | 9.00e-01 |
| MONOATOMIC ION TRANSMEMBRANE TRANSPORT | 975 | 1.99e-05 | 7.00e-04 | 0.0980 | -6.15e-02 | -2.04e-02 | -2.25e-02 | -6.97e-02 | 7.36e-03 | 1.15e-03 | 2.81e-01 | 2.35e-01 | 2.27e-04 | 6.97e-01 |
| CYTOPLASMIC MICROTUBULE ORGANIZATION | 59 | 7.60e-01 | 9.53e-01 | 0.0979 | -7.01e-02 | -4.88e-02 | -2.46e-02 | -7.26e-03 | 4.04e-02 | 3.52e-01 | 5.17e-01 | 7.43e-01 | 9.23e-01 | 5.91e-01 |
| ESTABLISHMENT OF LYMPHOCYTE POLARITY | 16 | 8.73e-01 | 9.78e-01 | 0.0978 | 1.48e-02 | -2.44e-03 | -3.05e-02 | 3.94e-02 | 8.28e-02 | 9.18e-01 | 9.87e-01 | 8.33e-01 | 7.85e-01 | 5.67e-01 |
| REGULATION OF ENDOTHELIAL CELL MIGRATION | 220 | 6.35e-01 | 9.12e-01 | 0.0975 | -5.66e-02 | -5.32e-02 | -2.86e-02 | -4.80e-02 | 1.86e-02 | 1.48e-01 | 1.74e-01 | 4.64e-01 | 2.20e-01 | 6.35e-01 |
| REGULATION OF MYELOID CELL APOPTOTIC PROCESS | 31 | 9.30e-01 | 9.90e-01 | 0.0974 | 6.15e-02 | 3.50e-02 | 9.14e-04 | 6.53e-02 | -1.53e-02 | 5.54e-01 | 7.36e-01 | 9.93e-01 | 5.29e-01 | 8.83e-01 |
| MONOATOMIC CATION TRANSMEMBRANE TRANSPORT | 814 | 1.43e-04 | 3.60e-03 | 0.0973 | -6.03e-02 | -2.26e-02 | -1.88e-02 | -6.74e-02 | 2.04e-02 | 3.44e-03 | 2.72e-01 | 3.62e-01 | 1.08e-03 | 3.22e-01 |
| POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 121 | 4.16e-01 | 7.99e-01 | 0.0973 | -1.90e-03 | -3.64e-02 | -7.49e-02 | -4.61e-02 | -1.98e-02 | 9.71e-01 | 4.89e-01 | 1.55e-01 | 3.81e-01 | 7.06e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO CELL PERIPHERY | 29 | 8.47e-01 | 9.76e-01 | 0.0971 | 3.18e-02 | -1.60e-02 | 1.28e-02 | 4.99e-02 | -7.42e-02 | 7.67e-01 | 8.81e-01 | 9.05e-01 | 6.42e-01 | 4.89e-01 |
| IONOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAY | 22 | 9.74e-01 | 9.95e-01 | 0.0971 | -5.40e-02 | -2.15e-02 | -1.12e-02 | -6.54e-02 | 4.06e-02 | 6.61e-01 | 8.61e-01 | 9.27e-01 | 5.95e-01 | 7.42e-01 |
| LEUKOCYTE MEDIATED CYTOTOXICITY | 135 | 9.28e-03 | 9.63e-02 | 0.0970 | -3.72e-03 | -4.54e-02 | 1.30e-02 | 7.44e-02 | -4.05e-02 | 9.41e-01 | 3.63e-01 | 7.93e-01 | 1.36e-01 | 4.17e-01 |
| LEUKOCYTE CELL CELL ADHESION | 403 | 1.18e-01 | 4.69e-01 | 0.0967 | 3.67e-02 | 2.32e-02 | 3.81e-02 | 6.98e-02 | 3.40e-02 | 2.06e-01 | 4.25e-01 | 1.90e-01 | 1.62e-02 | 2.42e-01 |
| PHYSIOLOGICAL CARDIAC MUSCLE HYPERTROPHY | 29 | 8.51e-01 | 9.76e-01 | 0.0966 | 1.08e-02 | 7.74e-02 | 4.87e-02 | -2.39e-03 | -2.91e-02 | 9.20e-01 | 4.71e-01 | 6.50e-01 | 9.82e-01 | 7.87e-01 |
| NEUROPEPTIDE SIGNALING PATHWAY | 102 | 8.39e-01 | 9.73e-01 | 0.0966 | 2.84e-03 | 3.16e-02 | 6.11e-02 | 3.60e-02 | 5.74e-02 | 9.60e-01 | 5.82e-01 | 2.87e-01 | 5.30e-01 | 3.16e-01 |
| PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 278 | 4.65e-01 | 8.25e-01 | 0.0965 | 4.94e-02 | 4.02e-02 | 4.10e-02 | 5.80e-02 | -1.45e-02 | 1.57e-01 | 2.48e-01 | 2.39e-01 | 9.59e-02 | 6.77e-01 |
| REGULATION OF G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 133 | 3.49e-01 | 7.52e-01 | 0.0965 | -9.58e-03 | 3.47e-02 | 5.14e-02 | 5.29e-02 | 5.07e-02 | 8.49e-01 | 4.90e-01 | 3.06e-01 | 2.92e-01 | 3.12e-01 |
| REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 72 | 6.92e-01 | 9.31e-01 | 0.0964 | 1.12e-02 | -1.43e-02 | -7.34e-02 | -3.96e-02 | -4.48e-02 | 8.70e-01 | 8.34e-01 | 2.82e-01 | 5.61e-01 | 5.11e-01 |
| REGULATION OF LONG CHAIN FATTY ACID IMPORT ACROSS PLASMA MEMBRANE | 6 | 8.65e-01 | 9.78e-01 | 0.0963 | -2.27e-02 | 2.76e-02 | -5.32e-02 | 6.78e-02 | 2.42e-02 | 9.23e-01 | 9.07e-01 | 8.22e-01 | 7.74e-01 | 9.18e-01 |
| NEGATIVE REGULATION OF EPIDERMIS DEVELOPMENT | 14 | 8.68e-01 | 9.78e-01 | 0.0963 | -7.56e-02 | 2.23e-02 | 4.00e-02 | -2.07e-02 | -3.20e-02 | 6.24e-01 | 8.85e-01 | 7.96e-01 | 8.93e-01 | 8.36e-01 |
| PROTEIN HOMOTETRAMERIZATION | 57 | 9.76e-01 | 9.96e-01 | 0.0962 | 1.53e-02 | 3.56e-02 | 5.77e-02 | 4.31e-02 | 5.05e-02 | 8.42e-01 | 6.42e-01 | 4.51e-01 | 5.74e-01 | 5.10e-01 |
| REGULATION OF CARTILAGE DEVELOPMENT | 70 | 4.20e-01 | 8.00e-01 | 0.0961 | -8.16e-02 | -2.62e-02 | -2.02e-02 | -8.94e-03 | 3.75e-02 | 2.38e-01 | 7.04e-01 | 7.70e-01 | 8.97e-01 | 5.88e-01 |
| CARDIAC CONDUCTION | 94 | 6.74e-01 | 9.28e-01 | 0.0961 | -6.19e-02 | -2.64e-02 | -1.34e-03 | -5.30e-02 | 4.35e-02 | 3.00e-01 | 6.59e-01 | 9.82e-01 | 3.75e-01 | 4.66e-01 |
| REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 61 | 9.89e-01 | 9.98e-01 | 0.0960 | -5.43e-02 | -5.12e-02 | -3.84e-02 | -4.61e-02 | -5.95e-03 | 4.63e-01 | 4.89e-01 | 6.04e-01 | 5.33e-01 | 9.36e-01 |
| NEGATIVE REGULATION OF GLUCONEOGENESIS | 18 | 8.94e-01 | 9.82e-01 | 0.0958 | -3.30e-02 | 4.27e-02 | -3.56e-03 | -3.35e-02 | 7.16e-02 | 8.09e-01 | 7.54e-01 | 9.79e-01 | 8.06e-01 | 5.99e-01 |
| PEPTIDYL GLUTAMIC ACID MODIFICATION | 26 | 9.68e-01 | 9.94e-01 | 0.0957 | -6.28e-02 | -1.23e-02 | -2.05e-02 | -6.78e-02 | 7.48e-03 | 5.79e-01 | 9.13e-01 | 8.56e-01 | 5.50e-01 | 9.47e-01 |
| LIPID BIOSYNTHETIC PROCESS | 707 | 3.27e-01 | 7.36e-01 | 0.0957 | 4.12e-02 | 4.47e-02 | 4.88e-02 | 4.07e-02 | 3.79e-02 | 6.17e-02 | 4.29e-02 | 2.71e-02 | 6.50e-02 | 8.61e-02 |
| RESPONSE TO TYPE II INTERFERON | 137 | 2.34e-01 | 6.36e-01 | 0.0957 | 6.75e-03 | 7.81e-03 | -6.38e-02 | -5.80e-02 | -4.03e-02 | 8.92e-01 | 8.75e-01 | 1.97e-01 | 2.41e-01 | 4.15e-01 |
| LONG CHAIN FATTY ACID IMPORT ACROSS PLASMA MEMBRANE | 10 | 9.26e-01 | 9.89e-01 | 0.0957 | -5.28e-03 | -1.44e-02 | -4.43e-02 | 3.85e-02 | 7.41e-02 | 9.77e-01 | 9.37e-01 | 8.08e-01 | 8.33e-01 | 6.85e-01 |
| DEFENSE RESPONSE TO GRAM POSITIVE BACTERIUM | 112 | 6.48e-01 | 9.17e-01 | 0.0957 | 6.70e-02 | 6.05e-02 | 2.04e-02 | 1.26e-02 | -2.09e-02 | 2.21e-01 | 2.69e-01 | 7.09e-01 | 8.17e-01 | 7.03e-01 |
| INNERVATION | 26 | 7.43e-01 | 9.50e-01 | 0.0956 | -4.00e-02 | 6.62e-02 | 3.30e-02 | -1.30e-02 | 4.34e-02 | 7.24e-01 | 5.59e-01 | 7.71e-01 | 9.09e-01 | 7.01e-01 |
| RESPONSE TO MONOSACCHARIDE | 201 | 2.94e-01 | 7.06e-01 | 0.0956 | 4.95e-03 | 5.18e-02 | 6.36e-02 | 1.62e-02 | 4.60e-02 | 9.04e-01 | 2.06e-01 | 1.20e-01 | 6.91e-01 | 2.61e-01 |
| BASIC AMINO ACID TRANSPORT | 21 | 7.96e-01 | 9.65e-01 | 0.0953 | -5.33e-03 | 9.22e-02 | 2.10e-02 | 4.17e-03 | 9.73e-03 | 9.66e-01 | 4.65e-01 | 8.68e-01 | 9.74e-01 | 9.38e-01 |
| REGULATION OF EPITHELIAL CELL MIGRATION | 282 | 6.17e-01 | 9.06e-01 | 0.0953 | -4.84e-02 | -5.32e-02 | -4.81e-02 | -3.97e-02 | 3.70e-03 | 1.62e-01 | 1.24e-01 | 1.64e-01 | 2.51e-01 | 9.15e-01 |
| REGULATION OF PRESYNAPTIC CYTOSOLIC CALCIUM ION CONCENTRATION | 13 | 9.33e-01 | 9.90e-01 | 0.0953 | 6.96e-02 | -1.96e-02 | 1.88e-03 | 1.37e-02 | -6.05e-02 | 6.64e-01 | 9.03e-01 | 9.91e-01 | 9.32e-01 | 7.06e-01 |
| RENAL SODIUM ION TRANSPORT | 15 | 9.49e-01 | 9.94e-01 | 0.0952 | 6.57e-02 | 1.35e-02 | -1.43e-02 | 4.35e-02 | 4.98e-02 | 6.59e-01 | 9.28e-01 | 9.24e-01 | 7.71e-01 | 7.38e-01 |
| POSITIVE REGULATION OF CELL CELL ADHESION | 311 | 1.18e-01 | 4.69e-01 | 0.0952 | 3.02e-02 | 3.26e-02 | 3.95e-02 | 7.28e-02 | 1.48e-02 | 3.59e-01 | 3.22e-01 | 2.31e-01 | 2.71e-02 | 6.54e-01 |
| FC GAMMA RECEPTOR SIGNALING PATHWAY | 33 | 9.06e-01 | 9.84e-01 | 0.0952 | -1.71e-03 | -4.07e-02 | -5.69e-02 | -6.31e-02 | -1.37e-02 | 9.86e-01 | 6.86e-01 | 5.72e-01 | 5.31e-01 | 8.92e-01 |
| POSITIVE REGULATION OF CREB TRANSCRIPTION FACTOR ACTIVITY | 16 | 8.66e-01 | 9.78e-01 | 0.0951 | 2.43e-02 | -7.22e-02 | -3.33e-02 | -6.15e-03 | 4.59e-02 | 8.66e-01 | 6.17e-01 | 8.18e-01 | 9.66e-01 | 7.50e-01 |
| MUSCLE CELL DIFFERENTIATION | 407 | 3.99e-01 | 7.87e-01 | 0.0950 | 2.23e-02 | 3.33e-02 | 4.58e-02 | 3.54e-02 | 6.39e-02 | 4.41e-01 | 2.50e-01 | 1.13e-01 | 2.21e-01 | 2.69e-02 |
| REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 74 | 9.63e-01 | 9.94e-01 | 0.0948 | -4.61e-02 | -5.86e-02 | -4.79e-02 | -3.37e-02 | -1.52e-03 | 4.93e-01 | 3.84e-01 | 4.76e-01 | 6.17e-01 | 9.82e-01 |
| NEGATIVE REGULATION OF CATION CHANNEL ACTIVITY | 46 | 9.08e-01 | 9.85e-01 | 0.0947 | -5.06e-02 | -5.77e-02 | -3.86e-03 | -2.61e-03 | 5.54e-02 | 5.53e-01 | 4.99e-01 | 9.64e-01 | 9.76e-01 | 5.16e-01 |
| AXON EXTENSION | 111 | 8.34e-01 | 9.73e-01 | 0.0947 | -5.93e-02 | -3.52e-02 | -4.36e-02 | -4.70e-02 | 1.05e-02 | 2.80e-01 | 5.22e-01 | 4.28e-01 | 3.92e-01 | 8.48e-01 |
| POSITIVE REGULATION OF LEUKOCYTE CHEMOTAXIS | 93 | 1.79e-01 | 5.63e-01 | 0.0947 | -7.98e-04 | 4.64e-02 | -3.09e-02 | -7.07e-02 | -2.92e-02 | 9.89e-01 | 4.40e-01 | 6.07e-01 | 2.38e-01 | 6.26e-01 |
| REGULATION OF DENDRITE MORPHOGENESIS | 57 | 8.11e-01 | 9.68e-01 | 0.0945 | -4.74e-02 | -7.99e-03 | -5.19e-02 | -6.27e-02 | 2.51e-03 | 5.36e-01 | 9.17e-01 | 4.98e-01 | 4.13e-01 | 9.74e-01 |
| REGULATION OF LEUKOCYTE MIGRATION | 218 | 1.23e-01 | 4.78e-01 | 0.0944 | 1.64e-02 | 1.71e-02 | -5.27e-02 | -4.16e-02 | -6.19e-02 | 6.76e-01 | 6.63e-01 | 1.80e-01 | 2.89e-01 | 1.15e-01 |
| REGULATION OF HEART CONTRACTION | 199 | 3.87e-02 | 2.54e-01 | 0.0943 | -2.35e-02 | 3.49e-02 | 5.52e-02 | -2.25e-02 | 5.98e-02 | 5.67e-01 | 3.97e-01 | 1.80e-01 | 5.84e-01 | 1.46e-01 |
| KERATINOCYTE PROLIFERATION | 59 | 3.58e-01 | 7.57e-01 | 0.0943 | -6.97e-02 | 2.83e-02 | -9.83e-03 | -5.46e-02 | 1.21e-02 | 3.54e-01 | 7.06e-01 | 8.96e-01 | 4.68e-01 | 8.73e-01 |
| NEGATIVE REGULATION OF STEM CELL PROLIFERATION | 26 | 7.19e-01 | 9.38e-01 | 0.0941 | -4.46e-02 | -1.55e-02 | 2.81e-02 | 6.92e-02 | 3.23e-02 | 6.94e-01 | 8.91e-01 | 8.04e-01 | 5.41e-01 | 7.75e-01 |
| T CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 117 | 3.15e-01 | 7.26e-01 | 0.0941 | 1.58e-02 | -3.29e-02 | -5.88e-02 | 1.35e-02 | -6.23e-02 | 7.68e-01 | 5.39e-01 | 2.72e-01 | 8.01e-01 | 2.44e-01 |
| REGULATION OF PROTEIN DEPOLYMERIZATION | 82 | 8.09e-01 | 9.68e-01 | 0.0940 | -4.58e-02 | -2.85e-02 | -4.82e-02 | -2.31e-02 | -5.54e-02 | 4.73e-01 | 6.56e-01 | 4.51e-01 | 7.18e-01 | 3.86e-01 |
| CORONARY VASCULATURE DEVELOPMENT | 48 | 8.52e-01 | 9.76e-01 | 0.0938 | -5.50e-02 | -5.12e-02 | 2.05e-02 | -4.90e-03 | 5.21e-02 | 5.10e-01 | 5.39e-01 | 8.06e-01 | 9.53e-01 | 5.32e-01 |
| LIPID MODIFICATION | 185 | 3.51e-02 | 2.39e-01 | 0.0938 | 3.44e-02 | 5.85e-02 | 5.45e-03 | 4.69e-02 | 4.44e-02 | 4.19e-01 | 1.70e-01 | 8.98e-01 | 2.72e-01 | 2.98e-01 |
| POSITIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 102 | 2.72e-01 | 6.80e-01 | 0.0938 | -6.97e-02 | -4.19e-02 | -7.43e-03 | 1.41e-02 | 4.40e-02 | 2.24e-01 | 4.65e-01 | 8.97e-01 | 8.05e-01 | 4.43e-01 |
| CYTOSKELETON DEPENDENT INTRACELLULAR TRANSPORT | 201 | 2.65e-01 | 6.73e-01 | 0.0938 | -4.34e-02 | -4.65e-02 | -2.68e-03 | -1.61e-03 | 6.89e-02 | 2.89e-01 | 2.56e-01 | 9.48e-01 | 9.69e-01 | 9.22e-02 |
| REGULATION OF MICROTUBULE BASED MOVEMENT | 50 | 5.49e-01 | 8.73e-01 | 0.0938 | -2.10e-02 | -1.94e-02 | -2.45e-04 | -7.08e-02 | 5.45e-02 | 7.97e-01 | 8.13e-01 | 9.98e-01 | 3.87e-01 | 5.05e-01 |
| REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 186 | 7.77e-01 | 9.58e-01 | 0.0936 | 2.60e-02 | 3.30e-02 | 4.78e-02 | 2.91e-02 | 6.22e-02 | 5.41e-01 | 4.37e-01 | 2.61e-01 | 4.93e-01 | 1.43e-01 |
| RESPONSE TO HORMONE | 841 | 1.58e-02 | 1.42e-01 | 0.0936 | 2.66e-02 | 4.49e-02 | 3.61e-02 | 3.45e-02 | 5.95e-02 | 1.90e-01 | 2.69e-02 | 7.50e-02 | 8.95e-02 | 3.35e-03 |
| REGULATION OF INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 46 | 7.42e-01 | 9.50e-01 | 0.0936 | -1.27e-02 | 6.26e-02 | 4.27e-02 | 2.27e-02 | 4.83e-02 | 8.81e-01 | 4.62e-01 | 6.16e-01 | 7.90e-01 | 5.71e-01 |
| AMINO ACID TRANSPORT | 142 | 3.03e-01 | 7.16e-01 | 0.0933 | 1.00e-02 | 5.94e-02 | 4.26e-02 | -7.22e-03 | 5.66e-02 | 8.37e-01 | 2.22e-01 | 3.80e-01 | 8.82e-01 | 2.44e-01 |
| EPITHELIAL CELL PROLIFERATION | 468 | 2.26e-02 | 1.81e-01 | 0.0933 | 1.84e-02 | 3.86e-02 | 2.58e-02 | 2.97e-02 | 7.29e-02 | 4.94e-01 | 1.52e-01 | 3.38e-01 | 2.71e-01 | 6.88e-03 |
| AGGRESOME ASSEMBLY | 5 | 9.97e-01 | 1.00e+00 | 0.0932 | 8.98e-03 | -1.10e-02 | 3.96e-02 | -1.22e-02 | 8.22e-02 | 9.72e-01 | 9.66e-01 | 8.78e-01 | 9.62e-01 | 7.50e-01 |
| SMOOTH MUSCLE CONTRACTION | 109 | 6.90e-01 | 9.31e-01 | 0.0931 | 3.35e-03 | 3.84e-02 | 4.83e-02 | 3.96e-03 | 6.96e-02 | 9.52e-01 | 4.88e-01 | 3.84e-01 | 9.43e-01 | 2.10e-01 |
| SPERMATID DIFFERENTIATION | 202 | 7.47e-01 | 9.51e-01 | 0.0931 | -2.36e-02 | -4.18e-02 | -5.21e-02 | -5.18e-02 | -3.11e-02 | 5.64e-01 | 3.06e-01 | 2.02e-01 | 2.04e-01 | 4.46e-01 |
| NEGATIVE REGULATION OF SMOOTHENED SIGNALING PATHWAY | 33 | 8.67e-01 | 9.78e-01 | 0.0930 | 1.67e-02 | 4.31e-02 | 1.29e-02 | 4.54e-02 | 6.55e-02 | 8.68e-01 | 6.68e-01 | 8.98e-01 | 6.52e-01 | 5.15e-01 |
| SYNAPTIC VESICLE RECYCLING | 76 | 7.54e-01 | 9.51e-01 | 0.0929 | 3.74e-03 | 2.88e-02 | 6.19e-02 | 4.54e-03 | 6.26e-02 | 9.55e-01 | 6.64e-01 | 3.51e-01 | 9.45e-01 | 3.45e-01 |
| CIRCADIAN RHYTHM | 196 | 3.62e-01 | 7.62e-01 | 0.0928 | 3.37e-02 | 1.08e-02 | 2.36e-02 | 3.98e-02 | 7.22e-02 | 4.15e-01 | 7.94e-01 | 5.68e-01 | 3.36e-01 | 8.13e-02 |
| NEGATIVE REGULATION OF BLOOD PRESSURE | 46 | 8.38e-01 | 9.73e-01 | 0.0928 | -5.59e-02 | -2.65e-02 | 1.59e-02 | -4.97e-02 | 4.54e-02 | 5.12e-01 | 7.56e-01 | 8.52e-01 | 5.60e-01 | 5.94e-01 |
| REGULATION OF CELL PROJECTION ASSEMBLY | 220 | 3.94e-01 | 7.85e-01 | 0.0925 | 4.75e-02 | 3.96e-02 | 2.37e-02 | 6.40e-02 | -9.02e-03 | 2.24e-01 | 3.11e-01 | 5.44e-01 | 1.02e-01 | 8.18e-01 |
| AMINO ACID TRANSMEMBRANE TRANSPORT | 93 | 6.35e-01 | 9.12e-01 | 0.0925 | -1.04e-02 | 4.37e-02 | 4.88e-02 | -2.44e-04 | 6.45e-02 | 8.62e-01 | 4.67e-01 | 4.16e-01 | 9.97e-01 | 2.82e-01 |
| MICROTUBULE BUNDLE FORMATION | 121 | 4.89e-01 | 8.40e-01 | 0.0924 | -1.95e-03 | 2.36e-02 | 2.62e-02 | -9.22e-03 | 8.49e-02 | 9.70e-01 | 6.54e-01 | 6.18e-01 | 8.61e-01 | 1.07e-01 |
| REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 76 | 5.93e-01 | 8.95e-01 | 0.0924 | -6.78e-02 | -8.98e-04 | -1.25e-03 | -4.82e-02 | 4.02e-02 | 3.07e-01 | 9.89e-01 | 9.85e-01 | 4.67e-01 | 5.45e-01 |
| NEGATIVE REGULATION OF HORMONE METABOLIC PROCESS | 12 | 9.66e-01 | 9.94e-01 | 0.0922 | 7.90e-02 | 1.20e-02 | -2.12e-02 | 3.46e-02 | 2.17e-02 | 6.35e-01 | 9.43e-01 | 8.99e-01 | 8.36e-01 | 8.96e-01 |
| CELLULAR RESPONSE TO GONADOTROPIN STIMULUS | 17 | 9.45e-01 | 9.94e-01 | 0.0921 | -2.27e-02 | 6.16e-02 | 3.60e-02 | 3.91e-03 | 5.36e-02 | 8.71e-01 | 6.60e-01 | 7.97e-01 | 9.78e-01 | 7.02e-01 |
| CELLULAR RESPONSE TO TYPE II INTERFERON | 115 | 7.01e-01 | 9.32e-01 | 0.0921 | -8.11e-03 | -9.47e-03 | -5.70e-02 | -5.69e-02 | -4.29e-02 | 8.81e-01 | 8.61e-01 | 2.91e-01 | 2.92e-01 | 4.26e-01 |
| CELLULAR RESPONSE TO AMYLOID BETA | 45 | 9.09e-01 | 9.85e-01 | 0.0921 | -2.75e-02 | -3.70e-02 | -6.96e-02 | -3.89e-02 | 1.71e-03 | 7.50e-01 | 6.67e-01 | 4.19e-01 | 6.52e-01 | 9.84e-01 |
| PEPTIDYL THREONINE MODIFICATION | 107 | 2.59e-01 | 6.66e-01 | 0.0919 | -3.85e-02 | -5.13e-02 | -5.58e-02 | 1.21e-02 | -3.28e-02 | 4.92e-01 | 3.59e-01 | 3.19e-01 | 8.29e-01 | 5.57e-01 |
| REGULATION OF MUSCLE CONTRACTION | 163 | 3.85e-02 | 2.54e-01 | 0.0918 | -4.56e-02 | 2.93e-02 | 4.00e-02 | -4.15e-02 | 4.65e-02 | 3.15e-01 | 5.19e-01 | 3.78e-01 | 3.60e-01 | 3.06e-01 |
| CELLULAR RESPONSE TO PROSTAGLANDIN STIMULUS | 20 | 9.52e-01 | 9.94e-01 | 0.0918 | 1.41e-02 | -3.85e-02 | -5.79e-02 | -5.36e-02 | -2.27e-02 | 9.13e-01 | 7.65e-01 | 6.54e-01 | 6.78e-01 | 8.61e-01 |
| PHOSPHATIDYLGLYCEROL METABOLIC PROCESS | 33 | 4.19e-01 | 8.00e-01 | 0.0918 | 3.55e-03 | 1.81e-02 | 2.25e-02 | -8.51e-02 | 1.82e-02 | 9.72e-01 | 8.57e-01 | 8.23e-01 | 3.98e-01 | 8.57e-01 |
| RECEPTOR LOCALIZATION TO SYNAPSE | 57 | 9.15e-01 | 9.86e-01 | 0.0916 | -3.72e-02 | -2.25e-02 | -3.30e-02 | -7.20e-02 | -1.51e-02 | 6.27e-01 | 7.68e-01 | 6.67e-01 | 3.47e-01 | 8.43e-01 |
| MULTICELLULAR ORGANISMAL RESPONSE TO STRESS | 89 | 7.22e-01 | 9.40e-01 | 0.0916 | -3.54e-02 | -1.24e-02 | 1.53e-02 | -2.29e-02 | 7.89e-02 | 5.64e-01 | 8.40e-01 | 8.04e-01 | 7.09e-01 | 1.99e-01 |
| L ALPHA AMINO ACID TRANSMEMBRANE TRANSPORT | 65 | 8.90e-01 | 9.80e-01 | 0.0916 | 1.07e-02 | 4.71e-02 | 4.80e-02 | 5.09e-02 | 3.41e-02 | 8.82e-01 | 5.12e-01 | 5.04e-01 | 4.78e-01 | 6.34e-01 |
| IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 315 | 1.35e-01 | 4.97e-01 | 0.0915 | 4.10e-02 | 8.79e-03 | 3.18e-02 | 6.79e-02 | 3.15e-02 | 2.11e-01 | 7.89e-01 | 3.32e-01 | 3.82e-02 | 3.36e-01 |
| GAMMA AMINOBUTYRIC ACID SIGNALING PATHWAY | 27 | 9.69e-01 | 9.95e-01 | 0.0913 | 2.60e-02 | 7.21e-02 | 4.74e-02 | 7.58e-03 | 1.25e-02 | 8.15e-01 | 5.16e-01 | 6.70e-01 | 9.46e-01 | 9.10e-01 |
| POSITIVE REGULATION OF CHEMOTAXIS | 140 | 9.43e-02 | 4.16e-01 | 0.0913 | -3.41e-03 | 3.99e-02 | -4.71e-02 | -5.09e-02 | -4.39e-02 | 9.44e-01 | 4.15e-01 | 3.36e-01 | 2.98e-01 | 3.70e-01 |
| PULMONARY VALVE MORPHOGENESIS | 19 | 9.81e-01 | 9.96e-01 | 0.0913 | -6.33e-02 | -2.26e-02 | 1.42e-02 | -4.29e-02 | 4.21e-02 | 6.33e-01 | 8.64e-01 | 9.15e-01 | 7.46e-01 | 7.51e-01 |
| REGULATION OF SPROUTING ANGIOGENESIS | 62 | 2.26e-01 | 6.28e-01 | 0.0913 | 6.82e-02 | 3.62e-02 | -2.39e-02 | -4.23e-02 | 2.37e-03 | 3.53e-01 | 6.22e-01 | 7.45e-01 | 5.65e-01 | 9.74e-01 |
| POSITIVE REGULATION OF MUSCLE HYPERTROPHY | 36 | 7.18e-01 | 9.38e-01 | 0.0912 | -4.81e-02 | -3.73e-02 | 4.21e-02 | -3.46e-02 | 4.05e-02 | 6.17e-01 | 6.98e-01 | 6.62e-01 | 7.20e-01 | 6.74e-01 |
| OLIGOSACCHARIDE METABOLIC PROCESS | 65 | 6.40e-01 | 9.14e-01 | 0.0912 | 2.29e-02 | 5.25e-02 | 1.14e-02 | 4.16e-02 | -5.63e-02 | 7.50e-01 | 4.64e-01 | 8.73e-01 | 5.62e-01 | 4.32e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 170 | 3.96e-01 | 7.85e-01 | 0.0911 | -4.09e-02 | -5.41e-02 | -4.25e-02 | -1.92e-02 | 3.91e-02 | 3.57e-01 | 2.23e-01 | 3.39e-01 | 6.66e-01 | 3.79e-01 |
| POSITIVE REGULATION OF MONOATOMIC ION TRANSPORT | 202 | 3.08e-01 | 7.19e-01 | 0.0910 | -6.25e-02 | -1.89e-02 | -3.39e-02 | -5.01e-02 | 1.91e-02 | 1.26e-01 | 6.44e-01 | 4.06e-01 | 2.19e-01 | 6.40e-01 |
| PHOSPHATIDYLINOSITOL ACYL CHAIN REMODELING | 6 | 9.81e-01 | 9.96e-01 | 0.0910 | 3.62e-02 | -1.91e-02 | -4.84e-02 | -5.74e-02 | 3.12e-02 | 8.78e-01 | 9.36e-01 | 8.37e-01 | 8.08e-01 | 8.95e-01 |
| LIPID HOMEOSTASIS | 170 | 1.91e-01 | 5.78e-01 | 0.0909 | -3.91e-02 | 1.27e-02 | -3.94e-02 | -6.20e-02 | -3.44e-02 | 3.79e-01 | 7.76e-01 | 3.76e-01 | 1.63e-01 | 4.39e-01 |
| REGULATION OF RESPONSE TO BIOTIC STIMULUS | 492 | 1.51e-01 | 5.20e-01 | 0.0909 | 6.49e-02 | 4.32e-02 | 2.04e-02 | 4.15e-02 | 6.78e-03 | 1.37e-02 | 1.01e-01 | 4.38e-01 | 1.15e-01 | 7.97e-01 |
| ACTIN FILAMENT ORGANIZATION | 443 | 1.93e-01 | 5.80e-01 | 0.0908 | 4.81e-02 | 5.98e-02 | 3.19e-02 | 2.43e-02 | 2.74e-02 | 8.23e-02 | 3.09e-02 | 2.50e-01 | 3.81e-01 | 3.22e-01 |
| MEMBRANE INVAGINATION | 64 | 9.21e-01 | 9.87e-01 | 0.0908 | 3.96e-02 | 6.15e-02 | 3.43e-02 | 2.84e-02 | -3.02e-02 | 5.83e-01 | 3.95e-01 | 6.35e-01 | 6.95e-01 | 6.76e-01 |
| RESPONSE TO KETONE | 198 | 1.53e-01 | 5.23e-01 | 0.0908 | 1.60e-02 | 3.55e-02 | 2.08e-02 | -5.63e-03 | 7.91e-02 | 6.98e-01 | 3.89e-01 | 6.13e-01 | 8.91e-01 | 5.49e-02 |
| EXOCYTIC PROCESS | 82 | 8.48e-01 | 9.76e-01 | 0.0906 | 3.19e-02 | 5.99e-02 | 4.82e-02 | 9.41e-03 | 3.45e-02 | 6.18e-01 | 3.48e-01 | 4.51e-01 | 8.83e-01 | 5.90e-01 |
| BLASTODERM SEGMENTATION | 24 | 8.13e-01 | 9.68e-01 | 0.0905 | -6.08e-03 | 8.04e-02 | 1.92e-02 | -3.52e-02 | -9.91e-03 | 9.59e-01 | 4.96e-01 | 8.71e-01 | 7.66e-01 | 9.33e-01 |
| ORGANIC ANION TRANSPORT | 429 | 8.12e-02 | 3.85e-01 | 0.0905 | -3.74e-02 | -1.24e-02 | -3.91e-02 | -6.76e-02 | -2.30e-02 | 1.83e-01 | 6.59e-01 | 1.65e-01 | 1.63e-02 | 4.15e-01 |
| GANGLIOSIDE BIOSYNTHETIC PROCESS | 17 | 6.98e-01 | 9.31e-01 | 0.0903 | -2.77e-02 | -1.22e-02 | 7.50e-02 | -4.00e-02 | 2.83e-03 | 8.43e-01 | 9.31e-01 | 5.92e-01 | 7.75e-01 | 9.84e-01 |
| RESPONSE TO STEROL | 35 | 7.53e-01 | 9.51e-01 | 0.0903 | -1.14e-02 | -3.09e-02 | -1.52e-02 | 4.49e-02 | 6.94e-02 | 9.07e-01 | 7.52e-01 | 8.76e-01 | 6.46e-01 | 4.78e-01 |
| PLASMA MEMBRANE ORGANIZATION | 161 | 5.38e-01 | 8.66e-01 | 0.0902 | -1.48e-04 | 4.60e-02 | 5.78e-02 | 2.64e-02 | 4.46e-02 | 9.97e-01 | 3.14e-01 | 2.05e-01 | 5.63e-01 | 3.29e-01 |
| REGULATION OF MODIFICATION OF POSTSYNAPTIC STRUCTURE | 9 | 9.96e-01 | 1.00e+00 | 0.0901 | -6.24e-02 | -2.28e-02 | 1.07e-02 | -8.19e-04 | 5.99e-02 | 7.46e-01 | 9.06e-01 | 9.56e-01 | 9.97e-01 | 7.56e-01 |
| BRAIN MORPHOGENESIS | 37 | 7.22e-01 | 9.40e-01 | 0.0900 | -1.68e-02 | -2.58e-02 | 1.50e-03 | 3.86e-02 | -7.53e-02 | 8.60e-01 | 7.86e-01 | 9.87e-01 | 6.85e-01 | 4.28e-01 |
| MYELOID LEUKOCYTE DIFFERENTIATION | 227 | 3.21e-01 | 7.32e-01 | 0.0900 | 4.60e-02 | 6.63e-02 | 1.64e-02 | 2.37e-02 | -2.76e-02 | 2.32e-01 | 8.54e-02 | 6.70e-01 | 5.39e-01 | 4.73e-01 |
| CHEMICAL SYNAPTIC TRANSMISSION POSTSYNAPTIC | 111 | 1.91e-01 | 5.78e-01 | 0.0900 | -5.38e-02 | 2.16e-02 | 4.91e-02 | 1.07e-02 | 4.70e-02 | 3.28e-01 | 6.94e-01 | 3.71e-01 | 8.46e-01 | 3.92e-01 |
| LEUKOCYTE MIGRATION | 383 | 4.43e-03 | 5.66e-02 | 0.0899 | 5.79e-02 | 5.66e-02 | -1.36e-02 | -7.60e-03 | -3.58e-02 | 5.18e-02 | 5.73e-02 | 6.48e-01 | 7.98e-01 | 2.29e-01 |
| OVARIAN FOLLICLE DEVELOPMENT | 54 | 5.54e-01 | 8.76e-01 | 0.0898 | 6.87e-03 | -5.16e-02 | -3.61e-02 | -5.20e-03 | 6.34e-02 | 9.30e-01 | 5.12e-01 | 6.47e-01 | 9.47e-01 | 4.20e-01 |
| ICOSANOID METABOLIC PROCESS | 118 | 4.19e-01 | 8.00e-01 | 0.0898 | 4.49e-02 | 4.99e-02 | 5.54e-02 | 1.15e-02 | -1.89e-02 | 4.00e-01 | 3.49e-01 | 2.99e-01 | 8.29e-01 | 7.22e-01 |
| REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 95 | 1.25e-01 | 4.80e-01 | 0.0897 | -4.85e-02 | 4.38e-02 | 5.49e-02 | 1.30e-02 | 2.44e-02 | 4.14e-01 | 4.61e-01 | 3.55e-01 | 8.27e-01 | 6.81e-01 |
| POSITIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE PROTEIN KINASE B SIGNAL TRANSDUCTION | 168 | 3.63e-01 | 7.63e-01 | 0.0896 | -1.45e-02 | 1.18e-02 | -4.79e-02 | -4.22e-02 | -6.01e-02 | 7.45e-01 | 7.92e-01 | 2.84e-01 | 3.45e-01 | 1.79e-01 |
| INTEGRIN MEDIATED SIGNALING PATHWAY | 110 | 7.61e-01 | 9.53e-01 | 0.0896 | 7.83e-03 | -1.36e-02 | -4.63e-02 | -8.68e-03 | -7.46e-02 | 8.87e-01 | 8.05e-01 | 4.01e-01 | 8.75e-01 | 1.76e-01 |
| MUSCLE CONTRACTION | 338 | 1.00e-02 | 1.01e-01 | 0.0896 | -5.33e-02 | -5.80e-03 | -5.44e-03 | -6.94e-02 | 1.77e-02 | 9.20e-02 | 8.55e-01 | 8.63e-01 | 2.84e-02 | 5.77e-01 |
| NEGATIVE REGULATION OF PROTEOLYSIS | 213 | 4.39e-01 | 8.11e-01 | 0.0896 | 5.61e-02 | 5.73e-02 | 1.39e-02 | 3.66e-02 | 8.19e-03 | 1.58e-01 | 1.50e-01 | 7.27e-01 | 3.58e-01 | 8.37e-01 |
| ACTIVATION OF IMMUNE RESPONSE | 502 | 2.53e-01 | 6.59e-01 | 0.0894 | 5.76e-02 | 3.30e-02 | 2.86e-02 | 5.22e-02 | 7.20e-03 | 2.72e-02 | 2.05e-01 | 2.73e-01 | 4.54e-02 | 7.82e-01 |
| RESPONSE TO BACTERIUM | 667 | 2.39e-04 | 5.44e-03 | 0.0894 | 5.17e-02 | 4.36e-02 | -1.85e-02 | -7.73e-03 | -5.49e-02 | 2.27e-02 | 5.47e-02 | 4.14e-01 | 7.34e-01 | 1.56e-02 |
| REGULATION OF LUTEINIZING HORMONE SECRETION | 6 | 9.84e-01 | 9.96e-01 | 0.0894 | 3.69e-02 | 4.70e-02 | -6.12e-02 | 7.04e-04 | -2.59e-02 | 8.75e-01 | 8.42e-01 | 7.95e-01 | 9.98e-01 | 9.12e-01 |
| POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 480 | 3.29e-01 | 7.37e-01 | 0.0893 | 5.20e-02 | 4.18e-02 | 2.69e-02 | 5.07e-02 | 1.52e-02 | 5.11e-02 | 1.17e-01 | 3.13e-01 | 5.69e-02 | 5.69e-01 |
| MEMBRANE LIPID CATABOLIC PROCESS | 38 | 9.16e-01 | 9.86e-01 | 0.0892 | 6.18e-02 | 3.20e-02 | 4.08e-02 | 1.76e-02 | 3.37e-02 | 5.10e-01 | 7.33e-01 | 6.63e-01 | 8.51e-01 | 7.19e-01 |
| AMYLOID BETA METABOLIC PROCESS | 64 | 9.00e-01 | 9.83e-01 | 0.0890 | 6.95e-02 | 2.52e-02 | 2.13e-02 | 4.47e-02 | 3.47e-03 | 3.36e-01 | 7.27e-01 | 7.68e-01 | 5.37e-01 | 9.62e-01 |
| CELLULAR OXIDANT DETOXIFICATION | 95 | 5.17e-01 | 8.56e-01 | 0.0889 | 2.53e-02 | 7.47e-02 | 2.44e-02 | 3.08e-02 | 1.21e-02 | 6.70e-01 | 2.08e-01 | 6.82e-01 | 6.03e-01 | 8.39e-01 |
| RELAXATION OF MUSCLE | 33 | 6.34e-01 | 9.12e-01 | 0.0889 | -5.43e-02 | 3.88e-02 | 5.16e-03 | -9.32e-03 | 5.77e-02 | 5.89e-01 | 6.99e-01 | 9.59e-01 | 9.26e-01 | 5.66e-01 |
| POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 182 | 1.06e-02 | 1.06e-01 | 0.0889 | 1.26e-02 | 7.65e-02 | 1.39e-02 | -3.87e-02 | 1.41e-02 | 7.69e-01 | 7.50e-02 | 7.46e-01 | 3.68e-01 | 7.42e-01 |
| DICARBOXYLIC ACID METABOLIC PROCESS | 92 | 5.13e-01 | 8.55e-01 | 0.0889 | 4.16e-02 | 6.51e-02 | 8.24e-03 | 1.86e-02 | 3.89e-02 | 4.91e-01 | 2.80e-01 | 8.91e-01 | 7.58e-01 | 5.19e-01 |
| POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 1014 | 2.31e-02 | 1.84e-01 | 0.0887 | 4.92e-02 | 4.58e-02 | 2.60e-02 | 5.14e-02 | 5.03e-03 | 8.01e-03 | 1.36e-02 | 1.61e-01 | 5.63e-03 | 7.87e-01 |
| REGULATION OF IMMUNE RESPONSE | 875 | 9.92e-02 | 4.28e-01 | 0.0886 | 5.12e-02 | 3.93e-02 | 2.90e-02 | 4.87e-02 | 2.19e-02 | 1.01e-02 | 4.83e-02 | 1.46e-01 | 1.45e-02 | 2.72e-01 |
| GLUTAMATE METABOLIC PROCESS | 32 | 4.31e-01 | 8.06e-01 | 0.0884 | 7.43e-03 | 4.07e-02 | -6.34e-02 | -2.54e-02 | 3.80e-02 | 9.42e-01 | 6.90e-01 | 5.35e-01 | 8.04e-01 | 7.10e-01 |
| REGULATION OF GLUCONEOGENESIS | 51 | 3.22e-01 | 7.33e-01 | 0.0884 | 4.61e-03 | -2.99e-03 | -8.46e-02 | -2.11e-02 | 1.30e-02 | 9.55e-01 | 9.71e-01 | 2.96e-01 | 7.94e-01 | 8.73e-01 |
| GLYCEROLIPID METABOLIC PROCESS | 372 | 5.24e-01 | 8.60e-01 | 0.0882 | 2.90e-02 | 5.21e-02 | 4.82e-02 | 2.89e-02 | 3.28e-02 | 3.37e-01 | 8.45e-02 | 1.10e-01 | 3.39e-01 | 2.78e-01 |
| BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 170 | 3.74e-01 | 7.73e-01 | 0.0880 | -1.59e-02 | 3.81e-03 | 2.63e-02 | -1.40e-02 | 8.12e-02 | 7.21e-01 | 9.32e-01 | 5.54e-01 | 7.53e-01 | 6.79e-02 |
| REGULATION OF CILIUM MOVEMENT | 38 | 5.17e-01 | 8.56e-01 | 0.0877 | -1.86e-03 | 9.41e-03 | 5.48e-03 | -8.10e-02 | 3.18e-02 | 9.84e-01 | 9.20e-01 | 9.53e-01 | 3.88e-01 | 7.35e-01 |
| NEGATIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 48 | 6.83e-01 | 9.30e-01 | 0.0877 | -4.80e-02 | 3.07e-02 | 5.12e-02 | -1.50e-05 | 4.26e-02 | 5.65e-01 | 7.13e-01 | 5.39e-01 | 1.00e+00 | 6.10e-01 |
| ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 223 | 3.98e-01 | 7.86e-01 | 0.0875 | 1.39e-02 | 1.93e-02 | 3.56e-02 | 5.83e-02 | 4.93e-02 | 7.21e-01 | 6.19e-01 | 3.60e-01 | 1.33e-01 | 2.05e-01 |
| NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH | 108 | 7.65e-01 | 9.54e-01 | 0.0875 | 2.28e-02 | 5.27e-02 | 3.02e-02 | 2.04e-02 | 5.50e-02 | 6.82e-01 | 3.44e-01 | 5.87e-01 | 7.15e-01 | 3.23e-01 |
| GMP METABOLIC PROCESS | 25 | 6.30e-01 | 9.10e-01 | 0.0875 | 7.89e-02 | -2.75e-02 | -1.15e-02 | -3.04e-03 | -2.31e-02 | 4.95e-01 | 8.12e-01 | 9.21e-01 | 9.79e-01 | 8.42e-01 |
| FOCAL ADHESION ASSEMBLY | 83 | 8.11e-01 | 9.68e-01 | 0.0874 | 4.43e-03 | -2.92e-02 | -6.21e-02 | -1.60e-02 | -5.15e-02 | 9.44e-01 | 6.46e-01 | 3.28e-01 | 8.01e-01 | 4.17e-01 |
| CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 89 | 8.82e-01 | 9.79e-01 | 0.0873 | -3.42e-02 | -4.17e-02 | -4.97e-02 | -4.38e-02 | 1.78e-02 | 5.77e-01 | 4.96e-01 | 4.17e-01 | 4.75e-01 | 7.71e-01 |
| REGULATION OF TRANSMEMBRANE TRANSPORT | 561 | 2.07e-02 | 1.70e-01 | 0.0872 | -4.91e-02 | -1.56e-02 | -2.92e-02 | -6.36e-02 | 6.48e-03 | 4.67e-02 | 5.27e-01 | 2.38e-01 | 9.94e-03 | 7.93e-01 |
| NEGATIVE REGULATION OF NEUROINFLAMMATORY RESPONSE | 18 | 9.51e-01 | 9.94e-01 | 0.0871 | -3.70e-02 | 4.82e-03 | -3.16e-03 | -7.86e-02 | 1.87e-03 | 7.86e-01 | 9.72e-01 | 9.81e-01 | 5.64e-01 | 9.89e-01 |
| REGULATION OF CILIUM BEAT FREQUENCY | 17 | 5.74e-01 | 8.84e-01 | 0.0871 | 2.09e-02 | -1.29e-02 | 7.95e-02 | -2.57e-02 | -2.04e-03 | 8.81e-01 | 9.26e-01 | 5.71e-01 | 8.54e-01 | 9.88e-01 |
| CALCIUM MEDIATED SIGNALING | 203 | 7.54e-01 | 9.51e-01 | 0.0870 | -2.97e-02 | -4.60e-02 | -4.88e-02 | -4.66e-02 | -5.08e-03 | 4.66e-01 | 2.58e-01 | 2.31e-01 | 2.53e-01 | 9.01e-01 |
| HOMEOSTASIS OF NUMBER OF CELLS WITHIN A TISSUE | 32 | 7.12e-01 | 9.35e-01 | 0.0870 | -1.41e-02 | 4.97e-02 | -1.05e-02 | -2.54e-02 | 6.44e-02 | 8.91e-01 | 6.27e-01 | 9.18e-01 | 8.04e-01 | 5.28e-01 |
| POSITIVE REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION | 29 | 7.16e-01 | 9.37e-01 | 0.0869 | -2.28e-02 | 5.63e-02 | -2.06e-02 | -5.80e-02 | 9.21e-03 | 8.31e-01 | 6.00e-01 | 8.47e-01 | 5.89e-01 | 9.32e-01 |
| SECOND MESSENGER MEDIATED SIGNALING | 298 | 8.07e-01 | 9.67e-01 | 0.0869 | -4.09e-02 | -3.84e-02 | -4.04e-02 | -5.03e-02 | -1.55e-02 | 2.24e-01 | 2.54e-01 | 2.30e-01 | 1.35e-01 | 6.46e-01 |
| ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 1213 | 2.30e-03 | 3.41e-02 | 0.0868 | 1.47e-02 | 4.19e-02 | 3.89e-02 | 2.54e-02 | 5.84e-02 | 3.90e-01 | 1.39e-02 | 2.25e-02 | 1.37e-01 | 6.10e-04 |
| CERAMIDE CATABOLIC PROCESS | 20 | 9.99e-01 | 1.00e+00 | 0.0868 | -3.73e-02 | -4.83e-02 | -4.55e-02 | -3.97e-02 | -1.26e-02 | 7.73e-01 | 7.09e-01 | 7.24e-01 | 7.59e-01 | 9.22e-01 |
| CAMP MEDIATED SIGNALING | 53 | 8.84e-01 | 9.80e-01 | 0.0865 | 1.34e-02 | 6.35e-02 | 5.15e-02 | 2.50e-02 | -5.96e-04 | 8.66e-01 | 4.24e-01 | 5.17e-01 | 7.53e-01 | 9.94e-01 |
| NEGATIVE REGULATION OF TYPE II INTERFERON PRODUCTION | 41 | 8.24e-01 | 9.71e-01 | 0.0865 | 1.36e-02 | -2.89e-02 | -5.75e-02 | -5.43e-02 | -1.41e-02 | 8.80e-01 | 7.49e-01 | 5.24e-01 | 5.47e-01 | 8.76e-01 |
| NEGATIVE REGULATION OF JNK CASCADE | 37 | 7.53e-01 | 9.51e-01 | 0.0863 | 5.14e-02 | -2.38e-02 | -2.68e-02 | -1.47e-02 | -5.75e-02 | 5.88e-01 | 8.02e-01 | 7.78e-01 | 8.77e-01 | 5.45e-01 |
| REGULATION OF POSTSYNAPTIC NEUROTRANSMITTER RECEPTOR INTERNALIZATION | 15 | 9.66e-01 | 9.94e-01 | 0.0861 | 9.65e-03 | 4.01e-02 | -4.94e-02 | -3.81e-02 | -4.27e-02 | 9.48e-01 | 7.88e-01 | 7.40e-01 | 7.98e-01 | 7.75e-01 |
| ALPHA AMINO ACID CATABOLIC PROCESS | 89 | 3.53e-01 | 7.53e-01 | 0.0861 | 1.33e-02 | 1.07e-02 | -7.12e-02 | -2.61e-02 | -3.71e-02 | 8.28e-01 | 8.61e-01 | 2.46e-01 | 6.71e-01 | 5.45e-01 |
| NEGATIVE REGULATION OF FATTY ACID OXIDATION | 14 | 9.60e-01 | 9.94e-01 | 0.0861 | 3.44e-02 | 6.61e-02 | -2.72e-02 | 4.92e-03 | -3.30e-02 | 8.24e-01 | 6.68e-01 | 8.60e-01 | 9.75e-01 | 8.31e-01 |
| POSITIVE REGULATION OF TYROSINE PHOSPHORYLATION OF STAT PROTEIN | 65 | 5.41e-01 | 8.68e-01 | 0.0859 | -4.52e-02 | 3.52e-03 | -5.85e-02 | -4.23e-02 | -1.10e-02 | 5.29e-01 | 9.61e-01 | 4.15e-01 | 5.56e-01 | 8.78e-01 |
| CELLULAR RESPONSE TO REACTIVE NITROGEN SPECIES | 16 | 9.27e-01 | 9.89e-01 | 0.0859 | -4.13e-02 | -3.32e-02 | -4.93e-02 | 2.27e-02 | -4.03e-02 | 7.75e-01 | 8.18e-01 | 7.33e-01 | 8.75e-01 | 7.80e-01 |
| ACTOMYOSIN STRUCTURE ORGANIZATION | 205 | 8.52e-01 | 9.76e-01 | 0.0859 | -4.31e-02 | -3.41e-02 | -4.59e-02 | -4.67e-02 | -8.43e-03 | 2.87e-01 | 4.00e-01 | 2.57e-01 | 2.49e-01 | 8.35e-01 |
| REGULATION OF CHONDROCYTE DIFFERENTIATION | 52 | 6.70e-01 | 9.25e-01 | 0.0858 | -6.58e-02 | -2.34e-02 | 1.30e-02 | 1.92e-02 | 4.41e-02 | 4.12e-01 | 7.71e-01 | 8.71e-01 | 8.11e-01 | 5.83e-01 |
| POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 272 | 2.82e-01 | 6.93e-01 | 0.0857 | -7.38e-03 | 1.91e-02 | 4.13e-02 | 3.13e-03 | 7.22e-02 | 8.34e-01 | 5.88e-01 | 2.41e-01 | 9.29e-01 | 4.04e-02 |
| ANTIMICROBIAL HUMORAL RESPONSE | 119 | 1.75e-01 | 5.60e-01 | 0.0857 | 1.79e-02 | 4.51e-02 | -2.70e-02 | -5.61e-02 | -3.32e-02 | 7.37e-01 | 3.95e-01 | 6.11e-01 | 2.90e-01 | 5.31e-01 |
| BINDING OF SPERM TO ZONA PELLUCIDA | 38 | 9.75e-01 | 9.95e-01 | 0.0857 | 4.40e-02 | 4.81e-02 | 9.62e-03 | 1.92e-02 | -5.13e-02 | 6.39e-01 | 6.08e-01 | 9.18e-01 | 8.38e-01 | 5.84e-01 |
| POSITIVE REGULATION OF WNT SIGNALING PATHWAY | 138 | 1.24e-01 | 4.80e-01 | 0.0856 | -4.21e-02 | -3.28e-02 | 7.26e-03 | 4.23e-02 | 5.15e-02 | 3.93e-01 | 5.06e-01 | 8.83e-01 | 3.91e-01 | 2.96e-01 |
| INOSITOL TRISPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 9.77e-01 | 9.96e-01 | 0.0855 | 3.13e-02 | -2.79e-02 | -3.77e-02 | 6.39e-02 | -7.47e-03 | 8.78e-01 | 8.91e-01 | 8.54e-01 | 7.54e-01 | 9.71e-01 |
| NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION | 61 | 8.29e-01 | 9.72e-01 | 0.0855 | -6.38e-02 | -1.05e-02 | -2.89e-02 | -4.61e-02 | 1.26e-02 | 3.89e-01 | 8.87e-01 | 6.96e-01 | 5.33e-01 | 8.65e-01 |
| REGULATION OF CELLULAR EXTRAVASATION | 38 | 8.53e-01 | 9.76e-01 | 0.0854 | 9.30e-04 | -2.46e-02 | -7.64e-02 | -2.02e-02 | -2.10e-02 | 9.92e-01 | 7.93e-01 | 4.15e-01 | 8.29e-01 | 8.22e-01 |
| RETINA DEVELOPMENT IN CAMERA TYPE EYE | 156 | 2.71e-01 | 6.79e-01 | 0.0854 | 1.16e-04 | 3.03e-03 | 7.02e-03 | -1.68e-02 | 8.34e-02 | 9.98e-01 | 9.48e-01 | 8.80e-01 | 7.18e-01 | 7.21e-02 |
| POSITIVE REGULATION OF PHOSPHOLIPASE ACTIVITY | 48 | 8.99e-01 | 9.83e-01 | 0.0852 | 3.12e-02 | 4.29e-03 | -4.86e-02 | -2.76e-03 | -6.24e-02 | 7.09e-01 | 9.59e-01 | 5.60e-01 | 9.74e-01 | 4.55e-01 |
| POSITIVE REGULATION OF LEUKOCYTE PROLIFERATION | 159 | 6.51e-01 | 9.18e-01 | 0.0851 | 5.43e-02 | 4.60e-02 | 1.07e-02 | 4.55e-02 | -1.46e-04 | 2.37e-01 | 3.17e-01 | 8.16e-01 | 3.22e-01 | 9.97e-01 |
| ERBB SIGNALING PATHWAY | 123 | 7.05e-01 | 9.33e-01 | 0.0850 | -1.21e-02 | -3.93e-02 | -6.47e-02 | -2.41e-02 | -2.77e-02 | 8.17e-01 | 4.52e-01 | 2.15e-01 | 6.45e-01 | 5.95e-01 |
| INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 51 | 6.32e-01 | 9.11e-01 | 0.0849 | -2.01e-02 | 3.34e-02 | 2.32e-02 | 4.32e-02 | 5.73e-02 | 8.04e-01 | 6.79e-01 | 7.74e-01 | 5.93e-01 | 4.79e-01 |
| ADULT HEART DEVELOPMENT | 13 | 9.77e-01 | 9.96e-01 | 0.0845 | -1.68e-02 | 6.40e-02 | 3.90e-02 | -7.47e-04 | 3.52e-02 | 9.16e-01 | 6.90e-01 | 8.08e-01 | 9.96e-01 | 8.26e-01 |
| VESICLE CYTOSKELETAL TRAFFICKING | 68 | 9.87e-01 | 9.97e-01 | 0.0843 | -3.82e-02 | -5.11e-02 | -4.39e-02 | -3.19e-02 | -9.88e-03 | 5.86e-01 | 4.67e-01 | 5.31e-01 | 6.50e-01 | 8.88e-01 |
| NEGATIVE REGULATION OF ERK1 AND ERK2 CASCADE | 71 | 7.48e-01 | 9.51e-01 | 0.0843 | 3.85e-02 | 6.17e-02 | 1.04e-02 | 2.30e-02 | 3.44e-02 | 5.75e-01 | 3.69e-01 | 8.79e-01 | 7.38e-01 | 6.16e-01 |
| REGULATION OF PRESYNAPTIC MEMBRANE POTENTIAL | 28 | 7.97e-01 | 9.66e-01 | 0.0843 | -3.94e-02 | 4.40e-02 | 3.12e-02 | -4.99e-02 | 1.21e-02 | 7.18e-01 | 6.87e-01 | 7.75e-01 | 6.47e-01 | 9.12e-01 |
| POSITIVE REGULATION OF RESPONSE TO BIOTIC STIMULUS | 353 | 7.11e-02 | 3.61e-01 | 0.0842 | 6.99e-02 | 2.89e-02 | -6.90e-04 | 3.13e-02 | -1.95e-02 | 2.40e-02 | 3.51e-01 | 9.82e-01 | 3.12e-01 | 5.30e-01 |
| TISSUE REMODELING | 179 | 2.84e-02 | 2.09e-01 | 0.0838 | -4.94e-03 | 4.78e-02 | -3.47e-02 | -5.09e-02 | -3.03e-02 | 9.09e-01 | 2.70e-01 | 4.23e-01 | 2.40e-01 | 4.85e-01 |
| REGULATION OF CELL SHAPE | 134 | 4.86e-01 | 8.38e-01 | 0.0838 | 1.43e-02 | -1.41e-02 | -6.07e-02 | -9.89e-03 | -5.32e-02 | 7.75e-01 | 7.79e-01 | 2.25e-01 | 8.43e-01 | 2.88e-01 |
| POSITIVE REGULATION OF DEPHOSPHORYLATION | 51 | 8.89e-01 | 9.80e-01 | 0.0837 | 1.80e-02 | 6.19e-02 | 5.00e-02 | 1.27e-03 | 1.85e-02 | 8.24e-01 | 4.44e-01 | 5.36e-01 | 9.87e-01 | 8.20e-01 |
| NEGATIVE REGULATION OF PROTEIN CONTAINING COMPLEX ASSEMBLY | 140 | 8.12e-01 | 9.68e-01 | 0.0837 | 1.11e-02 | 2.71e-02 | 4.52e-02 | 1.45e-02 | 6.23e-02 | 8.21e-01 | 5.80e-01 | 3.55e-01 | 7.67e-01 | 2.03e-01 |
| STRIATED MUSCLE TISSUE DEVELOPMENT | 260 | 2.80e-01 | 6.91e-01 | 0.0837 | 1.46e-02 | 4.91e-02 | 4.58e-02 | 3.81e-03 | 4.76e-02 | 6.85e-01 | 1.73e-01 | 2.03e-01 | 9.16e-01 | 1.87e-01 |
| CELLULAR MODIFIED AMINO ACID METABOLIC PROCESS | 122 | 2.29e-01 | 6.32e-01 | 0.0836 | 7.47e-03 | 8.34e-03 | -6.23e-02 | -5.26e-02 | -1.43e-02 | 8.87e-01 | 8.74e-01 | 2.35e-01 | 3.15e-01 | 7.85e-01 |
| REGULATION OF VESICLE FUSION | 24 | 7.69e-01 | 9.55e-01 | 0.0836 | -3.05e-03 | 2.60e-02 | 5.47e-02 | -2.40e-02 | -5.23e-02 | 9.79e-01 | 8.26e-01 | 6.43e-01 | 8.39e-01 | 6.57e-01 |
| CELLULAR RESPONSE TO CALCIUM ION | 84 | 3.72e-01 | 7.71e-01 | 0.0834 | 1.79e-02 | 5.48e-02 | 1.63e-02 | -3.43e-02 | 4.68e-02 | 7.76e-01 | 3.85e-01 | 7.97e-01 | 5.86e-01 | 4.59e-01 |
| SENSORY SYSTEM DEVELOPMENT | 394 | 2.85e-01 | 6.93e-01 | 0.0834 | 8.43e-03 | 2.70e-02 | 4.13e-02 | 1.41e-02 | 6.52e-02 | 7.74e-01 | 3.58e-01 | 1.59e-01 | 6.31e-01 | 2.63e-02 |
| ENERGY RESERVE METABOLIC PROCESS | 84 | 7.55e-01 | 9.51e-01 | 0.0833 | -4.67e-02 | -3.35e-02 | 2.06e-02 | 1.04e-02 | 5.57e-02 | 4.59e-01 | 5.95e-01 | 7.44e-01 | 8.70e-01 | 3.77e-01 |
| AMINE METABOLIC PROCESS | 107 | 5.26e-01 | 8.60e-01 | 0.0832 | -9.50e-03 | 3.74e-02 | 5.31e-02 | -9.22e-03 | 5.03e-02 | 8.65e-01 | 5.04e-01 | 3.42e-01 | 8.69e-01 | 3.69e-01 |
| POSITIVE REGULATION OF CYTOKINESIS | 43 | 8.65e-01 | 9.78e-01 | 0.0832 | -2.42e-02 | -6.89e-02 | -3.82e-02 | 1.01e-02 | 5.37e-03 | 7.84e-01 | 4.34e-01 | 6.65e-01 | 9.09e-01 | 9.51e-01 |
| POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 595 | 2.52e-02 | 1.94e-01 | 0.0831 | 6.15e-02 | 4.00e-02 | 2.86e-03 | 3.66e-02 | -1.28e-02 | 1.03e-02 | 9.52e-02 | 9.05e-01 | 1.27e-01 | 5.93e-01 |
| BIOLOGICAL PROCESS INVOLVED IN INTERSPECIES INTERACTION BETWEEN ORGANISMS | 1628 | 6.55e-03 | 7.50e-02 | 0.0830 | 5.56e-02 | 4.52e-02 | 2.48e-02 | 3.39e-02 | -1.70e-03 | 1.85e-04 | 2.35e-03 | 9.58e-02 | 2.27e-02 | 9.09e-01 |
| NEGATIVE REGULATION OF SUPRAMOLECULAR FIBER ORGANIZATION | 153 | 5.04e-01 | 8.50e-01 | 0.0830 | -5.26e-02 | -6.32e-03 | -3.61e-02 | -4.81e-02 | -2.15e-02 | 2.62e-01 | 8.93e-01 | 4.40e-01 | 3.05e-01 | 6.47e-01 |
| RESPONSE TO PEPTIDE | 502 | 9.22e-03 | 9.59e-02 | 0.0829 | 2.11e-02 | 4.41e-02 | 1.69e-02 | 2.29e-02 | 6.06e-02 | 4.19e-01 | 9.04e-02 | 5.17e-01 | 3.80e-01 | 2.01e-02 |
| L AMINO ACID TRANSPORT | 84 | 9.02e-01 | 9.84e-01 | 0.0827 | 2.92e-02 | 6.23e-02 | 3.48e-02 | 2.98e-02 | 3.52e-03 | 6.44e-01 | 3.24e-01 | 5.81e-01 | 6.37e-01 | 9.56e-01 |
| LEUKOCYTE PROLIFERATION | 333 | 1.65e-01 | 5.44e-01 | 0.0827 | 5.03e-02 | 3.99e-02 | 6.08e-03 | 4.87e-02 | -1.77e-02 | 1.15e-01 | 2.11e-01 | 8.49e-01 | 1.27e-01 | 5.79e-01 |
| NEGATIVE REGULATION OF VIRAL GENOME REPLICATION | 55 | 6.89e-01 | 9.31e-01 | 0.0827 | 1.90e-02 | 5.19e-02 | 1.04e-02 | 4.54e-02 | 4.02e-02 | 8.08e-01 | 5.06e-01 | 8.93e-01 | 5.60e-01 | 6.06e-01 |
| RESPONSE TO CYTOKINE | 905 | 4.51e-02 | 2.76e-01 | 0.0827 | 4.18e-02 | 3.82e-02 | 3.16e-02 | 2.55e-02 | 4.44e-02 | 3.27e-02 | 5.12e-02 | 1.06e-01 | 1.92e-01 | 2.34e-02 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION | 19 | 9.08e-01 | 9.85e-01 | 0.0826 | -1.72e-02 | 5.12e-02 | -2.03e-03 | -5.97e-02 | 1.83e-02 | 8.97e-01 | 6.99e-01 | 9.88e-01 | 6.52e-01 | 8.90e-01 |
| PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 74 | 4.97e-01 | 8.45e-01 | 0.0826 | -4.02e-02 | 1.87e-02 | -1.76e-03 | -6.94e-02 | 6.13e-03 | 5.50e-01 | 7.81e-01 | 9.79e-01 | 3.02e-01 | 9.27e-01 |
| CERAMIDE METABOLIC PROCESS | 106 | 8.73e-01 | 9.78e-01 | 0.0825 | 3.05e-02 | 1.74e-02 | 5.35e-02 | 3.66e-02 | 3.70e-02 | 5.88e-01 | 7.58e-01 | 3.41e-01 | 5.16e-01 | 5.10e-01 |
| RESPONSE TO ACETYLCHOLINE | 36 | 6.49e-01 | 9.17e-01 | 0.0825 | 2.79e-02 | -9.77e-03 | -4.76e-02 | -9.66e-03 | 5.97e-02 | 7.72e-01 | 9.19e-01 | 6.21e-01 | 9.20e-01 | 5.35e-01 |
| T CELL PROLIFERATION | 204 | 6.86e-01 | 9.31e-01 | 0.0824 | 5.17e-02 | 3.59e-02 | 1.73e-02 | 5.02e-02 | 2.79e-03 | 2.03e-01 | 3.77e-01 | 6.70e-01 | 2.16e-01 | 9.45e-01 |
| CELL CHEMOTAXIS | 309 | 2.99e-02 | 2.16e-01 | 0.0820 | 2.46e-02 | 2.91e-02 | -3.27e-02 | -4.17e-02 | -4.96e-02 | 4.57e-01 | 3.80e-01 | 3.23e-01 | 2.07e-01 | 1.33e-01 |
| REGULATION OF STEROID HORMONE BIOSYNTHETIC PROCESS | 15 | 9.63e-01 | 9.94e-01 | 0.0820 | -3.29e-03 | -6.39e-02 | -2.77e-02 | 3.10e-02 | 2.99e-02 | 9.82e-01 | 6.68e-01 | 8.53e-01 | 8.35e-01 | 8.41e-01 |
| TAXIS | 447 | 1.01e-03 | 1.77e-02 | 0.0818 | 2.25e-02 | 3.10e-02 | -3.99e-02 | -4.39e-02 | -4.14e-02 | 4.15e-01 | 2.62e-01 | 1.48e-01 | 1.12e-01 | 1.33e-01 |
| FEMALE SEX DIFFERENTIATION | 117 | 7.46e-01 | 9.51e-01 | 0.0818 | 4.47e-02 | 3.25e-02 | 1.56e-02 | 2.88e-02 | 5.06e-02 | 4.04e-01 | 5.43e-01 | 7.71e-01 | 5.91e-01 | 3.44e-01 |
| RAS PROTEIN SIGNAL TRANSDUCTION | 319 | 3.82e-01 | 7.78e-01 | 0.0816 | 2.26e-02 | 3.12e-02 | 2.77e-02 | 4.57e-02 | 4.82e-02 | 4.88e-01 | 3.39e-01 | 3.95e-01 | 1.61e-01 | 1.39e-01 |
| POSITIVE REGULATION OF HUMORAL IMMUNE RESPONSE MEDIATED BY CIRCULATING IMMUNOGLOBULIN | 7 | 9.98e-01 | 1.00e+00 | 0.0816 | 2.48e-02 | 6.49e-02 | 4.22e-02 | -5.89e-03 | 3.49e-03 | 9.09e-01 | 7.66e-01 | 8.47e-01 | 9.78e-01 | 9.87e-01 |
| POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY | 98 | 7.95e-01 | 9.65e-01 | 0.0815 | -3.97e-02 | -1.92e-02 | -3.01e-02 | -5.22e-02 | 3.25e-02 | 4.97e-01 | 7.42e-01 | 6.07e-01 | 3.72e-01 | 5.79e-01 |
| NEGATIVE REGULATION OF LOCOMOTION | 395 | 3.47e-01 | 7.50e-01 | 0.0814 | -4.32e-02 | -2.12e-02 | -4.49e-02 | -3.93e-02 | -2.76e-02 | 1.41e-01 | 4.69e-01 | 1.26e-01 | 1.80e-01 | 3.46e-01 |
| ENDOCYTOSIS | 684 | 2.34e-03 | 3.45e-02 | 0.0813 | 5.52e-02 | 5.04e-02 | -5.49e-03 | 8.65e-03 | -3.03e-02 | 1.38e-02 | 2.45e-02 | 8.07e-01 | 7.00e-01 | 1.76e-01 |
| ORGANIC CATION TRANSPORT | 62 | 7.94e-01 | 9.65e-01 | 0.0813 | -2.84e-02 | -2.00e-02 | 1.78e-02 | -3.48e-02 | 6.23e-02 | 6.99e-01 | 7.85e-01 | 8.09e-01 | 6.36e-01 | 3.96e-01 |
| RECEPTOR METABOLIC PROCESS | 71 | 8.87e-01 | 9.80e-01 | 0.0812 | 1.87e-02 | 4.00e-02 | 3.61e-02 | 5.64e-02 | 1.27e-02 | 7.85e-01 | 5.60e-01 | 5.99e-01 | 4.11e-01 | 8.54e-01 |
| REGULATION OF EXOCYTOSIS | 178 | 5.70e-01 | 8.82e-01 | 0.0811 | 2.71e-02 | 6.06e-02 | 4.15e-02 | 8.92e-03 | 1.89e-02 | 5.33e-01 | 1.63e-01 | 3.39e-01 | 8.37e-01 | 6.63e-01 |
| REGULATION OF ACTOMYOSIN STRUCTURE ORGANIZATION | 101 | 8.79e-01 | 9.79e-01 | 0.0810 | 5.30e-02 | 2.50e-02 | 1.86e-02 | 4.43e-02 | 2.88e-02 | 3.58e-01 | 6.64e-01 | 7.46e-01 | 4.42e-01 | 6.17e-01 |
| FC RECEPTOR SIGNALING PATHWAY | 54 | 5.99e-01 | 8.98e-01 | 0.0810 | 2.96e-02 | -3.96e-02 | -6.07e-02 | -1.99e-02 | -4.63e-03 | 7.06e-01 | 6.15e-01 | 4.40e-01 | 8.00e-01 | 9.53e-01 |
| REGULATION OF DENDRITIC CELL CHEMOTAXIS | 11 | 9.86e-01 | 9.97e-01 | 0.0809 | 5.05e-02 | -2.38e-02 | 1.79e-02 | 5.31e-02 | 1.65e-02 | 7.72e-01 | 8.91e-01 | 9.18e-01 | 7.60e-01 | 9.24e-01 |
| POSITIVE REGULATION OF LAMELLIPODIUM ORGANIZATION | 34 | 9.11e-01 | 9.85e-01 | 0.0808 | 2.47e-02 | -1.14e-02 | -1.77e-02 | 4.24e-02 | -6.06e-02 | 8.03e-01 | 9.08e-01 | 8.58e-01 | 6.69e-01 | 5.41e-01 |
| GLUCOSE IMPORT | 75 | 5.20e-01 | 8.57e-01 | 0.0808 | -3.19e-02 | 1.49e-03 | -1.71e-03 | 2.04e-02 | 7.13e-02 | 6.33e-01 | 9.82e-01 | 9.80e-01 | 7.60e-01 | 2.86e-01 |
| DNA DEALKYLATION | 37 | 7.63e-01 | 9.54e-01 | 0.0807 | 2.76e-02 | -4.01e-02 | -2.10e-02 | 5.38e-02 | -2.83e-02 | 7.72e-01 | 6.73e-01 | 8.25e-01 | 5.71e-01 | 7.66e-01 |
| FERTILIZATION | 194 | 6.18e-01 | 9.07e-01 | 0.0806 | -5.02e-02 | -1.39e-02 | -3.35e-02 | -4.85e-02 | -1.73e-02 | 2.28e-01 | 7.38e-01 | 4.22e-01 | 2.44e-01 | 6.78e-01 |
| POSITIVE REGULATION OF ORGANIC ACID TRANSPORT | 44 | 9.37e-01 | 9.92e-01 | 0.0805 | -4.54e-02 | -7.13e-03 | -2.03e-02 | -5.90e-02 | 2.21e-02 | 6.03e-01 | 9.35e-01 | 8.16e-01 | 4.99e-01 | 7.99e-01 |
| POSITIVE REGULATION OF PLASMA MEMBRANE BOUNDED CELL PROJECTION ASSEMBLY | 104 | 4.19e-01 | 8.00e-01 | 0.0805 | 2.49e-02 | 3.30e-02 | 1.38e-02 | 6.77e-02 | -1.03e-03 | 6.60e-01 | 5.61e-01 | 8.08e-01 | 2.33e-01 | 9.86e-01 |
| RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 287 | 7.71e-01 | 9.56e-01 | 0.0804 | 3.91e-02 | 3.49e-02 | 2.88e-02 | 4.34e-02 | 3.17e-02 | 2.54e-01 | 3.09e-01 | 4.02e-01 | 2.06e-01 | 3.55e-01 |
| RESPONSE TO PEPTIDE HORMONE | 415 | 1.83e-02 | 1.58e-01 | 0.0804 | 7.46e-03 | 3.55e-02 | 1.53e-02 | 2.13e-02 | 6.68e-02 | 7.94e-01 | 2.15e-01 | 5.93e-01 | 4.57e-01 | 1.96e-02 |
| INFLAMMATORY RESPONSE TO WOUNDING | 27 | 7.79e-01 | 9.59e-01 | 0.0803 | -1.41e-02 | 7.12e-02 | 5.93e-03 | -1.64e-02 | 2.95e-02 | 8.99e-01 | 5.22e-01 | 9.57e-01 | 8.83e-01 | 7.91e-01 |
| GLUCAN METABOLIC PROCESS | 73 | 7.64e-01 | 9.54e-01 | 0.0802 | -5.57e-02 | -3.43e-02 | 1.92e-02 | 7.40e-03 | 4.17e-02 | 4.11e-01 | 6.13e-01 | 7.77e-01 | 9.13e-01 | 5.37e-01 |
| NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 1192 | 1.36e-01 | 4.99e-01 | 0.0801 | 4.16e-02 | 4.79e-02 | 3.24e-02 | 3.28e-02 | 1.61e-02 | 1.54e-02 | 5.29e-03 | 5.94e-02 | 5.66e-02 | 3.49e-01 |
| TISSUE REGENERATION | 73 | 9.65e-01 | 9.94e-01 | 0.0801 | -5.42e-02 | -2.81e-02 | -3.27e-02 | -4.03e-02 | 2.00e-03 | 4.24e-01 | 6.78e-01 | 6.29e-01 | 5.52e-01 | 9.76e-01 |
| IMMUNE RESPONSE TO TUMOR CELL | 26 | 8.39e-01 | 9.73e-01 | 0.0800 | -4.91e-02 | 2.10e-03 | 3.99e-02 | 4.37e-02 | 2.21e-02 | 6.65e-01 | 9.85e-01 | 7.25e-01 | 7.00e-01 | 8.46e-01 |
| SPHINGOLIPID METABOLIC PROCESS | 162 | 8.52e-01 | 9.76e-01 | 0.0798 | 3.98e-02 | 2.55e-02 | 4.73e-02 | 3.69e-02 | 2.30e-02 | 3.82e-01 | 5.75e-01 | 2.99e-01 | 4.18e-01 | 6.13e-01 |
| HEART PROCESS | 245 | 4.02e-02 | 2.59e-01 | 0.0798 | -4.46e-02 | 1.07e-02 | 1.99e-02 | -4.78e-02 | 3.97e-02 | 2.29e-01 | 7.73e-01 | 5.92e-01 | 1.97e-01 | 2.84e-01 |
| REGULATION OF RENAL SYSTEM PROCESS | 21 | 8.78e-01 | 9.79e-01 | 0.0797 | -3.79e-02 | 1.88e-02 | 4.17e-02 | -5.23e-02 | 9.28e-03 | 7.64e-01 | 8.81e-01 | 7.41e-01 | 6.78e-01 | 9.41e-01 |
| TELOMERIC LOOP DISASSEMBLY | 9 | 9.83e-01 | 9.96e-01 | 0.0797 | -4.06e-03 | 4.19e-02 | 2.33e-03 | 3.46e-02 | 5.81e-02 | 9.83e-01 | 8.28e-01 | 9.90e-01 | 8.57e-01 | 7.63e-01 |
| ANTIMICROBIAL HUMORAL IMMUNE RESPONSE MEDIATED BY ANTIMICROBIAL PEPTIDE | 79 | 3.21e-01 | 7.32e-01 | 0.0796 | 1.65e-02 | 4.21e-02 | -6.74e-03 | -6.29e-02 | -1.68e-02 | 8.00e-01 | 5.17e-01 | 9.18e-01 | 3.34e-01 | 7.96e-01 |
| REGULATION OF MUSCLE SYSTEM PROCESS | 239 | 1.78e-02 | 1.55e-01 | 0.0793 | -1.32e-02 | 4.30e-02 | 4.58e-02 | -3.03e-02 | 3.53e-02 | 7.25e-01 | 2.52e-01 | 2.23e-01 | 4.20e-01 | 3.47e-01 |
| POSITIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 60 | 6.99e-01 | 9.31e-01 | 0.0792 | 5.23e-03 | -2.69e-02 | 6.70e-03 | 5.71e-02 | 4.72e-02 | 9.44e-01 | 7.19e-01 | 9.28e-01 | 4.45e-01 | 5.27e-01 |
| OUTFLOW TRACT SEPTUM MORPHOGENESIS | 26 | 8.15e-01 | 9.69e-01 | 0.0792 | -6.38e-02 | -2.61e-02 | 7.75e-04 | 3.31e-02 | 2.06e-02 | 5.73e-01 | 8.18e-01 | 9.95e-01 | 7.70e-01 | 8.56e-01 |
| NEURONAL STEM CELL POPULATION MAINTENANCE | 23 | 8.92e-01 | 9.81e-01 | 0.0792 | -6.87e-03 | -2.22e-02 | -1.41e-02 | 5.11e-02 | 5.41e-02 | 9.55e-01 | 8.54e-01 | 9.07e-01 | 6.72e-01 | 6.53e-01 |
| REGULATION OF CARDIAC MUSCLE ADAPTATION | 17 | 9.70e-01 | 9.95e-01 | 0.0792 | -3.75e-02 | -3.71e-02 | 1.51e-02 | -4.82e-02 | 3.06e-02 | 7.89e-01 | 7.91e-01 | 9.14e-01 | 7.31e-01 | 8.27e-01 |
| LAMELLIPODIUM ORGANIZATION | 86 | 3.75e-01 | 7.74e-01 | 0.0790 | 2.32e-02 | -3.02e-02 | -2.46e-02 | 5.15e-02 | -3.92e-02 | 7.10e-01 | 6.28e-01 | 6.93e-01 | 4.09e-01 | 5.30e-01 |
| POSITIVE REGULATION OF SIGNALING | 1731 | 1.35e-02 | 1.26e-01 | 0.0790 | 3.28e-02 | 3.48e-02 | 2.97e-02 | 3.96e-02 | 3.86e-02 | 2.31e-02 | 1.59e-02 | 3.96e-02 | 6.11e-03 | 7.48e-03 |
| NEGATIVE REGULATION OF AMIDE METABOLIC PROCESS | 329 | 8.64e-02 | 3.98e-01 | 0.0790 | 2.92e-02 | -7.80e-05 | 2.14e-02 | 6.33e-02 | 3.03e-02 | 3.62e-01 | 9.98e-01 | 5.05e-01 | 4.82e-02 | 3.46e-01 |
| HOMEOSTATIC PROCESS | 1660 | 9.64e-03 | 9.89e-02 | 0.0788 | 2.63e-02 | 4.80e-02 | 3.77e-02 | 2.68e-02 | 3.28e-02 | 7.43e-02 | 1.12e-03 | 1.05e-02 | 6.93e-02 | 2.60e-02 |
| GLYCOSPHINGOLIPID METABOLIC PROCESS | 62 | 4.38e-01 | 8.10e-01 | 0.0784 | 1.29e-02 | 3.26e-02 | 4.43e-02 | -2.19e-02 | -4.97e-02 | 8.61e-01 | 6.57e-01 | 5.46e-01 | 7.66e-01 | 4.98e-01 |
| MULTICELLULAR ORGANISMAL LEVEL CHEMICAL HOMEOSTASIS | 73 | 6.80e-01 | 9.28e-01 | 0.0783 | -4.14e-02 | -2.26e-02 | 5.22e-03 | -5.98e-02 | 1.73e-02 | 5.40e-01 | 7.38e-01 | 9.39e-01 | 3.77e-01 | 7.98e-01 |
| REGULATION OF ACUTE INFLAMMATORY RESPONSE | 48 | 8.13e-01 | 9.68e-01 | 0.0783 | 2.35e-03 | 1.90e-02 | -2.29e-03 | 1.94e-02 | 7.33e-02 | 9.78e-01 | 8.19e-01 | 9.78e-01 | 8.16e-01 | 3.79e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO MEMBRANE | 171 | 9.06e-01 | 9.84e-01 | 0.0781 | 1.83e-02 | 3.94e-02 | 4.68e-02 | 3.45e-02 | 2.91e-02 | 6.80e-01 | 3.74e-01 | 2.91e-01 | 4.37e-01 | 5.12e-01 |
| AZOLE TRANSMEMBRANE TRANSPORT | 13 | 9.52e-01 | 9.94e-01 | 0.0781 | -2.13e-02 | 9.97e-03 | -1.09e-02 | 3.60e-02 | 6.43e-02 | 8.94e-01 | 9.50e-01 | 9.46e-01 | 8.22e-01 | 6.88e-01 |
| SPONTANEOUS SYNAPTIC TRANSMISSION | 14 | 9.52e-01 | 9.94e-01 | 0.0781 | -3.52e-03 | 4.41e-02 | 4.77e-02 | -2.99e-02 | -3.10e-02 | 9.82e-01 | 7.75e-01 | 7.57e-01 | 8.46e-01 | 8.41e-01 |
| CARBOHYDRATE HOMEOSTASIS | 248 | 1.09e-01 | 4.51e-01 | 0.0780 | -1.06e-02 | 5.14e-02 | 4.37e-02 | 4.04e-03 | 3.76e-02 | 7.74e-01 | 1.63e-01 | 2.36e-01 | 9.13e-01 | 3.08e-01 |
| REGULATION OF SYNAPTIC PLASTICITY | 204 | 1.65e-01 | 5.44e-01 | 0.0780 | -7.94e-03 | 5.56e-02 | 3.89e-02 | 4.40e-03 | 3.74e-02 | 8.45e-01 | 1.71e-01 | 3.38e-01 | 9.14e-01 | 3.57e-01 |
| PROTEOGLYCAN METABOLIC PROCESS | 86 | 5.48e-01 | 8.73e-01 | 0.0780 | 9.92e-03 | 6.90e-02 | 2.49e-02 | 2.24e-02 | 1.00e-02 | 8.74e-01 | 2.69e-01 | 6.90e-01 | 7.20e-01 | 8.72e-01 |
| RESPONSE TO CARBOHYDRATE | 225 | 3.50e-01 | 7.52e-01 | 0.0779 | 1.19e-02 | 5.05e-02 | 4.42e-02 | 1.10e-03 | 3.77e-02 | 7.58e-01 | 1.92e-01 | 2.53e-01 | 9.77e-01 | 3.30e-01 |
| PROTEOGLYCAN BIOSYNTHETIC PROCESS | 63 | 5.35e-01 | 8.65e-01 | 0.0779 | 1.74e-02 | 7.19e-02 | -7.13e-03 | -1.85e-03 | -2.32e-02 | 8.11e-01 | 3.24e-01 | 9.22e-01 | 9.80e-01 | 7.50e-01 |
| REGULATION OF DEFENSE RESPONSE | 786 | 8.66e-03 | 9.22e-02 | 0.0778 | 5.73e-02 | 3.90e-02 | 3.03e-03 | 3.48e-02 | -5.15e-03 | 6.25e-03 | 6.30e-02 | 8.85e-01 | 9.66e-02 | 8.06e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL FISSION | 21 | 9.07e-01 | 9.84e-01 | 0.0778 | 7.41e-02 | 9.03e-03 | 1.99e-02 | 8.96e-03 | -5.99e-05 | 5.56e-01 | 9.43e-01 | 8.75e-01 | 9.43e-01 | 1.00e+00 |
| POSTSYNAPTIC MODULATION OF CHEMICAL SYNAPTIC TRANSMISSION | 27 | 9.66e-01 | 9.94e-01 | 0.0775 | 5.26e-02 | 4.91e-02 | -8.70e-03 | 2.73e-02 | -2.30e-03 | 6.36e-01 | 6.59e-01 | 9.38e-01 | 8.06e-01 | 9.84e-01 |
| MUSCLE ADAPTATION | 117 | 1.23e-01 | 4.76e-01 | 0.0775 | -2.34e-03 | 5.07e-02 | 3.69e-02 | -3.92e-02 | -2.31e-02 | 9.65e-01 | 3.44e-01 | 4.90e-01 | 4.64e-01 | 6.66e-01 |
| REGULATION OF MICROTUBULE POLYMERIZATION | 59 | 7.53e-01 | 9.51e-01 | 0.0775 | 5.18e-03 | 2.62e-02 | 3.21e-03 | 2.70e-02 | 6.75e-02 | 9.45e-01 | 7.28e-01 | 9.66e-01 | 7.20e-01 | 3.70e-01 |
| POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 120 | 4.92e-01 | 8.42e-01 | 0.0774 | -3.08e-02 | 6.77e-04 | -2.63e-02 | -6.09e-02 | 2.54e-02 | 5.60e-01 | 9.90e-01 | 6.18e-01 | 2.49e-01 | 6.31e-01 |
| PEPTIDE TRANSPORT | 254 | 2.15e-01 | 6.11e-01 | 0.0774 | 1.52e-02 | 6.26e-02 | 3.29e-02 | 8.91e-03 | 2.61e-02 | 6.76e-01 | 8.59e-02 | 3.66e-01 | 8.07e-01 | 4.74e-01 |
| ORGANIC ACID METABOLIC PROCESS | 937 | 4.99e-02 | 2.92e-01 | 0.0772 | 4.58e-02 | 3.94e-02 | 2.02e-02 | 3.30e-02 | 2.86e-02 | 1.74e-02 | 4.10e-02 | 2.94e-01 | 8.72e-02 | 1.38e-01 |
| REGULATION OF GLUCOSE IMPORT | 58 | 6.64e-01 | 9.22e-01 | 0.0771 | -6.44e-02 | -2.31e-02 | -3.39e-02 | -7.29e-03 | 7.86e-03 | 3.96e-01 | 7.60e-01 | 6.55e-01 | 9.23e-01 | 9.18e-01 |
| AXO DENDRITIC PROTEIN TRANSPORT | 9 | 9.87e-01 | 9.97e-01 | 0.0771 | -5.56e-03 | -2.74e-02 | 4.28e-02 | 5.70e-02 | -9.06e-03 | 9.77e-01 | 8.87e-01 | 8.24e-01 | 7.67e-01 | 9.62e-01 |
| REGULATION OF TRANSPORT | 1711 | 2.27e-03 | 3.37e-02 | 0.0771 | 3.42e-02 | 5.07e-02 | 3.35e-02 | 1.84e-02 | 2.74e-02 | 1.85e-02 | 4.88e-04 | 2.12e-02 | 2.06e-01 | 5.94e-02 |
| POSITIVE REGULATION OF PROTEIN ACETYLATION | 24 | 8.61e-01 | 9.78e-01 | 0.0771 | -3.57e-03 | -9.23e-03 | 1.38e-03 | 6.55e-02 | -3.94e-02 | 9.76e-01 | 9.38e-01 | 9.91e-01 | 5.79e-01 | 7.38e-01 |
| REGULATION OF GOLGI ORGANIZATION | 17 | 9.43e-01 | 9.93e-01 | 0.0771 | 1.69e-02 | 1.01e-03 | -5.52e-03 | 6.95e-02 | 2.81e-02 | 9.04e-01 | 9.94e-01 | 9.69e-01 | 6.20e-01 | 8.41e-01 |
| PYRIDINE CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 31 | 9.97e-01 | 1.00e+00 | 0.0770 | 2.90e-02 | 3.47e-02 | 3.18e-02 | 4.86e-02 | 2.28e-02 | 7.80e-01 | 7.38e-01 | 7.59e-01 | 6.40e-01 | 8.26e-01 |
| REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 175 | 9.13e-01 | 9.86e-01 | 0.0770 | 1.79e-02 | 2.40e-02 | 3.68e-02 | 2.93e-02 | 5.31e-02 | 6.82e-01 | 5.83e-01 | 4.01e-01 | 5.04e-01 | 2.26e-01 |
| REGULATION OF RECEPTOR INTERNALIZATION | 60 | 9.77e-01 | 9.96e-01 | 0.0769 | 5.38e-02 | 3.21e-02 | 1.35e-02 | 3.79e-02 | -1.90e-02 | 4.71e-01 | 6.67e-01 | 8.57e-01 | 6.12e-01 | 7.99e-01 |
| REGULATION OF VESICLE MEDIATED TRANSPORT | 507 | 2.47e-01 | 6.53e-01 | 0.0769 | 4.12e-02 | 5.49e-02 | 2.63e-02 | 1.85e-02 | 1.24e-02 | 1.12e-01 | 3.41e-02 | 3.10e-01 | 4.75e-01 | 6.32e-01 |
| PROTEIN LOCALIZATION TO NON MOTILE CILIUM | 12 | 9.90e-01 | 9.98e-01 | 0.0768 | 3.44e-03 | -2.51e-02 | 4.86e-02 | 3.08e-02 | 4.41e-02 | 9.84e-01 | 8.80e-01 | 7.71e-01 | 8.53e-01 | 7.92e-01 |
| EXPORT FROM CELL | 870 | 7.82e-03 | 8.53e-02 | 0.0768 | 2.93e-02 | 5.75e-02 | 3.14e-02 | 1.02e-02 | 2.51e-02 | 1.42e-01 | 3.96e-03 | 1.15e-01 | 6.08e-01 | 2.09e-01 |
| REGULATION OF POSTSYNAPTIC MEMBRANE POTENTIAL | 141 | 4.81e-01 | 8.36e-01 | 0.0768 | -2.98e-02 | 2.27e-02 | 4.26e-02 | -5.77e-05 | 5.17e-02 | 5.41e-01 | 6.42e-01 | 3.82e-01 | 9.99e-01 | 2.89e-01 |
| NEGATIVE REGULATION OF CALCIUM ION TRANSPORT | 66 | 6.85e-01 | 9.30e-01 | 0.0766 | -3.77e-02 | 2.90e-02 | 3.80e-02 | -2.02e-02 | 4.18e-02 | 5.96e-01 | 6.84e-01 | 5.93e-01 | 7.76e-01 | 5.57e-01 |
| NEGATIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 133 | 6.99e-01 | 9.31e-01 | 0.0765 | 1.91e-02 | 5.08e-02 | 2.39e-02 | 2.14e-02 | 4.33e-02 | 7.04e-01 | 3.12e-01 | 6.34e-01 | 6.71e-01 | 3.88e-01 |
| CELL ADHESION | 1467 | 2.71e-02 | 2.03e-01 | 0.0765 | -4.19e-02 | -2.24e-02 | -3.61e-02 | -4.12e-02 | -2.42e-02 | 7.15e-03 | 1.51e-01 | 2.06e-02 | 8.26e-03 | 1.21e-01 |
| POSITIVE REGULATION OF LIPID LOCALIZATION | 111 | 4.68e-01 | 8.28e-01 | 0.0765 | -1.26e-02 | 1.01e-02 | -5.37e-02 | -4.94e-02 | -1.60e-02 | 8.18e-01 | 8.54e-01 | 3.28e-01 | 3.68e-01 | 7.71e-01 |
| POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 126 | 9.49e-01 | 9.94e-01 | 0.0764 | 1.90e-02 | 3.15e-02 | 3.68e-02 | 2.29e-02 | 5.10e-02 | 7.13e-01 | 5.41e-01 | 4.75e-01 | 6.57e-01 | 3.23e-01 |
| RESPIRATORY SYSTEM PROCESS | 37 | 8.70e-01 | 9.78e-01 | 0.0763 | -1.26e-02 | 4.26e-03 | -2.46e-02 | -6.99e-02 | 1.25e-02 | 8.95e-01 | 9.64e-01 | 7.96e-01 | 4.62e-01 | 8.95e-01 |
| RAB PROTEIN SIGNAL TRANSDUCTION | 16 | 9.91e-01 | 9.98e-01 | 0.0763 | 4.22e-02 | -2.25e-03 | 1.92e-02 | 5.50e-02 | -2.52e-02 | 7.70e-01 | 9.88e-01 | 8.94e-01 | 7.03e-01 | 8.62e-01 |
| MONOATOMIC ION TRANSPORT | 1196 | 1.58e-04 | 3.89e-03 | 0.0762 | -4.40e-02 | -9.71e-03 | -2.12e-02 | -5.77e-02 | 1.98e-03 | 1.03e-02 | 5.72e-01 | 2.18e-01 | 7.76e-04 | 9.08e-01 |
| DEVELOPMENT OF PRIMARY FEMALE SEXUAL CHARACTERISTICS | 102 | 8.09e-01 | 9.68e-01 | 0.0762 | 5.53e-02 | 3.11e-02 | 1.23e-02 | 2.61e-02 | 3.09e-02 | 3.35e-01 | 5.87e-01 | 8.30e-01 | 6.49e-01 | 5.90e-01 |
| NEUROTRANSMITTER SECRETION | 138 | 4.86e-01 | 8.38e-01 | 0.0762 | -1.64e-02 | 1.94e-02 | 4.57e-02 | -1.20e-02 | 5.41e-02 | 7.40e-01 | 6.94e-01 | 3.54e-01 | 8.08e-01 | 2.72e-01 |
| ORGANIC HYDROXY COMPOUND TRANSPORT | 302 | 5.23e-01 | 8.60e-01 | 0.0762 | -1.65e-02 | -6.39e-03 | -4.33e-02 | -3.31e-02 | -5.01e-02 | 6.22e-01 | 8.49e-01 | 1.95e-01 | 3.22e-01 | 1.34e-01 |
| AXON GUIDANCE | 223 | 3.37e-01 | 7.43e-01 | 0.0761 | -4.63e-02 | -1.13e-02 | 7.30e-03 | -3.76e-02 | 4.54e-02 | 2.33e-01 | 7.71e-01 | 8.51e-01 | 3.33e-01 | 2.43e-01 |
| POSITIVE REGULATION OF IMMUNE RESPONSE | 700 | 1.53e-01 | 5.23e-01 | 0.0761 | 4.58e-02 | 3.20e-02 | 1.92e-02 | 4.80e-02 | -2.03e-03 | 3.91e-02 | 1.49e-01 | 3.86e-01 | 3.06e-02 | 9.27e-01 |
| MITOCHONDRIAL FISSION | 40 | 8.34e-01 | 9.73e-01 | 0.0760 | 6.55e-02 | 2.07e-03 | 1.62e-02 | 2.45e-02 | 2.51e-02 | 4.74e-01 | 9.82e-01 | 8.59e-01 | 7.89e-01 | 7.84e-01 |
| FATTY ACID METABOLIC PROCESS | 388 | 4.86e-01 | 8.38e-01 | 0.0759 | 3.63e-02 | 4.41e-02 | 2.40e-02 | 2.79e-02 | 3.36e-02 | 2.19e-01 | 1.35e-01 | 4.16e-01 | 3.45e-01 | 2.56e-01 |
| ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 979 | 1.54e-02 | 1.39e-01 | 0.0758 | 8.96e-03 | 2.42e-02 | 2.77e-02 | 3.29e-02 | 5.69e-02 | 6.35e-01 | 1.99e-01 | 1.42e-01 | 8.16e-02 | 2.58e-03 |
| REGULATION OF WNT PROTEIN SECRETION | 5 | 9.99e-01 | 1.00e+00 | 0.0758 | 9.67e-03 | -9.29e-03 | 6.32e-03 | -2.20e-02 | 7.11e-02 | 9.70e-01 | 9.71e-01 | 9.80e-01 | 9.32e-01 | 7.83e-01 |
| WNT PROTEIN SECRETION | 5 | 9.99e-01 | 1.00e+00 | 0.0758 | 9.67e-03 | -9.29e-03 | 6.32e-03 | -2.20e-02 | 7.11e-02 | 9.70e-01 | 9.71e-01 | 9.80e-01 | 9.32e-01 | 7.83e-01 |
| REGULATION OF MUSCLE ADAPTATION | 92 | 2.67e-01 | 6.75e-01 | 0.0757 | 1.05e-02 | 5.06e-02 | 3.98e-02 | -3.56e-02 | -1.43e-02 | 8.61e-01 | 4.01e-01 | 5.10e-01 | 5.55e-01 | 8.12e-01 |
| SUBSTRATE INDEPENDENT TELENCEPHALIC TANGENTIAL MIGRATION | 10 | 9.87e-01 | 9.97e-01 | 0.0757 | 5.14e-02 | 3.69e-02 | -1.33e-02 | -3.52e-02 | -1.75e-02 | 7.78e-01 | 8.40e-01 | 9.42e-01 | 8.47e-01 | 9.24e-01 |
| CELL JUNCTION ASSEMBLY | 423 | 2.78e-01 | 6.88e-01 | 0.0755 | -5.15e-02 | -1.90e-02 | -2.66e-02 | -3.90e-02 | -2.13e-02 | 6.95e-02 | 5.03e-01 | 3.47e-01 | 1.69e-01 | 4.52e-01 |
| 3 PHOSPHOADENOSINE 5 PHOSPHOSULFATE METABOLIC PROCESS | 15 | 9.39e-01 | 9.92e-01 | 0.0754 | 2.68e-03 | -3.28e-02 | -2.88e-02 | 5.40e-02 | 2.93e-02 | 9.86e-01 | 8.26e-01 | 8.47e-01 | 7.17e-01 | 8.44e-01 |
| REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 115 | 7.78e-01 | 9.58e-01 | 0.0752 | 4.56e-02 | 4.79e-02 | -2.87e-03 | 1.02e-02 | -3.42e-02 | 3.98e-01 | 3.75e-01 | 9.58e-01 | 8.50e-01 | 5.27e-01 |
| NUCLEOBASE METABOLIC PROCESS | 38 | 9.12e-01 | 9.85e-01 | 0.0752 | 4.32e-02 | -1.65e-02 | -3.89e-02 | 3.37e-03 | -4.46e-02 | 6.45e-01 | 8.60e-01 | 6.78e-01 | 9.71e-01 | 6.34e-01 |
| REGULATION OF ENDOCYTOSIS | 284 | 6.64e-02 | 3.44e-01 | 0.0751 | 3.80e-02 | 5.37e-02 | -8.62e-03 | -1.70e-02 | -3.08e-02 | 2.70e-01 | 1.19e-01 | 8.03e-01 | 6.23e-01 | 3.71e-01 |
| REGULATION OF MONOATOMIC ION TRANSPORT | 545 | 1.77e-02 | 1.54e-01 | 0.0751 | -3.92e-02 | -7.37e-03 | -2.02e-02 | -5.65e-02 | 2.10e-02 | 1.17e-01 | 7.68e-01 | 4.19e-01 | 2.40e-02 | 4.01e-01 |
| NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 58 | 9.88e-01 | 9.97e-01 | 0.0751 | 3.25e-02 | 2.27e-02 | 2.87e-02 | 3.04e-02 | 4.82e-02 | 6.69e-01 | 7.65e-01 | 7.05e-01 | 6.89e-01 | 5.26e-01 |
| DEPHOSPHORYLATION | 288 | 9.87e-02 | 4.28e-01 | 0.0750 | 3.14e-02 | 4.51e-03 | 1.48e-02 | 6.56e-02 | 9.25e-03 | 3.59e-01 | 8.95e-01 | 6.65e-01 | 5.52e-02 | 7.87e-01 |
| REPRODUCTION | 1419 | 2.65e-01 | 6.73e-01 | 0.0750 | 3.55e-02 | 3.69e-02 | 3.47e-02 | 3.54e-02 | 2.32e-02 | 2.51e-02 | 1.98e-02 | 2.83e-02 | 2.54e-02 | 1.43e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 2 PRODUCTION | 33 | 9.40e-01 | 9.92e-01 | 0.0749 | 5.35e-02 | 1.53e-02 | -3.05e-02 | -7.61e-03 | -3.89e-02 | 5.95e-01 | 8.79e-01 | 7.61e-01 | 9.40e-01 | 6.99e-01 |
| ADAPTATION OF SIGNALING PATHWAY | 20 | 9.59e-01 | 9.94e-01 | 0.0747 | 1.89e-02 | -1.45e-02 | 1.21e-02 | 6.82e-02 | -1.50e-02 | 8.83e-01 | 9.11e-01 | 9.25e-01 | 5.98e-01 | 9.08e-01 |
| REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 181 | 1.72e-01 | 5.56e-01 | 0.0747 | 1.28e-02 | -3.87e-03 | 2.58e-02 | 6.88e-02 | 1.60e-03 | 7.66e-01 | 9.28e-01 | 5.49e-01 | 1.10e-01 | 9.70e-01 |
| CELLULAR LIPID METABOLIC PROCESS | 972 | 3.65e-01 | 7.64e-01 | 0.0746 | 3.75e-02 | 3.85e-02 | 3.50e-02 | 2.90e-02 | 2.46e-02 | 4.74e-02 | 4.22e-02 | 6.45e-02 | 1.26e-01 | 1.93e-01 |
| REGULATION OF CALCIUM MEDIATED SIGNALING | 81 | 7.84e-01 | 9.61e-01 | 0.0745 | 9.25e-03 | -3.14e-02 | -5.65e-02 | -3.02e-02 | -1.96e-02 | 8.86e-01 | 6.25e-01 | 3.80e-01 | 6.38e-01 | 7.61e-01 |
| LACTATION | 37 | 9.61e-01 | 9.94e-01 | 0.0745 | 1.07e-02 | 2.41e-02 | 3.41e-02 | -8.79e-03 | 6.02e-02 | 9.10e-01 | 8.00e-01 | 7.20e-01 | 9.26e-01 | 5.26e-01 |
| CYTOKINE PRODUCTION | 840 | 9.70e-02 | 4.24e-01 | 0.0743 | 4.69e-02 | 4.30e-02 | 1.40e-02 | 3.34e-02 | -1.26e-02 | 2.08e-02 | 3.42e-02 | 4.91e-01 | 1.00e-01 | 5.35e-01 |
| SECRETION | 926 | 6.09e-03 | 7.10e-02 | 0.0743 | 2.79e-02 | 5.52e-02 | 3.06e-02 | 8.14e-03 | 2.61e-02 | 1.49e-01 | 4.37e-03 | 1.14e-01 | 6.74e-01 | 1.77e-01 |
| MOTILE CILIUM ASSEMBLY | 64 | 8.56e-01 | 9.77e-01 | 0.0743 | -6.32e-03 | -4.48e-02 | -3.78e-02 | -4.49e-02 | -4.50e-03 | 9.30e-01 | 5.35e-01 | 6.01e-01 | 5.34e-01 | 9.50e-01 |
| NEGATIVE REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS | 65 | 7.90e-01 | 9.63e-01 | 0.0741 | 3.54e-02 | 1.51e-02 | -8.18e-04 | 1.62e-02 | 6.11e-02 | 6.21e-01 | 8.33e-01 | 9.91e-01 | 8.21e-01 | 3.94e-01 |
| MONOATOMIC CATION TRANSPORT | 997 | 1.44e-03 | 2.35e-02 | 0.0740 | -4.55e-02 | -1.17e-02 | -1.66e-02 | -5.29e-02 | 1.39e-02 | 1.51e-02 | 5.32e-01 | 3.74e-01 | 4.67e-03 | 4.57e-01 |
| POSITIVE REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 24 | 9.15e-01 | 9.86e-01 | 0.0739 | 1.66e-02 | 2.42e-02 | 4.82e-02 | -2.38e-02 | 4.15e-02 | 8.88e-01 | 8.38e-01 | 6.83e-01 | 8.40e-01 | 7.25e-01 |
| NEGATIVE REGULATION OF SMALL MOLECULE METABOLIC PROCESS | 111 | 8.28e-01 | 9.72e-01 | 0.0739 | 2.35e-02 | 5.46e-02 | 2.49e-02 | 2.58e-02 | 2.54e-02 | 6.69e-01 | 3.20e-01 | 6.50e-01 | 6.39e-01 | 6.44e-01 |
| POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 139 | 1.52e-01 | 5.21e-01 | 0.0739 | -2.52e-02 | 3.27e-02 | -3.46e-02 | -4.79e-02 | -1.63e-02 | 6.09e-01 | 5.06e-01 | 4.81e-01 | 3.29e-01 | 7.41e-01 |
| MEMORY | 120 | 6.58e-01 | 9.20e-01 | 0.0738 | -2.84e-03 | 3.69e-02 | 2.21e-02 | 1.45e-04 | 5.99e-02 | 9.57e-01 | 4.85e-01 | 6.75e-01 | 9.98e-01 | 2.57e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 61 | 9.89e-01 | 9.98e-01 | 0.0738 | 2.31e-02 | 4.55e-02 | 4.08e-02 | 3.17e-02 | 1.29e-02 | 7.55e-01 | 5.39e-01 | 5.81e-01 | 6.68e-01 | 8.61e-01 |
| GENITALIA DEVELOPMENT | 46 | 8.14e-01 | 9.69e-01 | 0.0737 | -2.45e-02 | 3.38e-02 | 5.16e-03 | -2.86e-02 | 5.34e-02 | 7.74e-01 | 6.92e-01 | 9.52e-01 | 7.37e-01 | 5.31e-01 |
| ADENYLATE CYCLASE INHIBITING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 79 | 9.63e-01 | 9.94e-01 | 0.0736 | 3.98e-02 | 4.93e-02 | 1.78e-02 | 3.16e-02 | -9.88e-03 | 5.41e-01 | 4.49e-01 | 7.85e-01 | 6.27e-01 | 8.79e-01 |
| N GLYCAN PROCESSING | 17 | 7.88e-01 | 9.63e-01 | 0.0736 | -1.29e-02 | 3.73e-02 | -2.12e-02 | 4.34e-02 | 3.90e-02 | 9.26e-01 | 7.90e-01 | 8.80e-01 | 7.57e-01 | 7.80e-01 |
| POSITIVE REGULATION OF G1 S TRANSITION OF MITOTIC CELL CYCLE | 48 | 6.70e-01 | 9.25e-01 | 0.0735 | -1.17e-02 | -4.44e-02 | -3.68e-02 | 3.32e-02 | 2.92e-02 | 8.89e-01 | 5.95e-01 | 6.60e-01 | 6.91e-01 | 7.26e-01 |
| CELLULAR KETONE METABOLIC PROCESS | 220 | 9.09e-01 | 9.85e-01 | 0.0735 | 3.89e-02 | 4.28e-02 | 2.73e-02 | 2.99e-02 | 2.05e-02 | 3.20e-01 | 2.74e-01 | 4.85e-01 | 4.45e-01 | 6.00e-01 |
| REGULATION OF LIPID METABOLIC PROCESS | 329 | 4.97e-01 | 8.45e-01 | 0.0735 | 2.86e-02 | 4.29e-02 | 2.71e-02 | 1.56e-02 | 4.20e-02 | 3.73e-01 | 1.81e-01 | 3.98e-01 | 6.26e-01 | 1.90e-01 |
| REGULATION OF CELLULAR COMPONENT SIZE | 350 | 5.48e-01 | 8.73e-01 | 0.0734 | 2.30e-02 | 4.21e-02 | 2.80e-02 | 2.93e-02 | 3.79e-02 | 4.60e-01 | 1.76e-01 | 3.68e-01 | 3.47e-01 | 2.22e-01 |
| NEGATIVE REGULATION OF DEFENSE RESPONSE | 308 | 3.27e-01 | 7.35e-01 | 0.0731 | 4.80e-02 | 5.05e-02 | 8.12e-03 | 1.99e-02 | 5.46e-03 | 1.47e-01 | 1.27e-01 | 8.06e-01 | 5.47e-01 | 8.69e-01 |
| CELLULAR RESPONSE TO FATTY ACID | 33 | 5.55e-01 | 8.77e-01 | 0.0731 | 1.34e-02 | 4.60e-02 | -4.71e-02 | -2.56e-03 | 2.86e-02 | 8.94e-01 | 6.47e-01 | 6.40e-01 | 9.80e-01 | 7.76e-01 |
| REGULATION OF CARBOHYDRATE BIOSYNTHETIC PROCESS | 102 | 2.04e-01 | 5.96e-01 | 0.0728 | -9.35e-04 | -8.57e-03 | -4.63e-02 | -3.80e-03 | 5.53e-02 | 9.87e-01 | 8.81e-01 | 4.19e-01 | 9.47e-01 | 3.34e-01 |
| INFLAMMATORY RESPONSE | 851 | 2.18e-04 | 4.99e-03 | 0.0726 | 2.02e-02 | 1.13e-02 | -4.66e-02 | -2.88e-02 | -4.17e-02 | 3.16e-01 | 5.75e-01 | 2.10e-02 | 1.53e-01 | 3.89e-02 |
| RESPONSE TO NITRIC OXIDE | 19 | 9.44e-01 | 9.93e-01 | 0.0726 | -2.07e-02 | -9.85e-03 | -5.63e-03 | 3.71e-02 | -5.78e-02 | 8.76e-01 | 9.41e-01 | 9.66e-01 | 7.80e-01 | 6.63e-01 |
| PURINE NUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 18 | 9.09e-01 | 9.85e-01 | 0.0726 | -5.51e-02 | -2.39e-02 | -8.79e-04 | 3.37e-02 | -2.28e-02 | 6.85e-01 | 8.60e-01 | 9.95e-01 | 8.05e-01 | 8.67e-01 |
| CELL CELL SIGNALING | 1630 | 3.24e-03 | 4.44e-02 | 0.0724 | 1.16e-02 | 3.86e-02 | 3.69e-02 | 1.70e-02 | 4.44e-02 | 4.34e-01 | 9.40e-03 | 1.31e-02 | 2.53e-01 | 2.80e-03 |
| POSITIVE REGULATION OF RECEPTOR SIGNALING PATHWAY VIA STAT | 50 | 5.69e-01 | 8.82e-01 | 0.0723 | -4.92e-02 | 2.53e-02 | 8.71e-03 | 1.01e-02 | 4.45e-02 | 5.47e-01 | 7.57e-01 | 9.15e-01 | 9.02e-01 | 5.86e-01 |
| CELL SUBSTRATE ADHESION | 344 | 5.55e-01 | 8.77e-01 | 0.0723 | -2.75e-02 | -2.05e-02 | -4.83e-02 | -3.44e-02 | -2.29e-02 | 3.80e-01 | 5.14e-01 | 1.24e-01 | 2.72e-01 | 4.65e-01 |
| POSTSYNAPTIC NEUROTRANSMITTER RECEPTOR INTERNALIZATION | 23 | 8.37e-01 | 9.73e-01 | 0.0722 | -1.02e-02 | 6.45e-03 | -6.23e-02 | -1.77e-02 | 2.95e-02 | 9.32e-01 | 9.57e-01 | 6.05e-01 | 8.83e-01 | 8.06e-01 |
| PROTEIN LOCALIZATION TO CELL JUNCTION | 102 | 8.05e-01 | 9.67e-01 | 0.0721 | -3.05e-02 | -1.22e-02 | -2.85e-02 | -5.31e-02 | 2.20e-02 | 5.94e-01 | 8.32e-01 | 6.19e-01 | 3.54e-01 | 7.01e-01 |
| RESPONSE TO WOUNDING | 538 | 1.26e-01 | 4.82e-01 | 0.0721 | 3.60e-02 | 5.66e-02 | 1.86e-02 | 1.63e-02 | -9.40e-03 | 1.53e-01 | 2.48e-02 | 4.62e-01 | 5.17e-01 | 7.09e-01 |
| POSITIVE REGULATION OF LIPASE ACTIVITY | 59 | 9.69e-01 | 9.95e-01 | 0.0720 | -5.75e-03 | -1.40e-02 | -4.55e-02 | -1.37e-02 | -5.20e-02 | 9.39e-01 | 8.52e-01 | 5.46e-01 | 8.56e-01 | 4.89e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 12 PRODUCTION | 18 | 9.87e-01 | 9.97e-01 | 0.0720 | -1.92e-02 | -1.29e-02 | -3.03e-02 | -2.85e-02 | 5.41e-02 | 8.88e-01 | 9.24e-01 | 8.24e-01 | 8.34e-01 | 6.91e-01 |
| POSITIVE REGULATION OF TRANSPORT | 859 | 3.72e-02 | 2.49e-01 | 0.0720 | 3.64e-02 | 5.12e-02 | 2.25e-02 | 1.55e-02 | 2.20e-02 | 7.00e-02 | 1.08e-02 | 2.63e-01 | 4.40e-01 | 2.73e-01 |
| POSITIVE REGULATION OF BEHAVIOR | 24 | 9.90e-01 | 9.98e-01 | 0.0719 | -6.71e-03 | -9.50e-03 | -5.62e-02 | -2.37e-02 | -3.62e-02 | 9.55e-01 | 9.36e-01 | 6.34e-01 | 8.40e-01 | 7.59e-01 |
| CARBOHYDRATE TRANSMEMBRANE TRANSPORT | 132 | 9.28e-02 | 4.13e-01 | 0.0716 | -2.10e-02 | 3.21e-02 | -2.99e-02 | -3.78e-02 | 3.66e-02 | 6.77e-01 | 5.24e-01 | 5.54e-01 | 4.53e-01 | 4.68e-01 |
| CELL SUBSTRATE JUNCTION ORGANIZATION | 100 | 8.34e-01 | 9.73e-01 | 0.0716 | -8.70e-03 | -3.67e-02 | -4.72e-02 | -1.97e-03 | -3.84e-02 | 8.81e-01 | 5.26e-01 | 4.14e-01 | 9.73e-01 | 5.07e-01 |
| POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 335 | 5.29e-01 | 8.62e-01 | 0.0716 | -4.24e-02 | -2.07e-02 | -3.87e-02 | -3.36e-02 | -1.63e-02 | 1.82e-01 | 5.14e-01 | 2.23e-01 | 2.90e-01 | 6.08e-01 |
| BRANCHING INVOLVED IN SALIVARY GLAND MORPHOGENESIS | 21 | 9.88e-01 | 9.97e-01 | 0.0716 | 2.59e-02 | 1.12e-02 | 2.82e-02 | 3.98e-02 | -4.42e-02 | 8.37e-01 | 9.29e-01 | 8.23e-01 | 7.52e-01 | 7.26e-01 |
| POSITIVE REGULATION OF REGULATORY T CELL DIFFERENTIATION | 21 | 9.47e-01 | 9.94e-01 | 0.0714 | -2.95e-02 | 2.70e-04 | 1.88e-02 | 5.81e-03 | -6.19e-02 | 8.15e-01 | 9.98e-01 | 8.81e-01 | 9.63e-01 | 6.23e-01 |
| POSITIVE REGULATION OF CATALYTIC ACTIVITY | 900 | 5.71e-02 | 3.16e-01 | 0.0710 | 3.92e-02 | 4.52e-02 | 1.67e-02 | 3.02e-02 | 1.68e-02 | 4.62e-02 | 2.15e-02 | 3.96e-01 | 1.24e-01 | 3.92e-01 |
| RESPONSE TO NERVE GROWTH FACTOR | 47 | 9.42e-01 | 9.92e-01 | 0.0709 | 2.76e-02 | -5.76e-03 | 1.52e-02 | 5.24e-02 | 3.55e-02 | 7.43e-01 | 9.46e-01 | 8.57e-01 | 5.34e-01 | 6.74e-01 |
| ENDODERMAL CELL DIFFERENTIATION | 48 | 8.25e-01 | 9.72e-01 | 0.0708 | 4.69e-03 | 2.36e-02 | -2.36e-03 | 2.49e-02 | 6.17e-02 | 9.55e-01 | 7.77e-01 | 9.77e-01 | 7.65e-01 | 4.60e-01 |
| LYMPH VESSEL MORPHOGENESIS | 23 | 9.78e-01 | 9.96e-01 | 0.0708 | -4.92e-02 | -6.95e-03 | 3.02e-02 | 6.34e-03 | 3.98e-02 | 6.83e-01 | 9.54e-01 | 8.02e-01 | 9.58e-01 | 7.41e-01 |
| BLOOD VESSEL REMODELING | 46 | 8.90e-01 | 9.81e-01 | 0.0705 | 5.93e-03 | 3.39e-02 | 2.91e-02 | 7.18e-03 | -5.37e-02 | 9.45e-01 | 6.91e-01 | 7.33e-01 | 9.33e-01 | 5.29e-01 |
| NEGATIVE REGULATION OF CELL CELL ADHESION | 198 | 6.77e-01 | 9.28e-01 | 0.0705 | 4.20e-02 | 1.52e-02 | 1.66e-02 | 3.64e-02 | 3.70e-02 | 3.08e-01 | 7.13e-01 | 6.87e-01 | 3.77e-01 | 3.70e-01 |
| REGULATION OF POSTSYNAPTIC MEMBRANE NEUROTRANSMITTER RECEPTOR LEVELS | 81 | 6.91e-01 | 9.31e-01 | 0.0703 | -1.35e-02 | -3.73e-03 | -2.95e-02 | -4.98e-02 | 3.74e-02 | 8.33e-01 | 9.54e-01 | 6.46e-01 | 4.39e-01 | 5.61e-01 |
| REGULATION OF DNA METHYLATION | 20 | 9.78e-01 | 9.96e-01 | 0.0703 | -1.29e-02 | -1.13e-02 | 5.19e-03 | 4.16e-02 | 5.38e-02 | 9.21e-01 | 9.30e-01 | 9.68e-01 | 7.48e-01 | 6.77e-01 |
| AXON DEVELOPMENT | 481 | 2.77e-01 | 6.86e-01 | 0.0702 | -3.99e-03 | 1.38e-02 | 2.72e-02 | 1.13e-02 | 6.21e-02 | 8.81e-01 | 6.03e-01 | 3.07e-01 | 6.72e-01 | 1.96e-02 |
| MOLTING CYCLE | 113 | 8.65e-01 | 9.78e-01 | 0.0701 | 2.32e-02 | 2.99e-02 | 2.30e-02 | 5.02e-02 | 2.08e-02 | 6.70e-01 | 5.83e-01 | 6.73e-01 | 3.56e-01 | 7.03e-01 |
| ACTIN POLYMERIZATION OR DEPOLYMERIZATION | 186 | 7.59e-01 | 9.52e-01 | 0.0700 | 4.31e-02 | 4.40e-02 | 1.33e-02 | 2.38e-02 | 1.91e-02 | 3.10e-01 | 3.01e-01 | 7.54e-01 | 5.76e-01 | 6.53e-01 |
| BLOOD VESSEL MORPHOGENESIS | 679 | 2.02e-02 | 1.68e-01 | 0.0700 | 1.58e-02 | 4.41e-02 | 2.25e-02 | 6.35e-03 | 4.65e-02 | 4.82e-01 | 5.00e-02 | 3.17e-01 | 7.78e-01 | 3.90e-02 |
| MALE MEIOTIC NUCLEAR DIVISION | 54 | 7.83e-01 | 9.61e-01 | 0.0700 | -4.06e-02 | -3.45e-02 | 3.67e-03 | 8.87e-03 | -4.43e-02 | 6.06e-01 | 6.61e-01 | 9.63e-01 | 9.10e-01 | 5.73e-01 |
| REGULATION OF MYELINATION | 45 | 9.54e-01 | 9.94e-01 | 0.0700 | 3.18e-02 | 2.34e-02 | -3.12e-02 | -1.00e-02 | -4.76e-02 | 7.12e-01 | 7.86e-01 | 7.18e-01 | 9.07e-01 | 5.80e-01 |
| REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 144 | 7.21e-01 | 9.39e-01 | 0.0700 | -3.44e-02 | -1.38e-02 | 1.53e-02 | -2.17e-02 | 5.30e-02 | 4.75e-01 | 7.75e-01 | 7.51e-01 | 6.53e-01 | 2.72e-01 |
| REGULATION OF GLUCOSE TRANSMEMBRANE TRANSPORT | 76 | 4.81e-01 | 8.35e-01 | 0.0698 | -4.65e-02 | -5.08e-03 | -4.62e-02 | -1.13e-02 | -2.05e-02 | 4.83e-01 | 9.39e-01 | 4.86e-01 | 8.65e-01 | 7.57e-01 |
| AMINO ACID CATABOLIC PROCESS | 109 | 4.36e-01 | 8.09e-01 | 0.0698 | -4.45e-03 | 3.98e-03 | -6.10e-02 | -2.71e-02 | -1.95e-02 | 9.36e-01 | 9.43e-01 | 2.71e-01 | 6.26e-01 | 7.25e-01 |
| ADENYLATE CYCLASE MODULATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 240 | 4.68e-01 | 8.28e-01 | 0.0696 | -3.41e-02 | -1.36e-02 | -1.69e-02 | -5.63e-02 | -6.49e-03 | 3.63e-01 | 7.17e-01 | 6.52e-01 | 1.33e-01 | 8.62e-01 |
| SYNAPSE ASSEMBLY | 185 | 1.07e-01 | 4.47e-01 | 0.0695 | -2.70e-02 | 4.03e-02 | 2.52e-02 | -3.18e-02 | 2.90e-02 | 5.26e-01 | 3.45e-01 | 5.55e-01 | 4.56e-01 | 4.96e-01 |
| REGULATION OF TRANSPORTER ACTIVITY | 253 | 3.12e-01 | 7.24e-01 | 0.0695 | -3.12e-02 | -9.32e-03 | -1.94e-02 | -3.94e-02 | 4.30e-02 | 3.93e-01 | 7.99e-01 | 5.95e-01 | 2.81e-01 | 2.39e-01 |
| CELLULAR RESPONSE TO HORMONE STIMULUS | 589 | 1.21e-01 | 4.75e-01 | 0.0695 | 2.63e-02 | 3.52e-02 | 1.71e-02 | 2.66e-02 | 4.36e-02 | 2.76e-01 | 1.44e-01 | 4.79e-01 | 2.71e-01 | 7.04e-02 |
| RESPONSE TO TUMOR CELL | 42 | 9.67e-01 | 9.94e-01 | 0.0692 | -8.27e-03 | 3.76e-02 | 4.51e-02 | 1.67e-02 | 3.15e-02 | 9.26e-01 | 6.73e-01 | 6.13e-01 | 8.51e-01 | 7.24e-01 |
| REGULATION OF PROTEIN POLYMERIZATION | 195 | 7.12e-01 | 9.35e-01 | 0.0689 | 1.64e-02 | 3.14e-02 | 1.96e-02 | 2.29e-02 | 5.09e-02 | 6.93e-01 | 4.49e-01 | 6.38e-01 | 5.81e-01 | 2.20e-01 |
| GLUTAMINE FAMILY AMINO ACID METABOLIC PROCESS | 75 | 6.80e-01 | 9.28e-01 | 0.0689 | 2.57e-02 | 4.16e-02 | -2.95e-03 | -4.43e-03 | 4.82e-02 | 7.00e-01 | 5.33e-01 | 9.65e-01 | 9.47e-01 | 4.71e-01 |
| REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 53 | 8.19e-01 | 9.70e-01 | 0.0688 | 2.14e-02 | 1.68e-02 | -8.93e-03 | 2.40e-02 | 5.77e-02 | 7.88e-01 | 8.32e-01 | 9.10e-01 | 7.62e-01 | 4.67e-01 |
| NEGATIVE REGULATION OF STEROID METABOLIC PROCESS | 32 | 8.46e-01 | 9.76e-01 | 0.0687 | -1.64e-02 | 5.93e-02 | 2.21e-02 | 1.21e-02 | 1.74e-02 | 8.73e-01 | 5.61e-01 | 8.28e-01 | 9.06e-01 | 8.65e-01 |
| RENAL SYSTEM PROCESS | 117 | 2.41e-01 | 6.44e-01 | 0.0687 | -2.56e-02 | 5.12e-02 | 3.05e-02 | -2.16e-02 | 6.90e-03 | 6.32e-01 | 3.39e-01 | 5.68e-01 | 6.87e-01 | 8.97e-01 |
| RECEPTOR MEDIATED ENDOCYTOSIS INVOLVED IN CHOLESTEROL TRANSPORT | 8 | 9.67e-01 | 9.94e-01 | 0.0685 | -2.90e-02 | 2.73e-02 | -1.76e-03 | 4.92e-02 | 2.60e-02 | 8.87e-01 | 8.94e-01 | 9.93e-01 | 8.10e-01 | 8.99e-01 |
| PEPTIDYL SERINE MODIFICATION | 290 | 4.71e-02 | 2.85e-01 | 0.0684 | 3.82e-02 | -6.45e-03 | -3.33e-02 | 3.05e-02 | -3.38e-02 | 2.63e-01 | 8.50e-01 | 3.30e-01 | 3.72e-01 | 3.22e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 58 | 8.41e-01 | 9.74e-01 | 0.0683 | 5.27e-03 | 2.23e-02 | 2.57e-02 | 5.83e-02 | 9.11e-03 | 9.45e-01 | 7.69e-01 | 7.35e-01 | 4.42e-01 | 9.04e-01 |
| PROTEIN DEPOLYMERIZATION | 112 | 8.29e-01 | 9.72e-01 | 0.0681 | -5.16e-02 | -4.01e-02 | -7.11e-03 | -5.62e-03 | 1.65e-02 | 3.45e-01 | 4.63e-01 | 8.97e-01 | 9.18e-01 | 7.62e-01 |
| POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION | 71 | 9.58e-01 | 9.94e-01 | 0.0681 | 1.99e-02 | 1.54e-04 | 2.19e-02 | 3.17e-02 | 5.24e-02 | 7.71e-01 | 9.98e-01 | 7.49e-01 | 6.44e-01 | 4.45e-01 |
| ORGANIC ACID TRANSMEMBRANE TRANSPORT | 146 | 9.65e-01 | 9.94e-01 | 0.0679 | 2.03e-02 | 2.76e-02 | 4.37e-02 | 2.80e-02 | 2.72e-02 | 6.72e-01 | 5.65e-01 | 3.62e-01 | 5.60e-01 | 5.70e-01 |
| CALCIUM ION HOMEOSTASIS | 320 | 8.03e-01 | 9.67e-01 | 0.0678 | -3.96e-02 | -2.54e-02 | -3.44e-02 | -3.39e-02 | -7.41e-03 | 2.24e-01 | 4.34e-01 | 2.90e-01 | 2.97e-01 | 8.20e-01 |
| HYDROGEN PEROXIDE METABOLIC PROCESS | 49 | 9.68e-01 | 9.94e-01 | 0.0676 | 3.00e-02 | -2.61e-03 | 1.93e-02 | 4.21e-02 | 3.90e-02 | 7.16e-01 | 9.75e-01 | 8.15e-01 | 6.11e-01 | 6.36e-01 |
| RESPONSE TO PROSTAGLANDIN E | 23 | 9.68e-01 | 9.94e-01 | 0.0675 | 3.09e-02 | 1.80e-02 | -6.20e-03 | -2.70e-03 | 5.68e-02 | 7.98e-01 | 8.81e-01 | 9.59e-01 | 9.82e-01 | 6.37e-01 |
| CIRCULATORY SYSTEM DEVELOPMENT | 1175 | 1.57e-03 | 2.51e-02 | 0.0675 | 3.69e-03 | 3.56e-02 | 2.92e-02 | 1.78e-03 | 4.92e-02 | 8.31e-01 | 3.99e-02 | 9.19e-02 | 9.18e-01 | 4.48e-03 |
| POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 157 | 5.27e-01 | 8.60e-01 | 0.0675 | 2.50e-02 | 5.58e-02 | 1.80e-02 | -4.21e-03 | 2.16e-02 | 5.89e-01 | 2.27e-01 | 6.97e-01 | 9.27e-01 | 6.41e-01 |
| REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 167 | 6.41e-01 | 9.14e-01 | 0.0673 | -4.76e-02 | -5.78e-03 | -2.45e-02 | -3.98e-02 | -6.43e-03 | 2.88e-01 | 8.97e-01 | 5.85e-01 | 3.75e-01 | 8.86e-01 |
| REGULATION OF CELL CELL ADHESION | 479 | 3.11e-01 | 7.22e-01 | 0.0672 | 2.50e-02 | 1.93e-02 | 2.45e-02 | 5.06e-02 | 1.92e-02 | 3.48e-01 | 4.70e-01 | 3.59e-01 | 5.80e-02 | 4.72e-01 |
| NEGATIVE REGULATION OF CYTOKINE PRODUCTION | 359 | 1.28e-01 | 4.85e-01 | 0.0672 | 4.56e-02 | 1.42e-02 | -2.42e-02 | 6.20e-04 | -4.07e-02 | 1.38e-01 | 6.44e-01 | 4.32e-01 | 9.84e-01 | 1.86e-01 |
| EPIDERMIS DEVELOPMENT | 375 | 2.03e-01 | 5.96e-01 | 0.0672 | -2.67e-02 | -2.60e-03 | -2.50e-02 | -5.52e-02 | -1.07e-02 | 3.74e-01 | 9.31e-01 | 4.05e-01 | 6.62e-02 | 7.23e-01 |
| CILIUM ORGANIZATION | 410 | 3.57e-01 | 7.57e-01 | 0.0672 | 3.88e-02 | 2.61e-02 | 1.23e-02 | 3.52e-02 | 3.05e-02 | 1.77e-01 | 3.64e-01 | 6.68e-01 | 2.21e-01 | 2.89e-01 |
| REGULATION OF PROTEIN CONTAINING COMPLEX DISASSEMBLY | 117 | 7.87e-01 | 9.63e-01 | 0.0672 | 1.07e-02 | 2.37e-02 | 3.13e-02 | 5.22e-02 | 1.14e-02 | 8.42e-01 | 6.58e-01 | 5.59e-01 | 3.29e-01 | 8.31e-01 |
| RESPONSE TO TUMOR NECROSIS FACTOR | 248 | 4.53e-01 | 8.21e-01 | 0.0671 | 3.10e-02 | 2.40e-02 | 1.02e-02 | 1.89e-02 | 5.01e-02 | 4.01e-01 | 5.15e-01 | 7.82e-01 | 6.09e-01 | 1.74e-01 |
| PROTEIN LOCALIZATION TO POSTSYNAPSE | 40 | 8.75e-01 | 9.78e-01 | 0.0671 | -1.61e-02 | 8.03e-03 | 6.94e-03 | -5.38e-02 | 3.51e-02 | 8.60e-01 | 9.30e-01 | 9.39e-01 | 5.56e-01 | 7.01e-01 |
| NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 161 | 5.77e-01 | 8.85e-01 | 0.0671 | -3.75e-02 | -2.58e-03 | -2.14e-02 | -4.39e-02 | 2.64e-02 | 4.11e-01 | 9.55e-01 | 6.39e-01 | 3.37e-01 | 5.63e-01 |
| REGULATION OF LONG TERM NEURONAL SYNAPTIC PLASTICITY | 21 | 9.58e-01 | 9.94e-01 | 0.0670 | -1.85e-02 | 5.33e-02 | 3.34e-02 | -1.17e-02 | 7.09e-03 | 8.83e-01 | 6.72e-01 | 7.91e-01 | 9.26e-01 | 9.55e-01 |
| STEROID BIOSYNTHETIC PROCESS | 177 | 8.97e-01 | 9.82e-01 | 0.0668 | -3.41e-02 | -2.38e-02 | -3.19e-02 | -4.03e-02 | 9.44e-03 | 4.34e-01 | 5.84e-01 | 4.64e-01 | 3.55e-01 | 8.28e-01 |
| EPITHELIAL CELL DIFFERENTIATION | 722 | 5.58e-02 | 3.13e-01 | 0.0666 | 2.61e-04 | 1.73e-02 | 3.53e-02 | 8.87e-04 | 5.37e-02 | 9.90e-01 | 4.29e-01 | 1.06e-01 | 9.68e-01 | 1.39e-02 |
| MUSCLE SYSTEM PROCESS | 438 | 1.04e-02 | 1.04e-01 | 0.0662 | -3.30e-02 | 3.32e-03 | 3.42e-04 | -5.72e-02 | 3.71e-03 | 2.37e-01 | 9.05e-01 | 9.90e-01 | 4.02e-02 | 8.94e-01 |
| PEPTIDYL TYROSINE MODIFICATION | 271 | 2.30e-01 | 6.32e-01 | 0.0660 | -2.94e-02 | -3.23e-03 | -4.47e-02 | -2.56e-02 | -2.88e-02 | 4.04e-01 | 9.27e-01 | 2.05e-01 | 4.69e-01 | 4.14e-01 |
| REELIN MEDIATED SIGNALING PATHWAY | 7 | 9.99e-01 | 1.00e+00 | 0.0658 | -3.76e-02 | -4.45e-02 | 1.61e-02 | -3.12e-03 | 2.58e-02 | 8.63e-01 | 8.38e-01 | 9.41e-01 | 9.89e-01 | 9.06e-01 |
| PHAGOCYTOSIS ENGULFMENT | 48 | 9.07e-01 | 9.84e-01 | 0.0657 | -4.31e-05 | 3.81e-02 | -5.72e-03 | -6.47e-03 | -5.28e-02 | 1.00e+00 | 6.48e-01 | 9.45e-01 | 9.38e-01 | 5.27e-01 |
| RESPONSE TO AXON INJURY | 79 | 5.73e-01 | 8.84e-01 | 0.0655 | 3.28e-02 | 4.06e-02 | -2.23e-02 | -3.25e-02 | -3.94e-03 | 6.14e-01 | 5.33e-01 | 7.32e-01 | 6.17e-01 | 9.52e-01 |
| FEMALE GAMETE GENERATION | 158 | 6.84e-01 | 9.30e-01 | 0.0654 | 3.19e-02 | 2.25e-02 | 1.51e-02 | 8.27e-03 | -4.96e-02 | 4.88e-01 | 6.26e-01 | 7.43e-01 | 8.58e-01 | 2.82e-01 |
| SKIN DEVELOPMENT | 311 | 2.81e-01 | 6.92e-01 | 0.0654 | -3.05e-02 | -4.05e-03 | -1.81e-02 | -5.48e-02 | -2.04e-03 | 3.55e-01 | 9.02e-01 | 5.83e-01 | 9.67e-02 | 9.51e-01 |
| MUSCLE CELL DEVELOPMENT | 191 | 6.12e-01 | 9.05e-01 | 0.0654 | -4.42e-02 | -1.43e-02 | 1.16e-02 | -2.59e-02 | 3.62e-02 | 2.92e-01 | 7.34e-01 | 7.83e-01 | 5.37e-01 | 3.88e-01 |
| REGULATION OF TRIGLYCERIDE BIOSYNTHETIC PROCESS | 21 | 9.45e-01 | 9.94e-01 | 0.0654 | -4.93e-03 | 2.22e-02 | -4.96e-02 | -9.50e-03 | -3.47e-02 | 9.69e-01 | 8.60e-01 | 6.94e-01 | 9.40e-01 | 7.83e-01 |
| DEFENSE RESPONSE TO OTHER ORGANISM | 1152 | 1.15e-02 | 1.12e-01 | 0.0653 | 4.67e-02 | 3.43e-02 | 2.35e-03 | 1.35e-02 | -2.68e-02 | 7.49e-03 | 4.98e-02 | 8.93e-01 | 4.40e-01 | 1.25e-01 |
| REFLEX | 21 | 9.86e-01 | 9.97e-01 | 0.0651 | -1.10e-02 | 1.13e-02 | -2.51e-02 | 5.01e-04 | -5.80e-02 | 9.31e-01 | 9.28e-01 | 8.42e-01 | 9.97e-01 | 6.46e-01 |
| REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION | 172 | 1.84e-01 | 5.70e-01 | 0.0651 | -8.87e-03 | 2.08e-02 | 1.09e-02 | 4.12e-02 | 4.37e-02 | 8.41e-01 | 6.37e-01 | 8.05e-01 | 3.51e-01 | 3.23e-01 |
| LIGAND GATED ION CHANNEL SIGNALING PATHWAY | 31 | 9.91e-01 | 9.98e-01 | 0.0650 | 3.02e-02 | 5.13e-02 | 1.21e-02 | 2.17e-02 | -7.91e-03 | 7.71e-01 | 6.21e-01 | 9.07e-01 | 8.34e-01 | 9.39e-01 |
| LONG TERM SYNAPTIC POTENTIATION | 102 | 8.32e-01 | 9.73e-01 | 0.0648 | -4.33e-02 | -4.27e-03 | 7.22e-03 | -1.54e-02 | 4.49e-02 | 4.50e-01 | 9.41e-01 | 9.00e-01 | 7.88e-01 | 4.33e-01 |
| REGULATION OF MITOCHONDRIAL FISSION | 30 | 8.46e-01 | 9.76e-01 | 0.0646 | 5.07e-02 | -2.22e-02 | -1.80e-02 | -1.21e-02 | -2.54e-02 | 6.31e-01 | 8.33e-01 | 8.65e-01 | 9.09e-01 | 8.10e-01 |
| RESPONSE TO CATECHOLAMINE | 86 | 7.73e-01 | 9.57e-01 | 0.0645 | 2.76e-02 | 6.06e-03 | -7.35e-04 | 4.23e-02 | 3.97e-02 | 6.58e-01 | 9.23e-01 | 9.91e-01 | 4.98e-01 | 5.25e-01 |
| POSITIVE REGULATION OF PHOSPHORYLATION | 635 | 4.14e-01 | 7.98e-01 | 0.0645 | 4.32e-02 | 3.32e-02 | 1.45e-02 | 3.03e-02 | 7.83e-03 | 6.31e-02 | 1.53e-01 | 5.34e-01 | 1.93e-01 | 7.36e-01 |
| REGULATION OF INFLAMMATORY RESPONSE | 410 | 2.29e-02 | 1.83e-01 | 0.0643 | 3.97e-02 | 3.86e-02 | -2.26e-02 | 1.01e-02 | -2.12e-02 | 1.68e-01 | 1.79e-01 | 4.32e-01 | 7.25e-01 | 4.61e-01 |
| CYTOSKELETON ORGANIZATION | 1446 | 1.56e-01 | 5.28e-01 | 0.0639 | 3.41e-02 | 3.58e-02 | 2.16e-02 | 2.80e-02 | 1.98e-02 | 3.00e-02 | 2.28e-02 | 1.69e-01 | 7.44e-02 | 2.07e-01 |
| MICROTUBULE BASED MOVEMENT | 401 | 2.58e-01 | 6.65e-01 | 0.0638 | -2.08e-02 | -3.88e-02 | -1.93e-02 | -2.11e-02 | 3.63e-02 | 4.74e-01 | 1.82e-01 | 5.07e-01 | 4.68e-01 | 2.12e-01 |
| PYRIMIDINE NUCLEOBASE METABOLIC PROCESS | 20 | 9.92e-01 | 9.98e-01 | 0.0635 | 2.41e-02 | -6.35e-03 | -3.69e-02 | -2.93e-02 | -3.44e-02 | 8.52e-01 | 9.61e-01 | 7.75e-01 | 8.21e-01 | 7.90e-01 |
| HEPARAN SULFATE PROTEOGLYCAN METABOLIC PROCESS | 15 | 9.63e-01 | 9.94e-01 | 0.0631 | 4.72e-03 | 5.79e-02 | -8.93e-03 | 1.54e-02 | -1.70e-02 | 9.75e-01 | 6.98e-01 | 9.52e-01 | 9.18e-01 | 9.09e-01 |
| MICROVILLUS ORGANIZATION | 28 | 6.55e-01 | 9.20e-01 | 0.0630 | 4.63e-02 | -2.34e-02 | 1.88e-02 | -1.85e-02 | -2.42e-02 | 6.72e-01 | 8.30e-01 | 8.64e-01 | 8.66e-01 | 8.24e-01 |
| SPHINGOLIPID CATABOLIC PROCESS | 32 | 9.37e-01 | 9.92e-01 | 0.0629 | 3.50e-02 | 3.27e-03 | 3.46e-02 | 4.48e-03 | 3.88e-02 | 7.32e-01 | 9.74e-01 | 7.35e-01 | 9.65e-01 | 7.04e-01 |
| RESPONSE TO HYDROPEROXIDE | 18 | 9.83e-01 | 9.96e-01 | 0.0628 | 3.64e-03 | -4.85e-02 | -2.27e-02 | 1.27e-02 | 3.00e-02 | 9.79e-01 | 7.22e-01 | 8.67e-01 | 9.26e-01 | 8.26e-01 |
| POLYSACCHARIDE BIOSYNTHETIC PROCESS | 64 | 9.35e-01 | 9.91e-01 | 0.0627 | 1.43e-02 | 4.26e-02 | 2.43e-02 | 3.39e-02 | -1.36e-02 | 8.44e-01 | 5.56e-01 | 7.37e-01 | 6.39e-01 | 8.51e-01 |
| NEGATIVE REGULATION OF MAPK CASCADE | 164 | 9.60e-01 | 9.94e-01 | 0.0627 | 3.94e-02 | 3.77e-02 | 1.74e-02 | 2.56e-02 | -1.87e-04 | 3.84e-01 | 4.05e-01 | 7.01e-01 | 5.72e-01 | 9.97e-01 |
| REGULATION OF JNK CASCADE | 130 | 8.88e-01 | 9.80e-01 | 0.0626 | -6.50e-04 | -1.79e-02 | -3.66e-02 | -3.83e-02 | -2.81e-02 | 9.90e-01 | 7.24e-01 | 4.71e-01 | 4.51e-01 | 5.81e-01 |
| FATTY ACID DERIVATIVE BIOSYNTHETIC PROCESS | 44 | 9.66e-01 | 9.94e-01 | 0.0624 | 4.27e-03 | -1.01e-02 | -8.00e-04 | 1.14e-02 | 6.03e-02 | 9.61e-01 | 9.08e-01 | 9.93e-01 | 8.96e-01 | 4.89e-01 |
| DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 918 | 4.23e-01 | 8.03e-01 | 0.0622 | 3.57e-02 | 3.10e-02 | 2.09e-02 | 2.74e-02 | 2.13e-02 | 6.65e-02 | 1.12e-01 | 2.83e-01 | 1.60e-01 | 2.74e-01 |
| MONOSACCHARIDE BIOSYNTHETIC PROCESS | 96 | 6.41e-01 | 9.14e-01 | 0.0621 | -3.13e-03 | 1.17e-02 | -6.90e-03 | 1.47e-02 | 5.87e-02 | 9.58e-01 | 8.43e-01 | 9.07e-01 | 8.04e-01 | 3.20e-01 |
| REGULATION OF MONOATOMIC CATION TRANSMEMBRANE TRANSPORT | 299 | 4.16e-01 | 7.99e-01 | 0.0618 | -2.80e-02 | -1.12e-02 | -2.20e-02 | -3.96e-02 | 2.94e-02 | 4.04e-01 | 7.40e-01 | 5.13e-01 | 2.39e-01 | 3.83e-01 |
| TRABECULA MORPHOGENESIS | 47 | 8.19e-01 | 9.70e-01 | 0.0616 | -1.67e-02 | 4.85e-02 | 2.41e-02 | -1.98e-02 | -1.40e-02 | 8.43e-01 | 5.65e-01 | 7.75e-01 | 8.14e-01 | 8.68e-01 |
| PHOTORECEPTOR CELL MAINTENANCE | 43 | 1.00e+00 | 1.00e+00 | 0.0616 | -2.52e-02 | -2.68e-02 | -3.28e-02 | -2.78e-02 | -2.44e-02 | 7.75e-01 | 7.61e-01 | 7.10e-01 | 7.53e-01 | 7.82e-01 |
| TRANSMEMBRANE TRANSPORT | 1481 | 9.18e-04 | 1.64e-02 | 0.0615 | -3.68e-02 | -8.49e-03 | -1.48e-02 | -4.35e-02 | 1.56e-02 | 1.78e-02 | 5.85e-01 | 3.41e-01 | 5.11e-03 | 3.15e-01 |
| REGULATION OF BLOOD CIRCULATION | 247 | 1.28e-01 | 4.85e-01 | 0.0614 | -2.61e-02 | 9.98e-03 | 2.24e-02 | -3.91e-02 | 3.10e-02 | 4.80e-01 | 7.87e-01 | 5.44e-01 | 2.89e-01 | 4.02e-01 |
| REGULATION OF BODY FLUID LEVELS | 351 | 1.86e-01 | 5.72e-01 | 0.0614 | 1.55e-02 | 3.88e-02 | 8.47e-03 | -9.74e-03 | -4.31e-02 | 6.18e-01 | 2.12e-01 | 7.85e-01 | 7.54e-01 | 1.66e-01 |
| NEGATIVE REGULATION OF CELL JUNCTION ASSEMBLY | 30 | 8.85e-01 | 9.80e-01 | 0.0612 | 2.71e-02 | 2.75e-02 | -2.28e-03 | -4.72e-02 | 4.56e-03 | 7.97e-01 | 7.94e-01 | 9.83e-01 | 6.54e-01 | 9.66e-01 |
| POSITIVE REGULATION OF CELL GROWTH | 153 | 9.69e-01 | 9.95e-01 | 0.0609 | 2.10e-02 | 3.39e-02 | 2.60e-02 | 2.99e-02 | 2.36e-02 | 6.55e-01 | 4.69e-01 | 5.78e-01 | 5.24e-01 | 6.15e-01 |
| CARBOHYDRATE TRANSPORT | 154 | 1.54e-01 | 5.25e-01 | 0.0609 | -7.01e-03 | 3.95e-02 | -1.06e-02 | -1.31e-02 | 4.26e-02 | 8.81e-01 | 3.97e-01 | 8.21e-01 | 7.78e-01 | 3.62e-01 |
| MULTICELLULAR ORGANISMAL LEVEL IRON ION HOMEOSTASIS | 25 | 8.89e-01 | 9.80e-01 | 0.0609 | -3.60e-02 | 8.56e-03 | -4.63e-02 | -1.09e-02 | -8.61e-03 | 7.56e-01 | 9.41e-01 | 6.88e-01 | 9.25e-01 | 9.41e-01 |
| VASCULATURE DEVELOPMENT | 794 | 2.33e-02 | 1.85e-01 | 0.0609 | 5.57e-03 | 3.52e-02 | 2.10e-02 | 4.45e-04 | 4.46e-02 | 7.90e-01 | 9.14e-02 | 3.15e-01 | 9.83e-01 | 3.24e-02 |
| PHOSPHOLIPASE C ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 103 | 3.42e-01 | 7.48e-01 | 0.0608 | 5.10e-02 | 1.33e-02 | -2.06e-02 | -1.94e-02 | 1.07e-02 | 3.71e-01 | 8.16e-01 | 7.18e-01 | 7.33e-01 | 8.52e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE PROLIFERATION | 91 | 5.56e-01 | 8.77e-01 | 0.0607 | 4.80e-02 | -9.12e-03 | -2.29e-02 | 2.65e-02 | 8.08e-03 | 4.29e-01 | 8.80e-01 | 7.06e-01 | 6.62e-01 | 8.94e-01 |
| MEMBRANE PROTEIN PROTEOLYSIS | 56 | 9.47e-01 | 9.94e-01 | 0.0605 | 3.37e-02 | 4.77e-02 | 5.58e-03 | 3.68e-03 | 1.43e-02 | 6.63e-01 | 5.37e-01 | 9.42e-01 | 9.62e-01 | 8.53e-01 |
| POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 1069 | 1.31e-01 | 4.90e-01 | 0.0605 | 3.56e-02 | 2.86e-02 | 1.37e-02 | 3.17e-02 | 1.93e-02 | 4.89e-02 | 1.14e-01 | 4.49e-01 | 7.98e-02 | 2.86e-01 |
| ESTABLISHMENT OF CELL POLARITY | 153 | 7.47e-01 | 9.51e-01 | 0.0604 | 1.27e-03 | 9.02e-03 | 2.27e-02 | 4.30e-02 | 3.47e-02 | 9.78e-01 | 8.47e-01 | 6.28e-01 | 3.58e-01 | 4.59e-01 |
| CELL ADHESION MEDIATED BY INTEGRIN | 86 | 6.89e-01 | 9.31e-01 | 0.0602 | -3.51e-02 | 1.43e-02 | -1.89e-02 | -1.96e-02 | -3.81e-02 | 5.74e-01 | 8.19e-01 | 7.61e-01 | 7.54e-01 | 5.41e-01 |
| POSITIVE REGULATION OF BONE MINERALIZATION | 43 | 7.16e-01 | 9.37e-01 | 0.0602 | -5.20e-02 | 2.87e-03 | 1.34e-02 | 2.51e-02 | 9.70e-03 | 5.55e-01 | 9.74e-01 | 8.79e-01 | 7.75e-01 | 9.12e-01 |
| MAINTENANCE OF LOCATION IN CELL | 225 | 2.16e-01 | 6.12e-01 | 0.0601 | -4.73e-03 | 1.09e-02 | 3.13e-02 | 4.99e-02 | 7.13e-04 | 9.03e-01 | 7.77e-01 | 4.18e-01 | 1.97e-01 | 9.85e-01 |
| ORGANOPHOSPHATE CATABOLIC PROCESS | 142 | 4.27e-01 | 8.05e-01 | 0.0600 | 3.88e-02 | 3.68e-02 | 1.06e-02 | -1.77e-02 | 1.79e-02 | 4.25e-01 | 4.49e-01 | 8.27e-01 | 7.16e-01 | 7.13e-01 |
| NERVE GROWTH FACTOR SIGNALING PATHWAY | 13 | 9.87e-01 | 9.97e-01 | 0.0600 | -6.53e-03 | -3.22e-02 | -4.35e-03 | 4.92e-02 | -9.17e-03 | 9.68e-01 | 8.41e-01 | 9.78e-01 | 7.59e-01 | 9.54e-01 |
| REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 234 | 4.15e-01 | 7.99e-01 | 0.0599 | -2.29e-02 | 8.01e-03 | 1.98e-03 | -2.64e-02 | 4.80e-02 | 5.46e-01 | 8.33e-01 | 9.58e-01 | 4.87e-01 | 2.06e-01 |
| REGULATION OF INSULIN RECEPTOR SIGNALING PATHWAY | 69 | 5.33e-01 | 8.64e-01 | 0.0595 | 2.83e-02 | 3.78e-02 | -3.57e-02 | 2.73e-03 | 5.09e-03 | 6.84e-01 | 5.87e-01 | 6.08e-01 | 9.69e-01 | 9.42e-01 |
| NEGATIVE REGULATION OF TRANSPORT | 452 | 3.44e-01 | 7.50e-01 | 0.0593 | 4.89e-02 | 2.60e-02 | 7.85e-03 | 1.98e-02 | 1.52e-03 | 7.47e-02 | 3.44e-01 | 7.75e-01 | 4.71e-01 | 9.56e-01 |
| INTRA GOLGI VESICLE MEDIATED TRANSPORT | 33 | 9.32e-01 | 9.90e-01 | 0.0593 | 4.66e-02 | -1.56e-02 | -2.49e-02 | 3.43e-03 | -2.18e-02 | 6.43e-01 | 8.77e-01 | 8.05e-01 | 9.73e-01 | 8.29e-01 |
| REGULATION OF MEMBRANE POTENTIAL | 423 | 1.84e-01 | 5.70e-01 | 0.0592 | -3.25e-02 | 1.90e-03 | 8.37e-03 | -2.49e-02 | 4.19e-02 | 2.52e-01 | 9.46e-01 | 7.68e-01 | 3.79e-01 | 1.40e-01 |
| NEGATIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE PROTEIN KINASE B SIGNAL TRANSDUCTION | 67 | 6.87e-01 | 9.31e-01 | 0.0592 | 2.35e-02 | -2.33e-02 | -4.77e-02 | -2.92e-03 | 1.11e-02 | 7.40e-01 | 7.42e-01 | 5.00e-01 | 9.67e-01 | 8.75e-01 |
| ORGANIC HYDROXY COMPOUND BIOSYNTHETIC PROCESS | 242 | 7.04e-01 | 9.32e-01 | 0.0591 | -2.23e-02 | -9.79e-03 | 1.09e-02 | 3.73e-03 | 5.26e-02 | 5.51e-01 | 7.93e-01 | 7.71e-01 | 9.20e-01 | 1.59e-01 |
| REGULATION OF CELL JUNCTION ASSEMBLY | 199 | 7.64e-01 | 9.54e-01 | 0.0589 | -5.35e-03 | 1.40e-02 | 1.68e-02 | 5.97e-05 | 5.45e-02 | 8.96e-01 | 7.34e-01 | 6.82e-01 | 9.99e-01 | 1.85e-01 |
| INTRACELLULAR STEROL TRANSPORT | 35 | 9.58e-01 | 9.94e-01 | 0.0587 | 2.69e-02 | -2.38e-02 | -3.09e-02 | 1.97e-02 | -2.85e-02 | 7.83e-01 | 8.07e-01 | 7.52e-01 | 8.40e-01 | 7.70e-01 |
| PURINE CONTAINING COMPOUND CATABOLIC PROCESS | 57 | 7.44e-01 | 9.50e-01 | 0.0586 | 1.68e-02 | -4.65e-02 | -2.53e-02 | -1.85e-02 | 1.47e-03 | 8.26e-01 | 5.44e-01 | 7.41e-01 | 8.09e-01 | 9.85e-01 |
| VASCULAR PROCESS IN CIRCULATORY SYSTEM | 261 | 6.58e-01 | 9.20e-01 | 0.0586 | -2.54e-02 | -6.59e-03 | -1.88e-02 | -4.66e-02 | -1.47e-02 | 4.80e-01 | 8.55e-01 | 6.01e-01 | 1.95e-01 | 6.82e-01 |
| CELLULAR RESPONSE TO PEPTIDE | 367 | 2.73e-02 | 2.04e-01 | 0.0585 | 8.19e-03 | 3.17e-02 | -3.20e-03 | 1.30e-02 | 4.66e-02 | 7.88e-01 | 2.97e-01 | 9.16e-01 | 6.68e-01 | 1.25e-01 |
| RESPIRATORY GASEOUS EXCHANGE BY RESPIRATORY SYSTEM | 70 | 9.52e-01 | 9.94e-01 | 0.0583 | 3.63e-02 | 2.99e-02 | 3.34e-02 | 8.13e-03 | 3.00e-03 | 6.00e-01 | 6.65e-01 | 6.28e-01 | 9.06e-01 | 9.65e-01 |
| INTRACELLULAR GLUCOSE HOMEOSTASIS | 153 | 5.35e-01 | 8.65e-01 | 0.0581 | -1.96e-02 | 3.40e-02 | 3.22e-02 | -4.58e-03 | 2.79e-02 | 6.76e-01 | 4.68e-01 | 4.91e-01 | 9.22e-01 | 5.52e-01 |
| RECEPTOR CLUSTERING | 53 | 8.52e-01 | 9.76e-01 | 0.0581 | 3.34e-03 | 2.28e-02 | -3.93e-02 | -6.55e-03 | -3.54e-02 | 9.66e-01 | 7.74e-01 | 6.21e-01 | 9.34e-01 | 6.55e-01 |
| REGULATION OF NEURON PROJECTION DEVELOPMENT | 431 | 1.15e-01 | 4.62e-01 | 0.0580 | -3.39e-02 | -1.57e-03 | -2.02e-02 | -3.14e-02 | 2.87e-02 | 2.27e-01 | 9.55e-01 | 4.73e-01 | 2.64e-01 | 3.07e-01 |
| REGULATION OF VASCULATURE DEVELOPMENT | 337 | 2.79e-02 | 2.07e-01 | 0.0577 | 1.81e-02 | 4.76e-02 | -5.24e-03 | -2.06e-02 | 1.66e-02 | 5.68e-01 | 1.33e-01 | 8.69e-01 | 5.15e-01 | 6.00e-01 |
| REGULATION OF CELLULAR KETONE METABOLIC PROCESS | 139 | 9.91e-01 | 9.98e-01 | 0.0577 | 2.96e-02 | 2.74e-02 | 2.38e-02 | 2.42e-02 | 2.34e-02 | 5.47e-01 | 5.77e-01 | 6.28e-01 | 6.22e-01 | 6.34e-01 |
| THROMBIN ACTIVATED RECEPTOR SIGNALING PATHWAY | 13 | 9.98e-01 | 1.00e+00 | 0.0575 | 2.89e-02 | -3.85e-03 | 1.62e-02 | 4.05e-02 | -2.37e-02 | 8.57e-01 | 9.81e-01 | 9.19e-01 | 8.00e-01 | 8.83e-01 |
| VESICLE MEDIATED TRANSPORT IN SYNAPSE | 208 | 8.38e-01 | 9.73e-01 | 0.0575 | 8.31e-03 | 2.77e-02 | 2.66e-02 | 4.34e-03 | 4.17e-02 | 8.36e-01 | 4.91e-01 | 5.08e-01 | 9.14e-01 | 2.99e-01 |
| BIOMINERAL TISSUE DEVELOPMENT | 165 | 1.88e-01 | 5.73e-01 | 0.0575 | -3.11e-02 | 3.39e-02 | 1.17e-02 | -2.13e-02 | -2.44e-02 | 4.90e-01 | 4.52e-01 | 7.95e-01 | 6.36e-01 | 5.89e-01 |
| RESPONSE TO TYPE I INTERFERON | 83 | 9.73e-01 | 9.95e-01 | 0.0574 | -2.40e-03 | 2.08e-02 | 3.12e-02 | 2.70e-02 | 3.40e-02 | 9.70e-01 | 7.43e-01 | 6.23e-01 | 6.70e-01 | 5.93e-01 |
| HAIR CELL DIFFERENTIATION | 53 | 9.05e-01 | 9.84e-01 | 0.0573 | -3.90e-02 | -3.65e-02 | 1.51e-02 | -1.29e-02 | -5.40e-03 | 6.23e-01 | 6.46e-01 | 8.49e-01 | 8.71e-01 | 9.46e-01 |
| NEURON DEVELOPMENT | 1091 | 5.50e-02 | 3.11e-01 | 0.0572 | -1.82e-03 | 2.07e-02 | 2.25e-02 | 7.30e-03 | 4.77e-02 | 9.19e-01 | 2.48e-01 | 2.10e-01 | 6.84e-01 | 7.76e-03 |
| INNER EAR RECEPTOR CELL DEVELOPMENT | 46 | 9.86e-01 | 9.97e-01 | 0.0571 | -2.03e-02 | -2.13e-02 | -1.04e-02 | -3.37e-02 | -3.39e-02 | 8.12e-01 | 8.02e-01 | 9.03e-01 | 6.92e-01 | 6.91e-01 |
| TISSUE HOMEOSTASIS | 264 | 4.37e-02 | 2.71e-01 | 0.0570 | 1.49e-02 | 5.17e-02 | -1.58e-02 | -7.96e-03 | -6.86e-03 | 6.77e-01 | 1.48e-01 | 6.59e-01 | 8.24e-01 | 8.48e-01 |
| POSITIVE REGULATION OF TYPE II INTERFERON PRODUCTION | 74 | 8.02e-01 | 9.67e-01 | 0.0570 | -1.25e-02 | -2.21e-02 | -5.00e-02 | -7.63e-03 | 7.22e-03 | 8.52e-01 | 7.42e-01 | 4.57e-01 | 9.10e-01 | 9.14e-01 |
| POSITIVE REGULATION OF CELL ADHESION | 467 | 1.62e-01 | 5.38e-01 | 0.0568 | 2.71e-02 | 1.57e-02 | 7.54e-03 | 4.67e-02 | -2.12e-03 | 3.15e-01 | 5.61e-01 | 7.80e-01 | 8.37e-02 | 9.38e-01 |
| LIPID STORAGE | 93 | 8.10e-01 | 9.68e-01 | 0.0568 | 4.01e-02 | 2.99e-02 | -1.45e-02 | 2.20e-02 | -4.45e-03 | 5.03e-01 | 6.18e-01 | 8.10e-01 | 7.14e-01 | 9.41e-01 |
| REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 277 | 2.80e-01 | 6.90e-01 | 0.0567 | -1.40e-02 | -4.23e-03 | -4.06e-02 | -6.21e-03 | -3.63e-02 | 6.89e-01 | 9.04e-01 | 2.45e-01 | 8.59e-01 | 2.99e-01 |
| REGULATION OF METAL ION TRANSPORT | 381 | 9.16e-02 | 4.11e-01 | 0.0563 | -2.83e-02 | 3.75e-03 | -2.08e-02 | -2.89e-02 | 3.30e-02 | 3.43e-01 | 9.00e-01 | 4.86e-01 | 3.33e-01 | 2.68e-01 |
| POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 61 | 6.91e-01 | 9.31e-01 | 0.0561 | -3.97e-02 | 1.56e-02 | -2.92e-02 | -1.87e-02 | -1.13e-02 | 5.92e-01 | 8.34e-01 | 6.93e-01 | 8.00e-01 | 8.78e-01 |
| NEGATIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 462 | 5.71e-02 | 3.16e-01 | 0.0558 | 6.73e-03 | 3.04e-02 | -2.23e-02 | -2.48e-02 | -3.20e-02 | 8.04e-01 | 2.62e-01 | 4.12e-01 | 3.62e-01 | 2.38e-01 |
| SMAD PROTEIN SIGNAL TRANSDUCTION | 83 | 7.60e-01 | 9.52e-01 | 0.0557 | -3.27e-02 | -2.20e-02 | -5.25e-03 | 2.29e-02 | 3.16e-02 | 6.07e-01 | 7.29e-01 | 9.34e-01 | 7.18e-01 | 6.19e-01 |
| ENDOTHELIAL CELL MIGRATION | 270 | 7.17e-01 | 9.37e-01 | 0.0556 | -3.23e-02 | -1.32e-02 | -4.63e-03 | -2.69e-02 | 3.36e-02 | 3.60e-01 | 7.09e-01 | 8.96e-01 | 4.47e-01 | 3.43e-01 |
| WOUND HEALING | 407 | 2.65e-01 | 6.73e-01 | 0.0556 | 2.07e-02 | 4.23e-02 | 3.27e-03 | 5.65e-03 | -2.88e-02 | 4.75e-01 | 1.43e-01 | 9.10e-01 | 8.45e-01 | 3.18e-01 |
| AMIDE TRANSPORT | 344 | 3.37e-01 | 7.43e-01 | 0.0555 | 8.96e-03 | 4.39e-02 | 2.11e-02 | 1.18e-03 | 2.50e-02 | 7.75e-01 | 1.62e-01 | 5.02e-01 | 9.70e-01 | 4.26e-01 |
| NEGATIVE REGULATION OF VASCULATURE DEVELOPMENT | 139 | 5.80e-01 | 8.87e-01 | 0.0554 | 1.91e-02 | 1.61e-02 | -3.93e-02 | -2.14e-02 | -2.08e-02 | 6.97e-01 | 7.43e-01 | 4.23e-01 | 6.63e-01 | 6.72e-01 |
| CARBOHYDRATE DERIVATIVE CATABOLIC PROCESS | 170 | 7.86e-01 | 9.62e-01 | 0.0552 | 4.41e-02 | 2.22e-02 | -7.46e-03 | 1.90e-02 | -1.41e-02 | 3.22e-01 | 6.18e-01 | 8.67e-01 | 6.70e-01 | 7.52e-01 |
| REGULATION OF SYSTEM PROCESS | 539 | 1.08e-02 | 1.07e-01 | 0.0551 | -2.43e-02 | 9.51e-03 | 7.41e-03 | -4.47e-02 | 1.76e-02 | 3.34e-01 | 7.06e-01 | 7.69e-01 | 7.59e-02 | 4.85e-01 |
| ALPHA AMINO ACID METABOLIC PROCESS | 197 | 1.81e-01 | 5.66e-01 | 0.0551 | 2.99e-02 | 2.89e-02 | -1.77e-02 | 1.99e-02 | 2.45e-02 | 4.70e-01 | 4.85e-01 | 6.69e-01 | 6.30e-01 | 5.53e-01 |
| RHYTHMIC PROCESS | 287 | 3.14e-01 | 7.25e-01 | 0.0550 | 3.17e-02 | 6.03e-03 | 2.60e-03 | 1.34e-02 | 4.24e-02 | 3.55e-01 | 8.61e-01 | 9.40e-01 | 6.95e-01 | 2.16e-01 |
| STRIATED MUSCLE CELL DIFFERENTIATION | 298 | 6.71e-01 | 9.25e-01 | 0.0550 | -2.10e-02 | -4.29e-03 | 2.25e-02 | 2.20e-03 | 4.53e-02 | 5.32e-01 | 8.99e-01 | 5.04e-01 | 9.48e-01 | 1.78e-01 |
| NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 94 | 9.96e-01 | 1.00e+00 | 0.0550 | 3.32e-02 | 2.98e-02 | 1.73e-02 | 2.68e-02 | 4.18e-03 | 5.78e-01 | 6.18e-01 | 7.72e-01 | 6.53e-01 | 9.44e-01 |
| SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 462 | 6.28e-01 | 9.09e-01 | 0.0549 | 2.84e-02 | 3.03e-02 | 1.35e-02 | 3.30e-02 | 5.05e-03 | 2.96e-01 | 2.65e-01 | 6.19e-01 | 2.24e-01 | 8.52e-01 |
| NEGATIVE REGULATION OF CELL PROJECTION ORGANIZATION | 180 | 7.51e-01 | 9.51e-01 | 0.0549 | 1.29e-02 | 3.29e-02 | 1.17e-02 | 1.54e-02 | 3.73e-02 | 7.66e-01 | 4.46e-01 | 7.86e-01 | 7.22e-01 | 3.88e-01 |
| POSITIVE REGULATION OF SMALL MOLECULE METABOLIC PROCESS | 141 | 3.92e-01 | 7.84e-01 | 0.0549 | 7.90e-03 | 1.71e-02 | -2.03e-02 | -2.59e-02 | 3.97e-02 | 8.71e-01 | 7.26e-01 | 6.77e-01 | 5.96e-01 | 4.16e-01 |
| PULMONARY VALVE DEVELOPMENT | 23 | 9.98e-01 | 1.00e+00 | 0.0549 | -1.58e-02 | 4.75e-03 | 3.26e-02 | 1.19e-02 | 3.91e-02 | 8.96e-01 | 9.69e-01 | 7.86e-01 | 9.21e-01 | 7.45e-01 |
| CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 147 | 7.03e-01 | 9.32e-01 | 0.0548 | 1.08e-02 | 4.92e-02 | 2.04e-02 | -4.00e-03 | 5.58e-03 | 8.21e-01 | 3.03e-01 | 6.69e-01 | 9.33e-01 | 9.07e-01 |
| REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 54 | 5.98e-01 | 8.98e-01 | 0.0548 | -1.16e-02 | 2.42e-03 | -4.41e-02 | 6.47e-03 | 2.96e-02 | 8.83e-01 | 9.75e-01 | 5.75e-01 | 9.34e-01 | 7.07e-01 |
| DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 231 | 5.99e-01 | 8.98e-01 | 0.0547 | -4.08e-02 | -1.38e-02 | -7.03e-03 | -9.05e-03 | 3.17e-02 | 2.85e-01 | 7.18e-01 | 8.54e-01 | 8.13e-01 | 4.07e-01 |
| TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 617 | 2.79e-02 | 2.07e-01 | 0.0547 | -1.14e-02 | 8.38e-03 | 2.25e-03 | 1.19e-02 | 5.14e-02 | 6.29e-01 | 7.22e-01 | 9.24e-01 | 6.15e-01 | 2.91e-02 |
| POSITIVE REGULATION OF JNK CASCADE | 85 | 9.06e-01 | 9.84e-01 | 0.0547 | -1.84e-02 | 2.86e-03 | -2.02e-02 | -4.72e-02 | 2.17e-03 | 7.69e-01 | 9.64e-01 | 7.47e-01 | 4.52e-01 | 9.72e-01 |
| CELLULAR HOMEOSTASIS | 782 | 7.75e-02 | 3.77e-01 | 0.0546 | -6.54e-03 | 2.78e-02 | 2.92e-02 | 2.43e-03 | 3.62e-02 | 7.56e-01 | 1.86e-01 | 1.65e-01 | 9.08e-01 | 8.51e-02 |
| POSITIVE REGULATION OF SYNAPTIC TRANSMISSION | 166 | 7.88e-01 | 9.63e-01 | 0.0545 | -2.78e-02 | -1.31e-02 | 6.90e-03 | -2.88e-02 | 3.39e-02 | 5.36e-01 | 7.72e-01 | 8.78e-01 | 5.22e-01 | 4.52e-01 |
| REGULATION OF ERBB SIGNALING PATHWAY | 70 | 7.80e-01 | 9.59e-01 | 0.0542 | 2.14e-02 | -5.13e-03 | -1.98e-02 | 2.03e-02 | 4.06e-02 | 7.57e-01 | 9.41e-01 | 7.74e-01 | 7.69e-01 | 5.57e-01 |
| DEVELOPMENTAL CELL GROWTH | 226 | 8.97e-01 | 9.82e-01 | 0.0542 | -3.38e-02 | -1.82e-02 | -2.71e-02 | -2.68e-02 | 3.59e-03 | 3.81e-01 | 6.37e-01 | 4.83e-01 | 4.88e-01 | 9.26e-01 |
| ISOPRENOID METABOLIC PROCESS | 130 | 7.53e-01 | 9.51e-01 | 0.0539 | 3.56e-02 | -4.40e-03 | -2.19e-02 | -2.88e-03 | -3.36e-02 | 4.84e-01 | 9.31e-01 | 6.66e-01 | 9.55e-01 | 5.08e-01 |
| REGULATION OF EXTENT OF CELL GROWTH | 101 | 9.30e-01 | 9.90e-01 | 0.0535 | -2.58e-02 | -7.25e-03 | -3.42e-02 | -3.12e-02 | 1.46e-04 | 6.54e-01 | 9.00e-01 | 5.52e-01 | 5.87e-01 | 9.98e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE CELL CELL ADHESION | 146 | 7.39e-01 | 9.49e-01 | 0.0535 | 3.98e-02 | -3.31e-03 | 7.41e-03 | 3.44e-02 | 4.94e-03 | 4.07e-01 | 9.45e-01 | 8.77e-01 | 4.72e-01 | 9.18e-01 |
| RESPONSE TO PAIN | 34 | 9.17e-01 | 9.86e-01 | 0.0534 | 3.34e-02 | 2.54e-02 | 2.52e-02 | -2.14e-02 | 1.43e-03 | 7.36e-01 | 7.97e-01 | 7.99e-01 | 8.29e-01 | 9.89e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 87 | 3.21e-01 | 7.32e-01 | 0.0533 | 6.54e-03 | 2.22e-04 | 3.81e-02 | -3.17e-02 | 1.87e-02 | 9.16e-01 | 9.97e-01 | 5.39e-01 | 6.09e-01 | 7.63e-01 |
| REGULATED EXOCYTOSIS | 216 | 6.52e-01 | 9.19e-01 | 0.0533 | 1.07e-02 | 4.08e-02 | 2.57e-02 | -4.40e-03 | 1.94e-02 | 7.87e-01 | 3.01e-01 | 5.15e-01 | 9.11e-01 | 6.23e-01 |
| CELL CELL RECOGNITION | 72 | 7.53e-01 | 9.51e-01 | 0.0531 | -4.60e-02 | 9.29e-03 | 2.05e-02 | -1.35e-02 | -4.96e-03 | 5.00e-01 | 8.92e-01 | 7.64e-01 | 8.43e-01 | 9.42e-01 |
| L ASPARTATE TRANSMEMBRANE TRANSPORT | 11 | 9.98e-01 | 1.00e+00 | 0.0530 | -4.78e-03 | -2.68e-02 | 6.92e-03 | -1.49e-02 | 4.24e-02 | 9.78e-01 | 8.78e-01 | 9.68e-01 | 9.32e-01 | 8.08e-01 |
| L ALANINE TRANSPORT | 10 | 9.98e-01 | 1.00e+00 | 0.0527 | -7.39e-03 | 2.66e-02 | -2.63e-02 | -3.16e-02 | -1.79e-02 | 9.68e-01 | 8.84e-01 | 8.85e-01 | 8.63e-01 | 9.22e-01 |
| MAST CELL ACTIVATION | 67 | 9.76e-01 | 9.96e-01 | 0.0525 | 1.40e-02 | 4.29e-02 | 2.33e-02 | 1.11e-02 | -7.22e-03 | 8.43e-01 | 5.43e-01 | 7.41e-01 | 8.76e-01 | 9.19e-01 |
| POSITIVE REGULATION OF EXTRACELLULAR MATRIX ASSEMBLY | 12 | 9.98e-01 | 1.00e+00 | 0.0524 | 1.72e-02 | 4.90e-02 | 5.60e-03 | -1.86e-03 | 3.49e-03 | 9.18e-01 | 7.69e-01 | 9.73e-01 | 9.91e-01 | 9.83e-01 |
| MECHANORECEPTOR DIFFERENTIATION | 68 | 8.66e-01 | 9.78e-01 | 0.0524 | -1.21e-02 | 1.37e-02 | 4.30e-02 | -9.48e-03 | 2.18e-02 | 8.63e-01 | 8.45e-01 | 5.40e-01 | 8.92e-01 | 7.56e-01 |
| REGULATION OF TRANS SYNAPTIC SIGNALING | 469 | 5.52e-02 | 3.11e-01 | 0.0523 | -2.60e-02 | 2.27e-02 | 2.00e-02 | -1.76e-02 | 2.89e-02 | 3.34e-01 | 4.00e-01 | 4.58e-01 | 5.13e-01 | 2.83e-01 |
| ADAPTIVE IMMUNE RESPONSE | 448 | 1.79e-01 | 5.63e-01 | 0.0523 | 7.45e-03 | 4.11e-03 | 2.12e-02 | 4.63e-02 | 8.36e-03 | 7.87e-01 | 8.82e-01 | 4.43e-01 | 9.27e-02 | 7.62e-01 |
| SPERM EGG RECOGNITION | 51 | 8.60e-01 | 9.78e-01 | 0.0523 | -1.63e-02 | 4.40e-02 | 1.35e-02 | -1.41e-02 | -1.24e-02 | 8.41e-01 | 5.87e-01 | 8.68e-01 | 8.61e-01 | 8.78e-01 |
| SULFUR COMPOUND TRANSPORT | 53 | 9.33e-01 | 9.90e-01 | 0.0523 | -2.29e-02 | 1.67e-02 | -6.40e-03 | -3.04e-02 | 3.11e-02 | 7.73e-01 | 8.33e-01 | 9.36e-01 | 7.02e-01 | 6.96e-01 |
| SEXUAL REPRODUCTION | 989 | 5.49e-01 | 8.73e-01 | 0.0522 | 3.29e-02 | 2.05e-02 | 1.74e-02 | 3.03e-02 | 1.13e-03 | 7.96e-02 | 2.76e-01 | 3.54e-01 | 1.07e-01 | 9.52e-01 |
| REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION | 77 | 9.31e-01 | 9.90e-01 | 0.0517 | -1.15e-02 | -1.36e-02 | -4.48e-02 | -1.62e-02 | -9.04e-03 | 8.61e-01 | 8.36e-01 | 4.96e-01 | 8.06e-01 | 8.91e-01 |
| AMEBOIDAL TYPE CELL MIGRATION | 478 | 1.11e-01 | 4.54e-01 | 0.0516 | -1.09e-02 | 1.06e-02 | 1.22e-03 | 6.45e-03 | 4.89e-02 | 6.83e-01 | 6.92e-01 | 9.64e-01 | 8.09e-01 | 6.69e-02 |
| REGULATION OF LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 28 | 9.18e-01 | 9.86e-01 | 0.0516 | -3.75e-02 | 3.02e-02 | 8.74e-03 | 2.70e-03 | 1.63e-02 | 7.32e-01 | 7.82e-01 | 9.36e-01 | 9.80e-01 | 8.82e-01 |
| CELLULAR RESPONSE TO INSULIN STIMULUS | 203 | 1.71e-01 | 5.55e-01 | 0.0516 | -6.09e-03 | 1.51e-02 | -1.95e-02 | -1.48e-03 | 4.49e-02 | 8.81e-01 | 7.11e-01 | 6.31e-01 | 9.71e-01 | 2.70e-01 |
| REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 1087 | 4.29e-03 | 5.52e-02 | 0.0515 | 3.40e-02 | 3.37e-02 | -1.04e-02 | 9.50e-03 | -1.28e-02 | 5.86e-02 | 6.04e-02 | 5.64e-01 | 5.97e-01 | 4.76e-01 |
| REGULATION OF STEROID METABOLIC PROCESS | 101 | 8.36e-01 | 9.73e-01 | 0.0513 | -4.14e-03 | -1.90e-03 | -9.91e-03 | 5.45e-03 | 4.98e-02 | 9.43e-01 | 9.74e-01 | 8.63e-01 | 9.25e-01 | 3.87e-01 |
| CELLULAR COMPONENT MAINTENANCE | 72 | 9.11e-01 | 9.85e-01 | 0.0513 | 8.18e-03 | 5.87e-03 | -3.45e-03 | -1.29e-02 | 4.85e-02 | 9.04e-01 | 9.31e-01 | 9.60e-01 | 8.50e-01 | 4.77e-01 |
| CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM | 451 | 7.66e-01 | 9.55e-01 | 0.0512 | -4.26e-03 | -1.07e-02 | -2.89e-02 | -1.26e-02 | -3.87e-02 | 8.77e-01 | 6.97e-01 | 2.92e-01 | 6.46e-01 | 1.59e-01 |
| POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 983 | 3.05e-01 | 7.17e-01 | 0.0512 | 3.34e-02 | 2.71e-02 | 1.01e-02 | 2.23e-02 | 1.30e-02 | 7.66e-02 | 1.50e-01 | 5.91e-01 | 2.37e-01 | 4.89e-01 |
| REGULATION OF CELL SUBSTRATE ADHESION | 213 | 8.34e-01 | 9.73e-01 | 0.0510 | -7.90e-03 | -1.98e-02 | -4.06e-02 | -1.85e-02 | -1.23e-02 | 8.43e-01 | 6.19e-01 | 3.07e-01 | 6.42e-01 | 7.56e-01 |
| REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 224 | 3.47e-01 | 7.50e-01 | 0.0509 | -1.23e-02 | 2.31e-03 | -4.22e-02 | -1.26e-02 | -2.24e-02 | 7.51e-01 | 9.53e-01 | 2.77e-01 | 7.44e-01 | 5.64e-01 |
| NUCLEOSIDE PHOSPHATE CATABOLIC PROCESS | 83 | 7.32e-01 | 9.45e-01 | 0.0509 | 3.70e-02 | -6.43e-03 | -2.40e-03 | 3.55e-03 | 3.41e-02 | 5.60e-01 | 9.19e-01 | 9.70e-01 | 9.55e-01 | 5.91e-01 |
| NEGATIVE REGULATION OF T CELL PROLIFERATION | 68 | 8.18e-01 | 9.70e-01 | 0.0507 | 1.53e-02 | -3.65e-02 | -2.10e-02 | 3.62e-03 | 2.35e-02 | 8.27e-01 | 6.03e-01 | 7.65e-01 | 9.59e-01 | 7.37e-01 |
| SYNAPTIC VESICLE EXOCYTOSIS | 91 | 8.21e-01 | 9.71e-01 | 0.0507 | -8.81e-04 | 1.06e-02 | 2.28e-02 | -2.32e-02 | 3.74e-02 | 9.88e-01 | 8.61e-01 | 7.07e-01 | 7.02e-01 | 5.38e-01 |
| SYNAPTIC SIGNALING | 747 | 2.53e-02 | 1.95e-01 | 0.0506 | -1.40e-02 | 2.62e-02 | 2.52e-02 | -9.94e-03 | 3.07e-02 | 5.16e-01 | 2.22e-01 | 2.41e-01 | 6.44e-01 | 1.53e-01 |
| REGULATION OF PEPTIDASE ACTIVITY | 299 | 7.51e-01 | 9.51e-01 | 0.0505 | 1.21e-02 | 3.17e-02 | 2.08e-02 | 3.60e-03 | 3.10e-02 | 7.20e-01 | 3.46e-01 | 5.37e-01 | 9.15e-01 | 3.57e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO MEMBRANE | 100 | 8.68e-01 | 9.78e-01 | 0.0504 | -2.10e-02 | 1.90e-02 | 1.87e-02 | 8.25e-03 | 3.63e-02 | 7.17e-01 | 7.42e-01 | 7.46e-01 | 8.87e-01 | 5.30e-01 |
| INSULIN RECEPTOR SIGNALING PATHWAY | 123 | 2.78e-01 | 6.88e-01 | 0.0503 | 5.01e-03 | -1.64e-03 | -3.52e-02 | 1.76e-02 | 3.08e-02 | 9.24e-01 | 9.75e-01 | 5.00e-01 | 7.36e-01 | 5.56e-01 |
| REGULATION OF ANATOMICAL STRUCTURE SIZE | 486 | 8.27e-01 | 9.72e-01 | 0.0503 | 1.26e-02 | 2.27e-02 | 2.46e-02 | 1.25e-02 | 3.30e-02 | 6.34e-01 | 3.91e-01 | 3.53e-01 | 6.37e-01 | 2.13e-01 |
| ALDITOL METABOLIC PROCESS | 21 | 9.90e-01 | 9.98e-01 | 0.0502 | -1.72e-02 | -3.90e-03 | 2.37e-03 | -4.68e-02 | 3.28e-03 | 8.91e-01 | 9.75e-01 | 9.85e-01 | 7.11e-01 | 9.79e-01 |
| POSITIVE REGULATION OF OSSIFICATION | 52 | 8.59e-01 | 9.78e-01 | 0.0501 | -9.87e-03 | 1.88e-02 | 9.69e-03 | 3.93e-02 | 2.07e-02 | 9.02e-01 | 8.15e-01 | 9.04e-01 | 6.24e-01 | 7.97e-01 |
| VASODILATION | 46 | 9.92e-01 | 9.98e-01 | 0.0497 | -2.74e-02 | -1.06e-02 | 1.95e-02 | 1.14e-03 | 3.51e-02 | 7.48e-01 | 9.01e-01 | 8.19e-01 | 9.89e-01 | 6.81e-01 |
| OOGENESIS | 108 | 9.23e-01 | 9.88e-01 | 0.0496 | 2.38e-02 | 8.45e-03 | 2.91e-02 | 2.75e-02 | -1.49e-02 | 6.69e-01 | 8.79e-01 | 6.02e-01 | 6.21e-01 | 7.89e-01 |
| POSITIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 18 | 9.76e-01 | 9.96e-01 | 0.0492 | -3.27e-02 | 1.62e-02 | 4.45e-03 | 1.01e-02 | -3.11e-02 | 8.10e-01 | 9.05e-01 | 9.74e-01 | 9.41e-01 | 8.19e-01 |
| CARBOHYDRATE BIOSYNTHETIC PROCESS | 206 | 3.77e-01 | 7.75e-01 | 0.0491 | 1.57e-02 | 2.59e-02 | -2.46e-03 | 3.14e-02 | 2.24e-02 | 6.97e-01 | 5.22e-01 | 9.51e-01 | 4.37e-01 | 5.79e-01 |
| RESPONSE TO CALCIUM ION | 140 | 5.33e-01 | 8.64e-01 | 0.0491 | 6.15e-04 | 2.59e-02 | -1.56e-02 | -3.73e-02 | 1.02e-02 | 9.90e-01 | 5.96e-01 | 7.50e-01 | 4.46e-01 | 8.35e-01 |
| RESPONSE TO XENOBIOTIC STIMULUS | 424 | 1.33e-01 | 4.93e-01 | 0.0490 | -2.37e-02 | 2.05e-02 | 1.09e-02 | -1.62e-02 | 3.22e-02 | 4.03e-01 | 4.69e-01 | 7.00e-01 | 5.67e-01 | 2.56e-01 |
| NEGATIVE REGULATION OF VASCULAR PERMEABILITY | 18 | 9.19e-01 | 9.86e-01 | 0.0487 | 7.83e-03 | -2.90e-02 | 3.03e-02 | -1.77e-02 | -1.52e-02 | 9.54e-01 | 8.31e-01 | 8.24e-01 | 8.96e-01 | 9.11e-01 |
| ERK1 AND ERK2 CASCADE | 335 | 1.24e-01 | 4.80e-01 | 0.0486 | -1.79e-03 | 1.67e-02 | -2.48e-02 | -3.73e-02 | 8.21e-03 | 9.55e-01 | 5.99e-01 | 4.35e-01 | 2.41e-01 | 7.96e-01 |
| INORGANIC ION HOMEOSTASIS | 515 | 4.39e-01 | 8.11e-01 | 0.0483 | -2.64e-02 | -8.82e-03 | 1.52e-04 | -2.48e-02 | 3.08e-02 | 3.06e-01 | 7.32e-01 | 9.95e-01 | 3.35e-01 | 2.32e-01 |
| POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 52 | 8.26e-01 | 9.72e-01 | 0.0483 | -3.72e-02 | 1.84e-02 | 2.17e-02 | 1.19e-02 | 6.02e-04 | 6.43e-01 | 8.18e-01 | 7.87e-01 | 8.82e-01 | 9.94e-01 |
| JNK CASCADE | 157 | 9.38e-01 | 9.92e-01 | 0.0479 | 1.72e-04 | -1.65e-02 | -3.07e-02 | -2.73e-02 | -1.84e-02 | 9.97e-01 | 7.21e-01 | 5.07e-01 | 5.55e-01 | 6.91e-01 |
| NEGATIVE REGULATION OF IMMUNE EFFECTOR PROCESS | 122 | 9.67e-01 | 9.94e-01 | 0.0478 | 2.67e-02 | 1.80e-02 | -2.37e-03 | 1.79e-02 | -3.04e-02 | 6.10e-01 | 7.31e-01 | 9.64e-01 | 7.33e-01 | 5.62e-01 |
| REGULATION OF TUBE SIZE | 142 | 7.09e-01 | 9.35e-01 | 0.0478 | -2.05e-02 | -2.36e-02 | 1.56e-03 | -3.58e-02 | -5.09e-03 | 6.74e-01 | 6.28e-01 | 9.74e-01 | 4.62e-01 | 9.17e-01 |
| RESPONSE TO ALCOHOL | 246 | 4.40e-01 | 8.12e-01 | 0.0478 | -5.87e-03 | -4.41e-03 | -2.00e-02 | -1.47e-02 | 4.01e-02 | 8.74e-01 | 9.05e-01 | 5.88e-01 | 6.91e-01 | 2.78e-01 |
| CELL JUNCTION ORGANIZATION | 716 | 2.41e-01 | 6.45e-01 | 0.0476 | -3.28e-02 | -4.28e-03 | -1.78e-02 | -2.89e-02 | -4.41e-03 | 1.35e-01 | 8.45e-01 | 4.16e-01 | 1.87e-01 | 8.41e-01 |
| MUSCLE HYPERTROPHY IN RESPONSE TO STRESS | 31 | 9.82e-01 | 9.96e-01 | 0.0474 | -2.71e-02 | 2.14e-02 | 2.69e-02 | -3.58e-03 | 1.78e-02 | 7.94e-01 | 8.36e-01 | 7.96e-01 | 9.73e-01 | 8.64e-01 |
| CELLULAR COMPONENT MORPHOGENESIS | 753 | 3.85e-01 | 7.79e-01 | 0.0473 | -3.40e-02 | -1.20e-02 | -1.25e-02 | -2.44e-02 | 1.39e-02 | 1.12e-01 | 5.74e-01 | 5.58e-01 | 2.55e-01 | 5.17e-01 |
| DETOXIFICATION | 153 | 5.65e-01 | 8.81e-01 | 0.0473 | -7.61e-04 | 4.18e-02 | 7.18e-03 | -1.84e-02 | 9.95e-03 | 9.87e-01 | 3.73e-01 | 8.78e-01 | 6.94e-01 | 8.32e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE MEDIATED IMMUNITY | 67 | 9.81e-01 | 9.96e-01 | 0.0472 | -3.08e-02 | -3.42e-02 | -1.03e-02 | 1.06e-03 | -1.53e-03 | 6.63e-01 | 6.28e-01 | 8.85e-01 | 9.88e-01 | 9.83e-01 |
| INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 31 | 9.90e-01 | 9.98e-01 | 0.0470 | 5.38e-03 | -3.18e-02 | -3.07e-02 | -1.45e-02 | 4.21e-03 | 9.59e-01 | 7.59e-01 | 7.68e-01 | 8.89e-01 | 9.68e-01 |
| MUSCLE CELL MIGRATION | 100 | 8.63e-01 | 9.78e-01 | 0.0469 | -1.92e-02 | 1.14e-02 | -5.70e-03 | -7.00e-03 | -4.03e-02 | 7.41e-01 | 8.44e-01 | 9.21e-01 | 9.04e-01 | 4.86e-01 |
| REGENERATION | 181 | 7.32e-01 | 9.45e-01 | 0.0468 | 7.08e-03 | 3.01e-02 | 6.27e-03 | 2.22e-03 | 3.45e-02 | 8.70e-01 | 4.85e-01 | 8.84e-01 | 9.59e-01 | 4.23e-01 |
| MONOCARBOXYLIC ACID METABOLIC PROCESS | 612 | 4.78e-01 | 8.33e-01 | 0.0467 | 2.56e-02 | 2.94e-02 | 9.90e-03 | 1.11e-02 | 2.10e-02 | 2.80e-01 | 2.14e-01 | 6.76e-01 | 6.39e-01 | 3.76e-01 |
| REGULATION OF MUSCLE HYPERTROPHY | 69 | 9.20e-01 | 9.86e-01 | 0.0466 | 9.63e-03 | 1.44e-02 | 2.21e-02 | -2.56e-03 | -3.72e-02 | 8.90e-01 | 8.36e-01 | 7.51e-01 | 9.71e-01 | 5.93e-01 |
| CELL PROJECTION ASSEMBLY | 589 | 5.08e-01 | 8.53e-01 | 0.0466 | 2.54e-02 | 1.64e-02 | 8.05e-03 | 3.09e-02 | 1.55e-02 | 2.91e-01 | 4.95e-01 | 7.38e-01 | 2.00e-01 | 5.21e-01 |
| REGULATION OF BLOOD PRESSURE | 175 | 2.23e-01 | 6.23e-01 | 0.0464 | 1.72e-02 | 1.71e-02 | 8.98e-03 | -3.85e-02 | -2.21e-03 | 6.95e-01 | 6.96e-01 | 8.38e-01 | 3.80e-01 | 9.60e-01 |
| CELL PROJECTION ORGANIZATION | 1547 | 6.45e-02 | 3.38e-01 | 0.0464 | 6.22e-03 | 1.76e-02 | 1.39e-02 | 1.84e-02 | 3.57e-02 | 6.83e-01 | 2.47e-01 | 3.61e-01 | 2.27e-01 | 1.90e-02 |
| CELLULAR RESPONSE TO PEPTIDE HORMONE STIMULUS | 302 | 1.10e-01 | 4.54e-01 | 0.0464 | -1.04e-02 | 1.40e-02 | -1.51e-02 | -2.29e-03 | 4.02e-02 | 7.56e-01 | 6.75e-01 | 6.52e-01 | 9.46e-01 | 2.30e-01 |
| INNATE IMMUNE RESPONSE | 911 | 1.95e-01 | 5.83e-01 | 0.0461 | 3.59e-02 | 2.63e-02 | 1.21e-03 | 8.21e-03 | -8.51e-03 | 6.61e-02 | 1.78e-01 | 9.51e-01 | 6.74e-01 | 6.63e-01 |
| POSITIVE REGULATION OF EXOCYTOSIS | 74 | 9.78e-01 | 9.96e-01 | 0.0460 | 1.47e-02 | 2.23e-02 | 2.64e-02 | 1.42e-02 | -2.24e-02 | 8.27e-01 | 7.40e-01 | 6.94e-01 | 8.32e-01 | 7.39e-01 |
| LIPID CATABOLIC PROCESS | 329 | 1.67e-01 | 5.46e-01 | 0.0460 | 2.01e-02 | 2.91e-02 | -9.40e-03 | -2.75e-02 | -3.41e-03 | 5.30e-01 | 3.64e-01 | 7.70e-01 | 3.90e-01 | 9.15e-01 |
| REGULATION OF BEHAVIOR | 73 | 9.78e-01 | 9.96e-01 | 0.0459 | -1.29e-02 | 1.03e-02 | -1.40e-02 | -2.22e-02 | -3.39e-02 | 8.48e-01 | 8.79e-01 | 8.37e-01 | 7.43e-01 | 6.16e-01 |
| DEFENSE RESPONSE | 1743 | 9.54e-03 | 9.85e-02 | 0.0457 | 2.86e-02 | 2.40e-02 | -8.92e-03 | 1.23e-03 | -2.47e-02 | 4.68e-02 | 9.58e-02 | 5.36e-01 | 9.32e-01 | 8.69e-02 |
| CIRCULATORY SYSTEM PROCESS | 577 | 8.08e-02 | 3.84e-01 | 0.0454 | -1.47e-02 | 5.95e-03 | -6.53e-03 | -4.21e-02 | 1.24e-03 | 5.47e-01 | 8.07e-01 | 7.89e-01 | 8.41e-02 | 9.59e-01 |
| POSITIVE REGULATION OF MAPK CASCADE | 467 | 9.78e-02 | 4.26e-01 | 0.0454 | 5.50e-03 | 2.30e-02 | -2.39e-02 | -2.72e-02 | -1.38e-02 | 8.39e-01 | 3.94e-01 | 3.76e-01 | 3.14e-01 | 6.09e-01 |
| NEGATIVE REGULATION OF CYTOSKELETON ORGANIZATION | 150 | 8.89e-01 | 9.80e-01 | 0.0454 | -2.87e-02 | 1.22e-03 | -1.90e-02 | -2.56e-02 | -1.48e-02 | 5.45e-01 | 9.79e-01 | 6.87e-01 | 5.88e-01 | 7.54e-01 |
| REGULATION OF PROTEIN TYROSINE KINASE ACTIVITY | 54 | 9.86e-01 | 9.97e-01 | 0.0453 | 1.01e-02 | 2.80e-02 | 8.08e-03 | 1.19e-02 | 3.10e-02 | 8.98e-01 | 7.22e-01 | 9.18e-01 | 8.79e-01 | 6.94e-01 |
| RESPONSE TO ETHANOL | 117 | 7.76e-01 | 9.58e-01 | 0.0449 | -2.23e-02 | 4.37e-03 | -1.39e-02 | -8.39e-03 | 3.52e-02 | 6.77e-01 | 9.35e-01 | 7.95e-01 | 8.75e-01 | 5.11e-01 |
| IMPORT INTO CELL | 900 | 9.13e-03 | 9.55e-02 | 0.0446 | 1.60e-02 | 2.80e-02 | -1.23e-02 | -2.32e-02 | -1.60e-02 | 4.15e-01 | 1.55e-01 | 5.32e-01 | 2.37e-01 | 4.14e-01 |
| REGULATION OF CYTOSOLIC CALCIUM ION CONCENTRATION | 57 | 9.82e-01 | 9.96e-01 | 0.0440 | -4.88e-03 | -3.79e-03 | 3.41e-02 | 1.32e-02 | 2.37e-02 | 9.49e-01 | 9.61e-01 | 6.56e-01 | 8.63e-01 | 7.57e-01 |
| NEGATIVE REGULATION OF IMMUNE RESPONSE | 199 | 9.83e-01 | 9.96e-01 | 0.0436 | 1.68e-02 | 1.21e-02 | 1.54e-02 | 2.22e-02 | 2.72e-02 | 6.82e-01 | 7.68e-01 | 7.08e-01 | 5.90e-01 | 5.08e-01 |
| REGULATION OF CALCIUM ION TRANSPORT | 241 | 3.23e-01 | 7.33e-01 | 0.0435 | -3.46e-02 | 1.22e-02 | -3.57e-03 | -1.28e-02 | 1.92e-02 | 3.54e-01 | 7.44e-01 | 9.24e-01 | 7.33e-01 | 6.07e-01 |
| POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 697 | 3.60e-01 | 7.59e-01 | 0.0434 | 3.22e-02 | 2.53e-02 | 1.21e-03 | 1.31e-02 | 5.71e-03 | 1.47e-01 | 2.55e-01 | 9.56e-01 | 5.56e-01 | 7.97e-01 |
| ARACHIDONIC ACID METABOLIC PROCESS | 56 | 8.81e-01 | 9.79e-01 | 0.0432 | 1.09e-03 | 6.04e-03 | 2.23e-02 | -1.93e-02 | -3.10e-02 | 9.89e-01 | 9.38e-01 | 7.73e-01 | 8.02e-01 | 6.88e-01 |
| SYNAPSE ORGANIZATION | 449 | 2.47e-01 | 6.52e-01 | 0.0429 | -7.99e-03 | 2.92e-02 | 1.89e-02 | -1.05e-02 | 2.14e-02 | 7.71e-01 | 2.88e-01 | 4.93e-01 | 7.03e-01 | 4.37e-01 |
| LONG CHAIN FATTY ACYL COA METABOLIC PROCESS | 24 | 9.53e-01 | 9.94e-01 | 0.0428 | -1.19e-02 | 3.18e-02 | -1.52e-02 | 1.24e-03 | 2.12e-02 | 9.19e-01 | 7.88e-01 | 8.98e-01 | 9.92e-01 | 8.57e-01 |
| POSITIVE REGULATION OF CYTOSOLIC CALCIUM ION CONCENTRATION | 165 | 5.02e-01 | 8.48e-01 | 0.0427 | 1.01e-02 | 2.72e-02 | -1.85e-02 | -2.18e-02 | 1.29e-02 | 8.22e-01 | 5.46e-01 | 6.82e-01 | 6.29e-01 | 7.76e-01 |
| TYPE II INTERFERON PRODUCTION | 113 | 7.85e-01 | 9.61e-01 | 0.0425 | -2.98e-03 | -1.53e-02 | -3.89e-02 | -2.59e-03 | 6.86e-03 | 9.56e-01 | 7.78e-01 | 4.75e-01 | 9.62e-01 | 9.00e-01 |
| REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 889 | 1.22e-02 | 1.18e-01 | 0.0425 | 8.85e-03 | 2.60e-02 | -1.82e-03 | 4.07e-04 | 3.24e-02 | 6.54e-01 | 1.88e-01 | 9.27e-01 | 9.84e-01 | 1.02e-01 |
| REGULATION OF SKELETAL MUSCLE FIBER DEVELOPMENT | 11 | 1.00e+00 | 1.00e+00 | 0.0424 | -7.06e-03 | -2.03e-02 | -3.79e-03 | -8.43e-03 | 3.54e-02 | 9.68e-01 | 9.07e-01 | 9.83e-01 | 9.61e-01 | 8.39e-01 |
| CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 543 | 4.64e-01 | 8.25e-01 | 0.0423 | -1.77e-02 | 5.84e-03 | 9.67e-03 | -2.98e-03 | 3.66e-02 | 4.80e-01 | 8.16e-01 | 7.00e-01 | 9.05e-01 | 1.44e-01 |
| REGULATION OF MEIOTIC NUCLEAR DIVISION | 33 | 9.93e-01 | 9.99e-01 | 0.0421 | 1.35e-02 | -1.17e-02 | 2.26e-02 | 2.88e-02 | 1.08e-02 | 8.93e-01 | 9.08e-01 | 8.23e-01 | 7.75e-01 | 9.15e-01 |
| MULTICELLULAR ORGANISM REPRODUCTION | 876 | 2.04e-01 | 5.97e-01 | 0.0421 | 3.31e-02 | 1.90e-02 | -3.54e-03 | 1.73e-02 | -2.23e-03 | 9.64e-02 | 3.40e-01 | 8.59e-01 | 3.85e-01 | 9.11e-01 |
| REGULATION OF ACTIN FILAMENT BASED PROCESS | 362 | 8.46e-01 | 9.76e-01 | 0.0420 | 2.54e-02 | 2.84e-02 | 6.32e-03 | 1.53e-02 | 5.88e-03 | 4.07e-01 | 3.53e-01 | 8.36e-01 | 6.17e-01 | 8.48e-01 |
| NEGATIVE REGULATION OF GENE EXPRESSION | 1478 | 8.01e-02 | 3.83e-01 | 0.0417 | -9.45e-03 | -2.26e-02 | -2.63e-02 | -8.04e-04 | -2.11e-02 | 5.43e-01 | 1.46e-01 | 9.05e-02 | 9.59e-01 | 1.75e-01 |
| RESPONSE TO MECHANICAL STIMULUS | 209 | 5.63e-01 | 8.79e-01 | 0.0416 | -1.60e-02 | 1.37e-02 | -2.41e-02 | -1.61e-02 | -2.10e-02 | 6.89e-01 | 7.34e-01 | 5.47e-01 | 6.89e-01 | 6.00e-01 |
| MAINTENANCE OF LOCATION | 335 | 3.22e-01 | 7.32e-01 | 0.0415 | 3.59e-03 | 1.08e-02 | 1.01e-02 | 3.59e-02 | -1.42e-02 | 9.10e-01 | 7.34e-01 | 7.50e-01 | 2.59e-01 | 6.56e-01 |
| REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 41 | 9.82e-01 | 9.96e-01 | 0.0414 | -6.14e-04 | -1.98e-03 | -1.43e-02 | 3.76e-03 | 3.86e-02 | 9.95e-01 | 9.83e-01 | 8.74e-01 | 9.67e-01 | 6.69e-01 |
| POSITIVE REGULATION OF T CELL PROLIFERATION | 100 | 9.87e-01 | 9.97e-01 | 0.0410 | 1.62e-02 | -4.45e-04 | -1.44e-02 | 1.37e-03 | -3.48e-02 | 7.79e-01 | 9.94e-01 | 8.04e-01 | 9.81e-01 | 5.47e-01 |
| MAPK CASCADE | 746 | 3.69e-01 | 7.69e-01 | 0.0408 | 2.29e-02 | 2.94e-02 | 5.20e-03 | 9.15e-03 | 1.27e-02 | 2.86e-01 | 1.72e-01 | 8.09e-01 | 6.70e-01 | 5.54e-01 |
| ORGANIC HYDROXY COMPOUND METABOLIC PROCESS | 541 | 5.75e-01 | 8.84e-01 | 0.0404 | -2.33e-02 | -8.93e-03 | -1.32e-02 | -1.68e-02 | 2.35e-02 | 3.55e-01 | 7.22e-01 | 6.01e-01 | 5.03e-01 | 3.49e-01 |
| CARDIAC CELL DEVELOPMENT | 92 | 8.85e-01 | 9.80e-01 | 0.0400 | -7.97e-03 | 7.15e-03 | 1.82e-02 | -2.57e-02 | 2.23e-02 | 8.95e-01 | 9.06e-01 | 7.63e-01 | 6.70e-01 | 7.12e-01 |
| REGULATION OF HORMONE LEVELS | 522 | 3.29e-01 | 7.38e-01 | 0.0395 | -3.62e-03 | 1.45e-02 | -1.95e-02 | -2.54e-02 | -1.78e-02 | 8.88e-01 | 5.71e-01 | 4.46e-01 | 3.21e-01 | 4.86e-01 |
| REGULATION OF ACTIN FILAMENT LENGTH | 149 | 9.85e-01 | 9.97e-01 | 0.0395 | 2.17e-02 | 2.23e-02 | 7.65e-03 | 2.01e-02 | 1.11e-02 | 6.47e-01 | 6.38e-01 | 8.72e-01 | 6.72e-01 | 8.14e-01 |
| ACTIN FILAMENT BUNDLE ORGANIZATION | 160 | 9.49e-01 | 9.94e-01 | 0.0387 | 1.93e-02 | 2.63e-02 | 7.13e-03 | 3.39e-03 | 1.93e-02 | 6.74e-01 | 5.66e-01 | 8.76e-01 | 9.41e-01 | 6.74e-01 |
| ALCOHOL METABOLIC PROCESS | 355 | 5.66e-01 | 8.81e-01 | 0.0378 | -1.14e-02 | 3.36e-03 | -1.89e-03 | 4.77e-03 | 3.55e-02 | 7.12e-01 | 9.13e-01 | 9.51e-01 | 8.77e-01 | 2.50e-01 |
| CARBOHYDRATE DERIVATIVE TRANSPORT | 83 | 7.43e-01 | 9.50e-01 | 0.0372 | -6.90e-03 | 2.25e-02 | -2.69e-02 | -9.28e-03 | 4.07e-03 | 9.14e-01 | 7.23e-01 | 6.71e-01 | 8.84e-01 | 9.49e-01 |
| BLASTOCYST GROWTH | 22 | 9.93e-01 | 9.99e-01 | 0.0367 | 7.72e-03 | 1.45e-02 | -2.45e-02 | -1.75e-02 | 1.32e-02 | 9.50e-01 | 9.06e-01 | 8.42e-01 | 8.87e-01 | 9.15e-01 |
| POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 85 | 9.57e-01 | 9.94e-01 | 0.0366 | -1.74e-03 | 1.74e-02 | -1.13e-02 | -2.86e-02 | -9.37e-03 | 9.78e-01 | 7.81e-01 | 8.56e-01 | 6.49e-01 | 8.81e-01 |
| CELL MIGRATION IN HINDBRAIN | 16 | 9.98e-01 | 1.00e+00 | 0.0365 | 9.07e-03 | 1.65e-02 | 2.58e-03 | -2.59e-02 | 1.75e-02 | 9.50e-01 | 9.09e-01 | 9.86e-01 | 8.58e-01 | 9.04e-01 |
| STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 228 | 7.40e-01 | 9.49e-01 | 0.0364 | 6.88e-03 | 1.73e-02 | 1.81e-03 | -1.42e-02 | 2.78e-02 | 8.58e-01 | 6.52e-01 | 9.62e-01 | 7.11e-01 | 4.69e-01 |
| GERM CELL DEVELOPMENT | 345 | 9.06e-01 | 9.84e-01 | 0.0364 | 3.81e-03 | -1.31e-02 | -2.12e-02 | -1.52e-02 | -2.14e-02 | 9.03e-01 | 6.75e-01 | 4.98e-01 | 6.29e-01 | 4.95e-01 |
| REGULATION OF HYDROLASE ACTIVITY | 741 | 1.86e-01 | 5.72e-01 | 0.0362 | -3.35e-03 | 3.15e-03 | -2.98e-02 | -1.48e-02 | -1.36e-02 | 8.77e-01 | 8.84e-01 | 1.67e-01 | 4.93e-01 | 5.29e-01 |
| CYTOKINE MEDIATED SIGNALING PATHWAY | 487 | 4.19e-01 | 8.00e-01 | 0.0353 | 2.39e-03 | -2.26e-03 | -1.98e-02 | -2.91e-02 | -8.25e-04 | 9.28e-01 | 9.32e-01 | 4.54e-01 | 2.72e-01 | 9.75e-01 |
| INNER EAR RECEPTOR CELL STEREOCILIUM ORGANIZATION | 35 | 9.97e-01 | 1.00e+00 | 0.0352 | -3.18e-03 | 2.12e-03 | 2.47e-02 | 2.47e-02 | 2.97e-03 | 9.74e-01 | 9.83e-01 | 8.01e-01 | 8.00e-01 | 9.76e-01 |
| EXOCYTOSIS | 331 | 7.33e-01 | 9.46e-01 | 0.0351 | 7.53e-03 | 2.69e-02 | 8.31e-03 | -4.35e-03 | 1.91e-02 | 8.14e-01 | 4.01e-01 | 7.95e-01 | 8.92e-01 | 5.51e-01 |
| CELL PART MORPHOGENESIS | 644 | 5.99e-01 | 8.98e-01 | 0.0343 | -1.93e-02 | -4.46e-04 | 1.47e-03 | -9.64e-03 | 2.66e-02 | 4.02e-01 | 9.85e-01 | 9.49e-01 | 6.76e-01 | 2.49e-01 |
| POSITIVE REGULATION OF TRANSPORTER ACTIVITY | 89 | 9.38e-01 | 9.92e-01 | 0.0343 | -1.94e-02 | 2.02e-02 | 9.03e-03 | -1.10e-02 | 1.36e-02 | 7.51e-01 | 7.42e-01 | 8.83e-01 | 8.57e-01 | 8.25e-01 |
| REGULATION OF CELL ADHESION | 775 | 3.81e-01 | 7.78e-01 | 0.0340 | 9.42e-03 | 6.82e-03 | 7.19e-03 | 2.87e-02 | 1.22e-02 | 6.55e-01 | 7.47e-01 | 7.33e-01 | 1.74e-01 | 5.63e-01 |
| REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 185 | 7.01e-01 | 9.32e-01 | 0.0338 | 1.13e-02 | 9.00e-03 | -1.05e-02 | -2.83e-02 | 5.13e-03 | 7.91e-01 | 8.33e-01 | 8.06e-01 | 5.07e-01 | 9.04e-01 |
| MONOATOMIC ION HOMEOSTASIS | 581 | 7.62e-01 | 9.54e-01 | 0.0338 | -1.55e-02 | -6.30e-03 | 9.41e-03 | -7.63e-03 | 2.67e-02 | 5.23e-01 | 7.95e-01 | 6.98e-01 | 7.53e-01 | 2.70e-01 |
| CHEMICAL HOMEOSTASIS | 996 | 1.05e-01 | 4.42e-01 | 0.0333 | -1.35e-02 | 1.68e-02 | 1.27e-02 | -1.17e-02 | 1.87e-02 | 4.72e-01 | 3.70e-01 | 4.97e-01 | 5.32e-01 | 3.18e-01 |
| ACTIVATION OF GTPASE ACTIVITY | 96 | 8.39e-01 | 9.73e-01 | 0.0320 | -1.87e-02 | 1.77e-02 | -1.34e-02 | -1.03e-02 | 8.87e-03 | 7.51e-01 | 7.65e-01 | 8.20e-01 | 8.62e-01 | 8.81e-01 |
| ACTIN FILAMENT BASED PROCESS | 774 | 1.45e-01 | 5.12e-01 | 0.0320 | -2.29e-03 | 1.71e-02 | -1.57e-02 | -2.02e-02 | -8.37e-03 | 9.14e-01 | 4.19e-01 | 4.57e-01 | 3.40e-01 | 6.92e-01 |
| SUPRAMOLECULAR FIBER ORGANIZATION | 811 | 2.00e-01 | 5.90e-01 | 0.0318 | 1.61e-03 | 2.36e-02 | 7.06e-03 | -1.19e-02 | 1.61e-02 | 9.38e-01 | 2.53e-01 | 7.33e-01 | 5.65e-01 | 4.35e-01 |
| RESPONSE TO FATTY ACID | 55 | 9.02e-01 | 9.83e-01 | 0.0317 | -2.85e-04 | 1.12e-02 | -1.83e-02 | 1.84e-02 | 1.44e-02 | 9.97e-01 | 8.85e-01 | 8.15e-01 | 8.13e-01 | 8.54e-01 |
| PHOSPHATIDYLINOSITOL 3 KINASE PROTEIN KINASE B SIGNAL TRANSDUCTION | 285 | 7.84e-01 | 9.61e-01 | 0.0315 | -1.19e-03 | 1.25e-02 | -1.95e-02 | -1.53e-02 | -1.48e-02 | 9.72e-01 | 7.16e-01 | 5.71e-01 | 6.56e-01 | 6.67e-01 |
| POSITIVE REGULATION OF LOCOMOTION | 589 | 7.81e-02 | 3.79e-01 | 0.0308 | -1.11e-02 | 1.12e-02 | -2.30e-02 | -1.23e-02 | 4.12e-03 | 6.46e-01 | 6.44e-01 | 3.40e-01 | 6.09e-01 | 8.64e-01 |
| GAMETE GENERATION | 724 | 4.28e-01 | 8.05e-01 | 0.0290 | 2.37e-02 | 3.72e-03 | -1.17e-02 | 8.56e-03 | -7.61e-03 | 2.78e-01 | 8.64e-01 | 5.92e-01 | 6.95e-01 | 7.27e-01 |
| PROTEIN AUTOPHOSPHORYLATION | 189 | 6.42e-01 | 9.14e-01 | 0.0289 | -1.26e-02 | -6.95e-03 | -6.41e-03 | 2.38e-02 | 4.91e-03 | 7.65e-01 | 8.69e-01 | 8.79e-01 | 5.73e-01 | 9.07e-01 |
| VIRAL RNA GENOME REPLICATION | 29 | 9.98e-01 | 1.00e+00 | 0.0288 | 9.47e-03 | 8.33e-03 | -9.07e-03 | 1.95e-02 | -1.43e-02 | 9.30e-01 | 9.38e-01 | 9.33e-01 | 8.56e-01 | 8.94e-01 |
| SPHINGOLIPID BIOSYNTHETIC PROCESS | 110 | 9.45e-01 | 9.94e-01 | 0.0286 | -7.79e-03 | -1.87e-02 | 1.61e-02 | 7.38e-04 | 1.22e-02 | 8.88e-01 | 7.35e-01 | 7.71e-01 | 9.89e-01 | 8.25e-01 |
| TISSUE MIGRATION | 364 | 7.79e-01 | 9.59e-01 | 0.0279 | -1.35e-02 | -7.77e-04 | -1.56e-02 | -1.25e-02 | 1.40e-02 | 6.58e-01 | 9.80e-01 | 6.10e-01 | 6.83e-01 | 6.47e-01 |
| MALE GAMETE GENERATION | 571 | 6.60e-01 | 9.21e-01 | 0.0276 | 8.77e-03 | -1.03e-02 | -2.18e-02 | -5.40e-03 | -8.57e-03 | 7.20e-01 | 6.74e-01 | 3.72e-01 | 8.26e-01 | 7.26e-01 |
| NUCLEUS LOCALIZATION | 33 | 9.97e-01 | 1.00e+00 | 0.0272 | 1.12e-02 | -3.47e-03 | -1.93e-02 | -1.23e-02 | 8.80e-03 | 9.11e-01 | 9.73e-01 | 8.48e-01 | 9.03e-01 | 9.30e-01 |
| LONG CHAIN FATTY ACID METABOLIC PROCESS | 104 | 9.64e-01 | 9.94e-01 | 0.0270 | 7.61e-03 | 1.40e-02 | -8.23e-03 | -9.15e-03 | 1.81e-02 | 8.93e-01 | 8.05e-01 | 8.85e-01 | 8.72e-01 | 7.50e-01 |
| POLYSACCHARIDE METABOLIC PROCESS | 96 | 9.63e-01 | 9.94e-01 | 0.0269 | -7.05e-03 | 1.13e-02 | 4.59e-03 | 1.24e-02 | -1.93e-02 | 9.05e-01 | 8.48e-01 | 9.38e-01 | 8.33e-01 | 7.44e-01 |
| REGULATION OF CELL SIZE | 176 | 8.61e-01 | 9.78e-01 | 0.0265 | 7.22e-03 | 2.28e-02 | -6.71e-03 | 1.37e-03 | 9.17e-03 | 8.69e-01 | 6.01e-01 | 8.78e-01 | 9.75e-01 | 8.34e-01 |
| NEGATIVE REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 34 | 9.98e-01 | 1.00e+00 | 0.0265 | 5.76e-03 | -9.05e-03 | -1.80e-03 | 2.38e-02 | -3.84e-03 | 9.54e-01 | 9.27e-01 | 9.86e-01 | 8.10e-01 | 9.69e-01 |
| CELL MORPHOGENESIS | 914 | 5.66e-01 | 8.81e-01 | 0.0264 | -1.65e-02 | -1.59e-03 | -1.52e-02 | -1.38e-02 | -1.24e-04 | 3.98e-01 | 9.35e-01 | 4.36e-01 | 4.78e-01 | 9.95e-01 |
| REGULATION OF LOCOMOTION | 1082 | 9.37e-02 | 4.16e-01 | 0.0260 | -1.28e-02 | 8.14e-03 | -1.56e-02 | -1.39e-02 | 2.33e-03 | 4.76e-01 | 6.51e-01 | 3.86e-01 | 4.39e-01 | 8.97e-01 |
| LIPID METABOLIC PROCESS | 1354 | 8.11e-01 | 9.68e-01 | 0.0252 | 1.10e-02 | 1.42e-02 | 1.09e-02 | 3.31e-03 | 1.35e-02 | 4.98e-01 | 3.79e-01 | 5.00e-01 | 8.38e-01 | 4.04e-01 |
| POSITIVE REGULATION OF HYDROLASE ACTIVITY | 484 | 5.08e-01 | 8.53e-01 | 0.0251 | 2.71e-03 | 5.76e-03 | -2.28e-02 | -8.06e-03 | -2.49e-03 | 9.19e-01 | 8.28e-01 | 3.91e-01 | 7.61e-01 | 9.25e-01 |
| CELL MOTILITY | 1721 | 1.37e-01 | 4.99e-01 | 0.0250 | 2.40e-03 | 1.47e-02 | 1.04e-03 | 1.45e-04 | 2.01e-02 | 8.68e-01 | 3.11e-01 | 9.43e-01 | 9.92e-01 | 1.66e-01 |
| LOCOMOTION | 1266 | 1.13e-01 | 4.57e-01 | 0.0245 | 3.81e-03 | 1.61e-02 | -1.15e-02 | -1.34e-02 | -3.36e-03 | 8.20e-01 | 3.35e-01 | 4.90e-01 | 4.23e-01 | 8.41e-01 |
| NUCLEAR MIGRATION | 25 | 1.00e+00 | 1.00e+00 | 0.0243 | -6.54e-03 | 1.40e-02 | 5.25e-03 | -8.87e-03 | 1.56e-02 | 9.55e-01 | 9.04e-01 | 9.64e-01 | 9.39e-01 | 8.92e-01 |
| REGULATION OF CELL PROJECTION ORGANIZATION | 661 | 2.83e-01 | 6.93e-01 | 0.0242 | -6.10e-04 | 1.67e-02 | -3.56e-03 | 5.03e-03 | 1.65e-02 | 9.79e-01 | 4.64e-01 | 8.76e-01 | 8.25e-01 | 4.70e-01 |
| POSTSYNAPSE ORGANIZATION | 179 | 8.40e-01 | 9.73e-01 | 0.0241 | -1.86e-02 | 1.09e-02 | -2.30e-04 | 8.23e-04 | 1.07e-02 | 6.68e-01 | 8.01e-01 | 9.96e-01 | 9.85e-01 | 8.04e-01 |
| INTERFERON MEDIATED SIGNALING PATHWAY | 101 | 8.57e-01 | 9.77e-01 | 0.0240 | -1.43e-02 | 2.47e-03 | -1.34e-02 | 1.35e-02 | 1.54e-03 | 8.04e-01 | 9.66e-01 | 8.16e-01 | 8.15e-01 | 9.79e-01 |
| CELL CELL ADHESION | 922 | 3.71e-01 | 7.71e-01 | 0.0229 | -1.79e-02 | 2.01e-03 | 3.49e-03 | -5.86e-03 | -1.23e-02 | 3.56e-01 | 9.18e-01 | 8.57e-01 | 7.63e-01 | 5.26e-01 |
| REGULATION OF STEROID BIOSYNTHETIC PROCESS | 79 | 9.86e-01 | 9.97e-01 | 0.0219 | 3.47e-03 | -4.15e-03 | -1.89e-02 | 1.27e-03 | 9.52e-03 | 9.58e-01 | 9.49e-01 | 7.71e-01 | 9.84e-01 | 8.84e-01 |
| NEGATIVE REGULATION OF CELL ADHESION | 300 | 9.45e-01 | 9.94e-01 | 0.0200 | 1.67e-03 | 1.36e-03 | -6.50e-03 | -8.40e-03 | 1.68e-02 | 9.60e-01 | 9.68e-01 | 8.46e-01 | 8.02e-01 | 6.17e-01 |
| PYRIDINE NUCLEOTIDE BIOSYNTHETIC PROCESS | 28 | 1.00e+00 | 1.00e+00 | 0.0185 | 6.24e-03 | 4.45e-03 | 1.09e-04 | 1.13e-02 | 1.24e-02 | 9.54e-01 | 9.68e-01 | 9.99e-01 | 9.17e-01 | 9.09e-01 |
| RHO PROTEIN SIGNAL TRANSDUCTION | 128 | 9.84e-01 | 9.96e-01 | 0.0183 | 9.97e-03 | 1.07e-03 | -1.26e-02 | -1.77e-03 | 8.48e-03 | 8.46e-01 | 9.83e-01 | 8.05e-01 | 9.72e-01 | 8.68e-01 |
| PIGMENTATION | 108 | 9.99e-01 | 1.00e+00 | 0.0109 | -1.24e-03 | 1.06e-02 | 1.08e-03 | -2.37e-03 | 1.71e-04 | 9.82e-01 | 8.50e-01 | 9.85e-01 | 9.66e-01 | 9.98e-01 |
Detailed Gene set reports
XENOBIOTIC GLUCURONIDATION
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.00489 |
| p.adjustMANOVA | 0.0601 |
| s.dist | 1.68 |
| s.ADOS | -0.764 |
| s.diagnosis | -0.758 |
| s.iIQ | -0.815 |
| s.iLang | -0.844 |
| s.motor | -0.544 |
| p.ADOS | 0.000461 |
| p.diagnosis | 0.00051 |
| p.iIQ | 0.000187 |
| p.iLang | 0.000111 |
| p.motor | 0.0126 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | iIQ |
|---|---|---|
| UGT2B11 | -17526 | -20069 |
| UGT1A1 | -17008 | -19129 |
| UGT2B28 | -16047 | -19707 |
| UGT1A3 | -15782 | -16878 |
| UGT1A8 | -15554 | -17013 |
| UGT1A9 | -15694 | -16825 |
| UGT1A7 | -15366 | -16629 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| UGT1A1 | -14606 | -15982 | -19129 | -17008 | -13396 |
| UGT1A3 | -11327 | -12931 | -16878 | -15782 | -15198 |
| UGT1A7 | -11383 | -12572 | -16629 | -15366 | -13025 |
| UGT1A8 | -11904 | -13187 | -17013 | -15554 | -12754 |
| UGT1A9 | -11950 | -13143 | -16825 | -15694 | -12738 |
| UGT2B11 | -15125 | -16837 | -20069 | -17526 | -17288 |
| UGT2B28 | -13147 | -15286 | -19707 | -16047 | -12580 |
FLAVONOID GLUCURONIDATION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.0552 |
| p.adjustMANOVA | 0.311 |
| s.dist | 1.58 |
| s.ADOS | -0.716 |
| s.diagnosis | -0.694 |
| s.iIQ | -0.749 |
| s.iLang | -0.82 |
| s.motor | -0.505 |
| p.ADOS | 0.00559 |
| p.diagnosis | 0.00717 |
| p.iIQ | 0.00373 |
| p.iLang | 0.00149 |
| p.motor | 0.0503 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | iIQ |
|---|---|---|
| UGT1A1 | -17008 | -19129 |
| UGT1A3 | -15782 | -16878 |
| UGT1A8 | -15554 | -17013 |
| UGT1A9 | -15694 | -16825 |
| UGT1A7 | -15366 | -16629 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| UGT1A1 | -14606 | -15982 | -19129 | -17008 | -13396 |
| UGT1A3 | -11327 | -12931 | -16878 | -15782 | -15198 |
| UGT1A7 | -11383 | -12572 | -16629 | -15366 | -13025 |
| UGT1A8 | -11904 | -13187 | -17013 | -15554 | -12754 |
| UGT1A9 | -11950 | -13143 | -16825 | -15694 | -12738 |
FOREBRAIN NEURON FATE COMMITMENT
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.00455 |
| p.adjustMANOVA | 0.0575 |
| s.dist | 1.46 |
| s.ADOS | 0.4 |
| s.diagnosis | 0.636 |
| s.iIQ | 0.785 |
| s.iLang | 0.644 |
| s.motor | 0.738 |
| p.ADOS | 0.067 |
| p.diagnosis | 0.00354 |
| p.iIQ | 0.00032 |
| p.iLang | 0.00317 |
| p.motor | 0.000722 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | motor |
|---|---|---|
| TBR1 | 1491 | 2520 |
| ASCL1 | 1596 | 2105 |
| FEZF2 | 1131 | 2708 |
| BCL11B | 1018 | 2853 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ASCL1 | 5620 | 3512 | 1596 | 3203 | 2105 |
| BCL11B | -8155 | -5523 | 1018 | 2705 | 2853 |
| FEZF2 | 690 | 2541 | 1131 | 1495 | 2708 |
| GATA2 | -5672 | -36 | -6390 | -7567 | -3128 |
| NKX2-1 | 3904 | 3163 | -153 | 1564 | -2810 |
| PAX6 | 2846 | 2818 | -215 | -724 | -1329 |
| TBR1 | 2028 | 2275 | 1491 | 2250 | 2520 |
FLAVONE METABOLIC PROCESS
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.045 |
| p.adjustMANOVA | 0.276 |
| s.dist | 1.45 |
| s.ADOS | -0.672 |
| s.diagnosis | -0.607 |
| s.iIQ | -0.711 |
| s.iLang | -0.772 |
| s.motor | -0.439 |
| p.ADOS | 0.00433 |
| p.diagnosis | 0.0101 |
| p.iIQ | 0.00255 |
| p.iLang | 0.00106 |
| p.motor | 0.0626 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | iIQ |
|---|---|---|
| UGT1A1 | -17008 | -19129 |
| UGT1A10 | -15773 | -17149 |
| UGT1A8 | -15554 | -17013 |
| UGT1A9 | -15694 | -16825 |
| UGT1A7 | -15366 | -16629 |
| LCT | -12657 | -14505 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| LCT | -8605 | -7259 | -14505 | -12657 | -11265 |
| UGT1A1 | -14606 | -15982 | -19129 | -17008 | -13396 |
| UGT1A10 | -12081 | -13372 | -17149 | -15773 | -12911 |
| UGT1A7 | -11383 | -12572 | -16629 | -15366 | -13025 |
| UGT1A8 | -11904 | -13187 | -17013 | -15554 | -12754 |
| UGT1A9 | -11950 | -13143 | -16825 | -15694 | -12738 |
POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION OF STAT PROTEIN
| metric | value |
|---|---|
| setSize | 16 |
| pMANOVA | 1.24e-06 |
| p.adjustMANOVA | 5.72e-05 |
| s.dist | 1.45 |
| s.ADOS | -0.526 |
| s.diagnosis | -0.635 |
| s.iIQ | -0.678 |
| s.iLang | -0.649 |
| s.motor | -0.73 |
| p.ADOS | 0.000269 |
| p.diagnosis | 1.08e-05 |
| p.iIQ | 2.65e-06 |
| p.iLang | 6.84e-06 |
| p.motor | 4.22e-07 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | iIQ |
|---|---|---|
| IFNA16 | -18517 | -19993 |
| IFNA14 | -18645 | -19791 |
| IFNW1 | -18723 | -19483 |
| IFNB1 | -18496 | -19633 |
| IFNK | -17755 | -19533 |
| IFNA8 | -17513 | -19561 |
| IFNA1 | -17810 | -19112 |
| IFNA5 | -16810 | -19690 |
| IFNA13 | -16950 | -19297 |
| IFNG | -17522 | -18535 |
| IFNA7 | -16322 | -17745 |
| IFNA6 | -15983 | -17271 |
| LIF | -12160 | -13332 |
| IFNA21 | -7597 | -19722 |
| RET | -9068 | -2738 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| IFNA1 | -4713 | -15914 | -19112 | -13352 | -17810 |
| IFNA13 | -10620 | -16119 | -19297 | -15939 | -16950 |
| IFNA14 | -13197 | -16007 | -19791 | -16642 | -18645 |
| IFNA16 | -14281 | -15984 | -19993 | -17475 | -18517 |
| IFNA2 | 6523 | 4648 | 1393 | 3564 | -14872 |
| IFNA21 | -15342 | -16652 | -19722 | -17814 | -7597 |
| IFNA5 | -14172 | -16697 | -19690 | -15804 | -16810 |
| IFNA6 | -7582 | -14113 | -17271 | -10051 | -15983 |
| IFNA7 | -10626 | -10575 | -17745 | -17399 | -16322 |
| IFNA8 | -12468 | -11260 | -19561 | -16914 | -17513 |
| IFNB1 | -13298 | -15718 | -19633 | -17140 | -18496 |
| IFNG | -13409 | -16083 | -18535 | -15946 | -17522 |
| IFNK | -14117 | -16683 | -19533 | -16194 | -17755 |
| IFNW1 | -11086 | -15816 | -19483 | -16549 | -18723 |
| LIF | -13541 | -11608 | -13332 | -15819 | -12160 |
| RET | -27 | -1874 | -2738 | -4127 | -9068 |
PROTEIN UFMYLATION
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.00638 |
| p.adjustMANOVA | 0.0737 |
| s.dist | 1.44 |
| s.ADOS | 0.707 |
| s.diagnosis | 0.712 |
| s.iIQ | 0.758 |
| s.iLang | 0.704 |
| s.motor | 0.00627 |
| p.ADOS | 0.0027 |
| p.diagnosis | 0.00254 |
| p.iIQ | 0.00131 |
| p.iLang | 0.00283 |
| p.motor | 0.979 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | diagnosis |
|---|---|---|
| UFL1 | 1438 | 5037 |
| UFM1 | 1447 | 4863 |
| UFC1 | 1267 | 1816 |
| CDK5RAP3 | 1282 | 1564 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CDK5RAP3 | 6002 | 1564 | 1282 | 3589 | -13457 |
| DDRGK1 | -3763 | 1271 | -6280 | -4064 | -12404 |
| UBA5 | 2285 | -2030 | -2302 | -662 | 679 |
| UFC1 | 5457 | 1816 | 1267 | 3423 | -7883 |
| UFL1 | 6465 | 5037 | 1438 | 2942 | -5565 |
| UFM1 | 5176 | 4863 | 1447 | 1287 | -7727 |
ROSTROCAUDAL NEURAL TUBE PATTERNING
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0033 |
| p.adjustMANOVA | 0.0449 |
| s.dist | 1.4 |
| s.ADOS | 0.666 |
| s.diagnosis | 0.634 |
| s.iIQ | 0.675 |
| s.iLang | 0.634 |
| s.motor | 0.504 |
| p.ADOS | 0.000264 |
| p.diagnosis | 0.000517 |
| p.iIQ | 0.000219 |
| p.iLang | 0.000514 |
| p.motor | 0.00576 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | ADOS |
|---|---|---|
| FGF8 | 1833 | 6355 |
| GBX2 | 1284 | 6217 |
| HES1 | 1524 | 3273 |
| SOX17 | 876 | 4951 |
| EN1 | 609 | 5631 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BMI1 | 3476 | -2515 | -4450 | 95 | -2349 |
| EN1 | 5631 | 2801 | 609 | 3002 | -2420 |
| FGF8 | 6355 | 4302 | 1833 | 3795 | -1929 |
| GBX2 | 6217 | 2972 | 1284 | 3939 | 2450 |
| HES1 | 3273 | 3885 | 1524 | 2272 | 628 |
| KDM2B | -178 | -1469 | -6278 | -6331 | -8540 |
| PAX6 | 2846 | 2818 | -215 | -724 | -1329 |
| SOX17 | 4951 | 2997 | 876 | -578 | -881 |
| SSBP3 | -3790 | -5649 | -9632 | -3625 | -8118 |
| WNT1 | 2663 | 2074 | -21 | 1251 | 646 |
MIDBRAIN HINDBRAIN BOUNDARY DEVELOPMENT
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0408 |
| p.adjustMANOVA | 0.261 |
| s.dist | 1.39 |
| s.ADOS | 0.642 |
| s.diagnosis | 0.639 |
| s.iIQ | 0.668 |
| s.iLang | 0.662 |
| s.motor | 0.479 |
| p.ADOS | 0.00325 |
| p.diagnosis | 0.00343 |
| p.iIQ | 0.00221 |
| p.iLang | 0.00244 |
| p.motor | 0.0283 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| FGF8 | 1833 | 3795 |
| GBX2 | 1284 | 3939 |
| HES1 | 1524 | 2272 |
| EN1 | 609 | 3002 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| EN1 | 5631 | 2801 | 609 | 3002 | -2420 |
| FGF8 | 6355 | 4302 | 1833 | 3795 | -1929 |
| GBX2 | 6217 | 2972 | 1284 | 3939 | 2450 |
| HES1 | 3273 | 3885 | 1524 | 2272 | 628 |
| KDM2B | -178 | -1469 | -6278 | -6331 | -8540 |
| SSBP3 | -3790 | -5649 | -9632 | -3625 | -8118 |
| WNT1 | 2663 | 2074 | -21 | 1251 | 646 |
PROTEIN POLYUFMYLATION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.0599 |
| p.adjustMANOVA | 0.324 |
| s.dist | 1.39 |
| s.ADOS | 0.664 |
| s.diagnosis | 0.721 |
| s.iIQ | 0.725 |
| s.iLang | 0.659 |
| s.motor | 0.109 |
| p.ADOS | 0.0101 |
| p.diagnosis | 0.00524 |
| p.iIQ | 0.00498 |
| p.iLang | 0.0107 |
| p.motor | 0.672 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | diagnosis |
|---|---|---|
| UFL1 | 1438 | 5037 |
| UFM1 | 1447 | 4863 |
| UFC1 | 1267 | 1816 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DDRGK1 | -3763 | 1271 | -6280 | -4064 | -12404 |
| UBA5 | 2285 | -2030 | -2302 | -662 | 679 |
| UFC1 | 5457 | 1816 | 1267 | 3423 | -7883 |
| UFL1 | 6465 | 5037 | 1438 | 2942 | -5565 |
| UFM1 | 5176 | 4863 | 1447 | 1287 | -7727 |
PROXIMAL DISTAL PATTERN FORMATION INVOLVED IN NEPHRON DEVELOPMENT
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.114 |
| p.adjustMANOVA | 0.461 |
| s.dist | 1.38 |
| s.ADOS | 0.573 |
| s.diagnosis | 0.605 |
| s.iIQ | 0.658 |
| s.iLang | 0.634 |
| s.motor | 0.611 |
| p.ADOS | 0.0264 |
| p.diagnosis | 0.0192 |
| p.iIQ | 0.0108 |
| p.iLang | 0.0142 |
| p.motor | 0.0181 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| IRX3 | 562 | 2177 |
| IRX1 | 269 | 2261 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| HES5 | -2352 | -1956 | -2121 | -1604 | -2443 |
| IRX1 | 6119 | 4246 | 269 | 2261 | 338 |
| IRX2 | 5711 | 3771 | -1245 | 833 | 1366 |
| IRX3 | 3157 | 894 | 562 | 2177 | -3123 |
| OSR1 | -2062 | -2473 | -5632 | -2150 | -1135 |
SINOATRIAL NODE CELL DEVELOPMENT
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.0923 |
| p.adjustMANOVA | 0.413 |
| s.dist | 1.37 |
| s.ADOS | 0.482 |
| s.diagnosis | 0.602 |
| s.iIQ | 0.689 |
| s.iLang | 0.596 |
| s.motor | 0.68 |
| p.ADOS | 0.0617 |
| p.diagnosis | 0.0198 |
| p.iIQ | 0.0076 |
| p.iLang | 0.021 |
| p.motor | 0.00845 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | motor |
|---|---|---|
| SHOX2 | 1690 | 2282 |
| ISL1 | 1405 | 2473 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BVES | -8638 | -9083 | -8417 | -6590 | 35 |
| ISL1 | 4470 | 3239 | 1405 | 3175 | 2473 |
| SHOX2 | 5351 | 4345 | 1690 | 3706 | 2282 |
| TBX18 | 2570 | 3896 | -333 | 375 | -5790 |
| TBX3 | 1755 | 1933 | -776 | -1226 | -128 |
CELLULAR GLUCURONIDATION
| metric | value |
|---|---|
| setSize | 21 |
| pMANOVA | 1.55e-06 |
| p.adjustMANOVA | 6.93e-05 |
| s.dist | 1.37 |
| s.ADOS | -0.556 |
| s.diagnosis | -0.63 |
| s.iIQ | -0.67 |
| s.iLang | -0.672 |
| s.motor | -0.52 |
| p.ADOS | 1.04e-05 |
| p.diagnosis | 5.79e-07 |
| p.iIQ | 1.05e-07 |
| p.iLang | 9.57e-08 |
| p.motor | 3.68e-05 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | iIQ |
|---|---|---|
| UGT2B10 | -17752 | -19900 |
| UGT2B11 | -17526 | -20069 |
| UGT2B7 | -17315 | -19950 |
| UGT2B4 | -17604 | -19366 |
| UGT1A1 | -17008 | -19129 |
| UGT2B28 | -16047 | -19707 |
| UGT2A3 | -14594 | -19251 |
| UGT1A10 | -15773 | -17149 |
| UGT1A6 | -15866 | -16847 |
| UGT1A3 | -15782 | -16878 |
| UGT1A8 | -15554 | -17013 |
| UGT1A9 | -15694 | -16825 |
| UGT1A4 | -15476 | -16626 |
| UGT2A1 | -13658 | -18790 |
| UGT1A7 | -15366 | -16629 |
| UGT1A5 | -15271 | -16288 |
| UGT2B15 | -11946 | -16544 |
| PRKCE | -11834 | -15046 |
| UGT2A2 | -9147 | -17865 |
| UGT2B17 | -10643 | -999 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ABHD10 | 3354 | -3884 | -3800 | 1085 | 886 |
| PRKCE | -6414 | -9536 | -15046 | -11834 | -13489 |
| UGT1A1 | -14606 | -15982 | -19129 | -17008 | -13396 |
| UGT1A10 | -12081 | -13372 | -17149 | -15773 | -12911 |
| UGT1A3 | -11327 | -12931 | -16878 | -15782 | -15198 |
| UGT1A4 | -9639 | -12164 | -16626 | -15476 | -15179 |
| UGT1A5 | -10707 | -12353 | -16288 | -15271 | -13417 |
| UGT1A6 | -12037 | -13004 | -16847 | -15866 | -13043 |
| UGT1A7 | -11383 | -12572 | -16629 | -15366 | -13025 |
| UGT1A8 | -11904 | -13187 | -17013 | -15554 | -12754 |
| UGT1A9 | -11950 | -13143 | -16825 | -15694 | -12738 |
| UGT2A1 | -10207 | -15237 | -18790 | -13658 | -16945 |
| UGT2A2 | -11565 | -15273 | -17865 | -9147 | -15315 |
| UGT2A3 | -8902 | -14932 | -19251 | -14594 | -17876 |
| UGT2B10 | -13626 | -15378 | -19900 | -17752 | -18186 |
| UGT2B11 | -15125 | -16837 | -20069 | -17526 | -17288 |
| UGT2B15 | -9910 | -13508 | -16544 | -11946 | -11363 |
| UGT2B17 | 1363 | 1891 | -999 | -10643 | -5171 |
| UGT2B28 | -13147 | -15286 | -19707 | -16047 | -12580 |
| UGT2B4 | -14883 | -16708 | -19366 | -17604 | -17928 |
| UGT2B7 | -14774 | -16254 | -19950 | -17315 | -18297 |
RRNA TRANSPORT
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.145 |
| p.adjustMANOVA | 0.511 |
| s.dist | 1.36 |
| s.ADOS | 0.593 |
| s.diagnosis | 0.678 |
| s.iIQ | 0.685 |
| s.iLang | 0.591 |
| s.motor | 0.471 |
| p.ADOS | 0.0216 |
| p.diagnosis | 0.00867 |
| p.iIQ | 0.00798 |
| p.iLang | 0.022 |
| p.motor | 0.068 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | diagnosis |
|---|---|---|
| MRPL18 | 2052 | 4999 |
| NPM1 | 1698 | 4668 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| MRPL18 | 6544 | 4999 | 2052 | 4244 | -1404 |
| NPM1 | 6087 | 4668 | 1698 | 2760 | 239 |
| PNPT1 | -5310 | -1783 | -5938 | -10280 | -6391 |
| TSC1 | -381 | -2859 | -4063 | -1429 | -957 |
| TST | 4722 | 3531 | -412 | 3877 | -4239 |
STEM CELL FATE SPECIFICATION
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0162 |
| p.adjustMANOVA | 0.144 |
| s.dist | 1.36 |
| s.ADOS | 0.473 |
| s.diagnosis | 0.619 |
| s.iIQ | 0.72 |
| s.iLang | 0.456 |
| s.motor | 0.714 |
| p.ADOS | 0.0447 |
| p.diagnosis | 0.00865 |
| p.iIQ | 0.00226 |
| p.iLang | 0.0529 |
| p.motor | 0.00246 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | motor |
|---|---|---|
| SOX9 | 672 | 694 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DMRTA2 | -2650 | -1095 | -1211 | -6763 | -965 |
| GSC | 2463 | 2604 | -744 | 229 | 481 |
| SFRP2 | -7862 | -3404 | -4633 | -3517 | 965 |
| SOX17 | 4951 | 2997 | 876 | -578 | -881 |
| SOX18 | 5072 | 2240 | -637 | 2903 | 599 |
| SOX9 | 4018 | 2994 | 672 | -2292 | 694 |
SINOATRIAL NODE CELL DIFFERENTIATION
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0436 |
| p.adjustMANOVA | 0.271 |
| s.dist | 1.33 |
| s.ADOS | 0.458 |
| s.diagnosis | 0.515 |
| s.iIQ | 0.643 |
| s.iLang | 0.581 |
| s.motor | 0.729 |
| p.ADOS | 0.0522 |
| p.diagnosis | 0.029 |
| p.iIQ | 0.00636 |
| p.iLang | 0.0137 |
| p.motor | 0.00199 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | iIQ |
|---|---|---|
| SHOX2 | 2282 | 1690 |
| ISL1 | 2473 | 1405 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BVES | -8638 | -9083 | -8417 | -6590 | 35 |
| ISL1 | 4470 | 3239 | 1405 | 3175 | 2473 |
| MESP1 | -559 | -4948 | -4366 | -1142 | 3027 |
| SHOX2 | 5351 | 4345 | 1690 | 3706 | 2282 |
| TBX18 | 2570 | 3896 | -333 | 375 | -5790 |
| TBX3 | 1755 | 1933 | -776 | -1226 | -128 |
PATTERN SPECIFICATION INVOLVED IN KIDNEY DEVELOPMENT
| metric | value |
|---|---|
| setSize | 8 |
| pMANOVA | 0.0311 |
| p.adjustMANOVA | 0.222 |
| s.dist | 1.3 |
| s.ADOS | 0.562 |
| s.diagnosis | 0.615 |
| s.iIQ | 0.622 |
| s.iLang | 0.575 |
| s.motor | 0.524 |
| p.ADOS | 0.00593 |
| p.diagnosis | 0.00261 |
| p.iIQ | 0.00231 |
| p.iLang | 0.00489 |
| p.motor | 0.0103 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | diagnosis |
|---|---|---|
| FOXD1 | 1587 | 5015 |
| IRX1 | 269 | 4246 |
| IRX3 | 562 | 894 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| FOXD1 | 6678 | 5015 | 1587 | 3933 | -4185 |
| HES5 | -2352 | -1956 | -2121 | -1604 | -2443 |
| IRX1 | 6119 | 4246 | 269 | 2261 | 338 |
| IRX2 | 5711 | 3771 | -1245 | 833 | 1366 |
| IRX3 | 3157 | 894 | 562 | 2177 | -3123 |
| OSR1 | -2062 | -2473 | -5632 | -2150 | -1135 |
| PAX2 | 619 | -1902 | -1869 | -1306 | 544 |
| PAX8 | -1999 | 458 | -7827 | -6972 | -7092 |
NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO CHROMATIN
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0604 |
| p.adjustMANOVA | 0.325 |
| s.dist | 1.29 |
| s.ADOS | 0.696 |
| s.diagnosis | 0.566 |
| s.iIQ | 0.543 |
| s.iLang | 0.617 |
| s.motor | 0.436 |
| p.ADOS | 0.00316 |
| p.diagnosis | 0.0163 |
| p.iIQ | 0.0213 |
| p.iLang | 0.00885 |
| p.motor | 0.0644 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | iLang |
|---|---|---|
| VCP | 5964 | 2592 |
| PIAS4 | 4817 | 1048 |
| SIRT6 | 39 | 577 |
| RNF4 | 50 | 152 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CDK9 | 4524 | -2647 | -1590 | -479 | -2336 |
| PIAS4 | 4817 | 3749 | -885 | 1048 | -4133 |
| RNF4 | 50 | -1085 | -2202 | 152 | -3290 |
| SIRT6 | 39 | -1561 | -3225 | 577 | 2405 |
| SPI1 | 5460 | 1009 | -10750 | -3169 | -12655 |
| VCP | 5964 | 3362 | 1142 | 2592 | 2356 |
GRANULOCYTE COLONY STIMULATING FACTOR PRODUCTION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.0874 |
| p.adjustMANOVA | 0.4 |
| s.dist | 1.27 |
| s.ADOS | 0.746 |
| s.diagnosis | 0.656 |
| s.iIQ | 0.527 |
| s.iLang | 0.593 |
| s.motor | -0.0429 |
| p.ADOS | 0.00389 |
| p.diagnosis | 0.0111 |
| p.iIQ | 0.0413 |
| p.iLang | 0.0217 |
| p.motor | 0.868 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | diagnosis |
|---|---|---|
| LILRA2 | 6402 | 4840 |
| ISL1 | 4470 | 3239 |
| CD34 | 4708 | 2786 |
| TSLP | 2324 | 2282 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CD34 | 4708 | 2786 | -10444 | -6068 | -14641 |
| HAVCR2 | 2247 | -5825 | -7503 | -3043 | -11755 |
| ISL1 | 4470 | 3239 | 1405 | 3175 | 2473 |
| LILRA2 | 6402 | 4840 | 879 | 4011 | -11433 |
| TSLP | 2324 | 2282 | 202 | 1181 | -6010 |
PROTEIN DNA COVALENT CROSS LINKING REPAIR
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0765 |
| p.adjustMANOVA | 0.375 |
| s.dist | 1.26 |
| s.ADOS | 0.617 |
| s.diagnosis | 0.538 |
| s.iIQ | 0.677 |
| s.iLang | 0.613 |
| s.motor | 0.288 |
| p.ADOS | 0.00888 |
| p.diagnosis | 0.0225 |
| p.iIQ | 0.0041 |
| p.iLang | 0.00927 |
| p.motor | 0.222 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | ADOS |
|---|---|---|
| VCP | 1142 | 5964 |
| TEX264 | 146 | 3229 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| FAM111A | 63 | -7546 | -2873 | 742 | -2225 |
| SPRTN | 6023 | 4066 | -2100 | -1273 | -11224 |
| TEX264 | 3229 | 70 | 146 | 2913 | -4737 |
| TRAIP | 812 | 87 | -1995 | -7082 | -6704 |
| VCP | 5964 | 3362 | 1142 | 2592 | 2356 |
| VCPIP1 | -507 | 892 | -2883 | 2577 | -5007 |
REGULATION OF ENAMEL MINERALIZATION
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0569 |
| p.adjustMANOVA | 0.315 |
| s.dist | 1.26 |
| s.ADOS | -0.591 |
| s.diagnosis | -0.49 |
| s.iIQ | -0.591 |
| s.iLang | -0.647 |
| s.motor | -0.478 |
| p.ADOS | 0.00677 |
| p.diagnosis | 0.0246 |
| p.iIQ | 0.00681 |
| p.iLang | 0.00303 |
| p.motor | 0.0285 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | ADOS |
|---|---|---|
| MMP20 | -16997 | -14504 |
| DMP1 | -16699 | -14150 |
| AMTN | -16002 | -13268 |
| CFTR | -14739 | -12401 |
| ENAM | -15592 | -11287 |
| ODAPH | -14591 | -6976 |
| SLC4A2 | -3044 | -3342 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| AMTN | -13268 | -14192 | -19287 | -16002 | -17999 |
| CFTR | -12401 | -14077 | -15724 | -14739 | -13483 |
| DMP1 | -14150 | -12921 | -18163 | -16699 | -16848 |
| ENAM | -11287 | -15142 | -19214 | -15592 | -18025 |
| MMP20 | -14504 | -15977 | -18635 | -16997 | -16212 |
| ODAPH | -6976 | -5592 | -15898 | -14591 | -9327 |
| SLC4A2 | -3342 | -1150 | -1807 | -3044 | 73 |
EPITHELIAL MESENCHYMAL CELL SIGNALING
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0489 |
| p.adjustMANOVA | 0.289 |
| s.dist | 1.26 |
| s.ADOS | 0.347 |
| s.diagnosis | 0.426 |
| s.iIQ | 0.653 |
| s.iLang | 0.569 |
| s.motor | 0.729 |
| p.ADOS | 0.141 |
| p.diagnosis | 0.0705 |
| p.iIQ | 0.00559 |
| p.iLang | 0.0158 |
| p.motor | 0.00198 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | iIQ |
|---|---|---|
| SHH | 883 | 295 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BMP4 | -5132 | -3266 | -587 | -2199 | 2237 |
| FOXA1 | 357 | 1922 | -1209 | 1376 | 139 |
| PDGFA | 4938 | 1883 | -2339 | 2393 | -1525 |
| SHH | 1770 | 596 | 295 | 2317 | 883 |
| SMO | -3732 | -4910 | -4963 | -148 | -510 |
| WNT6 | -661 | -2753 | -1328 | -6223 | 710 |
COMMON BILE DUCT DEVELOPMENT
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.0385 |
| p.adjustMANOVA | 0.254 |
| s.dist | 1.23 |
| s.ADOS | 0.646 |
| s.diagnosis | 0.581 |
| s.iIQ | 0.549 |
| s.iLang | 0.411 |
| s.motor | 0.548 |
| p.ADOS | 0.0124 |
| p.diagnosis | 0.0243 |
| p.iIQ | 0.0336 |
| p.iLang | 0.112 |
| p.motor | 0.034 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | diagnosis |
|---|---|---|
| SOX17 | 4951 | 2997 |
| HES1 | 3273 | 3885 |
| SOX9 | 4018 | 2994 |
| MKS1 | 4570 | 2192 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| HES1 | 3273 | 3885 | 1524 | 2272 | 628 |
| MKS1 | 4570 | 2192 | -4828 | 1158 | -3076 |
| NOTCH2 | -2217 | -8874 | -12497 | -11446 | -5869 |
| SOX17 | 4951 | 2997 | 876 | -578 | -881 |
| SOX9 | 4018 | 2994 | 672 | -2292 | 694 |
MOTOR LEARNING
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0382 |
| p.adjustMANOVA | 0.253 |
| s.dist | 1.22 |
| s.ADOS | 0.547 |
| s.diagnosis | 0.642 |
| s.iIQ | 0.567 |
| s.iLang | 0.452 |
| s.motor | 0.506 |
| p.ADOS | 0.0121 |
| p.diagnosis | 0.00328 |
| p.iIQ | 0.00941 |
| p.iLang | 0.0382 |
| p.motor | 0.0205 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | iIQ |
|---|---|---|
| TACO1 | 4754 | 1155 |
| EN1 | 2801 | 609 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ADGRB3 | -2714 | 671 | -6992 | -6671 | -9627 |
| C1QL1 | 5381 | 3077 | -207 | 2313 | 1830 |
| DKK1 | 4127 | 2759 | -835 | 3307 | 1829 |
| EN1 | 5631 | 2801 | 609 | 3002 | -2420 |
| GIT1 | -9717 | -5548 | -9130 | -10432 | 970 |
| GPR88 | 4126 | 649 | -3156 | -7469 | 1701 |
| TACO1 | 5937 | 4754 | 1155 | 3950 | -9462 |
PANCREATIC A CELL DIFFERENTIATION
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.00507 |
| p.adjustMANOVA | 0.062 |
| s.dist | 1.22 |
| s.ADOS | 0.476 |
| s.diagnosis | 0.504 |
| s.iIQ | 0.696 |
| s.iLang | 0.551 |
| s.motor | 0.465 |
| p.ADOS | 0.00624 |
| p.diagnosis | 0.00379 |
| p.iIQ | 6.44e-05 |
| p.iLang | 0.00157 |
| p.motor | 0.00758 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| INSM1 | 1941 | 4124 |
| HES1 | 1524 | 2272 |
| NEUROD1 | 1334 | 2362 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| GATA6 | 2881 | 1834 | -3154 | 782 | -13585 |
| HES1 | 3273 | 3885 | 1524 | 2272 | 628 |
| INSM1 | 6524 | 3398 | 1941 | 4124 | 1610 |
| NEUROD1 | 4665 | 4537 | 1334 | 2362 | -906 |
| NKX2-2 | -10588 | -8205 | -630 | -6862 | -576 |
| NKX6-1 | 4743 | 3907 | -1476 | 2179 | -1984 |
| NKX6-2 | -8212 | -10401 | -1596 | -8006 | 1131 |
| ONECUT1 | 2118 | 1212 | -242 | -843 | -3964 |
| PAX6 | 2846 | 2818 | -215 | -724 | -1329 |
| RFX6 | 6015 | 4059 | -1323 | 3252 | -6237 |
| VHL | -2926 | -9508 | -9540 | -5383 | -3624 |
REGULATION OF AMACRINE CELL DIFFERENTIATION
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0159 |
| p.adjustMANOVA | 0.142 |
| s.dist | 1.21 |
| s.ADOS | 0.308 |
| s.diagnosis | 0.636 |
| s.iIQ | 0.603 |
| s.iLang | 0.56 |
| s.motor | 0.534 |
| p.ADOS | 0.192 |
| p.diagnosis | 0.00695 |
| p.iIQ | 0.0105 |
| p.iLang | 0.0175 |
| p.motor | 0.0234 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | iIQ |
|---|---|---|
| HES1 | 3885 | 1524 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DLX1 | -3476 | 1060 | -749 | -1623 | -191 |
| DLX2 | -132 | -3759 | 581 | 3009 | 2371 |
| GDF11 | 2898 | 3090 | -3965 | 1567 | -4376 |
| HES1 | 3273 | 3885 | 1524 | 2272 | 628 |
| POU4F2 | -5317 | 2975 | -2965 | -9002 | -9723 |
| TGIF2 | -2300 | 243 | -7914 | 701 | 196 |
REGULATION OF LOCOMOTION INVOLVED IN LOCOMOTORY BEHAVIOR
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.142 |
| p.adjustMANOVA | 0.508 |
| s.dist | 1.2 |
| s.ADOS | 0.576 |
| s.diagnosis | 0.593 |
| s.iIQ | 0.668 |
| s.iLang | 0.534 |
| s.motor | 0.185 |
| p.ADOS | 0.0257 |
| p.diagnosis | 0.0217 |
| p.iIQ | 0.00971 |
| p.iLang | 0.0385 |
| p.motor | 0.473 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | diagnosis |
|---|---|---|
| ARRDC3 | 1753 | 4235 |
| GHSR | 1 | 1077 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ARRDC3 | 5625 | 4235 | 1753 | 3969 | 1969 |
| DRD2 | -3619 | -4840 | -6546 | -5538 | -6746 |
| GHSR | 1370 | 1077 | 1 | -979 | -550 |
| GNB3 | 5212 | 4116 | -862 | -1851 | -12312 |
| VPS35 | 2127 | -757 | -1973 | 392 | -11030 |
RESPONSE TO SODIUM ARSENITE
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.151 |
| p.adjustMANOVA | 0.52 |
| s.dist | 1.2 |
| s.ADOS | 0.444 |
| s.diagnosis | 0.549 |
| s.iIQ | 0.658 |
| s.iLang | 0.54 |
| s.motor | 0.474 |
| p.ADOS | 0.0598 |
| p.diagnosis | 0.0198 |
| p.iIQ | 0.00525 |
| p.iLang | 0.0221 |
| p.motor | 0.0442 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | diagnosis |
|---|---|---|
| HNRNPA1 | 2032 | 5141 |
| ZC3H12A | 1410 | 1624 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DAXX | -7832 | -1535 | -1718 | -5353 | -149 |
| HNRNPA1 | 5995 | 5141 | 2032 | 3965 | 174 |
| HSF1 | -6427 | -4064 | -6243 | -8105 | -6152 |
| MAPK13 | 4364 | -1518 | -4866 | 890 | -10764 |
| NEFL | 4742 | 2025 | -427 | 1201 | -568 |
| ZC3H12A | 3178 | 1624 | 1410 | 2947 | 2368 |
CARDIOBLAST PROLIFERATION
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.00977 |
| p.adjustMANOVA | 0.0998 |
| s.dist | 1.2 |
| s.ADOS | 0.458 |
| s.diagnosis | 0.551 |
| s.iIQ | 0.577 |
| s.iLang | 0.579 |
| s.motor | 0.509 |
| p.ADOS | 0.00852 |
| p.diagnosis | 0.00154 |
| p.iIQ | 0.000927 |
| p.iLang | 0.000892 |
| p.motor | 0.00348 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | iIQ |
|---|---|---|
| MIR20A | 4010 | 2075 |
| ISL1 | 3175 | 1405 |
| HES1 | 2272 | 1524 |
| PIM1 | 1195 | 1604 |
| SIX1 | 1280 | 845 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CTNNB1 | -5826 | -11799 | -12748 | -2254 | -7864 |
| EYA1 | 2157 | -982 | -7174 | -4150 | -7572 |
| HAND2 | 523 | 2329 | -2042 | -4368 | -462 |
| HES1 | 3273 | 3885 | 1524 | 2272 | 628 |
| ISL1 | 4470 | 3239 | 1405 | 3175 | 2473 |
| MIR20A | 6443 | 5075 | 2075 | 4010 | -2281 |
| MKS1 | 4570 | 2192 | -4828 | 1158 | -3076 |
| NOTCH1 | -6533 | -1930 | -7034 | -5030 | -9312 |
| PIM1 | 5445 | 4440 | 1604 | 1195 | 1365 |
| SIX1 | -4989 | -4523 | 845 | 1280 | 2989 |
| TBX5 | -419 | 1400 | -1586 | -707 | -367 |
NEGATIVE REGULATION OF NUCLEASE ACTIVITY
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0745 |
| p.adjustMANOVA | 0.369 |
| s.dist | 1.19 |
| s.ADOS | 0.596 |
| s.diagnosis | 0.552 |
| s.iIQ | 0.491 |
| s.iLang | 0.61 |
| s.motor | 0.391 |
| p.ADOS | 0.00636 |
| p.diagnosis | 0.0115 |
| p.iIQ | 0.0246 |
| p.iLang | 0.00516 |
| p.motor | 0.0734 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | ADOS |
|---|---|---|
| GZMA | 4275 | 6670 |
| ABCE1 | 3027 | 6319 |
| DFFA | 3851 | 4075 |
| NEIL1 | 1419 | 4493 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ABCE1 | 6319 | 4930 | 1423 | 3027 | -10713 |
| DFFA | 4075 | 3790 | 1687 | 3851 | 844 |
| GZMA | 6670 | 5109 | 2109 | 4275 | 898 |
| NEIL1 | 4493 | 2638 | -3998 | 1419 | -1737 |
| TERF1 | -7420 | -10721 | -13776 | -4182 | -12416 |
| TERF2 | -2867 | -7170 | -12782 | -7313 | -4 |
| TMBIM6 | 5251 | 3585 | 859 | -760 | -995 |
TRANSLATIONAL TERMINATION
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 0.00239 |
| p.adjustMANOVA | 0.0351 |
| s.dist | 1.19 |
| s.ADOS | 0.566 |
| s.diagnosis | 0.532 |
| s.iIQ | 0.598 |
| s.iLang | 0.583 |
| s.motor | 0.345 |
| p.ADOS | 0.000146 |
| p.diagnosis | 0.000364 |
| p.iIQ | 5.99e-05 |
| p.iLang | 9.22e-05 |
| p.motor | 0.0208 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| ABCE1 | 1423 | 3027 |
| EIF5A | 1637 | 1986 |
| APEH | 1397 | 1895 |
| JMJD4 | 1245 | 2078 |
| MTRF1 | 639 | 3449 |
| MTRF1L | 636 | 2186 |
| OGFOD1 | 266 | 2955 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ABCE1 | 6319 | 4930 | 1423 | 3027 | -10713 |
| APEH | 2101 | 3282 | 1397 | 1895 | -2408 |
| EIF5A | 1555 | 4404 | 1637 | 1986 | 397 |
| EIF5A2 | 5746 | 2496 | -3176 | 253 | -2416 |
| ETF1 | -9774 | -10910 | -8476 | -9734 | -6049 |
| GFM2 | 4642 | 2371 | -6099 | -223 | -7024 |
| GSPT1 | 1761 | -5632 | -9383 | -3901 | -9637 |
| JMJD4 | 5915 | 4100 | 1245 | 2078 | -2310 |
| MRPL58 | 64 | -6638 | -5540 | -2678 | -622 |
| MTRF1 | 2851 | 1135 | 639 | 3449 | 1226 |
| MTRF1L | 4112 | 3786 | 636 | 2186 | -5971 |
| MTRFR | 5019 | 3175 | -61 | 2793 | -2596 |
| OGFOD1 | 2218 | -2340 | 266 | 2955 | -3726 |
| SHFL | -3630 | -5274 | -7595 | -8918 | -6284 |
| UPF1 | 1594 | 2331 | -1421 | 906 | -1271 |
RESPONSE TO PROSTAGLANDIN D
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.243 |
| p.adjustMANOVA | 0.648 |
| s.dist | 1.16 |
| s.ADOS | -0.488 |
| s.diagnosis | -0.551 |
| s.iIQ | -0.528 |
| s.iLang | -0.618 |
| s.motor | -0.381 |
| p.ADOS | 0.0588 |
| p.diagnosis | 0.0329 |
| p.iIQ | 0.041 |
| p.iLang | 0.0168 |
| p.motor | 0.14 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | diagnosis |
|---|---|---|
| AKR1C2 | -13547 | -15360 |
| TNC | -15000 | -13332 |
| PTGFR | -12167 | -12993 |
| AKR1C3 | -13261 | -11221 |
| PTGDR | -14141 | -6919 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| AKR1C2 | -10380 | -15360 | -17748 | -13547 | -17516 |
| AKR1C3 | -7726 | -11221 | -17796 | -13261 | -18013 |
| PTGDR | -10430 | -6919 | -7701 | -14141 | -4418 |
| PTGFR | -8447 | -12993 | -13107 | -12167 | -5777 |
| TNC | -11521 | -13332 | -17810 | -15000 | -14473 |
AIM2 INFLAMMASOME COMPLEX ASSEMBLY
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.296 |
| p.adjustMANOVA | 0.707 |
| s.dist | 1.16 |
| s.ADOS | -0.432 |
| s.diagnosis | -0.49 |
| s.iIQ | -0.621 |
| s.iLang | -0.56 |
| s.motor | -0.464 |
| p.ADOS | 0.094 |
| p.diagnosis | 0.0578 |
| p.iIQ | 0.0161 |
| p.iLang | 0.0302 |
| p.motor | 0.0725 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| AIM2 | -18350 | -16671 |
| GBP5 | -17669 | -16069 |
| CASP1 | -18051 | -15611 |
| GBP2 | -16998 | -10482 |
| TRIM11 | -8311 | -6057 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| AIM2 | -12561 | -10973 | -18350 | -16671 | -17512 |
| CASP1 | -11351 | -13912 | -18051 | -15611 | -15663 |
| GBP2 | -3629 | -13237 | -16998 | -10482 | -13442 |
| GBP5 | -13789 | -14181 | -17669 | -16069 | -16736 |
| TRIM11 | -4082 | -4131 | -8311 | -6057 | -1443 |
SENSORY PERCEPTION OF BITTER TASTE
| metric | value |
|---|---|
| setSize | 44 |
| pMANOVA | 9.84e-10 |
| p.adjustMANOVA | 7.26e-08 |
| s.dist | 1.15 |
| s.ADOS | -0.506 |
| s.diagnosis | -0.522 |
| s.iIQ | -0.569 |
| s.iLang | -0.537 |
| s.motor | -0.437 |
| p.ADOS | 6.43e-09 |
| p.diagnosis | 2.09e-09 |
| p.iIQ | 6.54e-11 |
| p.iLang | 6.78e-10 |
| p.motor | 5.3e-07 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| TAS2R4 | -20025 | -17677 |
| TAS2R19 | -19940 | -17704 |
| TAS2R43 | -19961 | -17623 |
| TAS2R30 | -19888 | -17267 |
| GNAT3 | -19944 | -17118 |
| TAS2R3 | -19539 | -17129 |
| TAS2R16 | -19782 | -16906 |
| TAS2R20 | -19131 | -17422 |
| TAS2R50 | -19658 | -16920 |
| TAS2R39 | -19517 | -16880 |
| TAS2R42 | -19681 | -16690 |
| CST2 | -18197 | -17861 |
| PIP | -18716 | -17342 |
| TAS2R41 | -18678 | -17329 |
| TAS2R8 | -19752 | -16370 |
| TAS2R1 | -19709 | -16232 |
| TAS2R60 | -18851 | -16861 |
| TAS2R9 | -19975 | -15596 |
| TAS2R7 | -19570 | -15832 |
| TAS2R14 | -19404 | -15703 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| AZGP1 | -11365 | -13527 | -12523 | -11838 | 1057 |
| CA6 | 1167 | -2477 | -5159 | -1849 | -9617 |
| CALHM1 | -5542 | -5088 | -6915 | -845 | -12634 |
| CST1 | -13596 | -14861 | -12635 | -16075 | -13854 |
| CST2 | -15259 | -16720 | -18197 | -17861 | 1323 |
| GNAT1 | -1490 | 1418 | -2484 | 1298 | -1565 |
| GNAT2 | -14815 | -16533 | -18445 | -16486 | -14897 |
| GNAT3 | -14553 | -16622 | -19944 | -17118 | -18092 |
| ITPR3 | -11473 | -8608 | -9681 | -10650 | -3867 |
| LPO | -5197 | -12137 | -15066 | -11629 | -9663 |
| PIGR | -5854 | -8486 | -11757 | -8279 | -24 |
| PIP | -14323 | -16361 | -18716 | -17342 | -11365 |
| PLCB2 | -5553 | -4314 | -11432 | -13088 | -6316 |
| REEP2 | 3923 | 332 | -323 | -1949 | -8673 |
| RGS21 | -12181 | -16287 | -19023 | -15497 | -18352 |
| RTP1 | -10857 | -9847 | -14395 | -14187 | -16702 |
| RTP2 | -15089 | -15832 | -15835 | -17509 | -7106 |
| RTP3 | 2682 | 4627 | 1756 | -258 | 1056 |
| RTP4 | 5070 | 5023 | 499 | 2946 | -12040 |
| RTP5 | -9843 | -5719 | -3579 | -2161 | 1134 |
| TAS2R1 | -14647 | -16597 | -19709 | -16232 | -16993 |
| TAS2R10 | -13848 | -16743 | -19145 | -11688 | -17196 |
| TAS2R13 | 4169 | 674 | -16594 | -10771 | -16116 |
| TAS2R14 | -13244 | -15663 | -19404 | -15703 | -17047 |
| TAS2R16 | -13603 | -16491 | -19782 | -16906 | -13212 |
| TAS2R19 | -15127 | -16367 | -19940 | -17704 | -18463 |
| TAS2R20 | -14114 | -16076 | -19131 | -17422 | -14135 |
| TAS2R3 | -14248 | -16147 | -19539 | -17129 | -17525 |
| TAS2R30 | -14405 | -16306 | -19888 | -17267 | -15874 |
| TAS2R31 | -3875 | -9326 | -18924 | -15043 | -18855 |
| TAS2R38 | -10226 | -14018 | -18357 | -9695 | -8345 |
| TAS2R39 | -14485 | -14417 | -19517 | -16880 | -18755 |
| TAS2R4 | -15213 | -16888 | -20025 | -17677 | -16403 |
| TAS2R40 | 1401 | -13299 | -17728 | -10873 | -17907 |
| TAS2R41 | -13670 | -12337 | -18678 | -17329 | -17549 |
| TAS2R42 | -14265 | -15927 | -19681 | -16690 | -16765 |
| TAS2R43 | -15261 | -12581 | -19961 | -17623 | -18503 |
| TAS2R46 | -8564 | -15685 | -19006 | -15500 | -17751 |
| TAS2R5 | -9825 | -6223 | -15618 | -9661 | -17347 |
| TAS2R50 | -13867 | -16325 | -19658 | -16920 | -18294 |
| TAS2R60 | -14795 | -15961 | -18851 | -16861 | -9832 |
| TAS2R7 | -11914 | -14552 | -19570 | -15832 | -17847 |
| TAS2R8 | -13590 | -16421 | -19752 | -16370 | -17883 |
| TAS2R9 | -13687 | -16116 | -19975 | -15596 | -17819 |
OLIGOPEPTIDE IMPORT ACROSS PLASMA MEMBRANE
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.276 |
| p.adjustMANOVA | 0.686 |
| s.dist | 1.14 |
| s.ADOS | -0.528 |
| s.diagnosis | -0.466 |
| s.iIQ | -0.579 |
| s.iLang | -0.53 |
| s.motor | -0.438 |
| p.ADOS | 0.0408 |
| p.diagnosis | 0.0712 |
| p.iIQ | 0.0249 |
| p.iLang | 0.0402 |
| p.motor | 0.0895 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| SLC15A2 | -18568 | -14813 |
| SLC15A3 | -15660 | -16108 |
| SLC15A1 | -15343 | -15372 |
| SLC7A11 | -17558 | -12504 |
| SLC15A4 | -9908 | -4431 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| SLC15A1 | -12627 | -14347 | -15343 | -15372 | -11377 |
| SLC15A2 | -12725 | -15303 | -18568 | -14813 | -13989 |
| SLC15A3 | -13088 | -7774 | -15660 | -16108 | -12206 |
| SLC15A4 | -2238 | -5010 | -9908 | -4431 | -11103 |
| SLC7A11 | -10067 | -12670 | -17558 | -12504 | -14708 |
NEGATIVE REGULATION OF AUTOPHAGY OF MITOCHONDRION
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.141 |
| p.adjustMANOVA | 0.506 |
| s.dist | 1.14 |
| s.ADOS | 0.581 |
| s.diagnosis | 0.568 |
| s.iIQ | 0.53 |
| s.iLang | 0.504 |
| s.motor | 0.326 |
| p.ADOS | 0.00775 |
| p.diagnosis | 0.00929 |
| p.iIQ | 0.0152 |
| p.iLang | 0.0208 |
| p.motor | 0.136 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | diagnosis |
|---|---|---|
| RNF41 | 5420 | 4456 |
| TSC2 | 2692 | 3026 |
| PINK1 | 3693 | 1220 |
| TSPO | 3314 | 1153 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| PINK1 | 3693 | 1220 | 1412 | 3131 | 1159 |
| RNF41 | 5420 | 4456 | 1531 | 705 | 111 |
| TIGAR | 2064 | -1475 | -3758 | -1559 | -5587 |
| TP53 | -2285 | 25 | -1637 | 317 | -200 |
| TSC2 | 2692 | 3026 | -3254 | -1319 | -10139 |
| TSPO | 3314 | 1153 | -6549 | -4394 | -1816 |
| USP30 | 501 | -5006 | -9174 | -4826 | -12735 |
CEREBRAL CORTEX GABAERGIC INTERNEURON DIFFERENTIATION
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0126 |
| p.adjustMANOVA | 0.12 |
| s.dist | 1.14 |
| s.ADOS | 0.317 |
| s.diagnosis | 0.451 |
| s.iIQ | 0.618 |
| s.iLang | 0.484 |
| s.motor | 0.616 |
| p.ADOS | 0.0824 |
| p.diagnosis | 0.0136 |
| p.iIQ | 0.000712 |
| p.iLang | 0.00798 |
| p.motor | 0.000742 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | motor |
|---|---|---|
| ASCL1 | 1596 | 2105 |
| FEZF2 | 1131 | 2708 |
| DLX2 | 581 | 2371 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ASCL1 | 5620 | 3512 | 1596 | 3203 | 2105 |
| CNTN2 | -7934 | -4244 | -4417 | -5541 | -264 |
| DLX1 | -3476 | 1060 | -749 | -1623 | -191 |
| DLX2 | -132 | -3759 | 581 | 3009 | 2371 |
| DRD1 | 3148 | 436 | -6900 | -5895 | -4514 |
| DRD2 | -3619 | -4840 | -6546 | -5538 | -6746 |
| FEZF2 | 690 | 2541 | 1131 | 1495 | 2708 |
| LHX6 | 209 | 1166 | -3519 | -3444 | -3439 |
| NKX2-1 | 3904 | 3163 | -153 | 1564 | -2810 |
| RAC3 | -5798 | -7200 | -1827 | -801 | 1382 |
RIBOSOMAL SMALL SUBUNIT EXPORT FROM NUCLEUS
| metric | value |
|---|---|
| setSize | 8 |
| pMANOVA | 0.0772 |
| p.adjustMANOVA | 0.377 |
| s.dist | 1.14 |
| s.ADOS | 0.5 |
| s.diagnosis | 0.507 |
| s.iIQ | 0.621 |
| s.iLang | 0.509 |
| s.motor | 0.384 |
| p.ADOS | 0.0143 |
| p.diagnosis | 0.013 |
| p.iIQ | 0.00236 |
| p.iLang | 0.0127 |
| p.motor | 0.06 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| NPM1 | 1698 | 2760 |
| RPS15 | 361 | 3498 |
| NOP9 | 121 | 1259 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| LTV1 | 1336 | -6130 | -8975 | -1643 | -11282 |
| NOP9 | 170 | -3147 | 121 | 1259 | 2354 |
| NPM1 | 6087 | 4668 | 1698 | 2760 | 239 |
| NUP88 | 3417 | 1930 | -1989 | -4973 | -11645 |
| RAN | 6186 | 3738 | 1214 | -753 | -337 |
| RIOK2 | -9139 | -3025 | -2724 | -7870 | -1705 |
| RPS15 | 2934 | 1127 | 361 | 3498 | 378 |
| XPO1 | -609 | -686 | -6096 | -946 | -6180 |
SENSORY PERCEPTION OF SMELL
| metric | value |
|---|---|
| setSize | 380 |
| pMANOVA | 2.88e-100 |
| p.adjustMANOVA | 7.22e-97 |
| s.dist | 1.14 |
| s.ADOS | -0.39 |
| s.diagnosis | -0.511 |
| s.iIQ | -0.593 |
| s.iLang | -0.508 |
| s.motor | -0.521 |
| p.ADOS | 3.91e-39 |
| p.diagnosis | 4.01e-66 |
| p.iIQ | 1.54e-88 |
| p.iLang | 3.18e-65 |
| p.motor | 1.88e-68 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | motor |
|---|---|---|
| OR4N4 | -20084 | -18813 |
| OR8D2 | -19869 | -18816 |
| OR5T3 | -19780 | -18758 |
| OR2A2 | -20009 | -18526 |
| OR2L2 | -19963 | -18558 |
| OR2L5 | -19910 | -18584 |
| OR2W3 | -19851 | -18605 |
| OR5B12 | -19624 | -18794 |
| OR5F1 | -20000 | -18433 |
| OR6C1 | -19704 | -18696 |
| OR8G2P | -19710 | -18687 |
| OR6C76 | -19832 | -18536 |
| OR13C8 | -19922 | -18421 |
| OR52A1 | -19801 | -18407 |
| OR6C75 | -19542 | -18648 |
| OR2F2 | -19510 | -18664 |
| OR8K3 | -19643 | -18529 |
| OR6C68 | -19696 | -18374 |
| OR10G4 | -19680 | -18278 |
| OR51B4 | -19751 | -18207 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ADCY3 | -3921.0 | -983.0 | -7192.0 | -6869.0 | -6457.0 |
| B2M | 2648.0 | 2172.0 | 1739.0 | 3883.0 | 2618.0 |
| B3GNT2 | 472.0 | -6329.0 | -10283.0 | -6827.0 | -14309.0 |
| BBS1 | -1355.0 | -3423.0 | -6705.0 | -4384.0 | -11528.0 |
| BBS4 | 3731.0 | -398.0 | -2225.0 | 405.0 | -6374.0 |
| BEST2 | 4531.0 | 2816.0 | -2692.0 | -2728.0 | -5551.0 |
| CFAP69 | -7868.0 | -7859.0 | -14185.0 | -10642.0 | -14941.0 |
| CNGA4 | -12954.0 | -6465.0 | -14168.0 | -16669.0 | -1371.0 |
| CNGB1 | -11131.0 | -6059.0 | -11040.0 | -14751.0 | -6224.0 |
| DRD2 | -3619.0 | -4840.0 | -6546.0 | -5538.0 | -6746.0 |
| FZD2 | -2140.0 | 1306.0 | -854.0 | -6860.0 | 3171.0 |
| GFY | 1113.0 | -4710.0 | -3087.0 | 1869.0 | -12230.0 |
| GJB4 | 3782.0 | 3522.0 | -5886.0 | -7260.0 | -7347.0 |
| GPR148 | 2856.0 | 3852.0 | 1960.0 | 1504.0 | -2606.0 |
| MKKS | 2875.0 | 2136.0 | -3600.0 | -5978.0 | -12262.0 |
| NAV2 | -8813.0 | -10496.0 | -13201.0 | -12415.0 | -10309.0 |
| NXNL2 | 1919.0 | 2612.0 | -1788.0 | -1499.0 | 817.0 |
| OBP2A | -13811.0 | -13278.0 | -3470.0 | -10674.0 | 1758.0 |
| OBP2B | -7563.0 | -6950.0 | -9951.0 | -1634.0 | -14532.0 |
| OMP | -7256.0 | -9429.0 | -12889.0 | -9619.0 | -10820.0 |
| OR10A2 | -6064.0 | -14958.0 | -18001.0 | -11561.0 | -17521.0 |
| OR10A3 | -7026.0 | -7596.0 | -10178.0 | -8149.0 | -2754.0 |
| OR10A4 | -14811.0 | -16817.0 | -19140.0 | -17335.0 | -11308.0 |
| OR10A5 | -14311.0 | -16414.0 | -17251.0 | -12454.0 | -16771.0 |
| OR10A6 | -14926.0 | -16699.0 | -19942.0 | -17383.0 | -16833.0 |
| OR10A7 | -13357.0 | -15983.0 | -19021.0 | -17615.0 | -18184.0 |
| OR10AD1 | -7706.0 | -4776.0 | -12313.0 | -7684.0 | -16039.0 |
| OR10AG1 | -13388.0 | -15474.0 | -18552.0 | -16558.0 | -16990.0 |
| OR10C1 | -13253.0 | -12077.0 | -14084.0 | -14823.0 | -3026.0 |
| OR10G2 | -9299.0 | -11468.0 | -18174.0 | -7784.0 | -11092.0 |
| OR10G3 | 735.0 | -10345.0 | -11941.0 | -9024.0 | -11168.0 |
| OR10G4 | -14219.0 | -16677.0 | -19680.0 | -16462.0 | -18278.0 |
| OR10G7 | -14406.0 | -12466.0 | -12262.0 | -10970.0 | -18587.0 |
| OR10G8 | -10615.0 | -15117.0 | -18859.0 | -14988.0 | -15895.0 |
| OR10G9 | -8283.0 | -12946.0 | -18973.0 | -10832.0 | -18283.0 |
| OR10H1 | -12204.0 | -14388.0 | -18628.0 | -15579.0 | -17280.0 |
| OR10H2 | -7610.0 | -11005.0 | -1140.0 | -813.0 | -1279.0 |
| OR10H3 | -1718.0 | -8563.0 | -6107.0 | -3001.0 | -13553.0 |
| OR10H4 | -14418.0 | -14556.0 | -19136.0 | -17382.0 | -17975.0 |
| OR10H5 | 578.0 | -12214.0 | -14309.0 | -8850.0 | -6848.0 |
| OR10J1 | -14002.0 | -15888.0 | -19638.0 | -17460.0 | -17646.0 |
| OR10J3 | -129.0 | 4263.0 | -1553.0 | -5238.0 | -9804.0 |
| OR10J5 | -2440.0 | -12080.0 | -15761.0 | -14008.0 | -2848.0 |
| OR10K1 | 5891.0 | -2399.0 | -14303.0 | 3352.0 | -18520.0 |
| OR10K2 | -11750.0 | -15185.0 | -17302.0 | -14510.0 | -4204.0 |
| OR10P1 | -8292.0 | -13484.0 | -16148.0 | -15992.0 | -3377.0 |
| OR10Q1 | -3352.0 | -8754.0 | -13981.0 | -2961.0 | -14746.0 |
| OR10R2 | 6863.0 | 5274.0 | 2157.0 | 4288.0 | -15788.0 |
| OR10S1 | -4806.0 | -14394.0 | -17616.0 | -12609.0 | -18894.0 |
| OR10T2 | 3673.0 | 161.0 | 2089.0 | 4133.0 | 2230.0 |
| OR10V1 | -10198.0 | -12885.0 | -14573.0 | -13245.0 | -5341.0 |
| OR10W1 | -14127.0 | -16204.0 | -18845.0 | -16953.0 | -18386.0 |
| OR10X1 | -13309.0 | -15410.0 | -19620.0 | -15430.0 | -16300.0 |
| OR10Z1 | -12515.0 | -14374.0 | -18107.0 | -16717.0 | -16093.0 |
| OR11A1 | -11183.0 | -13936.0 | -17605.0 | -14805.0 | -17841.0 |
| OR11G2 | -10964.0 | -15645.0 | -19730.0 | -16172.0 | -17210.0 |
| OR11H2 | -10828.0 | -15272.0 | -19865.0 | -17490.0 | -7391.0 |
| OR11H4 | 6218.0 | -2678.0 | -8662.0 | 279.0 | -17909.0 |
| OR11H6 | -14769.0 | -15843.0 | -19295.0 | -17365.0 | -14461.0 |
| OR11L1 | -3659.0 | -5234.0 | -15970.0 | -4287.0 | -17789.0 |
| OR12D2 | -14455.0 | -16107.0 | -17716.0 | -14140.0 | -10703.0 |
| OR12D3 | -13949.0 | -14864.0 | -18235.0 | -16725.0 | -13969.0 |
| OR13A1 | -14393.0 | -15819.0 | -19257.0 | -16388.0 | -15488.0 |
| OR13C2 | -15093.0 | -16577.0 | -20035.0 | -17428.0 | -16417.0 |
| OR13C3 | -8099.0 | -12827.0 | -18940.0 | -13011.0 | -18766.0 |
| OR13C4 | -15043.0 | -16816.0 | -20024.0 | -17483.0 | -17341.0 |
| OR13C8 | -14802.0 | -16702.0 | -19922.0 | -16649.0 | -18421.0 |
| OR13C9 | -11796.0 | -14566.0 | -19040.0 | -17322.0 | -18650.0 |
| OR13D1 | -1634.0 | -14401.0 | -15478.0 | -5120.0 | -18272.0 |
| OR13F1 | -15232.0 | -16838.0 | -19978.0 | -17707.0 | -14407.0 |
| OR13G1 | -14120.0 | -16246.0 | -20013.0 | -17202.0 | -17499.0 |
| OR13J1 | -12129.0 | -6848.0 | -7983.0 | -10573.0 | -7818.0 |
| OR14A16 | -14636.0 | -15732.0 | -19347.0 | -17160.0 | -17744.0 |
| OR14C36 | -13905.0 | -15531.0 | -18141.0 | -16910.0 | -7545.0 |
| OR14I1 | -13162.0 | -12377.0 | -17966.0 | -3914.0 | -15605.0 |
| OR14J1 | -13954.0 | -15472.0 | -15647.0 | -16183.0 | -8189.0 |
| OR1A1 | -10909.0 | -11839.0 | -16830.0 | -17171.0 | -18275.0 |
| OR1A2 | -14072.0 | -13752.0 | -18081.0 | -16777.0 | -17337.0 |
| OR1B1 | -6599.0 | -11805.0 | -17141.0 | -8076.0 | -1910.0 |
| OR1C1 | -14001.0 | -16633.0 | -19881.0 | -16685.0 | -15880.0 |
| OR1D2 | -926.0 | -13243.0 | -17450.0 | -9856.0 | -18016.0 |
| OR1E1 | -2958.0 | 2761.0 | -11653.0 | -15784.0 | -17297.0 |
| OR1E2 | -12666.0 | -12614.0 | -11306.0 | -11248.0 | -12489.0 |
| OR1F1 | -9929.0 | -4774.0 | -2644.0 | -10010.0 | -10617.0 |
| OR1F2P | -9404.0 | -10233.0 | -17544.0 | -16673.0 | -14365.0 |
| OR1G1 | -12034.0 | -8393.0 | -14085.0 | -16819.0 | -966.0 |
| OR1I1 | 816.0 | -8762.0 | -5414.0 | -6367.0 | 2837.0 |
| OR1J1 | -12591.0 | -14898.0 | -18746.0 | -15288.0 | -18619.0 |
| OR1J2 | -10216.0 | -16477.0 | -17895.0 | -5218.0 | -11764.0 |
| OR1J4 | 6169.0 | 4818.0 | 857.0 | 3156.0 | -18684.0 |
| OR1K1 | -9941.0 | -2143.0 | -16015.0 | -16471.0 | 2944.0 |
| OR1L1 | 3294.0 | -3323.0 | -14357.0 | -5361.0 | -11357.0 |
| OR1L3 | -704.0 | -12736.0 | -15191.0 | -1728.0 | -13006.0 |
| OR1L4 | 3993.0 | -7386.0 | -16810.0 | -2174.0 | -18633.0 |
| OR1L6 | 6657.0 | 4640.0 | -6397.0 | 3958.0 | -18485.0 |
| OR1L8 | -6792.0 | -13244.0 | -17900.0 | -8862.0 | -18350.0 |
| OR1M1 | -721.0 | 657.0 | -6667.0 | 150.0 | -6788.0 |
| OR1N1 | -13964.0 | -13763.0 | -16483.0 | -15533.0 | -10332.0 |
| OR1N2 | 740.0 | -3051.0 | -16008.0 | -16341.0 | -18129.0 |
| OR1Q1 | -12755.0 | -14442.0 | -17576.0 | -13182.0 | 2135.0 |
| OR1S1 | -13736.0 | -15530.0 | -19982.0 | -17114.0 | -12793.0 |
| OR1S2 | -14637.0 | -15642.0 | -19328.0 | -16359.0 | -18109.0 |
| OR2A12 | -13689.0 | -15201.0 | -19578.0 | -16947.0 | -18311.0 |
| OR2A14 | -14806.0 | -16200.0 | -19655.0 | -16234.0 | -6418.0 |
| OR2A2 | -15049.0 | -16723.0 | -20009.0 | -17693.0 | -18526.0 |
| OR2A25 | -11443.0 | 2177.0 | -5342.0 | -9519.0 | -18424.0 |
| OR2A5 | -14671.0 | -15808.0 | -19026.0 | -16417.0 | -14771.0 |
| OR2AE1 | 785.0 | 3240.0 | -10362.0 | -7911.0 | -18661.0 |
| OR2AG1 | -11576.0 | -12469.0 | -18431.0 | -15536.0 | -11811.0 |
| OR2AG2 | -14812.0 | -15805.0 | -18578.0 | -16733.0 | -15162.0 |
| OR2AK2 | 594.0 | -13186.0 | -18469.0 | -48.0 | -13966.0 |
| OR2AP1 | -441.0 | -1497.0 | -11609.0 | -4841.0 | -18900.0 |
| OR2AT4 | -12525.0 | -12664.0 | -18927.0 | -16457.0 | -18860.0 |
| OR2B11 | -1808.0 | -9784.0 | -14437.0 | -13602.0 | -15856.0 |
| OR2B2 | 2894.0 | -4079.0 | -16277.0 | -14888.0 | -18621.0 |
| OR2B3 | -14856.0 | -16450.0 | -19814.0 | -17287.0 | -16289.0 |
| OR2B6 | -14138.0 | -15413.0 | -19074.0 | -16434.0 | -5817.0 |
| OR2C1 | -1042.0 | -9522.0 | -10649.0 | -5209.0 | -8437.0 |
| OR2C3 | -111.0 | -11288.0 | -13208.0 | -12096.0 | -13838.0 |
| OR2D2 | -14287.0 | -13662.0 | -18190.0 | -17327.0 | -15341.0 |
| OR2D3 | -2541.0 | -13160.0 | -18332.0 | -12995.0 | -18763.0 |
| OR2F1 | -10447.0 | -15134.0 | -19111.0 | -16193.0 | -15687.0 |
| OR2F2 | -15000.0 | -16825.0 | -19510.0 | -17080.0 | -18664.0 |
| OR2G2 | -15299.0 | -16653.0 | -19743.0 | -17776.0 | -13247.0 |
| OR2G3 | -13426.0 | -16024.0 | -18672.0 | -15963.0 | -17222.0 |
| OR2G6 | -14672.0 | -15624.0 | -19124.0 | -17414.0 | -16200.0 |
| OR2H1 | -12421.0 | -14952.0 | -17774.0 | -14434.0 | -16793.0 |
| OR2H2 | -11580.0 | -8640.0 | -11666.0 | -10985.0 | -15074.0 |
| OR2J2 | -15158.0 | -16811.0 | -20051.0 | -17661.0 | -15865.0 |
| OR2K2 | -12772.0 | -11181.0 | -18914.0 | -17076.0 | -17815.0 |
| OR2L13 | -13377.0 | -14944.0 | -17806.0 | -15537.0 | -15086.0 |
| OR2L2 | -15090.0 | -16823.0 | -19963.0 | -17746.0 | -18558.0 |
| OR2L3 | -14279.0 | -16827.0 | -19687.0 | -16477.0 | -14262.0 |
| OR2L5 | -10320.0 | -13893.0 | -19910.0 | -16509.0 | -18584.0 |
| OR2L8 | -10283.0 | -15260.0 | -18644.0 | -15914.0 | -18785.0 |
| OR2M2 | -11349.0 | -9772.0 | -16330.0 | -16603.0 | -16051.0 |
| OR2M3 | -14378.0 | -13805.0 | -19274.0 | -17582.0 | -18123.0 |
| OR2M4 | -12926.0 | -14298.0 | -19627.0 | -17388.0 | -18030.0 |
| OR2M5 | -5149.0 | -16301.0 | -17683.0 | -11788.0 | -13501.0 |
| OR2M7 | -15144.0 | -16661.0 | -20015.0 | -17809.0 | -16174.0 |
| OR2S2 | -13927.0 | -9643.0 | -15635.0 | -16807.0 | -8816.0 |
| OR2T1 | -8883.0 | -13218.0 | -18170.0 | -15452.0 | -18390.0 |
| OR2T10 | -6789.0 | -14662.0 | -19333.0 | -14062.0 | -18286.0 |
| OR2T11 | -13443.0 | -15889.0 | -16986.0 | -16248.0 | -11402.0 |
| OR2T12 | -5071.0 | -12847.0 | -19397.0 | -15393.0 | -17857.0 |
| OR2T27 | -13778.0 | -15532.0 | -17300.0 | -16004.0 | -1174.0 |
| OR2T3 | -9591.0 | -10874.0 | -10123.0 | -11886.0 | -6668.0 |
| OR2T33 | -14508.0 | -16162.0 | -19840.0 | -17596.0 | -18110.0 |
| OR2T34 | -12062.0 | -13618.0 | -18824.0 | -11275.0 | -16695.0 |
| OR2T4 | -6411.0 | -12427.0 | -15055.0 | -13227.0 | -13651.0 |
| OR2T6 | -12349.0 | -15575.0 | -17868.0 | -11945.0 | 17.0 |
| OR2T8 | -14400.0 | -16509.0 | -19273.0 | -17035.0 | -17440.0 |
| OR2V1 | -9632.0 | -8660.0 | -4921.0 | -7507.0 | 1579.0 |
| OR2V2 | 5771.0 | 2647.0 | -3886.0 | 1717.0 | -16012.0 |
| OR2W1 | -14556.0 | -16731.0 | -19785.0 | -17303.0 | -17059.0 |
| OR2W3 | -15218.0 | -16534.0 | -19851.0 | -16404.0 | -18605.0 |
| OR2W5P | 1816.0 | -7134.0 | -12807.0 | -7068.0 | -16152.0 |
| OR2Y1 | -14237.0 | -14439.0 | -16725.0 | -16037.0 | -16851.0 |
| OR2Z1 | -9229.0 | -8008.0 | -17706.0 | -17253.0 | -13406.0 |
| OR3A1 | 1829.0 | -7336.0 | -13611.0 | -9687.0 | -13409.0 |
| OR3A2 | 6172.0 | 3797.0 | -14659.0 | -4609.0 | -18239.0 |
| OR3A3 | 3078.0 | -4766.0 | 690.0 | -2756.0 | 2974.0 |
| OR4A15 | -6204.0 | -8889.0 | -17790.0 | -16721.0 | -18036.0 |
| OR4A16 | -11074.0 | -16231.0 | -18374.0 | -14386.0 | -14727.0 |
| OR4A47 | -15130.0 | -12660.0 | -18077.0 | -17260.0 | -17786.0 |
| OR4A5 | 5363.0 | 5014.0 | -2966.0 | 941.0 | 1727.0 |
| OR4B1 | -13698.0 | -14640.0 | -18718.0 | -16930.0 | -18630.0 |
| OR4C12 | -5399.0 | -12525.0 | -18599.0 | -15386.0 | -18306.0 |
| OR4C13 | 6749.0 | 5077.0 | 2129.0 | 4338.0 | 3254.0 |
| OR4C15 | -11639.0 | -14745.0 | -18006.0 | -10988.0 | -15383.0 |
| OR4C16 | -14695.0 | -7595.0 | -12143.0 | -16863.0 | -7019.0 |
| OR4C3 | 2437.0 | -1814.0 | 433.0 | -122.0 | 2367.0 |
| OR4C45 | -13008.0 | -14661.0 | -20005.0 | -17739.0 | -17114.0 |
| OR4C46 | 6828.0 | 4923.0 | -187.0 | 4337.0 | -15791.0 |
| OR4C6 | 4047.0 | -9781.0 | -13720.0 | -7153.0 | 1268.0 |
| OR4D1 | -11025.0 | -14292.0 | -18983.0 | -14390.0 | -16500.0 |
| OR4D10 | 2194.0 | -10744.0 | -12195.0 | -6647.0 | -18219.0 |
| OR4D11 | -11678.0 | -15520.0 | -17397.0 | -13831.0 | -12155.0 |
| OR4D2 | -8461.0 | -15450.0 | -16409.0 | -12228.0 | -13175.0 |
| OR4D5 | -11487.0 | -15551.0 | -18573.0 | -15496.0 | -16890.0 |
| OR4D6 | -15058.0 | -16075.0 | -18993.0 | -17639.0 | -18515.0 |
| OR4D9 | 5101.0 | -11717.0 | -15614.0 | -650.0 | -17264.0 |
| OR4E2 | -15257.0 | -16252.0 | -19535.0 | -17712.0 | -14921.0 |
| OR4F15 | 1705.0 | -10939.0 | -17958.0 | -10683.0 | -18640.0 |
| OR4F6 | 4435.0 | -13008.0 | -9488.0 | 373.0 | -13727.0 |
| OR4K1 | -13542.0 | -15232.0 | -14587.0 | -11074.0 | -8950.0 |
| OR4K13 | -14895.0 | -16355.0 | -19918.0 | -16197.0 | -16010.0 |
| OR4K14 | -3799.0 | -8290.0 | -3883.0 | 2154.0 | 1998.0 |
| OR4K15 | 6037.0 | -2051.0 | 1961.0 | 3863.0 | -13014.0 |
| OR4K17 | -13229.0 | -14757.0 | -18856.0 | -16438.0 | -18523.0 |
| OR4K2 | -9130.0 | -11134.0 | -11550.0 | -5713.0 | -4912.0 |
| OR4K5 | 2079.0 | -14705.0 | -16434.0 | -5464.0 | -17652.0 |
| OR4L1 | -13410.0 | -15953.0 | -17248.0 | -16811.0 | -17245.0 |
| OR4M1 | -13611.0 | -15198.0 | -18633.0 | -15642.0 | -18673.0 |
| OR4M2 | -13858.0 | -15985.0 | -19930.0 | -17300.0 | -17531.0 |
| OR4N2 | -374.0 | -8325.0 | -758.0 | 4220.0 | -18823.0 |
| OR4N4 | -15088.0 | -16674.0 | -20084.0 | -17770.0 | -18813.0 |
| OR4N5 | -8038.0 | -9529.0 | -9114.0 | -6037.0 | -1699.0 |
| OR4P4 | -14963.0 | -16851.0 | -19877.0 | -17320.0 | -4393.0 |
| OR4Q3 | 4700.0 | 2168.0 | 1468.0 | -26.0 | -10791.0 |
| OR4S1 | -14651.0 | -15696.0 | -18514.0 | -17512.0 | -16533.0 |
| OR4S2 | -11620.0 | -13289.0 | -14712.0 | -11199.0 | -15999.0 |
| OR4X1 | 4852.0 | 4784.0 | 1831.0 | 3620.0 | -8077.0 |
| OR4X2 | -412.0 | 4597.0 | 1999.0 | 2434.0 | -1708.0 |
| OR51A2 | -9990.0 | -14728.0 | -19167.0 | -14905.0 | -18557.0 |
| OR51A4 | -6971.0 | -12556.0 | -16924.0 | -13838.0 | -17055.0 |
| OR51A7 | 5468.0 | -7105.0 | -12719.0 | -1617.0 | -14212.0 |
| OR51B2 | -5678.0 | -14009.0 | -18466.0 | -6628.0 | -16749.0 |
| OR51B4 | -14681.0 | -16046.0 | -19751.0 | -17522.0 | -18207.0 |
| OR51B5 | -12587.0 | -13962.0 | -18880.0 | -16352.0 | -17091.0 |
| OR51B6 | -7963.0 | -9454.0 | -17432.0 | -10773.0 | -11778.0 |
| OR51D1 | -15055.0 | -16934.0 | -19615.0 | -17595.0 | -2088.0 |
| OR51E1 | -13574.0 | -11220.0 | -12784.0 | -14428.0 | -3792.0 |
| OR51E2 | -11997.0 | -15929.0 | -19104.0 | -15576.0 | -18012.0 |
| OR51F1 | -12962.0 | -12231.0 | -17266.0 | -17361.0 | -6981.0 |
| OR51F2 | -14254.0 | -16347.0 | -19762.0 | -17208.0 | -17321.0 |
| OR51G1 | -11203.0 | -15336.0 | -12415.0 | -12902.0 | -9759.0 |
| OR51G2 | -12938.0 | -14045.0 | -17049.0 | -17211.0 | -14022.0 |
| OR51I1 | -10653.0 | -3304.0 | -14806.0 | -9559.0 | -17033.0 |
| OR51I2 | 3109.0 | -1118.0 | -17185.0 | -13573.0 | -17713.0 |
| OR51L1 | -7332.0 | -13194.0 | -16828.0 | -15630.0 | -18181.0 |
| OR51M1 | -6170.0 | -15293.0 | -18919.0 | -15139.0 | -17842.0 |
| OR51Q1 | -11652.0 | -11401.0 | -17557.0 | -16423.0 | -7986.0 |
| OR51S1 | -13673.0 | -15508.0 | -17295.0 | -16954.0 | -14068.0 |
| OR51T1 | -12050.0 | -12213.0 | -17841.0 | -17074.0 | -10373.0 |
| OR51V1 | -14891.0 | -16192.0 | -19628.0 | -17244.0 | -17302.0 |
| OR52A1 | -11901.0 | -15329.0 | -19801.0 | -17308.0 | -18407.0 |
| OR52A4P | -8995.0 | -15858.0 | -17455.0 | -9502.0 | -17746.0 |
| OR52A5 | 4721.0 | -3865.0 | -17511.0 | -549.0 | -18193.0 |
| OR52B2 | -12331.0 | -15634.0 | -16799.0 | -15605.0 | -7424.0 |
| OR52B4 | -10859.0 | -14098.0 | -18245.0 | -17012.0 | -17557.0 |
| OR52B6 | -9812.0 | -12309.0 | -15405.0 | -14536.0 | -18131.0 |
| OR52D1 | -8618.0 | -10375.0 | -17665.0 | -6666.0 | -18295.0 |
| OR52E2 | 4473.0 | 4346.0 | -12316.0 | -3966.0 | -18805.0 |
| OR52E4 | -15052.0 | -16155.0 | -20040.0 | -17683.0 | -15705.0 |
| OR52E6 | -14624.0 | -14838.0 | -18885.0 | -14893.0 | -10691.0 |
| OR52E8 | -15227.0 | -16727.0 | -19606.0 | -17243.0 | -17680.0 |
| OR52H1 | -13158.0 | -13781.0 | -19099.0 | -17123.0 | -17163.0 |
| OR52I1 | -10869.0 | -15072.0 | -19364.0 | -15595.0 | -12873.0 |
| OR52I2 | -14466.0 | -15395.0 | -18630.0 | -17128.0 | -8336.0 |
| OR52J3 | -15050.0 | -16700.0 | -19400.0 | -17666.0 | -13695.0 |
| OR52K1 | -11716.0 | -7740.0 | -16826.0 | -12091.0 | -16481.0 |
| OR52K2 | 4491.0 | 2937.0 | -16922.0 | -11526.0 | -18831.0 |
| OR52L1 | -10042.0 | -12952.0 | -17508.0 | -16214.0 | -16319.0 |
| OR52M1 | -10205.0 | -14150.0 | -13573.0 | -9930.0 | -17409.0 |
| OR52N1 | -11546.0 | -15857.0 | -17580.0 | -13243.0 | -17742.0 |
| OR52N2 | 2442.0 | -2697.0 | -16347.0 | -14267.0 | -18670.0 |
| OR52N5 | -12596.0 | -16085.0 | -19204.0 | -16911.0 | -18699.0 |
| OR52R1 | -13606.0 | -16412.0 | -18572.0 | -16991.0 | -14120.0 |
| OR52W1 | -10761.0 | -9241.0 | -15042.0 | -15375.0 | -13106.0 |
| OR56A1 | -14913.0 | -16197.0 | -18785.0 | -17264.0 | -18338.0 |
| OR56A3 | 3495.0 | -11907.0 | -9218.0 | 855.0 | -17092.0 |
| OR56A4 | -13396.0 | -15285.0 | -18858.0 | -17557.0 | -18125.0 |
| OR56A5 | -14731.0 | -15101.0 | -13432.0 | -6376.0 | -17335.0 |
| OR56B1 | -13517.0 | -16229.0 | -19808.0 | -17341.0 | -17320.0 |
| OR56B4 | -13237.0 | -3523.0 | -8376.0 | -16824.0 | 3251.0 |
| OR5A1 | -12626.0 | -11511.0 | -17578.0 | -16007.0 | -16684.0 |
| OR5A2 | -14505.0 | -14354.0 | -18250.0 | -17537.0 | -7100.0 |
| OR5AC2 | -14447.0 | -15080.0 | -19369.0 | -16117.0 | -16714.0 |
| OR5AK2 | -13600.0 | -16610.0 | -19960.0 | -16309.0 | -16528.0 |
| OR5AN1 | -12682.0 | -16327.0 | -19227.0 | -15532.0 | -15564.0 |
| OR5AP2 | 2590.0 | -11228.0 | -17986.0 | -15514.0 | -18107.0 |
| OR5AR1 | -13129.0 | -15268.0 | -17732.0 | -16147.0 | -18019.0 |
| OR5AS1 | 3958.0 | -8709.0 | -15544.0 | -10034.0 | -16578.0 |
| OR5AU1 | -9696.0 | -7704.0 | -177.0 | -8596.0 | -1563.0 |
| OR5B12 | -14752.0 | -16570.0 | -19624.0 | -17525.0 | -18794.0 |
| OR5B17 | -15341.0 | -16959.0 | -20070.0 | -17881.0 | -6169.0 |
| OR5B2 | 5935.0 | 5154.0 | 1905.0 | -2182.0 | -16953.0 |
| OR5B21 | -14061.0 | -14608.0 | -19017.0 | -16169.0 | -15576.0 |
| OR5B3 | -15020.0 | -16634.0 | -19685.0 | -16872.0 | -13359.0 |
| OR5C1 | -13431.0 | -12054.0 | -18878.0 | -16304.0 | -4849.0 |
| OR5D13 | -15131.0 | -16640.0 | -20048.0 | -17742.0 | -1605.0 |
| OR5D14 | -15293.0 | -16531.0 | -18671.0 | -17749.0 | -9675.0 |
| OR5D16 | -15217.0 | -16733.0 | -19816.0 | -17367.0 | -17537.0 |
| OR5D18 | 3443.0 | -9603.0 | -14466.0 | -6574.0 | -17397.0 |
| OR5F1 | -15098.0 | -16803.0 | -20000.0 | -17572.0 | -18433.0 |
| OR5H1 | -15249.0 | -15589.0 | -19477.0 | -15662.0 | -5687.0 |
| OR5H15 | -14147.0 | -16293.0 | -18609.0 | -15793.0 | -13514.0 |
| OR5H2 | -13841.0 | -15627.0 | -18913.0 | -17351.0 | -18764.0 |
| OR5H6 | -12845.0 | -15988.0 | -18285.0 | -15287.0 | -16932.0 |
| OR5I1 | -14700.0 | -16618.0 | -19467.0 | -17133.0 | -18115.0 |
| OR5J2 | -14379.0 | -16494.0 | -20053.0 | -17478.0 | -14589.0 |
| OR5K1 | -12164.0 | -14881.0 | -19165.0 | -16073.0 | -17959.0 |
| OR5K2 | -14584.0 | -16648.0 | -19972.0 | -17461.0 | -16803.0 |
| OR5K3 | -7910.0 | -15903.0 | -19177.0 | -16608.0 | -18176.0 |
| OR5K4 | -14706.0 | -16730.0 | -19835.0 | -15415.0 | -9200.0 |
| OR5L1 | -14322.0 | -11779.0 | -15106.0 | -15240.0 | -10284.0 |
| OR5L2 | -15082.0 | -16103.0 | -19977.0 | -17223.0 | -8299.0 |
| OR5M1 | -14969.0 | -16808.0 | -20030.0 | -17397.0 | -16580.0 |
| OR5M10 | -11388.0 | -15306.0 | -18440.0 | -15475.0 | -13061.0 |
| OR5M11 | -13222.0 | -15855.0 | -19602.0 | -16775.0 | -17640.0 |
| OR5M3 | 6798.0 | 5265.0 | 1301.0 | 4190.0 | -4680.0 |
| OR5M8 | -1441.0 | -2570.0 | -17086.0 | -11432.0 | -18259.0 |
| OR5M9 | -14759.0 | -16908.0 | -19051.0 | -15850.0 | -7331.0 |
| OR5P2 | -9181.0 | -14371.0 | -12287.0 | -8935.0 | -3480.0 |
| OR5P3 | -14298.0 | -16088.0 | -18005.0 | -15525.0 | -18200.0 |
| OR5T1 | -11320.0 | -15596.0 | -19883.0 | -17084.0 | -15595.0 |
| OR5T2 | -12424.0 | -15720.0 | -19986.0 | -16432.0 | -15911.0 |
| OR5T3 | -11795.0 | -15940.0 | -19780.0 | -17307.0 | -18758.0 |
| OR5V1 | -11060.0 | -14674.0 | -18436.0 | -15097.0 | -17207.0 |
| OR5W2 | -14494.0 | -16706.0 | -19820.0 | -17040.0 | -18095.0 |
| OR6A2 | -13098.0 | -15694.0 | -19640.0 | -16413.0 | -18214.0 |
| OR6B1 | -12592.0 | -14856.0 | -17171.0 | -12381.0 | -2028.0 |
| OR6B2 | -8806.0 | -4557.0 | -9447.0 | -13834.0 | -14856.0 |
| OR6B3 | 539.0 | -12156.0 | -15352.0 | -5509.0 | -10513.0 |
| OR6C1 | -13519.0 | -16282.0 | -19704.0 | -16810.0 | -18696.0 |
| OR6C2 | -8893.0 | -14263.0 | -18964.0 | -12894.0 | -18468.0 |
| OR6C3 | -11709.0 | -15828.0 | -18791.0 | -16322.0 | -16471.0 |
| OR6C4 | 1894.0 | -9003.0 | -12791.0 | -9875.0 | -17388.0 |
| OR6C6 | 6694.0 | 2860.0 | -7694.0 | 4236.0 | -18832.0 |
| OR6C65 | -13246.0 | -16101.0 | -19473.0 | -16702.0 | -18385.0 |
| OR6C68 | -13477.0 | -15847.0 | -19696.0 | -16144.0 | -18374.0 |
| OR6C70 | -13179.0 | -15739.0 | -19220.0 | -16256.0 | -17365.0 |
| OR6C74 | -14631.0 | -16165.0 | -18812.0 | -16048.0 | -17387.0 |
| OR6C75 | -14462.0 | -16569.0 | -19542.0 | -16968.0 | -18648.0 |
| OR6C76 | -13295.0 | -15815.0 | -19832.0 | -17489.0 | -18536.0 |
| OR6F1 | -9265.0 | -16234.0 | -17793.0 | -9414.0 | -9691.0 |
| OR6K2 | -11220.0 | -14249.0 | -19286.0 | -15659.0 | -18319.0 |
| OR6K3 | -12794.0 | -12467.0 | -17661.0 | -14156.0 | -13604.0 |
| OR6K6 | -13522.0 | -15301.0 | -17761.0 | -15330.0 | -14228.0 |
| OR6M1 | -12620.0 | -14176.0 | -16140.0 | -7092.0 | -10975.0 |
| OR6N1 | -14587.0 | -13903.0 | -18539.0 | -16448.0 | -17255.0 |
| OR6N2 | -12241.0 | -14201.0 | -16311.0 | -16525.0 | -18142.0 |
| OR6P1 | -2906.0 | -7100.0 | -17939.0 | -15259.0 | -9370.0 |
| OR6Q1 | -15352.0 | -16909.0 | -15801.0 | -17695.0 | 3333.0 |
| OR6S1 | -3929.0 | -9035.0 | -15627.0 | -3403.0 | -14305.0 |
| OR6T1 | -14841.0 | -16263.0 | -19309.0 | -16381.0 | -15629.0 |
| OR6V1 | -635.0 | -9642.0 | -12448.0 | -1300.0 | -13431.0 |
| OR6X1 | -10837.0 | -13635.0 | -18364.0 | -15295.0 | -18867.0 |
| OR6Y1 | -11552.0 | -12634.0 | -18058.0 | -15577.0 | -17076.0 |
| OR7A10 | -15271.0 | -16759.0 | -19924.0 | -17854.0 | -11684.0 |
| OR7A17 | 4136.0 | -11686.0 | -12898.0 | -1871.0 | -9859.0 |
| OR7A5 | -9326.0 | -14419.0 | -17303.0 | -9954.0 | -17912.0 |
| OR7C1 | -761.0 | -13382.0 | -16393.0 | -14316.0 | -13759.0 |
| OR7C2 | -11578.0 | -14165.0 | -15428.0 | -12662.0 | -11593.0 |
| OR7D2 | -10904.0 | -14559.0 | -17124.0 | -13344.0 | -17974.0 |
| OR7D4 | -11151.0 | -1843.0 | -15205.0 | -15134.0 | -18160.0 |
| OR7E24 | -15373.0 | -16859.0 | -19988.0 | -17867.0 | -8999.0 |
| OR7G1 | 2349.0 | 385.0 | -9807.0 | -6174.0 | -16668.0 |
| OR7G2 | -14242.0 | -14524.0 | -17083.0 | -16831.0 | -17153.0 |
| OR7G3 | 5203.0 | 4968.0 | -13825.0 | -15534.0 | -17379.0 |
| OR8A1 | -10338.0 | -13841.0 | -19113.0 | -15685.0 | -17930.0 |
| OR8B12 | 3461.0 | 399.0 | -17502.0 | -9296.0 | -16231.0 |
| OR8B2 | -14469.0 | -16737.0 | -19838.0 | -17090.0 | -17465.0 |
| OR8B4 | -13104.0 | -14914.0 | -11848.0 | -15553.0 | -11283.0 |
| OR8B8 | -12642.0 | -12654.0 | -17498.0 | -17570.0 | -16551.0 |
| OR8D1 | -14896.0 | -16344.0 | -19417.0 | -17345.0 | -17293.0 |
| OR8D2 | -13754.0 | -15862.0 | -19869.0 | -16607.0 | -18816.0 |
| OR8D4 | -5550.0 | -14361.0 | -18816.0 | -14874.0 | -16454.0 |
| OR8G1 | -3350.0 | -13688.0 | -17869.0 | -13488.0 | -18528.0 |
| OR8G2P | -14620.0 | -15104.0 | -19710.0 | -16787.0 | -18687.0 |
| OR8G5 | 4437.0 | -7523.0 | -17315.0 | -10108.0 | -17699.0 |
| OR8H1 | -1955.0 | -14000.0 | -18307.0 | -13461.0 | -17895.0 |
| OR8H2 | -13593.0 | -6815.0 | 2005.0 | -6058.0 | 3277.0 |
| OR8H3 | -15390.0 | -16963.0 | -20092.0 | -17700.0 | -10905.0 |
| OR8I2 | -8465.0 | 3535.0 | -9286.0 | -6316.0 | -15069.0 |
| OR8J3 | -12374.0 | -15606.0 | -19573.0 | -15604.0 | -12121.0 |
| OR8K1 | -14980.0 | -16278.0 | -18974.0 | -17477.0 | -14124.0 |
| OR8K3 | -14458.0 | -15683.0 | -19643.0 | -17086.0 | -18529.0 |
| OR8K5 | -11987.0 | -16233.0 | -19027.0 | -16338.0 | -16169.0 |
| OR8S1 | -5992.0 | -12082.0 | -17385.0 | -13130.0 | -16795.0 |
| OR8U1 | -9534.0 | -15482.0 | -19164.0 | -13489.0 | -17738.0 |
| OR8U3 | 1932.0 | -9019.0 | -18443.0 | -16567.0 | -15840.0 |
| OR8U8 | -6068.0 | -12627.0 | -18016.0 | -15094.0 | -16505.0 |
| OR9A2 | -5883.0 | -10825.0 | -18720.0 | -13925.0 | -12041.0 |
| OR9A4 | -14262.0 | -13462.0 | -19151.0 | -17508.0 | -17532.0 |
| OR9G1 | 4368.5 | -11701.5 | -14625.5 | -6640.5 | -4806.5 |
| OR9G4 | -12073.0 | -16402.0 | -19383.0 | -14756.0 | -16358.0 |
| OR9G9 | 4368.5 | -11701.5 | -14625.5 | -6640.5 | -4806.5 |
| OR9I1 | 5896.0 | 5104.0 | -7938.0 | 2806.0 | -5320.0 |
| OR9K2 | -14358.0 | -15446.0 | -19148.0 | -17360.0 | -17812.0 |
| OR9Q1 | -2537.0 | -5853.0 | -10924.0 | -9750.0 | -10973.0 |
| OR9Q2 | 4014.0 | 119.0 | -13182.0 | -1332.0 | -16187.0 |
| PDE4A | -2426.0 | -1625.0 | -5151.0 | -3488.0 | -3132.0 |
| SLC24A4 | -2581.0 | -4429.0 | -8386.0 | -7525.0 | -5631.0 |
| SLC6A3 | -1932.0 | -2148.0 | -4981.0 | -4748.0 | -6427.0 |
| SYT10 | -3077.0 | -8559.0 | -12739.0 | -6272.0 | -14628.0 |
| TTC8 | -6907.0 | -9562.0 | -15858.0 | -11382.0 | -13047.0 |
| UBR3 | -9271.0 | -13257.0 | -17644.0 | -13914.0 | -16106.0 |
| UGT2A1 | -10207.0 | -15237.0 | -18790.0 | -13658.0 | -16945.0 |
HIS PURKINJE SYSTEM DEVELOPMENT
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0505 |
| p.adjustMANOVA | 0.293 |
| s.dist | 1.14 |
| s.ADOS | 0.577 |
| s.diagnosis | 0.489 |
| s.iIQ | 0.463 |
| s.iLang | 0.499 |
| s.motor | 0.504 |
| p.ADOS | 0.00823 |
| p.diagnosis | 0.0252 |
| p.iIQ | 0.034 |
| p.iLang | 0.0221 |
| p.motor | 0.0209 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | motor |
|---|---|---|
| ID2 | 5458 | 2758 |
| NKX2-5 | 5616 | 1088 |
| HOPX | 236 | 1148 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DSG2 | -751 | -7986 | -15855 | -11153 | -16672 |
| HOPX | 236 | -5652 | -11132 | -4670 | 1148 |
| ID2 | 5458 | 3967 | 2055 | 3751 | 2758 |
| IRX3 | 3157 | 894 | 562 | 2177 | -3123 |
| NKX2-5 | 5616 | 2678 | 71 | 3492 | 1088 |
| TBX3 | 1755 | 1933 | -776 | -1226 | -128 |
| TBX5 | -419 | 1400 | -1586 | -707 | -367 |
CARDIAC PACEMAKER CELL DEVELOPMENT
| metric | value |
|---|---|
| setSize | 9 |
| pMANOVA | 0.0615 |
| p.adjustMANOVA | 0.329 |
| s.dist | 1.13 |
| s.ADOS | 0.445 |
| s.diagnosis | 0.511 |
| s.iIQ | 0.552 |
| s.iLang | 0.525 |
| s.motor | 0.487 |
| p.ADOS | 0.0207 |
| p.diagnosis | 0.00799 |
| p.iIQ | 0.00416 |
| p.iLang | 0.00638 |
| p.motor | 0.0114 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| SHOX2 | 1690 | 3706 |
| ISL1 | 1405 | 3175 |
| NKX2-5 | 71 | 3492 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BMPR1A | -10986 | -14305 | -15511 | -13024 | -11083 |
| BVES | -8638 | -9083 | -8417 | -6590 | 35 |
| ISL1 | 4470 | 3239 | 1405 | 3175 | 2473 |
| MAML1 | 6478 | 4536 | -1915 | 2650 | -9911 |
| NKX2-5 | 5616 | 2678 | 71 | 3492 | 1088 |
| SHOX2 | 5351 | 4345 | 1690 | 3706 | 2282 |
| TBX18 | 2570 | 3896 | -333 | 375 | -5790 |
| TBX3 | 1755 | 1933 | -776 | -1226 | -128 |
| TBX5 | -419 | 1400 | -1586 | -707 | -367 |
CELLULAR RESPONSE TO SODIUM ARSENITE
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.268 |
| p.adjustMANOVA | 0.676 |
| s.dist | 1.12 |
| s.ADOS | 0.371 |
| s.diagnosis | 0.518 |
| s.iIQ | 0.636 |
| s.iLang | 0.505 |
| s.motor | 0.439 |
| p.ADOS | 0.151 |
| p.diagnosis | 0.045 |
| p.iIQ | 0.0138 |
| p.iLang | 0.0507 |
| p.motor | 0.0888 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | diagnosis |
|---|---|---|
| HNRNPA1 | 2032 | 5141 |
| ZC3H12A | 1410 | 1624 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DAXX | -7832 | -1535 | -1718 | -5353 | -149 |
| HNRNPA1 | 5995 | 5141 | 2032 | 3965 | 174 |
| HSF1 | -6427 | -4064 | -6243 | -8105 | -6152 |
| MAPK13 | 4364 | -1518 | -4866 | 890 | -10764 |
| ZC3H12A | 3178 | 1624 | 1410 | 2947 | 2368 |
POSITIVE REGULATION OF PROTEIN MONOUBIQUITINATION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.266 |
| p.adjustMANOVA | 0.673 |
| s.dist | 1.11 |
| s.ADOS | 0.516 |
| s.diagnosis | 0.586 |
| s.iIQ | 0.575 |
| s.iLang | 0.527 |
| s.motor | 0.118 |
| p.ADOS | 0.0457 |
| p.diagnosis | 0.0232 |
| p.iIQ | 0.0259 |
| p.iLang | 0.0414 |
| p.motor | 0.648 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | iIQ |
|---|---|---|
| UBB | 4299 | 1996 |
| PEF1 | 3563 | 1151 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BIRC2 | -214 | -756 | -5030 | 59 | -13095 |
| FANCM | 4713 | 3010 | -2891 | 101 | -9109 |
| PDCD6 | -5886 | -6662 | -8008 | -9493 | -6434 |
| PEF1 | 5003 | 3563 | 1151 | 856 | -4267 |
| UBB | 3760 | 4299 | 1996 | 4047 | 483 |
MACROPHAGE COLONY STIMULATING FACTOR PRODUCTION
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0169 |
| p.adjustMANOVA | 0.149 |
| s.dist | 1.11 |
| s.ADOS | 0.665 |
| s.diagnosis | 0.531 |
| s.iIQ | 0.354 |
| s.iLang | 0.576 |
| s.motor | -0.219 |
| p.ADOS | 0.00229 |
| p.diagnosis | 0.0149 |
| p.iIQ | 0.105 |
| p.iLang | 0.00835 |
| p.motor | 0.316 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | iLang |
|---|---|---|
| LILRA2 | 6402 | 4011 |
| MIR128-1 | 4361 | 3545 |
| ISL1 | 4470 | 3175 |
| TSLP | 2324 | 1181 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CD34 | 4708 | 2786 | -10444 | -6068 | -14641 |
| FOXP1 | -2544 | -8152 | -12662 | -5189 | -11327 |
| HAVCR2 | 2247 | -5825 | -7503 | -3043 | -11755 |
| ISL1 | 4470 | 3239 | 1405 | 3175 | 2473 |
| LILRA2 | 6402 | 4840 | 879 | 4011 | -11433 |
| MIR128-1 | 4361 | 1392 | -7005 | 3545 | -18924 |
| TSLP | 2324 | 2282 | 202 | 1181 | -6010 |
MRNA 3 END PROCESSING BY STEM LOOP BINDING AND CLEAVAGE
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0609 |
| p.adjustMANOVA | 0.326 |
| s.dist | 1.11 |
| s.ADOS | 0.482 |
| s.diagnosis | 0.296 |
| s.iIQ | 0.489 |
| s.iLang | 0.645 |
| s.motor | 0.496 |
| p.ADOS | 0.041 |
| p.diagnosis | 0.209 |
| p.iIQ | 0.0379 |
| p.iLang | 0.00618 |
| p.motor | 0.0353 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | motor |
|---|---|---|
| ZNF473 | 1330 | 1841 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CPSF2 | 5573 | 2386 | 1043 | 4053 | -585 |
| CPSF3 | -851 | -6651 | -8733 | -2006 | -10111 |
| LSM10 | -3767 | -6892 | -4367 | -2085 | -1808 |
| LSM11 | 1079 | -4017 | -5549 | 812 | -2371 |
| SLBP | 79 | -3778 | -4852 | 513 | -610 |
| ZNF473 | 4449 | 3746 | 1394 | 1330 | 1841 |
RNA GUANINE N7 METHYLATION
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.12 |
| p.adjustMANOVA | 0.473 |
| s.dist | 1.1 |
| s.ADOS | 0.449 |
| s.diagnosis | 0.513 |
| s.iIQ | 0.655 |
| s.iLang | 0.444 |
| s.motor | 0.361 |
| p.ADOS | 0.057 |
| p.diagnosis | 0.0296 |
| p.iIQ | 0.00547 |
| p.iLang | 0.0594 |
| p.motor | 0.126 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | diagnosis |
|---|---|---|
| RAMAC | 1646 | 790 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BUD23 | -5502 | -4001 | -2399 | -4096 | -1496 |
| METTL1 | 4840 | 2807 | -661 | 1546 | -8732 |
| RAMAC | 4872 | 790 | 1646 | 2544 | 2805 |
| RNMT | 1054 | -2093 | -2501 | -3250 | -5209 |
| TRMT112 | 5103 | 3707 | -1149 | -1311 | -137 |
| WDR4 | -6020 | -1955 | -4952 | -6241 | -9908 |
RESPONSE TO OXYGEN GLUCOSE DEPRIVATION
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.0276 |
| p.adjustMANOVA | 0.205 |
| s.dist | 1.1 |
| s.ADOS | 0.549 |
| s.diagnosis | 0.471 |
| s.iIQ | 0.549 |
| s.iLang | 0.574 |
| s.motor | 0.243 |
| p.ADOS | 0.00161 |
| p.diagnosis | 0.0068 |
| p.iIQ | 0.0016 |
| p.iLang | 0.000985 |
| p.motor | 0.164 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | ADOS |
|---|---|---|
| PARP2 | 3439 | 5689 |
| BNIP3 | 3321 | 5658 |
| AQP3 | 2071 | 2731 |
| SOX2 | 1793 | 1841 |
| NPPC | 611 | 2007 |
| ATF4 | 223 | 5088 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| AQP3 | 2731 | 2623 | 522 | 2071 | 2146 |
| ATF4 | 5088 | 4065 | -964 | 223 | -15625 |
| BNIP2 | 3444 | -298 | -4976 | -3848 | -15348 |
| BNIP3 | 5658 | 3499 | -245 | 3321 | -5694 |
| CBL | 45 | -2778 | -7236 | -809 | -3171 |
| MAP3K7 | -8354 | -10178 | -7252 | -5164 | -1695 |
| NPPC | 2007 | -4962 | -1251 | 611 | -1864 |
| PARP2 | 5689 | 2951 | 985 | 3439 | -4434 |
| SOX2 | 1841 | 834 | -322 | 1793 | -898 |
| TSC1 | -381 | -2859 | -4063 | -1429 | -957 |
| ZEB2 | 2506 | 614 | -6491 | -4219 | -8516 |
APOPTOTIC PROCESS INVOLVED IN HEART MORPHOGENESIS
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0214 |
| p.adjustMANOVA | 0.174 |
| s.dist | 1.1 |
| s.ADOS | 0.219 |
| s.diagnosis | 0.448 |
| s.iIQ | 0.618 |
| s.iLang | 0.335 |
| s.motor | 0.682 |
| p.ADOS | 0.315 |
| p.diagnosis | 0.0402 |
| p.iIQ | 0.00465 |
| p.iLang | 0.125 |
| p.motor | 0.00179 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | iIQ |
|---|---|---|
| NKX2-5 | 1088 | 71 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BMP4 | -5132 | -3266 | -587 | -2199 | 2237 |
| CCN1 | -186 | 760 | -3211 | -1129 | 1558 |
| FOXC1 | -2026 | -3399 | -1148 | 969 | 2163 |
| FOXC2 | -7512 | -2749 | -485 | -10855 | 3142 |
| HAND2 | 523 | 2329 | -2042 | -4368 | -462 |
| NKX2-5 | 5616 | 2678 | 71 | 3492 | 1088 |
| TGFB2 | -4086 | -2292 | -7179 | -7040 | -11189 |
RRNA PSEUDOURIDINE SYNTHESIS
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0529 |
| p.adjustMANOVA | 0.304 |
| s.dist | 1.09 |
| s.ADOS | 0.336 |
| s.diagnosis | 0.435 |
| s.iIQ | 0.68 |
| s.iLang | 0.542 |
| s.motor | 0.37 |
| p.ADOS | 0.124 |
| p.diagnosis | 0.0462 |
| p.iIQ | 0.00183 |
| p.iLang | 0.013 |
| p.motor | 0.0904 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | iLang |
|---|---|---|
| GAR1 | 1820 | 3707 |
| NOP10 | 1434 | 3135 |
| RPUSD1 | 36 | 471 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| GAR1 | 6334 | 4631 | 1820 | 3707 | -7918 |
| NAF1 | 3908 | 1690 | -4260 | 312 | -13728 |
| NHP2 | 3785 | 1294 | -1348 | 1331 | -3454 |
| NOP10 | -4339 | -688 | 1434 | 3135 | 762 |
| RPUSD1 | -2621 | -2690 | 36 | 471 | -2235 |
| RPUSD2 | 1105 | 929 | -1151 | -2187 | -2062 |
| TSR3 | -11871 | -12106 | -6254 | -11753 | 2856 |
SERINE PHOSPHORYLATION OF STAT PROTEIN
| metric | value |
|---|---|
| setSize | 20 |
| pMANOVA | 4.31e-05 |
| p.adjustMANOVA | 0.00135 |
| s.dist | 1.09 |
| s.ADOS | -0.368 |
| s.diagnosis | -0.499 |
| s.iIQ | -0.501 |
| s.iLang | -0.468 |
| s.motor | -0.57 |
| p.ADOS | 0.00434 |
| p.diagnosis | 0.000112 |
| p.iIQ | 0.000104 |
| p.iLang | 0.000289 |
| p.motor | 1.03e-05 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | iIQ |
|---|---|---|
| IFNA16 | -18517 | -19993 |
| IFNA14 | -18645 | -19791 |
| IFNW1 | -18723 | -19483 |
| IFNB1 | -18496 | -19633 |
| IFNK | -17755 | -19533 |
| IFNA8 | -17513 | -19561 |
| IFNA1 | -17810 | -19112 |
| IFNA5 | -16810 | -19690 |
| IFNA13 | -16950 | -19297 |
| IFNG | -17522 | -18535 |
| IFNA7 | -16322 | -17745 |
| IFNA6 | -15983 | -17271 |
| NLK | -14149 | -15129 |
| LIF | -12160 | -13332 |
| IFNA21 | -7597 | -19722 |
| GGNBP2 | -9790 | -7969 |
| RET | -9068 | -2738 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| GADD45A | 6459 | 4859 | 1558 | 3110 | -5134 |
| GGNBP2 | -11501 | -8901 | -7969 | -11240 | -9790 |
| IFNA1 | -4713 | -15914 | -19112 | -13352 | -17810 |
| IFNA13 | -10620 | -16119 | -19297 | -15939 | -16950 |
| IFNA14 | -13197 | -16007 | -19791 | -16642 | -18645 |
| IFNA16 | -14281 | -15984 | -19993 | -17475 | -18517 |
| IFNA2 | 6523 | 4648 | 1393 | 3564 | -14872 |
| IFNA21 | -15342 | -16652 | -19722 | -17814 | -7597 |
| IFNA5 | -14172 | -16697 | -19690 | -15804 | -16810 |
| IFNA6 | -7582 | -14113 | -17271 | -10051 | -15983 |
| IFNA7 | -10626 | -10575 | -17745 | -17399 | -16322 |
| IFNA8 | -12468 | -11260 | -19561 | -16914 | -17513 |
| IFNB1 | -13298 | -15718 | -19633 | -17140 | -18496 |
| IFNG | -13409 | -16083 | -18535 | -15946 | -17522 |
| IFNK | -14117 | -16683 | -19533 | -16194 | -17755 |
| IFNW1 | -11086 | -15816 | -19483 | -16549 | -18723 |
| LIF | -13541 | -11608 | -13332 | -15819 | -12160 |
| NLK | 581 | -9026 | -15129 | -6958 | -14149 |
| PWP1 | -931 | -8141 | -5112 | -446 | 1145 |
| RET | -27 | -1874 | -2738 | -4127 | -9068 |
CARDIAC PACEMAKER CELL DIFFERENTIATION
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.014 |
| p.adjustMANOVA | 0.129 |
| s.dist | 1.08 |
| s.ADOS | 0.416 |
| s.diagnosis | 0.477 |
| s.iIQ | 0.488 |
| s.iLang | 0.469 |
| s.motor | 0.558 |
| p.ADOS | 0.017 |
| p.diagnosis | 0.00611 |
| p.iIQ | 0.00507 |
| p.iLang | 0.00706 |
| p.motor | 0.00134 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | iIQ |
|---|---|---|
| SHOX2 | 2282 | 1690 |
| ISL1 | 2473 | 1405 |
| NKX2-5 | 1088 | 71 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BMPR1A | -10986 | -14305 | -15511 | -13024 | -11083 |
| BVES | -8638 | -9083 | -8417 | -6590 | 35 |
| ISL1 | 4470 | 3239 | 1405 | 3175 | 2473 |
| KCNJ8 | -1703 | 580 | -9081 | -7526 | 975 |
| MAML1 | 6478 | 4536 | -1915 | 2650 | -9911 |
| MESP1 | -559 | -4948 | -4366 | -1142 | 3027 |
| NKX2-5 | 5616 | 2678 | 71 | 3492 | 1088 |
| SHOX2 | 5351 | 4345 | 1690 | 3706 | 2282 |
| TBX18 | 2570 | 3896 | -333 | 375 | -5790 |
| TBX3 | 1755 | 1933 | -776 | -1226 | -128 |
| TBX5 | -419 | 1400 | -1586 | -707 | -367 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.3.2 (2023-10-31)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 parallel stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.3.3
## [2] GGally_2.2.0
## [3] ggplot2_3.4.4
## [4] reshape2_1.4.4
## [5] beeswarm_0.4.0
## [6] gtools_3.9.5
## [7] tibble_3.2.1
## [8] dplyr_1.1.4
## [9] echarts4r_0.4.5
## [10] gplots_3.1.3
## [11] HGNChelper_0.8.1
## [12] eulerr_7.0.0
## [13] kableExtra_1.3.4
## [14] data.table_1.14.10
## [15] IlluminaHumanMethylationEPICanno.ilm10b4.hg19_0.6.0
## [16] minfi_1.48.0
## [17] bumphunter_1.44.0
## [18] locfit_1.5-9.8
## [19] iterators_1.0.14
## [20] foreach_1.5.2
## [21] Biostrings_2.70.1
## [22] XVector_0.42.0
## [23] SummarizedExperiment_1.32.0
## [24] Biobase_2.62.0
## [25] MatrixGenerics_1.14.0
## [26] matrixStats_1.2.0
## [27] GenomicRanges_1.54.1
## [28] GenomeInfoDb_1.38.5
## [29] IRanges_2.36.0
## [30] S4Vectors_0.40.2
## [31] BiocGenerics_0.48.1
## [32] mitch_1.15.2
## [33] limma_3.58.1
##
## loaded via a namespace (and not attached):
## [1] splines_4.3.2 later_1.3.2
## [3] BiocIO_1.12.0 bitops_1.0-7
## [5] filelock_1.0.3 preprocessCore_1.64.0
## [7] XML_3.99-0.16 lifecycle_1.0.4
## [9] lattice_0.22-5 MASS_7.3-60
## [11] base64_2.0.1 scrime_1.3.5
## [13] magrittr_2.0.3 sass_0.4.8
## [15] rmarkdown_2.25 jquerylib_0.1.4
## [17] yaml_2.3.8 httpuv_1.6.13
## [19] doRNG_1.8.6 askpass_1.2.0
## [21] DBI_1.2.0 RColorBrewer_1.1-3
## [23] abind_1.4-5 zlibbioc_1.48.0
## [25] quadprog_1.5-8 rvest_1.0.3
## [27] purrr_1.0.2 RCurl_1.98-1.14
## [29] rappdirs_0.3.3 GenomeInfoDbData_1.2.11
## [31] genefilter_1.84.0 annotate_1.80.0
## [33] svglite_2.1.3 DelayedMatrixStats_1.24.0
## [35] codetools_0.2-19 DelayedArray_0.28.0
## [37] xml2_1.3.6 tidyselect_1.2.0
## [39] farver_2.1.1 beanplot_1.3.1
## [41] BiocFileCache_2.10.1 illuminaio_0.44.0
## [43] webshot_0.5.5 jsonlite_1.8.8
## [45] GenomicAlignments_1.38.1 multtest_2.58.0
## [47] ellipsis_0.3.2 survival_3.5-7
## [49] systemfonts_1.0.5 tools_4.3.2
## [51] progress_1.2.3 Rcpp_1.0.12
## [53] glue_1.7.0 gridExtra_2.3
## [55] SparseArray_1.2.3 xfun_0.41
## [57] HDF5Array_1.30.0 withr_2.5.2
## [59] fastmap_1.1.1 rhdf5filters_1.14.1
## [61] fansi_1.0.6 openssl_2.1.1
## [63] caTools_1.18.2 digest_0.6.33
## [65] R6_2.5.1 mime_0.12
## [67] colorspace_2.1-0 biomaRt_2.58.0
## [69] RSQLite_2.3.4 utf8_1.2.4
## [71] tidyr_1.3.0 generics_0.1.3
## [73] rtracklayer_1.62.0 prettyunits_1.2.0
## [75] httr_1.4.7 htmlwidgets_1.6.4
## [77] S4Arrays_1.2.0 ggstats_0.5.1
## [79] pkgconfig_2.0.3 gtable_0.3.4
## [81] blob_1.2.4 siggenes_1.76.0
## [83] htmltools_0.5.7 scales_1.3.0
## [85] png_0.1-8 knitr_1.45
## [87] rstudioapi_0.15.0 tzdb_0.4.0
## [89] rjson_0.2.21 nlme_3.1-164
## [91] curl_5.2.0 cachem_1.0.8
## [93] rhdf5_2.46.1 stringr_1.5.1
## [95] KernSmooth_2.23-22 AnnotationDbi_1.64.1
## [97] restfulr_0.0.15 GEOquery_2.70.0
## [99] pillar_1.9.0 grid_4.3.2
## [101] reshape_0.8.9 vctrs_0.6.5
## [103] promises_1.2.1 dbplyr_2.4.0
## [105] xtable_1.8-4 evaluate_0.23
## [107] readr_2.1.5 GenomicFeatures_1.54.1
## [109] cli_3.6.2 compiler_4.3.2
## [111] Rsamtools_2.18.0 rlang_1.1.3
## [113] crayon_1.5.2 rngtools_1.5.2
## [115] labeling_0.4.3 nor1mix_1.3-2
## [117] mclust_6.0.1 plyr_1.8.9
## [119] stringi_1.8.3 viridisLite_0.4.2
## [121] BiocParallel_1.36.0 munsell_0.5.0
## [123] Matrix_1.6-4 hms_1.1.3
## [125] sparseMatrixStats_1.14.0 bit64_4.0.5
## [127] Rhdf5lib_1.24.1 KEGGREST_1.42.0
## [129] statmod_1.5.0 shiny_1.8.0
## [131] highr_0.10 memoise_2.0.1
## [133] bslib_0.6.1 bit_4.0.5END of report